PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Biggs, JR; Kraft, AS				Biggs, JR; Kraft, AS			The role of the Smad3 protein in phorbol ester-induced promoter expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							WAF1/CIP1 GENE PROMOTER; DNA-BINDING ACTIVITY; U937 LEUKEMIC-CELLS; TRANSCRIPTIONAL ACTIVATION; TERMINAL DIFFERENTIATION; SP1 SITES; INHIBITOR; KINASE; PHOSPHORYLATION; INDUCTION	The Spl transcription factor plays an important role in mediating the p53-independent activation of the p21(WAF1) (WAF1) promoter by phorbol 12-myristate13-acetate (PMA) in hematopoietic cells. Using GAL4-Sp1 fusion proteins and a luciferase reporter, PMA is shown to activate the transcriptional activity of Sp1 independent of the WAF1 promoter. This activation does not require the Ser/Thr-rich region of Sp1 and can be mediated by 41 amino acids (152-193) of Sp1 that are important for the interaction with human TAF130, Because transforming growth factor-beta enhances WAF1 promoter activity through both Sp1 and Smad proteins, the role of Smads in PMA transcriptional activation was examined. PMA addition to hematopoietic cells was found to activate a GAL4/Smad-dependent promoter and the transforming growth factor-beta-responsive promoter, p3TP-lux. Immunofluorescence data demonstrate that PMA addition to hematopoietic cells induces the translocation of Smads to the nucleus. However, Smad3 does not stimulate the WAF1 promoter, but rather slightly inhibits the PMA-mediated induction of transcription from this upstream region. Additionally, transfection of Smad3 did not enhance the activation of GAL4/Sp1 by PMA. These results demonstrate that, while PMA can activate Smad-mediated transcription Smad proteins do not appear to play a major role in the PMA induction of the WAF1 promoter.	Univ Colorado, Hlth Sci Ctr, Dept Med Oncol, Denver, CO 80262 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Biggs, JR (corresponding author), Univ Colorado, Hlth Sci Ctr, Dept Med Oncol, 4200 E 9th Ave, Denver, CO 80262 USA.				NATIONAL CANCER INSTITUTE [R01CA042533] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK044741] Funding Source: NIH RePORTER; NCI NIH HHS [R01-CA42533] Funding Source: Medline; NIDDK NIH HHS [R01-DK44741] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Armstrong SA, 1997, J BIOL CHEM, V272, P13489, DOI 10.1074/jbc.272.21.13489; Biggs JR, 1998, CELL GROWTH DIFFER, V9, P667; Biggs JR, 1996, J BIOL CHEM, V271, P901, DOI 10.1074/jbc.271.2.901; Billon N, 1996, ONCOGENE, V13, P2047; Datto MB, 1997, MOL CELL BIOL, V17, P2030, DOI 10.1128/MCB.17.4.2030; DATTO MB, 1995, J BIOL CHEM, V270, P28623, DOI 10.1074/jbc.270.48.28623; de Caestecker MP, 1998, GENE DEV, V12, P1587, DOI 10.1101/gad.12.11.1587; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Feng XH, 1998, GENE DEV, V12, P2153, DOI 10.1101/gad.12.14.2153; FRANKLIN CC, 1992, P NATL ACAD SCI USA, V89, P7247, DOI 10.1073/pnas.89.15.7247; Franklin CC, 1997, J BIOL CHEM, V272, P16917, DOI 10.1074/jbc.272.27.16917; GILL G, 1994, P NATL ACAD SCI USA, V91, P192, DOI 10.1073/pnas.91.1.192; HARPER JW, 1993, CELL, V75, P805; Hunt KK, 1998, CANCER RES, V58, P5656; Janknecht R, 1998, GENE DEV, V12, P2114, DOI 10.1101/gad.12.14.2114; Janknecht R, 1996, CURR BIOL, V6, P951, DOI 10.1016/S0960-9822(02)00636-X; KADONAGA JT, 1988, SCIENCE, V242, P1566, DOI 10.1126/science.3059495; Kretzschmar M, 1999, GENE DEV, V13, P804, DOI 10.1101/gad.13.7.804; Kurokawa M, 1998, NATURE, V394, P92, DOI 10.1038/27945; LEGGETT RW, 1995, J BIOL CHEM, V270, P25879, DOI 10.1074/jbc.270.43.25879; Liu XD, 1997, P NATL ACAD SCI USA, V94, P10669, DOI 10.1073/pnas.94.20.10669; MISSERO C, 1995, P NATL ACAD SCI USA, V92, P5451, DOI 10.1073/pnas.92.12.5451; Moustakas A, 1998, P NATL ACAD SCI USA, V95, P6733, DOI 10.1073/pnas.95.12.6733; Naar AM, 1999, NATURE, V398, P828, DOI 10.1038/19789; Nakano K, 1997, J BIOL CHEM, V272, P22199, DOI 10.1074/jbc.272.35.22199; Nakao A, 1997, EMBO J, V16, P5353, DOI 10.1093/emboj/16.17.5353; Owen GI, 1998, J BIOL CHEM, V273, P10696, DOI 10.1074/jbc.273.17.10696; Pouponnot C, 1998, J BIOL CHEM, V273, P22865, DOI 10.1074/jbc.273.36.22865; Puri PL, 1997, MOL CELL, V1, P35, DOI 10.1016/S1097-2765(00)80005-2; Ryu SJ, 1999, NATURE, V397, P446, DOI 10.1038/17141; Shen X, 1998, MOL BIOL CELL, V9, P3309, DOI 10.1091/mbc.9.12.3309; Shiohara M, 1996, J CELL PHYSIOL, V166, P568, DOI 10.1002/(SICI)1097-4652(199603)166:3<568::AID-JCP11>3.0.CO;2-3; Sowa Y, 1997, BIOCHEM BIOPH RES CO, V241, P142, DOI 10.1006/bbrc.1997.7786; STEINMAN RA, 1994, ONCOGENE, V9, P3389; TAIPALE J, 1994, CELL GROWTH DIFFER, V5, P1309; Vaziri H, 1997, EMBO J, V16, P6018, DOI 10.1093/emboj/16.19.6018; Waldman T, 1996, NATURE, V381, P713, DOI 10.1038/381713a0; Whalen AM, 1997, MOL CELL BIOL, V17, P1947, DOI 10.1128/MCB.17.4.1947; YANG JY, 1996, NATURE, P319; Zhang Y, 1998, NATURE, V394, P909, DOI 10.1038/29814; Zhang Y, 1996, NATURE, V383, P168, DOI 10.1038/383168a0	41	27	27	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 24	1999	274	52					36987	36994		10.1074/jbc.274.52.36987	http://dx.doi.org/10.1074/jbc.274.52.36987			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	267WR	10601254	hybrid			2022-12-25	WOS:000084382700025
J	Duan, CM; Liimatta, MB; Bottum, OL				Duan, CM; Liimatta, MB; Bottum, OL			Insulin-like growth factor (IGF)-I regulates IGF-binding protein-5 gene expression through the phosphatidylinositol 3-kinase, protein kinase B/Akt, and p70 S6 kinase signaling pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE CELLS; FACTOR-I; ELASTIN GENE; TRANSCRIPTIONAL ACTIVATION; PROLIFERATION; 3'-KINASE; RAPAMYCIN; SURVIVAL; DIFFERENTIATION; MECHANISMS	Expression of the insulin-like growth factor-binding protein 5 (IGFBP-5) gene in vascular smooth muscle cells is up-regulated by IGF-I through an IGF-I receptor-mediated mechanism. In this study, we studied the possible involvement of the mitogen-activated protein kinase (MAPK) and PI 3-kinase signaling pathways in mediating IGF-I-regulated IGFBP-5 gene expression. The addition of Des(1-3)IGF-1, an IGF analog with reduced affinity to IGFBPs, resulted in a transient activation of p44 and p42 MAPK. Inhibition of the MAPK activation by PD98059, however, did not affect IGF-I-stimulated IGFBP-5 expression. Des(1-3)IGF-I treatment also strongly activated PI 3-kinase. This activation was probably mediated through IRS-1, because IGF-1 stimulation resulted in a significant increase in IRS-1- but not IRS-2-associated PI 3-kinase activity, This activation occurred within 5 min and was sustained at high levels for over 6 h. Likewise, Des(1-3)IGF-I caused a long lasting activation of PKB/Akt and p70(s6k). When LY294002 and wortmannin, two specific inhibitors of PI 3-kinase, were added with Des(1-3)IGF-I, the IGF-I-regulated IGFBP-5 expression was negated. The addition of rapamycin, which inhibits IGF-I-induced p70(s6k) activation, significantly inhibited IGF-I-regulated IGFBP-5 gene expression, These results suggest that the action of IGF-I on IGFBP-5 gene expression requires the activation of the PI 3-kinase-PKB/Akt-p70(s6k) pathway but not the MAPK pathway in vascular smooth muscle cells.	Univ Michigan, Dept Biol, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan	Duan, CM (corresponding author), Univ Michigan, Dept Biol, Nat Sci Bldg, Ann Arbor, MI 48109 USA.	cduan@umich.edu			NIDDK NIH HHS [5P60DK-20572] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P60DK020572] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; Band CJ, 1997, J BIOL CHEM, V272, P138; Boes M, 1996, ENDOCRINOLOGY, V137, P5357, DOI 10.1210/en.137.12.5357; BORNFELDT KE, 1994, J CLIN INVEST, V93, P1266, DOI 10.1172/JCI117081; CHEATHAM L, 1995, P NATL ACAD SCI USA, V92, P11696, DOI 10.1073/pnas.92.25.11696; CHEN LI, 1994, MOL CELL BIOL, V14, P4380, DOI 10.1128/MCB.14.7.4380; Cichy SB, 1998, J BIOL CHEM, V273, P6482, DOI 10.1074/jbc.273.11.6482; COHICK WS, 1993, J CELL PHYSIOL, V157, P52, DOI 10.1002/jcp.1041570107; COHICK WS, 1995, J CELL PHYSIOL, V164, P187, DOI 10.1002/jcp.1041640123; Conn KJ, 1996, J BIOL CHEM, V271, P28853, DOI 10.1074/jbc.271.46.28853; DEGROOT RP, 1994, CELL, V79, P81, DOI 10.1016/0092-8674(94)90402-2; DUAN C, 1998, AM ZOOL, V38, P29; Duan CM, 1996, J BIOL CHEM, V271, P4280; DUAN CM, 1995, J BIOL CHEM, V270, P24844, DOI 10.1074/jbc.270.42.24844; Duan CM, 1998, J BIOL CHEM, V273, P16836, DOI 10.1074/jbc.273.27.16836; Dudek H, 1997, SCIENCE, V275, P661, DOI 10.1126/science.275.5300.661; FRANCIS GL, 1992, J MOL ENDOCRINOL, V8, P213, DOI 10.1677/jme.0.0080213; Franke TF, 1997, SCIENCE, V275, P665, DOI 10.1126/science.275.5300.665; GIANNELLANETO D, 1992, CIRC RES, V71, P646, DOI 10.1161/01.RES.71.3.646; Graves LM, 1996, J BIOL CHEM, V271, P505, DOI 10.1074/jbc.271.1.505; Guo SD, 1999, J BIOL CHEM, V274, P17184, DOI 10.1074/jbc.274.24.17184; HILL CS, 1995, CELL, V80, P199, DOI 10.1016/0092-8674(95)90403-4; Imai Y, 1999, ENDOCRINOLOGY, V140, P4228, DOI 10.1210/en.140.9.4228; JENSEN DE, 1995, J BIOL CHEM, V270, P6555, DOI 10.1074/jbc.270.12.6555; JONES JI, 1995, ENDOCR REV, V16, P3, DOI 10.1210/er.16.1.3; KAMYAR A, 1994, CIRC RES, V74, P576, DOI 10.1161/01.RES.74.4.576; Koyama H, 1996, CIRC RES, V79, P757, DOI 10.1161/01.RES.79.4.757; LEROITH D, 1995, ENDOCR REV, V16, P143, DOI 10.1210/er.16.2.143; LISCOVITCH M, 1994, CELL, V77, P329, DOI 10.1016/0092-8674(94)90148-1; Liu Q, 1998, J IMMUNOL, V160, P1393; Marte BM, 1997, TRENDS BIOCHEM SCI, V22, P355, DOI 10.1016/S0968-0004(97)01097-9; MARX SO, 1995, CIRC RES, V76, P412, DOI 10.1161/01.RES.76.3.412; Moriya S, 1996, P NATL ACAD SCI USA, V93, P151, DOI 10.1073/pnas.93.1.151; Parrizas M, 1997, J BIOL CHEM, V272, P154; PAVLOVICSURJANCEV B, 1992, J NEUROCHEM, V59, P2134; Proud CG, 1996, TRENDS BIOCHEM SCI, V21, P181, DOI 10.1016/0968-0004(96)10016-5; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; Rousse S, 1998, ENDOCRINOLOGY, V139, P1487, DOI 10.1210/en.139.4.1487; TAKAGI Y, 1995, ATHEROSCLEROSIS, V113, P19, DOI 10.1016/0021-9150(94)05422-F; Thommes KB, 1996, EXP CELL RES, V226, P59, DOI 10.1006/excr.1996.0202; Urban RJ, 1996, J BIOL CHEM, V271, P31695, DOI 10.1074/jbc.271.49.31695; VERVERIS J, 1994, AM J MED SCI, V307, P77, DOI 10.1097/00000441-199402000-00001; WENG QP, 1995, P NATL ACAD SCI USA, V92, P5744, DOI 10.1073/pnas.92.12.5744; White MF, 1998, MOL CELL BIOCHEM, V182, P3, DOI 10.1023/A:1006806722619; WOLFE BL, 1993, J BIOL CHEM, V268, P12418; YAMAMOTOHONDA R, 1995, J BIOL CHEM, V270, P2729, DOI 10.1074/jbc.270.6.2729; Yano KJ, 1999, ENDOCRINOLOGY, V140, P4622, DOI 10.1210/en.140.10.4622; Yao R, 1996, ONCOGENE, V13, P343	48	69	69	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 24	1999	274	52					37147	37153		10.1074/jbc.274.52.37147	http://dx.doi.org/10.1074/jbc.274.52.37147			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	267WR	10601276	hybrid			2022-12-25	WOS:000084382700047
J	Korhonen, JM; Said, FA; Wong, AJ; Kaplan, DR				Korhonen, JM; Said, FA; Wong, AJ; Kaplan, DR			Gab1 mediates neurite outgrowth DNA synthesis, and survival in PC12 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NERVE-GROWTH-FACTOR; ACTIVATED PROTEIN-KINASE; PHOSPHATIDYLINOSITOL 3-KINASE; NEURONAL DIFFERENTIATION; SIGNAL-TRANSDUCTION; INHIBITS APOPTOSIS; FACTOR RECEPTOR; TRK RECEPTORS; DOCKING SITE; IN-VITRO	The Gab1-docking protein has been shown to regulate phosphatidylinositol 3-kinase PI3K activity and potentiate nerve growth factor (NGF)-induced survival in PC12 cells. Here, we investigated the potential of Gab1 to induce-neurite outgrowth and DNA synthesis, two other important aspects of NGF-induced neuronal differentiation of PC12 cells and NGF independent survival. We generated a recombinant adenovirus encoding hemagglutinin (HA)-epitope-tagged Gab1 and expressed this protein in PC12 cells. HA-Gab1 was constitutively tyrosine-phosphorylated in PC12 cells and induced the phosphorylation of Akt/protein kinase B and p44/42 mitogen-activated protein kinase. HA-Gab1-stimulated a 10-fold increase in neurite outgrowth in the absence of NGF and a 5-fold increase in NGF-induced neurite outgrowth, HA-Gab1 also stimulated DNA synthesis and caused NGF-independent survival in PC12 cells. Finally, we found that HA-Gab1-induced neuritogenesis was completely suppressed by pharmacological inhibition of mitogen-activated protein kinase kinase (MEK) activity and 50% suppressed by inhibition of PI3K activity. In contrast, HA-Gab1-stimulated cell survival was efficiently suppressed only by inhibition of both PI3K and MEK activities. These results indicate that Gab1 is capable of mediating differentiation, DNA synthesis, and cell survival and uses both PI3K and MEK signaling pathways to achieve its effects.	McGill Univ, Montreal Neurol Inst, Brain Tumor Res Ctr, Montreal, PQ H3A 2B4, Canada; Thomas Jefferson Univ, Coll Med, Philadelphia, PA 19107 USA; Exogen Neurosci Inc, Montreal, PQ H2W 2P2, Canada	McGill University; Jefferson University	Kaplan, DR (corresponding author), McGill Univ, Montreal Neurol Inst, Brain Tumor Res Ctr, F-116,3801 Univ St, Montreal, PQ H3A 2B4, Canada.	mcdv@musica.mcgill.ca						ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; Ashcroft M, 1999, ONCOGENE, V18, P4586, DOI 10.1038/sj.onc.1202814; Bardelli A, 1997, ONCOGENE, V15, P3103, DOI 10.1038/sj.onc.1201561; BAXTER RM, 1995, EUR J BIOCHEM, V234, P84, DOI 10.1111/j.1432-1033.1995.084_c.x; BURSTEIN DE, 1982, DEV BIOL, V94, P477, DOI 10.1016/0012-1606(82)90364-5; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; Crowder RJ, 1998, J NEUROSCI, V18, P2933; Downward J, 1999, NAT CELL BIOL, V1, pE33, DOI 10.1038/10026; Dudek H, 1997, SCIENCE, V275, P661, DOI 10.1126/science.275.5300.661; Eves EM, 1998, MOL CELL BIOL, V18, P2143, DOI 10.1128/MCB.18.4.2143; Fixman ED, 1997, J BIOL CHEM, V272, P20167, DOI 10.1074/jbc.272.32.20167; GREENE LA, 1978, J CELL BIOL, V78, P747, DOI 10.1083/jcb.78.3.747; Greene LA., 1982, ADV CELL NEUROBIOL, V3, P373, DOI [10.1016/B978-0-12-008303-9.50016-5, DOI 10.1016/B978-0-12-008303-9.50016-5]; Gu HH, 1998, MOL CELL, V2, P729, DOI 10.1016/S1097-2765(00)80288-9; Hallberg B, 1998, ONCOGENE, V17, P691, DOI 10.1038/sj.onc.1201980; HolgadoMadruga M, 1996, NATURE, V379, P560, DOI 10.1038/379560a0; HolgadoMadruga M, 1997, P NATL ACAD SCI USA, V94, P12419, DOI 10.1073/pnas.94.23.12419; Ingham RJ, 1998, J BIOL CHEM, V273, P30630, DOI 10.1074/jbc.273.46.30630; Kaplan DR, 1997, CURR OPIN CELL BIOL, V9, P213, DOI 10.1016/S0955-0674(97)80065-8; KAPLAN DR, 1991, SCIENCE, V252, P554, DOI 10.1126/science.1850549; KIMURA K, 1994, J BIOL CHEM, V269, P18961; KLEIN R, 1991, CELL, V65, P189, DOI 10.1016/0092-8674(91)90419-Y; Klesse LJ, 1999, ONCOGENE, V18, P2055, DOI 10.1038/sj.onc.1202524; Klippel A, 1998, MOL CELL BIOL, V18, P5699, DOI 10.1128/MCB.18.10.5699; Kobayashi M, 1997, J BIOL CHEM, V272, P16089, DOI 10.1074/jbc.272.26.16089; Kouhara H, 1997, CELL, V89, P693, DOI 10.1016/S0092-8674(00)80252-4; Lecoq-Lafon C, 1999, BLOOD, V93, P2578, DOI 10.1182/blood.V93.8.2578.408k24_2578_2585; Lehr S, 1999, BIOCHEMISTRY-US, V38, P151, DOI 10.1021/bi9818265; Maroun CR, 1999, MOL CELL BIOL, V19, P1784; Morooka T, 1998, J BIOL CHEM, V273, P24285, DOI 10.1074/jbc.273.38.24285; Moscatello DK, 1998, J BIOL CHEM, V273, P200, DOI 10.1074/jbc.273.1.200; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; MYERS MG, 1992, P NATL ACAD SCI USA, V89, P10350, DOI 10.1073/pnas.89.21.10350; Niemann C, 1998, J CELL BIOL, V143, P533, DOI 10.1083/jcb.143.2.533; Nishida K, 1999, BLOOD, V93, P1809, DOI 10.1182/blood.V93.6.1809.406k35_1809_1816; PANG L, 1995, J BIOL CHEM, V270, P13585, DOI 10.1074/jbc.270.23.13585; Pap M, 1998, J BIOL CHEM, V273, P19929, DOI 10.1074/jbc.273.32.19929; Parrizas M, 1997, J BIOL CHEM, V272, P154; Qian XZ, 1998, NEURON, V21, P1017, DOI 10.1016/S0896-6273(00)80620-0; Rocchi S, 1998, MOL ENDOCRINOL, V12, P914, DOI 10.1210/me.12.7.914; RUDKIN BB, 1989, EMBO J, V8, P3319, DOI 10.1002/j.1460-2075.1989.tb08493.x; Segal RA, 1996, ANNU REV NEUROSCI, V19, P463, DOI 10.1146/annurev.ne.19.030196.002335; Slack RS, 1996, J CELL BIOL, V135, P1085, DOI 10.1083/jcb.135.4.1085; STEPHENS RM, 1994, NEURON, V12, P691, DOI 10.1016/0896-6273(94)90223-2; Takahashi-Tezuka M, 1998, MOL CELL BIOL, V18, P4109, DOI 10.1128/MCB.18.7.4109; Weidner KM, 1996, NATURE, V384, P173, DOI 10.1038/384173a0; YAO RJ, 1995, SCIENCE, V267, P2003, DOI 10.1126/science.7701324	47	61	63	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 24	1999	274	52					37307	37314		10.1074/jbc.274.52.37307	http://dx.doi.org/10.1074/jbc.274.52.37307			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	267WR	10601297	hybrid			2022-12-25	WOS:000084382700068
J	Murata, LB; Dodson, MS				Murata, LB; Dodson, MS			The herpes simplex virus type 1 origin-binding protein - Sequence-specific activation of adenosine triphosphatase activity by a double-stranded DNA containing box I	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REPLICATION ORIGIN; NUCLEOPROTEIN COMPLEX; HELICASE ACTIVITY; VIRAL ORIGIN; UL9 PROTEIN; DOMAIN; ORIS; IDENTIFICATION; PURIFICATION; RECOGNITION	Origin-dependent replication of the herpes simplex virus type 1 genome requires the virally encoded origin-binding protein, UL9. UL9 binds specifically to the herpes simplex virus type 1 replication origin at two high affinity binding sites on the DNA, Boxes I and II. UL9 also has ATP-dependent DNA helicase and DNA-stimulated ATPase activities that are used to unwind the origin DNA. Origin-specific binding is mediated by the C-terminal domain (C-domain) of the enzyme. ATPase and helicase activities are mediated by the N-terminal domain (N-domain). Previous studies have shown that single-stranded DNA is a good coeffector for ATPase activity. We have analyzed several DNAs for their ability to stimulate the ATPase activity of UL9 and of a truncated UL9 protein (UL9/N) consisting only of the N-domain. We report here that duplex Box I DNA specifically and potently stimulates the ATPase activity of UL9 but not of UL9/N. We also find that removal of the C-domain significantly increases the ATPase activity of UL9. We have incorporated these results into a model for initiation in which the C-domain of UL9 serves to regulate the enzymatic activity of the N-domain.	Univ Arizona, Dept Biochem, Tucson, AZ 85721 USA	University of Arizona	Dodson, MS (corresponding author), Univ Arizona, Dept Biochem, Biol Sci W Bldg,1041 E Lowell St, Tucson, AZ 85721 USA.	dodson@u.arizona.edu						ABBOTTS AP, 1995, J GEN VIROL, V76, P3125, DOI 10.1099/0022-1317-76-12-3125; Aguilar RM, 1999, ANAL BIOCHEM, V267, P344, DOI 10.1006/abio.1998.3018; BOEHMER PE, 1993, J BIOL CHEM, V268, P1220; BOEHMER PE, 1994, J BIOL CHEM, V269, P29329; BOEHMER PE, 1993, P NATL ACAD SCI USA, V90, P8444, DOI 10.1073/pnas.90.18.8444; Boehmer PE, 1997, ANNU REV BIOCHEM, V66, P347, DOI 10.1146/annurev.biochem.66.1.347; BRUCKNER RC, 1991, J BIOL CHEM, V266, P2669; Bullock PA, 1997, CRIT REV BIOCHEM MOL, V32, P503, DOI 10.3109/10409239709082001; CHALLBERG MD, 1989, ANNU REV BIOCHEM, V58, P671; DAVISON BL, 1979, J BIOL CHEM, V254, P9220; DEB S, 1991, J VIROL, V65, P2829, DOI 10.1128/JVI.65.6.2829-2838.1991; DODSON MS, 1993, J BIOL CHEM, V268, P1213; EARNSHAW DL, 1994, BIOCHEM BIOPH RES CO, V199, P1333, DOI 10.1006/bbrc.1994.1377; Edwards AM, 1998, CURR OPIN STRUC BIOL, V8, P49, DOI 10.1016/S0959-440X(98)80009-2; ELIAS P, 1992, J BIOL CHEM, V267, P17424; ELIAS P, 1990, J BIOL CHEM, V265, P17167; ELIAS P, 1988, P NATL ACAD SCI USA, V85, P2959, DOI 10.1073/pnas.85.9.2959; FIERER DS, 1992, J VIROL, V66, P3986, DOI 10.1128/JVI.66.7.3986-3995.1992; FIERER DS, 1995, J BIOL CHEM, V270, P7330, DOI 10.1074/jbc.270.13.7330; GORBALENYA AE, 1989, NUCLEIC ACIDS RES, V17, P4713, DOI 10.1093/nar/17.12.4713; GORBALENYA AE, 1993, CURR OPIN STRUC BIOL, V3, P419, DOI 10.1016/S0959-440X(05)80116-2; GUSTAFSSON CM, 1994, P NATL ACAD SCI USA, V91, P4629, DOI 10.1073/pnas.91.11.4629; HARDWICKE MA, 1995, J VIROL, V69, P1377, DOI 10.1128/JVI.69.3.1377-1388.1995; HAZUDA DJ, 1991, J BIOL CHEM, V266, P24621; HAZUDA DJ, 1992, J BIOL CHEM, V267, P14309; KOFF A, 1988, J VIROL, V62, P4096, DOI 10.1128/JVI.62.11.4096-4103.1988; KOFF A, 1991, J VIROL, V65, P3284, DOI 10.1128/JVI.65.6.3284-3292.1991; Kornberg A, 1992, DNA REPLICATION, P471; LANZETTA PA, 1979, ANAL BIOCHEM, V100, P95, DOI 10.1016/0003-2697(79)90115-5; Lee SSK, 1999, J BIOL CHEM, V274, P18613, DOI 10.1074/jbc.274.26.18613; Lee SSK, 1997, P NATL ACAD SCI USA, V94, P2838, DOI 10.1073/pnas.94.7.2838; LOCKSHON D, 1988, MOL CELL BIOL, V8, P4018, DOI 10.1128/MCB.8.10.4018; Makhov AM, 1996, EMBO J, V15, P1742, DOI 10.1002/j.1460-2075.1996.tb00520.x; MARTIN DW, 1994, VIROLOGY, V198, P71, DOI 10.1006/viro.1994.1009; MARTINEZ R, 1992, J VIROL, V66, P6735, DOI 10.1128/JVI.66.11.6735-6746.1992; MCGEOCH DJ, 1988, J VIROL, V62, P444, DOI 10.1128/JVI.62.2.444-453.1988; MCLEAN GW, 1994, J GEN VIROL, V75, P2699, DOI 10.1099/0022-1317-75-10-2699; OLIVO PD, 1988, P NATL ACAD SCI USA, V85, P5414, DOI 10.1073/pnas.85.15.5414; RABKIN SD, 1991, P NATL ACAD SCI USA, V88, P10946, DOI 10.1073/pnas.88.23.10946; Simonsson S, 1998, J BIOL CHEM, V273, P24633, DOI 10.1074/jbc.273.38.24633; STENLUND A, 1996, DNA REPLICATION EUKA, P679; Stow ND, 1998, VIROLOGY, V240, P183, DOI 10.1006/viro.1997.8910; STOW ND, 1993, VIROLOGY, V196, P413, DOI 10.1006/viro.1993.1496; SUMMERS MD, 1987, 1555 TEX A M U TEX A; WEIR HM, 1989, NUCLEIC ACIDS RES, V17, P1409, DOI 10.1093/nar/17.4.1409; WU CA, 1988, J VIROL, V62, P435, DOI 10.1128/JVI.62.2.435-443.1988	46	10	13	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 24	1999	274	52					37079	37086		10.1074/jbc.274.52.37079	http://dx.doi.org/10.1074/jbc.274.52.37079			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	267WR	10601266	hybrid			2022-12-25	WOS:000084382700037
J	Patra, D; Wang, SX; Kumagai, A; Dunphy, WG				Patra, D; Wang, SX; Kumagai, A; Dunphy, WG			The Xenopus Suc1/Cks protein promotes the phosphorylation of G(2)/M regulators	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PEPTIDYL-PROLYL ISOMERASE; CELL-CYCLE CONTROL; CRYSTAL-STRUCTURE; MITOSIS; KINASE; CDC25; PIN1; PURIFICATION; ACTIVATION; P13(SUC1)	The entry into mitosis is controlled by Cdc2/cyclin B, also known as maturation or M-phase promoting factor (MPF), In Xenopus egg extracts, the inhibitory phosphorylations of Cdc2 on Tyr-15 and Thr-14 are controlled by the phosphatase Cdc25 and the kinases Myt1 and Wee1, At mitosis, Cdc25 is activated and Myt1 and Wee1 are inactivated through phosphorylation by multiple kinases, including Cdc2 itself, The Cdc2-associated Suc1/Cks1 protein (p9) is also essential for entry of egg ex. tracts into mitosis, but the molecular basis of this requirement has been unknown. We find that p9 strongly stimulates the regulatory phosphorylations of Cdc25, Myt1, and Wee1 that are carried out by the Cdc2/cyclin B complex. Overexpression of the prolyl isomerase Pin1, which binds to the hyperphosphorylated forms of Cdc25, Myt1, and Wee1 found at M-phase, is known to block the initiation of mitosis in egg extracts. We have observed that Pin1 specifically antagonizes the stimulatory effect of p9 on phosphorylation of Cdc25 by Cdc2/cyclin B, This observation could explain why overexpression of Pin1 inhibits mitotic initiation. These findings suggest that p9 promotes the entry into mitosis by facilitating phosphorylation of the key upstream regulators of Cdc2.	CALTECH, Howard Hughes Med Inst, Div Biol 21676, Pasadena, CA 91125 USA	California Institute of Technology; Howard Hughes Medical Institute	Dunphy, WG (corresponding author), CALTECH, Howard Hughes Med Inst, Div Biol 21676, Pasadena, CA 91125 USA.							Bourne Y, 1996, CELL, V84, P863, DOI 10.1016/S0092-8674(00)81065-X; BOURNE Y, 1995, P NATL ACAD SCI USA, V92, P10232, DOI 10.1073/pnas.92.22.10232; Crenshaw DG, 1998, EMBO J, V17, P1315, DOI 10.1093/emboj/17.5.1315; ENDICOTT JA, 1995, EMBO J, V14, P1004, DOI 10.1002/j.1460-2075.1995.tb07081.x; HOFFMANN I, 1993, EMBO J, V12, P53, DOI 10.1002/j.1460-2075.1993.tb05631.x; IZUMI T, 1992, MOL BIOL CELL, V3, P927, DOI 10.1091/mbc.3.8.927; IZUMI T, 1993, MOL BIOL CELL, V4, P1337, DOI 10.1091/mbc.4.12.1337; Kaiser P, 1999, GENE DEV, V13, P1190, DOI 10.1101/gad.13.9.1190; KUMAGAI A, 1992, CELL, V70, P139, DOI 10.1016/0092-8674(92)90540-S; Kumagai A, 1996, SCIENCE, V273, P1377, DOI 10.1126/science.273.5280.1377; Lu KP, 1996, NATURE, V380, P544; Lu PJ, 1999, SCIENCE, V283, P1325, DOI 10.1126/science.283.5406.1325; MCGOWAN CH, 1995, EMBO J, V14, P2166, DOI 10.1002/j.1460-2075.1995.tb07210.x; MORENO S, 1989, CELL, V58, P361, DOI 10.1016/0092-8674(89)90850-7; Morgan DO, 1997, ANNU REV CELL DEV BI, V13, P261, DOI 10.1146/annurev.cellbio.13.1.261; MUELLER PR, 1995, SCIENCE, V270, P86, DOI 10.1126/science.270.5233.86; Patra D, 1996, GENE DEV, V10, P1503, DOI 10.1101/gad.10.12.1503; Patra D, 1998, GENE DEV, V12, P2549, DOI 10.1101/gad.12.16.2549; Ranganathan R, 1997, CELL, V89, P875, DOI 10.1016/S0092-8674(00)80273-1; Shen MH, 1998, GENE DEV, V12, P706, DOI 10.1101/gad.12.5.706; Shteinberg M, 1999, BIOCHEM BIOPH RES CO, V257, P12, DOI 10.1006/bbrc.1999.0409; SOLOMON MJ, 1990, CELL, V63, P1013, DOI 10.1016/0092-8674(90)90504-8; Sudakin V, 1997, J BIOL CHEM, V272, P18051, DOI 10.1074/jbc.272.29.18051; TANG Y, 1993, GENE DEV, V7, P822, DOI 10.1101/gad.7.5.822; WATANABE N, 1995, EMBO J, V14, P1878, DOI 10.1002/j.1460-2075.1995.tb07180.x	25	92	93	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 24	1999	274	52					36839	36842		10.1074/jbc.274.52.36839	http://dx.doi.org/10.1074/jbc.274.52.36839			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	267WR	10601234	hybrid, Green Accepted			2022-12-25	WOS:000084382700005
J	Sasaki, Y; Takahashi, Y; Nakayama, K; Kamataki, T				Sasaki, Y; Takahashi, Y; Nakayama, K; Kamataki, T			Cooperative regulation of CYP2C12 gene expression by STAT5 and liver-specific factors in female rats	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SEX-SPECIFIC FORMS; GROWTH-HORMONE SECRETION; DNA-BINDING PROTEIN; TYROSINE PHOSPHORYLATION; PITUITARY REGULATION; NUCLEAR FACTOR; TRANSCRIPTIONAL ACTIVATION; SIGNAL TRANSDUCER; CYTOCHROME-P-450; RECEPTOR	The purpose of this study was to clarify the mechanism(s) responsible for the growth hormone (GH)-induced expression of the CYP2C12 gene. To identify a functional GH-responsive element (GHRF) in vivo, we performed the direct injection of promoter-luciferase chimeric genes into female rat livers. The results showed that the luciferase activity was decreased to approximately 20% by the deletion of the sequence between nucleotides -4213 and -4161, Within this region, two copies of a possible GHRE were present. The sequence of the GHRE was overlapped with that of an interferon-gamma-activated sequence, known to be recognized by the signal transducer and activator of transcription (STAT) proteins, In fact, a supershift assay showed that STAT5 was capable of binding to the core sequence of the GHRE. Furthermore, a luciferase assay with reporter plasmids, Delta-4161/-3781, mutated hepatocyte nuclear factor-4 (HNF-4), and mutated HNF-6, revealed that the GH-stimulated expression of the CYP2C12 gene was regulated cooperatively by STAT5, HNF-4, HNF-6, and the factor(s) that binds to the elements, 2C12-I (-4095 to -4074) and 2C12-II (-4072 to -4045), The cooperative regulation by STAT5 and the liver-enriched transcription factors account for the GH-dependent and the liver-specific expression of the CYP2C12 gene in female rats.	Hokkaido Univ, Grad Sch Pharmaceut Sci, Div Pharmacobiodynam, Lab Drug Metab,Kita Ku, Sapporo, Hokkaido 0600812, Japan	Hokkaido University	Kamataki, T (corresponding author), Hokkaido Univ, Grad Sch Pharmaceut Sci, Div Pharmacobiodynam, Lab Drug Metab,Kita Ku, N12W6, Sapporo, Hokkaido 0600812, Japan.	kamataki@pharm.hokudai.ac.jp						ARGETSINGER LS, 1993, CELL, V74, P237, DOI 10.1016/0092-8674(93)90415-M; Argetsinger LS, 1996, PHYSIOL REV, V76, P1089, DOI 10.1152/physrev.1996.76.4.1089; Buggs C, 1998, MOL ENDOCRINOL, V12, P1294, DOI 10.1210/me.12.9.1294; Cella N, 1998, MOL CELL BIOL, V18, P1783, DOI 10.1128/MCB.18.4.1783; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; COMB M, 1986, NATURE, V323, P353, DOI 10.1038/323353a0; COSTA RH, 1989, MOL CELL BIOL, V9, P1415, DOI 10.1128/MCB.9.4.1415; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; EDEN S, 1979, ENDOCRINOLOGY, V105, P555, DOI 10.1210/endo-105-2-555; Fernandez L, 1998, ENDOCRINOLOGY, V139, P1815, DOI 10.1210/en.139.4.1815; Gebert CA, 1999, MOL ENDOCRINOL, V13, P213, DOI 10.1210/me.13.2.213; Gebert CA, 1997, MOL ENDOCRINOL, V11, P400, DOI 10.1210/me.11.4.400; GORSKI K, 1986, CELL, V47, P767, DOI 10.1016/0092-8674(86)90519-2; GRONOWSKI AM, 1995, MOL ENDOCRINOL, V9, P171, DOI 10.1210/me.9.2.171; KAMATAKI T, 1985, J PHARMACOL EXP THER, V233, P222; KAMATAKI T, 1983, ARCH BIOCHEM BIOPHYS, V225, P758, DOI 10.1016/0003-9861(83)90087-5; KAMATAKI T, 1985, BIOCHEM BIOPH RES CO, V130, P1247, DOI 10.1016/0006-291X(85)91748-6; KATO R, 1986, J BIOCHEM-TOKYO, V100, P895, DOI 10.1093/oxfordjournals.jbchem.a121802; KHAN KD, 1993, P NATL ACAD SCI USA, V90, P6806, DOI 10.1073/pnas.90.14.6806; Lahuna O, 1997, P NATL ACAD SCI USA, V94, P12309, DOI 10.1073/pnas.94.23.12309; LAI E, 1991, GENE DEV, V5, P416, DOI 10.1101/gad.5.3.416; Lecine P, 1996, MOL CELL BIOL, V16, P6829; LEGRAVEREND C, 1992, MOL ENDOCRINOL, V6, P259, DOI 10.1210/me.6.2.259; MACGEOCH C, 1984, J BIOL CHEM, V259, P5433; MACGEOCH C, 1985, ENDOCRINOLOGY, V117, P2085, DOI 10.1210/endo-117-5-2085; MACGEOCH C, 1987, BIOCHEM BIOPH RES CO, V143, P782, DOI 10.1016/0006-291X(87)91422-7; MALONE RW, 1994, J BIOL CHEM, V269, P29903; MATTHEWS RP, 1994, MOL CELL BIOL, V14, P6107, DOI 10.1128/MCB.14.9.6107; MISKIMINS WK, 1985, P NATL ACAD SCI USA, V82, P6741, DOI 10.1073/pnas.82.20.6741; MODE A, 1993, J REPROD FERTIL, P77; NITSCH D, 1993, MOL CELL BIOL, V13, P4494, DOI 10.1128/MCB.13.8.4494; Ooi GT, 1998, MOL ENDOCRINOL, V12, P675, DOI 10.1210/me.12.5.675; Park SH, 1999, J BIOL CHEM, V274, P7421, DOI 10.1074/jbc.274.11.7421; Park YK, 1996, J BIOL CHEM, V271, P23725, DOI 10.1074/jbc.271.39.23725; Pfitzner E, 1998, MOL ENDOCRINOL, V12, P1582, DOI 10.1210/mend.12.10.0180; Ram PA, 1996, J BIOL CHEM, V271, P5929, DOI 10.1074/jbc.271.10.5929; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SLIVA D, 1994, J BIOL CHEM, V269, P26208; STROM A, 1995, J BIOL CHEM, V270, P11276, DOI 10.1074/jbc.270.19.11276; SUBRAMANIAN A, 1995, MOL CELL BIOL, V15, P4672; SUNDSETH SS, 1992, J BIOL CHEM, V267, P3907; TANNENBAUM GS, 1976, ENDOCRINOLOGY, V98, P562, DOI 10.1210/endo-98-3-562; TOLLET P, 1995, MOL ENDOCRINOL, V9, P1771, DOI 10.1210/me.9.12.1771; TOLLET P, 1995, J BIOL CHEM, V270, P12569, DOI 10.1074/jbc.270.21.12569; TSAI SF, 1989, NATURE, V339, P446, DOI 10.1038/339446a0; Varin-Blank N, 1998, P NATL ACAD SCI USA, V95, P8750, DOI 10.1073/pnas.95.15.8750; WAGNER BJ, 1990, EMBO J, V9, P4477, DOI 10.1002/j.1460-2075.1990.tb07898.x; WAKAO H, 1994, EMBO J, V13, P2182, DOI 10.1002/j.1460-2075.1994.tb06495.x; Waxman DJ, 1996, J BIOL CHEM, V271, P29978, DOI 10.1074/jbc.271.47.29978; WAXMAN DJ, 1995, J BIOL CHEM, V270, P13262, DOI 10.1074/jbc.270.22.13262; WEGENKA UM, 1993, MOL CELL BIOL, V13, P276, DOI 10.1128/MCB.13.1.276; WOOD TJJ, 1995, J BIOL CHEM, V270, P9448, DOI 10.1074/jbc.270.16.9448; YAMAZOE Y, 1986, JPN J PHARMACOL, V42, P371, DOI 10.1254/jjp.42.371; ZAPHIROPOULOS PG, 1990, DNA CELL BIOL, V9, P49, DOI 10.1089/dna.1990.9.49; ZAPHIROPOULOS PG, 1988, P NATL ACAD SCI USA, V85, P4214, DOI 10.1073/pnas.85.12.4214	55	33	34	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 24	1999	274	52					37117	37124		10.1074/jbc.274.52.37117	http://dx.doi.org/10.1074/jbc.274.52.37117			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	267WR	10601272	hybrid			2022-12-25	WOS:000084382700043
J	Broyles, SS; Liu, X; Zhu, M; Kremer, M				Broyles, SS; Liu, X; Zhu, M; Kremer, M			Transcription factor YY1 is a vaccinia virus late promoter activator	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELLULAR PROTEIN; REGULATOR YY1; BINDING-SITES; GENES; PURIFICATION; DNA; TRANSACTIVATION; IDENTIFICATION; REPRESSION; SEQUENCE	Vaccinia virus has a DNA genome, yet replicates in the cytoplasmic compartment of the cell, We previously described the identification of a cellular protein having high affinity for vaccinia virus late promoter DNA. Sequence substitutions in the vaccinia I1L promoter were used to define a 5-nucleotide block at the transcription initiation site as essential for interaction with the protein. Within this sequence is the recognition motif for the nuclear transcription factor YY1. This factor regulates a multitude of cellular promoters, as an activator of transcription, as a repressor, or as an initiator element-binding protein. Antibodies directed against YY1 were used to show that YY1 copurified with the vaccinia late promoter-binding protein and was present in late promoter-protein complexes in gel supershift assays. Bacterially expressed YY1 also bound specifically to late promoter DNA. A dinucleotide replacement within the YY1 recognition motif directly adjacent to the transcription start site severely reduced the affinity of YY1 for the I1L promoter in vitro and impaired I1L promoter-dependent transcription in vivo. The intracellular localization of YY1 was shown by immunofluorescence microscopy to shift from primarily nuclear to the cytoplasm after vaccinia infection. These results indicate that YY1 has a positive role in the regulation of vaccinia virus late gene transcription and suggest that poxviruses have adapted cellular initiator elements as a means of regulating viral gene expression. This is the first identifiable cellular protein implicated in poxvirus transcription.	Purdue Univ, Dept Biochem, W Lafayette, IN 47907 USA	Purdue University System; Purdue University; Purdue University West Lafayette Campus	Broyles, SS (corresponding author), Purdue Univ, Dept Biochem, W Lafayette, IN 47907 USA.	broyles@biochem.purdue.edu						Austen M, 1997, J BIOL CHEM, V272, P1709, DOI 10.1074/jbc.272.3.1709; BAUKNECHT T, 1992, EMBO J, V11, P4607, DOI 10.1002/j.1460-2075.1992.tb05563.x; Bell A, 1998, VIROLOGY, V252, P149, DOI 10.1006/viro.1998.9440; BERTHOLET C, 1987, CELL, V50, P153, DOI 10.1016/0092-8674(87)90211-X; BROYLES SS, 1988, J BIOL CHEM, V263, P10754; CHEN S, 1992, J VIROL, V66, P4304, DOI 10.1128/JVI.66.7.4304-4314.1992; DAVISON AJ, 1989, J MOL BIOL, V210, P771, DOI 10.1016/0022-2836(89)90108-3; DIGNAM JD, 1990, METHOD ENZYMOL, V182, P194; Gunasinghe SK, 1998, J BIOL CHEM, V273, P27524, DOI 10.1074/jbc.273.42.27524; HARLOW E, 1988, ANTIBODIES LAB MANUA, P386; Heinemeyer T, 1999, NUCLEIC ACIDS RES, V27, P318, DOI 10.1093/nar/27.1.318; Houbaviy HB, 1996, P NATL ACAD SCI USA, V93, P13577, DOI 10.1073/pnas.93.24.13577; Hu XL, 1998, J VIROL, V72, P104, DOI 10.1128/JVI.72.1.104-112.1998; HYDEDERUYSCHER RP, 1995, NUCLEIC ACIDS RES, V23, P4457, DOI 10.1093/nar/23.21.4457; KECK JG, 1990, CELL, V61, P801, DOI 10.1016/0092-8674(90)90190-P; Knossl M, 1999, J VIROL, V73, P1254; Kovacs GR, 1996, J VIROL, V70, P6796, DOI 10.1128/JVI.70.10.6796-6802.1996; Martelli F, 1996, J VIROL, V70, P1433, DOI 10.1128/JVI.70.3.1433-1438.1996; MIKAELIAN I, 1992, NUCLEIC ACIDS RES, V20, P326; Miller JH., 1972, EXPT MOL GENETICS; Mobley CM, 1998, J VIROL, V72, P6592, DOI 10.1128/JVI.72.8.6592-6601.1998; MOMOEDA M, 1994, J VIROL, V68, P7159, DOI 10.1128/JVI.68.11.7159-7168.1994; MOSS B, 1968, J VIROL, V2, P1028, DOI 10.1128/JVI.2.10.1028-1037.1968; Moss B., 1996, FIELDS VIROLOGY, P2637; MOSS B, 1994, TRANSCRIPTION MECH R, P185; Pajunk HS, 1997, J GEN VIROL, V78, P3287, DOI 10.1099/0022-1317-78-12-3287; ROSALES R, 1994, P NATL ACAD SCI USA, V91, P3794, DOI 10.1073/pnas.91.9.3794; ROSEL JL, 1986, J VIROL, V60, P436, DOI 10.1128/JVI.60.2.436-449.1986; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SCHWER B, 1987, CELL, V50, P163, DOI 10.1016/0092-8674(87)90212-1; Senkevich TG, 1997, VIROLOGY, V233, P19, DOI 10.1006/viro.1997.8607; SHI Y, 1991, CELL, V67, P377, DOI 10.1016/0092-8674(91)90189-6; SHI Y, 1997, BIOCHIM BIOPHYS ACTA, V1332, P49; WRIGHT CF, 1993, J VIROL, V67, P7264, DOI 10.1128/JVI.67.12.7264-7270.1993; Zhu M, 1998, J VIROL, V72, P3893, DOI 10.1128/JVI.72.5.3893-3899.1998; ZOCK C, 1993, J VIROL, V67, P682, DOI 10.1128/JVI.67.2.682-693.1993	36	31	34	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 10	1999	274	50					35662	35667		10.1074/jbc.274.50.35662	http://dx.doi.org/10.1074/jbc.274.50.35662			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	264NG	10585445	hybrid			2022-12-25	WOS:000084187900057
J	Krupenko, SA; Wagner, C				Krupenko, SA; Wagner, C			Aspartate 142 is involved in both hydrolase and dehydrogenase catalytic centers of 10-formyltetrahydrofolate dehydrogenase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCINAMIDE RIBONUCLEOTIDE TRANSFORMYLASE; SITE-DIRECTED MUTAGENESIS; ESCHERICHIA-COLI; ACTIVE-SITE; RAT-LIVER; PROTEIN STABILITY; TERMINAL DOMAIN; BINDING-SITE; RESIDUES; FORMYLTRANSFERASE	The enzyme 10-formyltetrahydrofolate dehydrogenase (FDH) catalyzes conversion of 10-formyltetrahydrofolate to tetrahydrofolate in either a dehydrogenase or hydrolase reaction, The hydrolase reaction occurs in a 310-residue amino-terminal domain of FDH (N-t-FDH), whereas the dehydrogenase reaction requires the full-length enzyme. N-t-FDH shares some sequence identity with several 10-formyltetrahydrofolate-utilizing enzymes. All these enzymes have a strictly conserved aspartate, which is Asp(142) in the case of N-t-FDH. Replacement of the aspartate with alanine, asparagine, glutamate, or glutamine in N-t-FDH resulted in complete loss of hydrolase activity, All the mutants, however, were able to bind folate, although with lower affinity than wild-type N-t-FDH, Six other aspartate residues located near the conserved Asp(142) Were substituted with an alanine, and these substitutions did not result in any significant changes in the hydrolase activity, The expressed D142A mutant of the full-length enzyme completely lost both hydrolase and dehydrogenase activities. This study shows that Asp(142) is an essential residue in the enzyme mechanism for both the hydrolase and dehydrogenase reactions of FDH, suggesting that either the two catalytic centers of FDH are overlapped or the dehydrogenase reaction occurs within the hydrolase catalytic center.	Vanderbilt Univ, Sch Med, Dept Biochem, Nashville, TN 37232 USA; Dept Vet Affairs Med Ctr, Res Serv, Nashville, TN 37212 USA	Vanderbilt University; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Tennessee Valley Healthcare System	Krupenko, SA (corresponding author), Med Univ S Carolina, Dept Biochem & Mol Biol, Charleston, SC 29425 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK015289, R01DK015289, R01DK046788, P30DK026657] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK26657-19, DK46788, DK15289] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALBER T, 1989, ANNU REV BIOCHEM, V58, P765, DOI 10.1146/annurev.biochem.58.1.765; ALMASSY RJ, 1992, P NATL ACAD SCI USA, V89, P6114, DOI 10.1073/pnas.89.13.6114; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; CANDY JM, 1994, BIOCHEM J, V300, P7, DOI 10.1042/bj3000007; Chen PF, 1998, J BIOL CHEM, V273, P34164, DOI 10.1074/jbc.273.51.34164; CHOW SF, 1985, J BIOL CHEM, V260, P5516; COOK RJ, 1991, J BIOL CHEM, V266, P4965; EFTINK MR, 1981, ANAL BIOCHEM, V114, P199, DOI 10.1016/0003-2697(81)90474-7; Eftink MR, 1997, METHOD ENZYMOL, V278, P221; Ekberg M, 1998, J BIOL CHEM, V273, P21003, DOI 10.1074/jbc.273.33.21003; FERSHT AR, 1988, BIOCHEMISTRY-US, V27, P1577, DOI 10.1021/bi00405a027; GIBBS CS, 1991, J BIOL CHEM, V266, P8923; GUILLON JM, 1992, J BACTERIOL, V174, P4294, DOI 10.1128/JB.174.13.4294-4301.1992; HORNE DW, 1989, ARCH BIOCHEM BIOPHYS, V270, P729, DOI 10.1016/0003-9861(89)90556-0; INGLESE J, 1990, BIOCHEMISTRY-US, V29, P6678, DOI 10.1021/bi00480a018; Ketchum CJ, 1998, J BIOL CHEM, V273, P22292, DOI 10.1074/jbc.273.35.22292; Kim DW, 1996, BIOCHEMISTRY-US, V35, P15772, DOI 10.1021/bi9619684; Kirksey TJ, 1996, ARCH BIOCHEM BIOPHYS, V333, P251, DOI 10.1006/abbi.1996.0388; KLEIN C, 1995, J MOL BIOL, V249, P153, DOI 10.1006/jmbi.1995.0286; Krupenko SA, 1997, J BIOL CHEM, V272, P10266; Krupenko SA, 1997, J BIOL CHEM, V272, P10273; KRUPENKO SA, 1995, J BIOL CHEM, V270, P519, DOI 10.1074/jbc.270.2.519; Krupenko SA, 1998, PROTEIN EXPRES PURIF, V14, P146, DOI 10.1006/prep.1998.0937; KRUPENKO SA, 1995, BIOCHEM J, V306, P651, DOI 10.1042/bj3060651; KRUPENKO SA, 1995, PROTEIN EXPRES PURIF, V6, P457, DOI 10.1006/prep.1995.1061; KUTZBACH C, 1971, METHODS ENZYMOL B, V18, P793; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEARY JJ, 1983, P NATL ACAD SCI-BIOL, V80, P4045, DOI 10.1073/pnas.80.13.4045; LEMOUAL H, 1994, EUR J BIOCHEM, V221, P475; Lobau S, 1997, J BIOL CHEM, V272, P3648, DOI 10.1074/jbc.272.6.3648; MacKenzie R E, 1984, FOLATES PTERINS CHEM, V1, P255; MATTHEWS BW, 1987, BIOCHEMISTRY-US, V26, P6885, DOI 10.1021/bi00396a001; NAGY PL, 1995, J BACTERIOL, V177, P1292, DOI 10.1128/jb.177.5.1292-1298.1995; Osaka H, 1998, J BIOL CHEM, V273, P12758, DOI 10.1074/jbc.273.21.12758; PAKULA AA, 1990, NATURE, V344, P363, DOI 10.1038/344363a0; Pickard RT, 1996, J BIOL CHEM, V271, P19225, DOI 10.1074/jbc.271.32.19225; Pikuleva IA, 1999, J BIOL CHEM, V274, P2045, DOI 10.1074/jbc.274.4.2045; Rayl EA, 1996, J BIOL CHEM, V271, P2225, DOI 10.1074/jbc.271.4.2225; Richieri GV, 1997, J BIOL CHEM, V272, P16737, DOI 10.1074/jbc.272.27.16737; RIOSORLANDI EM, 1986, BIOCHIM BIOPHYS ACTA, V871, P24, DOI 10.1016/0167-4838(86)90129-9; Schmitt E, 1996, EMBO J, V15, P4749, DOI 10.1002/j.1460-2075.1996.tb00852.x; Schultz LW, 1998, BIOCHEMISTRY-US, V37, P8886, DOI 10.1021/bi972766q; SCRUTTON MC, 1979, BIOCHEM J, V177, P833, DOI 10.1042/bj1770833; SMITH GK, 1981, BIOCHEMISTRY-US, V20, P1241, DOI 10.1021/bi00508a029; Su Y, 1998, J MOL BIOL, V281, P485, DOI 10.1006/jmbi.1998.1931; TEPHLY TR, 1991, LIFE SCI, V48, P1031, DOI 10.1016/0024-3205(91)90504-5; Turko IV, 1998, J BIOL CHEM, V273, P6460, DOI 10.1074/jbc.273.11.6460; Wagner C, 1995, FOLATE HLTH DIS, P23; Warren MS, 1996, BIOCHEMISTRY-US, V35, P8855, DOI 10.1021/bi9528715; WELLS JA, 1987, P NATL ACAD SCI USA, V84, P1219, DOI 10.1073/pnas.84.5.1219; WOODCOCK SC, 1994, BIOCHEMISTRY-US, V33, P2688, DOI 10.1021/bi00175a043; Yuan CS, 1996, J BIOL CHEM, V271, P28009, DOI 10.1074/jbc.271.45.28009	53	14	15	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 10	1999	274	50					35777	35784		10.1074/jbc.274.50.35777	http://dx.doi.org/10.1074/jbc.274.50.35777			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	264NG	10585460	hybrid			2022-12-25	WOS:000084187900072
J	Wada, H; Yeh, ETH; Kamitani, T				Wada, H; Yeh, ETH; Kamitani, T			The von Hippel-Lindau tumor suppressor gene product promotes, but is not essential for, NEDD8 conjugation to Cullin-2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UBIQUITIN-LIKE PROTEIN; NUCLEAR-PORE COMPLEX; SENTRIN FAMILY; VHL GENE; MUTATIONS; DISEASE; RANGAP1; MEMBER; PML	We have previously shown that human cullin-2 (Cul-2) is covalently modified at Lys-689 by NEDD8 (Wada, H., Yeh, E. T. H., and Kamitani, T. (1999) Biochem. Biophys. Res. Commun. 257, 100-105). Cul-2 has also been reported to form a multiprotein complex, Cul-2 VBC, with the von Hippel-Lindau tumor suppressor gene product (pVHL) and elongins B and C. In this study, using an in vivo coexpression system in COS cells, we show that NEDD8 conjugation to Cul-2 is promoted by coexpression with wild-type pVHL and elongins B and C. Interestingly, tumorigenic mutants and deletion mutants of pVHL, which are unable to form a Cul-2 VBC complex, do not have the activity to promote NEDD8 conjugation to Cul-2, These results suggest that the complex formation is required for NEDD8 conjugation to Cul-2. Furthermore, we used a pVHL-deficient cell. line, 786-0, to show that Cul-2 is poorly but clearly conjugated by NEDD8, indicating that pVHL is not the only molecule that promotes NEDD8 conjugation to Cul-2. Taken together, the VBC complex appears to have ligase activity in the conjugation of NEDD8 to Cul-2.	Univ Texas, Hlth Sci Ctr, Div Mol Med, Dept Internal Med, Houston, TX 77030 USA; Univ Texas, Res Ctr Cardiovasc Dis, Inst Mol Med, Houston, TX 77030 USA	University of Texas System; University of Texas Health Science Center Houston; University of Texas System	Kamitani, T (corresponding author), Univ Texas, Hlth Sci Ctr, Div Mol Med, Dept Internal Med, 6431 Fannin,Suite 4-200, Houston, TX 77030 USA.	tetsuk@heart.med.uth.tmc.edu		Kamitani, Tetsu/0000-0002-3257-9630	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL045851] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK056298] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-45851] Funding Source: Medline; NIDDK NIH HHS [1 RO1 DK56298-01] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bai C, 1996, CELL, V86, P263, DOI 10.1016/S0092-8674(00)80098-7; Boddy MN, 1996, ONCOGENE, V13, P971; DUAN DR, 1995, SCIENCE, V269, P1402, DOI 10.1126/science.7660122; GARRETT KP, 1995, P NATL ACAD SCI USA, V92, P7172, DOI 10.1073/pnas.92.16.7172; Gnarra JR, 1996, BBA-REV CANCER, V1242, P201, DOI 10.1016/0304-419X(95)00012-5; GNARRA JR, 1994, NAT GENET, V7, P85, DOI 10.1038/ng0594-85; Gong LM, 1999, J BIOL CHEM, V274, P12036, DOI 10.1074/jbc.274.17.12036; HAAS AL, 1987, J BIOL CHEM, V262, P11315; Hatakeyama S, 1999, P NATL ACAD SCI USA, V96, P3859, DOI 10.1073/pnas.96.7.3859; Hochstrasser M, 1998, GENE DEV, V12, P901, DOI 10.1101/gad.12.7.901; Iliopoulos O, 1997, MOL MED, V3, P289, DOI 10.1007/BF03401807; ILIOPOULOS O, 1995, NAT MED, V1, P822, DOI 10.1038/nm0895-822; Kaelin WG, 1999, NATURE, V399, P203, DOI 10.1038/20309; Kamitani T, 1997, J BIOL CHEM, V272, P28557, DOI 10.1074/jbc.272.45.28557; Kamitani T, 1998, J BIOL CHEM, V273, P3117, DOI 10.1074/jbc.273.6.3117; Kamitani T, 1998, J BIOL CHEM, V273, P11349, DOI 10.1074/jbc.273.18.11349; Kamitani T, 1997, J BIOL CHEM, V272, P22307, DOI 10.1074/jbc.272.35.22307; Kipreos ET, 1996, CELL, V85, P829, DOI 10.1016/S0092-8674(00)81267-2; Kitagawa M, 1999, EMBO J, V18, P2401, DOI 10.1093/emboj/18.9.2401; Kroll M, 1999, J BIOL CHEM, V274, P7941, DOI 10.1074/jbc.274.12.7941; KUMAR S, 1993, BIOCHEM BIOPH RES CO, V195, P393, DOI 10.1006/bbrc.1993.2056; Latres E, 1999, ONCOGENE, V18, P849, DOI 10.1038/sj.onc.1202653; Liakopoulos D, 1999, P NATL ACAD SCI USA, V96, P5510, DOI 10.1073/pnas.96.10.5510; LINEHAN WM, 1995, JAMA-J AM MED ASSOC, V273, P564; Lonergan KM, 1998, MOL CELL BIOL, V18, P732, DOI 10.1128/MCB.18.2.732; Mahajan R, 1997, CELL, V88, P97, DOI 10.1016/S0092-8674(00)81862-0; Matunis MJ, 1996, J CELL BIOL, V135, P1457, DOI 10.1083/jcb.135.6.1457; Maxwell PH, 1999, NATURE, V399, P271, DOI 10.1038/20459; Okura T, 1996, J IMMUNOL, V157, P4277; Osaka F, 1998, GENE DEV, V12, P2263, DOI 10.1101/gad.12.15.2263; Pause A, 1997, P NATL ACAD SCI USA, V94, P2156, DOI 10.1073/pnas.94.6.2156; Stebbins CE, 1999, SCIENCE, V284, P455, DOI 10.1126/science.284.5413.455; Suzuki H, 1999, BIOCHEM BIOPH RES CO, V256, P127, DOI 10.1006/bbrc.1999.0289; Wada H, 1998, BIOCHEM BIOPH RES CO, V251, P688, DOI 10.1006/bbrc.1998.9532; Wada H, 1999, BIOCHEM BIOPH RES CO, V257, P100, DOI 10.1006/bbrc.1999.0339; Zbar B, 1996, HUM MUTAT, V8, P348, DOI 10.1002/(SICI)1098-1004(1996)8:4<348::AID-HUMU8>3.0.CO;2-3	36	26	26	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 10	1999	274	50					36025	36029		10.1074/jbc.274.50.36025	http://dx.doi.org/10.1074/jbc.274.50.36025			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	264NG	10585493	hybrid			2022-12-25	WOS:000084187900105
J	Ender, F; Hallmann, A; Amon, P; Sumper, M				Ender, F; Hallmann, A; Amon, P; Sumper, M			Response to the sexual pheromone and wounding in the green alga Volvox: Induction of an extracellular glycoprotein consisting almost exclusively of hydroxyproline	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL WALL PROTEIN; RICH GLYCOPROTEIN; CARTERI; MATRIX; GENE; CHLAMYDOMONAS; PURIFICATION; TRANSFORMATION; AMPLIFICATION; ARCHITECTURE	The extracellular matrix (ECM) of Volvox is modified during development or in response to external stimuli, like the sex-inducing pheromone. It has recently been demonstrated that a number of genes triggered by the sex-inducing pheromone are also inducible by wounding. By differential screening of a cDNA library, a novel gene was identified that is transcribed in response to the pheromone. Its gene product was characterized as an ECM glycoprotein with a striking feature: it exhibits a hydroxyproline content of 68% and therefore is an extreme member of the family of hydroxyproline-rich glycoproteins (HRGPs), HRGPs are known as constituents of higher plant ECMs and seem to function as structural barriers in defense responses. The Volvox HRGP is also found to be inducible by wounding. This indicates that the wound response scenarios of higher plants and multicellular green algae may be evolutionary related.	Univ Regensburg, Lehrstuhl Biochem 1, D-93053 Regensburg, Germany	University of Regensburg	Hallmann, A (corresponding author), Univ Regensburg, Lehrstuhl Biochem 1, Univ Str 31, D-93053 Regensburg, Germany.		Hallmann, Armin/G-5823-2011	Hallmann, Armin/0000-0001-5977-6143				ADAIR WS, 1987, J CELL BIOL, V105, P2373, DOI 10.1083/jcb.105.5.2373; ANDRES DA, 1993, J BIOL CHEM, V268, P1383; ArsenijevicMaksimovic I, 1997, MOL PLANT MICROBE IN, V10, P95, DOI 10.1094/MPMI.1997.10.1.95; BRADLEY DJ, 1992, CELL, V70, P21, DOI 10.1016/0092-8674(92)90530-P; COHEN SA, 1988, ANAL BIOCHEM, V174, P1, DOI 10.1016/0003-2697(88)90512-X; COOPER JB, 1984, STRUCTURE FUNCTION B, P75; DOMEN PL, 1990, J CHROMATOGR, V510, P293, DOI 10.1016/S0021-9673(01)93763-X; ERTL H, 1989, J CELL BIOL, V109, P3493, DOI 10.1083/jcb.109.6.3493; FRISCHAUF AM, 1983, J MOL BIOL, V170, P827, DOI 10.1016/S0022-2836(83)80190-9; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; GILLES R, 1983, NATURWISSENSCHAFTEN, V70, P571, DOI 10.1007/BF00376679; GODL K, 1995, PLANTA, V196, P781, DOI 10.1007/BF01106774; Godl K, 1997, EMBO J, V16, P25, DOI 10.1093/emboj/16.1.25; GOODENOUGH UW, 1985, J CELL BIOL, V101, P1550, DOI 10.1083/jcb.101.4.1550; HAAS E, 1991, FEBS LETT, V294, P282, DOI 10.1016/0014-5793(91)81449-I; HALLMANN A, 1994, P NATL ACAD SCI USA, V91, P11562, DOI 10.1073/pnas.91.24.11562; HALLMANN A, 1994, EUR J BIOCHEM, V221, P143, DOI 10.1111/j.1432-1033.1994.tb18723.x; Hallmann A, 1997, P NATL ACAD SCI USA, V94, P7469, DOI 10.1073/pnas.94.14.7469; Hallmann A, 1996, P NATL ACAD SCI USA, V93, P669, DOI 10.1073/pnas.93.2.669; Hengen PN, 1996, TRENDS BIOCHEM SCI, V21, P33, DOI 10.1016/0968-0004(96)80884-X; HENIKOFF S, 1984, GENE, V28, P351, DOI 10.1016/0378-1119(84)90153-7; HORTON RM, 1989, GENE, V77, P61, DOI 10.1016/0378-1119(89)90359-4; JOHN ME, 1995, PLANT PHYSIOL, V108, P669, DOI 10.1104/pp.108.2.669; KELLER B, 1989, GENE DEV, V3, P1639, DOI 10.1101/gad.3.10.1639; KIELISZEWSKI MJ, 1994, PLANT J, V5, P157, DOI 10.1046/j.1365-313X.1994.05020157.x; KIM HJ, 1994, BIOTECHNIQUES, V16, P576; KIRK DL, 1986, SCIENCE, V231, P51, DOI 10.1126/science.3941891; KIRK DL, 1986, J CELL SCI, V80, P207; Knox JP, 1997, INT REV CYTOL, V171, P79; KNOX JP, 1995, FASEB J, V9, P1004, DOI 10.1096/fasebj.9.11.7544308; KURZ EM, 1991, J CELL BIOL, V115, P1159, DOI 10.1083/jcb.115.4.1159; LEACH JE, 1982, PLANT PHYSIOL, V70, P1353, DOI 10.1104/pp.70.5.1353; MCCONLOGUE L, 1988, NUCLEIC ACIDS RES, V16, P9869, DOI 10.1093/nar/16.20.9869; MELLON JE, 1982, PLANT PHYSIOL, V70, P401, DOI 10.1104/pp.70.2.401; MILLER DH, 1974, J CELL BIOL, V63, P420, DOI 10.1083/jcb.63.2.420; MORT AJ, 1977, ANAL BIOCHEM, V82, P289, DOI 10.1016/0003-2697(77)90165-8; POMP D, 1991, BIOTECHNIQUES, V10, P58; Provasoli L., 1960, Special Publications Pymatuning Laboratory of Field Ecology, VNo. 2, P84; Sambrook J., 2002, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHIEDLMEIER B, 1994, P NATL ACAD SCI USA, V91, P5080, DOI 10.1073/pnas.91.11.5080; SHOWALTER AM, 1989, BIOCH PLANTS, V15, P485; Showalter AM, 1990, ORG ASSEMBLY PLANT A, P247; Starr R. C., 1969, Archiv fuer Protistenkunde, V111, P204; STARR RC, 1974, P NATL ACAD SCI USA, V71, P1050, DOI 10.1073/pnas.71.4.1050; STARR RC, 1970, DEVELOP BIOL       S, V4, P59; SUMPER M, 1993, EMBO J, V12, P831, DOI 10.1002/j.1460-2075.1993.tb05723.x; Sumper M, 1998, INT REV CYTOL, V180, P51; VARNER JE, 1989, CELL, V56, P231, DOI 10.1016/0092-8674(89)90896-9; WENZL S, 1984, EMBO J, V3, P739, DOI 10.1002/j.1460-2075.1984.tb01877.x; WENZL S, 1982, FEBS LETT, V143, P311, DOI 10.1016/0014-5793(82)80123-3; WENZL S, 1986, DEV BIOL, V115, P119, DOI 10.1016/0012-1606(86)90233-2	52	24	24	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 3	1999	274	49					35023	35028		10.1074/jbc.274.49.35023	http://dx.doi.org/10.1074/jbc.274.49.35023			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	260XW	10574980	hybrid			2022-12-25	WOS:000083979600074
J	Pacini, A; Quattrone, A; Denegri, M; Fiorillo, C; Nediani, C; Cajal, SRY; Nassi, P				Pacini, A; Quattrone, A; Denegri, M; Fiorillo, C; Nediani, C; Cajal, SRY; Nassi, P			Transcriptional down-regulation of poly(ADP-ribose) polymerase gene expression by E1A binding to pRb proteins protects murine keratinocytes from radiation-induced apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-DAMAGING AGENTS; FUNCTIONAL INTERACTIONS; CELLULAR PROTEINS; SP1 BINDING; RB PROTEIN; CELLS; INDUCTION; REGION; P53; TRANSFORMATION	Adenovirus E1A confers enhanced cell sensitivity to radiation and drug-induced DNA damage by a mechanism involving the binding to cellular proteins. Mutant analysis in E1A-transfected murine keratinocytes demonstrates that increased sensitivity to DNA damage requires at least E1A binding to the p300/CREB-binding protein (CBP) transcriptional coactivators and to pRb family members, indicating that this biological activity of E1A is the result of the concomitant perturbation of different cell pathways. Here we show that in the same cells E1A binding to members of the retinoblastoma protein family induces transcriptional down-regulation of the poly(ADP-ribose) polymerase (PARP) gene, coding for a NAD-dependent enzyme stimulated by DNA breaks, Inhibition of PARP expression is accompanied by a decrement of gamma-irradiation-induced apoptosis, which is overridden by reconstitution of wild type levels of PARP. Hence, E1A effects on PARP transcription are central determinant of the apoptotic sensitivity of E1A-expressing keratinocytes, Conversely, E1A binding to only p300/CBP results in an increase in PARP enzyme activity and consequently in cell death susceptibility to irradiation, which is effectively counteracted by the PARP chemical inhibitor 3-aminobenzamide. Therefore, our results identify in the E1A-mediated effects on PARP expression and activity a key molecular event involved in E1A-induced cell sensitization to genotoxic stress.	Univ Florence, Dept Biochem Sci, I-50121 Florence, Italy; CNR, Inst Genet & Evolutionary Biochem, I-27100 Pavia, Italy; NINDS, Lab Adapt Syst, NIH, Bethesda, MD 20892 USA; Clin Puerta Hierro, Dept Pathol, Madrid 28035, Spain	University of Florence; Consiglio Nazionale delle Ricerche (CNR); National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS); Clinica Veterinaria Puerta de Hierro; Hospital Puerta de Hierro-Majadahonda	Pacini, A (corresponding author), Univ Florence, Dept Biochem Sci, I-50121 Florence, Italy.	alepacini@dada.it	Ramon y Cajal, Santiago/H-4955-2016; Nediani, Chiara/AAO-8919-2020; Espinosas, Maribel/H-8083-2012; denegri, marco/D-9307-2019; Nediani, Chiara/R-2201-2019	Ramon y Cajal, Santiago/0000-0002-3867-1390; Nediani, Chiara/0000-0003-3190-3539; denegri, marco/0000-0003-1665-0625; Quattrone, Alessandro/0000-0003-3333-7630; Fiorillo, Claudia/0000-0003-1165-1581				BARBEAU D, 1994, ONCOGENE, V9, P359; BARBEAU D, 1992, BIOCHEM CELL BIOL, V70, P1123, DOI 10.1139/o92-158; Bergeron MJ, 1997, EUR J BIOCHEM, V250, P342, DOI 10.1111/j.1432-1033.1997.0342a.x; CHOI DW, 1988, NEURON, V1, P623, DOI 10.1016/0896-6273(88)90162-6; DEMURCIA G, 1994, TRENDS BIOCHEM SCI, V19, P172, DOI 10.1016/0968-0004(94)90280-1; Eliasson MJL, 1997, NAT MED, V3, P1089, DOI 10.1038/nm1097-1089; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; JAYARAMAN L, 1995, CELL, V81, P1021, DOI 10.1016/S0092-8674(05)80007-8; JENSEN DE, 1995, J BIOL CHEM, V270, P6555, DOI 10.1074/jbc.270.12.6555; KIM SJ, 1992, MOL CELL BIOL, V12, P2455, DOI 10.1128/MCB.12.6.2455; LAMARRE D, 1988, BIOCHIM BIOPHYS ACTA, V64, P368; Le Rhun Y, 1998, BIOCHEM BIOPH RES CO, V245, P1; Lill NL, 1997, NATURE, V387, P823, DOI 10.1038/42981; Lo EH, 1998, STROKE, V29, P830, DOI 10.1161/01.STR.29.4.830; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; MISSERO C, 1991, P NATL ACAD SCI USA, V88, P3489, DOI 10.1073/pnas.88.8.3489; MORAN E, 1993, CURR OPIN GENET DEV, V3, P63, DOI 10.1016/S0959-437X(05)80342-9; Mothersill C, 1997, INT J RADIAT BIOL, V71, P421, DOI 10.1080/095530097144030; NELSON WG, 1994, MOL CELL BIOL, V14, P1815, DOI 10.1128/MCB.14.3.1815; Park GT, 1996, J GEN VIROL, V77, P2775, DOI 10.1099/0022-1317-77-11-2775; POTVIN F, 1993, EUR J BIOCHEM, V215, P73, DOI 10.1111/j.1432-1033.1993.tb18008.x; POTVIN F, 1992, FEBS LETT, V302, P269, DOI 10.1016/0014-5793(92)80457-R; Quattrone A, 1995, HAEMATOLOGICA, V80, P495; RAO L, 1992, P NATL ACAD SCI USA, V89, P7742, DOI 10.1073/pnas.89.16.7742; Samuelson AV, 1997, P NATL ACAD SCI USA, V94, P12094, DOI 10.1073/pnas.94.22.12094; SANCHEZPRIETO R, 1995, ONCOGENE, V11, P675; SanchezPrieto R, 1996, ONCOGENE, V13, P1083; SANCHEZPRIETO R, 1995, INT J CANCER, V60, P235; Scolnick DM, 1997, CANCER RES, V57, P3693; SCOVASSI AI, 1984, J BIOL CHEM, V259, P973; SEED B, 1988, GENE, V67, P271, DOI 10.1016/0378-1119(88)90403-9; Shao RP, 1997, J BIOL CHEM, V272, P32739, DOI 10.1074/jbc.272.52.32739; Shisler J, 1996, J VIROL, V70, P68, DOI 10.1128/JVI.70.1.68-77.1996; Somasundaram K, 1997, ONCOGENE, V14, P1047, DOI 10.1038/sj.onc.1201002; Szumiel I, 1998, RADIAT RES, V150, pS92, DOI 10.2307/3579811; UDVADIA AJ, 1995, P NATL ACAD SCI USA, V92, P3953, DOI 10.1073/pnas.92.9.3953; UDVADIA AJ, 1993, P NATL ACAD SCI USA, V90, P3265, DOI 10.1073/pnas.90.8.3265; WHYTE P, 1989, CELL, V56, P67, DOI 10.1016/0092-8674(89)90984-7; WHYTE P, 1988, J VIROL, V62, P257, DOI 10.1128/JVI.62.1.257-265.1988; YOKOYAMA Y, 1990, EUR J BIOCHEM, V194, P521, DOI 10.1111/j.1432-1033.1990.tb15647.x; YUSPA SH, 1980, CANCER RES, V40, P4694; ZANTEMA A, 1995, CURR TOP MICROBIOL I, V119, P1; ZHANG J, 1994, SCIENCE, V263, P687, DOI 10.1126/science.8080500	43	20	20	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 3	1999	274	49					35107	35112		10.1074/jbc.274.49.35107	http://dx.doi.org/10.1074/jbc.274.49.35107			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	260XW	10574992	Green Submitted, hybrid			2022-12-25	WOS:000083979600086
J	Zhang, Y; Neo, SY; Wang, XH; Han, JH; Lin, SC				Zhang, Y; Neo, SY; Wang, XH; Han, JH; Lin, SC			Axin forms a complex with MEKK1 and activates c-Jun NH2-terminal kinase/stress-activated protein kinase through domains distinct from Wnt signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KAPPA-B ACTIVATION; MOUSE FUSED LOCUS; BETA-CATENIN; FUNCTIONAL INTERACTION; TRANSDUCTION PATHWAYS; NEGATIVE REGULATOR; XENOPUS EMBRYOS; RGS PROTEINS; TRANSCRIPTION; APOPTOSIS	Axin negatively regulates the Wnt pathway during axis formation and plays a central role in cell growth control and tumorigenesis, We found that Axin also serves as a scaffold protein for mitogen-activated protein kinase activation and further determined the structural requirement for this activation. Overexpression of Axin in 293T cells leads to differential activation of mitogen-activated protein kinases, with robust induction for c-Jun NH2-terminal kinase (JNK)/stress-activated protein kinase, moderate induction for p38, and negligible induction for extracellular signal-regulated kinase, Axin forms a complex with MEKK1 through a novel domain that we term MEKK1-interacting domain, MKK4 and MKK7, which act do downstream of MEKK1, are also involved in Axin-mediated JNK activation. Domains essential in Wnt signaling, i.e, binding sites for adenomatous polyposis coli, glycogen synthase kinase-3 beta, and beta-catenin, are not required for JNK activation, suggesting distinct domain utilization between the Wnt pathway and JNK signal transduction. Dimerization/oligomerization of Axin through its C terminus is required for JNK activation, although MEKK1 is capable of binding C terminus-deleted monomeric Axin, Furthermore, Axin without the MEKK1-interacting domain has a dominant-negative effect on JNK activation by wild-type Axin, Our results suggest that Axin, in addition to its function in the Wnt pathway, may play a dual role in cells through its activation of JNK/stress-activated protein kinase signaling cascade.	Natl Univ Singapore, Inst Mol & Cell Biol, Regulatory Biol Lab, Singapore 117609, Singapore; Scripps Res Inst, Dept Immunol, La Jolla, CA 92037 USA	Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Molecular & Cell Biology (IMCB); National University of Singapore; Scripps Research Institute	Lin, SC (corresponding author), Natl Univ Singapore, Inst Mol & Cell Biol, Regulatory Biol Lab, 30 Med Dr, Singapore 117609, Singapore.		Lin, SC/G-4666-2010; Han, J/G-4671-2010	Zhang, Yi/0000-0003-2785-1780	NIAID NIH HHS [AI41637] Funding Source: Medline; NIGMS NIH HHS [GM51417] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI041637] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Adachi-Yamada T, 1999, NATURE, V400, P166, DOI 10.1038/22112; Behrens J, 1998, SCIENCE, V280, P596, DOI 10.1126/science.280.5363.596; Behrens J, 1996, NATURE, V382, P638, DOI 10.1038/382638a0; Berman DM, 1998, J BIOL CHEM, V273, P1269, DOI 10.1074/jbc.273.3.1269; Boutros M, 1998, CELL, V94, P109, DOI 10.1016/S0092-8674(00)81226-X; Brown JD, 1998, CURR OPIN CELL BIOL, V10, P182, DOI 10.1016/S0955-0674(98)80140-3; Cadigan KM, 1997, GENE DEV, V11, P3286, DOI 10.1101/gad.11.24.3286; Chang HY, 1998, SCIENCE, V281, P1860, DOI 10.1126/science.281.5384.1860; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; Dohlman HG, 1997, J BIOL CHEM, V272, P3871, DOI 10.1074/jbc.272.7.3871; Fagotto F, 1999, J CELL BIOL, V145, P741, DOI 10.1083/jcb.145.4.741; Fanger GR, 1998, J BIOL CHEM, V273, P3476, DOI 10.1074/jbc.273.6.3476; Garrington TP, 1999, CURR OPIN CELL BIOL, V11, P211, DOI 10.1016/S0955-0674(99)80028-3; GLUECKSOHNSCHOENHEIMER S, 1949, J EXP ZOOL, V110, P47, DOI 10.1002/jez.1401100105; Han JH, 1996, J BIOL CHEM, V271, P2886, DOI 10.1074/jbc.271.6.2886; Hart MJ, 1998, CURR BIOL, V8, P573, DOI 10.1016/S0960-9822(98)70226-X; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; Hsu W, 1999, J BIOL CHEM, V274, P3439, DOI 10.1074/jbc.274.6.3439; Ichijo H, 1997, SCIENCE, V275, P90, DOI 10.1126/science.275.5296.90; Ikeda S, 1998, EMBO J, V17, P1371, DOI 10.1093/emboj/17.5.1371; Itoh K, 1998, CURR BIOL, V8, P591, DOI 10.1016/S0960-9822(98)70229-5; Khokhlatchev AV, 1998, CELL, V93, P605, DOI 10.1016/S0092-8674(00)81189-7; Kishida M, 1999, ONCOGENE, V18, P979, DOI 10.1038/sj.onc.1202388; Kishida S, 1999, MOL CELL BIOL, V19, P4414; Kishida S, 1998, J BIOL CHEM, V273, P10823, DOI 10.1074/jbc.273.18.10823; KRAVCHENKO VV, 1995, J BIOL CHEM, V270, P14928, DOI 10.1074/jbc.270.25.14928; Li L, 1999, J BIOL CHEM, V274, P129, DOI 10.1074/jbc.274.1.129; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; Molenaar M, 1996, CELL, V86, P391, DOI 10.1016/S0092-8674(00)80112-9; Pennisi E, 1998, SCIENCE, V281, P1438, DOI 10.1126/science.281.5382.1438; PERRY WL, 1995, GENETICS, V141, P321; Pomerance M, 1998, J BIOL CHEM, V273, P24301, DOI 10.1074/jbc.273.38.24301; Reed SC, 1937, GENETICS, V22, P1; Robinson MJ, 1997, CURR OPIN CELL BIOL, V9, P180, DOI 10.1016/S0955-0674(97)80061-0; Sakanaka C, 1999, J BIOL CHEM, V274, P14090, DOI 10.1074/jbc.274.20.14090; Sakanaka C, 1998, P NATL ACAD SCI USA, V95, P3020, DOI 10.1073/pnas.95.6.3020; Schaeffer HJ, 1999, MOL CELL BIOL, V19, P2435; Strutt DI, 1997, NATURE, V387, P292, DOI 10.1038/387292a0; Su B, 1996, CURR OPIN IMMUNOL, V8, P402, DOI 10.1016/S0952-7915(96)80131-2; Tilghman SM, 1996, GENOME RES, V6, P773, DOI 10.1101/gr.6.9.773; Tournier C, 1997, P NATL ACAD SCI USA, V94, P7337, DOI 10.1073/pnas.94.14.7337; Vasicek TJ, 1997, GENETICS, V147, P777; WHITMARSH AJ, 1995, SCIENCE, V269, P403, DOI 10.1126/science.7618106; Willert K, 1999, GENE DEV, V13, P1768, DOI 10.1101/gad.13.14.1768; Wodarz A, 1998, ANNU REV CELL DEV BI, V14, P59, DOI 10.1146/annurev.cellbio.14.1.59; Xia Y, 1998, GENE DEV, V12, P3369, DOI 10.1101/gad.12.21.3369; YAMAGUCHI K, 1995, SCIENCE, V270, P2008, DOI 10.1126/science.270.5244.2008; Yamamoto H, 1998, MOL CELL BIOL, V18, P2867, DOI 10.1128/MCB.18.5.2867; Yamamoto H, 1999, J BIOL CHEM, V274, P10681, DOI 10.1074/jbc.274.16.10681; YANAGAWA SI, 1995, GENE DEV, V9, P1087, DOI 10.1101/gad.9.9.1087; Zeng L, 1997, CELL, V90, P181, DOI 10.1016/S0092-8674(00)80324-4; Zhang Y, 1999, J BIOL CHEM, V274, P2851, DOI 10.1074/jbc.274.5.2851	53	103	114	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 3	1999	274	49					35247	35254		10.1074/jbc.274.49.35247	http://dx.doi.org/10.1074/jbc.274.49.35247			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	260XW	10575011	hybrid			2022-12-25	WOS:000083979600105
J	Chen, G; Templeton, D; Suttle, DP; Stacey, DW				Chen, G; Templeton, D; Suttle, DP; Stacey, DW			Ras stimulates DNA topoisomerase II alpha through MEK: A link between oncogenic signaling and a therapeutic target	ONCOGENE			English	Article						topoisomerase II alpha; Ras; ERK; JNK; MEKK; cell cycle	ACTIVATED PROTEIN-KINASE; C-JUN; REGULATED KINASE; NIH-3T3 CELLS; MAP KINASES; TRANSFORMATION; GROWTH; EXPRESSION; PATHWAY; GENE	Topoisomerase II alpha (topo II alpha) is a major target of antitumor treatments. In an effort to determine why this protein might be a better target in tumor cells than in normal cells, we attempted to determine if the altered proliferative signaling in a tumor cell might effect the levels of expression of the topo II alpha gene. In support of this idea, it was found that topo II alpha was elevated following microinjection of oncogenic Ras protein. Oncogenic was was further shown to stimulate the topo II alpha promoter. Stimulation by pas was independent of the normal cell cycle regulation of this promoter. Transactivation of topo II alpha by ras required both the MEK/ERK pathway, and the stress-associated protein kinase (SAPK) signaling pathway. As a direct confirmation that both ERK and SAPK were involved in topo II alpha regulation, a constitutively active MEKK that stimulates these two kinases simultaneously was shown to strongly induce topo II alpha promoter activity. Activation of either pathway alone, on the other hand, only slightly stimulated the topo II alpha promoter. Deletion analyses showed that elements near both the 5' and 3' ends of the promoter were responsible for the ras stimulation. Site-directed mutagenesis further demonstrated that an Ets-like binding site near the 5' end (-480 to -475) was one of the responsive elements. Taken together, these studies demonstrate the direct role of Ras signaling in stimulation of topo II alpha expression, and thereby establish a link between the action of a common tumor mutation and the target of multiple anti-tumor reagents.	Cleveland Clin Fdn, Dept Mol Biol, Cleveland, OH 44195 USA; Univ Tennessee, Dept Pharmacol, Memphis, TN 38163 USA; Vet Adm Med Ctr, Res Serv, Memphis, TN 38104 USA; Case Western Reserve Univ, Inst Pathol, Cleveland, OH 44106 USA	Cleveland Clinic Foundation; University of Tennessee System; University of Tennessee Health Science Center; US Department of Veterans Affairs; Veterans Health Administration (VHA); Memphis VA Medical Center; Case Western Reserve University	Stacey, DW (corresponding author), Cleveland Clin Fdn, Dept Mol Biol, NC2-150, Cleveland, OH 44195 USA.		Templeton, Dennis J/F-7695-2011		NATIONAL CANCER INSTITUTE [R01CA047941] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM052271] Funding Source: NIH RePORTER; NCI NIH HHS [CA47941] Funding Source: Medline; NIGMS NIH HHS [GM52271] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; BARSAGI D, 1985, CELL, V42, P841, DOI 10.1016/0092-8674(85)90280-6; Berger JM, 1996, NATURE, V379, P225, DOI 10.1038/379225a0; Bhat MA, 1996, CELL, V87, P1103, DOI 10.1016/S0092-8674(00)81804-8; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; Bokemeyer D, 1996, J BIOL CHEM, V271, P639, DOI 10.1074/jbc.271.2.639; BOS JL, 1989, CANCER RES, V49, P4682; CHEN AY, 1994, ANNU REV PHARMACOL, V34, P191, DOI 10.1146/annurev.pa.34.040194.001203; Chen G, 1997, ONCOGENE, V15, P1643, DOI 10.1038/sj.onc.1201347; Chen YR, 1996, J BIOL CHEM, V271, P31929, DOI 10.1074/jbc.271.50.31929; Clark GJ, 1997, J BIOL CHEM, V272, P1677, DOI 10.1074/jbc.272.3.1677; Cook SJ, 1997, J BIOL CHEM, V272, P13309, DOI 10.1074/jbc.272.20.13309; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; DOBROWOLSKI S, 1994, MOL CELL BIOL, V10, P5314; DOWNES CS, 1994, NATURE, V372, P467, DOI 10.1038/372467a0; Gangarosa LM, 1997, J BIOL CHEM, V272, P18926, DOI 10.1074/jbc.272.30.18926; HAUSER CA, 1995, METHOD ENZYMOL, V255, P412; HOCHHAUSER D, 1992, J BIOL CHEM, V267, P18961; HOLM C, 1985, CELL, V41, P553, DOI 10.1016/S0092-8674(85)80028-3; HORTON RM, 1993, METHOD ENZYMOL, V217, P270; HSIANG YH, 1988, CANCER RES, V48, P3230; Hunter T, 1997, CELL, V88, P333, DOI 10.1016/S0092-8674(00)81872-3; Irani K, 1997, SCIENCE, V275, P1649, DOI 10.1126/science.275.5306.1649; Isaacs RJ, 1996, J BIOL CHEM, V271, P16741, DOI 10.1074/jbc.271.28.16741; Johnson R, 1996, MOL CELL BIOL, V16, P4504; KAUFMANN SH, 1991, CANCER RES, V51, P3534; Koo HM, 1996, CANCER RES, V56, P5211; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; LANGECARTER CA, 1993, SCIENCE, V260, P315, DOI 10.1126/science.8385802; LIN AN, 1995, SCIENCE, V268, P286, DOI 10.1126/science.7716521; LIU YS, 1995, J BIOL CHEM, V270, P8377, DOI 10.1074/jbc.270.15.8377; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; McCarthy SA, 1997, MOL CELL BIOL, V17, P2401, DOI 10.1128/MCB.17.5.2401; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; MULCAHY LS, 1985, NATURE, V313, P241, DOI 10.1038/313241a0; NELSON WG, 1987, CANCER RES, V47, P3246; RUSSELL M, 1995, J BIOL CHEM, V270, P11757, DOI 10.1074/jbc.270.20.11757; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; Sandri MI, 1996, NUCLEIC ACIDS RES, V24, P4464, DOI 10.1093/nar/24.22.4464; SMITH MR, 1986, NATURE, V320, P540, DOI 10.1038/320540a0; STACEY DW, 1984, NATURE, V310, P508, DOI 10.1038/310508a0; STACEY DW, 1994, EMBO J, V13, P6107, DOI 10.1002/j.1460-2075.1994.tb06957.x; STACEY DW, 1991, MOL CELL BIOL, V11, P4053, DOI 10.1128/MCB.11.8.4053; THOMAS SM, 1992, CELL, V68, P1031, DOI 10.1016/0092-8674(92)90075-N; Wang JC, 1996, ANNU REV BIOCHEM, V65, P635, DOI 10.1146/annurev.bi.65.070196.003223; Wang QJ, 1997, MOL CELL BIOL, V17, P389, DOI 10.1128/MCB.17.1.389; Waskiewicz AJ, 1997, EMBO J, V16, P1909, DOI 10.1093/emboj/16.8.1909; WATT PM, 1994, BIOCHEM J, V303, P681, DOI 10.1042/bj3030681; WESTWICK JK, 1994, P NATL ACAD SCI USA, V91, P6030, DOI 10.1073/pnas.91.13.6030; WOESSNER RD, 1990, CANCER RES, V50, P2901; WOESSNER RD, 1991, CELL GROWTH DIFFER, V2, P209; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; YAN MH, 1994, NATURE, V372, P798; YAN MH, 1994, J BIOL CHEM, V269, P19067	55	23	25	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 25	1999	18	50					7149	7160		10.1038/sj.onc.1203149	http://dx.doi.org/10.1038/sj.onc.1203149			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	259PH	10597316				2022-12-25	WOS:000083901900022
J	Robertson, K; Hensey, C; Gautier, J				Robertson, K; Hensey, C; Gautier, J			Isolation and characterization of Xenopus ATM (X-ATM): expression, localization, and complex formation during oogenesis and early development	ONCOGENE			English	Article						xenopus; ATM; development; cell cycle; checkpoints	ATAXIA-TELANGIECTASIA GENE; DNA-DAMAGE; IONIZING-RADIATION; PROTEIN-KINASE; DEFICIENT MICE; BREAST-CANCER; P53 PROTEIN; C-ABL; LAEVIS; ACTIVATION	ATM, the gene product mutated in Ataxia Telangiectasia (A-T) encodes a 350-KDa protein involved in the regulation of several cellular responses to DNA breaks. We used a degenerate PCR-based strategy to isolate a partial clone of X-ATM, the Xenopus homologue of human ATM. Sequence analysis and confirmed that the clone was most closely related to human ATM. Xenopus ATM protein (X-ATM) is 85% identical to human ATM within the kinase domain and 71% identical over the carboxyl-terminal half of the protein. Polyclonal antibodies raised against recombinant Ii-ATM are highly specific for the ATM protein and recognize a single polypeptide of 370-kDa in oocytes, embryos, egg extracts and a,Xenopus cell line. We found that X-ATM, mas expressed maternally in eggs and as early as stage II pre-vitellogenic oocytes, and the protein and mRNA sere present at relatively constant levels throughout development. Subcellular fractionation showed that the protein mas nuclear in both the female and male germlines. The level of X-ATM protein did not change throughout the meiotic divisions or the synchronous mitotic cycles of cleavage stage embryos. In addition, we did not observe any change in the level or mobility of X-ATM protein following ii-irradiation of embryos. Finally, we also demonstrated that X-ATM was present in a high molecular weight complex of approximately 500 kDa containing the X-ATM protein and other, as yet unidentified component(s).	Columbia Univ Coll Phys & Surg, Dept Genet & Dev, New York, NY 10032 USA; Columbia Univ Coll Phys & Surg, Dept Dermatol, New York, NY 10032 USA	Columbia University; Columbia University	Gautier, J (corresponding author), Columbia Univ Coll Phys & Surg, Dept Genet & Dev, 630 W 168th St, New York, NY 10032 USA.		Gautier, jean/A-2774-2008; Hensey, Carmel/L-7456-2013	Hensey, Carmel/0000-0003-3319-4094				Anderson JA, 1997, MOL BIOL CELL, V8, P1195, DOI 10.1091/mbc.8.7.1195; Athma P, 1996, CANCER GENET CYTOGEN, V92, P130, DOI 10.1016/S0165-4608(96)00328-7; Banin S, 1998, SCIENCE, V281, P1674, DOI 10.1126/science.281.5383.1674; Barlow C, 1998, DEVELOPMENT, V125, P4007; Barlow C, 1996, CELL, V86, P159, DOI 10.1016/S0092-8674(00)80086-0; Baskaran R, 1997, NATURE, V387, P516, DOI 10.1038/387516a0; Beamish H, 1996, J BIOL CHEM, V271, P20486, DOI 10.1074/jbc.271.34.20486; BODER E, 1970, PSYCHIAT NEUROL MED, V14, P8; Brown AL, 1999, P NATL ACAD SCI USA, V96, P3745, DOI 10.1073/pnas.96.7.3745; Brown KD, 1997, P NATL ACAD SCI USA, V94, P1840, DOI 10.1073/pnas.94.5.1840; Canman CE, 1998, SCIENCE, V281, P1677, DOI 10.1126/science.281.5383.1677; Chen G, 1996, J BIOL CHEM, V271, P33693, DOI 10.1074/jbc.271.52.33693; Chen JD, 1998, CANCER RES, V58, P1376; Chen P, 1999, ONCOGENE, V18, P249, DOI 10.1038/sj.onc.1202257; Concannon P, 1997, HUM MUTAT, V10, P100, DOI 10.1002/(SICI)1098-1004(1997)10:2<100::AID-HUMU2>3.0.CO;2-O; COX LS, 1994, ONCOGENE, V9, P2951; DASSO M, 1990, CELL, V61, P811, DOI 10.1016/0092-8674(90)90191-G; DREYER C, 1983, DEV BIOL, V100, P412, DOI 10.1016/0012-1606(83)90235-X; DUMONT JN, 1972, J MORPHOL, V136, P153, DOI 10.1002/jmor.1051360203; Elson A, 1996, P NATL ACAD SCI USA, V93, P13084, DOI 10.1073/pnas.93.23.13084; FORD CC, 1977, J EMBRYOL EXP MORPH, V37, P203; Gately DP, 1998, MOL BIOL CELL, V9, P2361, DOI 10.1091/mbc.9.9.2361; GAUTIER J, 1991, EMBO J, V10, P177, DOI 10.1002/j.1460-2075.1991.tb07934.x; Hendrickson M, 1996, P NATL ACAD SCI USA, V93, P12223, DOI 10.1073/pnas.93.22.12223; Hensey C, 1995, Prog Cell Cycle Res, V1, P149; Hensey C, 1997, MECH DEVELOP, V69, P183, DOI 10.1016/S0925-4773(97)00191-3; Herzog KH, 1998, SCIENCE, V280, P1089, DOI 10.1126/science.280.5366.1089; Hoekstra MF, 1997, CURR OPIN GENET DEV, V7, P170, DOI 10.1016/S0959-437X(97)80125-6; Khanna KK, 1998, NAT GENET, V20, P398, DOI 10.1038/3882; Kumagai A, 1998, MOL BIOL CELL, V9, P345, DOI 10.1091/mbc.9.2.345; Kumagai A, 1998, J CELL BIOL, V142, P1559, DOI 10.1083/jcb.142.6.1559; Lavin MF, 1997, ANNU REV IMMUNOL, V15, P177, DOI 10.1146/annurev.immunol.15.1.177; Lim DS, 1998, P NATL ACAD SCI USA, V95, P10146, DOI 10.1073/pnas.95.17.10146; Matsuoka S, 1998, SCIENCE, V282, P1893, DOI 10.1126/science.282.5395.1893; MEYN MS, 1995, CANCER RES, V55, P5991; Morgan SE, 1997, MOL CELL BIOL, V17, P2020, DOI 10.1128/MCB.17.4.2020; MURRAY AW, 1991, METHOD CELL BIOL, V36, P581; Nakagawa K, 1999, MOL CELL BIOL, V19, P2828; PUDNEY M, 1973, EXPERIENTIA, V29, P466, DOI 10.1007/BF01926785; SAGATA N, 1988, NATURE, V335, P519, DOI 10.1038/335519a0; SAVITSKY K, 1995, SCIENCE, V268, P1749, DOI 10.1126/science.7792600; Scott SP, 1998, BIOCHEM BIOPH RES CO, V245, P144, DOI 10.1006/bbrc.1998.8137; Shafman T, 1997, NATURE, V387, P520, DOI 10.1038/387520a0; Shiloh Yosef, 1998, Biochimica et Biophysica Acta, V1378, pR11, DOI 10.1016/S0304-419X(98)00020-1; Smilenov LB, 1997, ONCOGENE, V15, P2659, DOI 10.1038/sj.onc.1201449; SOUSSI T, 1987, ONCOGENE, V1, P71; Stankovic T, 1999, LANCET, V353, P26, DOI 10.1016/S0140-6736(98)10117-4; SWIFT M, 1990, CANCER GENET CYTOGEN, V46, P21, DOI 10.1016/0165-4608(90)90004-T; Taylor AMR, 1998, INT J RADIAT BIOL, V73, P365, DOI 10.1080/095530098142185; TCHANG F, 1993, DEV BIOL, V159, P163, DOI 10.1006/dbio.1993.1230; Vaziri H, 1997, EMBO J, V16, P6018, DOI 10.1093/emboj/16.19.6018; Walter J, 1998, MOL CELL, V1, P519, DOI 10.1016/S1097-2765(00)80052-0; WANG Y, 1995, ONCOGENE, V10, P779; Waterman MJF, 1998, NAT GENET, V19, P175, DOI 10.1038/542; Xu Y, 1996, GENE DEV, V10, P2401, DOI 10.1101/gad.10.19.2401; Xu Y, 1996, GENE DEV, V10, P2411, DOI 10.1101/gad.10.19.2411; Yuille MAR, 1998, RECENT RES CANCER, V154, P156	57	25	25	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 25	1999	18	50					7070	7079		10.1038/sj.onc.1203194	http://dx.doi.org/10.1038/sj.onc.1203194			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	259PH	10597308				2022-12-25	WOS:000083901900014
J	Roubin, R; Naert, K; Popovici, C; Vatcher, G; Coulier, F; Thierry-Mieg, J; Pontarotti, P; Birnbaum, D; Baillie, D; Thierry-Mieg, D				Roubin, R; Naert, K; Popovici, C; Vatcher, G; Coulier, F; Thierry-Mieg, J; Pontarotti, P; Birnbaum, D; Baillie, D; Thierry-Mieg, D			let-756, a C-elegans fgf essential for worm development	ONCOGENE			English	Article						C-elegans; FGF; nematode; let-756; egl-17; worm development	FIBROBLAST GROWTH-FACTOR; CAENORHABDITIS-ELEGANS; SKELETAL DISORDERS; CHROMOSOME-III; SEX MYOBLASTS; FACTOR FAMILY; MUTATIONS; SEQUENCE; GENE; EXPRESSION	In vertebrates, Fibroblast Growth Factors (FGFs) and their receptors are involved in various developmental and pathological processes, including neoplasia. The number of FGFs and their large range of activities have made the understanding of their precise functions difficult. Investigating their biology in other species might be enlightening. A sequence encoding a putative protein presenting 30-40% identity with the conserved core of vertebrate FGFs has been identified by the C. elegans sequencing consortium. We show here that this gene is transcribed and encodes a putative protein of 425 amino acids (aa), The gene is expressed at all stages of development beyond late embryogenesis, peaking at the larval stages. Loss-of-function mutants of the let-756 gene are rescued by the wild type fgf gene in germline transformation experiments. Two partial loss-of-function alleles, s2613 and s2809, have a mutation that replaces aa 317 by a stop. The truncated protein retains the FGF core but lacks a C-terminus portion. These worms are small and develop slowly into clear and scrawny, yet viable and fertile adults. A third allele, s2887, is inactivated by an inversion that disrupts the first exon. It causes a developmental arrest early in the larval stages. Thus, in contrast to the other nematode fgf gene egl-17, let-756/fgf is essential for worm development.	INSERM, U119, Oncol Mol Lab, F-13009 Marseille, France; INSERM, U119, Lab Plast Genome & Evolut, F-13009 Marseille, France; CNRS, Ctr Rech Biochim Macromol, F-34293 Montpellier 5, France; Simon Fraser Univ, Inst Mol Biol & Biochem, Burnaby, BC V5A 1S6, Canada	Institut National de la Sante et de la Recherche Medicale (Inserm); Institut National de la Sante et de la Recherche Medicale (Inserm); Centre National de la Recherche Scientifique (CNRS); Universite de Montpellier; Simon Fraser University	Roubin, R (corresponding author), INSERM, U119, Oncol Mol Lab, 27 Blvd Lei Roure, F-13009 Marseille, France.		THIERRY-MIEG, Jean/F-1975-2017; , pontarotti/ABB-1753-2021; POPOVICI, Cornel/A-2027-2009; Coulier, François/G-6098-2015	THIERRY-MIEG, Jean/0000-0002-0396-6789; POPOVICI, Cornel/0000-0001-8226-3127; Coulier, François/0000-0002-6288-7773; Birnbaum, Daniel/0000-0001-7920-9883; Thierry-Mieg, Danielle/0000-0001-9568-4211; Pierre, Pontarotti/0000-0001-7202-3648				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; BALDIN V, 1990, EMBO J, V9, P1511, DOI 10.1002/j.1460-2075.1990.tb08269.x; BRENNER S, 1974, GENETICS, V77, P71; Burdine RD, 1998, DEVELOPMENT, V125, P1083; Burdine RD, 1997, P NATL ACAD SCI USA, V94, P2433, DOI 10.1073/pnas.94.6.2433; C elegans Sequencing Consortium, 1998, SCIENCE, V282, P2012, DOI 10.1126/science.282.5396.2012; Chesi M, 1997, NAT GENET, V16, P260, DOI 10.1038/ng0797-260; Coulier F, 1997, J MOL EVOL, V44, P43, DOI 10.1007/PL00006120; DeMoerlooze L, 1997, CURR OPIN GENET DEV, V7, P378, DOI 10.1016/S0959-437X(97)80152-9; DEVORE DL, 1995, CELL, V83, P611, DOI 10.1016/0092-8674(95)90101-9; DICKSON C, 1984, CELL, V37, P529, DOI 10.1016/0092-8674(84)90383-0; Dono R, 1998, EMBO J, V17, P4213, DOI 10.1093/emboj/17.15.4213; FELDMAN B, 1995, SCIENCE, V267, P246, DOI 10.1126/science.7809630; FELSENSTEIN J, 1985, EVOLUTION, V39, P783, DOI 10.1111/j.1558-5646.1985.tb00420.x; Fiore F, 1997, INT J DEV BIOL, V41, P639; Floss T, 1997, GENE DEV, V11, P2040, DOI 10.1101/gad.11.16.2040; Goldfarb Mitchell, 1996, Cytokine and Growth Factor Reviews, V7, P311, DOI 10.1016/S1359-6101(96)00039-1; Green PJ, 1996, BIOESSAYS, V18, P639, DOI 10.1002/bies.950180807; Guo LF, 1996, GENE DEV, V10, P165, DOI 10.1101/gad.10.2.165; HEBERT JM, 1994, CELL, V78, P1017, DOI 10.1016/0092-8674(94)90276-3; Janke DL, 1997, GENOME RES, V7, P974, DOI 10.1101/gr.7.10.974; KIEFER P, 1983, MOL CELL BIOL, V13, P5781; MANSOUR SL, 1994, MOL REPROD DEV, V39, P62, DOI 10.1002/mrd.1080390111; MASON IJ, 1994, CELL, V78, P547, DOI 10.1016/0092-8674(94)90520-7; MELLO CC, 1991, EMBO J, V10, P3959, DOI 10.1002/j.1460-2075.1991.tb04966.x; Meyers EN, 1998, NAT GENET, V18, P136, DOI 10.1038/ng0298-136; MIGNATTI P, 1992, J CELL PHYSIOL, V151, P81, DOI 10.1002/jcp.1041510113; MIYAMOTO M, 1993, MOL CELL BIOL, V13, P4251, DOI 10.1128/MCB.13.7.4251; Popovici C, 1998, P NATL ACAD SCI USA, V95, P5712, DOI 10.1073/pnas.95.10.5712; RAPPOLEE DA, 1994, DEVELOPMENT, V120, P2259; ROGALSKI TM, 1993, GENE DEV, V7, P1471, DOI 10.1101/gad.7.8.1471; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Stewart HI, 1998, MOL GEN GENET, V260, P280, DOI 10.1007/PL00013816; STEWART HI, 1991, MUTAT RES, V248, P37; Sutherland D, 1996, CELL, V87, P1091, DOI 10.1016/S0092-8674(00)81803-6; Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876; Webster MK, 1997, TRENDS GENET, V13, P178, DOI 10.1016/S0168-9525(97)01131-1; WILLIAMS BD, 1992, GENETICS, V131, P609; WILSON R, 1994, NATURE, V368, P32, DOI 10.1038/368032a0; Wood WB, 1988, NEMATODE CAENORHABDI; Xiao S, 1998, NAT GENET, V18, P84, DOI 10.1038/ng0198-84; Zhou M, 1998, NAT MED, V4, P201, DOI 10.1038/nm0298-201	42	37	42	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 18	1999	18	48					6741	6747		10.1038/sj.onc.1203074	http://dx.doi.org/10.1038/sj.onc.1203074			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	257QA	10597282				2022-12-25	WOS:000083792000016
J	Slosberg, ED; Klein, MG; Yao, Y; Han, EKH; Schieren, I; Weinstein, IB				Slosberg, ED; Klein, MG; Yao, Y; Han, EKH; Schieren, I; Weinstein, IB			The alpha isoform of protein kinase C mediates phorbol ester-induced growth inhibition and p21(cip1) induction in HC11 mammary epithelial cells	ONCOGENE			English	Article						protein kinase C; mammary; cell cycle; TPA; HC11; p21(cip1)	CYCLIN-DEPENDENT KINASES; NUCLEAR-LOCALIZATION; SIGNAL-TRANSDUCTION; GENE-EXPRESSION; MUTANT FORM; WILD-TYPE; CANCER; OVEREXPRESSION; SUPPRESSION; INVOLVEMENT	To clarify the roles of specific isoforms of PKC in regulating growth and cell cycle progression of the HC11 mammary epithelial cell line, we investigated the effects of activating endogenous PKC isoforms,vith the phorbol ester tumor promoter TPA, and also the effects of TPA on genetically engineered cells containing increased levels of individual PKC isoforms. We found that TPA treatment of HC11 cells induced a transient cell cycle arrest in G0/G1. Western blot analyses of the TPA treated cells provided evidence that the endogenous PKC alpha present in these cells mediated these effects, Indeed, derivatives of the HC11 cell line that inducibly overexpress an exogenous PKC alpha or ectopic PKC beta(1) exhibited more marked growth inhibition by TPA than control cells. Immunohistochemical staining of cells following treatment with TPA revealed selective translocation of PKC alpha into the nucleus, whereas PKC beta(1) remained in the cytoplasm. The transient arrest of HC11 cells following treatment with TPA was associated with marked induction of both p21(cip1) mRNA and protein. This induction was exaggerated in the derivatives that overexpressed either PKC alpha or PKC beta(1). Therefore, in mouse mammary epithelial cells activation of the endogenous PKC alpha can transiently arrest cells in G0/G1 which may be due, at least in part, to induction of the transcription of p21(cip1).	Columbia Univ, Herbert Irving Comprehens Canc Ctr, New York, NY 10032 USA; Novartis Pharmaceut Corp, Summit, NJ 07901 USA; Yeshiva Univ Albert Einstein Coll Med, Dept Biochem, Bronx, NY 10461 USA; Abbott Labs, Abbott Pk, IL 60064 USA	Columbia University; Novartis; Yeshiva University; Albert Einstein College of Medicine; Abbott Laboratories	Weinstein, IB (corresponding author), Columbia Univ, Herbert Irving Comprehens Canc Ctr, HHSC 1509,701 W 168th St, New York, NY 10032 USA.				NCI NIH HHS [T32CA09503, CA02656] Funding Source: Medline; NIGMS NIH HHS [T32GM07088] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA009503] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007088] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; ALVARO V, 1993, J CLIN ENDOCR METAB, V77, P1125, DOI 10.1210/jc.77.5.1125; Alvaro V, 1997, ONCOGENE, V14, P677, DOI 10.1038/sj.onc.1200880; BALL RK, 1988, EMBO J, V7, P2089, DOI 10.1002/j.1460-2075.1988.tb03048.x; BLUMBERG PM, 1994, PROG CLIN BIOL RES, V387, P3; BORNER C, 1987, INT J CANCER, V40, P344, DOI 10.1002/ijc.2910400310; BORNER C, 1991, NATURE, V353, P78, DOI 10.1038/353078a0; BORNER C, 1992, PROTEIN KINASE C CUR, P297; BUCHNER K, 1995, EUR J BIOCHEM, V228, P211; CACACE A, 1993, ONCOGENE, V8, P2094; CHOI PM, 1990, MOL CELL BIOL, V10, P4650, DOI 10.1128/MCB.10.9.4650; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COPPOCK DL, 1995, EXP CELL RES, V221, P92, DOI 10.1006/excr.1995.1356; DIVECHA N, 1993, CELL, V74, P405, DOI 10.1016/0092-8674(93)80041-C; ELDAR H, 1992, EXP CELL RES, V202, P259, DOI 10.1016/0014-4827(92)90073-H; Fabbro D, 1992, Cancer Treat Res, V61, P229; FABBRO D, 1986, CANCER RES, V46, P2720; Frey MR, 1997, J BIOL CHEM, V272, P9424; Fukumoto S, 1997, J BIOL CHEM, V272, P13816, DOI 10.1074/jbc.272.21.13816; GOLDSTEIN DR, 1995, CARCINOGENESIS, V16, P1121, DOI 10.1093/carcin/16.5.1121; GOODNIGHT J, 1994, ADV CANCER RES, V64, P159, DOI 10.1016/S0065-230X(08)60838-6; Gordge PC, 1996, EUR J CANCER, V32A, P2120, DOI 10.1016/S0959-8049(96)00255-9; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; HOUSEY GM, 1988, CELL, V52, P343, DOI 10.1016/S0092-8674(88)80027-8; HSIAO WLW, 1989, MOL CELL BIOL, V9, P2641, DOI 10.1128/MCB.9.6.2641; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; Jaken S, 1996, CURR OPIN CELL BIOL, V8, P168, DOI 10.1016/S0955-0674(96)80062-7; JAMES G, 1992, J CELL BIOL, V116, P863, DOI 10.1083/jcb.116.4.863; Kiley SC, 1996, J MAMMARY GLAND BIOL, V1, P177, DOI 10.1007/BF02013641; KISHIMOTO A, 1989, J BIOL CHEM, V264, P4088; LEACH KL, 1989, J CELL BIOL, V109, P685, DOI 10.1083/jcb.109.2.685; LEACH KL, 1993, BIOCHEM SOC T, V21, P879, DOI 10.1042/bst0210879; LEACH KL, 1992, J BIOL CHEM, V267, P21816; Lee HW, 1996, J BIOL CHEM, V271, P20973, DOI 10.1074/jbc.271.35.20973; Livneh E, 1997, EUR J BIOCHEM, V248, P1, DOI 10.1111/j.1432-1033.1997.t01-4-00001.x; LIVNEH E, 1994, SIGNAL ACTIVATED PHO, P165; Lu ZM, 1998, MOL CELL BIOL, V18, P839, DOI 10.1128/MCB.18.2.839; Manni A, 1996, CELL GROWTH DIFFER, V7, P1187; MARTE BM, 1994, CELL GROWTH DIFFER, V5, P239; MERLO GR, 1994, ONCOGENE, V9, P443; MOCHLYROSEN D, 1995, SCIENCE, V268, P247, DOI 10.1126/science.7716516; OBRIAN CA, 1989, CANCER RES, V49, P3215; OBRIAN CA, 1985, CANCER RES, V45, P2462; OLSON EN, 1993, CELL GROWTH DIFFER, V4, P699; SASAGURI T, 1993, EXP CELL RES, V208, P311, DOI 10.1006/excr.1993.1251; SAVART M, 1992, INT J CANCER, V52, P399, DOI 10.1002/ijc.2910520312; Schmalz D, 1996, J CELL SCI, V109, P2401; Sgambato A, 1996, CANCER RES, V56, P1389; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; STAUDINGER J, 1995, J CELL BIOL, V128, P263, DOI 10.1083/jcb.128.3.263; Thompson LJ, 1996, J BIOL CHEM, V271, P15045, DOI 10.1074/jbc.271.25.15045; TIEFENBRUN N, 1991, ONCOGENE, V6, P1001; VILCEK J, 1976, J INFECT DIS, V133, pA22, DOI 10.1093/infdis/133.Supplement_2.A22; WAYS DK, 1995, J CLIN INVEST, V95, P1906, DOI 10.1172/JCI117872; Weinstein I. B., 1996, ENCY CANC, V1, P256; ZHOU W, 1993, J BIOL CHEM, V268, P23041	56	30	32	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 18	1999	18	48					6658	6666		10.1038/sj.onc.1203083	http://dx.doi.org/10.1038/sj.onc.1203083			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	257QA	10597271				2022-12-25	WOS:000083792000005
J	Shammas, MA; Simmons, CG; Corey, DR; Reis, RJS				Shammas, MA; Simmons, CG; Corey, DR; Reis, RJS			Telomerase inhibition by peptide nucleic acids reverses 'immortality' of transformed human cells	ONCOGENE			English	Article						telomere; telomerase; peptide nucleic acid; cell transformation; immortality; cancer	HUMAN-DIPLOID FIBROBLASTS; LARGE T-ANTIGEN; SV40-MEDIATED IMMORTALIZATION; CELLULAR SENESCENCE; QUADRUPLEX DNA; LIFE-SPAN; RNA; CANCER; IDENTIFICATION; RECOMBINATION	Telomerase activity, the ability to add telomeric repeats to the ends of chromosomes, has been detected in most immortal cell lines including tumor cells, but is low or absent in most diploid, mortal cells such as those of somatic tissues. Peptide nucleic acids (PNAs), analogs of DNA or RNA which bind to complementary nucleic acids with very high affinity, were co-electroporated into immortal human cells along with a selectable plasmid, Introduction of PNAs inverse-complementary to telomerase RNA effectively inhibited telomerase activity in intact cells, shortened telomeres, reduced colony size, and arrested cell proliferation after a lag period of 5-30 cell generations, consistent with suppression of their 'immortality', Electroporation of selection plasmid alone had no effect, while PNAs of altered sequence were markedly less effective in each assay. This constitutes the first demonstration of cell growth arrest through telomerase inhibition, upon treatment of intact cells with an exogenous compound which call be efficiently delivered in vivo, The phenotype of telomerase-inhibited transformed cells differs from senescence of normal diploid fibroblasts, but rather resembles the crisis state of incompletely transformed cells.	Univ Arkansas Med Sci, Dept Geriatr, Little Rock, AR 72205 USA; Univ Arkansas Med Sci, Dept Med, Little Rock, AR 72205 USA; Univ Arkansas Med Sci, Dept Biochem & Mol Biol, Little Rock, AR 72205 USA; John L McClellan Mem Vet Adm Med Ctr, Little Rock, AR 72205 USA; Univ Texas, SW Med Ctr, Howard Hughes Med Inst, Dept Pharmacol, Dallas, TX 75235 USA; Univ Texas, SW Med Ctr, Howard Hughes Med Inst, Dept Biochem, Dallas, TX 75235 USA	University of Arkansas System; University of Arkansas Medical Sciences; University of Arkansas System; University of Arkansas Medical Sciences; University of Arkansas System; University of Arkansas Medical Sciences; Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Reis, RJS (corresponding author), Univ Arkansas Med Sci, Dept Geriatr, Little Rock, AR 72205 USA.		Shmookler Reis, Robert/C-4112-2009					Banga SS, 1997, ONCOGENE, V14, P313, DOI 10.1038/sj.onc.1200842; BLACKBURN EH, 1992, ANNU REV BIOCHEM, V61, P113, DOI 10.1146/annurev.bi.61.070192.000553; Blasco MA, 1997, CELL, V91, P25, DOI 10.1016/S0092-8674(01)80006-4; Bodnar AG, 1998, SCIENCE, V279, P349, DOI 10.1126/science.279.5349.349; BROCCOLI D, 1995, P NATL ACAD SCI USA, V92, P9082, DOI 10.1073/pnas.92.20.9082; CACHIANES G, 1993, BIOTECHNIQUES, V15, P255; Cheng RZ, 1997, EXP CELL RES, V234, P300, DOI 10.1006/excr.1997.3649; CHU G, 1987, NUCLEIC ACIDS RES, V15, P1311, DOI 10.1093/nar/15.3.1311; COUNTER CM, 1992, EMBO J, V11, P1921, DOI 10.1002/j.1460-2075.1992.tb05245.x; CRISTOFALO VJ, 1973, EXP CELL RES, V76, P419, DOI 10.1016/0014-4827(73)90394-7; DEMIDOV VV, 1994, BIOCHEM PHARMACOL, V48, P1310, DOI 10.1016/0006-2952(94)90171-6; EGHOLM M, 1993, NATURE, V365, P566, DOI 10.1038/365566a0; Fedoroff OY, 1998, BIOCHEMISTRY-US, V37, P12367, DOI 10.1021/bi981330n; FENG JL, 1995, SCIENCE, V269, P1236, DOI 10.1126/science.7544491; Fletcher TM, 1996, BIOCHEMISTRY-US, V35, P15611, DOI 10.1021/bi961228v; Hamilton SE, 1997, BIOCHEMISTRY-US, V36, P11873, DOI 10.1021/bi970438k; HARLEY CB, 1990, NATURE, V345, P458, DOI 10.1038/345458a0; HARLEY CB, 1978, J CELL PHYSIOL, V97, P509, DOI 10.1002/jcp.1040970326; Hayflick L, 1977, HDB BIOL AGING, P159; Holt Shawn E., 1996, Methods in Cell Science, V18, P237, DOI 10.1007/BF00132889; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; Kondo S, 1998, FASEB J, V12, P801, DOI 10.1096/fasebj.12.10.801; Kondo S, 1998, ONCOGENE, V16, P3323, DOI 10.1038/sj.onc.1201885; Lee HW, 1998, NATURE, V392, P569, DOI 10.1038/33345; MARTIN GM, 1970, LAB INVEST, V23, P86; MOERMAN EJ, 1986, METHODS DIABETES RES, V2, P283; NIELSEN PE, 1991, SCIENCE, V254, P1497, DOI 10.1126/science.1962210; Norton JC, 1996, NAT BIOTECHNOL, V14, P615, DOI 10.1038/nbt0596-615; NORTON JC, 1995, BIOORGAN MED CHEM, V3, P437, DOI 10.1016/0968-0896(95)00033-D; Ozer HL, 1996, EXP GERONTOL, V31, P303, DOI 10.1016/0531-5565(95)00024-0; Pai RB, 1998, CANCER RES, V58, P1909; PEREIRASMITH OM, 1988, P NATL ACAD SCI USA, V85, P6042, DOI 10.1073/pnas.85.16.6042; Pitts AE, 1998, P NATL ACAD SCI USA, V95, P11549, DOI 10.1073/pnas.95.20.11549; Pooga M, 1998, NAT BIOTECHNOL, V16, P857, DOI 10.1038/nbt0998-857; REID LH, 1991, MOL CELL BIOL, V11, P2769, DOI 10.1128/MCB.11.5.2769; REIS RJS, 1983, J BIOL CHEM, V258, P9078; Rubelj I, 1997, J GERONTOL A-BIOL, V52, pB229, DOI 10.1093/gerona/52A.5.B229; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SANDHU AK, 1994, P NATL ACAD SCI USA, V91, P5498, DOI 10.1073/pnas.91.12.5498; Shammas MA, 1997, GENETICS, V146, P1417; Sharma S, 1997, ANN ONCOL, V8, P1063, DOI 10.1023/A:1008206420505; Shay JW, 1997, EUR J CANCER, V33, P787, DOI 10.1016/S0959-8049(97)00062-2; SHAY JW, 1989, EXP CELL RES, V184, P109, DOI 10.1016/0014-4827(89)90369-8; Simmons CG, 1997, BIOORG MED CHEM LETT, V7, P3001, DOI 10.1016/S0960-894X(97)10136-6; SMITH JR, 1978, P NATL ACAD SCI USA, V75, P1353, DOI 10.1073/pnas.75.3.1353; WANG SS, 1990, NATURE, V345, P456, DOI 10.1038/345456a0; Wheelhouse RT, 1998, J AM CHEM SOC, V120, P3261, DOI 10.1021/ja973792e; WRIGHT WE, 1989, MOL CELL BIOL, V9, P3088, DOI 10.1128/MCB.9.7.3088; WRIGHT WE, 1995, NUCLEIC ACIDS RES, V23, P3794, DOI 10.1093/nar/23.18.3794; Xia SJJ, 1996, MUTAT RES-DNA REPAIR, V364, P1, DOI 10.1016/0921-8777(96)00015-8; Xia SJJ, 1997, MOL CELL BIOL, V17, P7151, DOI 10.1128/MCB.17.12.7151; Zakian VA, 1997, CELL, V91, P1, DOI 10.1016/S0092-8674(01)80001-5	52	132	144	1	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 4	1999	18	46					6191	6200		10.1038/sj.onc.1203069	http://dx.doi.org/10.1038/sj.onc.1203069			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	260DK	10597217				2022-12-25	WOS:000083934100002
J	Cristofari, G; Gabus, C; Ficheux, D; Bona, M; Le Grice, SFJ; Darlix, JL				Cristofari, G; Gabus, C; Ficheux, D; Bona, M; Le Grice, SFJ; Darlix, JL			Characterization of active reverse transcriptase and nucleoprotein complexes of the yeast retrotransposon Ty3 in vitro	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIV-1 NUCLEOCAPSID PROTEIN; RNA ANNEALING ACTIVITIES; PROVIRAL DNA-SYNTHESIS; TERMINAL ZINC-FINGER; PRIMER-BINDING-SITE; IN-VITRO; STRAND TRANSFER; VIRUS; NCP7; RECOMBINATION	Human immunodeficiency virus (HIV) and the distantly related yeast Ty3 retrotransposon encode reverse transcriptase (RT) and a nucleic acid-binding protein designated nucleocapsid protein (NCp) with either one or two zinc fingers, required for HIV-1 replication and Ty3 transposition, respectively. In vitro binding of HIV-1 NCp7 to viral 5' RNA and primer tRNA(3)(Lys) catalyzes formation of nucleoprotein complexes resembling the virion nucleocapsid. Nucleocapsid complex formation functions in viral RNA dimerization and tRNA annealing to the primer binding site (PBS). RT is recruited in these nucleoprotein complexes and synthesizes minus-strand cDNA initiated at the PBS. Recent results on yeast Ty3 have shown that the homologous NCp9 promotes annealing of primer tRNA(i)(Met) to a 5'-3' bipartite PBS, allowing RNA:tRNA dimer formation and initiation of cDNA synthesis at the 5' PBS (1), To compare specific cDNA synthesis in a retrotransposon and HIV-1, we have established a Ty3 model system comprising Ty3 RNA with the 5'-3' PBS, primer tRNA(i)(Met), NCp9, and for the first time, highly purified Ty3 RT. Here we report that Ty3 RT is as active as retroviral HIV-1 or murine leukemia virus RT using a synthetic template-primer system, Moreover, and in contrast to what was found with retroviral RTs, retrotransposon Ty3 RT was unable to direct cDNA synthesis by self-priming. We also show that Ty3 nucleoprotein complexes were formed in vitro and that the N terminus of NCp9, but not the zinc finger, is required for complex formation, tRNA annealing to the PBS, RNA dimerization, and primer tRNA-directed cDNA synthesis by Ty3 RT. These results indicate that NCp9 chaperones bona fide cDNA synthesis by RT in the yeast Ty3 retrotransposon, as illustrated for NCp7 in HIV-1, reinforcing the notion that Ty3 NCp9 is an ancestor of HIV-1 NCp7.	Ecole Normale Super Lyon, INSERM, LaboRetro, Unite Virol Humaine,U412, F-69364 Lyon 07, France; Inst Biol & Chim Prot, F-69367 Lyon, France; NCI, Frederick Canc Res & Dev Ctr, HIV Drug Resistance Program, Div Basic Sci,NIH, Frederick, MD 21702 USA	Ecole Normale Superieure de Lyon (ENS de LYON); Institut National de la Sante et de la Recherche Medicale (Inserm); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick	Darlix, JL (corresponding author), Ecole Normale Super Lyon, INSERM, LaboRetro, Unite Virol Humaine,U412, 46 Allee Italie, F-69364 Lyon 07, France.		Cristofari, Gael/A-2831-2011; LUC, DARLIX JEAN/AAE-9268-2020	Cristofari, Gael/0000-0001-5620-3091; 	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI031147] Funding Source: NIH RePORTER; NIAID NIH HHS [AI31147] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALLAIN B, 1994, EMBO J, V13, P973, DOI 10.1002/j.1460-2075.1994.tb06342.x; Auxilien S, 1999, J BIOL CHEM, V274, P4412, DOI 10.1074/jbc.274.7.4412; BARAT C, 1989, EMBO J, V8, P3279, DOI 10.1002/j.1460-2075.1989.tb08488.x; Berkowitz R, 1996, CURR TOP MICROBIOL, V214, P177; Berthoux L, 1997, J VIROL, V71, P6973, DOI 10.1128/JVI.71.9.6973-6981.1997; BOEKE JD, 1991, MOL CELLULAR BIOL YE, P193; CHEN MJ, 1980, P NATL ACAD SCI-BIOL, V77, P1296, DOI 10.1073/pnas.77.3.1296; COFFIN JM, 1985, RNA TUMOR VIRUSES, P261; DANNULL J, 1994, EMBO J, V13, P1525, DOI 10.1002/j.1460-2075.1994.tb06414.x; DARLIX JL, 1990, J MOL BIOL, V216, P689, DOI 10.1016/0022-2836(90)90392-Y; DARLIX JL, 1995, J MOL BIOL, V254, P523, DOI 10.1006/jmbi.1995.0635; De Guzman RN, 1998, SCIENCE, V279, P384, DOI 10.1126/science.279.5349.384; DEROCQUIGNY H, 1992, P NATL ACAD SCI USA, V89, P6472, DOI 10.1073/pnas.89.14.6472; Gabus C, 1998, EMBO J, V17, P4873, DOI 10.1093/emboj/17.16.4873; Gregoire CJ, 1997, J BIOL CHEM, V272, P25143, DOI 10.1074/jbc.272.40.25143; HU WS, 1990, SCIENCE, V250, P1227, DOI 10.1126/science.1700865; HU WS, 1990, P NATL ACAD SCI USA, V87, P1556, DOI 10.1073/pnas.87.4.1556; KATZ RA, 1994, ANNU REV BIOCHEM, V63, P133, DOI 10.1146/annurev.bi.63.070194.001025; KHAN R, 1992, J BIOL CHEM, V267, P6689; Kim JM, 1998, GENOME RES, V8, P464, DOI 10.1101/gr.8.5.464; KIRCHNER J, 1993, J VIROL, V67, P19, DOI 10.1128/JVI.67.1.19-28.1993; LapadatTapolsky M, 1997, J MOL BIOL, V268, P250, DOI 10.1006/jmbi.1997.0978; LAPADATTAPOLSKY M, 1995, NUCLEIC ACIDS RES, V23, P2434, DOI 10.1093/nar/23.13.2434; LAPADATTAPOLSKY M, 1993, NUCLEIC ACIDS RES, V21, P831, DOI 10.1093/nar/21.4.831; Lauermann V, 1997, EMBO J, V16, P6603, DOI 10.1093/emboj/16.21.6603; LeGrice SFJ, 1995, METHOD ENZYMOL, V262, P130, DOI 10.1016/0076-6879(95)62015-X; Lener D, 1998, J BIOL CHEM, V273, P33781, DOI 10.1074/jbc.273.50.33781; Li XG, 1996, J VIROL, V70, P4996, DOI 10.1128/JVI.70.8.4996-5004.1996; Mak J, 1997, J VIROL, V71, P8087, DOI 10.1128/JVI.71.11.8087-8095.1997; MORELLET N, 1994, J MOL BIOL, V235, P287, DOI 10.1016/S0022-2836(05)80033-6; Morellet N, 1998, J MOL BIOL, V283, P419, DOI 10.1006/jmbi.1998.2098; PELISKA JA, 1994, BIOCHEMISTRY-US, V33, P13817, DOI 10.1021/bi00250a036; PRATS AC, 1991, NUCLEIC ACIDS RES, V19, P3533, DOI 10.1093/nar/19.13.3533; Rein A, 1998, TRENDS BIOCHEM SCI, V23, P297, DOI 10.1016/S0968-0004(98)01256-0; RICE WG, 1993, NATURE, V361, P473, DOI 10.1038/361473a0; RODRIGUEZRODRIGUEZ L, 1995, J BIOL CHEM, V270, P15005, DOI 10.1074/jbc.270.25.15005; SENGER B, 1992, P NATL ACAD SCI USA, V89, P10768, DOI 10.1073/pnas.89.22.10768; SUMMERS MF, 1992, PROTEIN SCI, V1, P563, DOI 10.1002/pro.5560010502; Tanchou V, 1998, J VIROL, V72, P4442, DOI 10.1128/JVI.72.5.4442-4447.1998; TANCHOU V, 1995, J MOL BIOL, V252, P563, DOI 10.1006/jmbi.1995.0520; VARMUS H, 1985, RNA TUMOR VIRUSES MO, P369	41	24	26	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 17	1999	274	51					36643	36648		10.1074/jbc.274.51.36643	http://dx.doi.org/10.1074/jbc.274.51.36643			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	266AV	10593967	hybrid			2022-12-25	WOS:000084279200086
J	Kondo, R; Tikunova, SB; Cho, MJ; Johnson, JD				Kondo, R; Tikunova, SB; Cho, MJ; Johnson, JD			A point mutation in a plant calmodulin is responsible for its inhibition of nitric-oxide synthase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELECTRON-TRANSFER; CYCLIC-GMP; BINDING DOMAIN; ACTIVATION; CALCINEURIN; CALCIUM; MUTANTS; ISOFORM; SIGNAL; MUSCLE	The calcium/calmodulin-dependent activation of nitric-oxide synthase (NOS) and its production of nitric oxide (NO) play a key regulatory role in plant and animal cell function. SCaM-1 is a plant calmodulin (CaM) isoform that is 91% identical to mammalian CaM (wild type CaM (wtCaM)) and a selective competitive antagonist of NOS (Cho, M. J., Vaghy, P. L., Kondo, R., Lee, S. H., Davis, J. P., Rehl, R., Heo, W. D., and Johnson, J. D. (1998) Biochemistry 37, 15593-15597), We have used site-directed mutagenesis to show that a point mutation, involving the substitution of valine for methionine at position 144, is responsible for SCaM-1's inhibition of mammalian NOS. An M144V mutation in wild type CaM produced a mutant (M144V) which exhibited nearly identical inhibition of NOS's NO production and NADPH oxidation, with a similar K-i (similar to 15 nM) as SCaM-1, A V144M back mutation in SCaM-1 significantly restored its ability to activate NOS's catalytic functions. The length of the hydrophobic amino acid side chain at position 144 appears to be critical for NOS activation, since M144L and M144F activated NOS while M144V and M144C did not. Despite their competitive antagonism of NOS, M144V, like SCaM-1, exhibited a similar dose-dependent activation of phosphodiesterase and calcineurin as wtCaM. SCaM-1 and M144V produced greater inhibition of NOS's oxygenase domain function (NO production) than its reductase domain functions (NADPH oxidation and cytochrome c reduction). Thus, CaM's methionine 144 plays a critical role the activation of NOS, presumably by influencing the function of NOS's oxygenase domain.	Ohio State Univ, Med Ctr, Dept Mol & Cellular Biochem, Columbus, OH 43210 USA; Gyeongsang Natl Univ, Dept Biochem, Plant Mol Biol & Biotechnol Res Ctr, Chinju 660701, South Korea	University System of Ohio; Ohio State University; Gyeongsang National University	Johnson, JD (corresponding author), Ohio State Univ, Med Ctr, Dept Mol & Cellular Biochem, 333 Hamilton Hall,1645 Neil Ave, Columbus, OH 43210 USA.		Cho, Moo Je/F-1649-2010		NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK033727] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK33727] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ABUSOUD HM, 1994, J BIOL CHEM, V269, P32047; Berridge MJ, 1998, NATURE, V395, P645, DOI 10.1038/27094; Chin D, 1996, J BIOL CHEM, V271, P30465, DOI 10.1074/jbc.271.48.30465; CHO HJ, 1992, J EXP MED, V176, P599, DOI 10.1084/jem.176.2.599; Cho MJ, 1998, BIOCHEMISTRY-US, V37, P15593, DOI 10.1021/bi981497g; Christopoulos A., 1999, Life Sciences, V64, P1; CRIVICI A, 1995, ANNU REV BIOPH BIOM, V24, P85, DOI 10.1146/annurev.bb.24.060195.000505; Delledonne M, 1998, NATURE, V394, P585, DOI 10.1038/29087; Durner J, 1998, P NATL ACAD SCI USA, V95, P10328, DOI 10.1073/pnas.95.17.10328; Edwards RA, 1998, BIOCHEM J, V331, P149, DOI 10.1042/bj3310149; Gachhui R, 1998, J BIOL CHEM, V273, P5451, DOI 10.1074/jbc.273.10.5451; HANSEN RS, 1986, J BIOL CHEM, V261, P4636; Heo WD, 1999, P NATL ACAD SCI USA, V96, P766, DOI 10.1073/pnas.96.2.766; JOHNSON JD, 1987, ANAL BIOCHEM, V162, P291, DOI 10.1016/0003-2697(87)90039-X; KUO WN, 1995, BIOCHEM ARCH, V11, P73; LEE SH, 1995, J BIOL CHEM, V270, P21806, DOI 10.1074/jbc.270.37.21806; Lee SJ, 1998, J BIOL CHEM, V273, P27430, DOI 10.1074/jbc.273.42.27430; Leshem YY, 1996, PLANT GROWTH REGUL, V18, P155, DOI 10.1007/BF00024375; MARLETTA MA, 1994, CELL, V78, P927, DOI 10.1016/0092-8674(94)90268-2; McDonald LJ, 1996, P SOC EXP BIOL MED, V211, P1; MEADOR WE, 1992, SCIENCE, V257, P1251, DOI 10.1126/science.1519061; Ninnemann H, 1996, PHOTOCHEM PHOTOBIOL, V64, P393, DOI 10.1111/j.1751-1097.1996.tb02477.x; Persechini A, 1996, J BIOL CHEM, V271, P32217, DOI 10.1074/jbc.271.50.32217; Ribeiro EA, 1999, FEBS LETT, V445, P283, DOI 10.1016/S0014-5793(99)00138-6; Richards MK, 1996, BIOCHEMISTRY-US, V35, P7772, DOI 10.1021/bi952582g; ROADS AR, 1997, FASEB J, V11, P331; Siddhanta U, 1998, J BIOL CHEM, V273, P18950, DOI 10.1074/jbc.273.30.18950; Silvagno F, 1996, J BIOL CHEM, V271, P11204, DOI 10.1074/jbc.271.19.11204; StevensTruss R, 1997, BIOCHEMISTRY-US, V36, P12337, DOI 10.1021/bi970973k; Stuehr DJ, 1996, METHOD ENZYMOL, V268, P324; Stuehr DJ, 1997, ANNU REV PHARMACOL, V37, P339, DOI 10.1146/annurev.pharmtox.37.1.339; SU ZZ, 1995, J BIOL CHEM, V270, P29117, DOI 10.1074/jbc.270.49.29117; VORHERR T, 1993, BIOCHEMISTRY-US, V32, P6081, DOI 10.1021/bi00074a020; ZHANG MJ, 1994, J BIOL CHEM, V269, P981	34	35	38	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 17	1999	274	51					36213	36218		10.1074/jbc.274.51.36213	http://dx.doi.org/10.1074/jbc.274.51.36213			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	266AV	10593908	hybrid			2022-12-25	WOS:000084279200027
J	Yahagi, N; Shimano, H; Hasty, AH; Amemiya-Kudo, M; Okazaki, H; Tamura, Y; Iizuka, Y; Shionoiri, F; Ohashi, K; Osuga, J; Harada, K; Gotoda, T; Nagai, R; Ishibashi, S; Yamada, N				Yahagi, N; Shimano, H; Hasty, AH; Amemiya-Kudo, M; Okazaki, H; Tamura, Y; Iizuka, Y; Shionoiri, F; Ohashi, K; Osuga, J; Harada, K; Gotoda, T; Nagai, R; Ishibashi, S; Yamada, N			A crucial role of sterol regulatory element-binding protein-1 in the regulation of lipogenic gene expression by polyunsaturated fatty acids	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED RECEPTOR-ALPHA; ATP CITRATE-LYASE; TRANSGENIC MICE; CHOLESTEROL-SYNTHESIS; DIETARY-REGULATION; RAT-LIVER; TRANSCRIPTION; SYNTHASE; EICOSANOIDS; METABOLISM	Dietary polyunsaturated fatty acids (PUFA) are negative regulators of hepatic lipogenesis that exert their effects primarily at the level of transcription. Sterol regulatory element-binding proteins (SREBPs) are transcription factors responsible for the regulation of cho lesterol, fatty acid, and triglyceride synthesis. In particular, SREBP-1 is known to play a crucial role in the regulation of lipogenic gene expression in the liver. To explore the possible involvement of SREBP-1 in the suppression of hepatic lipogenesis by PUFA, we challenged wild-type mice and transgenic mice overexpressing a mature form of SREBP-1 in the liver with dietary PUFA. In the liver of wild-type mice, dietary PUFA drastically decreased the mature, cleaved form of SREBP-1 protein in the nucleus, whereas the precursor, uncleaved form in the membranes was not suppressed. The decreases in mature SREBP-1 paralleled those in mRNAs for Lipogenic enzymes such as fatty acid synthase and acetyl-CoA carboxylase. In the transgenic mice, dietary PUFA did not reduce the amount of transgenic SREBP-1 protein, excluding the possibility that PUFA accelerated the degradation of mature SREBP-1. The resulting sustained expression of mature SREBP-1 almost completely canceled the suppression of lipogenic gene expression by PUFA in the SREBP-1 transgenic mice. These results demonstrate that the suppressive effect of PUFA on Lipogenic enzyme genes in the liver is caused by a decrease in the mature form of SREBP-1 protein, which is presumably due to the reduced cleavage of SREBP-1 precursor protein.	Univ Tokyo, Fac Med, Dept Metab Dis, Tokyo 1138655, Japan	University of Tokyo	Shimano, H (corresponding author), 7-3-1 Hongo,Bunkyo Ku, Tokyo 1138655, Japan.		Shimano, Hitoshi/AAI-5648-2020; Harada, Kenji/J-2230-2016; Shimano, Hitoshi/V-1761-2019; Hasty, Alyssa/AAA-2757-2020; Yahagi, Naoya/D-2360-2014	Shimano, Hitoshi/0000-0002-5562-5572; Hasty, Alyssa/0000-0001-7302-8045; Yahagi, Naoya/0000-0002-1823-1865				ALLMANN DW, 1965, J LIPID RES, V6, P51; BENNETT MK, 1995, J BIOL CHEM, V270, P25578, DOI 10.1074/jbc.270.43.25578; Brown MS, 1997, CELL, V89, P331, DOI 10.1016/S0092-8674(00)80213-5; CLARKE SD, 1993, PROG LIPID RES, V32, P139, DOI 10.1016/0163-7827(93)90013-M; Forman BM, 1997, P NATL ACAD SCI USA, V94, P4312, DOI 10.1073/pnas.94.9.4312; Fukuda H, 1996, FEBS LETT, V380, P204, DOI 10.1016/0014-5793(96)00031-2; FUKUDA H, 1992, EUR J BIOCHEM, V209, P217, DOI 10.1111/j.1432-1033.1992.tb17279.x; Fukuda H, 1997, FEBS LETT, V406, P243, DOI 10.1016/S0014-5793(97)00219-6; GOODRIDGE AG, 1987, ANNU REV NUTR, V7, P157, DOI 10.1146/annurev.nu.07.070187.001105; Horton JD, 1998, P NATL ACAD SCI USA, V95, P5987, DOI 10.1073/pnas.95.11.5987; Horton JD, 1998, J CLIN INVEST, V101, P2331, DOI 10.1172/JCI2961; IRITANI N, 1992, EUR J BIOCHEM, V205, P433, DOI 10.1111/j.1432-1033.1992.tb16797.x; Jump DB, 1996, PROG LIPID RES, V35, P227, DOI 10.1016/S0163-7827(96)00007-0; Kliewer SA, 1997, P NATL ACAD SCI USA, V94, P4318, DOI 10.1073/pnas.94.9.4318; LIIMATTA M, 1994, MOL ENDOCRINOL, V8, P1147, DOI 10.1210/me.8.9.1147; Rawson RB, 1997, MOL CELL, V1, P47, DOI 10.1016/S1097-2765(00)80006-4; Ren B, 1997, J BIOL CHEM, V272, P26827, DOI 10.1074/jbc.272.43.26827; Sakai J, 1998, MOL CELL, V2, P505, DOI 10.1016/S1097-2765(00)80150-1; SHENG ZQ, 1995, P NATL ACAD SCI USA, V92, P935, DOI 10.1073/pnas.92.4.935; Shimano H, 1996, J CLIN INVEST, V98, P1575, DOI 10.1172/JCI118951; Shimano H, 1999, J BIOL CHEM, V274, P35832, DOI 10.1074/jbc.274.50.35832; Shimano H, 1997, J CLIN INVEST, V99, P846, DOI 10.1172/JCI119248; Shimano H, 1997, J CLIN INVEST, V100, P2115, DOI 10.1172/JCI119746; Shimomura I, 1998, J BIOL CHEM, V273, P35299, DOI 10.1074/jbc.273.52.35299; SHORT MK, 1992, MOL CELL BIOL, V12, P1007, DOI 10.1128/MCB.12.3.1007; Tabor DE, 1998, J BIOL CHEM, V273, P22052, DOI 10.1074/jbc.273.34.22052; Waters KM, 1997, BBA-LIPID LIPID MET, V1349, P33, DOI 10.1016/S0005-2760(97)00069-6; Worgall TS, 1998, J BIOL CHEM, V273, P25537, DOI 10.1074/jbc.273.40.25537	28	275	282	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 10	1999	274	50					35840	35844		10.1074/jbc.274.50.35840	http://dx.doi.org/10.1074/jbc.274.50.35840			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	264NG	10585468	hybrid			2022-12-25	WOS:000084187900080
J	Levadoux, M; Mahon, C; Beattie, JH; Wallace, HM; Hesketh, JE				Levadoux, M; Mahon, C; Beattie, JH; Wallace, HM; Hesketh, JE			Nuclear import of metallothionein requires its mRNA to be associated with the perinuclear cytoskeleton	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA LOCALIZATION; BOUND POLYSOMES; 3'-UNTRANSLATED REGION; PROTEIN-SYNTHESIS; RAT HEPATOCYTES; C-MYC; CYTOPLASM; SEQUENCES; CELLS; LIVER	The influence of mRNA localization on metallothionein-l protein distribution was studied by immunocytochemistry. We used Chinese hamster ovary cells that had been transfected with either a native metallothionein-l gene construct or metallothionein-l 5'-untranslated region and coding sequences linked to the 3'-untranslated region from glutathione peroxidase. The change in the 3'-untranslated region caused the delocalization of the mRNA with a loss of the perinuclear localization and association with the cytoskeleton. Clones were selected which expressed similar levels of metallothionein-l protein, as assessed by radioimmunoassay. The results showed that loss of metallothionein-l mRNA localization was associated with a loss of metallothionein-l protein localization, most notably with a lack of metallothionein-l protein in the nucleus of synchronized cells which were beginning to synthesize DNA This indicates that the association of metallothionein-l mRNA with the cytoskeleton around the nucleus is essential for efficient shuttling of the protein into the nucleus during the G(1) to S phase transition. This is the first demonstration of a physiological role for perinuclear mRNA localization and we propose that such localization may be important for a wide range of nuclear proteins, including those that shuttle between nucleus and cytoplasm in a cell cycle dependent manner.	Rowett Res Inst, Bucksburn AB21 9SB, Aberdeen, Scotland; Univ Aberdeen, Dept Med & Therapeut, Aberdeen AB25 2ZD, Scotland; Univ Aberdeen, Dept Biomed Sci, Aberdeen AB25 2ZD, Scotland	University of Aberdeen; University of Aberdeen; University of Aberdeen	Hesketh, JE (corresponding author), Univ Newcastle Upon Tyne, Dept Biol & Nutr Sci, Kings Rd, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England.							BREMNER I, 1990, ANNU REV NUTR, V10, P63, DOI 10.1146/annurev.nu.10.070190.000431; CHANG HL, 1977, J CELL PHYSIOL, V92, P333, DOI 10.1002/jcp.1040920302; CHUBATSU LS, 1993, BIOCHEM J, V291, P193, DOI 10.1042/bj2910193; DIN WS, 1985, BIOCHEM J, V230, P395, DOI 10.1042/bj2300395; HAMER DH, 1986, ANNU REV BIOCHEM, V55, P913, DOI 10.1146/annurev.biochem.55.1.913; HESKETH J, 1994, MOL BIOL REP, V19, P233, DOI 10.1007/BF00986965; HESKETH J, 1994, BIOCHEM J, V298, P143, DOI 10.1042/bj2980143; Hesketh JE, 1996, EXP CELL RES, V225, P219, DOI 10.1006/excr.1996.0172; KISLAUSKIS EH, 1993, J CELL BIOL, V123, P165, DOI 10.1083/jcb.123.1.165; Kondo Y, 1997, MOL PHARMACOL, V52, P195, DOI 10.1124/mol.52.2.195; Mahon P, 1997, BBA-MOL CELL RES, V1358, P153, DOI 10.1016/S0167-4889(97)00058-X; MAHON P, 1995, FEBS LETT, V373, P76, DOI 10.1016/0014-5793(95)01000-5; MEHRA RK, 1983, BIOCHEM J, V213, P459, DOI 10.1042/bj2130459; Micklem DR, 1995, DEV BIOL, V172, P377, DOI 10.1006/dbio.1995.8048; PANEMANGALORE M, 1983, DEV BIOL, V97, P95, DOI 10.1016/0012-1606(83)90067-2; PARDEE AB, 1978, ANNU REV BIOCHEM, V47, P715, DOI 10.1146/annurev.bi.47.070178.003435; STJOHNSTON D, 1995, CELL, V81, P161, DOI 10.1016/0092-8674(95)90324-0; Studer R, 1997, BIOCHEM J, V328, P63, DOI 10.1042/bj3280063; SUNDELL CL, 1990, J CELL BIOL, V111, P2397, DOI 10.1083/jcb.111.6.2397; TSUJIKAWA K, 1991, FEBS LETT, V283, P239, DOI 10.1016/0014-5793(91)80597-V; Veyrune JL, 1996, J CELL SCI, V109, P1185; WILLIAMS LM, 1989, TOXICOLOGY, V55, P307, DOI 10.1016/0300-483X(89)90020-6; ZAMBETTI G, 1990, J CELL BIOCHEM, V44, P177, DOI 10.1002/jcb.240440306	23	45	46	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 3	1999	274	49					34961	34966		10.1074/jbc.274.49.34961	http://dx.doi.org/10.1074/jbc.274.49.34961			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	260XW	10574972	hybrid			2022-12-25	WOS:000083979600066
J	D'Addario, M; Ahmad, A; Xu, JW; Menezes, J				D'Addario, M; Ahmad, A; Xu, JW; Menezes, J			Epstein-Barr virus envelope glycoprotein gp350 induces NF-kappa B activation and IL-1 beta synthesis in human monocytes-macrophages involving PKC and PI3-K	FASEB JOURNAL			English	Article						EBV gp350; interleukin 1 beta; signal transduction; transcription factors	TUMOR-NECROSIS-FACTOR; BLOOD MONONUCLEAR-CELLS; 2 DISTINCT PATHWAYS; HUMAN LYMPHOCYTES-B; C3D RECEPTOR CR-2; GENE-EXPRESSION; FACTOR-ALPHA; INTERLEUKIN-1-BETA GENE; SIGNAL-TRANSDUCTION; HERPES-SIMPLEX	Epstein-Barr virus (EBV) is a highly immunotropic human herpesvirus with oncogenic potential and is involved in numerous pathologies, EBV utilizes its major envelope glycoprotein gp350 to bind to its receptor CR2/CD21 on target cells for initiating the infection, We have previously shown that EBV is able to modulate transcription and translation of a number of cytokine genes via its gp350-mediated binding to this receptor. However, the effects of the binding of purified gp350 to CR2/CD21 on plastic-adherent monocyte-macrophages (AMM) have not been investigated, These cells are a rich source of potent proinflammatory and immune-modulating cytokines, and express low levels of CR2/CD21, We show here for the first time that recombinant gp350 (rgp350) causes production of the potent proinflammatory cytokine LG-1 beta in human AMM, Surprisingly, rgp350 is comparable in this capacity to the phorbol ester 12-0-tetradecanoylphorbol 13-acetate, This induction of IL-1 beta production was accompanied by increased steady-state levels of its mRNA in gp350-treated AMM, and was dependent on the specific binding of rgp350 to the EBV receptor CR2/CD21, We also show that the signaling pathways resulting in the induction of IL-1 beta synthesis by rgp350 required protein kinase C and phosphatidylinositol 3,4,5 triphosphate kinase activities and occurred via activation of the NF-kappa B family of transcription factors.	Hop St Justine, Lab Immunovirol, Montreal, PQ H3T 1C5, Canada; Univ Montreal, Dept Immunol & Microbiol, Lab Immunovirol, Montreal, PQ H3T 1C5, Canada; Univ Montreal, Pediat Res Ctr, Montreal, PQ H3T 1C5, Canada	Universite de Montreal; Universite de Montreal; Universite de Montreal	Menezes, J (corresponding author), Hop St Justine, Lab Immunovirol, 3175 Cote St Catherine, Montreal, PQ H3T 1C5, Canada.			Ahmad, Ali/0000-0001-7689-7115				Ahmad A, 1997, J IMMUNOL, V159, P3984; ANTWERP DJV, 1996, SCIENCE, V274, P787; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; BAREL M, 1995, MOL IMMUNOL, V32, P389, DOI 10.1016/0161-5890(95)00005-Y; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; BIRKENBACH M, 1992, J EXP MED, V176, P1405, DOI 10.1084/jem.176.5.1405; BLACKSHEAR PJ, 1988, FASEB J, V2, P2957, DOI 10.1096/fasebj.2.14.2972578; Bouillie S, 1999, J IMMUNOL, V162, P136; BOUILLIE S, 1995, EUR J IMMUNOL, V25, P2661, DOI 10.1002/eji.1830250939; Chang HW, 1997, SCIENCE, V276, P1848, DOI 10.1126/science.276.5320.1848; Chen WP, 1996, J VIROL, V70, P4849, DOI 10.1128/JVI.70.7.4849-4853.1996; COGSWELL JP, 1994, J IMMUNOL, V153, P712; COOPER NR, 1988, ANNU REV IMMUNOL, V6, P85; DADDARIO M, 1992, J IMMUNOL, V148, P1222; DADDARIO M, 1990, J VIROL, V64, P6080, DOI 10.1128/JVI.64.12.6080-6089.1990; Dinarello CA, 1996, BLOOD, V87, P2095, DOI 10.1182/blood.V87.6.2095.bloodjournal8762095; EPSTEIN MA, 1985, NATURE, V318, P287, DOI 10.1038/318287a0; FEARON DT, 1995, ANNU REV IMMUNOL, V13, P127, DOI 10.1146/annurev.immunol.13.1.127; FENTON MJ, 1988, J IMMUNOL, V140, P2267; FINGEROTH JD, 1988, J VIROL, V62, P1442, DOI 10.1128/JVI.62.4.1442-1447.1988; FINGEROTH JD, 1984, P NATL ACAD SCI-BIOL, V81, P4510, DOI 10.1073/pnas.81.14.4510; FLAMAND L, 1991, J VIROL, V65, P5105, DOI 10.1128/JVI.65.9.5105-5110.1991; FRADE R, 1985, P NATL ACAD SCI USA, V82, P1400; Franke TF, 1997, CELL, V88, P435, DOI 10.1016/S0092-8674(00)81883-8; GOSSELIN J, 1992, J IMMUNOL, V149, P181; GOSSELIN J, 1992, J CLIN INVEST, V89, P1849, DOI 10.1172/JCI115789; GOSSELIN J, 1991, EUR J IMMUNOL, V21, P203, DOI 10.1002/eji.1830210130; GRAY JG, 1993, MOL CELL BIOL, V13, P6678, DOI 10.1128/MCB.13.11.6678; HEDRICK JA, 1994, J IMMUNOL, V153, P4418; HISCOTT J, 1993, MOL CELL BIOL, V13, P6231, DOI 10.1128/MCB.13.10.6231; HOFFMAN GJ, 1980, P NATL ACAD SCI-BIOL, V77, P2979, DOI 10.1073/pnas.77.5.2979; INADA S, 1983, P NATL ACAD SCI-BIOL, V80, P2351, DOI 10.1073/pnas.80.8.2351; KASPAR RL, 1994, J IMMUNOL, V153, P277; KHANNA R, 1995, MICROBIOL REV, V59, P387, DOI 10.1128/MMBR.59.3.387-405.1995; Kieff E., 1996, FIELDS VIROLOGY, V2, P2343; LINT YZ, 1995, J BIOL CHEM, V270, P14255; Liu Y, 1997, J IMMUNOL, V158, P604; MADEJ M, 1992, VACCINE, V10, P777, DOI 10.1016/0264-410X(92)90513-J; May MJ, 1998, IMMUNOL TODAY, V19, P80, DOI 10.1016/S0167-5699(97)01197-3; MENEZES J, 1976, INFECT IMMUN, V13, P303, DOI 10.1128/IAI.13.2.303-310.1976; MILLER G, 1973, J EXP MED, V138, P1398, DOI 10.1084/jem.138.6.1398; MIYAMOTO S, 1995, ADV CANCER RES, V66, P255, DOI 10.1016/S0065-230X(08)60257-2; MOORE KW, 1993, ANNU REV IMMUNOL, V11, P165, DOI 10.1146/annurev.immunol.11.1.165; NEMEROW GR, 1985, J VIROL, V55, P347, DOI 10.1128/JVI.55.2.347-351.1985; PAHL HL, 1995, J VIROL, V69, P1480, DOI 10.1128/JVI.69.3.1480-1484.1995; Pan ZK, 1996, J CLIN INVEST, V98, P2042, DOI 10.1172/JCI119009; PATERSON RLK, 1995, J IMMUNOL, V154, P1440; RICKINSON AB, 1996, FIELDS VIROLOGY, P2397; SAUVAGEAU G, 1990, J GEN VIROL, V71, P379, DOI 10.1099/0022-1317-71-2-379; Sugano N, 1997, J EXP MED, V186, P731, DOI 10.1084/jem.186.5.731; SUN SC, 1994, MOL CELL BIOL, V14, P7377, DOI 10.1128/MCB.14.11.7377; TANNER J, 1987, CELL, V50, P203, DOI 10.1016/0092-8674(87)90216-9; Tanner JE, 1996, J VIROL, V70, P570, DOI 10.1128/JVI.70.1.570-575.1996; Tedder TF, 1997, IMMUNITY, V6, P107, DOI 10.1016/S1074-7613(00)80418-5; UNANUE ER, 1996, FUNDAMENTAL VIROLOGY, P111; [No title captured]	56	33	33	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	DEC	1999	13	15					2203	2213		10.1096/fasebj.13.15.2203	http://dx.doi.org/10.1096/fasebj.13.15.2203			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	266QN	10593868				2022-12-25	WOS:000084310800012
J	Koya, D; Dennis, JW; Warren, CE; Takahara, N; Schoen, FJ; Nishio, Y; Nakajima, T; Lipes, MA; King, GL				Koya, D; Dennis, JW; Warren, CE; Takahara, N; Schoen, FJ; Nishio, Y; Nakajima, T; Lipes, MA; King, GL			Overexpression of core 2 N-acetylglycosaminyltransferase enhances cytokine actions and induces hypertrophic myocardium in transgenic mice	FASEB JOURNAL			English	Article						O-linked glycans; diabetes; cardiac hypertrophy; MAP kinase activation	CARDIAC GENE-EXPRESSION; SELECTIN GLYCOPROTEIN LIGAND-1; P-SELECTIN; PROTEIN; SPECIFICITY; ACTIVATION; OLIGOSACCHARIDES; BIOSYNTHESIS; RECEPTORS; DISEASE	Elevated levels of glycocojugates, commonly observed in the myocardium of diabetic animals and patients, are postulated to contribute to the myocardial dysfunction in diabetes. Previously, we reported that UDP-GlcNAc: Gal beta 1-3GalNAc alpha R beta 1-6-N-acetylglucosaminyltransferase (core 2 GlcNAc-T), a developmentally regulated enzyme of O-linked glycans biosynthesis pathway, is specifically increased in the heart of diabetic animals and Is regulated by hyperglycemia and insulin. In this study, transgenic mice overexpressing core 2 GlcNAc-T with severe increase in cardiac core 2 GlcNAc-T activities were normal at birth but showed progressive and significant cardiac hypertrophy at 6 months of age. The heart of transgenic mice showed elevation of sialylated O-glycan and increases of c-fos gene expression and AP-I activity, which are characteristics of cardiac stress. Furthermore, transfection of PC12 cells with core 2 GlcNAc-T also induced c-fos promoter activation, mitogen activated-protein kinase (MAPK) phosphorylation, Trk receptor glycosylation, and cell differentiation. These results suggested a novel role for core 2 GlcNAc-T in the development of diabetic cardiomyopathy and modulation of the MAP kinase pathway in the heart.	Joslin Diabet Ctr, Div Res, Boston, MA 02215 USA; Harvard Univ, Sch Med, Boston, MA 02215 USA; Brigham & Womens Hosp, Dept Pathol, Boston, MA 02215 USA; Univ Toronto, Mt Sinai Hosp, Samuel Lunenfeld Res Inst, Toronto, ON M5G 1X5, Canada	Harvard University; Joslin Diabetes Center, Inc.; Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute	King, GL (corresponding author), Joslin Diabet Ctr, Div Res, 1 Joslin Pl, Boston, MA 02215 USA.	Kingg@joslab.harvard.edu	Koya, Daisuke/J-3257-2014; Takahara, Naminatsu/K-8497-2019; Dennis, James/E-7268-2013		NEI NIH HHS [EY05110] Funding Source: Medline; NIDDK NIH HHS [DK 36836, DK53281] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK036836, R01DK053281] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Barran P, 1997, GLYCOBIOLOGY, V7, P129, DOI 10.1093/glycob/7.1.129; BELL DSH, 1995, DIABETES CARE, V18, P708, DOI 10.2337/diacare.18.5.708; BIERHUIZEN MFA, 1995, GLYCOBIOLOGY, V5, P417, DOI 10.1093/glycob/5.4.417; Chakravarti D, 1996, NATURE, V383, P99, DOI 10.1038/383099a0; CHIEN KR, 1991, FASEB J, V5, P3037, DOI 10.1096/fasebj.5.15.1835945; FISHMAN GI, 1994, J CLIN INVEST, V93, P1864, DOI 10.1172/JCI117174; FRAIN M, 1989, CELL, V59, P145, DOI 10.1016/0092-8674(89)90877-5; GARCIA MJ, 1974, DIABETES, V23, P105, DOI 10.2337/diab.23.2.105; HAY N, 1989, GENE DEV, V3, P293, DOI 10.1101/gad.3.3.293; HIGGINS EA, 1991, J BIOL CHEM, V266, P6280; HILL CS, 1995, CELL, V80, P199, DOI 10.1016/0092-8674(95)90403-4; Ihara Y, 1997, J BIOL CHEM, V272, P9629; IZUMO S, 1988, P NATL ACAD SCI USA, V85, P339, DOI 10.1073/pnas.85.2.339; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; Koya D, 1998, DIABETES, V47, P859, DOI 10.2337/diabetes.47.6.859; Li FG, 1996, J BIOL CHEM, V271, P3255, DOI 10.1074/jbc.271.6.3255; LIPES MA, 1993, SCIENCE, V259, P1165, DOI 10.1126/science.8267690; MAHDAVI V, 1984, P NATL ACAD SCI-BIOL, V81, P2626, DOI 10.1073/pnas.81.9.2626; MANJUNATH N, 1995, NATURE, V377, P535, DOI 10.1038/377535a0; McEvoy LM, 1997, J EXP MED, V185, P1493, DOI 10.1084/jem.185.8.1493; Nakajima T, 1996, CELL, V86, P465, DOI 10.1016/S0092-8674(00)80119-1; Nesto RW, 1998, CIRCULATION, V97, P811; NISHIO Y, 1995, J CLIN INVEST, V96, P1759, DOI 10.1172/JCI118221; PILLER F, 1988, J BIOL CHEM, V263, P15146; Raman M, 1996, ENDOCRIN METAB CLIN, V25, P425, DOI 10.1016/S0889-8529(05)70331-5; ROGERIEUX F, 1993, ANAL BIOCHEM, V211, P200, DOI 10.1006/abio.1993.1257; SCHACHTER H, 1986, BIOCHEM CELL BIOL, V64, P163, DOI 10.1139/o86-026; SCHROTER H, 1990, EMBO J, V9, P1123, DOI 10.1002/j.1460-2075.1990.tb08218.x; SPIRO MJ, 1992, J MOL CELL CARDIOL, V24, P397, DOI 10.1016/0022-2828(92)93194-O; Tsuboi S, 1997, EMBO J, V16, P6364, DOI 10.1093/emboj/16.21.6364; URFER R, 1995, EMBO J, V14, P2795, DOI 10.1002/j.1460-2075.1995.tb07279.x; VACHINO G, 1995, J BIOL CHEM, V270, P21966, DOI 10.1074/jbc.270.37.21966; Wakasaki H, 1997, P NATL ACAD SCI USA, V94, P9320, DOI 10.1073/pnas.94.17.9320; YOUSEFI S, 1991, J BIOL CHEM, V266, P1772	34	21	27	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	1999	13	15					2329	2337		10.1096/fasebj.13.15.2329	http://dx.doi.org/10.1096/fasebj.13.15.2329			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	266QN	10593880				2022-12-25	WOS:000084310800024
J	Li, H; Cao, Y; Berndt, MC; Funder, JW; Liu, JP				Li, H; Cao, Y; Berndt, MC; Funder, JW; Liu, JP			Molecular interactions between telomerase and the tumor suppressor protein p53 in vitro	ONCOGENE			English	Article						telomerase reverse transcriptase (TERT); telomerase-associated protein 1 (TEP1); p53; telomerase inhibitory polypeptide 1 (TEIPP1); breast cancer cells	CATALYTIC SUBUNIT GENE; BREAST-CANCER CELLS; RNA COMPONENT; SPONTANEOUS IMMORTALIZATION; TETRAHYMENA TELOMERASE; REVERSE-TRANSCRIPTASE; MAMMALIAN TELOMERASE; MOUSE TELOMERASE; MUTANT P53; LIFE-SPAN	The telomere DNA polymerase (telomerase) and the tumor suppressor protein p53 are frequently associated with human cancers, and activation of telomerase and inactivation of p53 involved in cancer cell immortalization. In this report, we demonstrate a direct interaction of telomerase with p53 in the nuclear lysates of human breast cancer cells, and with recombinant human p53, by affinity chromatography and immunoprecipitation. On activity criteria, the interaction is between the carboxyl-terminal region of p53 and a region close to the amino-terminus of human telomerase-associated protein 1 (hTEP1). Incubation of recombinant p53 with nuclear telomerase extracts results in inhibition of telomerase activity, with the C-terminal region of p53 being essential for inhibition. This effect is not mediated by binding to telomerase substrate DNA, but requires the region near the N-terminus of hTEP1, in that a synthetic peptide derived from this region of hTEP1 similarly inhibits telomerase activity. Together, these in vitro interactions between telomerase and p53 suggest that the activity of telomerase may be regulated by p53, downregulation of which in turn would favor up-regulation of telomerase activity in cancer cell development.	Baker Med Res Inst, Mol Signalling Lab, Prahran, Vic 3181, Australia	Baker Heart and Diabetes Institute	Liu, JP (corresponding author), Baker Med Res Inst, Mol Signalling Lab, POB 6492,St Kilda Rd Cent, Melbourne, Vic 8008, Australia.		Berndt, Michael C/D-5580-2012; Liu, Jun-Ping/AAA-5521-2020	Liu, Jun-Ping/0000-0001-7442-2116				ATADJA P, 1995, P NATL ACAD SCI USA, V92, P8348, DOI 10.1073/pnas.92.18.8348; Beattie TL, 1998, CURR BIOL, V8, P177, DOI 10.1016/S0960-9822(98)70067-3; BLACKBURN EH, 1992, ANNU REV BIOCHEM, V61, P113, DOI 10.1146/annurev.bi.61.070192.000553; Blasco MA, 1996, NAT GENET, V12, P200, DOI 10.1038/ng0296-200; Bodnar AG, 1998, SCIENCE, V279, P349, DOI 10.1126/science.279.5349.349; BOND JA, 1994, ONCOGENE, V9, P1885; Broccoli D, 1996, MOL CELL BIOL, V16, P3765; COLLINS K, 1995, CELL, V81, P677, DOI 10.1016/0092-8674(95)90529-4; Counter CM, 1998, P NATL ACAD SCI USA, V95, P14723, DOI 10.1073/pnas.95.25.14723; Counter CM, 1997, P NATL ACAD SCI USA, V94, P9202, DOI 10.1073/pnas.94.17.9202; de Lange T, 1998, NATURE, V392, P753, DOI 10.1038/33790; DELANGE T, 1994, P NATL ACAD SCI USA, V91, P2882, DOI 10.1073/pnas.91.8.2882; FENG JL, 1995, SCIENCE, V269, P1236, DOI 10.1126/science.7544491; Fujimoto K, 1997, BIOCHEM BIOPH RES CO, V241, P775, DOI 10.1006/bbrc.1997.7806; Gollahon LS, 1998, ONCOGENE, V17, P709, DOI 10.1038/sj.onc.1201987; Gollahon LS, 1996, ONCOGENE, V12, P715; Greenberg RA, 1998, ONCOGENE, V16, P1723, DOI 10.1038/sj.onc.1201933; GREIDER CW, 1989, NATURE, V337, P331, DOI 10.1038/337331a0; Greider CW, 1998, CURR BIOL, V8, pR178, DOI 10.1016/S0960-9822(98)70105-8; Greider CW, 1996, ANNU REV BIOCHEM, V65, P337, DOI 10.1146/annurev.bi.65.070196.002005; HARLEY CB, 1994, COLD SPRING HARB SYM, V59, P307, DOI 10.1101/SQB.1994.059.01.035; Harrington L, 1997, GENE DEV, V11, P3109, DOI 10.1101/gad.11.23.3109; Harrington L, 1997, SCIENCE, V275, P973, DOI 10.1126/science.275.5302.973; Kilian A, 1997, HUM MOL GENET, V6, P2011, DOI 10.1093/hmg/6.12.2011; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; Klingelhutz AJ, 1996, NATURE, V380, P79, DOI 10.1038/380079a0; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Kondo S, 1998, FASEB J, V12, P801, DOI 10.1096/fasebj.12.10.801; Lee HW, 1998, NATURE, V392, P569, DOI 10.1038/33345; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Li H, 1998, J BIOL CHEM, V273, P33436, DOI 10.1074/jbc.273.50.33436; Li H, 1997, J BIOL CHEM, V272, P16729, DOI 10.1074/jbc.272.27.16729; Lingner J, 1996, P NATL ACAD SCI USA, V93, P10712, DOI 10.1073/pnas.93.20.10712; Lingner J, 1997, SCIENCE, V276, P561, DOI 10.1126/science.276.5312.561; Meyerson M, 1997, CELL, V90, P785, DOI 10.1016/S0092-8674(00)80538-3; Nakamura TM, 1997, SCIENCE, V277, P955, DOI 10.1126/science.277.5328.955; Nakayama JI, 1998, NAT GENET, V18, P65, DOI 10.1038/ng0198-65; Nakayama JI, 1997, CELL, V88, P875, DOI 10.1016/S0092-8674(00)81933-9; Niida H, 1998, NAT GENET, V19, P203, DOI 10.1038/580; Oren M, 1998, NATURE, V391, P233, DOI 10.1038/34551; Ouellette MM, 1999, BIOCHEM BIOPH RES CO, V254, P795, DOI 10.1006/bbrc.1998.0114; ROGAN EM, 1995, MOL CELL BIOL, V15, P4745; Roos G, 1998, INT J CANCER, V79, P343, DOI 10.1002/(SICI)1097-0215(19980821)79:4<343::AID-IJC6>3.0.CO;2-V; RUPPERT JM, 1993, MOL CELL BIOL, V13, P3811, DOI 10.1128/MCB.13.6.3811; Sedivy JM, 1998, P NATL ACAD SCI USA, V95, P9078, DOI 10.1073/pnas.95.16.9078; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Shay JW, 1997, EUR J CANCER, V33, P787, DOI 10.1016/S0959-8049(97)00062-2; SHIPPENLENTZ D, 1990, SCIENCE, V247, P546, DOI 10.1126/science.1689074; Takakura M, 1999, CANCER RES, V59, P551; Tsao DA, 1998, GENE, V221, P51, DOI 10.1016/S0378-1119(98)00432-6; Vaziri H, 1998, CURR BIOL, V8, P279, DOI 10.1016/S0960-9822(98)70109-5; Wang J, 1998, GENE DEV, V12, P1769, DOI 10.1101/gad.12.12.1769; Weinrich SL, 1997, NAT GENET, V17, P498, DOI 10.1038/ng1297-498; Wen JP, 1998, HUM MOL GENET, V7, P1137, DOI 10.1093/hmg/7.7.1137; WHITEHEAD RH, 1984, JNCI-J NATL CANCER I, V73, P643; Wu KJ, 1999, NAT GENET, V21, P220, DOI 10.1038/6010; WynfordThomas D, 1996, J PATHOL, V180, P118, DOI 10.1002/(SICI)1096-9896(199610)180:2<118::AID-PATH673>3.0.CO;2-I; ZAKIAN VA, 1995, SCIENCE, V270, P1601, DOI 10.1126/science.270.5242.1601	58	69	89	0	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 18	1999	18	48					6785	6794		10.1038/sj.onc.1203061	http://dx.doi.org/10.1038/sj.onc.1203061			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	257QA	10597287				2022-12-25	WOS:000083792000021
J	Somasundaram, K; MacLachlan, TK; Burns, TF; Sgagias, M; Cowan, KH; Weber, BL; El-Deiry, WS				Somasundaram, K; MacLachlan, TK; Burns, TF; Sgagias, M; Cowan, KH; Weber, BL; El-Deiry, WS			BRCA1 signals ARF-dependent stabilization and coactivation of p53	ONCOGENE			English	Article						p53; BRCA1; p14(ARF)	CELL-CYCLE CONTROL; TUMOR-SUPPRESSOR; OVARIAN-CANCER; TRANSCRIPTIONAL ACTIVATION; GENE BRCA1; DNA-DAMAGE; BREAST; EXPRESSION; APOPTOSIS; ARREST	The hereditary breast and ovarian tumor suppressor BRCA1 can activate p53-dependent gene expression. We show here that BRCA1 increases p53 protein levels through a post-transcriptional mechanism. BRCA1-stabilized p53 has increased sequence-specific DNA-binding and transcriptional activity, BRCA1 does not stabilize p53 in p14(ARF)-deficient cells. A deletion mutant of BRCA1 which inhibits p53-dependent transcription confers resistance to topoisomerase II-targeted chemotherapy, Our results suggest that BRCA1 may trigger the p53 pathway through two potentially separate mechanisms: accumulation of p53 through a direct or indirect induction of p14(ARF) as well as direct transcriptional coactivation of p53, BRCA1 may also enhance chemosensitivity and repair of DNA damage through binding to and coactivation of p53.	Univ Penn, Sch Med, Lab Mol Oncol & Cell Cycle Regulat, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Howard Hughes Med Inst, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Med & Genet, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Pharmacol, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Ctr Canc, Philadelphia, PA 19104 USA; NCI, Med Branch, Bethesda, MD 20892 USA	University of Pennsylvania; Howard Hughes Medical Institute; University of Pennsylvania; University of Pennsylvania; University of Pennsylvania; University of Pennsylvania; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	El-Deiry, WS (corresponding author), Univ Penn, Sch Med, Lab Mol Oncol & Cell Cycle Regulat, CRB 437A,415 Curie Blvd, Philadelphia, PA 19104 USA.		El-Deiry, Wafik/AAJ-6080-2020	El-Deiry, Wafik/0000-0002-9577-8266	NATIONAL CANCER INSTITUTE [R01CA076417] Funding Source: NIH RePORTER; NCI NIH HHS [CA7641701] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADAMS PD, 1995, SEMIN CANCER BIOL, V6, P99, DOI 10.1006/scbi.1995.0013; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; Bates S, 1998, NATURE, V395, P124, DOI 10.1038/25867; Blagosklonny MV, 1996, INT J CANCER, V67, P386, DOI 10.1002/(SICI)1097-0215(19960729)67:3<386::AID-IJC13>3.0.CO;2-6; Chapman MS, 1996, NATURE, V382, P678, DOI 10.1038/382678a0; de Stanchina E, 1998, GENE DEV, V12, P2434, DOI 10.1101/gad.12.15.2434; EASTON DF, 1995, AM J HUM GENET, V56, P265; El-Deiry WS, 1998, SEMIN CANCER BIOL, V8, P345, DOI 10.1006/scbi.1998.0097; ELDEIRY WS, 1994, CANCER RES, V54, P1169; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; ELDEIRY WS, 1995, CANCER RES, V55, P2910; Field SJ, 1996, CELL, V85, P549, DOI 10.1016/S0092-8674(00)81255-6; FUTREAL PA, 1994, SCIENCE, V266, P120, DOI 10.1126/science.7939630; Garcia-Patino E, 1998, CANCER GENET CYTOGEN, V104, P119, DOI 10.1016/S0165-4608(97)00460-3; Hakem R, 1996, CELL, V85, P1009, DOI 10.1016/S0092-8674(00)81302-1; HALL JM, 1990, SCIENCE, V250, P1684, DOI 10.1126/science.2270482; Katayose D, 1995, CLIN CANCER RES, V1, P889; LATHANGUE NB, 1994, CURR OPIN CELL BIOL, V6, P443, DOI 10.1016/0955-0674(94)90038-8; Li S, 1999, J BIOL CHEM, V274, P11334, DOI 10.1074/jbc.274.16.11334; LOVERING R, 1993, P NATL ACAD SCI USA, V90, P2112, DOI 10.1073/pnas.90.6.2112; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; Monteiro ANA, 1996, P NATL ACAD SCI USA, V93, P13595, DOI 10.1073/pnas.93.24.13595; Ouchi T, 1998, P NATL ACAD SCI USA, V95, P2302, DOI 10.1073/pnas.95.5.2302; Palmero I, 1998, NATURE, V395, P125, DOI 10.1038/25870; Polyak K, 1996, GENE DEV, V10, P1945, DOI 10.1101/gad.10.15.1945; Scully R, 1997, CELL, V88, P265, DOI 10.1016/S0092-8674(00)81847-4; Scully R, 1997, CELL, V90, P425, DOI 10.1016/S0092-8674(00)80503-6; Scully R, 1997, P NATL ACAD SCI USA, V94, P5605, DOI 10.1073/pnas.94.11.5605; Smith PD, 1999, ONCOGENE, V18, P2451, DOI 10.1038/sj.onc.1202565; Somasundaram K, 1997, NATURE, V389, P187, DOI 10.1038/38291; Somasundaram K, 1996, P NATL ACAD SCI USA, V93, P3088, DOI 10.1073/pnas.93.7.3088; Somasundaram K, 1997, ONCOGENE, V14, P1047, DOI 10.1038/sj.onc.1201002; STONE S, 1995, CANCER RES, V55, P2988; Stott FJ, 1998, EMBO J, V17, P5001, DOI 10.1093/emboj/17.17.5001; SZABO CI, 1995, HUM MOL GENET, V4, P1811, DOI 10.1093/hmg/4.suppl_1.1811; Thomas JE, 1997, CELL GROWTH DIFFER, V8, P801; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; Zeng YX, 1997, NAT GENET, V15, P78, DOI 10.1038/ng0197-78; Zhang HB, 1998, ONCOGENE, V16, P1713, DOI 10.1038/sj.onc.1201932; Zindy F, 1998, GENE DEV, V12, P2424, DOI 10.1101/gad.12.15.2424	40	57	59	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 11	1999	18	47					6605	6614		10.1038/sj.onc.1203284	http://dx.doi.org/10.1038/sj.onc.1203284			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	256CW	10597265				2022-12-25	WOS:000083709200025
J	Philips, A; Chambeyron, S; Lamb, N; Vie, A; Blanchard, JM				Philips, A; Chambeyron, S; Lamb, N; Vie, A; Blanchard, JM			CHF: a novel factor binding to cyclin A CHR corepressor element	ONCOGENE			English	Article						cyclin A; transcription; cell cycle	CELL-CYCLE; RETINOBLASTOMA PROTEIN; REGULATED TRANSCRIPTION; GENE-EXPRESSION; DNA-SYNTHESIS; A EXPRESSION; E2F SITE; REPRESSION; FIBROBLASTS; PROMOTER	Cell cycle modulation of cyclin A expression is due to the periodic relief of a transcriptional repression mediated by a bipartite negative DNA regulatory region. The 5' element (Cell Cycle Responsive Element: CCRE; cell CYcle Dependent Element: CDE) is clearly occupied in a cyclic manner in vivo, whereas the 3' element, whose sequence is shared by B-myb, cdc25C and cdc2 genes (cell Cycle gene Homology Region: CHR), is involved in more subtle interactions. Mutation of either element results in complete deregulation of cyclin A promoter activity. Whereas some reports claim that E2F/DP can bind to the CCRE/CDE, the nature of the protein(s) interacting with the CHR is unknown. In the present work me have characterized an activity present in quiescent cells and absent in cells blocked in S phase, which binds specifically to cyclin A CHR, but not to B-myb, or to cdc25C, or to cdc2 CHRs. A 90 kD protein, named CHF (cyclin A CHR binding factor), has been identified through preparative electrophoresis and UV crosslinking experiments. In order to address in more functional terms the binding of CHF to cyclin A CHR, we developed in vitro and in vivo oligonucleotide competition assays. Both in vitro transcription and in vivo microinjection experiments demonstrate that a functional difference exists between the composite CCRE/CDE-CHR repressor regions of cell cycle regulated genes such as cyclin A and cdc25C.	Inst Genet Mol, CNRS, UMR 5535, F-34293 Montpellier 5, France; Inst Genet Humaine, CNRS, F-34396 Montpellier, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Universite de Montpellier; Centre National de la Recherche Scientifique (CNRS); Universite de Montpellier	Blanchard, JM (corresponding author), Inst Genet Mol, CNRS, UMR 5535, 1919 Route Mende, F-34293 Montpellier 5, France.		PHILIPS, Alexandre/AAB-6047-2020	Chambeyron, severine/0000-0003-2775-6556				BARLAT I, 1995, ONCOGENE, V11, P1309; BARLAT I, 1993, CELL GROWTH DIFFER, V4, P105; DEGREGORI J, 1995, MOL CELL BIOL, V15, P4215; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; GIRARD F, 1991, CELL, V67, P1169, DOI 10.1016/0092-8674(91)90293-8; Herrera RE, 1996, MOL CELL BIOL, V16, P2402; Huet X, 1996, MOL CELL BIOL, V16, P3789; Knudsen ES, 1998, GENE DEV, V12, P2278, DOI 10.1101/gad.12.15.2278; Korner K, 1997, NUCLEIC ACIDS RES, V25, P4933, DOI 10.1093/nar/25.24.4933; Liu NS, 1996, NUCLEIC ACIDS RES, V24, P2905, DOI 10.1093/nar/24.15.2905; Liu NS, 1997, NUCLEIC ACIDS RES, V25, P4915, DOI 10.1093/nar/25.24.4915; Liu NS, 1998, ONCOGENE, V16, P2957, DOI 10.1038/sj.onc.1201838; Lucibello FC, 1997, NUCLEIC ACIDS RES, V25, P4921, DOI 10.1093/nar/25.24.4921; Magnaghi-Jaulin L, 1998, NATURE, V391, P601, DOI 10.1038/35410; Philips A, 1998, ONCOGENE, V16, P1373, DOI 10.1038/sj.onc.1201655; PHILIPS A, 1999, IN PRESS ONCOGENE; Plet A, 1997, ONCOGENE, V14, P2575, DOI 10.1038/sj.onc.1201103; SARDET C, 1997, ONCOGENES TRANSCRIPT, V2; SCHULZE A, 1995, P NATL ACAD SCI USA, V92, P11264, DOI 10.1073/pnas.92.24.11264; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; ZerfassThome K, 1997, MOL CELL BIOL, V17, P407, DOI 10.1128/MCB.17.1.407; ZWICKER J, 1995, EMBO J, V14, P4514, DOI 10.1002/j.1460-2075.1995.tb00130.x; ZWICKER J, 1998, TIG, V13, P3	24	36	36	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 4	1999	18	46					6222	6232		10.1038/sj.onc.1203017	http://dx.doi.org/10.1038/sj.onc.1203017			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	260DK	10597220				2022-12-25	WOS:000083934100005
J	Shiota, C; Coffey, J; Grimsby, J; Grippo, JF; Magnuson, MA				Shiota, C; Coffey, J; Grimsby, J; Grippo, JF; Magnuson, MA			Nuclear import of hepatic glucokinase depends upon glucokinase regulatory protein, whereas export is due to a nuclear export signal sequence in glucokinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-LIVER GLUCOKINASE; AMINO-ACID-SEQUENCE; TRANSGENIC MICE; MESSENGER-RNA; GLUCOSE; GENE; INSULIN; HEPATOCYTES; IDENTIFICATION; TRANSLOCATION	Hepatic glucokinase (GK) moves between the nucleus and cytoplasm in response to metabolic alterations. Here, using heterologous cell systems, we have found that at least two different mechanisms are involved in the intracellular movement of GK. In the absence of the GK regulatory protein (GKRP) GK resides only in the cytoplasm. However, in the presence of GKRP, GK moves to the nucleus and resides there in association with this protein until changes in the metabolic milieu prompt its release. GK does not contain a nuclear localization signal sequence and does not enter the nucleus in a GKRP-independent manner because cells treated with leptomycin B, a specific inhibitor of leucine-rich NES-dependent nuclear export, do not accumulate GR in the nucleus. Instead, entry of GK into the nucleus appears to occur via a piggy-back mechanism that involves binding to GKRP. Nuclear export of GK, which occurs after its release from GKRP, is due to a leucine-rich nuclear export signal within the protein ((ELVR)-E-300-LVLLKLV310). Thus, GKRP appears to function as both a nuclear chaperone and metabolic sensor and is a critical component of a hepatic GK translocation cycle for regulating the activity of this enzyme in response to metabolic alterations.	Vanderbilt Univ, Sch Med, Dept Mol Physiol & Biophys, Nashville, TN 37232 USA; Hoffmann La Roche Inc, Dept Metab Dis, Nutley, NJ 07110 USA	Vanderbilt University; Roche Holding	Magnuson, MA (corresponding author), Vanderbilt Univ, Sch Med, Dept Mol Physiol & Biophys, 723 Light Hall, Nashville, TN 37232 USA.	mark.magnuson@mcmail.vanderbilt.edu	Magnuson, Mark/AAY-7172-2021; Magnuson, Mark A/B-1335-2009	Magnuson, Mark/0000-0002-8824-6499; Magnuson, Mark A/0000-0002-8824-6499	NATIONAL CANCER INSTITUTE [P30CA068485] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK042612] Funding Source: NIH RePORTER; NCI NIH HHS [CA68485] Funding Source: Medline; NIDDK NIH HHS [DK42502, DK42612] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AGIUS L, 1995, BIOCHEM J, V309, P711, DOI 10.1042/bj3090711; AGIUS L, 1993, BIOCHEM J, V296, P785, DOI 10.1042/bj2960785; ANDREONE TL, 1989, J BIOL CHEM, V264, P363; Ardehali H, 1999, J BIOL CHEM, V274, P15986, DOI 10.1074/jbc.274.23.15986; BEDOYA FJ, 1986, J BIOL CHEM, V261, P760; Brown KS, 1997, DIABETES, V46, P179, DOI 10.2337/diabetes.46.2.179; CHARLES RS, 1994, DIABETES, V43, P784, DOI 10.2337/diab.43.6.784; DETHEUX M, 1991, EUR J BIOCHEM, V200, P553, DOI 10.1111/j.1432-1033.1991.tb16218.x; DWORETZKY SI, 1988, J CELL BIOL, V106, P575, DOI 10.1083/jcb.106.3.575; FELDHERR CM, 1984, J CELL BIOL, V99, P2216, DOI 10.1083/jcb.99.6.2216; Ferre T, 1996, FASEB J, V10, P1213, DOI 10.1096/fasebj.10.10.8751724; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; FISCHER U, 1995, CELL, V82, P475, DOI 10.1016/0092-8674(95)90436-0; Fukuda M, 1996, J BIOL CHEM, V271, P20024, DOI 10.1074/jbc.271.33.20024; GERACE L, 1992, Current Opinion in Cell Biology, V4, P637, DOI 10.1016/0955-0674(92)90083-O; GERACE L, 1995, CELL, V82, P341, DOI 10.1016/0092-8674(95)90420-4; GIDHJAIN M, 1993, P NATL ACAD SCI USA, V90, P1932, DOI 10.1073/pnas.90.5.1932; Hariharan N, 1997, DIABETES, V46, P11, DOI 10.2337/diabetes.46.1.11; IYNEDJIAN PB, 1988, J BIOL CHEM, V263, P740; IYNEDJIAN PB, 1987, J BIOL CHEM, V262, P6032; Jans DA, 1997, FEBS LETT, V410, P368, DOI 10.1016/S0014-5793(97)00622-4; JETTON TL, 1994, J BIOL CHEM, V269, P3641; JETTON TL, 1992, P NATL ACAD SCI USA, V89, P2619, DOI 10.1073/pnas.89.7.2619; KOGURE K, 1993, J BIOL CHEM, V268, P8422; Kogure K, 1996, J BIOL CHEM, V271, P15230, DOI 10.1074/jbc.271.25.15230; Kudo N, 1998, EXP CELL RES, V242, P540, DOI 10.1006/excr.1998.4136; LIANG Y, 1991, J BIOL CHEM, V266, P6999; MAGNUSON MA, 1989, P NATL ACAD SCI USA, V86, P4838, DOI 10.1073/pnas.86.13.4838; Miller J.H., 1992, SHORT COURSE BACTERI, P74; Mizuno T, 1996, J CELL SCI, V109, P2627; NISHI K, 1994, J BIOL CHEM, V269, P6320; Niswender KD, 1997, J BIOL CHEM, V272, P22570, DOI 10.1074/jbc.272.36.22570; ODoherty RM, 1996, J BIOL CHEM, V271, P20524, DOI 10.1074/jbc.271.34.20524; PETERS R, 1986, BIOCHIM BIOPHYS ACTA, V864, P305, DOI 10.1016/0304-4157(86)90003-1; Postic C, 1999, J BIOL CHEM, V274, P305, DOI 10.1074/jbc.274.1.305; PRINTZ RL, 1993, ANNU REV NUTR, V13, P463, DOI 10.1146/annurev.nu.13.070193.002335; PRINTZ RL, 1993, J BIOL CHEM, V268, P5209; TOYODA Y, 1995, HISTOCHEM CELL BIOL, V103, P31, DOI 10.1007/BF01464473; TOYODA Y, 1994, BIOCHEM BIOPH RES CO, V204, P252, DOI 10.1006/bbrc.1994.2452; Ullman KS, 1997, CELL, V90, P967, DOI 10.1016/S0092-8674(00)80361-X; VANDERCAMMEN A, 1993, BIOCHEM J, V294, P551, DOI 10.1042/bj2940551; VANDERCAMMEN A, 1990, EUR J BIOCHEM, V191, P483, DOI 10.1111/j.1432-1033.1990.tb19147.x; VANSCHAFTINGEN E, 1989, EUR J BIOCHEM, V179, P173; VANSCHAFTINGEN E, 1992, ADV ENZYME REGUL, V32, P133; VANSCHAFTINGEN E, 1989, EUR J BIOCHEM, V179, P179; VeigadaCunha M, 1996, DIABETOLOGIA, V39, P1173, DOI 10.1007/BF02658503; VeigadaCunha M, 1996, J BIOL CHEM, V271, P6292, DOI 10.1074/jbc.271.11.6292; Wada A, 1998, EMBO J, V17, P1635, DOI 10.1093/emboj/17.6.1635; WEN W, 1995, CELL, V82, P463, DOI 10.1016/0092-8674(95)90435-2	49	109	112	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 24	1999	274	52					37125	37130		10.1074/jbc.274.52.37125	http://dx.doi.org/10.1074/jbc.274.52.37125			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	267WR	10601273	hybrid			2022-12-25	WOS:000084382700044
J	Williamson, RA; Muskett, FW; Howard, MJ; Freedman, RB; Carr, MD				Williamson, RA; Muskett, FW; Howard, MJ; Freedman, RB; Carr, MD			The effect of matrix metalloproteinase complex formation on the conformational mobility of tissue inhibitor of metalloproteinases-2 (TIMP-2)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-TERMINAL DOMAIN; DNA-BINDING DOMAIN; HETERONUCLEAR NMR-SPECTROSCOPY; BACKBONE DYNAMICS; PROTEIN DYNAMICS; CATALYTIC DOMAIN; PROGELATINASE-A; EXPRESSION; RESOLUTION; CLONING	The backbone mobility of the N-terminal domain of tissue inhibitor of metalloproteinases-2 (N-TIMP-2) was determined both for the free protein and when bound to the catalytic domain of matrix metalloproteinase-3 (N-MMP-3). Regions of the protein with internal motion were identified by comparison of the T-1 and T-2 relaxation times and H-1-N-15 nuclear Overhauser effect values for the backbone amide N-15 signals for each residue in the sequence. This analysis revealed rapid internal motion on the picosecond to nanosecond time scale for several regions of free N-TIMP-2, including the extended beta-hairpin between beta-strands A and B, which forms part of the MMP binding site. Evidence of relatively slow motion indicative of exchange between two or more local conformations on a microsecond to millisecond time scale was also found in the free protein, including two other regions of the MMP binding site (the CD and EF loops). On formation of a tight N-TIMP-2, N-MMP-3 complex, the rapid internal motion of the AB beta-hairpin was largely abolished, a change consistent with tight binding of this region to the MMP-3 catalytic domain. The extended AB beta-hairpin is not a feature of all members of the TIMP family; therefore, the binding of this highly mobile region to a site distant from the catalytic cleft of the MMPs suggests a key role in TIMP-2 binding specificity.	Univ Kent, Dept Biosci, Canterbury CT2 7NJ, Kent, England	University of Kent	Carr, MD (corresponding author), Univ Kent, Dept Biosci, Canterbury CT2 7NJ, Kent, England.			Carr, Mark/0000-0002-3939-0996; Howard, Mark/0000-0002-0762-2887				APTE SS, 1994, GENOMICS, V19, P86, DOI 10.1006/geno.1994.1016; BARTELS C, 1995, J BIOMOL NMR, V6, P1, DOI 10.1007/BF00417486; BIRKEDALHANSEN H, 1995, CURR OPIN CELL BIOL, V7, P728, DOI 10.1016/0955-0674(95)80116-2; BOONE TC, 1990, P NATL ACAD SCI USA, V87, P2800, DOI 10.1073/pnas.87.7.2800; Broadhurst RW, 1995, BIOCHEMISTRY-US, V34, P16608, DOI 10.1021/bi00051a008; Butler GS, 1999, J BIOL CHEM, V274, P10846, DOI 10.1074/jbc.274.16.10846; Butler GS, 1999, J BIOL CHEM, V274, P20391, DOI 10.1074/jbc.274.29.20391; Carr MD, 1996, EUR J BIOCHEM, V235, P721, DOI 10.1111/j.1432-1033.1996.00721.x; Cawson T, 1998, MOL MED TODAY, V4, P130, DOI 10.1016/S1357-4310(97)01192-1; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; DOCHERTY AJP, 1985, NATURE, V318, P66, DOI 10.1038/318066a0; FARROW NA, 1994, BIOCHEMISTRY-US, V33, P5984, DOI 10.1021/bi00185a040; Fernandez-Catalan C, 1998, EMBO J, V17, P5238, DOI 10.1093/emboj/17.17.5238; GomisRuth FX, 1997, NATURE, V389, P77, DOI 10.1038/37995; GORMEZ DE, 1997, EUR J CELL BIOL, V74, P111; Greene J, 1996, J BIOL CHEM, V271, P30375, DOI 10.1074/jbc.271.48.30375; JARDETZKY O, 1994, FEBS LETT, V338, P246, DOI 10.1016/0014-5793(94)80277-7; Kay LE, 1998, NAT STRUCT BIOL, V5, P513, DOI 10.1038/755; KAY LE, 1989, BIOCHEMISTRY-US, V28, P8972, DOI 10.1021/bi00449a003; Kay LE, 1996, BIOCHEMISTRY-US, V35, P361, DOI 10.1021/bi9522312; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; MARCY AI, 1991, BIOCHEMISTRY-US, V30, P6476, DOI 10.1021/bi00240a018; McIntosh PB, 1998, BIOCHEMISTRY-US, V37, P9619, DOI 10.1021/bi972861z; MURPHY G, 1991, BIOCHEMISTRY-US, V30, P8097, DOI 10.1021/bi00247a001; MURPHY G, 1995, METHOD ENZYMOL, V248, P496; Muskett FW, 1998, J BIOL CHEM, V273, P21736, DOI 10.1074/jbc.273.34.21736; Noggle J.H.R.E.S., 1971, NUCL OVERHAUSER EFFE; PALMER AG, 1991, J AM CHEM SOC, V113, P4371, DOI 10.1021/ja00012a001; Polshakov VI, 1997, J MOL BIOL, V267, P418, DOI 10.1006/jmbi.1997.0896; STONE MJ, 1992, BIOCHEMISTRY-US, V31, P4394, DOI 10.1021/bi00133a003; Tuuttila A, 1998, J MOL BIOL, V284, P1133, DOI 10.1006/jmbi.1998.2223; Will H, 1996, J BIOL CHEM, V271, P17119, DOI 10.1074/jbc.271.29.17119; WILLENBROCK F, 1993, BIOCHEMISTRY-US, V32, P4330, DOI 10.1021/bi00067a023; WILLIAMSON RA, 1994, PROTEIN ENG, V7, P1035, DOI 10.1093/protein/7.8.1035; Williamson RA, 1996, EUR J BIOCHEM, V241, P476, DOI 10.1111/j.1432-1033.1996.00476.x; Williamson RA, 1997, BIOCHEMISTRY-US, V36, P13882, DOI 10.1021/bi9712091; Yong VW, 1998, TRENDS NEUROSCI, V21, P75	37	22	22	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 24	1999	274	52					37226	37232		10.1074/jbc.274.52.37226	http://dx.doi.org/10.1074/jbc.274.52.37226			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	267WR	10601286	hybrid			2022-12-25	WOS:000084382700057
J	Heeb, MJ; Kojima, Y; Rosing, J; Tans, G; Griffin, JH				Heeb, MJ; Kojima, Y; Rosing, J; Tans, G; Griffin, JH			C-terminal residues 621-635 of protein S are essential for binding to factor Va	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COAGULATION FACTOR XA; BLOOD-COAGULATION; C4B-BINDING PROTEIN; PROTHROMBINASE COMPLEX; THROMBOTIC DISEASE; ANTICOAGULANT ACTIVITY; MONOCLONAL-ANTIBODIES; PURPURA FULMINANS; HUMAN-PLASMA; LIGHT-CHAIN	Protein S is anticoagulant in the absence of activated protein C because of direct interactions with coagulation Factors Xa and Va. Synthetic peptides corresponding to amino acid sequences of protein S were tested for their ability to inhibit prothrombinase activity. The peptide containing the C-terminal sequence of protein S, residues 621-635 (PSP14), reversibly inhibited prothrombinase activity in the presence but not in the absence of Factor Va (K-i similar to 2 mu M). PSP14 inhibition of prothrombinase was independent of phospholipids but could be competitively overcome by increasing Factor Xa concentrations, suggesting that the C-terminal region of protein S may compete for a Factor Xa binding site on Factor Va. Studies using peptides with amino acid substitutions suggested that lysines 630, 631, and 633 were critical residues. PSP14 inhibited Factor Va activity in Factor Xa-one-stage clotting assays. PSP14 inhibited protein S binding to immobilized Factor Va. When preincubated with protein S, antibodies raised against PSP14 inhibited binding of protein S to Factor Va and blocked inhibition of prothrombinase activity by protein S, These results show that the C-terminal region of protein S containing residues 621-635 is essential for binding of protein S to Factor Va and that this interaction contributes to anticoagulant action.	Scripps Res Inst, Dept Mol & Expt Med, La Jolla, CA 92037 USA; Scripps Res Inst, Dept Vasc Biol, La Jolla, CA 92037 USA; Univ Maastricht, Dept Biochem, NL-6229 ER Maastricht, Netherlands	Scripps Research Institute; Scripps Research Institute; Maastricht University	Heeb, MJ (corresponding author), Scripps Res Inst, Dept Mol & Expt Med, MEM180,10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.			Griffin, John/0000-0002-4302-2547	NHLBI NIH HHS [R01HL21544] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL021544] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANNAMALAI AE, 1987, BLOOD, V70, P139; BERTINA RM, 1982, THROMB HAEMOSTASIS, V48, P1; BRANSON HE, 1983, LANCET, V2, P1165; BROEKMANS AW, 1985, THROMB HAEMOSTASIS, V53, P273; CHANG CTG, 1994, THROMB HAEMOSTASIS, V71, P461; CHATTOPADHYAY A, 1992, J BIOL CHEM, V267, P12323; COMP PC, 1984, J CLIN INVEST, V74, P2082, DOI 10.1172/JCI111632; DAHLBACK B, 1981, P NATL ACAD SCI-BIOL, V78, P2512, DOI 10.1073/pnas.78.4.2512; DISCIPIO RG, 1979, BIOCHEMISTRY-US, V18, P899, DOI 10.1021/bi00572a026; FERNANDEZ JA, 1993, J BIOL CHEM, V268, P16788; Fernandez JA, 1998, BLOOD CELL MOL DIS, V24, P101, DOI 10.1006/bcmd.1998.0175; Folsom AR, 1998, CIRCULATION, V98, P207; GALE AJ, 1997, THROMB HAEMOSTASIS S, P599; GRIFFIN JH, 1981, J CLIN INVEST, V68, P1370, DOI 10.1172/JCI110385; HACKENG TM, 1994, J BIOL CHEM, V269, P21051; He XH, 1997, BIOCHEMISTRY-US, V36, P3745, DOI 10.1021/bi962315q; HEEB MJ, 1994, P NATL ACAD SCI USA, V91, P2728, DOI 10.1073/pnas.91.7.2728; HEEB MJ, 1993, J BIOL CHEM, V268, P2872; Heeb MJ, 1996, PROTEIN SCI, V5, P1883, DOI 10.1002/pro.5560050914; HEEB MJ, 1995, THROMB HAEMOSTASIS, V73, P1121; HOUGHTEN RA, 1985, P NATL ACAD SCI USA, V82, P5131, DOI 10.1073/pnas.82.15.5131; JANE SM, 1991, BLOOD COAGUL FIBRIN, V2, P723, DOI 10.1097/00001721-199112000-00005; KALAFATIS M, 1994, BIOCHEMISTRY-US, V33, P6538, DOI 10.1021/bi00187a022; Kojima Y, 1998, J BIOL CHEM, V273, P14900, DOI 10.1074/jbc.273.24.14900; Linse S, 1997, J BIOL CHEM, V272, P14658, DOI 10.1074/jbc.272.23.14658; LUNDWALL A, 1986, P NATL ACAD SCI USA, V83, P6716, DOI 10.1073/pnas.83.18.6716; MAHASANDANA C, 1990, LANCET, V335, P61, DOI 10.1016/0140-6736(90)90201-F; MESTERS RM, 1993, PROTEIN SCI, V2, P1482, DOI 10.1002/pro.5560020912; MESTERS RM, 1991, J BIOL CHEM, V266, P24514; MESTERS RM, 1993, BIOCHEMISTRY-US, V32, P12656, DOI 10.1021/bi00210a014; Nyberg P, 1998, FEBS LETT, V433, P28, DOI 10.1016/S0014-5793(98)00877-1; Sabharwal AK, 1997, J BIOL CHEM, V272, P22037, DOI 10.1074/jbc.272.35.22037; SCHWARZ HP, 1984, BLOOD, V64, P1297; SCHWARZ HP, 1989, THROMB HAEMOSTASIS, V62, P25; SELIGSOHN U, 1984, NEW ENGL J MED, V310, P559, DOI 10.1056/NEJM198403013100904; SHEN L, 1994, J BIOL CHEM, V269, P18735; SOLYMOSS S, 1988, J BIOL CHEM, V263, P14884; THOMMEN D, 1989, SCHWEIZ MED WSCHR, V119, P493; TRACY PB, 1983, P NATL ACAD SCI-BIOL, V80, P2380, DOI 10.1073/pnas.80.8.2380; UPDYKE TV, 1984, J IMMUNOL METHODS, V73, P83, DOI 10.1016/0022-1759(84)90034-6; van Wijnen M, 1998, THROMB HAEMOSTASIS, V80, P930; VANTVEER C, 1995, BLOOD, V85, P1815, DOI 10.1182/blood.V85.7.1815.bloodjournal8571815; vanWijnen M, 1996, THROMB HAEMOSTASIS, V76, P397; WALKER FJ, 1981, J BIOL CHEM, V256, P1128; WALKER FJ, 1990, J BIOL CHEM, V265, P1484; WALKER FJ, 1980, J BIOL CHEM, V255, P5521; WIESEL ML, 1990, THROMB RES, V58, P461, DOI 10.1016/0049-3848(91)90251-Q	47	31	31	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 17	1999	274	51					36187	36192		10.1074/jbc.274.51.36187	http://dx.doi.org/10.1074/jbc.274.51.36187			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	266AV	10593904	hybrid			2022-12-25	WOS:000084279200023
J	Limatola, C; Mileo, AM; Giovannelli, A; Vacca, F; Ciotti, MT; Mercanti, D; Santoni, A; Eusebi, F				Limatola, C; Mileo, AM; Giovannelli, A; Vacca, F; Ciotti, MT; Mercanti, D; Santoni, A; Eusebi, F			The growth-related gene product beta induces sphingomyelin hydrolysis and activation of c-Jun N-terminal kinase in rat cerebellar granule neurones	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CENTRAL-NERVOUS-SYSTEM; HUMAN INTERLEUKIN-8 RECEPTORS; STRESS-INDUCED APOPTOSIS; PROGRAMMED CELL-DEATH; PROTEIN-KINASE; ACIDIC SPHINGOMYELINASE; CHEMOKINE RECEPTORS; PHOSPHOLIPASE-D; CERAMIDE; RELEASE	The growth-related gene product beta (GRO beta) is a small chemoattractant cytokine that belongs to the CXC chemokine family, and GRO beta receptors are expressed in the brain, including the cerebellum. We demonstrate that rat cerebellar granule neurones express the GRO beta receptor CXCR2. We also show that, in addition to the known stimulation of a phosphoinositide-specific phospholipase C, GRO beta activates both neutral (N-) and acidic (A-) sphingomyelinases (SMase) and the stress-activated c-Jun N-terminal kinase I (JNK1). Although both exogenous ceramide and bacterial SMase stimulate JNH1, GRO beta-induced JNK1 activation is an event probably in dependent of ceramide generated by A-SMase, since it is maintained in the presence of compounds that block A-SMase activity. This is the first report on the activation of the SMase pathway by chemokines.	Univ La Sapienza, Dip Med Sperimentale & Patol, I-00161 Rome, Italy; Ist Regina Elena, Ctr Ric Sperimentale, Lab Biofis, I-00158 Rome, Italy; Univ Aquila, Dipartimento Med Sperimentale, I-67100 Laquila, Italy; CNR, Ist Neurobiol, I-00137 Rome, Italy	Sapienza University Rome; IRCCS Istituti Fisioterapici Ospitalieri (IFO); IRCCS Regina Elena; University of L'Aquila; Consiglio Nazionale delle Ricerche (CNR)	Limatola, C (corresponding author), Univ La Sapienza, Dip Med Sperimentale & Patol, Viale Regina Elena 324, I-00161 Rome, Italy.		santoni, angela/K-8997-2016; Mileo, Anna Maria/J-3667-2016; Vacca, Fabrizio/A-5113-2009	santoni, angela/0000-0003-1206-7731; Mileo, Anna Maria/0000-0002-1970-3297; Mercanti, Delio/0000-0001-8301-2098; giovannelli, aldo/0000-0003-1863-6202; limatola, cristina/0000-0001-7504-8197				Baggiolini M, 1998, NATURE, V392, P565, DOI 10.1038/33340; Boldin S, 1997, J NEUROCHEM, V68, P882; BOUCHER LM, 1995, J EXP MED, V181, P2059, DOI 10.1084/jem.181.6.2059; Brenner B, 1998, CELL DEATH DIFFER, V5, P29, DOI 10.1038/sj.cdd.4400307; CAO YH, 1995, J EXP MED, V182, P2069, DOI 10.1084/jem.182.6.2069; CasacciaBonnefil P, 1996, J NEUROSCI RES, V43, P382, DOI 10.1002/(SICI)1097-4547(19960201)43:3<382::AID-JNR13>3.0.CO;2-7; Chen YR, 1996, J BIOL CHEM, V271, P31929, DOI 10.1074/jbc.271.50.31929; Courtney MJ, 1997, J NEUROSCI, V17, P4201; DARBONNE WC, 1991, J CLIN INVEST, V88, P1362, DOI 10.1172/JCI115442; DDAIBO GS, 1995, P NATL ACAD SCI USA, V92, P1347; DOBROWSKY RT, 1992, J BIOL CHEM, V267, P5048; DRISCOLL KE, 1995, J LEUKOCYTE BIOL, V58, P359, DOI 10.1002/jlb.58.3.359; Dunstan CAN, 1996, J BIOL CHEM, V271, P32770, DOI 10.1074/jbc.271.51.32770; Giovannelli A, 1998, J NEUROIMMUNOL, V92, P122, DOI 10.1016/S0165-5728(98)00192-1; Glabinski AR, 1997, AM J PATHOL, V150, P617; HAM J, 1995, NEURON, V14, P927, DOI 10.1016/0896-6273(95)90331-3; Hannun YA, 1996, SCIENCE, V274, P1855, DOI 10.1126/science.274.5294.1855; HAREL R, 1993, J BIOL CHEM, V268, P14476; Herdegen T, 1997, TRENDS NEUROSCI, V20, P227, DOI 10.1016/S0166-2236(96)01000-4; Hesselgesser J, 1998, CURR BIOL, V8, P595, DOI 10.1016/S0960-9822(98)70230-1; Hida H, 1998, J NEUROSCI, V18, P8712; Hofmeister R, 1997, J BIOL CHEM, V272, P27730, DOI 10.1074/jbc.272.44.27730; Horuk R, 1997, J IMMUNOL, V158, P2882; Huang CS, 1997, J BIOL CHEM, V272, P27753, DOI 10.1074/jbc.272.44.27753; HURWITZ R, 1994, BIOL CHEM H-S, V375, P447, DOI 10.1515/bchm3.1994.375.7.447; Ibitayo AI, 1998, AM J PHYSIOL-GASTR L, V275, pG705, DOI 10.1152/ajpgi.1998.275.4.G705; ITO A, 1995, J NEUROCHEM, V65, P463; JONES SA, 1995, FEBS LETT, V364, P211, DOI 10.1016/0014-5793(95)00397-R; KOLESNICK RN, 1987, J BIOL CHEM, V262, P16759; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; LEE J, 1992, J BIOL CHEM, V267, P16283; LEVI G, 1984, BRAIN RES, V290, P77, DOI 10.1016/0006-8993(84)90737-6; Limatola C, 1997, BIOCHEM J, V321, P497, DOI 10.1042/bj3210497; LOCATI M, 1994, J BIOL CHEM, V269, P4746; LOZANO J, 1994, J BIOL CHEM, V269, P19200; Manev H, 1997, NEUROCHEM INT, V31, P203, DOI 10.1016/S0197-0186(96)00149-0; OHANIAN J, 1997, FEBS SPEC M AMST JUN; Owen JD, 1997, INT J CANCER, V73, P94, DOI 10.1002/(SICI)1097-0215(19970926)73:1<94::AID-IJC15>3.0.CO;2-5; PACINI L, 1993, BIOCHEM J, V289, P269, DOI 10.1042/bj2890269; Pena LA, 1997, BIOCHEM PHARMACOL, V53, P615, DOI 10.1016/S0006-2952(96)00834-9; Ragozzino D, 1998, NEUROREPORT, V9, P3601, DOI 10.1097/00001756-199811160-00011; Ransohoff RM, 1998, TRENDS NEUROSCI, V21, P154, DOI 10.1016/S0166-2236(97)01198-3; Ransohoff RM, 1997, METHOD ENZYMOL, V287, P319; SCHRAW W, 1995, BIOCHEMISTRY-US, V34, P13760, DOI 10.1021/bi00042a006; Schwarz A, 1997, J NEUROSCI, V17, P2929; SOZZANI S, 1994, BLOOD, V84, P3895, DOI 10.1182/blood.V84.11.3895.bloodjournal84113895; Tani M, 1996, J CLIN INVEST, V98, P529, DOI 10.1172/JCI118821; VAN MEIR E, 1992, CANCER RES, V52, P4297; Verheij M, 1996, NATURE, V380, P75, DOI 10.1038/380075a0; Watson A, 1998, J NEUROSCI, V18, P751; WIEGMANN K, 1994, CELL, V78, P1005, DOI 10.1016/0092-8674(94)90275-5; WU DQ, 1993, SCIENCE, V261, P101, DOI 10.1126/science.8316840; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Zhang YH, 1997, CELL, V89, P63, DOI 10.1016/S0092-8674(00)80183-X; Zou YR, 1998, NATURE, V393, P595, DOI 10.1038/31269	55	22	22	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 17	1999	274	51					36537	36543		10.1074/jbc.274.51.36537	http://dx.doi.org/10.1074/jbc.274.51.36537			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	266AV	10593952	hybrid			2022-12-25	WOS:000084279200071
J	Yahiro, K; Niidome, T; Kimura, M; Hatakeyama, T; Aoyagi, H; Kurazono, H; Imagawa, K; Wada, A; Moss, J; Hirayama, T				Yahiro, K; Niidome, T; Kimura, M; Hatakeyama, T; Aoyagi, H; Kurazono, H; Imagawa, K; Wada, A; Moss, J; Hirayama, T			Activation of Helicobacter pylori VacA toxin by alkaline or acid conditions increases its binding to a 250-kDa receptor protein-tyrosine phosphatase beta	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VACUOLATING CYTOTOXIN; LECTIN; CELLS; GASTRITIS; DISEASE; UREASE; ZETA; PH	Helicobacter pylori, a Gram-negative gastric bacterium, secretes VacA, a cytotoxin that causes vacuolar degeneration of susceptible cells. Velocity sedimentation analysis showed that treatment of VacA at alkaline pH led to disassembly of VacA oligomers, an observation reported previously for acid-treated VacA, Exposure of VacA to acid or alkali increased its binding to AZ-521 cells, as shown by indirect immunofluorescence and flow cytometry, Moreover, immunoprecipitates with polyclonal antibodies against VacA from AZ-521 cells previously exposed to acid- or alkali-treated VacA had a 250-kDa glycoprotein containing galactose-beta(1-3)-N-acetylgalactosamine and galactose-beta(1-4)-N-acetylglucosamine, p250, purified by chromatography on peanut agglutinin affinity and Superose 6 columns, contained N-terminal and internal amino acid sequences of YRQQRKLVEEIGWSYT and LIIQDHILEATQDDY, respectively. These sequences are identical to those of a receptor protein-tyrosine phosphatase (RPTP beta/PTP zeta); in agreement, p250 reacted with anti-human RPTP beta monoclonal antibody. Immunoprecipitation with antihuman RPTP beta antibody of solubilized membrane preparations previously incubated with VacA or heat-inactivated VacA demonstrated that RPTP beta bound native, but not denatured, VacA. Acidic and alkaline treatments were associated with activation of VacA and increased binding to the cell surface RPTP beta.	Nagasaki Univ, Inst Trop Med, Dept Bacteriol, Nagasaki 8528523, Japan; Nagasaki Univ, Fac Engn, Dept Appl Chem, Nagasaki 8528523, Japan; Univ Tsukuba, Dept Microbiol, Inst Basic Med Sci, Tsukuba, Ibaraki 3050006, Japan; Otsuka Pharmaceut Co Ltd, Tokushima 7710192, Japan; NHLBI, Pulm Crit Care Med Branch, NIH, Bethesda, MD 20892 USA	Nagasaki University; Nagasaki University; University of Tsukuba; Otsuka Pharmaceutical; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	Hirayama, T (corresponding author), Nagasaki Univ, Inst Trop Med, Dept Bacteriol, Nagasaki 8528523, Japan.	hirayama@net.nagasaki-u.ac.jp	Niidome, Takuro/F-1508-2010	Niidome, Takuro/0000-0002-8070-8708; Hatakeyama, Tomomitsu/0000-0002-9505-1980; Yahiro, Kinnosuke/0000-0002-9813-0780	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [Z01HL000659, ZIAHL000659] Funding Source: NIH RePORTER	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ATHERTON JC, 1995, J BIOL CHEM, V270, P17771, DOI 10.1074/jbc.270.30.17771; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CASELLI M, 1989, AM J GASTROENTEROL, V84, P511; CHEN XG, 1983, AM J CLIN PATHOL, V86, P575; COVER TL, 1991, INFECT IMMUN, V59, P1264, DOI 10.1128/IAI.59.4.1264-1270.1991; COVER TL, 1992, J BIOL CHEM, V267, P10570; COVER TL, 1994, J BIOL CHEM, V269, P10566; Cover TL, 1997, J CELL BIOL, V138, P759, DOI 10.1083/jcb.138.4.759; CROWLEY JF, 1984, ARCH BIOCHEM BIOPHYS, V231, P524, DOI 10.1016/0003-9861(84)90417-X; Czajkowsky DM, 1999, P NATL ACAD SCI USA, V96, P2001, DOI 10.1073/pnas.96.5.2001; DEBERNARD M, 1995, J BIOL CHEM, V270, P23937, DOI 10.1074/jbc.270.41.23937; EATON KA, 1991, INFECT IMMUN, V59, P2470, DOI 10.1128/IAI.59.7.2470-2475.1991; FRIERI G, 1995, DIGESTION, V56, P107, DOI 10.1159/000201229; GHIRA P, 1995, INFECT IMMUN, V63, P4154, DOI 10.1128/IAI.63.10.4154-4160.1995; HESSEY SJ, 1990, GUT, V31, P134, DOI 10.1136/gut.31.2.134; Iwamatsu A, 1996, J BIOCHEM-TOKYO, V120, P29; KRUEGER NX, 1992, P NATL ACAD SCI USA, V89, P7417, DOI 10.1073/pnas.89.16.7417; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEVY JB, 1993, J BIOL CHEM, V268, P10573; MANETTI R, 1995, INFECT IMMUN, V63, P4476, DOI 10.1128/IAI.63.11.4476-4480.1995; Massari P, 1998, INFECT IMMUN, V66, P3981, DOI 10.1128/IAI.66.8.3981-3984.1998; NEUROHR KJ, 1980, J BIOL CHEM, V255, P9205; Nishiwaki T, 1998, J BIOCHEM-TOKYO, V123, P458; Pai R, 1998, AM J PATHOL, V152, P1617; SHIBUYA N, 1988, J BIOL CHEM, V263, P728; SHIBUYA N, 1987, J BIOL CHEM, V262, P1596; SMOOT DT, 1993, INFECT IMMUN, V61, P350, DOI 10.1128/IAI.61.1.350-355.1993; TELFORD JL, 1994, J EXP MED, V179, P1653, DOI 10.1084/jem.179.5.1653; WANG WC, 1988, J BIOL CHEM, V263, P4576; Yahiro K, 1997, BIOCHEM BIOPH RES CO, V238, P629, DOI 10.1006/bbrc.1997.7345; YAMADA T, 1994, JAMA-J AM MED ASSOC, V272, P65, DOI 10.1001/jama.272.1.65	31	140	151	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 17	1999	274	51					36693	36699		10.1074/jbc.274.51.36693	http://dx.doi.org/10.1074/jbc.274.51.36693			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	266AV	10593974	hybrid			2022-12-25	WOS:000084279200093
J	Han, ZG; Zhang, QH; Ye, M; Kan, LX; Gu, BW; He, KL; Shi, SL; Zhou, J; Fu, G; Mao, M; Chen, SJ; Yu, L; Chen, Z				Han, ZG; Zhang, QH; Ye, M; Kan, LX; Gu, BW; He, KL; Shi, SL; Zhou, J; Fu, G; Mao, M; Chen, SJ; Yu, L; Chen, Z			Molecular cloning of six novel Kruppel-like zinc finger genes from hematopoietic cells and identification of a novel transregulatory domain KRNB	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACUTE PROMYELOCYTIC LEUKEMIA; RECEPTOR-ALPHA LOCUS; LIM-DOMAIN; RAR-ALPHA; PROTEIN; TRANSLOCATION; EXPRESSION; FAMILY; FUSION; MOUSE	To clone zinc finger genes expressed in hematopoietic system, we designed primers based on conserved Cys(2)/ His, zinc finger sequences to amplify corresponding domains from mRNA of normal bone marrow and leukemia cell line NB4, DNA fragments of novel zinc finger genes were chosen and used as probe pool to screen cDNA libraries or subject to rapid amplification of cDNA ends in order to obtain full-length cDNA, Six cDNAs including whole open reading frame of zinc finger proteins, named. as ZNF191, ZNF253 (BMZF-1), ZNF255 (BMZF-2), ZNF256 (BMZF-3), ZNF257 (BMZF-4), and ZNF254 (BMZF-5) were obtained. All six belong to the Kruppel-like zinc finger gene family, and typical transcriptional regulatory motifs exist in the N-terminal moiety, such as the SCAN box in ZNF191, and the KRAB domains in ZNF253, ZNP254, ZNF256, and ZNF257, A previously undefined sequence nominated as Ki kruppel-related novel box, which may represent a new transregulatory motif, was revealed at the N terminus of ZNF255. The transregulatory function of non-zinc finger regions of ZNF191, ZNF253, and ZNF255 were addressed in yeast and mammalian cells. The re suits indicated that ZNF255 might be a conditional transactivator, whereas ZNF253 and ZNF191 displayed a suppressive effect on the transcription in yeast and/or mammalian systems.	Shanghai Second Med Univ, Rui Jin Hosp, Shanghai Inst Hematol, Key Lab Human Genome Res, Shanghai 200025, Peoples R China; Chinese Natl Human Genome Ctr, Shanghai 201203, Peoples R China; Fudan Univ, Inst Genet, Shanghai 200433, Peoples R China	Shanghai Jiao Tong University; Fudan University	Yu, L (corresponding author), Shanghai Second Med Univ, Rui Jin Hosp, Shanghai Inst Hematol, Key Lab Human Genome Res, 197 Rui Jin Rd 2, Shanghai 200025, Peoples R China.		kan, lixin/I-6665-2013	Shi, Shaolin/0000-0003-2297-6496; Han, Ze-Guang/0000-0002-1018-1752				ADAMS MD, 1991, SCIENCE, V252, P1651, DOI 10.1126/science.2047873; ALBAGLI O, 1995, CELL GROWTH DIFFER, V6, P1193; ALCALAY M, 1991, P NATL ACAD SCI USA, V88, P1977, DOI 10.1073/pnas.88.5.1977; BARLOW PN, 1994, J MOL BIOL, V237, P201, DOI 10.1006/jmbi.1994.1222; BELLEFROID EJ, 1991, P NATL ACAD SCI USA, V88, P3608, DOI 10.1073/pnas.88.9.3608; BELLEFROID EJ, 1989, DNA-J MOLEC CELL BIO, V8, P377, DOI 10.1089/dna.1.1989.8.377; BOEHM T, 1991, P NATL ACAD SCI USA, V88, P4367, DOI 10.1073/pnas.88.10.4367; Borden KLB, 1996, CURR OPIN STRUC BIOL, V6, P395, DOI 10.1016/S0959-440X(96)80060-1; Capone MC, 1996, J IMMUNOL, V157, P969; CHEN Z, 1993, EMBO J, V12, P1161, DOI 10.1002/j.1460-2075.1993.tb05757.x; CHENCHIK A, 1995, CLONTECHNIQUES, V10, P5; COOK M, 1995, P NATL ACAD SCI USA, V92, P2249, DOI 10.1073/pnas.92.6.2249; DETHE H, 1991, CELL, V66, P675, DOI 10.1016/0092-8674(91)90113-D; Dong S, 1996, P NATL ACAD SCI USA, V93, P3624, DOI 10.1073/pnas.93.8.3624; Friedman JR, 1996, GENE DEV, V10, P2067, DOI 10.1101/gad.10.16.2067; Hammarstrom A, 1996, BIOCHEMISTRY-US, V35, P12723, DOI 10.1021/bi961149j; Hong SH, 1997, P NATL ACAD SCI USA, V94, P9028, DOI 10.1073/pnas.94.17.9028; Hromas R, 1996, CURR TOP MICROBIOL, V211, P159; HUEBNER K, 1991, AM J HUM GENET, V48, P726; Hui P, 1995, BIOCHEMISTRY-US, V34, P16493, DOI 10.1021/bi00050a033; JACOBS GH, 1992, EMBO J, V11, P4507, DOI 10.1002/j.1460-2075.1992.tb05552.x; KLUG A, 1995, FASEB J, V9, P597, DOI 10.1096/fasebj.9.8.7768350; KNOCHEL W, 1989, P NATL ACAD SCI USA, V86, P6097, DOI 10.1073/pnas.86.16.6097; Liu LM, 1997, J BIOL CHEM, V272, P2984, DOI 10.1074/jbc.272.5.2984; NOCE T, 1992, DEV BIOL, V153, P356, DOI 10.1016/0012-1606(92)90120-6; NUEZ B, 1995, NATURE, V375, P316, DOI 10.1038/375316a0; PERKINS AC, 1995, NATURE, V375, P318; Quief S, 1996, LEUKEMIA, V10, P579; Rubnitz JE, 1996, LEUKEMIA, V10, P74; Shannon M, 1996, GENOMICS, V33, P112, DOI 10.1006/geno.1996.0166; Ting CN, 1996, NATURE, V384, P474, DOI 10.1038/384474a0; WILKINSON DG, 1989, NATURE, V337, P461, DOI 10.1038/337461a0; WILLIAMS AJ, 1995, J BIOL CHEM, V270, P22143, DOI 10.1074/jbc.270.38.22143	33	61	82	2	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 10	1999	274	50					35741	35748		10.1074/jbc.274.50.35741	http://dx.doi.org/10.1074/jbc.274.50.35741			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	264NG	10585455	hybrid			2022-12-25	WOS:000084187900067
J	Kostanjevecki, V; Leys, D; Van Driessche, G; Meyer, TE; Cusanovich, MA; Fischer, U; Guisez, Y; Van Beeumen, J				Kostanjevecki, V; Leys, D; Van Driessche, G; Meyer, TE; Cusanovich, MA; Fischer, U; Guisez, Y; Van Beeumen, J			Structure and characterization of Ectothiorhodospira vacuolata cytochrome b(558), a prokaryotic homologue of cytochrome b(5)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; POLYACRYLAMIDE GELS; PROTEIN; DNA	A soluble cytochrome b(558) from the purple phototropic bacterium Ectothiorhodospira vacuolata was completely sequenced by a combination of automated Edman degradation and mass spectrometry. The protein, with a measured mass of 10,094.7 Da, contains 90 residues and binds a single protoheme. Unexpectedly, the sequence shows homology to eukaryotic cytochromes b(5). As no prokaryotic homologue had been reported so far, we developed a protocol for the expression, purification, and crystallization of recombinant cytochrome b(558). The structure was solved by molecular replacement to a resolution of 1.65 Angstrom It shows that cytochrome b(558) is indeed the first bacterial cytochrome b(5) to be characterized and differs from its eukaryotic counterparts by the presence of a disulfide bridge and a four-residue insertion in front of the sixth ligand (histidine). Eukaryotes contain a variety of b(5) homologues, including soluble and membrane-bound multifunctional proteins as well as multidomain enzymes such as sulfite oxidase, fatty-acid desaturase, nitrate reductase, and lactate dehydrogenase. A search of the Mycobacterium tuberculosis genome showed that a previously unidentified gene encodes a fatty-acid desaturase with an N-terminal b(5) domain. Thus, it may provide another example of a bacterial b(5) homologue.	State Univ Ghent, Lab Prot Biochem & Prot Engn, Dept Biochem Physiol & Microbiol, B-9000 Ghent, Belgium; Univ Arizona, Dept Biochem, Tucson, AZ 85721 USA; Univ Bremen, Dept Marine Microbiol, D-28359 Bremen, Germany	Ghent University; University of Arizona; University of Bremen	Van Beeumen, J (corresponding author), State Univ Ghent, Lab Prot Biochem & Prot Engn, Dept Biochem Physiol & Microbiol, Ledeganckstr 35, B-9000 Ghent, Belgium.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM021277] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 21277] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMBLER RP, 1994, ARCH BIOCHEM BIOPHYS, V308, P78, DOI 10.1006/abbi.1994.1011; BARTSCH RG, 1971, J BIOL CHEM, V246, P4489; BLUM H, 1987, ELECTROPHORESIS, V8, P93, DOI 10.1002/elps.1150080203; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CASADABAN MJ, 1980, J MOL BIOL, V138, P179, DOI 10.1016/0022-2836(80)90283-1; FRIEDMAN M, 1980, ANAL BIOCHEM, V106, P27, DOI 10.1016/0003-2697(80)90114-1; Guisez Y, 1998, PROTEIN EXPRES PURIF, V12, P249, DOI 10.1006/prep.1997.0836; HAMADA K, 1995, J MOL BIOL, V247, P947, DOI 10.1006/jmbi.1995.0192; ITAGAKI E, 1966, J BIOL CHEM, V241, P3687; KUSCHE WH, 1984, Z NATURFORSCH C, V39, P894; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LEDERER F, 1994, BIOCHIMIE, V76, P674, DOI 10.1016/0300-9084(94)90144-9; MATTHEWS BW, 1968, J MOL BIOL, V33, P491, DOI 10.1016/0022-2836(68)90205-2; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; Mewes HW, 1997, NATURE, V387, P7, DOI 10.1038/387s007; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; RINGELING PL, 1994, EUR J BIOCHEM, V223, P847, DOI 10.1111/j.1432-1033.1994.tb19061.x; STORCH EM, 1995, BIOCHEMISTRY-US, V34, P9682, DOI 10.1021/bi00030a005; THOMAS PE, 1976, ANAL BIOCHEM, V75, P168, DOI 10.1016/0003-2697(76)90067-1	21	30	32	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 10	1999	274	50					35614	35620		10.1074/jbc.274.50.35614	http://dx.doi.org/10.1074/jbc.274.50.35614			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	264NG	10585439	hybrid			2022-12-25	WOS:000084187900051
J	Ma, HT; Favre, CJ; Patterson, RL; Stone, MR; Gill, DL				Ma, HT; Favre, CJ; Patterson, RL; Stone, MR; Gill, DL			Ca2+ entry activated by S-nitrosylation - Relationship to store-operated Ca2+ entry	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THAPSIGARGIN-RESISTANT CELLS; CAPACITATIVE CALCIUM-ENTRY; NUCLEOTIDE-GATED CHANNEL; NITRIC-OXIDE; POOL DEPLETION; GROWTH; MECHANISM; INFLUX; TRP; CONDUCTANCE	The coupling between Ca2+ pools and store-operated Ca2+ entry channels (SOCs) remains an unresolved question. Recently, we revealed that Ca2+ entry could be activated in response to S-nitrosylation and that this process was stimulated by Ca2+ pool emptying (Favre, C. J., Ufret-Vincenty, C. A., Stone, M. R., Ma, H-T., and Gill, D. L. (1998) J. Biol. Chem. 273, 30855-30858). In DDT,MF-S smooth muscle cells and DC-3F fibroblasts, Ca2+ entry activated by the lipophilic NO donor, GEA3162 (5-amino-3- (3,4-dichlorophenyl) 1,2,3,4-oxatriazolium), or the alkylator, N-ethylnaleimide, was observed to be strongly activated by transient external Ca2+ removal, closely resembling activation of SOC activity in the same cells. The nonadditivity of SOC and NO donor-activated Ca2+ entry suggested a single entry mechanism. Calyculin A-induced reorganization of the actin cytoskeleton prevented SOC but had no effect on GEA3162-induced Ca2+ entry. However, a single entry mechanism could account for both SOC and NO donor-activated entry if the latter reflected direct modification of the entry channel by S-nitrosylation, bypassing the normal coupling process between channels and pools. Small differences between SOC and GEA3162-activated Ba2+ entry and sensitivity to blockade by La3+ were observed, and in HEK293 cells SOC activity was observed without a response to thiol modification. It is concluded that in some cells, S-nitrosylation modifies an entry mechanism closely related to SOC and/or part of the regulatory machinery for SOC-mediated Ca2+ entry.	Univ Maryland, Sch Med, Dept Biochem & Mol Biol, Baltimore, MD 21201 USA	University System of Maryland; University of Maryland Baltimore	Gill, DL (corresponding author), Univ Maryland, Sch Med, Dept Biochem & Mol Biol, 108 N Greene St, Baltimore, MD 21201 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL055426] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL55426] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Berridge MJ, 1998, NATURE, V395, P645, DOI 10.1038/27094; Birnbaumer L, 1996, P NATL ACAD SCI USA, V93, P15195, DOI 10.1073/pnas.93.26.15195; BOLOTINA VM, 1994, NATURE, V368, P850, DOI 10.1038/368850a0; BREDT DS, 1994, ANNU REV BIOCHEM, V63, P175, DOI 10.1146/annurev.bi.63.070194.001135; Broillet MC, 1997, NEURON, V18, P951, DOI 10.1016/S0896-6273(00)80334-7; Broillet MC, 1996, NEURON, V16, P377, DOI 10.1016/S0896-6273(00)80055-0; Campbell DL, 1996, J GEN PHYSIOL, V108, P277, DOI 10.1085/jgp.108.4.277; CLAPHAM DE, 1995, CELL, V80, P259, DOI 10.1016/0092-8674(95)90408-5; Favre CJ, 1998, J BIOL CHEM, V273, P30855, DOI 10.1074/jbc.273.47.30855; GHOSH TK, 1989, NATURE, V340, P236, DOI 10.1038/340236a0; GHOSH TK, 1990, SCIENCE, V248, P1653, DOI 10.1126/science.2163543; Gill DL, 1996, BIOSCIENCE REP, V16, P139, DOI 10.1007/BF01206203; Graber MN, 1997, J BIOL CHEM, V272, P29546, DOI 10.1074/jbc.272.47.29546; Hofmann T, 1999, NATURE, V397, P259, DOI 10.1038/16711; Kiselyov K, 1998, NATURE, V396, P478, DOI 10.1038/24890; LIPTON SA, 1993, NATURE, V364, P626, DOI 10.1038/364626a0; LOUAZO CM, 1996, J BIOL CHEM, V271, P14807; McDonald LJ, 1996, P SOC EXP BIOL MED, V211, P1; McVey M, 1999, J BIOL CHEM, V274, P18887, DOI 10.1074/jbc.274.27.18887; MISSIAEN L, 1994, J BIOL CHEM, V269, P5817; Montell C, 1998, CURR OPIN NEUROBIOL, V8, P389, DOI 10.1016/S0959-4388(98)80066-4; Parekh AB, 1997, PHYSIOL REV, V77, P901, DOI 10.1152/physrev.1997.77.4.901; Patterson RL, 1999, CELL, V98, P487, DOI 10.1016/S0092-8674(00)81977-7; Putney JW, 1999, BIOESSAYS, V21, P38; PUTNEY JW, 1993, CELL, V75, P199, DOI 10.1016/0092-8674(93)80061-I; Santana LF, 1998, SCIENCE, V279, P1027, DOI 10.1126/science.279.5353.1027; SHORT AD, 1993, J BIOL CHEM, V268, P25887; SHORT AD, 1993, P NATL ACAD SCI USA, V90, P4986, DOI 10.1073/pnas.90.11.4986; Stamler JS, 1998, NAT STRUCT BIOL, V5, P247, DOI 10.1038/nsb0498-247; Stamler JS, 1997, NEURON, V18, P691, DOI 10.1016/S0896-6273(00)80310-4; STAMLER JS, 1992, SCIENCE, V258, P1898, DOI 10.1126/science.1281928; STAMLER JS, 1994, CELL, V78, P931, DOI 10.1016/0092-8674(94)90269-0; UFRETVINCENTY CA, 1995, J BIOL CHEM, V270, P26790, DOI 10.1074/jbc.270.45.26790; WALDRON RT, 1995, J BIOL CHEM, V270, P11955, DOI 10.1074/jbc.270.20.11955; Waldron RT, 1997, J BIOL CHEM, V272, P6440, DOI 10.1074/jbc.272.10.6440; Xu L, 1998, SCIENCE, V279, P234, DOI 10.1126/science.279.5348.234; Xu XZS, 1997, CELL, V89, P1155, DOI 10.1016/S0092-8674(00)80302-5; Zhu X, 1998, J BIOL CHEM, V273, P133, DOI 10.1074/jbc.273.1.133; ZWEIFACH A, 1995, J BIOL CHEM, V270, P14445, DOI 10.1074/jbc.270.24.14445	39	27	27	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 10	1999	274	50					35318	35324		10.1074/jbc.274.50.35318	http://dx.doi.org/10.1074/jbc.274.50.35318			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	264NG	10585397	hybrid			2022-12-25	WOS:000084187900009
J	Vaxillaire, M; Abderrahman, A; Boutin, P; Bailleul, B; Froguel, P; Yaniv, M; Pontoglio, M				Vaxillaire, M; Abderrahman, A; Boutin, P; Bailleul, B; Froguel, P; Yaniv, M; Pontoglio, M			Anatomy of a homeoprotein revealed by the analysis of human MODY3 mutations	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR FACTOR-1-ALPHA GENE; DEPENDENT DIABETES-MELLITUS; NMR-SOLUTION STRUCTURE; TRANSCRIPTION FACTOR; DNA-BINDING; EARLY-ONSET; NONCLASSICAL HOMEODOMAIN; CHROMOSOME 12Q; YOUNG MODY1; LFB1 HNF1	Hepatocyte nuclear factor 1 alpha (HNF1 alpha) is an atypical dimeric homeodomain-containing protein that is expressed in liver, intestine, stomach, kidney, and pancreas. Mutations in the HNF1 alpha gene are associated with an autosomal dominant form of non-insulin-dependent diabetes mellitus called maturity-onset diabetes of the young (MODY3). More than 80 different mutations have been identified so far, many of which involve highly conserved amino acid residues among vertebrate HNF1 alpha. In the present work, we investigated the molecular mechanisms by which MODY3 mutations could affect HNF1 alpha function. For this purpose, we analyzed the properties of 10 mutants resulting in amino acid substitutions or protein truncation. Some mutants have a reduced protein stability, whereas others are either defective in the DNA binding or impaired in their intrinsic trans-activation potential. Three mutants, characterized by a complete loss of trans-activation, behave as dominant negatives when transfected with the wildtype protein. These data define a clear causative relationship between MODY3 mutations and functional defects in HNF1 alpha trans-activation. In addition, our analysis sheds new light on the structure of a homeoprotein playing a key role in pancreatic beta cell function.	Inst Pasteur, Dept Biotechnol, Unite Virus Oncogenes, URA 1644,CNRS, F-75724 Paris 15, France; Inst Pasteur, CNRS, Unite Propre Rech & Enseignement Super A8090, Inst Biol Lille, F-59019 Lille, France	Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Universite de Lille - ISITE; Institut Pasteur Lille	Yaniv, M (corresponding author), Inst Pasteur, Dept Biotechnol, Unite Virus Oncogenes, URA 1644,CNRS, 25 Rue Dr Roux, F-75724 Paris 15, France.		Abderrahmani, Amar/O-3124-2017; FROGUEL, Philippe/O-6799-2017	Abderrahmani, Amar/0000-0003-0752-0343; FROGUEL, Philippe/0000-0003-2972-0784				BACH I, 1991, NUCLEIC ACIDS RES, V19, P3553, DOI 10.1093/nar/19.13.3553; BACH I, 1993, EMBO J, V12, P4229, DOI 10.1002/j.1460-2075.1993.tb06107.x; BAUMHUETER S, 1990, GENE DEV, V4, P372, DOI 10.1101/gad.4.3.372; BELL GI, 1991, P NATL ACAD SCI USA, V88, P1484, DOI 10.1073/pnas.88.4.1484; Byrne MM, 1996, DIABETES, V45, P1503, DOI 10.2337/diabetes.45.11.1503; CESKA TA, 1993, EMBO J, V12, P1805, DOI 10.1002/j.1460-2075.1993.tb05828.x; Chouard T, 1997, BIOCHIMIE, V79, P707, DOI 10.1016/S0300-9084(97)86928-3; CHOUARD T, 1990, NUCLEIC ACIDS RES, V18, P5853, DOI 10.1093/nar/18.19.5853; CITRON BA, 1992, P NATL ACAD SCI USA, V89, P11891, DOI 10.1073/pnas.89.24.11891; COURTOIS G, 1987, SCIENCE, V238, P688, DOI 10.1126/science.3499668; DEMERET C, 1994, J VIROL, V68, P7075, DOI 10.1128/JVI.68.11.7075-7082.1994; DESIMONE V, 1991, EMBO J, V10, P1435, DOI 10.1002/j.1460-2075.1991.tb07664.x; EMENS LA, 1992, P NATL ACAD SCI USA, V89, P7300, DOI 10.1073/pnas.89.16.7300; FRAIN M, 1989, CELL, V59, P145, DOI 10.1016/0092-8674(89)90877-5; Frayling TM, 1997, DIABETES, V46, P720, DOI 10.2337/diabetes.46.4.720; FROGUEL P, 1992, NATURE, V356, P162, DOI 10.1038/356162a0; Froguel P, 1997, DIABETES REV, V5, P123; FROGUEL P, 1993, NEW ENGL J MED, V328, P697, DOI 10.1056/NEJM199303113281005; Glucksmann MA, 1997, DIABETES, V46, P1081, DOI 10.2337/diabetes.46.6.1081; Gong WR, 1997, MOL ENDOCRINOL, V11, P1476, DOI 10.1210/me.11.10.1476; GORMAN CM, 1982, P NATL ACAD SCI-BIOL, V79, P6777, DOI 10.1073/pnas.79.22.6777; Hansen T, 1997, DIABETES, V46, P726, DOI 10.2337/diabetes.46.4.726; Harlow E., 1988, ANTIBODIES LAB MANUA; Iwasaki N, 1997, DIABETES, V46, P1504, DOI 10.2337/diabetes.46.9.1504; Johnson KR, 1998, HUM MOL GENET, V7, P1033, DOI 10.1093/hmg/7.6.1033; Kaisaki PJ, 1997, DIABETES, V46, P528, DOI 10.2337/diabetes.46.3.528; KUO CJ, 1992, NATURE, V355, P457, DOI 10.1038/355457a0; LEITING B, 1993, EMBO J, V12, P1797, DOI 10.1002/j.1460-2075.1993.tb05827.x; MATSCHINSKY F, 1993, J CLIN INVEST, V92, P2092, DOI 10.1172/JCI116809; MENDEL DB, 1991, SCIENCE, V254, P1762, DOI 10.1126/science.1763325; NICOSIA A, 1990, CELL, V61, P1225, DOI 10.1016/0092-8674(90)90687-A; NICOSIA A, 1992, NUCLEIC ACIDS RES, V20, P5321, DOI 10.1093/nar/20.20.5321; Oakley RH, 1996, J BIOL CHEM, V271, P9550, DOI 10.1074/jbc.271.16.9550; Pontoglio M, 1996, CELL, V84, P575, DOI 10.1016/S0092-8674(00)81033-8; Pontoglio M, 1998, J CLIN INVEST, V101, P2215, DOI 10.1172/JCI2548; REYCAMPOS J, 1991, EMBO J, V10, P1445, DOI 10.1002/j.1460-2075.1991.tb07665.x; Schott O, 1997, J MOL BIOL, V267, P673, DOI 10.1006/jmbi.1997.0905; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SOURDIVE DJD, 1993, CR ACAD SCI III-VIE, V316, P385; Stoffel M, 1997, P NATL ACAD SCI USA, V94, P13209, DOI 10.1073/pnas.94.24.13209; THONY B, 1993, ADV EXP MED BIOL, V338, P103; TOMEI L, 1992, EMBO J, V11, P4119, DOI 10.1002/j.1460-2075.1992.tb05505.x; Vahava O, 1998, SCIENCE, V279, P1950, DOI 10.1126/science.279.5358.1950; VAXILLAIRE M, 1995, NAT GENET, V9, P418, DOI 10.1038/ng0495-418; Vaxillaire M, 1997, HUM MOL GENET, V6, P583, DOI 10.1093/hmg/6.4.583; Velho G, 1996, DIABETES CARE, V19, P915, DOI 10.2337/diacare.19.9.915; Yamagata K, 1996, NATURE, V384, P458, DOI 10.1038/384458a0; Yamagata K, 1996, NATURE, V384, P455, DOI 10.1038/384455a0; YEE C, 1985, AM J PATHOL, V119, P361	49	80	81	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 10	1999	274	50					35639	35646		10.1074/jbc.274.50.35639	http://dx.doi.org/10.1074/jbc.274.50.35639			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	264NG	10585442	hybrid			2022-12-25	WOS:000084187900054
J	Yamada, K; Yamada, S; Tobimatsu, T; Toraya, T				Yamada, K; Yamada, S; Tobimatsu, T; Toraya, T			Heterologous high level expression, purification, and enzymological properties of recombinant rat cobalamin-dependent methionine synthase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE LOOP; DIOL DEHYDRASE; CDNA CLONING; X-RAY; B-12; GENE; PROTEINS; BINDING; CRYSTAL; DOMAIN	Rat methionine synthase was expressed chiefly as apoenzyme in recombinant baculovirus-infected insect cells (Yamada, K,, Tohimatsu, T,, and Toraya, T, (1998) Biosci, Biotech, Biochem, 62, 2155-2160). The apoenzyme produced was very unstable, and therefore, after complexation with methylcobalamin, the functional holoenzyme was purified to homogeneity, The specific activity and apparent K-m values for substrates were in good agreement with those obtained with purified rat liver enzyme. The electronic spectrum of the purified recombinant enzyme resembled that of cob(II)alamin and changed to a methylcobalamin-like one upon incubation of the enzyme with titanium(III) and S-adenosylmethionine, The rate of oxidative inactivation of the enzyme in the absence of S-adenosylmethionine was slower with a stronger reducing agent like titanium(III). The nucleotide moiety, especially the phosphodiester group, was shown to play an important role in the binding of the coenzyme to apoprotein and thus for catalysis, Upon incubation with the apoenzyme in the absence of a reducing agent, cyano- and aquacobalamin were not effective or were effective only slightly in reconstituting holoenzyme, Ethyl- and propylcobalamin formed inactive complexes with apoenzyme, which were converted to holoenzyme by photolytic activation. Adenosylcobalamin was not able to form a complex with apoenzyme, which was convertible to holoenzyme by photoirradiation.	Okayama Univ, Fac Engn, Dept Biosci & Biotechnol, Okayama 7008530, Japan	Okayama University	Toraya, T (corresponding author), Okayama Univ, Fac Engn, Dept Biosci & Biotechnol, 3-1-1 Tsushima Naka, Okayama 7008530, Japan.		TOBIMATSU, Takamasa/B-2646-2011					BANERJEE RV, 1989, J BIOL CHEM, V264, P13888; BANERJEE RV, 1990, FASEB J, V4, P1450, DOI 10.1096/fasebj.4.5.2407589; BEAVEN GH, 1955, NATURE, V176, P1264, DOI 10.1038/1761264b0; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Chen LH, 1997, J BIOL CHEM, V272, P3628, DOI 10.1074/jbc.272.6.3628; CHEN ZQ, 1995, J BIOL CHEM, V270, P19246, DOI 10.1074/jbc.270.33.19246; Dixon MM, 1996, STRUCTURE, V4, P1263, DOI 10.1016/S0969-2126(96)00135-9; DRENNAN CL, 1994, SCIENCE, V266, P1669, DOI 10.1126/science.7992050; FRASCA V, 1988, BIOCHEMISTRY-US, V27, P8458, DOI 10.1021/bi00422a025; FUJII K, 1974, J BIOL CHEM, V249, P6745; Gulati S, 1997, J BIOL CHEM, V272, P19171, DOI 10.1074/jbc.272.31.19171; HAYWARD GC, 1965, J CHEM SOC, P6485, DOI 10.1039/jr9650006485; HILL HAO, 1965, PROC R SOC LON SER-A, V288, P352, DOI 10.1098/rspa.1965.0227; HOGENKAMP HP, 1965, J BIOL CHEM, V240, P3641; ISHIDA A, 1993, BIOCHEMISTRY-US, V32, P1535, DOI 10.1021/bi00057a018; ISHIDA A, 1994, ARCH MICROBIOL, V161, P293; KOLHOUSE JF, 1991, J BIOL CHEM, V266, P23010; KRATKY C, 1995, J AM CHEM SOC, V117, P4654, DOI 10.1021/ja00121a022; KRAUTLER B, 1989, J AM CHEM SOC, V111, P8936; KRAUTLER B, 1994, INORG CHEM, V33, P4128; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Leclerc D, 1998, P NATL ACAD SCI USA, V95, P3059, DOI 10.1073/pnas.95.6.3059; Leclerc D, 1996, HUM MOL GENET, V5, P1867, DOI 10.1093/hmg/5.12.1867; Li YN, 1996, HUM MOL GENET, V5, P1851, DOI 10.1093/hmg/5.12.1851; ROSSI M, 1985, J AM CHEM SOC, V107, P1729, DOI 10.1021/ja00292a046; SMITH EL, 1963, BIOCH J, V86; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; TAYLOR RT, 1969, ARCH BIOCHEM BIOPHYS, V129, P745, DOI 10.1016/0003-9861(69)90235-5; TORAYA T, 1991, J BIOL CHEM, V266, P5430; WEISSBACH H, 1966, FED PROC, V25, P1649; Yamada K, 1997, J NUTR SCI VITAMINOL, V43, P177, DOI 10.3177/jnsv.43.177; Yamada K, 1998, BIOSCI BIOTECH BIOCH, V62, P2155, DOI 10.1271/bbb.62.2155; ZEHNDER AJB, 1976, SCIENCE, V194, P1165, DOI 10.1126/science.793008	33	15	17	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 10	1999	274	50					35571	35576		10.1074/jbc.274.50.35571	http://dx.doi.org/10.1074/jbc.274.50.35571			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	264NG	10585432	hybrid			2022-12-25	WOS:000084187900044
J	Yan, Q; Moreland, RJ; Conaway, JW; Conaway, RC				Yan, Q; Moreland, RJ; Conaway, JW; Conaway, RC			Dual roles for transcription factor IIF in promoter escape by RNA polymerase II	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAJOR LATE PROMOTER; DNA-BINDING DOMAIN; PREINITIATION COMPLEX; FACTOR-SIII; ABORTIVE INITIATION; ELONGATION-FACTOR; FACTOR-DELTA; FUNCTIONAL-PROPERTIES; IMMEDIATELY UPSTREAM; FACTOR-EPSILON	Transcription factor (TF) IIF is a multifunctional RNA polymerase II transcription factor that has well established roles in both transcription initiation, where it functions as a component of the preinitiation complex and is required for formation of the open complex and synthesis of the first phosphodiester bond of nascent transcripts, and in transcription elongation, where it is capable of interacting directly with the ternary elongation complex and stimulating the rate of transcription. In this report, we present evidence that TFIIF is also required for efficient promoter escape by RNA polymerase II. Our findings argue that TFIIF performs dual roles in this process. We observe (i) that TFIIF suppresses the frequency of abortive transcription by very early RNA polymerase II elongation intermediates by increasing their processivity and (ii) that TFIIF cooperates with TFIIH to prevent premature arrest of early elongation intermediates. In addition, our findings argue that two TFIIF functional domains mediate TFIIF action in promoter escape. First, we observe that a TFIIF mutant selectively lacking elongation activity supports TFIIH action in promoter escape, but is defective in suppressing the frequency of abortive transcription by very early RNA polymerase II elongation intermediates. Second, a TFIIF mutant selectively lacking initiation activity is more active than wild type TFIIF in increasing the processivity of very early elongation intermediates, but is defective in supporting TFIIH action in promoter escape. Taken together, our findings bring to light a function for TFIIF in promoter escape and support a role for TFIIF elongation activity in this process.	Oklahoma Med Res Fdn, Program Mol & Cell Biol, Oklahoma City, OK 73104 USA; Univ Oklahoma, Hlth Sci Ctr, Dept Biochem & Mol Biol, Oklahoma City, OK 73190 USA; Howard Hughes Med Inst, Oklahoma City, OK 73104 USA	Oklahoma Medical Research Foundation; University of Oklahoma System; University of Oklahoma Health Sciences Center; Howard Hughes Medical Institute	Conaway, RC (corresponding author), Oklahoma Med Res Fdn, Program Mol & Cell Biol, 825 Ne 13Th St, Oklahoma City, OK 73104 USA.		Yan, Qin/E-8893-2012	Yan, Qin/0000-0003-4077-453X; Conaway, Joan/0000-0002-2786-0663	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM041628, R01GM041628] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM41628] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ASO T, 1995, SCIENCE, V269, P1439, DOI 10.1126/science.7660129; BRADSHER JN, 1993, J BIOL CHEM, V268, P25594; BRADSHER JN, 1993, J BIOL CHEM, V268, P25587; BURATOWSKI S, 1991, P NATL ACAD SCI USA, V88, P7509, DOI 10.1073/pnas.88.17.7509; CARPOUSIS AJ, 1980, BIOCHEMISTRY-US, V19, P3245, DOI 10.1021/bi00555a023; CONAWAY JW, 1993, CELL MOL BIOL RES, V39, P323; CONAWAY JW, 1992, J BIOL CHEM, V267, P10142; CONAWAY JW, 1991, J BIOL CHEM, V266, P7804; Conaway JW, 1998, COLD SPRING HARB SYM, V63, P357, DOI 10.1101/sqb.1998.63.357; CONAWAY RC, 1991, P NATL ACAD SCI USA, V88, P6205, DOI 10.1073/pnas.88.14.6205; CONAWAY RC, 1988, J BIOL CHEM, V263, P2962; CONAWAY RC, 1993, ANNU REV BIOCHEM, V62, P161; CONAWAY RC, 1990, J BIOL CHEM, V265, P7559; COULOMBE B, 1994, J BIOL CHEM, V269, P19962; Dvir A, 1996, J BIOL CHEM, V271, P23352, DOI 10.1074/jbc.271.38.23352; Dvir A, 1997, P NATL ACAD SCI USA, V94, P9006, DOI 10.1073/pnas.94.17.9006; Dvir A, 1996, J BIOL CHEM, V271, P7245, DOI 10.1074/jbc.271.13.7245; FLORES O, 1992, J BIOL CHEM, V267, P2786; Fu JH, 1998, J MOL BIOL, V280, P317, DOI 10.1006/jmbi.1998.1557; GARRETT KP, 1992, J BIOL CHEM, V267, P23942; Groft CM, 1998, P NATL ACAD SCI USA, V95, P9117, DOI 10.1073/pnas.95.16.9117; Holstege FCP, 1997, EMBO J, V16, P7468, DOI 10.1093/emboj/16.24.7468; Holstege FCP, 1996, EMBO J, V15, P1666, DOI 10.1002/j.1460-2075.1996.tb00512.x; HOLSTEGE FCP, 1995, EMBO J, V14, P810, DOI 10.1002/j.1460-2075.1995.tb07059.x; JACOB GA, 1991, J BIOL CHEM, V266, P22537; JIANG Y, 1995, J BIOL CHEM, V270, P27332, DOI 10.1074/jbc.270.45.27332; KADESCH TR, 1982, J MOL BIOL, V155, P1, DOI 10.1016/0022-2836(82)90489-2; KADESCH TR, 1982, J BIOL CHEM, V257, P5286; Keene RG, 1999, J BIOL CHEM, V274, P11526, DOI 10.1074/jbc.274.17.11526; KEPHART DD, 1994, J BIOL CHEM, V269, P13536; Kim TK, 1997, P NATL ACAD SCI USA, V94, P12268, DOI 10.1073/pnas.94.23.12268; Kugel JF, 1998, P NATL ACAD SCI USA, V95, P9232, DOI 10.1073/pnas.95.16.9232; Kumar KP, 1998, P NATL ACAD SCI USA, V95, P9767, DOI 10.1073/pnas.95.17.9767; LAVIALLE C, 1982, J BIOL CHEM, V257, P2458; Li XY, 1998, GENE DEV, V12, P2992, DOI 10.1101/gad.12.19.2992; LUSE DS, 1987, J BIOL CHEM, V262, P14990; MCCLURE WR, 1978, J BIOL CHEM, V253, P8941; Moreland RJ, 1999, J BIOL CHEM, V274, P22127, DOI 10.1074/jbc.274.32.22127; PAN GH, 1994, J BIOL CHEM, V269, P30101; PARVIN JD, 1993, CELL, V73, P533, DOI 10.1016/0092-8674(93)90140-L; PETERSON MG, 1991, NATURE, V354, P369; RICE GA, 1991, P NATL ACAD SCI USA, V88, P4245, DOI 10.1073/pnas.88.10.4245; Robert F, 1996, J BIOL CHEM, V271, P8517, DOI 10.1074/jbc.271.15.8517; Robert F, 1998, MOL CELL, V2, P341, DOI 10.1016/S1097-2765(00)80278-6; Selby CP, 1997, P NATL ACAD SCI USA, V94, P11205, DOI 10.1073/pnas.94.21.11205; SERIZAWA H, 1992, P NATL ACAD SCI USA, V89, P7476, DOI 10.1073/pnas.89.16.7476; Shilatifard A, 1997, P NATL ACAD SCI USA, V94, P3639, DOI 10.1073/pnas.94.8.3639; Shilatifard A, 1996, SCIENCE, V271, P1873, DOI 10.1126/science.271.5257.1873; TAKAGI Y, 1995, J BIOL CHEM, V270, P24300, DOI 10.1074/jbc.270.41.24300; TAN SY, 1994, J BIOL CHEM, V269, P25684; TAN SY, 1994, P NATL ACAD SCI USA, V91, P9808, DOI 10.1073/pnas.91.21.9808; TAN SY, 1995, P NATL ACAD SCI USA, V92, P6042, DOI 10.1073/pnas.92.13.6042; TANTIN D, 1994, J BIOL CHEM, V269, P17397; Tirode F, 1999, MOL CELL, V3, P87, DOI 10.1016/S1097-2765(00)80177-X; TSUBOI A, 1992, NUCLEIC ACIDS RES, V20, P3250, DOI 10.1093/nar/20.12.3250; WANG BQ, 1995, J BIOL CHEM, V270, P27035, DOI 10.1074/jbc.270.45.27035	56	61	61	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 10	1999	274	50					35668	35675		10.1074/jbc.274.50.35668	http://dx.doi.org/10.1074/jbc.274.50.35668			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	264NG	10585446	hybrid			2022-12-25	WOS:000084187900058
J	Kiley, SC; Clark, KJ; Duddy, SK; Welch, DR; Jaken, S				Kiley, SC; Clark, KJ; Duddy, SK; Welch, DR; Jaken, S			Increased protein kinase C delta in mammary tumor cells: relationship to transformation and metastatic progression	ONCOGENE			English	Article						protein kinase C; metastasis; adducin; mammary; breast cancer	TYROSINE PHOSPHORYLATION; SIGNAL-TRANSDUCTION; CHO CELLS; ACTIVATION; EXPRESSION; EPSILON; DOMAINS; GROWTH; ALPHA; BINDING	Relatively little is known about the molecular mechanisms of tumor promotion/progression in mammary carcinogenesis. Increased protein kinase C (PKC) activity is known to promote tumor formation in several tissues; however, its role in mammary carcinogenesis is not yet known. To determine if individual PKCs may selectively regulate properties of mammary tumor cells, we compared PKC isozyme levels in mammary tumor cell lines,vith low, moderate and high metastatic potential. All three cell lines expressed alpha, delta, epsilon and zeta PKCs; however, PKC delta levels were relatively increased in the highly metastatic cells. To determine if increased PKC delta could contribute to promotion/progression, we overexpressed PKC delta in the low and moderately metastatic cell lines, PKC delta overexpression had no significant effect on growth of adherent cells, but significantly increased anchorage-independent growth. Conversely, expressing the regulatory domain of PKC delta (RD delta), a putative PKC delta inhibitory fragment, inhibited anchorage-independent growth. The efficacy of RD delta as a PKC delta inhibitor was demonstrated by showing that RD delta selectively interfered with PKC delta subcellular location and significantly interfered with phosphorylation of the PKC cytoskeletal substrate, adducin, PKC-dependent phosphorylation of cytoskeletal substrate proteins, such as adducin, provides a mechanistic link between increased PKC delta activity and phenotypic changes in cytoskeletal-dependent processes such as migration and attachment, two processes that are relevant to metastatic potential. The reciprocal growth effects of expressing PKC delta and RD delta as gain and loss of function constructs, respectively, provide strong evidence that PKC delta regulates processes important for anchorage-independent growth in these mammary tumor cells.	Adirondack Biomed Res Inst Inc, Lake Placid, NY 12946 USA; Penn State Univ, Coll Med, Jake Gittlen Canc Res Inst C7810, Hershey, PA 17033 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health	Jaken, S (corresponding author), Univ Vermont, Dept Pathol, Med Alumni Bldg,A249, Burlington, VT 05405 USA.		Welch, Danny R/B-7310-2009	Welch, Danny R/0000-0002-1951-4947	NCI NIH HHS [CA 071604] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bornancin F, 1997, J BIOL CHEM, V272, P3544, DOI 10.1074/jbc.272.6.3544; CACACE AM, 1993, ONCOGENE, V8, P2095; CHAPLINE C, 1993, J BIOL CHEM, V268, P6858; Dekker LV, 1997, J BIOL CHEM, V272, P12747, DOI 10.1074/jbc.272.19.12747; Denning MF, 1996, J BIOL CHEM, V271, P5325, DOI 10.1074/jbc.271.10.5325; DONG LQ, 1995, J BIOL CHEM, V270, P25534, DOI 10.1074/jbc.270.43.25534; Edwards AS, 1999, J BIOL CHEM, V274, P6461, DOI 10.1074/jbc.274.10.6461; Fowler L, 1998, CELL GROWTH DIFFER, V9, P177; Fowler L, 1998, CELL GROWTH DIFFER, V9, P405; HANSEN MB, 1989, J IMMUNOL METHODS, V119, P203, DOI 10.1016/0022-1759(89)90397-9; HUG H, 1993, BIOCHEM J, V291, P329, DOI 10.1042/bj2910329; JAKEN S, 1997, PROTEIN KINASE C, P179; KAHN SM, 1994, CARCINOGENESIS, V15, P2915; KILEY SC, 1990, MOL ENDOCRINOL, V4, P59, DOI 10.1210/mend-4-1-59; Kiley SC, 1999, CANCER RES, V59, P3230; LEACH KL, 1988, J BIOL CHEM, V263, P13223; Li WQ, 1996, ONCOGENE, V13, P731; Li WQ, 1998, MOL CELL BIOL, V18, P5888, DOI 10.1128/MCB.18.10.5888; LI WQ, 1994, J BIOL CHEM, V269, P2349; Li XL, 1998, J BIOL CHEM, V273, P19329, DOI 10.1074/jbc.273.30.19329; LIAO L, 1994, BIOCHEMISTRY-US, V33, P1229, DOI 10.1021/bi00171a024; LIAO L, 1994, CELL GROWTH DIFFER, V5, P1185; Lu ZM, 1997, MOL CELL BIOL, V17, P3418, DOI 10.1128/MCB.17.6.3418; MISCHAK H, 1993, J BIOL CHEM, V268, P6090; Mochly-Rosen D, 1998, FASEB J, V12, P35; NERI A, 1982, J NATL CANCER I, V68, P507; NISHIZUKA Y, 1995, FASEB J, V9, P484, DOI 10.1096/fasebj.9.7.7737456; OGITA K, 1992, P NATL ACAD SCI USA, V89, P1592, DOI 10.1073/pnas.89.5.1592; Parissenti AM, 1998, J BIOL CHEM, V273, P8940, DOI 10.1074/jbc.273.15.8940; SCHAAP D, 1989, FEBS LETT, V243, P351, DOI 10.1016/0014-5793(89)80160-7; van Huizen R, 1998, EMBO J, V17, P2285, DOI 10.1093/emboj/17.8.2285; VAUX DL, 1993, MOL CELL BIOL, V13, P7000, DOI 10.1128/MCB.13.11.7000; WATANABE T, 1992, P NATL ACAD SCI USA, V89, P10159, DOI 10.1073/pnas.89.21.10159; WAYS DK, 1995, J CLIN INVEST, V95, P1906, DOI 10.1172/JCI117872; WAYS DK, 1992, J BIOL CHEM, V267, P4799; Weinstein IB, 1997, CLIN CANCER RES, V3, P2696; WEINSTEIN IB, 1979, J SUPRAMOLECULAR STR, V12, P527; WELCH DR, 1983, INVAS METAST, V3, P65; Wu SL, 1998, J BIOL CHEM, V273, P1130, DOI 10.1074/jbc.273.2.1130; YAMAGUCHI K, 1995, BIOCHEM BIOPH RES CO, V210, P639, DOI 10.1006/bbrc.1995.1708; YAO L, 1994, P NATL ACAD SCI USA, V91, P9175, DOI 10.1073/pnas.91.19.9175	41	93	96	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 18	1999	18	48					6748	6757		10.1038/sj.onc.1203101	http://dx.doi.org/10.1038/sj.onc.1203101			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	257QA	10597283				2022-12-25	WOS:000083792000017
J	McKay, LM; Carpenter, B; Roberts, SGE				McKay, LM; Carpenter, B; Roberts, SGE			Regulation of the Wilms' tumour suppressor protein transcriptional activation domain	ONCOGENE			English	Article						Wilms' tumour; WT1; transcription	DNA-BINDING SPECIFICITY; GENE-PRODUCT; REPRESSES TRANSCRIPTION; INHIBITOR DOMAIN; SELF-ASSOCIATION; MUTANT PROTEINS; WT1; RNA; EXPRESSION; INTERACTS	The Wilms' tumour suppressor protein WT1 contains a transcriptional regulatory domain that can either activate or repress transcription depending upon its cellular environment. The mechanistic basis for this dichotomy is unclear however. Here, we dissect the transcriptional regulatory domains of WT1. We find that a region within the domain of WT1 attributed to transcriptional repression is a potent suppressor of the activation domain at several promoters and in different cell types. In vitro transcription analysis suggests that the mechanism of suppression of the activation domain occurs at the level of transcription initiation. Furthermore we find that the WT1 suppression domain is able to inhibit a heterologous activation domain when fused in cis. Dissection of this domain resulted in the delineation of a 30 amino acid region that was sufficient to confer suppression of a transcriptional activation domain both in vivo and in vitro. Additionally, we find that the WT1 transcriptional activation domain interacts with the general transcription factor TFIIB and that this interaction is not affected by the suppression domain. Taken together, these studies suggest that the suppression domain of WT1 interacts with a cosuppressor protein to mediate inhibition of the WT1 transcriptional activation domain.	Univ Dundee, Dept Biochem, Div Gene Express, Dundee DD1 5EH, Scotland	University of Dundee	Roberts, SGE (corresponding author), Univ Dundee, Dept Biochem, Div Gene Express, Dundee DD1 5EH, Scotland.		Roberts, Stefan GE/R-5537-2016	Roberts, Stefan GE/0000-0002-7535-6365	Wellcome Trust Funding Source: Medline; Worldwide Cancer Research [02-0275] Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission); Worldwide Cancer Research		AUSTIN RJ, 1995, MOL CELL BIOL, V15, P4683; Bardeesy N, 1998, NUCLEIC ACIDS RES, V26, P1784, DOI 10.1093/nar/26.7.1784; BICKMORE WA, 1992, SCIENCE, V257, P235, DOI 10.1126/science.1321494; Brehm A, 1998, NATURE, V391, P597, DOI 10.1038/35404; BROWN HJ, 1995, EMBO J, V14, P124, DOI 10.1002/j.1460-2075.1995.tb06982.x; CAREY M, 1990, NATURE, V345, P361, DOI 10.1038/345361a0; Caricasole A, 1996, P NATL ACAD SCI USA, V93, P7562, DOI 10.1073/pnas.93.15.7562; Cook DM, 1996, ONCOGENE, V13, P1789; Davies RC, 1998, GENE DEV, V12, P3217, DOI 10.1101/gad.12.20.3217; Dennig J, 1996, EMBO J, V15, P5659, DOI 10.1002/j.1460-2075.1996.tb00950.x; DRUMMOND IA, 1992, SCIENCE, V257, P674, DOI 10.1126/science.1323141; Englert C, 1998, TRENDS BIOCHEM SCI, V23, P389, DOI 10.1016/S0968-0004(98)01277-8; Hampsey M, 1998, MICROBIOL MOL BIOL R, V62, P465, DOI 10.1128/MMBR.62.2.465-503.1998; HASTIE ND, 1994, ANNU REV GENET, V28, P523; Hawkes NA, 1999, J BIOL CHEM, V274, P14337, DOI 10.1074/jbc.274.20.14337; Holmes G, 1997, BIOCHEM BIOPH RES CO, V233, P723, DOI 10.1006/bbrc.1997.6545; JAYARAMAN PS, 1994, EMBO J, V13, P2192, DOI 10.1002/j.1460-2075.1994.tb06496.x; Johnstone RW, 1996, MOL CELL BIOL, V16, P6945; Johnstone RW, 1998, J BIOL CHEM, V273, P10880, DOI 10.1074/jbc.273.18.10880; Kennedy D, 1996, NAT GENET, V12, P329, DOI 10.1038/ng0396-329; KENT J, 1995, ONCOGENE, V11, P1781; KREIDBERG JA, 1993, CELL, V74, P679, DOI 10.1016/0092-8674(93)90515-R; LARSSON SH, 1995, CELL, V81, P391, DOI 10.1016/0092-8674(95)90392-5; LEE KAW, 1988, GENE ANAL TECH, V5, P22, DOI 10.1016/0735-0651(88)90023-4; Li C, 1998, MOL CELL BIOL, V18, P3771, DOI 10.1128/MCB.18.7.3771; LIN YS, 1991, CELL, V64, P971, DOI 10.1016/0092-8674(91)90321-O; Liu YZ, 1998, NUCLEIC ACIDS RES, V26, P2464, DOI 10.1093/nar/26.10.2464; MADDEN SL, 1993, ONCOGENE, V8, P1713; MADDEN SL, 1991, SCIENCE, V253, P1550, DOI 10.1126/science.1654597; Maheswaran S, 1998, GENE DEV, V12, P1108, DOI 10.1101/gad.12.8.1108; MAHESWARAN S, 1995, GENE DEV, V9, P2143, DOI 10.1101/gad.9.17.2143; Maheswaran S, 1998, ONCOGENE, V16, P2041, DOI 10.1038/sj.onc.1201741; MARTIN K, 1995, NATURE, V375, P691, DOI 10.1038/375691a0; MOFFETT P, 1995, P NATL ACAD SCI USA, V92, P11105, DOI 10.1073/pnas.92.24.11105; Nachtigal MW, 1998, CELL, V93, P445, DOI 10.1016/S0092-8674(00)81172-1; Novina CD, 1996, TRENDS GENET, V12, P351, DOI 10.1016/0168-9525(96)10034-2; PritchardJones K, 1997, LEUKEMIA LYMPHOMA, V27, P207, DOI 10.3109/10428199709059677; PRITCHARDJONES K, 1990, NATURE, V346, P194, DOI 10.1038/346194a0; REDDY JC, 1995, J BIOL CHEM, V270, P29976; REDDY JC, 1995, J BIOL CHEM, V270, P10878, DOI 10.1074/jbc.270.18.10878; Reddy JC, 1996, BBA-REV CANCER, V1287, P1, DOI 10.1016/0304-419X(95)00014-7; REECE RJ, 1993, GENE, V126, P105, DOI 10.1016/0378-1119(93)90596-U; Renshaw J, 1997, GENE CHROMOSOME CANC, V19, P256, DOI 10.1002/(SICI)1098-2264(199708)19:4<256::AID-GCC8>3.0.CO;2-W; ROBERTS SGE, 1995, CURR BIOL, V5, P508, DOI 10.1016/S0960-9822(95)00103-5; SOUTHGATE CD, 1991, GENE DEV, V5, P2496, DOI 10.1101/gad.5.12b.2496; Thate C, 1998, ONCOGENE, V17, P1287, DOI 10.1038/sj.onc.1202055; UM M, 1995, MOL CELL BIOL, V15, P5007; WANG ZY, 1995, ONCOGENE, V10, P415; WANG ZY, 1993, J BIOL CHEM, V268, P9172; WANG ZY, 1995, ONCOGENE, V10, P1243	50	24	24	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 11	1999	18	47					6546	6554		10.1038/sj.onc.1203046	http://dx.doi.org/10.1038/sj.onc.1203046			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	256CW	10597258				2022-12-25	WOS:000083709200018
J	Bubb, MR; Lenox, RH; Edison, AS				Bubb, MR; Lenox, RH; Edison, AS			Phosphorylation-dependent conformational changes induce a switch in the actin-binding function of MARCKS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; SUBSTRATE MARCKS; RAT-BRAIN; CALMODULIN; PEPTIDES; MEMBRANE; MICE; ASSOCIATION; EXPRESSION; RECEPTOR	Phosphorylation of myristoylated alanine-rich protein kinase C substrate (MARCKS) by protein kinase C eliminates actin filament cross-linking activity, but residual filament binding activity docks phosphorylated MARCKS on filamentous actin. The postulated actin-binding region of MARCKS, which includes a Ca2+-calmodulin-binding site, has been portrayed with alpha-helical structure, analogous to other calmodulin-binding domains. Previous speculation suggested that MARCKS may dimerize to form the two functional actin-binding sites requisite for cross-linking activity. Contrary to these hypotheses, we show that MARCKS peptide with actin-cross-linking activity has an extended structure in aqueous solution but assumes a more compact structure upon phosphorylation. We hypothesize that structural changes in the MARCKS peptide induced by phosphorylation create a dynamic structure that, on average, has only one actin-binding site. Moreover, independent of the state of phosphorylation, this peptide is monomeric rather than dimeric, implying that two distinct actin-binding sites are responsible for the actin-crosslinking activity of unphosphorylated MARCKS. These studies uniquely elucidate the mechanism by which phosphorylation of MARCKS induces structural changes and suggest how these structural changes determine biological activity.	Univ Florida, Dept Biochem & Mol Biol, Gainesville, FL 32610 USA; Univ Florida, Dept Med, Gainesville, FL 32610 USA; Univ Florida, Dept Biochem, Gainesville, FL 32610 USA; Univ Penn, Dept Psychiat, Philadelphia, PA 19104 USA; Univ Penn, Dept Pharmacol, Philadelphia, PA 19104 USA; Univ Penn, Dept Neurosci, Philadelphia, PA 19104 USA	State University System of Florida; University of Florida; State University System of Florida; University of Florida; State University System of Florida; University of Florida; University of Pennsylvania; University of Pennsylvania; University of Pennsylvania	Edison, AS (corresponding author), Univ Florida, Dept Biochem & Mol Biol, Gainesville, FL 32610 USA.			Edison, Arthur/0000-0002-5686-2350				ADEREM A, 1992, CELL, V71, P713, DOI 10.1016/0092-8674(92)90546-O; BLACKSHEAR PJ, 1993, J BIOL CHEM, V268, P1501; Blackshear PJ, 1997, EXP NEUROL, V145, P46, DOI 10.1006/exnr.1997.6475; BRAUNSCHWEILER L, 1983, J MAGN RESON, V53, P521, DOI 10.1016/0022-2364(83)90226-3; BUBB MR, 1991, J BIOL CHEM, V266, P3820; Callihan D, 1996, J MAGN RESON SER B, V112, P82, DOI 10.1006/jmrb.1996.0114; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; DYSON HJ, 1988, J MOL BIOL, V201, P201, DOI 10.1016/0022-2836(88)90447-0; EDELSTEIN SJ, 1967, J BIOL CHEM, V242, P306; GEORGE DJ, 1992, J BIOL CHEM, V267, P24879; GRAFF JM, 1989, SCIENCE, V246, P503, DOI 10.1126/science.2814478; GRAFF JM, 1989, J BIOL CHEM, V264, P21818; HARTWIG JH, 1992, NATURE, V356, P618, DOI 10.1038/356618a0; HEEMSKERK FMJ, 1993, BIOCHEM BIOPH RES CO, V190, P236, DOI 10.1006/bbrc.1993.1036; HERGET T, 1995, EUR J BIOCHEM, V233, P448, DOI 10.1111/j.1432-1033.1995.448_2.x; JOHNSON BA, 1994, J BIOMOL NMR, V4, P603, DOI 10.1007/BF00404272; KIRSCHNER MW, 1971, BIOCHEMISTRY-US, V10, P1900, DOI 10.1021/bi00786a027; KUMAR A, 1980, BIOCHEM BIOPH RES CO, V95, P1, DOI 10.1016/0006-291X(80)90695-6; Lenox RH, 1996, J CLIN PSYCHIAT, V57, P23; MAHONEY CW, 1995, CELL SIGNAL, V7, P679, DOI 10.1016/0898-6568(95)00043-O; MANENTI S, 1992, J BIOL CHEM, V267, P22310; Matsubara M, 1998, FEBS LETT, V421, P203, DOI 10.1016/S0014-5793(97)01557-3; MCLAUGHLIN S, 1995, TRENDS BIOCHEM SCI, V20, P272, DOI 10.1016/S0968-0004(00)89042-8; McNamara RK, 1997, J COMP NEUROL, V379, P48; McNamara RK, 1998, J COMP NEUROL, V397, P337; McNamara RK, 1998, P NATL ACAD SCI USA, V95, P14517, DOI 10.1073/pnas.95.24.14517; MIICK SM, 1992, NATURE, V359, P653, DOI 10.1038/359653a0; Porumb T, 1997, EUR BIOPHYS J BIOPHY, V25, P239, DOI 10.1007/s002490050036; Qin ZH, 1996, BIOCHEMISTRY-US, V35, P2917, DOI 10.1021/bi9521452; Qin ZH, 1996, BIOCHEMISTRY-US, V35, P13272, DOI 10.1021/bi961747y; ROBINSON PJ, 1991, MOL NEUROBIOL, V5, P87, DOI 10.1007/BF02935541; STATES DJ, 1982, J MAGN RESON, V48, P286, DOI 10.1016/0022-2364(82)90279-7; STUMPO DJ, 1995, P NATL ACAD SCI USA, V92, P944, DOI 10.1073/pnas.92.4.944; Tang JX, 1996, J BIOL CHEM, V271, P8556, DOI 10.1074/jbc.271.15.8556; THELEN M, 1991, NATURE, V351, P320, DOI 10.1038/351320a0; WANG JKT, 1989, P NATL ACAD SCI USA, V86, P2253, DOI 10.1073/pnas.86.7.2253; Watson DG, 1996, J NEUROCHEM, V67, P767; Wiederkehr A, 1997, EXP CELL RES, V236, P103, DOI 10.1006/excr.1997.3709; Wuthrich K, 1986, NMR PROTEINS NUCL AC	39	41	41	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 17	1999	274	51					36472	36478		10.1074/jbc.274.51.36472	http://dx.doi.org/10.1074/jbc.274.51.36472			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	266AV	10593944	hybrid			2022-12-25	WOS:000084279200063
J	Friedman, KJ; Kole, J; Cohn, JA; Knowles, MR; Silverman, LM; Kole, R				Friedman, KJ; Kole, J; Cohn, JA; Knowles, MR; Silverman, LM; Kole, R			Correction of aberrant splicing of the cystic fibrosis transmembrane conductance regulator (CFTR) gene by antisense oligonucleotides	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA; EPITHELIAL-CELLS; RECEPTOR GENE; GLOBIN GENE; MOLECULAR MECHANISMS; MEDIATED INSERTION; PULMONARY-DISEASE; BETA-THALASSEMIA; LEPTIN RECEPTOR; POINT MUTATION	The CFTR splicing mutation 3849 + 10 kb C --> T creates a novel donor site 10 kilobases (kb) into intron 19 of the gene and is one of the more common splicing mutations that causes cystic fibrosis (CF). It has an elevated prevalence among patients with atypically mild disease and normal sweat electrolytes and is especially prominent in Ashkenazi Jews. This class of splicing mutations, reported in several genes, involves novel splice sites activated deep within introns while leaving wild type splice elements intact. CFTR cDNA constructs that modeled the 3849 + 10 kb C --> T mutation were expressed in 3T3 mouse fibroblasts and in CFT1 human tracheal and C127 mouse mammary epithelial cells. In all three cell types, aberrant splicing of CFTR pre-mRNA was comparable to that reported in vivo in CF patients. Treatment of the cells with 2'-O-methyl phosphorothioate oligoribonucleotides antisense toward the aberrant donor and acceptor splice sites or to the retained exon-like sequence, disfavored aberrant splicing and enhanced normal processing of CFTR pre-mRNA. This antisense-mediated correction of splicing was dose- and sequence-dependent and was accompanied by increased production of CFTR protein that was appropriately glycosylated. Antisense-mediated correction of splicing in a mutation-specific context represents a potential gene therapy modality with applicability to many inherited disorders.	Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA; Univ N Carolina, Dept Pathol & Lab Med, Chapel Hill, NC 27599 USA; Univ N Carolina, Dept Pharmacol, Chapel Hill, NC 27599 USA; Duke Univ, Med Ctr, Dept Med, Durham, NC 27710 USA; Vet Affairs Med Ctr, Durham, NC 27710 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; Duke University; US Department of Veterans Affairs; Veterans Health Administration (VHA)	Kole, R (corresponding author), Univ N Carolina, Lineberger Comprehens Canc Ctr, CB7295, Chapel Hill, NC 27599 USA.							ABELIOVICH D, 1992, AM J HUM GENET, V51, P951; AUGARTEN A, 1993, LANCET, V342, P25, DOI 10.1016/0140-6736(93)91885-P; BERGET SM, 1995, J BIOL CHEM, V270, P2411, DOI 10.1074/jbc.270.6.2411; Bruggenwirth HT, 1997, AM J HUM GENET, V61, P1067, DOI 10.1086/301605; Chen H, 1996, CELL, V84, P491, DOI 10.1016/S0092-8674(00)81294-5; CHENG TC, 1984, P NATL ACAD SCI-BIOL, V81, P2821, DOI 10.1073/pnas.81.9.2821; CHILLON M, 1995, AM J HUM GENET, V56, P623; COHN JA, 1992, P NATL ACAD SCI USA, V89, P2340, DOI 10.1073/pnas.89.6.2340; COLLINS FS, 1992, SCIENCE, V256, P774, DOI 10.1126/science.1375392; Crooke ST, 1998, BIOTECHNOL GENET ENG, V15, P121, DOI 10.1080/02648725.1998.10647954; CUTTING GR, 1993, SEM RESP CRIT CARE M, P356; DOBKIN C, 1983, P NATL ACAD SCI-BIOL, V80, P1184, DOI 10.1073/pnas.80.5.1184; DOMINSKI Z, 1994, MOL CELL BIOL, V14, P7445, DOI 10.1128/MCB.14.11.7445; DOMINSKI Z, 1993, P NATL ACAD SCI USA, V90, P8673, DOI 10.1073/pnas.90.18.8673; Dreyfus DH, 1996, AM J RESP CRIT CARE, V153, P858, DOI 10.1164/ajrccm.153.2.8564145; Dunckley MG, 1998, HUM MOL GENET, V7, P1083, DOI 10.1093/hmg/7.7.1083; GILBERT F, 1995, AM J MED GENET, V58, P356, DOI 10.1002/ajmg.1320580411; GILBERT W, 1978, NATURE, V271, P501, DOI 10.1038/271501a0; Gorman L, 1998, P NATL ACAD SCI USA, V95, P4929, DOI 10.1073/pnas.95.9.4929; HIGHSMITH WE, 1994, NEW ENGL J MED, V331, P974, DOI 10.1056/NEJM199410133311503; Hovnanian A, 1997, AM J HUM GENET, V61, P599, DOI 10.1086/515495; Ikeda H, 1997, HUM GENET, V100, P637, DOI 10.1007/s004390050566; JONES DH, 1990, BIOTECHNIQUES, V8, P178; KNEBELMANN B, 1995, HUM MOL GENET, V4, P675, DOI 10.1093/hmg/4.4.675; KRAWCZAK M, 1992, HUM GENET, V90, P41; Lee GH, 1996, NATURE, V379, P632, DOI 10.1038/379632a0; LEE LG, 1992, NUCLEIC ACIDS RES, V20, P2471, DOI 10.1093/nar/20.10.2471; LUKACS GL, 1994, EMBO J, V13, P6076, DOI 10.1002/j.1460-2075.1994.tb06954.x; MAQUAT LE, 1995, RNA, V1, P453; MARSHALL J, 1994, J BIOL CHEM, V269, P2987; McConville CM, 1996, AM J HUM GENET, V59, P320; MITCHELL GA, 1991, P NATL ACAD SCI USA, V88, P815, DOI 10.1073/pnas.88.3.815; Nyce JW, 1997, NATURE, V385, P721, DOI 10.1038/385721a0; Nyce JW, 1999, TRENDS PHARMACOL SCI, V20, P79, DOI 10.1016/S0165-6147(99)01305-X; O'Neil JP, 1998, MUTAT RES-REV MUTAT, V411, P179, DOI 10.1016/S1383-5742(98)00013-1; Okuyama E, 1997, J CLIN ENDOCR METAB, V82, P2337, DOI 10.1210/jc.82.7.2337; OLSEN JC, 1992, HUM GENE THER, V3, P253, DOI 10.1089/hum.1992.3.3-253; OLSEN JC, 1995, HUM GENE THER, V6, P1195, DOI 10.1089/hum.1995.6.9-1195; OLSEN JC, 1995, METHODS MOL MED, P153; ORKIN SH, 1982, NATURE, V300, P768, DOI 10.1038/300768a0; Perrin G, 1996, HUM MUTAT, V7, P172, DOI 10.1002/(SICI)1098-1004(1996)7:2<172::AID-HUMU15>3.0.CO;2-#; Roest PAM, 1996, J MED GENET, V33, P935, DOI 10.1136/jmg.33.11.935; SANDHU GS, 1989, BIOTECHNIQUES, V7, P689; SATOKATA I, 1995, HUM MOL GENET, V4, P1993, DOI 10.1093/hmg/4.10.1993; Seeberger PH, 1998, APPLIED ANTISENSE OLIGONUCLEOTIDE TECHNOLOGY, P51; SHAPIRO MB, 1987, NUCLEIC ACIDS RES, V15, P7155, DOI 10.1093/nar/15.17.7155; Sierakowska H, 1996, P NATL ACAD SCI USA, V93, P12840, DOI 10.1073/pnas.93.23.12840; SPRITZ RA, 1981, P NATL ACAD SCI-BIOL, V78, P2455, DOI 10.1073/pnas.78.4.2455; TASSARA C, 1995, HUM MOL GENET, V4, P1693, DOI 10.1093/hmg/4.9.1693; Teraoka SN, 1999, AM J HUM GENET, V64, P1617, DOI 10.1086/302418; TREISMAN R, 1983, NATURE, V302, P591, DOI 10.1038/302591a0; TSUI LC, 1992, TRENDS GENET, V8, P392, DOI 10.1016/0168-9525(92)90301-J; Tsuruta M, 1998, J HUM GENET, V43, P91, DOI 10.1007/s100380050047; Urban Z, 1999, HUM GENET, V104, P135, DOI 10.1007/s004390050926; Vervoort R, 1998, HUM GENET, V103, P686, DOI 10.1007/PL00008709; Wang M, 1997, BREAST CANCER RES TR, V44, P145, DOI 10.1023/A:1005753117205; WELSH MJ, 1993, CELL, V73, P1251, DOI 10.1016/0092-8674(93)90353-R; WELSH MJ, 1995, METABOLIC MOL BASES, V3, P3799; Wilton SD, 1999, NEUROMUSCULAR DISORD, V9, P330, DOI 10.1016/S0960-8966(99)00010-3; YANKASKAS JR, 1993, AM J PHYSIOL, V264, pC1219, DOI 10.1152/ajpcell.1993.264.5.C1219; Yew NS, 1997, HUM GENE THER, V8, P575, DOI 10.1089/hum.1997.8.5-575	61	114	144	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 17	1999	274	51					36193	36199		10.1074/jbc.274.51.36193	http://dx.doi.org/10.1074/jbc.274.51.36193			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	266AV	10593905	hybrid, Green Published			2022-12-25	WOS:000084279200024
J	Labbe, S; Pena, MMO; Fernandes, AR; Thiele, DJ				Labbe, S; Pena, MMO; Fernandes, AR; Thiele, DJ			A copper-sensing transcription factor regulates iron uptake genes in Schizosaccharomyces pombe	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE ENCODES; FISSION YEAST; DNA-BINDING; MOLECULAR CHARACTERIZATION; FUNCTIONALLY SUBSTITUTE; SUPEROXIDE-DISMUTASE; METALLOTHIONEIN GENE; FERRIC REDUCTASE; CANDIDA-GLABRATA; SHUTTLE VECTORS	Copper and iron serve essential functions as catalytic co-factors in a wide variety of critical cellular enzymes. Studies in yeast have demonstrated an absolute dependence upon copper acquisition for proper assembly and function of the iron transport machinery. We have cloned genes for a high affinity copper transporter (Ctr4) and copper-sensing transcription factor (Cuf1) from Schizosaccharomyces pombe. Interestingly, the primary structure of Ctr4 and a putative human high affinity copper transport protein, hCtr1, suggests that they are derived from a fusion of the functionally redundant but structurally distinct Ctr1 and Ctr3 copper transporters from Saccharomyces cerevisiae. Furthermore, although Cuf1 activates ctr4(+) gene expression under copper starvation conditions, under these same conditions Cuf1 directly represses expression of genes encoding components of the iron transport machinery. These studies have identified an evolutionary step in which copper transport modules have been fused, and describe a mechanism by which a copper-sensing factor directly represses expression of the iron uptake genes under conditions in which the essential copper co-factor is scarce.	Univ Michigan, Dept Biol Chem, Sch Med, Ann Arbor, MI 48109 USA; Ctr Engn Biol & Quim, Inst Super Tecn, P-1046001 Lisbon, Portugal	University of Michigan System; University of Michigan; Universidade de Lisboa; Instituto Superior Tecnico	Thiele, DJ (corresponding author), Univ Michigan, Dept Biol Chem, Sch Med, Ann Arbor, MI 48109 USA.	dthiele@umich.edu	Fernandes, Alexandra R/C-7465-2011	Fernandes, Alexandra R/0000-0003-2054-4438; Labbe, Simon/0000-0002-4947-523X	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM018089, R01GM041840] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM41840, F32 GM18089] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALFA C, 1993, EXPT FISSION YEAST L, P1; Anderson GJ, 1999, LANCET, V353, P2089, DOI 10.1016/S0140-6736(99)00113-0; ANDERSON GJ, 1994, ADV EXP MED BIOL, V356, P81; Andrews NC, 1999, NUTR REV, V57, P114, DOI 10.1111/j.1753-4887.1999.tb06934.x; Askwith C, 1998, TRENDS BIOCHEM SCI, V23, P135, DOI 10.1016/S0968-0004(98)01192-X; Askwith C, 1997, J BIOL CHEM, V272, P401; ASKWITH C, 1994, CELL, V76, P403, DOI 10.1016/0092-8674(94)90346-8; BARBET N, 1992, GENE, V114, P59, DOI 10.1016/0378-1119(92)90707-V; Borghouts C, 1998, MOL GEN GENET, V260, P492, DOI 10.1007/s004380050922; BULL PC, 1994, TRENDS GENET, V10, P246, DOI 10.1016/0168-9525(94)90172-4; Chang F, 1996, CELL, V84, P191, DOI 10.1016/S0092-8674(00)80973-3; COTTAREL G, 1993, CURR GENET, V23, P547, DOI 10.1007/BF00312650; Culotta VC, 1997, J BIOL CHEM, V272, P23469, DOI 10.1074/jbc.272.38.23469; DANCIS A, 1994, CELL, V76, P393, DOI 10.1016/0092-8674(94)90345-X; Dancis A, 1998, J PEDIATR-US, V132, pS24, DOI 10.1016/S0022-3476(98)70524-4; DANCIS A, 1992, P NATL ACAD SCI USA, V89, P3869, DOI 10.1073/pnas.89.9.3869; Davis-Kaplan SR, 1998, P NATL ACAD SCI USA, V95, P13641, DOI 10.1073/pnas.95.23.13641; DESILVA DM, 1995, J BIOL CHEM, V270, P1098, DOI 10.1074/jbc.270.3.1098; DiDonato M, 1997, BBA-MOL BASIS DIS, V1360, P3, DOI 10.1016/S0925-4439(96)00064-6; Eide DJ, 1998, ANNU REV NUTR, V18, P441, DOI 10.1146/annurev.nutr.18.1.441; FURST P, 1988, CELL, V55, P705, DOI 10.1016/0092-8674(88)90229-2; Gaxiola RA, 1998, P NATL ACAD SCI USA, V95, P4046, DOI 10.1073/pnas.95.7.4046; GEORGATSOU E, 1994, MOL CELL BIOL, V14, P3065, DOI 10.1128/MCB.14.5.3065; Glerum DM, 1996, J BIOL CHEM, V271, P14504, DOI 10.1074/jbc.271.24.14504; Graden JA, 1997, P NATL ACAD SCI USA, V94, P5550, DOI 10.1073/pnas.94.11.5550; GREENE JR, 1993, MOL GEN GENET, V241, P542, DOI 10.1007/BF00279896; GRIMM C, 1988, MOL GEN GENET, V215, P81, DOI 10.1007/BF00331307; GUBLER CJ, 1952, BLOOD, V7, P1075, DOI 10.1182/blood.V7.11.1075.1075; Harris ZL, 1996, AM J CLIN NUTR, V63, P836; HASSETT R, 1995, J BIOL CHEM, V270, P128, DOI 10.1074/jbc.270.1.128; Hassett RF, 1998, J BIOL CHEM, V273, P23274, DOI 10.1074/jbc.273.36.23274; HAYLES J, 1992, ANNU REV GENET, V26, P373, DOI 10.1146/annurev.ge.26.120192.002105; Jensen LT, 1998, J BIOL CHEM, V273, P23805, DOI 10.1074/jbc.273.37.23805; Jensen LT, 1998, EMBO J, V17, P5400, DOI 10.1093/emboj/17.18.5400; JUNGMANN J, 1993, EMBO J, V12, P5051, DOI 10.1002/j.1460-2075.1993.tb06198.x; Kaplan J, 1996, SCIENCE, V271, P1510, DOI 10.1126/science.271.5255.1510; Kim J, 1998, GENETICS, V149, P795; Knight SAB, 1996, GENE DEV, V10, P1917, DOI 10.1101/gad.10.15.1917; Koch KA, 1997, CHEM BIOL, V4, P549, DOI 10.1016/S1074-5521(97)90241-6; Koch KA, 1996, MOL CELL BIOL, V16, P724; Kumagai, 1997, FOREIGN GENE EXPRESS, P3; Labbe S, 1997, J BIOL CHEM, V272, P15951, DOI 10.1074/jbc.272.25.15951; LEE GR, 1968, J CLIN INVEST, V47, P2058, DOI 10.1172/JCI105891; Lin SJ, 1997, J BIOL CHEM, V272, P9215; Liu XD, 1997, EMBO J, V16, P6466, DOI 10.1093/emboj/16.21.6466; Martins LJ, 1998, J BIOL CHEM, V273, P23716, DOI 10.1074/jbc.273.37.23716; Morano KA, 1999, MOL CELL BIOL, V19, P402; MORENO S, 1991, METHOD ENZYMOL, V194, P795; Osiewacz HD, 1996, MOL GEN GENET, V252, P115, DOI 10.1007/BF02173211; Pena MMO, 1999, J NUTR, V129, P1251, DOI 10.1093/jn/129.7.1251; Petris MJ, 1999, ADV EXP MED BIOL, V448, P53; Pufahl RA, 1997, SCIENCE, V278, P853, DOI 10.1126/science.278.5339.853; Radisky D, 1999, J BIOL CHEM, V274, P4481, DOI 10.1074/jbc.274.8.4481; ROMAN DG, 1993, MOL CELL BIOL, V13, P4342, DOI 10.1128/MCB.13.7.4342; SANTORO N, 1997, YEAST STRESS RESPONS, P171; Schaefer M, 1999, AM J PHYSIOL-GASTR L, V276, pG311, DOI 10.1152/ajpgi.1999.276.2.G311; Shiozaki K, 1996, GENE DEV, V10, P2276, DOI 10.1101/gad.10.18.2276; Solioz M, 1996, TRENDS BIOCHEM SCI, V21, P237; Stearman R, 1996, SCIENCE, V271, P1552, DOI 10.1126/science.271.5255.1552; TAMAI KT, 1993, P NATL ACAD SCI USA, V90, P8013, DOI 10.1073/pnas.90.17.8013; THIELE DJ, 1986, SCIENCE, V231, P854, DOI 10.1126/science.3080806; THIELE DJ, 1988, MOL CELL BIOL, V8, P2745, DOI 10.1128/MCB.8.7.2745; Turner RB, 1998, NAT STRUCT BIOL, V5, P551, DOI 10.1038/805; Vulpe CD, 1999, NAT GENET, V21, P195, DOI 10.1038/5979; Wilkinson MG, 1996, GENE DEV, V10, P2289, DOI 10.1101/gad.10.18.2289; Winge DR, 1998, PROG NUCLEIC ACID RE, V58, P165; Winzerling JJ, 1997, ANNU REV NUTR, V17, P501, DOI 10.1146/annurev.nutr.17.1.501; YAMAGUCHIIWAI Y, 1995, EMBO J, V14, P1231, DOI 10.1002/j.1460-2075.1995.tb07106.x; YamaguchiIwai Y, 1997, J BIOL CHEM, V272, P17711, DOI 10.1074/jbc.272.28.17711; YamaguchiIwai Y, 1996, EMBO J, V15, P3377, DOI 10.1002/j.1460-2075.1996.tb00703.x; Yu JM, 1998, J BIOL CHEM, V273, P6909, DOI 10.1074/jbc.273.12.6909; YUAN DS, 1995, P NATL ACAD SCI USA, V92, P2632, DOI 10.1073/pnas.92.7.2632; Zhou B, 1997, P NATL ACAD SCI USA, V94, P7481, DOI 10.1073/pnas.94.14.7481; ZHOU PB, 1991, P NATL ACAD SCI USA, V88, P6112, DOI 10.1073/pnas.88.14.6112; Zhu ZW, 1998, J BIOL CHEM, V273, P1277, DOI 10.1074/jbc.273.3.1277	75	92	98	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 17	1999	274	51					36252	36260		10.1074/jbc.274.51.36252	http://dx.doi.org/10.1074/jbc.274.51.36252			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	266AV	10593913	hybrid			2022-12-25	WOS:000084279200032
J	Lee, H; Raskin, I				Lee, H; Raskin, I			Purification, cloning, and expression of a pathogen inducible UDP-glucose: Salicylic acid glucosyltransferase from tobacco	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SYSTEMIC ACQUIRED-RESISTANCE; DISEASE RESISTANCE; MOSAIC-VIRUS; GENE; CONJUGATION; INDUCTION; SIGNAL; PLANTS; PROTEINS	Salicylic acid (SA) plays an important role in plant disease resistance. Inoculation of tobacco leaves with incompatible pathogens triggers the biosynthesis of SA which accumulates primarily as the SA 8-O-beta-D-glucoside (SAG) and glucosyl salicylate (GS). The tobacco UDP-glucose:salicylic acid glucosyltransferase (SA GTase) capable of forming both SAG and GS was purified, characterized, and partially sequenced. It has an apparent molecular mass of 48 kDa, a pH optimum of 7.0, and an isoelectric point at pH 4.4. UDP-glucose was the sole sugar donor for the enzyme. However, SA and several phenolics served as glucose accepters. The apparent K-m values for UDP-glucose and SA were 0.27 and 1-2 mar, respectively. Zn2+ and UDP inhibited its activity. The corresponding cDNA clone which encoded a protein of 459 amino acids was isolated from an SA-induced tobacco cDNA library and overexpressed in Escherichia coli. The recombinant protein catalyzed the formation of SAG and GS, and exhibited a broad specificity to simple phenolics, similar to that of the purified enzyme. Northern blot analysis showed that the SA GTase mRNA was induced both by SA and incompatible pathogens. The rapid induction timing of the mRNA by SA indicates that it belongs to the early SA response genes.	Rutgers State Univ, Cook Coll, Biotech Ctr, New Brunswick, NJ 08901 USA	Rutgers State University New Brunswick	Lee, H (corresponding author), Rutgers State Univ, Cook Coll, Biotech Ctr, 59 Dudley Rd, New Brunswick, NJ 08901 USA.							Abel S, 1996, PLANT PHYSIOL, V111, P9, DOI 10.1104/pp.111.1.9; ALMENDRAL JM, 1988, MOL CELL BIOL, V8, P2140, DOI 10.1128/MCB.8.5.2140; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; DELANEY TP, 1995, P NATL ACAD SCI USA, V92, P6602, DOI 10.1073/pnas.92.14.6602; Draper J, 1997, TRENDS PLANT SCI, V2, P162, DOI 10.1016/S1360-1385(97)01030-3; Durner J, 1997, TRENDS PLANT SCI, V2, P266, DOI 10.1016/S1360-1385(97)86349-2; EDWARDS R, 1994, J PLANT PHYSIOL, V143, P609, DOI 10.1016/S0176-1617(11)81146-6; ENYEDI AJ, 1992, P NATL ACAD SCI USA, V89, P2480, DOI 10.1073/pnas.89.6.2480; ENYEDI AJ, 1993, PLANT PHYSIOL, V101, P1375, DOI 10.1104/pp.101.4.1375; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; GAFFNEY T, 1993, SCIENCE, V261, P754, DOI 10.1126/science.261.5122.754; HammondKosack KE, 1996, PLANT PHYSIOL, V110, P1381, DOI 10.1104/pp.110.4.1381; Horvath DM, 1996, PLANT MOL BIOL, V31, P1061, DOI 10.1007/BF00040724; Horvath DM, 1998, MOL PLANT MICROBE IN, V11, P895, DOI 10.1094/MPMI.1998.11.9.895; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lee HI, 1998, PHYTOPATHOLOGY, V88, P692, DOI 10.1094/PHYTO.1998.88.7.692; LINDGREN PB, 1986, J BACTERIOL, V168, P512, DOI 10.1128/jb.168.2.512-522.1986; MALAMY J, 1990, SCIENCE, V250, P1002, DOI 10.1126/science.250.4983.1002; Martin RC, 1999, P NATL ACAD SCI USA, V96, P284, DOI 10.1073/pnas.96.1.284; METRAUX JP, 1990, SCIENCE, V250, P1004, DOI 10.1126/science.250.4983.1004; RALSTON EJ, 1988, GENETICS, V119, P185; Shulaev V, 1997, NATURE, V385, P718, DOI 10.1038/385718a0; SZERSZEN JB, 1994, SCIENCE, V265, P1699, DOI 10.1126/science.8085154; YALPANI N, 1992, PLANT PHYSIOL, V100, P457, DOI 10.1104/pp.100.1.457; YALPANI N, 1991, PLANT CELL, V3, P809, DOI 10.1105/tpc.3.8.809	25	102	116	0	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 17	1999	274	51					36637	36642		10.1074/jbc.274.51.36637	http://dx.doi.org/10.1074/jbc.274.51.36637			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	266AV	10593966	hybrid			2022-12-25	WOS:000084279200085
J	Rusterucci, C; Montillet, JL; Agnel, JP; Battesti, C; Alonso, B; Knoll, A; Bessoule, JJ; Etienne, P; Suty, L; Blein, JP; Triantaphylides, C				Rusterucci, C; Montillet, JL; Agnel, JP; Battesti, C; Alonso, B; Knoll, A; Bessoule, JJ; Etienne, P; Suty, L; Blein, JP; Triantaphylides, C			Involvement of lipoxygenase-dependent production of fatty acid hydroperoxides in the development of the hypersensitive cell death induced by cryptogein on tobacco leaves	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DISEASE RESISTANCE RESPONSE; PLANT-PATHOGEN INTERACTIONS; ACQUIRED-RESISTANCE; FUNGAL ELICITOR; OXIDATIVE BURST; CHEMOENZYMATIC SYNTHESIS; PHOSPHOLIPASE-ACTIVITY; LIPID-PEROXIDATION; METHYL JASMONATE; TOMATO LEAVES	Lipid peroxidation was investigated in relation with the hypersensitive reaction in cryptogein-elicited tobacco leaves. A massive production of free polyunsaturated fatty acid (PUFA) hydroperoxides dependent on a 9-lipoxygenase (LOX) activity was characterized during the development of leaf necrosis. The process occurred after a lag phase of 12 h, was accompanied by the concomitant increase of 9-LOX activity, and preceded by a transient accumulation of LOX transcripts. Free radical-mediated lipid peroxidation represented 10% of the process. Inhibition and activation of the LOX pathway was shown to inhibit or to activate cell death, and evidence was provided that fatty acid hydroperoxides are able to mimic leaf necrotic symptoms. Within 24 h, about 50% of leaf PUFAs were consumed, chloroplast lipids being the major source of PUFAs. The results minimize the direct participation of active oxygen species from the oxidative burst in membrane lipid peroxidation. They suggest, furthermore, the involvement of lipase activity to provide the free PUFA substrates for LOX. The LOX-dependent peroxidative pathway, responsible for tissue necrosis, appears as being one of the features of hypersensitive programmed cell death.	CEA, Lab Radiobiol Vegetale, Dept Ecophysiol Vegetable & Microbiol, Ctr Etud Cadarache,Direct Sci Vivant, F-13108 St Paul Durance, France; Univ Victor Segalan Bordeaux 2, Lab Biogenese Membranaire, CNRS UMR 5544, F-33076 Bordeaux, France; Univ Bourgogne 692, UA INRA, Lab Phytopharm & Biochim Interact Cellulaires, Dijon, France	CEA; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite de Bordeaux; INRAE; Universite de Bourgogne	Triantaphylides, C (corresponding author), CEA, Lab Radiobiol Vegetale, Dept Ecophysiol Vegetable & Microbiol, Ctr Etud Cadarache,Direct Sci Vivant, F-13108 St Paul Durance, France.		ETIENNE, Philippe/AAS-2211-2021; Knoll-Gellida, Anja/B-3886-2011	ETIENNE, Philippe/0000-0002-4531-3874; Knoll-Gellida, Anja/0000-0002-3687-1778				ADAM A, 1989, PHYSIOL MOL PLANT P, V34, P13, DOI 10.1016/0885-5765(89)90013-1; Allan AC, 1997, PLANT CELL, V9, P1559, DOI 10.1105/tpc.9.9.1559; AVDIUSHKO S, 1995, PLANT PHYSIOL, V109, P1227, DOI 10.1104/pp.109.4.1227; Blee E, 1996, PLANT PHYSIOL, V110, P445, DOI 10.1104/pp.110.2.445; Blee Elizabeth, 1996, P138, DOI 10.1201/9781439831977.ch8; Bonnet P, 1996, EUR J PLANT PATHOL, V102, P181, DOI 10.1007/BF01877105; BOSTOCK RM, 1992, PLANT PHYSIOL, V100, P1448, DOI 10.1104/pp.100.3.1448; BOTTIN A, 1994, PLANT PHYSIOL BIOCH, V32, P373; BOWLES DJ, 1990, ANNU REV BIOCHEM, V59, P873, DOI 10.1146/annurev.bi.59.070190.004301; BROWSE J, 1991, ANNU REV PLANT PHYS, V42, P467, DOI 10.1146/annurev.pp.42.060191.002343; Chapman KD, 1998, TRENDS PLANT SCI, V3, P419, DOI 10.1016/S1360-1385(98)01326-0; CROFT KPC, 1990, PHYSIOL MOL PLANT P, V36, P49, DOI 10.1016/0885-5765(90)90091-B; DEGOUSEE N, 1995, ANAL BIOCHEM, V224, P524, DOI 10.1006/abio.1995.1082; DEGOUSEE N, 1994, PLANT PHYSIOL, V104, P945, DOI 10.1104/pp.104.3.945; del Pozo O, 1998, CURR BIOL, V8, P1129, DOI 10.1016/S0960-9822(98)70469-5; Delledonne M, 1998, NATURE, V394, P585, DOI 10.1038/29087; DILVA L, 1988, EXP CELL ES, V245, P389; DOKE N, 1988, PHYSIOL MOL PLANT P, V32, P163, DOI 10.1016/S0885-5765(88)80013-4; DOKE N, 1997, OXIDATIVE STRESS MOL, V1, P785; Farmer EE, 1998, PLANTA, V206, P167, DOI 10.1007/s004250050388; FARMER EE, 1992, PLANT CELL, V4, P129, DOI 10.1105/tpc.4.2.129; FARMER EE, 1994, PLANT MOL BIOL, V26, P1423, DOI 10.1007/BF00016483; Feussner I, 1997, J BIOL CHEM, V272, P21635, DOI 10.1074/jbc.272.34.21635; FOURNIER J, 1993, PLANT J, V3, P63, DOI 10.1111/j.1365-313X.1993.tb00011.x; Green DR, 1998, CELL, V94, P695, DOI 10.1016/S0092-8674(00)81728-6; Greenberg JT, 1997, ANNU REV PLANT PHYS, V48, P525, DOI 10.1146/annurev.arplant.48.1.525; Heitz T, 1997, PLANT PHYSIOL, V114, P1085, DOI 10.1104/pp.114.3.1085; HILDEBRAND DF, 1989, PHYSIOL PLANTARUM, V76, P249, DOI 10.1111/j.1399-3054.1989.tb05641.x; HOCKENBERY DM, 1993, CELL, V75, P241, DOI 10.1016/0092-8674(93)80066-N; Hunt MD, 1996, CRIT REV PLANT SCI, V15, P583, DOI 10.1080/07352689609382371; Jabs T, 1996, SCIENCE, V273, P1853, DOI 10.1126/science.273.5283.1853; KATO T, 1992, BIOSCI BIOTECH BIOCH, V56, P373, DOI 10.1271/bbb.56.373; Kenton P, 1999, MOL PLANT MICROBE IN, V12, P74, DOI 10.1094/MPMI.1999.12.1.74; KONDO Y, 1993, BIOCHIM BIOPHYS ACTA, V1170, P301, DOI 10.1016/0005-2760(93)90014-Z; LEVINE A, 1994, CELL, V79, P583, DOI 10.1016/0092-8674(94)90544-4; Levine A, 1996, CURR BIOL, V6, P427, DOI 10.1016/S0960-9822(02)00510-9; Malcomson RDG, 1996, BIOLOGICALS, V24, P295, DOI 10.1006/biol.1996.0040; MARTINI D, 1994, BIOCATALYSIS, V11, P47, DOI 10.3109/10242429409034376; Martini D, 1996, TETRAHEDRON-ASYMMETR, V7, P1489, DOI 10.1016/0957-4166(96)00167-X; May MJ, 1996, PLANT PHYSIOL, V110, P1367, DOI 10.1104/pp.110.4.1367; MILAT ML, 1991, PHYTOPATHOLOGY, V81, P1364, DOI 10.1094/Phyto-81-1364; MIQUEL M, 1992, J BIOL CHEM, V267, P1502; MITTLER R, 1995, PLANT CELL, V7, P1951, DOI 10.1105/tpc.7.11.1951; Mittler R, 1996, PLANT CELL, V8, P1991, DOI 10.1105/tpc.8.11.1991; Mittler R, 1997, J CELL SCI, V110, P1333; PENG YL, 1994, J BIOL CHEM, V269, P3755; Pike SM, 1998, PHYSIOL MOL PLANT P, V53, P39, DOI 10.1006/pmpp.1998.0167; Pontier D, 1998, MOL PLANT MICROBE IN, V11, P544, DOI 10.1094/MPMI.1998.11.6.544; PORTER NA, 1995, LIPIDS, V30, P277, DOI 10.1007/BF02536034; Rance I, 1998, P NATL ACAD SCI USA, V95, P6554, DOI 10.1073/pnas.95.11.6554; RICCI P, 1989, EUR J BIOCHEM, V183, P555, DOI 10.1111/j.1432-1033.1989.tb21084.x; Rosahl S, 1996, Z NATURFORSCH C, V51, P123; ROY S, 1995, PLANT SCI, V107, P17, DOI 10.1016/0168-9452(95)04086-A; Rusterucci C, 1996, PLANT PHYSIOL, V111, P885, DOI 10.1104/pp.111.3.885; Ryerson DE, 1996, PLANT CELL, V8, P393, DOI 10.1105/tpc.8.3.393; SANDSTROM PA, 1995, FEBS LETT, V365, P66, DOI 10.1016/0014-5793(95)00443-D; Simon-Plas F, 1997, PLANT CELL ENVIRON, V20, P1573, DOI 10.1046/j.1365-3040.1997.d01-45.x; Slusarenko Alan J., 1996, P176, DOI 10.1201/9781439831977.ch10; Solomon M, 1999, PLANT CELL, V11, P431, DOI 10.1105/tpc.11.3.431; Suty L, 1996, PLANT PHYSIOL BIOCH, V34, P443; TENHAKEN R, 1995, P NATL ACAD SCI USA, V92, P4158, DOI 10.1073/pnas.92.10.4158; Veronesi C, 1996, PLANT PHYSIOL, V112, P997, DOI 10.1104/pp.112.3.997; VERONESI C, 1995, PLANT PHYSIOL, V108, P1342; Weber H, 1999, PLANT CELL, V11, P485, DOI 10.1105/tpc.11.3.485; Wojtaszek P, 1997, BIOCHEM J, V322, P681, DOI 10.1042/bj3220681; Zhuang H, 1996, PLANT PHYSIOL, V111, P805, DOI 10.1104/pp.111.3.805	66	202	217	0	24	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 17	1999	274	51					36446	36455		10.1074/jbc.274.51.36446	http://dx.doi.org/10.1074/jbc.274.51.36446			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	266AV	10593941	Green Published, hybrid			2022-12-25	WOS:000084279200060
J	Estavillo, D; Ritchie, A; Diacovo, TG; Cruz, MA				Estavillo, D; Ritchie, A; Diacovo, TG; Cruz, MA			Functional analysis of a recombinant glycoprotein Ia/IIa (integrin alpha(2)beta(1)) I domain that inhibits platelet adhesion to collagen and endothelial matrix under flow conditions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VON-WILLEBRAND-FACTOR; ALPHA-2-BETA-1 VLA-2; CRYSTAL-STRUCTURE; LAMININ RECEPTOR; BINDING-SITE; CELLS; IDENTIFICATION; DEFICIENCY; ACTIVATION; CD49B/CD29	The interaction of platelets with collagen plays an important role in primary hemostasis. Glycoprotein Ia/IIa (GPIa/IIa, integrin alpha(2)beta(1)) is a major platelet receptor for collagen, The binding site for collagen has been mapped to the I domain within the alpha(2) subunit (GPIa), In order to assess the role of the alpha(2)-I domain structure in GPIa/IIa binding to collagen, a recombinant I domain (amino acids 126-337) was expressed in Escherichia coli, The alpha(2)-I protein bound human types I and III collagen in a saturable and divalent cation-dependent manner and was blocked by the alpha(2)beta(1) function blocking antibody 6F1. The alpha(2)-I protein inhibited collagen-induced platelet aggregation (IC50 = 600 nM). Unexpectedly, 6F1, an antibody that fails to inhibit platelet aggregation in platelet-rich plasma, blocked the inhibitory effect of the alpha(2)-I protein, The alpha(2)-I protein was able to prevent platelet adhesion to a collagen surface exposed to flowing blood under low shear stress. Interestingly, it inhibited platelet adhesion to extracellular matrix at high shear stress. These results, taken together, provide firm evidence that GPIa/IIa directly mediates the first contact of platelets with collagen under both stirring and flow conditions.	Brigham & Womens Hosp, Div Hematol, Dept Med, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School	Cruz, MA (corresponding author), Brigham & Womens Hosp, Div Hematol, Dept Med, 221 Longwood Ave,LMRC-605, Boston, MA 02115 USA.	cruz@calvin.bwh.harvard.edu			NHLBI NIH HHS [R01 HL54876] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL054876] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BAHOU WF, 1994, BLOOD, V84, P3734, DOI 10.1182/blood.V84.11.3734.bloodjournal84113734; BERGELSON JM, 1992, SCIENCE, V255, P1718, DOI 10.1126/science.1553561; Chiang TM, 1997, J CLIN INVEST, V100, P514, DOI 10.1172/JCI119560; Cines DB, 1998, BLOOD, V91, P3527; COLLER BS, 1989, BLOOD, V74, P182; CRUZ MA, 1995, J BIOL CHEM, V270, P10822, DOI 10.1074/jbc.270.18.10822; DECKMYN H, 1990, THROMB HAEMOSTASIS, V64, P74; Depraetere H, 1997, THROMB HAEMOSTASIS, V77, P981; DIAZRICART M, 1993, BLOOD, V82, P491; Dickeson SK, 1997, J BIOL CHEM, V272, P7661, DOI 10.1074/jbc.272.12.7661; ELICES MJ, 1989, P NATL ACAD SCI USA, V86, P9906, DOI 10.1073/pnas.86.24.9906; Emsley J, 1997, J BIOL CHEM, V272, P28512, DOI 10.1074/jbc.272.45.28512; HANDA M, 1995, THROMB HAEMOSTASIS, V73, P521; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; Ichinohe T, 1997, J BIOL CHEM, V272, P63; KAMATA T, 1994, J BIOL CHEM, V269, P26006; KAMATA T, 1994, J BIOL CHEM, V269, P9659; KEHREL B, 1993, BLOOD, V82, P3364; KEHREL B, 1988, BLOOD, V71, P1074; KUNICKI TJ, 1993, BLOOD, V82, P2693; LANGUINO LR, 1989, J CELL BIOL, V109, P2455, DOI 10.1083/jcb.109.5.2455; LEE JO, 1995, CELL, V80, P631, DOI 10.1016/0092-8674(95)90517-0; Matsuno K, 1996, BRIT J HAEMATOL, V92, P960, DOI 10.1046/j.1365-2141.1996.422962.x; MCKEOWN L, 1994, BLOOD, V83, P2866, DOI 10.1182/blood.V83.10.2866.2866; Nakamura T, 1999, J BIOL CHEM, V274, P11897, DOI 10.1074/jbc.274.17.11897; Nakamura T, 1998, J BIOL CHEM, V273, P4338, DOI 10.1074/jbc.273.8.4338; NIEUWENHUIS HK, 1985, NATURE, V318, P470, DOI 10.1038/318470a0; PISCHEL KD, 1987, J IMMUNOL, V138, P226; Polgar J, 1997, J BIOL CHEM, V272, P13576, DOI 10.1074/jbc.272.21.13576; SAELMAN EUM, 1994, BLOOD, V83, P1244; SANTORO SA, 1995, THROMB HAEMOSTASIS, V74, P813; TANDON NN, 1989, J BIOL CHEM, V264, P7576; TUCKWELL D, 1995, J CELL SCI, V108, P1629; Verkleij MW, 1998, BLOOD, V91, P3808; Wu YP, 1996, ARTERIOSCL THROM VAS, V16, P611, DOI 10.1161/01.ATV.16.5.611; YAMADA KM, 1991, J BIOL CHEM, V266, P12809; YAMAMOTO N, 1992, BRIT J HAEMATOL, V81, P86, DOI 10.1111/j.1365-2141.1992.tb08177.x	38	11	12	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 10	1999	274	50					35921	35926		10.1074/jbc.274.50.35921	http://dx.doi.org/10.1074/jbc.274.50.35921			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	264NG	10585478	hybrid			2022-12-25	WOS:000084187900090
J	Frick, DN; Richardson, CC				Frick, DN; Richardson, CC			Interaction of bacteriophage T7 gene 4 primase with its template recognition site	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STRAND DNA-SYNTHESIS; NUCLEOSIDE 5'-TRIPHOSPHATASE ACTIVITY; ACID REPLICATION INVITRO; NUCLEOTIDE-BINDING SITE; RNA PRIMER SYNTHESIS; DEOXYRIBONUCLEIC-ACID; HELICASE ACTIVITY; HEXAMERIC HELICASE; ZINC MOTIF; PROTEIN	The primase fragment of the bacteriophage T7 63-kDa gene 4 helicase/primase protein contains the 271 N-terminal amino acid residues and lacks helicase activity. The primase fragment catalyzes the synthesis of oligoribonucleotides at rates similar to those catalyzed by the full-length protein in the presence of a 5-nucleotide DNA template containing a primase recognition site (5'-GGGTC-3', 5'-TGGTC-3', 5'-GTGTC-3', or 5'-TTGTC-3'). Although it is not copied into the oligoribonucleotides, the cytosine at the 3'-position is essential for synthesis and template binding. Two nucleotides flanking the 3'-end of the recognition site are required for tight DNA binding and rapid oligoribonucleotide synthesis. Nucleotides added to the 5'-end have no effect on the rate of oligoribonucleotide synthesis or the affinity of the primase for DNA, The binding of either ATP or CTP significantly increases the affinity of the primase for its DNA template. DNA lacking a primase recognition site does not inhibit oligoribonucleotide synthesis, suggesting that the primase binds DNA in a sequence-specific manner. The affinity of the primase for templates is weak, ranging from 10 to 150 mu M. The tight DNA binding (<1 mu M) observed with the 63-kDa gene 4 protein occurs via interactions between DNA templates and the helicase domain.	Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA	Harvard University; Harvard Medical School	Richardson, CC (corresponding author), Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, 240 Longwood Ave, Boston, MA 02115 USA.			Frick, David/0000-0002-2434-7223	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI006045, R01AI006045] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-06045] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Ahnert P, 1997, J BIOL CHEM, V272, P32267, DOI 10.1074/jbc.272.51.32267; ARAI K, 1979, P NATL ACAD SCI USA, V76, P4308, DOI 10.1073/pnas.76.9.4308; BERNSTEIN JA, 1988, J BIOL CHEM, V263, P14891; BERNSTEIN JA, 1989, J BIOL CHEM, V264, P13066; BERNSTEIN JA, 1988, P NATL ACAD SCI USA, V85, P396, DOI 10.1073/pnas.85.2.396; Bird LE, 1997, NUCLEIC ACIDS RES, V25, P2620, DOI 10.1093/nar/25.13.2620; DEBYSER Z, 1994, CELL, V77, P157, DOI 10.1016/0092-8674(94)90243-7; Dong F, 1996, J BIOL CHEM, V271, P19625, DOI 10.1074/jbc.271.32.19625; DUNN JJ, 1983, J MOL BIOL, V166, P477, DOI 10.1016/S0022-2836(83)80282-4; EGELMAN EH, 1995, P NATL ACAD SCI USA, V92, P3869, DOI 10.1073/pnas.92.9.3869; Frick DN, 1998, P NATL ACAD SCI USA, V95, P7957, DOI 10.1073/pnas.95.14.7957; Frick DN, 1999, J BIOL CHEM, V274, P35899, DOI 10.1074/jbc.274.50.35899; GRIEP MA, 1995, INDIAN J BIOCHEM BIO, V32, P171; Guo SY, 1999, J BIOL CHEM, V274, P30303, DOI 10.1074/jbc.274.42.30303; Hacker KJ, 1997, BIOCHEMISTRY-US, V36, P14080, DOI 10.1021/bi971644v; HINE AV, 1994, P NATL ACAD SCI USA, V91, P12327, DOI 10.1073/pnas.91.25.12327; HINGORANI MM, 1993, BIOCHEMISTRY-US, V32, P12478, DOI 10.1021/bi00097a028; HINTON DM, 1987, J BIOL CHEM, V262, P10873; ILYINA TV, 1992, J MOL EVOL, V34, P351, DOI 10.1007/BF00160243; KOLODNER R, 1977, P NATL ACAD SCI USA, V74, P1525, DOI 10.1073/pnas.74.4.1525; Kusakabe T, 1998, EMBO J, V17, P1542, DOI 10.1093/emboj/17.5.1542; Kusakabe T, 1999, P NATL ACAD SCI USA, V96, P4295, DOI 10.1073/pnas.96.8.4295; Kusakabe T, 1997, J BIOL CHEM, V272, P12446, DOI 10.1074/jbc.272.19.12446; Kusakabe T, 1996, J BIOL CHEM, V271, P19563, DOI 10.1074/jbc.271.32.19563; Kusakabe T, 1997, J BIOL CHEM, V272, P5943, DOI 10.1074/jbc.272.9.5943; LECHNER RL, 1983, J BIOL CHEM, V258, P1185; Lee J, 1998, MOL CELL, V1, P1001, DOI 10.1016/S1097-2765(00)80100-8; Lineweaver H, 1934, J AM CHEM SOC, V56, P658, DOI 10.1021/ja01318a036; LIU CC, 1981, J BIOL CHEM, V256, P2821; MATSON SW, 1985, J BIOL CHEM, V260, P2281; MATSON SW, 1983, J BIOL CHEM, V258, P4017; MATSON SW, 1983, J BIOL CHEM, V258, P4009; MENDELMAN LV, 1994, EMBO J, V13, P3909, DOI 10.1002/j.1460-2075.1994.tb06702.x; MENDELMAN LV, 1995, BIOCHEMISTRY-US, V34, P10187, DOI 10.1021/bi00032a012; MENDELMAN LV, 1992, P NATL ACAD SCI USA, V89, P10638, DOI 10.1073/pnas.89.22.10638; MENDELMAN LV, 1993, J BIOL CHEM, V268, P27208; MENDELMAN LV, 1991, J BIOL CHEM, V266, P23240; NAKAI H, 1986, J BIOL CHEM, V261, P5217; NAKAI H, 1986, J BIOL CHEM, V261, P5208; NAKAI H, 1988, J BIOL CHEM, V263, P9831; NAKAI H, 1988, J BIOL CHEM, V263, P9818; NOTARNICOLA SM, 1993, J BIOL CHEM, V268, P27198; Park K, 1998, J BIOL CHEM, V273, P5260, DOI 10.1074/jbc.273.9.5260; PATEL SS, 1993, J BIOL CHEM, V268, P10668; PATEL SS, 1994, BIOCHEMISTRY-US, V33, P7857, DOI 10.1021/bi00191a013; ROMANO LJ, 1979, J BIOL CHEM, V254, P483; ROSENBERG AH, 1992, J BIOL CHEM, V267, P15005; SCHERZINGER E, 1977, EUR J BIOCHEM, V72, P543, DOI 10.1111/j.1432-1033.1977.tb11278.x; SCHERZINGER E, 1977, NUCLEIC ACIDS RES, V4, P4151, DOI 10.1093/nar/4.12.4151; SHEAFF RJ, 1993, BIOCHEMISTRY-US, V32, P3027, DOI 10.1021/bi00063a014; Swart JR, 1995, BIOCHEMISTRY-US, V34, P16097, DOI 10.1021/bi00049a025; TABOR S, 1981, P NATL ACAD SCI-BIOL, V78, P205, DOI 10.1073/pnas.78.1.205; Washington MT, 1998, J BIOL CHEM, V273, P7880, DOI 10.1074/jbc.273.14.7880; YONG YQ, 1995, J BIOL CHEM, V270, P24509, DOI 10.1074/jbc.270.41.24509	54	50	52	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 10	1999	274	50					35889	35898		10.1074/jbc.274.50.35889	http://dx.doi.org/10.1074/jbc.274.50.35889			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	264NG	10585474	Green Published, hybrid			2022-12-25	WOS:000084187900086
J	Hu, PPC; Shen, X; Huang, D; Liu, YY; Counter, C; Wang, XF				Hu, PPC; Shen, X; Huang, D; Liu, YY; Counter, C; Wang, XF			The MEK pathway is required for stimulation of p21(WAF1/CIP1) by transforming growth factor-beta	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-CYCLE ARREST; TGF-BETA; TRANSCRIPTIONAL ACTIVATION; EPITHELIAL-CELLS; PROMOTER; PROTEIN; SMAD3; SIGNALS; BINDING; IDENTIFICATION	Transforming growth factor-beta (TGF-beta)can induce the cyclin-dependent kinase inhibitors p21 and p15 in a variety of cell types. We have shown previously that Smad3 is required for the growth inhibitory activity of TGF-beta, whereas overexpression of Smads is not sufficient to activate the expression of p21 in HaCaT cells. These data suggest that an additional signaling pathway may be involved in stimulating p21 in HaCaT cells. Given the recent finding that the mitogen-activated protein kinase (MAPK) pathway can cause p21 induction and arrest cells, we examined the involvement of this pathway for p21 and p15 induction by TGF-beta, We found that TGF-beta can regulate the MAPK pathway, leading to the increased transactivation ability of transcription factor Elk, Constitutively active components in the MAPK pathway activate pal expression, and inhibitors or dominant negative constructs for the MAPK pathway significantly decrease p21 induction by TGF-beta, Both constitutively active MEK and inhibitors for MEK have no effect on Smad activity, including DNA binding, localization, and interaction with coactivator p800/CBP, These findings suggest that the MAPK pathway may be an independent pathway that is involved in p21 and p15 induction by TGF-beta.	Duke Univ, Med Ctr, Dept Pharmacol & Canc Biol, Durham, NC 27710 USA	Duke University	Wang, XF (corresponding author), Duke Univ, Med Ctr, Dept Pharmacol & Canc Biol, Box 3813, Durham, NC 27710 USA.			Counter, Christopher M/0000-0003-0748-3079	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK045746] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-45746] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Adnane J, 1998, MOL CELL BIOL, V18, P6962, DOI 10.1128/MCB.18.12.6962; Ahn S, 1999, J BIOL CHEM, V274, P1185, DOI 10.1074/jbc.274.3.1185; Atfi A, 1997, J BIOL CHEM, V272, P1429, DOI 10.1074/jbc.272.3.1429; Billon N, 1999, ONCOGENE, V18, P2872, DOI 10.1038/sj.onc.1202712; Counter CM, 1998, P NATL ACAD SCI USA, V95, P14723, DOI 10.1073/pnas.95.25.14723; Datto MB, 1999, MOL CELL BIOL, V19, P2495; DATTO MB, 1995, J BIOL CHEM, V270, P28623, DOI 10.1074/jbc.270.48.28623; DAVIS RJ, 1995, MOL REPROD DEV, V42, P459, DOI 10.1002/mrd.1080420414; de Caestecker MP, 1998, GENE DEV, V12, P1587, DOI 10.1101/gad.12.11.1587; Dennler S, 1998, EMBO J, V17, P3091, DOI 10.1093/emboj/17.11.3091; Derynck R, 1997, BIOCHIM BIOPHYS ACTA, V1333, P105; Feng XH, 1998, GENE DEV, V12, P2153, DOI 10.1101/gad.12.14.2153; Frey RS, 1997, CANCER RES, V57, P628; Haapajarvi T, 1999, EXP CELL RES, V248, P272, DOI 10.1006/excr.1999.4403; HALEVY O, 1995, SCIENCE, V267, P1018, DOI 10.1126/science.7863327; HERSKOWITZ I, 1995, CELL, V80, P187, DOI 10.1016/0092-8674(95)90402-6; HILL CS, 1995, CELL, V80, P199, DOI 10.1016/0092-8674(95)90403-4; Hu PPC, 1998, ENDOCR REV, V19, P349, DOI 10.1210/er.19.3.349; Janknecht R, 1998, GENE DEV, V12, P2114, DOI 10.1101/gad.12.14.2114; Jonk LJC, 1998, J BIOL CHEM, V273, P21145, DOI 10.1074/jbc.273.33.21145; Kretzschmar M, 1999, GENE DEV, V13, P804, DOI 10.1101/gad.13.7.804; Lin AW, 1998, GENE DEV, V12, P3008, DOI 10.1101/gad.12.19.3008; Lloyd AC, 1997, GENE DEV, V11, P663, DOI 10.1101/gad.11.5.663; MISSERO C, 1995, P NATL ACAD SCI USA, P28491; Moustakas A, 1998, P NATL ACAD SCI USA, V95, P6733, DOI 10.1073/pnas.95.12.6733; MULDER KM, 1992, J BIOL CHEM, V267, P5029; Nishihara A, 1998, GENES CELLS, V3, P613, DOI 10.1046/j.1365-2443.1998.00217.x; Olson MF, 1998, NATURE, V394, P295, DOI 10.1038/28425; Shen X, 1998, MOL BIOL CELL, V9, P3309, DOI 10.1091/mbc.9.12.3309; Stroschein SL, 1999, J BIOL CHEM, V274, P9431, DOI 10.1074/jbc.274.14.9431; Vindevoghel L, 1998, J BIOL CHEM, V273, P13053, DOI 10.1074/jbc.273.21.13053; Wong C, 1999, MOL CELL BIOL, V19, P1821; Woods D, 1997, MOL CELL BIOL, V17, P5598, DOI 10.1128/MCB.17.9.5598; Xiao HY, 1999, J CELL BIOCHEM, V73, P291, DOI 10.1002/(SICI)1097-4644(19990601)73:3<291::AID-JCB1>3.0.CO;2-5; YAMAGUCHI K, 1995, SCIENCE, V270, P2008, DOI 10.1126/science.270.5244.2008; Yingling JM, 1997, MOL CELL BIOL, V17, P7019, DOI 10.1128/MCB.17.12.7019; Yue JB, 1998, ONCOGENE, V17, P47, DOI 10.1038/sj.onc.1201903; Zawel L, 1998, MOL CELL, V1, P611, DOI 10.1016/S1097-2765(00)80061-1; Zhang Y, 1996, NATURE, V383, P168, DOI 10.1038/383168a0; Zhang YG, 1999, J BIOL CHEM, V274, P12367, DOI 10.1074/jbc.274.18.12367	40	144	150	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 10	1999	274	50					35381	35387		10.1074/jbc.274.50.35381	http://dx.doi.org/10.1074/jbc.274.50.35381			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	264NG	10585406	hybrid			2022-12-25	WOS:000084187900018
J	Levy, H; Kindle, KL; Stern, DB				Levy, H; Kindle, KL; Stern, DB			Target and specificity of a nuclear gene product that participates in mRNA 3 '-end formation in Chlamydomonas chloroplasts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA ACCUMULATION; 5' UNTRANSLATED REGION; 3' INVERTED REPEATS; ESCHERICHIA-COLI; REINHARDTII CHLOROPLASTS; 3'-UNTRANSLATED REGIONS; ARABIDOPSIS-THALIANA; TRANSCRIPTION UNIT; BINDING PROTEIN; EXPRESSION	Chloroplast mRNA maturation is catalyzed by nucleus-encoded processing enzymes. We previously described a recessive nuclear mutation (crp3) that affects 3'-end formation of several chloroplast mRNAs in Chlamydomonas reinhardtii (Levy, H,, Kindle, K, L., and Stern, D, B, (1997) Plant Cell 9, 825-836). In the crp3 background, atpB mRNA lacking a 3'-inverted repeat normally required for stability accumulates as a discrete transcript. The mutation also affects the atpA gene cluster; polycistronic mRNAs with psbI or cemA 3'-ends accumulate to a lower level in the crp3 background. Here, we demonstrate that the crp3 mutation also alters S'-end formation of psbI mRNA and cemA-containing mRNAs. A novel 3'-end is formed in monocistronic psbI transcripts, and this is the only terminus observed when the psbI 3'-untranslated region is fused to an aadA reporter gene. Accumulation of mRNAs with 3'-ends between cemA and atpH, which is immediately downstream, was reduced. However, this sequence was not recognized as a 3'-end formation element in chimeric genes. The crp3 mutation was able to confer stability to three different atpB 3'-stem-loop-disrupting mutations that lack sequence similarity, but are located at a similar distance from the translation termination codon, We propose that the wild-type CRP3 gene product is part of the general 3' --> 5' processing machinery.	Cornell Univ, Bruce Thompson Inst Plant Res, Ithaca, NY 14853 USA; Cornell Univ, Plant Sci Ctr, Ithaca, NY 14853 USA	Cornell University; Cornell University	Stern, DB (corresponding author), Cornell Univ, Bruce Thompson Inst Plant Res, Tower Rd, Ithaca, NY 14853 USA.	ds28@cornell.edu						BARKAN A, 1988, EMBO J, V7, P2637, DOI 10.1002/j.1460-2075.1988.tb03116.x; BARKAN A, 1994, EMBO J, V13, P3170, DOI 10.1002/j.1460-2075.1994.tb06616.x; BLOWERS AD, 1993, MOL GEN GENET, V238, P339, DOI 10.1007/BF00291992; CHEN HC, 1991, MOL CELL BIOL, V11, P4380, DOI 10.1128/MCB.11.9.4380; Dinkins RD, 1997, PLANT PHYSIOL, V113, P1023, DOI 10.1104/pp.113.4.1023; Drager RG, 1996, RNA, V2, P652; Drager RG, 1998, PLANT J, V13, P85, DOI 10.1046/j.1365-313X.1998.00016.x; Drapier D, 1998, PLANT PHYSIOL, V117, P629, DOI 10.1104/pp.117.2.629; DRAPIER D, 1992, PLANT CELL, V4, P283, DOI 10.2307/3869540; GOLDSCHMIDTCLERMONT M, 1991, NUCLEIC ACIDS RES, V19, P4083, DOI 10.1093/nar/19.15.4083; Gumpel NJ, 1995, PLANT MOL BIOL, V29, P921, DOI 10.1007/BF00014966; Harris E. H., 1989, CHLAMYDOMONAS SOURCE; HOLTON TA, 1991, NUCLEIC ACIDS RES, V19, P1156, DOI 10.1093/nar/19.5.1156; Jenkins BD, 1997, PLANT CELL, V9, P283, DOI 10.1105/tpc.9.3.283; KINDLE KL, 1994, PLANT CELL, V6, P187, DOI 10.2307/3869638; KLUG G, 1992, GENE, V121, P95, DOI 10.1016/0378-1119(92)90166-M; KUCHKA MR, 1989, CELL, V58, P869, DOI 10.1016/0092-8674(89)90939-2; KUNSTNER P, 1995, J BIOL CHEM, V270, P9651; Lee H, 1996, PLANT MOL BIOL, V31, P337, DOI 10.1007/BF00021794; Levy H, 1997, PLANT CELL, V9, P825, DOI 10.2307/3870435; MAYFIELD SP, 1994, J CELL BIOL, V127, P1537, DOI 10.1083/jcb.127.6.1537; Memon AR, 1996, PLANT MOL BIOL, V30, P1195, DOI 10.1007/BF00019552; Meurer J, 1998, MOL GEN GENET, V258, P342, DOI 10.1007/s004380050740; Meurer J, 1996, PLANT CELL, V8, P1193, DOI 10.1105/tpc.8.7.1193; MONOD C, 1992, MOL GEN GENET, V231, P449, DOI 10.1007/BF00292715; NICKELSEN J, 1993, PLANT J, V3, P537, DOI 10.1046/j.1365-313X.1993.03040537.x; NICKELSEN J, 1994, EMBO J, V13, P3182, DOI 10.1002/j.1460-2075.1994.tb06617.x; Nickelsen J, 1999, PLANT CELL, V11, P957, DOI 10.1105/tpc.11.5.957; PATEL AM, 1992, J BACTERIOL, V174, P3541, DOI 10.1128/JB.174.11.3541-3548.1992; REGNIER P, 1991, J MOL BIOL, V217, P283, DOI 10.1016/0022-2836(91)90542-E; Rochaix JD, 1996, PLANT MOL BIOL, V32, P327, DOI 10.1007/BF00039389; Rolland N, 1997, EMBO J, V16, P6713, DOI 10.1093/emboj/16.22.6713; Rott R, 1996, MOL GEN GENET, V252, P676, DOI 10.1007/BF02173973; Rott R, 1998, PLANT MOL BIOL, V36, P307, DOI 10.1023/A:1005943701253; Rott R, 1998, MOL CELL BIOL, V18, P4605, DOI 10.1128/MCB.18.8.4605; SAKAMOTO W, 1994, MOL CELL BIOL, V14, P6180, DOI 10.1128/MCB.14.9.6180; SAKAMOTO W, 1994, PLANT J, V6, P503, DOI 10.1046/j.1365-313X.1994.6040503.x; SCHUSTER G, 1991, EMBO J, V10, P1493, DOI 10.1002/j.1460-2075.1991.tb07669.x; SIEBURTH LE, 1991, PLANT CELL, V3, P175, DOI 10.2307/3869287; STAUB JM, 1994, PLANT J, V6, P547, DOI 10.1046/j.1365-313X.1994.6040547.x; STERN DB, 1993, MOL CELL BIOL, V13, P2277, DOI 10.1128/MCB.13.4.2277; STERN DB, 1989, J BIOL CHEM, V264, P18742; STERN DB, 1987, CELL, V51, P1145, DOI 10.1016/0092-8674(87)90600-3; STERN DB, 1991, PLANT CELL, V3, P285; STOLLAR NE, 1994, J PLANT PHYSIOL, V144, P141, DOI 10.1016/S0176-1617(11)80535-3; STURM NR, 1994, MOL CELL BIOL, V14, P6171, DOI 10.1128/MCB.14.9.6171; WESTHOFF P, 1988, EUR J BIOCHEM, V171, P551, DOI 10.1111/j.1432-1033.1988.tb13824.x; Yang JJ, 1996, PLANT CELL, V8, P1409, DOI 10.1105/tpc.8.8.1409	48	10	12	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 10	1999	274	50					35955	35962		10.1074/jbc.274.50.35955	http://dx.doi.org/10.1074/jbc.274.50.35955			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	264NG	10585484	hybrid			2022-12-25	WOS:000084187900096
J	Pierce, KL; Fujino, H; Srinivasan, D; Regan, JW				Pierce, KL; Fujino, H; Srinivasan, D; Regan, JW			Activation of FP prostanoid receptor isoforms leads to Rho-mediated changes in cell morphology and in the cell cytoskeleton	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT VENTRICULAR MYOCYTES; STRESS FIBER FORMATION; TYROSINE PHOSPHORYLATION; COUPLED RECEPTOR; CORPUS-LUTEUM; PROSTAGLANDIN-F2-ALPHA; CLONING; EXPRESSION; GROWTH; CDNA	Prostaglandin F-2 alpha (PGF(2 alpha)) exerts its biological effects by binding to and activating FP prostanoid receptors. These receptors, which include two isoforms, the FPA and FPB, have been cloned from a number of species and are members of the superfamily of G-protein-coupled receptors. Previous studies have shown that the activation of FP receptors leads to phosphatidylinositol hydrolysis, intracellular calcium release, and activation of protein kinase C. Here, we demonstrate that PGF(2 alpha) treatment of 293-EBNA (Epstein-Barr nuclear antigen) cells that have been stably transfected with either the FPA or FPB receptor isoforms leads to changes in cell morphology and in the cell cytoskeleton. Specifically, cells treated with PGF(2 alpha) show retraction of filopodia and become rounded, and actin stress fibers are formed. Pretreatment of the cells with bisindolylmaleimide I, a protein kinase C inhibitor, has no effect on the PGF(2 alpha)-induced changes in cell morphology, although it does block the effects of phorbol myristate acetate on cell morphology. On the other hand, the PGF(2 alpha)-induced changes in cell morphology and formation of actin stress fibers can be blocked by pretreatment of the cells with C3 exoenzyme, a specific inhibitor of the small G-protein, Rho. Consistent with FP receptor induced formation of actin stress fibers and focal adhesions, FPA receptor activation also leads to rapid (within two minutes) tyrosine phosphorylation of p125 focal adhesion kinase (FAK) which can be blocked by pretreating the cells with C3 exoenzyme. Taken together, these results suggest that the FP receptor isoforms are coupled to at least two second messenger pathways, one pathway associated with protein kinase C activation, and the other with activation of Rho.	Univ Arizona, Coll Pharm, Dept Pharmacol & Toxicol, Tucson, AZ 85721 USA; Univ Arizona, Coll Pharm, Dept Physiol, Tucson, AZ 85721 USA; Univ Arizona, Coll Pharm, Neurosci Program, Tucson, AZ 85721 USA	University of Arizona; University of Arizona; University of Arizona	Regan, JW (corresponding author), Univ Arizona, Coll Pharm, Dept Pharmacol & Toxicol, Tucson, AZ 85721 USA.				NEI NIH HHS [EY11291] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY011291] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		ABRAMOVITZ M, 1994, J BIOL CHEM, V269, P2632; Adams JW, 1998, CIRC RES, V83, P167, DOI 10.1161/01.RES.83.2.167; Adams JW, 1996, J BIOL CHEM, V271, P1179, DOI 10.1074/jbc.271.2.1179; Betuing S, 1998, J BIOL CHEM, V273, P15804, DOI 10.1074/jbc.273.25.15804; BUHL AM, 1995, J BIOL CHEM, V270, P24631, DOI 10.1074/jbc.270.42.24631; CAMRAS CB, 1992, ARCH OPHTHALMOL-CHIC, V110, P1733, DOI 10.1001/archopht.1992.01080240073034; DILLON ST, 1995, METHOD ENZYMOL, V256, P174; Gohla A, 1998, J BIOL CHEM, V273, P4653, DOI 10.1074/jbc.273.8.4653; GRAVES PE, 1995, ENDOCRINOLOGY, V136, P3430, DOI 10.1210/en.136.8.3430; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Hasegawa H, 1997, BIOCHEM BIOPH RES CO, V234, P631, DOI 10.1006/bbrc.1997.6655; KATOH H, 1996, J BIOL CHEM, V271, P29978; Kunapuli P, 1998, J BIOL CHEM, V273, P22442, DOI 10.1074/jbc.273.35.22442; Lai J, 1996, AM J PHYSIOL-HEART C, V271, pH2197, DOI 10.1152/ajpheart.1996.271.6.H2197; Lee MJ, 1998, SCIENCE, V279, P1552, DOI 10.1126/science.279.5356.1552; Majumdar M, 1998, J BIOL CHEM, V273, P10099, DOI 10.1074/jbc.273.17.10099; MCCRACKEN JA, 1970, J CLIN ENDOCR METAB, V30, P544, DOI 10.1210/jcem-30-4-544; Needham LK, 1998, J BIOL CHEM, V273, P14626, DOI 10.1074/jbc.273.23.14626; Pierce KL, 1997, J BIOL CHEM, V272, P883, DOI 10.1074/jbc.272.2.883; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; SAKAMOTO K, 1994, J BIOL CHEM, V269, P3881; SUGIMOTO Y, 1994, J BIOL CHEM, V269, P1356; WATANABE T, 1994, J BIOL CHEM, V269, P17619	23	88	90	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 10	1999	274	50					35944	35949		10.1074/jbc.274.50.35944	http://dx.doi.org/10.1074/jbc.274.50.35944			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	264NG	10585482	hybrid			2022-12-25	WOS:000084187900094
J	Puglielli, L; Hirschberg, CB				Puglielli, L; Hirschberg, CB			Reconstitution, identification, and purification of the rat liver Golgi membrane GDP-fucose transporter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADENOSINE 3'-PHOSPHATE 5'-PHOSPHOSULFATE; N-ACETYLGLUCOSAMINE TRANSPORTER; UDP-GALACTOSE TRANSPORTER; SIALIC ACID TRANSPORTER; MOLECULAR-CLONING; NUCLEOTIDE SULFATE; ENDOPLASMIC-RETICULUM; APPARATUS MEMBRANE; SUGAR NUCLEOTIDES; TRANSLOCATION	Glycosylation of glycoproteins, proteoglycans, and glycolipids occurring in the Golgis apparatus requires the translocation of nucleotide sugars from the cytosol into the lumen of the Golgi. Translocation is mediated by specific nucleotide sugar transporters, integral Golgis membrane proteins that regulate the above glycosylation reactions. A defect in GDP-fucose transport into the lumen of the Golgis apparatus has been recently identified in a patient affected by leukocyte adhesion deficiency type II syndrome (Lubke, T., Marquardt, T., von Figura, R., and Korner, C. (1999) J. Biol. Chem. 274, 25986-25989). We have now identified and purified the rat liver Golgi membrane GDP-fucose transporter, a protein with an apparent molecular mass of 39 kDa, by a combination of column chromatography, native functional size determination on a glycerol gradient, and photoaffinity labeling with 8-azidoguanosine-5'-[alpha-P-32] triphosphate, an analog of GDP-fucose. The purified transporter appears to exist as a homodimer within the Golgis membrane. When reconstituted into phosphatidylcholine liposomes, it was active in GDP-fucose transport and was specifically photolabeled with 8-azidoguanosine-5'- [alpha-P-32]triphosphate. Transport was also stimulated 2-3-fold after preloading proteoliposomes with GMP, the putative antiporter.	Boston Univ, Goldman Sch Dent Med, Dept Mol & Cell Biol, Boston, MA 02118 USA	Boston University	Hirschberg, CB (corresponding author), Boston Univ, Goldman Sch Dent Med, Dept Mol & Cell Biol, 715 Albany St W-200, Boston, MA 02118 USA.	chirschb@bu.edu		Hirschberg, Carlos/0000-0003-2299-7721	NIGMS NIH HHS [GM30365] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM030365, R37GM030365] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abeijon C, 1996, P NATL ACAD SCI USA, V93, P5963, DOI 10.1073/pnas.93.12.5963; Abeijon C, 1997, TRENDS BIOCHEM SCI, V22, P203, DOI 10.1016/S0968-0004(97)01053-0; Anderson DC, 1995, METABOLIC MOL BASES, P3955; CAPASSO JM, 1989, J BIOL CHEM, V264, P5233; CAPASSO JM, 1984, P NATL ACAD SCI-BIOL, V81, P7051, DOI 10.1073/pnas.81.22.7051; CAPASSO JM, 1984, BIOCHIM BIOPHYS ACTA, V777, P133, DOI 10.1016/0005-2736(84)90505-4; CAREY DJ, 1981, J BIOL CHEM, V256, P989; DESCOTEAUX A, 1995, SCIENCE, V269, P1869, DOI 10.1126/science.7569927; Eckhardt M, 1997, EUR J BIOCHEM, V248, P187, DOI 10.1111/j.1432-1033.1997.00187.x; Eckhardt M, 1996, P NATL ACAD SCI USA, V93, P7572, DOI 10.1073/pnas.93.15.7572; Guillen E, 1998, P NATL ACAD SCI USA, V95, P7888, DOI 10.1073/pnas.95.14.7888; Hirschberg CB, 1998, ANNU REV BIOCHEM, V67, P49, DOI 10.1146/annurev.biochem.67.1.49; Ishida N, 1996, J BIOCHEM, V120, P1074; LEELAVATHI DE, 1970, BIOCHIM BIOPHYS ACTA, V211, P124, DOI 10.1016/0005-2736(70)90087-8; Lubke T, 1999, J BIOL CHEM, V274, P25986, DOI 10.1074/jbc.274.37.25986; Ma DQ, 1997, J BIOL CHEM, V272, P3799, DOI 10.1074/jbc.272.6.3799; MANDON E, 1994, J BIOL CHEM, V269, P11729; MANDON EC, 1994, P NATL ACAD SCI USA, V91, P10707, DOI 10.1073/pnas.91.22.10707; MAYINGER P, 1993, EMBO J, V12, P659, DOI 10.1002/j.1460-2075.1993.tb05699.x; Miera N, 1996, J BIOCHEM-TOKYO, V120, P236; MILLA ME, 1992, J BIOL CHEM, V267, P103; Puglielli L, 1999, J BIOL CHEM, V274, P12665, DOI 10.1074/jbc.274.18.12665; Puglielli L, 1999, J BIOL CHEM, V274, P4474, DOI 10.1074/jbc.274.7.4474; SOMMERS LW, 1982, J BIOL CHEM, V257, P811; Tabuchi M, 1997, BIOCHEM BIOPH RES CO, V232, P121, DOI 10.1006/bbrc.1997.6239; Thomas GH, 1995, METABOLIC MOL BASES, P2529; YANAGISAWA K, 1990, J BIOL CHEM, V265, P19351	27	78	91	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 10	1999	274	50					35596	35600		10.1074/jbc.274.50.35596	http://dx.doi.org/10.1074/jbc.274.50.35596			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	264NG	10585436	hybrid			2022-12-25	WOS:000084187900048
J	Neri, LM; Martelli, AM; Borgatti, P; Colamussi, ML; Marchisio, M; Capitani, S				Neri, LM; Martelli, AM; Borgatti, P; Colamussi, ML; Marchisio, M; Capitani, S			Increase in nuclear phosphatidylinositol 3-kinase activity and phosphatidylinositol (3,4,5) trisphosphate synthesis precede PKC-zeta translocation to the nucleus of NGF-treated PC12 cells	FASEB JOURNAL			English	Article						signal transduction; nuclear translocation	PROTEIN-KINASE-C; NERVE GROWTH-FACTOR; SWISS 3T3 CELLS; PHOSPHOINOSITIDE 3-KINASE; PHOSPHOLIPASE-C; GLUCOSE-TRANSPORT; FAMILY MEMBERS; ACTIVATION; DIACYLGLYCEROL; ASSOCIATION	We and others have previously demonstrated the existence of an autonomous nuclear polyphosphoinositide cycle that generates second messengers such as diacylglycerol (DAG), capable of attracting to the nucleus specific protein kinase C (PKC) isoforms (Neri et al. (1998) J. Biol. Chem. 273, 29738-29744). Recently, however, nuclei have also been shown to contain the enzymes responsible for the synthesis of the non-canonical 3-phosphorylated inositides. To clarify a possible role of this peculiar class of inositol lipids we have examined the question of whether nerve growth factor (NGF) induces PKC-zeta nuclear translocation in PC12 cells and whether this translocation is dependent on nuclear phosphatidylinositol 3-kinase (PI 3-K) activity and its product, phosphatidylinositol 3,4,5-trisphosphate [PtdIns(3,4,5)P-3]. NGF increased both the amount and the enzyme activity of immunoprecipitable PI 3-K in PC12 cell nuclei. Activation of the enzyme, but not its translocation, was blocked by PI 3-K inhibitors wortmannin and LY294002. Treatment of PC12 cells for 9 min with NGF led to an increase in the nuclear levels of PtdIns(3,4,5)P-3. Maximal translocation of PKC-zeta from the cytoplasm to the nucleus (as evaluated by immunoblotting, enzyme activity, and confocal microscopy) occurred after 12 min of exposure to NGF and was completely abrogated by either wortmannin or LY294002. Zn contrast, these two inhibitors did not block nuclear translocation of the conventional, DAG-sensitive, PKC-alpha. On the other hand, the specific phosphatidylinositol phospholipase C inhibitor, 1-O-octadeyl-2-O-methyl-sn-glycero-3-phosphocoline was unable to abrogate nuclear translocation of the DAG-insensitive PKC-zeta. These data suggest that a nuclear increase in PI 3-K activity and PtdIns(3,4,5)P-3 production are necessary for the subsequent nuclear translocation of PKC-zeta. Furthermore, they point to the likelihood that PKC-zeta is a putative nuclear downstream target of PI 3-K during NGF-promoted neural differentiation.	Univ Ferrara, Dipartimento Morfol & Embriol, Sez Anat Umana, I-44100 Ferrara, Italy; CNR, Ist Citomorfol Normale & Patol, IOR, I-40137 Bologna, Italy; Univ Trieste, Dipartimento Morfol Umana Normale, I-34138 Trieste, Italy	University of Ferrara; Consiglio Nazionale delle Ricerche (CNR); University of Trieste	Neri, LM (corresponding author), Univ Ferrara, Dipartimento Morfol & Embriol, Sez Anat Umana, Via Fossato Mortara 66, I-44100 Ferrara, Italy.		Neri, Luca Maria/AAU-1772-2021; Neri, Luca Maria/J-2462-2017	Neri, Luca Maria/0000-0002-7924-1477; CAPITANI, Silvano/0000-0003-2795-6814; Marchisio, Marco/0000-0003-3058-3422				Bae YS, 1998, J BIOL CHEM, V273, P4465, DOI 10.1074/jbc.273.8.4465; Bandyopadhyay G, 1997, ENDOCRINOLOGY, V138, P4721, DOI 10.1210/en.138.11.4721; Bavelloni A, 1999, J CELL SCI, V112, P631; Bertagnolo V, 1999, CANCER RES, V59, P542; Borgatti P, 1996, EXP CELL RES, V224, P72, DOI 10.1006/excr.1996.0112; Carpenter CL, 1996, BBA-REV CANCER, V1288, pM11, DOI 10.1016/0304-419X(96)00018-2; Chou MM, 1998, CURR BIOL, V8, P1069, DOI 10.1016/S0960-9822(98)70444-0; D'Santos CS, 1998, BBA-MOL CELL BIOL L, V1436, P201, DOI 10.1016/S0005-2760(98)00146-5; DING JB, 1995, J BIOL CHEM, V270, P11684, DOI 10.1074/jbc.270.19.11684; DIVECHA N, 1991, EMBO J, V10, P3207, DOI 10.1002/j.1460-2075.1991.tb04883.x; DIVECHA N, 1993, CELL, V74, P405, DOI 10.1016/0092-8674(93)80041-C; Divecha N, 1998, NATURE, V394, P619, DOI 10.1038/29174; Domin J, 1997, FEBS LETT, V410, P91, DOI 10.1016/S0014-5793(97)00617-0; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; HerreraVelit P, 1997, J BIOL CHEM, V272, P16445, DOI 10.1074/jbc.272.26.16445; KAPELLER R, 1993, MOL CELL BIOL, V13, P6052, DOI 10.1128/MCB.13.10.6052; Kim SJ, 1998, BIOCHEM MOL BIOL INT, V46, P187; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Le Good JA, 1998, SCIENCE, V281, P2042, DOI 10.1126/science.281.5385.2042; Li ZM, 1997, P NATL ACAD SCI USA, V94, P13820, DOI 10.1073/pnas.94.25.13820; Liu Q, 1998, J IMMUNOL, V160, P1393; Lu PJ, 1998, BIOCHEMISTRY-US, V37, P5738, DOI 10.1021/bi972551g; Marchisio M, 1998, BIOCHEM BIOPH RES CO, V253, P346, DOI 10.1006/bbrc.1998.9787; MARMIROLI S, 1995, BIOL CELL, V86, P121; MARTELLI AM, 1992, NATURE, V358, P242, DOI 10.1038/358242a0; Meier R, 1997, J BIOL CHEM, V272, P30491, DOI 10.1074/jbc.272.48.30491; Mellor H, 1998, BIOCHEM J, V332, P281, DOI 10.1042/bj3320281; Minshall C, 1996, J IMMUNOL, V156, P939; Mizukami Y, 1997, FEBS LETT, V401, P247, DOI 10.1016/S0014-5793(96)01481-0; Moriya S, 1996, P NATL ACAD SCI USA, V93, P151, DOI 10.1073/pnas.93.1.151; NAKANISHI H, 1993, J BIOL CHEM, V268, P13; Neri LM, 1999, HISTOL HISTOPATHOL, V14, P321, DOI 10.14670/HH-14.321; Neri LM, 1998, J BIOL CHEM, V273, P29738, DOI 10.1074/jbc.273.45.29738; Neri LM, 1999, BIOCHEM BIOPH RES CO, V259, P314, DOI 10.1006/bbrc.1999.0786; NERI LM, 1994, CELL MOL BIOL, V40, P619; RAMEH LE, 1995, CELL, V83, P821, DOI 10.1016/0092-8674(95)90195-7; Shepherd PR, 1998, BIOCHEM J, V333, P471, DOI 10.1042/bj3330471; SOLTOFF SP, 1992, J BIOL CHEM, V267, P17472; Standaert ML, 1997, J BIOL CHEM, V272, P30075, DOI 10.1074/jbc.272.48.30075; Sun B, 1997, J BIOL CHEM, V272, P26313, DOI 10.1074/jbc.272.42.26313; Tanaka K, 1999, J BIOL CHEM, V274, P3919, DOI 10.1074/jbc.274.7.3919; TOKER A, 1994, J BIOL CHEM, V269, P32358; Wooten MW, 1997, J NEUROSCI RES, V49, P393, DOI 10.1002/(SICI)1097-4547(19970815)49:4<393::AID-JNR1>3.0.CO;2-3; Zauli G, 1996, BRIT J HAEMATOL, V93, P542, DOI 10.1046/j.1365-2141.1996.d01-1700.x; Zhou GS, 1997, J BIOL CHEM, V272, P31130, DOI 10.1074/jbc.272.49.31130; Zini N, 1996, HISTOCHEM CELL BIOL, V106, P457, DOI 10.1007/BF02473307	46	99	102	0	8	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	DEC	1999	13	15					2299	2310		10.1096/fasebj.13.15.2299	http://dx.doi.org/10.1096/fasebj.13.15.2299			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	266QN	10593877				2022-12-25	WOS:000084310800021
J	Kiaris, H; Schally, AV; Sun, B; Armatis, P; Groot, K				Kiaris, H; Schally, AV; Sun, B; Armatis, P; Groot, K			Inhibition of growth of human malignant glioblastoma in nude mice by antagonists of bombesin/gastrin-releasing peptide	ONCOGENE			English	Article						brain tumors; cancer therapy; peptide analogs; oncogene stimulation; autocrine; paracrine	CELL LUNG-CANCER; SOMATOSTATIN ANALOG RC-160; BINDING AFFINITIES; MESSENGER-RNA; IN-VITRO; C-FOS; RC-3095; RECEPTORS; CARCINOMA; LINES	The effects of antagonists of bombesin/gastrin-releasing peptide (GRP) on the growth of human malignant glioblastoma cell line U-87MG xenografted into nude mice were evaluated. Nude mice bearing s.c. implanted U-87MG tumors were treated with bombesin/GRP antagonists RC-3095 and RC-3940-II. RC-3095 and RC-3940-II administered s.c. at a dose of 20 mu g/day for 4 weeks decreased the volume of U-87MG xenografts by 60 and 74%, respectively, compared with controls. RT-PCR analysis showed that U-87MG xenografts expressed mRNA for bombesin receptor subtype (BRS)-1 (GRP receptor) and BRS-2 (neuromedin-B receptor), but the mRNA for GRP ligand was not detected in U-87MG cells suggesting that GRP may stimulate the growth of U-87MG glioblastomas by a paracrine mechanism. The levels of mRNA for c-fos oncogene mere decreased by 30-40% in U-87MG tumors treated with RC-3095 or RC-3940-II. In U-373MG glioblastoma cells, which also express BRS-1, and U-87MG cells, cultured in vitro, GRP(14-27) induced the expression of c-fos mRNA, and some c-jun mRNA, in a time-dependent manner with the maximal effect occurring 2 h after the stimulation and a return to basal levels after 8 h. Antagonist RC-3940-II inhibited the stimulation of c-fos by GRP(14-27), Our results indicate that antagonists of bombesin/GRP inhibit the growth of U-87MG glioblastomas by a mechanism that may involve the downregulation of c-fos oncogene.	Vet Adm Med Ctr, Inst Endocrine Polypeptide & Canc, New Orleans, LA 70112 USA; Tulane Univ, Sch Med, Dept Med, Sect Expt Med, New Orleans, LA 70112 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); Tulane University	Schally, AV (corresponding author), Vet Adm Med Ctr, Inst Endocrine Polypeptide & Canc, 1601 Perdido St, New Orleans, LA 70112 USA.			Schally, Andrew/0000-0003-1273-6747; Kiaris, Hippokratis/0000-0002-8999-8289				DRAOUI M, 1993, CELL GROWTH DIFFER, V4, P723; DRAOUI M, 1995, PEPTIDES, V16, P289, DOI 10.1016/0196-9781(94)00173-1; HALAZONETIS TD, 1988, CELL, V55, P917, DOI 10.1016/0092-8674(88)90147-X; Halmos G, 1997, P NATL ACAD SCI USA, V94, P956, DOI 10.1073/pnas.94.3.956; HOCHBERG F, 1987, HARRISONS PRINCIPLES, P1968; Koppan M, 1998, CANCER, V83, P1335, DOI 10.1002/(SICI)1097-0142(19981001)83:7<1335::AID-CNCR10>3.0.CO;2-5; LIEBOW C, 1994, P NATL ACAD SCI USA, V91, P3804, DOI 10.1073/pnas.91.9.3804; MAHMOUD S, 1991, CANCER RES, V51, P1798; MOODY TW, 1979, BIOCHEM BIOPH RES CO, V90, P7, DOI 10.1016/0006-291X(79)91582-1; MOODY TW, 1987, BIOCHEM BIOPH RES CO, V147, P189, DOI 10.1016/S0006-291X(87)80105-5; MOODY TW, 1981, SCIENCE, V214, P1246, DOI 10.1126/science.6272398; MOODY TW, 1989, J MOL NEUROSCI, V1, P235; OLSON JJ, 1988, CANCER, V61, P952, DOI 10.1002/1097-0142(19880301)61:5<952::AID-CNCR2820610516>3.0.CO;2-R; OSHEA EK, 1989, SCIENCE, V245, P646, DOI 10.1126/science.2503872; PAOLETTI P, 1990, J NEUROSURG, V73, P736, DOI 10.3171/jns.1990.73.5.0736; PINSKI J, 1994, BRIT J CANCER, V70, P886, DOI 10.1038/bjc.1994.415; PINSKI J, 1994, INT J CANCER, V57, P574, DOI 10.1002/ijc.2910570422; PINSKI J, 1993, J CLIN ENDOCR METAB, V77, P1388, DOI 10.1210/jc.77.5.1388; PINSKI J, 1994, CANCER RES, V54, P5895; PINSKI J, 1994, CANCER RES, V54, P169; Poisson M, 1983, J Neurooncol, V1, P179, DOI 10.1007/BF00165601; QIN YF, 1994, J CANCER RES CLIN, V120, P519, DOI 10.1007/BF01221028; QIN YF, 1994, CANCER RES, V54, P1035; RADULOVIC S, 1991, INT J PEPT PROT RES, V38, P593; REILE H, 1995, INT J ONCOL, V7, P749; Schally A.V., 1997, CANCER MED-US, V4th, P1067; SCHOENBERG BS, 1983, ONCOLOGY NERVOUS SYS, P1; Sharif TR, 1997, MOL CELL ENDOCRINOL, V130, P119, DOI 10.1016/S0303-7207(97)00080-4; SIEGFRIED JM, 1994, J BIOL CHEM, V269, P8596; SPINDEL ER, 1993, RECENT PROG HORM RES, V48, P365; STALEY J, 1993, J MOL NEUROSCI, V4, P29, DOI 10.1007/BF02736688; SZEPESHAZI K, 1992, J NATL CANCER I, V84, P1915, DOI 10.1093/jnci/84.24.1915; SZEPESHAZI K, 1991, CANCER RES, V51, P5980; WANG QJ, 1996, INT J CANCER, V68, P1; YANO T, 1992, CANCER RES, V52, P4545	35	44	47	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 25	1999	18	50					7168	7173		10.1038/sj.onc.1203213	http://dx.doi.org/10.1038/sj.onc.1203213			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	259PH	10597318				2022-12-25	WOS:000083901900024
J	Okano, H; Saito, Y; Miyazawa, T; Shinbo, T; Chou, DZ; Kosugi, S; Takahashi, Y; Odani, S; Niwa, O; Kominami, R				Okano, H; Saito, Y; Miyazawa, T; Shinbo, T; Chou, DZ; Kosugi, S; Takahashi, Y; Odani, S; Niwa, O; Kominami, R			Homozygous deletions and point mutations of the Ikaros gene in gamma-ray-induced mouse thymic lymphomas	ONCOGENE			English	Article						tumor suppressor gene; Ikaros; allelic loss (or LOH) analysis; somatic mutation; gamma-ray-induced thymic lymphoma	TUMOR-SUPPRESSOR GENES; DNA-BINDING PROTEINS; CENTROMERIC HETEROCHROMATIN; TRANSCRIPTION FACTOR; P53; FAMILY; CANCER; CELLS; MICE; CHROMOSOME-16	Our previous genome-wide analysis of allelic loss for thymic lymphomas that were induced by gamma-irradiation in F-1 hybrid mice between BALB/c and MSM strains suggested the centromeric region on chromosome 11 as a site harboring a tumor suppressor gene. Interestingly, to this region the mouse Ikaros gene was mapped which was postulated to participate in oncogenic process from the study of Ikaros knockout mice. Here we show fine allelic loss mapping in the vicinity of Ikaros in 191 lymphomas, indicating that the critical region of allelic loss was centered at the Ikaros locus. PCR analysis revealed that nine lymphomas failed to give PCR-amplification for either of two exon primer pairs, indicative of homozygous deletion, Six and five mutations were detected in the N-terminal zinc finger domain and the activation domain of Ikaros, respectively, and six of the eleven were frameshift or nonsense mutations that resulted in truncation of Ikaros protein. The results strongly suggest a direct role for Ikaros in development of mouse thymic lymphomas, This provides the experimental basis for further analysis of Ikaros mutations in human cancer.	Niigata Univ, Sch Med, Dept Biochem, Niigata 9518122, Japan; Niigata Univ, Grad Sch Sci & Technol, Div Life Sci, Niigata 9502181, Japan; Kyoto Univ, Ctr Radiat Biol, Sakyou Ku, Yoshida Konoecho 6068315, Japan	Niigata University; Niigata University; Kyoto University	Kominami, R (corresponding author), Niigata Univ, Sch Med, Dept Biochem, Asahimachi 1-757, Niigata 9518122, Japan.		Kosugi, S./K-5142-2019	Kosugi, Shin-ichi/0000-0002-6602-7412				BONHOMME F, 1989, GENETIC VARIANTS STR, P658; Brown KE, 1997, CELL, V91, P845, DOI 10.1016/S0092-8674(00)80472-9; DIETRICH WF, 1994, P NATL ACAD SCI USA, V91, P9451, DOI 10.1073/pnas.91.20.9451; Dietrich WF, 1996, NATURE, V380, P149, DOI 10.1038/380149a0; FRIEDBERG EC, 1995, DNA REPAIR MUTAGENES; GEORGOPOULOS K, 1994, CELL, V79, P143, DOI 10.1016/0092-8674(94)90407-3; GEORGOPOULOS K, 1992, SCIENCE, V258, P808, DOI 10.1126/science.1439790; Ghebranious N, 1998, ONCOGENE, V17, P3385, DOI 10.1038/sj.onc.1202573; Giaccia AJ, 1998, GENE DEV, V12, P2973, DOI 10.1101/gad.12.19.2973; Hahm K, 1998, GENE DEV, V12, P782, DOI 10.1101/gad.12.6.782; HALEVY O, 1991, ONCOGENE, V6, P1593; HARTWELL LH, 1994, SCIENCE, V266, P1821, DOI 10.1126/science.7997877; HAYASHI T, 1993, GENOMICS, V17, P490, DOI 10.1006/geno.1993.1352; Kelley CM, 1998, CURR BIOL, V8, P508, DOI 10.1016/S0960-9822(98)70202-7; KEMP CJ, 1993, CANCER RES, V53, P6022; Klug CA, 1998, P NATL ACAD SCI USA, V95, P657, DOI 10.1073/pnas.95.2.657; KNUDSON AG, 1985, CANCER RES, V45, P1437; Koide N, 1999, MOL CARCINOGEN, V24, P57, DOI 10.1002/(SICI)1098-2744(199901)24:1<57::AID-MC8>3.0.CO;2-5; Kolodner R, 1996, GENE DEV, V10, P1433, DOI 10.1101/gad.10.12.1433; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; Lengauer C, 1998, NATURE, V396, P643, DOI 10.1038/25292; Little JB, 1997, RADIAT RES, V148, P299, DOI 10.2307/3579514; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; Matsumoto Y, 1998, ONCOGENE, V16, P2747, DOI 10.1038/sj.onc.1201810; MOLNAR A, 1994, MOL CELL BIOL, V14, P8292, DOI 10.1128/MCB.14.12.8292; Molnar A, 1996, J IMMUNOL, V156, P585; Morgan B, 1997, EMBO J, V16, P2004, DOI 10.1093/emboj/16.8.2004; ORITA M, 1989, GENOMICS, V5, P874, DOI 10.1016/0888-7543(89)90129-8; Sato S, 1998, ONCOGENE, V17, P105, DOI 10.1038/sj.onc.1201913; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Shinbo T, 1999, ONCOGENE, V18, P4131, DOI 10.1038/sj.onc.1202767; Sun L, 1996, EMBO J, V15, P5358, DOI 10.1002/j.1460-2075.1996.tb00920.x; Takaku K, 1998, CELL, V92, P645, DOI 10.1016/S0092-8674(00)81132-0; THACKER J, 1992, ADV RADIAT BIOL, V16, P77; TSUKADA T, 1993, ONCOGENE, V8, P3313; VOGELSTEIN B, 1993, TRENDS GENET, V9, P138, DOI 10.1016/0168-9525(93)90209-Z; Wang JH, 1996, IMMUNITY, V5, P537, DOI 10.1016/S1074-7613(00)80269-1; WEINBERG RA, 1991, SCIENCE, V254, P1138, DOI 10.1126/science.1659741; WILLIAMS BO, 1994, NAT GENET, V7, P480, DOI 10.1038/ng0894-480; WINANDY S, 1995, CELL, V83, P289, DOI 10.1016/0092-8674(95)90170-1	40	53	53	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 18	1999	18	48					6677	6683		10.1038/sj.onc.1203100	http://dx.doi.org/10.1038/sj.onc.1203100			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	257QA	10597273				2022-12-25	WOS:000083792000007
J	Yin, XY; Gupta, K; Han, WP; Levitan, ES; Prochownik, EV				Yin, XY; Gupta, K; Han, WP; Levitan, ES; Prochownik, EV			Mmip-2, a novel RING finger protein that interacts with mad members of the Myc oncoprotein network	ONCOGENE			English	Article						RING finger proteins; zinc finger proteins; helix-loop-helix; leucine zipper proteins; mad; mxi1; max; myc	C-MYC; TRANSCRIPTIONAL REPRESSION; DNA-BINDING; CELL-GROWTH; EPIDERMAL DIFFERENTIATION; GENE-EXPRESSION; ZIPPER PROTEIN; IN-VITRO; DOMAIN; COMPLEX	Mad proteins are basic-helix-loop - helix -leucine zipper (bHLH-ZIP)-containing members of the myc oncoprotein network. They interact with the bHLH-ZIP protein max, compete for the same DNA binding sites as myc-max heterodimers and down-regulate myc-responsive genes. Using the bHLH-ZIP domain of mad1 as a yeast two-hybrid 'bait', we identified Mmip-2, a novel RING finger protein that interacts with all mad members, but weakly or not at all with c-myc, max or unrelated bHLH or bZIP proteins. The mad1-Mmip-2 interaction is mediated by the ZIP domain in the former protein and by at least two regions in the latter which do not include the RING finger. Mmip-2 can disrupt max-mad DNA binding and can reverse the suppressive effects of mad proteins on c-myc-responsive target genes and on c-myc+ras-mediated focus formation in fibroblasts. Tagging with spectral variants of green fluorescent protein showed that Mmip-2 and mad proteins reside in separate cytoplasmic and nuclear compartments, respectively. When co-expressed, however, the proteins interact and translocate to the cellular compartment occupied by the more abundant protein. These observations suggest a novel way by which Mmip-2 can modulate the transcriptional activity of myc oncoproteins.	Univ Pittsburgh, Inst Canc, Childrens Hosp Pittsburgh, Hematol Oncol Sect, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Inst Canc, Dept Mol Genet & Biochem, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Inst Canc, Med Ctr, Dept Pharmacol, Pittsburgh, PA 15213 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Prochownik, EV (corresponding author), Univ Pittsburgh, Inst Canc, Childrens Hosp Pittsburgh, Hematol Oncol Sect, 3705 5th Ave, Pittsburgh, PA 15213 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL033741] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS032385] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL33741] Funding Source: Medline; NINDS NIH HHS [NS32385] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Anand G, 1997, J BIOL CHEM, V272, P19140, DOI 10.1074/jbc.272.31.19140; AYER DE, 1995, CELL, V80, P767, DOI 10.1016/0092-8674(95)90355-0; AYER DE, 1993, CELL, V72, P211, DOI 10.1016/0092-8674(93)90661-9; AYER DE, 1993, GENE DEV, V7, P2110, DOI 10.1101/gad.7.11.2110; BARRETT J, 1992, MOL CELL BIOL, V12, P3130, DOI 10.1128/MCB.12.7.3130; BEIJERSBERGEN RL, 1994, EMBO J, V13, P4080, DOI 10.1002/j.1460-2075.1994.tb06725.x; Bellon SF, 1997, NAT STRUCT BIOL, V4, P586, DOI 10.1038/nsb0797-586; BLACKWELL TK, 1993, MOL CELL BIOL, V13, P5216, DOI 10.1128/MCB.13.9.5216; BLACKWOOD EM, 1992, GENE DEV, V6, P71, DOI 10.1101/gad.6.1.71; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; BORROW J, 1990, SCIENCE, V249, P1577, DOI 10.1126/science.2218500; Dang CV, 1999, MOL CELL BIOL, V19, P1; DEPINHO RA, 1991, ADV CANCER RES, V57, P1; DETHE H, 1991, CELL, V66, P675, DOI 10.1016/0092-8674(91)90113-D; DYCK JA, 1994, CELL, V76, P333, DOI 10.1016/0092-8674(94)90340-9; EVAN GI, 1993, CURR OPIN GENET DEV, V3, P44, DOI 10.1016/S0959-437X(05)80339-9; Facchini LM, 1998, FASEB J, V12, P633, DOI 10.1096/fasebj.12.9.633; FINKEL T, 1993, J BIOL CHEM, V268, P5; Foley KP, 1998, EMBO J, V17, P774, DOI 10.1093/emboj/17.3.774; FREEMONT PS, 1993, ANN NY ACAD SCI, V684, P174, DOI 10.1111/j.1749-6632.1993.tb32280.x; GAUBATZ S, 1995, EMBO J, V14, P1508, DOI 10.1002/j.1460-2075.1995.tb07137.x; GU W, 1994, SCIENCE, V264, P251, DOI 10.1126/science.8146655; Gupta K, 1998, ONCOGENE, V16, P1149, DOI 10.1038/sj.onc.1201634; GUPTA S, 1993, P NATL ACAD SCI USA, V90, P3216, DOI 10.1073/pnas.90.8.3216; Hassig CA, 1997, CELL, V89, P341, DOI 10.1016/S0092-8674(00)80214-7; Hemenway CS, 1998, ONCOGENE, V16, P2541, DOI 10.1038/sj.onc.1202042; Henriksson M, 1996, ADV CANCER RES, V68, P109, DOI 10.1016/S0065-230X(08)60353-X; HU HM, 1994, J BIOL CHEM, V269, P30069; HURLIN PJ, 1995, EMBO J, V14, P5646, DOI 10.1002/j.1460-2075.1995.tb00252.x; Hurlin PJ, 1995, ONCOGENE, V11, P2487; Jensen DE, 1998, ONCOGENE, V16, P1097, DOI 10.1038/sj.onc.1201861; KATO GJ, 1990, MOL CELL BIOL, V10, P5914, DOI 10.1128/MCB.10.11.5914; Kim SS, 1996, P NATL ACAD SCI USA, V93, P15299, DOI 10.1073/pnas.93.26.15299; LACHMAN HM, 1984, NATURE, V310, P592, DOI 10.1038/310592a0; Laherty CD, 1997, CELL, V89, P349, DOI 10.1016/S0092-8674(00)80215-9; LAHOZ EG, 1994, P NATL ACAD SCI USA, V91, P5503, DOI 10.1073/pnas.91.12.5503; Langlands K, 1997, ANAL BIOCHEM, V249, P250, DOI 10.1006/abio.1997.2184; Langlands K, 1997, J BIOL CHEM, V272, P19785, DOI 10.1074/jbc.272.32.19785; LARSSON LG, 1994, ONCOGENE, V9, P1247; LEU TMJ, 1995, MOL CELL BIOL, V15, P5657; LONGO L, 1990, J EXP MED, V172, P1571, DOI 10.1084/jem.172.6.1571; MA A, 1993, ONCOGENE, V8, P1093; McMahon SB, 1998, CELL, V94, P363, DOI 10.1016/S0092-8674(00)81479-8; Moilanen AM, 1998, MOL CELL BIOL, V18, P5128, DOI 10.1128/MCB.18.9.5128; Nesbit CE, 1999, ONCOGENE, V18, P3004, DOI 10.1038/sj.onc.1202746; PACKHAM G, 1994, MOL CELL BIOL, V14, P5741, DOI 10.1128/MCB.14.9.5741; Peukert K, 1997, EMBO J, V16, P5672, DOI 10.1093/emboj/16.18.5672; PRENDERGAST GC, 1991, CELL, V65, P395, DOI 10.1016/0092-8674(91)90457-A; PROCHOWNIK EV, 1993, P NATL ACAD SCI USA, V90, P960, DOI 10.1073/pnas.90.3.960; Queva C, 1998, ONCOGENE, V16, P967, DOI 10.1038/sj.onc.1201611; Sakamuro D, 1996, NAT GENET, V14, P69, DOI 10.1038/ng0996-69; Saurin AJ, 1996, TRENDS BIOCHEM SCI, V21, P208, DOI 10.1016/S0968-0004(96)80017-X; Schreiber-Agus N, 1998, BIOESSAYS, V20, P808, DOI 10.1002/(SICI)1521-1878(199810)20:10<808::AID-BIES6>3.0.CO;2-U; Schreiber-Agus N, 1998, NATURE, V393, P483, DOI 10.1038/31008; SCHREIBERAGUS N, 1995, CELL, V80, P777, DOI 10.1016/0092-8674(95)90356-9; Scully R, 1997, CELL, V88, P265, DOI 10.1016/S0092-8674(00)81847-4; Shrivastava A, 1996, P NATL ACAD SCI USA, V93, P10638, DOI 10.1073/pnas.93.20.10638; SHRIVASTAVA A, 1993, SCIENCE, V262, P1889, DOI 10.1126/science.8266081; STARNAUD R, 1988, ONCOGENE, V3, P553; TASSAN JP, 1995, EMBO J, V14, P5608, DOI 10.1002/j.1460-2075.1995.tb00248.x; VASTRIK I, 1995, J CELL BIOL, V128, P1197, DOI 10.1083/jcb.128.6.1197; Wu LJC, 1996, NAT GENET, V14, P430, DOI 10.1038/ng1296-430; Yin XY, 1998, ONCOGENE, V16, P2629, DOI 10.1038/sj.onc.1201777; ZERVOS, 1994, CELL, V79, P389; ZERVOS AS, 1993, CELL, V72, P223, DOI 10.1016/0092-8674(93)90662-A; Zhang H, 1997, J BIOL CHEM, V272, P17416, DOI 10.1074/jbc.272.28.17416; ZIMMERMAN KA, 1986, NATURE, V319, P780, DOI 10.1038/319780a0	67	16	25	0	0	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 18	1999	18	48					6621	6634		10.1038/sj.onc.1203097	http://dx.doi.org/10.1038/sj.onc.1203097			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	257QA	10597267				2022-12-25	WOS:000083792000001
J	Ma, L; Gauville, C; Berthois, Y; Millot, G; Johnson, GR; Calvo, F				Ma, L; Gauville, C; Berthois, Y; Millot, G; Johnson, GR; Calvo, F			Antisense expression for amphiregulin suppresses tumorigenicity of a transformed human breast epithelial cell line	ONCOGENE			English	Article						epidermal growth factor receptor; amphiregulin; antisense RNA expression constructs; transformed phenotype	EPIDERMAL-GROWTH-FACTOR; MOUSE MAMMARY-GLAND; FACTOR RECEPTOR; FACTOR-ALPHA; CANCER CELLS; HUMAN COLON; CARCINOMA; EGF; INDUCTION; SURFACE	The epidermal growth factor (EGF) family of receptors and their respective ligands play a major role in breast cancer progression and are the targets of new therapeutic approaches. Following immortalization with SV40 T antigen of normal human breast epithelial cells, a transformed variant cell line (NS2T2A1) was selected for its increased tumorigenicity in nude mice. This cell line was shown to have a higher expression of EGF receptors (EGFR) and amphiregulin (AR) when compared to their normal counterparts or less aggressive transformed cells. Dual staining of EGFR and AR was observed in 50-60% of NS2T2A1 cells, while 30-40% cells expressed AR only, To explore the potential tumorigenic role of AR, a 1.1 kb AR cDNA in an antisense orientation was transfected in NS2T2A1 cells. Three clones, selected by hygromycin B, expressed AR antisense RNA (AR AS1, AR AS2 and AR AS3 cell lines) in which AR protein expression was reduced (ranging from about 50 to <5%), The anchorage-independent growth of AR AS cell lines was reduced to levels ranging from 32.4-6.8% relative to the control cell line transfected with the vector alone. The clones expressing AR antisense RNA showed a reversion of the malignant phenotype when injected in nude mice, since a significant reduction of tumor intake was observed coincident with a significant tumor mass reduction (>96%), Moreover, intra-tumoral vascularization decreased significantly in tumors derived from AR AS cells (26.7, 70.7 and 50.4% of control). These in vitro and in vivo data reveal the oncogenic nature of AR in transformed breast epithelial cells and imply a role for AR in tumor angiogenesis.	Inst Genet Mol, Lab Pharmacol Expt & Clin, INSERM, EP 9932, F-75010 Paris, France; Fac Med Nord, F-13916 Marseille, France; US FDA, Ctr Biol Evaluat & Res, Div Cytokine Biol, Bethesda, MD 20892 USA	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Aix-Marseille Universite; US Food & Drug Administration (FDA)	Ma, L (corresponding author), Inst Genet Mol, Lab Pharmacol Expt & Clin, INSERM, EP 9932, 27 Rue Juliette Dodu, F-75010 Paris, France.		Berthois, Yolande/O-1168-2017	calvo, fabien/0000-0002-0298-7633; BERTHOIS, Yolande/0000-0001-9603-1626				BARNARD JA, 1994, J BIOL CHEM, V269, P22817; Bennett KL, 1992, GROWTH FACTORS, V7, DOI 10.3109/08977199209046925; BERTHON P, 1992, INT J CANCER, V52, P92, DOI 10.1002/ijc.2910520117; Brown CL, 1998, J BIOL CHEM, V273, P17258, DOI 10.1074/jbc.273.27.17258; COOK PW, 1991, MOL CELL BIOL, V11, P2547, DOI 10.1128/MCB.11.5.2547; CORDELL JL, 1984, J HISTOCHEM CYTOCHEM, V32, P219, DOI 10.1177/32.2.6198355; DETMAR M, 1994, J EXP MED, V180, P1141, DOI 10.1084/jem.180.3.1141; DVIS LG, 1986, BASIC METHODS MOL BI, P130; ETHIER SP, 1995, J NATL CANCER I, V87, P964, DOI 10.1093/jnci/87.13.964; Funatomi H, 1997, INT J CANCER, V72, P512, DOI 10.1002/(SICI)1097-0215(19970729)72:3<512::AID-IJC21>3.0.CO;2-C; Gille J, 1997, EMBO J, V16, P750, DOI 10.1093/emboj/16.4.750; Herrington EE, 1997, J CELL PHYSIOL, V170, P47; IGLESIAS M, 1995, AM J PATHOL, V146, P944; JOHNSON GR, 1992, J CELL BIOL, V118, P741, DOI 10.1083/jcb.118.3.741; JOHNSON GR, 1991, BIOCHEM BIOPH RES CO, V180, P481, DOI 10.1016/S0006-291X(05)81090-3; JOHNSON GR, 1993, J BIOL CHEM, V268, P18835; JOHNSON GR, 1994, J BIOL CHEM, V269, P27149; JOHNSON GR, 1993, J BIOL CHEM, V268, P2924; Kenney Nicholas, 1993, Molecular and Cellular Differentiation, V1, P163; Kenney NJ, 1996, MOL CARCINOGEN, V15, P44; KENNEY NJ, 1995, MOL REPROD DEV, V41, P277, DOI 10.1002/mrd.1080410302; Kenney NJ, 1996, CELL GROWTH DIFFER, V7, P1769; KLIJN JGM, 1992, ENDOCR REV, V13, P3, DOI 10.1210/er.13.1.3; Kondapaka SB, 1997, INT J CANCER, V70, P722, DOI 10.1002/(SICI)1097-0215(19970317)70:6<722::AID-IJC15>3.3.CO;2-5; LEBEAU J, 1995, INT J CANCER, V60, P244, DOI 10.1002/ijc.2910600219; LEJEUNE S, 1993, CANCER RES, V53, P3597; LI SW, 1992, J CELL PHYSIOL, V153, P103, DOI 10.1002/jcp.1041530114; Ma L, 1998, INT J CANCER, V78, P112, DOI 10.1002/(SICI)1097-0215(19980925)78:1<112::AID-IJC18>3.0.CO;2-D; Ma L, 1996, FUND CLIN PHARMACOL, V10, P97, DOI 10.1111/j.1472-8206.1996.tb00153.x; MARTINEZLACACI I, 1995, ENDOCRINOLOGY, V136, P3983, DOI 10.1210/en.136.9.3983; MartinezLacaci I, 1996, J CELL PHYSIOL, V169, P497, DOI 10.1002/(SICI)1097-4652(199612)169:3<497::AID-JCP10>3.0.CO;2-3; MODJTAHEDI H, 1994, INT J ONCOL, V4, P277; NORMANNO N, 1994, P NATL ACAD SCI USA, V91, P2790, DOI 10.1073/pnas.91.7.2790; NORMANNO N, 1995, INT J CANCER, V62, P762, DOI 10.1002/ijc.2910620619; Panico L, 1996, INT J CANCER, V65, P51, DOI 10.1002/(SICI)1097-0215(19960103)65:1<51::AID-IJC9>3.0.CO;2-0; PLOWMAN GD, 1990, MOL CELL BIOL, V10, P1969, DOI 10.1128/MCB.10.5.1969; QI CF, 1994, BRIT J CANCER, V69, P903, DOI 10.1038/bjc.1994.174; SCHREIBER AB, 1986, SCIENCE, V232, P1250, DOI 10.1126/science.2422759; SHOYAB M, 1989, SCIENCE, V243, P1074, DOI 10.1126/science.2466334; SHOYAB M, 1988, P NATL ACAD SCI USA, V85, P6528, DOI 10.1073/pnas.85.17.6528; Silvy M, 1998, ENDOCRINOLOGY, V139, P2382, DOI 10.1210/en.139.5.2382; Solic N, 1997, EXP CELL RES, V234, P465, DOI 10.1006/excr.1997.3635; Thompson SA, 1996, J BIOL CHEM, V271, P17927, DOI 10.1074/jbc.271.30.17927; VARDY DA, 1995, J CELL PHYSIOL, V163, P257, DOI 10.1002/jcp.1041630206; WOODWORTH CD, 1995, P NATL ACAD SCI USA, V92, P2840, DOI 10.1073/pnas.92.7.2840	45	43	48	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 11	1999	18	47					6513	6520		10.1038/sj.onc.1203042	http://dx.doi.org/10.1038/sj.onc.1203042			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	256CW	10597254				2022-12-25	WOS:000083709200014
J	Mori, A; Higashi, H; Hoshikawa, Y; Imamura, M; Asaka, M; Hatakeyama, M				Mori, A; Higashi, H; Hoshikawa, Y; Imamura, M; Asaka, M; Hatakeyama, M			Granulocytic differentiation of myeloid progenitor cells by p130, the retinoblastoma tumor suppressor homologue	ONCOGENE			English	Article						p130; pRB; granulocytic differentiation; 32Dc13 cell; E1A	DEPENDENT KINASE-ACTIVITY; ADENOVIRUS E1A PROTEINS; PRB-RELATED P130; HUMAN CYCLIN-A; GENE-PRODUCT; TRANSCRIPTIONAL ACTIVATION; FUNCTIONAL INACTIVATION; GROWTH SUPPRESSION; CELLULAR PROTEIN; P107 PROTEIN	The retinoblastoma protein (pRB) and the related pocket proteins, p107 and p130, play crucial roles in mammalian cell cycle control. Recent studies indicate that these pocket proteins are also involved in cellular differentiation processes. We demonstrate in this work that the pRB-related p130 selectively accumulates during the in vitro differentiation of the myeloid progenitor cell, 32Dc13, into granulocyte in response to granulocyte-colony stimulating factor (G-CSF). This G-CSF-dependent granulocytic differentiation is blocked by the adenovirus E1A oncoprotein, which binds to and inactivates the pRB family of pocket proteins including p130. Furthermore, enforced overexpression of p130 but not PRE inhibits the myeloid cell proliferation that is concomitantly associated with granulocytic differentiation morphologically characterized by nuclear segmentation. However, simple G1-cell cycle al rest induced by cytokine deprivation or ectopic overexpression of the p27 cyclin-dependent kinase inhibitor, or inhibition of E2F activities by dominant negative DP-1 is not sufficient to trigger granulocytic differentiation. The differentiation-promoting activity of p130 in myeloid cells requires both the pocket domain and the spacer domain. Our results indicate that the pRB-related p130 plays a critical role in myeloid cell differentiation and suggest that coupling of cell cycle exit with the cellular differentiation program may be specifically achieved by p130.	Japanese Fdn Canc Res, Inst Canc, Dept Viral Oncol, Toshima Ku, Tokyo 1708455, Japan; Hokkaido Univ, Sch Med, Dept Hematol & Oncol, Sapporo, Hokkaido 0608638, Japan; Hokkaido Univ, Sch Med, Dept Internal Med 3, Sapporo, Hokkaido 0608638, Japan	Japanese Foundation for Cancer Research; Hokkaido University; Hokkaido University	Hatakeyama, M (corresponding author), Japanese Fdn Canc Res, Inst Canc, Dept Viral Oncol, Toshima Ku, 1-37-1 Kami Ikebukuro, Tokyo 1708455, Japan.		Asaka, Masahiro/A-5948-2012; Higashi, Hideaki/F-6872-2012					BALDI A, 1995, J CELL BIOCHEM, V59, P402, DOI 10.1002/jcb.240590311; Beijersbergen RL, 1996, BBA-REV CANCER, V1287, P103, DOI 10.1016/0304-419X(96)00002-9; BEIJERSBERGEN RL, 1995, GENE DEV, V9, P1340, DOI 10.1101/gad.9.11.1340; BEIJERSBERGEN RL, 1994, GENE DEV, V8, P2680, DOI 10.1101/gad.8.22.2680; BOULUKOS KE, 1993, ONCOGENE, V8, P237; Castano E, 1998, MOL CELL BIOL, V18, P5380, DOI 10.1128/MCB.18.9.5380; Chen PL, 1996, GENE DEV, V10, P2794, DOI 10.1101/gad.10.21.2794; CLARKE AR, 1992, NATURE, V359, P328, DOI 10.1038/359328a0; COBRINIK D, 1993, GENE DEV, V7, P2392, DOI 10.1101/gad.7.12a.2392; Cobrinik D, 1996, GENE DEV, V10, P1633, DOI 10.1101/gad.10.13.1633; EGAN C, 1988, MOL CELL BIOL, V8, P3955, DOI 10.1128/MCB.8.9.3955; EWEN ME, 1992, SCIENCE, V255, P85, DOI 10.1126/science.1532457; EWEN ME, 1991, CELL, V66, P1155, DOI 10.1016/0092-8674(91)90038-Z; FAHA B, 1992, SCIENCE, V255, P87, DOI 10.1126/science.1532458; Garriga J, 1998, BIOCHEM J, V333, P645, DOI 10.1042/bj3330645; GIORDANO A, 1991, ONCOGENE, V6, P481; GREEN MR, 1983, CELL, V35, P137, DOI 10.1016/0092-8674(83)90216-7; GREENBERGER JS, 1983, P NATL ACAD SCI-BIOL, V80, P2931, DOI 10.1073/pnas.80.10.2931; GU W, 1993, CELL, V72, P309, DOI 10.1016/0092-8674(93)90110-C; HATAKEYAMA M, 1989, CELL, V59, P837, DOI 10.1016/0092-8674(89)90607-7; HATAKEYAMA M, 1994, GENE DEV, V8, P1759, DOI 10.1101/gad.8.15.1759; HIJMANS EM, 1995, MOL CELL BIOL, V15, P3082; Hoshikawa Y, 1998, ANAL BIOCHEM, V261, P211, DOI 10.1006/abio.1998.2742; Hoshikawa Y, 1998, P NATL ACAD SCI USA, V95, P8574, DOI 10.1073/pnas.95.15.8574; Hurford RK, 1997, GENE DEV, V11, P1447, DOI 10.1101/gad.11.11.1447; Ikeda M, 1996, P NATL ACAD SCI USA, V93, P3215, DOI 10.1073/pnas.93.8.3215; JACKS T, 1992, NATURE, V359, P295, DOI 10.1038/359295a0; JELSMA TN, 1989, VIROLOGY, V171, P120, DOI 10.1016/0042-6822(89)90518-7; KALMAN D, 1993, MOL BIOL CELL, V4, P353, DOI 10.1091/mbc.4.4.353; KAO HT, 1983, MOL CELL BIOL, V3, P2058, DOI 10.1128/MCB.3.11.2058; KATO JY, 1993, P NATL ACAD SCI USA, V90, P11513, DOI 10.1073/pnas.90.24.11513; Knudsen ES, 1996, J BIOL CHEM, V271, P8313, DOI 10.1074/jbc.271.14.8313; KOH J, 1995, NATURE, V375, P506, DOI 10.1038/375506a0; Lacy S, 1997, ONCOGENE, V14, P2395, DOI 10.1038/sj.onc.1201085; LeCouter JE, 1998, DEVELOPMENT, V125, P4669; LeCouter JE, 1998, MOL CELL BIOL, V18, P7455, DOI 10.1128/MCB.18.12.7455; LEE EYHP, 1992, NATURE, V359, P288, DOI 10.1038/359288a0; LEES E, 1992, GENE DEV, V6, P1874, DOI 10.1101/gad.6.10.1874; LILLIE JW, 1987, CELL, V50, P1091, DOI 10.1016/0092-8674(87)90175-9; LUKAS J, 1995, MOL CELL BIOL, V15, P2600; LUKAS J, 1995, NATURE, V375, P503, DOI 10.1038/375503a0; Lundberg AS, 1998, MOL CELL BIOL, V18, P753, DOI 10.1128/MCB.18.2.753; MATSUSHIME H, 1994, MOL CELL BIOL, V14, P2066, DOI 10.1128/MCB.14.3.2066; Mayol X, 1996, ONCOGENE, V13, P237; MAYOL X, 1995, ONCOGENE, V11, P801; MEDEMA RH, 1995, P NATL ACAD SCI USA, V92, P6289, DOI 10.1073/pnas.92.14.6289; MEYERSON M, 1994, MOL CELL BIOL, V14, P2077, DOI 10.1128/MCB.14.3.2077; Mizuguchi R, 1998, J BIOL CHEM, V273, P32297, DOI 10.1074/jbc.273.48.32297; Moberg K, 1996, MOL CELL BIOL, V16, P1436; MORAN E, 1986, MOL CELL BIOL, V6, P3470, DOI 10.1128/MCB.6.10.3470; MYMRYK JS, 1992, MOL BIOL CELL, V3, P1107, DOI 10.1091/mbc.3.10.1107; Nevins JR, 1997, J CELL PHYSIOL, V173, P233, DOI 10.1002/(SICI)1097-4652(199711)173:2<233::AID-JCP27>3.0.CO;2-F; RESNITZKY D, 1995, MOL CELL BIOL, V15, P3463; Rodel JE, 1996, BLOOD, V87, P858, DOI 10.1182/blood.V87.3.858.bloodjournal873858; SARDET C, 1995, P NATL ACAD SCI USA, V92, P2403, DOI 10.1073/pnas.92.6.2403; Sellers WR, 1998, GENE DEV, V12, P95, DOI 10.1101/gad.12.1.95; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; SMITH EJ, 1995, MOL CELL BIOL, V15, P338, DOI 10.1128/MCB.15.1.338; TAM SW, 1994, ONCOGENE, V9, P2663; Tevosian SG, 1997, GENE DEV, V11, P383, DOI 10.1101/gad.11.3.383; Tiainen M, 1996, MOL CELL BIOL, V16, P5302; VAIRO G, 1995, GENE DEV, V9, P869, DOI 10.1101/gad.9.7.869; VALTIERI M, 1987, J IMMUNOL, V138, P3829; VELCICH A, 1988, MOL CELL BIOL, V8, P2177, DOI 10.1128/MCB.8.5.2177; WEBSTER KA, 1988, NATURE, V332, P553, DOI 10.1038/332553a0; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; WEINTRAUB SJ, 1992, NATURE, V358, P259, DOI 10.1038/358259a0; WHYTE P, 1989, CELL, V56, P67, DOI 10.1016/0092-8674(89)90984-7; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0; Woo MSA, 1997, MOL CELL BIOL, V17, P3566, DOI 10.1128/MCB.17.7.3566; Wu CL, 1996, MOL CELL BIOL, V16, P3698; Xiao ZX, 1996, P NATL ACAD SCI USA, V93, P4633, DOI 10.1073/pnas.93.10.4633; Yee Amy S., 1998, Frontiers in Bioscience, V3, pD532; Zacksenhaus E, 1996, GENE DEV, V10, P3051, DOI 10.1101/gad.10.23.3051; Zarkowska T, 1997, J BIOL CHEM, V272, P12738, DOI 10.1074/jbc.272.19.12738; Zhang HS, 1999, CELL, V97, P53, DOI 10.1016/S0092-8674(00)80714-X; ZHU L, 1995, GENE DEV, V9, P1740, DOI 10.1101/gad.9.14.1740	77	13	13	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 4	1999	18	46					6209	6221		10.1038/sj.onc.1203044	http://dx.doi.org/10.1038/sj.onc.1203044			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	260DK	10597219				2022-12-25	WOS:000083934100004
J	Borngraber, S; Browner, M; Gillmor, S; Gerth, C; Anton, M; Fletterick, R; Kuhn, H				Borngraber, S; Browner, M; Gillmor, S; Gerth, C; Anton, M; Fletterick, R; Kuhn, H			Shape and specificity in mammalian 15-lipoxygenase active site - The functional, interplay of sequence determinants for the reaction specificity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POSITIONAL SPECIFICITY; SOYBEAN LIPOXYGENASE-1; LINOLEIC-ACID; 12-LIPOXYGENASE; STEREOCHEMISTRY; 5-LIPOXYGENASE; LEUKOTRIENES; MUTAGENESIS; MECHANISM; PRODUCTS	Previous mutagenesis studies along with molecular modeling using the x-ray coordinates of the rabbit 15-lipoxygenase have led to the suggestion that the size of the substrate binding pocket may play an essential role in determining the oxygenation specificity of 5-, 12-, and 15-lipoxygenases, Based on the x-ray crystal structure of rabbit 15-lipoxygenase, Ile(593) appeared to be important in defining size and shape of the substrate-binding site in 15-lipoxygenases, We found that substitution of Ile593 with alanine shifted the positional specificity of this enzyme toward 12-lipoxygenation, To compare the importance of position 593 with previously defined determinants for the oxygenation specificity, we introduced small (alanine-scan) or large amino acids (phenylalanine-scan) at critical positions surrounding the putative fatty acid-binding site, so that the volume of the pocket was either increased or decreased. Enlargement or alteration in packing density within the substrate binding pocket in the rabbit 15-lipoxygenase increased the share of 12-lipoxygenase products, whereas a smaller active site favored 15-lipoxygenation. Simultaneous substitution of both large and small residues in the context of either a 15- or 12-lipoxygenase indicated that there is a functional interplay of the sequence determinants for Lipoxygenation specificity. If the 15-lipoxygenase active site is enlarged excessively, however, no lipoxygenation was observed anymore. Together these results indicate the importance of the overall size and shape of the arachidonic acid binding pocket in defining the specificity of lipoxygenase reaction.	Humboldt Univ, Univ Clin Charite, Inst Biochem, D-10115 Berlin, Germany; Roche Biosci, Inflammatory Dis Unit, Palo Alto, CA 94304 USA; Univ Calif San Francisco, Dept Biochem & Biophys, San Francisco, CA 94143 USA	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Roche Holding; University of California System; University of California San Francisco	Kuhn, H (corresponding author), Humboldt Univ, Univ Clin Charite, Inst Biochem, Hess Str 3-4, D-10115 Berlin, Germany.							AHARONY D, 1986, J BIOL CHEM, V261, P1512; Borngraber S, 1996, J MOL BIOL, V264, P1145, DOI 10.1006/jmbi.1996.0702; Browner MF, 1998, NAT STRUCT BIOL, V5, P179, DOI 10.1038/nsb0398-179; CHEN XS, 1993, FASEB J, V7, P694, DOI 10.1096/fasebj.7.8.8500694; DEGROOT JJM, 1975, BIOCHIM BIOPHYS ACTA, V377, P71, DOI 10.1016/0005-2744(75)90287-9; DRAHEIM JE, 1989, ARCH BIOCHEM BIOPHYS, V269, P208, DOI 10.1016/0003-9861(89)90102-1; EGMOND MR, 1973, BIOCHEM BIOPH RES CO, V54, P1178, DOI 10.1016/0006-291X(73)90816-4; Funk CD, 1997, NAT STRUCT BIOL, V4, P966, DOI 10.1038/nsb1297-966; Gan QF, 1996, J BIOL CHEM, V271, P25412, DOI 10.1074/jbc.271.41.25412; GARDNER HW, 1989, BIOCHIM BIOPHYS ACTA, V1001, P274, DOI 10.1016/0005-2760(89)90111-2; Gillmor SA, 1997, NAT STRUCT BIOL, V4, P1003, DOI 10.1038/nsb1297-1003; HAY DWP, 1995, TRENDS PHARMACOL SCI, V16, P304, DOI 10.1016/S0165-6147(00)89059-8; Hornung E, 1999, P NATL ACAD SCI USA, V96, P4192, DOI 10.1073/pnas.96.7.4192; Kuhn H, 1997, CURR OPIN LIPIDOL, V8, P111; KUHN H, 1993, BIOCHIM BIOPHYS ACTA, V1168, P73, DOI 10.1016/0005-2760(93)90268-E; KUHN H, 1986, ADV ENZYMOL RAMB, V58, P273; KUHN H, 1990, J BIOL CHEM, V265, P16300; LEHMANN WD, 1994, FREE RADICAL BIO MED, V16, P241, DOI 10.1016/0891-5849(94)90149-X; LEWIS RA, 1990, NEW ENGL J MED, V323, P645; LUDWIG P, 1987, EUR J BIOCHEM, V168, P325, DOI 10.1111/j.1432-1033.1987.tb13424.x; Prigge ST, 1998, NAT STRUCT BIOL, V5, P178, DOI 10.1038/nsb0398-178; Prigge ST, 1996, PROTEINS, V24, P275; RAPOPORT SM, 1990, BLOOD CELL BIOCH, V1, P151; Sendobry SM, 1997, BRIT J PHARMACOL, V120, P1199, DOI 10.1038/sj.bjp.0701007; SIEDOW JN, 1991, ANNU REV PLANT PHYS, V42, P145, DOI 10.1146/annurev.pp.42.060191.001045; SLOANE DL, 1991, NATURE, V354, P149, DOI 10.1038/354149a0; SLOANE DL, 1995, PROTEIN ENG, V8, P275, DOI 10.1093/protein/8.3.275; SUZUKI H, 1994, BBA-LIPID LIPID MET, V1210, P308, DOI 10.1016/0005-2760(94)90234-8; van Leyen K, 1998, NATURE, V395, P392, DOI 10.1038/26500; WATANABE T, 1993, BIOCHEM BIOPH RES CO, V192, P1023, DOI 10.1006/bbrc.1993.1519; WIESNER R, 1983, BIOMED BIOCHIM ACTA, V5, P431; YAMAMOTO S, 1989, PROSTAG LEUKOTR ESS, V35, P219, DOI 10.1016/0952-3278(89)90005-7; YAMAMOTO S, 1992, BIOCHIM BIOPHYS ACTA, V1128, P117, DOI 10.1016/0005-2760(92)90297-9	33	110	112	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 24	1999	274	52					37345	37350		10.1074/jbc.274.52.37345	http://dx.doi.org/10.1074/jbc.274.52.37345			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	267WR	10601303	hybrid			2022-12-25	WOS:000084382700074
J	Foger, B; Chase, M; Amar, MJ; Vaisman, BL; Shamburek, RD; Paigen, B; Furchart-Najib, J; Paiz, JA; Koch, CA; Hoyt, RF; Brewer, HB; Santamarina-Fojo, S				Foger, B; Chase, M; Amar, MJ; Vaisman, BL; Shamburek, RD; Paigen, B; Furchart-Najib, J; Paiz, JA; Koch, CA; Hoyt, RF; Brewer, HB; Santamarina-Fojo, S			Cholesteryl ester transfer protein corrects dysfunctional high density lipoproteins and reduces aortic atherosclerosis in lecithin cholesterol acyltransferase transgenic mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							APOLIPOPROTEIN-A-I; DIET-INDUCED ATHEROSCLEROSIS; HUMAN ADENOVIRUS TYPE-5; OXIDATIVE MODIFICATION; EARLY ATHEROGENESIS; HEPATIC LIPASE; HEART-DISEASE; HUMAN-PLASMA; EXPRESSION; GENE	Expression of human lecithin cholesterol acyltransferase (LCAT) in mice (LCAT-Tg) leads to increased high density lipoprotein (HDL) cholesterol levels but paradoxically, enhanced atherosclerosis, We have hypothesized that the absence of cholesteryl ester transfer protein (CETP) in LCAT-Tg mice facilitates the accumulation of dysfunctional HDL leading to impaired reverse cholesterol transport and the development of a pro-atherogenic state. To test this hypothesis we crossbred LCAT-Tg with CETP-Tg mice. On both regular chow and high fat, high cholesterol diets, expression of CETP in LCAT-Tg mice reduced total cholesterol (-39% and -13%, respectively; p < 0.05), reflecting a decrease in HDL cholesterol levels. CETP normalized both the plasma clearance of [H-3]cholesteryl esters ([H-3]CE) from HDL (fractional catabolic rate in days(-1): LCAT-Tg = 3.7 +/- 0.34, LCATxCETP-Tg = 6.1 +/- 0.16, and controls = 6.4 +/- 0.16) as well as the liver uptake of [H-3]CE from HDL (LCAT-Tg = 36%, LCATxCETP-Tg = 65%, and controls = 63%) in LCAT Tg mice. On the pro-atherogenic diet the mean aortic lesion area was reduced by 41% in LCATx- CETP-Tg (21.2 +/- 2.0 mu m(2) x 10(3)) compared with LCAT-Tg mice (35.7 +/- 2.0 mu m(2) x 10(3); p < 0.001), Adenovirus-mediated expression of scavenger receptor class B (SR-BI) failed to normalize the plasma clearance and liver up take of [H-3]CE from LCAT-Tg HDL, Thus, the ability of SR-BI to facilitate the selective uptake of CE from LCAT-Tg HDL is impaired, indicating a potential mechanism leading to impaired reverse cholesterol transport and atherosclerosis in these animals. We conclude that CETP expression reduces atherosclerosis in LCAT-Tg mice by restoring the functional properties of LCAT-Tg mouse HDL and promoting the hepatic uptake of HDL CE. These findings provide definitive in vivo evidence supporting the proposed anti-atherogenic role of CETP in facilitating HDL-mediated reverse cholesterol transport and demonstrate that CETP expression is beneficial in pro-atherogenic states that result from impaired reverse cholesterol transport.	NHLBI, Mol Dis Branch, NIH, Bethesda, MD 20892 USA; NHLBI, Lab Anim Med Surg, NIH, Bethesda, MD 20892 USA; Jackson Lab, Bar Harbor, ME 04609 USA; Inst Pasteur, Fac Pharm, INSERM, U325, F-59019 Lille, France	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); Jackson Laboratory; Institut National de la Sante et de la Recherche Medicale (Inserm); Le Reseau International des Instituts Pasteur (RIIP); Universite de Lille - ISITE; Institut Pasteur Lille; Universite de Lille	Santamarina-Fojo, S (corresponding author), NHLBI, Mol Dis Branch, NIH, Bldg 10,Rm 7N115,10 Ctr Dr,MSC 1666, Bethesda, MD 20892 USA.		Vaisman, Boris L/B-3453-2008; Amar, Marcelo/AAD-5599-2019		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL030086, R01HL032087] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 32087, HL 30086] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Acton S, 1996, SCIENCE, V271, P518, DOI 10.1126/science.271.5248.518; AGELLON LB, 1991, J BIOL CHEM, V266, P10796; Albanese N, 1998, CIRCULATION, V98, P450; ALBERS JJ, 1984, ARTERIOSCLEROSIS, V4, P49, DOI 10.1161/01.ATV.4.1.49; Amar MJA, 1998, CIRCULATION, V98, P35; BADIMON JJ, 1990, J CLIN INVEST, V85, P1234, DOI 10.1172/JCI114558; BARTLETT GR, 1959, J BIOL CHEM, V234, P466; Berard AM, 1997, NAT MED, V3, P744, DOI 10.1038/nm0797-744; CALVO D, 1993, J BIOL CHEM, V268, P18929; CHEN CH, 1982, J LIPID RES, V23, P680; COCKERILL GW, 1995, ARTERIOSCL THROM VAS, V15, P1987, DOI 10.1161/01.ATV.15.11.1987; Dugi KA, 1997, J LIPID RES, V38, P1822; Duverger N, 1996, CIRCULATION, V94, P713, DOI 10.1161/01.CIR.94.4.713; FIELDING CJ, 1995, J LIPID RES, V36, P211; Francone OL, 1997, J LIPID RES, V38, P813; FRANCONE OL, 1995, J CLIN INVEST, V96, P1440, DOI 10.1172/JCI118180; GLOMSET JA, 1968, J LIPID RES, V9, P155; GORDON DJ, 1989, NEW ENGL J MED, V321, P1311; GORDON DJ, 1989, CIRCULATION, V79, P8, DOI 10.1161/01.CIR.79.1.8; HARRISON T, 1977, VIROLOGY, V77, P319, DOI 10.1016/0042-6822(77)90428-7; HAYEK T, 1993, J CLIN INVEST, V92, P1143, DOI 10.1172/JCI116683; HAYEK T, 1995, J CLIN INVEST, V96, P2071, DOI 10.1172/JCI118255; HAYEK T, 1992, J CLIN INVEST, V90, P505, DOI 10.1172/JCI115887; HIRANO K, 1995, ARTERIOSCL THROM VAS, V15, P1849, DOI 10.1161/01.ATV.15.11.1849; Hirano K, 1997, ARTERIOSCL THROM VAS, V17, P1053, DOI 10.1161/01.ATV.17.6.1053; Hoeg JM, 1996, J BIOL CHEM, V271, P4396; Hoeg JM, 1996, P NATL ACAD SCI USA, V93, P11448, DOI 10.1073/pnas.93.21.11448; IKEWAKI K, 1993, J CLIN INVEST, V92, P1650, DOI 10.1172/JCI116750; INAZU A, 1990, NEW ENGL J MED, V323, P1234, DOI 10.1056/NEJM199011013231803; ISHIGAMI M, 1994, J BIOCHEM-TOKYO, V116, P257, DOI 10.1093/oxfordjournals.jbchem.a124516; KASHYAP VS, 1995, J CLIN INVEST, V96, P1612, DOI 10.1172/JCI118200; KHOO JC, 1990, J LIPID RES, V31, P645; KUNITAKE ST, 1992, J LIPID RES, V33, P1807; MACKNESS MI, 1993, ATHEROSCLEROSIS, V104, P129, DOI 10.1016/0021-9150(93)90183-U; MAROTTI KR, 1993, NATURE, V364, P73, DOI 10.1038/364073a0; MasucciMagoulas L, 1997, SCIENCE, V275, P391, DOI 10.1126/science.275.5298.391; MCGRORY WJ, 1988, VIROLOGY, V163, P614, DOI 10.1016/0042-6822(88)90302-9; MCKINNON RD, 1982, GENE, V19, P33, DOI 10.1016/0378-1119(82)90186-X; Mehlum A, 1997, APMIS, V105, P861, DOI 10.1111/j.1699-0463.1997.tb05095.x; MEHLUM A, 1995, EUR J BIOCHEM, V230, P567; MILLER NE, 1987, AM HEART J, V113, P589, DOI 10.1016/0002-8703(87)90638-7; MILLER NE, 1985, NATURE, V314, P109, DOI 10.1038/314109a0; MORTON RE, 1981, J BIOL CHEM, V256, P1992; MORTON RE, 1983, J BIOL CHEM, V258, P1751; Murao K, 1997, J BIOL CHEM, V272, P17551, DOI 10.1074/jbc.272.28.17551; NAVAB M, 1991, J CLIN INVEST, V88, P2039, DOI 10.1172/JCI115532; NEWNHAM HH, 1990, BIOCHIM BIOPHYS ACTA, V1044, P57, DOI 10.1016/0005-2760(90)90218-M; PAIGEN B, 1987, ATHEROSCLEROSIS, V68, P231, DOI 10.1016/0021-9150(87)90202-4; PAPE ME, 1991, BIOCHIM BIOPHYS ACTA, V1086, P326, DOI 10.1016/0005-2760(91)90177-J; PARTHASARATHY S, 1990, BIOCHIM BIOPHYS ACTA, V1044, P275, DOI 10.1016/0005-2760(90)90314-N; Plump AS, 1999, ARTERIOSCL THROM VAS, V19, P1105, DOI 10.1161/01.ATV.19.4.1105; PLUMP AS, 1994, P NATL ACAD SCI USA, V91, P9607, DOI 10.1073/pnas.91.20.9607; ROTHBLAT GH, 1992, J LIPID RES, V33, P1091; RUBIN EM, 1991, NATURE, V353, P265, DOI 10.1038/353265a0; Sacks FM, 1998, CIRCULATION, V98, P791; SAITO F, 1984, METABOLISM, V33, P629, DOI 10.1016/0026-0495(84)90061-1; SAKAI N, 1995, CIRCULATION S, V92, P495; SAKU K, 1985, THROMB RES, V39, P1, DOI 10.1016/0049-3848(85)90116-1; SHAMBUREK RD, 1993, CIRCULATION, V88, P75; Sugano M, 1998, J BIOL CHEM, V273, P5033, DOI 10.1074/jbc.273.9.5033; Sullivan PM, 1997, J BIOL CHEM, V272, P17972, DOI 10.1074/jbc.272.29.17972; TALL AR, 1993, J LIPID RES, V34, P1255; Tollefson J H, 1986, Methods Enzymol, V129, P797; VAISMAN BL, 1995, J BIOL CHEM, V270, P12269, DOI 10.1074/jbc.270.20.12269; WILLIAMS KJ, 1995, ARTERIOSCL THROM VAS, V15, P551, DOI 10.1161/01.ATV.15.5.551; YAMASHITA S, 1990, J CLIN INVEST, V86, P688, DOI 10.1172/JCI114764; Zhong SB, 1996, J CLIN INVEST, V97, P2917, DOI 10.1172/JCI118751; [No title captured]	69	181	189	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 24	1999	274	52					36912	36920		10.1074/jbc.274.52.36912	http://dx.doi.org/10.1074/jbc.274.52.36912			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	267WR	10601244	hybrid			2022-12-25	WOS:000084382700015
J	Halappanavar, SS; Le Rhun, Y; Mounir, S; Martins, LM; Huot, J; Earnshaw, WC; Shah, GM				Halappanavar, SS; Le Rhun, Y; Mounir, S; Martins, LM; Huot, J; Earnshaw, WC; Shah, GM			Survival and proliferation of cells expressing caspase-uncleavable poly(ADP-ribose) polymerase in response to death-inducing DNA damage by an alkylating agent	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ICE/CED-3 PROTEASE; INDUCED APOPTOSIS; NUCLEAR PROTEINS; ADP-RIBOSYLATION; C3H10T1/2 CELLS; ICE-LIKE; CLEAVAGE; ACTIVATION; INHIBITORS; METABOLISM	To determine whether caspase-3-induced cleavage of poly(ADP-ribose) polymerase (PARP), a DNA damage-sensitive enzyme, alters the balance between survival and death of the cells following DNA damage, we created stable cell lines that express either caspase-uncleavable mutant or wild type PARP in the background of PARP (-/-) fibroblasts. The survival and apoptotic responses of these cells were compared after exposure to N-methyl-N'-nitro-N-nitrosoguanidine (MNNG), a DNA-damaging agent that activates PARP, or to tumor necrosis factor-alpha, which causes apoptosis without initial DNA damage. In response to MNNG, the cells with caspase-uncleavable PARP were very resistant to loss of viability or induction of apoptosis. Most significantly, similar to 25% of these cells survived and retained clonogenicity at a level of DNA damage that eliminated the cells with wild type PARP or PARP (-/-) cells. Expression of caspase-uncleavable PARP could not protect the cells from death induced by tumor necrosis factor, although there was a slower progression of apoptotic events in these cells. Therefore, one of the functions for cleavage of PARP during apoptosis induced by alkylating agents is to prevent survival of the extensively damaged cells.	Univ Laval, Fac Med, Ctr Hosp Univ Quebec, Med Res Ctr,Lab Skin Canc Res, Quebec City, PQ G1V 4G2, Canada; Univ Edinburgh, Inst Cell & Mol Biol, Edinburgh EH9 3JR, Midlothian, Scotland; Univ Laval, Hotel Dieu, Ctr Rech Cancerol, Quebec City, PQ G1K 7P4, Canada	Laval University; University of Edinburgh; Laval University	Shah, GM (corresponding author), Univ Laval, Med Res Ctr, CHUL, Lab Skin Canc Res, RC-9700,2705 Laurier Blvd, Quebec City, PQ G1V 4G2, Canada.	girish.shah@crchul.ulaval.ca	Earnshaw, William/AAY-7438-2020; Shah, Girish M/A-5153-2008	Shah, Girish/0000-0002-9291-1164; Earnshaw, William/0000-0002-7191-0621	Wellcome Trust [073915] Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Alnemri ES, 1996, CELL, V87, P171, DOI 10.1016/S0092-8674(00)81334-3; Ame JC, 1999, J BIOL CHEM, V274, P17860, DOI 10.1074/jbc.274.25.17860; Babiychuk E, 1998, PLANT J, V15, P635, DOI 10.1046/j.1365-313x.1998.00240.x; BANASIK M, 1992, J BIOL CHEM, V267, P1569; BERGER NA, 1985, RADIAT RES, V101, P4, DOI 10.2307/3576299; Berghammer H, 1999, FEBS LETT, V449, P259, DOI 10.1016/S0014-5793(99)00448-2; Boise LH, 1997, P NATL ACAD SCI USA, V94, P3759, DOI 10.1073/pnas.94.8.3759; Boulares AH, 1999, J BIOL CHEM, V274, P22932, DOI 10.1074/jbc.274.33.22932; Burkart V, 1999, NAT MED, V5, P314, DOI 10.1038/6535; Cardone MH, 1997, CELL, V90, P315, DOI 10.1016/S0092-8674(00)80339-6; Casiano CA, 1998, CELL DEATH DIFFER, V5, P183, DOI 10.1038/sj.cdd.4400336; Charron MJ, 1999, NAT MED, V5, P269, DOI 10.1038/6479; Cheng EHY, 1997, SCIENCE, V278, P1966, DOI 10.1126/science.278.5345.1966; Dantzer F, 1999, BIOCHIMIE, V81, P69, DOI 10.1016/S0300-9084(99)80040-6; DEMURCIA G, 1994, TRENDS BIOCHEM SCI, V19, P172, DOI 10.1016/0968-0004(94)90280-1; deMurcia JM, 1997, P NATL ACAD SCI USA, V94, P7303, DOI 10.1073/pnas.94.14.7303; Duriez PJ, 1997, BIOCHEM CELL BIOL, V75, P337, DOI 10.1139/bcb-75-4-337; Eliasson MJL, 1997, NAT MED, V3, P1089, DOI 10.1038/nm1097-1089; Enari M, 1996, NATURE, V380, P723, DOI 10.1038/380723a0; Fagagna F., 1999, NAT GENET, V23, P76; FERNANDESALNEMRI T, 1994, J BIOL CHEM, V269, P30761; Froelich CJ, 1996, J BIOL CHEM, V271, P29073, DOI 10.1074/jbc.271.46.29073; Herceg Z, 1999, MOL CELL BIOL, V19, P5124; Huot J, 1998, J CELL BIOL, V143, P1361, DOI 10.1083/jcb.143.5.1361; JACOBSON EL, 1985, CARCINOGENESIS, V6, P715, DOI 10.1093/carcin/6.5.715; Jeggo PA, 1998, CURR BIOL, V8, pR49, DOI 10.1016/S0960-9822(98)70032-6; Johansson M, 1999, GENOMICS, V57, P442, DOI 10.1006/geno.1999.5799; KAUFMANN SH, 1993, CANCER RES, V53, P3976; KAWAMITSU H, 1984, BIOCHEMISTRY-US, V23, P3771, DOI 10.1021/bi00311a032; LAUTIER D, 1993, MOL CELL BIOCHEM, V122, P171, DOI 10.1007/BF01076101; LAZEBNIK YA, 1994, NATURE, V371, P346, DOI 10.1038/371346a0; Le Rhun Y, 1998, BIOCHEM BIOPH RES CO, V245, P1; Levkau B, 1998, MOL CELL, V1, P553, DOI 10.1016/S1097-2765(00)80055-6; LINDAHL T, 1995, TRENDS BIOCHEM SCI, V20, P405, DOI 10.1016/S0968-0004(00)89089-1; Masutani M, 1999, P NATL ACAD SCI USA, V96, P2301, DOI 10.1073/pnas.96.5.2301; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; Oei S L, 1997, Rev Physiol Biochem Pharmacol, V131, P127; Oliver FJ, 1999, AM J HUM GENET, V64, P1282, DOI 10.1086/302389; Oliver FJ, 1998, J BIOL CHEM, V273, P33533, DOI 10.1074/jbc.273.50.33533; Pieper AA, 1999, P NATL ACAD SCI USA, V96, P3059, DOI 10.1073/pnas.96.6.3059; Ramsamooj P, 1996, INT J ONCOL, V8, P803; Rao L, 1996, J CELL BIOL, V135, P1441, DOI 10.1083/jcb.135.6.1441; Rosen A, 1997, J CELL BIOCHEM, V64, P50, DOI 10.1002/(SICI)1097-4644(199701)64:1<50::AID-JCB8>3.0.CO;2-Z; Rudel T, 1997, SCIENCE, V276, P1571, DOI 10.1126/science.276.5318.1571; Ruscetti T, 1998, J BIOL CHEM, V273, P14461, DOI 10.1074/jbc.273.23.14461; Scovassi AI, 1998, EUR J HISTOCHEM, V42, P251; Shah GM, 1996, BBA-MOL CELL RES, V1312, P1, DOI 10.1016/0167-4889(96)00004-3; Shah GM, 1995, ANAL BIOCHEM, V232, P251, DOI 10.1006/abio.1995.0016; SHAH GM, 1995, ANAL BIOCHEM, V227, P1, DOI 10.1006/abio.1995.1245; Shah GM, 1996, BIOCHEM BIOPH RES CO, V229, P838, DOI 10.1006/bbrc.1996.1889; Shieh WM, 1998, J BIOL CHEM, V273, P30069, DOI 10.1074/jbc.273.46.30069; Simbulan-Rosenthal CM, 1998, J BIOL CHEM, V273, P13703, DOI 10.1074/jbc.273.22.13703; SIMONIN F, 1990, J BIOL CHEM, V265, P19249; Smith S, 1998, SCIENCE, V282, P1484, DOI 10.1126/science.282.5393.1484; Smulson ME, 1998, CANCER RES, V58, P3495; Tan XQ, 1998, TRENDS CELL BIOL, V8, P116, DOI 10.1016/S0962-8924(97)01208-7; TERUI Y, 1995, J CELL PHYSIOL, V164, P74, DOI 10.1002/jcp.1041640110; TEWARI M, 1995, CELL, V81, P801, DOI 10.1016/0092-8674(95)90541-3; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Trucco C, 1998, NUCLEIC ACIDS RES, V26, P2644, DOI 10.1093/nar/26.11.2644; Wang ZQ, 1997, GENE DEV, V11, P2347, DOI 10.1101/gad.11.18.2347; WANG ZQ, 1995, GENE DEV, V9, P509, DOI 10.1101/gad.9.5.509; Wohrl W, 1999, BIOCHEM BIOPH RES CO, V254, P552, DOI 10.1006/bbrc.1998.9982	63	45	48	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 24	1999	274	52					37097	37104		10.1074/jbc.274.52.37097	http://dx.doi.org/10.1074/jbc.274.52.37097			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	267WR	10601269	hybrid			2022-12-25	WOS:000084382700040
J	Krauss, K; Altevogt, P				Krauss, K; Altevogt, P			Integrin leukocyte function-associated antigen-1-mediated cell binding can be activated by clustering of membrane rafts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GPI-ANCHORED PROTEINS; CROSS-LINKING; PHOSPHATIDYLINOSITOL 3-KINASE; CONFORMATIONAL CHANGE; SIGNAL-TRANSDUCTION; ADHESION; SURFACE; DOMAINS; LIGAND; CHOLESTEROL	The leukocyte function-associated antigen-1 (LFA-1) integrin (CD11a/CD18) is an important adhesion molecule for lymphocyte migration and the initiation of an immune response, At the cell surface, LFA-1 activity can be regulated by divalent cations that enhance receptor affinity but also by membrane clustering induced by treatment of cells with substances such as phorbol esters. Membrane clustering leads to increased LFA-1 avidity. We report here that LFA-1-mediated binding of mouse thymocytes or activated T lymphocytes to intercellular adhesion molecule 1 can be rapidly induced by clustering of membrane rafts using antibodies to the glycosylphophatidylinositol-anchored molecule CD24 or cholera toxin (CTx). CD24 and CD18 were found to colocalize in rafts and cross-linking with CTx lead to enhanced LFA-1 clustering. We observed that disruption of raft, integrity by lowering the membrane cholesterol content abolished the CTx and the phorbol la-myristate 13-acetate-induced LFA-1 binding but left the ability to activate LFA-1 with Mg2+/EGTA unimpaired. In contrast to activation with Mg2+/EGTA, activation via raft clustering was dependent on PI3-kinase, required cytoskeletal mobility, and was accompanied by Tyr phosphorylation of a 18-kDa protein. Our results support the notion that rafts as preformed adhesion platforms could be important for the rapid regulation of lymphocyte adhesion.	German Canc Res Ctr, Tumor Immunol Programme, D-69120 Heidelberg, Germany	Helmholtz Association; German Cancer Research Center (DKFZ)	Altevogt, P (corresponding author), German Canc Res Ctr, Tumor Immunol Programme, G0100,Neuenheimer Feld 280, D-69120 Heidelberg, Germany.							ALTEVOGT P, 1994, EUR J IMMUNOL, V24, P731, DOI 10.1002/eji.1830240336; ALTEVOGT P, 1995, J EXP MED, V182, P345, DOI 10.1084/jem.182.2.345; BARRETT TB, 1991, J IMMUNOL, V146, P1722; Bazzoni G, 1998, TRENDS BIOCHEM SCI, V23, P30, DOI 10.1016/S0968-0004(97)01141-9; BEEKHUIZEN H, 1993, J IMMUNOL, V150, P950; BROWN DA, 1992, CELL, V68, P533, DOI 10.1016/0092-8674(92)90189-J; BUBB MR, 1994, J BIOL CHEM, V269, P14869; CINEK T, 1992, J IMMUNOL, V149, P2262; DIAMOND MS, 1994, CURR BIOL, V4, P506, DOI 10.1016/S0960-9822(00)00111-1; Duronio V, 1998, CELL SIGNAL, V10, P233, DOI 10.1016/S0898-6568(97)00129-0; DUSTIN ML, 1989, NATURE, V341, P619, DOI 10.1038/341619a0; Friedrichson T, 1998, NATURE, V394, P802, DOI 10.1038/29570; Gahmberg CG, 1997, CURR OPIN CELL BIOL, V9, P643, DOI 10.1016/S0955-0674(97)80117-2; Harder T, 1999, EUR J IMMUNOL, V29, P556, DOI 10.1002/(SICI)1521-4141(199902)29:02<556::AID-IMMU556>3.0.CO;2-2; Harder T, 1997, CURR OPIN CELL BIOL, V9, P534, DOI 10.1016/S0955-0674(97)80030-0; Hato T, 1998, J CELL BIOL, V141, P1685, DOI 10.1083/jcb.141.7.1685; Hmama Z, 1999, J BIOL CHEM, V274, P1050, DOI 10.1074/jbc.274.2.1050; HooshmandRad R, 1997, EXP CELL RES, V234, P434, DOI 10.1006/excr.1997.3636; Hope HR, 1996, MOL BIOL CELL, V7, P843, DOI 10.1091/mbc.7.6.843; Jacobson K, 1999, TRENDS CELL BIOL, V9, P87, DOI 10.1016/S0962-8924(98)01495-0; Jones SM, 1997, J CELL BIOL, V139, P339, DOI 10.1083/jcb.139.2.339; Keller P, 1998, J CELL BIOL, V140, P1357, DOI 10.1083/jcb.140.6.1357; Kolanus W, 1997, CURR OPIN CELL BIOL, V9, P725, DOI 10.1016/S0955-0674(97)80127-5; Kolanus W, 1996, CELL, V86, P233, DOI 10.1016/S0092-8674(00)80095-1; LISANTI MP, 1994, J CELL BIOL, V126, P111, DOI 10.1083/jcb.126.1.111; McDowall A, 1998, J BIOL CHEM, V273, P27396, DOI 10.1074/jbc.273.42.27396; Montixi C, 1998, EMBO J, V17, P5334, DOI 10.1093/emboj/17.18.5334; Moran M, 1998, IMMUNITY, V9, P787, DOI 10.1016/S1074-7613(00)80644-5; Nagel W, 1998, J BIOL CHEM, V273, P14853, DOI 10.1074/jbc.273.24.14853; Penninger JM, 1999, CELL, V96, P9, DOI 10.1016/S0092-8674(00)80954-X; ROBINSON PJ, 1991, IMMUNOL TODAY, V12, P35, DOI 10.1016/0167-5699(91)90110-F; Ruppert M, 1995, J CELL BIOL, V131, P1881, DOI 10.1083/jcb.131.6.1881; Sammar M, 1997, BIOCHEM BIOPH RES CO, V234, P330, DOI 10.1006/bbrc.1997.6639; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; Stewart M, 1996, J CELL BIOCHEM, V61, P554, DOI 10.1002/(SICI)1097-4644(19960616)61:4<554::AID-JCB8>3.0.CO;2-N; Stewart MP, 1998, J CELL BIOL, V140, P699, DOI 10.1083/jcb.140.3.699; Stulnig TM, 1997, J BIOL CHEM, V272, P19242, DOI 10.1074/jbc.272.31.19242; VANKOOYK Y, 1994, J CELL BIOL, V124, P1061, DOI 10.1083/jcb.124.6.1061; Varma R, 1998, NATURE, V394, P798, DOI 10.1038/29563; Viola A, 1999, SCIENCE, V283, P680, DOI 10.1126/science.283.5402.680; WALTER P, 1983, METHOD ENZYMOL, V96, P84; WENGER RH, 1991, EUR J IMMUNOL, V21, P1039, DOI 10.1002/eji.1830210427; Xavier R, 1998, IMMUNITY, V8, P723, DOI 10.1016/S1074-7613(00)80577-4; Yauch RL, 1997, J EXP MED, V186, P1347, DOI 10.1084/jem.186.8.1347; Zauli G, 1997, BLOOD, V89, P883, DOI 10.1182/blood.V89.3.883; Zhang WG, 1998, IMMUNITY, V9, P239, DOI 10.1016/S1074-7613(00)80606-8	46	153	153	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 24	1999	274	52					36921	36927		10.1074/jbc.274.52.36921	http://dx.doi.org/10.1074/jbc.274.52.36921			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	267WR	10601245	hybrid			2022-12-25	WOS:000084382700016
J	Lazo, ND; Downing, DT				Lazo, ND; Downing, DT			A mixture of alpha-helical and 3(10)-helical conformations for involucrin in the human epidermal corneocyte envelope provides a scaffold for the attachment of both lipids and proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CORNIFIED CELL-ENVELOPE; INTERMEDIATE FILAMENTS; CIRCULAR-DICHROISM; GENE-EXPRESSION; STRATUM-CORNEUM; TRIFLUOROETHANOL; KERATINOCYTES; PEPTIDES; WATER; POLYPEPTIDES	Involucrin plays an important role in the lipid and protein compound envelopes of mammalian epidermal corneocytes. In the present study, model peptides containing the consensus repeating units PEQQEGQLEL and LEQQEGQLEH, found in the central region of human involucrin, were studied by circular dichroism spectroscopy, molecular modeling, and energy minimization, These peptides have intrinsic alpha-helix-forming properties as indicated by their circular dichroic spectra obtained in the presence of 2,2,2-trifluoroethanol. Peptide (LEQQEGQLEH)(3) had an alpha-helix content of 100% in 100% 2,2,2-trifluoroethanol at 0 degrees C, The energy-minimized alpha-helix showed that only 50% of the glutamate side chains may be available for the attachment of lipids. However, when a 3(10)-helix was assumed for the GQL or GQLE residues in LEQQEGQLEH, all of the glutamate side chains were arrayed on one face of the helix, and all of the glutamine side chains were arrayed on the opposite face. A similar result was obtained when the nonhelical part of PEQQEGQLEL was assumed to contain a beta-turn III, which is equivalent to a short portion of 3(10)-helix, The results of this study suggest that when the central segment of human involucrin is predominantly alpha-helical, accompanied by short 3(10)-helical segments, the protein can function as a scaffold for the attachment of both lipids and proteins.	Univ Iowa, Dept Dermatol, Iowa City, IA 52242 USA	University of Iowa	Lazo, ND (corresponding author), Univ Iowa, Dept Dermatol, Iowa City, IA 52242 USA.		Lazo, Noel/U-8393-2019	Lazo, Noel/0000-0003-1769-7572	NIAMS NIH HHS [AR 32374] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR032374] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		BARLOW DJ, 1988, J MOL BIOL, V201, P601, DOI 10.1016/0022-2836(88)90641-9; BLABER M, 1993, SCIENCE, V260, P1637, DOI 10.1126/science.8503008; CammersGoodwin A, 1996, J AM CHEM SOC, V118, P3082, DOI 10.1021/ja952900z; Creighton T. E., 1993, PROTEINS STRUCTURES; DOWNING DT, 1992, J LIPID RES, V33, P301; DOWNING DT, 1995, PROTEINS, V23, P204, DOI 10.1002/prot.340230210; ECKERT RL, 1993, J INVEST DERMATOL, V100, P613, DOI 10.1111/1523-1747.ep12472288; GERSTEIN M, 1991, J MOL BIOL, V220, P133, DOI 10.1016/0022-2836(91)90387-L; GRECO MA, 1995, J INVEST DERMATOL, V104, P204, DOI 10.1111/1523-1747.ep12612759; GREENBERG CS, 1991, FASEB J, V5, P3071, DOI 10.1096/fasebj.5.15.1683845; HOHL D, 1991, J BIOL CHEM, V266, P6626; HOLZWARTH G, 1965, J AM CHEM SOC, V87, P218, DOI 10.1021/ja01080a015; KARTASOVA T, 1988, MOL CELL BIOL, V8, P2195, DOI 10.1128/MCB.8.5.2195; KARTASOVA T, 1987, NUCLEIC ACIDS RES, V15, P5945, DOI 10.1093/nar/15.15.5945; Kentsis A, 1998, BIOCHEMISTRY-US, V37, P14613, DOI 10.1021/bi981641y; LAZO ND, 1995, J INVEST DERMATOL, V105, P296, DOI 10.1111/1523-1747.ep12318985; Lazo ND, 1997, BIOCHEMISTRY-US, V36, P2559, DOI 10.1021/bi963061b; LEE SC, 1993, J BIOL CHEM, V268, P12164; Luo PZ, 1997, BIOCHEMISTRY-US, V36, P8413, DOI 10.1021/bi9707133; MAHREL T, 1990, CELL, V61, P1103; Marekov LN, 1998, J BIOL CHEM, V273, P17763, DOI 10.1074/jbc.273.28.17763; MCPHALEN CA, 1992, J MOL BIOL, V227, P197, DOI 10.1016/0022-2836(92)90691-C; MILLHAUSER GL, 1995, BIOCHEMISTRY-US, V34, P3873, DOI 10.1021/bi00012a001; NONOMURA K, 1994, J INVEST DERMATOL, V103, P88, DOI 10.1111/1523-1747.ep12391802; PIELA L, 1987, BIOPOLYMERS, V26, P1587, DOI 10.1002/bip.360260910; RICE RH, 1977, CELL, V11, P417, DOI 10.1016/0092-8674(77)90059-9; Robinson NA, 1996, J INVEST DERMATOL, V107, P101, DOI 10.1111/1523-1747.ep12298323; SCHOLTZ JM, 1991, BIOPOLYMERS, V31, P1463, DOI 10.1002/bip.360311304; SMYTHE ML, 1993, J AM CHEM SOC, V115, P11594, DOI 10.1021/ja00077a067; SOMAN KV, 1991, BIOPOLYMERS, V31, P1351, DOI 10.1002/bip.360311202; SONNICHSEN FD, 1992, BIOCHEMISTRY-US, V31, P8790, DOI 10.1021/bi00152a015; Steinert P M, 1995, Cell Death Differ, V2, P33; STEINERT PM, 1995, J BIOL CHEM, V270, P17702, DOI 10.1074/jbc.270.30.17702; Steinert PM, 1997, J BIOL CHEM, V272, P2021, DOI 10.1074/jbc.272.3.2021; STEVEN AC, 1994, J CELL SCI, V107, P693; SUDHA TS, 1983, INT J PEPT PROT RES, V22, P464; SWARTZENDRUBER DC, 1987, J INVEST DERMATOL, V88, P709, DOI 10.1111/1523-1747.ep12470383; TAKAHASHI M, 1992, FEBS LETT, V308, P79, DOI 10.1016/0014-5793(92)81055-Q; TONIOLO C, 1991, TRENDS BIOCHEM SCI, V16, P350; TSENG H, 1990, MOL BIOL EVOL, V7, P293; WERTZ PW, 1989, J INVEST DERMATOL, V92, P109, DOI 10.1111/1523-1747.ep13071317; WERTZ PW, 1987, BIOCHIM BIOPHYS ACTA, V917, P108, DOI 10.1016/0005-2760(87)90290-6; WHITE SH, 1988, BIOCHEMISTRY-US, V27, P3725, DOI 10.1021/bi00410a031; YAFFE MB, 1992, J BIOL CHEM, V267, P12233; YONEDA K, 1992, J BIOL CHEM, V267, P18060	45	17	18	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 24	1999	274	52					37340	37344		10.1074/jbc.274.52.37340	http://dx.doi.org/10.1074/jbc.274.52.37340			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	267WR	10601302	hybrid			2022-12-25	WOS:000084382700073
J	Loland, CJ; Norregaard, L; Gether, U				Loland, CJ; Norregaard, L; Gether, U			Defining proximity relationships in the tertiary structure of the dopamine transporter - Identification of a conserved glutamic acid as a third coordinate in the endogenous Zn2+-binding site	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TACHYKININ NK-1 RECEPTOR; METAL-BINDING SITES; SEROTONIN TRANSPORTER; NEUROTRANSMITTER TRANSPORTERS; NOREPINEPHRINE TRANSPORTERS; TRANSMEMBRANE DOMAIN; COCAINE BINDING; AMINO-ACID; ZINC IONS; RECOGNITION	Recently, we have described a distance constraint in the unknown tertiary structure of the human dopamine transporter (hDAT) by identification of two histidines, His(193) in the second extracellular loop and His(375) at the top of transmembrane (TM) 7, that form two coordinates in an endogenous, high affinity Zn2+-binding site. To achieve further insight into the tertiary organization of hDAT, we set out to identify additional residues involved in Zn2+ binding and subsequently to engineer artificial Zn2+-binding sites. Ten aspartic acids and glutamic acids, predicted to be on the extracellular side, were mutated to asparagine and glutamine, respectively. Mutation of Glu(396) (E396Q) at the top of TM 8 increased the IC50 value for Zn2+ inhibition of [H-3]dopamine uptake from 1.1 to 530 mu M and eliminated Zn2+ induced potentiation of [H-3]WIN 35,428 binding. These data suggest that Glu(396) is involved in Zn2+ binding to hDAT, Importantly, Zn2+ sensitivity was preserved following substitution of Glu(396) with histidine, indicating that the effect of mutating Glu(396) is not an indirect effect because of the removal of a negatively charged residue. The common participation of Glu(396), His(193), and His(375) in binding the small Zn2+ ion implies their proximity in the unknown tertiary structure of hDAT, The close association between TM. 7 and 8 was further established by engineering of a Zn2+-binding site between His(375) and a cysteine inserted in position 400 in TM 8, Summarized, our data define an important set of proximity relationships in hDAT that should prove an important template for further exploring the molecular architecture of Na+/Cl--dependent neurotransmitter transporters.	Univ Copenhagen, Panum Inst, Dept Med Physiol 12522, Div Cellular& Mol Physiol, DK-2200 Copenhagen N, Denmark	University of Copenhagen	Gether, U (corresponding author), Univ Copenhagen, Panum Inst, Dept Med Physiol 12522, Div Cellular& Mol Physiol, Blegdamsvej 3, DK-2200 Copenhagen N, Denmark.	gether@mfi.ku.dk	Loland, Claus/E-5975-2014	Loland, Claus/0000-0002-1773-1446; Gether, Ulrik/0000-0002-0020-3807				Alberts IL, 1998, PROTEIN SCI, V7, P1700, DOI 10.1002/pro.5560070805; AMARA SG, 1993, ANNU REV NEUROSCI, V16, P73, DOI 10.1146/annurev.ne.16.030193.000445; ASSAF SY, 1984, NATURE, V308, P734, DOI 10.1038/308734a0; Barker EL, 1999, J NEUROSCI, V19, P4705; Barker EL, 1996, MOL PHARMACOL, V50, P957; Barker EL, 1998, J BIOL CHEM, V273, P19459, DOI 10.1074/jbc.273.31.19459; BARKER EL, 1994, MOL PHARMACOL, V46, P799; Bismuth Y, 1997, J BIOL CHEM, V272, P16096, DOI 10.1074/jbc.272.26.16096; BLOOMENTHAL AB, 1994, MOL PHARMACOL, V46, P1156; Buck KJ, 1995, MOL PHARMACOL, V48, P1030; BUCK KJ, 1994, P NATL ACAD SCI USA, V91, P12584, DOI 10.1073/pnas.91.26.12584; Chen JG, 1997, J BIOL CHEM, V272, P28321, DOI 10.1074/jbc.272.45.28321; Chen JG, 1998, J BIOL CHEM, V273, P12675, DOI 10.1074/jbc.273.20.12675; ELLING CE, 1995, NATURE, V374, P74, DOI 10.1038/374074a0; Elling CE, 1996, EMBO J, V15, P6213, DOI 10.1002/j.1460-2075.1996.tb01011.x; Ferrer JV, 1998, P NATL ACAD SCI USA, V95, P9238, DOI 10.1073/pnas.95.16.9238; FREDERICKSON CJ, 1989, INT REV NEUROBIOL, V31, P145; FREDERICKSON CJ, 1984, NEUROBIOLOGY ZINC NE; GETHER U, 1992, FEBS LETT, V296, P241, DOI 10.1016/0014-5793(92)80295-R; Giros B, 1996, NATURE, V379, P606, DOI 10.1038/379606a0; GIROS B, 1994, J BIOL CHEM, V269, P15985; GIROS B, 1993, TRENDS PHARMACOL SCI, V14, P43, DOI 10.1016/0165-6147(93)90029-J; GIROS B, 1992, MOL PHARMACOL, V42, P383; GLUSKER JP, 1991, ADV PROTEIN CHEM, V42, P1; HE MM, 1995, BIOCHEMISTRY-US, V34, P15667, DOI 10.1021/bi00048a010; HOLLMANN M, 1993, NEURON, V10, P943, DOI 10.1016/0896-6273(93)90209-A; Horenstein J, 1998, MOL PHARMACOL, V53, P870; HORN AS, 1990, PROG NEUROBIOL, V34, P387, DOI 10.1016/0301-0082(90)90033-D; Huang EP, 1997, P NATL ACAD SCI USA, V94, P13386, DOI 10.1073/pnas.94.25.13386; JOHANSEN TE, 1990, FEBS LETT, V267, P289, DOI 10.1016/0014-5793(90)80947-H; KITAYAMA S, 1992, P NATL ACAD SCI USA, V89, P7782, DOI 10.1073/pnas.89.16.7782; LAUBE B, 1995, J PHYSIOL-LONDON, V483, P613, DOI 10.1113/jphysiol.1995.sp020610; Nelson N, 1998, J NEUROCHEM, V71, P1785; Norregaard L, 1998, EMBO J, V17, P4266, DOI 10.1093/emboj/17.15.4266; PANTANOWITZ S, 1993, J BIOL CHEM, V268, P3222; Penado KMY, 1998, J BIOL CHEM, V273, P28098, DOI 10.1074/jbc.273.43.28098; PETERS S, 1987, SCIENCE, V236, P589, DOI 10.1126/science.2883728; PIFL C, 1993, J NEUROSCI, V13, P4246, DOI 10.1523/jneurosci.13-10-04246.1993; REGAN L, 1995, TRENDS BIOCHEM SCI, V20, P280, DOI 10.1016/S0968-0004(00)89044-1; RITZ MC, 1987, SCIENCE, V237, P1219, DOI 10.1126/science.2820058; Schetz JA, 1999, J PHARMACOL EXP THER, V289, P956; SCHWABE JWR, 1994, NAT STRUCT BIOL, V1, P345, DOI 10.1038/nsb0694-345; Sheikh SP, 1996, NATURE, V383, P347, DOI 10.1038/383347a0; Stephan MM, 1997, BIOCHEMISTRY-US, V36, P1322, DOI 10.1021/bi962150l; VALLEE BL, 1993, PHYSIOL REV, V73, P79, DOI 10.2466/pr0.1993.73.1.79; Vandenberg RJ, 1998, MOL PHARMACOL, V54, P189, DOI 10.1124/mol.54.1.189; WANG TL, 1995, J NEUROSCI, V15, P7684; WESTBROOK GL, 1987, NATURE, V328, P640, DOI 10.1038/328640a0; Wise RA, 1996, ANNU REV NEUROSCI, V19, P319, DOI 10.1146/annurev.ne.19.030196.001535	49	92	94	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 24	1999	274	52					36928	36934		10.1074/jbc.274.52.36928	http://dx.doi.org/10.1074/jbc.274.52.36928			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	267WR	10601246	hybrid			2022-12-25	WOS:000084382700017
J	Wotton, D; Lo, RS; Swaby, LAC; Massague, J				Wotton, D; Lo, RS; Swaby, LAC; Massague, J			Multiple modes of repression by the Smad transcriptional corepressor TGIF	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TATA-BINDING PROTEIN; HISTONE DEACETYLASE; HOMEOBOX GENE; HOMEODOMAIN PROTEINS; N-COR; COMPLEX; SEQUENCE; DOMAIN; HOX; COACTIVATORS	TGIF is a DNA-binding homeodomain protein that has been demonstrated to play a role in transforming growth factor P-regulated transcription and implicated in the control of retinoid-responsive transcription. We investigated the intrinsic transcriptional activity of TGIF fused to a heterologous DNA-binding domain. Our results demonstrate that TGIF is a transcriptional repressor able to repress transcription from several different promoters. Repression by TGIF is insensitive to the distance at which it is bound from the promoter, Moreover, the wild type TGIF effectively represses transcription when bound to its cognate DNA-binding site via its homeodomain, Deletion analysis revealed the presence of at least two separable repression domains within TGIF, Repression by one of these is dependent on the activity of histone deacetylases (HDACs), whereas the other appears not to require HDAC activity. Finally, we demonstrate that TGIF interacts with HDACs via its carboxyl-terminal repression domain. Together, these results suggest that TGIF is a multifunctional transcriptional repressor, which acts in part by recruiting HDAC activity.	Mem Sloan Kettering Canc Ctr, Howard Hughes Med Inst, Cell Biol Program, New York, NY 10021 USA	Howard Hughes Medical Institute; Memorial Sloan Kettering Cancer Center	Massague, J (corresponding author), Mem Sloan Kettering Canc Ctr, Howard Hughes Med Inst, Cell Biol Program, Box 116,1275 York Ave, New York, NY 10021 USA.			Massague, Joan/0000-0001-9324-8408; Wotton, David/0000-0002-4652-5350	NCI NIH HHS [CA34610] Funding Source: Medline; NIGMS NIH HHS [GM07739] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA034610, R37CA034610] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alland L, 1997, NATURE, V387, P49, DOI 10.1038/387049a0; ASTELL CR, 1981, CELL, V27, P15, DOI 10.1016/0092-8674(81)90356-1; Berthelsen J, 1998, EMBO J, V17, P1423, DOI 10.1093/emboj/17.5.1423; Berthelsen J, 1998, EMBO J, V17, P1434, DOI 10.1093/emboj/17.5.1434; Bertolino E, 1995, J BIOL CHEM, V270, P31178, DOI 10.1074/jbc.270.52.31178; Bertolino E, 1996, DEV DYNAM, V205, P410, DOI 10.1002/(SICI)1097-0177(199604)205:4<410::AID-AJA5>3.0.CO;2-L; Burglin TR, 1997, NUCLEIC ACIDS RES, V25, P4173, DOI 10.1093/nar/25.21.4173; Edwards MC, 1997, GENETICS, V147, P1063; Feng XH, 1998, GENE DEV, V12, P2153, DOI 10.1101/gad.12.14.2153; GEHRING WJ, 1994, CELL, V78, P211, DOI 10.1016/0092-8674(94)90292-5; GEHRING WJ, 1994, ANNU REV BIOCHEM, V63, P487, DOI 10.1146/annurev.biochem.63.1.487; Hassig CA, 1997, CELL, V89, P341, DOI 10.1016/S0092-8674(00)80214-7; Hata A, 1997, NATURE, V388, P82, DOI 10.1038/40424; Heinzel T, 1997, NATURE, V387, P43, DOI 10.1038/387043a0; Jacobs Y, 1999, MOL CELL BIOL, V19, P5134, DOI 10.1128/mcb.19.7.5134; Janknecht R, 1998, GENE DEV, V12, P2114, DOI 10.1101/gad.12.14.2114; JOHNSON AD, 1995, CELL, V81, P655, DOI 10.1016/0092-8674(95)90524-3; Kadosh D, 1997, CELL, V89, P365, DOI 10.1016/S0092-8674(00)80217-2; KAMPS MP, 1990, CELL, V60, P547, DOI 10.1016/0092-8674(90)90658-2; Laherty CD, 1997, CELL, V89, P349, DOI 10.1016/S0092-8674(00)80215-9; Li C, 1998, MOL CELL BIOL, V18, P3771, DOI 10.1128/MCB.18.7.3771; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; Mann RS, 1998, CURR OPIN GENET DEV, V8, P423, DOI 10.1016/S0959-437X(98)80113-5; Mann RS, 1996, TRENDS GENET, V12, P258, DOI 10.1016/0168-9525(96)10026-3; MCGINNIS W, 1984, NATURE, V308, P428, DOI 10.1038/308428a0; MCGINNIS W, 1984, CELL, V37, P403, DOI 10.1016/0092-8674(84)90370-2; Ming JE, 1998, CLIN GENET, V53, P155; MONCOLLIN V, 1986, EMBO J, V5, P2577, DOI 10.1002/j.1460-2075.1986.tb04537.x; MOSKOW JJ, 1995, MOL CELL BIOL, V15, P5434; Nagy L, 1997, CELL, V89, P373, DOI 10.1016/S0092-8674(00)80218-4; NOURSE J, 1990, CELL, V60, P535, DOI 10.1016/0092-8674(90)90657-Z; OVERHAUSER J, 1995, AM J HUM GENET, V57, P1080; Piper DE, 1999, CELL, V96, P587, DOI 10.1016/S0092-8674(00)80662-5; Pouponnot C, 1998, J BIOL CHEM, V273, P22865, DOI 10.1074/jbc.273.36.22865; Schnabel CA, 1996, MOL CELL BIOL, V16, P2678; Struhl K, 1998, GENE DEV, V12, P599, DOI 10.1101/gad.12.5.599; Swirnoff AH, 1998, MOL CELL BIOL, V18, P512, DOI 10.1128/MCB.18.1.512; Wolffe AP, 1996, SCIENCE, V272, P371, DOI 10.1126/science.272.5260.371; Wotton D, 1999, CELL, V97, P29, DOI 10.1016/S0092-8674(00)80712-6; Yang WM, 1997, J BIOL CHEM, V272, P28001, DOI 10.1074/jbc.272.44.28001; Zhang HL, 1996, P NATL ACAD SCI USA, V93, P1764, DOI 10.1073/pnas.93.5.1764; Zhang Y, 1997, CELL, V89, P357, DOI 10.1016/S0092-8674(00)80216-0	42	156	162	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 24	1999	274	52					37105	37110		10.1074/jbc.274.52.37105	http://dx.doi.org/10.1074/jbc.274.52.37105			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	267WR	10601270	hybrid			2022-12-25	WOS:000084382700041
J	Bera, AK; Chen, SH; Smith, JL; Zalkin, H				Bera, AK; Chen, SH; Smith, JL; Zalkin, H			Interdomain signaling in glutamine phosphoribosylpyrophosphate amidotransferase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; SITE	The glutamine phosphoribosylpyrophosphate (PRPP) amidotransferase-catalyzed synthesis of phosphoribosylamine from PRPP and glutamine is the sum of two half-reactions at separated catalytic sites in different domains. Binding of PRPP to a C-terminal phosphoribosyltransferase domain is required to activate the reaction at the N-terminal glutaminase domain. Interdomain signaling was monitored by intrinsic tryptophan fluorescence and by measurements of glutamine binding and glutamine site catalysis. Enzymes were engineered to contain a single tryptophan fluorescence reporter in key positions in the glutaminase domain. Trp(83) in the glutamine loop (residues 73-84) and Trp(482) in the C-terminal helix (residues 471-492) reported fluorescence changes in the glutaminase domain upon binding of PRPP and glutamine. The fluorescence changes were perturbed by Ile(335) and Tyr(74) mutations that disrupt interdomain signaling. Fluoresence titrations of PRPP and glutamine binding indicated that signaling defects increased the K-d for glutamine but had little or no effect on PRPP binding. It was concluded that the contact between Ile(335) in the phosphoribosyltransferase domain and Tyr(74) in the glutamine site is a primary molecular interaction for interdomain signaling. Analysis of enzymes with mutations in the glutaminase domain C-terminal helix and a 404-420 peptide point to additional signaling interactions that activate the glutamine site when PRPP binds.	Purdue Univ, Dept Biochem, W Lafayette, IN 47907 USA; Purdue Univ, Dept Biol Sci, W Lafayette, IN 47907 USA	Purdue University System; Purdue University; Purdue University West Lafayette Campus; Purdue University System; Purdue University; Purdue University West Lafayette Campus	Zalkin, H (corresponding author), Purdue Univ, Dept Biochem, W Lafayette, IN 47907 USA.		Bera, Aloke Kumar/AAD-9541-2022		NIDDK NIH HHS [R37 DK042303, DK42303] Funding Source: Medline; NIGMS NIH HHS [GM 24658] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK042303, R37DK042303] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM024658, R37GM024658] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Chen SH, 1999, BIOCHEMISTRY-US, V38, P11659, DOI 10.1021/bi991060o; DOHERTY AJ, 1995, NUCLEIC ACIDS RES, V23, P2074, DOI 10.1093/nar/23.11.2074; GOTO Y, 1976, J BIOL CHEM, V251, P941; Kim JH, 1996, J BIOL CHEM, V271, P15549, DOI 10.1074/jbc.271.26.15549; Krahn JM, 1997, BIOCHEMISTRY-US, V36, P11061, DOI 10.1021/bi9714114; KRAHN JM, 1998, THESIS PURDUE U; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; MESSENGER LJ, 1979, J BIOL CHEM, V254, P3382; Miles BW, 1998, BIOCHEMISTRY-US, V37, P16773, DOI 10.1021/bi982018g; Miles EW, 1999, J BIOL CHEM, V274, P12193, DOI 10.1074/jbc.274.18.12193; Muchmore CRA, 1998, PROTEIN SCI, V7, P39, DOI 10.1002/pro.5560070104; Smith JL, 1998, CURR OPIN STRUC BIOL, V8, P686, DOI 10.1016/S0959-440X(98)80087-0; Zalkin H, 1998, ADV ENZYMOL RAMB, V72, P87	13	18	20	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 17	1999	274	51					36498	36504		10.1074/jbc.274.51.36498	http://dx.doi.org/10.1074/jbc.274.51.36498			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	266AV	10593947	hybrid			2022-12-25	WOS:000084279200066
J	Billin, AN; Eilers, AL; Queva, C; Ayer, DE				Billin, AN; Eilers, AL; Queva, C; Ayer, DE			Mix, a novel max-like BHLHZip protein that interacts with the max network of transcription factors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HISTONE DEACETYLASE ACTIVITY; DNA-BINDING PROTEIN; C-MYC; CELL-GROWTH; EPIDERMAL DIFFERENTIATION; RAS COTRANSFORMATION; OPPOSITE REGULATION; REPRESSION; COMPLEX; MXI1	Mad:Max heterodimers oppose the growth-promoting action of Myc:Max heterodimers by recruiting the mSin3-histone deacetylase (mSin3.HDAC) complex to DNA and functioning as potent transcriptional repressors. There are four known members of the Mad family that are indistinguishable in their abilities to interact with Max, bind DNA, repress transcription, and block Myc + Ras co-transformation. To investigate functional differences between Mad family proteins, we have identified additional proteins that interact with this family. Here we present the identification and characterization of the novel basic-helix-loop-helix zipper protein M1x (Max-like protein x), which is structurally and functionally related to Max. The similarities between M1x and Max include 1) broad expression in many tissues, 2) long protein half-life, and 3) formation of heterodimers with Mad family proteins that are capable of specific CACGTG binding. We show that transcriptional repression by Mad1:M1x heterodimers is dependent on dimerization, DNA binding, and recruitment of the mSin3A.HDAC corepressor complex. In contrast with Max, M1x interacts only with Mad1 and Mad4. Together, these findings suggest that M1x may act to diversify Mad family function by its restricted association with a subset of the Mad family of transcriptional repressors.	Univ Utah, Huntsman Canc Inst, Salt Lake City, UT 84112 USA; Fred Hutchinson Canc Res Ctr, Div Basic Sci, Seattle, WA 98109 USA	Huntsman Cancer Institute; Utah System of Higher Education; University of Utah; Fred Hutchinson Cancer Center	Ayer, DE (corresponding author), Univ Utah, Huntsman Canc Inst, 2000 East North Campus Dr, Salt Lake City, UT 84112 USA.			Billin, Andrew/0000-0001-7752-0934; Ayer, Donald/0000-0002-5595-3269	NATIONAL CANCER INSTITUTE [P30CA042014] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM055668] Funding Source: NIH RePORTER; NCI NIH HHS [3P30CA42014] Funding Source: Medline; NIGMS NIH HHS [R01 GM055668, GM5568-01] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMATI B, 1994, CURR OPIN GENET DEV, V4, P102, DOI 10.1016/0959-437X(94)90098-1; AMATI B, 1992, NATURE, V359, P423, DOI 10.1038/359423a0; Atchley WR, 1997, P NATL ACAD SCI USA, V94, P5172, DOI 10.1073/pnas.94.10.5172; Ayer DE, 1996, MOL CELL BIOL, V16, P5772; AYER DE, 1995, CELL, V80, P767, DOI 10.1016/0092-8674(95)90355-0; AYER DE, 1993, CELL, V72, P211, DOI 10.1016/0092-8674(93)90661-9; AYER DE, 1993, GENE DEV, V7, P2110, DOI 10.1101/gad.7.11.2110; BERBERICH S, 1992, ONCOGENE, V7, P775; BERNARDS R, 1995, CURR BIOL, V5, P859, DOI 10.1016/S0960-9822(95)00173-4; Bjerknes M, 1996, GENE, V181, P7, DOI 10.1016/S0378-1119(96)00376-9; BLACKWELL TK, 1993, MOL CELL BIOL, V13, P5216, DOI 10.1128/MCB.13.9.5216; BLACKWELL TK, 1990, SCIENCE, V250, P1149, DOI 10.1126/science.2251503; Blackwood EM, 1992, CURR OPIN GENET DEV, V2, P227, DOI 10.1016/S0959-437X(05)80278-3; BLACKWOOD EM, 1992, GENE DEV, V6, P71, DOI 10.1101/gad.6.1.71; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; CHEN J, 1995, NAT MED, V1, P638, DOI 10.1038/nm0795-638; CHIN L, 1995, P NATL ACAD SCI USA, V92, P8488, DOI 10.1073/pnas.92.18.8488; COLE MD, 1986, ANNU REV GENET, V20, P361, DOI 10.1146/annurev.ge.20.120186.002045; DELGADO MD, 1995, ONCOGENE, V10, P1659; EDELHOFF S, 1994, ONCOGENE, V9, P665; FERRE DA, 1994, EMBO J, V13, P180; FERREDAMARE AR, 1993, NATURE, V363, P38, DOI 10.1038/363038a0; FISHER F, 1992, EMBO J, V11, P4103, DOI 10.1002/j.1460-2075.1992.tb05503.x; Foley KP, 1998, EMBO J, V17, P774, DOI 10.1093/emboj/17.3.774; GU W, 1993, P NATL ACAD SCI USA, V90, P2935, DOI 10.1073/pnas.90.7.2935; HANN SR, 1985, NATURE, V314, P366, DOI 10.1038/314366a0; Hassig CA, 1997, CELL, V89, P341, DOI 10.1016/S0092-8674(00)80214-7; Henriksson M, 1996, ADV CANCER RES, V68, P109, DOI 10.1016/S0065-230X(08)60353-X; HIRAI H, 1995, MOL CELL BIOL, V15, P2672; HOLLENBERG SM, 1995, MOL CELL BIOL, V15, P3813; HURLIN PJ, 1995, EMBO J, V14, P5646, DOI 10.1002/j.1460-2075.1995.tb00252.x; Hurlin PJ, 1995, ONCOGENE, V11, P2487; Hurlin PJ, 1997, GENE DEV, V11, P44, DOI 10.1101/gad.11.1.44; Kasten MM, 1996, MOL CELL BIOL, V16, P4215; KATO GJ, 1992, GENE DEV, V6, P81, DOI 10.1101/gad.6.1.81; KOSKINEN PJ, 1995, CELL GROWTH DIFFER, V6, P623; Kretzner L, 1992, Curr Top Microbiol Immunol, V182, P435; Laherty CD, 1997, CELL, V89, P349, DOI 10.1016/S0092-8674(00)80215-9; LARSSON LG, 1994, ONCOGENE, V9, P1247; LUSCHER B, 1990, GENE DEV, V4, P2025, DOI 10.1101/gad.4.12a.2025; MUKHERJEE B, 1992, GENE DEV, V6, P1480, DOI 10.1101/gad.6.8.1480; MULLER AJ, 1991, MOL CELL BIOL, V11, P1785, DOI 10.1128/MCB.11.4.1785; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; PRENDERGAST GC, 1991, CELL, V65, P395, DOI 10.1016/0092-8674(91)90457-A; Queva C, 1998, ONCOGENE, V16, P967, DOI 10.1038/sj.onc.1201611; Roussel MF, 1996, MOL CELL BIOL, V16, P2796; Schreiber-Agus N, 1998, NATURE, V393, P483, DOI 10.1038/31008; Shimizu T, 1997, EMBO J, V16, P4689, DOI 10.1093/emboj/16.15.4689; Sommer A, 1997, CURR BIOL, V7, P357, DOI 10.1016/S0960-9822(06)00183-7; VASTRIK I, 1995, J CELL BIOL, V128, P1197, DOI 10.1083/jcb.128.6.1197; Wu SJ, 1996, ONCOGENE, V12, P621; ZERVOS AS, 1993, CELL, V72, P223, DOI 10.1016/0092-8674(93)90662-A	52	77	81	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 17	1999	274	51					36344	36350		10.1074/jbc.274.51.36344	http://dx.doi.org/10.1074/jbc.274.51.36344			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	266AV	10593926	hybrid			2022-12-25	WOS:000084279200045
J	Connolly, CN; Kittler, JT; Thomas, P; Uren, JM; Brandon, NJ; Smart, TG; Moss, SJ				Connolly, CN; Kittler, JT; Thomas, P; Uren, JM; Brandon, NJ; Smart, TG; Moss, SJ			Cell surface stability of gamma-aminobutyric acid type A receptors - Dependence on protein kinase C activity and subunit composition	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							A RECEPTOR; PHOSPHORYLATION SITES; GABA(A) RECEPTORS; BETA-SUBUNITS; NEUROTRANSMITTER; FIBROBLASTS; TRANSFERRIN; ENDOCYTOSIS; EXPRESSION; SUBTYPES	Type A gamma-aminobutyric acid receptors (GABA(A)), the major sites of fast synaptic inhibition in the brain, are believed to be composed predominantly of alpha, beta, and gamma subunits, Although cell surface expression is essential for GABA,receptor function, little is known regarding its regulation, To address this issue, the membrane stability of recombinant alpha(1)beta(2) or alpha(1)beta(2)gamma(2) receptors was analyzed in human embryonic kidney cells. alpha(1)beta(2)gamma(2), but not alpha(1)beta(2) receptors were found to recycle constitutively between the cell surface and a microtubule-dependent, perinuclear endosomal compartment. Similar GABA, receptor endocytosis was also seen in cultured hippocampal and cortical neurons. GABA, receptor surface levels were reduced upon protein kinase C (PKC) activation. Like basal endocytosis, this response required the gamma(2) subunit but not receptor phosphorylation. Although inhibiting PKC activity did not block alpha(1)beta(2)gamma(2) receptor endocytosis, it did prevent receptor down-regulation, suggesting that PKC activity may block alpha(1)beta(2)gamma(2) receptor recycling to the cell surface, In agreement with this observation, blocking recycling from endosomes with wortmannin selectively reduced surface levels of gamma(2)-containing receptors, Together, our results demonstrate that the surface stability of GABA(A) receptors can be dynamically and specifically regulated, enabling neurons to modulate cell surface receptor number upon the appropriate cues.	UCL, MRC, LMCB, London WC1E 6BT, England; UCL, Dept Pharmacol, London WC1E 6BT, England; Sch Pharm, Dept Pharmacol, London WC1E 1AX, England	University of London; University College London; University of London; University College London; University of London; University College London; University of London School of Pharmacy	Moss, SJ (corresponding author), UCL, MRC, LMCB, Gower St, London WC1E 6BT, England.	steve.moss@ucl.ac.uk	Kittler, Josef T/E-9113-2010; Kittler, Josef/N-7589-2019	Kittler, Josef T/0000-0002-3437-9456; Kittler, Josef/0000-0002-3437-9456; Brandon, Nicholas/0000-0002-3917-0096; Connolly, Christopher/0000-0002-0445-8874				Barnes EM, 1996, INT REV NEUROBIOL, V39, P53, DOI 10.1016/S0074-7742(08)60663-7; BORDEN LA, 1984, SCIENCE, V226, P857, DOI 10.1126/science.6093257; Brickley SG, 1999, J NEUROSCI, V19, P2960; CALKIN PA, 1994, J BIOL CHEM, V269, P1548; Chapell R, 1998, J BIOL CHEM, V273, P32595, DOI 10.1074/jbc.273.49.32595; Connolly CN, 1999, MOL CELL NEUROSCI, V13, P259, DOI 10.1006/mcne.1999.0746; Connolly CN, 1996, J BIOL CHEM, V271, P89, DOI 10.1074/jbc.271.1.89; Davies PA, 1997, NATURE, V385, P820, DOI 10.1038/385820a0; Essrich C, 1998, NAT NEUROSCI, V1, P563, DOI 10.1038/2798; GAROFALO RS, 1992, J BIOL CHEM, V267, P11470; Goslin K., 1991, CULTURING NERVE CELL, P251; GYENES M, 1994, MOL PHARMACOL, V46, P542; HOPKINS CR, 1994, J CELL BIOL, V125, P1265, DOI 10.1083/jcb.125.6.1265; Jess TJ, 1996, CELL SIGNAL, V8, P297, DOI 10.1016/0898-6568(96)00054-X; KELLENBERGER S, 1992, J BIOL CHEM, V267, P25660; KRISHEK BJ, 1994, NEURON, V12, P1081, DOI 10.1016/0896-6273(94)90316-6; Kurashima K, 1998, J BIOL CHEM, V273, P20828, DOI 10.1074/jbc.273.33.20828; LAURIE DJ, 1992, J NEUROSCI, V12, P4151; MACDONALD RL, 1994, ANNU REV NEUROSCI, V17, P569, DOI 10.1146/annurev.neuro.17.1.569; Martys JL, 1996, J BIOL CHEM, V271, P10953, DOI 10.1074/jbc.271.18.10953; McDonald BJ, 1998, NAT NEUROSCI, V1, P23, DOI 10.1038/223; Moss SJ, 1996, INT REV NEUROBIOL, V39, P1, DOI 10.1016/S0074-7742(08)60662-5; Nusser Z, 1998, NATURE, V395, P172, DOI 10.1038/25999; PELCHENMATTHEWS A, 1993, J EXP MED, V178, P1209, DOI 10.1084/jem.178.4.1209; Poisbeau P, 1997, J NEUROSCI, V17, P3467; RABOW LE, 1995, SYNAPSE, V21, P189, DOI 10.1002/syn.890210302; Smart TG, 1997, CURR OPIN NEUROBIOL, V7, P358, DOI 10.1016/S0959-4388(97)80063-3; SUR C, 1995, EUR J NEUROSCI, V7, P1323, DOI 10.1111/j.1460-9568.1995.tb01123.x; Wan Q, 1997, NATURE, V388, P686, DOI 10.1038/41792; Wang HB, 1999, NATURE, V397, P69, DOI 10.1038/16264; WHITING P, 1990, P NATL ACAD SCI USA, V87, P9966, DOI 10.1073/pnas.87.24.9966; Wooltorton JRA, 1997, J PHYSIOL-LONDON, V505, P633, DOI 10.1111/j.1469-7793.1997.633ba.x; YAMASHIRO DJ, 1984, CELL, V37, P789, DOI 10.1016/0092-8674(84)90414-8	33	151	159	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 17	1999	274	51					36565	36572		10.1074/jbc.274.51.36565	http://dx.doi.org/10.1074/jbc.274.51.36565			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	266AV	10593956	hybrid			2022-12-25	WOS:000084279200075
J	Fong, LG; Le, D				Fong, LG; Le, D			The processing of ligands by the class A scavenger receptor is dependent on signal information located in the cytoplasmic domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY-LIPOPROTEIN; MOUSE PERITONEAL-MACROPHAGES; MONOCYTE-DERIVED MACROPHAGES; LIPID-PROTEIN ADDUCTS; SMOOTH-MUSCLE CELLS; INSULIN-RECEPTOR; GROWTH-FACTOR; ATHEROSCLEROTIC LESIONS; MESSENGER-RNA; TRANSFERRIN RECEPTOR	The mechanisms that regulate the transport of the macrophage class A scavenger receptor during ligand uptake were investigated. Kinetic analysis of the changes in receptor phosphorylation demonstrated that serine phosphorylation increased during the internalization of acetyl-low density lipoproteins (LDL) by macrophages. The increase was maximal at about 2.5 min after the initiation of ligand uptake. Oxidized LDL also stimulated serine phosphorylation, but the relative increase was smaller and the time to maximum was shorter. Receptor mutants expressed in Chinese hamster ovary and COS cells showed that elimination of the potential phosphorylation site at Ser(21) increased acetyILDL metabolism, whereas inactivation of the site at Ser(49) reduced acetyl-LDL uptake. The increase in uptake by the Ser(21) mutant was due to an increase in surface receptor expression. in contrast, elimination of the site at Ser(49) did not affect receptor expression but slowed receptor internalization. To identify potential internalization signal sequences, beta-turn structure in the cytosolic domain was targeted for mutagenesis. Disruption of one region near Asp(25) inhibited receptor activity. The studies support a model whereby receptor internalization requires the presence of an internalization signal motif but that the rate of receptor internalization is governed by the pattern of receptor phosphorylation induced by the ligand.	Palo Alto Med Fdn, Res Inst, Palo Alto, CA 94301 USA	Palo Alto Medical Foundation Research Institute	Fong, LG (corresponding author), Palo Alto Med Fdn, Res Inst, 860 Bryant St, Palo Alto, CA 94301 USA.	lgfong@pamfri.org						ACTON SL, 1994, J BIOL CHEM, V269, P21003; AJIOKA RS, 1986, P NATL ACAD SCI USA, V83, P6445, DOI 10.1073/pnas.83.17.6445; ANDERSON RGW, 1977, CELL, V10, P351, DOI 10.1016/0092-8674(77)90022-8; Andersson L, 1998, J BIOL CHEM, V273, P19592, DOI 10.1074/jbc.273.31.19592; ARUFFO A, 1991, CURRENT PROTOCOLS MO, V2; ASHKENAS J, 1993, J LIPID RES, V34, P983; BACKER JM, 1992, J CELL BIOL, V118, P831, DOI 10.1083/jcb.118.4.831; BERNINI F, 1995, ARTERIOSCL THROM VAS, V15, P1352, DOI 10.1161/01.ATV.15.9.1352; BICKEL PE, 1992, J CLIN INVEST, V90, P1450, DOI 10.1172/JCI116012; BROWN MS, 1980, J SUPRAMOL STR CELL, V13, P67, DOI 10.1002/jss.400130107; CARPENTIER JL, 1993, J CELL BIOL, V122, P1243, DOI 10.1083/jcb.122.6.1243; CHOU PY, 1978, ANNU REV BIOCHEM, V47, P251, DOI 10.1146/annurev.bi.47.070178.001343; COLLAWN JF, 1990, CELL, V63, P1061, DOI 10.1016/0092-8674(90)90509-D; DAVIS CG, 1986, CELL, V45, P15, DOI 10.1016/0092-8674(86)90533-7; DAVIS CG, 1987, J BIOL CHEM, V262, P4075; DOI T, 1994, J BIOL CHEM, V269, P25598; DOI T, 1993, J BIOL CHEM, V268, P2126; ELOMAA O, 1995, CELL, V80, P603, DOI 10.1016/0092-8674(95)90514-6; ENDEMANN G, 1993, J BIOL CHEM, V268, P11811; FALLON RJ, 1994, J BIOL CHEM, V269, P11011; FONG LG, 1991, J LIPID RES, V32, P1899; FONG LG, 1990, J BIOL CHEM, V265, P11751; Fong LG, 1996, J LIPID RES, V37, P574; FRASER I, 1993, NATURE, V364, P343, DOI 10.1038/364343a0; FREEMAN M, 1991, P NATL ACAD SCI USA, V88, P4931, DOI 10.1073/pnas.88.11.4931; FROSTEGARD J, 1990, P NATL ACAD SCI USA, V87, P904, DOI 10.1073/pnas.87.3.904; FUKUDA S, 1986, VIRCHOWS ARCH B, V52, P1, DOI 10.1007/BF02889945; HABERLAND ME, 1988, SCIENCE, V241, P215, DOI 10.1126/science.2455346; HAFT CR, 1994, J BIOL CHEM, V269, P26286; Hamer I, 1997, J BIOL CHEM, V272, P21685, DOI 10.1074/jbc.272.35.21685; HAMILTON TA, 1990, J IMMUNOL, V144, P2343; Han JH, 1997, J BIOL CHEM, V272, P21654, DOI 10.1074/jbc.272.34.21654; HAVEL RJ, 1955, J CLIN INVEST, V34, P1345, DOI 10.1172/JCI103182; HEINECKE JW, 1986, J CLIN INVEST, V77, P757, DOI 10.1172/JCI112371; HENRIKSEN T, 1981, P NATL ACAD SCI-BIOL, V78, P6499, DOI 10.1073/pnas.78.10.6499; Hsu HY, 1998, J BIOL CHEM, V273, P1240, DOI 10.1074/jbc.273.2.1240; JOHNSON KF, 1992, J CELL BIOL, V119, P249, DOI 10.1083/jcb.119.2.249; KEEN JH, 1990, ANNU REV BIOCHEM, V59, P415, DOI 10.1146/annurev.biochem.59.1.415; KINGSTON RE, 1990, CURRENT PROTOCOLS MO, V1; KODAMA T, 1990, NATURE, V343, P531, DOI 10.1038/343531a0; LETOURNEUR F, 1992, CELL, V69, P1143, DOI 10.1016/0092-8674(92)90636-Q; LOUGHEED M, 1991, J BIOL CHEM, V266, P14519; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MALDEN LT, 1991, J BIOL CHEM, V266, P13901; MATSUMOTO A, 1990, P NATL ACAD SCI USA, V87, P9133, DOI 10.1073/pnas.87.23.9133; Maxeiner H, 1998, J EXP MED, V188, P2257, DOI 10.1084/jem.188.12.2257; Miki S, 1996, FEBS LETT, V399, P241, DOI 10.1016/S0014-5793(96)01332-4; MOMMAASKIENHUIS AM, 1985, HISTOCHEMISTRY, V83, P29, DOI 10.1007/BF00495296; MORI T, 1994, LAB INVEST, V71, P409; Nagy L, 1998, CELL, V93, P229, DOI 10.1016/S0092-8674(00)81574-3; NAITO M, 1991, AM J PATHOL, V139, P1411; NESTEROV A, 1995, J BIOL CHEM, V270, P6320, DOI 10.1074/jbc.270.11.6320; PEARSE BMF, 1990, ANNU REV CELL BIOL, V6, P151, DOI 10.1146/annurev.cb.06.110190.001055; PYTOWSKI B, 1995, J BIOL CHEM, V270, P9067, DOI 10.1074/jbc.270.16.9067; QUINN MT, 1987, P NATL ACAD SCI USA, V84, P2995, DOI 10.1073/pnas.84.9.2995; RAMPRASAD MP, 1995, P NATL ACAD SCI USA, V92, P9580, DOI 10.1073/pnas.92.21.9580; ROBENEK H, 1984, J HISTOCHEM CYTOCHEM, V32, P1017, DOI 10.1177/32.10.6481148; ROMA P, 1992, J LIPID RES, V33, P819; ROSENFELD ME, 1990, ARTERIOSCLEROSIS, V10, P336, DOI 10.1161/01.ATV.10.3.336; ROSENFELD ME, 1991, J CLIN INVEST, V87, P90, DOI 10.1172/JCI115006; Sakai M, 1996, J BIOL CHEM, V271, P27346, DOI 10.1074/jbc.271.44.27346; Sambrook J., 1989, MOL CLONING, pA1; SHACKELFORD RE, 1995, J BIOL CHEM, V270, P3475, DOI 10.1074/jbc.270.8.3475; SPARROW CP, 1989, J BIOL CHEM, V264, P2599; STANTON LW, 1992, J BIOL CHEM, V267, P22446; STEINBERG D, 1989, NEW ENGL J MED, V320, P915; Steinberg D, 1997, J BIOL CHEM, V272, P20963, DOI 10.1074/jbc.272.34.20963; Sulistiyani, 1997, ARTERIOSCL THROM VAS, V17, P1691, DOI 10.1161/01.ATV.17.9.1691; Suzuki H, 1997, NATURE, V386, P292, DOI 10.1038/386292a0; TORONTONOZ P, 1998, CELL, V93, P241; TROWBRIDGE IS, 1993, ANNU REV CELL BIOL, V9, P129, DOI 10.1146/annurev.cb.09.110193.001021; VANBERKEL TJC, 1981, FEBS LETT, V132, P61; VANDERGEER P, 1994, CELL BIOL LAB HDB, V3, P422; WILEY HS, 1991, J BIOL CHEM, V266, P11083; Yoshida H, 1998, ARTERIOSCL THROM VAS, V18, P794, DOI 10.1161/01.ATV.18.5.794	75	44	44	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 17	1999	274	51					36808	36816		10.1074/jbc.274.51.36808	http://dx.doi.org/10.1074/jbc.274.51.36808			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	266AV	10593991	hybrid			2022-12-25	WOS:000084279200110
J	Guan, ZH; Buckman, SY; Springer, LD; Morrison, AR				Guan, ZH; Buckman, SY; Springer, LD; Morrison, AR			Both p38 alpha(MAPK) and JNK/SAPK pathways are important for induction of nitric-oxide synthase by interleukin-1 beta in rat glomerular mesangial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-TRANSDUCTION PATHWAY; ACTIVATED PROTEIN-KINASES; JUN NH2-TERMINAL KINASE; TRANSCRIPTIONAL REGULATION; P38; EXPRESSION; GENE; REQUIRES; STRESS; ALPHA	Interleukin 1 beta (IL-1 beta) induces expression of the inducible nitric-oxide synthase (iNOS) with concomitant release of nitric oxide (NO) from glomerular mesangial cells. These events are preceded by activation of the c-Jun NH2-terminal kinase/stress-activated protein kinase (JNK/SAPK) and p38(MAPK). Our current study demonstrates that overexpression of the dominant negative form of JNK1 or p54 SAPK beta/JNK2 significantly reduces the iNOS protein expression and NO production induced by IL-1 beta. Similarly, overexpression of the kinase-dead mutant form of p38 alpha(MAPK) also inhibits IL-1 beta-induced iNOS expression and NO production. In previous studies we demonstrated that IL-1 beta can activate MKK4/SEK1, MKK3, and MKK6 in renal mesangial cells; therefore, we examined the role of these MAPK kinases in the modulation of iNOS induced by IL-1 beta. Overexpression of the dominant negative form of MKK4/SEK1 decreases IL-1 beta-induced iNOS expression and NO production with inhibition of both SAPK/JNK and p38(MAPK) phosphorylation. Overexpression of the kinase-dead mutant form of MKK3 or MKK6 demonstrated that either of these two mutant kinase inhibited IL-1 beta-induced p38(MAPK) (but not JNK/SAPK) phosphorylation and iNOS expression. Interestingly overexpression of wild type MKK3/6 was associated with phosphorylation of p38(MAPK); however, in the absence of IL-1 beta, iNOS expression was not enhanced. This study suggests that the activation of both SAPK/JNK and p38 alpha(MAPK) Signaling cascades are necessary for the IL-1 beta-induced expression of iNOS and production of NO in renal mesangial cells.	Washington Univ, Sch Med, Dept Med & Mol Biol & Pharmacol, St Louis, MO 63110 USA	Washington University (WUSTL)	Morrison, AR (corresponding author), Barnes Jewish Hosp, Div Renal, 216 S Kings Highway,Box 8305, St Louis, MO 63110 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK050606] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 50606] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bergmann M, 1998, J BIOL CHEM, V273, P6607, DOI 10.1074/jbc.273.12.6607; Carey M, 1998, CELL, V92, P5, DOI 10.1016/S0092-8674(00)80893-4; DaSilva J, 1997, J BIOL CHEM, V272, P28373, DOI 10.1074/jbc.272.45.28373; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; deVera ME, 1996, P NATL ACAD SCI USA, V93, P1054, DOI 10.1073/pnas.93.3.1054; Ellwood K, 1999, MOL CELL BIOL, V19, P2613; Enslen H, 1998, J BIOL CHEM, V273, P1741, DOI 10.1074/jbc.273.3.1741; Ganiatsas S, 1998, P NATL ACAD SCI USA, V95, P6881, DOI 10.1073/pnas.95.12.6881; Garrington TP, 1999, CURR OPIN CELL BIOL, V11, P211, DOI 10.1016/S0955-0674(99)80028-3; Gaudreau L, 1999, P NATL ACAD SCI USA, V96, P2668, DOI 10.1073/pnas.96.6.2668; Grabowski PS, 1997, BRIT J RHEUMATOL, V36, P651; Guan ZH, 1997, J BIOL CHEM, V272, P8083, DOI 10.1074/jbc.272.12.8083; Guan ZH, 1996, AM J PHYSIOL-RENAL, V270, pF634, DOI 10.1152/ajprenal.1996.270.4.F634; Guan ZH, 1998, J BIOL CHEM, V273, P28670, DOI 10.1074/jbc.273.44.28670; GUPTA S, 1995, SCIENCE, V267, P389, DOI 10.1126/science.7824938; Han JH, 1996, J BIOL CHEM, V271, P2886, DOI 10.1074/jbc.271.6.2886; Hu MCT, 1999, J BIOL CHEM, V274, P7095, DOI 10.1074/jbc.274.11.7095; Jiang Y, 1997, J BIOL CHEM, V272, P30122, DOI 10.1074/jbc.272.48.30122; Kinugawa K, 1997, CIRC RES, V81, P911; Kleinert H, 1998, BRIT J PHARMACOL, V123, P1716, DOI 10.1038/sj.bjp.0701782; Kunz D, 1996, P NATL ACAD SCI USA, V93, P255, DOI 10.1073/pnas.93.1.255; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; Kyriakis JM, 1996, BIOESSAYS, V18, P567, DOI 10.1002/bies.950180708; Kyriakis JM, 1996, J BIOL CHEM, V271, P24313, DOI 10.1074/jbc.271.40.24313; Larsen CM, 1998, J BIOL CHEM, V273, P15294, DOI 10.1074/jbc.273.24.15294; Lee FS, 1998, P NATL ACAD SCI USA, V95, P9319, DOI 10.1073/pnas.95.16.9319; Lee FS, 1997, CELL, V88, P213, DOI 10.1016/S0092-8674(00)81842-5; Marks-Konczalik J, 1998, J BIOL CHEM, V273, P22201, DOI 10.1074/jbc.273.35.22201; McCafferty DM, 1997, GASTROENTEROLOGY, V112, P1022, DOI 10.1053/gast.1997.v112.pm9041266; Miller BW, 1997, AM J PHYSIOL-CELL PH, V273, pC130, DOI 10.1152/ajpcell.1997.273.1.C130; Mosley K, 1999, EXP NEPHROL, V7, P26; Pierrat B, 1998, J BIOL CHEM, V273, P29661, DOI 10.1074/jbc.273.45.29661; Ptashne M, 1997, NATURE, V386, P569, DOI 10.1038/386569a0; Raingeaud J, 1996, MOL CELL BIOL, V16, P1247; Tetsuka T, 1996, J BIOL CHEM, V271, P11689, DOI 10.1074/jbc.271.20.11689; TETSUKA T, 1995, AM J PHYSIOL-CELL PH, V269, pC55, DOI 10.1152/ajpcell.1995.269.1.C55; Widmann C, 1999, PHYSIOL REV, V79, P143, DOI 10.1152/physrev.1999.79.1.143; Yang D, 1997, P NATL ACAD SCI USA, V94, P3004, DOI 10.1073/pnas.94.7.3004; Yang SH, 1998, MOL CELL BIOL, V18, P710, DOI 10.1128/MCB.18.2.710; Zhao Q, 1999, J BIOL CHEM, V274, P8355, DOI 10.1074/jbc.274.13.8355; Zheng J, 1999, ENDOCRINOLOGY, V140, P1399, DOI 10.1210/en.140.3.1399	41	70	72	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 17	1999	274	51					36200	36206		10.1074/jbc.274.51.36200	http://dx.doi.org/10.1074/jbc.274.51.36200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	266AV	10593906	hybrid			2022-12-25	WOS:000084279200025
J	Johnson, TK; Schweppe, RE; Septer, J; Lewis, RE				Johnson, TK; Schweppe, RE; Septer, J; Lewis, RE			Phosphorylation of B-Myb regulates its transactivation potential and DNA binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-CYCLE; C-MYB; SELECTIVE ACTIVATION; FUNCTIONAL DOMAINS; DEPENDENT KINASE; GENE-PRODUCT; S-PHASE; EXPRESSION; PROTEIN; TRANSCRIPTION	The transcription factor B-Myb is a cell cycle-regulated phosphoprotein and a potent regulator of cell cycle progression. Previous studies demonstrated that B-Myb was phosphorylated at the onset of S phase, suggesting that it could be due to cyclin-dependent kinases. We identified 10 B-Myb phosphorylation sites by automated peptide radiosequencing of tryptic phosphopeptides derived from in vivo P-32-labeled B-Myb. Each B-Myb phosphorylation site contained a phosphoserine or phosphothreonine followed by a proline, suggesting that this phosphorylation is due to a proline-directed kinase, Cyclin A-Cdk2 and cyclin E-Cdk2 complexes each phosphorylated B-Myb in a cell-free system on the same sites as in intact cells. Furthermore, the ability of B-Myb to activate a reporter plasmid was enhanced by the cotransfection of cyclin A, whereas mutagenesis of the 10 identified phosphorylation sites from B-Myb blocked the effect of cyclin A coexpression, Additional analysis revealed that the effect of phosphorylation on B-Myb transactivation potential was enhanced by phosphorylation sites in its carboxyl-terminal half. One phosphorylation site (Ser(581)) appeared to negatively regulate DNA binding, as mutation of this site enhanced the ability of B-Myb to bind a Myb-binding sequence. These data suggest that B-Myb is a target for phosphorylation by cyclin-Cdk2 and that phosphorylation of B-Myb regulates its transcriptional activity.	Univ Nebraska, Med Ctr, Eppley Inst Res Canc & Allied Dis, Omaha, NE 68198 USA; Univ Nebraska, Med Ctr, Dept Pathol & Microbiol, Omaha, NE 68198 USA; Univ Nebraska, Med Ctr, Dept Biochem & Mol Biol, Omaha, NE 68198 USA	University of Nebraska System; University of Nebraska Medical Center; University of Nebraska System; University of Nebraska Medical Center; University of Nebraska System; University of Nebraska Medical Center	Lewis, RE (corresponding author), Univ Nebraska, Med Ctr, Eppley Inst Res Canc & Allied Dis, 600 S 42nd St, Omaha, NE 68198 USA.		Lewis, Robert E./H-3404-2019	Schweppe, Rebecca/0000-0001-7502-0151	NCI NIH HHS [CA09476, P30 CA36727] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA036727, T32CA009476] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Al-Shami A, 1998, J BIOL CHEM, V273, P1058, DOI 10.1074/jbc.273.2.1058; ARSURA M, 1992, BLOOD, V79, P2708; Bartsch O, 1999, EUR J BIOCHEM, V260, P384, DOI 10.1046/j.1432-1327.1999.00191.x; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; FOOS G, 1993, ONCOGENE, V8, P1775; FOOS G, 1992, EMBO J, V11, P4619, DOI 10.1002/j.1460-2075.1992.tb05564.x; Holmes JK, 1996, J BIOL CHEM, V271, P25240, DOI 10.1074/jbc.271.41.25240; HOWE KM, 1991, NUCLEIC ACIDS RES, V19, P3913, DOI 10.1093/nar/19.14.3913; LAM EWF, 1992, ONCOGENE, V7, P1885; LAM EWF, 1993, EMBO J, V12, P2705, DOI 10.1002/j.1460-2075.1993.tb05932.x; Lane S, 1997, ONCOGENE, V14, P2445, DOI 10.1038/sj.onc.1201086; LIN D, 1992, P NATL ACAD SCI USA, V89, P9210, DOI 10.1073/pnas.89.19.9210; LIN D, 1994, P NATL ACAD SCI USA, V91, P10079, DOI 10.1073/pnas.91.21.10079; Marhamati DJ, 1996, J BIOL CHEM, V271, P3359; NAKAGOSHI H, 1992, ONCOGENE, V7, P1233; NAKAGOSHI H, 1993, J BIOL CHEM, V268, P14161; Ness SA, 1996, BBA-REV CANCER, V1288, pF123, DOI 10.1016/S0304-419X(96)00027-3; NESS SA, 1989, CELL, V59, P1115, DOI 10.1016/0092-8674(89)90767-8; NOMURA N, 1988, NUCLEIC ACIDS RES, V16, P11075, DOI 10.1093/nar/16.23.11075; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; Robinson C, 1996, ONCOGENE, V12, P1855; Rogers JA, 1996, J BIOL CHEM, V271, P17519, DOI 10.1074/jbc.271.29.17519; SAKURA H, 1989, P NATL ACAD SCI USA, V86, P5758, DOI 10.1073/pnas.86.15.5758; SALA A, 1992, P NATL ACAD SCI USA, V89, P10415, DOI 10.1073/pnas.89.21.10415; Sala A, 1996, J BIOL CHEM, V271, P9363, DOI 10.1074/jbc.271.16.9363; Sala A, 1997, P NATL ACAD SCI USA, V94, P532, DOI 10.1073/pnas.94.2.532; Sala A, 1996, J BIOL CHEM, V271, P28738, DOI 10.1074/jbc.271.46.28738; Saville MK, 1998, ONCOGENE, V17, P2679, DOI 10.1038/sj.onc.1202503; Saville MK, 1998, ADV CANCER RES, V72, P109; TASHIRO S, 1995, ONCOGENE, V10, P1699; Tauer TJ, 1996, J BIOL CHEM, V271, P331, DOI 10.1074/jbc.271.1.331; Volle DJ, 1999, BIOCHEMISTRY-US, V38, P5130, DOI 10.1021/bi983050d; WATSON RJ, 1993, NUCLEIC ACIDS RES, V21, P267, DOI 10.1093/nar/21.2.267; WESTON K, 1989, CELL, V58, P85, DOI 10.1016/0092-8674(89)90405-4; Ziebold U, 1997, CURR BIOL, V7, P253, DOI 10.1016/S0960-9822(06)00121-7	35	44	45	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 17	1999	274	51					36741	36749		10.1074/jbc.274.51.36741	http://dx.doi.org/10.1074/jbc.274.51.36741			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	266AV	10593981	hybrid			2022-12-25	WOS:000084279200100
J	Okino, N; Ichinose, S; Omori, A; Imayama, S; Nakamura, T; Ito, M				Okino, N; Ichinose, S; Omori, A; Imayama, S; Nakamura, T; Ito, M			Molecular cloning, sequencing, and expression of the gene encoding alkaline ceramidase from Pseudomonas aeruginosa - Cloning of a ceramidase homologue from Mycobacterium tuberculosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN ACID CERAMIDASE; PROTEIN; SPHINGOSINE; INHIBITION; SPHINGOMYELINASE; PURIFICATION; BIOSYNTHESIS; ACTIVATION; RECEPTOR; INVITRO	We previously reported the purification and characterization of a novel type of alkaline ceramidase from Pseudomonas aeruginosa strain AN17 (Okino, N., Tani, M., Imayama, S., and Ito, IM. (1998) J. Biol. Chem. 273, 14368-14373). Here, we report the molecular cloning, sequencing, and expression of the gene encoding the ceramidase of this strain. Specific oligonucleotide primers were synthesized using the peptide sequences of the purified ceramidase obtained by digestion with lysylendopeptidase and used for polymerase chain reaction. DNA fragments thus amplified were used as probes to clone the gene encoding the ceramidase from a genomic library of strain AN17. The open reading frame of 2,010 nucleotides encoded a polypeptide of 670 amino acids including a signal sequence of 24 residues, 64 residues of which matched the amino acid sequence determined for the purified enzyme. The molecular weight of the mature enzyme was estimated to be 70,767 from the deduced amino acid sequence. Expression of the ceramidase gene in Escherichia coli, resulted in production of a soluble enzyme with the identical N-terminal amino acid sequence. Recombinant ceramidase was purified to homogeneity from the lysate of E. coli cells and con firmed to be identical to the Pseudomonas enzyme in its specificity and other enzymatic properties. No significant sequence similarities were found in other known functional proteins including human acid ceramidase. However, we found a sequence homologous to the ceramidase in hypothetical proteins encoded in Mycobacterium tuberculosis, Dictyostelium discoideum, and Arabidopsis thaliana. The homologue of the ceramidase gene was thus cloned from an M. tuberculosis cosmid and expressed in E. coli, and the gene was demonstrated to encode an alkaline ceramidase. This is the first report for the cloning of an alkaline ceramidase.	Kyushu Univ, Grad Sch, Dept Biosci & Biotechnol, Div Bioresource & Bioenvironm Sci,Higashi Ku, Fukuoka 8128581, Japan; Kyushu Univ, Grad Sch, Fac Med, Dept Dermatol,Higashi Ku, Fukuoka 8128581, Japan; Mitsubishi Kasei Inst Life Sci, Machida, Tokyo 1948511, Japan	Kyushu University; Kyushu University	Ito, M (corresponding author), Kyushu Univ, Grad Sch, Dept Biosci & Biotechnol, Div Bioresource & Bioenvironm Sci,Higashi Ku, Hakozaki 6-10-1, Fukuoka 8128581, Japan.		Ito, Makoto/Q-6164-2019; Okino, Nozomu/AAY-2635-2021	ito, Makoto/0000-0003-3159-7818				ABRAHMSEN L, 1985, EMBO J, V4, P3901, DOI 10.1002/j.1460-2075.1985.tb04164.x; BERNARDO K, 1995, J BIOL CHEM, V270, P11098, DOI 10.1074/jbc.270.19.11098; Bielawska A, 1996, J BIOL CHEM, V271, P12646, DOI 10.1074/jbc.271.21.12646; BODEY GP, 1983, REV INFECT DIS, V5, P279; Cole ST, 1998, NATURE, V393, P537, DOI 10.1038/31159; CORONEOS E, 1995, J BIOL CHEM, V270, P23305, DOI 10.1074/jbc.270.40.23305; DAINESE HP, 1997, EUR J BIOCHEM, V264, P336; GATT S, 1966, J BIOL CHEM, V241, P3724; HANNUN YA, 1986, J BIOL CHEM, V261, P2604; HASSLER DF, 1993, ADV LIPID RES, V26, P49; ITO M, 1995, J BIOL CHEM, V270, P24370, DOI 10.1074/jbc.270.41.24370; Koch J, 1996, J BIOL CHEM, V271, P33110, DOI 10.1074/jbc.271.51.33110; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lee MJ, 1998, SCIENCE, V279, P1552, DOI 10.1126/science.279.5356.1552; Li CM, 1998, GENOMICS, V50, P267, DOI 10.1006/geno.1998.5334; MERRILL AH, 1986, J BIOL CHEM, V261, P3764; NikolovaKarakashian M, 1997, J BIOL CHEM, V272, P18718, DOI 10.1074/jbc.272.30.18718; OISHI K, 1990, J BIOL CHEM, V265, P70; Okamoto H, 1998, J BIOL CHEM, V273, P27104, DOI 10.1074/jbc.273.42.27104; Okino N, 1998, J BIOL CHEM, V273, P14368, DOI 10.1074/jbc.273.23.14368; PUSHKAREVA MY, 1992, J BIOL CHEM, V267, P15246; SAITO H, 1963, BIOCHIM BIOPHYS ACTA, V72, P619, DOI 10.1016/0926-6550(63)90386-4; Sambrook H., 1989, MOL CLONING LAB MANU; Spiegel S, 1996, CURR OPIN CELL BIOL, V8, P159, DOI 10.1016/S0955-0674(96)80061-5; Spiegel S, 1996, FASEB J, V10, P1388, DOI 10.1096/fasebj.10.12.8903509; STOFFEL W, 1974, H-S Z PHYSIOL CHEM, V355, P61, DOI 10.1515/bchm2.1974.355.1.61; SUGITA M, 1972, SCIENCE, V178, P1100, DOI 10.1126/science.178.4065.1100; Tani M, 1998, ANAL BIOCHEM, V263, P183, DOI 10.1006/abio.1998.2781; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Zhang P, 1997, J BIOL CHEM, V272, P9609; ZUHERINGDORF DM, 1997, FEBS LETT, V410, P34	32	61	70	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 17	1999	274	51					36616	36622		10.1074/jbc.274.51.36616	http://dx.doi.org/10.1074/jbc.274.51.36616			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	266AV	10593963	hybrid			2022-12-25	WOS:000084279200082
J	Paka, L; Goldberg, IJ; Obunike, JC; Choi, SY; Saxena, U; Goldberg, ID; Pillarisetti, S				Paka, L; Goldberg, IJ; Obunike, JC; Choi, SY; Saxena, U; Goldberg, ID; Pillarisetti, S			Perlecan mediates the antiproliferative effect of apolipoprotein E on smooth muscle cells - An underlying mechanism for the modulation of smooth muscle cell growth?	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPARAN-SULFATE PROTEOGLYCANS; ACTIVATED PROTEIN-KINASE; LOW-DENSITY-LIPOPROTEIN; IN-VIVO; ENDOTHELIAL-CELLS; SUBENDOTHELIAL MATRIX; NEOINTIMAL FORMATION; STABLE EXPRESSION; GENE-EXPRESSION; CORE PROTEIN	Apolipoprotein E (apoE) is known to inhibit cell proliferation; however, the mechanism of this inhibition is not clear. We recently showed that apoE stimulates endothelial production of heparan sulfate (I-IS) enriched in heparin-like sequences. Because heparin and HS are potent inhibitors of smooth muscle cell (SMC) proliferation, in this study we determined apoE effects on SMC HS production and cell growth. In confluent SMCs, apoE (10 mu g/ml) increased (SO4)-S-35 incorporation into PG in media by 25-30%. The increase in the medium was exclusively due to an increase in HSPGs (2.2-fold), and apoE did not alter chondroitin and dermatan sulfate proteoglycans. In proliferating SMCs, apoE inhibited [H-3]thymidine incorporation into DNA by 50%; however, despite decreasing cell number, apoE increased the ratio of (SO4)-S-35 to [H-3]thymidine from 2 to 3.6, suggesting increased HS per cell. Purified HSPGs from apoE-stimulated cells inhibited cell proliferation in the absence of apoE, ApoE did not inhibit proliferation of endothelial cells, which are resistant to heparin inhibition. Analysis of the conditioned medium from apoE stimulated cells revealed that the HSPG increase was in perlecan and that apoE also stimulated perlecan mRNA expression by >2-fold. The ability of apoE isoforms to inhibit cell proliferation correlated with their ability to stimulate perlecan expression. An anti-perlecan antibody completely abrogated the antiproliferative effect of apoE. Thus, these data show that perlecan is a potent inhibitor of SMC proliferation and is required to mediate the antiproliferative effect of apoE. Because other growth modulators also regulate perlecan expression, this may be a key pathway in the regulation of SMC growth.	N Shore Long Isl Jewish Hlth Syst, Dept Radiat Oncol, Manhasset, NY 11030 USA; Columbia Univ, Dept Med, Div Prevent Med, New York, NY 10032 USA; Palo Alto Med Fdn, Palo Alto, CA 94301 USA; Atherogen Inc, Alpharetta, GA 30004 USA	Northwell Health; Columbia University; Palo Alto Medical Foundation Research Institute	Pillarisetti, S (corresponding author), N Shore Long Isl Jewish Hlth Syst, Dept Radiat Oncol, Boas Marks Biomed Res Bldg,Rm 129,350 Community D, Manhasset, NY 11030 USA.	heparin@email.com			NHLBI NIH HHS [HL62301, HLK14-03323, HL56984] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K14HL003323, P50HL056984, R01HL062301] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Adatia R, 1997, ANN ONCOL, V8, P1257, DOI 10.1023/A:1008243115385; AU YPT, 1992, J BIOL CHEM, V267, P3438; Aviezer D, 1997, MOL CELL BIOL, V17, P1938, DOI 10.1128/MCB.17.4.1938; AVIEZER D, 1994, CELL, V79, P1005, DOI 10.1016/0092-8674(94)90031-0; BATTAGLIA C, 1992, EUR J BIOCHEM, V208, P359, DOI 10.1111/j.1432-1033.1992.tb17195.x; Belknap JK, 1999, AM J RESP CELL MOL, V20, P24, DOI 10.1165/ajrcmb.20.1.3321; BELLOSTA S, 1995, J CLIN INVEST, V96, P2170, DOI 10.1172/JCI118271; Bingley JA, 1998, J VASC SURG, V28, P308, DOI 10.1016/S0741-5214(98)70167-3; Brown CT, 1999, J BIOL CHEM, V274, P7111, DOI 10.1074/jbc.274.11.7111; CASTELLOT JJ, 1981, J CELL BIOL, V90, P372, DOI 10.1083/jcb.90.2.372; Chai YC, 1996, J BIOL CHEM, V271, P17791, DOI 10.1074/jbc.271.30.17791; CHOI SSY, 1994, J LIPID RES, V35, P848; CLOWES AW, 1977, NATURE, V265, P625, DOI 10.1038/265625a0; de Beer F, 1999, ARTERIOSCL THROM VAS, V19, P633, DOI 10.1161/01.ATV.19.3.633; Fazio S, 1997, P NATL ACAD SCI USA, V94, P4647, DOI 10.1073/pnas.94.9.4647; Fujii N, 1997, THROMB RES, V88, P299, DOI 10.1016/S0049-3848(97)00257-0; GARG UC, 1989, J CLIN INVEST, V83, P1774, DOI 10.1172/JCI114081; Gauer S, 1996, EUR J CELL BIOL, V70, P233; HAMMERLE H, 1991, VASA-J VASCULAR DIS, V20, P207; HAYASHI K, 1992, J CELL BIOL, V119, P945, DOI 10.1083/jcb.119.4.945; HUANG YD, 1994, P NATL ACAD SCI USA, V91, P1834, DOI 10.1073/pnas.91.5.1834; IOZZO RV, 1994, BIOCHEM J, V302, P625, DOI 10.1042/bj3020625; Iozzo RV, 1997, J BIOL CHEM, V272, P5219, DOI 10.1074/jbc.272.8.5219; Ishigami M, 1998, J BIOL CHEM, V273, P20156, DOI 10.1074/jbc.273.32.20156; Ishigami M, 1998, CIRCULATION, V98, P734; Ji ZS, 1998, J BIOL CHEM, V273, P13452, DOI 10.1074/jbc.273.22.13452; JI ZS, 1994, ARTERIOSCLER THROMB, V14, P2025, DOI 10.1161/01.ATV.14.12.2025; KELLY ME, 1994, CELL IMMUNOL, V159, P124, DOI 10.1006/cimm.1994.1302; KINSELLA MG, 1988, BIOCHEMISTRY-US, V27, P2136, DOI 10.1021/bi00406a048; KISILEVSKY R, 1995, NAT MED, V1, P143, DOI 10.1038/nm0295-143; KLEIN G, 1995, MATRIX BIOL, V14, P457, DOI 10.1016/0945-053X(95)90003-9; Koyama N, 1998, CIRC RES, V83, P305, DOI 10.1161/01.RES.83.3.305; MAHLEY RW, 1988, SCIENCE, V240, P622, DOI 10.1126/science.3283935; MAJACK RA, 1988, J CELL BIOL, V107, P1207, DOI 10.1083/jcb.107.3.1207; MCCAFFREY TA, 1989, J CELL BIOL, V109, P441, DOI 10.1083/jcb.109.1.441; Miyata M, 1996, NAT GENET, V14, P55, DOI 10.1038/ng0996-55; OTTLINGER ME, 1993, J BIOL CHEM, V268, P19173; Paka L, 1999, J BIOL CHEM, V274, P4816, DOI 10.1074/jbc.274.8.4816; Pillarisetti S, 1997, J CLIN INVEST, V100, P867, DOI 10.1172/JCI119602; Pillarisetti S, 1995, J BIOL CHEM, V270, P29760; Rapraeger AC, 1998, CURR OPIN CELL BIOL, V10, P620, DOI 10.1016/S0955-0674(98)80038-0; REILLY CF, 1988, J CELL PHYSIOL, V136, P23, DOI 10.1002/jcp.1041360104; Riddell DR, 1997, J BIOL CHEM, V272, P89; Rosenberg RD, 1997, J CLIN INVEST, V99, P2062, DOI 10.1172/JCI119377; SAXENA U, 1993, J BIOL CHEM, V268, P14812; SCHREIBER BM, 1994, J LIPID RES, V35, P1177; Schwartz SM, 1998, ANNU REV MED, V49, P437; Sharma B, 1998, J CLIN INVEST, V102, P1599, DOI 10.1172/JCI3793; SHIMANO H, 1995, J CLIN INVEST, V95, P469, DOI 10.1172/JCI117687; Silver PJ, 1998, EUR J PHARMACOL, V351, P79, DOI 10.1016/S0014-2999(98)00293-3; SIVARAM P, 1992, J BIOL CHEM, V267, P16517; SNOW AD, 1994, NEURON, V12, P219, DOI 10.1016/0896-6273(94)90165-1; Sperinde GV, 1998, BIOCHEMISTRY-US, V37, P13153, DOI 10.1021/bi980600z; VOGEL T, 1994, J CELL BIOCHEM, V54, P299, DOI 10.1002/jcb.240540306; Wang WZ, 1996, J CLIN INVEST, V98, P443, DOI 10.1172/JCI118810; Weiser MCM, 1997, MOL BIOL CELL, V8, P999, DOI 10.1091/mbc.8.6.999; Weiser MCM, 1996, MATRIX BIOL, V15, P331, DOI 10.1016/S0945-053X(96)90136-5; WEISGRABER KH, 1994, ADV PROTEIN CHEM, V45, P249	58	45	50	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 17	1999	274	51					36403	36408		10.1074/jbc.274.51.36403	http://dx.doi.org/10.1074/jbc.274.51.36403			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	266AV	10593935	hybrid			2022-12-25	WOS:000084279200054
J	Park, JE; Lenter, MC; Zimmermann, RN; Garin-Chesa, P; Old, LJ; Rettig, WJ				Park, JE; Lenter, MC; Zimmermann, RN; Garin-Chesa, P; Old, LJ; Rettig, WJ			Fibroblast activation protein, a dual specificity serine protease expressed in reactive human tumor stromal fibroblasts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							T-CELL ACTIVATION; DIPEPTIDYLPEPTIDASE-IV; EPITHELIAL CANCERS; DIFFERENTIAL EXPRESSION; MOLECULAR-CLONING; TISSUE INHIBITOR; GROWTH-FACTORS; UP-REGULATION; GELATINASE-A; FREE ENZYME	Proteolytic degradation of extracellular matrix (ECM) components during tissue remodeling plays a pivotal role in normal and pathological processes including wound healing, inflammation, tumor invasion, and metastasis. Proteolytic enzymes in tumors may activate or release growth factors from the ECM or act directly on the ECM itself thereby facilitating angiogenesis or tumor cell migration. Fibroblast activation protein (FAP) is a cell surface antigen of reactive tumor stromal fibroblasts found in epithelial cancers and in granulation tissue during wound healing. It is absent from most normal adult human tissues. FAP is conserved throughout chordate evolution, with homologues in mouse and Xenopus laevis, whose expression correlates with tissue remodeling events. Using recombinant and purified natural FAP, we show that FAP has both dipeptidyl peptidase activity and a collagenolytic activity capable of degrading gelatin and type I collagen; by sequence, FAP belongs to the serine protease family rather than the matrix metalloprotease family. Mutation of the putative catalytic serine residue of FAP to alanine abolishes both enzymatic activities. Consistent with its in vivo expression pattern determined by immunohistochemistry, FAP enzyme activity was detected by an immunocapture assay in human cancerous tissues but not in matched normal tissues. This study demonstrates that FAP is present as an active cell surface-bound collagenase in epithelial tumor stroma and opens up investigation into physiological substrates of its novel, tumor-associated dipeptidyl peptidase activity.	Boehringer Ingelheim Pharma KG, Dept Oncol Res, D-88397 Biberach, Germany; Mem Sloan Kettering Canc Ctr, Biochem Pharmacol Lab, Ludwig Inst Canc Res, New York, NY 10021 USA	Boehringer Ingelheim; Ludwig Institute for Cancer Research; Memorial Sloan Kettering Cancer Center	Park, JE (corresponding author), Boehringer Ingelheim Pharma KG, Dept Oncol Res, Birkendorferstr 65, D-88397 Biberach, Germany.							Andreasen PA, 1997, INT J CANCER, V72, P1, DOI 10.1002/(SICI)1097-0215(19970703)72:1<1::AID-IJC1>3.0.CO;2-Z; Barrett A. J., 1998, HDB PROTEOLYTIC ENZY; Bermpohl F, 1998, FEBS LETT, V428, P152, DOI 10.1016/S0014-5793(98)00515-8; Bond M, 1998, FEBS LETT, V435, P29, DOI 10.1016/S0014-5793(98)01034-5; Brown DD, 1996, P NATL ACAD SCI USA, V93, P1924, DOI 10.1073/pnas.93.5.1924; Brubaker PL, 1997, ENDOCRINOLOGY, V138, P4837, DOI 10.1210/en.138.11.4837; CAMPO E, 1992, HUM PATHOL, V23, P1395, DOI 10.1016/0046-8177(92)90060-G; Davidson B, 1997, PATHOL RES PRACT, V193, P491, DOI 10.1016/S0344-0338(97)80102-1; DOCHERTY K, 1982, P NATL ACAD SCI-BIOL, V79, P4613, DOI 10.1073/pnas.79.15.4613; DVORAK AM, 1980, J INVEST DERMATOL, V75, P388, DOI 10.1111/1523-1747.ep12523627; FLEISCHER B, 1994, IMMUNOL TODAY, V15, P180, DOI 10.1016/0167-5699(94)90316-6; FRIDMAN R, 1993, BIOCHEM J, V289, P411, DOI 10.1042/bj2890411; FRIDMAN R, 1995, CANCER RES, V55, P2548; GARINCHESA P, 1990, P NATL ACAD SCI USA, V87, P7235, DOI 10.1073/pnas.87.18.7235; GORDON SG, 1981, J CLIN INVEST, V67, P1665, DOI 10.1172/JCI110203; GORVEL JP, 1991, GASTROENTEROLOGY, V101, P618, DOI 10.1016/0016-5085(91)90517-O; HAYASHI R, 1975, J BIOCHEM-TOKYO, V77, P1313; Hayashi T, 1996, AM J PATHOL, V149, P1241; Jackson RC, 1997, SEMIN ONCOL, V24, P164; Kinoh H, 1996, J CELL SCI, V109, P953; KLEINER DE, 1994, ANAL BIOCHEM, V218, P325, DOI 10.1006/abio.1994.1186; KOHN EC, 1995, CANCER RES, V55, P1856; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANE P, 1993, J EXP MED, V177, P1209, DOI 10.1084/jem.177.4.1209; Liotta L A, 1990, Semin Cancer Biol, V1, P99; MANTEUFFEL R, 1983, J BIOCHEM BIOPH METH, V7, P293, DOI 10.1016/0165-022X(83)90054-4; MATHEW S, 1995, GENOMICS, V25, P335, DOI 10.1016/0888-7543(95)80157-H; MEDEIROS MD, 1994, ENDOCRINOLOGY, V134, P2088, DOI 10.1210/en.134.5.2088; Medeiros MD, 1996, NEUROCHEM RES, V21, P1125, DOI 10.1007/BF02532423; MEDEIROS MS, 1994, BIOCHIMIE, V76, P283, DOI 10.1016/0300-9084(94)90159-7; MONSKY WL, 1994, CANCER RES, V54, P5702; Mountain A, 1992, Biotechnol Genet Eng Rev, V10, P1; NAGATSU T, 1985, ANAL BIOCHEM, V147, P80, DOI 10.1016/0003-2697(85)90011-9; Niedermeyer J, 1997, INT J CANCER, V71, P383, DOI 10.1002/(SICI)1097-0215(19970502)71:3<383::AID-IJC14>3.0.CO;2-H; O'Reilly D.R., 1994, BACULOVIRUS EXPRESSI; Oravecz T, 1997, J EXP MED, V186, P1865, DOI 10.1084/jem.186.11.1865; PARK JE, 1991, SOMAT CELL MOLEC GEN, V17, P137, DOI 10.1007/BF01232971; PARK JE, 1994, J BIOL CHEM, V269, P25646; PEDERSEN H, 1994, CANCER RES, V54, P4671; PEI DQ, 1995, NATURE, V375, P244, DOI 10.1038/375244a0; PineiroSanchez ML, 1997, J BIOL CHEM, V272, P7595, DOI 10.1074/jbc.272.12.7595; Proost P, 1998, J BIOL CHEM, V273, P7222, DOI 10.1074/jbc.273.13.7222; Rasmussen HS, 1997, PHARMACOL THERAPEUT, V75, P69, DOI 10.1016/S0163-7258(97)00023-5; RETTIG WJ, 1993, CANCER RES, V53, P3327; RETTIG WJ, 1994, INT J CANCER, V58, P385, DOI 10.1002/ijc.2910580314; RETTIG WJ, 1988, P NATL ACAD SCI USA, V85, P3110, DOI 10.1073/pnas.85.9.3110; RIEMANN D, 1995, CLIN EXP IMMUNOL, V100, P277; RYAN DH, 1988, CLIN CHIM ACTA, V171, P125, DOI 10.1016/0009-8981(88)90142-8; SCANLAN MJ, 1994, P NATL ACAD SCI USA, V91, P5657, DOI 10.1073/pnas.91.12.5657; SCHUTKOWSKI M, 1994, EUR J BIOCHEM, V221, P455, DOI 10.1111/j.1432-1033.1994.tb18758.x; STETLERSTEVENSON WG, 1993, FASEB J, V7, P1434, DOI 10.1096/fasebj.7.15.8262328; Su SM, 1998, J CELL BIOCHEM, V70, P517, DOI 10.1002/(SICI)1097-4644(19980915)70:4<517::AID-JCB8>3.0.CO;2-M; TANAKA T, 1992, J IMMUNOL, V149, P481; TOMBIN H, 1979, P NATL ACAD SCI USA, V76, P4350; vonBonin A, 1997, IMMUNOL LETT, V55, P179, DOI 10.1016/S0165-2478(97)02705-3; WADA K, 1992, P NATL ACAD SCI USA, V89, P197, DOI 10.1073/pnas.89.1.197; WAHLBY S, 1968, BIOCHIM BIOPHYS ACTA, V151, P402, DOI 10.1016/0005-2744(68)90107-1; WEAVER TE, 1992, AM J PHYSIOL, V263, pL95, DOI 10.1152/ajplung.1992.263.1.L95; YOKOTANI N, 1993, HUM MOL GENET, V2, P1037, DOI 10.1093/hmg/2.7.1037; YUN SL, 1977, BIOCHIM BIOPHYS ACTA, V480, P1, DOI 10.1016/0005-2744(77)90315-1	60	418	464	3	41	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 17	1999	274	51					36505	36512		10.1074/jbc.274.51.36505	http://dx.doi.org/10.1074/jbc.274.51.36505			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	266AV	10593948	hybrid			2022-12-25	WOS:000084279200067
J	Sun, MF; Zhao, MM; Gailani, D				Sun, MF; Zhao, MM; Gailani, D			Identification of amino acids in the factor XI apple 3 domain required for activation of factor IX	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BLOOD-COAGULATION FACTOR; HUMAN-PLASMA PREKALLIKREIN; KININOGEN BINDING-SITE; 4 TANDEM REPEATS; FUNCTIONAL-CHARACTERIZATION; DISULFIDE BONDS; HEAVY-CHAIN; PURIFICATION; THROMBIN; MECHANISM	Activated coagulation factor XI (factor XIa) proteolytically cleaves its substrate, factor IX, in an interaction requiring the factor XI A3 domain (Sun, Y., and Gailani, D, (1996) J, Biol, Chem, 271, 29023-29028). To identify key amino acids involved in factor IX activation, recombinant factor XIa proteins containing alanine substitutions for wild-type sequence were expressed in 293 fibroblasts and tested in a plasma clotting assay. Substitutions for Ile(183)-Val(191) and Ser(195)-Ile(197) at the N terminus and for Ser(258)-Ser(264) at the C terminus of the A3 domain markedly decreased factor XI coagulant activity. The plasma protease prekallikrein is structurally homologous to factor XI, but activated factor IX poorly. A chimeric factor XIa molecule with the AS domain replaced with A3 from prekallikrein (FXI/PKA3) activated factor M with a K-m 35-fold greater than that of wild-type factor XI. FXI/PKA3 was used as a template for a series of proteins in which prekallikrein A3 sequence was replaced with factor XI sequence to restore factor M activation. Clotting and kinetics studies using these chimeras confirmed the results obtained with alanine mutants. Amino acids between Ile(183) and Val(191) are necessary for proper factor M activation, but additional sequence between Ser(195) and Ile(197) or between Phe(260) and Ser(265) is required for complete restoration of activation.	Vanderbilt Univ, Div Hematol Oncol, Dept Pathol, Nashville, TN 37232 USA; Vanderbilt Univ, Dept Med, Nashville, TN 37232 USA	Vanderbilt University; Vanderbilt University	Gailani, D (corresponding author), Vanderbilt Univ, Div Hematol Oncol, Dept Pathol, 538 MRB 2,2220 Pierce Ave, Nashville, TN 37232 USA.	dave.gailani@mcmail.vanderbilt.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL058837, K08HL002917] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL02917, HL58837] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BAGLIA FA, 1995, J BIOL CHEM, V270, P6734, DOI 10.1074/jbc.270.12.6734; BAGLIA FA, 1992, J BIOL CHEM, V267, P4247; BAGLIA FA, 1990, J BIOL CHEM, V265, P4149; Baglia FA, 1996, J BIOL CHEM, V271, P3652; BAGLIA FA, 1993, J BIOL CHEM, V268, P3838; Baglia FA, 1998, BIOCHEMISTRY-US, V37, P2271, DOI 10.1021/bi972113+; BELL WN, 1954, NATURE, V174, P880, DOI 10.1038/174880a0; BOUMA BN, 1977, J BIOL CHEM, V252, P6432; CHUNG DW, 1986, BIOCHEMISTRY-US, V25, P2410, DOI 10.1021/bi00357a017; DAVIE EW, 1991, BIOCHEMISTRY-US, V30, P10363, DOI 10.1021/bi00107a001; DISCIPIO RG, 1978, J CLIN INVEST, V61, P1528, DOI 10.1172/JCI109073; FUJIKAWA K, 1986, BIOCHEMISTRY-US, V25, P2417, DOI 10.1021/bi00357a018; FURIE B, 1988, CELL, V53, P505, DOI 10.1016/0092-8674(88)90567-3; GAILANI D, 1991, SCIENCE, V253, P909, DOI 10.1126/science.1652157; Gailani D, 1997, BLOOD, V90, P1055, DOI 10.1182/blood.V90.3.1055.1055_1055_1064; Ho DH, 1998, J BIOL CHEM, V273, P16382, DOI 10.1074/jbc.273.26.16382; Ho DH, 1996, BLOOD, V88, P1120; KOIDE T, 1977, BIOCHEMISTRY-US, V16, P2279, DOI 10.1021/bi00629a037; MASHIKO H, 1994, BIOL CHEM H-S, V375, P481; MCMULLEN BA, 1991, BIOCHEMISTRY-US, V30, P2056, DOI 10.1021/bi00222a008; MCMULLEN BA, 1991, BIOCHEMISTRY-US, V30, P2050, DOI 10.1021/bi00222a007; MEIJERS JCM, 1992, BIOCHEMISTRY-US, V31, P4680, DOI 10.1021/bi00134a021; NAITO K, 1991, J BIOL CHEM, V266, P7353; OSTERUD B, 1978, J BIOL CHEM, V253, P5946; SINHA D, 1985, J BIOL CHEM, V260, P714; SINHA D, 1987, BIOCHEMISTRY-US, V26, P3768, DOI 10.1021/bi00387a005; Sun YH, 1996, J BIOL CHEM, V271, P29023, DOI 10.1074/jbc.271.46.29023; VANDERGRAAF F, 1983, J BIOL CHEM, V258, P9669; WAGENVOORD R, 1990, HAEMOSTASIS, V20, P276; WALSH PN, 1984, J CLIN INVEST, V73, P1392, DOI 10.1172/JCI111343; WIGGINS RC, 1979, THROMB RES, V15, P475, DOI 10.1016/0049-3848(79)90153-1; Zhao MM, 1998, J BIOL CHEM, V273, P31153, DOI 10.1074/jbc.273.47.31153	32	59	64	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 17	1999	274	51					36373	36378		10.1074/jbc.274.51.36373	http://dx.doi.org/10.1074/jbc.274.51.36373			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	266AV	10593931	hybrid			2022-12-25	WOS:000084279200050
J	Yuan, YP; Kulkarni, S; Ulsemer, P; Cranmer, SL; Yap, CL; Nesbitt, WS; Harper, I; Mistry, N; Dopheide, SM; Hughan, SC; Williamson, D; de la Salle, C; Salem, HH; Lanza, F; Jackson, SP				Yuan, YP; Kulkarni, S; Ulsemer, P; Cranmer, SL; Yap, CL; Nesbitt, WS; Harper, I; Mistry, N; Dopheide, SM; Hughan, SC; Williamson, D; de la Salle, C; Salem, HH; Lanza, F; Jackson, SP			The von Willebrand factor-glycoprotein Ib/V/IX interaction induces actin polymerization and cytoskeletal reorganization in rolling platelets and glycoprotein Ib/V/IX-transfected cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VONWILLEBRAND-FACTOR BINDING; IIB-IIIA; SHEAR-STRESS; SIGNAL-TRANSDUCTION; THROMBUS FORMATION; GP-IB; ACTIVATION; ADHESION; AGGREGATION; FIBRINOGEN	Platelet adhesion to sites of vascular injury is initiated by the binding of the platelet glycoprotein (GP) Ib-V-M complex to matrix-bound von Willebrand factor (vWf). This receptor-ligand interaction is characterized by a rapid on-off rate that enables efficient platelet tethering and rolling under conditions of rapid blood flow. We demonstrate here that platelets adhering to immobilized vWf under flow conditions undergo rapid morphological conversion from flat discs to spiny spheres during surface translocation. Studies of Glanzmann thrombasthenic platelets (lacking integrin alpha(IIb)beta(3)) and Chinese hamster ovary (CHO) cells transfected with GPIb/IX (CHO-Ib/IX) confirmed that vWf binding to GPIb/IX was sufficient to induce actin polymerization and cytoskeletal reorganization independent of integrin alpha(IIb)beta(3). vWf-induced cytoskeletal reorganization occurred independently of several well characterized signaling processes linked to platelet activation, including calcium influx, prostaglandin metabolism, protein tyrosine phosphorylation, activation of protein kinase C or phosphatidylinositol 3-kinase but was critically dependent on the mobilization of intracellular calcium. Studies of Oregon Green 488 1,2-bis(o-amino-5-fluorophenoxy)ethane-N,N,N',N-tetraacetic acid tetraacetoxymethyl ester-loaded platelets and CHO-Ib/IX cells demonstrated that these cells mobilize intracellular calcium in a shear-dependent manner during surface translocation on vWf. Taken together, these studies suggest that the vWf-GPIb interaction stimulates actin polymerization and cytoskeletal reorganization in rolling platelets via a shear-sensitive signaling pathway linked to intracellular calcium mobilization.	Australian Ctr Blood Dis, Dept Med, Monash Med Sch, Box Hill, Vic, Australia; Box Hill Hosp, Dept Pathol, Box Hill, Vic, Australia; INSERM, Etab Transfus Sanguine, U311, F-67065 Strasbourg, France	Monash University; Box Hill Hospital; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Jackson, SP (corresponding author), Box Hill Hosp, Australian Ctr Blood Dis, Dept Med, Monash Med Sch, Arnold St, Box Hill, Vic 3128, Australia.	Shaun.Jackson@med.monash.edu.au	Lanza, Francois/H-9252-2016	Lanza, Francois/0000-0002-5802-4748; Harper, Ian/0000-0002-5499-2231; Jackson, Shaun/0000-0002-4750-1991; Nesbitt, Warwick/0000-0001-5644-7053				ASAZUMA N, 1998, BLOOD, V90, P727; BLIKSTAD I, 1978, CELL, V15, P935, DOI 10.1016/0092-8674(78)90277-5; CARRELL NA, 1985, J BIOL CHEM, V260, P1743; CHOW TW, 1992, BLOOD, V80, P113; COOPER JA, 1987, J CELL BIOL, V105, P1473, DOI 10.1083/jcb.105.4.1473; Cranmer SL, 1999, J BIOL CHEM, V274, P6097, DOI 10.1074/jbc.274.10.6097; Cunningham JG, 1996, J BIOL CHEM, V271, P11581, DOI 10.1074/jbc.271.19.11581; DEMARCO L, 1985, J CLIN INVEST, V75, P1198, DOI 10.1172/JCI111816; ESCOLAR G, 1994, J LAB CLIN MED, V123, P536; FOX JEB, 1993, J BIOL CHEM, V268, P25973; FOX JEB, 1981, ANAL BIOCHEM, V117, P170, DOI 10.1016/0003-2697(81)90707-7; Goto S, 1998, J CLIN INVEST, V101, P479, DOI 10.1172/JCI973; GRALNICK HR, 1985, J CLIN INVEST, V75, P19; HARTWIG JH, 1992, J CELL BIOL, V118, P1421, DOI 10.1083/jcb.118.6.1421; Hartwig JH, 1996, J BIOL CHEM, V271, P32986, DOI 10.1074/jbc.271.51.32986; HARTWIG JH, 1995, CELL, V82, P643, DOI 10.1016/0092-8674(95)90036-5; HENSLER ME, 1992, AM J PATHOL, V141, P707; HEPTINSTALL S, 1992, THROMB HAEMOSTASIS, V68, P727; IKEDA Y, 1993, THROMB HAEMOSTASIS, V69, P496; JACKSON SP, 1994, J BIOL CHEM, V269, P27093; Kovacsovics TJ, 1996, BLOOD, V87, P618, DOI 10.1182/blood.V87.2.618.bloodjournal872618; KROLL MH, 1991, J CLIN INVEST, V88, P1568, DOI 10.1172/JCI115468; KROLL MH, 1993, J BIOL CHEM, V268, P3520; Kuwahara M, 1999, BLOOD, V94, P1149, DOI 10.1182/blood.V94.4.1149.416k18_1149_1155; LAWRENCE MB, 1991, CELL, V65, P859, DOI 10.1016/0092-8674(91)90393-D; Meyer SC, 1997, THROMB HAEMOSTASIS, pSC677; MONTGOMERY RR, 1978, J CLIN INVEST, V61, P1498, DOI 10.1172/JCI109070; Poole A, 1997, EMBO J, V16, P2333, DOI 10.1093/emboj/16.9.2333; QUILLIAM AL, 1993, IMMUNOLOGY, V78, P358; RAZDAN K, 1994, BIOCHEM J, V302, P681, DOI 10.1042/bj3020681; REDDICK RL, 1982, P NATL ACAD SCI-BIOL, V79, P5076, DOI 10.1073/pnas.79.16.5076; Ruggeri ZM, 1993, CURR OPIN CELL BIOL, V5, P898, DOI 10.1016/0955-0674(93)90041-N; Ruggeri ZM, 1997, J CLIN INVEST, V99, P559, DOI 10.1172/JCI119195; RUGGERI ZM, 1983, J CLIN INVEST, V72, P1, DOI 10.1172/JCI110946; SAKARIASSEN KS, 1986, BRIT J HAEMATOL, V63, P681, DOI 10.1111/j.1365-2141.1986.tb07552.x; Savage B, 1996, CELL, V84, P289, DOI 10.1016/S0092-8674(00)80983-6; SAVAGE B, 1992, J BIOL CHEM, V267, P11300; SPECTOR I, 1989, CELL MOTIL CYTOSKEL, V13, P127, DOI 10.1002/cm.970130302; SPRINGER TA, 1994, CELL, V76, P301, DOI 10.1016/0092-8674(94)90337-9; Sullam PM, 1998, J BIOL CHEM, V273, P5331, DOI 10.1074/jbc.273.9.5331; Torti M, 1999, J BIOL CHEM, V274, P13690, DOI 10.1074/jbc.274.19.13690; WEISS HJ, 1986, BLOOD, V67, P322; YABUSAKI K, 1997, THROMB HAEMOSTASIS S, V465; Yuan YP, 1997, J BIOL CHEM, V272, P21847, DOI 10.1074/jbc.272.35.21847	45	97	99	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 17	1999	274	51					36241	36251		10.1074/jbc.274.51.36241	http://dx.doi.org/10.1074/jbc.274.51.36241			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	266AV	10593912	hybrid			2022-12-25	WOS:000084279200031
J	Cheng, DM; Marner, J; Rubenstein, PA				Cheng, DM; Marner, J; Rubenstein, PA			Interaction in vivo and in vitro between the yeast fimbrin, SAC6P, and a polymerization-defective yeast actin (V266G and L267G)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SEVERELY DECREASED HYDROPHOBICITY; F-ACTIN; SACCHAROMYCES-CEREVISIAE; BINDING PROTEINS; ATP HYDROLYSIS; CROSS-LINKING; ATOMIC MODEL; FILAMENTS; SUPPRESSION; MUTATION	A mutant yeast actin (GG) has decreased hydrophobicity in a subdomain 3/4 hydrophobic plug believed to be involved in a hydrophobic cross-strand "plug-pocket" interaction necessary for actin filament stability. This actin will not polymerize in vitro but is compatible with cell viability. We have assessed the ability of Sac6p, the yeast homologue of the actin filament stabilizing and bundling protein fimbrin, to restore polymerization in vitro and to facilitate GG-actin function in vivo. Sac6p rescues GG-actin polymerization at 25 degrees C but not at 4 degrees C. The actin polymerizes into bundles at room temperature with a fimbrin:actin molar ratio of 1:4. At this ratio, every actin monomer contacts a Sac6p actin binding domain. Following cold-induced depolymerization, actin/Sac6p mixtures repolymerize beginning at 15 degrees C instead of the 25 degrees C required for de novo assembly, because of the presence of residual actin-Sac6p nuclei. Generation of haploid Delta sac6/GG-actin cells from either diploid or haploid cells was unsuccessful. The facile isolation of cells with either mutation alone indicates a synthetic lethal relationship between this actin allele and the SAC6 gene. Sac6p may allow GG-actin function in vivo by stabilizing the actin in bundles thereby helping maintain sufficient levels of an otherwise destabilized actin monomer within the cell.	Univ Iowa, Coll Med, Dept Biochem, Iowa City, IA 52242 USA	University of Iowa	Rubenstein, PA (corresponding author), Univ Iowa, Coll Med, Dept Biochem, Iowa City, IA 52242 USA.	peter-rubenstein@uiowa.edu		Rubenstein, Peter/0000-0003-1225-4414	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM033689] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-33689] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADAMS AEM, 1989, SCIENCE, V243, P231, DOI 10.1126/science.2643162; ADAMS AEM, 1991, NATURE, V354, P404, DOI 10.1038/354404a0; ADAMS AEM, 1995, MOL CELL BIOL, V15, P69, DOI 10.1128/MCB.15.1.69; BRETSCHER A, 1980, J CELL BIOL, V86, P335, DOI 10.1083/jcb.86.1.335; BUTLER G, 1988, CURR GENET, V14, P405, DOI 10.1007/BF00521261; COMBEAU C, 1988, J BIOL CHEM, V263, P17429; COOK RK, 1992, PRACTICAL APPROACHES, P99; DEARRUDA MV, 1990, J CELL BIOL, V111, P1069, DOI 10.1083/jcb.111.3.1069; DRUBIN DG, 1988, J CELL BIOL, V107, P2551, DOI 10.1083/jcb.107.6.2551; GLENNEY JR, 1981, J BIOL CHEM, V256, P9283; Hanein D, 1998, NAT STRUCT BIOL, V5, P787, DOI 10.1038/1828; Hanein D, 1997, J CELL BIOL, V139, P387, DOI 10.1083/jcb.139.2.387; HOLMES KC, 1990, NATURE, V347, P44, DOI 10.1038/347044a0; HONTS JE, 1994, J CELL BIOL, V126, P413, DOI 10.1083/jcb.126.2.413; KARPOVA TS, 1995, J CELL BIOL, V131, P1483, DOI 10.1083/jcb.131.6.1483; KRON SJ, 1992, P NATL ACAD SCI USA, V89, P4466, DOI 10.1073/pnas.89.10.4466; Kuang B, 1997, J BIOL CHEM, V272, P1237, DOI 10.1074/jbc.272.2.1237; Kuang B, 1997, J BIOL CHEM, V272, P4412, DOI 10.1074/jbc.272.7.4412; KUBLER E, 1993, EMBO J, V12, P2855, DOI 10.1002/j.1460-2075.1993.tb05947.x; LIN CS, 1994, MOL CELL BIOL, V14, P2457, DOI 10.1128/MCB.14.4.2457; LORENZ M, 1993, J MOL BIOL, V234, P826, DOI 10.1006/jmbi.1993.1628; MATSUDAIRA P, 1991, TRENDS BIOCHEM SCI, V16, P87, DOI 10.1016/0968-0004(91)90039-X; NAMBA Y, 1992, J BIOCHEM-TOKYO, V112, P503, DOI 10.1093/oxfordjournals.jbchem.a123929; NG R, 1980, P NATL ACAD SCI-BIOL, V77, P3912, DOI 10.1073/pnas.77.7.3912; ORLOVA A, 1992, J MOL BIOL, V227, P1043, DOI 10.1016/0022-2836(92)90520-T; POLLARD TD, 1986, ANNU REV BIOCHEM, V55, P987, DOI 10.1146/annurev.bi.55.070186.005011; POLLARD TD, 1986, J CELL BIOL, V103, P2747, DOI 10.1083/jcb.103.6.2747; Prassler J, 1997, MOL BIOL CELL, V8, P83, DOI 10.1091/mbc.8.1.83; Sandrock TM, 1997, GENETICS, V147, P1635; SHERMAN F, 1991, METHOD ENZYMOL, V194, P3; Steinmetz MO, 1998, J MOL BIOL, V276, P1, DOI 10.1006/jmbi.1997.1529	31	18	18	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 10	1999	274	50					35873	35880		10.1074/jbc.274.50.35873	http://dx.doi.org/10.1074/jbc.274.50.35873			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	264NG	10585472	hybrid			2022-12-25	WOS:000084187900084
J	Navarro, L; David, M				Navarro, L; David, M			p38-dependent activation of interferon regulatory factor 3 by lipopolysaccharide	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOUBLE-STRANDED-RNA; TRANSCRIPTIONAL INDUCTION; GAMMA-INTERFERON; RESPONSE ELEMENT; VIRUS-INFECTION; INDUCIBLE GENE; EXPRESSION; PROTEIN; IDENTIFICATION; COMPLEX	Interferon regulatory factor 3 (IRF3) is known to participate in the transcriptional induction of interferon (IFN) cu and IFN beta genes, as well. as of a number of interferon-stimulated genes (ISGs), as a result of viral infection. In the present study we demonstrate the activation of IRF3 followed by ISG induction after exposure of cells to the bacterial cell wall component lipopolysaccharide. Engagement of Toll-like receptors by lipopolysaccharide triggered the nuclear translocation of IRF3, followed by its DNA binding and the subsequent induction of several interferon-regulated genes. Transcriptional activation of ISGs occurred in a protein synthesis independent manner, but was sensitive to inhibition of the stress-activated protein kinase, p38. The activation of IRF3 by viral particles or bacterial membrane components suggests that this signaling pathway might contribute to the evolutionary conserved innate immune response.	Univ Calif San Diego, Dept Biol, La Jolla, CA 92093 USA; Univ Calif San Diego, Ctr Canc, La Jolla, CA 92093 USA	University of California System; University of California San Diego; University of California System; University of California San Diego	David, M (corresponding author), Univ Calif San Diego, Dept Biol, Bonner Hall 3138,9500 Gilman Dr, La Jolla, CA 92093 USA.							BANDYOPADHYAY SK, 1995, J BIOL CHEM, V270, P19624, DOI 10.1074/jbc.270.33.19624; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; DECKER T, 1989, EMBO J, V8, P2009, DOI 10.1002/j.1460-2075.1989.tb03608.x; DUSTIN ML, 1986, J IMMUNOL, V137, P245; HARADA H, 1993, SCIENCE, V259, P971, DOI 10.1126/science.8438157; HARADA H, 1989, CELL, V58, P729, DOI 10.1016/0092-8674(89)90107-4; HASSEL BA, 1993, EMBO, V12, P3917; Juang YT, 1999, J BIOL CHEM, V274, P18060, DOI 10.1074/jbc.274.25.18060; KATZE MG, 1991, MOL CELL BIOL, V11, P5497, DOI 10.1128/MCB.11.11.5497; Kopp EB, 1999, CURR OPIN IMMUNOL, V11, P13, DOI 10.1016/S0952-7915(99)80003-X; LARNER AC, 1984, P NATL ACAD SCI-BIOL, V81, P6733, DOI 10.1073/pnas.81.21.6733; LEVY D, 1986, P NATL ACAD SCI USA, V83, P8929, DOI 10.1073/pnas.83.23.8929; Lin RT, 1998, MOL CELL BIOL, V18, P2986, DOI 10.1128/MCB.18.5.2986; LOH JE, 1992, EMBO J, V11, P1351, DOI 10.1002/j.1460-2075.1992.tb05180.x; LUSTER AD, 1987, MOL CELL BIOL, V7, P3723, DOI 10.1128/MCB.7.10.3723; Marie I, 1998, EMBO J, V17, P6660, DOI 10.1093/emboj/17.22.6660; MAROTTA G, 1993, BLOOD, V81, P267; Medzhitov R, 1997, NATURE, V388, P394, DOI 10.1038/41131; Navarro L, 1998, MOL CELL BIOL, V18, P3796, DOI 10.1128/MCB.18.7.3796; PORTER ACG, 1988, EMBO J, V7, P85, DOI 10.1002/j.1460-2075.1988.tb02786.x; Qureshi ST, 1999, J EXP MED, V189, P615, DOI 10.1084/jem.189.4.615; SCHUMANN RR, 1998, GILA, V3, P295; Wathelet MG, 1998, MOL CELL, V1, P507, DOI 10.1016/S1097-2765(00)80051-9; Weaver BK, 1998, MOL CELL BIOL, V18, P1359, DOI 10.1128/MCB.18.3.1359; Yang RB, 1998, NATURE, V395, P284, DOI 10.1038/26239; Yoneyama M, 1998, EMBO J, V17, P1087, DOI 10.1093/emboj/17.4.1087; ZHOU AM, 1993, CELL, V72, P753, DOI 10.1016/0092-8674(93)90403-D	27	102	105	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 10	1999	274	50					35535	35538		10.1074/jbc.274.50.35535	http://dx.doi.org/10.1074/jbc.274.50.35535			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	264NG	10585427	Green Published, hybrid			2022-12-25	WOS:000084187900039
J	Shimano, H; Yahagi, N; Amemiya-Kudo, M; Hasty, AH; Osuga, J; Tamura, Y; Shionoiri, F; Iizuka, Y; Ohashi, K; Harada, K; Gotoda, T; Ishibashi, S; Yamada, N				Shimano, H; Yahagi, N; Amemiya-Kudo, M; Hasty, AH; Osuga, J; Tamura, Y; Shionoiri, F; Iizuka, Y; Ohashi, K; Harada, K; Gotoda, T; Ishibashi, S; Yamada, N			Sterol regulatory element-binding protein-1 as a key transcription factor for nutritional induction of lipogenic enzyme genes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FATTY-ACID SYNTHASE; CARBOHYDRATE RESPONSE ELEMENT; UPSTREAM STIMULATORY FACTOR; ACTIVATED RECEPTOR-ALPHA; LEUCINE ZIPPER PROTEIN; PYRUVATE-KINASE GENE; MOLECULAR-CLONING; TRANSGENIC MICE; MESSENGER-RNA; DIFFERENTIATION FACTOR-1	To elucidate the physiological role of sterol regulatory element-binding protein-1 (SREBP-1), the hepatic mRNA levels of genes encoding various lipogenic enzymes were estimated in SREBP-1 gene knockout mice after a fasting-refeeding treatment, which is an established dietary manipulation for the induction of lipogenic enzymes. In the fasted state, the mRNA levels of all lipogenic enzymes were consistently low in both wildtype and SREBP-1(-/-) mice. However, the absence of SREBP-1 severely impaired the marked induction of hepatic mRNAs of fatty acid synthetic genes, such as acetyl-CoA carboxylase, fatty acid synthase, and stearoyl-CoA desaturase, that was observed upon refeeding in the wild-type mice. Furthermore, the refeeding responses of other lipogenic enzymes, glycerol-3-phosphate acyltransferase, ATP citrate lyase, malic enzyme, glucose-6-phosphate dehydrogenase, and S14 mRNAs, were completely abolished in SREBP-1(-/-) mice. In contrast, mRNA levels for cholesterol biosynthetic genes were elevated in the refed SREBP-1(-/-) livers accompanied by an increase in nuclear SREBP-8 protein. When fed a high carbohydrate diet for 14 days, the mRNA levels for these lipogenic enzymes were also strikingly lower in SREBP-1(-/-) mice than those in wild-type mice. These data demonstrate that SREBP-1 plays a crucial role in the induction of lipogenesis but not cholesterol biosynthesis in liver when excess energy by carbohydrates is consumed.	Univ Tokyo, Fac Med, Dept Metab Dis, Tokyo 1138655, Japan	University of Tokyo	Shimano, H (corresponding author), 7-3-1 Hongo,Bunkyo Ku, Tokyo 1138655, Japan.		Yahagi, Naoya/D-2360-2014; Shimano, Hitoshi/V-1761-2019; Hasty, Alyssa/AAA-2757-2020; Shimano, Hitoshi/AAI-5648-2020; Harada, Kenji/J-2230-2016	Yahagi, Naoya/0000-0002-1823-1865; Shimano, Hitoshi/0000-0002-5562-5572; Hasty, Alyssa/0000-0001-7302-8045; 				AMRI EZ, 1995, J BIOL CHEM, V270, P2367, DOI 10.1074/jbc.270.5.2367; Brown MS, 1997, CELL, V89, P331, DOI 10.1016/S0092-8674(00)80213-5; Casado M, 1999, J BIOL CHEM, V274, P2009, DOI 10.1074/jbc.274.4.2009; ELSHOURBAGY NA, 1990, J BIOL CHEM, V265, P1430; Ericsson J, 1996, P NATL ACAD SCI USA, V93, P945, DOI 10.1073/pnas.93.2.945; Ericsson J, 1997, J BIOL CHEM, V272, P7298, DOI 10.1074/jbc.272.11.7298; GOODRIDGE AG, 1987, ANNU REV NUTR, V7, P157, DOI 10.1146/annurev.nu.07.070187.001105; GRANNER D, 1990, J BIOL CHEM, V265, P10173; GUAN GM, 1995, J BIOL CHEM, V270, P21958, DOI 10.1074/jbc.270.37.21958; Hasegawa J, 1999, J BIOL CHEM, V274, P1100, DOI 10.1074/jbc.274.2.1100; Heng YM, 1997, BIOCHEM J, V325, P741, DOI 10.1042/bj3250741; HILLGARTNER F, 1995, PHYSIOL REV, V75, P47, DOI 10.1152/physrev.1995.75.1.47; Horton JD, 1998, P NATL ACAD SCI USA, V95, P5987, DOI 10.1073/pnas.95.11.5987; Horton JD, 1998, J CLIN INVEST, V101, P2331, DOI 10.1172/JCI2961; HUA XX, 1993, P NATL ACAD SCI USA, V90, P11603, DOI 10.1073/pnas.90.24.11603; Kaytor EN, 1997, J BIOL CHEM, V272, P7525, DOI 10.1074/jbc.272.11.7525; KIM JB, 1995, MOL CELL BIOL, V15, P2582; Kim JB, 1996, GENE DEV, V10, P1096, DOI 10.1101/gad.10.9.1096; Kim JB, 1998, J CLIN INVEST, V101, P1, DOI 10.1172/JCI1411; Kroetz DL, 1998, J BIOL CHEM, V273, P31581, DOI 10.1074/jbc.273.47.31581; KROWCZYNSKA AM, 1989, NUCLEIC ACIDS RES, V17, P6408, DOI 10.1093/nar/17.15.6408; LIU ZR, 1993, J BIOL CHEM, V268, P12787; Lopez JM, 1996, P NATL ACAD SCI USA, V93, P1049, DOI 10.1073/pnas.93.3.1049; MIYAZAWA S, 1987, J BIOL CHEM, V262, P8131; MOUSTAID N, 1994, J BIOL CHEM, V269, P5629; NOGUCHI T, 1983, J BIOL CHEM, V258, P5220; Pai JT, 1998, J BIOL CHEM, V273, P26138, DOI 10.1074/jbc.273.40.26138; Parraga A, 1998, STRUCT FOLD DES, V6, P661, DOI 10.1016/S0969-2126(98)00067-7; Ren B, 1997, J BIOL CHEM, V272, P26827, DOI 10.1074/jbc.272.43.26827; Sato R, 1996, J BIOL CHEM, V271, P26461, DOI 10.1074/jbc.271.43.26461; SATO R, 1994, J BIOL CHEM, V269, P17267; SHENG ZQ, 1995, P NATL ACAD SCI USA, V92, P935, DOI 10.1073/pnas.92.4.935; SHIH HM, 1995, J BIOL CHEM, V270, P21991, DOI 10.1074/jbc.270.37.21991; SHIH HM, 1994, J BIOL CHEM, V269, P9380; SHIH HM, 1992, J BIOL CHEM, V267, P13222; Shimano H, 1996, J CLIN INVEST, V98, P1575, DOI 10.1172/JCI118951; Shimano H, 1997, J CLIN INVEST, V99, P846, DOI 10.1172/JCI119248; Shimano H, 1997, J CLIN INVEST, V100, P2115, DOI 10.1172/JCI119746; Shimomura I, 1998, J BIOL CHEM, V273, P35299, DOI 10.1074/jbc.273.52.35299; Shimomura I, 1997, J CLIN INVEST, V99, P838, DOI 10.1172/JCI119247; Shimomura I, 1998, GENE DEV, V12, P3182, DOI 10.1101/gad.12.20.3182; SIMON MP, 1983, J BIOL CHEM, V258, P4576; Sommer A, 1998, J BIOL CHEM, V273, P6632, DOI 10.1074/jbc.273.12.6632; SUL HS, 1984, J BIOL CHEM, V259, P555; Tabor DE, 1998, J BIOL CHEM, V273, P22052, DOI 10.1074/jbc.273.34.22052; THOMPSON KS, 1991, J BIOL CHEM, V266, P8679; TONTONOZ P, 1993, MOL CELL BIOL, V13, P4753, DOI 10.1128/MCB.13.8.4753; TOWLE HC, 1995, J BIOL CHEM, V270, P23235, DOI 10.1074/jbc.270.40.23235; Vallet VS, 1997, J BIOL CHEM, V272, P21944, DOI 10.1074/jbc.272.35.21944; Vallet VS, 1998, J BIOL CHEM, V273, P20175, DOI 10.1074/jbc.273.32.20175; WANG D, 1995, J BIOL CHEM, V270, P28716, DOI 10.1074/jbc.270.48.28716; Wang D, 1997, J BIOL CHEM, V272, P26367, DOI 10.1074/jbc.272.42.26367; YOKODE M, 1990, SCIENCE, V250, P1273, DOI 10.1126/science.2244210; YOKOYAMA C, 1993, CELL, V75, P187, DOI 10.1016/S0092-8674(05)80095-9	54	541	555	1	26	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 10	1999	274	50					35832	35839		10.1074/jbc.274.50.35832	http://dx.doi.org/10.1074/jbc.274.50.35832			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	264NG	10585467	hybrid			2022-12-25	WOS:000084187900079
J	Jordan-Sciutto, KL; Dragich, JM; Rhodes, JL; Bowser, R				Jordan-Sciutto, KL; Dragich, JM; Rhodes, JL; Bowser, R			Fetal Alz-50 clone 1, a novel zinc finger protein, binds a specific DNA sequence and acts as a transcriptional regulator	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALZHEIMERS-DISEASE; GENE; DOMAIN; DROSOPHILA; FAC1; EXPRESSION; COMPLEX; NEURONS; REGION; FAMILY	Fetal Alz-50 clone 1 (FAC1) is a novel, developmentally regulated gene that exhibits changes in protein expression and subcellular localization during neuronal development and neurodegeneration, To understand the functional implications of altered subcellular localization, we have established a normal cellular function of FAC1, The FAC1 amino acid sequence contains regional homology to transcriptional regulators. Using the polymerase chain reaction-assisted binding site selection assay, we have identified a DNA sequence recognized by recombinant FAC1, Mutation of any 2 adjacent base pairs in the identified binding site dramatically reduced the binding preference of FAC1, demonstrating that the binding is specific for the identified site. Nuclear extracts from neural and non-neural cell lines contained a DNA-binding activity with similar specificity and nucleotide requirements as the recombinant FAC1 protein, This DNA-binding activity can be attributed to FAC1 since it is dependent upon the presence of FAC1 and behaves identically on a nondenaturing polyacrylamide gel as transiently transfected FAC1. In NIH3T3 cells, luciferase reporter plasmids containing the identified binding site (CACAACAC) were repressed by cotransfected FAC1 whether the binding site was proximal or distal to the transcription initiation site. This study indicates that FAC1 is a DNA-binding protein that functions as a transcription factor when localized to the nucleus.	Univ Pittsburgh, Sch Med, Dept Pathol, Pittsburgh, PA 15261 USA; Univ Pittsburgh, Sch Med, Dept Neurobiol, Pittsburgh, PA 15261 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Bowser, R (corresponding author), Univ Pittsburgh, Sch Med, Dept Pathol, BST S-420,3500 Terrace St, Pittsburgh, PA 15261 USA.		Jordan-Sciutto, Kelly L/A-1046-2007	Dragich, Joanna/0000-0002-8007-7408	NIA NIH HHS [AG05133, P50 AG005133, AG13208] Funding Source: Medline; NINDS NIH HHS [F32 NS010572, F32 NS010572-01, NS10572, F32 NS010572-02] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [F32NS010572] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R29AG013208, P50AG005133] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		AASLAND R, 1995, TRENDS BIOCHEM SCI, V20, P56, DOI 10.1016/S0968-0004(00)88957-4; AUSUBEL FM, 1994, CURRENT PROTOCOLS MO, V2; BOWSER R, 1995, DEV NEUROSCI-BASEL, V17, P20, DOI 10.1159/000111270; EDMONDSON DG, 1993, J BIOL CHEM, V268, P755; FRANKE A, 1992, EMBO J, V11, P2941, DOI 10.1002/j.1460-2075.1992.tb05364.x; GOODMAN Y, 1994, EXP NEUROL, V128, P1, DOI 10.1006/exnr.1994.1107; JACOBS Y, 1993, MOL CELL BIOL, V13, P7321, DOI 10.1128/MCB.13.12.7321; JORDAN KL, 1994, ONCOGENE, V9, P1177; JOrdan KL, 1996, BIOCHEMISTRY-US, V35, P12320, DOI 10.1021/bi9611927; Jordan-Sciutto KL, 1999, BIOCHEM BIOPH RES CO, V260, P785, DOI 10.1006/bbrc.1999.0986; KAUFMANN E, 1994, EUR J BIOCHEM, V223, P329, DOI 10.1111/j.1432-1033.1994.tb18998.x; KIM HT, 1994, BIOCHEM BIOPH RES CO, V201, P1526, DOI 10.1006/bbrc.1994.1877; Locker J., 1996, P12; LOGAN T, 1997, J CELL BIOCHEM, V64, P1; MAZO AM, 1990, P NATL ACAD SCI USA, V87, P2112, DOI 10.1073/pnas.87.6.2112; MINOWA T, 1992, BIOCHEMISTRY-US, V31, P8389, DOI 10.1021/bi00151a001; Mu XJ, 1997, EXP NEUROL, V146, P17, DOI 10.1006/exnr.1997.6508; OVERDIER DG, 1994, MOL CELL BIOL, V14, P2755, DOI 10.1128/MCB.14.4.2755; PETERSON CL, 1994, P NATL ACAD SCI USA, V91, P2905, DOI 10.1073/pnas.91.8.2905; Pierce JES, 1996, J NEUROSCI, V16, P1083; Roberson MR, 1997, BRAIN RES REV, V25, P50, DOI 10.1016/S0165-0173(97)00016-7; SAHA V, 1995, P NATL ACAD SCI USA, V92, P9737, DOI 10.1073/pnas.92.21.9737; SALBAUM JM, 1988, EMBO J, V7, P2807, DOI 10.1002/j.1460-2075.1988.tb03136.x; SCHINDLER U, 1993, PLANT J, V4, P137, DOI 10.1046/j.1365-313X.1993.04010137.x; Schoonover S, 1996, J NEUROPATH EXP NEUR, V55, P444, DOI 10.1097/00005072-199604000-00007; VORONOVA A, 1991, P NATL ACAD SCI USA, V91, P5952; WEINTRAUB H, 1993, CELL, V75, P1241, DOI 10.1016/0092-8674(93)90610-3; XIANG MQ, 1995, J NEUROSCI, V15, P4762; Zhu P, 1996, BBA-GENE STRUCT EXPR, V1309, P5, DOI 10.1016/S0167-4781(96)00127-3; ZOLLMAN S, 1994, P NATL ACAD SCI USA, V91, P10717, DOI 10.1073/pnas.91.22.10717	30	26	28	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 3	1999	274	49					35262	35268		10.1074/jbc.274.49.35262	http://dx.doi.org/10.1074/jbc.274.49.35262			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	260XW	10575013	Green Accepted, hybrid			2022-12-25	WOS:000083979600107
J	Lee, WL; Ostap, EM; Zot, HG; Pollard, TD				Lee, WL; Ostap, EM; Zot, HG; Pollard, TD			Organization and ligand binding properties of the tail of Acanthamoeba myosin-IA - Identification of an actin-binding site in the basic (tail homology-1) domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED ATPASE ACTIVITY; TERMINAL SH3 DOMAIN; HEAVY-CHAIN; AMINO-ACID; CRYOELECTRON MICROSCOPY; NUCLEOTIDE-SEQUENCE; CIRCULAR-DICHROISM; IN-VIVO; PROTEIN; CASTELLANII	The Acanthamoeba myosin-LA heavy chain gene encodes a 134-kDa protein with a catalytic domain, three potential light chain binding sites, and a tail with separately folded tail homology (TH) -1, -2, and -3 domains. TH-1 is highly resistant to trypsin digestion despite consisting of 15% lysine and arginine, TH-2/3 is resistant to alpha-chymotrypsin digestion. The peptide link between TH-1 and TH-2/3 is cleaved by trypsin, alpha-chymotrypsin, and endo-AspN but not V8 protease, The CD spectra of TH-2/3 indicate predominantly random structure, turns, and beta-strands but no alpha-helix, The hydrodynamic properties of TH-2/3 (Stokes' radius of 3.0 nn, sedimentation coefficient of 1.8 S, and molecular mass of 21.6 kDa) indicate that these domains are as long as the whole myosin-I tail in reconstructions of electron micrographs. Furthermore, separately expressed and purified TH-1 binds with high affinity to TH-2/3, Thus we propose that TH-1 and TH-2/3 are arranged side by side in the myosin-IA tail. Separate TH-1, TH-2, and TH-2/3 each binds muscle actin filaments with high affinity, Salt inhibits TH-2/3 binding to muscle actin but not amoeba actin filaments. TH-1 enhances binding of TH-2/3 to muscle actin filaments at physiological salt concentration, indicating that TH-1 and TH-2/3 cooperate in actin binding. An intrinsic fluorescence assay shows that TH-2/3 also binds with high affinity to the protein Acan125 similar to the SH3 domain of myosin-IC, Phylogenetic analysis of SH3 sequences suggests that myosin-I acquired SH3 domain after the divergence of the genes for myosin-I isoforms.	Salk Inst Biol Studies, Struct Biol Lab, La Jolla, CA 92037 USA; Eastern Michigan Univ, Dept Biol, Ypsilanti, MI 48197 USA; Johns Hopkins Univ, Sch Med, BCMB Grad Program, Baltimore, MD 21205 USA; Univ Penn, Sch Med, Dept Physiol, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Penn Muscle Inst, Philadelphia, PA 19104 USA	Salk Institute; Eastern Michigan University; Johns Hopkins University; University of Pennsylvania; University of Pennsylvania	Pollard, TD (corresponding author), Salk Inst Biol Studies, Struct Biol Lab, 10010 N Torrey Pines Rd, La Jolla, CA 92037 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM026132, R37GM026132] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-26132] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ACKERS GK, 1967, J BIOL CHEM, V242, P3237; ADAMS RJ, 1989, NATURE, V340, P565, DOI 10.1038/340565a0; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; Anderson BL, 1998, J CELL BIOL, V141, P1357, DOI 10.1083/jcb.141.6.1357; BAINES IC, 1995, J CELL BIOL, V130, P591, DOI 10.1083/jcb.130.3.591; BAINES IC, 1992, J CELL BIOL, V119, P1193, DOI 10.1083/jcb.119.5.1193; Blanchoin L, 1998, J BIOL CHEM, V273, P25106, DOI 10.1074/jbc.273.39.25106; BOHM G, 1992, PROTEIN ENG, V5, P191, DOI 10.1093/protein/5.3.191; BRZESKA H, 1989, J BIOL CHEM, V264, P19340; BRZESKA H, 1989, J BIOL CHEM, V264, P10243; Buchanan SGS, 1996, PROG BIOPHYS MOL BIO, V65, P1, DOI 10.1016/S0079-6107(96)00003-X; Carragher BO, 1998, P NATL ACAD SCI USA, V95, P15206, DOI 10.1073/pnas.95.26.15206; DOBERSTEIN SK, 1992, J CELL BIOL, V117, P1241, DOI 10.1083/jcb.117.6.1241; DOBERSTEIN SK, 1993, NATURE, V365, P841, DOI 10.1038/365841a0; Goodson HV, 1996, J CELL BIOL, V133, P1277, DOI 10.1083/jcb.133.6.1277; HAGEN SJ, 1986, J CELL BIOL, V103, P2121, DOI 10.1083/jcb.103.6.2121; HAMMER JA, 1987, J CELL BIOL, V105, P913, DOI 10.1083/jcb.105.2.913; HAYDEN SM, 1990, J CELL BIOL, V111, P443, DOI 10.1083/jcb.111.2.443; Horita DA, 1998, J MOL BIOL, V278, P253, DOI 10.1006/jmbi.1998.1690; HOROWITZ JA, 1990, J BIOL CHEM, V265, P20646; JOHNSON ML, 1981, BIOPHYS J, V36, P575, DOI 10.1016/S0006-3495(81)84753-4; Jontes JD, 1997, J CELL BIOL, V139, P683, DOI 10.1083/jcb.139.3.683; Jontes JD, 1998, J CELL BIOL, V141, P155, DOI 10.1083/jcb.141.1.155; JUNG G, 1989, GENE, V82, P269, DOI 10.1016/0378-1119(89)90052-8; JUNG G, 1987, P NATL ACAD SCI USA, V84, P6720, DOI 10.1073/pnas.84.19.6720; JUNG G, 1994, FEBS LETT, V342, P197, DOI 10.1016/0014-5793(94)80500-8; KATOH T, 1984, J BIOCHEM-TOKYO, V96, P1223, DOI 10.1093/oxfordjournals.jbchem.a134940; KOHDA D, 1994, STRUCTURE, V2, P1029, DOI 10.1016/S0969-2126(94)00106-5; KOHDA D, 1993, CELL, V72, P953, DOI 10.1016/0092-8674(93)90583-C; LAU TM, 1992, ANAL ULTRACENTRIFUGA, P90; LEE CH, 1995, EMBO J, V14, P5006, DOI 10.1002/j.1460-2075.1995.tb00183.x; Lila T, 1997, MOL BIOL CELL, V8, P367, DOI 10.1091/mbc.8.2.367; LYNCH TJ, 1987, J BIOL CHEM, V262, P13842; LYNCH TJ, 1986, J BIOL CHEM, V261, P7156; MARUTA H, 1979, J BIOL CHEM, V254, P3624; MCGOLDRICK CA, 1995, J CELL BIOL, V128, P577, DOI 10.1083/jcb.128.4.577; MIYATA H, 1989, J CELL BIOL, V109, P1519, DOI 10.1083/jcb.109.4.1519; NELLEN W, 1982, J MOL BIOL, V159, P1, DOI 10.1016/0022-2836(82)90028-6; Novak KD, 1998, MOL BIOL CELL, V9, P75, DOI 10.1091/mbc.9.1.75; Ostap EM, 1996, J CELL BIOL, V132, P1053, DOI 10.1083/jcb.132.6.1053; PANTALONI D, 1985, J BIOL CHEM, V260, P1180; Philo JS, 1997, BIOPHYS J, V72, P435, DOI 10.1016/S0006-3495(97)78684-3; Politou AS, 1998, J MOL BIOL, V276, P189, DOI 10.1006/jmbi.1997.1521; POLLARD TD, 1973, J BIOL CHEM, V248, P4682; POLLARD TD, 1973, J BIOL CHEM, V248, P4691; POLLARD TD, 1984, J CELL BIOL, V99, P769, DOI 10.1083/jcb.99.3.769; ROSENFELD SS, 1994, BIOCHEMISTRY-US, V33, P2322, DOI 10.1021/bi00174a045; SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626; Sambrook J., 2002, MOL CLONING LAB MANU; Sellers JR, 1996, J MUSCLE RES CELL M, V17, P7, DOI 10.1007/BF00140320; SPUDICH JA, 1971, J BIOL CHEM, V246, P4866; STAFFORD WF, 1992, ANAL BIOCHEM, V203, P295, DOI 10.1016/0003-2697(92)90316-Y; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Vaduva G, 1997, J CELL BIOL, V139, P1821, DOI 10.1083/jcb.139.7.1821; Vinson VK, 1998, BIOCHEMISTRY-US, V37, P10871, DOI 10.1021/bi980093l; Wang ZY, 1997, J MUSCLE RES CELL M, V18, P395, DOI 10.1023/A:1018686428955; WAY M, 1990, EMBO J, V9, P4103, DOI 10.1002/j.1460-2075.1990.tb07632.x; WONG JM, 1992, NUCLEIC ACIDS RES, V20, P4817, DOI 10.1093/nar/20.18.4817; WU XD, 1995, STRUCTURE, V3, P215, DOI 10.1016/S0969-2126(01)00151-4; XIE X, 1994, NATURE, V368, P306, DOI 10.1038/368306a0; XU P, 1995, J BIOL CHEM, V270, P25316, DOI 10.1074/jbc.270.43.25316; Xu P, 1997, P NATL ACAD SCI USA, V94, P3685, DOI 10.1073/pnas.94.8.3685; YANG JT, 1986, METHOD ENZYMOL, V130, P208; ZHANG W, 1991, NUCLEIC ACIDS RES, V19, P6649, DOI 10.1093/nar/19.23.6649; ZOT HG, 1992, J CELL BIOL, V116, P367, DOI 10.1083/jcb.116.2.367	65	38	38	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 3	1999	274	49					35159	35171		10.1074/jbc.274.49.35159	http://dx.doi.org/10.1074/jbc.274.49.35159			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	260XW	10574999	hybrid			2022-12-25	WOS:000083979600093
J	Carvalho, E; Jansson, PA; Axelsen, M; Eriksson, JW; Huang, XD; Groop, L; Rondinone, C; Sjostrom, L; Smith, U				Carvalho, E; Jansson, PA; Axelsen, M; Eriksson, JW; Huang, XD; Groop, L; Rondinone, C; Sjostrom, L; Smith, U			Low cellular IRS 1 gene and protein expression predict insulin resistance and NIDDM	FASEB JOURNAL			English	Article						diabetes; obesity; insulin receptor substrate 1; insulin signaling; insulin action	NECROSIS-FACTOR-ALPHA; RECEPTOR SUBSTRATE-1; DIABETES-MELLITUS; PHOSPHATIDYLINOSITOL 3-KINASE; GLUCOSE-TRANSPORT; 3T3-L1 ADIPOCYTES; OBESITY; MEN; STIMULATION; INTOLERANCE	We examined the gene and protein expression of IRS 1 (insulin receptor substrate 1) in adipocytes from two groups of healthy individuals with an increased propensity for non-insulin-dependent diabetes mellitus (NIDDM): those with two first-degree relatives with diabetes and another group with massive obesity. A low expression of IRS 1 (less than or equal to 50% of the matched control group) was seen in approximate to 30% of both groups and these individuals were characterized by insulin resistance and its hallmarks: higher levels of insulin, glucose, and triglycerides. Two individuals with previously unknown NIDDM were diagnosed and both had low IRS 1 expression. Low TRS I protein expression was associated with low mRNA levels but not with the common Gly972Arg polymorphism of the IRS I gene. Taken together, our present and previous findings show that a low expression of IRS 1 in fat cells predicts insulin resistance and NIDDM. Furthermore, they support the likelihood that an impaired transcriptional activation may play a key role in the pathogenesis of NIDDM.	Sahlgrens Univ Hosp, Dept Internal Med, Lundberg Lab Diabet Res, SE-41345 Gothenburg, Sweden; Sahlgrens Univ Hosp, Dept Internal Med, SOS Obes Res Lab, SE-41345 Gothenburg, Sweden; Univ Lund, Malmo Univ Hosp, Dept Endocrinol, Malmo, Sweden	Sahlgrenska University Hospital; Sahlgrenska University Hospital; Lund University; Skane University Hospital	Smith, U (corresponding author), Sahlgrens Univ Hosp, Dept Internal Med, Lundberg Lab Diabet Res, Grona Straket 8, SE-41345 Gothenburg, Sweden.		Eriksson, Jan/AAB-5820-2021; Carvalho, Eugenia/AAV-6868-2021	Carvalho, Eugenia/0000-0001-6264-3632				ATTVALL S, 1987, J CLIN INVEST, V80, P437, DOI 10.1172/JCI113091; AXELSEN M, 1995, J INTERN MED, V237, P449, DOI 10.1111/j.1365-2796.1995.tb00869.x; Bjornholm M, 1997, DIABETES, V46, P524, DOI 10.2337/diabetes.46.3.524; CLAUSEN JO, 1995, LANCET, V346, P397, DOI 10.1016/S0140-6736(95)92779-4; DEFRONZO RA, 1988, DIABETES, V37, P667, DOI 10.2337/diab.37.6.667; DeFronzo RA, 1979, AM J PHYSIOL, V233, P214; ELBEIN SC, 1991, DIABETES, V40, P1024, DOI 10.2337/diabetes.40.8.1024; ELIASSON B, 1994, ARTERIOSCLER THROMB, V14, P1946, DOI 10.1161/01.ATV.14.12.1946; ERIKSSON KF, 1990, DIABETOLOGIA, V33, P526, DOI 10.1007/BF00404139; HARA K, 1994, P NATL ACAD SCI USA, V91, P7415, DOI 10.1073/pnas.91.16.7415; HOTAMISLIGIL GS, 1994, J CLIN INVEST, V94, P1543, DOI 10.1172/JCI117495; Krook A, 1997, J BIOL CHEM, V272, P30208, DOI 10.1074/jbc.272.48.30208; KROTKIEWSKI M, 1983, J CLIN INVEST, V72, P1150, DOI 10.1172/JCI111040; LAPIDUS L, 1992, DIABETES CARE, V15, P1455, DOI 10.2337/diacare.15.11.1455; Moitra J, 1998, GENE DEV, V12, P3168, DOI 10.1101/gad.12.20.3168; OHLSON LO, 1985, DIABETES, V34, P1055, DOI 10.2337/diabetes.34.10.1055; REAVEN GM, 1995, PHYSIOL REV, V75, P473, DOI 10.1152/physrev.1995.75.3.473; RICORT JM, 1995, DIABETOLOGIA, V38, P1148, DOI 10.1007/s001250050406; RIMM EB, 1995, BRIT MED J, V310, P555, DOI 10.1136/bmj.310.6979.555; Rondinone CM, 1997, P NATL ACAD SCI USA, V94, P4171, DOI 10.1073/pnas.94.8.4171; Rossetti L, 1997, J BIOL CHEM, V272, P27758, DOI 10.1074/jbc.272.44.27758; SMITH U, 1972, J LIPID RES, V13, P822; Stephens JM, 1997, J BIOL CHEM, V272, P971, DOI 10.1074/jbc.272.2.971; Stoffel M, 1997, P NATL ACAD SCI USA, V94, P13209, DOI 10.1073/pnas.94.24.13209; TAYLOR SI, 1991, J CLIN ENDOCR METAB, V73, P1158, DOI 10.1210/jcem-73-6-1158; ZHANG YY, 1994, NATURE, V372, P425, DOI 10.1038/372425a0	26	116	131	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	DEC	1999	13	15					2173	2178		10.1096/fasebj.13.15.2173	http://dx.doi.org/10.1096/fasebj.13.15.2173			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	266QN	10593864	Bronze			2022-12-25	WOS:000084310800008
J	Sjoblom, T; Boureux, A; Ronnstrand, L; Heldin, CH; Ghysdael, J; Ostman, A				Sjoblom, T; Boureux, A; Ronnstrand, L; Heldin, CH; Ghysdael, J; Ostman, A			Characterization of the chronic myelomonocytic leukemia associated TEL-PDGF beta R fusion protein	ONCOGENE			English	Article						chronic myelomonocytic leukemia; chromosomal translocation; platelet-derived growth factor; TEL	ACUTE LYMPHOBLASTIC-LEUKEMIA; BCR-ABL; TRANSFORMING PROTEIN; PHOSPHORYLATION SITE; TYROSINE KINASE; RECEPTOR-BETA; GENE FUSION; GROWTH; ETS; DOMAIN	The t(5;12) translocation, associated with chronic myelomonocytic leukemia, generates a novel gene encoding a protein, TEL-PDGF beta R, composed of the 154 amino-terminal amino acids of the transcription factor TEL and the transmembrane and intracellular part of the PDGF beta-receptor (PDGF beta R). TEL also occurs as a tumor-associated fusion partner for the tyrosine kinases c-ABL, JAK2 and TRK-C. Previous studies have demonstrated growth promoting activity of TEL-PDGF beta R and also indicated that the TEL moiety activates the tyrosine kinase of the PDGF beta R through the formation of TEL-PDGF beta R oligomers. We demonstrate that tyrosine phosphorylation of the fusion protein can be attenuated through overexpression of the TEL part of TEL-PDGF beta R, suggesting a strategy for antagonizing the signaling of TEL-PDGF beta R, and other TEL-fusion proteins containing tyrosine kinase domains. Comparison of BaF/3 cell lines expressing TEL-PDGF beta R and ligand-stimulated PDGF beta R revealed that only TEL-PDGF beta R expression conferred IL-3-independent growth, suggesting differences in signaling capacity of the two proteins. Finally, tyrosine residues 17 and 27 in TEL-PDGF beta R was identified as autophosphorylation sites in TEL-PDGF beta R.	Ludwig Inst Canc Res, S-75124 Uppsala, Sweden; Ctr Univ Orsay, Inst Curie, CNRS UMR 146, Sect Rech, F-91405 Orsay, France	Ludwig Institute for Cancer Research; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Universite Paris Saclay	Ostman, A (corresponding author), Ludwig Inst Canc Res, Box 595, S-75124 Uppsala, Sweden.		GHYSDAEL, Jacques/F-3377-2013; Ronnstrand, Lars/A-2429-2011	Ronnstrand, Lars/0000-0003-1275-5809				Abe A, 1997, BLOOD, V90, P4271, DOI 10.1182/blood.V90.11.4271.4271_4271_4277; BLUMEJENSEN P, 1995, J BIOL CHEM, V270, P14192, DOI 10.1074/jbc.270.23.14192; Carroll M, 1996, P NATL ACAD SCI USA, V93, P14845, DOI 10.1073/pnas.93.25.14845; Carroll M, 1997, BLOOD, V90, P4947, DOI 10.1182/blood.V90.12.4947.4947_4947_4952; Chase A, 1999, BLOOD, V93, P1025, DOI 10.1182/blood.V93.3.1025.403a20_1025_1031; CLAESSONWELSH L, 1988, MOL CELL BIOL, V8, P3476, DOI 10.1128/MCB.8.8.3476; DRUMMONDBARBOSA D, 1995, MOL CELL BIOL, V15, P2570; GHYSDAEL J, 1997, ONCOGENES TRANSCRIPT, P29; GOGA A, 1995, CELL, V82, P981, DOI 10.1016/0092-8674(95)90277-5; GOLUB TR, 1994, CELL, V77, P307, DOI 10.1016/0092-8674(94)90322-0; Golub TR, 1996, MOL CELL BIOL, V16, P4107; GOLUB TR, 1995, P NATL ACAD SCI USA, V92, P4917, DOI 10.1073/pnas.92.11.4917; Hansen K, 1996, EMBO J, V15, P5299, DOI 10.1002/j.1460-2075.1996.tb00915.x; Heldin CH, 1998, BBA-REV CANCER, V1378, pF79, DOI 10.1016/S0304-419X(98)00015-8; HELDIN CH, 1986, MOL CELLULAR BIOL WO, P249; Jousset C, 1997, EMBO J, V16, P69, DOI 10.1093/emboj/16.1.69; Knezevich SR, 1998, NAT GENET, V18, P184, DOI 10.1038/ng0298-184; KOVALENKO M, 1994, CANCER RES, V54, P6106; Lacronique V, 1997, SCIENCE, V278, P1309, DOI 10.1126/science.278.5341.1309; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; PAPADOPOULOS P, 1995, CANCER RES, V55, P34; PENDERGAST AM, 1993, CELL, V75, P175, DOI 10.1016/S0092-8674(05)80094-7; ROMANA SP, 1995, BLOOD, V85, P3662, DOI 10.1182/blood.V85.12.3662.bloodjournal85123662; Ross TS, 1998, BLOOD, V91, P4419, DOI 10.1182/blood.V91.12.4419.412k43_4419_4426; SAWYERS CL, 1994, CELL, V77, P171, DOI 10.1016/0092-8674(94)90307-7; Schwaller J, 1998, EMBO J, V17, P5321, DOI 10.1093/emboj/17.18.5321; Slupsky CM, 1998, P NATL ACAD SCI USA, V95, P12129, DOI 10.1073/pnas.95.21.12129; STAEBLER A, 1995, J VIROL, V69, P6507, DOI 10.1128/JVI.69.10.6507-6517.1995	28	30	34	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 25	1999	18	50					7055	7062		10.1038/sj.onc.1203190	http://dx.doi.org/10.1038/sj.onc.1203190			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	259PH	10597306				2022-12-25	WOS:000083901900012
J	Theodosiou, A; Smith, A; Gillieron, C; Arkinstall, S; Ashworth, A				Theodosiou, A; Smith, A; Gillieron, C; Arkinstall, S; Ashworth, A			MKP5, a new member of the MAP kinase phosphatase family, which selectively dephosphorylates stress-activated kinases	ONCOGENE			English	Article						dual-specificity phosphatase; JNK/SAPK beta; p38 MAP kinase	PROTEIN-TYROSINE-PHOSPHATASE; DUAL-SPECIFICITY PHOSPHATASE; IMMEDIATE-EARLY GENE; CHROMOSOMAL LOCALIZATION; IN-VIVO; INFLAMMATORY CYTOKINES; GENOMIC ORGANIZATION; MAMMALIAN-CELLS; HEAT-SHOCK; EXPRESSION	Dual-specificity protein tyrosine phosphatases are a burgeoning family of enzymes, some of which, the MKPs, are implicated in the regulation of mitogen-activated protein (MAP) kinases. MKPs have been shown to reverse the activation of the MAP kinases by hydrolyzing phosphothreonine and phosphotyrosine residues present in the substrates. Here we describe the characterization of a novel member of the MKP family, MKP5. The MKP5 gene, which maps to human chromosome lq32, is expressed tissue-specifically as two transcripts of approximately 3.4 and 2.4kb in human liver and skeletal muscle. When expressed in mammalian cells, MKP5 blocks the enzymatic activation of MAP kinases with the selectivity p38 approximate to JNK/SAPK>>ERK. Immunoprecipitation of endogenous MAP kinases by the catalytically inactive transfected MKP5 demonstrates that it preferentially binds to the p38 and JNK/SAPK kinases. These findings suggest that the selectivity of this phosphatase may be determined at least in part at the level of substrate binding.	Inst Canc Res, Chester Beatty Labs, Sect Gene Funct & Regulat, London SW3 6JB, England; Serona Pharmaceut Res Inst, CH-1228 Geneva, Switzerland	Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK	Ashworth, A (corresponding author), Inst Canc Res, Chester Beatty Labs, Sect Gene Funct & Regulat, 237 Fulham Rd, London SW3 6JB, England.							Ben-Levy R, 1998, CURR BIOL, V8, P1049, DOI 10.1016/S0960-9822(98)70442-7; Benitez J, 1997, CANCER RES, V57, P4217; BRONDELLO JM, 1995, ONCOGENE, V10, P1895; Camps M, 1998, SCIENCE, V280, P1262, DOI 10.1126/science.280.5367.1262; CANO E, 1995, TRENDS BIOCHEM SCI, V20, P117, DOI 10.1016/S0968-0004(00)88978-1; CHARLES CH, 1992, ONCOGENE, V7, P187; Chu YF, 1996, J BIOL CHEM, V271, P6497, DOI 10.1074/jbc.271.11.6497; Cohen P, 1997, TRENDS CELL BIOL, V7, P353, DOI 10.1016/S0962-8924(97)01105-7; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; DINGWALL C, 1991, TRENDS BIOCHEM SCI, V16, P478, DOI 10.1016/0968-0004(91)90184-W; Franklin CC, 1997, J BIOL CHEM, V272, P16917, DOI 10.1074/jbc.272.27.16917; Furukawa T, 1998, CYTOGENET CELL GENET, V82, P156, DOI 10.1159/000015091; Groom LA, 1996, EMBO J, V15, P3621, DOI 10.1002/j.1460-2075.1996.tb00731.x; GUAN KL, 1995, J BIOL CHEM, V270, P7197, DOI 10.1074/jbc.270.13.7197; Hirsch DD, 1997, J BIOL CHEM, V272, P4568, DOI 10.1074/jbc.272.7.4568; Ichijo H, 1997, SCIENCE, V275, P90, DOI 10.1126/science.275.5296.90; Ip YT, 1998, CURR OPIN CELL BIOL, V10, P205, DOI 10.1016/S0955-0674(98)80143-9; ISHIBASHI T, 1994, J BIOL CHEM, V269, P29897; Jacobs D, 1999, GENE DEV, V13, P163, DOI 10.1101/gad.13.2.163; Keyse SM, 1998, SEMIN CELL DEV BIOL, V9, P143, DOI 10.1006/scdb.1997.0219; KEYSE SM, 1992, NATURE, V359, P644, DOI 10.1038/359644a0; KEYSE SM, 1993, TRENDS BIOCHEM SCI, V18, P377, DOI 10.1016/0968-0004(93)90092-2; KEYSE SM, 1995, BBA-MOL CELL RES, V1265, P152, DOI 10.1016/0167-4889(94)00211-V; King AG, 1995, ONCOGENE, V11, P2553; KWAK SP, 1995, J BIOL CHEM, V270, P1156, DOI 10.1074/jbc.270.3.1156; Kyriakis JM, 1996, BIOESSAYS, V18, P567, DOI 10.1002/bies.950180708; Loda M, 1996, AM J PATHOL, V149, P1553; MagiGalluzzi C, 1997, LAB INVEST, V76, P37; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; Martell KJ, 1998, MOL CELLS, V8, P2; MARTELL KJ, 1994, GENOMICS, V22, P462, DOI 10.1006/geno.1994.1411; MARTELL KJ, 1995, J NEUROCHEM, V65, P1823; MISRAPRESS A, 1995, J BIOL CHEM, V270, P14587, DOI 10.1074/jbc.270.24.14587; Mourey RJ, 1996, J BIOL CHEM, V271, P3795; Muda M, 1996, J BIOL CHEM, V271, P27205, DOI 10.1074/jbc.271.44.27205; Muda M, 1996, J BIOL CHEM, V271, P4319; Muda M, 1998, J BIOL CHEM, V273, P9323, DOI 10.1074/jbc.273.15.9323; Muda M, 1997, J BIOL CHEM, V272, P5141, DOI 10.1074/jbc.272.8.5141; Nesbit MA, 1997, GENOMICS, V42, P284, DOI 10.1006/geno.1997.4737; NOGUCHI T, 1993, MOL CELL BIOL, V13, P5195, DOI 10.1128/MCB.13.9.5195; PAGES G, 1993, P NATL ACAD SCI USA, V90, P8319, DOI 10.1073/pnas.90.18.8319; RAINGEAUD J, 1995, J BIOL CHEM, V270, P7420, DOI 10.1074/jbc.270.13.7420; Robinson MJ, 1997, CURR OPIN CELL BIOL, V9, P180, DOI 10.1016/S0955-0674(97)80061-0; ROHAN PJ, 1993, SCIENCE, V259, P1763, DOI 10.1126/science.7681221; SCHAAP D, 1993, J BIOL CHEM, V268, P20232; Schuler GD, 1996, SCIENCE, V274, P540, DOI 10.1126/science.274.5287.540; Smith A, 1997, GENOMICS, V42, P524, DOI 10.1006/geno.1997.4756; Steiner G, 1996, CANCER RES, V56, P5044; SUHAI S, 1994, COMPUTATIONAL METHOD; SUN H, 1993, CELL, V75, P487, DOI 10.1016/0092-8674(93)90383-2; SUN H, 1994, SCIENCE, V266, P285, DOI 10.1126/science.7939666; Theodosiou AM, 1996, HUM MOL GENET, V5, P675, DOI 10.1093/hmg/5.5.675; Verheij M, 1996, NATURE, V380, P75, DOI 10.1038/380075a0; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Yang XL, 1997, CELL, V89, P1067, DOI 10.1016/S0092-8674(00)80294-9; YI HF, 1995, GENOMICS, V28, P92, DOI 10.1006/geno.1995.1110; Yokoyama A, 1997, BIOCHEM BIOPH RES CO, V239, P746, DOI 10.1006/bbrc.1997.7547	58	116	126	0	7	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 25	1999	18	50					6981	6988		10.1038/sj.onc.1203185	http://dx.doi.org/10.1038/sj.onc.1203185			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	259PH	10597297				2022-12-25	WOS:000083901900003
J	Chauhan, D; Hideshima, T; Pandey, P; Treon, S; Teoh, G; Raje, N; Rosen, S; Krett, N; Husson, H; Avraham, S; Kharbanda, S; Anderson, KC				Chauhan, D; Hideshima, T; Pandey, P; Treon, S; Teoh, G; Raje, N; Rosen, S; Krett, N; Husson, H; Avraham, S; Kharbanda, S; Anderson, KC			RAFTK/PYK2-dependent and -independent apoptosis in multiple myeloma cells	ONCOGENE			English	Article						multiple myeloma; irradiation; dexamethasone; apoptosis	FOCAL TYROSINE KINASE; HEMATOPOIETIC-CELLS; ACTIVATION; INTERLEUKIN-6; ASSOCIATION; PYK2; PHOSPHORYLATION; MEGAKARYOCYTES; STIMULATION; PAXILLIN	Related Adhesion Focal Tyrosine Kinase (RAFTK; also known as Pyk2), is a member of the Focal Adhesion Kinase (FAK) subfamily and is activated by TNF alpha, UV light and increases in intracellular calcium levels. However, the function of RAFTK remains largely unknown. Our previous studies demonstrated that treatment with dexamethasone (Dex), ionizing radiation (IR), and anti-Fas mAb induces apoptosis in multiple myeloma (MM) cells. In the present study, we examined the potential role of RAFTK during induction of apoptosis in human MM cells triggered by these three stimuli. Dex-induced apoptosis, in contrast to apoptosis triggered by anti-Fas mAb or IR, is associated with activation of RAFTK. Transient overexpression of RAFTK wild type (RAFTK WT) induces apoptosis, whereas transient overexpression of Kinase inactive RAFTK (RAFTK K-M) blocks Dex-induced apoptosis. In contrast, transient overexpression of RAFTK K-M has no effect on apoptosis triggered by IR or Fas. In Dex-resistant cells, Dex does not trigger either RAFTK activation or apoptosis. Finally, interleukin-6 (IL-6), a known survival factor for MM cells, inhibits both activation of RAFTK and apoptosis of MM.1S cells triggered by Dex. Our studies therefore demonstrate Dex-induced RAFTK-dependent, and IR or Fas induced RAFTK-independent apoptotic signaling cascades in MM cells.	Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Adult Oncol, Boston, MA 02115 USA; Harvard Inst Med, Beth Israel Deaconess Med Ctr, Div Expt Med & Hematol Oncol, Boston, MA 02115 USA; Northwestern Univ, Sch Med, Robert H Lurie Canc Ctr, Chicago, IL 60611 USA	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Northwestern University; Robert H. Lurie Comprehensive Cancer Center	Anderson, KC (corresponding author), Dana Farber Canc Inst, 44 Binney St, Boston, MA 02215 USA.				NCI NIH HHS [CA50947, CA75216] Funding Source: Medline; NHLBI NIH HHS [HL55445] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA050947, R01CA075216] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL055445] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ASTEIR A, 1997, J BIOL CHEM, V272, P19719; Astier A, 1997, J BIOL CHEM, V272, P228; AVRAHAM S, 1995, J BIOL CHEM, V270, P27742, DOI 10.1074/jbc.270.46.27742; Avraham S, 1997, LEUKEMIA LYMPHOMA, V27, P247, DOI 10.3109/10428199709059681; Berg NN, 1997, J IMMUNOL, V159, P1753; CHAUHAN D, 1995, J EXP MED, V182, P1801, DOI 10.1084/jem.182.6.1801; Chauhan D, 1997, J BIOL CHEM, V272, P29995, DOI 10.1074/jbc.272.48.29995; Chauhan D, 1997, BLOOD, V89, P227, DOI 10.1182/blood.V89.1.227.227_227_234; Chauhan D, 1997, ONCOGENE, V15, P837, DOI 10.1038/sj.onc.1201253; Derkinderen P, 1998, EUR J NEUROSCI, V10, P1667, DOI 10.1046/j.1460-9568.1998.00174.x; Dikic I, 1998, J BIOL CHEM, V273, P14301, DOI 10.1074/jbc.273.23.14301; FU X, 1998, BLOOD, V92, P241; Hamel W, 1996, CYTOMETRY, V25, P173, DOI 10.1002/(SICI)1097-0320(19961001)25:2<173::AID-CYTO6>3.0.CO;2-I; HARDIN J, 1994, BLOOD, V84, P3063; HARDIN JA, 1992, J IMMUNOL METHODS, V154, P99, DOI 10.1016/0022-1759(92)90217-H; Hiregowdara D, 1997, J BIOL CHEM, V272, P10804; KLEIN B, 1995, BLOOD, V85, P863, DOI 10.1182/blood.V85.4.863.bloodjournal854863; LEV S, 1995, NATURE, V376, P737, DOI 10.1038/376737a0; Li X, 1999, J BIOL CHEM, V274, P8917, DOI 10.1074/jbc.274.13.8917; Pandey P, 1999, J BIOL CHEM, V274, P10140, DOI 10.1074/jbc.274.15.10140; Pandey P, 1999, J BIOL CHEM, V274, P8618, DOI 10.1074/jbc.274.13.8618; Salgia R, 1996, J BIOL CHEM, V271, P31222, DOI 10.1074/jbc.271.49.31222; SASAKI H, 1995, J BIOL CHEM, V270, P21206, DOI 10.1074/jbc.270.36.21206; Swanson KD, 1998, J BIOL CHEM, V273, P19965, DOI 10.1074/jbc.273.32.19965; THORNBERRY AT, 1997, APOPTOSIS, P155; Tokiwa G, 1996, SCIENCE, V273, P792, DOI 10.1126/science.273.5276.792; Tsuchida M, 1999, J BIOL CHEM, V274, P6735, DOI 10.1074/jbc.274.10.6735; Verheij M, 1996, NATURE, V380, P75, DOI 10.1038/380075a0; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Xiong WC, 1997, J CELL BIOL, V139, P529, DOI 10.1083/jcb.139.2.529; Yu H, 1996, J BIOL CHEM, V271, P29993, DOI 10.1074/jbc.271.47.29993	31	94	95	1	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 18	1999	18	48					6733	6740		10.1038/sj.onc.1203082	http://dx.doi.org/10.1038/sj.onc.1203082			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	257QA	10597281				2022-12-25	WOS:000083792000015
J	Kieran, MW; Katz, S; Vail, B; Zon, LI; Mayer, BJ				Kieran, MW; Katz, S; Vail, B; Zon, LI; Mayer, BJ			Concentration-dependent positive and negative regulation of a MAP kinase by a MAP kinase kinase	ONCOGENE			English	Article						MAP kinase; stress-activated kinase; JNK	ACTIVATED PROTEIN-KINASE; SIGNAL-TRANSDUCTION PATHWAY; PHEROMONE RESPONSE PATHWAY; HIGH-AFFINITY INTERACTION; JUN NH2-TERMINAL KINASE; C-JUN; INFLAMMATORY CYTOKINES; NUCLEAR TRANSLOCATION; DUAL PHOSPHORYLATION; STRUCTURAL BASIS	There are at least three distinct MAP kinase signaling modules in mammalian cells, distinguished by the family of kinases (Erk, SAPK/JNK, or p38) that is ultimately activated. Many input signals activate multiple MAP kinase cascades, and the mechanisms that control the specificity of signal output are not well understood. We show that SEK1/MKK4, a MAP kinase kinase proposed to activate SAPK/JNK, is a very potent inhibitor of p54 SAPK beta/JNK3 both in vitro and irt vivo if present at equimolar or higher ratios. In contrast SEK can activate SAPK when present in substoichiometric amounts, but this activation is slow, consistent with the rate-limiting step in activation being the dissociation of an inactive SEK:SAPK complex. The N-terminal unique region of SEK is both necessary and partially sufficient for inhibition of SAPK, and is also necessary for activation of SAPK by SEK in vitro. We have also used the p38 MAP kinase and its activator MKK6 to examine the regulatory relationships among different kinases involved in stress responses. We show using purified kinases that inhibitory activity is specific for the combination of SEK and SAPK: SEK can activate but not inhibit p38, and MKK6 can activate but not inhibit SAPK beta and p38. These results reveal a potential mechanism for regulating stress-activated kinases, adding to a growing body of evidence suggesting that MAP kinases are controlled by relatively stable interactions with their activators.	Harvard Univ, Sch Med, Howard Hughes Med Inst, Childrens Hosp,Dept Microbiol & Mol Genet, Boston, MA 02115 USA; Childrens Hosp, Howard Hughes Med Inst, Div Hematol Oncol, Boston, MA 02115 USA	Harvard University; Boston Children's Hospital; Harvard Medical School; Howard Hughes Medical Institute; Harvard University; Boston Children's Hospital; Howard Hughes Medical Institute	Mayer, BJ (corresponding author), Harvard Univ, Sch Med, Howard Hughes Med Inst, Childrens Hosp,Dept Microbiol & Mol Genet, 320 Longwood Ave, Boston, MA 02115 USA.			Kieran, Mark/0000-0003-2184-7692				Bardwell L, 1996, TRENDS BIOCHEM SCI, V21, P373, DOI 10.1016/S0968-0004(96)30032-7; Bardwell L, 1996, MOL CELL BIOL, V16, P3637; Canagarajah BJ, 1997, CELL, V90, P859, DOI 10.1016/S0092-8674(00)80351-7; CHEN RH, 1992, MOL CELL BIOL, V12, P915, DOI 10.1128/MCB.12.3.915; CHOI KY, 1994, CELL, V78, P499; CLARKLEWIS I, 1991, J BIOL CHEM, V266, P15180; COBB MH, 1995, J BIOL CHEM, V270, P14843, DOI 10.1074/jbc.270.25.14843; Cuenda A, 1996, EMBO J, V15, P4156, DOI 10.1002/j.1460-2075.1996.tb00790.x; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; Dickens M, 1997, SCIENCE, V277, P693, DOI 10.1126/science.277.5326.693; FRESHNEY NW, 1994, CELL, V78, P1039, DOI 10.1016/0092-8674(94)90278-X; Fukuda M, 1997, EMBO J, V16, P1901, DOI 10.1093/emboj/16.8.1901; Ganiatsas S, 1998, P NATL ACAD SCI USA, V95, P6881, DOI 10.1073/pnas.95.12.6881; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; Han JH, 1996, J BIOL CHEM, V271, P2886, DOI 10.1074/jbc.271.6.2886; Holland PM, 1997, J BIOL CHEM, V272, P24994, DOI 10.1074/jbc.272.40.24994; Johnson LN, 1996, CELL, V85, P149, DOI 10.1016/S0092-8674(00)81092-2; Khokhlatchev AV, 1998, CELL, V93, P605, DOI 10.1016/S0092-8674(00)81189-7; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; Kyriakis JM, 1996, BIOESSAYS, V18, P567, DOI 10.1002/bies.950180708; LEE LR, 1994, MOL ENDOCRINOL, V8, P746, DOI 10.1210/me.8.6.746; LENORMAND P, 1993, J CELL BIOL, V122, P1079, DOI 10.1083/jcb.122.5.1079; Lewis TS, 1998, ADV CANCER RES, V74, P49, DOI 10.1016/S0065-230X(08)60765-4; LIN AN, 1995, SCIENCE, V268, P286, DOI 10.1126/science.7716521; MARCUS S, 1994, P NATL ACAD SCI USA, V91, P7762, DOI 10.1073/pnas.91.16.7762; Mendelson KG, 1996, P NATL ACAD SCI USA, V93, P12908, DOI 10.1073/pnas.93.23.12908; Moriguchi T, 1996, J BIOL CHEM, V271, P13675, DOI 10.1074/jbc.271.23.13675; Moriguchi T, 1997, EMBO J, V16, P7045, DOI 10.1093/emboj/16.23.7045; Moriguchi T, 1996, J BIOL CHEM, V271, P26981, DOI 10.1074/jbc.271.43.26981; Nishina H, 1997, NATURE, V385, P350, DOI 10.1038/385350a0; Paul A, 1997, CELL SIGNAL, V9, P403, DOI 10.1016/S0898-6568(97)00042-9; Pelech SL, 1996, CURR BIOL, V6, P551, DOI 10.1016/S0960-9822(02)00540-7; PRINTEN JA, 1994, GENETICS, V138, P609; RAINGEAUD J, 1995, J BIOL CHEM, V270, P7420, DOI 10.1074/jbc.270.13.7420; Raingeaud J, 1996, MOL CELL BIOL, V16, P1247; ROUSE J, 1994, CELL, V78, P1027, DOI 10.1016/0092-8674(94)90277-1; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; Schaeffer HJ, 1998, SCIENCE, V281, P1668, DOI 10.1126/science.281.5383.1668; SETH A, 1992, J BIOL CHEM, V267, P24796; Shim J, 1996, NATURE, V381, P804, DOI 10.1038/381804a0; Songyang Z, 1996, MOL CELL BIOL, V16, P6486; Stein B, 1996, J BIOL CHEM, V271, P11427, DOI 10.1074/jbc.271.19.11427; TANAKA M, 1995, MOL CELL BIOL, V15, P6829; Tournier C, 1997, P NATL ACAD SCI USA, V94, P7337, DOI 10.1073/pnas.94.14.7337; WASKIEWICZ AJ, 1995, CURR OPIN CELL BIOL, V7, P798, DOI 10.1016/0955-0674(95)80063-8; Whitmarsh AJ, 1998, SCIENCE, V281, P1671, DOI 10.1126/science.281.5383.1671; Wu ZG, 1997, MOL CELL BIOL, V17, P7407, DOI 10.1128/MCB.17.12.7407; Yang D, 1997, P NATL ACAD SCI USA, V94, P3004, DOI 10.1073/pnas.94.7.3004; Yao ZB, 1997, J BIOL CHEM, V272, P32378, DOI 10.1074/jbc.272.51.32378; YASHAR BM, 1993, MOL CELL BIOL, V13, P5738, DOI 10.1128/MCB.13.9.5738; Zanke BW, 1996, J BIOL CHEM, V271, P29876, DOI 10.1074/jbc.271.47.29876	52	12	12	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 18	1999	18	48					6647	6657		10.1038/sj.onc.1203057	http://dx.doi.org/10.1038/sj.onc.1203057			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	257QA	10597270				2022-12-25	WOS:000083792000004
J	Terris, B; Pineau, P; Bregeaud, L; Valla, D; Belghiti, J; Tiollais, P; Degott, C; Dejean, A				Terris, B; Pineau, P; Bregeaud, L; Valla, D; Belghiti, J; Tiollais, P; Degott, C; Dejean, A			Close correlation between beta-catenin gene alterations and nuclear accumulation of the protein in human hepatocellular carcinomas	ONCOGENE			English	Article						beta-catenin; hepatocellular carcinoma; APC; immunohistochemistry	FAMILIAL ADENOMATOUS POLYPOSIS; SOMATIC MUTATIONS; COLORECTAL-CANCER; TUMOR; APC; ACTIVATION; EXPRESSION; HEPATITIS; DELETIONS; PATHWAY	Several lines of evidence indicate that beta-catenin acquires oncogenic activity when its intracellular concentration increases as a result of either mutation in the beta-catenin gene itself or inactivation of the adenomatous polyposis coli (APC) gene. In an attempt to elucidate the molecular mechanisms underlying hepatocellular carcinogenesis, we have studied the frequency of beta-catenin gene alterations in exon 3, a region known to represent a mutation hot spot, and its inappropriate protein expression by immunohistochemistry in 73 hepatocellular carcinomas (HCCs). The results were correlated with different clinical and pathological data, particularly with the presence or not of an associated cirrhosis, Fourteen (19%) HCCs showed beta-catenin gene alterations with missense mutations in nine cases and interstitial deletions in five cases. These genetic alterations were present in both cirrhotic and non-cirrhotic groups. By contrast, we did not find any beta-catenin gene alterations in the nine fibromellar carcinomas we examined. Nuclear accumulation of the protein was observed in 18 of them (25%), Remarkably, these included ten of the 14 tumors harboring somatic mutations in the beta-catenin gene (P<0.001). Our results indicate that accumulation of beta-catenin resulting from genetic mutations is a frequent event in non-fibrolamellar type hepatocellular carcinoma. The close association between increased beta-catenin protein stability and mutation indicates that immunohistochemistry may he a powerful method for the detection of the mutated protein in future clinical practice.	Hop Beaujon, Serv Anat Pathol, Clichy, France; Hop Beaujon, Serv Hepatol, Clichy, France; Hop Beaujon, Serv Chirurg Digest, Clichy, France; Inst Pasteur, INSERM, Unite Recombinaison & Express Genet, U163, F-75724 Paris, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Beaujon - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Beaujon - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Beaujon - APHP; UDICE-French Research Universities; Universite Paris Cite; Institut National de la Sante et de la Recherche Medicale (Inserm); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	Terris, B (corresponding author), Hop Beaujon, Serv Anat Pathol, Clichy, France.		Terris, Benoit/P-1497-2017; Dejean, Anne/L-5145-2018; Pineau, Pascal/AAP-5614-2020	Pineau, Pascal/0000-0002-9407-1592; Valla, Dominique/0000-0002-4460-7643				Aberle H, 1996, J CELL BIOCHEM, V61, P514, DOI 10.1002/(SICI)1097-4644(19960616)61:4<514::AID-JCB4>3.0.CO;2-R; Alman BA, 1997, AM J PATHOL, V151, P329; Behrens J, 1996, NATURE, V382, P638, DOI 10.1038/382638a0; Boige V, 1997, CANCER RES, V57, P1986; de La Coste A, 1998, P NATL ACAD SCI USA, V95, P8847; DEJEAN A, 1986, NATURE, V322, P70, DOI 10.1038/322070a0; EDMONDSON HA, 1954, CANCER-AM CANCER SOC, V7, P462, DOI 10.1002/1097-0142(195405)7:3<462::AID-CNCR2820070308>3.0.CO;2-E; Fukuchi T, 1998, CANCER RES, V58, P3526; GREENBLATT MS, 1994, CANCER RES, V54, P4855; Gruner BA, 1998, J PEDIAT HEMATOL ONC, V20, P274, DOI 10.1097/00043426-199805000-00018; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; Hirohashi S, 1998, AM J PATHOL, V153, P333, DOI 10.1016/S0002-9440(10)65575-7; Inomata M, 1996, CANCER RES, V56, P2213; ISHAK K, 1995, J HEPATOL, V22, P696, DOI 10.1016/0168-8278(95)80226-6; Iwao K, 1998, CANCER RES, V58, P1021; Kitaeva MN, 1997, CANCER RES, V57, P4478; Koch A, 1999, CANCER RES, V59, P269; LAURENTPUIG P, 1992, HEPATOLOGY, V16, P1171, DOI 10.1016/0270-9139(92)90010-7; Marchio A, 1997, GENE CHROMOSOME CANC, V18, P59, DOI 10.1002/(SICI)1098-2264(199701)18:1<59::AID-GCC7>3.0.CO;2-0; Miyoshi Y, 1998, CANCER RES, V58, P2524; Molenaar M, 1996, CELL, V86, P391, DOI 10.1016/S0092-8674(00)80112-9; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; Muller O, 1998, GENE CHROMOSOME CANC, V22, P37; MURAKAMI Y, 1991, CANCER RES, V51, P5520; Nagai H, 1997, ONCOGENE, V14, P2927, DOI 10.1038/sj.onc.1201136; Nollet F, 1996, GENOMICS, V32, P413, DOI 10.1006/geno.1996.0136; Oda H, 1996, CANCER RES, V56, P3320; OKUDA K, 1989, GASTROENTEROLOGY, V97, P140, DOI 10.1016/0016-5085(89)91427-3; Piao Z, 1997, CANCER-AM CANCER SOC, V80, P865; Rubinfeld B, 1997, SCIENCE, V275, P1790, DOI 10.1126/science.275.5307.1790; Sparks AB, 1998, CANCER RES, V58, P1130; Terris B, 1996, J CLIN PATHOL-CL MOL, V49, pM203; TREVISANI F, 1995, CANCER-AM CANCER SOC, V75, P2220, DOI 10.1002/1097-0142(19950501)75:9<2220::AID-CNCR2820750906>3.0.CO;2-4; Voeller HJ, 1998, CANCER RES, V58, P2520; WANG J, 1990, NATURE, V343, P555, DOI 10.1038/343555a0; Willert K, 1998, CURR OPIN GENET DEV, V8, P95, DOI 10.1016/S0959-437X(98)80068-3; ZHANG X, 1994, CANCER RES, V54, P4177; ZHANG YJ, 1993, BIOCHEM BIOPH RES CO, V196, P1010, DOI 10.1006/bbrc.1993.2350	38	105	108	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 11	1999	18	47					6583	6588		10.1038/sj.onc.1203051	http://dx.doi.org/10.1038/sj.onc.1203051			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	256CW	10597262				2022-12-25	WOS:000083709200022
J	Krause, E; Schmid, A; Gonzalez, A; Schulz, I				Krause, E; Schmid, A; Gonzalez, A; Schulz, I			Low cytoplasmic [Ca2+] activates I-CRAC independently of global Ca2+ store depletion in RBL-1 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CAPACITATIVE CALCIUM-ENTRY; BASOPHILIC LEUKEMIA-CELLS; FLUORESCENT INDICATORS; PROTEIN-KINASE; T-LYMPHOCYTES; RELEASE; INFLUX; INACTIVATION; RETICULUM; ATP	Release of Ca2+ from inositol (1,4,5)-trisphosphate-sensitive Ca2+ stores causes "capacitative calcium entry," which is mediated by the so-called "Ca2+ release-activated Ca2+ current" (I-CRAC) in RBL-1 cells. Refilling of the Ca2+ stores or high cytoplasmic [Ca2+] ([Ca2+](cyt)) inactivate I-CRAC. Here we address the question if also [Ca2+](cyt) lower than the resting [Ca2+](cyt) influences store operated channels. We therefore combined patch clamp and mag fura-2 fluorescence methods to determine simultaneously both I-CRAC and [Ca2+] within Ca2+ stores of RBL-1 cells ([Ca2+](store)). We found that low [Ca2+](cyt) in the range of 30-50 nM activates I-CRAC and Ca2+ influx spontaneously and independently of global Ca2+ store depletion, while elevation of [Ca2+](cyt) to the resting [Ca2+](cyt) (100 nM) resulted in store dependence of I-CRAC activation. We conclude that spontaneous activation of I-CRAC by low [Ca2+](cyt) could serve as a feedback mechanism keeping the resting [Ca2+](cyt) constant.	Univ Saarlandes, Inst Physiol 2, D-66421 Homburg, Germany	Saarland University	Schulz, I (corresponding author), Univ Saarlandes, Inst Physiol 2, D-66421 Homburg, Germany.		Gonzalez, Antonio/C-5428-2018	Gonzalez, Antonio/0000-0001-8380-0270; Krause, Elmar/0000-0003-0891-2373				Barritt GJ, 1998, CELL CALCIUM, V23, P65, DOI 10.1016/S0143-4160(98)90075-6; BERRIDGE MJ, 1995, BIOCHEM J, V312, P1, DOI 10.1042/bj3120001; Christian EP, 1996, BRIT J PHARMACOL, V119, P647, DOI 10.1111/j.1476-5381.1996.tb15722.x; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; Hofer AM, 1996, FASEB J, V10, P302, DOI 10.1096/fasebj.10.2.8641563; Hofer AM, 1996, CELL CALCIUM, V20, P235, DOI 10.1016/S0143-4160(96)90029-9; Hofer AM, 1998, J CELL BIOL, V140, P325, DOI 10.1083/jcb.140.2.325; HOFER AM, 1993, P NATL ACAD SCI USA, V90, P2598, DOI 10.1073/pnas.90.7.2598; HOTH M, 1992, NATURE, V355, P353, DOI 10.1038/355353a0; Huang Y, 1998, J BIOL CHEM, V273, P19554, DOI 10.1074/jbc.273.31.19554; IRVINE RF, 1990, FEBS LETT, V263, P5, DOI 10.1016/0014-5793(90)80692-C; KAO JPY, 1994, METHOD CELL BIOL, V40, P155; Krause E, 1996, J BIOL CHEM, V271, P32523, DOI 10.1074/jbc.271.51.32523; Liu XB, 1998, J BIOL CHEM, V273, P33295, DOI 10.1074/jbc.273.50.33295; Louzao MC, 1996, J BIOL CHEM, V271, P14807, DOI 10.1074/jbc.271.25.14807; LYTTON J, 1992, J BIOL CHEM, V267, P14483; Mogami H, 1998, EMBO J, V17, P435, DOI 10.1093/emboj/17.2.435; Parekh AB, 1998, J BIOL CHEM, V273, P14925, DOI 10.1074/jbc.273.24.14925; PAREKH AB, 1995, P NATL ACAD SCI USA, V92, P7907, DOI 10.1073/pnas.92.17.7907; Parekh AB, 1997, PHYSIOL REV, V77, P901, DOI 10.1152/physrev.1997.77.4.901; Parekh AB, 1997, CELL, V89, P973, DOI 10.1016/S0092-8674(00)80282-2; PUTNEY JW, 1986, CELL CALCIUM, V7, P1, DOI 10.1016/0143-4160(86)90026-6; PUTNEY JW, 1990, CELL CALCIUM, V11, P611, DOI 10.1016/0143-4160(90)90016-N; RANDRIAMAMPITA C, 1993, NATURE, V364, P809, DOI 10.1038/364809a0; Schofield GG, 1996, J MEMBRANE BIOL, V153, P217, DOI 10.1007/s002329900125; Scott SR, 1998, PFLUG ARCH EUR J PHY, V436, P928, DOI 10.1007/s004240050725; Sims SM, 1997, AM J PHYSIOL-CELL PH, V273, pC1679, DOI 10.1152/ajpcell.1997.273.5.C1679; TOYOFUKU T, 1993, J BIOL CHEM, V268, P2809; WORLEY JF, 1994, J BIOL CHEM, V269, P32055; ZWEIFACH A, 1995, J BIOL CHEM, V270, P14445, DOI 10.1074/jbc.270.24.14445; ZWEIFACH A, 1993, P NATL ACAD SCI USA, V90, P6295, DOI 10.1073/pnas.90.13.6295	32	30	32	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 24	1999	274	52					36957	36962		10.1074/jbc.274.52.36957	http://dx.doi.org/10.1074/jbc.274.52.36957			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	267WR	10601250	hybrid			2022-12-25	WOS:000084382700021
J	Barthel, TK; Walker, GC				Barthel, TK; Walker, GC			Inferences concerning the ATPase properties of DnaK and other HSP70s are affected by the ADP kinase activity of copurifying nucleoside-diphosphate kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK PROTEINS; MOLECULAR CHAPERONE DNAK; ESCHERICHIA-COLI; SUBSTRATE-BINDING; MYXOCOCCUS-XANTHUS; CRYSTAL-STRUCTURE; RNA-POLYMERASE; GRPE; HYDROLYSIS; REPLICATION	Preparations of Escherichia coli DnaK from our lab as well as preparations of DnaK and other HSP70 proteins from several major labs in the field produce a stoichiometric initial burst of [alpha-P-32]ADP when incubated with [alpha-P-32]ATP and contain an ADP kinase activity. We determined that the initial burst activity results from the transfer of gamma-phosphate from the radiolabeled substrate [alpha-P-32]ATP to unlabeled ADP bound by the DnaK and is the same activity that results in ADP phosphorylation. The purification of DnaK from E. coli cells that carry a disrupted ndk gene, ndk::km, results in preparations with greatly reduced ADP kinase activities compared with preparations of DnaK purified from ndk(+) cells. The reduction in the amount of ADP kinase activity in preparations of DnaK purified from ndk::lm cells shows that nucleoside-diphosphate kinase (NDP kinase) is responsible for most of the ADP kinase activity present in DnaK preparations isolated from ndk(+) cells. The remaining ADP kinase activity in preparations hom ndk::km cells, which varies between preparations, is also a property of NDP kinase, which is most likely expressed because of a low frequency reversion of the disrupted ndk gene. A weak, but measurable physical interaction exists between DnaK. and NDP kinase and may be at least partially responsible for the co-purification of NDP kinase with DnaK The presence of contaminating NDP kinase can explain the range of k(cat) values reported for the ATPase activity of DnaK as well as recent reports of initial burst kinetics by DnaK (Banecki, B., and Zylicz, M. (1996) J. Biol. Chem. 271, 6137-6143) and an ADP-ATP exchange activity of DnaK (Hiromura, M., Yano, M., Mori, H., Inoue, M., and Kido, H. (1998) J. Biol. Chem. 273, 5435-5438).	MIT, Dept Biol 68633, Cambridge, MA 02139 USA	Massachusetts Institute of Technology (MIT)	Walker, GC (corresponding author), MIT, Dept Biol 68633, 77 Massachusetts Ave, Cambridge, MA 02139 USA.			/0000-0001-7243-8261	NCI NIH HHS [CA21615] Funding Source: Medline; NIGMS NIH HHS [GM28988] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA021615] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM028988] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALMAULA N, 1995, J BACTERIOL, V177, P2524, DOI 10.1128/jb.177.9.2524-2529.1995; ANG D, 1991, J BIOL CHEM, V266, P24233; Banecki B, 1996, J BIOL CHEM, V271, P6137, DOI 10.1074/jbc.271.11.6137; Beissinger M, 1998, BIOL CHEM, V379, P245; BUCHBERGER A, 1995, J BIOL CHEM, V270, P16903, DOI 10.1074/jbc.270.28.16903; BUCHBERGER A, 1994, EMBO J, V13, P1687, DOI 10.1002/j.1460-2075.1994.tb06433.x; BUKAU B, 1993, MOL MICROBIOL, V9, P671, DOI 10.1111/j.1365-2958.1993.tb01727.x; BUKAU B, 1990, EMBO J, V9, P4027, DOI 10.1002/j.1460-2075.1990.tb07624.x; Bukau B, 1998, CELL, V92, P351, DOI 10.1016/S0092-8674(00)80928-9; BURKHOLDER WF, 1994, J MOL BIOL, V242, P364, DOI 10.1006/jmbi.1994.1587; CRAIG EA, 1993, MICROBIOL REV, V57, P402, DOI 10.1128/MMBR.57.2.402-414.1993; deCrouyChanel A, 1996, J BIOL CHEM, V271, P15486, DOI 10.1074/jbc.271.26.15486; Farr CD, 1998, J BIOL CHEM, V273, P9744, DOI 10.1074/jbc.273.16.9744; FLAHERTY KM, 1990, NATURE, V346, P623, DOI 10.1038/346623a0; FREEMAN BC, 1995, EMBO J, V14, P2281, DOI 10.1002/j.1460-2075.1995.tb07222.x; GAO BC, 1994, BIOCHEMISTRY-US, V33, P2048, DOI 10.1021/bi00174a010; HAMA H, 1991, GENE, V105, P31, DOI 10.1016/0378-1119(91)90510-I; Harrison CJ, 1997, SCIENCE, V276, P431, DOI 10.1126/science.276.5311.431; HARTL FU, 1994, TRENDS BIOCHEM SCI, V19, P20, DOI 10.1016/0968-0004(94)90169-4; Hartl FU, 1996, NATURE, V381, P571, DOI 10.1038/381571a0; HENDRICK JP, 1993, ANNU REV BIOCHEM, V62, P349, DOI 10.1146/annurev.bi.62.070193.002025; HOFFMANN HJ, 1992, P NATL ACAD SCI USA, V89, P12108, DOI 10.1073/pnas.89.24.12108; JORDAN R, 1995, J BIOL CHEM, V270, P4563, DOI 10.1074/jbc.270.9.4563; KAVANAUGHBLACK A, 1994, P NATL ACAD SCI USA, V91, P5883, DOI 10.1073/pnas.91.13.5883; LANDRY SJ, 1992, NATURE, V355, P455, DOI 10.1038/355455a0; LANGER T, 1992, NATURE, V356, P683, DOI 10.1038/356683a0; Leung SM, 1997, J BIOL CHEM, V272, P2607, DOI 10.1074/jbc.272.5.2607; LIBEREK K, 1991, J BIOL CHEM, V266, P14491; LU Q, 1995, J MOL BIOL, V254, P337, DOI 10.1006/jmbi.1995.0620; MCCARTY JS, 1994, J BACTERIOL, V176, P764, DOI 10.1128/jb.176.3.764-780.1994; MCCARTY JS, 1991, P NATL ACAD SCI USA, V88, P9513, DOI 10.1073/pnas.88.21.9513; MCCARTY JS, 1995, J MOL BIOL, V249, P126, DOI 10.1006/jmbi.1995.0284; MUNOZDORADO J, 1990, J BIOL CHEM, V265, P2707; Osipiuk J, 1997, BBA-GENE STRUCT EXPR, V1353, P253, DOI 10.1016/S0167-4781(97)00071-7; PAEK KH, 1987, J BACTERIOL, V169, P283, DOI 10.1128/jb.169.1.283-290.1987; PALLEROS DR, 1993, NATURE, V365, P664, DOI 10.1038/365664a0; Pierpaoli EV, 1997, J MOL BIOL, V269, P757, DOI 10.1006/jmbi.1997.1072; ROTHMAN JE, 1989, CELL, V59, P591, DOI 10.1016/0092-8674(89)90005-6; Rudiger S, 1997, EMBO J, V16, P1501, DOI 10.1093/emboj/16.7.1501; Russell R, 1998, BIOCHEMISTRY-US, V37, P596, DOI 10.1021/bi972025p; Sambrook J., 2002, MOL CLONING LAB MANU; SCHMID D, 1994, SCIENCE, V263, P971, DOI 10.1126/science.8310296; SCHRODER H, 1993, EMBO J, V12, P4137, DOI 10.1002/j.1460-2075.1993.tb06097.x; SKOWYRA D, 1990, CELL, V62, P939, DOI 10.1016/0092-8674(90)90268-J; Slepenkov SV, 1998, BIOCHEMISTRY-US, V37, P1015, DOI 10.1021/bi9720484; STRAUS D, 1990, GENE DEV, V4, P2202, DOI 10.1101/gad.4.12a.2202; Theyssen H, 1996, J MOL BIOL, V263, P657, DOI 10.1006/jmbi.1996.0606; TILLY K, 1983, CELL, V34, P641, DOI 10.1016/0092-8674(83)90396-3; WEI JY, 1995, J BIOL CHEM, V270, P26677, DOI 10.1074/jbc.270.44.26677; WICKNER S, 1992, P NATL ACAD SCI USA, V89, P10345, DOI 10.1073/pnas.89.21.10345; WICKNER S, 1991, P NATL ACAD SCI USA, V88, P7903, DOI 10.1073/pnas.88.18.7903; WILD J, 1992, P NATL ACAD SCI USA, V89, P7139, DOI 10.1073/pnas.89.15.7139; WILLIAMS RL, 1993, J MOL BIOL, V234, P1230, DOI 10.1006/jmbi.1993.1673; Zaborina O, 1999, MOL MICROBIOL, V31, P1333, DOI 10.1046/j.1365-2958.1999.01240.x; Zhu XT, 1996, SCIENCE, V272, P1606, DOI 10.1126/science.272.5268.1606; ZYLICZ M, 1983, P NATL ACAD SCI-BIOL, V80, P6431, DOI 10.1073/pnas.80.21.6431; [No title captured]	57	22	23	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 17	1999	274	51					36670	36678		10.1074/jbc.274.51.36670	http://dx.doi.org/10.1074/jbc.274.51.36670			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	266AV	10593971	hybrid			2022-12-25	WOS:000084279200090
J	Berman, B; Ostrovsky, O; Shlissel, M; Lang, T; Regan, D; Vlodavsky, I; Ishai-Michaeli, R; Ron, D				Berman, B; Ostrovsky, O; Shlissel, M; Lang, T; Regan, D; Vlodavsky, I; Ishai-Michaeli, R; Ron, D			Similarities and differences between the effects of heparin and glypican-1 on the bioactivity of acidic fibroblast growth factor and the keratinocyte growth factor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGH-AFFINITY RECEPTOR; BINDING SPECIFICITIES; CELL-SURFACE; KGF RECEPTOR; SULFATE; LIGAND; EXPRESSION; MOLECULES; FGF; ACTIVATION	The keratinocyte growth factor (KGF or FGF-7) is unique among its family members both in its target cell specificity and its inhibition by the addition of heparin and the native heparan-sulfate proteoglycan (HSPG), glypican-1 in cells expressing endogenous HSPGs. FGF-1, which binds the FGF-7 receptor with a similar affinity as FGF-7, is stimulated by both molecules. In the present study, we investigated the modulation of FGF-7 activities by heparin and glypican-1 in MS-free background utilizing either HS-deficient cells expressing the FGF-7 receptor (designated BaF/KGFR cells) or soluble extracellular domain of the receptor. At physiological concentrations of FGF-7, heparin was required for high affinity receptor binding and for signaling in BaF/KGFR cells. In contrast, binding of FGF-7 to the soluble form of the receptor did not require heparin, However, high concentrations of heparin inhibited the binding of FGF-7 to both the cell surface and the soluble receptor, similar to the reported effect of heparin in cells expressing endogenous HSPGs. The difference in heparin dependence for high affinity interaction between the cell surface and soluble receptor may be due to other molecule(s) present on cell surfaces, Glypican-1 differed from heparin in that it stimulated FGF-1 but not FGF-7 activities in BaF/KGFR cells. Glypican-1 abrogated the stimulatory effect of heparin, and heparin reversed the inhibitory effect of glypican-1, indicating that this HSPG inhibits FGF-7 activities by acting, most likely, as a competitive inhibitor of stimulatory HSPG species for FGF-7, The regulatory effect of glypican-1 is mediated at the level of interaction with the growth factor as glypican-1 did not bind the KGFR. The effect of heparin and glypican-1 on FGF-I and FGF-7 oligomerization was studied employing high and physiological concentrations of growth factors, We did not find a correlation between the effects of these glycosaminoglycans on FGFs biological activity and oligomerization, Altogether, our findings argue against the heparin-linked dimer presentation model as key in FGFR activation, and support the notion that HSPGs primarily affect high affinity interaction of FGFs with their receptors.	Technion Israel Inst Technol, Dept Biol, IL-32000 Haifa, Israel; Hadassah Univ Hosp, Dept Oncol, IL-21120 Jerusalem, Israel	Technion Israel Institute of Technology; Hebrew University of Jerusalem	Ron, D (corresponding author), Technion Israel Inst Technol, Dept Biol, IL-32000 Haifa, Israel.	DinaR@tx.technion.ac.il						Asaka M, 1997, GASTROENTEROLOGY, V113, pS56, DOI 10.1016/S0016-5085(97)80013-3; BASILICO C, 1992, ADV CANCER RES, V59, P115, DOI 10.1016/S0065-230X(08)60305-X; BonnehBarkay D, 1997, J BIOL CHEM, V272, P12415, DOI 10.1074/jbc.272.19.12415; BOTTARO DP, 1990, J BIOL CHEM, V265, P12767; Brauchle M, 1996, AM J PATHOL, V149, P521; DiGabriele AD, 1998, NATURE, V393, P812, DOI 10.1038/31741; DIONNE CA, 1990, EMBO J, V9, P2685, DOI 10.1002/j.1460-2075.1990.tb07454.x; FINCH PW, 1995, DEV DYNAM, V203, P223, DOI 10.1002/aja.1002030210; FLANAGAN JG, 1990, CELL, V63, P185, DOI 10.1016/0092-8674(90)90299-T; Gengrinovitch S, 1999, J BIOL CHEM, V274, P10816, DOI 10.1074/jbc.274.16.10816; GUIMOND S, 1993, J BIOL CHEM, V268, P23906; Hsu YR, 1999, BIOCHEMISTRY-US, V38, P2523, DOI 10.1021/bi9821317; Jang JH, 1997, IN VITRO CELL DEV-AN, V33, P819; JOHNSON DE, 1993, ADV CANCER RES, V60, P1; KAN MK, 1993, SCIENCE, V259, P1918, DOI 10.1126/science.8456318; LaRochelle WJ, 1999, BIOCHEMISTRY-US, V38, P1765, DOI 10.1021/bi982092z; Lopez-Otin C, 1998, ENDOCR REV, V19, P365, DOI 10.1210/er.19.4.365; MACH H, 1993, BIOCHEMISTRY-US, V32, P5480, DOI 10.1021/bi00071a026; McKeehan WL, 1998, PROG NUCLEIC ACID RE, V59, P135; MIKI T, 1992, P NATL ACAD SCI USA, V89, P246, DOI 10.1073/pnas.89.1.246; MIKI T, 1991, SCIENCE, V251, P72, DOI 10.1126/science.1846048; Moy FJ, 1997, BIOCHEMISTRY-US, V36, P4782, DOI 10.1021/bi9625455; NUGENT MA, 1992, BIOCHEMISTRY-US, V31, P8876, DOI 10.1021/bi00152a026; ORNITZ DM, 1992, J BIOL CHEM, V267, P16305; ORNITZ DM, 1992, MOL CELL BIOL, V12, P240, DOI 10.1128/MCB.12.1.240; PANTOLIANO MW, 1994, BIOCHEMISTRY-US, V33, P10229, DOI 10.1021/bi00200a003; PARKS TD, 1994, ANAL BIOCHEM, V216, P413, DOI 10.1006/abio.1994.1060; PINEDALUCENA A, 1994, EUR J BIOCHEM, V222, P425, DOI 10.1111/j.1432-1033.1994.tb18881.x; Pye DA, 1999, J BIOL CHEM, V274, P13456, DOI 10.1074/jbc.274.19.13456; RAPRAEGER AC, 1994, METHOD ENZYMOL, V245, P219; RAPRAEGER AC, 1991, SCIENCE, V252, P1705, DOI 10.1126/science.1646484; REICHSLOTKY R, 1994, J BIOL CHEM, V269, P32279; REICHSLOTKY R, 1995, J BIOL CHEM, V270, P29813; ROGHANI M, 1994, J BIOL CHEM, V269, P3976; RON D, 1993, J BIOL CHEM, V268, P2984; RON D, 1993, J BIOL CHEM, V268, P5388; Rubin J. S., 1995, V74, P191; SAKSELA O, 1988, J CELL BIOL, V107, P743, DOI 10.1083/jcb.107.2.743; SCHLESSINGER J, 1995, CELL, V83, P357, DOI 10.1016/0092-8674(95)90112-4; SHAOUL E, 1995, ONCOGENE, V10, P1553; Sher I, 1999, J BIOL CHEM, V274, P35016, DOI 10.1074/jbc.274.49.35016; SPIVAKKROIZMAN T, 1994, CELL, V79, P1015, DOI 10.1016/0092-8674(94)90032-9; SPRINGER BA, 1994, J BIOL CHEM, V269, P26879; STRAIN AJ, 1994, EXP CELL RES, V210, P253, DOI 10.1006/excr.1994.1037; Venkataraman G, 1999, P NATL ACAD SCI USA, V96, P1892, DOI 10.1073/pnas.96.5.1892; Vlodavsky I, 1996, CANCER METAST REV, V15, P177, DOI 10.1007/BF00437470; VLODAVSKY I, 1991, ANN NY ACAD SCI, V638, P207; Wells JA, 1996, P NATL ACAD SCI USA, V93, P1, DOI 10.1073/pnas.93.1.1; WERNER S, 1992, MOL CELL BIOL, V12, P82, DOI 10.1128/MCB.12.1.82; YAYON A, 1991, CELL, V64, P841, DOI 10.1016/0092-8674(91)90512-W; YUEN S, 1991, METHOD ENZYMOL, V198, P91	51	44	44	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 17	1999	274	51					36132	36138		10.1074/jbc.274.51.36132	http://dx.doi.org/10.1074/jbc.274.51.36132			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	266AV	10593896	hybrid			2022-12-25	WOS:000084279200015
J	Hofmann, MW; Honing, S; Rodionov, D; Dobberstein, B; von Figura, K; Bakke, O				Hofmann, MW; Honing, S; Rodionov, D; Dobberstein, B; von Figura, K; Bakke, O			The leucine-based sorting motifs in the cytoplasmic domain of the invariant chain are recognized by the clathrin adaptors AP1 and AP2 and their medium chains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CLASS-II MOLECULES; SURFACE-PLASMON RESONANCE; COATED VESICLES; HLA-DR; INTRACELLULAR-TRANSPORT; RAPID INTERNALIZATION; ENDOCYTIC PATHWAY; SELECTIVE BINDING; MDCK CELLS; IN-VITRO	Recognition of sorting signals within the cytoplasmic tail of membrane proteins by adaptor protein complexes is a crucial step in membrane protein sorting. The three known adaptor complexes, AP1, AP2, and AP3, have all been shown to recognize tyrosine- and leucine-based sorting signals, which are the most common sorting signals within membrane protein cytoplasmic tails, Although tyrosine-based signals are recognized by the mu-chains of adaptor complexes, the subunit recognizing leucine-based sorting signals is less clear. In this report we show by surface plasmon resonance that the two leucine-based sorting signals within the cytoplasmic tail of the invariant chain bind independently from each other to API and AP2 but not to AP3, We also show that both motifs can be recognized by the mu-chains of API and AP2, Moreover, by using monomeric as well as trimeric invariant chain constructs, we show that adaptor binding does not require trimerization of the invariant chain.	Univ Oslo, Dept Biol, N-0316 Oslo, Norway; Univ Gottingen, Inst Biochem 2, D-37073 Gottingen, Germany	University of Oslo; University of Gottingen	Bakke, O (corresponding author), Univ Oslo, Dept Biol, Box 1050 Blindern, N-0316 Oslo, Norway.			Hofmann, Michael Werner/0000-0002-2729-6062; Bakke, Oddmund/0000-0003-4843-7626				BAKKE O, 1990, CELL, V63, P707, DOI 10.1016/0092-8674(90)90137-4; BENAROCH P, 1995, EMBO J, V14, P37, DOI 10.1002/j.1460-2075.1995.tb06973.x; BIJLMAKERS MJE, 1994, J EXP MED, V180, P623, DOI 10.1084/jem.180.2.623; BOLL W, 1995, CURR BIOL, V5, P1168, DOI 10.1016/S0960-9822(95)00233-8; BREMNES B, 1994, J CELL SCI, V107, P2021; Bremnes T, 1998, J BIOL CHEM, V273, P8638, DOI 10.1074/jbc.273.15.8638; CRESSWELL P, 1994, ANNU REV IMMUNOL, V12, P259, DOI 10.1146/annurev.immunol.12.1.259; Dell'Angelica EC, 1998, SCIENCE, V280, P431, DOI 10.1126/science.280.5362.431; Dietrich J, 1997, J CELL BIOL, V138, P271, DOI 10.1083/jcb.138.2.271; GeddeDahl M, 1997, J BIOL CHEM, V272, P8281, DOI 10.1074/jbc.272.13.8281; GERMAIN RN, 1993, ANNU REV IMMUNOL, V11, P403, DOI 10.1146/annurev.immunol.11.1.403; Heilker R, 1996, EMBO J, V15, P2893, DOI 10.1002/j.1460-2075.1996.tb00650.x; Hirst J, 1998, BBA-MOL CELL RES, V1404, P173, DOI 10.1016/S0167-4889(98)00056-1; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Honing S, 1998, EMBO J, V17, P1304, DOI 10.1093/emboj/17.5.1304; Honing S, 1996, EMBO J, V15, P5230, DOI 10.1002/j.1460-2075.1996.tb00908.x; Honing S, 1997, J BIOL CHEM, V272, P19884, DOI 10.1074/jbc.272.32.19884; JONSSON U, 1991, BIOTECHNIQUES, V11, P620; KARLSSON R, 1991, J IMMUNOL METHODS, V145, P229, DOI 10.1016/0022-1759(91)90331-9; KEEN JH, 1979, CELL, V16, P303, DOI 10.1016/0092-8674(79)90007-2; LAMB CA, 1992, J IMMUNOL, V148, P3478; LINDNER R, 1994, CELL BIOL LAB HDB, V1, P525; Liu SH, 1998, J CELL BIOL, V140, P1023, DOI 10.1083/jcb.140.5.1023; LOTTEAU V, 1990, NATURE, V348, P600, DOI 10.1038/348600a0; MANFREDI JJ, 1987, J BIOL CHEM, V262, P12182; Marks MS, 1997, TRENDS CELL BIOL, V7, P124, DOI 10.1016/S0962-8924(96)10057-X; MOTTA A, 1995, J BIOL CHEM, V270, P27165, DOI 10.1074/jbc.270.45.27165; Nordeng TW, 1998, CURR TOP MICROBIOL, V232, P179; ODORIZZI CG, 1994, J CELL BIOL, V126, P317, DOI 10.1083/jcb.126.2.317; OHNO H, 1995, SCIENCE, V269, P1872, DOI 10.1126/science.7569928; OSHANNESSY DJ, 1993, ANAL BIOCHEM, V212, P457, DOI 10.1006/abio.1993.1355; PIETERS J, 1993, J CELL SCI, V106, P831; Pitcher C, 1999, MOL BIOL CELL, V10, P677, DOI 10.1091/mbc.10.3.677; POND L, 1995, J BIOL CHEM, V270, P19989, DOI 10.1074/jbc.270.34.19989; Rapoport I, 1998, EMBO J, V17, P2148, DOI 10.1093/emboj/17.8.2148; ROCHE PA, 1993, P NATL ACAD SCI USA, V90, P8581, DOI 10.1073/pnas.90.18.8581; ROCHE PA, 1991, NATURE, V354, P392, DOI 10.1038/354392a0; Rodionov DG, 1998, J BIOL CHEM, V273, P6005, DOI 10.1074/jbc.273.11.6005; Salamero J, 1996, J BIOL CHEM, V271, P30318, DOI 10.1074/jbc.271.48.30318; Sandoval Ignacio V., 1994, Trends in Cell Biology, V4, P292, DOI 10.1016/0962-8924(94)90220-8; Simonsen A, 1997, J CELL SCI, V110, P597; Simonsen A, 1998, EUR J CELL BIOL, V76, P25, DOI 10.1016/S0171-9335(98)80014-9; Simpson F, 1997, J CELL BIOL, V137, P835, DOI 10.1083/jcb.137.4.835; Traub LM, 1997, TRENDS CELL BIOL, V7, P43, DOI 10.1016/S0962-8924(96)20042-X; VOGT AB, 1995, J IMMUNOL, V155, P4757; Wang K, 1997, J BIOL CHEM, V272, P17055, DOI 10.1074/jbc.272.27.17055	46	85	85	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 17	1999	274	51					36153	36158		10.1074/jbc.274.51.36153	http://dx.doi.org/10.1074/jbc.274.51.36153			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	266AV	10593899	hybrid			2022-12-25	WOS:000084279200018
J	Hruz, PW; Mueckler, MM				Hruz, PW; Mueckler, MM			Cysteine-scanning mutagenesis of transmembrane segment 7 of the GLUT1 glucose transporter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXOFACIAL LIGAND-BINDING; XENOPUS OOCYTES; MEMBRANE; SITE; EXPRESSION; PROTEINS; TOPOLOGY; RESIDUES; PATHWAY; FAMILY	The human erythrocyte facilitative glucose transporter (Glut1) is predicted to contain 12 transmembrane spanning alpha-helices based upon hydropathy plot analysis of the primary sequence. Five of these helices (3, 5, 7, 8, and 11) are capable of forming amphipathic structures, A model of GLUT1 tertiary structure has therefore been proposed in which the hydrophilic faces of several amphipathic helices are arranged to form a central aqueous channel through which glucose traverses the hydrophobic lipid bilayer. In order to test this model, we individually mutated each of the amino acid residues in transmembrane segment 7 to cysteine in an engineered GLUT1 molecule devoid of all native cysteines (C-less). Measurement of 2-deoxyglucose uptake in a Xenopus oocyte expression system revealed that nearly all of these mutants retain measurable transport activity, Over one-half of the cysteine mutants had significantly reduced specific activity relative to the C-less protein. The solvent accessibility and relative orientation of the residues within the helix was investigated by determining the sensitivity of the mutant transporters to inhibition by the sulfhydryl directed reagent p-chloromercuribenzene sulfonate (pCMBS). Cysteine replacement at six positions (GLn(282), Gln(283), Ile(287), Ala(289), Val(290), and Phe(291)), all near the exofacial side of the cell membrane, produced transporters that were inhibited by incubation with extracellular pCMBS. Residues predicted to be near the cytoplasmic side of the cell membrane were minimally affected by pCMBS. These data demonstrate that the exofacial portion of transmembrane segment 7 is accessible to the external solvent and provide evidence for the positioning of this alpha-helix within the glucose permeation pathway.	Washington Univ, Sch Med, Dept Cell Biol & Physiol, St Louis, MO 63110 USA	Washington University (WUSTL)	Mueckler, MM (corresponding author), Washington Univ, Sch Med, Dept Cell Biol & Physiol, 660 S Euclid Ave, St Louis, MO 63110 USA.	mike@cellbio.wustl.edu	Mueckler, Mike M/F-6115-2012	Hruz, Paul/0000-0002-1478-3355	NIDDK NIH HHS [DK 43695] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK043695] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALVAREZ J, 1987, J BIOL CHEM, V262, P3502; BALDWIN SA, 1993, BIOCHIM BIOPHYS ACTA, V1154, P17, DOI 10.1016/0304-4157(93)90015-G; CAIRNS MT, 1987, BIOCHIM BIOPHYS ACTA, V905, P295, DOI 10.1016/0005-2736(87)90458-5; CARRUTHERS A, 1990, PHYSIOL REV, V70, P1135, DOI 10.1152/physrev.1990.70.4.1135; CHIN JJ, 1987, P NATL ACAD SCI USA, V84, P4113, DOI 10.1073/pnas.84.12.4113; DAVIES A, 1990, BIOCHEM J, V266, P799; Frillingos S, 1998, FASEB J, V12, P1281, DOI 10.1096/fasebj.12.13.1281; GARCIA JC, 1992, J BIOL CHEM, V267, P7770; GOULD GW, 1993, BIOCHEM J, V295, P329, DOI 10.1042/bj2950329; HASHIRAMOTO M, 1992, J BIOL CHEM, V267, P17502; HRESKO RC, 1994, J BIOL CHEM, V269, P32110; HRESKO RC, 1994, J BIOL CHEM, V269, P20482; KASAHARA M, 1977, J BIOL CHEM, V252, P7384; KELLER K, 1989, J BIOL CHEM, V264, P18884; MORI H, 1994, J BIOL CHEM, V269, P11578; Mueckler M, 1999, J BIOL CHEM, V274, P10923, DOI 10.1074/jbc.274.16.10923; MUECKLER M, 1994, EUR J BIOCHEM, V219, P713, DOI 10.1111/j.1432-1033.1994.tb18550.x; MUECKLER M, 1994, J BIOL CHEM, V269, P17765; MUECKLER M, 1994, J BIOL CHEM, V269, P20533; Mueckler M, 1997, J BIOL CHEM, V272, P30141, DOI 10.1074/jbc.272.48.30141; MUECKLER M, 1985, SCIENCE, V229, P941, DOI 10.1126/science.3839598; Olsowski A, 1998, BIOCHEMISTRY-US, V37, P10738, DOI 10.1021/bi980440r; WELLNER M, 1994, BIOCHEM J, V299, P813, DOI 10.1042/bj2990813; YAN RT, 1995, P NATL ACAD SCI USA, V92, P5973, DOI 10.1073/pnas.92.13.5973; Zeng H, 1996, BIOPHYS J, V70, P14, DOI 10.1016/S0006-3495(96)79560-7	25	53	54	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 17	1999	274	51					36176	36180		10.1074/jbc.274.51.36176	http://dx.doi.org/10.1074/jbc.274.51.36176			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	266AV	10593902	hybrid			2022-12-25	WOS:000084279200021
J	Lardinois, OM; Medzihradszky, KF; de Montellano, PRO				Lardinois, OM; Medzihradszky, KF; de Montellano, PRO			Spin trapping and protein cross-linking of the lactoperoxidase protein radical	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME-C PEROXIDASE; EOSINOPHIL PEROXIDASE; COMPOUND-I; BOVINE LACTOPEROXIDASE; HUMAN MYELOPEROXIDASE; HYDROGEN-PEROXIDE; PROSTHETIC GROUP; HEME; REDUCTION; MECHANISM	Lactoperoxidase (LPO) reacts with H2O2 to sequentially give two Compound I intermediates: the first with a ferryl (Fe-IV=O) species and a porphyrin radical cation, and the second with the same ferryl species and a presumed protein radical. However, little actual evidence is available for the protein radical. We report here that LPO reacts with the spin trap 3,5-dibromo-4-nitrosobenzenesulfonic acid to give a 1:1 protein-bound radical adduct, Furthermore, LPO undergoes the H2O2-dependent formation of dimeric and trimeric products. Proteolytic digestion and mass spectrometric analysis indicates that the dimer is held together by a dityrosine link between Tyr-289 in each of two LPO molecules, The dimer retains full catalytic activity and reacts to the same extent with the spin trap, indicating that the spin trap reacts with a radical center other than Tyr-289. The monomeric protein recovered from incubations of LPO with H2O2 is fully active but no longer forms dimers when incubated with H2O2, clear evidence that it has also been structurally modified. Myeloperoxidase, a naturally dimeric protein, and eosinophil peroxidase do not undergo H2O2-dependent oligomerization, Analysis of the interface in the LPO dimers indicates that the same protein surface is involved in LPO dimerization as in the normal formation of myeloperoxidase dimers, Oligomerization of LPO alters its physical properties and may alter its ability to interact with macromolecular substrates.	Univ Calif San Francisco, Sch Pharm, Dept Pharmaceut Chem, San Francisco, CA 94143 USA	University of California System; University of California San Francisco	de Montellano, PRO (corresponding author), Univ Calif San Francisco, Sch Pharm, Dept Pharmaceut Chem, San Francisco, CA 94143 USA.				NCRR NIH HHS [RR01614] Funding Source: Medline; NIDDK NIH HHS [5 P30 DK26743] Funding Source: Medline; NIGMS NIH HHS [GM32488] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR001614] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK026743] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM032488] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AGNER K, 1958, ACTA CHEM SCAND, V12, P89, DOI 10.3891/acta.chem.scand.12-0089; Andersen S.O, 1966, ACTA PHYSIOL SC S263, V66, P1; ANDREWS PC, 1981, J BIOL CHEM, V256, P4211; Barr DP, 1996, J BIOL CHEM, V271, P15498, DOI 10.1074/jbc.271.26.15498; BAYSE GS, 1972, BIOCHIM BIOPHYS ACTA, V284, P34; BIEMANN K, 1990, METHOD ENZYMOL, V193, P886, DOI 10.1016/0076-6879(90)93460-3; BOLSCHER BGJM, 1984, BIOCHIM BIOPHYS ACTA, V784, P177, DOI 10.1016/0167-4838(84)90125-0; CALS MM, 1991, EUR J BIOCHEM, V198, P733, DOI 10.1111/j.1432-1033.1991.tb16073.x; Chen YR, 1999, J BIOL CHEM, V274, P3308, DOI 10.1074/jbc.274.6.3308; CHILDS RE, 1975, BIOCHEM J, V145, P93, DOI 10.1042/bj1450093; COURTIN F, 1984, BIOCHEM BIOPH RES CO, V121, P463, DOI 10.1016/0006-291X(84)90205-5; COURTIN F, 1982, EUR J BIOCHEM, V124, P603; DeGioia L, 1996, J BIOL INORG CHEM, V1, P476; DEMONTELLANO O, 1992, ANN REV PHARM TOXICO, V32, P89; DePillis GD, 1997, J BIOL CHEM, V272, P8857; DULL TJ, 1990, DNA CELL BIOL, V9, P499, DOI 10.1089/dna.1990.9.499; DUNFORD HB, 1999, HEME PEROXIDASES, P18; ERMAN JE, 1989, BIOCHEMISTRY-US, V28, P7992, DOI 10.1021/bi00446a004; Fayadat L, 1999, J BIOL CHEM, V274, P10533, DOI 10.1074/jbc.274.15.10533; FENNA R, 1995, ARCH BIOCHEM BIOPHYS, V316, P653, DOI 10.1006/abbi.1995.1086; GIULIVI C, 1993, J BIOL CHEM, V268, P8752; GROSS AJ, 1959, J BIOL CHEM, V234, P1611; GUNTHER MR, 1995, J BIOL CHEM, V270, P16075, DOI 10.1074/jbc.270.27.16075; HIRAMOTO K, 1994, FREE RADICAL RES, V21, P341, DOI 10.3109/10715769409056586; HOUSEMAN ALP, 1993, BIOCHEMISTRY-US, V32, P4430, DOI 10.1021/bi00067a036; HU SH, 1991, J AM CHEM SOC, V113, P7189, DOI 10.1021/ja00019a015; HUYETT JE, 1995, J AM CHEM SOC, V117, P9033, DOI 10.1021/ja00140a021; KIMURA S, 1979, ARCH BIOCHEM BIOPHYS, V198, P580, DOI 10.1016/0003-9861(79)90534-4; KOOSER RG, 1969, J CHEM PHYS, V50, P5243, DOI 10.1063/1.1671041; Kooter IM, 1997, J AM CHEM SOC, V119, P11542, DOI 10.1021/ja9725460; MANSSONRAHEMTULLA B, 1986, ARCH ORAL BIOL, V31, P661, DOI 10.1016/0003-9969(86)90095-6; MANSSONRAHEMTULLA B, 1988, BIOCHEMISTRY-US, V27, P233, DOI 10.1021/bi00401a035; Monzani E, 1997, BIOCHEMISTRY-US, V36, P1918, DOI 10.1021/bi961868y; OHLSSON PI, 1983, ACTA CHEM SCAND B, V37, P917, DOI 10.3891/acta.chem.scand.37b-0917; OLSEN RL, 1984, BIOCHEM J, V222, P701, DOI 10.1042/bj2220701; Oxvig C, 1999, J BIOL CHEM, V274, P16953, DOI 10.1074/jbc.274.24.16953; Paul K. G., 1985, Immunology Series, V27, P15; Rae TD, 1996, J AM CHEM SOC, V118, P2103, DOI 10.1021/ja952650m; Rae TD, 1998, J BIOL CHEM, V273, P27968, DOI 10.1074/jbc.273.43.27968; SPANGLER BD, 1986, BIOCHIM BIOPHYS ACTA, V872, P155; Taurog A, 1996, ARCH BIOCHEM BIOPHYS, V330, P24, DOI 10.1006/abbi.1996.0222; TAUROG A, 1994, ARCH BIOCHEM BIOPHYS, V315, P82, DOI 10.1006/abbi.1994.1474; TAYLOR KL, 1995, ARCH BIOCHEM BIOPHYS, V316, P635, DOI 10.1006/abbi.1995.1083; TENOVUO J, 1979, ARCH ORAL BIOL, V24, P591, DOI 10.1016/0003-9969(79)90018-9; TENOVUO J, 1981, ARCH ORAL BIOL, V26, P1051, DOI 10.1016/0003-9969(81)90116-3; TEW D, 1988, J BIOL CHEM, V263, P17880; Thomas EL, 1985, LACTOPEROXIDASE SYST, P31; Ueda T, 1997, EUR J BIOCHEM, V243, P32, DOI 10.1111/j.1432-1033.1997.0032a.x; ZENG J, 1992, J MOL BIOL, V226, P185, DOI 10.1016/0022-2836(92)90133-5	49	63	64	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 10	1999	274	50					35441	35448		10.1074/jbc.274.50.35441	http://dx.doi.org/10.1074/jbc.274.50.35441			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	264NG	10585414	hybrid			2022-12-25	WOS:000084187900026
J	Hong, YJ; Maeda, Y; Watanabe, R; Ohishi, K; Mishkind, M; Riezman, H; Kinoshita, T				Hong, YJ; Maeda, Y; Watanabe, R; Ohishi, K; Mishkind, M; Riezman, H; Kinoshita, T			Pig-n, a mammalian homologue of yeast Mcd4p, is involved in transferring phosphoethanolamine to the first mannose of the glycosylphosphatidylinositol	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANCHOR BIOSYNTHESIS; PHOSPHATIDYLINOSITOL; CELLS; IDENTIFICATION; MANNOSYLATION; PRECURSOR; PROTEINS; GENE	Many cell surface proteins are anchored to the membrane via a glycosylphosphatidylinositol (GPI) moiety, which is attached to the C terminus of the proteins. The core of the GPI anchor is conserved in all eukaryotes but is modified by various side chains. We cloned a mouse phosphatidylinositol glycan-class N (Pig-n) gene that encodes a 931amino acid protein expressed in the endoplasmic reticulum, which is homologous to yeast Mcd4p. We disrupted the gene in F9 embryonal carcinoma cells. In the Pig-n knockout cells, the first mannose in the GPI precursors was not modified by phosphoethanolamine, Nevertheless, further biosynthetic steps continued with the addition of the third mannose and the terminal phosphoethanolamine. The surface expression of Thy-1 was only partially affected, indicating that modification of the first mannose by phosphoethanolamine is not essential for attachment of GPI anchors in mammalian cells. An inhibitor of GPI biosynthesis, YW3548/BE49385A, inhibited transfer of phosphoethanolamine to the first mannose in mammalian cells but only slightly affected the surface expression of GPI-anchored proteins. Biosynthesis of GPI in the Pig-n knockout cells was not affected by YW3548/BE49385A, and yeast overexpressing MCD4 was highly resistant to YW3548/BE49385A, suggesting that Pig-n and Mcd4p are targets of this drug.	Osaka Univ, Microbial Dis Res Inst, Suita, Osaka 5650871, Japan; Bennington Coll, Dept Biol, Bennington, VT 05201 USA; Univ Basel, Biozentrum, CH-4056 Basel, Switzerland	Osaka University; University of Basel	Kinoshita, T (corresponding author), Osaka Univ, Microbial Dis Res Inst, 3-1 Yamada Oka, Suita, Osaka 5650871, Japan.	tkinoshi@biken.osaka-u.ac.jp	Kinoshita, Taroh/C-7353-2009	Riezman, Howard/0000-0003-4680-9422; Watanabe, Reika/0000-0002-7427-7702				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; Benachour A, 1999, J BIOL CHEM, V274, P15251, DOI 10.1074/jbc.274.21.15251; CAMP LA, 1993, J BIOL CHEM, V268, P6721; Canivenc-Gansel E, 1998, GLYCOBIOLOGY, V8, P761, DOI 10.1093/glycob/8.8.761; Doerrler WT, 1996, J BIOL CHEM, V271, P27031, DOI 10.1074/jbc.271.43.27031; ENGLUND PT, 1993, ANNU REV BIOCHEM, V62, P121, DOI 10.1146/annurev.bi.62.070193.001005; Gaynor EC, 1999, MOL BIOL CELL, V10, P627, DOI 10.1091/mbc.10.3.627; GUNTER KC, 1984, J EXP MED, V159, P716, DOI 10.1084/jem.159.3.716; HIROSE S, 1992, J BIOL CHEM, V267, P16968; HOLLANDER N, 1988, J IMMUNOL, V141, P4283; Hong Y, 1999, J BIOL CHEM, V274, P18582, DOI 10.1074/jbc.274.26.18582; INOUE N, 1993, J BIOL CHEM, V268, P6882; Kapteyn JC, 1999, BBA-GEN SUBJECTS, V1426, P373, DOI 10.1016/S0304-4165(98)00137-8; Kinoshita T, 1997, J BIOCHEM-TOKYO, V122, P251; KINOSHITA T, 1985, J EXP MED, V162, P75, DOI 10.1084/jem.162.1.75; MCCONVILLE MJ, 1993, BIOCHEM J, V294, P305, DOI 10.1042/bj2940305; PUOTI A, 1993, J BIOL CHEM, V268, P7215; PUOTI A, 1991, J BIOL CHEM, V266, P21051; Schuler GD, 1996, SCIENCE, V274, P540, DOI 10.1126/science.274.5287.540; Schultz C, 1998, TRENDS PLANT SCI, V3, P426, DOI 10.1016/S1360-1385(98)01328-4; Sharma DK, 1997, BIOCHEM J, V328, P171; Smith TK, 1997, EMBO J, V16, P6667, DOI 10.1093/emboj/16.22.6667; STEVENS VL, 1995, BIOCHEM J, V310, P361, DOI 10.1042/bj3100361; SUGITA Y, 1994, IMMUNOLOGY, V82, P34; SUGIYAMA E, 1991, J BIOL CHEM, V266, P12119; Sutterlin C, 1998, BIOCHEM J, V332, P153; Sutterlin C, 1997, EMBO J, V16, P6374, DOI 10.1093/emboj/16.21.6374; Tiede A, 1999, BIOL CHEM, V380, P503, DOI 10.1515/BC.1999.066; Tujioka H, 1998, BIOCHEM BIOPH RES CO, V251, P737, DOI 10.1006/bbrc.1998.9542; TYBULEWICZ VLJ, 1991, CELL, V65, P1153, DOI 10.1016/0092-8674(91)90011-M; UEDA E, 1993, J BIOL CHEM, V268, P9998; VIDUGIRIENE J, 1993, J CELL BIOL, V121, P987, DOI 10.1083/jcb.121.5.987	32	107	111	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 3	1999	274	49					35099	35106		10.1074/jbc.274.49.35099	http://dx.doi.org/10.1074/jbc.274.49.35099			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	260XW	10574991	hybrid			2022-12-25	WOS:000083979600085
J	Savarino, A; Bottarel, F; Calosso, L; Fleito, MJ; Bensi, T; Bragardo, M; Rojo, JM; Pugliese, A; Abbate, I; Capobianchi, MR; Dianzani, F; Malavasi, F; Dianzani, U				Savarino, A; Bottarel, F; Calosso, L; Fleito, MJ; Bensi, T; Bragardo, M; Rojo, JM; Pugliese, A; Abbate, I; Capobianchi, MR; Dianzani, F; Malavasi, F; Dianzani, U			Effects of the human CD38 glycoprotein on the early stages of the HIV-1 replication cycle	FASEB JOURNAL			English	Article						susceptibility to HIV-1; gp120/CD4-dependent virus binding	IMMUNODEFICIENCY-VIRUS TYPE-1; LYMPHOCYTE SURFACE MOLECULES; 3-COLOR FLOW-CYTOMETRY; CD4(+) T-CELLS; ANTIVIRAL COMPOUNDS; ACTIVATION ANTIGEN; CD28 COSTIMULATION; ADULT-BLOOD; CORD-BLOOD; EXPRESSION	CD38 displays lateral association with the HIV-1 receptor CD4. This association is potentiated by the HIV-1 envelope glycoprotein gp120. The aim of this work was to evaluate the CD38 role in T cell susceptibility to HTV-1 infection. Using laboratory X4 HIV-1 strains and X4 and X4/R5 primary isolates, we found that CD38 expression was negatively correlated to cell susceptibility to infection, evaluated as percentage of infected cells, release of HN p24 in the supernatants, and cytopathogenicity. This correlation was at first suggested by results obtained in a panel of human CD4(+) T cell lines expressing different CD38 levels (MT-4, MT-2, C8166, CEMx174, Supt-1, and H9) and then demonstrated using CD38 transfectants of MT-4 cells (the line with the lowest CD38 expression). To address whether CD38 affected viral binding, we used mouse T cells that are non-permissive for productive infection. Gene transfection in mouse SR.D10.CD4(-).F1 T cells produced four Lines expressing human CD4 and/or CD38. Ability of CD4(+)CD38(+) cells to bind HIV-1 or purified recombinant gp120 was significantly lower than that of CD4(+)CD38(-) cells. These data suggest that CD38 expression inhibits lymphocyte susceptibility to HIV infection, probably by inhibiting gp120/CD4-dependent viral binding to target cells.	Univ A Avogadro Eastern Piedmont, Dept Med Sci, I-28100 Novara, Italy; Univ Turin, Dept Med & Surg Sci, I-10124 Turin, Italy; Univ Roma La Sapienza, Dept Expt Med & Pathol, Rome, Italy; CSIC, Ctr Invest Biol, Dept Immunol, Madrid, Spain; Univ Ancona, Inst Biol & Genet, I-60128 Ancona, Italy	University of Eastern Piedmont Amedeo Avogadro; University of Turin; Sapienza University Rome; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Investigaciones Biologicas (CIB); Marche Polytechnic University	Dianzani, U (corresponding author), Univ A Avogadro Eastern Piedmont, Dept Med Sci, Via Solaroli 17, I-28100 Novara, Italy.		Feito, Maria José/AAE-7813-2020; Dianzani, Umberto/K-1952-2016; Rojo, Jose/ABH-1189-2020; Abbate, Isabella/K-6434-2016	Feito, Maria José/0000-0001-8623-4913; Rojo, Jose M./0000-0001-9032-0072; Savarino, Andrea/0000-0003-0983-3693; Capobianchi, Maria Rosaria/0000-0003-3465-0071; DIANZANI, Umberto/0000-0001-6723-3931; MALAVASI, Fabio/0000-0002-1844-174X				Amlot PL, 1996, CLIN EXP IMMUNOL, V105, P176, DOI 10.1046/j.1365-2249.1996.d01-722.x; Autran B, 1997, SCIENCE, V277, P112, DOI 10.1126/science.277.5322.112; BOFILL M, 1994, J IMMUNOL, V152, P5613; Bragardo M, 1997, J IMMUNOL, V159, P1619; CALLEBAUT C, 1993, SCIENCE, V262, P2045, DOI 10.1126/science.7903479; Capobianchi MR, 1998, AIDS RES HUM RETROV, V14, P233, DOI 10.1089/aid.1998.14.233; Carroll RG, 1997, SCIENCE, V276, P273, DOI 10.1126/science.276.5310.273; CAYOTA A, 1993, CLIN EXP IMMUNOL, V91, P241; Cesano A, 1998, J IMMUNOL, V160, P1106; Chan DC, 1998, CELL, V93, P681, DOI 10.1016/S0092-8674(00)81430-0; Cohen J, 1997, SCIENCE, V275, P1261, DOI 10.1126/science.275.5304.1261; DASILVA CP, 1998, IMMUNOL REV, V161, P79; De Martino M, 1998, PEDIATR RES, V43, P752, DOI 10.1203/00006450-199806000-00007; DIANZANI U, 1995, EUR J IMMUNOL, V25, P1306, DOI 10.1002/eji.1830250526; DIANZANI U, 1994, J IMMUNOL, V153, P952; DIEZOREJAS R, 1994, EMBO J, V13, P90, DOI 10.1002/j.1460-2075.1994.tb06238.x; Dittmar MT, 1997, NATURE, V385, P495, DOI 10.1038/385495a0; Dolei A, 1998, AIDS, V12, P183, DOI 10.1097/00002030-199802000-00008; DUKES CS, 1995, J VIROL, V69, P4000, DOI 10.1128/JVI.69.7.4000-4005.1995; Dull T, 1998, J VIROL, V72, P8463, DOI 10.1128/JVI.72.11.8463-8471.1998; Feito MJ, 1997, INT IMMUNOL, V9, P1141, DOI 10.1093/intimm/9.8.1141; Ferrero E, 1999, J LEUKOCYTE BIOL, V65, P151, DOI 10.1002/jlb.65.2.151; Frank I, 1996, AIDS, V10, P1611, DOI 10.1097/00002030-199612000-00004; FURLINI G, 1991, MICROBIOLOGICA, V14, P141; Greenough TC, 1997, J INFECT DIS, V176, P118, DOI 10.1086/514013; He JL, 1997, NATURE, V385, P645, DOI 10.1038/385645a0; HOWARD M, 1993, SCIENCE, V262, P1056, DOI 10.1126/science.8235624; Kitchen SG, 1998, J VIROL, V72, P9054, DOI 10.1128/JVI.72.11.9054-9060.1998; Levine BL, 1996, SCIENCE, V272, P1939, DOI 10.1126/science.272.5270.1939; Liu Z, 1998, J ACQ IMMUN DEF SYND, V18, P332, DOI 10.1097/00042560-199808010-00004; Liu ZY, 1996, CYTOMETRY, V26, P1; Lund FE, 1996, J IMMUNOL, V157, P1455; Maciaszek JW, 1998, J VIROL, V72, P5862, DOI 10.1128/JVI.72.7.5862-5869.1998; MALAVASI F, 1984, HUM IMMUNOL, V9, P9, DOI 10.1016/0198-8859(84)90003-X; MATHESON PB, 1995, AM J EPIDEMIOL, V142, P714, DOI 10.1093/oxfordjournals.aje.a117701; McCloskey TW, 1997, CLIN IMMUNOL IMMUNOP, V84, P46, DOI 10.1006/clin.1997.4370; Mehta K, 1996, FASEB J, V10, P1408, DOI 10.1096/fasebj.10.12.8903511; Mo HM, 1998, AIDS RES HUM RETROV, V14, P607, DOI 10.1089/aid.1998.14.607; MORRA M, 1998, FASEB J, V330, P1129; MURRAY MF, 1995, BIOCHEM BIOPH RES CO, V210, P954, DOI 10.1006/bbrc.1995.1749; NAKASHIMA H, 1989, J VIROL METHODS, V26, P319, DOI 10.1016/0166-0934(89)90114-6; North ME, 1996, CLIN EXP IMMUNOL, V105, P517, DOI 10.1046/j.1365-2249.1996.d01-795.x; ORAVECZ T, 1995, NAT MED, V1, P919, DOI 10.1038/nm0995-919; Ostrowski MA, 1999, J VIROL, V73, P6430, DOI 10.1128/JVI.73.8.6430-6435.1999; PAUWELS R, 1987, J VIROL METHODS, V16, P171, DOI 10.1016/0166-0934(87)90002-4; Platt EJ, 1997, J VIROL, V71, P883, DOI 10.1128/JVI.71.2.883-890.1997; Savarino A, 1996, J BIOL REG HOMEOS AG, V10, P13; Savarino A, 1999, CELL BIOCHEM FUNCT, V17, P47, DOI 10.1002/(SICI)1099-0844(199903)17:1<47::AID-CBF810>3.0.CO;2-V; SCHEGLOVITOVA O, 1993, ARCH VIROL, V132, P267, DOI 10.1007/BF01309538; SCHNITTMAN SM, 1990, P NATL ACAD SCI USA, V87, P6058, DOI 10.1073/pnas.87.16.6058; SIRERA R, 1998, 12 WORLD AIDS C GEN, P528; Strizki JM, 1997, J VIROL, V71, P5678, DOI 10.1128/JVI.71.7.5678-5683.1997; SZOLLOSI J, 1984, CYTOMETRY, V5, P210, DOI 10.1002/cyto.990050216; Vigano A, 1998, LANCET, V352, P1905, DOI 10.1016/S0140-6736(05)60396-0; Wyatt R, 1998, SCIENCE, V280, P1884, DOI 10.1126/science.280.5371.1884	55	14	17	1	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	1999	13	15					2265	2276		10.1096/fasebj.13.15.2265	http://dx.doi.org/10.1096/fasebj.13.15.2265			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	266QN	10593874				2022-12-25	WOS:000084310800018
J	Nomoto, S; Haruki, N; Takahashi, T; Masuda, A; Koshikawa, T; Takahashi, T; Fujii, Y; Osada, H; Takahashi, T				Nomoto, S; Haruki, N; Takahashi, T; Masuda, A; Koshikawa, T; Takahashi, T; Fujii, Y; Osada, H; Takahashi, T			Search for in vivo somatic mutations in the mitotic checkpoint gene, hMAD1, in human lung cancers	ONCOGENE			English	Article						lung cancer; mitotic checkpoint; hMAD1; somatic mutation; genetic instability	SPINDLE ASSEMBLY CHECKPOINT; BUDDING YEAST; ARREST	We previously reported the presence of mitotic checkpoint impairment in about 40% of lung cancer cell lines. To gain an insight into the molecular basis of this impairment, we examined 49 lung cancer specimens for alterations in the hMAD1 mitotic checkpoint gene and identified a somatic, non-conservative missense mutation, which substitutes alanine (GCG) for threonine (GCG) at codon 299, together with a number of amino acid substituting, single nucleotide polymorphisms. This is the first demonstration of hMAD1 mutation in any type of human cancers. The present finding marks hMAD1 as a potential target, although with low frequency, for genetic alterations in lung cancer. Thus, further studies of hMAD1 dysfunction caused by other mechanisms appear to be warranted, as well as potential involvement of other components of the mitotic checkpoint.	Aichi Canc Ctr, Res Inst, Lab Ultrastruct Res, Chikusa Ku, Nagoya, Aichi 4648681, Japan; Aichi Canc Ctr, Res Inst, Pathophysiol Unit, Chikusa Ku, Nagoya, Aichi 4648681, Japan; Aichi Canc Ctr, Res Inst, Immunol Lab, Chikusa Ku, Nagoya, Aichi 4648681, Japan; Aichi Canc Ctr Hosp, Dept Pathol & Clin Labs, Chikusa Ku, Nagoya, Aichi 4648681, Japan; Nagoya City Univ, Sch Med, Dept Surg 2, Mizuho Ku, Nagoya, Aichi 4678601, Japan	Aichi Cancer Center; Aichi Cancer Center; Aichi Cancer Center; Aichi Cancer Center; Nagoya City University	Takahashi, T (corresponding author), Aichi Canc Ctr, Res Inst, Lab Ultrastruct Res, Chikusa Ku, 1-1 Kanokoden, Nagoya, Aichi 4648681, Japan.		Osada, Hiroyuki/AAY-6254-2020; Takahashi, Takashi/I-7262-2014	Takahashi, Takashi/0000-0003-0615-7001				Cahill DP, 1998, NATURE, V392, P300, DOI 10.1038/32688; Elledge SJ, 1998, SCIENCE, V279, P999, DOI 10.1126/science.279.5353.999; Gotoh K, 1999, CARCINOGENESIS, V20, P499, DOI 10.1093/carcin/20.3.499; HARDWICK KG, 1995, J CELL BIOL, V131, P709, DOI 10.1083/jcb.131.3.709; Hardwick KG, 1996, SCIENCE, V273, P953, DOI 10.1126/science.273.5277.953; HIBI K, 1994, ONCOGENE, V9, P611; HOYT MA, 1991, CELL, V66, P507, DOI 10.1016/0092-8674(81)90014-3; Jin DY, 1998, CELL, V93, P81, DOI 10.1016/S0092-8674(00)81148-4; Lengauer C, 1998, NATURE, V396, P643, DOI 10.1038/25292; LI R, 1991, CELL, V66, P519, DOI 10.1016/0092-8674(81)90015-5; Li Y, 1996, SCIENCE, V274, P246, DOI 10.1126/science.274.5285.246; MINNA JD, 1997, CANC PRINCIPLES PRAC, V1, P849; Nagatake M, 1996, CANCER RES, V56, P2718; Paulovich AG, 1997, CELL, V88, P315, DOI 10.1016/S0092-8674(00)81870-X; Rudner AD, 1996, CURR OPIN CELL BIOL, V8, P773, DOI 10.1016/S0955-0674(96)80077-9; Smith AL, 1996, BRIT J CANCER, V73, P203, DOI 10.1038/bjc.1996.36; *STAT INF DEP, 1998, VIT STAT JAP, V3, P384; Takahashi T, 1999, ONCOGENE, V18, P4295, DOI 10.1038/sj.onc.1202807; TESTA JR, 1996, LUNG CANC PRINCIPLES, P55; WASHIMI O, 1995, CANCER RES, V55, P514	20	50	55	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 25	1999	18	50					7180	7183		10.1038/sj.onc.1203141	http://dx.doi.org/10.1038/sj.onc.1203141			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	259PH	10597320				2022-12-25	WOS:000083901900026
J	Budhram-Mahadeo, V; Ndisang, D; Ward, T; Weber, BL; Latchman, DS				Budhram-Mahadeo, V; Ndisang, D; Ward, T; Weber, BL; Latchman, DS			The Brn-3b POU family transcription factor represses expression of the BRCA-1 anti-oncogene in breast cancer cells	ONCOGENE			English	Article						BRCA-1; breast cancer; transcriptional control; Brn-3b; POU family transcription factors	NEURONAL CELLS; GENE BRCA1; DOMAIN; PROTEIN; DIFFERENTIATION; PROMOTER; GROWTH; MUTATIONS; DISTINCT; OPPOSITE	The BRCA-1 tumour supressor gene was identified on the basis of mutations which occur in familial breast cancer indicating that its inactivation can cause this disease. Although BRCA-1 does not appear to be mutated in sporadic breast cancer, its expression has been shown to be reduced in tumour material from such cases. We show here that mammary tumours which have reduced levels of BRCA-1 expression show enhanced expression of the Brn-3b POU family transcription factor at both the mRNA and protein levels. This elevated expression of Brn-3b is not found in normal mammary cells, benign tumours or in malignant tumour samples which do not exhibit reduced levels of BRCA-1. In contrast, no correlation was noted between BRCA-1 and expression of the related factor Brn-3a. Moreover, Brn-3b but not Brn-3a can strongly repress the BRCA-1 promoter approximately 20-fold in mammary tumour cells. To our knowledge, this is the first report of a transcription factor which regulates BRCA-1 expression. Thus, Brn-3b may play an important role in regulating expression of BRCA-1 in mammary tumours with enhanced expression of Brn-3b resulting in reduced BRCA-1 expression and thereby being potentially important in tumour development.	UCL, Windeyer Inst Med Sci, Dept Mol Pathol, London W1P 6DB, England; Univ Penn, Sch Med, Dept Med, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Genet, Philadelphia, PA 19104 USA	University of London; University College London; University of Pennsylvania; University of Pennsylvania	Latchman, DS (corresponding author), UCL, Windeyer Inst Med Sci, Dept Mol Pathol, Windeyer Bldg,46 Cleveland St, London W1P 6DB, England.							ABKEN H, 1992, NUCLEIC ACIDS RES, V20, P3527, DOI 10.1093/nar/20.13.3527; ANDERSEN B, 1994, J BIOL CHEM, V269, P29335; BENNETT LM, 1995, GENOMICS, V29, P576, DOI 10.1006/geno.1995.9963; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Budhram-Mahadeo V, 1998, MOL CELL BIOL, V18, P1029, DOI 10.1128/MCB.18.2.1029; BUDHRAMMAHADEO V, 1995, J BIOL CHEM, V270, P2853, DOI 10.1074/jbc.270.6.2853; Casey Graham, 1997, Current Opinion in Oncology, V9, P88; DEKOK YJM, 1995, SCIENCE, V267, P685, DOI 10.1126/science.7839145; DHILLON VB, 1993, ANN RHEUM DIS, V52, P436, DOI 10.1136/ard.52.6.436; FUTREAL PA, 1994, SCIENCE, V266, P120, DOI 10.1126/science.7939630; GERRERO MR, 1993, P NATL ACAD SCI USA, V90, P10841, DOI 10.1073/pnas.90.22.10841; GORMAN C, 1985, DNA CLONING PRACTICA, V2, P143; GUDAS JM, 1995, CANCER RES, V55, P4561; Holt JT, 1996, NAT GENET, V12, P298, DOI 10.1038/ng0396-298; LANE TF, 1995, GENE DEV, V9, P2712, DOI 10.1101/gad.9.21.2712; Latchman DS, 1997, INT J ONCOL, V10, P1133; LeblondFrancillard M, 1997, J CLIN ENDOCR METAB, V82, P89, DOI 10.1210/jc.82.1.89; LILLYCROP KA, 1992, NUCLEIC ACIDS RES, V20, P5093, DOI 10.1093/nar/20.19.5093; MARQUIS ST, 1995, NAT GENET, V11, P17, DOI 10.1038/ng0995-17; MIGLIACCIO A, 1993, ONCOGENE, V8, P2183; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; MILTON NGN, 1995, J BIOL CHEM, V270, P15143, DOI 10.1074/jbc.270.25.15143; MORRIS PJ, 1994, MOL CELL BIOL, V14, P6907, DOI 10.1128/MCB.14.10.6907; Morris PJ, 1996, MOL BRAIN RES, V43, P279, DOI 10.1016/S0169-328X(96)00207-0; Ndisdang D, 1998, J CLIN INVEST, V101, P1687, DOI 10.1172/JCI1089; NINKINA NN, 1993, NUCLEIC ACIDS RES, V21, P3175, DOI 10.1093/nar/21.14.3175; Rao VN, 1996, ONCOGENE, V12, P523; Ryan AK, 1997, GENE DEV, V11, P1207, DOI 10.1101/gad.11.10.1207; Smith MD, 1996, INT J CANCER, V67, P653; Smith MD, 1997, J BIOL CHEM, V272, P21325, DOI 10.1074/jbc.272.34.21325; Smith MD, 1998, J BIOL CHEM, V273, P16715, DOI 10.1074/jbc.273.27.16715; THEIL T, 1993, NUCLEIC ACIDS RES, V21, P5921, DOI 10.1093/nar/21.25.5921; TURNER EE, 1994, NEURON, V12, P205, DOI 10.1016/0896-6273(94)90164-3; VAHAUA O, 1995, NAT GENET, V9, P444; Vahava O, 1998, SCIENCE, V279, P1950, DOI 10.1126/science.279.5358.1950; VERRIJZER CP, 1993, BIOCHIM BIOPHYS ACTA, V1173, P1, DOI 10.1016/0167-4781(93)90237-8; XI H, 1989, NATURE, V340, P35, DOI 10.1038/340035a0	37	62	64	1	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 18	1999	18	48					6684	6691		10.1038/sj.onc.1203072	http://dx.doi.org/10.1038/sj.onc.1203072			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	257QA	10597274				2022-12-25	WOS:000083792000008
J	Fang, XJ; Yu, SX; Eder, A; Mao, ML; Bast, RC; Boyd, D; Mills, GB				Fang, XJ; Yu, SX; Eder, A; Mao, ML; Bast, RC; Boyd, D; Mills, GB			Regulation of BAD phosphorylation at serine 112 by the Ras-mitogen-activated protein kinase pathway	ONCOGENE			English	Article						BAD; MAPK; Ras; Akt; phosphorylation; apoptosis	GROWTH-FACTOR-I; PHOSPHATIDYLINOSITOL 3-KINASE; SIGNALING PATHWAY; AKT; SURVIVAL; APOPTOSIS; INSULIN; DEATH; TRANSFORMATION; EXPRESSION	The function of the pro-apoptotic molecule BAD is regulated by phosphorylation of two sites, serine-112 (Ser-112) and serine-136 (Ser-136), Phosphorylation at either site results in loss of the ability of BAD to heterodimerize with the survival proteins BCL-X-L or BCL-2, Phosphorylated BAD binds to 14-3-3 and is sequestered in the cytoplasm, It has been shown that phosphorylation of BAD at Ser-136 is mediated by the serine/threonine protein kinase Akt-1/PKB which is downstream of phosphatidylinositol 3-kinase (PI3K), The signaling process leading to phosphorylation of BAD at Ser-112 has not been identified. In this study, we show that phosphorylation of the two serine residues of BAD is differentially regulated. While Ser-136 phosphorylation is concordant with activation of Akt, Ser-112. phosphorylation does not correlate with Akt activation. Instead, we demonstrate that activated Ras and Raf, which are upstream of mitogen-activated protein kinases (MAPK), stimulate selective phosphorylation of BAD at Ser-112, Furthermore, phosphorylation of Ser-112, but not Ser-136 requires activation of the MAPK pathway as the MEK inhibitor, PD 98059, blocks EGF-, as web as activated Ras- or Raf-mediated phosphorylation of BAD at Ser-112, Therefore, the PI3K-Akt and Ras-MAPK pathways converge at BAD by mediating phosphorylation of distinct serine residues.	Univ Texas, MD Anderson Canc Ctr, Dept Mol Oncol, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Clin Invest, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Canc Biol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Mills, GB (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Mol Oncol, Box 317,1515 Holcombe Blvd, Houston, TX 77030 USA.		Bast, Robert C/E-6585-2011	Bast, Robert C/0000-0003-4621-8462	NATIONAL CANCER INSTITUTE [P01CA064602] Funding Source: NIH RePORTER; NCI NIH HHS [CA 64602] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; Bergmann A, 1998, CELL, V95, P331, DOI 10.1016/S0092-8674(00)81765-1; BRUDER JT, 1992, GENE DEV, V6, P545, DOI 10.1101/gad.6.4.545; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; CHUNG J, 1992, CELL, V69, P1227, DOI 10.1016/0092-8674(92)90643-Q; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; Craddock BL, 1999, J BIOL CHEM, V274, P10633, DOI 10.1074/jbc.274.15.10633; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; delPeso L, 1997, SCIENCE, V278, P687; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; FANG XJ, 1992, CANCER RES, V52, P173; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; Gardner AM, 1996, J BIOL CHEM, V271, P14560, DOI 10.1074/jbc.271.24.14560; HARRINGTON EA, 1994, EMBO J, V13, P3286, DOI 10.1002/j.1460-2075.1994.tb06630.x; Kennedy SG, 1997, GENE DEV, V11, P701, DOI 10.1101/gad.11.6.701; Kulik G, 1998, MOL CELL BIOL, V18, P6711, DOI 10.1128/MCB.18.11.6711; Kulik G, 1997, MOL CELL BIOL, V17, P1595, DOI 10.1128/MCB.17.3.1595; Kurada P, 1998, CELL, V95, P319, DOI 10.1016/S0092-8674(00)81764-X; Parrizas M, 1997, J BIOL CHEM, V272, P154; Patton SE, 1998, CANCER RES, V58, P2253; Salomoni P, 1998, J EXP MED, V187, P1995, DOI 10.1084/jem.187.12.1995; Scheid MP, 1998, P NATL ACAD SCI USA, V95, P7439, DOI 10.1073/pnas.95.13.7439; SOUTHERLAND C, 1993, BIOCHEM J, V296, P15; STAMBOLIC V, 1994, BIOCHEM J, V303, P701, DOI 10.1042/bj3030701; Wang HG, 1996, CELL, V87, P629, DOI 10.1016/S0092-8674(00)81383-5; White E, 1996, GENE DEV, V10, P1, DOI 10.1101/gad.10.1.1; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; YANG E, 1995, CELL, V80, P285, DOI 10.1016/0092-8674(95)90411-5; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3	31	229	233	0	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 18	1999	18	48					6635	6640		10.1038/sj.onc.1203076	http://dx.doi.org/10.1038/sj.onc.1203076			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	257QA	10597268				2022-12-25	WOS:000083792000002
J	Wu, GS; Burns, TF; McDonald, ER; Meng, RD; Kao, G; Muschel, R; Yen, T; El-Deiry, WS				Wu, GS; Burns, TF; McDonald, ER; Meng, RD; Kao, G; Muschel, R; Yen, T; El-Deiry, WS			Induction of the TRAIL receptor KILLER/DR5 in p53-dependent apoptosis but not growth arrest	ONCOGENE			English	Article						p53; KILLER/DR5; TRAIL; ATM; G1 arrest; apoptosis	CELL-CYCLE CHECKPOINT; FADD-DEPENDENT APOPTOSIS; CYTOTOXIC LIGAND TRAIL; TUMOR-SUPPRESSOR P53; NF-KAPPA-B; DNA-DAMAGE; ATAXIA-TELANGIECTASIA; IONIZING-RADIATION; IN-VITRO; BAX GENE	The TRAIL death receptor KILLER/DR5 is induced by DNA damaging agents in wild-type p53-expressing cells. Here me show that, unlike the p53-target CDK-inhibitor p21(WAF1/CIP1), the TRAIL death receptor KILLER/DR5 is only induced in cells undergoing p53-dependent apoptosis and not cell cycle arrest. Thus GM glioblastoma cells carrying an inducible MMTV-driven p53 gene undergo cell cycle arrest and upregulate p21 but not KILLER/DR5 expression upon dexamethasone exposure. W138 normal lung fibroblasts undergoing cell cycle arrest in response to ionizing irradiation also induce p21 but not KILLER/DR5 gene expression. KILLER/DR5 upregulation is also deficient in irradiated lymphoblastoid cells derived from patients with Ataxia Teleangiectasia suggesting a role for the ATM-p53 pathway in regulating KILLER/DR5 expression after DNA damage. Inhibition of transcription by Actinomycin D blocks both KILLER/DR5 and p21 induction in cells undergoing p53-dependent apoptosis. Our results suggest that the p53-dependent transcriptional induction of KILLER/DR5 death receptor is restricted to cells undergoing apoptosis and not cells undergoing exclusively p53-dependent GI arrest.	Univ Penn, Sch Med, Howard Hughes Med Inst, Dept Med,Lab Mol Oncol & Cell Cycle Regulat, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Howard Hughes Med Inst, Dept Genet,Lab Mol Oncol & Cell Cycle Regulat, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Howard Hughes Med Inst, Dept Radiat Oncol,Lab Mol Oncol & Cell Cycle Regu, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Howard Hughes Med Inst, Dept Pathol,Lab Mol Oncol & Cell Cycle Regulat, Philadelphia, PA 19104 USA; Fox Chase Canc Ctr, Philadelphia, PA 19111 USA	Howard Hughes Medical Institute; University of Pennsylvania; Howard Hughes Medical Institute; University of Pennsylvania; Howard Hughes Medical Institute; University of Pennsylvania; Howard Hughes Medical Institute; University of Pennsylvania; Fox Chase Cancer Center	El-Deiry, WS (corresponding author), Univ Penn, Sch Med, Howard Hughes Med Inst, Dept Med,Lab Mol Oncol & Cell Cycle Regulat, Philadelphia, PA 19104 USA.		El-Deiry, Wafik/AAJ-6080-2020	El-Deiry, Wafik/0000-0002-9577-8266; Yen, Tim/0000-0003-2159-0997	NATIONAL CANCER INSTITUTE [P01CA075138] Funding Source: NIH RePORTER; NCI NIH HHS [CA75138-01] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; Banin S, 1998, SCIENCE, V281, P1674, DOI 10.1126/science.281.5383.1674; Barlow C, 1997, NAT GENET, V17, P453, DOI 10.1038/ng1297-453; Bennett M, 1998, SCIENCE, V282, P290, DOI 10.1126/science.282.5387.290; Blagosklonny MV, 1996, INT J CANCER, V67, P386, DOI 10.1002/(SICI)1097-0215(19960729)67:3<386::AID-IJC13>3.0.CO;2-6; CAELLES C, 1994, NATURE, V370, P220, DOI 10.1038/370220a0; CANMAN CE, 1994, CANCER RES, V54, P5054; Canman CE, 1998, SCIENCE, V281, P1677, DOI 10.1126/science.281.5383.1677; Chaudhary PM, 1997, IMMUNITY, V7, P821, DOI 10.1016/S1074-7613(00)80400-8; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; El-Deiry WS, 1998, SEMIN CANCER BIOL, V8, P345, DOI 10.1006/scbi.1998.0097; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Golstein P, 1997, CURR BIOL, V7, pR750, DOI 10.1016/S0960-9822(06)90000-1; GREENBLATT MS, 1994, CANCER RES, V54, P4855; HARPER JW, 1993, CELL, V75, P805; Hermeking H, 1997, MOL CELL, V1, P3, DOI 10.1016/S1097-2765(00)80002-7; Herzog KH, 1998, SCIENCE, V280, P1089, DOI 10.1126/science.280.5366.1089; HOPKIN K, 1997, J NIH RES, V9, P22; Kastan M, 1997, NAT GENET, V17, P130, DOI 10.1038/ng1097-130; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KNUDSON CM, 1995, SCIENCE, V270, P96, DOI 10.1126/science.270.5233.96; LEONARDO AD, 1994, GENE DEV, V8, P2540; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; MacFarlane M, 1997, J BIOL CHEM, V272, P25417, DOI 10.1074/jbc.272.41.25417; Marsters SA, 1997, CURR BIOL, V7, P1003, DOI 10.1016/S0960-9822(06)00422-2; McCurrach ME, 1997, P NATL ACAD SCI USA, V94, P2345, DOI 10.1073/pnas.94.6.2345; Meng RD, 1998, CLIN CANCER RES, V4, P251; MERCER WE, 1990, P NATL ACAD SCI USA, V87, P6166, DOI 10.1073/pnas.87.16.6166; MIYASHITA T, 1995, CELL, V80, P293; MIYASHITA T, 1994, ONCOGENE, V9, P1799; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; OWENSCHAUB LB, 1995, MOL CELL BIOL, V15, P3032; Pan GH, 1997, SCIENCE, V277, P815, DOI 10.1126/science.277.5327.815; Pan GH, 1997, SCIENCE, V276, P111, DOI 10.1126/science.276.5309.111; Pitt RM, 1996, J BIOL CHEM, V271, P12687, DOI 10.1074/jbc.271.22.12687; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; Prives C, 1998, CELL, V95, P5, DOI 10.1016/S0092-8674(00)81774-2; Schneider P, 1997, IMMUNITY, V7, P831, DOI 10.1016/S1074-7613(00)80401-X; Schneider P, 1997, FEBS LETT, V416, P329, DOI 10.1016/S0014-5793(97)01231-3; Screaton GR, 1997, CURR BIOL, V7, P693, DOI 10.1016/S0960-9822(06)00297-1; Sheridan JP, 1997, SCIENCE, V277, P818, DOI 10.1126/science.277.5327.818; Shieh SY, 1997, CELL, V91, P325, DOI 10.1016/S0092-8674(00)80416-X; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; Walczak H, 1997, EMBO J, V16, P5386, DOI 10.1093/emboj/16.17.5386; Westphal CH, 1997, NAT GENET, V16, P397, DOI 10.1038/ng0897-397; Wiley SR, 1995, IMMUNITY, V3, P673, DOI 10.1016/1074-7613(95)90057-8; Wu GS, 1998, ONCOGENE, V16, P2177, DOI 10.1038/sj.onc.1201755; Wu GS, 1997, NAT GENET, V17, P141, DOI 10.1038/ng1097-141; Yuan JY, 1997, CURR OPIN CELL BIOL, V9, P247, DOI 10.1016/S0955-0674(97)80069-5	52	99	99	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 11	1999	18	47					6411	6418		10.1038/sj.onc.1203025	http://dx.doi.org/10.1038/sj.onc.1203025			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	256CW	10597242				2022-12-25	WOS:000083709200002
J	Fischer, AE; Beuning, PJ; Musier-Forsyth, K				Fischer, AE; Beuning, PJ; Musier-Forsyth, K			Identification of discriminator base atomic groups that modulate the alanine aminoacylation reaction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSFER-RNA-SYNTHETASE; ESCHERICHIA-COLI TRNA(ALA); ACCEPTOR STEM MICROHELICES; MINOR-GROOVE; CRYSTAL-STRUCTURE; HUMAN TRNA(LEU); HELIX; PAIR; RECOGNITION; IDENTITY	Specific aminoacylation of tRNAs involves activation of an amino acid with ATP followed by amino acid transfer to the tRNA. Previous work showed that the transfer of alanine from Escherichia coli alanyl-tRNA synthetase to a cognate RNA minihelix involves a transition state sensitive to changes in the tRNA acceptor stem. Specifically, the "discriminator" base at position 73 of minihelix(Ala) is a critical determinant of the transfer step of aminoacylation, This single-stranded nucleotide has previously been shown by solution NMR to be stacked predominantly onto G(1) of the first base pair of the alanine acceptor stem helix. In this work, RNA duplex(Ala) variants were prepared to investigate the role of specific discriminator base atomic groups in aminoacylation catalytic efficiency. Results indicate that the purine structure appears to be important for stabilization of the transition state and that major groove elements are more critical than those located in the minor groove. This result is in accordance with the predicted orientation of a class II synthetase at the end of the acceptor helix. In particular, substitution of the exocyclic amino group of A(73) with a keto-oxygen resulted in negative discrimination at this site. Taken together, these new results are consistent with the involvement of major groove atomic groups of the discriminator base in the formation of the transition state for the amino acid transfer step.	Univ Minnesota, Dept Chem, Minneapolis, MN 55455 USA	University of Minnesota System; University of Minnesota Twin Cities	Musier-Forsyth, K (corresponding author), Univ Minnesota, Dept Chem, 207 Pleasant St SE, Minneapolis, MN 55455 USA.	musier@chem.umn.edu			NIGMS NIH HHS [GM49928] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R55GM049928, R29GM049928, R01GM049928] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Beuning PJ, 1997, J AM CHEM SOC, V119, P8397, DOI 10.1021/ja971020c; Breitschopf K, 1996, NUCLEIC ACIDS RES, V24, P405, DOI 10.1093/nar/24.3.405; BREITSCHOPF K, 1994, EMBO J, V13, P3166, DOI 10.1002/j.1460-2075.1994.tb06615.x; BUECHTER DD, 1995, BIOCHEMISTRY-US, V34, P6014, DOI 10.1021/bi00018a002; CROTHERS DM, 1972, P NATL ACAD SCI USA, V69, P3063, DOI 10.1073/pnas.69.10.3063; Cusack S, 1996, EMBO J, V15, P2834, DOI 10.1002/j.1460-2075.1996.tb00644.x; Giege R, 1998, NUCLEIC ACIDS RES, V26, P5017, DOI 10.1093/nar/26.22.5017; Hou YM, 1997, CHEM BIOL, V4, P93, DOI 10.1016/S1074-5521(97)90252-0; HOU YM, 1988, NATURE, V333, P140, DOI 10.1038/333140a0; LIMMER S, 1993, P NATL ACAD SCI USA, V90, P6199, DOI 10.1073/pnas.90.13.6199; Limmer S, 1996, FEBS LETT, V385, P15, DOI 10.1016/0014-5793(96)00339-0; MCCLAIN WH, 1988, SCIENCE, V240, P793, DOI 10.1126/science.2452483; MCCLAIN WH, 1991, P NATL ACAD SCI USA, V88, P9272, DOI 10.1073/pnas.88.20.9272; Metzger AU, 1997, NUCLEIC ACIDS RES, V25, P4551, DOI 10.1093/nar/25.22.4551; Musier-Forsyth K, 1999, ACCOUNTS CHEM RES, V32, P368, DOI 10.1021/ar970148w; MUSIERFORSYTH K, 1991, P NATL ACAD SCI USA, V88, P209, DOI 10.1073/pnas.88.1.209; MUSIERFORSYTH K, 1992, NATURE, V357, P513, DOI 10.1038/357513a0; MUSIERFORSYTH K, 1991, SCIENCE, V253, P784, DOI 10.1126/science.1876835; PUGLISI EV, 1994, P NATL ACAD SCI USA, V91, P11467, DOI 10.1073/pnas.91.24.11467; Ramos A, 1997, NUCLEIC ACIDS RES, V25, P2083, DOI 10.1093/nar/25.11.2083; RUFF M, 1991, SCIENCE, V252, P1682, DOI 10.1126/science.2047877; SANTALUCIA J, 1991, J AM CHEM SOC, V113, P4313, DOI 10.1021/ja00011a039; SCARINGE SA, 1990, NUCLEIC ACIDS RES, V18, P5433, DOI 10.1093/nar/18.18.5433; SHI JP, 1991, J BIOL CHEM, V266, P2705; SHI JP, 1990, BIOCHEMISTRY-US, V29, P3621, DOI 10.1021/bi00467a005; SHIMIZU M, 1992, J MOL EVOL, V35, P436; SPROAT B, 1995, NUCLEOS NUCLEOT, V14, P255, DOI 10.1080/15257779508014668; SUGIMOTO N, 1987, BIOCHEMISTRY-US, V26, P4554, DOI 10.1021/bi00388a058; TURNER DH, 1988, ANNU REV BIOPHYS BIO, V17, P167; TURNER DH, 1987, J AM CHEM SOC, V109, P3783, DOI 10.1021/ja00246a047	30	13	14	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 24	1999	274	52					37093	37096		10.1074/jbc.274.52.37093	http://dx.doi.org/10.1074/jbc.274.52.37093			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	267WR	10601268	hybrid			2022-12-25	WOS:000084382700039
J	Ren, YS; Reddy, SAG; Liao, WSL				Ren, YS; Reddy, SAG; Liao, WSL			Purification and identification of a tissue-specific repressor involved in serum amyloid A1 gene expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR AP-2; ACUTE-PHASE RESPONSE; NF-KAPPA-B; NUCLEAR FACTOR; C/EBP-LIKE; PROTEIN; ACTIVATION; DROSOPHILA; BINDING; POLYMERASE	We have previously demonstrated that the 5'-flanking regions from the rat serum amyloid A1 (SAA1) promoter are necessary and sufficient to confer specific cytokine induced expression in cultured hepatoma cells. Deletion analysis identified a tissue-specific repressor (TSR) regulatory element, located between bp -289 and -256, that functioned as a silencer, contributing to the transcription repression on SAA1 promoter in nonliver cells. When this 34-base pair TSR-binding element was used as a probe in electrophoretic mobility shift assays, an intense DNA-protein complex was detected in nuclear extracts from HeLa and several other nonliver tissues, This TSR binding activity, however, was undetectable in extracts from liver or liver-derived cells. The distribution of TSR binding activity is therefore consistent with its regulatory role in repressing SAA1 expression in a tissue-specific manner. In this study, we purified TSR protein from HeLa nuclear extracts and showed that it has a molecular mass of approximately 50 kDa. Surprisingly, protein sequencing and antibody supershift experiments identified TSR as transcription factor AP-2. Subsequent functional analysis showed that forced expression of AP-2 in HepG2 cells could indeed inhibit conditioned medium-induced SAA1 promoter activation. Moreover, expression of a dominant-negative mutant of AP-2 in HeLa cells or mutation of the AP-2-binding site led to derepression of the SAA1 promoter, presumably by neutralizing the inhibitory effects of the endogenous wild-type AP-2. Our results therefore demonstrate a novel function for AP-2 in the transcriptional repression of SAA1 promoter. Together with its tissue distribution, AP-2 may contribute to SAA1's highly liver-specific expression pattern by restricting its expression in nonliver cells.	Univ Texas, MD Anderson Canc Ctr, Dept Biochem & Mol Biol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center	Liao, WSL (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Biochem & Mol Biol, Box 117, Houston, TX 77030 USA.	wliao@odin.mdacc.tmc.edu			NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R29AR038858, R01AR038858] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR 38858] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		BENSON MD, 1979, J IMMUNOL, V122, P2077; BENSON MD, 1980, J IMMUNOL, V124, P495; BETTS JC, 1993, J BIOL CHEM, V268, P25624; Bisgrove DA, 1997, MOL CELL BIOL, V17, P5935, DOI 10.1128/MCB.17.10.5935; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUETTNER R, 1993, MOL CELL BIOL, V13, P4174, DOI 10.1128/MCB.13.7.4174; Butler A, 1996, IMMUNOGENETICS, V44, P468, DOI 10.1007/BF02602809; Chen AP, 1996, J BIOL CHEM, V271, P25994, DOI 10.1074/jbc.271.42.25994; Chen TT, 1997, MOL CELL BIOL, V17, P3056, DOI 10.1128/MCB.17.6.3056; CHODOSH LA, 1986, MOL CELL BIOL, V6, P4723, DOI 10.1128/MCB.6.12.4723; CHONG JHA, 1995, CELL, V80, P949, DOI 10.1016/0092-8674(95)90298-8; CORCORAN LM, 1993, GENE DEV, V7, P570, DOI 10.1101/gad.7.4.570; COWELL IG, 1994, TRENDS BIOCHEM SCI, V19, P38, DOI 10.1016/0968-0004(94)90172-4; DEBEER MC, 1994, J BIOL CHEM, V269, P4661; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; EDBROOKE MR, 1989, MOL CELL BIOL, V9, P1908, DOI 10.1128/MCB.9.5.1908; GABRIELSEN OS, 1993, METHOD ENZYMOL, V218, P508; GAUBATZ S, 1995, EMBO J, V14, P1508, DOI 10.1002/j.1460-2075.1995.tb07137.x; GETMAN DK, 1995, J BIOL CHEM, V270, P23511, DOI 10.1074/jbc.270.40.23511; GOREVIC PD, 1981, ANNU REV MED, V32, P261, DOI 10.1146/annurev.me.32.020181.001401; Gray S, 1996, GENE DEV, V10, P700, DOI 10.1101/gad.10.6.700; HERSCHBACH BM, 1993, ANNU REV CELL BIOL, V9, P479, DOI 10.1146/annurev.cellbio.9.1.479; HOCH M, 1992, SCIENCE, V256, P94, DOI 10.1126/science.1348871; HUANG JH, 1990, MOL CELL BIOL, V10, P3619, DOI 10.1128/MCB.10.7.3619; HUANG JH, 1994, MOL CELL BIOL, V14, P4475, DOI 10.1128/MCB.14.7.4475; IMAGAWA M, 1987, CELL, V51, P251, DOI 10.1016/0092-8674(87)90152-8; Jiang MS, 1998, P NATL ACAD SCI USA, V95, P3467, DOI 10.1073/pnas.95.7.3467; JOHNSON AD, 1995, CELL, V81, P655, DOI 10.1016/0092-8674(95)90524-3; JOHNSON FB, 1992, GENE DEV, V6, P2177, DOI 10.1101/gad.6.11.2177; JOHNSON PF, 1989, ANNU REV BIOCHEM, V58, P799, DOI 10.1146/annurev.biochem.58.1.799; KAKKIS E, 1989, NATURE, V339, P718, DOI 10.1038/339718a0; KANNAN F, 1994, GENE DEV, V8, P1258, DOI 10.1101/gad.8.11.1258; Kirchhamer CV, 1996, P NATL ACAD SCI USA, V93, P13849, DOI 10.1073/pnas.93.24.13849; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEASK A, 1991, P NATL ACAD SCI USA, V88, P7948, DOI 10.1073/pnas.88.18.7948; LEE HS, 1992, GENE DEV, V6, P284, DOI 10.1101/gad.6.2.284; Li L, 1999, BIOCHEM BIOPH RES CO, V264, P395, DOI 10.1006/bbrc.1999.1527; LI S, 1990, NATURE, V347, P528, DOI 10.1038/347528a0; LI X, 1992, NUCLEIC ACIDS RES, V20, P4765, DOI 10.1093/nar/20.18.4765; LI XX, 1991, J BIOL CHEM, V266, P15192; LIU YH, 1994, MOL CELL BIOL, V14, P7046, DOI 10.1128/MCB.14.11.7046; LOWELL CA, 1986, J BIOL CHEM, V261, P8453; LU SY, 1994, MOL CELL BIOL, V14, P6253, DOI 10.1128/MCB.14.9.6253; MANIATIS T, 1987, SCIENCE, V236, P1237, DOI 10.1126/science.3296191; MEIER P, 1995, DEV BIOL, V169, P1, DOI 10.1006/dbio.1995.1121; MOSER M, 1995, DEVELOPMENT, V121, P2779; Moshage H, 1997, J PATHOL, V181, P257, DOI 10.1002/(SICI)1096-9896(199703)181:3<257::AID-PATH756>3.0.CO;2-U; OAKLEY BR, 1980, ANAL BIOCHEM, V105, P361, DOI 10.1016/0003-2697(80)90470-4; OHSAKO S, 1994, GENE DEV, V8, P2743, DOI 10.1101/gad.8.22.2743; Pannen B H, 1995, New Horiz, V3, P183; PAROUSH Z, 1994, CELL, V79, P805, DOI 10.1016/0092-8674(94)90070-1; RIENHOFF HY, 1990, MOL BIOL MED, V7, P287; SCHOENHERR CJ, 1995, SCIENCE, V267, P1360, DOI 10.1126/science.7871435; Schorle H, 1996, NATURE, V381, P235, DOI 10.1038/381235a0; WEINTRAUB H, 1991, SCIENCE, V251, P761, DOI 10.1126/science.1846704; WEINTRAUB SJ, 1995, NATURE, V375, P812, DOI 10.1038/375812a0; WILLIAMS T, 1988, GENE DEV, V2, P1557, DOI 10.1101/gad.2.12a.1557; Zhang JA, 1996, NATURE, V381, P238, DOI 10.1038/381238a0	58	6	6	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 24	1999	274	52					37154	37160		10.1074/jbc.274.52.37154	http://dx.doi.org/10.1074/jbc.274.52.37154			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	267WR	10601277	hybrid			2022-12-25	WOS:000084382700048
J	Croce, K; Flaumenhaft, R; Rivers, M; Furie, B; Furie, BC; Herman, IM; Potter, DA				Croce, K; Flaumenhaft, R; Rivers, M; Furie, B; Furie, BC; Herman, IM; Potter, DA			Inhibition of calpain blocks platelet secretion, aggregation, and spreading	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; NUCLEAR-LOCALIZATION SEQUENCE; CALCIUM-DEPENDENT PROTEASE; MARCKS-RELATED DOMAIN; ACTIN-FILAMENTS; BARBED ENDS; II CELLS; INTEGRIN ALPHA(IIB)BETA(3); CA2+-DEPENDENT PROTEASE; THROMBIN RECEPTOR	Previous studies have indicated that the Ca2+-dependent protease, calpain, is activated in platelets within 30-60 s of thrombin stimulation, but specific roles of calpain in platelets remain to be identified. To directly test the functions of calpain during platelet activation, a novel strategy was developed for introducing calpain's specific biological inhibitor, calpastatin, into platelets prior to activation. This method involves treatment of platelets with a fusion peptide, calpastat, consisting of the cell-penetrating signal sequence from Kaposi's fibroblast growth factor connected to a calpain-inhibiting consensus sequence derived from calpastatin.Calpastat specifically inhibits thrombin peptide (SFLLR)-induced alpha-granule secretion (IC50 = 20 mu M) during the first 30 s of activation, thrombin-induced platelet aggregation (IC50 = 50 mu M), and platelet spreading on glass surfaces (IC50 = 34 mu M). Calpastat-Ala, a mutant peptide in which alanine is substituted at conserved calpastatin residues, lacks calpain inhibitory activity and fails to inhibit secretion, aggregation, or spreading. The peptidyl calpain inhibitors calpeptin, MDL 28,170 (MDL) and E64d also inhibit secretion, aggregation and spreading, but require 3-10fold higher concentrations than calpastat for biological activity. Together, these findings demonstrate that calpain regulates platelet secretion, aggregation, and spreading and indicate that calpain plays an earlier role in platelet activation following thrombin receptor stimulation than had been previously detected.	Tufts Univ New England Med Ctr, Dept Med, Tupper Res Inst, Boston, MA 02111 USA; Tufts Univ New England Med Ctr, Div Hematol Oncol, Boston, MA 02111 USA; Tufts Univ, Sch Med, Dept Biochem, Boston, MA 02111 USA; Beth Israel Deaconess Med Ctr, Ctr Hemostasis & Thrombosis Res, Boston, MA 02215 USA; Harvard Univ, Sch Med, Boston, MA 02215 USA; Tufts Univ, Sch Med, Howard Hughes Med Inst, Boston, MA 02111 USA; Tufts Univ, Sch Med, Dept Physiol, Boston, MA 02111 USA	Tufts Medical Center; Tufts Medical Center; Tufts University; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School; Howard Hughes Medical Institute; Tufts University; Tufts University	Potter, DA (corresponding author), Tufts Univ New England Med Ctr, Dept Med, Tupper Res Inst, 245,750 Washington St, Boston, MA 02111 USA.	dpotter_mhc@opal.tufts.edu			NATIONAL CANCER INSTITUTE [K08CA001562] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL042443, R01HL051926] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK034928] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM055110] Funding Source: NIH RePORTER; NCI NIH HHS [K08 CA001562-04, K08-CA 1562] Funding Source: Medline; NHLBI NIH HHS [R01 HL051926, P01 HL042443] Funding Source: Medline; NIDDK NIH HHS [P30 DK034928, P30 DK34928] Funding Source: Medline; NIGMS NIH HHS [GM55110] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMIEVA MR, 1995, EXP CELL RES, V219, P180, DOI 10.1006/excr.1995.1218; ANAGLI J, 1993, BIOCHEM J, V289, P93, DOI 10.1042/bj2890093; ANAGLI J, 1991, BIOCHEM J, V274, P497, DOI 10.1042/bj2740497; Banfic H, 1998, J BIOL CHEM, V273, P11630, DOI 10.1074/jbc.273.19.11630; BOTTECCHIA D, 1976, HAEMOSTASIS, V5, P176; BRONK SF, 1993, AM J PHYSIOL, V264, pG744, DOI 10.1152/ajpgi.1993.264.4.G744; Carafoli E, 1998, BIOCHEM BIOPH RES CO, V247, P193, DOI 10.1006/bbrc.1998.8378; Cooray P, 1996, BIOCHEM J, V318, P41, DOI 10.1042/bj3180041; CRAMER EM, 1994, BLOOD, V84, P1722; Crawford C., 1990, INTRACELLULAR CALCIU, P75; CROALL DE, 1994, BIOCHEMISTRY-US, V33, P13223, DOI 10.1021/bi00249a008; CROALL DE, 1991, PHYSIOL REV, V71, P813, DOI 10.1152/physrev.1991.71.3.813; DELLIBOVI P, 1988, MOL CELL BIOL, V8, P2933, DOI 10.1128/MCB.8.7.2933; DU XP, 1995, J BIOL CHEM, V270, P26146, DOI 10.1074/jbc.270.44.26146; Flaumenhaft R, 1999, J BIOL CHEM, V274, P2492, DOI 10.1074/jbc.274.4.2492; FOX JEB, 1987, BLOOD, V69, P537; FOX JEB, 1983, J BIOL CHEM, V258, P9973; FOX JEB, 1993, J CELL BIOL, V120, P1501, DOI 10.1083/jcb.120.6.1501; FRANGIONI JV, 1993, EMBO J, V12, P4843, DOI 10.1002/j.1460-2075.1993.tb06174.x; Furman MI, 1998, P NATL ACAD SCI USA, V95, P3082, DOI 10.1073/pnas.95.6.3082; GARTNER TK, 1981, BLOOD, V58, P153; HARTWIG JH, 1995, CELL, V82, P643, DOI 10.1016/0092-8674(95)90036-5; Hato T, 1998, J CELL BIOL, V141, P1685, DOI 10.1083/jcb.141.7.1685; HOPGOOD MF, 1977, BIOCHEM J, V164, P399, DOI 10.1042/bj1640399; HSULIN SC, 1984, J BIOL CHEM, V259, P9121; Huang J, 1998, P NATL ACAD SCI USA, V95, P12100, DOI 10.1073/pnas.95.21.12100; Huttenlocher A, 1997, J BIOL CHEM, V272, P32719, DOI 10.1074/jbc.272.52.32719; Inomata M, 1996, ARCH BIOCHEM BIOPHYS, V328, P129, DOI 10.1006/abbi.1996.0152; JACOBS M, 1994, J BIOL CHEM, V269, P25494; KAWASAKI H, 1989, J BIOCHEM, V106, P274, DOI 10.1093/oxfordjournals.jbchem.a122844; Kuhlman PA, 1996, J BIOL CHEM, V271, P7986, DOI 10.1074/jbc.271.14.7986; Kuhlman PA, 1997, BIOCHEMISTRY-US, V36, P13461, DOI 10.1021/bi970601b; Li HL, 1998, CELL SIGNAL, V10, P137, DOI 10.1016/S0898-6568(97)00101-0; Li XL, 1998, J BIOL CHEM, V273, P19329, DOI 10.1074/jbc.273.30.19329; Lin YZ, 1996, J BIOL CHEM, V271, P5305, DOI 10.1074/jbc.271.10.5305; LIN YZ, 1995, J BIOL CHEM, V270, P14255, DOI 10.1074/jbc.270.24.14255; Liu XY, 1996, P NATL ACAD SCI USA, V93, P11819, DOI 10.1073/pnas.93.21.11819; MAKI M, 1989, J BIOL CHEM, V264, P18866; MAKI M, 1988, J BIOL CHEM, V263, P10254; Maki M., 1990, INTRACELLULAR CALCIU, P37; Matsuoka Y, 1998, J CELL BIOL, V142, P485, DOI 10.1083/jcb.142.2.485; Murachi T, 1980, Adv Enzyme Regul, V19, P407; NISHIURA I, 1979, EXPERIENTIA, V35, P1006, DOI 10.1007/BF01949908; Norris FA, 1997, J BIOL CHEM, V272, P10987; ODA A, 1993, J BIOL CHEM, V268, P12603; PHILLIPS DR, 1977, J BIOL CHEM, V252, P5602; PONTREMOLI S, 1990, J BIOL CHEM, V265, P706; Potter DA, 1998, J CELL BIOL, V141, P647, DOI 10.1083/jcb.141.3.647; SAIDO TC, 1993, J BIOL CHEM, V268, P7422; SCARAMUZZINO DA, 1993, P NATL ACAD SCI USA, V90, P3398, DOI 10.1073/pnas.90.8.3398; Schafer DA, 1996, J CELL BIOL, V135, P169, DOI 10.1083/jcb.135.1.169; SCHMAIER AH, 1990, BLOOD, V75, P1273; Schoenwaelder SM, 1997, J BIOL CHEM, V272, P1694, DOI 10.1074/jbc.272.3.1694; Shcherbina A, 1999, FEBS LETT, V443, P31, DOI 10.1016/S0014-5793(98)01674-3; SHUSTER CB, 1995, J CELL BIOL, V128, P837, DOI 10.1083/jcb.128.5.837; Shuster CB, 1996, CELL MOTIL CYTOSKEL, V35, P175; Stewart MP, 1998, J CELL BIOL, V140, P699, DOI 10.1083/jcb.140.3.699; VUORI K, 1993, J BIOL CHEM, V268, P21459; WALLACE RW, 1987, BIOCHEMISTRY-US, V26, P2766, DOI 10.1021/bi00384a017; WAXMAN L, 1978, J BIOL CHEM, V253, P5888; WHITE JG, 1974, AM J PATHOL, V77, P135; YOSHIDA K, 1986, FEBS LETT, V206, P273, DOI 10.1016/0014-5793(86)80995-4; Zimmerman UJP, 1999, IUBMB LIFE, V48, P453, DOI 10.1080/713803537; ZIMMERMAN UJP, 1995, CELL CALCIUM, V18, P1, DOI 10.1016/0143-4160(95)90040-3; ZIMMERMAN UJP, 1992, BIOCHIM BIOPHYS ACTA, V1137, P127, DOI 10.1016/0167-4889(92)90193-F	65	104	105	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 17	1999	274	51					36321	36327		10.1074/jbc.274.51.36321	http://dx.doi.org/10.1074/jbc.274.51.36321			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	266AV	10593923	Green Accepted, hybrid			2022-12-25	WOS:000084279200042
J	Olsson, PA; Korhonen, L; Mercer, EA; Lindholm, D				Olsson, PA; Korhonen, L; Mercer, EA; Lindholm, D			MIR is a novel ERM-like protein that interacts with myosin regulatory light chain and inhibits neurite outgrowth	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH CONE MORPHOLOGY; PLASMA-MEMBRANE; SMOOTH-MUSCLE; CELLS; RHO; KINASE; EZRIN; CYTOSKELETON; RADIXIN; NEURONS	The ERM protein family members ezrin, radixin, and moesin are cytoskeletal effector proteins linking actin to membrane-bound proteins at the cell surface. Here we report on the cloning of myosin regulatory light chain interacting protein (MIR), a protein with an ERM-homology domain and a carboxyl-terminal RING finger, that is expressed, among other tissues, in brain. MIR is distributed in cultured COS cells, in a punctated manner as shown using enhanced green fluorescent protein (EGFP)-tagged MIR and by staining with a specific antibody for MIR. In the yeast two-hybrid system and in transfected COS cells, MIR interacts with myosin regulatory light chain B, which in turn regulates the activity of the actomyosin complex. Overexpression of MIR cDNA in PC12 cells abrogated neurite outgrowth induced by nerve growth factor (NGF) without affecting TrkA signaling. The results show that MIR, a novel ERM-like protein, affects cytoskeleton interactions regulating cell motility, such as neurite outgrowth.	Uppsala Univ, Dept Neurosci, S-75123 Uppsala, Sweden	Uppsala University	Lindholm, D (corresponding author), Uppsala Univ, Dept Neurosci, Box 587 Biomed Ctr, S-75123 Uppsala, Sweden.	dan.lindholm@neuro.uu.se	Lindholm, Dan/B-3777-2014; Korhonen, Laura/AAW-3256-2020	Korhonen, Laura/0000-0002-1837-5930				AMIEVA MR, 1995, EXP CELL RES, V219, P180, DOI 10.1006/excr.1995.1218; ASPENSTROM P, 1995, METHOD ENZYMOL, V256, P228; Bretscher A, 1997, J CELL SCI, V110, P3011; Clem RJ, 1997, TRENDS CELL BIOL, V7, P337, DOI 10.1016/S0962-8924(97)01088-X; FEINSTEIN DL, 1991, MOL BRAIN RES, V10, P97, DOI 10.1016/0169-328X(91)90099-J; FREEMONT PS, 1993, ANN NY ACAD SCI, V684, P174, DOI 10.1111/j.1749-6632.1993.tb32280.x; Frisen J, 1998, J NEUROSCI, V18, P5714; GonzalezAgosti C, 1996, CELL MOTIL CYTOSKEL, V34, P122, DOI 10.1002/(SICI)1097-0169(1996)34:2<122::AID-CM4>3.0.CO;2-D; GOULD KL, 1989, EMBO J, V8, P4133, DOI 10.1002/j.1460-2075.1989.tb08598.x; Hasson T, 1997, CURR OPIN NEUROBIOL, V7, P615, DOI 10.1016/S0959-4388(97)80080-3; Helander TS, 1996, NATURE, V382, P265, DOI 10.1038/382265a0; Hirose M, 1998, J CELL BIOL, V141, P1625, DOI 10.1083/jcb.141.7.1625; Howard J, 1997, NATURE, V389, P561, DOI 10.1038/39247; INAGAKI N, 1995, EUR J NEUROSCI, V7, P1125, DOI 10.1111/j.1460-9568.1995.tb01102.x; Katoh H, 1998, J BIOL CHEM, V273, P2489, DOI 10.1074/jbc.273.5.2489; Korhonen L, 1997, EUR J NEUROSCI, V9, P2489, DOI 10.1111/j.1460-9568.1997.tb01666.x; Machesky LM, 1996, TRENDS CELL BIOL, V6, P304, DOI 10.1016/0962-8924(96)10026-X; Mangeat P, 1999, TRENDS CELL BIOL, V9, P187, DOI 10.1016/S0962-8924(99)01544-5; Matsui T, 1998, J CELL BIOL, V140, P647, DOI 10.1083/jcb.140.3.647; Paglini G, 1998, J CELL BIOL, V143, P443, DOI 10.1083/jcb.143.2.443; REES DJG, 1990, NATURE, V347, P685, DOI 10.1038/347685a0; SATO N, 1992, J CELL SCI, V103, P131; SOMLYO AP, 1994, NATURE, V372, P231, DOI 10.1038/372231a0; Takahashi K, 1997, J BIOL CHEM, V272, P23371, DOI 10.1074/jbc.272.37.23371; TAUBMAN MB, 1987, J CELL BIOL, V104, P1505, DOI 10.1083/jcb.104.6.1505; Tsukita S, 1997, TRENDS BIOCHEM SCI, V22, P53, DOI 10.1016/S0968-0004(96)10071-2; Uehata M, 1997, NATURE, V389, P990, DOI 10.1038/40187; Vaheri A, 1997, CURR OPIN CELL BIOL, V9, P659, DOI 10.1016/S0955-0674(97)80119-6; Wylie SR, 1998, P NATL ACAD SCI USA, V95, P12967, DOI 10.1073/pnas.95.22.12967; Xu HM, 1998, J NEUROSCI RES, V51, P403, DOI 10.1002/(SICI)1097-4547(19980201)51:3<403::AID-JNR13>3.0.CO;2-7; ZHANG SH, 1995, J BIOL CHEM, V270, P20067, DOI 10.1074/jbc.270.34.20067	31	64	69	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 17	1999	274	51					36288	36292		10.1074/jbc.274.51.36288	http://dx.doi.org/10.1074/jbc.274.51.36288			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	266AV	10593918	hybrid			2022-12-25	WOS:000084279200037
J	Qiu, XY; Janson, CA; Konstantinidis, AK; Nwagwu, S; Silverman, C; Smith, WW; Khandekar, S; Lonsdale, J; Abdel-Meguid, SS				Qiu, XY; Janson, CA; Konstantinidis, AK; Nwagwu, S; Silverman, C; Smith, WW; Khandekar, S; Lonsdale, J; Abdel-Meguid, SS			Crystal structure of beta-ketoacyl-acyl carrier protein synthase III - A key condensing enzyme in bacterial fatty acid biosynthesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PEROXISOMAL 3-KETOACYL-COA THIOLASE; ESCHERICHIA-COLI; SACCHAROMYCES-CEREVISIAE; FABH; INITIATION; DOMAINS; GENE	beta-Ketoacyl-acyl carrier protein synthase III (FabH), the most divergent member of the family of condensing enzymes, is a key catalyst in bacterial fatty acid biosynthesis and a promising target for novel antibiotics, We report here the crystal structures of FabH determined in the presence and absence of acetyl-CoA. These structures display a fold that is common for condensing enzymes. The observed acetylation of Cys(112) proves its catalytic role and clearly defines the primer binding pocket, Modeling based on a bound CoA molecule suggests catalytic roles for His(244) and Asn(274), The structures provide the molecular basis for FabH substrate specificity and reaction mechanism and are important for structure-based design of novel antibiotics.	SmithKline Beecham Pharmaceut, King Of Prussia, PA 19406 USA	GlaxoSmithKline	Qiu, XY (corresponding author), SmithKline Beecham Pharmaceut, King Of Prussia, PA 19406 USA.		ID, IMCACAT/D-5867-2014					Brunger A.T., 1993, X PLOR VERSION 3 1 S; Cane DE, 1998, SCIENCE, V282, P63, DOI 10.1126/science.282.5386.63; CLARK JD, 1988, BIOCHEMISTRY-US, V27, P5961, DOI 10.1021/bi00416a020; CLOUGH RC, 1992, J BIOL CHEM, V267, P20992; Collaborative Computational Project, 1994, ACTA CRYST D, V50, P760; Cronan JE, 1996, ESCHERICHIA COLI SAL, V1, P612; Han L, 1998, J BACTERIOL, V180, P4481, DOI 10.1128/JB.180.17.4481-4486.1998; Heath RJ, 1996, J BIOL CHEM, V271, P1833, DOI 10.1074/jbc.271.4.1833; Heath RJ, 1996, J BIOL CHEM, V271, P10996, DOI 10.1074/jbc.271.18.10996; HOPWOOD DA, 1990, ANNU REV GENET, V24, P37, DOI 10.1146/annurev.ge.24.120190.000345; Huang WJ, 1998, EMBO J, V17, P1183, DOI 10.1093/emboj/17.5.1183; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KRESZE GB, 1977, EUR J BIOCHEM, V79, P191, DOI 10.1111/j.1432-1033.1977.tb11797.x; MAGNUSON K, 1993, MICROBIOL REV, V57, P522, DOI 10.1128/MMBR.57.3.522-542.1993; Mathieu M, 1997, J MOL BIOL, V273, P714, DOI 10.1006/jmbi.1997.1331; MATHIEU M, 1994, STRUCTURE, V2, P797, DOI 10.1016/S0969-2126(94)00081-6; MAYO KH, 1985, BIOCHEMISTRY-US, V24, P7834, DOI 10.1021/bi00347a049; McDaniel R, 1999, P NATL ACAD SCI USA, V96, P1846, DOI 10.1073/pnas.96.5.1846; McRee D.E., 1999, PRACTICAL PROTEIN CR, V2nd ed., P91; Moche M, 1999, J BIOL CHEM, V274, P6031, DOI 10.1074/jbc.274.10.6031; NICHOLLS A, 1991, J COMPUT CHEM, V12, P435, DOI 10.1002/jcc.540120405; OMURA S, 1976, BACTERIOL REV, V40, P681, DOI 10.1128/MMBR.40.3.681-697.1976; Qiu XY, 1996, NATURE, V383, P275, DOI 10.1038/383275a0; Siggaard-Andersen Mads, 1993, Protein Sequences and Data Analysis, V5, P325; Stinson SC, 1996, CHEM ENG NEWS, V74, P75, DOI 10.1021/cen-v074n039.p075; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; TRAVIS J, 1994, SCIENCE, V264, P360, DOI 10.1126/science.8153615; TSAY JT, 1992, J BIOL CHEM, V267, P6807; VERWOERT IIGS, 1995, PLANT MOL BIOL, V27, P875, DOI 10.1007/BF00037016	29	140	145	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 17	1999	274	51					36465	36471		10.1074/jbc.274.51.36465	http://dx.doi.org/10.1074/jbc.274.51.36465			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	266AV	10593943	hybrid			2022-12-25	WOS:000084279200062
J	Ayers, NA; Wilkinson, DA; Fitzgerald, TJ; Carlson, GM				Ayers, NA; Wilkinson, DA; Fitzgerald, TJ; Carlson, GM			Self-association of the alpha subunit of phosphorylase kinase as determined by two-hybrid screening	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RABBIT-SKELETAL-MUSCLE; LINKED LIVER GLYCOGENOSIS; BETA-SUBUNITS; LEUCINE-ZIPPER; CROSS-LINKING; CDNA CLONING; MOLECULAR-BASIS; GAMMA-DELTA; IDENTIFICATION; ACTIVATION	The structural organization of the (alpha beta gamma delta)(4) phosphorylase kinase complex has been studied using the yeast two-hybrid screen for the purpose of elucidating regions of alpha subunit interactions. By screening a rabbit skeletal muscle cDNA library with residues 1-1059 of the alpha subunit of phosphorylase kinase, we have isolated 16 interacting, independent, yet overlapping transcripts of the a subunit containing its C-terminal region. Domain mapping of binary interactions between alpha constructs revealed two regions involved in the self-association of the alpha subunit: residues 833-854, a previously unrecognized leucine zipper, and an unspecified region within residues 1015-1237, The cognate binding partner for the latter domain has been inferred to lie within the stretch from residues 864-1059. Indirect evidence from the literature suggests that the interacting domains contained within the latter two, overlapping regions may be further narrowed to the stretches from 1057 to 1237 and from 864 to 971. Cross-linking of the nonactivated holoenzyme with N-(gamma-maleimidobutyroxy) sulfosuccinimide ester produced intramolecularly cross-linked alpha-alpha dimers, consistent with portions of two alpha subunits in the holoenyzme being in sufficient proximity to associate. This is the first report to identify potential areas of contact between the alpha subunits of phosphorylase kinase. Additionally, issues regarding the general utility of two-hybrid screening as a method for studying homodimeric interactions are discussed.	Univ Missouri, Sch Biol Sci, Div Mol Biol & Biochem, Kansas City, MO 64110 USA; Univ Tennessee, Coll Med, Dept Biochem, Memphis, TN 38163 USA	University of Missouri System; University of Missouri Kansas City; University of Tennessee System; University of Tennessee Health Science Center	Carlson, GM (corresponding author), Univ Missouri, Sch Biol Sci, Div Mol Biol & Biochem, 503 Biol Sci Bldg,5100 Rockhill Rd, Kansas City, MO 64110 USA.	carlsongm@umkc.edu			NIDDK NIH HHS [DK32953] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK032953, R56DK032953] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AUSEMBEL FM, 1996, CURRENT PROTOCOLS MO; Ayers NA, 1998, BIOCHEM J, V331, P137, DOI 10.1042/bj3310137; Barr MM, 1996, MOL CELL BIOL, V16, P5597; BRANDEN C, 1999, INTRO PROTEIN SRUCTU, P175; CHAN KFJ, 1982, J BIOL CHEM, V257, P5948; CHENG A, 1988, J BIOL CHEM, V263, P5534; COHEN P, 1973, EUR J BIOCHEM, V34, P1, DOI 10.1111/j.1432-1033.1973.tb02721.x; COHEN P, 1978, FEBS LETT, V92, P287, DOI 10.1016/0014-5793(78)80772-8; DASGUPTA M, 1989, J BIOL CHEM, V264, P17156; DAVIDSON JJ, 1992, P NATL ACAD SCI USA, V89, P2096, DOI 10.1073/pnas.89.6.2096; ESTOJAK J, 1995, MOL CELL BIOL, V15, P5820; FIELDS S, 1994, TRENDS GENET, V10, P286, DOI 10.1016/0168-9525(90)90012-U; FITZGERALD TJ, 1984, J BIOL CHEM, V259, P3266; FRANCKE U, 1989, AM J HUM GENET, V45, P276; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; Golemis EA, 1997, YEAST 2 HYBRID SYSTE, P43; GYURIS J, 1993, CELL, V75, P791, DOI 10.1016/0092-8674(93)90498-F; HARMANN B, 1991, J BIOL CHEM, V266, P15631; HAYAKAWA T, 1973, BIOCHEMISTRY-US, V12, P574, DOI 10.1021/bi00728a002; HAYAKAWA T, 1973, BIOCHEMISTRY-US, V12, P567, DOI 10.1021/bi00728a001; HEILMEYER LMG, 1992, P NATL ACAD SCI USA, V89, P9554, DOI 10.1073/pnas.89.20.9554; HEILMEYER LMG, 1991, BIOCHIM BIOPHYS ACTA, V1094, P168, DOI 10.1016/0167-4889(91)90005-I; HEILMEYER LMG, 1993, MOL CELL BIOCHEM, V128, P19, DOI 10.1007/BF01076754; HENDRICKX J, 1994, GENOMICS, V21, P620, DOI 10.1006/geno.1994.1322; Hendrickx J, 1996, HUM MOL GENET, V5, P649, DOI 10.1093/hmg/5.5.649; Hendrickx J, 1996, HUM GENET, V97, P551; Hendrickx J, 1999, AM J HUM GENET, V64, P1541, DOI 10.1086/302399; HENDRICKX J, 1993, HUM MOL GENET, V2, P583, DOI 10.1093/hmg/2.5.583; HESSOVA Z, 1985, EUR J BIOCHEM, V146, P107, DOI 10.1111/j.1432-1033.1985.tb08626.x; HINRICHSEN A, 1989, BIOL CHEM H-S, V370, P125, DOI 10.1515/bchm3.1989.370.1.125; HUIJING F, 1969, AM J HUM GENET, V21, P275; JAMES P, 1991, J BIOL CHEM, V266, P7087; Junius FK, 1996, J BIOL CHEM, V271, P13663, DOI 10.1074/jbc.271.23.13663; KILIMANN MW, 1988, P NATL ACAD SCI USA, V85, P9381, DOI 10.1073/pnas.85.24.9381; KING MM, 1981, J BIOL CHEM, V256, P1058; KUO MS, 1986, CARBOHYD RES, V156, P173, DOI 10.1016/S0008-6215(00)90109-5; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMBOOY PK, 1982, ARCH BIOCHEM BIOPHYS, V213, P551, DOI 10.1016/0003-9861(82)90583-5; Nadeau OW, 1998, BIOCHEM BIOPH RES CO, V251, P637, DOI 10.1006/bbrc.1998.9507; Nadeau OW, 1999, BIOCHEMISTRY-US, V38, P2551, DOI 10.1021/bi982060b; NADEAU OW, 1994, J BIOL CHEM, V269, P29670; NORCUM MT, 1994, J MOL BIOL, V241, P94, DOI 10.1006/jmbi.1994.1476; PARK WY, 1995, BIOCHEM BIOPH RES CO, V211, P447, DOI 10.1006/bbrc.1995.1834; PAUDEL HK, 1988, ARCH BIOCHEM BIOPHYS, V264, P641, DOI 10.1016/0003-9861(88)90330-X; PAUDEL HK, 1987, J BIOL CHEM, V262, P11912; Pickett-Gies CA., 1986, ENZYMES, V17, P395; PICTON C, 1980, EUR J BIOCHEM, V111, P553, DOI 10.1111/j.1432-1033.1980.tb04971.x; RAMACHANDRAN C, 1987, J BIOL CHEM, V262, P3210; Sambrook J., 1989, MOL CLONING LAB MANU, V2; TREMPE MR, 1987, J BIOL CHEM, V262, P4333; VRANA KE, 1994, J NEUROCHEM, V63, P2014; Wilkinson DA, 1997, J MOL BIOL, V265, P319, DOI 10.1006/jmbi.1996.0739; WILKINSON DA, 1994, J MOL BIOL, V235, P974, DOI 10.1006/jmbi.1994.1051; WULLRICH A, 1993, J BIOL CHEM, V268, P23208; ZANDER NF, 1988, P NATL ACAD SCI USA, V85, P2929, DOI 10.1073/pnas.85.9.2929	55	15	15	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 10	1999	274	50					35583	35590		10.1074/jbc.274.50.35583	http://dx.doi.org/10.1074/jbc.274.50.35583			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	264NG	10585434				2022-12-25	WOS:000084187900046
J	Basu-Modak, S; Braissant, O; Escher, P; Desvergne, B; Honegger, P; Wahli, W				Basu-Modak, S; Braissant, O; Escher, P; Desvergne, B; Honegger, P; Wahli, W			Peroxisome proliferator-activated receptor beta regulates acyl-CoA synthetase 2 in reaggregated rat brain cell cultures	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COENZYME-A SYNTHETASE; ALPHA PPAR-ALPHA; FATTY-ACIDS; DIFFERENTIAL EXPRESSION; GENE-EXPRESSION; TISSUE DISTRIBUTION; GAMMA; LIGANDS; PATHWAY; THIAZOLIDINEDIONE	Peroxisome proliferator-activated receptors (PPARs) are nuclear hormone receptors that regulate the expression of many genes involved in lipid metabolism. The biological roles of PPAR alpha and PPAR gamma are relatively well understood, but little is known about the function of PPAR beta. To address this question, and because PPAR beta is expressed to a high level in the developing brain, we used reaggregated brain cell cultures prepared from dissociated fetal rat telencephalon as experimental model. In these primary cultures, the fetal cells initially form random aggregates, which progressively acquire a tissue-specific pattern resembling that of the brain. PPARs are differentially expressed in these aggregates, with PPAR beta being the prevalent isotype. PPAR alpha is present at a very low level, and PPAR gamma is absent. Cell type-specific expression analyses revealed that PPAR beta is ubiquitous and most abundant in some neurons, whereas PPARa is predominantly astrocytic. We chose acyl-CoA synthetases (ACSs) 1, 2, and 3 as potential target genes of PPAR beta and first analyzed their temporal and cell type-specific pattern. This analysis indicated that ACS2 and PPAR beta mRNAs have overlapping expression patterns, thus designating the ACS2 gene as a putative target of PPAR beta. Using a selective PPAR beta activator, we found that the ACS2 gene is transcriptionally regulated by PPARP beta, demonstrating a role for PPAR beta in brain lipid metabolism.	Univ Lausanne, Inst Biol Anim, CH-1015 Lausanne, Switzerland; Univ Lausanne, Inst Physiol, CH-1005 Lausanne, Switzerland	University of Lausanne; University of Lausanne	Wahli, W (corresponding author), Univ Lausanne, Inst Biol Anim, Batiment Biol, CH-1015 Lausanne, Switzerland.		Wahli, Walter/B-1398-2009; Wahli, Walter/I-3194-2019; Desvergne, Beatrice/C-8892-2016	Wahli, Walter/0000-0002-5966-9089; Desvergne, Beatrice/0000-0001-5483-288X				Altiok S, 1997, GENE DEV, V11, P1987, DOI 10.1101/gad.11.15.1987; Aoyama T, 1998, J BIOL CHEM, V273, P5678, DOI 10.1074/jbc.273.10.5678; Berger J, 1999, J BIOL CHEM, V274, P6718, DOI 10.1074/jbc.274.10.6718; Braissant O, 1998, ENDOCRINOLOGY, V139, P2748, DOI 10.1210/en.139.6.2748; Braissant O, 1996, ENDOCRINOLOGY, V137, P354, DOI 10.1210/en.137.1.354; Brown PJ, 1997, CHEM BIOL, V4, P909, DOI 10.1016/S1074-5521(97)90299-4; CAMPAGNONI AT, 1988, MOL NEUROBIOL, V2, P41, DOI 10.1007/BF02935632; CORTHESYTHEULAZ I, 1990, AM J PHYSIOL, V258, pC1062, DOI 10.1152/ajpcell.1990.258.6.C1062; Cullingford TE, 1998, J NEUROCHEM, V70, P1366; DESVERGNE B, 1995, INDUCIBLE GENE EXPRE, V1, P142; Devchand PR, 1996, NATURE, V384, P39, DOI 10.1038/384039a0; DREYER C, 1993, BIOL CELL, V77, P67, DOI 10.1016/S0248-4900(05)80176-5; DUMONTEIL E, 1994, J PHYSIOL-LONDON, V479, P29, DOI 10.1113/jphysiol.1994.sp020275; Faergeman NJ, 1997, BIOCHEM J, V323, P1; Forman BM, 1997, P NATL ACAD SCI USA, V94, P4312, DOI 10.1073/pnas.94.9.4312; Fujino T, 1996, J BIOL CHEM, V271, P16748, DOI 10.1074/jbc.271.28.16748; FULCERI R, 1994, CELL CALCIUM, V15, P109, DOI 10.1016/0143-4160(94)90049-3; FULCERI R, 1993, BIOCHEM J, V295, P663, DOI 10.1042/bj2950663; Garbay B, 1997, DEV BRAIN RES, V98, P197, DOI 10.1016/S0165-3806(96)00169-1; Granneman J, 1998, J NEUROSCI RES, V51, P563, DOI 10.1002/(SICI)1097-4547(19980301)51:5<563::AID-JNR3>3.0.CO;2-D; Honegger P, 1998, DEV BRAIN RES, V105, P219, DOI 10.1016/S0165-3806(97)00194-6; HONEGGER P, 1979, NATURE, V282, P305, DOI 10.1038/282305a0; HONEGGER P, 1988, EXPERIENTIA, V44, P817, DOI 10.1007/BF01941177; HONEGGER P, 1985, CELL CULTURE NEUROSC, P223; Honegger Paul, 1997, P25; Iijima H, 1996, EUR J BIOCHEM, V242, P186, DOI 10.1111/j.1432-1033.1996.0186r.x; Jumpsen J., 1995, BRAIN DEV RELATIONSH; KAKAR SS, 1987, J BIOL CHEM, V262, P42; KLIEWER SA, 1994, P NATL ACAD SCI USA, V91, P7355, DOI 10.1073/pnas.91.15.7355; Krey G, 1997, MOL ENDOCRINOL, V11, P779, DOI 10.1210/me.11.6.779; Larsson O, 1996, J BIOL CHEM, V271, P10623, DOI 10.1074/jbc.271.18.10623; Lefebvre AM, 1998, NAT MED, V4, P1053, DOI 10.1038/2036; LEHMANN JM, 1995, J BIOL CHEM, V270, P12953, DOI 10.1074/jbc.270.22.12953; LEMBERGER T, 1994, J BIOL CHEM, V269, P24527; Lemberger T, 1996, ANNU REV CELL DEV BI, V12, P335, DOI 10.1146/annurev.cellbio.12.1.335; MASTERS CJ, 1995, MECH AGEING DEV, V80, P69, DOI 10.1016/0047-6374(94)01563-2; MONNETTSCHUDI F, 1993, DEV NEUROSCI-BASEL, V15, P395, DOI 10.1159/000111363; Mukherjee R, 1997, J BIOL CHEM, V272, P8071, DOI 10.1074/jbc.272.12.8071; PFANNER N, 1989, CELL, V59, P95, DOI 10.1016/0092-8674(89)90872-6; REDDY TS, 1985, NEUROCHEM RES, V10, P377, DOI 10.1007/BF00964606; RIEDERER BM, 1992, J NEUROCHEM, V58, P649, DOI 10.1111/j.1471-4159.1992.tb09767.x; Roberts RA, 1998, CARCINOGENESIS, V19, P43, DOI 10.1093/carcin/19.1.43; Saez E, 1998, NAT MED, V4, P1058, DOI 10.1038/2042; Sarraf P, 1998, NAT MED, V4, P1046, DOI 10.1038/2030; SCHOONJANS K, 1995, J BIOL CHEM, V270, P19269, DOI 10.1074/jbc.270.33.19269; SEED B, 1988, GENE, V67, P271, DOI 10.1016/0378-1119(88)90403-9; Sleeman MW, 1998, J BIOL CHEM, V273, P3132, DOI 10.1074/jbc.273.6.3132; Spiegelman BM, 1998, DIABETES, V47, P507, DOI 10.2337/diabetes.47.4.507; Staels B, 1998, NATURE, V393, P790, DOI 10.1038/31701; TYRRELL RM, 1994, METHOD ENZYMOL, V234, P224; VASWANI KK, 1987, J NEUROSCI RES, V17, P65, DOI 10.1002/jnr.490170110; WAHLI W, 1995, CHEM BIOL, V2, P261, DOI 10.1016/1074-5521(95)90045-4; Willson TM, 1997, CURR OPIN CHEM BIOL, V1, P235, DOI 10.1016/S1367-5931(97)80015-4; Xing GQ, 1995, BIOCHEM BIOPH RES CO, V217, P1015, DOI 10.1006/bbrc.1995.2871	54	107	112	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 10	1999	274	50					35881	35888		10.1074/jbc.274.50.35881	http://dx.doi.org/10.1074/jbc.274.50.35881			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	264NG	10585473	hybrid, Green Submitted			2022-12-25	WOS:000084187900085
J	Ogino, T; Iwama, M; Kinouchi, J; Shibagaki, Y; Tsukamoto, T; Mizumoto, K				Ogino, T; Iwama, M; Kinouchi, J; Shibagaki, Y; Tsukamoto, T; Mizumoto, K			Involvement of a cellular glycolytic enzyme, phosphoglycerate kinase, in Sendai virus transcription	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RESPIRATORY SYNCYTIAL VIRUS; MESSENGER-RNA SYNTHESIS; MICROTUBULE-ASSOCIATED PROTEINS; P-PROTEIN; GLYCERALDEHYDE-3-PHOSPHATE DEHYDROGENASE; IN-VITRO; GENOME REPLICATION; INVITRO SYSTEM; BINDING DOMAIN; TYPE-3	In vitro mRNA synthesis of Sendai virus is almost entirely dependent on the addition of cellular proteins (host factors). Previous studies indicated that the host factor activity from bovine brain was resolved into at least two complementary fractions, one of which may be tubulin. In this study, the host factor activity that stimulates the transcription in the presence of tubulin was further purified from bovine brain. This fraction was found to contain at least two complementary factors, and one of them was purified to a single polypeptide chain with an apparent M-r of 46,000 (p46). From the amino acid sequence, biochemical, and immunological analyses, p46 was identified as a glycolytic enzyme, phosphoglycerate kinase (PGK). Purified native PGK from rabbit and yeast, and a recombinant human PGK substituted for p46. Although, as previously suggested, tubulin was involved in the transcription initiation complex formation by being integrated into the complex, p46 and its complementary factor had little effect on the complex formation. On the other hand, when p46 and the complementary factor were added to the RNA chain elongation reaction from the isolated initiation complex formed with tubulin, mRNA synthesis was dramatically stimulated. The enzymatic activity per se of PGK did not seem Do be required for its activity. West-Western blot analysis showed that PGK could directly interact with tubulin. These data suggest that PGK stimulates Sendai virus mRNA synthesis at the elongation step, probably through its interaction with tubulin in the initiation complex.	Kitasato Univ, Sch Pharmaceut Sci, Dept Biochem, Minato Ku, Tokyo 1088641, Japan; Kitasato Inst, Biol Res Ctr, Minato Ku, Tokyo 1088642, Japan	Kitasato University	Mizumoto, K (corresponding author), Kitasato Univ, Sch Pharmaceut Sci, Dept Biochem, Minato Ku, 5-9-1 Shirokane, Tokyo 1088641, Japan.	mizumotok@pharm.kitasato-u.ac.jp	Ogino, Tomoaki/M-2824-2017	Ogino, Tomoaki/0000-0002-4154-1781				BARIK S, 1992, P NATL ACAD SCI USA, V89, P6570, DOI 10.1073/pnas.89.14.6570; BARIK S, 1992, J VIROL, V66, P6813, DOI 10.1128/JVI.66.11.6813-6818.1992; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Burke E, 1998, VIROLOGY, V252, P137, DOI 10.1006/viro.1998.9471; Collins P. L., 1996, FIELDS VIROLOGY, P1205; CURRAN J, 1992, VIROLOGY, V189, P647, DOI 10.1016/0042-6822(92)90588-G; CURRAN J, 1995, J VIROL, V69, P849, DOI 10.1128/JVI.69.2.849-855.1995; CURRAN J, 1994, VIROLOGY, V202, P875, DOI 10.1006/viro.1994.1409; Das T, 1998, P NATL ACAD SCI USA, V95, P1449, DOI 10.1073/pnas.95.4.1449; Das T, 1996, METHOD ENZYMOL, V275, P99; DAS T, 1995, VIROLOGY, V211, P218, DOI 10.1006/viro.1995.1394; DE BP, 1990, J VIROL, V64, P1135, DOI 10.1128/JVI.64.3.1135-1142.1990; DE BP, 1993, J BIOL CHEM, V268, P5703; DE BP, 1991, J VIROL, V65, P3268, DOI 10.1128/JVI.65.6.3268-3275.1991; De BP, 1996, J BIOL CHEM, V271, P24728, DOI 10.1074/jbc.271.40.24728; De BP, 1997, ADV VIRUS RES, V48, P169, DOI 10.1016/S0065-3527(08)60288-2; DE BP, 1995, P NATL ACAD SCI USA, V92, P5204, DOI 10.1073/pnas.92.11.5204; Fields B. N, 1996, FIELDS VIROLOGY, V1, P1177; Ghosh A, 1996, VIRUS RES, V41, P69, DOI 10.1016/0168-1702(95)01276-1; Gupta S, 1998, J VIROL, V72, P2655, DOI 10.1128/JVI.72.4.2655-2662.1998; HILL VM, 1986, P NATL ACAD SCI USA, V83, P5410, DOI 10.1073/pnas.83.15.5410; HILL VM, 1990, J GEN VIROL, V71, P289, DOI 10.1099/0022-1317-71-2-289; HORIKAMI SM, 1992, J VIROL, V66, P4901, DOI 10.1128/JVI.66.8.4901-4908.1992; HUANG YT, 1993, VIROLOGY, V193, P862, DOI 10.1006/viro.1993.1195; HUITOREL P, 1985, EUR J BIOCHEM, V150, P265, DOI 10.1111/j.1432-1033.1985.tb09016.x; Huntley CC, 1997, J BIOL CHEM, V272, P16578, DOI 10.1074/jbc.272.26.16578; JINDAL HK, 1990, J BIOL CHEM, V265, P6540; KUNTZ GWK, 1982, METHOD ENZYMOL, V90, P103; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE CY, 1982, METHOD ENZYMOL, V90, P121; LEHOTZKY A, 1993, J BIOL CHEM, V268, P10888; Liu Z, 1997, VIROLOGY, V232, P198, DOI 10.1006/viro.1997.8548; MACCIONI RB, 1995, PHYSIOL REV, V75, P835, DOI 10.1152/physrev.1995.75.4.835; MALHOTRA OP, 1995, EUR J BIOCHEM, V227, P556, DOI 10.1111/j.1432-1033.1995.tb20424.x; MEJEAN C, 1989, BIOCHEM J, V264, P671, DOI 10.1042/bj2640671; MICHELSON AM, 1985, P NATL ACAD SCI USA, V82, P6965, DOI 10.1073/pnas.82.20.6965; MINASCHEK G, 1992, EUR J CELL BIOL, V58, P418; MIZUMOTO K, 1995, J BIOCHEM-TOKYO, V117, P527, DOI 10.1093/oxfordjournals.jbchem.a124740; MORI N, 1986, GENE, V45, P275; MOSCONA A, 1991, J VIROL, V65, P4470, DOI 10.1128/JVI.65.8.4470-4474.1991; MOYER SA, 1986, P NATL ACAD SCI USA, V83, P5405, DOI 10.1073/pnas.83.15.5405; MOYER SA, 1990, J GEN VIROL, V71, P775, DOI 10.1099/0022-1317-71-4-775; MOYER SA, 1991, PARAMYXOVIRUSES, P249; Oglesbee MJ, 1996, J GEN VIROL, V77, P2125, DOI 10.1099/0022-1317-77-9-2125; PAGLIARO L, 1988, J CELL BIOL, V107, P981, DOI 10.1083/jcb.107.3.981; PERKINS RE, 1983, BIOCHEM J, V211, P199, DOI 10.1042/bj2110199; Pringle CR, 1997, SEMIN VIROL, V8, P49, DOI 10.1006/smvy.1997.0105; SHELANSK.ML, 1973, P NATL ACAD SCI USA, V70, P765, DOI 10.1073/pnas.70.3.765; SHIBUTA H, 1979, MICROBIOL IMMUNOL, V23, P617, DOI 10.1111/j.1348-0421.1979.tb00502.x; SMALLWOOD S, 1994, VIROLOGY, V202, P154, DOI 10.1006/viro.1994.1331; TAKAGI T, 1995, J BIOCHEM-TOKYO, V118, P390, DOI 10.1093/oxfordjournals.jbchem.a124919; Takagi T, 1996, ARCH VIROL, V141, P1623, DOI 10.1007/BF01718287; TAKEUCHI K, 1993, ARCH VIROL, V128, P177, DOI 10.1007/BF01309799; TOMPA P, 1986, EUR J BIOCHEM, V154, P643, DOI 10.1111/j.1432-1033.1986.tb09446.x; Tsukamoto T, 1998, BIOCHEM BIOPH RES CO, V251, P27, DOI 10.1006/bbrc.1998.9402; Vertessy BG, 1997, J BIOL CHEM, V272, P25542, DOI 10.1074/jbc.272.41.25542; VILLANUEVA N, 1994, J GEN VIROL, V75, P555, DOI 10.1099/0022-1317-75-3-555; VISHWANATHA JK, 1992, J CELL SCI, V101, P25; Volker KW, 1997, ARCH BIOCHEM BIOPHYS, V338, P237, DOI 10.1006/abbi.1996.9819; WALSH JL, 1989, BIOCHIM BIOPHYS ACTA, V999, P64, DOI 10.1016/0167-4838(89)90031-9; WEINGARTEN MD, 1975, P NATL ACAD SCI USA, V72, P1858, DOI 10.1073/pnas.72.5.1858	61	48	50	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 10	1999	274	50					35999	36008		10.1074/jbc.274.50.35999	http://dx.doi.org/10.1074/jbc.274.50.35999			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	264NG	10585490	hybrid			2022-12-25	WOS:000084187900102
J	Stieglitz, K; Seaton, B; Roberts, MF				Stieglitz, K; Seaton, B; Roberts, MF			The role of interfacial binding in the activation of Streptomyces chromofuscus phospholipase D by phosphatidic acid	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SHORT-CHAIN PHOSPHOLIPIDS; NEUTROPHILS; INHIBITION; CLEAVAGE; MEMBRANE; LIPASE	The Streptomyces chromofuscus phospholipase D (PLD) cleavage of phosphatidylcholine in bilayers can be enhanced by the addition of the product phosphatidic acid (PA). Other anionic lipids such as phosphatidylinositol, oleic acid, or phosphatidylmethanol do not activate this PLD. This allosteric activation by PA could involve a conformational change in the enzyme that alters PLD binding to phospholipid surfaces. To test this, the binding of intact PLD and proteolytically cleaved isoforms to styrene divinylbenzene beads coated with a phospholipid monolayer and to unilamellar vesicles was examined. The results indicate that intact PLD has a very high affinity for PA bilayers at pH greater than or equal to 7 in the presence of EGTA that is weakened as Ca2+ or Ba2+ are added to the system. Proteolytically clipped PLD also binds tightly to PA in the absence of metal ions. However, the isolated catalytic fragment has a considerably weaker affinity for PA surfaces. In contrast to PA surfaces, all PLD forms exhibited very low affinity for PC interfaces with an increased binding when Ba2+ was added. All PLD form's also bound tightly to other anionic phospholipid surfaces (e.g, phosphatidylserine, phosphatidylinositol, and phosphatidylmethanol). However, this binding was not modulated in the same way by divalent cations. Chemical cross-linking studies suggested that a major effect of PLD binding to PA Ca2+ surfaces is aggregation of the enzyme. These results indicate that PLD partitioning to phospholipid surfaces and kinetic activation are two separate events and suggest that the Ca2+ modulation of PA PLD binding involves protein aggregation that may be the critical interaction for activation.	Boston Coll, Merkert Chem Ctr, Chestnut Hill, MA 02467 USA; Boston Univ, Sch Med, Dept Physiol, Boston, MA 02118 USA	Boston College; Boston University	Roberts, MF (corresponding author), Boston Coll, Merkert Chem Ctr, Chestnut Hill, MA 02467 USA.	mary.roberts@bc.edu		Seaton, Barbara/0000-0003-4654-7709; Stieglitz, Kimberly/0000-0001-6086-3682	NIGMS NIH HHS [GM 26762] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM026762] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Carpio LC, 1998, PROSTAG LEUKOTR ESS, V59, P101, DOI 10.1016/S0952-3278(98)90088-6; COCKCROFT S, 1992, BIOCHIM BIOPHYS ACTA, V1113, P135, DOI 10.1016/0304-4157(92)90036-A; DENNIS EA, 1973, J LIPID RES, V14, P152; DEREWENDA U, 1992, BIOCHEMISTRY-US, V31, P1532, DOI 10.1021/bi00120a034; DEREWENDA ZS, 1992, J MOL BIOL, V227, P818, DOI 10.1016/0022-2836(92)90225-9; Dong GA, 1999, BBA-PROTEIN STRUCT M, V1430, P234, DOI 10.1016/S0167-4838(99)00005-9; EIBL H, 1981, METHOD ENZYMOL, V72, P633; Exton JH, 1997, PHYSIOL REV, V77, P303, DOI 10.1152/physrev.1997.77.2.303; Geng D, 1998, J BIOL CHEM, V273, P12195, DOI 10.1074/jbc.273.20.12195; HOLBROOK PG, 1991, BIOCHIM BIOPHYS ACTA, V1084, P155, DOI 10.1016/0005-2760(91)90214-3; HORIUTI Y, 1977, J BIOCHEM-TOKYO, V81, P1639, DOI 10.1093/oxfordjournals.jbchem.a131623; IMAMURA S, 1979, J BIOCHEM, V85, P79, DOI 10.1093/oxfordjournals.jbchem.a132334; JONES GA, 1993, J BIOL CHEM, V268, P20845; Kim Y, 1997, ANAL BIOCHEM, V250, P109, DOI 10.1006/abio.1997.2200; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOPEZ I, 1995, J BIOL CHEM, V270, P19465, DOI 10.1074/jbc.270.33.19465; MURAYAMA T, 1987, J BIOL CHEM, V262, P5522; ROBERTS MF, 1991, METHOD ENZYMOL, V197, P95; ROBERTS MF, 1991, METHOD ENZYMOL, V197, P31; Stuckey JA, 1999, NAT STRUCT BIOL, V6, P278; SWAIRJO MA, 1994, BBA-BIOMEMBRANES, V1191, P354, DOI 10.1016/0005-2736(94)90186-4; Xu YJ, 1996, AM J PHYSIOL-HEART C, V271, pH651, DOI 10.1152/ajpheart.1996.271.2.H651; YANG SF, 1967, J BIOL CHEM, V242, P477; Zhou C, 1998, BIOCHEMISTRY-US, V37, P16430, DOI 10.1021/bi980601r	24	33	33	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 10	1999	274	50					35367	35374		10.1074/jbc.274.50.35367	http://dx.doi.org/10.1074/jbc.274.50.35367			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	264NG	10585404	hybrid			2022-12-25	WOS:000084187900016
J	Ouellet, M; Barbeau, B; Tremblay, MJ				Ouellet, M; Barbeau, B; Tremblay, MJ			p56(lck), ZAP-70, SLP-76, and calcium-regulated effecters are involved in NF-kappa B activation by bisperoxovanadium phosphotyrosyl phosphatase inhibitors in human T cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SEVERE COMBINED IMMUNODEFICIENCY; PROTEIN-TYROSINE PHOSPHATASES; NECROSIS FACTOR-ALPHA; ANTIGEN RECEPTOR; SIGNAL-TRANSDUCTION; PEROXOVANADIUM COMPOUNDS; GENETIC-EVIDENCE; PROLIFERATIVE RESPONSES; TRANSCRIPTION FACTOR; CYCLOSPORINE-A	This study investigates the second messengers involved in NF-kappa B activation by the bisperoxovanadium (bpV) phosphotyrosyl phosphatase inhibitors, We first initiated a time course analysis of bpV-mediated activation of the human immunodeficiency virus type-1 long terminal repeat- and NF-kappa B-driven reporter gene. Our results showed a slower and more transient activation of both kappa B-regulated luciferase-encoding vectors by bpV compounds when compared with the action of tumor necrosis factor-alpha (TNF), Time course analyses of NF-kappa B translocation by shift assay experiments further confirmed these results, hence implying distinct pathways of NF-kappa B activation for bpV compounds and TNF. Attempts to characterize the bpV-dependent signaling cascade revealed that the src family protein tyrosine kinase p56(lck) was critical for NF-kappa B induction by bpV. Furthermore, p56(lck) interaction with the intracytoplasmic tail of CD4 markedly enhanced such induction. Optimal activation of NF-kappa B following bpV treatment necessitated downstream effecters of p56(lck) such as the syk family protein tyrosine kinase ZAP-70 and the molecular adaptor SLP-76, Importantly, reduced NF-kappa B activation was observed when capacitative calcium entry was deficient but also upon pharmacological inhibition of calmodulin and calcineurin. Altogether, these results suggest that induction of NF-kappa B by phosphotyrosyl phosphatase bpV inhibitors necessitates both proximal and distal effecters of T cell activation.	Univ Quebec, Ctr Hosp, Unite Immunoretrovirol Humaine, Ctr Rech Infectiol, St Foy, PQ G1V 4G2, Canada; Univ Laval, Fac Med, Dept Med Biol, Quebec City, PQ G1V 4G2, Canada	Laval University; University of Quebec; Laval University	Tremblay, MJ (corresponding author), Univ Quebec, Ctr Hosp, Unite Immunoretrovirol Humaine, Ctr Rech Infectiol, RC709,Pavillon CHUL,2705 Blvd Laurier, St Foy, PQ G1V 4G2, Canada.		Barbeau, Benoit/A-1174-2010; Ouellet, Michel/ABC-3759-2020; Ouellet, Michel/C-9942-2015	Barbeau, Benoit/0000-0002-4108-8155; Ouellet, Michel/0000-0002-2353-7535; Ouellet, Michel/0000-0002-2353-7535	NIAID NIH HHS [AI-15575] Funding Source: Medline	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AGUILARCORDOVA E, 1994, AIDS RES HUM RETROV, V10, P295, DOI 10.1089/aid.1994.10.295; BAEUERLE PA, 1988, SCIENCE, V242, P540, DOI 10.1126/science.3140380; Barbeau B, 1997, J BIOL CHEM, V272, P12968, DOI 10.1074/jbc.272.20.12968; BARBER EK, 1989, P NATL ACAD SCI USA, V86, P3277, DOI 10.1073/pnas.86.9.3277; BEG AA, 1995, NATURE, V376, P167, DOI 10.1038/376167a0; Bevan AP, 1995, MOL CELL BIOCHEM, V153, P49, DOI 10.1007/BF01075918; BRAM RJ, 1993, MOL CELL BIOL, V13, P4760, DOI 10.1128/MCB.13.8.4760; CHAN AC, 1994, SCIENCE, V264, P1599, DOI 10.1126/science.8202713; CHEN ZJ, 1995, GENE DEV, V9, P1586, DOI 10.1101/gad.9.13.1586; Costello PS, 1999, P NATL ACAD SCI USA, V96, P3035, DOI 10.1073/pnas.96.6.3035; COUTURE C, 1994, MOL CELL BIOL, V14, P5249, DOI 10.1128/MCB.14.8.5249; Doi TS, 1997, J EXP MED, V185, P953, DOI 10.1084/jem.185.5.953; Elder ME, 1996, PEDIATR RES, V39, P743, DOI 10.1203/00006450-199605000-00001; ELDER ME, 1994, SCIENCE, V264, P1596, DOI 10.1126/science.8202712; Eriksson JW, 1996, DIABETOLOGIA, V39, P235, DOI 10.1007/BF00403968; FANGER CM, 1995, J CELL BIOL, V131, P655, DOI 10.1083/jcb.131.3.655; Finco TS, 1998, IMMUNITY, V9, P617, DOI 10.1016/S1074-7613(00)80659-7; FOLKS T, 1986, SCIENCE, V231, P600, DOI 10.1126/science.3003906; FRANTZ B, 1994, EMBO J, V13, P861, DOI 10.1002/j.1460-2075.1994.tb06329.x; Fusaki N, 1997, J BIOL CHEM, V272, P6214, DOI 10.1074/jbc.272.10.6214; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; GILLIS S, 1980, J EXP MED, V152, P1709, DOI 10.1084/jem.152.6.1709; Huyer G, 1997, J BIOL CHEM, V272, P843, DOI 10.1074/jbc.272.2.843; Imbert V, 1996, J INFLAMM, V46, P65; IMBERT V, 1994, BIOCHEM J, V297, P163, DOI 10.1042/bj2970163; Imbert V, 1996, CELL, V86, P787, DOI 10.1016/S0092-8674(00)80153-1; JACKMAN JK, 1995, J BIOL CHEM, V270, P7029, DOI 10.1074/jbc.270.13.7029; JAMIESON C, 1991, J IMMUNOL, V147, P416; Kanno T, 1996, J IMMUNOL, V157, P5277; KONTGEN F, 1995, GENE DEV, V9, P1965, DOI 10.1101/gad.9.16.1965; Krebs J, 1998, BIOMETALS, V11, P375, DOI 10.1023/A:1009226316146; Krejsa CM, 1997, J BIOL CHEM, V272, P11541; Law CL, 1999, J EXP MED, V189, P1243, DOI 10.1084/jem.189.8.1243; Liu SK, 1999, CURR BIOL, V9, P67, DOI 10.1016/S0960-9822(99)80017-7; LOWENTHAL JW, 1989, P NATL ACAD SCI USA, V86, P2331, DOI 10.1073/pnas.86.7.2331; Malek S, 1998, J BIOL CHEM, V273, P25427, DOI 10.1074/jbc.273.39.25427; Morinville A, 1998, TRENDS PHARMACOL SCI, V19, P452, DOI 10.1016/S0165-6147(98)01257-7; MORLEY BJ, 1988, J EXP MED, V168, P1971, DOI 10.1084/jem.168.6.1971; Natoli G, 1997, J BIOL CHEM, V272, P26079, DOI 10.1074/jbc.272.42.26079; NEL AE, 1995, J BIOL CHEM, V270, P18428, DOI 10.1074/jbc.270.31.18428; NEUMEISTER EN, 1995, MOL CELL BIOL, V15, P3171; Olivier M, 1998, J BIOL CHEM, V273, P13944, DOI 10.1074/jbc.273.22.13944; OSBORN L, 1989, P NATL ACAD SCI USA, V86, P2336, DOI 10.1073/pnas.86.7.2336; POSNER BI, 1994, J BIOL CHEM, V269, P4596; PUTNEY JW, 1993, CELL, V75, P199, DOI 10.1016/0092-8674(93)80061-I; Raab M, 1997, IMMUNITY, V6, P155, DOI 10.1016/S1074-7613(00)80422-7; Rodriguez MS, 1996, ONCOGENE, V12, P2425; SECRIST JP, 1993, J BIOL CHEM, V268, P5886; SHAW AS, 1990, MOL CELL BIOL, V10, P1853, DOI 10.1128/MCB.10.5.1853; Shibasaki F, 1997, NATURE, V386, P728, DOI 10.1038/386728a0; Snapper CM, 1996, J EXP MED, V184, P1537, DOI 10.1084/jem.184.4.1537; STEFFAN NM, 1995, J IMMUNOL, V155, P4685; STRAUS DB, 1992, CELL, V70, P585, DOI 10.1016/0092-8674(92)90428-F; TRAENCKNER EBM, 1995, EMBO J, V14, P2876, DOI 10.1002/j.1460-2075.1995.tb07287.x; TREMBLAY M, 1994, EMBO J, V13, P774, DOI 10.1002/j.1460-2075.1994.tb06320.x; Tuosto L, 1996, J EXP MED, V184, P1161, DOI 10.1084/jem.184.3.1161; VEILLETTE A, 1989, NATURE, V338, P257, DOI 10.1038/338257a0; VONWILLEBRAND M, 1994, EUR J IMMUNOL, V24, P234, DOI 10.1002/eji.1830240137; WANGE RL, 1993, J BIOL CHEM, V268, P19797; Wardenburg JB, 1996, J BIOL CHEM, V271, P19641, DOI 10.1074/jbc.271.33.19641; WEIH F, 1995, CELL, V80, P331, DOI 10.1016/0092-8674(95)90416-6; WEISS A, 1984, J EXP MED, V160, P1284, DOI 10.1084/jem.160.5.1284; Werlen G, 1998, EMBO J, V17, P3101, DOI 10.1093/emboj/17.11.3101; WIEDERRECHT G, 1993, ANN NY ACAD SCI, V696, P9, DOI 10.1111/j.1749-6632.1993.tb17137.x; Williams BL, 1998, MOL CELL BIOL, V18, P1388, DOI 10.1128/MCB.18.3.1388; Wu J, 1996, IMMUNITY, V4, P593, DOI 10.1016/S1074-7613(00)80485-9; Yablonski D, 1998, SCIENCE, V281, P413, DOI 10.1126/science.281.5375.413; Zhang WG, 1998, CELL, V92, P83, DOI 10.1016/S0092-8674(00)80901-0; Zhao ZZ, 1996, J BIOL CHEM, V271, P22251, DOI 10.1074/jbc.271.36.22251	69	21	22	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 3	1999	274	49					35029	35036		10.1074/jbc.274.49.35029	http://dx.doi.org/10.1074/jbc.274.49.35029			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	260XW	10574981	hybrid			2022-12-25	WOS:000083979600075
J	Yonekura, H; Sakurai, S; Liu, XX; Migita, H; Wang, H; Yamagishi, S; Nomura, M; Abedin, MJ; Unoki, H; Yamamoto, Y; Yamamoto, H				Yonekura, H; Sakurai, S; Liu, XX; Migita, H; Wang, H; Yamagishi, S; Nomura, M; Abedin, MJ; Unoki, H; Yamamoto, Y; Yamamoto, H			Placenta growth factor and vascular endothelial growth factor B and C expression in microvascular endothelial cells and pericytes - Implication in autocrine and paracrine regulation of angiogenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR TYROSINE KINASES; HIGH-AFFINITY BINDING; VEGF-C; GENOMIC ORGANIZATION; TUMOR ANGIOGENESIS; MESSENGER-RNA; IN-VITRO; MOUSE; FLT-1; FLK-1/KDR	We have shown previously that vascular endothelial growth factor (VEGF) synthesized by the cellular constituents of small vessels per se, viz. endothelial cells and pericytes, participates in the hypoxia-driven proliferation of both cell types (Nomura, M,, Yamagishi, S., Harada, S., Hayashi, Y., Yamashima, T., Yamashita, J., Yamamoto, Ii. (1995) J. Biol. Chem. 270, 28316-28324; Yamagishi, S., Yonekura, H., Yamamoto, Y., Fujimori, H., Sakurai, S., Tanaka, N., and Yamamoto, H. (1999) Lab. Invest. 79, 501-509). In this study, Re examined the expression of the recently isolated VEGF gene family members (placenta growth factor (P1GF), VEGF-B, and VEGF-C) in human dermal microvascular endothelial cells and bovine retinal pericytes cultured under various oxygen tensions. Quantitative reverse transcription-polymerase chain reaction analyses demonstrated that the two cell types possess not only VEGF (VEGF-A) mRNA, but also VEGF-B, VEGF-C, and P1GF mRNAs. Among them, only VEGF-A mRNA was induced under hypoxia. Competitive reverse transcription-polymerase chain reaction showed that, under normoxic conditions, the rank order of mRNA content in endothelial cells was P1GF > VEGF-B > VEGF-C > VEGF-A and that mRNA coding for PIGF was expressed at >100-fold higher levels than VEGF-A mRNA, In pericytes, the rank order was VEGF-C > VEGF-A > VEGF-B > PIGF, and similar to 7-fold higher levels of VEGF-C mRNA compared with VEGF-A mRNA were noted in this cell type. Furthermore, antisense inhibition of PIGF protein production lowered the endothelial cell synthesis of DNA under hypoxic conditions. The results suggest that these VEGF family members mag also take active parts in angiogenesis.	Kanazawa Univ, Sch Med, Dept Biochem, Kanazawa, Ishikawa 9208640, Japan	Kanazawa University	Yamamoto, H (corresponding author), Kanazawa Univ, Sch Med, Dept Biochem, 13-1 Takara Machi, Kanazawa, Ishikawa 9208640, Japan.		Unoki-Kubota, Hiroyuki/H-7268-2019	Unoki-Kubota, Hiroyuki/0000-0003-4827-8805				Achen MG, 1997, GROWTH FACTORS, V15, P69, DOI 10.3109/08977199709002113; Achen MG, 1998, P NATL ACAD SCI USA, V95, P548, DOI 10.1073/pnas.95.2.548; Barillari G, 1998, AM J PATHOL, V152, P1161; Cao YH, 1996, J BIOL CHEM, V271, P3154, DOI 10.1074/jbc.271.6.3154; Chilov D, 1997, J BIOL CHEM, V272, P25176, DOI 10.1074/jbc.272.40.25176; Clark DE, 1998, J ENDOCRINOL, V159, P459, DOI 10.1677/joe.0.1590459; Enholm B, 1997, ONCOGENE, V14, P2475, DOI 10.1038/sj.onc.1201090; FOLKMAN J, 1995, NAT MED, V1, P27, DOI 10.1038/nm0195-27; Hewett PW, 1996, BIOCHEM BIOPH RES CO, V221, P697, DOI 10.1006/bbrc.1996.0659; Hiratsuka S, 1998, P NATL ACAD SCI USA, V95, P9349, DOI 10.1073/pnas.95.16.9349; Jeltsch M, 1997, SCIENCE, V276, P1423, DOI 10.1126/science.276.5317.1423; Joukov V, 1996, EMBO J, V15, P290; Korpelainen EI, 1998, CURR OPIN CELL BIOL, V10, P159, DOI 10.1016/S0955-0674(98)80137-3; Lagercrantz J, 1998, BBA-GENE STRUCT EXPR, V1398, P157, DOI 10.1016/S0167-4781(98)00040-2; LEUNG DW, 1989, SCIENCE, V246, P1306, DOI 10.1126/science.2479986; MAGLIONE D, 1991, P NATL ACAD SCI USA, V88, P9267, DOI 10.1073/pnas.88.20.9267; MAGLIONE D, 1993, ONCOGENE, V8, P925; MUSTONEN T, 1995, J CELL BIOL, V129, P895, DOI 10.1083/jcb.129.4.895; Neufeld G, 1999, FASEB J, V13, P9, DOI 10.1096/fasebj.13.1.9; Nicosia RF, 1998, AM J PATHOL, V153, P11, DOI 10.1016/S0002-9440(10)65539-3; NOMURA M, 1995, J BIOL CHEM, V270, P28316; Ogawa S, 1998, J BIOL CHEM, V273, P31273, DOI 10.1074/jbc.273.47.31273; Olofsson B, 1996, J BIOL CHEM, V271, P19310, DOI 10.1074/jbc.271.32.19310; Olofsson B, 1996, P NATL ACAD SCI USA, V93, P2576, DOI 10.1073/pnas.93.6.2576; PARK JE, 1994, J BIOL CHEM, V269, P25646; Risau W, 1997, NATURE, V386, P671, DOI 10.1038/386671a0; Salven P, 1998, AM J PATHOL, V153, P103, DOI 10.1016/S0002-9440(10)65550-2; Sowter HM, 1997, LAB INVEST, V77, P607; WANG AM, 1989, P NATL ACAD SCI USA, V86, P9717, DOI 10.1073/pnas.86.24.9717; Yamagishi S, 1999, LAB INVEST, V79, P501; Yamagishi S, 1997, J BIOL CHEM, V272, P8723, DOI 10.1074/jbc.272.13.8723; Yamagishi S, 1999, MICROVASC RES, V57, P329, DOI 10.1006/mvre.1999.2145; YAMAGISHI S, 1993, BIOCHEM BIOPH RES CO, V190, P418, DOI 10.1006/bbrc.1993.1064; Yonekura H, 1999, NUCLEIC ACIDS RES, V27, P2591, DOI 10.1093/nar/27.13.2591; YONEKURA H, 1988, J BIOL CHEM, V263, P2990	35	155	166	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 3	1999	274	49					35172	35178		10.1074/jbc.274.49.35172	http://dx.doi.org/10.1074/jbc.274.49.35172			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	260XW	10575000	hybrid			2022-12-25	WOS:000083979600094
J	Jimenez-Chillaron, JC; Newgard, CB; Gomez-Foix, AM				Jimenez-Chillaron, JC; Newgard, CB; Gomez-Foix, AM			Increased glucose disposal induced by adenovirus-mediated transfer of glucokinase to skeletal muscle in vivo	FASEB JOURNAL			English	Article						glucose phosphorylating activity; glucokinase expression; GLUT4 expression; non-insulin-dependent diabetes mellitus	GLYCOGEN-SYNTHESIS; TRANSGENIC MICE; INSULIN; EXPRESSION; TRANSPORT; CELLS; RAT; PHOSPHORYLATION; OVEREXPRESSION; INVIVO	In non-insulin-dependent diabetes mellitus, insulin-stimulated glucose uptake is impaired in muscle, contributing in a major way to development of hyperglycemia, We previously showed that expression of the glucose phosphorylating enzyme glucokinase (GK) in cultured human myocytes improved glucose storage and disposal, suggesting that GK delivery to muscle in situ could potentially enhance glucose clearance. Here we have tested this idea directly by intramuscular delivery of an adenovirus containing the liver GK cDNA (AdCMV-GKL) into one hind limb, We injected an adenovirus containing the beta-galactosidase gene (AdCMV-lacZ) into the hind limb of newborn rats. beta-Galactosidase activity was localized in muscle for as long as 1 month after delivery, with a large percentage of fibers staining positive in the gastrocnemius, Using the same approach with AdCMV-GKL, GK protein content was increased from zero to 50-400% of the GK in normal liver sample, and total glucose phosphorylating activity was increased in GK-expressing muscles relative to the counterpart uninfected muscle, Expression of GK in muscle improved glucose tolerance rather than changing basal glycemic control. Glucose levels were reduced by similar to 35% 10 min after administration of a glucose bolus to fed animals treated with AdCMV-GKL relative to AdCMV-lacZ-treated controls. The enhanced rate of glucose clearance was reflected in increases in muscle 2-deoxy glucose uptake and blood lactate levels. We conclude that restricted expression of GK in muscle leads to an enhanced capacity for muscle glucose disposal and whole body glucose tolerance under conditions of maximal glucose-insulin stimulation, suggesting that under these conditions glucose phosphorylation becomes rate-limiting. Our findings also show that gene delivery to a fraction of the whole body is sufficient to improve glucose disposal, providing a rationale for the development of new therapeutic strategies for treatment of diabetes.	Univ Barcelona, Fac Quim, Dept Bioquim & Biol Mol, E-08028 Barcelona, Spain; Univ Texas, SW Med Ctr, Dept Biochem, Dallas, TX 75235 USA; Univ Texas, SW Med Ctr, Dept Internal Med, Dallas, TX 75235 USA; Univ Texas, SW Med Ctr, Gifford Labs Diabet Res, Dallas, TX 75235 USA	University of Barcelona; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Gomez-Foix, AM (corresponding author), Univ Barcelona, Fac Quim, Dept Bioquim & Biol Mol, Marti & Franques 1, E-08028 Barcelona, Spain.		Jimenez-Chillaron, Josep/L-5854-2015					Baque S, 1998, DIABETES, V47, P1185, DOI 10.2337/diabetes.47.8.1185; Baque S, 1998, DIABETES, V47, P1392, DOI 10.2337/diabetes.47.9.1392; BECKER TC, 1994, METHOD CELL BIOL, V43, P161; Becker TC, 1996, J BIOL CHEM, V271, P390, DOI 10.1074/jbc.271.1.390; Chang PY, 1996, J BIOL CHEM, V271, P14834, DOI 10.1074/jbc.271.25.14834; Clark SA, 1997, DIABETES, V46, P958, DOI 10.2337/diabetes.46.6.958; DEFRONZO RA, 1981, DIABETES, V30, P1000, DOI 10.2337/diab.30.12.1000; HERZ J, 1993, P NATL ACAD SCI USA, V90, P2812, DOI 10.1073/pnas.90.7.2812; JAMES DE, 1985, J CLIN INVEST, V76, P657, DOI 10.1172/JCI112019; KUBO K, 1986, AM J PHYSIOL, V250, pE100, DOI 10.1152/ajpendo.1986.250.1.E100; KUWAJIMA M, 1986, J BIOL CHEM, V261, P8849; MacGregor GR, 1991, GENE TRANSFER EXPRES, P217; Perseghin G, 1996, NEW ENGL J MED, V335, P1357, DOI 10.1056/NEJM199610313351804; QUANTIN B, 1992, P NATL ACAD SCI USA, V89, P2581, DOI 10.1073/pnas.89.7.2581; REN JM, 1993, J BIOL CHEM, V268, P16113; SOMOGYI M, 1945, J BIOL CHEM, V160, P69; SPENCE JT, 1983, J BIOL CHEM, V258, P9143; STRATFORDPERRICAUDET LD, 1992, J CLIN INVEST, V90, P626, DOI 10.1172/JCI115902; YANG YP, 1994, P NATL ACAD SCI USA, V91, P4407, DOI 10.1073/pnas.91.10.4407; YKIJARVINEN H, 1987, J CLIN INVEST, V79, P1713, DOI 10.1172/JCI113011	20	16	18	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	DEC	1999	13	15					2153	2160		10.1096/fasebj.13.15.2153	http://dx.doi.org/10.1096/fasebj.13.15.2153			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	266QN	10593862	Bronze			2022-12-25	WOS:000084310800006
J	El-Naggar, AK; Lai, SL; Tucker, SA; Clayman, GL; Goepfert, H; Hong, WK; Huff, V				El-Naggar, AK; Lai, SL; Tucker, SA; Clayman, GL; Goepfert, H; Hong, WK; Huff, V			Frequent loss of imprinting at the IGF2 and H19 genes in head and neck squamous carcinoma	ONCOGENE			English	Article						imprinting; loss of imprinting; head and neck squamous carcinoma; epigenetic alterations; insulin growth factor-2 and H19 genes	GROWTH-FACTOR-II; BECKWITH-WIEDEMANN SYNDROME; WILMS-TUMOR; CELL-CARCINOMA; REDUCED EXPRESSION; INVASIVE HEAD; HUMAN TISSUES; CANCER; INACTIVATION; METHYLATION	Genomic imprinting is an inherited epigenetic phenomenon that results in parental-origin-specific gene expression in somatic cells. Relaxation or loss of this feature in certain genes has been demonstrated in several pediatric and adult neoplasms, suggesting an association with tumorigenesis. We analysed 64 primary untreated head and neck squamous carcinoma for the loss of imprinting in the IGF2 and H19 genes to determine the implications of this alteration in the development and progression of these tumors. Forty-nine (77%) of the 64 tumors were informative for imprinting analyses of these genes. IGF2 and H19 were imprinted in all normal squamous epithelium examined. Twelve (37.5%) of 32 tumors informative for H19 and 11 (40.7%) of 27 tumors informative for IGF2 manifested loss of imprinting. Ten tumors were informative for both genes, of which four maintained the constitutional imprinting and six showed loss of imprinting at either H19 or IGF2. These data suggest that loss of imprinting at the IGF2 and H19 loci play a role in the oncogenesis of head and neck carcinoma.	Univ Texas, MD Anderson Canc Ctr, Dept Pathol, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Biomath, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Head & Neck Surg, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Thorac Head & Neck, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Expt Pediat, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	El-Naggar, AK (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Pathol, Box 85,1515 Holcombe Blvd, Houston, TX 77030 USA.				NIDCR NIH HHS [1P50DE11906-01] Funding Source: Medline; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [P50DE011906] Funding Source: NIH RePORTER	NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		AHSEE KW, 1994, CANCER RES, V54, P1617; *AM CANC SOC INC, 1997, CANC FACTS FIG; Barlow DP, 1997, EMBO J, V16, P6899, DOI 10.1093/emboj/16.23.6899; BARTOLOMEI MS, 1994, NAT GENET, V6, P220, DOI 10.1038/ng0394-220; Baylin SB, 1997, SCIENCE, V277, P1948, DOI 10.1126/science.277.5334.1948; CATTANACH BM, 1990, DEVELOPMENT, P63; CHAO LY, 1993, NAT GENET, V3, P127, DOI 10.1038/ng0293-127; CHRISTOFORI G, 1995, NAT GENET, V10, P196, DOI 10.1038/ng0695-196; CHRISTOFORI G, 1994, NATURE, V369, P414, DOI 10.1038/369414a0; Chung WY, 1996, HUM MOL GENET, V5, P1101, DOI 10.1093/hmg/5.8.1101; CROUSE H, 1996, GENETICS, V45, P1425; Cui HM, 1998, NAT MED, V4, P1276, DOI 10.1038/3260; Cui HM, 1997, CANCER RES, V57, P4469; Dao D, 1999, HUM MOL GENET, V8, P1337, DOI 10.1093/hmg/8.7.1337; DAO DD, 1987, AM J HUM GENET, V41, P202; DAVIES SM, 1993, CANCER RES, V53, P4781; DECHIARA TM, 1991, CELL, V64, P849, DOI 10.1016/0092-8674(91)90513-X; ElNaggar AK, 1996, CLIN CANCER RES, V2, P903; ELNAGGAR AK, 1995, CANCER RES, V55, P2656; ELNAGGAR AK, 1995, INT J CANCER, V64, P196, DOI 10.1002/ijc.2910640309; ElNaggar AK, 1997, AM J PATHOL, V151, P1767; EZZELL C, 1994, J NIH RES, V6, P53; FEINBERG AP, 1993, NAT GENET, V4, P110, DOI 10.1038/ng0693-110; Fukuzawa R, 1999, INT J CANCER, V82, P490, DOI 10.1002/(SICI)1097-0215(19990812)82:4<490::AID-IJC4>3.0.CO;2-I; Greally JM, 1998, HUM MOL GENET, V7, P91, DOI 10.1093/hmg/7.1.91; HAO Y, 1993, NATURE, V365, P764, DOI 10.1038/365764a0; HERMAN JG, 1995, CANCER RES, V55, P4525; Hibi K, 1996, CANCER RES, V56, P480; JINNO Y, 1994, NAT GENET, V6, P305, DOI 10.1038/ng0394-305; Kim HT, 1998, AM J MED GENET, V80, P391, DOI 10.1002/(SICI)1096-8628(19981204)80:4<391::AID-AJMG16>3.0.CO;2-H; KONDO M, 1995, ONCOGENE, V10, P1193; Lee MP, 1999, HUM MOL GENET, V8, P683, DOI 10.1093/hmg/8.4.683; Li XR, 1997, CANCER RES, V57, P2048; Mannens M., 1994, European Journal of Human Genetics, V2, P3; McCann AH, 1996, HUM MOL GENET, V5, P1123, DOI 10.1093/hmg/5.8.1123; Mitsuya K, 1997, HUM MOL GENET, V6, P2243, DOI 10.1093/hmg/6.13.2243; MONTAGNA M, 1994, J CANCER RES CLIN, V120, P732, DOI 10.1007/BF01194272; MORRISON IM, 1996, NAT MED, V2, P331; NEUMANN B, 1995, NAT GENET, V9, P12, DOI 10.1038/ng0195-12; Nonomura N, 1997, CANCER RES, V57, P2575; Oda H, 1998, INT J CANCER, V75, P343, DOI 10.1002/(SICI)1097-0215(19980130)75:3<343::AID-IJC3>3.0.CO;2-2; Ouyang H, 1997, CANCER RES, V57, P1851; Papadimitrakopoulou VA, 1998, CLIN CANCER RES, V4, P539; PARKIN DM, 1988, INT J CANCER, V41, P184, DOI 10.1002/ijc.2910410205; Pershouse MA, 1997, ONCOGENE, V14, P369, DOI 10.1038/sj.onc.1200836; PETERSON K, 1993, ANNU REV GENET, V27, P7, DOI 10.1146/annurev.ge.27.120193.000255; Rachmilewitz J, 1996, ONCOGENE, V13, P1687; RAINIER S, 1993, NATURE, V362, P747, DOI 10.1038/362747a0; Randhawa GS, 1998, BLOOD, V91, P3144, DOI 10.1182/blood.V91.9.3144.3144_3144_3147; Reed AL, 1996, CANCER RES, V56, P3630; REEVE AE, 1989, MOL CELL BIOL, V9, P1799, DOI 10.1128/MCB.9.4.1799; REIK W, 1994, HUM MOL GENET, V3, P1297, DOI 10.1093/hmg/3.8.1297; REIK W, 1995, HUM MOL GENET, V4, P2379, DOI 10.1093/hmg/4.12.2379; Ross JA, 1999, CANCER, V85, P1389, DOI 10.1002/(SICI)1097-0142(19990315)85:6<1389::AID-CNCR24>3.3.CO;2-M; Sabbioni S, 1997, CANCER RES, V57, P4493; STEENMAN MJC, 1994, NAT GENET, V7, P433, DOI 10.1038/ng0794-433; SUZUKI H, 1994, NAT GENET, V6, P332, DOI 10.1038/ng0494-332; SWAIN JL, 1987, CELL, V50, P719, DOI 10.1016/0092-8674(87)90330-8; TEMPLE IK, 1995, NAT GENET, V9, P109; Thompson JS, 1996, CANCER RES, V56, P5723; Uyeno S, 1996, CANCER RES, V56, P5356; van Roozendaal CEP, 1998, FEBS LETT, V437, P107, DOI 10.1016/S0014-5793(98)01211-3; Verkerk AJMH, 1997, ONCOGENE, V14, P95, DOI 10.1038/sj.onc.1200802; Vrana PB, 1998, NAT GENET, V20, P362, DOI 10.1038/3833; WADA M, 1995, CANCER RES, V55, P3386; Wu MS, 1997, CANCER LETT, V120, P9, DOI 10.1016/S0304-3835(97)00279-6; Zhan SL, 1995, ONCOGENE, V11, P2503	67	43	43	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 25	1999	18	50					7063	7069		10.1038/sj.onc.1203192	http://dx.doi.org/10.1038/sj.onc.1203192			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	259PH	10597307				2022-12-25	WOS:000083901900013
J	Liu, XF; Baker, E; Eyre, HJ; Sutherland, GR; Zhou, MD				Liu, XF; Baker, E; Eyre, HJ; Sutherland, GR; Zhou, MD			gamma-Heregulin: a fusion gene of DOC-4 and neuregulin-1 derived from a chromosome translocation	ONCOGENE			English	Article						gamma-heregulin; neuregulin-1; DOC-4; gene localization; MDA-MB-175 cell line	NEU DIFFERENTIATION FACTOR; CARDIAC DEVELOPMENT; IDENTIFICATION; RECEPTOR; LIGANDS; DOMAIN; ERBB2	gamma-Heregulin was identified as an isoform resulting from alternate splicing of the neuregulin-1 gene, after cloning of its cDNA from the MDA-MB-175 breast cancer cell line, gamma-Heregulin was shown to promote growth of cultured MDA-MB-175 cells resulting from activation of its cognate ErbB tyrosine kinase reporters. We show here that gamma-heregulin is transcribed from a fusion gene resulting from a chromosome translocation in MDA-MB-175 cells. The fusion chromosome is described as dic(8:11)(8qter-->8p12::11q13-->11pter). As a result, the 5' end of the gamma-heregulin gene is derived from the stress-induced gene, DOC-4 (11q13), while the 3' end is from the neuregulin-1 gene (8p12). Thus, expression of gamma-heregulin is under the control of the DOC-4 promoter, By contrast with MDA-MB-175 cells, RT-PCR failed to detect a gamma-heregulin transcript in either E9.5 to E13.5 embryonic mouse tissues, adult mouse tissues or other human tumour cell lines. We conclude, therefore, that gamma-heregulin is not a native isoform of the neuregulin-1 gene, but a novel growth factor that may contribute to tumour cell proliferation.	Victor Chang Cardiac Res Inst, Darlinghurst, NSW 2010, Australia; Univ New S Wales, Sch Biochem & Mol Genet, Sydney, NSW 2052, Australia; Womens & Childrens Hosp, Ctr Med Genet, Dept Cytogenet & Mol Genet, Adelaide, SA 5006, Australia	Victor Chang Cardiac Research Institute; University of New South Wales Sydney; Womens & Childrens Hospital Australia	Zhou, MD (corresponding author), Victor Chang Cardiac Res Inst, 384 Victoria St, Darlinghurst, NSW 2010, Australia.		Sutherland, Grant Robert/D-2606-2012					CALLEN DF, 1990, ANN GENET-PARIS, V33, P219; Chausovsky A, 1998, MOL BIOL CELL, V9, P3195, DOI 10.1091/mbc.9.11.3195; GASSMANN M, 1995, NATURE, V378, P390, DOI 10.1038/378390a0; Grimm S, 1997, J EXP MED, V185, P1137, DOI 10.1084/jem.185.6.1137; HO WH, 1995, J BIOL CHEM, V270, P14523, DOI 10.1074/jbc.270.24.14523; HOLMES WE, 1992, SCIENCE, V256, P1205, DOI 10.1126/science.256.5060.1205; LEE KF, 1995, NATURE, V378, P394, DOI 10.1038/378394a0; Liu XF, 1998, J BIOL CHEM, V273, P34335, DOI 10.1074/jbc.273.51.34335; Liu XF, 1998, P NATL ACAD SCI USA, V95, P13024, DOI 10.1073/pnas.95.22.13024; MARCHIONNI MA, 1993, NATURE, V362, P312, DOI 10.1038/362312a0; MEYER D, 1995, NATURE, V378, P386, DOI 10.1038/378386a0; PELES E, 1993, BIOESSAYS, V15, P815, DOI 10.1002/bies.950151207; PELLESTOR F, 1994, HUM GENET, V94, P346; Schaefer G, 1997, ONCOGENE, V15, P1385, DOI 10.1038/sj.onc.1201317; Wang XZ, 1998, EMBO J, V17, P3619, DOI 10.1093/emboj/17.13.3619; WEN DZ, 1994, MOL CELL BIOL, V14, P1909, DOI 10.1128/MCB.14.3.1909; WEN DZ, 1992, CELL, V69, P559, DOI 10.1016/0092-8674(92)90456-M	17	28	30	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 25	1999	18	50					7110	7114		10.1038/sj.onc.1203136	http://dx.doi.org/10.1038/sj.onc.1203136			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	259PH	10597312				2022-12-25	WOS:000083901900018
J	Vaillant, F; Blyth, K; Terry, A; Bell, M; Cameron, ER; Neil, J; Stewart, M				Vaillant, F; Blyth, K; Terry, A; Bell, M; Cameron, ER; Neil, J; Stewart, M			A full-length Cbfa1 gene product perturbs T-cell development and promotes lymphomagenesis in synergy with MYC	ONCOGENE			English	Article						Cbfa1; myc; T-cell lymphoma; apoptosis	ACUTE MYELOID-LEUKEMIA; TRANSCRIPTION FACTOR OSF2/CBFA1; CD2-MYC TRANSGENIC MICE; OSTEOBLAST DIFFERENTIATION; CLEIDOCRANIAL DYSPLASIA; RUNT DOMAIN; TGF-BETA; DEFINITIVE HEMATOPOIESIS; NERVOUS-SYSTEM; DNA-BINDING	The C6fa1/PEBP2 alpha A/AML3 gene plays an essential role in osteogenesis but is also expressed in the T-cell lineage where it has been implicated in lymphoma development as a target for retroviral insertional mutagenesis. As lymphoma cells with til-1 insertion express at least five distinct Cbfa1 isoforms, it is important to establish which, if any, have intrinsic oncogenic potential. We have generated transgenic mice in which the most abundant lymphoma isoform (G1/p57) is expressed under the control of the CD2 locus control region. Co-precipitation analysis of transgenic thymus revealed high levels of Cbfa1 protein in an abundant complex containing the binding cofactor Cbfb. CD2-Cbfa1-G1 mice displayed abnormal T-cell development, with a pronounced skew towards CD8 SP cells in the thymus and developed a low incidence of spontaneous lymphomas (6% at 12 months) with cells of similar phenotype. Strongly synergistic tumour development was seen when CD2-Cbfa1-G1 mice were crossed with lines carrying myc transgenes (CD2-myc or tamoxifen-regulatable CD2-mycER(TM)) and Cbfa1 was found to rescue expression of the CD2-myc transgene in preleukaemic mice. However, synergy did not appear to be due to a dominant block of myc-induced apoptosis by Cbfa1 as explanted primary tumours and cell lines from CD2-Cbfa1-G1/CD2-mycER(TM) mice showed accelerated death on induction with tamoxifen at similar rates to CD2-mycER(TM) controls. Moreover, thymocytes from preleukaemic CD2-Cbfa1-G1 mice showed reduced survival in vitro and increased sensitivity to the inhibitory effects of TGF-beta. This study demonstrates that a full-length Cbf alpha-chain gene can act as an oncogene without fusion to a heterologous protein.	Univ Glasgow, Sch Vet, Dept Vet Pathol, Mol Oncol Lab, Glasgow G61 1QH, Lanark, Scotland; Univ Glasgow, Sch Vet, Div Vet Clin Studies, Glasgow G61 1QH, Lanark, Scotland	University of Glasgow; University of Glasgow	Stewart, M (corresponding author), Univ Glasgow, Sch Vet, Dept Vet Pathol, Mol Oncol Lab, Bearsden Rd, Glasgow G61 1QH, Lanark, Scotland.			Blyth, Karen/0000-0002-9304-439X				Alexandrow MG, 1997, J CELL BIOCHEM, V66, P427, DOI 10.1002/(SICI)1097-4644(19970915)66:4<427::AID-JCB1>3.3.CO;2-Y; BAE SC, 1993, ONCOGENE, V8, P809; BAE SC, 1995, GENE, V159, P245, DOI 10.1016/0378-1119(95)00060-J; BLYTH K, 1995, ONCOGENE, V10, P1717; Cameron ER, 1996, BRIT J CANCER, V73, P13, DOI 10.1038/bjc.1996.3; Chang DJ, 1998, J BIOL CHEM, V273, P4892, DOI 10.1074/jbc.273.9.4892; Ducy P, 1997, CELL, V89, P747, DOI 10.1016/S0092-8674(00)80257-3; HEDRICK SM, 1984, NATURE, V308, P149, DOI 10.1038/308149a0; Ji CH, 1998, J CELL BIOCHEM, V69, P353, DOI 10.1002/(SICI)1097-4644(19980601)69:3<353::AID-JCB12>3.3.CO;2-W; KANIA MA, 1990, GENE DEV, V4, P1701, DOI 10.1101/gad.4.10.1701; Kim WY, 1999, EMBO J, V18, P1609, DOI 10.1093/emboj/18.6.1609; Kogan SC, 1998, P NATL ACAD SCI USA, V95, P11863, DOI 10.1073/pnas.95.20.11863; Komori T, 1997, CELL, V89, P755, DOI 10.1016/S0092-8674(00)80258-5; Lee B, 1997, NAT GENET, V16, P307, DOI 10.1038/ng0797-307; Letterio JJ, 1998, ANNU REV IMMUNOL, V16, P137, DOI 10.1146/annurev.immunol.16.1.137; LEVANON D, 1994, GENOMICS, V23, P425, DOI 10.1006/geno.1994.1519; LITTLEWOOD TD, 1995, NUCLEIC ACIDS RES, V23, P1686, DOI 10.1093/nar/23.10.1686; LIU P, 1993, SCIENCE, V261, P1041, DOI 10.1126/science.8351518; LU J, 1995, MOL CELL BIOL, V15, P1651; Meyers S, 1996, ONCOGENE, V13, P303; MEYERS S, 1995, MOL CELL BIOL, V15, P1974; Meyers S, 1995, CRIT REV EUKAR GENE, V5, P365, DOI 10.1615/CritRevEukarGeneExpr.v5.i3-4.70; MIYOSHI H, 1991, P NATL ACAD SCI USA, V88, P10431, DOI 10.1073/pnas.88.23.10431; Mundlos S, 1997, CELL, V89, P773, DOI 10.1016/S0092-8674(00)80260-3; NUCIFORA G, 1995, BLOOD, V86, P1; OGAWA E, 1993, P NATL ACAD SCI USA, V90, P6859, DOI 10.1073/pnas.90.14.6859; OGAWA E, 1993, VIROLOGY, V194, P314, DOI 10.1006/viro.1993.1262; Okuda T, 1996, CELL, V84, P321, DOI 10.1016/S0092-8674(00)80986-1; Okuda T, 1998, BLOOD, V91, P3134, DOI 10.1182/blood.V91.9.3134.3134_3134_3143; Otto F, 1997, CELL, V89, P765, DOI 10.1016/S0092-8674(00)80259-7; Rubnitz JE, 1999, LEUKEMIA, V13, P6, DOI 10.1038/sj.leu.2401258; SATAKE M, 1995, MOL CELL BIOL, V15, P1662; STEWART M, 1993, INT J CANCER, V53, P1023; Stewart M, 1997, P NATL ACAD SCI USA, V94, P8646, DOI 10.1073/pnas.94.16.8646; Stewart M, 1996, J GEN VIROL, V77, P443, DOI 10.1099/0022-1317-77-3-443; TAKAHASHI A, 1995, BLOOD, V86, P607, DOI 10.1182/blood.V86.2.607.bloodjournal862607; TANAKA T, 1995, EMBO J, V14, P341, DOI 10.1002/j.1460-2075.1995.tb07008.x; TANAKA T, 1995, MOL CELL BIOL, V15, P2383; Thirunavukkarasu K, 1998, MOL CELL BIOL, V18, P4197, DOI 10.1128/MCB.18.7.4197; Wang Q, 1996, CELL, V87, P697, DOI 10.1016/S0092-8674(00)81389-6; Wang Q, 1996, P NATL ACAD SCI USA, V93, P3444, DOI 10.1073/pnas.93.8.3444; WANG SW, 1993, MOL CELL BIOL, V13, P3324, DOI 10.1128/MCB.13.6.3324; Yergeau DA, 1997, NAT GENET, V15, P303, DOI 10.1038/ng0397-303; Zaiman AL, 1996, J VIROL, V70, P5618, DOI 10.1128/JVI.70.8.5618-5629.1996; ZHUMABEKOV T, 1995, J IMMUNOL METHODS, V185, P133, DOI 10.1016/0022-1759(95)00124-S	45	77	79	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 25	1999	18	50					7124	7134		10.1038/sj.onc.1203202	http://dx.doi.org/10.1038/sj.onc.1203202			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	259PH	10597314				2022-12-25	WOS:000083901900020
J	Hall-Jackson, CA; Cross, DAE; Morrice, N; Smythe, C				Hall-Jackson, CA; Cross, DAE; Morrice, N; Smythe, C			ATR is a caffeine-sensitive, DNA-activated protein kinase with a substrate specificity distinct from DNA-PK	ONCOGENE			English	Article						ATR; checkpoint; protein kinase; DNA damage; caffeine	ATAXIA-TELANGIECTASIA GENE; CELL-CYCLE CHECKPOINTS; SACCHAROMYCES-CEREVISIAE; PHOSPHATIDYLINOSITOL 3-KINASE; IONIZING-RADIATION; SCHIZOSACCHAROMYCES-POMBE; INDUCED PHOSPHORYLATION; SIGNALING PATHWAY; MAMMALIAN-CELLS; FISSION YEAST	ATR is a large, >300 kDa protein containing a carboxy-terminus kinase domain related to PI-3 kinase, and is homologous to the ATM gene product in human cells and the rad3/MEC1 proteins in yeast. These proteins, together with the DNA-PK, are part of a new family of PI-3 kinase related proteins. All members of this family play important roles in checkpoints which operate to permit cell survival following many forms of DNA damage. We have expressed ATR protein in HEK293 cells and purified the protein to near-homogeneity. We show that pure ATR is a protein kinase which is activated by circular single-stranded, double-stranded or linear DNA. Thus ATR is a new member of a sub-family of PIK related kinases, founded by the DNA-PK, which are activated in the presence of DNA, Unlike DNA-PK, ATR does not appear to require Ku proteins for its activation by DNA, We show directly that, like ATM and DIVA-PK, ATR phosphorylates the genome surveillance protein p53 on serine 15, a site which is up-regulated in response to DNA damage. In addition, we find that ATR has a substrate specificity similar to, but unique from, the DNA-PK in vitro, suggesting that these proteins have overlapping but distinct functions in vivo. Finally, we find that the kinase activity of ATR in the presence and absence of DNA is suppressed by caffeine, a compound which is known to induce loss of checkpoint control. Our results are consistent with the notion that ATR plays a role in monitoring DIVA structure and phosphorylation of proteins involved in the DNA damage response pathways.	Univ Dundee, Dept Biochem, Prot Phosphorylat Unit, MCR, Dundee DD1 5EH, Scotland	University of Dundee	Smythe, C (corresponding author), Univ Dundee, Dept Biochem, Prot Phosphorylat Unit, MCR, MSI WTB Complex,Dow St, Dundee DD1 5EH, Scotland.							ALKHODAIRY F, 1994, MOL BIOL CELL, V5, P147, DOI 10.1091/mbc.5.2.147; Banin S, 1998, SCIENCE, V281, P1674, DOI 10.1126/science.281.5383.1674; Bentley NJ, 1996, EMBO J, V15, P6641, DOI 10.1002/j.1460-2075.1996.tb01054.x; Brown EJ, 1996, CELL, V86, P517, DOI 10.1016/S0092-8674(00)80125-7; Brunn GJ, 1996, EMBO J, V15, P5256, DOI 10.1002/j.1460-2075.1996.tb00911.x; Canman CE, 1998, SCIENCE, V281, P1677, DOI 10.1126/science.281.5383.1677; CARPENTER CL, 1993, MOL CELL BIOL, V13, P1657, DOI 10.1128/MCB.13.3.1657; CHEATHAM B, 1994, MOL CELL BIOL, V14, P4902, DOI 10.1128/MCB.14.7.4902; Cimprich KA, 1996, P NATL ACAD SCI USA, V93, P2850, DOI 10.1073/pnas.93.7.2850; Cliby WA, 1998, EMBO J, V17, P159, DOI 10.1093/emboj/17.1.159; CROMPTON NEA, 1993, RADIAT RES, V135, P372, DOI 10.2307/3578877; Cross DAE, 1998, EXP CELL RES, V241, P12, DOI 10.1006/excr.1998.4023; DHAND R, 1994, EMBO J, V13, P522, DOI 10.1002/j.1460-2075.1994.tb06290.x; DOWNES CS, 1994, NATURE, V372, P467, DOI 10.1038/372467a0; Furnari B, 1997, SCIENCE, V277, P1495, DOI 10.1126/science.277.5331.1495; Gately DP, 1998, MOL BIOL CELL, V9, P2361, DOI 10.1091/mbc.9.9.2361; GREENWELL PW, 1995, CELL, V82, P823, DOI 10.1016/0092-8674(95)90479-4; Hall MN, 1996, BIOCHEM SOC T, V24, P234, DOI 10.1042/bst0240234; Hammarsten O, 1998, P NATL ACAD SCI USA, V95, P525, DOI 10.1073/pnas.95.2.525; HARI KL, 1995, CELL, V82, P815, DOI 10.1016/0092-8674(95)90478-6; HARTLEY KO, 1995, CELL, V82, P849, DOI 10.1016/0092-8674(95)90482-4; HARTWELL LH, 1994, SCIENCE, V266, P1821, DOI 10.1126/science.7997877; Hoekstra MF, 1997, CURR OPIN GENET DEV, V7, P170, DOI 10.1016/S0959-437X(97)80125-6; HUNTER T, 1995, CELL, V83, P1, DOI 10.1016/0092-8674(95)90225-2; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; JACKSON SP, 1995, TRENDS BIOCHEM SCI, V20, P412, DOI 10.1016/S0968-0004(00)89090-8; Keegan KS, 1996, GENE DEV, V10, P2423, DOI 10.1101/gad.10.19.2423; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; LEESMILLER SP, 1992, MOL CELL BIOL, V12, P5041, DOI 10.1128/MCB.12.11.5041; LIU VF, 1993, MOL CELL BIOL, V13, P7222, DOI 10.1128/MCB.13.12.7222; Lopez-Girona A, 1999, NATURE, V397, P172, DOI 10.1038/16488; Martinho RG, 1998, EMBO J, V17, P7239, DOI 10.1093/emboj/17.24.7239; Morgan SE, 1997, CANCER RES, V57, P3386; MORROW DM, 1995, CELL, V82, P831, DOI 10.1016/0092-8674(95)90480-8; NISHIMOTO T, 1978, CELL, V15, P475, DOI 10.1016/0092-8674(78)90017-X; Osman F, 1998, MOL GEN GENET, V260, P319, DOI 10.1007/s004380050901; OSMANI SA, 1988, CELL, V52, P241, DOI 10.1016/0092-8674(88)90513-2; Peng CY, 1997, SCIENCE, V277, P1501, DOI 10.1126/science.277.5331.1501; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; Sanchez Y, 1997, SCIENCE, V277, P1497, DOI 10.1126/science.277.5331.1497; Sarkaria JN, 1998, CANCER RES, V58, P4375; SAVITSKY K, 1995, HUM MOL GENET, V4, P2025, DOI 10.1093/hmg/4.11.2025; SCHLEGEL R, 1986, SCIENCE, V232, P1264, DOI 10.1126/science.2422760; SCHU PV, 1993, SCIENCE, V260, P88, DOI 10.1126/science.8385367; Shieh SY, 1997, CELL, V91, P325, DOI 10.1016/S0092-8674(00)80416-X; SMYTHE C, 1992, CELL, V68, P787, DOI 10.1016/0092-8674(92)90153-4; STACK JH, 1994, J BIOL CHEM, V269, P31552; STOKOE D, 1992, EMBO J, V11, P3985, DOI 10.1002/j.1460-2075.1992.tb05492.x; Tibbetts RS, 1999, GENE DEV, V13, P152, DOI 10.1101/gad.13.2.152; Tishkoff DX, 1997, CELL, V88, P253, DOI 10.1016/S0092-8674(00)81846-2; WEINERT TA, 1988, SCIENCE, V241, P317, DOI 10.1126/science.3291120; Woo RA, 1998, NATURE, V394, P700, DOI 10.1038/29343; Wright JA, 1998, P NATL ACAD SCI USA, V95, P7445, DOI 10.1073/pnas.95.13.7445; Zeng Y, 1998, NATURE, V395, P507, DOI 10.1038/26766	54	201	241	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 18	1999	18	48					6707	6713		10.1038/sj.onc.1203077	http://dx.doi.org/10.1038/sj.onc.1203077			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	257QA	10597277				2022-12-25	WOS:000083792000011
J	Sherman, L; Sleeman, JP; Hennigan, RF; Herrlich, P; Ratner, N				Sherman, L; Sleeman, JP; Hennigan, RF; Herrlich, P; Ratner, N			Overexpression of activated neu/erbB2 initiates immortalization and malignant transformation of immature Schwann cells in vitro	ONCOGENE			English	Article						Schwann cells; neu; erbB2; transformation; immortalization	EPIDERMAL GROWTH-FACTOR; NEU DIFFERENTIATION FACTOR; TYROSINE KINASE-ACTIVITY; HUMAN BREAST-CANCER; NERVOUS-SYSTEM; WALLERIAN DEGENERATION; INCREASED EXPRESSION; SIGNAL-TRANSDUCTION; PERIPHERAL-NERVE; MULTISTEP NATURE	The neu/erbB2 protooncogene is overexpressed in numerous human cancers and is mutationally activated in N-ethyl-N-nitrosourea (ENU)-induced rodent tumors of the Schwann cell lineage. We investigated whether expression of activated neu in Schwann cells is sufficient to initiate their immortalization and transformation. Clones of embryonic dorsal root ganglia cells infected with a retrovirus bearing activated neu (NID cells) were selected based on their expression of Schwann cell-specific markers. Compared to embryonic Schwann cells infected,vith a virus encoding empty vector, we found that NID cells have altered shapes and disorganized cytoskeletons, grow in the absence of growth factors required for normal Schwann cell survival and proliferation, and can be repeatedly passaged. Furthermore, NID cells are invasive in an in vitro matrix invasion assay and form metastatic tumors when injected into syngeneic animals. The neu-induced growth and invasive phenotypes could be reversed by drugs that inhibit Ras and Src activity. Interestingly, later stage Schwann cells infected with activated neu failed to become immortalized. These findings indicate that constitutive activation of erbB2 is sufficient to initiate the immortalization and transformation of immature Schwann cells, and support the notion that Schwann cells have particular developmental stages during which they are susceptible to immortalizing and transforming events.	Univ Cincinnati, Coll Med, Dept Cell Biol Neurobiol & Anat, Cincinnati, OH 45267 USA; Forschungszentrum Karlsruhe, Inst Genet, D-76021 Karlsruhe, Germany	University System of Ohio; University of Cincinnati; Helmholtz Association; Karlsruhe Institute of Technology	Sherman, L (corresponding author), Univ Cincinnati, Coll Med, Dept Cell Biol Neurobiol & Anat, 231 Bethesda Ave, Cincinnati, OH 45267 USA.		Sleeman, Jonathan P/H-2515-2013	Sleeman, Jonathan P/0000-0003-1718-7687; RATNER, NANCY/0000-0001-5030-9354	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS028840] Funding Source: NIH RePORTER; NINDS NIH HHS [NS10297, NS28840] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BARGMANN CI, 1988, EMBO J, V7, P2043, DOI 10.1002/j.1460-2075.1988.tb03044.x; BISHOP JM, 1987, SCIENCE, V235, P305, DOI 10.1126/science.3541204; BRADBURY JM, 1993, ONCOGENE, V8, P1551; Carroll SL, 1997, J NEUROSCI, V17, P1642; COHEN JA, 1992, J NEUROSCI RES, V31, P622, DOI 10.1002/jnr.490310406; DIFIORE PP, 1987, SCIENCE, V237, P178, DOI 10.1126/science.2885917; DIMARCO E, 1990, MOL CELL BIOL, V10, P3247, DOI 10.1128/MCB.10.6.3247; DONG Z, 1995, NEURON, V15, P585, DOI 10.1016/0896-6273(95)90147-7; DOUGALL WC, 1994, ONCOGENE, V9, P2109; DRUCKREY H, 1973, Z KREBSFORSCH KLIN O, V79, P282, DOI 10.1007/BF00304022; FUKAZAWA H, 1991, BIOCHEM PHARMACOL, V42, P1661; GOLDMAN R, 1990, BIOCHEMISTRY-US, V29, P11024, DOI 10.1021/bi00502a002; GrausPorta D, 1997, EMBO J, V16, P1647, DOI 10.1093/emboj/16.7.1647; Grinspan JB, 1996, J NEUROSCI, V16, P6107; HENNIGAN RF, 1994, ONCOGENE, V9, P3591; HUDZIAK RM, 1987, P NATL ACAD SCI USA, V84, P7159, DOI 10.1073/pnas.84.20.7159; HYNES NE, 1994, BBA-REV CANCER, V1198, P165, DOI 10.1016/0304-419X(94)90012-4; JAMES GL, 1993, SCIENCE, V260, P1937, DOI 10.1126/science.8316834; JANES PW, 1994, ONCOGENE, V9, P3601; JENUWEIN T, 1985, CELL, V41, P629, DOI 10.1016/S0092-8674(85)80035-0; JIN JJ, 1993, CELL GROWTH DIFFER, V4, P227; Kim HA, 1997, J NEUROSCI RES, V49, P236; Kim HA, 1997, MOL CELL BIOL, V17, P862, DOI 10.1128/MCB.17.2.862; KLEITMAN N, 1991, CULTURING NERVE CELL, P251; Lamb RF, 1997, MOL CELL BIOL, V17, P963, DOI 10.1128/MCB.17.2.963; LEVI ADO, 1995, J NEUROSCI, V15, P1329; LUTTRELL DK, 1994, P NATL ACAD SCI USA, V91, P83, DOI 10.1073/pnas.91.1.83; MARCHIONNI MA, 1993, NATURE, V362, P312, DOI 10.1038/362312a0; MCCORMICK JJ, 1988, MUTAT RES, V199, P273; MORRISSEY TK, 1995, P NATL ACAD SCI USA, V92, P1431, DOI 10.1073/pnas.92.5.1431; MUTHUSWAMY SK, 1994, MOL CELL BIOL, V14, P735, DOI 10.1128/MCB.14.1.735; MUTHUSWAMY SK, 1995, ONCOGENE, V11, P271; Namba M, 1996, CRIT REV ONCOGENESIS, V7, P19, DOI 10.1615/CritRevOncog.v7.i1-2.20; NEWBOLD RF, 1993, TOXICOL LETT, V67, P211, DOI 10.1016/0378-4274(93)90057-5; NIKITIN AY, 1991, P NATL ACAD SCI USA, V88, P9939, DOI 10.1073/pnas.88.22.9939; Nikitin AY, 1996, ONCOGENE, V12, P1309; Pelton PD, 1998, ONCOGENE, V17, P2195, DOI 10.1038/sj.onc.1202141; PENG WW, 1982, SCIENCE, V215, P1102, DOI 10.1126/science.7063842; PERANTONI AO, 1987, P NATL ACAD SCI USA, V84, P6317, DOI 10.1073/pnas.84.17.6317; PinkasKramarski R, 1996, EMBO J, V15, P2452, DOI 10.1002/j.1460-2075.1996.tb00603.x; PRENDERGAST GC, 1994, MOL CELL BIOL, V14, P4193, DOI 10.1128/MCB.14.6.4193; RAJEWSKY MF, 1983, RECENT RES CANCER, V84, P63; RHIM JS, 1990, CANCER RES, V50, pS5653; SALZER JL, 1980, J CELL BIOL, V84, P739, DOI 10.1083/jcb.84.3.739; SCHUBERT D, 1974, NATURE, V249, P224, DOI 10.1038/249224a0; Sherman L, 1997, ONCOGENE, V15, P2505, DOI 10.1038/sj.onc.1201418; Sobko A, 1998, EMBO J, V17, P4723, DOI 10.1093/emboj/17.16.4723; Stancovski I, 1994, Cancer Treat Res, V71, P161; TOMOZAWA Y, 1978, P NATL ACAD SCI USA, V75, P6305, DOI 10.1073/pnas.75.12.6305; Tzahar E, 1996, MOL CELL BIOL, V16, P5276; Tzahar E, 1998, BBA-REV CANCER, V1377, pM25, DOI 10.1016/S0304-419X(97)00032-2; UEHARA Y, 1989, BIOCHEM BIOPH RES CO, V163, P803, DOI 10.1016/0006-291X(89)92293-6; Vartanian T, 1997, J CELL BIOL, V137, P211, DOI 10.1083/jcb.137.1.211; VOGELSTEIN B, 1993, TRENDS GENET, V9, P138, DOI 10.1016/0168-9525(93)90209-Z; WADA T, 1990, CELL, V61, P1339, DOI 10.1016/0092-8674(90)90697-D; WEINBERG RA, 1989, CANCER RES, V49, P3713; WEINER DB, 1989, NATURE, V339, P230, DOI 10.1038/339230a0	57	12	13	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 18	1999	18	48					6692	6699		10.1038/sj.onc.1203055	http://dx.doi.org/10.1038/sj.onc.1203055			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	257QA	10597275				2022-12-25	WOS:000083792000009
J	Brockhaus, F; Brune, B				Brockhaus, F; Brune, B			p53 accumulation in apoptotic macrophages is an energy demanding process that precedes cytochrome c release in response to nitric oxide	ONCOGENE			English	Article						apoptosis; nitric oxide; macrophages; p53; cytochrome c; Bcl-2	BCL-X-L; CELL-DEATH; P53-DEPENDENT APOPTOSIS; MITOCHONDRIAL CONTROL; PROTEASE ACTIVATION; CASPASE ACTIVATION; SIGNALING PATHWAYS; FAMILY; INHIBITION; COMPLEX	Apoptosis in response to stress signals activates effector caspases known to be regulated by the release of cytochrome c (Cyt c) from mitochondria and the subsequent ATP-dependent activation of the death regulator apoptotic protease-activating factor I (Apaf-1). Experiments were carried out to determine whether the release of Cyt c is evoked by NO. in RAW 264.7 macrophages and to position signaling components relative to mitochondria. S-nitrosoglutathione and spermine-NO caused a fast p53 accumulation, followed by Bcl-x(L) downregulation, Cyt c release, and caspase activation. These alterations mere absent in p53 antisense expressing macrophages (R Delta p53asn-11). In Bcl-2 overexpressing cells (Rbc12-14) Cyt c relocation and caspase activation were abrogated although p53 accumulation remained intact. The use of caspase inhibitors revealed Cyt c release and decreased Bcl-x(L) expression to be caspase independent. ATP-depIeted cells showed a shift from apoptosis towards necrosis and no p53 accumulation or caspase activation upon NO. addition. Conclusively, NO.-mediated apoptosis in macrophages is entirely controlled by the mitochondrial pathway with the implication that Cyt c relocation demands p53 accumulation. Moreover, pulse-chase-experiments in combination with the ATP-depletion protocol identified p53 accumulation and stabilization as an energy requiring process. This allowed to dissect two ATP-dependent steps, one is in association with Apaf-1 formation, while the other resides in p53 accumulation.	Univ Erlangen Nurnberg, Fac Med, Dept Med 4, Div Expt, D-91054 Erlangen, Germany	University of Erlangen Nuremberg	Brune, B (corresponding author), Univ Erlangen Nurnberg, Fac Med, Dept Med 4, Div Expt, Loschgestr 8, D-91054 Erlangen, Germany.							Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; Albina JE, 1996, J IMMUNOL, V157, P279; Bossy-Wetzel E, 1998, EMBO J, V17, P37, DOI 10.1093/emboj/17.1.37; Brockhaus F, 1999, BIOCHEM J, V338, P295, DOI 10.1042/0264-6021:3380295; Brune B, 1998, EUR J PHARMACOL, V351, P261, DOI 10.1016/S0014-2999(98)00274-X; CAELLES C, 1994, NATURE, V370, P220, DOI 10.1038/370220a0; Castedo M, 1996, J IMMUNOL, V157, P512; Chao DT, 1998, ANNU REV IMMUNOL, V16, P395, DOI 10.1146/annurev.immunol.16.1.395; Chauhan D, 1997, J BIOL CHEM, V272, P29995, DOI 10.1074/jbc.272.48.29995; Chlichlia K, 1998, BLOOD, V91, P4311, DOI 10.1182/blood.V91.11.4311.411k07_4311_4320; Cohen GM, 1997, BIOCHEM J, V326, P1, DOI 10.1042/bj3260001; Eguchi Y, 1997, CANCER RES, V57, P1835; Ferrari D, 1998, J EXP MED, V188, P979, DOI 10.1084/jem.188.5.979; Green DR, 1998, CELL, V94, P695, DOI 10.1016/S0092-8674(00)81728-6; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; HART TW, 1985, TETRAHEDRON LETT, V26, P2013, DOI 10.1016/S0040-4039(00)98368-0; Hu YM, 1998, P NATL ACAD SCI USA, V95, P4386, DOI 10.1073/pnas.95.8.4386; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; Kroemer G, 1997, IMMUNOL TODAY, V18, P44, DOI 10.1016/S0167-5699(97)80014-X; Lee JM, 1998, ONCOGENE, V17, P1653, DOI 10.1038/sj.onc.1202102; Leist M, 1997, J EXP MED, V185, P1481, DOI 10.1084/jem.185.8.1481; Leist M, 1998, MOL PHARMACOL, V54, P789, DOI 10.1124/mol.54.5.789; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; MCCONKEY DJ, 1989, ARCH BIOCHEM BIOPHYS, V269, P365, DOI 10.1016/0003-9861(89)90119-7; MESSMER UK, 1995, MOL PHARMACOL, V47, P757; Messmer UK, 1998, EUR J PHARMACOL, V349, P333, DOI 10.1016/S0014-2999(98)00189-7; Messmer UK, 1996, BIOCHEM J, V319, P299, DOI 10.1042/bj3190299; Messmer UK, 1996, J BIOL CHEM, V271, P20192, DOI 10.1074/jbc.271.33.20192; Moreno MB, 1996, J IMMUNOL, V157, P3845; NEWMEYER DD, 1994, CELL, V79, P353, DOI 10.1016/0092-8674(94)90203-8; OREN M, 1994, SEMIN CANCER BIOL, V5, P221; Pan GH, 1998, J BIOL CHEM, V273, P5841, DOI 10.1074/jbc.273.10.5841; Patel T, 1996, FASEB J, V10, P587, DOI 10.1096/fasebj.10.5.8621058; Pitkanen K, 1998, ONCOGENE, V16, P459, DOI 10.1038/sj.onc.1201528; Reed JC, 1998, BBA-BIOENERGETICS, V1366, P127, DOI 10.1016/S0005-2728(98)00108-X; Sakaguchi K, 1997, BIOCHEMISTRY-US, V36, P10117, DOI 10.1021/bi970759w; Soengas MS, 1999, SCIENCE, V284, P156, DOI 10.1126/science.284.5411.156; Stassi G, 1997, J EXP MED, V186, P1193, DOI 10.1084/jem.186.8.1193; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; VanderHeiden MG, 1997, CELL, V91, P627, DOI 10.1016/S0092-8674(00)80450-X; Vaux DL, 1996, P NATL ACAD SCI USA, V93, P2239, DOI 10.1073/pnas.93.6.2239; WHITESELL L, 1994, P NATL ACAD SCI USA, V91, P8324, DOI 10.1073/pnas.91.18.8324; WULFF K, 1985, METHOD ENZYMAT AN, V7, P357; Wyllie A H, 1980, Int Rev Cytol, V68, P251; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; Zamzami N, 1996, J EXP MED, V183, P1533, DOI 10.1084/jem.183.4.1533	46	57	58	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 11	1999	18	47					6403	6410		10.1038/sj.onc.1203058	http://dx.doi.org/10.1038/sj.onc.1203058			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	256CW	10597241				2022-12-25	WOS:000083709200001
J	Haridas, V; Shrivastava, A; Su, J; Yu, GL; Ni, J; Liu, D; Chen, SF; Ni, YS; Ruben, SM; Gentz, R; Aggarwal, BB				Haridas, V; Shrivastava, A; Su, J; Yu, GL; Ni, J; Liu, D; Chen, SF; Ni, YS; Ruben, SM; Gentz, R; Aggarwal, BB			VEGI, a new member of the TNF family activates Nuclear Factor-kappa B and c-Jun N-terminal kinase and modulates cell growth	ONCOGENE			English	Article						VEGI; NF-kappa B; apoptosis; JNK	TUMOR-NECROSIS-FACTOR; FACTOR RECEPTOR FAMILY; LIGAND; APOPTOSIS; SUPERFAMILY; DEATH; ANGIOGENESIS; LYMPHOTOXIN; INHIBITOR; CYTOKINE	Recently a new member of the human tumor necrosis factor (TNF) family named as VEGI was reported. However, very little is known about the biological activities displayed by this cytokine. In this report, we show that in myeloid cells VEGI activated the transcription factor kappa B (NF-kappa B) as determined by the electrophoretic mobility shift assay, induced degradation of I kappa B alpha, and nuclear translocation of p65 subunit of NF-kappa B. VEGI also activated NF-kappa B-dependent reporter gene expression. In addition, VEGI activated c-Jun N-terminal kinase. When examined for growth modulatory effects, VEGI inhibited the proliferation of breast carcinoma (MCF-7), epithelial (HeLa), and myeloid (U-937 and ML-1a) tumor cells; and activated caspase-3 leading to PARP cleavage. VEGI-induced cytotoxicity was potentiated by inhibitors of protein synthesis. VEGI also induced proliferation of normal human foreskin fibroblast cells. The activity of VEGI could neither be neutralized by antibodies against TNF, nor could it compete with TNF binding, indicating that the activity of VEGI is not due to TNF and it binds to a distinct receptor. These results suggest that VEGI, a new member of the TNF family, has a signaling pathway similar to TNF and is most likely a multifunctional cytokine.	Univ Texas, MD Anderson Canc Ctr, Dept Mol Oncol, Cytokine Res Sect, Houston, TX 77030 USA; Human Genome Sci Inc, Rockville, MD 20850 USA	University of Texas System; UTMD Anderson Cancer Center; GlaxoSmithKline; Human Genome Sciences Inc	Aggarwal, BB (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Mol Oncol, Cytokine Res Sect, 1515 Holcombe Blvd, Houston, TX 77030 USA.		Aggarwal, Bharat B/G-3388-2013					Aggarwal BB, 1996, EUR CYTOKINE NETW, V7, P93; AGGARWAL BB, 1985, METHOD ENZYMOL, V116, P441; Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; BEUTLER B, 1994, SCIENCE, V264, P667, DOI 10.1126/science.8171316; Chen YR, 1996, J BIOL CHEM, V271, P631, DOI 10.1074/jbc.271.2.631; Chicheportiche Y, 1997, J BIOL CHEM, V272, P32401, DOI 10.1074/jbc.272.51.32401; Darnay BG, 1997, J LEUKOCYTE BIOL, V61, P559, DOI 10.1002/jlb.61.5.559; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; GOOD DJ, 1990, P NATL ACAD SCI USA, V87, P6624, DOI 10.1073/pnas.87.17.6624; GRUSS HJ, 1995, BLOOD, V85, P3378, DOI 10.1182/blood.V85.12.3378.bloodjournal85123378; Hahne M, 1998, J EXP MED, V188, P1185, DOI 10.1084/jem.188.6.1185; HANSEN MB, 1989, J IMMUNOL METHODS, V119, P203, DOI 10.1016/0022-1759(89)90397-9; Haridas V, 1998, J IMMUNOL, V161, P1; HIGUCHI M, 1992, ANAL BIOCHEM, V204, P53, DOI 10.1016/0003-2697(92)90138-W; Kumar A, 1998, J IMMUNOL, V161, P776; Marsters SA, 1996, CURR BIOL, V6, P1669, DOI 10.1016/S0960-9822(02)70791-4; Mauri DN, 1998, IMMUNITY, V8, P21, DOI 10.1016/S1074-7613(00)80455-0; Mukhopadhyay A, 1999, J BIOL CHEM, V274, P15978, DOI 10.1074/jbc.274.23.15978; OREILLY MS, 1994, CELL, V79, P315, DOI 10.1016/0092-8674(94)90200-3; Pitt RM, 1996, J BIOL CHEM, V271, P12687, DOI 10.1074/jbc.271.22.12687; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SINGH S, 1995, J BIOL CHEM, V270, P24995, DOI 10.1074/jbc.270.42.24995; SINGH S, 1995, J BIOL CHEM, V270, P10631, DOI 10.1074/jbc.270.18.10631; SMITH CA, 1994, CELL, V76, P959, DOI 10.1016/0092-8674(94)90372-7; Tan KB, 1997, GENE, V204, P35, DOI 10.1016/S0378-1119(97)00509-X; TEWARI M, 1995, CELL, V81, P801, DOI 10.1016/0092-8674(95)90541-3; Torigoe K, 1997, J BIOL CHEM, V272, P25737, DOI 10.1074/jbc.272.41.25737; TOTPAL K, 1994, J IMMUNOL, V153, P2248; VANLINT J, 1992, J BIOL CHEM, V267, P25916; WESTWICK JK, 1994, J BIOL CHEM, V269, P26396; Wiley SR, 1995, IMMUNITY, V3, P673, DOI 10.1016/1074-7613(95)90057-8; Wong BR, 1997, J BIOL CHEM, V272, P25190, DOI 10.1074/jbc.272.40.25190; Yue TL, 1999, J BIOL CHEM, V274, P1479, DOI 10.1074/jbc.274.3.1479; Zhai YF, 1999, FASEB J, V13, P181, DOI 10.1096/fasebj.13.1.181	35	62	70	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 11	1999	18	47					6496	6504		10.1038/sj.onc.1203059	http://dx.doi.org/10.1038/sj.onc.1203059			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	256CW	10597252				2022-12-25	WOS:000083709200012
J	Rao, RN; Stamm, NB; Otto, K; Kovacevic, S; Watkins, SA; Rutherford, P; Lemke, S; Cocke, K; Beckmann, RP; Houck, K; Johnson, D; Skidmore, BJ				Rao, RN; Stamm, NB; Otto, K; Kovacevic, S; Watkins, SA; Rutherford, P; Lemke, S; Cocke, K; Beckmann, RP; Houck, K; Johnson, D; Skidmore, BJ			Conditional transformation of rat embryo fibroblast cells by a cyclin D1-cdk4 fusion gene	ONCOGENE			English	Article						cyclin D1; cdk4; transformation; cell models	DEPENDENT KINASE-4 CDK4; BREAST-CARCINOMA CELLS; RETINOBLASTOMA-PROTEIN; TUMOR-SUPPRESSOR; MAMMALIAN-CELLS; TRANSGENIC MICE; CRYSTAL-STRUCTURE; HA-RAS; MALIGNANT TRANSFORMATION; PHYSICAL INTERACTION	Cyclin D1 gene overexpression is a frequent event in a number of human cancers. These observations have led to the suggestion that cyclin D1 alterations might play a role in the etiology of cancer. This possibility is supported by the finding that transfection of mammalian cells with cyclin D1 can accelerate progression through the G1 phase of the cell cycle. Moreover, cyclin D1 can function as an oncogene by cooperating with activated Ha-ras to transform primary rat embryo fibroblasts (REFs). In addition, cyclin D1 transgenics develop hyperplasia and neoplasia of the thymus and mammary gland. We have constructed a novel fusion gene consisting of full-length human cyclin D1 and cdk4 genes. This fusion gene was expressed in insect cells and the fusion protein was shown to be enzymatically active. The fusion gene was expressed in mammalian cells under the control of tet-repressor. This fusion gene immortalized primary REFs, and cooperated with activated Haras to transform primary REFs, in terms of anchorage-independent growth in vitro and formation of tumors in vivo. Utilizing a tet-regulated gene expression system, we have shown that proliferation of stably transfected primary REFs in vitro and in vivo is dependent on the continued expression of the cyclin D1-cdk4 fusion gene. These cell lines could be useful in the discovery of novel cancer therapeutics to modulate cyclin D1.cdk4 activity.	Lilly Corp Ctr, Lilly Res Labs, Canc Res Div, Indianapolis, IN 46285 USA; Lilly Res Labs, Res Technol & Prot, Indianapolis, IN 46285 USA; Sphinx Pharmaceut, Durham, NC 27707 USA	Eli Lilly; Eli Lilly	Rao, RN (corresponding author), Lilly Corp Ctr, Lilly Res Labs, Canc Res Div, Drop Code 0424, Indianapolis, IN 46285 USA.		Houck, Keith/G-8654-2014	Houck, Keith/0000-0002-0055-2249; Johnson, David/0000-0002-6223-1790				ALBANESE C, 1995, J BIOL CHEM, V270, P23589, DOI 10.1074/jbc.270.40.23589; Andersen G, 1997, EMBO J, V16, P958, DOI 10.1093/emboj/16.5.958; Andersen G, 1996, FEBS LETT, V397, P65, DOI 10.1016/S0014-5793(96)01143-X; Arber N, 1997, CANCER RES, V57, P1569; Arguello F, 1998, BLOOD, V91, P2482; BIGGS JR, 1995, J MOL MED-JMM, V73, P509; BROWN NR, 1995, STRUCTURE, V3, P1235, DOI 10.1016/S0969-2126(01)00259-3; Carlson BA, 1996, CANCER RES, V56, P2973; Dai K, 1996, J BIOL CHEM, V271, P22030, DOI 10.1074/jbc.271.36.22030; DEBONDT HL, 1993, NATURE, V363, P595, DOI 10.1038/363595a0; DEGREGORI J, 1995, MOL CELL BIOL, V15, P4215; Donnellan R, 1998, J CLIN PATHOL-MOL PA, V51, P1; DOWDY SF, 1993, CELL, V73, P499, DOI 10.1016/0092-8674(93)90137-F; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; Elledge SJ, 1996, SCIENCE, V274, P1664, DOI 10.1126/science.274.5293.1664; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; EWEN ME, 1993, CELL, V73, P487, DOI 10.1016/0092-8674(93)90136-E; Fahraeus R, 1998, ONCOGENE, V16, P587, DOI 10.1038/sj.onc.1201580; FIFE RS, 1995, J LAB CLIN MED, V125, P407; Fife RS, 1998, CANCER LETT, V127, P37, DOI 10.1016/S0304-3835(98)00003-2; FILMUS J, 1994, ONCOGENE, V9, P3627; FREEDMAN VH, 1974, CELL, V3, P355, DOI 10.1016/0092-8674(74)90050-6; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; Gray NS, 1998, SCIENCE, V281, P533, DOI 10.1126/science.281.5376.533; Haas K, 1997, ONCOGENE, V15, P179, DOI 10.1038/sj.onc.1201171; Hall M, 1996, ADV CANCER RES, V68, P67, DOI 10.1016/S0065-230X(08)60352-8; Harlow E, 1999, USING ANTIBODIES LAB, P495; HARVEY DM, 1991, GENE DEV, V5, P2375, DOI 10.1101/gad.5.12b.2375; HINDS PW, 1994, P NATL ACAD SCI USA, V91, P709, DOI 10.1073/pnas.91.2.709; HIRAMA T, 1995, BLOOD, V86, P841; HUSTON JS, 1988, P NATL ACAD SCI USA, V85, P5879, DOI 10.1073/pnas.85.16.5879; JEFFREY PD, 1995, NATURE, V376, P313, DOI 10.1038/376313a0; JIANG W, 1993, ONCOGENE, V8, P3447; Kamijo T, 1997, CELL, V91, P649, DOI 10.1016/S0092-8674(00)80452-3; KATO J, 1993, GENE DEV, V7, P331; KATO JY, 1994, MOL CELL BIOL, V14, P2713, DOI 10.1128/MCB.14.4.2713; KERKHOFF E, 1995, EMBO J, V14, P1892, DOI 10.1002/j.1460-2075.1995.tb07181.x; Kim HG, 1998, BIOCHEMISTRY-US, V37, P2666, DOI 10.1021/bi972399i; Kim KK, 1996, NAT STRUCT BIOL, V3, P849, DOI 10.1038/nsb1096-849; Konstantinidis AK, 1998, J BIOL CHEM, V273, P26506, DOI 10.1074/jbc.273.41.26506; KROON AM, 1984, CANCER LETT, V25, P33, DOI 10.1016/S0304-3835(84)80023-3; LaBaer J, 1997, GENE DEV, V11, P847, DOI 10.1101/gad.11.7.847; LADANYI M, 1995, J PATHOL, V175, P211, DOI 10.1002/path.1711750209; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; Latham KM, 1996, MOL CELL BIOL, V16, P4445; LaThangue NB, 1996, BIOCHEM SOC T, V24, P54; Liggett WH, 1998, J CLIN ONCOL, V16, P1197, DOI 10.1200/JCO.1998.16.3.1197; LIU JJ, 1995, MOL CELL BIOL, V15, P3654; LOVEC H, 1994, ONCOGENE, V9, P323; LOVEC H, 1994, EMBO J, V13, P3487, DOI 10.1002/j.1460-2075.1994.tb06655.x; LUKAS J, 1995, NATURE, V375, P503, DOI 10.1038/375503a0; MATSUOKA M, 1994, MOL CELL BIOL, V14, P7265, DOI 10.1128/MCB.14.11.7265; MATSUSHIME H, 1994, MOL CELL BIOL, V14, P2066, DOI 10.1128/MCB.14.3.2066; MEDEMA RH, 1995, P NATL ACAD SCI USA, V92, P6289, DOI 10.1073/pnas.92.14.6289; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; Nakagawa H, 1997, ONCOGENE, V14, P1185, DOI 10.1038/sj.onc.1200937; NEUMAN E, 1994, MOL CELL BIOL, V14, P6607, DOI 10.1128/MCB.14.10.6607; Nevins JR, 1998, CELL GROWTH DIFFER, V9, P585; NEVINS JR, 1992, SCIENCE, V258, P424; NEWBOLD RF, 1983, NATURE, V304, P648, DOI 10.1038/304648a0; OBrien K, 1997, GENE, V184, P115, DOI 10.1016/S0378-1119(96)00583-5; Peeper DS, 1997, NATURE, V386, P177, DOI 10.1038/386177a0; Petronio J, 1996, J NEUROSURG, V84, P1020, DOI 10.3171/jns.1996.84.6.1020; QUELLE DE, 1993, GENE DEV, V7, P1559, DOI 10.1101/gad.7.8.1559; RESNITZKY D, 1994, MOL CELL BIOL, V14, P1669, DOI 10.1128/MCB.14.3.1669; Robles AI, 1998, GENE DEV, V12, P2469, DOI 10.1101/gad.12.16.2469; Robles AI, 1996, P NATL ACAD SCI USA, V93, P7634, DOI 10.1073/pnas.93.15.7634; Rollbrocker B, 1996, ACTA NEUROPATHOL, V92, P70, DOI 10.1007/s004010050491; RULEY HE, 1983, NATURE, V304, P602, DOI 10.1038/304602a0; Sandig V, 1997, NAT MED, V3, P313, DOI 10.1038/nm0397-313; SAUTER C, 1988, BRIT J CANCER, V57, P514, DOI 10.1038/bjc.1988.117; SCHMIDT TGM, 1994, J CHROMATOGR A, V676, P337, DOI 10.1016/0021-9673(94)80434-6; Sellers WR, 1997, J CLIN ONCOL, V15, P3301, DOI 10.1200/JCO.1997.15.11.3301; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Serrano M, 1996, CELL, V85, P27, DOI 10.1016/S0092-8674(00)81079-X; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; SMITH MC, 1988, J BIOL CHEM, V263, P7211; Stepanova L, 1996, GENE DEV, V10, P1491, DOI 10.1101/gad.10.12.1491; TERADA Y, 1995, NATURE, V376, P358, DOI 10.1038/376358a0; TUCKER RW, 1977, CANCER RES, V37, P1571; VANDENBOGERT C, 1986, CANCER RES, V46, P3283; VANDENHEUVEL S, 1993, SCIENCE, V262, P2050, DOI 10.1126/science.8266103; WANG TC, 1994, NATURE, V369, P669, DOI 10.1038/369669a0; Weber JD, 1997, J BIOL CHEM, V272, P32966, DOI 10.1074/jbc.272.52.32966; WIGLER M, 1979, P NATL ACAD SCI USA, V76, P1373, DOI 10.1073/pnas.76.3.1373; WOLFEL T, 1995, SCIENCE, V269, P1281, DOI 10.1126/science.7652577; WORZALLA JF, 1990, INVEST NEW DRUG, V8, P241; Zindy F, 1997, ONCOGENE, V15, P203, DOI 10.1038/sj.onc.1201178; Zuo L, 1996, NAT GENET, V12, P97, DOI 10.1038/ng0196-97; Zwicker J, 1999, ONCOGENE, V18, P19, DOI 10.1038/sj.onc.1202286	91	18	20	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 4	1999	18	46					6343	6356		10.1038/sj.onc.1203009	http://dx.doi.org/10.1038/sj.onc.1203009			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	260DK	10597234				2022-12-25	WOS:000083934100019
J	Arnold, RJ; Polevoda, B; Reilly, JP; Sherman, F				Arnold, RJ; Polevoda, B; Reilly, JP; Sherman, F			The action of N-terminal acetyltransferases on yeast ribosomal proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; ESCHERICHIA-COLI; METHIONINE AMINOPEPTIDASE; LONG-ISLAND; PHOSPHORYLATION; METHYLATION; ACETYLATION; EXTENSION; CHAIN	Matrix-assisted laser desorption/ionization time-of-flight mass spectrometry was used to determine the state of N-terminal acetylation of 68 ribosomal proteins from a normal strain of Saccharomyces cerevisiae and from the ard1-Delta, nat3-Delta, and mak3-Delta mutants (4), each lacking a catalytic subunit of three different N-terminal acetyltransferases. A total 30 of the of 68 ribosomal proteins were N-terminal-acetylated, and 24 of these (80%) were NatA substrates, unacetylated in solely the ard1-Delta mutant and having mainly Ac-Ser- termini and a few with Ac-Ala- or Ac-Thr- termini, Only 4 (13%) were NatB substrates, unacetylated in solely the nat3-Delta mutant, and having Ac-Met-Asp- or Ac-Met-Glu- termini. No NatC substrates were uncovered, e.g. unacetylated in solely mak3-Delta mutants, consistent with finding that none of the ribosomal proteins had Ac-Met-Ile-, Ac-Met-Leu-, or Ac-Met-Phe- termini, Interestingly, two new types of the unusual Nato substrates were uncovered, having either Ac-Ser-Asp-Phe- or Ac-Ser-Asp-Ala- termini that were unacetylated in the ard1-Delta mutant, and only partially acetylated in the mak3-Delta mutant and, for one case, also only partially in the nat3-Delta mutant. We suggest that the acetylation of Nato substrates requires not only Ard1p and Nat1p, but also auxiliary factors that are acetylated by the Mak3p and Nat3p N-terminal acetyltransferases.	Indiana Univ, Dept Chem, Bloomington, IN 47405 USA; Univ Rochester, Sch Med & Dent, Dept Biochem & Biophys, Rochester, NY 14642 USA	Indiana University System; Indiana University Bloomington; University of Rochester	Sherman, F (corresponding author), Univ Rochester, Sch Med, Dept Biochem & Biophys, Box 712, Rochester, NY 14642 USA.		Polevoda, Bogdan/A-4880-2008		NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM012702] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM12702] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Arnold RJ, 1999, ANAL BIOCHEM, V269, P105, DOI 10.1006/abio.1998.3077; BARWICK RC, 1985, P NATL ACAD SCI USA, V82, P4602, DOI 10.1073/pnas.82.14.4602; Colby SM, 1996, ANAL CHEM, V68, P1419, DOI 10.1021/ac950716q; DEVLIN PE, 1988, GENE, V65, P13, DOI 10.1016/0378-1119(88)90412-X; HIREL PH, 1989, P NATL ACAD SCI USA, V86, P8247, DOI 10.1073/pnas.86.21.8247; HUANG S, 1987, BIOCHEMISTRY-US, V26, P8242, DOI 10.1021/bi00399a033; KIMURA Y, 2000, IN PRESS J BIOL CHEM; KRUISWIJK T, 1978, BIOCHEM J, V175, P213, DOI 10.1042/bj1750213; KRUISWIJK T, 1978, BIOCHEM J, V175, P221, DOI 10.1042/bj1750221; Mager WH, 1997, NUCLEIC ACIDS RES, V25, P4872, DOI 10.1093/nar/25.24.4872; MOERSCHELL RP, 1990, J BIOL CHEM, V265, P19638; MULLEN JR, 1989, EMBO J, V8, P2067, DOI 10.1002/j.1460-2075.1989.tb03615.x; NARANDA T, 1991, P NATL ACAD SCI USA, V88, P10563, DOI 10.1073/pnas.88.23.10563; PARK EC, 1992, EMBO J, V11, P2087, DOI 10.1002/j.1460-2075.1992.tb05267.x; Planta RJ, 1998, YEAST, V14, P471, DOI 10.1002/(SICI)1097-0061(19980330)14:5<471::AID-YEA241>3.0.CO;2-U; Polevoda B, 1999, EMBO J, V18, P6155, DOI 10.1093/emboj/18.21.6155; PRCHAL JT, 1986, P NATL ACAD SCI USA, V83, P24, DOI 10.1073/pnas.83.1.24; SHERMAN F, 1985, BIOESSAYS, V3, P27, DOI 10.1002/bies.950030108; SPEDDING G, 1990, RIBOSOMES PROTEIN SY, P1; TAKAKURA H, 1992, J BIOL CHEM, V267, P5442; TERCERO JC, 1993, J BACTERIOL, V175, P3192, DOI 10.1128/JB.175.10.3192-3194.1993; Williamson NA, 1997, EUR J BIOCHEM, V246, P786, DOI 10.1111/j.1432-1033.1997.00786.x; YAMADA T, 1986, BIOCHEM BIOPH RES CO, V135, P837, DOI 10.1016/0006-291X(86)91004-1; ZINKER S, 1976, J BIOL CHEM, V251, P1799	24	68	131	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 24	1999	274	52					37035	37040		10.1074/jbc.274.52.37035	http://dx.doi.org/10.1074/jbc.274.52.37035			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	267WR	10601260	hybrid			2022-12-25	WOS:000084382700031
J	Kester, HCM; Magaud, D; Roy, C; Anker, D; Doutheau, A; Shevchik, V; Hugouvieux-Cotte-Pattat, N; Benen, JAE; Visser, J				Kester, HCM; Magaud, D; Roy, C; Anker, D; Doutheau, A; Shevchik, V; Hugouvieux-Cotte-Pattat, N; Benen, JAE; Visser, J			Performance of selected microbial pectinases on synthetic monomethyl-esterified di- and trigalacturonates	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ASPERGILLUS-NIGER; ERWINIA-CHRYSANTHEMI; MOLECULAR-CLONING; GENE; POLYGALACTURONASES; DERIVATIVES; FAMILY	Two monomethyl esters of alpha-(1-4)-linked D-galacturonic dimers and three monomethyl esters of alpha-(1-4)-linked D-galacturonic acid trimers were synthesized chemically and further used as substrates in order to establish the substrate specificity of six different endopolygalacturonases from Aspergillus niger, one exopolygalacturonase from Aspergillus tubingensis, and four selected Erwinia chrysanthemi pectinases; exopolygalacturonan hydrolase X (PehX), exopolygalacturonate lyase X (PelX), exopectate lyase W (PelW), and oligogalacturonan lyase (Ogl). All A. niger endopolygalacturonases (PGs) were unable to hydrolyze the two monomethyldigalacturonates and 2-methyltrigalacturonate, whereas 1-methyltrigalacturonate was only cleaved by PGI, PGII, and PGB albeit at an extremely low rate. The hydrolysis of 3-methyltrigalacturonate into 2-methyldigalaeturonate and galacturonate by all endopolygalacturonases demonstrates that these enzymes can accommodate a methylgalacturonate at subsite -2. The A. tubingensis exopolygalacturonase hydrolyzed the monomethyl-esterified digalacturonates and trigalacturonates although at lower rates than for the corresponding oligogalacturonates. 1-Methyltrigalacturonate was hydrolyzed at the same rate as trigalacturonate which demonstrates that the presence of a methyl ester at the third galacturonic acid from the nonreducing end does not have any effect on the performance of exopolygalacturonase. Of the four E. chrysanthemi pectinases, Ogl was the only enzyme able to cleave digalacturonate, whereas all four enzymes cleaved trigalacturonate. Ogl does not cleave monomethyl-esterified digalacturonate and trigalacturonate in case the second galacturonic acid residue from the reducing end is methyl-esterified. PehX did not hydrolyze any of the monomethyl-esterified trigalacturonates. The two lyases, PelX and PelW, were both only able to cleave 1-methyltrigalacturonate into Delta 4,5-unsaturated 1-methyldigalacturonate and galacturonate.	Agr Univ Wageningen, Sect Mol Genet Ind Microorganisms, NL-6703 HA Wageningen, Netherlands; Inst Natl Sci Appl, Lab Genet Mol Microorganismes & Interact Cellulai, CNRS, URA 1486, F-69621 Villeurbanne, France; Inst Natl Sci Appl, Chim Organ Lab, CNRS, UMR 5622, F-69621 Villeurbanne, France	Wageningen University & Research; Centre National de la Recherche Scientifique (CNRS); Institut National des Sciences Appliquees de Lyon - INSA Lyon; Centre National de la Recherche Scientifique (CNRS); Institut National des Sciences Appliquees de Lyon - INSA Lyon	Visser, J (corresponding author), Agr Univ Wageningen, Sect Mol Genet Ind Microorganisms, Dreijenlaan 2, NL-6703 HA Wageningen, Netherlands.			Shevchik, Vladimir/0000-0002-8031-8638; COTTE-PATTAT, Nicole/0000-0002-4322-160X				Benen JAE, 1999, EUR J BIOCHEM, V259, P577, DOI 10.1046/j.1432-1327.1999.00080.x; BUSSINK HJD, 1991, CURR GENET, V20, P301, DOI 10.1007/BF00318519; BUSSINK HJD, 1990, FEBS LETT, V273, P127, DOI 10.1016/0014-5793(90)81066-W; BUSSINK HJD, 1992, APPL MICROBIOL BIOT, V37, P324, DOI 10.1007/BF00210987; BUSSINK HJD, 1992, EUR J BIOCHEM, V208, P83, DOI 10.1111/j.1432-1033.1992.tb17161.x; De Vries J, 1982, CARBOHYD POLYM, V2, P25, DOI DOI 10.1016/0144-8617(82)90043-1; EDELHOCH H, 1967, BIOCHEMISTRY-US, V6, P1948, DOI 10.1021/bi00859a010; HugouvieuxCottePattat N, 1996, ANNU REV MICROBIOL, V50, P213, DOI 10.1146/annurev.micro.50.1.213; Kester HCM, 1999, BIOTECHNOL APPL BIOC, V30, P53; Kester HCM, 1996, EUR J BIOCHEM, V240, P738, DOI 10.1111/j.1432-1033.1996.0738h.x; KESTER HCM, 1990, BIOTECHNOL APPL BIOC, V12, P150; Korner R, 1999, ANAL CHEM, V71, P1421, DOI 10.1021/ac981240o; LIPTAK A, 1983, ACTA CHIM HUNG, V113, P415; Magaud D, 1997, TETRAHEDRON LETT, V38, P241, DOI 10.1016/S0040-4039(96)02308-8; Magaud D, 1998, CARBOHYD RES, V314, P189, DOI 10.1016/S0008-6215(98)00312-7; Parenicova L, 1998, EUR J BIOCHEM, V251, P72, DOI 10.1046/j.1432-1327.1998.2510072.x; RANA SS, 1980, CARBOHYD RES, V83, P170, DOI 10.1016/S0008-6215(00)85380-X; REVERCHON S, 1987, GENE, V55, P125, DOI 10.1016/0378-1119(87)90255-1; Scavetta RD, 1999, PLANT CELL, V11, P1081, DOI 10.1105/tpc.11.6.1081; Shevchik VE, 1999, J BACTERIOL, V181, P3912, DOI 10.1128/JB.181.13.3912-3919.1999; Shevchik VE, 1999, J BACTERIOL, V181, P1652, DOI 10.1128/JB.181.5.1652-1663.1999; Tardy F, 1997, J BACTERIOL, V179, P2503, DOI 10.1128/jb.179.8.2503-2511.1997	22	23	24	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 24	1999	274	52					37053	37059		10.1074/jbc.274.52.37053	http://dx.doi.org/10.1074/jbc.274.52.37053			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	267WR	10601263	hybrid			2022-12-25	WOS:000084382700034
J	Ravanti, L; Hakkinen, L; Larjava, H; Saarialho-Kere, U; Foschi, M; Han, JH; Kahari, VM				Ravanti, L; Hakkinen, L; Larjava, H; Saarialho-Kere, U; Foschi, M; Han, JH; Kahari, VM			Transforming growth factor-beta induces collagenase-3 expression by human gingival fibroblasts via p38 mitogen-activated protein kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SQUAMOUS-CELL CARCINOMAS; MATRIX METALLOPROTEINASE-13; TISSUE INHIBITOR; GENE-EXPRESSION; MESSENGER-RNA; BREAST CARCINOMAS; MAP KINASE; I COLLAGEN; MMP-13; KERATINOCYTES	Human collagenase-3 (matrix metalloproteinase 13 (MMP-13)) is characterized by exceptionally wide substrate specificity and restricted tissue specific expression. Human skin fibroblasts in culture express MMP-13 only when they are in three-dimensional collagen (Ravanti, L., Heino, J., Lopez-Otin, C,, and Kahari. V.-M. (1999) J. Biol. Chem. 274, 2446-2455). Here we show that MMP-13 is expressed by fibroblasts during normal human gingival wound repair. Expression of MMP-13 by human gingival fibroblasts cultured in monolayer or in collagen gel was induced by transforming growth factor-beta 1 (TGF-beta 1). Treatment of gingival fibroblasts with TGF-beta 1 activated two distinct mitogen-activated protein kinases (MAPKs): extracellular signal-regulated kinase 1/2 (ERK1/2) in 15 min and p38 MAPK in 1 and 2 h. Induction of MMP-13 expression by TGF-beta 1 was blocked by SB203580, a specific inhibitor of p38 MAPK, but not by PD98059, a selective inhibitor of ERK1/2 activation. Adenovirus-mediated expression of dominant negative p38 alpha and c-Jun potently inhibited induction of MMP-13 expression in gingival fibroblasts by TGF-beta 1. Infection of gingival fibroblasts with adenovirus for constitutively active MEK1 resulted in activation of ERK1/2 and JNK1 and up-regulation of collagenase-1 (MMP-1) and stromelysin-1 (MMP-3) production but did not induce MMP-13 expression. In addition, activation of p38 MAPK by constitutively active MKK6b or MKK3b was not sufficient to induce MMP-13 expression. These results show that TGF-beta-elicited induction of MMP-13 expression by gingival fibroblasts is dependent on the activity of p38 MAPK and the presence of functional AP-1 dimers. These observations demonstrate a fundamental difference in the regulation of collagenolytic capacity between gingival and dermal fibroblasts and suggest a role for MMP-13 in rapid turnover of collagenous matrix during repair of gingival wounds, which heal with minimal scarring.	Univ Turku, MediCity Res Lab, FIN-20520 Turku, Finland; Univ Turku, Dept Biochem Med, FIN-20520 Turku, Finland; Univ Turku, Cent Hosp, Dept Dermatol, FIN-20520 Turku, Finland; Univ British Columbia, Dept Oral Biol & Med Sci, Vancouver, BC V6T 1Z3, Canada; Univ Helsinki, Cent Hosp, Dept Dermatol, FIN-00250 Helsinki, Finland; Univ Florence, Dept Internal Med, I-50134 Florence, Italy; Scripps Res Inst, Dept Immunol, La Jolla, CA 92121 USA	University of Turku; University of Turku; University of Turku; University of British Columbia; University of Helsinki; Helsinki University Central Hospital; University of Florence; Scripps Research Institute	Kahari, VM (corresponding author), Univ Turku, MediCity Res Lab, Tykistokatu 6A, FIN-20520 Turku, Finland.	veli-matti.kahari@utu.fi	Larjava, Hannu/GRO-4325-2022; Kähäri, Veli-Matti/E-5144-2011; Han, J/G-4671-2010; Hakkinen, Lari/B-2228-2016; Kahari, Veli-Matti/T-4925-2019	Kähäri, Veli-Matti/0000-0003-2421-9368; Kahari, Veli-Matti/0000-0003-2421-9368				Ahonen M, 1998, CANCER RES, V58, P2310; Airola K, 1999, BRIT J CANCER, V80, P733, DOI 10.1038/sj.bjc.6690417; Airola K, 1997, J INVEST DERMATOL, V109, P225, DOI 10.1111/1523-1747.ep12319441; ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; Auer KL, 1998, MOL BIOL CELL, V9, P561, DOI 10.1091/mbc.9.3.561; BIRKEDALHANSEN H, 1993, CRIT REV ORAL BIOL M, V4, P197, DOI 10.1177/10454411930040020401; Cazorla M, 1998, J PATHOL, V186, P144, DOI 10.1002/(SICI)1096-9896(1998100)186:2<144::AID-PATH147>3.0.CO;2-#; Chen SJ, 1999, J INVEST DERMATOL, V112, P49, DOI 10.1046/j.1523-1747.1999.00477.x; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CUENDA A, 1995, FEBS LETT, V364, P229, DOI 10.1016/0014-5793(95)00357-F; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; EDWARDS DR, 1987, EMBO J, V6, P1899, DOI 10.1002/j.1460-2075.1987.tb02449.x; FORT P, 1985, NUCLEIC ACIDS RES, V13, P1431, DOI 10.1093/nar/13.5.1431; Fosang AJ, 1996, FEBS LETT, V380, P17, DOI 10.1016/0014-5793(95)01539-6; Foschi M, 1997, EMBO J, V16, P6439, DOI 10.1093/emboj/16.21.6439; FREIJE JMP, 1994, J BIOL CHEM, V269, P16766; Garlick JA, 1996, J DENT RES, V75, P912, DOI 10.1177/00220345960750030801; GHAHARY A, 1995, CYTOKINE, V7, P184, DOI 10.1006/cyto.1995.1025; Giambernardi TA, 1998, MATRIX BIOL, V16, P483, DOI 10.1016/S0945-053X(98)90019-1; GOLDBERG GI, 1986, J BIOL CHEM, V261, P6600; Heppner KJ, 1996, AM J PATHOL, V149, P273; Hocevar BA, 1999, EMBO J, V18, P1345, DOI 10.1093/emboj/18.5.1345; INOUE M, 1995, J INVEST DERMATOL, V104, P479, DOI 10.1111/1523-1747.ep12605917; Johansson N, 1999, AM J PATHOL, V154, P469, DOI 10.1016/S0002-9440(10)65293-5; Johansson N, 1997, DEV DYNAM, V208, P387, DOI 10.1002/(SICI)1097-0177(199703)208:3<387::AID-AJA9>3.0.CO;2-E; Johansson N, 1997, CELL GROWTH DIFFER, V8, P243; Johansson N, 1997, AM J PATHOL, V151, P499; Kahari VM, 1999, ANN MED, V31, P34, DOI 10.3109/07853899909019260; Knauper V, 1996, J BIOL CHEM, V271, P1544, DOI 10.1074/jbc.271.3.1544; Knauper V, 1997, J BIOL CHEM, V272, P7608, DOI 10.1074/jbc.272.12.7608; Krane SM, 1996, J BIOL CHEM, V271, P28509, DOI 10.1074/jbc.271.45.28509; Kumar S, 1996, J BIOL CHEM, V271, P30864, DOI 10.1074/jbc.271.48.30451; LARJAVA H, 1993, J CLIN INVEST, V92, P1425, DOI 10.1172/JCI116719; Lindy O, 1997, ARTHRITIS RHEUM-US, V40, P1391, DOI 10.1002/art.1780400806; MAKELA JK, 1988, NUCLEIC ACIDS RES, V16, P349, DOI 10.1093/nar/16.1.349; Mattila L, 1998, J INVEST DERMATOL, V110, P416, DOI 10.1046/j.1523-1747.1998.00138.x; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; Mitchell PG, 1996, J CLIN INVEST, V97, P761, DOI 10.1172/JCI118475; OVERALL CM, 1991, J BIOL CHEM, V266, P14064; PELTONEN J, 1990, J INVEST DERMATOL, V94, P365, DOI 10.1111/1523-1747.ep12874491; PELTONEN J, 1991, J INVEST DERMATOL, V97, P240, DOI 10.1111/1523-1747.ep12480289; Pilcher BK, 1997, J CELL BIOL, V137, P1445, DOI 10.1083/jcb.137.6.1445; Ravanti L, 1999, J BIOL CHEM, V274, P2446, DOI 10.1074/jbc.274.4.2446; Reboul P, 1996, J CLIN INVEST, V97, P2011, DOI 10.1172/JCI118636; Reunanen N, 1998, J BIOL CHEM, V273, P5137, DOI 10.1074/jbc.273.9.5137; Saarialho-Kere UK, 1998, ARCH DERMATOL RES, V290, pS47, DOI 10.1007/PL00007453; SAARIALHOKERE UK, 1993, J CLIN INVEST, V92, P2858, DOI 10.1172/JCI116906; SALO T, 1994, LAB INVEST, V70, P176; Sano Y, 1999, J BIOL CHEM, V274, P8949, DOI 10.1074/jbc.274.13.8949; SAUS J, 1988, J BIOL CHEM, V263, P6742; Schor S L, 1996, Oral Dis, V2, P155; SCIUBBA JJ, 1978, J ORAL PATHOL MED, V7, P214, DOI 10.1111/j.1600-0714.1978.tb01596.x; SHAH M, 1994, J CELL SCI, V107, P1137; Shapiro SD, 1998, CURR OPIN CELL BIOL, V10, P602, DOI 10.1016/S0955-0674(98)80035-5; StahleBackdahl M, 1997, LAB INVEST, V76, P717; Sulciner DJ, 1996, MOL CELL BIOL, V16, P7115; Taichman NS, 1998, LAB INVEST, V78, P869; Uitto VJ, 1998, AM J PATHOL, V152, P1489; Uria JA, 1998, J BIOL CHEM, V273, P9769, DOI 10.1074/jbc.273.16.9769; Uria JA, 1998, AM J PATHOL, V153, P91, DOI 10.1016/S0002-9440(10)65549-6; Uria JA, 1997, CANCER RES, V57, P4882; Vaalamo M, 1998, AM J PATHOL, V152, P1005; Vaalamo M, 1997, J INVEST DERMATOL, V109, P96, DOI 10.1111/1523-1747.ep12276722; Vindevoghel L, 1998, P NATL ACAD SCI USA, V95, P14769, DOI 10.1073/pnas.95.25.14769; Wang YB, 1998, J BIOL CHEM, V273, P2161, DOI 10.1074/jbc.273.4.2161; WILKINSON GWG, 1992, NUCLEIC ACIDS RES, V20, P2233, DOI 10.1093/nar/20.9.2233; Yang J, 1996, AM J PHYSIOL-GASTR L, V270, pG191, DOI 10.1152/ajpgi.1996.270.1.G191; Zhang Y, 1998, NATURE, V394, P909, DOI 10.1038/29814	68	189	194	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 24	1999	274	52					37292	37300		10.1074/jbc.274.52.37292	http://dx.doi.org/10.1074/jbc.274.52.37292			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	267WR	10601295	hybrid			2022-12-25	WOS:000084382700066
J	Burke, JR; Wood, MK; Ryseck, RP; Walther, S; Meyers, CA				Burke, JR; Wood, MK; Ryseck, RP; Walther, S; Meyers, CA			Peptides corresponding to the N and C termini of I kappa B-alpha, -beta, and -epsilon as probes of the two catalytic subunits of I kappa B kinase, IKK-1 and IKK-2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEIN-KINASE; ACTIVATION; PHOSPHORYLATION; COMPLEX; DEGRADATION; SITE; UBIQUITINATION; PROTEOLYSIS; DOMAIN; ERK	The signal-inducible phosphorylation of serines 32 and 36 of I kappa B-alpha is the key step in regulating the subsequent ubiquitination and proteolysis of I kappa B-alpha, which then releases NF-KB to promote gene transcription, The multisubunit I kappa B kinase (msIKK) responsible for this phosphorylation contains two catalytic subunits, termed IKK-1 and IKK-2. Using recombinant IKK-2, a kinetic pattern consistent with a random, sequential binding mechanism was observed with the use of a peptide corresponding to amino acids 26-42 of I kappa B-alpha Values of 313 mu M 15.5 mu M, and 1.7 min(-1) were obtained for K-peptide, K-ATP, and k(cat), respectively. The value of alpha, a factor by which binding of one substrate changes the dissociation constant for the other substrate, was determined to be 0.2. Interestingly, the recombinant IKK-1 subunit gave similar values for alpha and K-ATP, but values of 1950 mu M and 0.016 min(-1) were calculated for K-peptide and k(cat), respectively. This suggests that the IKK-2 catalytic subunit provides nearly all of the catalytic activity of the msIKK complex with the IKK-1 subunit providing Little contribution to catalysis. Using peptides corresponding to different regions of I kappa B-alpha within amino acids 21-47, it was shown that amino acids 31-37 provide most binding interactions (-4.7 kcal/mol of binding free energy) of the full-length I kappa B-alpha (-7.9 kcal/mol) with the IKK-2, This is consistent with the observation that IKK-2 is able to phosphorylate the I kappa B-beta and I kappa B-epsilon proteins, which have consensus phosphorylation sites nearly identical to that of amino acids 31-37 of I kappa B-alpha A peptide corresponding to amino acids 279-303 in the C-terminal domain of I kappa B-alpha was unable to activate IKK-2 to phosphorylate an N-terminal peptide, which is in contrast to the results observed with the msIKK. Moreover, the IKK-2 catalyzes the phosphorylation of the full-length I kappa B-alpha and the amino acid 26-42 peptide with nearly equal efficiency, while the msIKK catalyzes the phosphorylation of the full-length I kappa B-alpha 25,000 times more efficiently than the 26-42 peptide, Therefore, the C terminus of I kappa B-alpha is important in activating the msIKK through interactions with subunits other than the IKK-2.	Bristol Myers Squibb Pharmaceut Res Inst, Drug Discovery Res, Princeton, NJ 08543 USA	Bristol-Myers Squibb	Burke, JR (corresponding author), Bristol Myers Squibb Pharmaceut Res Inst, Drug Discovery Res, POB 4000, Princeton, NJ 08543 USA.							Aoki T, 1996, ONCOGENE, V12, P1159; Baldi L, 1996, J BIOL CHEM, V271, P376, DOI 10.1074/jbc.271.1.376; Bauerle PA, 1996, CELL, V87, P13; Beauparlant P, 1996, J BIOL CHEM, V271, P10690, DOI 10.1074/jbc.271.18.10690; BHATNAGAR D, 1983, BIOCHEMISTRY-US, V22, P6310, DOI 10.1021/bi00295a042; BROWN K, 1995, SCIENCE, V267, P1485, DOI 10.1126/science.7878466; Brown K, 1997, MOL CELL BIOL, V17, P3021, DOI 10.1128/MCB.17.6.3021; Burke JR, 1998, J BIOL CHEM, V273, P12041, DOI 10.1074/jbc.273.20.12041; Chen ZJ, 1996, CELL, V84, P853, DOI 10.1016/S0092-8674(00)81064-8; Cleland W W, 1979, Methods Enzymol, V63, P103; Cohen L, 1998, NATURE, V395, P292, DOI 10.1038/26254; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; FINCO TS, 1994, P NATL ACAD SCI USA, V91, P11884, DOI 10.1073/pnas.91.25.11884; Fromm H J, 1979, Methods Enzymol, V63, P467; Harhaj EW, 1998, J BIOL CHEM, V273, P25185, DOI 10.1074/jbc.273.39.25185; Horiuchi KY, 1998, BIOCHEMISTRY-US, V37, P8879, DOI 10.1021/bi972731q; Kroll M, 1997, ONCOGENE, V15, P1841, DOI 10.1038/sj.onc.1201560; Lamers MBAC, 1999, J MOL BIOL, V285, P713, DOI 10.1006/jmbi.1998.2369; Lee FS, 1997, CELL, V88, P213, DOI 10.1016/S0092-8674(00)81842-5; Li J, 1998, J BIOL CHEM, V273, P30736, DOI 10.1074/jbc.273.46.30736; Mercurio F, 1997, SCIENCE, V278, P860, DOI 10.1126/science.278.5339.860; Nakano H, 1998, P NATL ACAD SCI USA, V95, P3537, DOI 10.1073/pnas.95.7.3537; O'Connell MA, 1998, J BIOL CHEM, V273, P30410, DOI 10.1074/jbc.273.46.30410; Prade L, 1997, STRUCTURE, V5, P1627, DOI 10.1016/S0969-2126(97)00310-9; Regnier CH, 1997, CELL, V90, P373, DOI 10.1016/S0092-8674(00)80344-X; Roff M, 1996, J BIOL CHEM, V271, P7844, DOI 10.1074/jbc.271.13.7844; Rothwarf DM, 1998, NATURE, V395, P297, DOI 10.1038/26261; Schwarz EM, 1996, MOL CELL BIOL, V16, P3554; SEGEL IH, 1976, ENZYME KINETICS, P274; SIEBENLIST U, 1994, ANNU REV CELL BIOL, V10, P405, DOI 10.1146/annurev.cb.10.110194.002201; THOMPSON JE, 1995, CELL, V80, P573, DOI 10.1016/0092-8674(95)90511-1; Uhlik M, 1998, J BIOL CHEM, V273, P21132, DOI 10.1074/jbc.273.33.21132; WALSH C, 1979, ENZYMATIC REACTION M, P35; Weil R, 1997, J BIOL CHEM, V272, P9942; Whiteside ST, 1997, EMBO J, V16, P1413, DOI 10.1093/emboj/16.6.1413; Whiteside ST, 1997, SEMIN CANCER BIOL, V8, P75, DOI 10.1006/scbi.1997.0058; Woronicz JD, 1997, SCIENCE, V278, P866, DOI 10.1126/science.278.5339.866; Zandi E, 1997, CELL, V91, P243, DOI 10.1016/S0092-8674(00)80406-7; Zandi E, 1998, SCIENCE, V281, P1360, DOI 10.1126/science.281.5381.1360	39	13	17	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 17	1999	274	51					36146	36152		10.1074/jbc.274.51.36146	http://dx.doi.org/10.1074/jbc.274.51.36146			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	266AV	10593898	hybrid			2022-12-25	WOS:000084279200017
J	Huang, C; Zhou, J; Feng, AK; Lynch, CC; Klumperman, J; DeArmond, SJ; Mobley, WC				Huang, C; Zhou, J; Feng, AK; Lynch, CC; Klumperman, J; DeArmond, SJ; Mobley, WC			Nerve growth factor signaling in caveolae-like domains at the plasma membrane	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AFFINITY NEUROTROPHIN RECEPTOR; TRK PROTOONCOGENE PRODUCT; TYROSINE KINASE-ACTIVITY; PC12 CELLS; NEURONAL DIFFERENTIATION; SPHINGOMYELIN HYDROLYSIS; ACCESSORY PROTEIN; FACTOR BINDING; IL-1 RECEPTOR; LOCALIZATION	Nerve growth factor (NGF) binding to its receptors TrkA and p75(NTR) enhances the survival, differentiation, and maintenance of neurons. Recent studies have suggested that NGF receptor activation may occur in caveolae or caveolae-like membranes (CLM). This is an intriguing possibility because caveolae have been shown to contain many of the signaling intermediates in the TrkA signaling cascade. To examine the membrane localization of TrkA and p75NTR, We isolated caveolae from 3T3-TrkA-p75 cells and CLM from PC12 cells. Immunoblot analysis showed that TrkA and p75NTR were enriched about 13- and 25-fold, respectively, in caveolae and CLM. Binding and cross-linking studies demonstrated that the NGF binding to both TrkA and p75NTR was considerably enriched in CLM and that about 90% of high affinity binding to TrkA was present in CLM. When PC12 cells were treated with NGF, virtually all activated (i.e. tyrosine phosphorylated) TrkA was found in the CLM. Remarkably, in NGF-treated cells, it was only in CLM that activated TrkA was coimmunoprecipitated with phosphorylated Shc and PLC gamma. These results document a signaling role for TrkA in CLM and suggest that both TrkA and p75(NTR) Signaling are initiated from these membranes.	Stanford Univ, Dept Neurol & Neurol Sci, Stanford, CA 94305 USA; Stanford Univ, Dept Pediat, Stanford, CA 94305 USA; Stanford Univ, Neurosci Program, Stanford, CA 94305 USA; Univ Calif San Francisco, Neurosci Program, San Francisco, CA 94143 USA; Univ Utrecht, Sch Med, NL-3584 CX Utrecht, Netherlands; Univ Calif San Francisco, Dept Pathol, San Francisco, CA 94143 USA	Stanford University; Stanford University; Stanford University; University of California System; University of California San Francisco; Utrecht University; University of California System; University of California San Francisco	Huang, C (corresponding author), Stanford Univ, Dept Neurol & Neurol Sci, Stanford, CA 94305 USA.				NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS024054] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P01AG010770] Funding Source: NIH RePORTER; NIA NIH HHS [AG10770] Funding Source: Medline; NINDS NIH HHS [NS24054] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Anderson RGW, 1998, ANNU REV BIOCHEM, V67, P199, DOI 10.1146/annurev.biochem.67.1.199; BARKER PA, 1994, J BIOL CHEM, V269, P30645; BARKER PA, 1994, NEURON, V13, P203, DOI 10.1016/0896-6273(94)90470-7; Bibel M, 1999, EMBO J, V18, P616, DOI 10.1093/emboj/18.3.616; Bilderback TR, 1997, J BIOL CHEM, V272, P10922; Bilderback TR, 1999, J BIOL CHEM, V274, P257, DOI 10.1074/jbc.274.1.257; Brown DA, 1998, ANNU REV CELL DEV BI, V14, P111, DOI 10.1146/annurev.cellbio.14.1.111; Carter BD, 1997, NEURON, V18, P187, DOI 10.1016/S0896-6273(00)80259-7; Carter BD, 1996, SCIENCE, V272, P542, DOI 10.1126/science.272.5261.542; CasacciaBonnefil P, 1996, NATURE, V383, P716, DOI 10.1038/383716a0; CHAO MV, 1992, CELL, V68, P995, DOI 10.1016/0092-8674(92)90068-N; CHAO MV, 1995, TRENDS NEUROSCI, V18, P321, DOI 10.1016/0166-2236(95)93922-K; Connor B, 1998, BRAIN RES REV, V27, P1, DOI 10.1016/S0165-0173(98)00004-6; Couet J, 1997, J BIOL CHEM, V272, P6525, DOI 10.1074/jbc.272.10.6525; Cullinan EB, 1998, J IMMUNOL, V161, P5614; DIETZEN DJ, 1995, J BIOL CHEM, V270, P6838, DOI 10.1074/jbc.270.12.6838; DOBROWSKY RT, 1994, SCIENCE, V265, P1596, DOI 10.1126/science.8079174; DOBROWSKY RT, 1995, J BIOL CHEM, V270, P22135, DOI 10.1074/jbc.270.38.22135; Galbiati F, 1998, P NATL ACAD SCI USA, V95, P10257, DOI 10.1073/pnas.95.17.10257; GarciaCardena G, 1996, P NATL ACAD SCI USA, V93, P6448, DOI 10.1073/pnas.93.13.6448; Gargano N, 1997, J NEUROSCI RES, V50, P1; Grimes ML, 1996, J NEUROSCI, V16, P7950; HANTZOPOULOS PA, 1994, NEURON, V13, P187, DOI 10.1016/0896-6273(94)90469-3; HEMPSTEAD BL, 1990, J BIOL CHEM, V265, P9595; Huang JN, 1997, P NATL ACAD SCI USA, V94, P12829, DOI 10.1073/pnas.94.24.12829; HUBER LJ, 1995, J NEUROSCI RES, V40, P557, DOI 10.1002/jnr.490400415; JING SQ, 1992, NEURON, V9, P1067, DOI 10.1016/0896-6273(92)90066-M; Kaplan DR, 1997, CURR OPIN CELL BIOL, V9, P213, DOI 10.1016/S0955-0674(97)80065-8; KAPLAN DR, 1991, NATURE, V350, P158, DOI 10.1038/350158a0; KAPLAN DR, 1991, SCIENCE, V252, P554, DOI 10.1126/science.1850549; KLEIN R, 1991, CELL, V65, P189, DOI 10.1016/0092-8674(91)90419-Y; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANDRETH GE, 1980, P NATL ACAD SCI-BIOL, V77, P4751, DOI 10.1073/pnas.77.8.4751; LEVIMONTALCINI R, 1987, SCIENCE, V237, P1154, DOI 10.1126/science.3306916; Liou W, 1996, HISTOCHEM CELL BIOL, V106, P41, DOI 10.1007/BF02473201; Liu J, 1997, J BIOL CHEM, V272, P7211, DOI 10.1074/jbc.272.11.7211; LIU PS, 1995, J BIOL CHEM, V270, P27179, DOI 10.1074/jbc.270.45.27179; Liu PS, 1996, J BIOL CHEM, V271, P10299, DOI 10.1074/jbc.271.17.10299; Loughlin, 1993, NEUROTROPHIC FACTORS, P209; MAHADEO D, 1994, J BIOL CHEM, V269, P6884; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MEAKIN SO, 1992, TRENDS NEUROSCI, V15, P323, DOI 10.1016/0166-2236(92)90047-C; MEAKIN SO, 1991, P NATL ACAD SCI USA, V88, P5862, DOI 10.1073/pnas.88.13.5862; MEAKIN SO, 1992, P NATL ACAD SCI USA, V89, P2374, DOI 10.1073/pnas.89.6.2374; Mineo C, 1996, J BIOL CHEM, V271, P11930, DOI 10.1074/jbc.271.20.11930; NGUYEN TT, 1993, J BIOL CHEM, V268, P9803; OBERMEIER A, 1994, EMBO J, V13, P1585, DOI 10.1002/j.1460-2075.1994.tb06421.x; Orlinick JR, 1998, CELL SIGNAL, V10, P543, DOI 10.1016/S0898-6568(98)00018-7; RODRIGUEZTEBAR A, 1992, EMBO J, V11, P917, DOI 10.1002/j.1460-2075.1992.tb05130.x; Ross AH, 1996, J CELL BIOL, V132, P945, DOI 10.1083/jcb.132.5.945; Ross GM, 1998, EUR J NEUROSCI, V10, P890, DOI 10.1046/j.1460-9568.1998.00094.x; SCHECHTER AL, 1981, CELL, V24, P867, DOI 10.1016/0092-8674(81)90112-4; Schlegel A, 1998, CELL SIGNAL, V10, P457, DOI 10.1016/S0898-6568(98)00007-2; SCHNITZER JE, 1994, J CELL BIOL, V127, P1217, DOI 10.1083/jcb.127.5.1217; SHENOYSCARIA AM, 1994, J CELL BIOL, V126, P353, DOI 10.1083/jcb.126.2.353; SLOT JW, 1991, J CELL BIOL, V113, P123, DOI 10.1083/jcb.113.1.123; SMART EJ, 1995, P NATL ACAD SCI USA, V92, P10104, DOI 10.1073/pnas.92.22.10104; Song KS, 1996, J BIOL CHEM, V271, P9690, DOI 10.1074/jbc.271.16.9690; SUTTER A, 1979, J BIOL CHEM, V254, P5972; THOENEN H, 1991, TRENDS NEUROSCI, V14, P165, DOI 10.1016/0166-2236(91)90097-E; TRAVERSE S, 1994, CURR BIOL, V4, P694, DOI 10.1016/S0960-9822(00)00154-8; TRAVERSE S, 1992, BIOCHEM J, V288, P351, DOI 10.1042/bj2880351; VERDI JM, 1994, NEURON, V12, P733, DOI 10.1016/0896-6273(94)90327-1; Wesche H, 1998, FEBS LETT, V429, P303, DOI 10.1016/S0014-5793(98)00468-2; WESKAMP G, 1991, NEURON, V6, P649, DOI 10.1016/0896-6273(91)90067-A; WOLF DE, 1995, J BIOL CHEM, V270, P2133, DOI 10.1074/jbc.270.5.2133; Wolven A, 1997, MOL BIOL CELL, V8, P1159, DOI 10.1091/mbc.8.6.1159; WOODRUFF NR, 1986, BIOCHEMISTRY-US, V25, P7956, DOI 10.1021/bi00372a026; Wu CB, 1997, J BIOL CHEM, V272, P3554, DOI 10.1074/jbc.272.6.3554; Yuen EC, 1996, ANN NEUROL, V40, P346, DOI 10.1002/ana.410400304; ZHANG L, 1994, J NEUROSCI, V14, P5187; ZHOU J, 1994, P NATL ACAD SCI USA, V91, P3824, DOI 10.1073/pnas.91.9.3824	72	119	128	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 17	1999	274	51					36707	36714		10.1074/jbc.274.51.36707	http://dx.doi.org/10.1074/jbc.274.51.36707			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	266AV	10593976	hybrid			2022-12-25	WOS:000084279200095
J	Safaiyan, F; Kolset, SO; Prydz, K; Gottfridsson, E; Lindahl, U; Salmivirta, M				Safaiyan, F; Kolset, SO; Prydz, K; Gottfridsson, E; Lindahl, U; Salmivirta, M			Selective effects of sodium chlorate treatment on the sulfation of heparan sulfate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-DEACETYLASE/N-SULFOTRANSFERASE; HAMSTER OVARY CELLS; FIBROBLAST GROWTH; PROTEOGLYCANS; EXPRESSION; BINDING; MOUSE; DEPOLYMERIZATION; DIFFERENTIATION; BIOSYNTHESIS	We have analyzed the effect of sodium chlorate treatment of Madin-Darby canine kidney cells on the structure of heparan sulfate (HS), to assess how the various sulfation reactions during HS biosynthesis are affected by decreased availability of the sulfate donor 3'-phosphoadenosine 5'-phosphosulfate. Metabolically [H-3]glucosamine-labeled HS was isolated from chlorate-treated and untreated Madin-Darby canine kidney cells and subjected to low pH nitrous acid cleavage. Saccharides representing (i) the N-sulfated domains, (ii) the domains of alternating N-acetylated and N-sulfated disaccharide units, and (iii) the N-acetylated domains were recovered and subjected to compositional disaccharide analysis. Upon treatment with 50 mM chlorate, overall O-sulfation of HS was inhibited by similar to 70%, whereas N-sulfation remained essentially unchanged. Low chlorate concentrations (5 or 2 mM) selectively reduced the 6-O-sulfation of HS, whereas treatment with 50 mM chlorate reduced both 2-O and 6-O-sulfation. Analysis of saccharides representing the different domain types indicated that 6-O-sulfation was preferentially inhibited in the alternating domains. These data suggest that reduced 3'-phosphoadenosine 5'-phosphosulfate availability has distinct effects on the N- and O-sulfation of HS and that O-sulfation is affected in a domain-specific fashion.	Univ Uppsala, Ctr Biomed, Dept Med Biochem & Microbiol, S-75123 Uppsala, Sweden; Univ Oslo, Inst Nutr Res, N-0316 Oslo, Norway; Univ Oslo, Dept Biochem, N-0316 Oslo, Norway	Uppsala University; University of Oslo; University of Oslo	Salmivirta, M (corresponding author), Turku Ctr Biotechnol, Tykistokatu 6, FIN-20520 Turku, Finland.							Aikawa J, 1999, J BIOL CHEM, V274, P2690, DOI 10.1074/jbc.274.5.2690; BERNFIELD M, 1992, ANNU REV CELL BIOL, V8, P365, DOI 10.1146/annurev.cb.08.110192.002053; BIENKOWSKI MJ, 1985, J BIOL CHEM, V260, P356; Brickman YG, 1998, J BIOL CHEM, V273, P4350, DOI 10.1074/jbc.273.8.4350; Cheung WF, 1996, BIOCHEMISTRY-US, V35, P5250, DOI 10.1021/bi952325b; Delehedde M, 1996, EXP CELL RES, V229, P398, DOI 10.1006/excr.1996.0385; FARLEY JR, 1978, ARCH BIOCHEM BIOPHYS, V185, P376, DOI 10.1016/0003-9861(78)90180-7; Feyzi E, 1998, J BIOL CHEM, V273, P13395, DOI 10.1074/jbc.273.22.13395; GALLAGHER JT, 1992, INT J BIOCHEM, V24, P553, DOI 10.1016/0020-711X(92)90326-V; Girard JP, 1998, FASEB J, V12, P603, DOI 10.1096/fasebj.12.7.603; GREVE H, 1988, J BIOL CHEM, V263, P12886; GUO Y, 1989, ANAL BIOCHEM, V176, P96, DOI 10.1016/0003-2697(89)90278-9; HABUCHI H, 1995, J BIOL CHEM, V270, P4172, DOI 10.1074/jbc.270.8.4172; HOOGEWERF AJ, 1991, J BIOL CHEM, V266, P16564; Humphries DE, 1997, BIOCHEM J, V325, P351, DOI 10.1042/bj3250351; Jayson GC, 1998, J BIOL CHEM, V273, P51, DOI 10.1074/jbc.273.1.51; KATO M, 1994, J BIOL CHEM, V269, P18881; Kispert A, 1996, DEVELOPMENT, V122, P3627; KJELLEN L, 1983, DIABETES, V32, P337, DOI 10.2337/diabetes.32.4.337; Klaassen CD, 1997, FASEB J, V11, P404, DOI 10.1096/fasebj.11.6.9194521; Kobayashi M, 1996, J BIOL CHEM, V271, P7645, DOI 10.1074/jbc.271.13.7645; Kolset SO, 1999, J CELL SCI, V112, P1797; Kreuger J, 1999, GLYCOBIOLOGY, V9, P723, DOI 10.1093/glycob/9.7.723; Kusche-Gullberg M, 1998, J BIOL CHEM, V273, P11902, DOI 10.1074/jbc.273.19.11902; LIDHOLT K, 1989, BIOCHEM J, V261, P999, DOI 10.1042/bj2610999; Lindahl B, 1997, J BIOL CHEM, V272, P26091, DOI 10.1074/jbc.272.42.26091; LINDAHL B, 1995, BIOCHEM J, V306, P177, DOI 10.1042/bj3060177; Lindahl U, 1998, J BIOL CHEM, V273, P24979, DOI 10.1074/jbc.273.39.24979; Maccarana M, 1996, J BIOL CHEM, V271, P17804, DOI 10.1074/jbc.271.30.17804; ORELLANA A, 1994, J BIOL CHEM, V269, P2270; PEJLER G, 1987, J BIOL CHEM, V262, P5036; Petersen F, 1999, J BIOL CHEM, V274, P12376, DOI 10.1074/jbc.274.18.12376; RAPRAEGER AC, 1991, SCIENCE, V252, P1705, DOI 10.1126/science.1646484; Rosenberg RD, 1997, J CLIN INVEST, V99, P2062, DOI 10.1172/JCI119377; Salmivirta M, 1996, FASEB J, V10, P1270, DOI 10.1096/fasebj.10.11.8836040; Salmivirta M, 1998, GLYCOBIOLOGY, V8, P1029, DOI 10.1093/glycob/8.10.1029; SHIVELY JE, 1976, BIOCHEMISTRY-US, V15, P3932, DOI 10.1021/bi00663a005; UhlinHansen L, 1997, J BIOL CHEM, V272, P3200, DOI 10.1074/jbc.272.6.3200; WINTERBOURNE DJ, 1981, J BIOL CHEM, V256, P4310; YANAGISHITA M, 1983, J BIOL CHEM, V258, P2857	40	132	136	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 17	1999	274	51					36267	36273		10.1074/jbc.274.51.36267	http://dx.doi.org/10.1074/jbc.274.51.36267			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	266AV	10593915	hybrid			2022-12-25	WOS:000084279200034
J	Stoylova, SS; Lenting, PJ; Kemball-Cook, G; Holzenburg, A				Stoylova, SS; Lenting, PJ; Kemball-Cook, G; Holzenburg, A			Electron crystallography of human blood coagulation factor VIII bound to phospholipid monolayers	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							X-RAY STRUCTURE; HUMAN FACTOR-V; FACTOR-IXA; LIGHT-CHAIN; BINDING-SITE; ACTIVE-SITE; CRYSTAL-STRUCTURE; INTERACTIVE SITE; A1 SUBUNIT; C2 DOMAIN	Coagulation factor WI binds to negatively charged platelets prior to assembly with the serine protease, factor Ma, to form the factor X-activating enzyme (FX-ase) complex. The macromolecular organization of membrane-bound factor VIII has been studied by electron crystallography for the first time. For this purpose two-dimensional crystals of human factor VIII were grown onto phosphatidylserine-containing phospholipid monolayers, under near to physiological conditions (pH and salt concentration), Electron crystallographic analysis revealed that the factor VIII molecules were organized as monomers onto the lipid layer,with unit cell dimensions: a = 81.5 Angstrom, b = 67.2 Angstrom, gamma = 66.5 degrees, P1 symmetry. Based on a homology-derived molecular model of the factor VIII (FVIII) A domains, the FVIII projection structure solved at 15-Angstrom resolution presents the A1, A2, and A3 domain heterotrimer tilted approximately 65 degrees relative to the membrane plane. The A1 domain is projecting on top of the A3, C1, and C2 domains and with the A2 domain protruding partially between A1 and A3. This organization of factor VIII allows the factor IXa protease and epidermal growth factor-like domain binding sites (localized in the A2 and A3 domains, respectively) to be situated at the appropriate position for the binding of factor IXa The conformation of the lipid-bound FVIII is therefore very close to that for the activated factor VIIIa predicted in the FX-ase complex.	Univ Leeds, Sch Biochem & Mol Biol, Leeds LS2 9JT, W Yorkshire, England; Univ Leeds, Sch Biol, Leeds LS2 9JT, W Yorkshire, England; CLB, Dept Plasma Prot Technol, NL-1066 CX Amsterdam, Netherlands; Hammersmith Hosp, ICMS, MRC, Ctr Clin Sci,Haemostasis Res Grp, London W12 0NN, England	University of Leeds; University of Leeds; Imperial College London	Stoylova, SS (corresponding author), Univ Leeds, Sch Biochem & Mol Biol, Leeds LS2 9JT, W Yorkshire, England.	svetla@bmb.leeds.ac.uk	Lenting, Peter/F-8269-2013; Lenting, Peter/AAH-5663-2019	Lenting, Peter/0000-0002-7937-3429; Lenting, Peter/0000-0002-7937-3429				AMOS LA, 1983, PROG BIOPHYS MOL BIO, V39, P183, DOI 10.1016/0079-6107(83)90017-2; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BRANDSTETTER H, 1995, P NATL ACAD SCI USA, V92, P9796, DOI 10.1073/pnas.92.21.9796; BRISSON A, 1994, BIOL CELL, V80, P221, DOI 10.1016/0248-4900(94)90045-0; Christophe OD, 1998, J BIOL CHEM, V273, P222, DOI 10.1074/jbc.273.1.222; Crowther RA, 1996, J STRUCT BIOL, V116, P9, DOI 10.1006/jsbi.1996.0003; EATON D, 1986, BIOCHEMISTRY-US, V25, P505, DOI 10.1021/bi00350a035; FAY PJ, 1989, J BIOL CHEM, V264, P14005; FAY PJ, 1994, J BIOL CHEM, V269, P20522; FAY PJ, 1988, ARCH BIOCHEM BIOPHYS, V262, P525, DOI 10.1016/0003-9861(88)90404-3; FOWLER WE, 1990, P NATL ACAD SCI USA, V87, P7648, DOI 10.1073/pnas.87.19.7648; Gilbert GE, 1996, J BIOL CHEM, V271, P11120, DOI 10.1074/jbc.271.19.11120; HOVMOLLER S, 1992, ULTRAMICROSCOPY, V41, P121, DOI 10.1016/0304-3991(92)90102-P; HUSTEN EJ, 1987, J BIOL CHEM, V262, P12953; ITO N, 1994, J MOL BIOL, V238, P794, DOI 10.1006/jmbi.1994.1335; KANE WH, 1986, P NATL ACAD SCI USA, V83, P6800, DOI 10.1073/pnas.83.18.6800; KAUFMAN RJ, 1988, J BIOL CHEM, V263, P6352; Kaufman RJ, 1998, HAEMOPHILIA, V4, P370, DOI 10.1046/j.1365-2516.1998.440370.x; Kemball-Cook G, 1998, NUCLEIC ACIDS RES, V26, P216, DOI 10.1093/nar/26.1.216; Kolkman JA, 1999, BIOCHEM J, V339, P217, DOI 10.1042/0264-6021:3390217; Lapan KA, 1997, J BIOL CHEM, V272, P2082; Lapan KA, 1998, THROMB HAEMOSTASIS, V80, P418, DOI 10.1055/s-0037-1615223; Lenting PJ, 1996, J BIOL CHEM, V271, P25332, DOI 10.1074/jbc.271.41.25332; Lenting PJ, 1996, J BIOL CHEM, V271, P1935, DOI 10.1074/jbc.271.4.1935; Lenting PJ, 1998, BLOOD, V92, P3983, DOI 10.1182/blood.V92.11.3983.423k51_3983_3996; LENTING PJ, 1994, J BIOL CHEM, V269, P7150; MANN KG, 1993, METHOD ENZYMOL, V222, P1; MANN KG, 1990, BLOOD, V76, P1; MISELL DL, 1978, PRACTICAL METHODS EL, V7; MOSESSON MW, 1990, J CLIN INVEST, V85, P1983, DOI 10.1172/JCI114662; MUTUCUMARANA VP, 1992, J BIOL CHEM, V267, P17012; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; OBRIEN LM, 1995, J BIOL CHEM, V270, P27087, DOI 10.1074/jbc.270.45.27087; PADMANABHAN K, 1993, J MOL BIOL, V232, P947, DOI 10.1006/jmbi.1993.1441; Patek AJ, 1937, J CLIN INVEST, V16, P113, DOI 10.1172/JCI100829; Pellequer JL, 1998, BLOOD CELL MOL DIS, V24, P448, DOI 10.1006/bcmd.1998.0214; Pemberton S, 1997, BLOOD, V89, P2413, DOI 10.1182/blood.V89.7.2413; Saenko EL, 1997, J BIOL CHEM, V272, P18007, DOI 10.1074/jbc.272.29.18007; Saenko EL, 1998, J BIOL CHEM, V273, P27918, DOI 10.1074/jbc.273.43.27918; STOYLOVA S, 1994, FEBS LETT, V351, P330, DOI 10.1016/0014-5793(94)00881-7; Stoylova S, 1998, BBA-PROTEIN STRUCT M, V1383, P175, DOI 10.1016/S0167-4838(97)00219-7; Tagliavacca L, 1997, J BIOL CHEM, V272, P27428, DOI 10.1074/jbc.272.43.27428; TUDDENHAM EGD, 1994, MOL GENTICS HAEMOSTA; Veeraraghavan S, 1998, BIOCHEM J, V332, P549, DOI 10.1042/bj3320549; VEHAR GA, 1984, NATURE, V312, P337, DOI 10.1038/312337a0; Villoutreix BO, 1998, J MOL MODEL, V4, P268, DOI 10.1007/s008940050084; VONHIPPEL PH, 1989, J BIOL CHEM, V264, P675; Zaitseva I, 1996, J BIOL INORG CHEM, V1, P15, DOI 10.1007/s007750050018	48	44	46	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 17	1999	274	51					36573	36578		10.1074/jbc.274.51.36573	http://dx.doi.org/10.1074/jbc.274.51.36573			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	266AV	10593957	hybrid			2022-12-25	WOS:000084279200076
J	Subbaiah, PV; Subramanian, VS; Wang, KW				Subbaiah, PV; Subramanian, VS; Wang, KW			Novel physiological function of sphingomyelin in plasma - Inhibition of lipid peroxidation in low density lipoproteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LECITHIN-CHOLESTEROL ACYLTRANSFERASE; OXIDATIVE SUSCEPTIBILITY; PHOSPHOLIPASE A(2); HEART-DISEASE; LDL; SUBFRACTIONS; ANTIOXIDANTS; MEMBRANE; AGGREGATION; MECHANISMS	Although sphingomyelin (SPH) is a major constituent of all lipoproteins, its physiological function in plasma is not known. In this study, we tested the hypothesis that SPH inhibits lipid peroxidation in low density lipoproteins (LDL) because of its effects on surface fluidity and packing density and that the relative resistance of the buoyant LDL to oxidation, compared with the dense LDL, is partly due to their higher SPH content, Depletion of SPH by treatment with SPHase resulted in shortened lag times and increased rates of oxidation in both LDL subfractions, as measured by the conjugated diene formation in the presence of Cu2+, Oxidation of LDL by soybean lipoxygenase was similarly stimulated by the degradation of SPH, Oxidation-induced fluorescence decay of diphenylhexatriene-labeled phosphatidylcholine (PC), equilibrated with LDL-PC, was accelerated significantly by the enzymatic depletion of SPH from the lipoprotein, Oxidation of 16:0-18:2 PC in the proteoliposomes was inhibited progressively by the incorporation of increasing amounts of egg SPH into the Liposomes, Treatment of SPH-containing proteoliposomes with SPHase reversed the effect of SPH, showing that the presence of intact SPH is necessary for the inhibition of oxidation, Although the incorporation of SPH into the same liposome as the PC (intrinsic SPH) protected the PC against oxidation, the addition of SPH liposomes to PC liposomes (extrinsic SPH) was not effective. Oxidation of 16:0-18:2 PC in liposomes was also inhibited by the incorporation of dipalmitoyl-PC, but not by fi ee cholesterol, These results suggest that SPH acts as a physiological inhibitor of lipoprotein oxidation, possibly by modifying the fluidity of the phospholipid monolayer and thereby inhibiting the lateral propagation of the lipid peroxy radicals.	Rush Med Coll, Sect Endocrinol & Metab, Dept Med, Chicago, IL 60612 USA; Rush Med Coll, Sect Endocrinol & Metab, Dept Biochem, Chicago, IL 60612 USA	Rush University; Rush University	Subbaiah, PV (corresponding author), Rush Med Coll, Sect Endocrinol & Metab, Dept Med, 1653 W Congress Pkway, Chicago, IL 60612 USA.		Subbaiah, Papasani/U-1104-2019		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL052597] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-52597] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Arimoto I, 1998, J LIPID RES, V39, P143; AUSTIN MA, 1994, INT J CLIN LAB RES, V24, P187, DOI 10.1007/BF02592460; BARENHOLZ Y, 1984, PHYSL MEMBRANE FLUID, P131; Brown RE, 1998, J CELL SCI, V111, P1; CHAIT A, 1993, AM J MED, V94, P350, DOI 10.1016/0002-9343(93)90144-E; Chang YH, 1997, FREE RADICAL BIO MED, V23, P202, DOI 10.1016/S0891-5849(96)00626-0; CHEN CH, 1982, J LIPID RES, V23, P680; DEGRAAF J, 1991, ARTERIOSCLER THROMB, V11, P298, DOI 10.1161/01.ATV.11.2.298; Diaz MN, 1997, NEW ENGL J MED, V337, P408, DOI 10.1056/NEJM199708073370607; ESTERBAUER H, 1992, FREE RADICAL BIO MED, V13, P341, DOI 10.1016/0891-5849(92)90181-F; Fruebis J, 1997, J LIPID RES, V38, P2455; HABERLAND ME, 1992, MONOGR HUM GENET, V14, P35; HOFER G, 1995, FREE RADICAL RES, V23, P317, DOI 10.3109/10715769509065253; JANERO DR, 1989, RES COMMUN CHEM PATH, V63, P163; Jeong TS, 1998, J CLIN INVEST, V101, P905, DOI 10.1172/JCI870; Koumanov K, 1997, BIOCHEM J, V326, P227, DOI 10.1042/bj3260227; LIU M, 1992, J BIOL CHEM, V267, P5139; Lobo LIB, 1997, BBA-LIPID LIPID MET, V1349, P122, DOI 10.1016/S0005-2760(97)00127-6; MARINETTI GV, 1962, J LIPID RES, V3, P1; MARKWELL MAK, 1978, ANAL BIOCHEM, V87, P206, DOI 10.1016/0003-2697(78)90586-9; MOREL DW, 1994, BIOCHEM BIOPH RES CO, V200, P408, DOI 10.1006/bbrc.1994.1464; MYHER JJ, 1989, LIPIDS, V24, P408, DOI 10.1007/BF02535148; Oorni K, 1998, J BIOL CHEM, V273, P29127, DOI 10.1074/jbc.273.44.29127; Patel RP, 1996, J LIPID RES, V37, P2361; RANKIN SM, 1991, J LIPID RES, V32, P449; REICHL D, 1992, BIOCHIM BIOPHYS ACTA, V1127, P28, DOI 10.1016/0005-2760(92)90197-4; Schissel SL, 1996, J CLIN INVEST, V98, P1455, DOI 10.1172/JCI118934; SLOTTE JP, 1990, J LIPID RES, V31, P2235; STEINBERG D, 1989, NEW ENGL J MED, V320, P915; SUBBAIAH PV, 1993, J BIOL CHEM, V268, P20156; SUBBAIAH PV, 1992, BIOCHIM BIOPHYS ACTA, V1128, P83, DOI 10.1016/0005-2760(92)90261-S; TRIBBLE DL, 1992, ATHEROSCLEROSIS, V93, P189, DOI 10.1016/0021-9150(92)90255-F; TRIBBLE DL, 1995, J LIPID RES, V36, P662; TRIBBLE DL, 1994, P NATL ACAD SCI USA, V91, P1183, DOI 10.1073/pnas.91.3.1183; WISEMAN H, 1993, FEBS LETT, V330, P53, DOI 10.1016/0014-5793(93)80918-K	35	39	40	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 17	1999	274	51					36409	36414		10.1074/jbc.274.51.36409	http://dx.doi.org/10.1074/jbc.274.51.36409			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	266AV	10593936	hybrid			2022-12-25	WOS:000084279200055
J	Vanoni, M; Bertini, R; Sacco, E; Fontanella, L; Rieppi, M; Colombo, S; Martegani, E; Carrera, V; Moroni, A; Bizzarri, C; Sabbatini, V; Cattozzo, M; Colagrande, A; Alberghina, L				Vanoni, M; Bertini, R; Sacco, E; Fontanella, L; Rieppi, M; Colombo, S; Martegani, E; Carrera, V; Moroni, A; Bizzarri, C; Sabbatini, V; Cattozzo, M; Colagrande, A; Alberghina, L			Characterization and properties of dominant-negative mutants of the Ras-specific guanine nucleotide exchange factor CDC25(Mm)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MUSCLE CELL-PROLIFERATION; SDC25 C-DOMAIN; SACCHAROMYCES-CEREVISIAE; TYROSINE-KINASE; CORONARY ANGIOPLASTY; SIGNALING PATHWAY; MOLECULAR-CLONING; GENE-EXPRESSION; PROTEINS; ACTIVATION	Res proteins are small GTPases playing a pivotal role in cell proliferation and differentiation. Their activation depends on the competing action of GTPase activating proteins and guanine nucleotide exchange factors (GEF). The properties of two dominant-negative mutants within the catalytic domains of the ras-specific GEF, CDC25(Mm), are described. In vitro, the mutant GEF(W1056E) and GEF(T1184E) proteins are catalytically inactive, are able to efficiently displace wild-type GEF from p21(ras), and strongly reduce affinity of the nucleotide-free ras GEF complex for the incoming nucleotide, thus resulting in the formation of a stable ras GEF binary complex. Consistent with their in vitro properties, the two mutant GEFs bring about a dramatic reduction in ras-dependent fos-luciferase activity in mouse fibroblasts. The stable ectopic expression of the GEF(W1056E) mutant in smooth muscle cells effectively reduced growth rate and DNA synthesis with no detectable morphological changes.	Univ Milan Bicocca, Dipartimento Biotecnol & Biosci, I-20126 Milan, Italy; Consorzio Biolaq, Laquila, Italy; Ctr Ric Dompe, Laquila, Italy	University of Milano-Bicocca; Dompe	Alberghina, L (corresponding author), Univ Milan Bicocca, Dipartimento Biotecnol & Biosci, Piazza Sci 2, I-20126 Milan, Italy.		Sacco, Elena/T-3274-2018	Sacco, Elena/0000-0002-3190-7671; VANONI, MARCO ERCOLE/0000-0002-8690-2587; Martegani, Enzo/0000-0001-9196-4224; Alberghina, Lilia/0000-0003-1694-931X; Colombo, Sonia/0000-0001-5104-508X				Ausubel F.A., 1997, CURRENT PROTOCOLS MO, DOI DOI 10.1.4; BARLAT I, 1993, ONCOGENE, V8, P215; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; Boriack-Sjodin PA, 1998, NATURE, V394, P337, DOI 10.1038/28548; Brambilla R, 1997, NATURE, V390, P281, DOI 10.1038/36849; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; CAMONIS JH, 1990, GENE, V86, P263, DOI 10.1016/0378-1119(90)90288-3; CAMUS C, 1995, ONCOGENE, V11, P951; Carrera V, 1998, FEBS LETT, V440, P291, DOI 10.1016/S0014-5793(98)01481-1; CHARDIN P, 1993, SCIENCE, V260, P1338, DOI 10.1126/science.8493579; CRECHET JB, 1990, SCIENCE, V248, P866, DOI 10.1126/science.2188363; Crechet JB, 1996, J BIOL CHEM, V271, P17234, DOI 10.1074/jbc.271.29.17234; DAMAK F, 1991, MOL CELL BIOL, V11, P202, DOI 10.1128/MCB.11.1.202; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; FARNSWORTH CL, 1995, NATURE, V376, P524, DOI 10.1038/376524a0; FEIG LA, 1994, CURR OPIN CELL BIOL, V6, P204, DOI 10.1016/0955-0674(94)90137-6; FRASCOTTI G, 1991, BIOCHIM BIOPHYS ACTA, V1089, P206, DOI 10.1016/0167-4781(91)90009-B; Freshney NW, 1997, FEBS LETT, V407, P111, DOI 10.1016/S0014-5793(97)00309-8; Giglione C, 1997, J BIOL CHEM, V272, P25128, DOI 10.1074/jbc.272.40.25128; Giglione C, 1998, J BIOL CHEM, V273, P34737, DOI 10.1074/jbc.273.52.34737; INDOLFI C, 1995, NAT MED, V1, P541, DOI 10.1038/nm0695-541; IRANI K, 1994, BIOCHEM BIOPH RES CO, V202, P1252, DOI 10.1006/bbrc.1994.2065; JACQUET E, 1992, J BIOL CHEM, V267, P24181; JACQUET E, 1995, BIOCHEMISTRY-US, V34, P12347, DOI 10.1021/bi00038a031; LENZEN C, 1995, METHOD ENZYMOL, V255, P95; Lenzen C, 1998, BIOCHEMISTRY-US, V37, P7420, DOI 10.1021/bi972621j; Leonardsen L, 1996, ONCOGENE, V13, P2177; LOWY DR, 1993, ANNU REV BIOCHEM, V62, P851, DOI 10.1146/annurev.bi.62.070193.004223; MARTEGANI E, 1986, EMBO J, V5, P2363, DOI 10.1002/j.1460-2075.1986.tb04505.x; MARTEGANI E, 1992, EMBO J, V11, P2151, DOI 10.1002/j.1460-2075.1992.tb05274.x; MCBRIDE W, 1988, NEW ENGL J MED, V318, P1734, DOI 10.1056/NEJM198806303182606; MEDEMA RH, 1991, MOL CELL BIOL, V11, P5963, DOI 10.1128/MCB.11.12.5963; MISTOU MY, 1992, EMBO J, V11, P2391, DOI 10.1002/j.1460-2075.1992.tb05303.x; MULCAHY LS, 1985, NATURE, V313, P241, DOI 10.1038/313241a0; OHNO T, 1994, SCIENCE, V265, P781, DOI 10.1126/science.8047883; Park WM, 1997, ONCOGENE, V14, P831, DOI 10.1038/sj.onc.1200893; PARK WM, 1994, MOL CELL BIOL, V14, P8117, DOI 10.1128/MCB.14.12.8117; POLAKIS P, 1993, J BIOL CHEM, V268, P9157; SAKAUE M, 1995, MOL CELL BIOL, V15, P379, DOI 10.1128/MCB.15.1.379; Sambrook J., 2002, MOL CLONING LAB MANU; SCHIESTL RH, 1989, CURR GENET, V16, P339, DOI 10.1007/BF00340712; SCHWEIGHOFFER F, 1993, ONCOGENE, V8, P1477; SEGAL M, 1995, EUR J BIOCHEM, V228, P96, DOI 10.1111/j.1432-1033.1995.tb20235.x; Sherman F., 1986, METHODS YEAST GENETI; SHOU C, 1992, NATURE, V358, P351, DOI 10.1038/358351a0; SIGAL IS, 1986, P NATL ACAD SCI USA, V83, P952, DOI 10.1073/pnas.83.4.952; SIMON MA, 1991, CELL, V67, P701, DOI 10.1016/0092-8674(91)90065-7; Sturani E, 1997, EXP CELL RES, V235, P117, DOI 10.1006/excr.1997.3660; VANBIESEN T, 1995, NATURE, V376, P781, DOI 10.1038/376781a0; VERNET T, 1987, GENE, V52, P225, DOI 10.1016/0378-1119(87)90049-7; VIRMANI R, 1994, AM HEART J, V127, P163, DOI 10.1016/0002-8703(94)90522-3; ZIPPEL R, 1994, INT J ONCOL, V4, P175; Zippel R, 1996, ONCOGENE, V12, P2697	53	21	24	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 17	1999	274	51					36656	36662		10.1074/jbc.274.51.36656	http://dx.doi.org/10.1074/jbc.274.51.36656			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	266AV	10593969	hybrid			2022-12-25	WOS:000084279200088
J	Ying, ZT; Mulligan, RM; Janney, N; Houtz, RL				Ying, ZT; Mulligan, RM; Janney, N; Houtz, RL			Rubisco small and large subunit N-methyltransferases - Bi- and mono-functional methyltransferases that methylate the small and large subunits of Rubisco	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RIBULOSE-1,5-BISPHOSPHATE CARBOXYLASE OXYGENASE; EPSILON-METHYLTRANSFERASE; MESSENGER-RNA; BINDING MOTIF; CHLOROPLASTS; GENE; PURIFICATION; ORGANIZATION; PROTEINS; ENZYME	Ribulose-1,5-bisphosphate carboxylase/oxygenase (Rubisco)is methylated at the alpha-amino group of the N-terminal methionine of the processed form of the small subunit (SS), and at the epsilon-amino group of lysine-14 of the large subunit (LS) in some species. The Rubisco LS methyltransferase (LSMT) gene has been cloned and ex pressed from pea and specifically methylates lysine-14 of the LS of Rubisco. We determine here that both pea and tobacco Rubisco LSMT also exhibit N-alpha-methyltransferase activity toward the SS of Rubisco, suggesting that a single gene product can produce a bifunctional protein methyltransferase capable of catalyzing both N-alpha-methylation of the SS and N-epsilon-methylation of the LS. A homologue of the Rubisco LSMT gene (rbcMT-S) has also been identified in spinach that is closely related to Rubisco LSMT sequences from pea and tobacco. Two mRNAs are produced from rbcMT-S, and both long and short forms of the spinach cDNAs were expressed in Escherichia coli cells and shown to catalyze methylation of the alpha-amino group of the N-terminal methionine of the SS of Rubisco. Thus, the absence of lysine-14 methylation in species like spinach is apparently a consequence of a monofunctional protein methyltransferase incapable of methylating Lys-14, with activity limited to methylation of the SS.	Univ Kentucky, Dept Hort, Plant Physiol Biochem Mol Biol Program, Lexington, KY 40546 USA; Univ Calif Irvine, Dept Dev & Cell Biol, Irvine, CA 92697 USA	University of Kentucky; University of California System; University of California Irvine	Houtz, RL (corresponding author), Univ Kentucky, Dept Hort, Plant Physiol Biochem Mol Biol Program, N318 Agr Sci N, Lexington, KY 40546 USA.							BACK E, 1988, MOL GEN GENET, V212, P20, DOI 10.1007/BF00322440; Brown JWS, 1996, PLANT J, V10, P771, DOI 10.1046/j.1365-313X.1996.10050771.x; Emanuelsson O, 1999, PROTEIN SCI, V8, P978, DOI 10.1110/ps.8.5.978; Frohman M.A., 1990, PCR PROTOCOLS GUIDE, P28; Grimm R, 1997, FEBS LETT, V408, P350, DOI 10.1016/S0014-5793(97)00462-6; HOBBS M, 1993, MOL MICROBIOL, V10, P233, DOI 10.1111/j.1365-2958.1993.tb01949.x; HOUTZ RL, 1992, PLANT PHYSIOL, V98, P1170, DOI 10.1104/pp.98.3.1170; HOUTZ RL, 1991, PLANT PHYSIOL, V97, P913, DOI 10.1104/pp.97.3.913; HOUTZ RL, 1989, P NATL ACAD SCI USA, V86, P1855, DOI 10.1073/pnas.86.6.1855; HUBBS A, 1992, PLANT PHYSIOL, V100, P272, DOI 10.1104/pp.100.1.272; Keeling PJ, 1996, TRENDS BIOCHEM SCI, V21, P285; KLEIN RR, 1995, PLANT MOL BIOL, V27, P249, DOI 10.1007/BF00020181; KOBE B, 1994, TRENDS BIOCHEM SCI, V19, P415, DOI 10.1016/0968-0004(94)90090-6; Kohler RH, 1997, SCIENCE, V276, P2039, DOI 10.1126/science.276.5321.2039; LIU XQ, 1986, PLANT PHYSIOL, V81, P603, DOI 10.1104/pp.81.2.603; Lory S, 1997, GENE, V192, P117, DOI 10.1016/S0378-1119(96)00830-X; Martin W, 1996, PLANT MOL BIOL, V32, P485, DOI 10.1007/BF00019100; MILLS WR, 1980, PLANTA, V148, P75, DOI 10.1007/BF00385445; MULLIGAN RM, 1988, P NATL ACAD SCI USA, V85, P1513, DOI 10.1073/pnas.85.5.1513; PAIK WK, 1990, PROTEIN METHYLATION; PETTIGREW GW, 1977, NATURE, V265, P661, DOI 10.1038/265661a0; PUGSLEY AP, 1993, MICROBIOL REV, V57, P50, DOI 10.1128/MMBR.57.1.50-108.1993; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHMIDT GW, 1983, P NATL ACAD SCI-BIOL, V80, P2632, DOI 10.1073/pnas.80.9.2632; Simpson GG, 1996, PLANT MOL BIOL, V32, P1, DOI 10.1007/BF00039375; STOCK A, 1987, FEBS LETT, V220, P8, DOI 10.1016/0014-5793(87)80866-9; STOCK A, 1988, ADV POSTTRANSLATIONA, P201; STROM MS, 1993, P NATL ACAD SCI USA, V90, P2404, DOI 10.1073/pnas.90.6.2404; STROM MS, 1993, ANNU REV MICROBIOL, V47, P565, DOI 10.1146/annurev.micro.47.1.565; VANDERVERE PS, 1995, P NATL ACAD SCI USA, V92, P7177, DOI 10.1073/pnas.92.16.7177; VANET A, 1994, MOL MICROBIOL, V14, P947, DOI 10.1111/j.1365-2958.1994.tb01330.x; VESK MARET, 1965, AUSTRALIAN J BOT, V13, P161; WANG P, 1995, PROTEIN EXPRES PURIF, V6, P528, DOI 10.1006/prep.1995.1070; WEIER TE, 1962, AM J BOT, V49, P807, DOI 10.2307/2439692; WILDMAN SG, 1962, SCIENCE, V138, P434, DOI 10.1126/science.138.3538.434; Ying ZT, 1996, GENE, V171, P243, DOI 10.1016/0378-1119(95)00891-8; Ying ZT, 1996, PLANT MOL BIOL, V32, P663, DOI 10.1007/BF00020207	37	49	52	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 17	1999	274	51					36750	36756		10.1074/jbc.274.51.36750	http://dx.doi.org/10.1074/jbc.274.51.36750			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	266AV	10593982	hybrid, Green Submitted			2022-12-25	WOS:000084279200101
J	Abo-Hashema, KAH; Cake, MH; Power, GW; Clarke, D				Abo-Hashema, KAH; Cake, MH; Power, GW; Clarke, D			Evidence for triacylglycerol synthesis in the lumen of microsomes via a lipolysis-esterification pathway involving carnitine acyltransferases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COA-BINDING PROTEIN; TRIGLYCERIDE TRANSFER PROTEIN; LOW-DENSITY LIPOPROTEIN; MALONYL-COA; ACYL-COA; RAT-LIVER; DIACYLGLYCEROL ACYLTRANSFERASE; BETA-OXIDATION; PALMITOYLTRANSFERASE-I; LIPID-COMPOSITION	In this study a pathway for the synthesis of triacylglycerol (TAG) within the lumen of the endoplasmic reticulum has been identified, using microsomes that had been preconditioned by depleting their endogenous substrates and then fusing them with biotinylated phosphatidylserine liposomes containing CoASH and Mg2+ Incubating these fused microsomes with tri[H-3] oleoylglycerol and [C-14]oleoyl-CoA yielded microsome-associated triacylglycerol, which resisted extensive washing and had a [3H]:[14C] ratio close to 2:1, The data suggest that the precursor tri[H-3]oleoylglycerol was hydrolyzed by microsomal lipase to membrane-bound di[3H]oleoylglycerol and subsequently re-esterified with luminal [C-14]oleoyl-CoA. The accumulation of TAG within the microsomes, even when overt diacylglycerol acyltransferase (DGAT I) was inactive, is consistent with the existence of a latent diacylglycerol acyltransferase (DGAT II) within the microsomal lumen. Moreover, because luminal synthesis of TAG was carnitine-dependent and markedly reduced by glybenclamide, a potent carnitine acyltransferase inhibitor, microsomal carnitine acyltransferase appears to be essential for trafficking the [C-14]oleoyl CoA into the microsomal lumen for subsequent incorporation into newly synthesized TAG. This study thus provides the first direct demonstration of an enzymatic process leading to the synthesis of luminal triacylglycerol, which is a major component of very low density lipoproteins.	Murdoch Univ, Sch Biol Sci & Biotechnol, Div Sci & Engn, Murdoch, WA 6150, Australia; Murdoch Univ, Sch Math & Phys Sci, Div Sci & Engn, Murdoch, WA 6150, Australia; Off Minster Hlth, W Perth, WA 6005, Australia	Murdoch University; Murdoch University	Cake, MH (corresponding author), Murdoch Univ, Sch Biol Sci & Biotechnol, Div Sci & Engn, Murdoch, WA 6150, Australia.		Cake, Max H/G-4159-2014	Cake, Max H/0000-0002-5899-7291				Abo-Hashema KAH, 1999, BIOCHEM BIOPH RES CO, V258, P778, DOI 10.1006/bbrc.1999.0542; ALLAN D, 1978, NATURE, V276, P289, DOI 10.1038/276289a0; ARION WJ, 1976, J BIOL CHEM, V251, P4901; BAYER EA, 1979, BIOCHIM BIOPHYS ACTA, V550, P464, DOI 10.1016/0005-2736(79)90149-4; BELL RM, 1981, J LIPID RES, V22, P391; BHUIYAN AKMJ, 1994, BIOCHEM MOL BIOL INT, V34, P493; BISHOP JE, 1980, ANAL BIOCHEM, V106, P344, DOI 10.1016/0003-2697(80)90531-X; Broadway NM, 1997, BIOCHEM J, V322, P435, DOI 10.1042/bj3220435; BROADWAY NM, 1995, BIOCHEM J, V310, P989, DOI 10.1042/bj3100989; Cases S, 1998, P NATL ACAD SCI USA, V95, P13018, DOI 10.1073/pnas.95.22.13018; Chang BHJ, 1999, J BIOL CHEM, V274, P6051, DOI 10.1074/jbc.274.10.6051; COLEMAN R, 1976, J BIOL CHEM, V251, P4537; COLEMAN RA, 1983, BIOCHIM BIOPHYS ACTA, V751, P230, DOI 10.1016/0005-2760(83)90177-7; COLEMAN RA, 1992, METHOD ENZYMOL, V209, P99; DEPIERRE JW, 1975, BIOCHIM BIOPHYS ACTA, V415, P411, DOI 10.1016/0304-4157(75)90006-4; FALLON HJ, 1975, J LIPID RES, V16, P107; Fraser F, 1999, FEBS LETT, V445, P41, DOI 10.1016/S0014-5793(99)00095-2; FREDRIKSON G, 1983, J BIOL CHEM, V258, P4253; GARLAND PB, 1965, BIOCHEM J, V97, P587, DOI 10.1042/bj0970587; Gordon DA, 1996, J BIOL CHEM, V271, P33047, DOI 10.1074/jbc.271.51.33047; GRAHAM J, 1983, IODINATED DENSITY GR, P195; GROENER JEM, 1981, BIOCHIM BIOPHYS ACTA, V665, P306, DOI 10.1016/0005-2760(81)90015-1; HOPE MJ, 1980, BIOCHEM BIOPH RES CO, V92, P846, DOI 10.1016/0006-291X(80)90780-9; HOUSSAIS JF, 1983, IODINATED DENSITY GR, P43; JAMIL H, 1995, J BIOL CHEM, V270, P6549, DOI 10.1074/jbc.270.12.6549; Kunau WH, 1995, PROG LIPID RES, V34, P267, DOI 10.1016/0163-7827(95)00011-9; Lehner R, 1999, BIOCHEM J, V338, P761, DOI 10.1042/0264-6021:3380761; Lehner R, 1997, BIOCHEMISTRY-US, V36, P1861, DOI 10.1021/bi962186d; MANDRUP S, 1991, BIOCHEM J, V276, P817, DOI 10.1042/bj2760817; MANNAERTS GP, 1979, J BIOL CHEM, V254, P4585; Markwell M A, 1981, Methods Enzymol, V72, P296; MARSHALL MO, 1977, EUR J BIOCHEM, V81, P259, DOI 10.1111/j.1432-1033.1977.tb11947.x; MAY JM, 1989, J MEMBRANE BIOL, V108, P227, DOI 10.1007/BF01871737; MCGARRY JD, 1983, BIOCHEM J, V214, P21, DOI 10.1042/bj2140021; MILLER JC, 1981, J BIOL CHEM, V256, P2662; MURTHY MSR, 1994, J BIOL CHEM, V269, P18283; Nicodeme E, 1999, J BIOL CHEM, V274, P1986, DOI 10.1074/jbc.274.4.1986; Oelkers P, 1998, J BIOL CHEM, V273, P26765, DOI 10.1074/jbc.273.41.26765; OSMUNDSEN H, 1991, BIOCHIM BIOPHYS ACTA, V1085, P141, DOI 10.1016/0005-2760(91)90089-Z; Owen MR, 1997, BIOCHEM J, V323, P17, DOI 10.1042/bj3230017; PAHLER A, 1987, J BIOL CHEM, V262, P13933; PANDE SV, 1980, J BIOL CHEM, V255, P2994; PANDE SV, 1986, BIOCHIM BIOPHYS ACTA, V877, P223, DOI 10.1016/0005-2760(86)90298-5; PAULY DF, 1988, J BIOL CHEM, V263, P18160; PISTOLESI R, 1990, MEMBRANE BIOCHEM, V9, P253, DOI 10.3109/09687689009025845; Raabe M, 1999, J CLIN INVEST, V103, P1287, DOI 10.1172/JCI6576; RAKOWSKA M, 1994, J MEMBRANE BIOL, V142, P35; RAMSAY RR, 1975, FEBS LETT, V54, P21, DOI 10.1016/0014-5793(75)81059-3; RASMUSSEN JT, 1994, BIOCHEM J, V299, P165, DOI 10.1042/bj2990165; RASMUSSEN JT, 1990, BIOCHEM J, V265, P849, DOI 10.1042/bj2650849; Savitz AJ, 1997, J BIOL CHEM, V272, P13140, DOI 10.1074/jbc.272.20.13140; SHEPHERD JC, 1993, CELL, V74, P577, DOI 10.1016/0092-8674(93)80058-M; TSAO FHC, 1986, LIPIDS, V21, P498, DOI 10.1007/BF02535636; Wasan KM, 1997, J PHARM SCI, V86, P872, DOI 10.1021/js960495j; WIGGINS D, 1992, BIOCHEM J, V284, P457, DOI 10.1042/bj2840457; YANG LY, 1995, J LIPID RES, V36, P125	56	53	57	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 10	1999	274	50					35577	35582		10.1074/jbc.274.50.35577	http://dx.doi.org/10.1074/jbc.274.50.35577			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	264NG	10585433	hybrid, Green Published			2022-12-25	WOS:000084187900045
J	Brundiers, R; Lavie, A; Veit, T; Reinstein, J; Schlichting, I; Ostermann, N; Goody, RS; Konrad, M				Brundiers, R; Lavie, A; Veit, T; Reinstein, J; Schlichting, I; Ostermann, N; Goody, RS; Konrad, M			Modifying human thymidylate kinase to potentiate azidothymidine activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AZT ACTIVATION; PHOSPHORYLATION; EXPRESSION; YEAST; GENE	Based on the knowledge of the crystal structures of yeast and Escherichia coli thymidylate kinases (TmpKs) and the observation that TmpK from E. coli can phosphorylate azidothymidine monophosphate (AZT-MP) much more efficiently than either the yeast or the highly homologous human enzyme, we have engineered yeast and human TmpKs to obtain enzymes that have dramatically improved AZT-MP phosphorylation properties. These modified enzymes have properties that make them attractive candidates for gene therapeutic approaches to potentiating the action of AZT as an inhibitor of human immunodeficiency virus (HIV) replication. In particular, insertion of the lid domain of the bacterial TmpK into the human enzyme results in a pronounced change of the acceptance of AZT-MP such that it is now phosphorylated even faster than TMP.	Max Planck Inst Mol Physiol, Dept Phys Biochem, D-44227 Dortmund, Germany; Max Planck Inst Biophys Chem, Dept Mol Genet, D-37070 Gottingen, Germany	Max Planck Society; Max Planck Society	Goody, RS (corresponding author), Max Planck Inst Mol Physiol, Dept Phys Biochem, Otto Hahn Str 11, D-44227 Dortmund, Germany.		Goody, Roger S/J-8845-2014; Schlichting, Ilme/I-1339-2013; Lavie, Arnon/H-4927-2012	Goody, Roger S/0000-0002-0772-0444; Lavie, Arnon/0000-0001-5591-8722				Agarwal K C, 1978, Methods Enzymol, V51, P483; Ayabe T, 1997, BIOCHEMISTRY-US, V36, P4027, DOI 10.1021/bi961796a; Balzarini J, 1998, NAT MED, V4, P132, DOI 10.1038/nm0298-132a; BALZARINI J, 1989, J BIOL CHEM, V264, P6127; Christians FC, 1999, NAT BIOTECHNOL, V17, P259, DOI 10.1038/7003; FURMAN PA, 1986, P NATL ACAD SCI USA, V83, P8333, DOI 10.1073/pnas.83.21.8333; Guettari N, 1997, VIROLOGY, V235, P398, DOI 10.1006/viro.1997.8706; HUANG SH, 1994, DNA CELL BIOL, V13, P461, DOI 10.1089/dna.1994.13.461; Lavie A, 1997, NAT STRUCT BIOL, V4, P601, DOI 10.1038/nsb0897-601; Lavie A, 1998, P NATL ACAD SCI USA, V95, P14045, DOI 10.1073/pnas.95.24.14045; Lavie A, 1998, BIOCHEMISTRY-US, V37, P3677, DOI 10.1021/bi9720787; Lavie A, 1997, NAT MED, V3, P922, DOI 10.1038/nm0897-922; MOOLTEN FL, 1994, CANCER GENE THER, V1, P279; SARASTE M, 1990, TRENDS BIOCHEM SCI, V15, P430, DOI 10.1016/0968-0004(90)90281-F; SCHULZ GE, 1990, J MOL BIOL, V213, P627, DOI 10.1016/S0022-2836(05)80250-5; SU JY, 1991, NUCLEIC ACIDS RES, V19, P823, DOI 10.1093/nar/19.4.823	16	51	54	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 10	1999	274	50					35289	35292		10.1074/jbc.274.50.35289	http://dx.doi.org/10.1074/jbc.274.50.35289			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	264NG	10585390	hybrid			2022-12-25	WOS:000084187900002
J	Georgellis, D; Kwon, O; Lin, ECC				Georgellis, D; Kwon, O; Lin, ECC			Amplification of signaling activity of the are two-component system of Escherichia coli by anaerobic metabolites - An in vitro study with different protein modules	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SENSOR PROTEIN; TRANSDUCTION SYSTEM; REGULATOR PROTEIN; AEROBIC PATHWAYS; DNA-BINDING; ARCB; PHOSPHORYLATION; PHOSPHORELAY; REPRESSION; TRANSPHOSPHORYLATION	In Escherichia coli, changes in redox condition of growth are sensed and signaled by the Are two-component system. This system consists of ArcB as the membrane-associated sensor kinase and ArcA as the cytoplasmic response regulator. ArcB is a tripartite kinase, possessing a primary transmitter, a receiver, and a secondary transmitter domain that catalyzes the phosphorylation of ArcA via a His --> Asp --> His --> Asp phosphorelay, as well as the dephosphorylation of ArcA-P by a reverse phosphorelay. When ArcA and ArcB were incubated with ATP, the peak levels of phosphorylated proteins increased in the presence of the fermentation metabolites D-lactate, acetate, or pyruvate. In this study, we report that these effecters accelerate the autophosphorylation activity of ArcB and enhance the transphosphorylation of ArcA, but have no effect on the dephosphorylation of ArcA-P. Moreover, the presence of the receiver domain of ArcB is essential for the effecters to influence the autophosphorylation rate of the primary transmitter domain of ArcB.	Harvard Univ, Sch Med, Dept Microbiol & Mol Genet, Boston, MA 02115 USA	Harvard University; Harvard Medical School	Lin, ECC (corresponding author), Harvard Univ, Sch Med, Dept Microbiol & Mol Genet, 200 Longwood Ave, Boston, MA 02115 USA.		Georgellis, Dimitris/U-2517-2017	Georgellis, Dimitris/0000-0002-6114-795X	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM030693, R01GM040993] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM30693, GM40993] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BURBULYS D, 1991, CELL, V64, P545, DOI 10.1016/0092-8674(91)90238-T; Georgellis D, 1998, J BIOL CHEM, V273, P32864, DOI 10.1074/jbc.273.49.32864; Georgellis D, 1997, J BACTERIOL, V179, P5429, DOI 10.1128/jb.179.17.5429-5435.1997; Hoch JA, 1995, 2 COMPONENT SIGNAL T; ISHIGE K, 1994, EMBO J, V13, P5195, DOI 10.1002/j.1460-2075.1994.tb06850.x; IUCHI S, 1992, J BACTERIOL, V174, P3972, DOI 10.1128/jb.174.12.3972-3980.1992; IUCHI S, 1993, J BIOL CHEM, V268, P23972; IUCHI S, 1990, MOL MICROBIOL, V4, P715, DOI 10.1111/j.1365-2958.1990.tb00642.x; IUCHI S, 1988, P NATL ACAD SCI USA, V85, P1888, DOI 10.1073/pnas.85.6.1888; Jourlin C, 1997, J MOL BIOL, V267, P770, DOI 10.1006/jmbi.1997.0919; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; Lin ECC, 1996, ESCHERICHIA COLI SAL, P1526; Lynch AS, 1996, J BACTERIOL, V178, P6238, DOI 10.1128/JB.178.21.6238-6249.1996; Matsushika A, 1998, J BACTERIOL, V180, P3973, DOI 10.1128/JB.180.15.3973-3977.1998; McGuire AM, 1999, MOL MICROBIOL, V32, P219, DOI 10.1046/j.1365-2958.1999.01347.x; PARKINSON JS, 1992, ANNU REV GENET, V26, P71, DOI 10.1146/annurev.ge.26.120192.000443; Uhl MA, 1996, EMBO J, V15, P1028, DOI 10.1002/j.1460-2075.1996.tb00440.x	17	78	79	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 10	1999	274	50					35950	35954		10.1074/jbc.274.50.35950	http://dx.doi.org/10.1074/jbc.274.50.35950			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	264NG	10585483	Green Submitted, hybrid			2022-12-25	WOS:000084187900095
J	Guillou, JL; Nakata, H; Cooper, DMF				Guillou, JL; Nakata, H; Cooper, DMF			Inhibition by calcium of mammalian adenylyl cyclases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CAPACITATIVE CA2+ ENTRY; TURKEY ERYTHROCYTE; NCB-20 CELLS; RAT-BRAIN; CARDIAC TISSUE; IN-VIVO; EXPRESSION; MEMBRANES; CLONING; SENSITIVITY	Ca2+ regulates mammalian adenylyl cyclases in a type-specific manner. Stimulatory regulation is moderately well understood, By contrast, even the concentration range over which Ca2+ inhibits adenylyl cyclases AC5 and AC6 is not unambiguously defined; even less so is the mechanism of inhibition. In the present study, we compared the regulation of Ca2+-stimulable and Ca2+-inhibitable adenylyl cyclases expressed in Sf9 cells with tissues that predominantly express these activities in the mouse brain. Soluble forms of AC5 containing either intact or truncated major cytosolic domains were also examined. All adenylyl cyclases, except AC2 and the soluble forms of AC5, displayed biphasic Ca2+ responses, suggesting the presence of two Ca2+ sites of high (similar to 0.2 mu M) and low affinity (similar to 0.1 mM). With a high affinity, Ca2+ (i) stimulated AC1 and cerebellar adenylyl cyclases, (ii) inhibited AC6 and striatal adenylyl cyclase, and (iii) was without effect on AC2, With a low affinity, Ca2+ inhibited all adenylyl cyclases, including AC1, AC2, AC6, and both soluble forms of AC5, The mechanism of both high and low affinity inhibition was revealed to be competition for a stimulatory Mg2+ site(s). A remarkable selectivity for Ca2+ was displayed by the high affinity site, with a K-i value of similar to 0.2 mu M, in the face of a 5000-fold excess of Mg2+. The present results show that high and low affinity inhibition by Ca2+ can be clearly distinguished and that the inhibition occurs type-specifically in discrete adenylyl cyclases, Distinction between these sites is essential, or quite spurious inferences may be drawn on the nature or location of high affinity binding sites in the Ca2+-inhibitable adenylyl cyclases.	Univ Colorado, Hlth Sci Ctr, Dept Pharmacol, Denver, CO 80262 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Cooper, DMF (corresponding author), Univ Colorado, Hlth Sci Ctr, Dept Pharmacol, 4200 E 9th Ave,Campus Box C-236, Denver, CO 80262 USA.	dermot.cooper@uchsc.edu	Jean-Louis, Guillou/Y-2569-2019	Jean-Louis, Guillou/0000-0002-4497-9551	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM032483] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 32483] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AHLIJANIAN MK, 1987, J PHARMACOL EXP THER, V241, P407; BELLORINFONT E, 1981, J CLIN ENDOCR METAB, V52, P499, DOI 10.1210/jcem-52-3-499; BEUVE A, 1990, J BACTERIOL, V172, P2614, DOI 10.1128/jb.172.5.2614-2621.1990; BOYAJIAN CL, 1991, J BIOL CHEM, V266, P4995; BOYAJIAN CL, 1990, CELL CALCIUM, V11, P299, DOI 10.1016/0143-4160(90)90007-H; CALDWELL KK, 1988, ANAL BIOCHEM, V175, P177, DOI 10.1016/0003-2697(88)90376-4; CALI JJ, 1994, J BIOL CHEM, V269, P12190; CERDAN S, 1984, J BIOL CHEM, V259, P323; Chern YJ, 1996, FEBS LETT, V385, P205, DOI 10.1016/0014-5793(96)00370-5; CHETKOVICH DM, 1991, P NATL ACAD SCI USA, V88, P6467, DOI 10.1073/pnas.88.15.6467; COLVIN RA, 1991, CELL CALCIUM, V12, P19, DOI 10.1016/0143-4160(91)90081-O; Cooper Dermot M.F., 1998, Advances in Second Messenger and Phosphoprotein Research, V32, P23; COOPER DMF, 1994, BIOCHEM J, V297, P437, DOI 10.1042/bj2970437; COOPER DMF, 1994, METHOD ENZYMOL, V238, P71; COOPER DMF, 1993, TRENDS PHARMACOL SCI, V14, P34, DOI 10.1016/0165-6147(93)90027-H; COOPER DMF, 1995, NATURE, V374, P421, DOI 10.1038/374421a0; Demirel E, 1998, PHARMACOLOGY, V57, P222, DOI 10.1159/000028245; DOKAS LA, 1993, NEUROBIOL AGING, V14, P65, DOI 10.1016/0197-4580(93)90024-6; Drake SK, 1996, BIOCHEMISTRY-US, V35, P6697, DOI 10.1021/bi952430l; DRUMMOND GI, 1970, J BIOL CHEM, V245, P976; DUDAI Y, 1984, NEUROSCI LETT, V47, P119, DOI 10.1016/0304-3940(84)90416-6; Fagan KA, 1998, J BIOL CHEM, V273, P9297, DOI 10.1074/jbc.273.15.9297; Fraichard A, 1996, BIOCHIMIE, V78, P259, DOI 10.1016/0300-9084(96)82189-4; GARRITSEN A, 1992, J NEUROCHEM, V59, P1630, DOI 10.1111/j.1471-4159.1992.tb10992.x; GIANNATTASIO G, 1987, ENDOCRINOLOGY, V120, P2611, DOI 10.1210/endo-120-6-2611; GLATT CE, 1993, NATURE, V361, P536, DOI 10.1038/361536a0; GLOWINSKI J, 1966, J NEUROCHEM, V13, P655, DOI 10.1111/j.1471-4159.1966.tb09873.x; Gu C, 1999, J BIOL CHEM, V274, P8012, DOI 10.1074/jbc.274.12.8012; HANSKI E, 1977, EUR J BIOCHEM, V76, P513, DOI 10.1111/j.1432-1033.1977.tb11621.x; ISHIKAWA Y, 1992, J BIOL CHEM, V267, P13553; JACOBOWITZ O, 1994, P NATL ACAD SCI USA, V91, P10630, DOI 10.1073/pnas.91.22.10630; KANDEL ER, 1986, NEUROSCI RES, V36, P498; LASKER RD, 1982, ARCH BIOCHEM BIOPHYS, V216, P345, DOI 10.1016/0003-9861(82)90220-X; LEVIN LR, 1995, J BIOL CHEM, V270, P7573, DOI 10.1074/jbc.270.13.7573; Lovry O.H., 1951, J BIOL CHEM, V193, P265; MATSUZAK.S, 1972, BIOCHIM BIOPHYS ACTA, V284, P227, DOI 10.1016/0005-2744(72)90061-7; MONS N, 1994, MOL BRAIN RES, V22, P236, DOI 10.1016/0169-328X(94)90052-3; MONS N, 1993, SYNAPSE, V14, P51, DOI 10.1002/syn.890140108; Mons N, 1999, CELL MOL LIFE SCI, V55, P525, DOI 10.1007/s000180050311; Nakahashi Y, 1997, J BIOL CHEM, V272, P18093, DOI 10.1074/jbc.272.29.18093; OLDHAM SB, 1984, ENDOCRINOLOGY, V114, P207, DOI 10.1210/endo-114-1-207; OLDHAM SB, 1984, ENDOCRINOLOGY, V115, P1883, DOI 10.1210/endo-115-5-1883; PIASCIK MT, 1985, ARCH BIOCHEM BIOPHYS, V241, P28, DOI 10.1016/0003-9861(85)90357-1; Potter J D, 1980, Ann N Y Acad Sci, V356, P220, DOI 10.1111/j.1749-6632.1980.tb29613.x; ROY A, 1982, MOL GEN GENET, V188, P465, DOI 10.1007/BF00330050; SALOMON Y, 1974, ANAL BIOCHEM, V58, P541, DOI 10.1016/0003-2697(74)90222-X; Scholich K, 1997, P NATL ACAD SCI USA, V94, P2915, DOI 10.1073/pnas.94.7.2915; Smith RA, 1998, J AESTHET EDUC, V32, P1; STEER ML, 1975, J BIOL CHEM, V250, P2080; STEVENS T, 1995, P NATL ACAD SCI USA, V92, P2696, DOI 10.1073/pnas.92.7.2696; Storm DR, 1998, NEURON, V20, P1199, DOI 10.1016/S0896-6273(00)80500-0; SUMMERS MD, 1987, TEX AGR EXP STN B, V155, P1; Sunahara RK, 1996, ANNU REV PHARMACOL, V36, P461, DOI 10.1146/annurev.pa.36.040196.002333; TANG WJ, 1991, J BIOL CHEM, V266, P8595; Tesmer JJG, 1999, SCIENCE, V285, P756, DOI 10.1126/science.285.5428.756; WALLACH J, 1994, FEBS LETT, V338, P257, DOI 10.1016/0014-5793(94)80279-3; WU ZL, 1993, J BIOL CHEM, V268, P23766; YOSHIMURA M, 1992, P NATL ACAD SCI USA, V89, P6716, DOI 10.1073/pnas.89.15.6716; YOVELL Y, 1987, P NATL ACAD SCI USA, V84, P9285, DOI 10.1073/pnas.84.24.9285; YU HJ, 1993, MOL PHARMACOL, V44, P689; Zimmermann G, 1998, J BIOL CHEM, V273, P19650, DOI 10.1074/jbc.273.31.19650	61	91	93	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 10	1999	274	50					35539	35545		10.1074/jbc.274.50.35539	http://dx.doi.org/10.1074/jbc.274.50.35539			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	264NG	10585428	hybrid			2022-12-25	WOS:000084187900040
J	Nguyen, VAT; Gao, B				Nguyen, VAT; Gao, B			Cross-talk between alpha(1B)-adrenergic receptor (alpha(1B)AR) and interleukin-6 (IL-6) signaling pathways - Activation of alpha(1B)AR inhibits IL-6-activated STAT3 in hepatic cells by a p42/44 mitogen-activated protein kinase-dependent mechanism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE-PHOSPHATASE; REGENERATING LIVER; COUPLED RECEPTORS; DOWN-REGULATION; INTERFERON; TRANSDUCTION; STIMULATION; HYPERTROPHY; INVOLVEMENT; HEPATOCYTES	Treatment of primary rat hepatocytes or tranfected HepG2 cells with the alpha(1B)-adrenergic receptor (alpha(1B)AR) agonist phenylephrine (PE) significantly inhibited interleukin 6 (IL-6)-induced STAT3 binding, tyrosine phosphorylation, and IL-B-induced serum amyloid A mRNA expression. Western analyses and in vitro kinase assays indicate that this inhibition is not due to either down-regulation of STAT3 protein expression nor inactivation of upstream-located JAK1 and JAK2. Blocking the new RNA and protein syntheses antagonized the inhibitory effect of PE on IL-B-activated STAT3, suggesting synthesis of an inhibitory factor(s) is involved. The inhibitory effect of PE on IL-6 activation of STAT3 was also abolished by the tyrosine phosphatase inhibitor sodium vanadate, indicating involvement of protein tyrosine phosphatases. Furthermore, preincubation of the cells with the specific MEK1 inhibitor PD98059 or a dominant negative MEK1 reversed the inhibitory effect of PE, and expression of constitutively activated MEK1 alone abolished IL-B-activated STAT3. Taken together, these data indicate that PE inhibits IL-6 activation of STAT3 in hepatic cells by a p42/44 mitogen-activated protein kinase-dependent mechanism, and tyrosine phosphatases are involved. This inhibitory cross-talk between the alpha(1B)AR and IL-6 signaling pathways implicates the alpha(1B)AR involvement in regulating the IL-g-mediated inflammatory responses.	Virginia Commonwealth Univ, Med Coll Virginia, Dept Pharmacol & Toxicol, Richmond, VA 23298 USA	Virginia Commonwealth University	Gao, B (corresponding author), Virginia Commonwealth Univ, Med Coll Virginia, Dept Pharmacol & Toxicol, Box 980613, Richmond, VA 23298 USA.				NCI NIH HHS [CA72681] Funding Source: Medline; NIAAA NIH HHS [AA11823] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA072681] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R03AA011823] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		Akira S, 1997, INT J BIOCHEM CELL B, V29, P1401, DOI 10.1016/S1357-2725(97)00063-0; Allgood VE, 1997, BIOCHEMISTRY-US, V36, P224, DOI 10.1021/bi961125c; Aragane Y, 1997, P NATL ACAD SCI USA, V94, P11490, DOI 10.1073/pnas.94.21.11490; Auer KL, 1998, FEBS LETT, V436, P131, DOI 10.1016/S0014-5793(98)01074-6; BASBAUM AI, 1991, CAN J PHYSIOL PHARM, V69, P647, DOI 10.1139/y91-096; Bogoyevitch MA, 1996, BIOCHEM J, V314, P115, DOI 10.1042/bj3140115; Boluyt MO, 1997, CIRC RES, V81, P176, DOI 10.1161/01.RES.81.2.176; Chen EH, 1998, IMMUNOL TODAY, V19, P338, DOI 10.1016/S0167-5699(98)01295-X; Chen JP, 1997, BIOCHEM BIOPH RES CO, V239, P666, DOI 10.1006/bbrc.1997.7531; Chung CD, 1997, SCIENCE, V278, P1803, DOI 10.1126/science.278.5344.1803; COLLINS SM, 1999, CAN J GASTROENTEROL, V13, P47; Cressman DE, 1996, SCIENCE, V274, P1379, DOI 10.1126/science.274.5291.1379; CRUISE JL, 1987, HEPATOLOGY, V7, P1189, DOI 10.1002/hep.1840070604; CRUISE JL, 1985, SCIENCE, V227, P149; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; David M, 1996, J BIOL CHEM, V271, P4585; DellaRocca GJ, 1997, J BIOL CHEM, V272, P19125, DOI 10.1074/jbc.272.31.19125; ELIAS JA, 1992, J LAB CLIN MED, V120, P672; Endo TA, 1997, NATURE, V387, P921, DOI 10.1038/43213; FONG YM, 1989, J IMMUNOL, V142, P2321; GAO B, 1995, J BIOL CHEM, V270, P5614, DOI 10.1074/jbc.270.10.5614; Gao B, 1996, MOL CELL BIOL, V16, P5997; GOOL JV, 1990, CLIN IMMUNOL IMMUNOP, V57, P200; Graham RM, 1996, CIRC RES, V78, P737, DOI 10.1161/01.RES.78.5.737; HAQUE SJ, 1995, J BIOL CHEM, V270, P25709, DOI 10.1074/jbc.270.43.25709; Haspel RL, 1996, EMBO J, V15, P6262, DOI 10.1002/j.1460-2075.1996.tb01016.x; Heinrich PC, 1998, BIOCHEM J, V334, P297, DOI 10.1042/bj3340297; Ihle JN, 1998, ANN NY ACAD SCI, V865, P1, DOI 10.1111/j.1749-6632.1998.tb11157.x; Kim TK, 1996, SCIENCE, V273, P1717, DOI 10.1126/science.273.5282.1717; Liu B, 1998, P NATL ACAD SCI USA, V95, P10626, DOI 10.1073/pnas.95.18.10626; Luttrell LM, 1997, ADV SEC MESS PHOSPH, V31, P263; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MINNEMAN KP, 1994, ANNU REV PHARMACOL, V34, P117; Naka T, 1997, NATURE, V387, P924, DOI 10.1038/43219; NYSTEN MWN, 1987, LANCET, V2, P921; Petricoin E, 1996, MOL CELL BIOL, V16, P1419; Sengupta TK, 1998, P NATL ACAD SCI USA, V95, P11107, DOI 10.1073/pnas.95.19.11107; Sengupta TK, 1996, P NATL ACAD SCI USA, V93, P9499, DOI 10.1073/pnas.93.18.9499; Spector MS, 1997, MOL CELL BIOL, V17, P3556, DOI 10.1128/MCB.17.7.3556; Starr R, 1997, NATURE, V387, P917, DOI 10.1038/43206; Wang DM, 1996, MOL CELL BIOL, V16, P6141; Yasukawa H, 1999, EMBO J, V18, P1309, DOI 10.1093/emboj/18.5.1309; You M, 1999, MOL CELL BIOL, V19, P2416, DOI 10.1128/mcb.19.3.2416; Yu CL, 1997, J BIOL CHEM, V272, P14017, DOI 10.1074/jbc.272.22.14017; Zupke CA, 1998, BIOTECHNOL BIOENG, V58, P222, DOI 10.1002/(SICI)1097-0290(19980420)58:2/3<222::AID-BIT15>3.3.CO;2-F	45	27	27	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 10	1999	274	50					35492	35498		10.1074/jbc.274.50.35492	http://dx.doi.org/10.1074/jbc.274.50.35492			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	264NG	10585421	hybrid			2022-12-25	WOS:000084187900033
J	Yang, XN; Safrany, ST; Shears, SB				Yang, XN; Safrany, ST; Shears, SB			Site-directed mutagenesis of diphosphoinositol polyphosphate phosphohydrolase, a dual specificity NUDT enzyme that attacks diadenosine polyphosphates and diphosphoinositol polyphosphates	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MYO-INOSITOL PHOSPHATES; AMINO-ACID-SEQUENCE; COLI MUTT ENZYME; ATP-BINDING; IN-VITRO; P-LOOP; TETRAKISPHOSPHATE; PROTEIN; DICTYOSTELIUM; KINASE	Diphosphoinositol polyphosphate phosphohydrolase (DIPP) hydrolyzes diadenosine 5',5"-P-1,P-6-hexaphosphate (Ap(6)A), a Nudix (nucleoside diphosphate attached-moiety "x") substrate, and two non-Nudix compounds: diphosphoinositol pentakisphosphate (PP-InsP(5),) and bis-diphosphoinositol tetrakisphosphate (PP)(2)-InsP(4)), Guided by multiple sequence alignments, we used site-directed mutagenesis to obtain new information concerning catalytically essential amino acid residues in DIPP, Mutagenesis of either of two conserved glutamate residues (Glu(66) and Glu(70)) within the Nudt (Nudix-type) catalytic motif impaired hydrolysis of Ap(6)A, PP-InsP(5), and (PP)(2)-InsP(4) >95%; thus, all three substrates are hydrolyzed at the same active site, Two Gly-rich domains (glycine-rich regions 1 and 2 (GR1 and GR2) flank the Nudt motif with potential sites for cation coordination and substrate binding. GR1 comprises a GGG tripeptide, while GR2 is identified as a new functional motif (GX(2)GX(6)G) that is conserved in yeast homologues of DIPP. Mutagenesis of any of these Gly residues in GR1 and GR2 reduced catalytic activity toward all three substrates by up to 95%. More distal to the Nudt motif, H91L and F84Y mutations substantially decreased the rate of Ap(6)A and (PP)(2)-InsP(4) metabolism (by 71 and 96%), yet PP-InsP(5) hydrolysis was only mildly reduced (by 30%); these results indicate substrate-specific roles for His(91) and phe(84), This new information helps define DIPP's structural, functional, and evolutionary relationships to Nudix hydrolases.	NIEHS, Inositide Signaling Grp, Lab Signal Transduct, NIH, Res Triangle Pk, NC 27709 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)	Yang, XN (corresponding author), NIEHS, Inositide Signaling Grp, Lab Signal Transduct, NIH, POB 12233, Res Triangle Pk, NC 27709 USA.	yang3@niehs.nih.gov	Shears, Stephen B/C-6335-2019; Safrany, Stephen/AAX-3332-2020	Shears, Stephen B/0000-0001-7309-8916; Safrany, Stephen/0000-0002-9592-4112	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [ZIAES080046, Z01ES080046] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Albert C, 1997, BIOCHEM J, V327, P553, DOI 10.1042/bj3270553; ALI N, 1995, BIOCHEM J, V310, P279, DOI 10.1042/bj3100279; Bessman MJ, 1996, J BIOL CHEM, V271, P25059, DOI 10.1074/jbc.271.41.25059; BOSSEMEYER D, 1994, TRENDS BIOCHEM SCI, V19, P201, DOI 10.1016/0968-0004(94)90022-1; Brearley CA, 1996, BIOCHEM J, V318, P279, DOI 10.1042/bj3180279; Cai JP, 1997, NUCLEIC ACIDS RES, V25, P1170, DOI 10.1093/nar/25.6.1170; Cartwright JL, 1999, BIOCHEM BIOPH RES CO, V256, P474, DOI 10.1006/bbrc.1999.0354; Conyers GB, 1999, J BIOL CHEM, V274, P1203, DOI 10.1074/jbc.274.3.1203; EUROPEFINNER GN, 1991, BIOCHEM BIOPH RES CO, V181, P191, DOI 10.1016/S0006-291X(05)81400-7; FLEISCHER B, 1994, J BIOL CHEM, V269, P17826; FRICK DN, 1995, J BIOL CHEM, V270, P24086, DOI 10.1074/jbc.270.41.24086; FRICK DN, 1995, BIOCHEMISTRY-US, V34, P5577, DOI 10.1021/bi00016a032; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; GLENNON MC, 1993, BIOCHEM J, V293, P583, DOI 10.1042/bj2930583; Hemmer W, 1997, J BIOL CHEM, V272, P16946, DOI 10.1074/jbc.272.27.16946; Holden CP, 1996, J NEUROCHEM, V67, P574; Huang CF, 1998, BIOCHEMISTRY-US, V37, P14998, DOI 10.1021/bi981920l; Ingram SW, 1999, BIOCHEMISTRY-US, V38, P3649, DOI 10.1021/bi982951j; Jovanovic A, 1998, FEBS LETT, V423, P314, DOI 10.1016/S0014-5793(98)00114-8; KOONIN EV, 1993, NUCLEIC ACIDS RES, V21, P4847, DOI 10.1093/nar/21.20.4847; Laussmann T, 1997, BIOCHEM J, V322, P31, DOI 10.1042/bj3220031; Laussmann T, 1998, FEBS LETT, V426, P145, DOI 10.1016/S0014-5793(98)00329-9; Lin J, 1996, BIOCHEMISTRY-US, V35, P6715, DOI 10.1021/bi953071x; Lin J, 1997, BIOCHEMISTRY-US, V36, P1199, DOI 10.1021/bi962619c; MARTIN JB, 1995, J EUKARYOT MICROBIOL, V42, P183, DOI 10.1111/j.1550-7408.1995.tb01560.x; MARTIN JB, 1993, EUR J BIOCHEM, V214, P711, DOI 10.1111/j.1432-1033.1993.tb17972.x; MATHEW N, 1995, BIOCHEM J, V311, P717, DOI 10.1042/bj3110717; MENNITI FS, 1993, J BIOL CHEM, V268, P3850; Miras-Portugal MT, 1998, FEBS LETT, V430, P78, DOI 10.1016/S0014-5793(98)00560-2; O'Handley SF, 1998, J BIOL CHEM, V273, P3192, DOI 10.1074/jbc.273.6.3192; OGILVIE A, 1996, J AUTON PHARMACOL, V16, P157; PAI EF, 1989, NATURE, V341, P209, DOI 10.1038/341209a0; Safrany ST, 1999, J BIOL CHEM, V274, P21735, DOI 10.1074/jbc.274.31.21735; Safrany ST, 1998, EMBO J, V17, P1710, DOI 10.1093/emboj/17.6.1710; Safrany ST, 1998, EMBO J, V17, P6599, DOI 10.1093/emboj/17.22.6599; SARASTE M, 1990, TRENDS BIOCHEM SCI, V15, P430, DOI 10.1016/0968-0004(90)90281-F; SCHLUTER H, 1994, NATURE, V367, P186, DOI 10.1038/367186a0; SHEARS SB, 1995, J BIOL CHEM, V270, P10489, DOI 10.1074/jbc.270.18.10489; Shears SB, 1998, BBA-MOL CELL BIOL L, V1436, P49, DOI 10.1016/S0005-2760(98)00131-3; Smith CA, 1996, BIOPHYS J, V70, P1590, DOI 10.1016/S0006-3495(96)79745-X; STEPHENS L, 1993, J BIOL CHEM, V268, P4009; Voglmaier SM, 1996, P NATL ACAD SCI USA, V93, P4305, DOI 10.1073/pnas.93.9.4305; YE WL, 1995, J BIOL CHEM, V270, P1564, DOI 10.1074/jbc.270.4.1564; York JD, 1999, SCIENCE, V285, P96, DOI 10.1126/science.285.5424.96	44	36	38	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 10	1999	274	50					35434	35440		10.1074/jbc.274.50.35434	http://dx.doi.org/10.1074/jbc.274.50.35434			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	264NG	10585413	hybrid			2022-12-25	WOS:000084187900025
J	Babiychuk, EB; Palstra, RJTS; Schaller, J; Kampfer, U; Draeger, A				Babiychuk, EB; Palstra, RJTS; Schaller, J; Kampfer, U; Draeger, A			Annexin VI participates in the formation of a reversible, membrane-cytoskeleton complex in smooth muscle cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CONTRACTILE PROPERTIES; PHOSPHOLIPID-BINDING; ACTIN; LOCALIZATION; CAVEOLAE; PROTEIN; TRANSLOCATION; CALCIUM; LUNG; FIBROBLASTS	The plasmalemma of smooth muscle cells is periodically banded. This arrangement ensures efficient transmission of contractile activity, via the firm, actin-anchoring regions, while the more elastic caveolae-containing "hinge" regions facilitate rapid cellular adaptation to changes in cell length. Since cellular mechanics are undoubtedly regulated by components of the membrane and cytoskeleton, we have investigated the potential role played by annexins (a family of phospholipid- and actin-binding, Ca2+-regulated proteins) in regulating sarcolemmal organization, Stimulation of smooth muscle cells elicited a relocation of annexin VI from the cytoplasm to the plasmalemma, In smooth, but not in striated muscle extracts, annexins II and VI coprecipitated with actomyosin and the caveolar fraction of the sarcolemma at elevated Ca2+ concentrations. Recombination of actomyosin, annexins, and caveolar lipids in the presence of Ca2+ led to formation of a structured precipitate. Participation of all 3 components was required, indicating that a Ca2+-dependent, cytoskeleton-membrane complex had been generated. This association, which occurred at physiological Ca2+ concentrations, corroborates our biochemical fractionation and immunohistochemical findings and suggests that annexins play a role in regulating sarcolemmal organization during smooth muscle contraction.	Univ Bern, Inst Anat, CH-3012 Bern, Switzerland; Kiev State Univ, Inst Physiol, UA-352031 Kiev, Ukraine; Univ Bern, Inst Biochem, CH-3012 Bern, Switzerland	University of Bern; Ministry of Education & Science of Ukraine; Taras Shevchenko National University Kiev; University of Bern	Babiychuk, EB (corresponding author), Univ Bern, Inst Anat, CH-3012 Bern, Switzerland.		Babiychuk, Eduard/AAV-7223-2021	Babiychuk, Eduard/0000-0003-1786-0085; Palstra, Robert-Jan/0000-0003-4600-2303				Barwise JL, 1996, FEBS LETT, V394, P213, DOI 10.1016/0014-5793(96)00950-7; Blanchard S, 1996, J NEUROCHEM, V67, P805; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BURRIDGE K, 1988, ANNU REV CELL BIOL, V4, P487, DOI 10.1146/annurev.cb.04.110188.002415; CHANG WJ, 1994, J CELL BIOL, V126, P127, DOI 10.1083/jcb.126.1.127; ChasserotGolaz S, 1996, J CELL BIOL, V133, P1217, DOI 10.1083/jcb.133.6.1217; Diakonova M, 1997, J CELL SCI, V110, P1199; DRAEGER A, 1989, J CELL SCI, V94, P703; Ehler E, 1996, CELL MOTIL CYTOSKEL, V34, P288, DOI 10.1002/(SICI)1097-0169(1996)34:4<288::AID-CM4>3.0.CO;2-4; FABIATO A, 1979, J PHYSIOL-PARIS, V75, P463; FUJIMOTO T, 1992, J CELL BIOL, V119, P1507, DOI 10.1083/jcb.119.6.1507; GABELLA G, 1976, CELL TISSUE RES, V170, P187; GERKE V, 1984, EMBO J, V3, P227, DOI 10.1002/j.1460-2075.1984.tb01789.x; Gerke V, 1997, BBA-MOL CELL RES, V1357, P129, DOI 10.1016/S0167-4889(97)00038-4; GLENNEY J, 1986, P NATL ACAD SCI USA, V83, P4258, DOI 10.1073/pnas.83.12.4258; GLENNEY JR, 1987, J CELL BIOL, V104, P503, DOI 10.1083/jcb.104.3.503; HARRISON SM, 1989, AM J PHYSIOL, V256, pC1250, DOI 10.1152/ajpcell.1989.256.6.C1250; HARTSHORNE DJ, 1987, PHYSL GASTROINTESTIN, P423; HOSOYA H, 1992, CELL MOTIL CYTOSKEL, V22, P200, DOI 10.1002/cm.970220307; HUNKAPILLER MW, 1983, METHOD ENZYMOL, V91, P399; IIDA H, 1992, J HISTOCHEM CYTOCHEM, V40, P1899, DOI 10.1177/40.12.1453007; IKEBUCHI NW, 1990, J BIOL CHEM, V265, P3392; IZUMI T, 1988, ANAT REC, V220, P225, DOI 10.1002/ar.1092200302; Jostarndt-Fogen K, 1998, HISTOCHEM CELL BIOL, V110, P273, DOI 10.1007/s004180050289; Kang SA, 1996, BRIT J PHARMACOL, V117, P1780, DOI 10.1111/j.1476-5381.1996.tb15354.x; Kaufman M, 1996, BIOCHEM J, V316, P35, DOI 10.1042/bj3160035; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LISANTI MP, 1994, J CELL BIOL, V126, P111, DOI 10.1083/jcb.126.1.111; MACALA LJ, 1983, J LIPID RES, V24, P1243; Massey-Harroche D, 1998, J CELL SCI, V111, P3007; Parkin ET, 1996, BIOCHEM J, V319, P887, DOI 10.1042/bj3190887; Raynal P, 1996, FEBS LETT, V392, P263, DOI 10.1016/0014-5793(96)00827-7; Raynal P, 1997, BIOCHEM J, V322, P365, DOI 10.1042/bj3220365; RAYNAL P, 1994, BBA-REV BIOMEMBRANES, V1197, P63, DOI 10.1016/0304-4157(94)90019-1; Sagot I, 1997, FEBS LETT, V410, P229, DOI 10.1016/S0014-5793(97)00594-2; SCHNITZER JE, 1995, SCIENCE, V269, P1435, DOI 10.1126/science.7660128; Selbert S, 1996, EXP CELL RES, V222, P199, DOI 10.1006/excr.1996.0025; SMALL JV, 1995, BIOESSAYS, V17, P785, DOI 10.1002/bies.950170908; SMALL JV, 1992, EUR J BIOCHEM, V208, P559, DOI 10.1111/j.1432-1033.1992.tb17220.x; SMART EJ, 1995, P NATL ACAD SCI USA, V92, P10104, DOI 10.1073/pnas.92.22.10104; SOBIESZEK A, 1975, EUR J BIOCHEM, V55, P49, DOI 10.1111/j.1432-1033.1975.tb02137.x; Stan RV, 1997, MOL BIOL CELL, V8, P595, DOI 10.1091/mbc.8.4.595; TOKUYASU KT, 1980, HISTOCHEM J, V12, P381, DOI 10.1007/BF01011956; TOKUYASU KT, 1989, HISTOCHEM J, V21, P163, DOI 10.1007/BF01007491; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VILLA A, 1993, J CELL BIOL, V121, P1041, DOI 10.1083/jcb.121.5.1041	46	87	87	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 3	1999	274	49					35191	35195		10.1074/jbc.274.49.35191	http://dx.doi.org/10.1074/jbc.274.49.35191			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	260XW	10575003	hybrid			2022-12-25	WOS:000083979600097
J	Li, XR; Chong, ASF; Wu, JM; Roebuck, KA; Kumar, A; Parrillo, JE; Rapp, UR; Kimberly, RP; Williams, JW; Xu, XL				Li, XR; Chong, ASF; Wu, JM; Roebuck, KA; Kumar, A; Parrillo, JE; Rapp, UR; Kimberly, RP; Williams, JW; Xu, XL			Transcriptional regulation of fas gene expression by GA-binding protein and AP-1 in T cell antigen receptor CD3 complex-stimulated T cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-TRANSDUCTION PATHWAY; LIGAND EXPRESSION; MAP KINASE; INDUCED APOPTOSIS; RESPONSE ELEMENT; CYCLOSPORINE-A; DEATH FACTOR; ACTIVATION; PROMOTER; CD95	Fas (CD95 or APO-1), a transmembrane cell surface receptor of the tumor necrosis factor receptor family, is up-regulated in activated T lymphocytes. Our present study identified an upstream enhancer element (between nucleotide positions -862 and -682) containing a GA-binding protein (GABP) site and a low affinity activating protein-1 (AP-l)-binding site. T cell activation increased the DNA binding of GABP and AP-1 to this enhancer site. The specificity of GABP and AP-1 binding was demonstrated by competition electrophoretic mobility shift assay and supershift electrophoretic mobility shift assay with antibodies against GABP and AP-1, respectively. Mutational analysis of Fas promoter revealed that both GABP- and AP-l-binding sites were required for initiating Fas gene transcription. We further show that anti-CD3 mAb, phorbol 12-myristate 13-acetate, and phorbol l2-myristate 13-acetate/ionomycin strongly activated promoters carrying multiple copies of the Fas enhancer, and mutation of either the GABP or AP-1 binding site severely reduced transcriptional activity. Taken together, these results suggest that the transcription factors GABP and AP-1 play a critical role in the induction of Fas gene expression in T cell antigen receptor CD3-stimulated Jurkat cells.	Rush Presbyterian St Lukes Med Ctr, Dept Gen Surg, Chicago, IL 60612 USA; Rush Presbyterian St Lukes Med Ctr, Dept Immunol Microbiol, Chicago, IL 60612 USA; Rush Presbyterian St Lukes Med Ctr, Dept Med, Chicago, IL 60612 USA; Univ Alabama, Dept Med, Sch Med, Div Clin Immunol & Rheumatol, Birmingham, AL 35284 USA; Univ Wurzburg, Inst Med Radiat Res & Cell Biol, D-97080 Wurzburg, Germany	Rush University; Rush University; Rush University; University of Alabama System; University of Alabama Birmingham; University of Wurzburg	Xu, XL (corresponding author), Rush Presbyterian St Lukes Med Ctr, Dept Gen Surg, 1653 W Congress Pkwy, Chicago, IL 60612 USA.			Kimberly, Robert/0000-0002-5330-3086	NATIONAL CANCER INSTITUTE [R29CA076407] Funding Source: NIH RePORTER; NCI NIH HHS [R29-CA 76407] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AlberolaIla J, 1997, ANNU REV IMMUNOL, V15, P125, DOI 10.1146/annurev.immunol.15.1.125; Avots A, 1997, MOL CELL BIOL, V17, P4381, DOI 10.1128/MCB.17.8.4381; Avraham A, 1998, EUR J IMMUNOL, V28, P2320, DOI 10.1002/(SICI)1521-4141(199808)28:08<2320::AID-IMMU2320>3.0.CO;2-K; BASSUK AG, 1995, IMMUNITY, V3, P223, DOI 10.1016/1074-7613(95)90092-6; BEHRMANN I, 1994, EUR J IMMUNOL, V24, P3057, DOI 10.1002/eji.1830241221; BRUNNER T, 1995, NATURE, V373, P441, DOI 10.1038/373441a0; Brunner T, 1996, INT IMMUNOL, V8, P1017, DOI 10.1093/intimm/8.7.1017; CANO E, 1995, TRENDS BIOCHEM SCI, V20, P117, DOI 10.1016/S0968-0004(00)88978-1; Cantrell D, 1996, ANNU REV IMMUNOL, V14, P259, DOI 10.1146/annurev.immunol.14.1.259; CARTER RS, 1994, J BIOL CHEM, V269, P4381; Chan H, 1999, MOL CELL BIOL, V19, P2098, DOI 10.1128/mcb.19.3.2098; CHEN RH, 1992, MOL CELL BIOL, V12, P915, DOI 10.1128/MCB.12.3.915; CHENG JH, 1995, J IMMUNOL, V154, P1239; COBB MH, 1995, J BIOL CHEM, V270, P14843, DOI 10.1074/jbc.270.25.14843; CREWS CM, 1992, SCIENCE, V258, P478, DOI 10.1126/science.1411546; DAVIS RJ, 1994, TRENDS BIOCHEM SCI, V19, P470, DOI 10.1016/0968-0004(94)90132-5; DENT P, 1992, SCIENCE, V257, P1404, DOI 10.1126/science.1326789; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DHEIN J, 1995, NATURE, V373, P438, DOI 10.1038/373438a0; Faris M, 1998, J IMMUNOL, V160, P134; Faris M, 1998, MOL CELL BIOL, V18, P5414, DOI 10.1128/MCB.18.9.5414; Flory E, 1996, J VIROL, V70, P2260, DOI 10.1128/JVI.70.4.2260-2268.1996; FUKUNAGA R, 1997, EMBO J, V16, P1962; GUPTA S, 1995, SCIENCE, V267, P389, DOI 10.1126/science.7824938; Han JH, 1996, J BIOL CHEM, V271, P2886, DOI 10.1074/jbc.271.6.2886; HIBI M, 1993, GENE DEV, V7, P21235; Hoffmeyer A, 1998, J BIOL CHEM, V273, P10112, DOI 10.1074/jbc.273.17.10112; Holtz-Heppelmann CJ, 1998, J BIOL CHEM, V273, P4416, DOI 10.1074/jbc.273.8.4416; HOWE LR, 1992, CELL, V71, P335, DOI 10.1016/0092-8674(92)90361-F; Ichijo H, 1997, SCIENCE, V275, P90, DOI 10.1126/science.275.5296.90; Jacinto E, 1998, IMMUNITY, V8, P31, DOI 10.1016/S1074-7613(00)80456-2; Janknecht R, 1997, EMBO J, V16, P1620, DOI 10.1093/emboj/16.7.1620; JONES NC, 1988, GENE DEV, V2, P267, DOI 10.1101/gad.2.3.267; JU ST, 1995, NATURE, V373, P444, DOI 10.1038/373444a0; KLAS C, 1993, INT IMMUNOL, V5, P625, DOI 10.1093/intimm/5.6.625; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; LAMARCO K, 1991, SCIENCE, V253, P789, DOI 10.1126/science.1876836; LAMARCO KL, 1989, GENE DEV, V3, P1372, DOI 10.1101/gad.3.9.1372; Latinis KM, 1997, J IMMUNOL, V158, P4602; Latinis KM, 1997, J BIOL CHEM, V272, P31427, DOI 10.1074/jbc.272.50.31427; Li-Weber M, 1998, EUR J IMMUNOL, V28, P2373, DOI 10.1002/(SICI)1521-4141(199808)28:08<2373::AID-IMMU2373>3.0.CO;2-T; Mittelstadt PR, 1998, MOL CELL BIOL, V18, P3744, DOI 10.1128/MCB.18.7.3744; NAGATA S, 1995, SCIENCE, V267, P1449, DOI 10.1126/science.7533326; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; Norian LA, 1998, J IMMUNOL, V161, P1078; PRICE MA, 1995, EMBO J, V14, P2589, DOI 10.1002/j.1460-2075.1995.tb07257.x; Raingeaud J, 1996, MOL CELL BIOL, V16, P1247; Rudd CE, 1996, IMMUNITY, V4, P527, DOI 10.1016/S1074-7613(00)80479-3; SEGER R, 1995, FASEB J, V9, P726, DOI 10.1096/fasebj.9.9.7601337; STOKOE D, 1992, EMBO J, V11, P3985, DOI 10.1002/j.1460-2075.1992.tb05492.x; Su B, 1996, CURR OPIN IMMUNOL, V8, P402, DOI 10.1016/S0952-7915(96)80131-2; THOMPSON CC, 1991, SCIENCE, V253, P765; WADA N, 1995, J BIOL CHEM, V270, P18007, DOI 10.1074/jbc.270.30.18007; Wang RX, 1998, J IMMUNOL, V161, P2201; Wange RL, 1996, IMMUNITY, V5, P197, DOI 10.1016/S1074-7613(00)80315-5; WASYLYK B, 1993, EUR J BIOCHEM, V211, P7, DOI 10.1111/j.1432-1033.1993.tb19864.x; WATANABE H, 1993, MOL CELL BIOL, V13, P1385, DOI 10.1128/MCB.13.3.1385; WEISS A, 1994, CELL, V76, P263, DOI 10.1016/0092-8674(94)90334-4; Werlen G, 1998, EMBO J, V17, P3101, DOI 10.1093/emboj/17.11.3101; WOOD KW, 1992, CELL, V68, P1041, DOI 10.1016/0092-8674(92)90076-O; YAMAGUCHI K, 1995, SCIENCE, V270, P2008, DOI 10.1126/science.270.5244.2008	61	42	48	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 3	1999	274	49					35203	35210		10.1074/jbc.274.49.35203	http://dx.doi.org/10.1074/jbc.274.49.35203			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	260XW	10575005	hybrid			2022-12-25	WOS:000083979600099
J	Sher, I; Weizman, A; Lubinsky-Mink, S; Lang, T; Adir, N; Schomburg, D; Ron, D				Sher, I; Weizman, A; Lubinsky-Mink, S; Lang, T; Adir, N; Schomburg, D; Ron, D			Mutations uncouple human fibroblast growth factor (FGF)-7 biological activity and receptor binding and support broad specificity in the secondary receptor binding site of FGFs	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							3-DIMENSIONAL STRUCTURES; SIGNAL-TRANSDUCTION; HEPARAN-SULFATE; FACTOR FAMILY; KGF RECEPTOR; EXPRESSION; MOLECULES; LIGAND; CLONING; PROTEIN	The fibroblast growth factor (FGF) family plays a key role in a multitude of physiological and pathological processes. The activities of FGFs are mediated by a family of tyrosine kinase receptors, designated FGFRs, The mechanism by which FGFs induce receptor activation is controversial. Despite their structural similarity, FGFs display distinct receptor binding characteristics and cell type specificity. Previous studies with FGF-2 identified a low affinity receptor binding site that is located within a loop connecting its 9th and 10th beta-strands, The corresponding residues in the other family members are highly variable, and it was proposed that the variability might confer on FGFs unique receptor binding characteristics. We studied the role of this loop in FGF-7 by both site-directed mutagenesis and loop replacement. Unlike the other members of the FGF family, FGF-7 recognizes only one FGFR isoform and is, therefore, ideal for studies of how the specificity in the FGF-FGFR interaction is conferred at the structural level, Point mutations in the loop of FGF-7 did not change receptor binding affinity but resulted in reduced mitogenic potency and reduced ability to induce receptor-mediated phosphorylation events. These results suggest that the loop of FGF-I? fulfills the role of low affinity binding site required for receptor activation. The observation that it is possible to uncouple FGF-7 receptor binding and biological activity favors a bivalent model for FGFR dimerization, and it may be clinically relevant to the design of FGF-7 antagonists. Reciprocal loop replacement between FGF-7 and FGF-S had no effect on their known receptor binding affinities nor did it alter their known specificity in eliciting a mitogenic response. In conclusion, these results suggest that, despite the diversity in the loop structure of FGF-2 and FGF-7, the loop has a similar function in both growth factors.	Technion Israel Inst Technol, Dept Biol, IL-32000 Haifa, Israel; Technion Israel Inst Technol, Dept Chem, IL-32000 Haifa, Israel; Univ Cologne, Inst Biochem, D-50674 Cologne, Germany	Technion Israel Institute of Technology; Technion Israel Institute of Technology; University of Cologne	Ron, D (corresponding author), Technion Israel Inst Technol, Dept Biol, IL-32000 Haifa, Israel.	Dinar@tx.technion.ac.il	Adir, Noam/ABE-6990-2020	Schomburg, Dietmar/0000-0002-3354-822X				AARONSON SA, 1991, ANN NY ACAD SCI, V638, P62, DOI 10.1111/j.1749-6632.1991.tb49018.x; ARMSTRONG E, 1992, CANCER RES, V52, P2004; BASILICO C, 1992, ADV CANCER RES, V59, P115, DOI 10.1016/S0065-230X(08)60305-X; BOTTARO DP, 1990, J BIOL CHEM, V265, P12767; Brauchle M, 1996, AM J PATHOL, V149, P521; COPELAND RA, 1991, ARCH BIOCHEM BIOPHYS, V289, P53, DOI 10.1016/0003-9861(91)90441-K; DIONNE CA, 1990, EMBO J, V9, P2685, DOI 10.1002/j.1460-2075.1990.tb07454.x; FECHTELER T, 1995, J MOL BIOL, V253, P114, DOI 10.1006/jmbi.1995.0540; FLANAGAN JG, 1990, CELL, V63, P185, DOI 10.1016/0092-8674(90)90299-T; GENGRINOVITCH S, 1995, J BIOL CHEM, V270, P15059, DOI 10.1074/jbc.270.25.15059; Hsu YR, 1999, BIOCHEMISTRY-US, V38, P2523, DOI 10.1021/bi9821317; JAYE M, 1992, BIOCHIM BIOPHYS ACTA, V1135, P185, DOI 10.1016/0167-4889(92)90136-Y; LEMMON MA, 1994, TRENDS BIOCHEM SCI, V19, P459, DOI 10.1016/0968-0004(94)90130-9; Lessel U, 1997, PROTEIN ENG, V10, P659, DOI 10.1093/protein/10.6.659; Lopez-Otin C, 1998, ENDOCR REV, V19, P365, DOI 10.1210/er.19.4.365; MARCHUK D, 1991, NUCLEIC ACIDS RES, V19, P1154, DOI 10.1093/nar/19.5.1154; McKeehan WL, 1998, PROG NUCLEIC ACID RE, V59, P135; MIKI T, 1991, SCIENCE, V251, P72, DOI 10.1126/science.1846048; OLWIN BB, 1989, J CELL BIOCHEM, V39, P443, DOI 10.1002/jcb.240390410; Ong SH, 1996, BIOCHEM BIOPH RES CO, V225, P1021, DOI 10.1006/bbrc.1996.1288; ORNITZ DM, 1992, J BIOL CHEM, V267, P16305; Osslund TD, 1998, PROTEIN SCI, V7, P1681, DOI 10.1002/pro.5560070803; PANTOLIANO MW, 1994, BIOCHEMISTRY-US, V33, P10229, DOI 10.1021/bi00200a003; PARKS TD, 1994, ANAL BIOCHEM, V216, P413, DOI 10.1006/abio.1994.1060; PEARLMAN DA, 1995, COMPUT PHYS COMMUN, V91, P1, DOI 10.1016/0010-4655(95)00041-D; REICHSLOTKY R, 1994, J BIOL CHEM, V269, P32279; REICHSLOTKY R, 1995, J BIOL CHEM, V270, P29813; RON D, 1993, J BIOL CHEM, V268, P2984; RON D, 1993, J BIOL CHEM, V268, P5388; Rubin J S, 1995, EXS, V74, P191; RUBIN JS, 1989, P NATL ACAD SCI USA, V86, P802, DOI 10.1073/pnas.86.3.802; SAIKI RK, 1985, SCIENCE, V230, P1350, DOI 10.1126/science.2999980; SCHOMBURG D, 1988, J MOL GRAPHICS, V6, P161, DOI 10.1016/0263-7855(88)80069-9; SEDDON AP, 1995, BIOCHEMISTRY-US, V34, P731, DOI 10.1021/bi00003a004; SHAOUL E, 1995, ONCOGENE, V10, P1553; SPIVAKKROIZMAN T, 1994, CELL, V79, P1015, DOI 10.1016/0092-8674(94)90032-9; SPRINGER BA, 1994, J BIOL CHEM, V269, P26879; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; Venkataraman G, 1999, P NATL ACAD SCI USA, V96, P3658, DOI 10.1073/pnas.96.7.3658; Vlodavsky I, 1996, CANCER METAST REV, V15, P177, DOI 10.1007/BF00437470; Wells JA, 1996, P NATL ACAD SCI USA, V93, P1, DOI 10.1073/pnas.93.1.1; WERNER S, 1992, MOL CELL BIOL, V12, P82, DOI 10.1128/MCB.12.1.82; YASUKAWA T, 1995, J BIOL CHEM, V270, P25328, DOI 10.1074/jbc.270.43.25328; ZHU X, 1991, SCIENCE, V251, P90, DOI 10.1126/science.1702556	44	16	21	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 3	1999	274	49					35016	35022		10.1074/jbc.274.49.35016	http://dx.doi.org/10.1074/jbc.274.49.35016			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	260XW	10574979	hybrid			2022-12-25	WOS:000083979600073
J	Maung, K; Easty, DJ; Hill, SP; Bennett, DC				Maung, K; Easty, DJ; Hill, SP; Bennett, DC			Requirement for focal adhesion kinase in tumor cell adhesion	ONCOGENE			English	Article						FAK; tyrosine kinase; melanoma; antisense oligonucleotides; focal adhesion	PROTEIN-TYROSINE KINASE; NORMAL HUMAN MELANOCYTES; SIGNAL-TRANSDUCTION; MALIGNANT-MELANOMA; EXPRESSION; PP125(FAK); PHOSPHORYLATION; FIBRONECTIN; APOPTOSIS; MATRIX	Focal adhesion kinase (FAK) is a nonreceptor protein tyrosine kinase and a major phosphotyrosine-containing protein. FAK is found in cell-matrix attachment sites (focal adhesions), and is activated on integrin-ligand binding and by other signaling pathways. Several roles have been proposed for FAK; here we report a novel function. We observed abundant FAK protein in all human melanoma cell lines tested except COLO839, a line that grows predominantly in suspension and was derived from peripheral blood. Five adherent lines, isolated from solid metastases in the same patient as COLO839, did express FAK. We derived four adherent sublines from COLO839. These did express FAK, even when plated on bacteriological plastic, to which they did not adhere. Thus, substrate attachment was not required for FAK expression. Three of the adherent sublines were then grown in the presence of antisense oligonucleotides to the initial FAK coding sequence. All showed substantially reduced FAK expression and, interestingly, the cells largely detached from the substrate while continuing to grow. Similar results were obtained with an independent melanoma line, DX3. Thus, FAK expression appears to be required by melanoma cells for substrate adhesion.	St George Hosp, Sch Med, Dept Anat & Dev Biol, London SW17 0RE, England	St Georges University London	Bennett, DC (corresponding author), St George Hosp, Sch Med, Dept Anat & Dev Biol, Cranmer Terrace, London SW17 0RE, England.		Bennett, Dorothy C/C-2418-2008	Bennett, Dorothy C/0000-0002-3639-7527				AKASAKA T, 1995, J INVEST DERMATOL, V105, P104, DOI 10.1111/1523-1747.ep12313396; ANDRE E, 1993, BIOCHEM BIOPH RES CO, V190, P140, DOI 10.1006/bbrc.1993.1022; BURRIDGE K, 1992, J CELL BIOL, V119, P893, DOI 10.1083/jcb.119.4.893; Crooke ST, 1996, ANNU REV PHARMACOL, V36, P107, DOI 10.1146/annurev.pa.36.040196.000543; EASTY DJ, 1993, J INVEST DERMATOL, V101, P679, DOI 10.1111/1523-1747.ep12371675; EASTY DJ, 1995, INT J CANCER, V60, P129, DOI 10.1002/ijc.2910600119; Easty DJ, 1997, INT J CANCER, V71, P1061, DOI 10.1002/(SICI)1097-0215(19970611)71:6<1061::AID-IJC24>3.0.CO;2-F; Frisch SM, 1996, J CELL BIOL, V134, P793, DOI 10.1083/jcb.134.3.793; FURUTA Y, 1995, ONCOGENE, V11, P1989; GUAN JL, 1992, NATURE, V358, P690, DOI 10.1038/358690a0; HANKS SK, 1992, P NATL ACAD SCI USA, V89, P8487, DOI 10.1073/pnas.89.18.8487; Ilic D, 1997, J CELL SCI, V110, P401; ILLC D, 1995, NATURE, V377, P539; KANNER SB, 1990, P NATL ACAD SCI USA, V87, P3328, DOI 10.1073/pnas.87.9.3328; Khwaja A, 1997, EMBO J, V16, P2783, DOI 10.1093/emboj/16.10.2783; KORNBERG L, 1992, J BIOL CHEM, V267, P23439; LEE ST, 1993, ONCOGENE, V8, P3403; MIELE ME, 1994, EXP CELL RES, V214, P231, DOI 10.1006/excr.1994.1253; MORSE HG, 1993, CANCER GENET CYTOGEN, V69, P108, DOI 10.1016/0165-4608(93)90083-X; Otey CA, 1996, INT REV CYTOL, V167, P161, DOI 10.1016/S0074-7696(08)61347-9; OWENS LV, 1995, CANCER RES, V55, P2752; Richardson A, 1997, MOL CELL BIOL, V17, P6906, DOI 10.1128/MCB.17.12.6906; RICHARDSON A, 1995, BIOESSAYS, V17, P229, DOI 10.1002/bies.950170309; Richardson A, 1996, NATURE, V380, P538, DOI 10.1038/380538a0; ROZENGURT E, 1995, CANCER SURV, V24, P81; SCHALLER MD, 1992, P NATL ACAD SCI USA, V89, P5192, DOI 10.1073/pnas.89.11.5192; SCHLAEPFER DD, 1994, NATURE, V372, P786; SCOTT G, 1995, EXP CELL RES, V219, P197, DOI 10.1006/excr.1995.1219; Scott G, 1997, J INVEST DERMATOL, V108, P147, DOI 10.1111/1523-1747.ep12332650; Shibata K, 1998, CANCER RES, V58, P900; Sonoda Y, 1997, BIOCHEM BIOPH RES CO, V241, P769, DOI 10.1006/bbrc.1997.7895; Takeuchi Y, 1997, J BIOL CHEM, V272, P29309, DOI 10.1074/jbc.272.46.29309; VANDENOORD JJ, 1994, AM J PATHOL, V145, P294; WEINER TM, 1993, LANCET, V342, P1024, DOI 10.1016/0140-6736(93)92881-S; WHITNEY GS, 1993, DNA CELL BIOL, V12, P823, DOI 10.1089/dna.1993.12.823; Xu LH, 1998, CELL GROWTH DIFFER, V9, P999; Xu LH, 1996, CELL GROWTH DIFFER, V7, P413; ZHANG XA, 1995, GENE, V160, P219, DOI 10.1016/0378-1119(95)00153-W	38	49	56	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 18	1999	18	48					6824	6828		10.1038/sj.onc.1203094	http://dx.doi.org/10.1038/sj.onc.1203094			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	257QA	10597292				2022-12-25	WOS:000083792000026
J	Peterziel, H; Mink, S; Schonert, A; Becker, M; Klocker, H; Cato, ACB				Peterziel, H; Mink, S; Schonert, A; Becker, M; Klocker, H; Cato, ACB			Rapid signalling by androgen receptor in prostate cancer cells	ONCOGENE			English	Article						androgen receptor; anti-androgens; growth factors; MAP kinase; rapid response	PROTEIN-KINASE CASCADE; MAMMARY-TUMOR VIRUS; DNA-BINDING DOMAIN; INTRACELLULAR CALCIUM; WITHDRAWAL SYNDROME; MAP KINASE; ACTIVATION; TRANSCRIPTION; GROWTH; MOUSE	Androgens are important growth regulators in prostate cancer. Their known mode of action in target cells requires binding to a cytoplasmic androgen receptor followed by a nuclear translocation event and modulation of the expression of specific genes. Here, we report another mode of action of this receptor. Treatment of androgen responsive prostate cancer cells with dihydrotestosterone leads to a rapid and reversible activation of mitogen-activated protein kinases MAPKs (also called extracellular signal-regulated kinases or Erks). Transient transfection assays demonstrated that the androgen receptor-mediated activation of MAP kinase results in enhanced activity of the transcription factor Elk-1. This action of the androgen receptor differs from its known transcriptional activity since it is rapid and insensitive to androgen antagonists such as hydroxyflutamide or casodex. Biochemical studies as well as analyses with dominant negative mutants showed the involvement of kinases such as MAPK/Erk kinase, phosphatidyl-inositol 3-kinase and protein kinase C in the androgen receptor-mediated activation of MAP kinase. These results demonstrate a novel regulatory action of the androgen receptor and prove that in addition to its known transcriptional effects, it also uses non-conventional means to modulate several cellular signalling processes.	Forschungszentrum Karlsruhe, Inst Genet & Toxikol, D-76021 Karlsruhe, Germany; Univ Innsbruck, Dept Urol, A-6020 Innsbruck, Austria	Helmholtz Association; Karlsruhe Institute of Technology; University of Innsbruck	Cato, ACB (corresponding author), Forschungszentrum Karlsruhe, Inst Genet & Toxikol, Postfach 3640, D-76021 Karlsruhe, Germany.		Klocker, Helmut/AAI-7130-2020; Cato, Andrew C. B./H-2071-2013	Cato, Andrew C. B./0000-0001-8508-3834				AHN NG, 1991, J BIOL CHEM, V266, P4220; BEATO M, 1995, CELL, V83, P851, DOI 10.1016/0092-8674(95)90201-5; BEATO M, 1989, CELL, V56, P335, DOI 10.1016/0092-8674(89)90237-7; BERREVOETS CA, 1993, J STEROID BIOCHEM, V46, P731, DOI 10.1016/0960-0760(93)90313-L; Brennan P, 1997, IMMUNITY, V7, P679, DOI 10.1016/S1074-7613(00)80388-X; BRUDER JT, 1992, GENE DEV, V6, P545, DOI 10.1101/gad.6.4.545; Castoria G, 1999, EMBO J, V18, P2500, DOI 10.1093/emboj/18.9.2500; CATO ACB, 1987, EMBO J, V6, P363, DOI 10.1002/j.1460-2075.1987.tb04763.x; CUNHA GR, 1987, ENDOCR REV, V8, P338, DOI 10.1210/edrv-8-3-338; CURRAN T, 1982, J VIROL, V44, P674, DOI 10.1128/JVI.44.2.674-682.1982; DiDomenico M, 1996, CANCER RES, V56, P4516; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; Endoh H, 1997, BIOCHEM BIOPH RES CO, V235, P99, DOI 10.1006/bbrc.1997.6746; FABBRO D, 1986, BIOCHEM BIOPH RES CO, V135, P65, DOI 10.1016/0006-291X(86)90943-5; FORT P, 1985, NUCLEIC ACIDS RES, V13, P1431, DOI 10.1093/nar/13.5.1431; GILLE H, 1995, CURR BIOL, V5, P1191, DOI 10.1016/S0960-9822(95)00235-1; GILLE H, 1995, EMBO J, V14, P951, DOI 10.1002/j.1460-2075.1995.tb07076.x; HAM J, 1988, NUCLEIC ACIDS RES, V16, P5263, DOI 10.1093/nar/16.12.5263; HE WW, 1991, NUCLEIC ACIDS RES, V19, P2373, DOI 10.1093/nar/19.9.2373; Heck S, 1997, EMBO J, V16, P4698, DOI 10.1093/emboj/16.15.4698; Improta-Brears T, 1999, P NATL ACAD SCI USA, V96, P4686, DOI 10.1073/pnas.96.8.4686; KALLIO PJ, 1995, MOL ENDOCRINOL, V9, P1017, DOI 10.1210/me.9.8.1017; Kamano H, 1995, ONCOGENE, V11, P2575; KLOCKER H, 1992, AM J HUM GENET, V50, P1318; Kortenjann M, 1995, CRIT REV ONCOGENESIS, V6, P99; LIEBERHERR M, 1994, J BIOL CHEM, V269, P7217; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; MARCELLI M, 1991, J CLIN INVEST, V87, P1123, DOI 10.1172/JCI115076; Marcinkowska E, 1997, BIOCHEM BIOPH RES CO, V241, P419, DOI 10.1006/bbrc.1997.7832; McEwan IJ, 1997, P NATL ACAD SCI USA, V94, P8485, DOI 10.1073/pnas.94.16.8485; Migliaccio A, 1996, EMBO J, V15, P1292, DOI 10.1002/j.1460-2075.1996.tb00471.x; Migliaccio A, 1998, EMBO J, V17, P2008, DOI 10.1093/emboj/17.7.2008; Moul J W, 1995, Semin Urol, V13, P157; OFFRINGA R, 1990, CELL, V62, P527, DOI 10.1016/0092-8674(90)90017-9; Razandi M, 1999, MOL ENDOCRINOL, V13, P307, DOI 10.1210/me.13.2.307; SCHER HI, 1993, J CLIN ONCOL, V11, P1566, DOI 10.1200/JCO.1993.11.8.1566; Schneikert J, 1996, J BIOL CHEM, V271, P23907, DOI 10.1074/jbc.271.39.23907; SMALL EJ, 1994, UROLOGY, V43, P408, DOI 10.1016/0090-4295(94)90092-2; STEINSAPIR J, 1991, BIOCHEM BIOPH RES CO, V179, P90, DOI 10.1016/0006-291X(91)91338-D; TOULLEC D, 1991, J BIOL CHEM, V266, P15771; Treisman R, 1996, CURR OPIN CELL BIOL, V8, P205, DOI 10.1016/S0955-0674(96)80067-6; Voegel JJ, 1996, EMBO J, V15, P3667, DOI 10.1002/j.1460-2075.1996.tb00736.x; Ward SG, 1996, IMMUNOL TODAY, V17, P187, DOI 10.1016/0167-5699(96)80618-9; Yang SH, 1998, MOL CELL BIOL, V18, P710, DOI 10.1128/MCB.18.2.710; Yeh SY, 1996, P NATL ACAD SCI USA, V93, P5517, DOI 10.1073/pnas.93.11.5517; Zhang J, 1997, PROSTATE, V30, P117	46	213	220	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 4	1999	18	46					6322	6329		10.1038/sj.onc.1203032	http://dx.doi.org/10.1038/sj.onc.1203032			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	260DK	10597231				2022-12-25	WOS:000083934100016
J	Armulik, A; Nilsson, I; von Heijne, G; Johansson, S				Armulik, A; Nilsson, I; von Heijne, G; Johansson, S			Determination of the border between the transmembrane and cytoplasmic domains of human integrin subunits	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FOCAL ADHESION KINASE; CORE-GLYCOSYLATION EFFICIENCY; OUT SIGNAL-TRANSDUCTION; MAJOR COAT PROTEIN; CELL-ADHESION; AMINO-ACID; TYROSINE PHOSPHORYLATION; AMPHIPATHIC HELIX; ALPHA-ACTININ; MEMBRANE	In this study we have determined the position of the C-terminal end of the transmembrane domains of human integrin subunits (alpha 2, alpha 5, beta 1, beta 2) in microsomal membranes using the glycosylation mapping technique. In contrast to the common view, the transmembrane helices were found to extend roughly to Phe(1129) in alpha 2, to Phe(1026) in alpha 5, to Ile(757) in beta 1, and to His(728) in beta 2. The alpha-carbon of the conserved lysine present near the C-terminal end of the transmembrane helix (Lys(1125) in alpha 2, Lys(1022) in alpha 5, Lys(752) in beta 1, and Lys(724) in beta 2) is buried in the plasma membrane, and the charged amino group most likely reaches into the polar head-group region of the lipid bilayer. A possible role for the conserved lysine in integrin function is discussed.	Univ Uppsala, Ctr Biomed, Dept Med Biochem & Microbiol, S-75123 Uppsala, Sweden; Univ Stockholm, Dept Biochem, S-10691 Stockholm, Sweden; Karolinska Inst, NOVUM, Dept Biosci, S-14157 Huddinge, Sweden	Uppsala University; Stockholm University; Karolinska Institutet	Johansson, S (corresponding author), Univ Uppsala, Ctr Biomed, Dept Med Biochem & Microbiol, Box 575, S-75123 Uppsala, Sweden.		von Heijne, Gunnar/F-5576-2011; von Heijne, Gunnar/AAH-9389-2019	von Heijne, Gunnar/0000-0002-4490-8569; Keller, Annika/0000-0003-1466-3633				ARGRAVES WS, 1987, J CELL BIOL, V105, P1183, DOI 10.1083/jcb.105.3.1183; Briesewitz R, 1996, MOL BIOL CELL, V7, P1499, DOI 10.1091/mbc.7.10.1499; CHEN YP, 1994, J BIOL CHEM, V269, P18307; COPPOLINO M, 1995, J BIOL CHEM, V270, P23132, DOI 10.1074/jbc.270.39.23132; Coppolino MG, 1999, BIOCHEM J, V340, P41, DOI 10.1042/0264-6021:3400041; Coppolino MG, 1997, NATURE, V386, P843, DOI 10.1038/386843a0; COSSON P, 1991, NATURE, V351, P414, DOI 10.1038/351414a0; deMelker AA, 1997, BIOCHEM J, V328, P529, DOI 10.1042/bj3280529; FERNANDEZ C, 1998, FRONT BIOSCI, V3, P684; GAVEL Y, 1988, FEBS LETT, V235, P173, DOI 10.1016/0014-5793(88)81257-2; Guan JL, 1997, MATRIX BIOL, V16, P195, DOI 10.1016/S0945-053X(97)90008-1; Haas TA, 1997, PROTEIN ENG, V10, P1395, DOI 10.1093/protein/10.12.1395; HAYASHI Y, 1990, J CELL BIOL, V110, P175, DOI 10.1083/jcb.110.1.175; Hemler ME, 1996, BBA-REV CANCER, V1287, P67, DOI 10.1016/0304-419X(96)00007-8; HUGHES PE, 1995, J BIOL CHEM, V270, P12411, DOI 10.1074/jbc.270.21.12411; Hughes PE, 1996, J BIOL CHEM, V271, P6571, DOI 10.1074/jbc.271.12.6571; HUHTALA P, 1995, J CELL BIOL, V129, P867, DOI 10.1083/jcb.129.3.867; Hynes RO, 1996, DEV BIOL, V180, P402, DOI 10.1006/dbio.1996.0314; Ilic Dusko, 1995, Nature (London), V377, P539, DOI 10.1038/377539a0; KASSNER PD, 1994, J BIOL CHEM, V269, P19859; KAWAGUCHI S, 1994, MOL BIOL CELL, V5, P977, DOI 10.1091/mbc.5.9.977; KAWAGUCHI S, 1993, J BIOL CHEM, V268, P16279; LAFLAMME SE, 1994, J CELL BIOL, V126, P1287, DOI 10.1083/jcb.126.5.1287; Lewis JM, 1996, J CELL BIOL, V134, P1323, DOI 10.1083/jcb.134.5.1323; Liliental J, 1998, J BIOL CHEM, V273, P2379, DOI 10.1074/jbc.273.4.2379; LILJESTROM P, 1991, J VIROL, V65, P147; Lu CF, 1997, J IMMUNOL, V159, P268; Mellquist JL, 1998, BIOCHEMISTRY-US, V37, P6833, DOI 10.1021/bi972217k; MISHRA VK, 1994, J BIOL CHEM, V269, P7185; Monne M, 1998, J MOL BIOL, V284, P1177, DOI 10.1006/jmbi.1998.2218; Nilsson I, 1998, J MOL BIOL, V284, P1165, DOI 10.1006/jmbi.1998.2217; OTEY CA, 1993, J BIOL CHEM, V268, P21193; OTEY CA, 1990, J CELL BIOL, V111, P721, DOI 10.1083/jcb.111.2.721; OTOOLE TE, 1994, J CELL BIOL, V124, P1047, DOI 10.1083/jcb.124.6.1047; PARDI R, 1995, J IMMUNOL, V155, P1252; PETER K, 1995, J EXP MED, V181, P315, DOI 10.1084/jem.181.1.315; Reddy KB, 1998, J BIOL CHEM, V273, P35039, DOI 10.1074/jbc.273.52.35039; SCHALLER MD, 1995, J CELL BIOL, V130, P1181, DOI 10.1083/jcb.130.5.1181; Schwartz MA, 1995, ANNU REV CELL DEV BI, V11, P549, DOI 10.1146/annurev.cellbio.11.1.549; SEGREST JP, 1990, PROTEINS, V8, P103, DOI 10.1002/prot.340080202; ShakinEshleman SH, 1996, J BIOL CHEM, V271, P6363, DOI 10.1074/jbc.271.11.6363; SHAW ARE, 1995, J BIOL CHEM, V270, P24092, DOI 10.1074/jbc.270.41.24092; SHAW LM, 1995, J BIOL CHEM, V270, P23648, DOI 10.1074/jbc.270.40.23648; Spruijt RB, 1996, BIOCHEMISTRY-US, V35, P10383, DOI 10.1021/bi960410t; Stopar D, 1996, BIOCHEMISTRY-US, V35, P15467, DOI 10.1021/bi961770j; VUORI K, 1993, J BIOL CHEM, V268, P21459; Wennerberg K, 1998, J CELL SCI, V111, P1117; Williams Michael J., 1994, Trends in Cell Biology, V4, P109, DOI 10.1016/0962-8924(94)90059-0; Yanez-Mo M, 1998, J CELL BIOL, V141, P791, DOI 10.1083/jcb.141.3.791; ZHANG ZH, 1995, P NATL ACAD SCI USA, V92, P6161, DOI 10.1073/pnas.92.13.6161	50	63	64	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 24	1999	274	52					37030	37034		10.1074/jbc.274.52.37030	http://dx.doi.org/10.1074/jbc.274.52.37030			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	267WR	10601259	hybrid			2022-12-25	WOS:000084382700030
J	Huang, XD; Cuajungco, MP; Atwood, CS; Hartshorn, MA; Tyndall, JDA; Hanson, GR; Stokes, KC; Leopold, M; Multhaup, G; Goldstein, LE; Scarpa, RC; Saunders, AJ; Lim, J; Moir, RD; Glabe, C; Bowden, EF; Masters, CL; Fairlie, DP; Tanzi, RE; Bush, AI				Huang, XD; Cuajungco, MP; Atwood, CS; Hartshorn, MA; Tyndall, JDA; Hanson, GR; Stokes, KC; Leopold, M; Multhaup, G; Goldstein, LE; Scarpa, RC; Saunders, AJ; Lim, J; Moir, RD; Glabe, C; Bowden, EF; Masters, CL; Fairlie, DP; Tanzi, RE; Bush, AI			Cu(II) potentiation of Alzheimer A beta neurotoxicity - Correlation with cell-free hydrogen peroxide production and metal reduction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CEREBROSPINAL-FLUID; LIPID-PEROXIDATION; OXIDATIVE STRESS; SENILE PLAQUES; IN-VIVO; DISEASE; PROTEIN; TOXICITY; PRECURSOR; PEPTIDE	Oxidative stress markers as well as high concentrations of copper are found in the vicinity of A beta amyloid deposits in Alzheimer's disease. The neurotoxicity of A beta in cell culture has been linked to H2O2 generation by an unknown mechanism. We now report that Cu(II) markedly potentiates the neurotoxicity exhibited by A beta in cell culture. The potentiation of toxicity is greatest for A beta 1-42 > A beta 1-40 >> mouse/rat A beta 1-40, corresponding to their relative capacities to reduce Cu(II) to Cu(I), form H2O2 in cell-free assays and to exhibit amyloid pathology. The copper complex of A beta 1-42 has a highly positive formal reduction potential (approximate to+500-550 mV versus Ag/AgCl) characteristic of strongly reducing cupro-proteins. These findings suggest that certain redox active metal ions may be important in exacerbating and perhaps facilitating A beta-mediated oxidative damage in Alzheimer's disease.	Harvard Univ, Sch Med, Massachusetts Gen Hosp, Lab Oxidat Biol,Genet & Aging Unit, Charlestown, MA 02129 USA; Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Psychiat, Charlestown, MA 02129 USA; Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Neurol, Charlestown, MA 02129 USA; Univ Heidelberg, ZMBH, Ctr Mol Biol, D-69120 Heidelberg, Germany; N Carolina State Univ, Dept Chem, Raleigh, NC 27695 USA; Univ Calif Irvine, Dept Mol Biol & Biochem, Irvine, CA 92717 USA; Univ Melbourne, Dept Pathol, Parkville, Vic 3052, Australia; Mental Hlth Res Inst Victoria, Neuropathol Lab, Parkville, Vic 3052, Australia; Univ Queensland, Ctr Drug Design & Dev, Brisbane, Qld 4072, Australia; Univ Queensland, Ctr Magnet Resonance, Brisbane, Qld 4072, Australia	Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Ruprecht Karls University Heidelberg; University of North Carolina; North Carolina State University; University of California System; University of California Irvine; University of Melbourne; University of Queensland; University of Queensland	Huang, XD (corresponding author), Massachusetts Gen Hosp E, Lab Oxidat Biol, Genet & Aging Unit, Bldg 149,13th St, Charlestown, MA 02129 USA.		tyndall, joel/C-2803-2008; Fairlie, David P/F-8865-2014; Cuajungco, Math/B-2647-2008; Bush, Ashley/Y-2457-2019; Bush, Ashley I/A-1186-2007; Moir, Robert D./M-7612-2017; Tanzi, Rudolph/AAE-9622-2019; /C-3940-2008; , Craig/AAB-3963-2022	tyndall, joel/0000-0003-0783-1635; Fairlie, David P/0000-0002-7856-8566; Cuajungco, Math/0000-0003-0749-9564; Bush, Ashley/0000-0001-8259-9069; Bush, Ashley I/0000-0001-8259-9069; Moir, Robert D./0000-0001-5431-3553; Tanzi, Rudolph/0000-0002-7032-1454; /0000-0003-0306-4360; Saunders, Aleister/0000-0002-7298-7823; Goldstein, Lee/0000-0001-8419-9800; Bowden, Edmond/0000-0002-1908-7594				Atwood CS, 1998, J BIOL CHEM, V273, P12817, DOI 10.1074/jbc.273.21.12817; BARROW CJ, 1991, SCIENCE, V253, P179, DOI 10.1126/science.1853202; BASUN H, 1991, J NEURAL TRANSM-PARK, V3, P231; BEHL C, 1994, CELL, V77, P817, DOI 10.1016/0092-8674(94)90131-7; Bondy SC, 1998, BRAIN RES, V799, P91, DOI 10.1016/S0006-8993(98)00461-2; Brown DR, 1997, NATURE, V390, P684, DOI 10.1038/37733; Cherny RA, 1999, J BIOL CHEM, V274, P23223, DOI 10.1074/jbc.274.33.23223; DASILVA JJR, 1991, BIOL CHEM EL; Deibel MA, 1996, J NEUROL SCI, V143, P137, DOI 10.1016/S0022-510X(96)00203-1; Dikalov SI, 1999, J BIOL CHEM, V274, P9392, DOI 10.1074/jbc.274.14.9392; Dore S, 1997, P NATL ACAD SCI USA, V94, P4772, DOI 10.1073/pnas.94.9.4772; Duff K, 1996, NATURE, V383, P710, DOI 10.1038/383710a0; HALLIWELL B, 1984, BIOCHEM J, V219, P1, DOI 10.1042/bj2190001; Han J, 1996, ANAL BIOCHEM, V234, P107, DOI 10.1006/abio.1996.0059; HARTTER DE, 1988, J BIOL CHEM, V263, P799; HENSLEY K, 1994, P NATL ACAD SCI USA, V91, P3270, DOI 10.1073/pnas.91.8.3270; HENSLEY K, 1995, J NEUROCHEM, V65, P2146; HERSHEY CO, 1983, NEUROLOGY, V33, P1350, DOI 10.1212/WNL.33.10.1350; HODGSON EK, 1975, BIOCHEMISTRY-US, V14, P5294, DOI 10.1021/bi00695a010; Huang XD, 1999, BIOCHEMISTRY-US, V38, P7609, DOI 10.1021/bi990438f; ITO N, 1991, NATURE, V350, P87, DOI 10.1038/350087a0; KANG J, 1987, NATURE, V325, P733, DOI 10.1038/325733a0; LANDERS JW, 1958, AM J CLIN PATHOL, V29, P590; Lovell MA, 1998, J NEUROL SCI, V158, P47, DOI 10.1016/S0022-510X(98)00092-6; Mark RJ, 1997, J NEUROCHEM, V68, P255; Mattson MP, 1997, BRAIN RES, V771, P147, DOI 10.1016/S0006-8993(97)00824-X; PALMER AM, 1994, BRAIN RES, V645, P338, DOI 10.1016/0006-8993(94)91670-5; PILBROW JR, 1993, METHOD ENZYMOL, V227, P330, DOI 10.1016/0076-6879(93)27013-7; Rae TD, 1999, SCIENCE, V284, P805, DOI 10.1126/science.284.5415.805; Sayre LM, 1996, SCIENCE, V274, P1933, DOI 10.1126/science.274.5294.1933; Scheuner D, 1996, NAT MED, V2, P864, DOI 10.1038/nm0896-864; SCHUBERT D, 1995, BIOCHEM BIOPH RES CO, V216, P702, DOI 10.1006/bbrc.1995.2678; SHIVERS BD, 1988, EMBO J, V7, P1365, DOI 10.1002/j.1460-2075.1988.tb02952.x; Smith MA, 1998, J NEUROCHEM, V70, P2212, DOI 10.1046/j.1471-4159.1998.70052212.x; Smith MA, 1996, NATURE, V382, P120, DOI 10.1038/382120b0; STADTMAN ER, 1991, J BIOL CHEM, V266, P2005; SUZUKI N, 1994, SCIENCE, V264, P1336, DOI 10.1126/science.8191290; VAUGHAN DW, 1981, J NEUROPATH EXP NEUR, V40, P472, DOI 10.1097/00005072-198107000-00009; WANG DM, 1995, J MAGN RESON SER A, V117, P1, DOI 10.1006/jmra.1995.9978; White AR, 1999, J NEUROCHEM, V72, P2092, DOI 10.1046/j.1471-4159.1999.0722092.x	40	691	715	1	77	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 24	1999	274	52					37111	37116		10.1074/jbc.274.52.37111	http://dx.doi.org/10.1074/jbc.274.52.37111			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	267WR	10601271	hybrid			2022-12-25	WOS:000084382700042
J	Sato, T; Kondo, T; Fujisawa, T; Seiki, M; Ito, A				Sato, T; Kondo, T; Fujisawa, T; Seiki, M; Ito, A			Furin-independent pathway of membrane type 1-matrix metalloproteinase activation in rabbit dermal fibroblasts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UTERINE CERVICAL FIBROBLASTS; PRO-GELATINASE-A; PROHORMONE CONVERTASES PC1; MATRIX METALLOPROTEINASE; TISSUE INHIBITOR; DEVELOPMENTAL EXPRESSION; IV COLLAGENASE; PROPROTEIN CONVERTASES; EXTRACELLULAR-MATRIX; INSITU HYBRIDIZATION	We investigated the gene expression and intracellular activity of processing protease furin and its involvement in the process of membrane type 1-matrix metalloproteinase (MT1-MMP) activation in rabbit dermal fibroblasts, When the rabbit fibroblasts were treated with concanavalin A (ConA), pro-MMP-2 was converted to an active 62-kDa MMP-2 through the appearance of a 64-kDa intermediate MMP-2. The ConA-induced pro-MMP-2 activation resulted from increasing the gene expression and production of MT1-MMP in the rabbit fibroblasts, Reverse transcriptase-polymerase chain reaction demonstrated that in rabbit dermal fibroblasts furin mRNA was detected and, unlike MT1-MMP, was not increased by ConA, These findings are further supported by the fact that the intracellular furin activity also was constitutively detected and was unchanged by the ConA. treatment. Very similar phenomena were also observed in human uterine cervical fibroblasts, which are known to produce MT1-MMP by ConA stimulation. These results suggest that the expression of the furin gene and the intracellular activity are not regulated by Conk On the other hand, neither a synthetic furin inhibitor, decanoyl-RVKR-CH2Cl (25-100 mu M) nor a furin antisense oligonucleotide (40 mu M) inhibited the MT1-MMP-mediated pro-MMP-2 activation in ConA-treated rabbit dermal fibroblasts, whereas these compounds interfered with pro-MMP-2 activation in ConA-treated human uterine cervical fibroblasts. Nonetheless, the furin antisense oligonucleotide completely suppressed furin gene expression in both rabbit and human fibroblasts, These results suggest that furin does not participate in the process of MT1-MMP activation induced by ConA in rabbit dermal fibroblasts.	Tokyo Univ Pharm & Life Sci, Sch Pharm, Dept Biochem, Tokyo 1920392, Japan; Fuji Chem Ind Ltd, Res Inst, Toyama 9338511, Japan; Univ Tokyo, Inst Med Sci, Dept Canc Cell Res, Minato Ku, Tokyo 1080071, Japan	Tokyo University of Pharmacy & Life Sciences; University of Tokyo	Sato, T (corresponding author), Tokyo Univ Pharm & Life Sci, Sch Pharm, Dept Biochem, 1432-1 Horinouchi, Tokyo 1920392, Japan.		Seiki, Motoharu/K-9443-2015					ANGLIKER H, 1993, BIOCHEM J, V293, P75, DOI 10.1042/bj2930075; BROWN PD, 1993, CLIN EXP METASTAS, V11, P183, DOI 10.1007/BF00114976; Buttner FH, 1997, ARTHRITIS RHEUM, V40, P704, DOI 10.1002/art.1780400415; Cao JA, 1996, J BIOL CHEM, V271, P30174, DOI 10.1074/jbc.271.47.30174; Chan VT, 1998, J INVEST DERMATOL, V111, P1153, DOI 10.1046/j.1523-1747.1998.00416.x; Fosang AJ, 1998, FEBS LETT, V430, P186, DOI 10.1016/S0014-5793(98)00667-X; HATSUZAWA K, 1992, J BIOCHEM-TOKYO, V111, P296, DOI 10.1093/oxfordjournals.jbchem.a123753; HATSUZAWA K, 1990, J BIOL CHEM, V265, P22075; Ito A, 1998, EUR J BIOCHEM, V251, P353, DOI 10.1046/j.1432-1327.1998.2510353.x; ITO A, 1991, J BIOL CHEM, V266, P13598; Itoh Y, 1998, J BIOL CHEM, V273, P24360, DOI 10.1074/jbc.273.38.24360; Kinoh H, 1996, J CELL SCI, V109, P953; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lohi J, 1996, EUR J BIOCHEM, V239, P239, DOI 10.1111/j.1432-1033.1996.0239u.x; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Maquoi E, 1998, FEBS LETT, V424, P262, DOI 10.1016/S0014-5793(98)00187-2; MARCINKIEWICZ M, 1994, ENDOCRINOLOGY, V135, P1651, DOI 10.1210/en.135.4.1651; MARCINKIEWICZ M, 1993, P NATL ACAD SCI USA, V90, P4922, DOI 10.1073/pnas.90.11.4922; Migita K, 1996, IMMUNOLOGY, V89, P553, DOI 10.1046/j.1365-2567.1996.d01-789.x; MOLLOY SS, 1992, J BIOL CHEM, V267, P16396; Nagase H, 1997, BIOL CHEM, V378, P151; Nakayama K, 1997, BIOCHEM J, V327, P625, DOI 10.1042/bj3270625; Ohuchi E, 1997, J BIOL CHEM, V272, P2446, DOI 10.1074/jbc.272.4.2446; OJIMA Y, 1989, BIOCHIM BIOPHYS ACTA, V1011, P61, DOI 10.1016/0167-4889(89)90079-7; Okada A, 1997, J CELL BIOL, V137, P67, DOI 10.1083/jcb.137.1.67; OKADA A, 1995, P NATL ACAD SCI USA, V92, P2730, DOI 10.1073/pnas.92.7.2730; OVERALL CM, 1989, J BIOL CHEM, V264, P1860; Puente XS, 1996, CANCER RES, V56, P944; PYKE C, 1992, CANCER RES, V52, P1336; SALO T, 1991, J BIOL CHEM, V266, P11436; Santavicca M, 1996, BIOCHEM J, V315, P953, DOI 10.1042/bj3150953; SATO H, 1994, NATURE, V370, P61, DOI 10.1038/370061a0; Sato H, 1996, J BIOCHEM-TOKYO, V119, P209; Sato H, 1996, FEBS LETT, V393, P101, DOI 10.1016/0014-5793(96)00861-7; Sato T, 1996, FEBS LETT, V392, P175, DOI 10.1016/0014-5793(96)00808-3; Sato T, 1997, J CELL SCI, V110, P589; SCHAFER MKH, 1993, J NEUROSCI, V13, P1258; SCHALKEN JA, 1987, J CLIN INVEST, V80, P1545, DOI 10.1172/JCI113240; Shofuda K, 1998, J BIOCHEM-TOKYO, V124, P462, DOI 10.1093/oxfordjournals.jbchem.a022136; SIEZEN RJ, 1994, EUR J BIOCHEM, V222, P255, DOI 10.1111/j.1432-1033.1994.tb18864.x; STEARNS ME, 1993, CANCER RES, V53, P878; STETLERSTEVENSON WG, 1993, ANNU REV CELL BIOL, V9, P541, DOI 10.1146/annurev.cb.09.110193.002545; STRONGIN AY, 1993, J BIOL CHEM, V268, P14033; TAKINO T, 1995, J BIOL CHEM, V270, P23013, DOI 10.1074/jbc.270.39.23013; Ueno H, 1997, CANCER RES, V57, P2055; VANDENOUWELAND AMW, 1990, NUCLEIC ACIDS RES, V18, P664, DOI 10.1093/nar/18.3.664; VATER CA, 1983, J BIOL CHEM, V258, P9374; Wang H, 1998, J VASC RES, V35, P45, DOI 10.1159/000025564; WARD RV, 1991, BIOCHIM BIOPHYS ACTA, V1079, P242, DOI 10.1016/0167-4838(91)90132-J; WILL H, 1995, EUR J BIOCHEM, V231, P602, DOI 10.1111/j.1432-1033.1995.0602d.x; WOESSNER JF, 1991, FASEB J, V5, P2145, DOI 10.1096/fasebj.5.8.1850705; Yamamoto M, 1996, CANCER RES, V56, P384; Zheng M, 1997, DEV BIOL, V181, P268, DOI 10.1006/dbio.1996.8402; ZHENG M, 1994, J NEUROSCI, V14, P4656	54	48	48	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 24	1999	274	52					37280	37284		10.1074/jbc.274.52.37280	http://dx.doi.org/10.1074/jbc.274.52.37280			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	267WR	10601293	hybrid			2022-12-25	WOS:000084382700064
J	Yokota, S; Yanagi, H; Yura, T; Kubota, H				Yokota, S; Yanagi, H; Yura, T; Kubota, H			Cytosolic chaperonin is up-regulated during cell growth - Preferential, expression and binding to tubulin at G(1)/S transition through early S phase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							T-COMPLEX POLYPEPTIDE-1; CYTOPLASMIC CHAPERONIN; EUKARYOTIC CYTOSOL; CONTAINING TCP-1; MOLECULAR CHAPERONES; CCT CHAPERONIN; SACCHAROMYCES-CEREVISIAE; SUBUNIT COMPOSITION; BETA-ACTIN; IN-VITRO	The chaperonin containing t-complex polypeptide 1 (CCT) is a heterooligomeric molecular chaperone assisting in the folding of actin, tubulin, and other cytosolic proteins. The expression levels of CCT subunits varied among seven mouse cell lines tested but showed a close correlation with growth rate. Both the CCT protein and mRNA levels in the human promyelolytic cell HL60 decreased concomitant with growth arrest during differentiation. More rapid decrease in CCT level occurred when the mouse interleukin (IL)-3-dependent myeloid DA3 cells were starved for IL-3. Readdition of IL-3 caused rapid resumption of CCT synthesis during synchronous growth: the maximum CCT protein and mRNA levels were observed at G(1)/S transition through early S phase. The turnover rate of CCT was nearly constant regardless of growth. Gel filtration and immunoprecipitation analyses indicated that CCT in vivo is associated with tubulin at early S phase, but not at G(0)/G(1) phase. These results demonstrated that CCT expression is strongly up-regulated during cell growth especially from G(1)/S transition to early S phase and is primarily controlled at the mRNA level. CCT appears to play important roles for cell growth by assisting in the folding of tubulin and other proteins.	HSP Res Inst, Shimogyo Ku, Kyoto 6008813, Japan		Kubota, H (corresponding author), HSP Res Inst, Shimogyo Ku, Kyoto Res Pk,17 Chudoji Minami Machi, Kyoto 6008813, Japan.		Yokota, Shin-ichi/K-8139-2019	Yokota, Shin-ichi/0000-0002-0831-3429				BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; COLLINS SJ, 1987, BLOOD, V70, P1233; CREUTZ CE, 1994, J BIOL CHEM, V269, P32035; Cyrne L, 1996, FEBS LETT, V383, P277, DOI 10.1016/0014-5793(96)00240-2; Dittmar G, 1997, CELL BIOL INT, V21, P383, DOI 10.1006/cbir.1997.0158; ELLIS RJ, 1991, ANNU REV BIOCHEM, V60, P321, DOI 10.1146/annurev.bi.60.070191.001541; Farr GW, 1997, CELL, V89, P927, DOI 10.1016/S0092-8674(00)80278-0; FRYDMAN J, 1992, EMBO J, V11, P4767, DOI 10.1002/j.1460-2075.1992.tb05582.x; Frydman J, 1996, SCIENCE, V272, P1497, DOI 10.1126/science.272.5267.1497; FRYDMAN J, 1994, NATURE, V370, P111, DOI 10.1038/370111a0; GAO YJ, 1992, CELL, V69, P1043, DOI 10.1016/0092-8674(92)90622-J; Gebauer M, 1998, J BIOL CHEM, V273, P29475, DOI 10.1074/jbc.273.45.29475; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; Hartl FU, 1996, NATURE, V381, P571, DOI 10.1038/381571a0; Hynes G, 1996, ELECTROPHORESIS, V17, P1720, DOI 10.1002/elps.1150171109; HYNES G, 1995, FEBS LETT, V358, P129, DOI 10.1016/0014-5793(94)01408-S; IHLE JN, 1985, CONTEMP TOP MOLEC IM, V10, P93; Iijima M, 1998, GENE, V213, P101, DOI 10.1016/S0378-1119(98)00190-5; KATAGIRI K, 1993, J IMMUNOL, V150, P585; KUBOTA H, 1995, EUR J BIOCHEM, V230, P3, DOI 10.1111/j.1432-1033.1995.0003i.x; Kubota H, 1999, EUR J BIOCHEM, V262, P492, DOI 10.1046/j.1432-1327.1999.00405.x; KUBOTA H, 1992, GENE, V120, P207, DOI 10.1016/0378-1119(92)90095-7; KUBOTA H, 1994, CURR BIOL, V4, P89, DOI 10.1016/S0960-9822(94)00024-2; Kubota H, 1997, FEBS LETT, V402, P53, DOI 10.1016/S0014-5793(96)01501-3; KUBOTA H, 1995, GENE, V154, P231, DOI 10.1016/0378-1119(94)00880-2; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lewis SA, 1996, J CELL BIOL, V132, P1, DOI 10.1083/jcb.132.1.1; LEWIS VA, 1992, NATURE, V358, P249, DOI 10.1038/358249a0; Lin P, 1997, P NATL ACAD SCI USA, V94, P10780, DOI 10.1073/pnas.94.20.10780; Liou AKF, 1997, EMBO J, V16, P4311, DOI 10.1093/emboj/16.14.4311; Llorca O, 1998, J BIOL CHEM, V273, P10091, DOI 10.1074/jbc.273.17.10091; MARCO S, 1994, BIOPHYS J, V67, P364, DOI 10.1016/S0006-3495(94)80489-8; Melki R, 1997, BIOCHEMISTRY-US, V36, P5817, DOI 10.1021/bi962830o; OHTSUBO M, 1993, SCIENCE, V259, P1908, DOI 10.1126/science.8384376; Pause B, 1997, FEBS LETT, V414, P95, DOI 10.1016/S0014-5793(97)00975-7; Rademacher F, 1998, MICROBIOL-SGM, V144, P2951, DOI 10.1099/00221287-144-11-2951; RESNITZKY D, 1994, MOL CELL BIOL, V14, P1669, DOI 10.1128/MCB.14.3.1669; ROOBOL A, 1995, J CELL SCI, V108, P1477; ROVERA G, 1980, NATURE, V284, P69, DOI 10.1038/284069a0; Sambrook J., 2002, MOL CLONING LAB MANU; SANCHEZ ER, 1985, J EMBRYOL EXP MORPH, V89, P113; SEVIGNY G, 1995, BIOCHEM BIOPH RES CO, V216, P279, DOI 10.1006/bbrc.1995.2621; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; Siegers K, 1999, EMBO J, V18, P75, DOI 10.1093/emboj/18.1.75; SOARES H, 1994, J BIOL CHEM, V269, P29299; STERNLICHT H, 1993, P NATL ACAD SCI USA, V90, P9422, DOI 10.1073/pnas.90.20.9422; Stoldt V, 1996, YEAST, V12, P523, DOI 10.1002/(SICI)1097-0061(199605)12:6<523::AID-YEA962>3.3.CO;2-3; Thulasiraman V, 1999, EMBO J, V18, P85, DOI 10.1093/emboj/18.1.85; TIAN GL, 1995, NATURE, V375, P250, DOI 10.1038/375250a0; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Vainberg IE, 1998, CELL, V93, P863, DOI 10.1016/S0092-8674(00)81446-4; VANSNICK J, 1986, CONTRIB MICROBIOL IM, V11, P73; Willison Keith R., 1996, P107, DOI 10.1016/B978-012237455-5/50006-3; WILLISON KR, 1990, GENET RES, V56, P193, DOI 10.1017/S0016672300035291; WILLISON KR, 1986, CELL, V44, P727, DOI 10.1016/0092-8674(86)90839-1; Won KA, 1998, MOL CELL BIOL, V18, P7584, DOI 10.1128/MCB.18.12.7584; XIE XL, 1994, BLOOD, V84, P2171	57	106	113	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 24	1999	274	52					37070	37078		10.1074/jbc.274.52.37070	http://dx.doi.org/10.1074/jbc.274.52.37070			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	267WR	10601265	hybrid			2022-12-25	WOS:000084382700036
J	Grabenhorst, E; Conradt, HS				Grabenhorst, E; Conradt, HS			The cytoplasmic, transmembrane, and stem regions of glycosyltransferases specify their in vivo functional sublocalization and stability in the Golgi	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-TRACE PROTEIN; N-ACETYLGLUCOSAMINYLTRANSFERASE-I; MEMBRANE-SPANNING DOMAIN; GALACTOSIDE ALPHA-2,6-SIALYLTRANSFERASE; IMMUNOELECTRON MICROSCOPY; FUCOSYL-TRANSFERASE; KIN RECOGNITION; HELA-CELLS; MOLECULAR CHARACTERIZATION; EXPRESSION CLONING	We provide evidence for the presence of targeting signals in the cytoplasmic, transmembrane, and stem (CTS) regions of Golgi glycosyltransferases that mediate sorting of their intracellular catalytic activity into different functional subcompartmental areas of the Golgi, We have constructed chimeras of human alpha 1,3-fucosyltransferase VI (FT6) by replacement of its CTS region with those of late and early acting Golgi glycosyltransferases and have stably coexpressed these constructs in BHK-81 cells together with the secretory reporter glycoprotein human beta-trace protein. The sialyl Lewis X:Lewis X ratios detected in beta-trace protein indicate that the CTS regions of the early acting GlcNAc-transferases I (GnT-I) and III (GnT-III) specify backward targeting of the FT6 catalytic domain, whereas the CTS region of the late acting human alpha 1,3-fucosyltransferase VII (FT7) causes forward targeting of the FT6 in vivo activity in the biosynthetic glycosylation pathway. The analysis of the in vivo functional activity of nine different CTS chimeras toward beta-trace protein allowed for a mapping of the CTS donor glycosyltransferases within the Golgi/trans-Golgi network: GnT-I < (ST6Gal I, ST3Gal III) < GnT-III < ST8Sia IV < GalT-I < (FT3, FT6) < ST3Gal TV < FT7, The sensitivity or resistance of the donor glycosyl transferases toward intracellular proteolysis is transferred to the chimeric enzymes together with their CTS regions. Apparently, there are at least three different signals contained in the CTS regions of glycosyltransferases mediating: first, their Golgi retention; second, their targeting to specific in vivo functional areas; and third, their susceptibility toward intracellular proteolysis as a tool for the regulation of the intracellular turnover.	Gesell Biotechnol Forsch mbH, Prot Glycosylat Grp, D-38124 Braunschweig, Germany	Gesellschaft fur Biotechnologische Forschung mbH	Grabenhorst, E (corresponding author), Gesell Biotechnol Forsch mbH, Prot Glycosylat Grp, Mascheroder Weg 1, D-38124 Braunschweig, Germany.	egr@gbf.de						AOKI D, 1992, P NATL ACAD SCI USA, V89, P4319, DOI 10.1073/pnas.89.10.4319; BJORK I, 1992, BIOCHEM J, V286, P793; Borsig L, 1998, GLYCOBIOLOGY, V8, P259, DOI 10.1093/glycob/8.3.259; Borsig L, 1996, EUR J CELL BIOL, V70, P42; BOSSHART H, 1992, EUR J BIOCHEM, V208, P341, DOI 10.1111/j.1432-1033.1992.tb17192.x; BRETSCHER MS, 1993, SCIENCE, V261, P1280, DOI 10.1126/science.8362242; Britten CJ, 1998, GLYCOBIOLOGY, V8, P321, DOI 10.1093/glycob/8.4.321; Burger PC, 1998, GLYCOBIOLOGY, V8, P245, DOI 10.1093/glycob/8.3.245; BURKE J, 1992, J BIOL CHEM, V267, P24433; Colley KJ, 1997, GLYCOBIOLOGY, V7, P1, DOI 10.1093/glycob/7.1.1-b; COLLEY KJ, 1992, J BIOL CHEM, V267, P7784; Costa J, 1997, J BIOL CHEM, V272, P11613; ECKHARDT M, 1995, NATURE, V373, P715, DOI 10.1038/373715a0; Gleeson PA, 1998, HISTOCHEM CELL BIOL, V109, P517, DOI 10.1007/s004180050252; Grabenhorst E, 1998, J BIOL CHEM, V273, P30985, DOI 10.1074/jbc.273.47.30985; Grabenhorst E, 1999, GLYCOCONJUGATE J, V16, P81, DOI 10.1023/A:1026466408042; GRABENHORST E, 1995, EUR J BIOCHEM, V232, P718, DOI 10.1111/j.1432-1033.1995.718zz.x; Hoffmann A, 1997, GLYCOBIOLOGY, V7, P499, DOI 10.1093/glycob/7.4.499; HOFFMANN A, 1994, J NEUROCHEM, V63, P2185; IHARA Y, 1993, J BIOCHEM-TOKYO, V113, P692, DOI 10.1093/oxfordjournals.jbchem.a124105; Jaskiewicz E, 1996, J BIOL CHEM, V271, P26395, DOI 10.1074/jbc.271.42.26395; JOHNSON PH, 1993, GLYCOCONJUGATE J, V10, P152, DOI 10.1007/BF00737712; JOHNSON PH, 1992, GLYCOCONJUGATE J, V9, P241, DOI 10.1007/BF00731136; KITAGAWA H, 1993, BIOCHEM BIOPH RES CO, V194, P375, DOI 10.1006/bbrc.1993.1830; KOBATA A, 1992, EUR J BIOCHEM, V209, P483, DOI 10.1111/j.1432-1033.1992.tb17313.x; Kotani N, 1999, BIOCHEM BIOPH RES CO, V260, P94, DOI 10.1006/bbrc.1999.0872; KUMAR R, 1990, P NATL ACAD SCI USA, V87, P9948, DOI 10.1073/pnas.87.24.9948; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE EU, 1989, J BIOL CHEM, V264, P13848; Lo NW, 1998, GLYCOBIOLOGY, V8, P517, DOI 10.1093/glycob/8.5.517; Lovelock C, 1998, EUR J CELL BIOL, V76, P18, DOI 10.1016/S0171-9335(98)80013-7; MASIBAY AS, 1993, J BIOL CHEM, V268, P9908; MASRI KA, 1988, BIOCHEM BIOPH RES CO, V157, P657, DOI 10.1016/S0006-291X(88)80300-0; Munro S, 1998, TRENDS CELL BIOL, V8, P11, DOI 10.1016/S0962-8924(97)01197-5; MUNRO S, 1995, EMBO J, V14, P4695, DOI 10.1002/j.1460-2075.1995.tb00151.x; MUNRO S, 1991, EMBO J, V10, P3577, DOI 10.1002/j.1460-2075.1991.tb04924.x; Nakayama J, 1998, PATHOL INT, V48, P665, DOI 10.1111/j.1440-1827.1998.tb03967.x; NILSSON T, 1994, EMBO J, V13, P562, DOI 10.1002/j.1460-2075.1994.tb06294.x; Nilsson T, 1996, J CELL SCI, V109, P1975; NILSSON T, 1993, FEBS LETT, V330, P1, DOI 10.1016/0014-5793(93)80906-B; NILSSON T, 1993, J CELL BIOL, V120, P5, DOI 10.1083/jcb.120.1.5; NILSSON T, 1991, EMBO J, V10, P3567, DOI 10.1002/j.1460-2075.1991.tb04923.x; Nimtz M, 1998, GLYCOCONJUGATE J, V15, P873, DOI 10.1023/A:1006907031940; NIMTZ M, 1993, EUR J BIOCHEM, V213, P39, DOI 10.1111/j.1432-1033.1993.tb17732.x; Osman N, 1996, J BIOL CHEM, V271, P33105, DOI 10.1074/jbc.271.51.33105; PAULSON JC, 1989, J BIOL CHEM, V264, P17615; Pohl S, 1997, GLYCOBIOLOGY, V7, P1077, DOI 10.1093/glycob/7.8.1077; RABOUILLE C, 1995, J CELL SCI, V108, P1617; ROTH J, 1985, CELL, V43, P287, DOI 10.1016/0092-8674(85)90034-0; RUSSO RN, 1992, J BIOL CHEM, V267, P9241; SASAKI K, 1993, J BIOL CHEM, V268, P22782; SASAKI K, 1994, J BIOL CHEM, V269, P14730; Shinoda K, 1997, J BIOL CHEM, V272, P31992, DOI 10.1074/jbc.272.51.31992; Skrincosky D, 1997, J BIOL CHEM, V272, P22695, DOI 10.1074/jbc.272.36.22695; STROUS GJAM, 1982, J BIOL CHEM, V257, P7623; SUEYOSHI S, 1994, J BIOL CHEM, V269, P32342; SUGANUMA T, 1991, J HISTOCHEM CYTOCHEM, V39, P299, DOI 10.1177/39.3.1899684; TAATJES DJ, 1988, J BIOL CHEM, V263, P6302; TANG BL, 1992, J BIOL CHEM, V267, P10122; TEASDALE RD, 1992, J BIOL CHEM, V267, P4084; TEASDALE RD, 1994, GLYCOBIOLOGY, V4, P917, DOI 10.1093/glycob/4.6.917; Ujita M, 1998, J BIOL CHEM, V273, P34843, DOI 10.1074/jbc.273.52.34843; Ujita M, 1999, J BIOL CHEM, V274, P16717, DOI 10.1074/jbc.274.24.16717; Ujita M, 1999, J BIOL CHEM, V274, P9296, DOI 10.1074/jbc.274.14.9296; WATZELE G, 1990, NUCLEIC ACIDS RES, V18, P7174, DOI 10.1093/nar/18.23.7174; WEISZ OA, 1993, J CELL BIOL, V122, P1185, DOI 10.1083/jcb.122.6.1185; WONG SH, 1992, J CELL BIOL, V117, P245, DOI 10.1083/jcb.117.2.245; Xu XH, 1996, J BIOL CHEM, V271, P8818, DOI 10.1074/jbc.271.15.8818	68	68	92	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 17	1999	274	51					36107	36116		10.1074/jbc.274.51.36107	http://dx.doi.org/10.1074/jbc.274.51.36107			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	266AV	10593893	hybrid			2022-12-25	WOS:000084279200012
J	Murray, I; Sniderman, AD; Havel, PJ; Cianflone, K				Murray, I; Sniderman, AD; Havel, PJ; Cianflone, K			Acylation stimulating protein (ASP) deficiency alters postprandial and adipose tissue metabolism in male mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN LIPOPROTEIN-LIPASE; HIGH-FAT DIET; IMPAIRED GLUCOSE-TOLERANCE; TRANSGENIC MICE; HUMAN ADIPOCYTES; ALTERNATIVE PATHWAY; DENSITY-LIPOPROTEIN; INSULIN-RESISTANCE; IN-VIVO; OBESITY	Acylation stimulating protein (ASP) is a potent stimulator of triglyceride synthesis in adipocytes. In the present study, we have examined the effect of an ASP functional knockout (ASP(-/-)) on lipid metabolism in male mice. In both young (14 weeks) and older (26 weeks) mice there were marked delays in postprandial triglyceride clearance (80% increase at 14 weeks and 120% increase at 26 weeks versus wild type (+/+)). Postprandial nonesterified fatty acids were also increased in ASP(-/-) mice versus ASP(+/+) mice by 37% (low fat 10% Kcal) and by 73% (high fat 40% Kcal) diets, although there were no differences in fasting lipid levels. The ASP(-/-) mice had moderately increased energy intake (16% +/- 2% p < 0.0001) and reduced feed efficiency (33% increase in calories/g of body weight gained on low fat diet) versus wild type, The ASP(-/-) mice also had modest changes in insulin/glucose metabolism (30% to 40% decrease ill insulin glucose product), implying increased insulin sensitivity. As well, there were decreases in leptin (29% shift in leptin to body weight ratio) and up to a 26% decrease in specific adipose tissue depots versus the wild type mice on both low fat and high fat diets, These results demonstrate that ASP plays an important role in adipose tissue metabolism and fat partitioning.	McGill Univ, Mike Rosenbloom Lab Cardiovasc Res, Ctr Hlth, Montreal, PQ H3A 1A1, Canada; Univ Calif Davis, Dept Nutr, Davis, CA 95616 USA	McGill University; University of California System; University of California Davis	Cianflone, K (corresponding author), Royal Victoria Hosp, H 7-30,687 Pine Ave W, Montreal, PQ H3A 1A1, Canada.	mdkc@musica.mcgill.ca	Murray, Ian/O-5983-2015	Murray, Ian/0000-0003-1196-1360; Havel, Peter/0000-0003-3652-8301	NIDDK NIH HHS [DK-35747, DK-50129] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK035747, R01DK050129] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ahren B, 1997, AM J PHYSIOL-REG I, V273, pR113, DOI 10.1152/ajpregu.1997.273.1.R113; APPEL B, 1992, AM J PHYSIOL, V262, pE695, DOI 10.1152/ajpendo.1992.262.5.E695; BALDO A, 1993, J CLIN INVEST, V92, P1543, DOI 10.1172/JCI116733; BENGTSSON G, 1979, FEBS LETT, V106, P345, DOI 10.1016/0014-5793(79)80529-3; BJORNTORP P, 1990, ARTERIOSCLEROSIS, V10, P493, DOI 10.1161/01.ATV.10.4.493; Bjorntorp Per, 1997, Human Reproduction (Oxford), V12, P21; Charlesworth JA, 1998, INT J OBESITY, V22, P1096, DOI 10.1038/sj.ijo.0800733; Choy LN, 1996, OBES RES, V4, P521, DOI 10.1002/j.1550-8528.1996.tb00266.x; CIANFLONE K, 1995, EUR J CLIN INVEST, V25, P817, DOI 10.1111/j.1365-2362.1995.tb01690.x; CIANFLONE K, 1994, BIOCHEMISTRY-US, V33, P9489, DOI 10.1021/bi00198a014; Cianflone K, 1999, SEMIN CELL DEV BIOL, V10, P31, DOI 10.1006/scdb.1998.0272; CIANFLONE KM, 1990, J CLIN INVEST, V85, P722, DOI 10.1172/JCI114497; Circolo A, 1999, IMMUNOPHARMACOLOGY, V42, P135, DOI 10.1016/S0162-3109(99)00021-1; Despres J.-P., 1991, CURR OPIN LIPIDOL, V2, P5; FREDERICH RC, 1995, NAT MED, V1, P1311, DOI 10.1038/nm1295-1311; GERMINARIO R, 1993, METABOLISM, V42, P574, DOI 10.1016/0026-0495(93)90215-A; GNUDI L, 1995, ENDOCRINOLOGY, V136, P995, DOI 10.1210/en.136.3.995; Hamann A, 1996, ENDOCRINOLOGY, V137, P21, DOI 10.1210/en.137.1.21; Hotamisligil GS, 1996, SCIENCE, V274, P1377, DOI 10.1126/science.274.5291.1377; Jensen DR, 1997, AM J PHYSIOL-REG I, V273, pR683, DOI 10.1152/ajpregu.1997.273.2.R683; JESMOK GJ, 1981, JPEN-PARENTER ENTER, V5, P200, DOI 10.1177/0148607181005003200; Kopecky J, 1996, AM J PHYSIOL-ENDOC M, V270, pE768, DOI 10.1152/ajpendo.1996.270.5.E768; LEMONNIER D, 1972, J CLIN INVEST, V51, P2907, DOI 10.1172/JCI107115; LESAVRE PH, 1979, J IMMUNOL, V123, P529; LIU MS, 1994, J BIOL CHEM, V269, P11417; LOMBARDO YB, 1983, HORM METAB RES, V16, P37; Lubinski JM, 1998, J VIROL, V72, P8257, DOI 10.1128/JVI.72.10.8257-8263.1998; MAEDA N, 1994, J BIOL CHEM, V269, P23610; Maslowska M, 1997, INT J OBESITY, V21, P261, DOI 10.1038/sj.ijo.0800396; Maslowska M, 1997, J LIPID RES, V38, P1; McGarry JD, 1998, AM J CLIN NUTR, V67, p500S, DOI 10.1093/ajcn/67.3.500S; McKnight SL, 1998, GENE DEV, V12, P3145, DOI 10.1101/gad.12.20.3145; MENAHAN LA, 1983, METABOLISM, V32, P172, DOI 10.1016/0026-0495(83)90225-1; Merkel M, 1998, P NATL ACAD SCI USA, V95, P13841, DOI 10.1073/pnas.95.23.13841; Merkel M, 1998, J CLIN INVEST, V102, P893, DOI 10.1172/JCI2912; Moller DE, 1996, ENDOCRINOLOGY, V137, P2397, DOI 10.1210/en.137.6.2397; Morin CL, 1997, ENDOCRINOLOGY, V138, P4665, DOI 10.1210/en.138.11.4665; Muller-Eberhard H J, 1980, Adv Immunol, V29, P1, DOI 10.1016/S0065-2776(08)60042-5; Murray I, 1999, AM J PHYSIOL-ENDOC M, V277, pE474, DOI 10.1152/ajpendo.1999.277.3.E474; Murray I, 1997, J LIPID RES, V38, P2492; Murray I, 1999, J LIPID RES, V40, P1671; PETERSON J, 1990, P NATL ACAD SCI USA, V87, P909, DOI 10.1073/pnas.87.3.909; PURCELLHUYNH DA, 1995, J CLIN INVEST, V95, P2246, DOI 10.1172/JCI117915; RANDLE PJ, 1963, LANCET, V1, P785; Ranheim T, 1997, ARTERIOSCL THROM VAS, V17, P3286, DOI 10.1161/01.ATV.17.11.3286; REUE K, 1993, J LIPID RES, V34, P893; Saleh J, 1998, J LIPID RES, V39, P884; SAXENA U, 1989, J BIOL CHEM, V264, P4349; Scantlebury T, 1998, J BIOL CHEM, V273, P20903, DOI 10.1074/jbc.273.33.20903; SHENG J, 1990, METABOLISM, V39, P155, DOI 10.1016/0026-0495(90)90069-O; SHEPHERD PR, 1993, J BIOL CHEM, V268, P22243; SHIMADA M, 1995, BIOCHEM BIOPH RES CO, V211, P761, DOI 10.1006/bbrc.1995.1878; SHIMADA M, 1993, J BIOL CHEM, V268, P17924; SNIDERMAN AD, 1987, NIH PUBLICATION; SRIVASTAVA RAK, 1991, BIOCHIM BIOPHYS ACTA, V1086, P29, DOI 10.1016/0005-2760(91)90151-7; SURWIT RS, 1995, METABOLISM, V44, P645, DOI 10.1016/0026-0495(95)90123-X; Tao YH, 1997, BBA-LIPID LIPID MET, V1344, P221, DOI 10.1016/S0005-2760(96)00144-0; Van Hermelen V, 1999, J BIOL CHEM, V274, P18243, DOI 10.1074/jbc.274.26.18243; VanHeek M, 1997, J CLIN INVEST, V99, P385, DOI 10.1172/JCI119171; Weinstock PH, 1995, J CLIN INVEST, V96, P2555, DOI 10.1172/JCI118319; Wetsel RA, 1999, J BIOL CHEM, V274, P19429, DOI 10.1074/jbc.274.27.19429; YASUSHI I, 1990, SCIENCE, V249, P790; Zhang XJ, 1998, EUR J CLIN INVEST, V28, P730	63	68	75	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 17	1999	274	51					36219	36225		10.1074/jbc.274.51.36219	http://dx.doi.org/10.1074/jbc.274.51.36219			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	266AV	10593909	Green Published, hybrid			2022-12-25	WOS:000084279200028
J	Shi, J; Vlamis-Gardikas, V; Aslund, F; Holmgren, A; Rosen, BP				Shi, J; Vlamis-Gardikas, V; Aslund, F; Holmgren, A; Rosen, BP			Reactivity of glutaredoxins 1, 2, and 3 from Escherichia coli shows that glutaredoxin 2 is the primary hydrogen donor to ArsC-catalyzed arsenate reduction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RIBONUCLEOTIDE REDUCTASE; MIXED DISULFIDE; THIOREDOXIN; GLUTATHIONE; PROTEIN; CLONING; MUTANT	In Escherichia coli ArsC catalyzes the reduction of arsenate to arsenite using GSH with glutaredoxin as electron donors. E. coli has three glutaredoxins: 1, 2, and 3, each with a classical -Cys-Pro-Tyr-Cys- active site. Glutaredoxin 2 is the major glutathione disulfide oxidoreductase in E. coli, but its function remains unknown. In this report glutaredoxin 2 is shown to be the most effective hydrogen donor for the reduction of arsenate by ArsC. Analysis of single or double cysteine-to-serine substitutions in the active site of the three glutaredoxins indicated that only the N-terminal cysteine residue is essential for activity. This suggests that, during the catalytic cycle, ArsC forms a mixed disulfide with GSH before being reduced by glutaredoxin to regenerate the active ArsC reductase.	Wayne State Univ, Dept Biochem & Mol Biol, Sch Med, Detroit, MI 48201 USA; Karolinska Inst, Dept Med Biochem & Biophys, S-17177 Stockholm, Sweden	Wayne State University; Karolinska Institutet	Rosen, BP (corresponding author), Wayne State Univ, Dept Biochem & Mol Biol, Sch Med, 540 E Canfield Ave, Detroit, MI 48201 USA.		Vlamis, Alexios/AAF-5152-2020	Vlamis, Alexios/0000-0001-5068-6459; Rosen, Barry P./0000-0002-5230-4271	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM052216] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM52216] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ASLUND F, 1994, P NATL ACAD SCI USA, V91, P9813, DOI 10.1073/pnas.91.21.9813; Bjornberg O, 1991, Protein Expr Purif, V2, P287, DOI 10.1016/1046-5928(91)90085-W; BUSHWELLER JH, 1992, BIOCHEMISTRY-US, V31, P9288, DOI 10.1021/bi00153a023; CHUNG CT, 1989, P NATL ACAD SCI USA, V86, P2172, DOI 10.1073/pnas.86.7.2172; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; GLADYSHEVA TB, 1994, BIOCHEMISTRY-US, V33, P7288, DOI 10.1021/bi00189a033; GRAVINA SA, 1993, BIOCHEMISTRY-US, V32, P3368, DOI 10.1021/bi00064a021; HOLMGREN A, 1976, P NATL ACAD SCI USA, V73, P2275, DOI 10.1073/pnas.73.7.2275; HOLMGREN A, 1995, METHOD ENZYMOL, V252, P283; JI GY, 1994, BIOCHEMISTRY-US, V33, P7294, DOI 10.1021/bi00189a034; Jordan A, 1997, J BIOL CHEM, V272, P18044, DOI 10.1074/jbc.272.29.18044; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lillig CH, 1999, J BIOL CHEM, V274, P7695, DOI 10.1074/jbc.274.12.7695; Liu JY, 1997, J BIOL CHEM, V272, P21084, DOI 10.1074/jbc.272.34.21084; Miranda-Vizuete A, 1997, J BIOL CHEM, V272, P30841, DOI 10.1074/jbc.272.49.30841; MIRANDAVIZUETE A, 1994, J BIOL CHEM, V269, P16631; ODEN KL, 1994, MOL MICROBIOL, V12, P301, DOI 10.1111/j.1365-2958.1994.tb01018.x; Rosen BP, 1999, TRENDS MICROBIOL, V7, P207, DOI 10.1016/S0966-842X(99)01494-8; RUSSEL M, 1990, J BACTERIOL, V172, P1923, DOI 10.1128/jb.172.4.1923-1929.1990; Sambrook J., 2002, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Stewart EJ, 1998, EMBO J, V17, P5543, DOI 10.1093/emboj/17.19.5543; VlamisGardikas A, 1997, J BIOL CHEM, V272, P11236	23	116	121	0	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 17	1999	274	51					36039	36042		10.1074/jbc.274.51.36039	http://dx.doi.org/10.1074/jbc.274.51.36039			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	266AV	10593884	hybrid			2022-12-25	WOS:000084279200003
J	Kranenburg, O; Verlaan, I; Moolenaar, WH				Kranenburg, O; Verlaan, I; Moolenaar, WH			Dynamin is required for the activation of mitogen-activated protein (MAP) kinase by MAP kinase kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CLATHRIN-MEDIATED ENDOCYTOSIS; GROWTH-FACTOR RECEPTOR; TYROSINE-KINASE; NUCLEAR TRANSLOCATION; LYSOPHOSPHATIDIC ACID; SIGNAL-TRANSDUCTION; COUPLED RECEPTORS; EGF RECEPTOR; FIBROBLASTS; PATHWAYS	Internalization of activated receptors from the plasma membrane has been implicated in the activation of mitogen-activated protein (MAP) kinase. However, the mechanism whereby membrane trafficking may regulate mitogenic signaling remains unclear. Here we report that dominant-negative dynamin (K44A), an inhibitor of endocytic vesicle formation, abrogates MAP kinase activation in response to epidermal growth factor, lysophosphatidic acid, and protein kinase C-activating phorbol ester. In contrast, dynamin-K44A does not affect the activation of Pas, Raf, and MAP kinase kinase (MEK) by either agonist. Through immunofluorescence and subcellular fractionation studies, we find that activated MEK is present both at the plasma membrane and in intracellular vesicles but not in the cytosol. Our findings suggest that dynamin-regulated endocytosis of activated MEK, rather than activated receptors, is a critical event in the MAP kinase activation cascade.	Netherlands Canc Inst, Div Cellular Biochem, NL-1066 CX Amsterdam, Netherlands; Ctr Biomed Genet, NL-1066 CX Amsterdam, Netherlands	Netherlands Cancer Institute	Moolenaar, WH (corresponding author), Netherlands Canc Inst, Div Cellular Biochem, Plesmanlaan 121, NL-1066 CX Amsterdam, Netherlands.		Kranenburg, Onno/K-4115-2015	Kranenburg, Onno/0000-0002-2112-4390				Ahn S, 1999, J BIOL CHEM, V274, P1185, DOI 10.1074/jbc.274.3.1185; Brunet A, 1999, EMBO J, V18, P664, DOI 10.1093/emboj/18.3.664; Budd DC, 1999, J BIOL CHEM, V274, P12355, DOI 10.1074/jbc.274.18.12355; Ceresa BP, 1998, MOL CELL BIOL, V18, P3862, DOI 10.1128/MCB.18.7.3862; Chow JC, 1998, J BIOL CHEM, V273, P4672, DOI 10.1074/jbc.273.8.4672; Cobb MH, 1999, PROG BIOPHYS MOL BIO, V71, P479, DOI 10.1016/S0079-6107(98)00056-X; Daaka Y, 1998, J BIOL CHEM, V273, P685, DOI 10.1074/jbc.273.2.685; DAMKE H, 1994, J CELL BIOL, V127, P915, DOI 10.1083/jcb.127.4.915; Daub H, 1996, NATURE, V379, P557, DOI 10.1038/379557a0; Della Rocca GJ, 1999, J BIOL CHEM, V274, P4749, DOI 10.1074/jbc.274.8.4749; DOWNWARD J, 1990, NATURE, V346, P719, DOI 10.1038/346719a0; Fukuda M, 1996, J BIOL CHEM, V271, P20024, DOI 10.1074/jbc.271.33.20024; Garrington TP, 1999, CURR OPIN CELL BIOL, V11, P211, DOI 10.1016/S0955-0674(99)80028-3; GONZALEZ FA, 1993, J CELL BIOL, V122, P1089, DOI 10.1083/jcb.122.5.1089; Ignatova EG, 1999, J NEUROSCI, V19, P56, DOI 10.1523/JNEUROSCI.19-01-00056.1999; Jiang Y, 1998, NATURE, V395, P808, DOI 10.1038/27454; Kelly RB, 1999, NAT CELL BIOL, V1, pE8, DOI 10.1038/8957; Khokhlatchev AV, 1998, CELL, V93, P605, DOI 10.1016/S0092-8674(00)81189-7; Kranenburg O, 1999, MOL BIOL CELL, V10, P1851, DOI 10.1091/mbc.10.6.1851; Kranenburg O, 1999, BIOCHEM J, V339, P11, DOI 10.1042/0264-6021:3390011; Kranenburg O, 1997, EMBO J, V16, P3097, DOI 10.1093/emboj/16.11.3097; LENORMAND P, 1993, J CELL BIOL, V122, P1079, DOI 10.1083/jcb.122.5.1079; Lewis TS, 1998, ADV CANCER RES, V74, P49, DOI 10.1016/S0065-230X(08)60765-4; Luttrell LM, 1997, J BIOL CHEM, V272, P31648, DOI 10.1074/jbc.272.50.31648; Marais R, 1998, SCIENCE, V280, P109, DOI 10.1126/science.280.5360.109; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; Moolenaar WH, 1997, CURR OPIN CELL BIOL, V9, P168, DOI 10.1016/S0955-0674(97)80059-2; Robinson MJ, 1998, CURR BIOL, V8, P1141, DOI 10.1016/S0960-9822(07)00485-X; Schmid SL, 1998, CURR OPIN CELL BIOL, V10, P504, DOI 10.1016/S0955-0674(98)80066-5; Soltoff SP, 1998, J BIOL CHEM, V273, P23110, DOI 10.1074/jbc.273.36.23110; Urrutia R, 1997, P NATL ACAD SCI USA, V94, P377, DOI 10.1073/pnas.94.2.377; van der Bliek AM, 1999, TRENDS CELL BIOL, V9, P96, DOI 10.1016/S0962-8924(98)01490-1; van Dijk MCM, 1998, CURR BIOL, V8, P386, DOI 10.1016/S0960-9822(98)70157-5; VANBIESEN T, 1995, NATURE, V376, P781, DOI 10.1038/376781a0; VANCORVEN EJ, 1993, P NATL ACAD SCI USA, V90, P1257, DOI 10.1073/pnas.90.4.1257; vanDijk MCM, 1997, BIOCHEM J, V325, P303, DOI 10.1042/bj3250303; Vieira AV, 1996, SCIENCE, V274, P2086, DOI 10.1126/science.274.5295.2086; WELLS A, 1990, SCIENCE, V247, P962, DOI 10.1126/science.2305263; Yang WN, 1999, CURR BIOL, V9, pR511, DOI 10.1016/S0960-9822(99)80323-6	39	145	147	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 10	1999	274	50					35301	35304		10.1074/jbc.274.50.35301	http://dx.doi.org/10.1074/jbc.274.50.35301			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	264NG	10585393	hybrid			2022-12-25	WOS:000084187900005
J	Sinn, PL; Davis, DR; Sigmund, CD				Sinn, PL; Davis, DR; Sigmund, CD			Highly regulated cell type-restricted expression of human renin in mice containing 140-or 160-kilobase pair P1 phage artificial chromosome transgenes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA; HUMAN ANGIOTENSINOGEN; GENE-EXPRESSION; PLASMA-RENIN; HYPERTENSION; TRANSCRIPTION; PROMOTER; ELEMENTS; PROTEIN; KIDNEY	We generated transgenic mice with two P1 artificial chromosomes, each containing the human renin (HREN) gene and extending to -35 and -75 kilobase pairs, respectively. HREN protein production was restricted to juxtaglomerular cells of the kidney, and its expression was tightly regulated by angiotensin II and sodium. The magnitude of the up- and down-regulation in HREN mRNA caused by the stimuli tested was identical to the endogenous renin gene, suggesting tight physiological regulation. P1 artificial chromosome mice were mated with transgenic mice overexpressing human angiotensinogen to determine if there was a chronic compensatory down-regulation of the transgene, Despite a 3-fold down-regulation of HREN mRNA, plasma angiotensin II and blood pressure was modestly elevated in the double transgenic mice. Nevertheless, this elevation was significantly less than a different double transgenic model containing a poorly regulated HREN transgene. The increase in blood pressure, despite the decrease in HREN mRNA, suggests that the HREN gene can partially, but not completely, compensate for excess circulating angiotensinogen. These data suggest the possibility that increases in circulating or tissue angiotensinogen may cause an increase in blood pressure in humans, even in the presence of a functionally active servo-mechanism to downregulate HREN expression.	Univ Iowa, Coll Med, Dept Internal Med, Iowa City, IA 52242 USA; Univ Iowa, Coll Med, Dept Physiol & Biophys, Iowa City, IA 52242 USA	University of Iowa; University of Iowa	Sigmund, CD (corresponding author), Univ Iowa, Dept Internal Med & Physiol & Biophys, Med Lab 2191, Coll Med, Iowa City, IA 52242 USA.	curt-sigmund@uiowa.edu	Sigmund, Curt D./W-1611-2019; Sinn, Patrick/M-8026-2018	Sigmund, Curt D./0000-0002-1453-0921; Sinn, Patrick/0000-0002-9746-966X	NHLBI NIH HHS [HL48058, HL55006] Funding Source: Medline; NINDS NIH HHS [NS24621] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL048058, P50HL055006, R01HL048058] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P01NS024621] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Antoch MP, 1997, CELL, V89, P655, DOI 10.1016/S0092-8674(00)80246-9; Catanzaro DF, 1999, HYPERTENSION, V33, P318, DOI 10.1161/01.HYP.33.1.318; CHEN M, 1993, J BIOL CHEM, V268, P24138; Davisson RL, 1999, PHYSIOL GENOMICS, V1, P3, DOI 10.1152/physiolgenomics.1999.1.1.3; DZAU VJ, 1988, CIRCULATION, V77, P4; Ellis J, 1996, EMBO J, V15, P562, DOI 10.1002/j.1460-2075.1996.tb00388.x; FUKAMIZU A, 1989, BIOCHEM BIOPH RES CO, V165, P826, DOI 10.1016/S0006-291X(89)80040-3; GALEN FX, 1979, J CLIN ENDOCR METAB, V48, P1041, DOI 10.1210/jcem-48-6-1041; Germain S, 1998, J BIOL CHEM, V273, P25292, DOI 10.1074/jbc.273.39.25292; GOMEZ RA, 1989, AM J PHYSIOL, V257, pF850, DOI 10.1152/ajprenal.1989.257.5.F850; GROSVELD F, 1987, CELL, V51, P975, DOI 10.1016/0092-8674(87)90584-8; HATAE T, 1994, MOL CELL BIOCHEM, V131, P43, DOI 10.1007/BF01075723; Inoue I, 1997, J CLIN INVEST, V99, P1786, DOI 10.1172/JCI119343; IWAO H, 1988, AM J PHYSIOL, V255, pE129, DOI 10.1152/ajpendo.1988.255.2.E129; JEUNEMAITRE X, 1992, CELL, V71, P169, DOI 10.1016/0092-8674(92)90275-H; JOHNS DW, 1990, AM J PHYSIOL, V259, pF882, DOI 10.1152/ajprenal.1990.259.6.F882; Jones CA, 1997, EUR J BIOCHEM, V243, P181, DOI 10.1111/j.1432-1033.1997.0181a.x; Kim HS, 1999, J BIOL CHEM, V274, P14210, DOI 10.1074/jbc.274.20.14210; Merrill DC, 1996, J CLIN INVEST, V97, P1047, DOI 10.1172/JCI118497; MILLER CCJ, 1989, J HYPERTENS, V7, P861, DOI 10.1097/00004872-198911000-00002; Morgan T, 1997, J CLIN INVEST, V100, P1406, DOI 10.1172/JCI119661; *NAT RES COUNC, 1996, GUID CAR US LAB AN; Petrovic N, 1996, J BIOL CHEM, V271, P22499, DOI 10.1074/jbc.271.37.22499; RAPP JP, 1989, SCIENCE, V243, P542, DOI 10.1126/science.2563177; SEALEY JE, 1991, CLIN CHEM, V37, P1811; SIGMUND CD, 1992, CIRC RES, V70, P1070, DOI 10.1161/01.RES.70.5.1070; Sinn PL, 2000, V CH MO CAR, V1, P259; Sinn PL, 1999, AM J PHYSIOL-RENAL, V277, pF634, DOI 10.1152/ajprenal.1999.277.4.F634; Sinn PL, 1999, HYPERTENSION, V33, P900, DOI 10.1161/01.HYP.33.3.900; Takimoto E, 1996, SCIENCE, V274, P995, DOI 10.1126/science.274.5289.995; Thompson MW, 1996, HYPERTENSION, V28, P290, DOI 10.1161/01.HYP.28.2.290; Yan Y, 1998, CIRC RES, V83, P1279, DOI 10.1161/01.RES.83.12.1279; Yan Y, 1998, HYPERTENSION, V32, P205, DOI 10.1161/01.HYP.32.2.205; Yan Y, 1997, CIRC RES, V81, P558, DOI 10.1161/01.RES.81.4.558; YANG GY, 1994, J BIOL CHEM, V269, P32497; Yang XDW, 1997, NAT BIOTECHNOL, V15, P859, DOI 10.1038/nbt0997-859	36	49	49	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 10	1999	274	50					35785	35793		10.1074/jbc.274.50.35785	http://dx.doi.org/10.1074/jbc.274.50.35785			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	264NG	10585461	hybrid			2022-12-25	WOS:000084187900073
J	Bannasch, D; Weis, I; Schwab, M				Bannasch, D; Weis, I; Schwab, M			Nmi protein interacts with regions that differ between MycN and Myc and is localized in the cytoplasm of neuroblastoma cells in contrast to nuclear MycN	ONCOGENE			English	Article						protein-protein interactions; two-hybrid; Max; immunofluorescence; Ga14 DNA binding domain; amplification	C-MYC; N-MYC; TRANSCRIPTIONAL ACTIVATION; DNA-BINDING; NEURO-BLASTOMA; IN-VIVO; MAX; GENE; EXPRESSION; AMPLIFICATION	Myc family proteins play an important role in cellular processes such as proliferation, differentiation, apoptosis and transformation. A number of interaction partners of Myc have been identified, such as Max, p107, TBP, YY1, Miz-1, AP-2 and Nmi. Both Max and Nmi also bind to MycN. In contrast to the well defined binding of Max to Myc family proteins the interaction of Nmi with Myc or MycN is only poorly characterized. By employing the yeast two-hybrid system we have mapped the regions of MycN and Myc responsible for binding to Nmi. For MycN exclusively a central region mediates binding to Nmi. In contrast, for Myc a C-terminal portion of the protein, and possibly also a central part, is involved in Nmi interaction. Nmi does not interact with Max and has no transactivation capabilities in yeast, suggesting that Nmi alone is not a transcriptional activator in mammalian cells. Immunofluorescence demonstrates that both in 293 embryonic kidney cells and in Kelly neuroblastoma cells all detectable ectopically expressed Nmi is localized in the cytoplasm, in part in a punctate, granular pattern. MycN, which is highly expressed in Kelly cells consequent to amplification, appears to be localized exclusively in the nuclei. This directly demonstrates that in the same cell at least the major proportion of MycN and Nmi is localized in different cellular compartments. This result is confirmed by the finding that endogenous Nmi, which is expressed in Kelly cells only after stimulation with interferon gamma, is detected exclusively in the cytoplasm of these cells. Therefore only a very small amount of MycN and Nmi is likely to be involved in MycN/Nmi interaction in vivo.	Deutsch Krebsforschungszentrum, Div Cytogenet H0400, D-69120 Heidelberg, Germany	Helmholtz Association; German Cancer Research Center (DKFZ)	Schwab, M (corresponding author), Deutsch Krebsforschungszentrum, Div Cytogenet H0400, Neuenheimer Feld 280, D-69120 Heidelberg, Germany.							ALEXANDROVA N, 1995, MOL CELL BIOL, V15, P5188; AMATI B, 1992, NATURE, V359, P423, DOI 10.1038/359423a0; AMIN C, 1993, MOL CELL BIOL, V13, P383, DOI 10.1128/MCB.13.1.383; AYER DE, 1993, CELL, V72, P211, DOI 10.1016/0092-8674(93)90661-9; BANNASCH D, 1999, IN PRESS PLASMID, V42; Bao JX, 1996, ONCOGENE, V12, P2171; BEIJERSBERGEN RL, 1994, EMBO J, V13, P4080, DOI 10.1002/j.1460-2075.1994.tb06725.x; BLACKWELL TK, 1990, SCIENCE, V250, P1149, DOI 10.1126/science.2251503; BLACKWOOD EM, 1992, GENE DEV, V6, P71, DOI 10.1101/gad.6.1.71; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; Bush A, 1998, GENE DEV, V12, P3797, DOI 10.1101/gad.12.24.3797; CERNI C, 1995, ONCOGENE, V11, P587; Cheng SWG, 1999, NAT GENET, V22, P102, DOI 10.1038/8811; DEPINHO RA, 1991, ADV CANCER RES, V57, P1; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; Facchini LM, 1998, FASEB J, V12, P633, DOI 10.1096/fasebj.12.9.633; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; GAUBATZ S, 1994, MOL CELL BIOL, V14, P3853, DOI 10.1128/MCB.14.6.3853; GAUBATZ S, 1995, EMBO J, V14, P1508, DOI 10.1002/j.1460-2075.1995.tb07137.x; GRANDORI C, 1998, TIBS, V22, P177; GU W, 1994, SCIENCE, V264, P251, DOI 10.1126/science.8146655; GU W, 1993, P NATL ACAD SCI USA, V90, P2935, DOI 10.1073/pnas.90.7.2935; Henriksson M, 1996, ADV CANCER RES, V68, P109, DOI 10.1016/S0065-230X(08)60353-X; HURLIN PJ, 1995, EMBO J, V14, P5646, DOI 10.1002/j.1460-2075.1995.tb00252.x; Ingvarsson S, 1990, Semin Cancer Biol, V1, P359; Kalenik JL, 1997, NUCLEIC ACIDS RES, V25, P843, DOI 10.1093/nar/25.4.843; KERKHOFF E, 1991, P NATL ACAD SCI USA, V88, P4323, DOI 10.1073/pnas.88.10.4323; KHANNA R, 1995, MICROBIOL REV, V59, P387, DOI 10.1128/MMBR.59.3.387-405.1995; KRETZNER L, 1992, NATURE, V359, P426, DOI 10.1038/359426a0; Lebrun SJ, 1998, J INTERF CYTOK RES, V18, P767, DOI 10.1089/jir.1998.18.767; LECH K, 1988, CELL, V52, P179, DOI 10.1016/0092-8674(88)90506-5; LEE WH, 1984, NATURE, V309, P458, DOI 10.1038/309458a0; MAHESWARAN S, 1994, MOL CELL BIOL, V14, P1147, DOI 10.1128/MCB.14.2.1147; Mateyak MK, 1997, CELL GROWTH DIFFER, V8, P1039; McMahon SB, 1998, CELL, V94, P363, DOI 10.1016/S0092-8674(00)81479-8; NAU MM, 1986, P NATL ACAD SCI USA, V83, P1092, DOI 10.1073/pnas.83.4.1092; NERLOV C, 1995, EMBO J, V14, P4318, DOI 10.1002/j.1460-2075.1995.tb00106.x; Peukert K, 1997, EMBO J, V16, P5672, DOI 10.1093/emboj/16.18.5672; PRENDERGAST GC, 1991, SCIENCE, V251, P186, DOI 10.1126/science.1987636; Sakamuro D, 1996, NAT GENET, V14, P69, DOI 10.1038/ng0996-69; Schreiber-Agus N, 1998, BIOESSAYS, V20, P808, DOI 10.1002/(SICI)1521-1878(199810)20:10<808::AID-BIES6>3.0.CO;2-U; SCHWAB M, 1983, NATURE, V305, P245, DOI 10.1038/305245a0; SCHWAB M, 1984, P NATL ACAD SCI-BIOL, V81, P4940, DOI 10.1073/pnas.81.15.4940; Schwab M, 1998, BIOESSAYS, V20, P473, DOI 10.1002/(SICI)1521-1878(199806)20:6<473::AID-BIES5>3.3.CO;2-N; SCHWAB M, 1988, ONCOGENE HDB, P381; Shrivastava A, 1996, P NATL ACAD SCI USA, V93, P10638, DOI 10.1073/pnas.93.20.10638; VANLOHUIZEN M, 1989, EMBO J, V8, P133, DOI 10.1002/j.1460-2075.1989.tb03357.x; WAGNER AJ, 1993, CELL GROWTH DIFFER, V4, P879; WAKAMATSU Y, 1993, NEURON, V10, P1, DOI 10.1016/0896-6273(93)90236-K; Wang Q, 1998, ONCOGENE, V17, P1939, DOI 10.1038/sj.onc.1202403; WENZEL A, 1991, EMBO J, V10, P3703, DOI 10.1002/j.1460-2075.1991.tb04938.x; ZERVOS AS, 1993, CELL, V72, P223, DOI 10.1016/0092-8674(93)90662-A; Zhu MH, 1999, CELL, V96, P121, DOI 10.1016/S0092-8674(00)80965-4; ZIMMERMAN KA, 1986, NATURE, V319, P780, DOI 10.1038/319780a0	54	32	33	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 18	1999	18	48					6810	6817		10.1038/sj.onc.1203090	http://dx.doi.org/10.1038/sj.onc.1203090			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	257QA	10597290				2022-12-25	WOS:000083792000024
J	Corcoran, MM; Mould, SJ; Orchard, JA; Ibbotson, RE; Chapman, RM; Boright, AP; Platt, C; Tsui, LC; Scherer, SW; Oscier, DG				Corcoran, MM; Mould, SJ; Orchard, JA; Ibbotson, RE; Chapman, RM; Boright, AP; Platt, C; Tsui, LC; Scherer, SW; Oscier, DG			Dysregulation of cyclin dependent kinase 6 expression in splenic marginal zone lymphoma through chromosome 7q translocations	ONCOGENE			English	Article						CDK6; 7q translocations; SMZL; SLVL	CHRONIC LYMPHOCYTIC-LEUKEMIA; MOLECULAR DELINEATION; VILLOUS LYMPHOCYTES; GROWTH ARREST; HUMAN CANCER; CELL; GENE; REGION; DNA; HUMAN-CHROMOSOME-7	The increased or inappropriate expression of genes with oncogenic properties through specific chromosome translocations is an important event in the pathogenesis of B-cell lymphoproliferative diseases. Recent studies have found deletions or translocations of chromosome 7q to be the most common cytogenetic abnormality observed in SLVL, a leukemic variant of SMZL, with the q21-q22 region being most frequently affected. In three patients with translocations between chromosomes 2 and 7, the cloning of the breakpoints at 7q21 revealed that each was located within a small region of DNA 3.6 kb upstream of the transcription start site of cyclin dependent kinase 6 (CDK6). In each case the translocation event was consistent with aberrant VJ recombination between the immunoglobulin light chain region (Ig kappa) on chromosome 2p12 and DNA sequences at 7q21, resembling the heptamer recombination site. The t(7;21) breakpoint in an additional patient with splenic marginal zone lymphoma (SMZL), resided 66 kb telomeric to the t(2;7) breakpoints juxtaposing CDK6 to an uncharacterized transcript. In two of the SLVL patient samples, the CDK6 protein was found to be markedly over expressed. These results suggest that dysregulation of CDK6 gene expression contributes to the pathogenesis of SLVL and SMZL.	Royal Bournemouth Hosp, Dept Haematol, Bournemouth BH7 7DW, Dorset, England; Hosp Sick Children, Dept Genet, Toronto, ON M5G 1X8, Canada	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids)	Oscier, DG (corresponding author), Royal Bournemouth Hosp, Dept Haematol, Castle Lane E, Bournemouth BH7 7DW, Dorset, England.		Scherer, Stephen W./B-3785-2013; Tsui, Lap-chee/A-1081-2010	Scherer, Stephen W./0000-0002-8326-1999; 				BULLRICH F, 1995, CANCER RES, V55, P1199; Chesi M, 1997, NAT GENET, V16, P260, DOI 10.1038/ng0797-260; Chilosi M, 1998, AM J PATHOL, V152, P209; Corcoran MM, 1998, BLOOD, V91, P1382, DOI 10.1182/blood.V91.4.1382; Costello JF, 1997, CANCER RES, V57, P1250; Dascalescu CM, 1999, CANCER GENET CYTOGEN, V109, P21, DOI 10.1016/S0165-4608(98)00139-3; Easton J, 1998, CANCER RES, V58, P2624; Fischer K, 1997, BLOOD, V89, P2036, DOI 10.1182/blood.V89.6.2036; Goossens T, 1998, P NATL ACAD SCI USA, V95, P2463, DOI 10.1073/pnas.95.5.2463; HENG HHQ, 1994, CYTOGENET CELL GENET, V66, P135, DOI 10.1159/000133685; Hernandez JM, 1997, GENE CHROMOSOME CANC, V18, P147, DOI 10.1002/(SICI)1098-2264(199702)18:2<147::AID-GCC10>3.0.CO;2-H; Hernandez JM, 1997, CANCER GENET CYTOGEN, V93, P147, DOI 10.1016/S0165-4608(96)00183-5; Hiom K, 1998, CELL, V94, P463, DOI 10.1016/S0092-8674(00)81587-1; JAFFE EF, 1997, AM J SURG PATHOL, V21, P109; Kaldis P, 1998, MOL BIOL CELL, V9, P2545, DOI 10.1091/mbc.9.9.2545; Konig A, 1997, BLOOD, V90, P4307; KORSMEYER SJ, 1992, ANNU REV IMMUNOL, V10, P785, DOI 10.1146/annurev.immunol.10.1.785; KUMAR S, 1995, HUM GENET, V95, P641; KUNZ J, 1994, GENOMICS, V22, P439, DOI 10.1006/geno.1994.1407; Latham KM, 1996, MOL CELL BIOL, V16, P4445; LORENZ W, 1988, MOL IMMUNOL, V25, P479, DOI 10.1016/0161-5890(88)90168-X; Mishmar D, 1998, P NATL ACAD SCI USA, V95, P8141, DOI 10.1073/pnas.95.14.8141; OFFIT K, 1995, BLOOD, V86, P2365, DOI 10.1182/blood.V86.6.2365.bloodjournal8662365; Oscier DG, 1996, CANCER GENET CYTOGEN, V92, P24, DOI 10.1016/S0165-4608(96)00025-8; RABBITTS TH, 1994, NATURE, V372, P143, DOI 10.1038/372143a0; Schneider E, 1998, ONCOGENE, V17, P2733, DOI 10.1038/sj.onc.1202504; SZEPESI A, 1994, BLOOD, V84, P3413; Tambini CE, 1997, GENOMICS, V41, P84, DOI 10.1006/geno.1997.4636; Timmermann S, 1997, CELL GROWTH DIFFER, V8, P361; Wahbi K, 1997, LEUKEMIA, V11, P1214, DOI 10.1038/sj.leu.2400716; Wong KF, 1998, CANCER GENET CYTOGEN, V102, P145, DOI 10.1016/S0165-4608(97)00367-1; Zeng WR, 1997, ONCOGENE, V14, P2355, DOI 10.1038/sj.onc.1201076	33	107	109	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 4	1999	18	46					6271	6277		10.1038/sj.onc.1203033	http://dx.doi.org/10.1038/sj.onc.1203033			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	260DK	10597225				2022-12-25	WOS:000083934100010
J	Craig, AL; Blaydes, JP; Burch, LR; Thompson, AM; Hupp, TR				Craig, AL; Blaydes, JP; Burch, LR; Thompson, AM; Hupp, TR			Dephosphorylation of p53 at Ser20 after cellular exposure to low levels of non-ionizing radiation	ONCOGENE			English	Article						p53; transcription; kinase; radiation; phosphorylation	DNA-BINDING FUNCTION; WILD-TYPE P53; PROTEIN; PHOSPHORYLATION; CELLS; DAMAGE; MDM2; TRANSCRIPTION; STABILITY; ACTIVATE	Induction of the transactivation function of p53 after cellular irradiation was studied under conditions in which upstream signaling events modulating p53 activation were uncoupled from those regulating stabilization. This investigation prompted the discovery of a novel radiation-responsive kinase pathway targeting Ser20 that results in the masking of the DO-1 epitope in undamaged cells. Unmasking of the DO-1 epitope via dephosphorylation occurs in response to low doses of nonionizing radiation. Our data show that phosphorylation at Ser20 reduces binding of the mdm2 protein, suggesting that a function of the Ser20-kinase pathway may be to produce a stable pool of inactive p53 in undamaged cells which can be readily activated after cellular injury. Phospho-specific monoclonal antibodies were used to determine whether the Ser20 signaling pathway is coupled to the Ser15 and Ser392 radiation-responsive kinase pathways. These results demonstrated that: (1) dephosphorylation at Ser20 is co-ordinated with an increased steady-state phosphorylation at Ser392 after irradiation, without p53 protein stabilization, and (2) stabilization of p53 protein can occur without Ser15 phosphorylation at higher doses of radiation. These data show that the Ser20 and Ser392 phosphorylation sites are both targeted by an integrated network of signaling pathways which is acutely sensitive to radiation injury.	Univ Dundee, Dundee Canc Res Inst, Dept Mol & Cellular Pathol, Dundee DD1 9SY, Scotland; Univ Dundee, Dundee Canc Res Inst, Dept Mol Oncol, Dundee DD1 9SY, Scotland; Univ Dundee, Dundee Canc Res Inst, Dept Surg, Dundee DD1 9SY, Scotland	University of Dundee; University of Dundee; University of Dundee	Hupp, TR (corresponding author), Univ Dundee, Dundee Canc Res Inst, Dept Mol & Cellular Pathol, Dundee DD1 9SY, Scotland.		Blaydes, Jeremy/AAC-6939-2019	Blaydes, Jeremy/0000-0001-8525-0209				Berns EMJJ, 1998, J CLIN ONCOL, V16, P121, DOI 10.1200/JCO.1998.16.1.121; Blaydes JP, 1997, ONCOGENE, V14, P1859, DOI 10.1038/sj.onc.1201018; Blaydes JP, 1998, ONCOGENE, V17, P1045, DOI 10.1038/sj.onc.1202014; BOND J, 1999, IN PRESS ONCOGENE; Bottger A, 1997, CURR BIOL, V7, P860, DOI 10.1016/S0960-9822(06)00374-5; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Cairns CA, 1998, EMBO J, V17, P3112, DOI 10.1093/emboj/17.11.3112; Chesnokov I, 1996, MOL CELL BIOL, V16, P7084; DOVER R, 1994, J CELL SCI, V107, P1181; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; HUPP TR, 1995, CELL, V83, P237, DOI 10.1016/0092-8674(95)90165-5; HUPP TR, 1995, J BIOL CHEM, V270, P18165, DOI 10.1074/jbc.270.30.18165; HUPP TR, 1994, COLD SPRING HARB SYM, V59, P195, DOI 10.1101/SQB.1994.059.01.024; Kaghad M, 1997, CELL, V90, P809, DOI 10.1016/S0092-8674(00)80540-1; KASTAN MB, 1991, CANCER RES, V51, P6304; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Kussie PH, 1996, SCIENCE, V274, P948, DOI 10.1126/science.274.5289.948; Lambert PF, 1998, J BIOL CHEM, V273, P33048, DOI 10.1074/jbc.273.49.33048; LU X, 1993, CELL, V75, P765, DOI 10.1016/0092-8674(93)90496-D; Lutzker SG, 1996, NAT MED, V2, P804, DOI 10.1038/nm0796-804; Midgley CA, 1997, ONCOGENE, V15, P1179, DOI 10.1038/sj.onc.1201459; Oren M, 1996, BBA-REV CANCER, V1288, pR13, DOI 10.1016/S0304-419X(96)00030-3; Pise-Masison CA, 1998, J VIROL, V72, P6348, DOI 10.1128/JVI.72.8.6348-6355.1998; Ravera MW, 1998, ONCOGENE, V16, P1993, DOI 10.1038/sj.onc.1201717; Sakaguchi K, 1997, BIOCHEMISTRY-US, V36, P10117, DOI 10.1021/bi970759w; Shieh SY, 1997, CELL, V91, P325, DOI 10.1016/S0092-8674(00)80416-X; Siliciano JD, 1997, GENE DEV, V11, P3471, DOI 10.1101/gad.11.24.3471; Soussi T, 1996, J MOL BIOL, V260, P623, DOI 10.1006/jmbi.1996.0425; STEPHEN CW, 1995, J MOL BIOL, V248, P58, DOI 10.1006/jmbi.1995.0202; THOMPSON AM, 1998, BRIT J SURG, V82, P210; Unger T, 1999, EMBO J, V18, P1805, DOI 10.1093/emboj/18.7.1805; Van Der Geer P., 1993, PROTEIN PHOSPHORYLAT, P31; Venkatachalam S, 1998, EMBO J, V17, P4657, DOI 10.1093/emboj/17.16.4657; VOJTESEK B, 1995, ONCOGENE, V10, P389; Waterman MJF, 1998, NAT GENET, V19, P175, DOI 10.1038/542; YEARGIN J, 1995, CURR BIOL, V5, P423, DOI 10.1016/S0960-9822(95)00083-2	36	32	33	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 4	1999	18	46					6305	6312		10.1038/sj.onc.1203085	http://dx.doi.org/10.1038/sj.onc.1203085			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	260DK	10597229				2022-12-25	WOS:000083934100014
J	Chao, TH; Hayashi, M; Tapping, RI; Kato, Y; Lee, JD				Chao, TH; Hayashi, M; Tapping, RI; Kato, Y; Lee, JD			MEKK3 directly regulates MEK5 activity as part of the big mitogen-activated protein kinase 1 (BMK1) signaling pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR MEF2C; MAP-KINASE; ERK; RAF-1; EXPRESSION; BMK1/ERK5; DOMAIN; YEAST	Big mitogen-activated protein (MAP) kinase (BMK1), also known as ERK5, is a member of the MAP kinase family whose cellular activity is elevated in response to growth factors, oxidative stress, and hyperosmolar conditions. Previous studies have identified MEK5 as a cellular kinase directly regulating BMK1 activity; however, signaling molecules that directly regulate MEK5 activity have not yet been defined. Through utilization of a yeast two-hybrid screen, we have identified MEKK3 as a molecule that physically interacts with MEK5, This interaction appears to take place in mammalian cells as evidenced by the fact that cellular MEK5 and MEKK3 co-immunoprecipitate. In addition, we show that a dominant active form of MEKK3 stimulates BMK1 activity through MEK5. Moreover, we demonstrate that MEKK3 activity is required for growth factor mediated cellular activation of endogenous BMK1. Taken together, these results identify MEKK3 as a kinase that regulates the activity of MEK5 and BMK1 during growth factor-induced cellular stimulation.	Scripps Res Inst, Dept Immunol, La Jolla, CA 92037 USA; Aichi Med Univ, Dept Microbiol & Immunol, Nagakute, Aichi 4801195, Japan	Scripps Research Institute; Aichi Medical University	Lee, JD (corresponding author), Scripps Res Inst, Dept Immunol, 10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM053214] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM53214] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abe J, 1996, J BIOL CHEM, V271, P16586, DOI 10.1074/jbc.271.28.16586; Blank JL, 1996, J BIOL CHEM, V271, P5361, DOI 10.1074/jbc.271.10.5361; BOULTON TG, 1990, SCIENCE, V249, P64, DOI 10.1126/science.2164259; CHOW YH, 1995, J BIOL CHEM, V270, P14100, DOI 10.1074/jbc.270.23.14100; Cobb MH, 1999, PROG BIOPHYS MOL BIO, V71, P479, DOI 10.1016/S0079-6107(98)00056-X; COBB MH, 1994, CELL MOL BIOL RES, V40, P253; DAVIS RJ, 1995, MOL REPROD DEV, V42, P459, DOI 10.1002/mrd.1080420414; DAVIS RJ, 1995, MOL REPROD DEV, V42, P456; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; EllingerZiegelbauer H, 1997, J BIOL CHEM, V272, P2668, DOI 10.1074/jbc.272.5.2668; ENGLISH JM, 1995, J BIOL CHEM, V270, P28897, DOI 10.1074/jbc.270.48.28897; Fanger GR, 1998, J BIOL CHEM, V273, P3476, DOI 10.1074/jbc.273.6.3476; GARDNER AM, 1993, J BIOL CHEM, V268, P17896; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; Han J, 1997, NATURE, V386, P296, DOI 10.1038/386296a0; Kato Y, 1997, EMBO J, V16, P7054, DOI 10.1093/emboj/16.23.7054; Kato Y, 1998, NATURE, V395, P713, DOI 10.1038/27234; LEE JD, 1995, BIOCHEM BIOPH RES CO, V213, P715, DOI 10.1006/bbrc.1995.2189; MAGNUSON NS, 1994, SEMIN CANCER BIOL, V5, P247; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; Schlesinger Thomas K., 1998, Frontiers in Bioscience, V3, pD1181; STANTON VP, 1989, MOL CELL BIOL, V9, P639, DOI 10.1128/MCB.9.2.639; Sugden PH, 1997, CELL SIGNAL, V9, P337, DOI 10.1016/S0898-6568(96)00191-X; Whitmarsh AJ, 1998, TRENDS BIOCHEM SCI, V23, P481, DOI 10.1016/S0968-0004(98)01309-7; Widmann C, 1999, PHYSIOL REV, V79, P143, DOI 10.1152/physrev.1999.79.1.143; Xu SC, 1996, P NATL ACAD SCI USA, V93, P5291, DOI 10.1073/pnas.93.11.5291; ZHOU GC, 1995, J BIOL CHEM, V270, P12665, DOI 10.1074/jbc.270.21.12665	27	151	155	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 17	1999	274	51					36035	36038		10.1074/jbc.274.51.36035	http://dx.doi.org/10.1074/jbc.274.51.36035			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	266AV	10593883	hybrid			2022-12-25	WOS:000084279200002
J	Goehring, UM; Schmidt, G; Pederson, KJ; Aktories, K; Barbieri, JT				Goehring, UM; Schmidt, G; Pederson, KJ; Aktories, K; Barbieri, JT			The N-terminal domain of Pseudomonas aeruginosa exoenzyme S is a GTPase-activating protein for Rho GTPases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; GENE-PRODUCT; DEAMIDATION; COMPLEX; FAMILY; GLN-63; CDC42; RAS	Pseudomonas aeruginosa exoenzyme S (ExoS) is a bifunctional cytotoxin. The ADP-ribosyltransferase domain is located within the C terminus part of ExoS. Recent studies showed that the N terminus part of ExoS (amino acid residues 1-234, ExoS(1-234)), which does not possess ADP-ribosyltransferase activity, stimulates cell rounding when transfected or microinjected into eukaryotic cells. Here we studied the effects of ExoS(1-234) on nucleotide binding and hydrolysis by Rho GTPases. ExoS(1-234) (100-500 nM) did not influence nucleotide exchange of Rho, Rac, and Cdc42 but increased GTP hydrolysis. A similar increase in GTPase activity was stimulated by full-length ExoS. Half-maximal stimulation of GTP hydrolysis by Rho, Rac, and Cdc42 was observed at 10-11 nM ExoS(1-234), respectively. We identified arginine 146 of ExoS to be essential for the stimulation of GTPase activity of Rho proteins. These data identify ExoS as a GTPase-activating protein for Rho GTPases.	Med Coll Wisconsin, Milwaukee, WI 53226 USA; Univ Freiburg, Inst Pharmakol & Toxikol, D-79104 Freiburg, Germany	Medical College of Wisconsin; University of Freiburg	Barbieri, JT (corresponding author), Med Coll Wisconsin, 8701 Watertown Plank Rd, Milwaukee, WI 53226 USA.		Aktories, Klaus/CAJ-5682-2022	Aktories, Klaus/0000-0002-5397-0436	NIAID NIH HHS [AI10017, AI30162] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI030162, F32AI010017] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AKTORIES K, 1989, BIOCHEM BIOPH RES CO, V158, P209, DOI 10.1016/S0006-291X(89)80199-8; Aktories K, 1997, TRENDS MICROBIOL, V5, P282, DOI 10.1016/S0966-842X(97)01067-6; BARFOD ET, 1993, J BIOL CHEM, V268, P26059; Caron E, 1998, SCIENCE, V282, P1717, DOI 10.1126/science.282.5394.1717; CHARDIN P, 1989, EMBO J, V8, P1087, DOI 10.1002/j.1460-2075.1989.tb03477.x; COBURN J, 1989, J BIOL CHEM, V264, P9004; COBURN J, 1991, INFECT IMMUN, V59, P4259, DOI 10.1128/IAI.59.11.4259-4262.1991; DIEKMANN D, 1991, NATURE, V351, P400, DOI 10.1038/351400a0; Flatau G, 1997, NATURE, V387, P729, DOI 10.1038/42743; FU H, 1993, P NATL ACAD SCI USA, V90, P2320, DOI 10.1073/pnas.90.6.2320; Ganesan AK, 1999, J BIOL CHEM, V274, P21823, DOI 10.1074/jbc.274.31.21823; Ganesan AK, 1998, J BIOL CHEM, V273, P7332, DOI 10.1074/jbc.273.13.7332; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; HIRATSUKA T, 1983, BIOCHIM BIOPHYS ACTA, V742, P496, DOI 10.1016/0167-4838(83)90267-4; Horiguchi Y, 1997, P NATL ACAD SCI USA, V94, P11623, DOI 10.1073/pnas.94.21.11623; JUST I, 1995, J BIOL CHEM, V270, P13932, DOI 10.1074/jbc.270.23.13932; JUST I, 1995, NATURE, V375, P500, DOI 10.1038/375500a0; KULICH SM, 1993, INFECT IMMUN, V61, P307, DOI 10.1128/IAI.61.1.307-313.1993; LANCASTER CA, 1994, J BIOL CHEM, V269, P1137; Lerm M, 1999, INFECT IMMUN, V67, P496, DOI 10.1128/IAI.67.2.496-503.1999; Massol P, 1998, EMBO J, V17, P6219, DOI 10.1093/emboj/17.21.6219; PEDERSON KJ, 1998, MICROBIOLOGY, V32, P393; REINHARD J, 1995, EMBO J, V14, P697, DOI 10.1002/j.1460-2075.1995.tb07048.x; Rittinger K, 1997, NATURE, V389, P758, DOI 10.1038/39651; Scheffzek K, 1997, SCIENCE, V277, P333, DOI 10.1126/science.277.5324.333; Schmidt G, 1997, NATURE, V387, P725, DOI 10.1038/42735; Schmidt G, 1998, NATURWISSENSCHAFTEN, V85, P253, DOI 10.1007/s001140050495; SEKINE A, 1989, J BIOL CHEM, V264, P8602; VanAelst L, 1997, GENE DEV, V11, P2295, DOI 10.1101/gad.11.18.2295	29	233	243	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 17	1999	274	51					36369	36372		10.1074/jbc.274.51.36369	http://dx.doi.org/10.1074/jbc.274.51.36369			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	266AV	10593930	hybrid			2022-12-25	WOS:000084279200049
J	Krief, S; Faivre, JF; Robert, P; Le Douarin, B; Brument-Larignon, N; Lefrere, I; Bouzyk, MM; Anderson, KM; Greller, LD; Tobin, FL; Souchet, M; Bril, A				Krief, S; Faivre, JF; Robert, P; Le Douarin, B; Brument-Larignon, N; Lefrere, I; Bouzyk, MM; Anderson, KM; Greller, LD; Tobin, FL; Souchet, M; Bril, A			Identification and characterization of cvHsp - A novel human small stress protein selectively expressed in cardiovascular and insulin-sensitive tissues	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIN-BINDING PROTEIN; HEAT-SHOCK-PROTEIN; ALPHA-B-CRYSTALLIN; GLYCOPROTEIN IB-ALPHA; FILAMIN; DISEASE; CELLS; MODULATION; BIOLOGY; ABP-280	Starting with computational tools that search for tissue-selective expression of assembled expressed sequenced tags, we have identified by focusing on heart libraries a novel small stress protein of 170 amino acids that we named cvHsp. cvHsp was found as being computationally selectively and highly (0.3% of the total RNA) expressed in human heart. The cvHsp gene mapped to 1p36.23-p34.3 between markers D1S434 and D1S507. The expression of cvHsp was analyzed with RNA dot, Northern blots, or reverse transcription-polymerase chain reaction: expression was high in heart, medium in skeletal muscle, and low in aorta or adipose tissues. In the heart of rat models of cardiac pathologies, cvHsp mRNA ex pression was either unchanged (spontaneous hypertension), up-regulated (right ventricular hypertrophy induced by monocrotaline treatment), or down-regulated (left ventricular hypertrophy following aortic banding). In obese Zucker rats, cvHsp mRNA was increased in skeletal muscle, brown, and white adipose tissues but remained unchanged in the heart. Western blot analysis using antipeptide polyclonal antibodies revealed two specific bands at 23 and 25 kDa for cvHsp in human heart. cvHsp interacted in both yeast two-hybrid and immunoprecipitation experiments with alpha-filamin or actin-binding protein 280. Within cvHsp, amino acid residues 56-119 mere shown to be important for its specific interaction with the C-terminal tail of alpha-filamin.	SmithKline Beecham, Lab Pharmaceut, F-35762 St Gregoire, France; CNRS, Unite Propre 041, Rennes, France; SmithKline Beecham Pharmaceut, Harlow CM19 5AD, Essex, England; SmithKline Beecham Pharmaceut, King Of Prussia, PA 19406 USA	GlaxoSmithKline; Centre National de la Recherche Scientifique (CNRS); GlaxoSmithKline; GlaxoSmithKline	Krief, S (corresponding author), SmithKline Beecham, Lab Pharmaceut, 4 Rue Chesnay Beauregard,BP 58, F-35762 St Gregoire, France.	Stephane_Krief@sbphrd.com	FAIVRE, Jean-Francois/P-5097-2016	Krief, Stephane/0000-0002-5543-731X; ROBERT, Philippe/0000-0002-5975-9252				Andrade MA, 1997, CURR OPIN BIOTECH, V8, P675, DOI 10.1016/S0958-1669(97)80118-8; ANDREWS RK, 1991, J BIOL CHEM, V266, P7144; Baur EV, 1996, EMBO J, V15, P110, DOI 10.1002/j.1460-2075.1996.tb00339.x; BELL GI, 1990, DIABETES CARE, V13, P198, DOI 10.2337/diacare.13.3.198; Benjamin IJ, 1998, CIRC RES, V83, P117, DOI 10.1161/01.RES.83.2.117; BENNARDINI F, 1992, CIRC RES, V71, P288, DOI 10.1161/01.RES.71.2.288; Callebaut I, 1997, CELL MOL LIFE SCI, V53, P621, DOI 10.1007/s000180050082; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COOPER LF, 1994, J BIOL CHEM, V269, P7869; CURRIE RW, 1988, CIRC RES, V63, P543, DOI 10.1161/01.RES.63.3.543; Ferrari R, 1996, J MOL CELL CARDIOL, V28, P2383, DOI 10.1006/jmcc.1996.0231; GOOD IJ, 1956, BIOMETRIKA, V43, P45; GOOD IJ, 1953, BIOMETRIKA, V40, P237, DOI 10.2307/2333344; GORLIN JB, 1990, J CELL BIOL, V111, P1089, DOI 10.1083/jcb.111.3.1089; Greller LD, 1999, GENOME RES, V9, P282; HONGBROWN LQ, 1994, GLIA, V12, P211, DOI 10.1002/glia.440120306; James P, 1996, GENETICS, V144, P1425; Kato K, 1998, J BIOL CHEM, V273, P28346, DOI 10.1074/jbc.273.43.28346; Kato K, 1996, J NEUROCHEM, V66, P946; KRIEF S, 1994, J BIOL CHEM, V269, P6664; LEDOUARIN B, 1995, NUCLEIC ACIDS RES, V23, P876, DOI 10.1093/nar/23.5.876; LEEDMAN PJ, 1993, P NATL ACAD SCI USA, V90, P5994, DOI 10.1073/pnas.90.13.5994; Leroux MR, 1997, J BIOL CHEM, V272, P24646, DOI 10.1074/jbc.272.39.24646; LINDQUIST S, 1988, ANNU REV GENET, V22, P631, DOI 10.1146/annurev.ge.22.120188.003215; LIU AYC, 1990, BIOCHEM BIOPH RES CO, V172, P1, DOI 10.1016/S0006-291X(05)80164-0; Liu GP, 1997, J CELL BIOL, V139, P1719, DOI 10.1083/jcb.139.7.1719; MARBER MS, 1993, CIRCULATION, V88, P1264, DOI 10.1161/01.CIR.88.3.1264; Marti A, 1997, J BIOL CHEM, V272, P2620, DOI 10.1074/jbc.272.5.2620; Masuhara M, 1997, BIOCHEM BIOPH RES CO, V239, P439, DOI 10.1006/bbrc.1997.7484; Matz JM, 1996, AM J PHYSIOL-REG I, V270, pR525, DOI 10.1152/ajpregu.1996.270.3.R525; MAYER RJ, 1991, BIOCHIM BIOPHYS ACTA, V1089, P141, DOI 10.1016/0167-4781(91)90002-4; Meyer SC, 1997, J BIOL CHEM, V272, P2914, DOI 10.1074/jbc.272.5.2914; MIRON T, 1991, J CELL BIOL, V114, P255, DOI 10.1083/jcb.114.2.255; OHTA Y, 1991, CELL, V67, P275, DOI 10.1016/0092-8674(91)90179-3; Ott I, 1998, J CELL BIOL, V140, P1241, DOI 10.1083/jcb.140.5.1241; Perez-Reyes E, 1998, NATURE, V391, P896, DOI 10.1038/36110; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SHADIACK AM, 1991, J NEUROBIOL, V22, P617, DOI 10.1002/neu.480220607; SHARMA CP, 1995, J IMMUNOL, V154, P3461; SIKELA JM, 1993, NAT GENET, V3, P189, DOI 10.1038/ng0393-189; Suzuki A, 1998, J CELL BIOL, V140, P1113, DOI 10.1083/jcb.140.5.1113; SWYNGHEDAUW B, 1992, BASIC RES CARDIOL, V87, P1; Takafuta T, 1998, J BIOL CHEM, V273, P17531, DOI 10.1074/jbc.273.28.17531; Vasmatzis G, 1998, P NATL ACAD SCI USA, V95, P300, DOI 10.1073/pnas.95.1.300; Vicart P, 1998, NAT GENET, V20, P92, DOI 10.1038/1765; Vincent HK, 1999, INT J OBESITY, V23, P67, DOI 10.1038/sj.ijo.0800761; WEIHING RR, 1985, CAN J BIOCHEM CELL B, V63, P397, DOI 10.1139/o85-059; Wu YQ, 1999, HUM MOL GENET, V8, P313, DOI 10.1093/hmg/8.2.313; Xu WF, 1998, BLOOD, V92, P1268, DOI 10.1182/blood.V92.4.1268.416k12_1268_1276; Zeng ZZ, 1997, BIOCHEM BIOPH RES CO, V236, P389, DOI 10.1006/bbrc.1997.6935; Zhang WJ, 1998, J NEUROSCI, V18, P914; ZHU Y, 1994, BLOOD, V84, P3715, DOI 10.1182/blood.V84.11.3715.bloodjournal84113715; Zweiger G, 1997, CURR OPIN BIOTECH, V8, P684, DOI 10.1016/S0958-1669(97)80119-X	53	90	99	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 17	1999	274	51					36592	36600		10.1074/jbc.274.51.36592	http://dx.doi.org/10.1074/jbc.274.51.36592			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	266AV	10593960	hybrid			2022-12-25	WOS:000084279200079
J	Kannenberg, F; Ellinghaus, P; Assmann, G; Seedorf, U				Kannenberg, F; Ellinghaus, P; Assmann, G; Seedorf, U			Aberrant oxidation of the cholesterol side chain in bile acid synthesis of sterol carrier protein-2/sterol carrier protein-x knockout mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OXYSTEROL 7-ALPHA-HYDROXYLASE; CHENODEOXYCHOLIC ACID; GAS-CHROMATOGRAPHY; COENZYME-A; GENE SCP2; THIOLASE; IDENTIFICATION; METABOLISM; PEROXISOMES; DEFICIENCY	Peroxisomal beta-oxidation plays an important role in the metabolism of a wide range of substrates, including various fatty acids and the steroid side chain in bile acid synthesis. Two distinct thiolases have been implicated to function in peroxisomal beta-oxidation: the long known 41-kDa beta-ketothiolase identified by Hashimoto and coworkers (Hijikata, M,, Ishii, N,, Kagamiyama, H., Osumi, T,, and Hashimoto, T, (1987) J, BioE, Chem, 262, 8151-8158) and the recently discovered 60-kDa SCPx thiolase, that consists of an N-terminal domain with beta-ketothiolase activity and a C-terminal moiety of sterol carrier protein-alpha (SCPS, a lipid carrier or transfer protein), Recently, gene targeting of the SCP2/SCPx gene has shown in mice that the SCPx beta-ketothiolase is involved in peroxisomal beta-oxidation of alpha-methyl-branched chain fatty acids like pristanic acid. In our present work we have investigated bile acid synthesis in the SCP2/SCPx knockout mice. Specific inhibition of beta-oxidation at the thiolytic cleavage step in bile acid synthesis is supported by our finding of pronounced accumulation in bile and serum from the knockout mice of 3 alpha,7 alpha,12 alpha-trihydroxy-27-nor-5 beta-cholestane-24-one (which is known bile alcohol derivative of the cholic acid synthetic intermediate 3 alpha,7 alpha,12 alpha-trihydroxy-24-keto-cholestanoyl-coenzyme A). Moreover, these mice have elevated concentrations of bile acids with shortened side chains (i,e, 23-norcholic acid and 23-norchenodeoxycholic acid), which may be produced via alpha- rather than beta-oxidation, Our results demonstrate that the SCPx thiolase is critical for beta-oxidation of the steroid side chain in conversion of cholesterol into bile acids.	Univ Munster, Inst Arterioskleroseforsch, D-48129 Munster, Germany; Univ Munster, Inst Klin Chem & Lab Med, Zent Lab, D-48129 Munster, Germany	University of Munster; University of Munster	Seedorf, U (corresponding author), Univ Munster, Inst Arterioskleroseforsch, Domagkstr 3, D-48129 Munster, Germany.							Antonenkov VD, 1997, J BIOL CHEM, V272, P26023, DOI 10.1074/jbc.272.41.26023; Baum CL, 1997, J BIOL CHEM, V272, P6490, DOI 10.1074/jbc.272.10.6490; Bjorkhem I., 1995, METABOLIC MOL BASES, P2073; CHIJIIWA K, 1988, J CHROMATOGR-BIOMED, V431, P17, DOI 10.1016/S0378-4347(00)83065-0; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLAYTON PT, 1990, J CLIN INVEST, V85, P1267, DOI 10.1172/JCI114563; Ellinghaus P, 1999, J BIOL CHEM, V274, P2766, DOI 10.1074/jbc.274.5.2766; FORT P, 1985, NUCLEIC ACIDS RES, V13, P1431, DOI 10.1093/nar/13.5.1431; HIJIKATA M, 1987, J BIOL CHEM, V262, P8151; Ishibashi S, 1996, J BIOL CHEM, V271, P18017, DOI 10.1074/jbc.271.30.18017; Lazarow P. B., 1995, METABOLIC MOL BASES, P2287; Merrill JR, 1996, J LIPID RES, V37, P98; NAKATOMI F, 1985, J PHARMACOBIO-DYNAM, V8, P557; NOMA Y, 1988, Steroids, V51, P385, DOI 10.1016/0039-128X(88)90026-8; OHBA T, 1995, BIOCHEMISTRY-US, V34, P10660, DOI 10.1021/bi00033a042; OHBA T, 1994, GENOMICS, V24, P370, DOI 10.1006/geno.1994.1630; PFEIFER SM, 1993, J STEROID BIOCHEM, V47, P167, DOI 10.1016/0960-0760(93)90071-4; PUGLIELLI L, 1995, J BIOL CHEM, V270, P18726; Raabe M, 1996, CYTOGENET CELL GENET, V73, P279, DOI 10.1159/000134355; REDDY JK, 1994, ANNU REV NUTR, V14, P343, DOI 10.1146/annurev.nu.14.070194.002015; Rosen H, 1998, J BIOL CHEM, V273, P14805, DOI 10.1074/jbc.273.24.14805; SCHTEINGART CD, 1988, J LIPID RES, V29, P1387; Schwarz M, 1996, J BIOL CHEM, V271, P18024, DOI 10.1074/jbc.271.30.18017; Schwarz M, 1997, J BIOL CHEM, V272, P23995, DOI 10.1074/jbc.272.38.23995; SEEDORF U, 1994, J BIOL CHEM, V269, P21277; SEEDORF U, 1991, J BIOL CHEM, V266, P630; Seedorf U, 1998, GENE DEV, V12, P1189, DOI 10.1101/gad.12.8.1189; SETCHELL KD, 1988, BILE ACIDS CHEM PHYS, V4, P582; Setchell KDR, 1998, J CLIN INVEST, V102, P1690, DOI 10.1172/JCI2962; Stolowich NJ, 1997, BIOCHEMISTRY-US, V36, P1719, DOI 10.1021/bi962317a; STREET JM, 1985, J CHROMATOGR, V343, P259, DOI 10.1016/S0378-4347(00)84596-X; Suzuki M, 1997, J CHROMATOGR B, V693, P11, DOI 10.1016/S0378-4347(97)00063-7; van Grunsven EG, 1998, P NATL ACAD SCI USA, V95, P2128, DOI 10.1073/pnas.95.5.2128; VANDENBOSCH H, 1992, ANNU REV BIOCHEM, V61, P157, DOI 10.1146/annurev.bi.61.070192.001105; VESSEY DA, 1983, BIOCHEM J, V214, P923, DOI 10.1042/bj2140923; Wanders RJA, 1998, J INHERIT METAB DIS, V21, P302, DOI 10.1023/A:1005349028853; Wanders RJA, 1997, BIOCHEM BIOPH RES CO, V236, P565, DOI 10.1006/bbrc.1997.7007; Wirtz KWA, 1998, BIOCHEM SOC T, V26, P374, DOI 10.1042/bst0260374; WOLTHERS BG, 1983, CLIN CHIM ACTA, V131, P53, DOI 10.1016/0009-8981(83)90352-2; Wouters FS, 1998, EMBO J, V17, P7179, DOI 10.1093/emboj/17.24.7179; Yeh HZ, 1997, HEPATOLOGY, V26, P374, DOI 10.1002/hep.510260218; YURI M, 1993, CHEM PHARM BULL, V41, P1327	42	66	67	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 10	1999	274	50					35455	35460		10.1074/jbc.274.50.35455	http://dx.doi.org/10.1074/jbc.274.50.35455			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	264NG	10585416	hybrid			2022-12-25	WOS:000084187900028
J	Schmidtke, G; Holzhutter, HG; Bogyo, M; Kairies, N; Groll, M; de Giuli, R; Emch, S; Groettrup, M				Schmidtke, G; Holzhutter, HG; Bogyo, M; Kairies, N; Groll, M; de Giuli, R; Emch, S; Groettrup, M			How an inhibitor of the HIV-I protease modulates proteasome activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAJOR HISTOCOMPATIBILITY COMPLEX; 20S PROTEASOME; INTERFERON-GAMMA; BETA-SUBUNITS; INCREMENTAL CONSTRUCTION; ANTIGEN PRESENTATION; PEPTIDE; YEAST; DEGRADATION; SITE	The human immunodeficiency virus, type I protease inhibitor Ritonavir has been used successfully in AIDS therapy for 4 years. Clinical observations suggested that Ritonavir may exert a direct effect on the immune system unrelated to inhibition of the human immunodeficiency virus, type I protease. In fact, Ritonavir inhibited the major histocompatibility complex class I restricted presentation of several viral antigens at therapeutically relevant concentrations (5 mu M). In search of a molecular target we found that Ritonavir inhibited the chymotrypsin-like activity of the proteasome whereas the tryptic activity was enhanced. In this study we kinetically analyzed how Ritonavir modulates proteasome activity and what consequences this has on cellular functions of the proteasome. Ritonavir is a reversible effector of proteasome activity that protected the subunits MB-1 (X) and/or LMP7 from covalent active site modification with the vinyl sulfone inhibitor(125)I-NLVS, suggesting that they are the prime targets for competitive inhibition by Ritonavir. At low concentrations of Ritonavir (5 mu M) cells were more sensitive to canavanine but proliferated normally whereas at higher concentrations (50 mu M) protein degradation was affected, and the cell cycle was arrested in the G(1)/S phase, Ritonavir thus modulates antigen processing at concentrations at which vital cellular functions of the proteasome are not yet severely impeded. Proteasome modulators may hence qualify as therapeutics for the control of the cytotoxic immune response.	Cantonal Hosp St Gall, Res Dept, CH-9007 St Gallen, Switzerland; Humboldt Univ, Fac Med Charite, Inst Biochem, D-10117 Berlin, Germany; Univ Calif San Francisco, Dept Biochem & Biophys, San Francisco, CA 94143 USA; Max Planck Inst Biochem, D-82152 Martinsried, Germany	Kantonsspital St. Gallen; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; University of California System; University of California San Francisco; Max Planck Society	Groettrup, M (corresponding author), Kantonsspital, Lab Forsch Abt, Haus 09, CH-9007 St Gallen, Switzerland.		Groll, Michael/F-5572-2015; Groll, Michael/C-1174-2010	Holzhutter, Hermann-Georg/0000-0002-5054-6023; Bogyo, Matthew/0000-0003-3753-4412				ACHSTETTER T, 1984, J BIOL CHEM, V259, P3344; Andre P, 1998, P NATL ACAD SCI USA, V95, P13120, DOI 10.1073/pnas.95.22.13120; Beninga J, 1998, J BIOL CHEM, V273, P18734, DOI 10.1074/jbc.273.30.18734; Bogyo M, 1997, P NATL ACAD SCI USA, V94, P6629, DOI 10.1073/pnas.94.13.6629; Bogyo M, 1998, CHEM BIOL, V5, P307, DOI 10.1016/S1074-5521(98)90169-7; CIECHANOVER A, 1984, CELL, V37, P57, DOI 10.1016/0092-8674(84)90300-3; Coux O, 1996, ANNU REV BIOCHEM, V65, P801, DOI 10.1146/annurev.bi.65.070196.004101; Deeks SG, 1997, JAMA-J AM MED ASSOC, V277, P145, DOI 10.1001/jama.277.2.145; Dick TP, 1998, J BIOL CHEM, V273, P25637, DOI 10.1074/jbc.273.40.25637; ERICKSON J, 1990, SCIENCE, V249, P527, DOI 10.1126/science.2200122; FENTEANY G, 1994, P NATL ACAD SCI USA, V91, P3358, DOI 10.1073/pnas.91.8.3358; FENTEANY G, 1995, SCIENCE, V268, P726, DOI 10.1126/science.7732382; Groettrup M, 1999, DRUG DISCOV TODAY, V4, P63, DOI 10.1016/S1359-6446(98)01292-6; Groettrup M, 1996, IMMUNOL TODAY, V17, P429, DOI 10.1016/0167-5699(96)10051-7; GROETTRUP M, 1995, J BIOL CHEM, V270, P23808, DOI 10.1074/jbc.270.40.23808; Groll M, 1997, NATURE, V386, P463, DOI 10.1038/386463a0; Heinemeyer W, 1997, J BIOL CHEM, V272, P25200, DOI 10.1074/jbc.272.40.25200; KEIL GM, 1985, J VIROL, V54, P422, DOI 10.1128/JVI.54.2.422-428.1985; KEMPF DJ, 1995, P NATL ACAD SCI USA, V92, P2484, DOI 10.1073/pnas.92.7.2484; KLEBE G, 1994, J COMPUT AID MOL DES, V8, P583, DOI 10.1007/BF00123667; KUCKELKORN U, 1995, EUR J IMMUNOL, V25, P2605, DOI 10.1002/eji.1830250930; Levy F, 1996, P NATL ACAD SCI USA, V93, P4907, DOI 10.1073/pnas.93.10.4907; Moyle G, 1996, DRUGS, V51, P701, DOI 10.2165/00003495-199651050-00001; NIEDERMANN G, 1995, IMMUNITY, V2, P289, DOI 10.1016/1074-7613(95)90053-5; Nussbaum AK, 1998, P NATL ACAD SCI USA, V95, P12504, DOI 10.1073/pnas.95.21.12504; OHATA Y, 1997, BIOORGAN MED CHEM, V5, P461; Perrin L, 1998, SCIENCE, V280, P1871, DOI 10.1126/science.280.5371.1871; Rarey M, 1996, J MOL BIOL, V261, P470, DOI 10.1006/jmbi.1996.0477; Rarey M, 1997, J COMPUT AID MOL DES, V11, P369, DOI 10.1023/A:1007913026166; ROCK KL, 1994, CELL, V78, P761, DOI 10.1016/S0092-8674(94)90462-6; SALTER RD, 1986, EMBO J, V5, P943, DOI 10.1002/j.1460-2075.1986.tb04307.x; Salzmann U, 1999, FEBS LETT, V454, P11, DOI 10.1016/S0014-5793(99)00768-1; Schmidtke G, 1998, J EXP MED, V187, P1641, DOI 10.1084/jem.187.10.1641; SHERWOOD SW, 1993, P NATL ACAD SCI USA, V90, P3353, DOI 10.1073/pnas.90.8.3353	34	137	144	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 10	1999	274	50					35734	35740		10.1074/jbc.274.50.35734	http://dx.doi.org/10.1074/jbc.274.50.35734			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	264NG	10585454	hybrid			2022-12-25	WOS:000084187900066
J	Tomic, M; Koshimizu, TA; Yuan, D; Andric, SA; Zivadinovic, D; Stojilkovic, SS				Tomic, M; Koshimizu, TA; Yuan, D; Andric, SA; Zivadinovic, D; Stojilkovic, SS			Characterization of a plasma membrane calcium oscillator in rat pituitary somatotrophs	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTRACELLULAR CA2+ CONCENTRATION; NUCLEOTIDE-ACTIVATED CHANNEL; HORMONE-RELEASING HORMONE; ANTERIOR-PITUITARY; ACTION-POTENTIALS; CONCENTRATION <CA2+>I; SYMPATHETIC NEURONS; PROLACTIN SECRETION; RYANODINE RECEPTORS; PACEMAKER ACTIVITY	In excitable cells, oscillations in intracellular free calcium concentrations ([Ca2+](i)) can arise from action-potential-driven Ca2+ influx, and such signals can have either a localized or global form, depending on the coupling of voltage-gated Ca2+ influx to intracellular Ca2+ release pathway. Here we show that rat pituitary somatotrophs generate spontaneous [Ca2+](i) oscillations, which rise from fluctuations in the influx of external Ca2+ and propagate within the cytoplasm and nucleus. The addition of caffeine and ryanodine, modulators of ryanodine-receptor channels, and the depletion of intracellular Ca2+ stores by thapsigargin and ionomycin did not affect the global nature of spontaneous [Ca2+](i) signals. Bay K 8644, an L-type Ca2+ channel agonist, initiated [Ca2+](i) signaling in quiescent cells, increased the amplitude of [Ca2+](i) spikes in spontaneously active cells, and stimulated growth hormone secretion in perifused pituitary cells. Nifedipine, a blocker of L-type Ca2+ channels, decreased the amplitude of spikes and basal growth hormone secretion, whereas Ni2+, a blocker of T-type Ca2+ channels, abolished spontaneous [Ca2+](i) oscillations, Spiking was also abolished by the removal of extracellular Na+ and by the addition of 10 mM Ca2+, Mg2+, or Sr2+, the blockers of cyclic nucleotide-gated channels. Reverse transcriptase-polymerase chain reaction and Southern blot analyses indicated the expression of mRNAs for these channels in mixed pituitary cells and purified somatotrophs, Growth hormone-releasing hormone, an agonist that stimulated cAMP and cGMP productions in a dose-dependent manner, initiated spiking in quiescent cells and increased the frequency of spiking in spontaneously active cells, These results indicate that in somatotrophs a cyclic nucleotide-controlled plasma membrane Ca2+ oscillator is capable of generating global Ca2+ signals spontaneously and in response to agonist stimulation. The Ca2+-signaling activity of this oscillator is dependent on voltage-gated Ca2+ influx but not on Ca2+ release from intracellular stores.	NICHD, Endocrinol & Reprod Res Branch, Sect Cellular Signaling, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)	Stojilkovic, SS (corresponding author), NICHD, Endocrinol & Reprod Res Branch, Sect Cellular Signaling, Bldg 49,Room 6A-36,49 Convent Dr, Bethesda, MD 20892 USA.		Tomic, Melanija/C-3371-2016	Andric, Silvana/0000-0002-2908-8136; Koshimizu, Taka-aki/0000-0001-5292-7535	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [ZIAHD000195] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [Z01HD000195] Funding Source: NIH RePORTER	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ALMOHANNA FA, 1994, NATURE, V367, P745, DOI 10.1038/367745a0; BIALES B, 1977, NATURE, V267, P172, DOI 10.1038/267172a0; BRADY KD, 1994, BIOPHYS J, V66, P1697, DOI 10.1016/S0006-3495(94)80961-0; BRANSTABLE CJ, 1995, J MOL NEUROSCI, V6, P289; Cataldi M, 1999, BBA-MOL CELL RES, V1449, P186, DOI 10.1016/S0167-4889(99)00013-0; Charles AC, 1999, J BIOL CHEM, V274, P7508, DOI 10.1074/jbc.274.11.7508; CHEN C, 1995, AM J PHYSIOL-ENDOC M, V268, pE204, DOI 10.1152/ajpendo.1995.268.2.E204; DHALLAN RS, 1990, NATURE, V347, P184, DOI 10.1038/347184a0; DUFY B, 1979, SCIENCE, V204, P309; EHRLICH BE, 1994, TRENDS PHARMACOL SCI, V15, P145, DOI 10.1016/0165-6147(94)90074-4; Fiekers JF, 1996, CELL CALCIUM, V19, P327, DOI 10.1016/S0143-4160(96)90073-1; FRIEL DD, 1992, NEURON, V8, P1109, DOI 10.1016/0896-6273(92)90132-W; HAJNOCZKY G, 1994, NATURE, V370, P474, DOI 10.1038/370474a0; Hille B., 1991, IONIC CHANNELS EXCIT; INGRAM CD, 1986, ENDOCRINOLOGY, V119, P2508, DOI 10.1210/endo-119-6-2508; Jacobs JM, 1997, J NEUROSCI, V17, P4129; KIDOKORO Y, 1975, NATURE, V258, P741, DOI 10.1038/258741a0; KORN SJ, 1991, J PHYSIOL-LONDON, V439, P423, DOI 10.1113/jphysiol.1991.sp018674; Koshimizu T, 1998, MOL ENDOCRINOL, V12, P901, DOI 10.1210/me.12.7.901; KOSHIYAMA H, 1991, J BIOL CHEM, V266, P16985; KURYSHEV YA, 1995, ENDOCRINOLOGY, V136, P3925, DOI 10.1210/en.136.9.3925; Kwiecien R, 1997, J PHYSIOL-LONDON, V499, P613, DOI 10.1113/jphysiol.1997.sp021954; Kwiecien R, 1998, J PHYSIOL-LONDON, V508, P883, DOI 10.1111/j.1469-7793.1998.883bp.x; Kwiecien R, 1998, NEUROENDOCRINOLOGY, V68, P135, DOI 10.1159/000054360; LECHLEITER JD, 1992, CELL, V69, P283, DOI 10.1016/0092-8674(92)90409-6; LEWIS DL, 1988, ENDOCRINOLOGY, V123, P611, DOI 10.1210/endo-123-1-611; LI YX, 1995, BIOPHYS J, V69, P785, DOI 10.1016/S0006-3495(95)79952-0; LIN C, 1994, CELL CALCIUM, V16, P247, DOI 10.1016/0143-4160(94)90088-4; LIPSCOMBE D, 1988, NEURON, V1, P355, DOI 10.1016/0896-6273(88)90185-7; LOESSBERG PA, 1991, J BIOL CHEM, V266, P1363; Louzao MC, 1996, J BIOL CHEM, V271, P14807, DOI 10.1074/jbc.271.25.14807; LUSSIER BT, 1991, ENDOCRINOLOGY, V128, P570, DOI 10.1210/endo-128-1-570; LUSSIER BT, 1991, ENDOCRINOLOGY, V128, P583, DOI 10.1210/endo-128-1-583; LUSSIER BT, 1991, ENDOCRINOLOGY, V128, P592, DOI 10.1210/endo-128-1-592; Misaka T, 1997, J BIOL CHEM, V272, P22623, DOI 10.1074/jbc.272.36.22623; NAUMOV AP, 1994, PFLUG ARCH EUR J PHY, V427, P414, DOI 10.1007/BF00374255; OMALLEY DM, 1994, J NEUROSCI, V14, P5741; PerezTerzic C, 1997, CELL CALCIUM, V21, P275, DOI 10.1016/S0143-4160(97)90115-9; ROONEY TA, 1990, J BIOL CHEM, V265, P10792; Sankaranarayanan S, 1996, AM J PHYSIOL-CELL PH, V271, pC1927, DOI 10.1152/ajpcell.1996.271.6.C1927; SCHLEGEL W, 1987, NATURE, V329, P719, DOI 10.1038/329719a0; SHAM JSK, 1995, P NATL ACAD SCI USA, V92, P121, DOI 10.1073/pnas.92.1.121; SIMS SM, 1991, J PHYSIOL-LONDON, V441, P615, DOI 10.1113/jphysiol.1991.sp018770; STOJILKOVIC SS, 1992, P NATL ACAD SCI USA, V89, P4081, DOI 10.1073/pnas.89.9.4081; STOJILKOVIC SS, 1992, ENDOCR REV, V13, P256, DOI 10.1210/er.13.2.256; STOJILKOVIC SS, 1988, J BIOL CHEM, V263, P13054; Sundaresan S, 1997, ENDOCRINOLOGY, V138, P2056, DOI 10.1210/en.138.5.2056; TAKEMURA H, 1989, J BIOL CHEM, V264, P12266; TANAKA Y, 1993, BIOCHEMISTRY-US, V32, P12062, DOI 10.1021/bi00096a017; WAGNER KA, 1993, BIOCHEM J, V292, P175, DOI 10.1042/bj2920175; Zagotta WN, 1996, ANNU REV NEUROSCI, V19, P235, DOI 10.1146/annurev.ne.19.030196.001315	51	42	42	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 10	1999	274	50					35693	35702		10.1074/jbc.274.50.35693	http://dx.doi.org/10.1074/jbc.274.50.35693			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	264NG	10585449	hybrid			2022-12-25	WOS:000084187900061
J	Itoh, H; Komatsuda, A; Wakui, H; Miura, AB; Tashima, Y				Itoh, H; Komatsuda, A; Wakui, H; Miura, AB; Tashima, Y			Mammalian HSP60 is a major target for an immunosuppressant mizoribine	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK-PROTEIN; STRESS PROTEIN; BREDININ; ACTIVATION; CHAPERONIN; DEOXYSPERGUALIN; IDENTIFICATION; IMMUNOPHILINS; INHIBITOR; BACTERIAL	It has been reported that immunosuppressant cyclosporin A or FK506 binds to immunophilins in the cell and that these immunophilins make a complex with molecular chaperones HSP70 or HSP90, Although mizoribine has been used clinically as an immunosuppressant, immunophilins of the agent have not yet been fully understood. We investigated their specific binding proteins using mizoribine affinity column chromatography and porcine kidney cytosols, By increasing mizoribine in the eluant from the column, two major proteins (with molecular masses of 60 and 43 kDa) were detected by SDS-polyacrylamide gel electrophoresis. Based on the amino acid sequence analysis of these proteins, 60- and 43-kDa mizoribine-binding proteins were identified with HSP60 and cytosolic actin, respectively. A considerable amount of actin was also eluted from the affinity column by nucleotides, but a very low quantity of HSP60 was eluted under the same conditions. On the other hand, HSP60 was eluted as a major protein in the eluant that was eluted preferentially, with nucleotide followed by mizoribine. Actin was also detected in the eluant, but the quantity of the protein was very low. These results indicated that HSP60 has high affinity to mizoribine, and the interaction was also observed on surface plasmon resonance analysis. Although HSP60 or GroE facilitated refolding of citrate synthase in vitro, mizoribine interfered with the chaperone activity of HSP60. On different types of mizoribine affinity columns, HSP60 or actin recognized the NH2 group of mizoribine, and this group may be a functional group of the agent.	Akita Univ, Sch Med, Dept Biochem, Akita 0108543, Japan; Akita Univ, Sch Med, Dept Internal Med 3, Akita 0108543, Japan	Akita University; Akita University	Itoh, H (corresponding author), Akita Univ, Sch Med, Dept Biochem, 1-1-1 Hondo, Akita 0108543, Japan.							BRUSCHI SA, 1993, J BIOL CHEM, V268, P23157; BUCHNER J, 1991, BIOCHEMISTRY-US, V30, P1586, DOI 10.1021/bi00220a020; ERBA HP, 1988, MOL CELL BIOL, V8, P1775, DOI 10.1128/MCB.8.4.1775; Fenton WA, 1997, PROTEIN SCI, V6, P743; FRUMAN DA, 1994, FASEB J, V8, P391, DOI 10.1096/fasebj.8.6.7513288; FUKUI M, 1982, CANCER RES, V42, P1098; GALAT A, 1993, EUR J BIOCHEM, V216, P689, DOI 10.1111/j.1432-1033.1993.tb18189.x; Halloran PF, 1996, CLIN TRANSPLANT, V10, P118; Hartl FU, 1996, NATURE, V381, P571, DOI 10.1038/381571a0; IKAWA S, 1992, P NATL ACAD SCI USA, V89, P2012, DOI 10.1073/pnas.89.6.2012; ITOH H, 1995, J BIOL CHEM, V270, P13429, DOI 10.1074/jbc.270.22.13429; Itoh H, 1997, BIOCHEM J, V326, P567, DOI 10.1042/bj3260567; ITOH H, 1993, INT J BIOCHEM, V25, P69; JINDAL S, 1989, MOL CELL BIOL, V9, P2279, DOI 10.1128/MCB.9.5.2279; KOYAMA H, 1983, BIOCHEM PHARMACOL, V32, P3547, DOI 10.1016/0006-2952(83)90301-5; KUSUMI T, 1989, CELL BIOCHEM FUNCT, V7, P201, DOI 10.1002/cbf.290070308; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MIZUNO K, 1974, J ANTIBIOT, V27, P775, DOI 10.7164/antibiotics.27.775; MOSS ML, 1992, J BIOL CHEM, V267, P22054; NADEAU K, 1994, BIOCHEMISTRY-US, V33, P2561, DOI 10.1021/bi00175a027; NADLER SG, 1992, SCIENCE, V258, P484, DOI 10.1126/science.1411548; NAKAJIMA A, 1985, AM J OPHTHALMOL, V100, P161, DOI 10.1016/S0002-9394(14)74999-2; SCHMIDT M, 1994, J BIOL CHEM, V269, P10304; SHIOKAWA Y, 1991, JPN J INFLAMM, V11, P375; TAI PKK, 1992, SCIENCE, V256, P1315, DOI 10.1126/science.1376003; TAJIMA A, 1984, TRANSPLANTATION, V38, P116, DOI 10.1097/00007890-198408000-00005; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TURKA LA, 1991, J CLIN INVEST, V87, P940, DOI 10.1172/JCI115101; vanRoon JAG, 1997, J CLIN INVEST, V100, P459, DOI 10.1172/JCI119553; Viitanen PV, 1998, METHOD ENZYMOL, V290, P203, DOI 10.1016/S0076-6879(98)90020-9	30	72	74	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 3	1999	274	49					35147	35151		10.1074/jbc.274.49.35147	http://dx.doi.org/10.1074/jbc.274.49.35147			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	260XW	10574997	hybrid			2022-12-25	WOS:000083979600091
J	Hortelano, S; Alvarez, AM; Bosca, L				Hortelano, S; Alvarez, AM; Bosca, L			Nitric oxide induces tyrosine nitration and release of cytochrome c preceding an increase of mitochondrial transmembrane potential in macrophages	FASEB JOURNAL			English	Article						apoptosis; NO; nitric oxide synthase; mitochondria	PROGRAMMED CELL-DEATH; PERMEABILITY TRANSITION; APOPTOSIS; PEROXYNITRITE; BCL-2; RESPIRATION; INHIBITION; PATHWAYS; COMPLEX; INFLAMMATION	Treatment of elicited peritoneal macrophages or the macrophage cell line RAW 264.7 with high concentrations of nitric oxide donors is followed by apoptotic cell death. Analysis of the changes in the mitochondrial transmembrane potential (Delta Psi(m)) with specific fluorescent probes showed a rapid and persistent increase of Delta Psi(m), potential that usually decreases in cells undergoing apoptosis through mitochondrial-dependent mechanisms. Using confocal microscopy, the release of cytochrome c from the mitochondria to the cytosol was characterized as an early event preceding the rise of Delta Psi(m). The cytochrome c from cells treated with nitric oxide donors was modified chemically, probably through the formation of nitrotyrosine residues, suggesting the synthesis of peroxynitrite in the mitochondria, These results indicate that nitric oxide-dependent apoptosis in macrophages occurs in the presence of a sustained increase of Delta Psi(m), and that the chemical modification and release of cytochrome c from the mitochondria precede the changes of Delta Psi(m).	Univ Complutense Madrid, Fac Farm, Inst Bioquim, Ctr Mixto,CSIC, E-28040 Madrid, Spain; Univ Complutense Madrid, Fac Farm, Ctr Citometria Flujo & Microscopia Confocal, E-28040 Madrid, Spain	Complutense University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); Complutense University of Madrid	Bosca, L (corresponding author), Univ Complutense Madrid, Fac Farm, Inst Bioquim, Ctr Mixto,CSIC, E-28040 Madrid, Spain.		Bosca, Lisardo/A-2059-2008; Hortelano, Sonsoles/A-7954-2010; Alvarez-Barrientos, Alberto/L-9299-2014	Bosca, Lisardo/0000-0002-0253-5469; Hortelano, Sonsoles/0000-0003-2528-0072; Alvarez-Barrientos, Alberto/0000-0003-4761-0212				Albina JE, 1998, CANCER METAST REV, V17, P39, DOI 10.1023/A:1005904704618; Anderson GP, 1996, TRENDS PHARMACOL SCI, V17, P438, DOI 10.1016/S0165-6147(96)01004-8; ASCENZI P, 1994, J INORG BIOCHEM, V53, P273, DOI 10.1016/0162-0134(94)85114-X; Bossy-Wetzel E, 1998, EMBO J, V17, P37, DOI 10.1093/emboj/17.1.37; Brown GC, 1997, MOL CELL BIOCHEM, V174, P189, DOI 10.1023/A:1006800322719; Clementi E, 1998, P NATL ACAD SCI USA, V95, P7631, DOI 10.1073/pnas.95.13.7631; Davey GP, 1996, J NEUROCHEM, V66, P1617; Dugas B, 1995, RES IMMUNOL, V146, P664, DOI 10.1016/0923-2494(96)84914-5; Finucane DM, 1999, J BIOL CHEM, V274, P2225, DOI 10.1074/jbc.274.4.2225; GENARO AM, 1995, J CLIN INVEST, V95, P1884, DOI 10.1172/JCI117869; GIRARD P, 1993, FEBS LETT, V320, P7, DOI 10.1016/0014-5793(93)81645-G; Green DR, 1998, CELL, V94, P695, DOI 10.1016/S0092-8674(00)81728-6; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Guh JH, 1998, MOL PHARMACOL, V53, P467, DOI 10.1124/mol.53.3.467; Hashimoto S, 1998, P NATL ACAD SCI USA, V95, P3094, DOI 10.1073/pnas.95.6.3094; Hortelano S, 1999, BRIT J PHARMACOL, V126, P1139, DOI 10.1038/sj.bjp.0702422; Hortelano S, 1997, FEBS LETT, V410, P373, DOI 10.1016/S0014-5793(97)00623-6; Jurgensmeier JM, 1998, P NATL ACAD SCI USA, V95, P4997, DOI 10.1073/pnas.95.9.4997; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; KROEMER G, 1995, FASEB J, V9, P1277, DOI 10.1096/fasebj.9.13.7557017; Kroemer G, 1997, IMMUNOL TODAY, V18, P44, DOI 10.1016/S0167-5699(97)80014-X; Kroemer G, 1998, ANNU REV PHYSIOL, V60, P619, DOI 10.1146/annurev.physiol.60.1.619; Kroemer Guido, 1997, P1111; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; LIMBACH KJ, 1985, NUCLEIC ACIDS RES, V13, P617, DOI 10.1093/nar/13.2.617; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; Lizasoain I, 1996, BIOCHEM J, V314, P877, DOI 10.1042/bj3140877; Macho A, 1996, CYTOMETRY, V25, P333, DOI 10.1002/(SICI)1097-0320(19961201)25:4<333::AID-CYTO4>3.0.CO;2-E; MacMicking J, 1997, ANNU REV IMMUNOL, V15, P323, DOI 10.1146/annurev.immunol.15.1.323; Mallozzi C, 1997, FASEB J, V11, P1281, DOI 10.1096/fasebj.11.14.9409547; Marzo I, 1998, SCIENCE, V281, P2027, DOI 10.1126/science.281.5385.2027; Marzo I, 1998, J EXP MED, V187, P1261, DOI 10.1084/jem.187.8.1261; MOLLOY A, 1994, J EXP MED, V180, P1499, DOI 10.1084/jem.180.4.1499; MORO MA, 1994, P NATL ACAD SCI USA, V91, P6702, DOI 10.1073/pnas.91.14.6702; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; NATHAN C, 1995, CELL, V82, P873, DOI 10.1016/0092-8674(95)90019-5; PACKER MA, 1994, FEBS LETT, V345, P237, DOI 10.1016/0014-5793(94)00461-7; Sarti P, 1999, FASEB J, V13, P191, DOI 10.1096/fasebj.13.1.191; Savill J, 1997, J LEUKOCYTE BIOL, V61, P375, DOI 10.1002/jlb.61.4.375; Sharpe MA, 1998, J BIOL CHEM, V273, P30961, DOI 10.1074/jbc.273.47.30961; Simon DI, 1996, P NATL ACAD SCI USA, V93, P4736, DOI 10.1073/pnas.93.10.4736; Stamler J S, 1995, Curr Top Microbiol Immunol, V196, P19; Susin SA, 1996, J EXP MED, V184, P1331, DOI 10.1084/jem.184.4.1331; TERENZI F, 1995, J BIOL CHEM, V270, P6017, DOI 10.1074/jbc.270.11.6017; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; Velasco M, 1997, J IMMUNOL, V158, P4437; Virag L, 1998, IMMUNOLOGY, V94, P345, DOI 10.1046/j.1365-2567.1998.00534.x; Williams G T, 1994, Trends Microbiol, V2, P463, DOI 10.1016/0966-842X(94)90648-3; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; Yoshida H, 1998, CELL, V94, P739, DOI 10.1016/S0092-8674(00)81733-X	51	120	122	0	12	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	DEC	1999	13	15					2311	2317		10.1096/fasebj.13.15.2311	http://dx.doi.org/10.1096/fasebj.13.15.2311			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	266QN	10593878	Bronze			2022-12-25	WOS:000084310800022
J	Peet, NM; Grabowski, PS; Laketic-Ljubojevic, I; Skerry, TM				Peet, NM; Grabowski, PS; Laketic-Ljubojevic, I; Skerry, TM			The glutamate receptor antagonist MK801 modulates bone resorption in vitro by a mechanism predominantly involving osteoclast differentiation	FASEB JOURNAL			English	Article						osteoclast; differentiation; electrophysiology; glutamate receptor; MK801 maleate (Dizocilpine)	VASOACTIVE-INTESTINAL-PEPTIDE; TYROSINE PHOSPHORYLATION; SEALING ZONE; NITRIC-OXIDE; CELLS; EXPRESSION; HORMONES	Recent identification in bone of transporters, receptors, and components of synaptic signaling suggests a role for glutamate in the skeleton. We investigated effects of glutamate and its antagonist MK801 on osteoclasts in vitro. Glutamate applied to patch clamped osteoclasts induced significant increases in whole-cell membrane currents (P<0.01) in the presence of the coagonist glycine. Agonist-elicited currents were significantly decreased after application of MK801 (100 mu M, P<0.01), but MK801 had no effect on actin ring formation necessary for osteoclast polarization, attachment, and resorption. In cocultures of bone marrow cells and osteoblasts in which osteoclasts develop, MK801 inhibited osteoclast differentiation and reduced resorption of pits in dentine (3 to 100 mu M; P<0.001). MK801 added early in the culture (for as little as 2-4 days) was as effective as addition for the entire culture period. Addition of MK801 for any time after day 7 of culture was ineffective in reducing osteoclast activity. Using; rat and rabbit mature osteoclasts cultured on dentine or explants of mouse calvariae prelabeled with Ca-45, we could not detect significant effects of MK801 on osteoclastic resorption. These data show clearly that glutamate receptor function is critical during osteoclastogenesis and suggest that glutamate is less important in regulating mature osteoclast activity.	Univ York, Dept Biol, York YO10 5YW, N Yorkshire, England	University of York - UK	Peet, NM (corresponding author), Univ York, Dept Biol, POB 373, York YO10 5YW, N Yorkshire, England.			Skerry, Timothy/0000-0003-1319-5575				Arnett TR, 1996, BONE, V18, P277, DOI 10.1016/8756-3282(95)00486-6; BARKA T, 1962, J HISTOCHEM CYTOCHEM, V10, P741, DOI 10.1177/10.6.741; CHAMBERS TJ, 1985, ENDOCRINOLOGY, V116, P234, DOI 10.1210/endo-116-1-234; Chenu C, 1998, BONE, V22, P295, DOI 10.1016/S8756-3282(97)00295-0; Duong LT, 1998, J CLIN INVEST, V102, P881, DOI 10.1172/JCI3212; FORREST D, 1994, NEURON, V13, P325, DOI 10.1016/0896-6273(94)90350-6; GENEVER PG, 1999, IN PRESS BLOOD; GENEVER PG, 1999, IN PRESS J INVEST DE; GOLDRING MB, 1990, CLIN ORTHOP RELAT R, P245; Hamill OP, 1996, PHARMACOL REV, V48, P231; HOHMANN EL, 1984, ENDOCRINOLOGY, V114, P1321, DOI 10.1210/endo-114-4-1321; HOLLMANN M, 1994, ANNU REV NEUROSCI, V17, P31, DOI 10.1146/annurev.ne.17.030194.000335; Ilvesaro JM, 1998, EXP CELL RES, V242, P75, DOI 10.1006/excr.1998.4081; INAGAKI N, 1995, FASEB J, V9, P686, DOI 10.1096/fasebj.9.8.7768362; Insogna KL, 1997, J CLIN INVEST, V100, P2476, DOI 10.1172/JCI119790; Konttinen YT, 1996, ACTA ORTHOP SCAND, V67, P632, DOI 10.3109/17453679608997772; LAKETICLJUBOJEV.I, 1999, IN PRESS BONE; MALONE JD, 1986, P NATL ACAD SCI USA, V83, P3307, DOI 10.1073/pnas.83.10.3307; Mason DJ, 1997, BONE, V20, P199, DOI 10.1016/S8756-3282(96)00386-9; MULLER G, 1998, EXCITATORY AMINO ACI, V23, P109; MUNDY GR, 1994, NATURE, V367, P216, DOI 10.1038/367216a0; Murthy VN, 1998, NATURE, V392, P497, DOI 10.1038/33152; Nakamura I, 1998, J BIOL CHEM, V273, P11144, DOI 10.1074/jbc.273.18.11144; Patton AJ, 1998, BONE, V22, P645, DOI 10.1016/S8756-3282(98)00061-1; PATTON AJ, 1997, BONE, V20, P225; RAHMAN S, 1992, REGUL PEPTIDES, V37, P111, DOI 10.1016/0167-0115(92)90660-M; RAHMAN S, 1992, BIOCHIM BIOPHYS ACTA, V1135, P97, DOI 10.1016/0167-4889(92)90172-8; RALSTON SH, 1995, J BONE MINER RES, V10, P1040; Rosenmund C, 1998, SCIENCE, V280, P1596, DOI 10.1126/science.280.5369.1596; Said SI, 1996, P NATL ACAD SCI USA, V93, P4688, DOI 10.1073/pnas.93.10.4688; SCHIPANI E, 1995, SCIENCE, V268, P98, DOI 10.1126/science.7701349; SHANNON HE, 1989, J PHARMACOL EXP THER, V251, P518; TAKAHASHI N, 1988, ENDOCRINOLOGY, V122, P1373, DOI 10.1210/endo-122-4-1373; WALSH CA, 1991, J BONE MINER RES, V6, P661; Yasuda H, 1998, P NATL ACAD SCI USA, V95, P3597, DOI 10.1073/pnas.95.7.3597; YONEDA Y, 1986, BRAIN RES, V383, P387, DOI 10.1016/0006-8993(86)90046-6	36	81	83	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	DEC	1999	13	15					2179	2185		10.1096/fasebj.13.15.2179	http://dx.doi.org/10.1096/fasebj.13.15.2179			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	266QN	10593865				2022-12-25	WOS:000084310800009
J	Allemand, I; Anglo, A; Jeantet, AY; Cerutti, I; May, E				Allemand, I; Anglo, A; Jeantet, AY; Cerutti, I; May, E			Testicular wild-type p53 expression in transgenic mice induces spermiogenesis alterations ranging from differentiation defects to apoptosis	ONCOGENE			English	Article						p53; transgenic mice; spermatogenesis; apoptosis	TUMOR-SUPPRESSOR P53; GERM-CELL DEATH; DNA-DAMAGE; TERATOCARCINOMA CELLS; FUNCTIONAL DOMAIN; DEFICIENT MICE; IRRADIATED RAT; IN-VIVO; SPERMATOGENESIS; RADIATION	While p53 is dispensable for development, an excess of p53 has dramatic consequences on the embryogenesis and on the cell differentiation. In an attempt to analyse in vivo the effects of p53 activity, we have generated transgenic mice expressing the wild-type p53 under the control of the metallothionein I promoter. In the three transgenic lines established, exogenous p53 is expressed constitutively in the postmeiotic cells of transgenic males and two lines are subfertile, Transgenic males expressing the upper level of p53 produce few spermatozoa since the majority of developing spermatids undergo apoptosis, In the subfertile males exhibiting an intermediate amount of p53, teratozoospermia is obvious suggesting an altered terminal differentiation of postmeiotic cells. In contrast lower level of p53 does not lead the third line to sterility. These results suggest that the activity of p53 is dependent irt vivo on the amount of p53 present within cells, as it has been already demonstrated in vitro.	CEA, DSV, DRR, Lab Cancerogenese Mol,UMR 217,CNRS, F-92265 Fontenay Aux Roses, France; Univ Paris 06, Lab Cytophysiol Analyt, F-75006 Paris, France; Inst Rech Sci Canc, SEAT, F-94801 Villejuif, France	CEA; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Sorbonne Universite	Allemand, I (corresponding author), CEA, DSV, DRR, Lab Radiobiol Cellules Germinales, BP6, F-92265 Fontenay Aux Roses, France.			allemand, isabelle/0000-0002-8861-7632				Adachi J, 1998, CELL DEATH DIFFER, V5, P148, DOI 10.1038/sj.cdd.4400325; Agarwal ML, 1998, J BIOL CHEM, V273, P1, DOI 10.1074/jbc.273.1.1; BELLGRAU D, 1995, NATURE, V377, P630, DOI 10.1038/377630a0; Beumer TL, 1997, MOL REPROD DEV, V47, P240, DOI 10.1002/(SICI)1098-2795(199707)47:3&lt;240::AID-MRD2&gt;3.0.CO;2-L; Beumer TL, 1998, CELL DEATH DIFFER, V5, P669, DOI 10.1038/sj.cdd.4400396; BlancoRodriguez J, 1996, CELL PROLIFERAT, V29, P13, DOI 10.1046/j.1365-2184.1996.d01-5.x; BRAUN RE, 1989, NATURE, V337, P373, DOI 10.1038/337373a0; BRUGAROLAS J, 1995, NATURE, V377, P552, DOI 10.1038/377552a0; Burger H, 1998, BRIT J CANCER, V77, P1562, DOI 10.1038/bjc.1998.257; CAELLES C, 1994, NATURE, V370, P220, DOI 10.1038/370220a0; Chen XB, 1996, GENE DEV, V10, P2438, DOI 10.1101/gad.10.19.2438; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; Chresta CM, 1996, CANCER RES, V56, P1834; DE SK, 1991, MOL ENDOCRINOL, V5, P628, DOI 10.1210/mend-5-5-628; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; ELIYAHU D, 1985, NATURE, V316, P158, DOI 10.1038/316158a0; GARRITY PA, 1990, MOL CELL BIOL, V10, P5646, DOI 10.1128/MCB.10.11.5646; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; GERSTEN K, 1997, NAT GENET, V378, P378; Godley LA, 1996, GENE DEV, V10, P836, DOI 10.1101/gad.10.7.836; Gottlieb E, 1997, EMBO J, V16, P1381, DOI 10.1093/emboj/16.6.1381; Gromoll J, 1997, BIOL REPROD, V57, P1312, DOI 10.1095/biolreprod57.6.1312; HALL PA, 1997, CURR BIOL, V7, P144; Hasegawa M, 1998, RADIAT RES, V149, P263, DOI 10.2307/3579959; HAUPT Y, 1995, GENE DEV, V9, P2170, DOI 10.1101/gad.9.17.2170; Hendry JH, 1996, INT J RADIAT BIOL, V70, P677, DOI 10.1080/095530096144563; Houldsworth J, 1998, ONCOGENE, V16, P2345, DOI 10.1038/sj.onc.1201770; KNUDSON CM, 1995, SCIENCE, V270, P96, DOI 10.1126/science.270.5233.96; Komarova EA, 1998, ONCOGENE, V17, P1089, DOI 10.1038/sj.onc.1202303; Komarova EA, 1997, EMBO J, V16, P1391, DOI 10.1093/emboj/16.6.1391; Lee JW, 1997, ENDOCRINOLOGY, V138, P2081, DOI 10.1210/en.138.5.2081; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Lutzker SG, 1996, NAT MED, V2, P804, DOI 10.1038/nm0796-804; MacCallum DE, 1996, ONCOGENE, V13, P2575; MIYASHITA T, 1995, CELL, V80, P293; NAKAMURA T, 1995, P NATL ACAD SCI USA, V92, P6142, DOI 10.1073/pnas.92.13.6142; Odorisio T, 1998, NAT GENET, V18, P257, DOI 10.1038/ng0398-257; Orlovskaya EI, 1997, MOL BIOL+, V31, P184; OWENSCHAUB LB, 1995, MOL CELL BIOL, V15, P3032; PALMITER RD, 1983, SCIENCE, V222, P809, DOI 10.1126/science.6356363; PENG HQ, 1993, CANCER RES, V53, P3574; Piette J, 1997, ONCOGENE, V15, P1001, DOI 10.1038/sj.onc.1201432; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; Print CG, 1998, P NATL ACAD SCI USA, V95, P12424, DOI 10.1073/pnas.95.21.12424; Reinke V, 1997, ONCOGENE, V15, P1527, DOI 10.1038/sj.onc.1201316; RHEE K, 1995, DEV DYNAM, V204, P406, DOI 10.1002/aja.1002040407; RIOU G, 1995, MOL CARCINOGEN, V12, P124, DOI 10.1002/mc.2940120303; Rodriguez I, 1997, EMBO J, V16, P2262, DOI 10.1093/emboj/16.9.2262; Ross AJ, 1998, NAT GENET, V18, P251, DOI 10.1038/ng0398-251; ROTTER V, 1993, P NATL ACAD SCI USA, V90, P9075, DOI 10.1073/pnas.90.19.9075; Russell L. D., 1990, HISTOLOGICAL HISTOPA; Sakamuro D, 1997, ONCOGENE, V15, P887, DOI 10.1038/sj.onc.1201263; SassoneCorsi P, 1997, CELL, V88, P163, DOI 10.1016/S0092-8674(00)81834-6; SCHWARTZ D, 1993, ONCOGENE, V8, P1487; Sjoblom T, 1996, ONCOGENE, V12, P2499; Venot C, 1998, EMBO J, V17, P4668, DOI 10.1093/emboj/17.16.4668; West A, 1997, INT J RADIAT BIOL, V71, P283, DOI 10.1080/095530097144166; WILLIE AH, 1992, CANCER METAST REV, V11, P95; Zamble DB, 1998, P NATL ACAD SCI USA, V95, P6163, DOI 10.1073/pnas.95.11.6163; Zheng H, 1997, INT J RADIAT BIOL, V71, P275, DOI 10.1080/095530097144157; Zhu JH, 1998, J BIOL CHEM, V273, P13030, DOI 10.1074/jbc.273.21.13030	61	27	27	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 11	1999	18	47					6521	6530		10.1038/sj.onc.1203052	http://dx.doi.org/10.1038/sj.onc.1203052			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	256CW	10597255				2022-12-25	WOS:000083709200015
J	Izaguirre, G; Aguirre, L; Ji, P; Aneskievich, B; Haimovich, B				Izaguirre, G; Aguirre, L; Ji, P; Aneskievich, B; Haimovich, B			Tyrosine phosphorylation of alpha-actinin in activated platelets	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCOPROTEIN-IIB-IIIA; HUMAN BLOOD-PLATELETS; PROTEIN-KINASE-C; SIGNAL-TRANSDUCTION; CYTOPLASMIC DOMAIN; CELL MOTILITY; 3T3 CELLS; INTEGRIN; THROMBIN; BINDING	The integrin alpha(IIb)beta(3) mediates tyrosine phosphorylation of a 105-kDa protein (pp105) in activated platelets. We have partially purified a 105-kDa tyrosine-phosphorylated protein from platelets stimulated with phorbol 12-myristate 18 acetate and obtained the sequence of an internal 12-mer peptide derived from this protein. The sequence was identical to human alpha-actinin sequences deposited in the Swiss Protein Database. alpha-Actinin, a 105-kDa protein in platelets, was subsequently purified from activated platelets by four sequential chromatographic steps. Fractions were analyzed by Western blotting and probed with alpha-actinin and anti-phosphotyrosine antibodies. The distribution of alpha-actinin and pp105 overlapped throughout the purification. Furthermore, in the course of this purification, a 105-kDa tyrosine-phosphorylated protein was only detected in fractions that contained alpha-actinin, The purified alpha-actinin protein was immunoprecipitated with antibodies to phosphotyrosine in the absence but not in the presence of phenyl phosphate, alpha-Actinin resolved by two-dimensional gel electrophoresis of activated platelet lysates was recognized by the antibodies to phosphotyrosine, whereas pretreatment of the platelets with bisindolylmaleimide, a protein kinase C inhibitor that prevents tyrosine phosphorylation of pp105, inhibited the reactivity of the antibodies to phosphotyrosine with alpha-actinin, Taken together, these data demonstrate that a fraction of alpha-actinin is tyrosine-phosphorylated in activated platelets.	Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Surg, Piscataway, NJ 08854 USA; Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Biochem, Piscataway, NJ 08854 USA; Univ Connecticut, Dept Pharmaceut Sci, Storrs, CT 06269 USA	Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers State University New Brunswick; Rutgers State University Medical Center; University of Connecticut	Haimovich, B (corresponding author), Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Surg, Res Tower,Rm 234,675 Hoes Lane, Piscataway, NJ 08854 USA.			Aguirre, Lina/0000-0003-0711-314X	NHLBI NIH HHS [HL-54104] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL054104, R01HL054104] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BEGGS AH, 1992, J BIOL CHEM, V267, P9281; Cichowski K, 1996, J BIOL CHEM, V271, P7544, DOI 10.1074/jbc.271.13.7544; CLARK EA, 1995, SCIENCE, V268, P233, DOI 10.1126/science.7716514; CRAWFORD AW, 1992, J CELL BIOL, V116, P1381, DOI 10.1083/jcb.116.6.1381; DUBERNARD V, 1995, FEBS LETT, V364, P109, DOI 10.1016/0014-5793(95)00362-D; Egerton M, 1996, BIOCHEM BIOPH RES CO, V224, P666, DOI 10.1006/bbrc.1996.1082; FERNANDEZ J, 1992, ANAL BIOCHEM, V201, P255, DOI 10.1016/0003-2697(92)90336-6; FERRELL JE, 1989, P NATL ACAD SCI USA, V86, P2234, DOI 10.1073/pnas.86.7.2234; FOX JEB, 1993, J CELL BIOL, V120, P1501, DOI 10.1083/jcb.120.6.1501; FOX JEB, 1993, J BIOL CHEM, V268, P25973; Giancotti FG, 1997, CURR OPIN CELL BIOL, V9, P691, DOI 10.1016/S0955-0674(97)80123-8; Giuriato S, 1997, J BIOL CHEM, V272, P26857, DOI 10.1074/jbc.272.43.26857; GLUCK U, 1994, J CELL SCI, V107, P1773; GLUCK U, 1993, P NATL ACAD SCI USA, V90, P383, DOI 10.1073/pnas.90.2.383; GOLDEN A, 1989, P NATL ACAD SCI USA, V86, P901, DOI 10.1073/pnas.86.3.901; GOLDEN A, 1990, J CELL BIOL, V111, P3117, DOI 10.1083/jcb.111.6.3117; GRAVEL P, 1995, ELECTROPHORESIS, V16, P1152, DOI 10.1002/elps.11501601191; HAIMOVICH B, 1993, J BIOL CHEM, V268, P15868; Haimovich B, 1996, BLOOD, V87, P152, DOI 10.1182/blood.V87.1.152.bloodjournal871152; Haimovich B, 1996, J BIOL CHEM, V271, P16332, DOI 10.1074/jbc.271.27.16332; Haimovich B, 1999, THROMB HAEMOSTASIS, V81, P618; Hamazaki Y, 1998, ONCOGENE, V16, P2773, DOI 10.1038/sj.onc.1201799; HAMMINGS L, 1995, BIOCHEM SOC T, V23, P619; Honda K, 1998, J CELL BIOL, V140, P1383, DOI 10.1083/jcb.140.6.1383; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; Ji P, 1999, BBA-MOL CELL RES, V1448, P543, DOI 10.1016/S0167-4889(98)00160-8; KNUDSEN KA, 1995, J CELL BIOL, V130, P67, DOI 10.1083/jcb.130.1.67; KRAMER RM, 1995, J BIOL CHEM, V270, P27395, DOI 10.1074/jbc.270.46.27395; LANDON F, 1983, BIOCHIM BIOPHYS ACTA, V742, P129, DOI 10.1016/0167-4838(83)90368-0; LAZARIDES E, 1975, CELL, V6, P289, DOI 10.1016/0092-8674(75)90180-4; LEWIS JM, 1995, MOL BIOL CELL, V6, P151, DOI 10.1091/mbc.6.2.151; LIPFERT L, 1992, J CELL BIOL, V119, P905, DOI 10.1083/jcb.119.4.905; MILLAKE DB, 1989, NUCLEIC ACIDS RES, V17, P6725, DOI 10.1093/nar/17.16.6725; MIYAMOTO S, 1995, SCIENCE, V267, P883, DOI 10.1126/science.7846531; Mukai H, 1997, J BIOL CHEM, V272, P4740, DOI 10.1074/jbc.272.8.4740; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; OTEY CA, 1993, J BIOL CHEM, V268, P21193; OTEY CA, 1990, J CELL BIOL, V111, P721, DOI 10.1083/jcb.111.2.721; PAPKOFF J, 1994, MOL CELL BIOL, V14, P463, DOI 10.1128/MCB.14.1.463; Puius YA, 1998, CURR OPIN CELL BIOL, V10, P23, DOI 10.1016/S0955-0674(98)80083-5; Raja S, 1997, J BIOL CHEM, V272, P10941; ROSENBERG S, 1981, J BIOL CHEM, V256, P2986; Sampath R, 1998, J BIOL CHEM, V273, P33588, DOI 10.1074/jbc.273.50.33588; Schlaepfer DD, 1999, PROG BIOPHYS MOL BIO, V71, P435, DOI 10.1016/S0079-6107(98)00052-2; Schoenwaelder SM, 1999, J BIOL CHEM, V274, P14359, DOI 10.1074/jbc.274.20.14359; Schoenwaelder SM, 1997, J BIOL CHEM, V272, P1694, DOI 10.1074/jbc.272.3.1694; Schoenwaelder SM, 1999, CURR OPIN CELL BIOL, V11, P274, DOI 10.1016/S0955-0674(99)80037-4; Schwartz MA, 1997, J CELL BIOL, V139, P575, DOI 10.1083/jcb.139.3.575; SEFTON BM, 1981, CELL, V24, P165, DOI 10.1016/0092-8674(81)90512-2; Shattil SJ, 1998, BLOOD, V91, P2645, DOI 10.1182/blood.V91.8.2645.2645_2645_2657; SHATTIL SJ, 1994, CURR OPIN CELL BIOL, V6, P695, DOI 10.1016/0955-0674(94)90096-5; SHATTIL SJ, 1994, J BIOL CHEM, V269, P14738; Sheetz MP, 1998, TRENDS CELL BIOL, V8, P51, DOI 10.1016/S0962-8924(98)80005-6; SHIBASAKI F, 1994, BIOCHEM J, V302, P551, DOI 10.1042/bj3020551; TANIGUCHI T, 1993, J BIOL CHEM, V268, P2277; TOULLEC D, 1991, J BIOL CHEM, V266, P15771; WACHSSTOCK DH, 1987, BIOCHEM BIOPH RES CO, V146, P554, DOI 10.1016/0006-291X(87)90564-X; WAITES GT, 1992, J BIOL CHEM, V267, P6263; WEHLAND J, 1979, J CELL SCI, V37, P257; YOUSSOUFIAN H, 1990, AM J HUM GENET, V47, P62	60	33	33	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 24	1999	274	52					37012	37020		10.1074/jbc.274.52.37012	http://dx.doi.org/10.1074/jbc.274.52.37012			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	267WR	10601257	hybrid			2022-12-25	WOS:000084382700028
J	Kristensen, C; Wiberg, FC; Andersen, AS				Kristensen, C; Wiberg, FC; Andersen, AS			Specificity of insulin and insulin-like growth factor I receptors investigated using chimeric mini-receptors - Role of C-teriminal of receptor alpha subunit	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALANINE-SCANNING MUTAGENESIS; LIGAND-BINDING DOMAIN; IDENTIFICATION; DETERMINANTS; SITE; EXPRESSION; AFFINITY; REGIONS; FAMILY	We have investigated the role of the C-terminal of the alpha-subunit in the insulin receptor family by characterizing chimeric mini-receptor constructs comprising the first three domains (468 amino acids) of insulin receptor (IR) or insulin-like growth factor I receptor (IGFIR) combined with C-terminal domain from either insulin receptor (IR) (residues 704-719), IGFIR, or insulin receptor-related receptor (IRRR), The constructs were stably expressed in baby hamster kidney cells and purified, and binding affinities were determined for insulin, IGFI, and a single chain insulin/IGFI hybrid. The C-terminal domain of IRRR was found to abolish binding in PR and IGFIR context, whereas other constructs bound ligands, The two constructs with first three domains of the IR demonstrated low specificity for ligands, all affinities ranging from 3.0 to 15 nM. In contrast, the constructs with the first three domains of the IGFIR had high specificity, the affinity of the novel minimized IGFIR for IGFI was 1.5 nM, whereas the affinity for insulin was more than 3000 nM. When swapping the C-terminal domains in either receptor context only minor changes were observed in affinities (<3-fold), demonstrating that the carboxyl-terminal of IR and IGFIR alpha-subunits are interchangeable and suggesting that this domain is part of the common binding site.	Novo Nordisk AS, Insulin Res, DK-2880 Bagsvaerd, Denmark; Novo Nordisk AS, Hlth Care Discovery, Cell Technol, DK-2880 Bagsvaerd, Denmark	Novo Nordisk; Novo Nordisk	Kristensen, C (corresponding author), Novo Nordisk AS, Insulin Res, Novo Alle,6B1-90, DK-2880 Bagsvaerd, Denmark.		Kristensen, Claus/O-8047-2015	Kristensen, Claus/0000-0002-2594-7722				ANDERSEN AS, 1990, BIOCHEMISTRY-US, V29, P7363, DOI 10.1021/bi00484a002; ANDERSEN AS, 1992, J BIOL CHEM, V267, P13681; BAJAJ M, 1987, BIOCHIM BIOPHYS ACTA, V916, P220, DOI 10.1016/0167-4838(87)90112-9; BLUM WF, 1989, ENDOCRINOLOGY, V125, P766, DOI 10.1210/endo-125-2-766; EBINA Y, 1985, CELL, V40, P747, DOI 10.1016/0092-8674(85)90334-4; Garrett TPJ, 1998, NATURE, V394, P395, DOI 10.1038/28668; KJELDSEN T, 1991, P NATL ACAD SCI USA, V88, P4404, DOI 10.1073/pnas.88.10.4404; KRISTENSEN C, 1995, BIOCHEM J, V305, P981, DOI 10.1042/bj3050981; Kristensen C, 1998, J BIOL CHEM, V273, P17780, DOI 10.1074/jbc.273.28.17780; KUROSE T, 1994, J BIOL CHEM, V269, P29190; LEE JS, 1994, AM J PHYSIOL, V266, pC319, DOI 10.1152/ajpcell.1994.266.2.C319; Mynarcik DC, 1996, J BIOL CHEM, V271, P2439, DOI 10.1074/jbc.271.5.2439; Mynarcik DC, 1997, J BIOL CHEM, V272, P18650, DOI 10.1074/jbc.272.30.18650; PASHMFOROUSH M, 1994, J BIOL CHEM, V269, P32639; SCHAFFER L, 1992, BIOCHEM BIOPH RES CO, V189, P650, DOI 10.1016/0006-291X(92)92250-2; SCHUMACHER R, 1991, J BIOL CHEM, V266, P19288; SHIER P, 1989, J BIOL CHEM, V264, P14605; Sparrow LG, 1997, J BIOL CHEM, V272, P29460, DOI 10.1074/jbc.272.47.29460; TAVARE JM, 1993, BIOCHIM BIOPHYS ACTA, V1178, P21, DOI 10.1016/0167-4889(93)90106-Y; ULLRICH A, 1986, EMBO J, V5, P2503, DOI 10.1002/j.1460-2075.1986.tb04528.x; ULLRICH A, 1985, NATURE, V313, P756, DOI 10.1038/313756a0; WARD CW, 1995, PROTEINS, V22, P141, DOI 10.1002/prot.340220207; WAUGH SM, 1989, BIOCHEMISTRY-US, V28, P2722, DOI 10.1021/bi00432a053; WEDEKIND F, 1989, BIOL CHEM H-S, V370, P251, DOI 10.1515/bchm3.1989.370.1.251; WILLIAMS PF, 1995, J BIOL CHEM, V270, P3012, DOI 10.1074/jbc.270.7.3012; ZHANG B, 1991, BIOCHEMISTRY-US, V30, P5113, DOI 10.1021/bi00235a001; ZHANG B, 1992, J BIOL CHEM, V267, P18320	27	56	61	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 24	1999	274	52					37351	37356		10.1074/jbc.274.52.37351	http://dx.doi.org/10.1074/jbc.274.52.37351			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	267WR	10601304	hybrid			2022-12-25	WOS:000084382700075
J	Ray, WJ; Yao, M; Mumm, J; Schroeter, EH; Saftig, P; Wolfe, M; Selkoe, DJ; Kopan, R; Goate, AM				Ray, WJ; Yao, M; Mumm, J; Schroeter, EH; Saftig, P; Wolfe, M; Selkoe, DJ; Kopan, R; Goate, AM			Cell surface presenilin-1 participates in the gamma-secretase-like proteolysis of notch	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMYLOID PRECURSOR PROTEIN; CAENORHABDITIS-ELEGANS; ALZHEIMERS-DISEASE; INTRACELLULAR DOMAIN; SEL-12 PRESENILIN; LOCALIZATION; EXPRESSION; BRAIN; DEFICIENCY; CLEAVAGE	Presenilin-1 (PS1), a polytopic membrane protein primarily localized to the endoplasmic reticulum, is required for efficient proteolysis of both Notch and beta-amyloid precursor protein (APP) within their transmembrane domains. The activity that cleaves APP (called gamma-secretase) has properties of an aspartyl protease, and mutation of either of the two aspartate residues located in adjacent transmembrane domains of PS1 inhibits gamma-secretase processing of APP. We show here that these aspartates are required for Notch processing, since mutation of these residues prevents PS1 from inducing the gamma-secretase-like proteolysis of a Notch1 derivative. Thus PSI might function in Notch cleavage as an aspartyl protease or di aspartyl protease cofactor. However, the ER localization of PSI is inconsistent with that hypothesis, since Notch cleavage occurs near the cell surface. Using pulse-chase and biotinylation assays, we provide evidence that PS1 binds Notch in the ER/Golgi and is then co-transported to the plasma membrane as a complex. PS1 aspartate mutants were indistinguishable from wild-type PS1 in their ability to bind Notch or traffic with it to the cell surface, and did not alter the secretion of Notch. Thus, PS1 appears to function specifically in Notch proteolysis near the plasma membrane as an aspartyl protease or cofactor.	Washington Univ, Sch Med, Dept Psychiat, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Genet, St Louis, MO 63110 USA; Washington Univ, Sch Med, Div Dermatol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Mol Biol & Pharmacol, St Louis, MO 63110 USA; Univ Gottingen, Zentrum Biochem & Mol Zellbiol, Abt Biochem 2, D-37073 Gottingen, Germany; Harvard Univ, Sch Med, Ctr Neurol Dis, Boston, MA 02115 USA; Brigham & Womens Hosp, Boston, MA 02115 USA	Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL); University of Gottingen; Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital	Goate, AM (corresponding author), Washington Univ, Sch Med, Dept Psychiat, Box 8134, St Louis, MO 63110 USA.		Kopan, Raphael/AAF-1357-2022; Kopan, Raphael/AFG-3275-2022; Mumm, Jeff S/F-3125-2013; Saftig, Paul/A-7966-2010; Ray, William J/E-9834-2016	Goate, Alison/0000-0002-0576-2472; Kopan, Raphael/0000-0002-0350-2730; Mumm, Jeff/0000-0002-2575-287X; Ray, William/0000-0002-4491-167X				ARTAVANISTSAKONAS S, 1995, SCIENCE, V268, P225, DOI 10.1126/science.7716513; Berezovska O, 1997, J NEUROPATH EXP NEUR, V56, P40, DOI 10.1097/00005072-199701000-00004; Berezovska O, 1998, J NEUROPATH EXP NEUR, V57, P738, DOI 10.1097/00005072-199808000-00003; Blaumueller CM, 1997, CELL, V90, P281, DOI 10.1016/S0092-8674(00)80336-0; Capell A, 1997, J NEUROCHEM, V69, P2432; De Strooper B, 1999, NATURE, V398, P518, DOI 10.1038/19083; De Strooper B, 1998, NATURE, V391, P387, DOI 10.1038/34910; Haass C, 1997, NEURON, V18, P687, DOI 10.1016/S0896-6273(00)80309-8; Hardy J, 1997, TRENDS NEUROSCI, V20, P154, DOI 10.1016/S0166-2236(96)01030-2; Kidd S, 1998, GENE DEV, V12, P3728, DOI 10.1101/gad.12.23.3728; KOPAN R, 1994, DEVELOPMENT, V120, P2385; Kopan R, 1996, P NATL ACAD SCI USA, V93, P1683, DOI 10.1073/pnas.93.4.1683; Lah JJ, 1997, J NEUROSCI, V17, P1971; Levitan D, 1998, DEVELOPMENT, V125, P3599; LEVITAN D, 1995, NATURE, V377, P351, DOI 10.1038/377351a0; Li XJ, 1997, P NATL ACAD SCI USA, V94, P12204, DOI 10.1073/pnas.94.22.12204; Logeat F, 1998, P NATL ACAD SCI USA, V95, P8108, DOI 10.1073/pnas.95.14.8108; Naruse S, 1998, NEURON, V21, P1213, DOI 10.1016/S0896-6273(00)80637-6; Podlisny MB, 1997, NEUROBIOL DIS, V3, P325, DOI 10.1006/nbdi.1997.0129; Ray WJ, 1999, P NATL ACAD SCI USA, V96, P3263, DOI 10.1073/pnas.96.6.3263; Saura CA, 1999, J BIOL CHEM, V274, P13818, DOI 10.1074/jbc.274.20.13818; Schroeter EH, 1998, NATURE, V393, P382, DOI 10.1038/30756; Schwarzman AL, 1999, P NATL ACAD SCI USA, V96, P7932, DOI 10.1073/pnas.96.14.7932; Selkoe DJ, 1998, TRENDS CELL BIOL, V8, P447, DOI 10.1016/S0962-8924(98)01363-4; Selkoe DJ, 1999, NATURE, V399, pA23, DOI 10.1038/399a023; Shen J, 1997, CELL, V89, P629, DOI 10.1016/S0092-8674(00)80244-5; Steiner H, 1999, J BIOL CHEM, V274, P28669, DOI 10.1074/jbc.274.40.28669; Struhl G, 1998, CELL, V93, P649, DOI 10.1016/S0092-8674(00)81193-9; Struhl G, 1999, NATURE, V398, P522, DOI 10.1038/19091; Takashima A, 1996, BIOCHEM BIOPH RES CO, V227, P423, DOI 10.1006/bbrc.1996.1523; Weinmaster G, 1997, MOL CELL NEUROSCI, V9, P91, DOI 10.1006/mcne.1997.0612; Wolfe MS, 1999, BIOCHEMISTRY-US, V38, P4720, DOI 10.1021/bi982562p; Wolfe MS, 1999, NATURE, V398, P513, DOI 10.1038/19077; Wong PC, 1997, NATURE, V387, P288, DOI 10.1038/387288a0; Xia WM, 1997, P NATL ACAD SCI USA, V94, P8208, DOI 10.1073/pnas.94.15.8208; Ye YH, 1998, MECH DEVELOP, V79, P199, DOI 10.1016/S0925-4773(98)00169-5; Ye YH, 1999, NATURE, V398, P525, DOI 10.1038/19096; Yu G, 1998, J BIOL CHEM, V273, P16470, DOI 10.1074/jbc.273.26.16470; Zhang WJ, 1998, J NEUROSCI, V18, P914	39	244	252	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 17	1999	274	51					36801	36807		10.1074/jbc.274.51.36801	http://dx.doi.org/10.1074/jbc.274.51.36801			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	266AV	10593990	hybrid			2022-12-25	WOS:000084279200109
J	Albert, PR; Sajedi, N; Lemonde, S; Ghahremani, MH				Albert, PR; Sajedi, N; Lemonde, S; Ghahremani, MH			Constitutive G(i2)-dependent activation of adenylyl cyclase type II by the 5-HT1A receptor - Inhibition by anxiolytic partial agonists	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN ALPHA-SUBUNITS; RAT HIPPOCAMPUS; 5-HYDROXYTRYPTAMINE(1A) RECEPTOR; HUMAN 5-HT1A-RECEPTORS; FUNCTIONAL EXPRESSION; OPIOID RECEPTOR; INVERSE AGONIST; SF9 CELLS; SEROTONIN; ANXIETY	The 5-HT1A receptor is implicated in depression and anxiety. This receptor couples to G(i) proteins to inhibit adenylyl cyclase (AC) activity but can stimulate AC in tissues (e,g, hippocampus) that express ACII, The role of ACII in receptor-mediated stimulation of cAMP formation was examined in HEK-293 cells transfected with the 5-HT1A receptor, which mediated inhibition of basal and G(s)-induced cAMP formation in the absence of ACII, In cells cotransfected with 5-HT1A receptor and ACII plasmids, 5-HT1A agonists induced a 1.5-fold increase in cAMP level, Cotransfection of 5-HT1A receptor, ACII, and G alpha(i2), but not G alpha(i1), G alpha(i3), or G alpha(o), resulted in an agonist-independent B-fold increase in the basal cAMP level, suggesting that Gi, preferentially coupled the receptor to ACII, The 5-HT1B receptor also constitutively activated ACII, Constitutive activity of the 5-HT1A receptor was blocked by pertussis toxin and the G beta gamma antagonist, PCT, suggesting an important role for G beta gamma-mediated activation of ACII. The Thr-149 --> Ala mutation in the second intracellular domain of the 5-HT1A receptor disrupted G beta gamma-selective activation of ACII, Spontaneous 5-HT1A receptor activity was partially attenuated by 5-HT1A receptor partial agonists with anxiolytic activity (e,g, buspirone and flesinoxan) but was not altered by full agonists or antagonists. Thus, anxiolytic activity may involve inhibition of spontaneous 5-HT1A receptor activity.	Univ Ottawa, Neurosci Res Inst, Dept Med, Ottawa, ON K1H 8M5, Canada; Univ Ottawa, Neurosci Res Inst, Dept Cellular & Mol Med, Ottawa, ON K1H 8M5, Canada; McGill Univ, Dept Pharmacol & Therapeut, Montreal, PQ H3G 1Y6, Canada	University of Ottawa; University of Ottawa; McGill University	Albert, PR (corresponding author), Univ Ottawa, Neurosci Res Inst, Dept Med, 451 Smyth Rd, Ottawa, ON K1H 8M5, Canada.	palbert@uottawa.ca	Ghahremani, Mohammad H/F-1615-2013; Albert, Paul/E-4804-2010	Ghahremani, Mohammad H/0000-0001-5051-6214; Albert, Paul/0000-0002-1809-3554				Albert PR, 1996, NEUROPSYCHOPHARMACOL, V14, P19, DOI 10.1016/S0893-133X(96)80055-8; ALBERT PR, 1990, J BIOL CHEM, V265, P5825; ALBERT RP, 1998, ANN NY ACAD SCI, V861, P146; ANDRADE R, 1993, NEURON, V10, P83, DOI 10.1016/0896-6273(93)90244-L; Artigas F, 1996, TRENDS NEUROSCI, V19, P378, DOI 10.1016/S0166-2236(96)10037-0; Baker LP, 1999, J NEUROSCI, V19, P180, DOI 10.1523/JNEUROSCI.19-01-00180.1999; Barr AJ, 1997, J BIOL CHEM, V272, P2223; BERTIN B, 1992, J BIOL CHEM, V267, P8200; BLIER P, 1994, TRENDS PHARMACOL SCI, V15, P220, DOI 10.1016/0165-6147(94)90315-8; BUTKERAIT P, 1995, J BIOL CHEM, V270, P18691, DOI 10.1074/jbc.270.31.18691; CADOGAN AK, 1994, J NEUROCHEM, V62, P1816; CHAN JSC, 1995, J NEUROCHEM, V65, P2682; CHARNEY DS, 1990, ANNU REV MED, V41, P437; Dunlop J, 1998, J PHARMACOL TOXICOL, V40, P47, DOI 10.1016/S1056-8719(98)00035-5; FEDERMAN AD, 1992, NATURE, V356, P159, DOI 10.1038/356159a0; FLETCHER A, 1993, TRENDS PHARMACOL SCI, V14, P441, DOI 10.1016/0165-6147(93)90185-M; Ghahremani MH, 1999, J BIOL CHEM, V274, P9238, DOI 10.1074/jbc.274.14.9238; Heisler LK, 1998, P NATL ACAD SCI USA, V95, P15049, DOI 10.1073/pnas.95.25.15049; HOYER D, 1993, TRENDS PHARMACOL SCI, V14, P270, DOI 10.1016/0165-6147(93)90129-8; HOYER D, 1994, PHARMACOL REV, V46, P157; JIN H, 1992, J BIOL CHEM, V267, P5735; KENAKIN T, 1995, TRENDS PHARMACOL SCI, V16, P232, DOI 10.1016/S0165-6147(00)89032-X; Kenakin T, 1997, TRENDS PHARMACOL SCI, V18, P416, DOI 10.1016/S0165-6147(97)01127-9; KOCH WJ, 1994, J BIOL CHEM, V269, P6193; Leff P, 1997, TRENDS PHARMACOL SCI, V18, P355, DOI 10.1016/S0165-6147(97)90664-7; Lembo PMC, 1999, MOL ENDOCRINOL, V13, P138, DOI 10.1210/me.13.1.138; Lembo PMC, 1997, MOL PHARMACOL, V52, P164, DOI 10.1124/mol.52.1.164; Lembo PMC, 1995, MOL PHARMACOL, V48, P1024; LIU YF, 1992, MOL ENDOCRINOL, V6, P1815, DOI 10.1210/me.6.11.1815; Liu YF, 1999, J BIOL CHEM, V274, P16444, DOI 10.1074/jbc.274.23.16444; Lucki I, 1996, J CLIN PSYCHIAT, V57, P5; MARKSTEIN R, 1986, N-S ARCH PHARMACOL, V333, P335, DOI 10.1007/BF00500006; Mongeau R, 1997, BRAIN RES REV, V23, P145, DOI 10.1016/S0165-0173(96)00017-3; MULHERON JG, 1994, J BIOL CHEM, V269, P12954; NewmanTancredi A, 1997, NEUROPHARMACOLOGY, V36, P451, DOI 10.1016/S0028-3908(97)00022-1; NewmanTancredi A, 1997, BRIT J PHARMACOL, V120, P737, DOI 10.1038/sj.bjp.0701025; Olivier B, 1999, Prog Drug Res, V52, P103; Parks CL, 1998, P NATL ACAD SCI USA, V95, P10734, DOI 10.1073/pnas.95.18.10734; PAUWELS PJ, 1993, BIOCHEM PHARMACOL, V45, P375, DOI 10.1016/0006-2952(93)90073-6; PEROUTKA SJ, 1993, J NEUROCHEM, V60, P408, DOI 10.1111/j.1471-4159.1993.tb03166.x; Ramboz S, 1998, P NATL ACAD SCI USA, V95, P14476, DOI 10.1073/pnas.95.24.14476; RAYMOND JR, 1993, BIOCHEMISTRY-US, V32, P11064, DOI 10.1021/bi00092a016; Rudolph U, 1996, P NATL ACAD SCI USA, V93, P3209, DOI 10.1073/pnas.93.8.3209; Schoeffter P, 1997, NEUROPHARMACOLOGY, V36, P429, DOI 10.1016/S0028-3908(97)00043-9; SHENKER A, 1987, MOL PHARMACOL, V31, P357; Stanhope KJ, 1996, PSYCHOPHARMACOLOGY, V128, P293, DOI 10.1007/s002130050137; Sunahara RK, 1996, ANNU REV PHARMACOL, V36, P461, DOI 10.1146/annurev.pa.36.040196.002333; Taylor DP, 1990, ANN N Y ACAD SCI, V600, P545; TOUHARA K, 1995, J BIOL CHEM, V270, P17000, DOI 10.1074/jbc.270.28.17000; TSU RC, 1995, MOL PHARMACOL, V47, P835; TSU RC, 1995, J NEUROCHEM, V64, P2700	51	57	60	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 10	1999	274	50					35469	35474		10.1074/jbc.274.50.35469	http://dx.doi.org/10.1074/jbc.274.50.35469			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	264NG	10585418	hybrid			2022-12-25	WOS:000084187900030
J	Ashton, AW; Yokota, R; John, G; Zhao, SM; Suadicani, SO; Spray, DC; Ware, JA				Ashton, AW; Yokota, R; John, G; Zhao, SM; Suadicani, SO; Spray, DC; Ware, JA			Inhibition of endothelial cell migration, intercellular communication, and vascular tube formation by thromboxane A(2)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GAP-JUNCTIONAL COMMUNICATION; IN-VITRO; STRESS FIBERS; G-PROTEINS; RECEPTOR; ANGIOGENESIS; EXPRESSION; VIVO; ORGANIZATION; REQUIREMENT	The eicosanoid thromboxane A(2) (TXA(2)) is released by activated platelets, monocytes, and the vessel wall and interacts with high affinity receptors expressed in several tissues including endothelium. Whether TXA(2) might alter endothelial migration and tube formation, two determinants of angiogenesis, is unknown. Thus, we investigated the effect of the TXA(2) mimetic [1S-(1 alpha,2 beta(5Z)),3 alpha(1E,3R),4 alpha]-7-[3-(3-hydroxy-4-(4'-iodophenoxy)-1-butenyl)-7-oxabicyclo-[2.2.1]heptan-2-yl]-5'-heptenoic acid (IBOP) on human endothelial cell (HEC) migration and angiogenesis in vitro. IBOP stimulation inhibited REC migration by 50% and in vitro capillary formation by 75%. These effects of IBOP were time- and concentration-dependent with an IC50 of 25 nM. IBOP did not affect integrin expression or cytoskeletal morphology of HEC. Since gap junction-mediated intercellular communication increases in migrating HEC, we determined whether IBOP might inhibit coupling or connexin expression in HEC. IBOP reduced the passage of microinjected dyes between HEC by 50%, and the effects of IBOP on migration and tube formation were mimicked by the gap junction inhibitor 18 beta-glycyrrhetinic acid (1 mu M) with a similar time course and efficacy. IBOP (24 h) did not affect the expression or phosphorylation of connexin 43 in whole HEC lysates. Immunohistologic examination of HEC suggested that IBOP may impair functional coupling by altering the cellular distribution of gap junctions, leading to increased connexin 43 internalization. Thus, this finding that TXA(2) mimetics can prevent HEC migration and tube formation, possibly by impairing intercellular communication, suggests that antagonizing TXA(2) signaling might enhance vascularization of ischemic tissue.	Yeshiva Univ Albert Einstein Coll Med, Dept Cardiol, Bronx, NY 10461 USA; Yeshiva Univ Albert Einstein Coll Med, Dept Med, Bronx, NY 10461 USA; Yeshiva Univ Albert Einstein Coll Med, Dept Mol Pharmacol, Bronx, NY 10461 USA; Yeshiva Univ Albert Einstein Coll Med, Dept Neurosci, Bronx, NY 10461 USA; Univ Sao Judas Tadeu, BR-03166000 Sao Paulo, Brazil; Yeshiva Univ Albert Einstein Coll Med, Dept Pathol, Bronx, NY 10461 USA	Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Universidade Sao Judas Tadeu; Yeshiva University; Albert Einstein College of Medicine	Ashton, AW (corresponding author), Yeshiva Univ Albert Einstein Coll Med, Dept Cardiol, 1300 Morris Pk Ave,Rm G42,Forchheimer Bldg, Bronx, NY 10461 USA.	ashton@aecom.yu.edu		Spray, David/0000-0001-8368-5073	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL047032, R01HL038449] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL47032-05, HL38449] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALLISON AC, 1986, AM J MED, V81, P34, DOI 10.1016/S0002-9343(86)80008-0; ASHTON AW, 1995, GROWTH FACTORS, V12, P111, DOI 10.3109/08977199509028957; BALDASSARE JJ, 1993, BIOCHEM J, V291, P235, DOI 10.1042/bj2910235; Banerjee D K, 1998, P R Health Sci J, V17, P327; BAUER J, 1992, J CELL PHYSIOL, V153, P437, DOI 10.1002/jcp.1041530302; BROOKS PC, 1994, SCIENCE, V264, P569, DOI 10.1126/science.7512751; CAMUSSI G, 1995, J IMMUNOL, V154, P6492; D'Amore P A, 1992, Semin Cancer Biol, V3, P49; FITZGERALD DJ, 1986, NEW ENGL J MED, V315, P983, DOI 10.1056/NEJM198610163151602; GIARETTI W, 1994, METHOD CELL BIOL, V41, P389; GOTLIEB AI, 1990, TOXICOL PATHOL, V18, P603; HANASAKI K, 1990, BIOCHEM PHARMACOL, V40, P2535, DOI 10.1016/0006-2952(90)90096-4; HII CST, 1994, BIOCHEM J, V303, P475, DOI 10.1042/bj3030475; HIRATA M, 1991, NATURE, V349, P617, DOI 10.1038/349617a0; Hirata T, 1996, J CLIN INVEST, V97, P949, DOI 10.1172/JCI118518; HIRSH PD, 1981, NEW ENGL J MED, V304, P687; Hu GF, 1998, P NATL ACAD SCI USA, V95, P9791, DOI 10.1073/pnas.95.17.9791; Hu J, 1997, J CLIN INVEST, V99, P2312, DOI 10.1172/JCI119410; Jones MK, 1998, BIOCHEM BIOPH RES CO, V249, P118, DOI 10.1006/bbrc.1998.9095; Jordan K, 1999, MOL BIOL CELL, V10, P2033, DOI 10.1091/mbc.10.6.2033; Kinsella BT, 1997, J PHARMACOL EXP THER, V281, P957; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MORBIDELLI L, 1995, AM J PHYSIOL-HEART C, V269, pH686, DOI 10.1152/ajpheart.1995.269.2.H686; MORENO AP, 1994, BIOPHYS J, V67, P113, DOI 10.1016/S0006-3495(94)80460-6; Nagy JI, 1996, CELL GROWTH DIFFER, V7, P745; OGLETREE ML, 1987, FED PROC, V46, P133; PEPPER MS, 1989, J CELL BIOL, V109, P3027, DOI 10.1083/jcb.109.6.3027; Postma FR, 1998, J CELL BIOL, V140, P1199, DOI 10.1083/jcb.140.5.1199; RAYCHOWDHURY MK, 1995, J BIOL CHEM, V270, P7011, DOI 10.1074/jbc.270.12.7011; Renner U, 1996, EUR J ENDOCRINOL, V135, P515, DOI 10.1530/eje.0.1350515; ROMER LH, 1994, MOL BIOL CELL, V5, P349, DOI 10.1091/mbc.5.3.349; SAEZ JC, 1993, ADV SEC MESS PHOSPH, V27, P163; Saitoh M, 1997, CARCINOGENESIS, V18, P1319, DOI 10.1093/carcin/18.7.1319; SAKAI N, 1992, CAN J PHYSIOL PHARM, V70, P358, DOI 10.1139/y92-045; Shirinsky V P, 1988, Health Psychol, V7 Suppl, P61, DOI 10.1037/h0090271; Spray DC, 1998, CIRC RES, V83, P679, DOI 10.1161/01.RES.83.6.679; Tanaka K, 1998, J CELL PHYSIOL, V176, P235, DOI 10.1002/(SICI)1097-4652(199808)176:2<235::AID-JCP2>3.0.CO;2-P; Tang SQ, 1997, J BIOL CHEM, V272, P28704, DOI 10.1074/jbc.272.45.28704; vanRijen HVM, 1997, AM J PHYSIOL-CELL PH, V272, pC117, DOI 10.1152/ajpcell.1997.272.1.C117; Wang YJ, 1997, J CELL SCI, V110, P301; WANG YJ, 1995, J CELL SCI, V108, P3501; WELLES SL, 1985, INFLAMMATION, V9, P439, DOI 10.1007/BF00916343; XIE HQ, 1994, EXP CELL RES, V214, P172, DOI 10.1006/excr.1994.1246; Yukawa M, 1997, CIRC RES, V80, P551, DOI 10.1161/01.RES.80.4.551; ZICHE M, 1994, J CLIN INVEST, V94, P2036, DOI 10.1172/JCI117557	45	135	137	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 10	1999	274	50					35562	35570		10.1074/jbc.274.50.35562	http://dx.doi.org/10.1074/jbc.274.50.35562			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	264NG	10585431	hybrid			2022-12-25	WOS:000084187900043
J	Estienne, V; Blanchet, C; Niccoli-Sire, P; Duthoit, C; Durand-Gorde, JM; Geourjon, C; Baty, D; Carayon, P; Ruf, J				Estienne, V; Blanchet, C; Niccoli-Sire, P; Duthoit, C; Durand-Gorde, JM; Geourjon, C; Baty, D; Carayon, P; Ruf, J			Molecular model, calcium sensitivity, and disease specificity of a conformational thyroperoxidase B-cell epitope	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN THYROID PEROXIDASE; EPIDERMAL GROWTH-FACTOR; FACTOR-LIKE DOMAINS; EGF-LIKE DOMAINS; BINDING; SEQUENCE; ANTIGEN; MYELOPEROXIDASE; FIBRILLIN-1; ALIGNMENT	While studying the humoral mechanisms involved in thyroid autoimmunity, we located a B-cell autoepitope in the extracellular C-terminal region of human thyroperoxidase, Structural modeling showed that this region encompasses both a Sushi-like and an epidermal growth factor-like domain, the flexible arrangement of which was putatively stabilized by calcium. The recombinant peptide was found to contain the previously identified conformational thyroperoxidase autoepitope. The occurrence of a calcium-induced conformational change was confirmed using a recombinant peptide monoclonal antibody, the decrease of which in binding to calcium-saturated thyroperoxidase was reversed by a chelating agent. The disease specificity of recombinant peptide, which was more frequently recognized by Hashimoto's than by Graves' patients, adds to its potential value as a diagnostic and preventive tool in the context of B-cell, autoimmunity.	Univ Mediterranee, Fac Med Timone, INSERM, Lab Biochim Endocrinienne & Metab,U38, F-13385 Marseille 5, France; CNRS, IBCP, UPR 412, Pole Bioinformat Lyonnais, F-69367 Lyon 07, France; CNRS, IBSM, Lab Ingn Syst Macromol, F-13402 Marseille 20, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille; Centre National de la Recherche Scientifique (CNRS); Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Aix-Marseille Universite	Ruf, J (corresponding author), Univ Mediterranee, Fac Med Timone, INSERM, Lab Biochim Endocrinienne & Metab,U38, 27 Blvd Jean Moulin, F-13385 Marseille 5, France.	Jean.Ruf@medecine.univ-mrs.fr	Ruf, Jean/E-3963-2016	Ruf, Jean/0000-0003-4300-8048; Baty, Daniel/0000-0001-8443-4444				Abola EE, 1996, J RES NATL INST STAN, V101, P231, DOI 10.6028/jres.101.025; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; Banga JP, 1998, CURR OPINION ENDOCRI, V5, P275; BARLOW PN, 1993, J MOL BIOL, V232, P268, DOI 10.1006/jmbi.1993.1381; BOGNER U, 1984, J CLIN ENDOCR METAB, V59, P734, DOI 10.1210/jcem-59-4-734; Brunger A. T., 1992, XPLOR VERSION 3 1 SY; CZARNOCKA B, 1985, FEBS LETT, V190, P147, DOI 10.1016/0014-5793(85)80446-4; DAVIE EW, 1986, COLD SPRING HARB SYM, V51, P509, DOI 10.1101/SQB.1986.051.01.062; DAVIES DR, 1990, ANNU REV BIOCHEM, V59, P439, DOI 10.1146/annurev.bi.59.070190.002255; DOOLITTLE RF, 1986, COLD SPRING HARB SYM, V51, P447, DOI 10.1101/SQB.1986.051.01.054; Downing AK, 1996, CELL, V85, P597, DOI 10.1016/S0092-8674(00)81259-3; Estienne V, 1998, J BIOL CHEM, V273, P8056, DOI 10.1074/jbc.273.14.8056; FALK RJ, 1988, NEW ENGL J MED, V318, P1651, DOI 10.1056/NEJM198806233182504; FINKE R, 1991, J CLIN ENDOCR METAB, V73, P919, DOI 10.1210/jcem-73-4-919; GEOURJON C, 1995, J MOL GRAPHICS, V13, P209, DOI 10.1016/0263-7855(95)00035-5; HANDFORD P, 1995, J BIOL CHEM, V270, P6751, DOI 10.1074/jbc.270.12.6751; HANDFORD PA, 1991, NATURE, V351, P164, DOI 10.1038/351164a0; Kettle S, 1999, J MOL BIOL, V285, P1277, DOI 10.1006/jmbi.1998.2368; Krych M, 1998, J BIOL CHEM, V273, P8623, DOI 10.1074/jbc.273.15.8623; LANZAVECCHIA A, 1993, SCIENCE, V260, P937, DOI 10.1126/science.8493532; LAVER WG, 1990, CELL, V61, P553, DOI 10.1016/0092-8674(90)90464-P; LEE B, 1971, J MOL BIOL, V55, P379, DOI 10.1016/0022-2836(71)90324-X; LIBERT F, 1987, EMBO J, V6, P4193, DOI 10.1002/j.1460-2075.1987.tb02766.x; LIVINGSTONE AM, 1987, ANNU REV IMMUNOL, V5, P477, DOI 10.1146/annurev.immunol.5.1.477; LOZIER J, 1984, P NATL ACAD SCI-BIOL, V81, P3640, DOI 10.1073/pnas.81.12.3640; MAGNUSSON RP, 1987, MOL ENDOCRINOL, V1, P856, DOI 10.1210/mend-1-11-856; MAYHEW M, 1992, PROTEIN ENG, V5, P489, DOI 10.1093/protein/5.6.489; MCLACHLAN SM, 1987, ACTA ENDOCRINOL-COP, V115, P125; Niccoli P, 1997, J BIOL CHEM, V272, P29487, DOI 10.1074/jbc.272.47.29487; Nishikawa T, 1996, ENDOCRINOLOGY, V137, P1000, DOI 10.1210/en.137.3.1000; RAO Z, 1995, CELL, V82, P131, DOI 10.1016/0092-8674(95)90059-4; Rapoport B., 1994, ENDOCRINE REVS, V3, P96; REES DJG, 1988, EMBO J, V7, P2053, DOI 10.1002/j.1460-2075.1988.tb03045.x; Reinhardt DP, 1997, J BIOL CHEM, V272, P1231, DOI 10.1074/jbc.272.2.1231; Rodien P, 1996, J CLIN ENDOCR METAB, V81, P2595, DOI 10.1210/jc.81.7.2595; RUF J, 1989, ENDOCRINOLOGY, V125, P1211, DOI 10.1210/endo-125-3-1211; SAVAGE CR, 1972, J BIOL CHEM, V247, P7612; Taurog Alvin, 1996, P47; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Wadeleux P, 1989, Autoimmunity, V4, P247, DOI 10.3109/08916938909014701; Wiles AP, 1997, J MOL BIOL, V272, P253, DOI 10.1006/jmbi.1997.1241; ZENG J, 1992, J MOL BIOL, V226, P185, DOI 10.1016/0022-2836(92)90133-5	42	22	23	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 10	1999	274	50					35313	35317		10.1074/jbc.274.50.35313	http://dx.doi.org/10.1074/jbc.274.50.35313			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	264NG	10585396	hybrid			2022-12-25	WOS:000084187900008
J	Nellist, M; van Slegtenhorst, MA; Goedbloed, M; van den Ouweland, AMW; Halley, DJJ; van der Sluijs, P				Nellist, M; van Slegtenhorst, MA; Goedbloed, M; van den Ouweland, AMW; Halley, DJJ; van der Sluijs, P			Characterization of the cytosolic tuberin-hamartin complex - Tuberin is a cytosolic chaperone for hamartin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTPASE-ACTIVATING-PROTEIN; SCLEROSIS GENE-2 PRODUCT; TSC1; RAP1; IDENTIFICATION	Tuberous sclerosis (TSC) is an autosomal dominant disorder characterized by a broad phenotypic spectrum that includes seizures, mental retardation, renal dysfunction and dermatological abnormalities. Mutations to either the TSC1 or TSC2 gene are responsible for the disease. The TSC1 gene encodes hamartin, a 130-kDa protein without significant homology to other known mammalian proteins, Analysis of the amino acid sequence of tuberin, the 200-kDa product of the TSC2 gene, identified a region with limited homology to GTPase-activating proteins. Previously, we demonstrated direct binding between tuberin and hamartin, Here we investigate this interaction in more detail. We show that the complex is predominantly cytosolic and may contain additional, as yet uncharacterized components alongside tuberin and hamartin, Furthermore, because oligomerization of the hamartin carboxyl-terminal coiled coil domain was inhibited by the presence of tuberin, we propose that tuberin acts as a chaperone, preventing hamartin self-aggregation.	Erasmus Univ, Dept Clin Genet, NL-3000 DR Rotterdam, Netherlands; Univ Utrecht, Sch Med, Dept Cell Biol, NL-3584 CX Utrecht, Netherlands	Erasmus University Rotterdam; Utrecht University	Halley, DJJ (corresponding author), Erasmus Univ, Dept Clin Genet, POB 1788, NL-3000 DR Rotterdam, Netherlands.							BRAAKMAN I, 1991, J CELL BIOL, V114, P401, DOI 10.1083/jcb.114.3.401; Chen FL, 1997, P NATL ACAD SCI USA, V94, P12485, DOI 10.1073/pnas.94.23.12485; GOMEZ MR, 1980, TUBEROUS SCLEROSIS; Henry KW, 1998, J BIOL CHEM, V273, P20535, DOI 10.1074/jbc.273.32.20535; HERMANS MMP, 1991, J BIOL CHEM, V266, P13507; Jones AC, 1997, HUM MOL GENET, V6, P2155, DOI 10.1093/hmg/6.12.2155; KLEBE RJ, 1983, GENE, V25, P333, DOI 10.1016/0378-1119(83)90238-X; Kurachi H, 1997, J BIOL CHEM, V272, P28081, DOI 10.1074/jbc.272.44.28081; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; NELLIST M, 1993, CELL, V75, P1305; Perutz MF, 1999, TRENDS BIOCHEM SCI, V24, P58, DOI 10.1016/S0968-0004(98)01350-4; Plank TL, 1998, CANCER RES, V58, P4766; Sambrook J., 2002, MOL CLONING LAB MANU; SAMPSON JR, 1994, HUM MOL GENET, V3, P1477, DOI 10.1093/hmg/3.suppl_1.1477; Soucek T, 1998, ONCOGENE, V16, P2197, DOI 10.1038/sj.onc.1201743; Soucek T, 1997, J BIOL CHEM, V272, P29301, DOI 10.1074/jbc.272.46.29301; STENMARK H, 1995, CELL, V83, P423, DOI 10.1016/0092-8674(95)90120-5; Tsuchiya H, 1996, CANCER RES, V56, P429; van Slegtenhorst M, 1998, HUM MOL GENET, V7, P1053, DOI 10.1093/hmg/7.6.1053; vanSlegtenhorst M, 1997, SCIENCE, V277, P805, DOI 10.1126/science.277.5327.805; Wienecke R, 1996, ONCOGENE, V13, P913; WIENECKE R, 1995, J BIOL CHEM, V270, P16409, DOI 10.1074/jbc.270.27.16409; Xiao GH, 1997, J BIOL CHEM, V272, P6097, DOI 10.1074/jbc.272.10.6097	23	148	155	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 10	1999	274	50					35647	35652		10.1074/jbc.274.50.35647	http://dx.doi.org/10.1074/jbc.274.50.35647			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	264NG	10585443	hybrid			2022-12-25	WOS:000084187900055
J	Shewchuk, BM; Asa, SL; Cooke, NE; Liebhaber, SA				Shewchuk, BM; Asa, SL; Cooke, NE; Liebhaber, SA			Pit-1 binding sites at the somatotrope-specific DNase I hypersensitive sites I, II of the human growth hormone locus control region are essential for in vivo hGH-N gene activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-GLOBIN GENE; POSITION-EFFECT VARIEGATION; TRANS-ACTING FACTOR; TRANSCRIPTIONAL ACTIVATION; CHORIONIC SOMATOMAMMOTROPIN; PHYSICAL LINKAGE; CELL PHENOTYPES; EXPRESSION; MICE; DOMAIN	The human growth hormone gene cluster is composed of five closely related genes. The 5'-most gene in the cluster, hGH-N, is expressed exclusively in somatotropes and lactosomatotropes of the anterior pituitary, Although the hGH-N promoter contains functional binding sites for multiple transcription factors, including Spl, Zn-15, and Pit-1, predictable and developmentally appropriate expression of hGH-N transgenes in the mouse pituitary requires the presence of a previously characterized locus control region (LCR) composed of multiple chromatin DNase I hypersensitive sites (HS), LCR determinant(s) necessary for hGH-N transgene activation are largely conferred by two closely spaced HS (HS I,II) located 14.5 kilobase pairs upstream of the hGH-N gene. The region sufficient to mediate this activity has recently been sublocalized to a 404-base pair segment of HS I,II (F14 segment). In the present study, we identified multiple binding sites for the pituitary POU domain transcription factor Pit-1 within this segment. Using a transgenic founder assay, these sites were shown to be required for high level, position-independent, and somatotrope-specific expression of a linked hGH-N transgene, Because the Pit-1 sites in the hGH-N gene promoter are insufficient for such gene activation in vivo, these data suggested a unique chromatin-mediated developmental role for Pit-1 in the hGH LCR.	Univ Penn, Dept Genet, Philadelphia, PA 19104 USA; Univ Penn, Dept Med, Philadelphia, PA 19104 USA; Univ Penn, Howard Hughes Med Inst, Philadelphia, PA 19104 USA; Univ Toronto, Mt Sinai Hosp, Dept Pathol & Lab Med, Toronto, ON M5G 1X5, Canada	University of Pennsylvania; University of Pennsylvania; Howard Hughes Medical Institute; University of Pennsylvania; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute	Liebhaber, SA (corresponding author), Univ Penn, Dept Genet, 415 Curie Blvd,428 Clin Res Bldg, Philadelphia, PA 19104 USA.		Shewchuk, Brian/AAA-3388-2021	Asa, Sylvia/0000-0001-8418-5054	NICHD NIH HHS [R01 HD25147] Funding Source: Medline; NIDDK NIH HHS [F32 DK09783, F32 DK009782] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [R01HD025147] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [F32DK009782] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANDERSEN B, 1994, J BIOL CHEM, V269, P29335; ANTONIOU M, 1988, EMBO J, V7, P377, DOI 10.1002/j.1460-2075.1988.tb02824.x; Bennani-Baiti IM, 1998, GENOMICS, V48, P258, DOI 10.1006/geno.1997.5171; Bennani-Baiti IM, 1998, P NATL ACAD SCI USA, V95, P10655, DOI 10.1073/pnas.95.18.10655; BENNANIBAITI IM, 1995, GENOMICS, V29, P647, DOI 10.1006/geno.1995.9954; BODNER M, 1987, CELL, V50, P267, DOI 10.1016/0092-8674(87)90222-4; CHEN EY, 1989, GENOMICS, V4, P479, DOI 10.1016/0888-7543(89)90271-1; DRISCOLL MC, 1989, P NATL ACAD SCI USA, V86, P7470, DOI 10.1073/pnas.86.19.7470; DYER RB, 1995, BIOTECHNIQUES, V19, P192; EISSENBERG JC, 1989, BIOESSAYS, V11, P14, DOI 10.1002/bies.950110105; ELSHOLTZ HP, 1990, GENE DEV, V4, P43, DOI 10.1101/gad.4.1.43; EVANS T, 1990, ANNU REV CELL BIOL, V6, P95, DOI 10.1146/annurev.cellbio.6.1.95; Festenstein R, 1996, SCIENCE, V271, P1123, DOI 10.1126/science.271.5252.1123; FRIED M, 1981, NUCLEIC ACIDS RES, V9, P6505, DOI 10.1093/nar/9.23.6505; GALAS DJ, 1978, NUCLEIC ACIDS RES, V5, P3157, DOI 10.1093/nar/5.9.3157; GONG QH, 1993, MOL CELL BIOL, V13, P911, DOI 10.1128/MCB.13.2.911; Gong QH, 1996, MOL CELL BIOL, V16, P6055; GROSVELD F, 1987, CELL, V51, P975, DOI 10.1016/0092-8674(87)90584-8; HAMMER RE, 1984, NATURE, V311, P65, DOI 10.1038/311065a0; HENIKOFF S, 1990, TRENDS GENET, V6, P422, DOI 10.1016/0168-9525(90)90304-O; HOLLOWAY JM, 1995, GENE DEV, V9, P1992, DOI 10.1101/gad.9.16.1992; INGRAHAM HA, 1990, CELL, V61, P1021, DOI 10.1016/0092-8674(90)90067-O; Jacobson EM, 1997, GENE DEV, V11, P198, DOI 10.1101/gad.11.2.198; JONES BK, 1995, MOL CELL BIOL, V15, P7010; Kamakaka RT, 1997, TRENDS BIOCHEM SCI, V22, P124, DOI 10.1016/S0968-0004(96)10074-8; Kioussis D, 1997, CURR OPIN GENET DEV, V7, P614, DOI 10.1016/S0959-437X(97)80008-1; KIOUSSIS D, 1983, NATURE, V306, P662, DOI 10.1038/306662a0; KOLLIAS G, 1986, CELL, V46, P89, DOI 10.1016/0092-8674(86)90862-7; LEFEVRE C, 1987, EMBO J, V6, P971, DOI 10.1002/j.1460-2075.1987.tb04847.x; LEW D, 1993, GENE DEV, V7, P683, DOI 10.1101/gad.7.4.683; LIEBHABER SA, 1989, J CLIN INVEST, V83, P1985, DOI 10.1172/JCI114108; LIPKIN SM, 1993, GENE DEV, V7, P1674, DOI 10.1101/gad.7.9.1674; MACLEOD JN, 1992, J BIOL CHEM, V267, P14219; MAGRAM J, 1985, NATURE, V315, P338, DOI 10.1038/315338a0; Maxam A M, 1980, Methods Enzymol, V65, P499; MCWILLIAMS D, 1980, ENDOCRINOLOGY, V107, P761, DOI 10.1210/endo-107-3-761; NELSON C, 1988, SCIENCE, V239, P1400, DOI 10.1126/science.2831625; NICKEL BE, 1990, BIOCHEM J, V267, P653, DOI 10.1042/bj2670653; PHILIPSEN S, 1993, EMBO J, V12, P1077, DOI 10.1002/j.1460-2075.1993.tb05749.x; Ptashne M, 1997, NATURE, V386, P569, DOI 10.1038/386569a0; Rosenfeld MG, 1996, RECENT PROG HORM RES, V51, P217; SEEBURG PH, 1982, DNA-J MOLEC CELL BIO, V1, P239, DOI 10.1089/dna.1.1982.1.239; SHARP ZD, 1995, BIOCHEM BIOPH RES CO, V206, P40, DOI 10.1006/bbrc.1995.1006; TANSEY WP, 1991, J BIOL CHEM, V266, P9805; THEILL LE, 1989, NATURE, V342, P945, DOI 10.1038/342945a0; TJIAN R, 1994, CELL, V77, P5, DOI 10.1016/0092-8674(94)90227-5; TOWNES TM, 1985, EMBO J, V4, P15; Vallejo Abbe N., 1995, P603; Wade PA, 1997, TRENDS BIOCHEM SCI, V22, P128, DOI 10.1016/S0968-0004(97)01016-5; WALTERS MC, 1995, P NATL ACAD SCI USA, V92, P7125, DOI 10.1073/pnas.92.15.7125; Walters MC, 1996, GENE DEV, V10, P185, DOI 10.1101/gad.10.2.185; Xu L, 1998, NATURE, V395, P301, DOI 10.1038/26270	52	60	60	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 10	1999	274	50					35725	35733		10.1074/jbc.274.50.35725	http://dx.doi.org/10.1074/jbc.274.50.35725			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	264NG	10585453	hybrid			2022-12-25	WOS:000084187900065
J	Mao, SS; Cooper, CM; Wood, T; Shafer, JA; Gardell, SJ				Mao, SS; Cooper, CM; Wood, T; Shafer, JA; Gardell, SJ			Characterization of plasmin-mediated activation of plasma procarboxypeptidase B - Modulation by glycosaminoglycans	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVABLE FIBRINOLYSIS INHIBITOR; CARBOXYPEPTIDASE-U; THROMBIN; TAFI; COAGULATION; MECHANISM; THROMBOMODULIN; PURIFICATION; HEPARIN; CLOTS	Plasma carboxypeptidase B (PCB) is an exopeptidase that exerts an antifibrinolytic effect by releasing C-terminal Lys and Arg residues from partially degraded fibrin, PCB is produced in plasma via limited proteolysis of the zymogen, pro-PCB, In this report, we show that the K-m (55 nM) for plasmin-catalyzed activation of pro-PCB is similar to the plasma concentration of pro-PCB (50-70 nM), whereas the K-m for the thrombin- or thrombin:thrombomodulin-catalyzed reaction is 10-40-fold higher than the pro-PCB level in plasma. Additionally, tissue-type plasminogen activator triggers activation of pro-PCB in blood plasma in a reaction that is stimulated by a neutralizing antibody versus alpha(2)-antiplasmin, Together, these results show that plasmin-mediated activation of pro-PCB can occur in blood plasma. Heparin (UH) and other anionic glycosaminoglycans stimulate pro-PCB activation by plasmin but not by thrombin or thrombin:thrombomodulin. Pro-PCB is a more favorable substrate for plasmin in the presence of UH (16-fold increase in k(cat)/K-m). UH also stabilizes PCB against spontaneous inactivation. The presence of UH in clots prepared with prothrombin-deficient plasma delays tissue-type plasminogen activator-triggered lysis; this effect of UH on clot lysis is blocked by a PCB inhibitor from potato tubers. These results show that UH accelerates plasmin-catalyzed activation of pro-PCB in plasma and PCB, in turn, stabilizes fibrin against fibrinolysis. We propose that glycosaminoglycans in the subendothelial extracellular matrix serve to augment the levels of PCB activity thereby stabilizing blood clots at sites where there is a breach in the integrity of the vasculature.	Merck Res Labs, Dept Biol Chem, W Point, PA 19486 USA	Merck & Company	Mao, SS (corresponding author), Merck Res Labs, Dept Biol Chem, WP42-300, W Point, PA 19486 USA.							Bajzar L, 1996, J BIOL CHEM, V271, P16603, DOI 10.1074/jbc.271.28.16603; BAJZAR L, 1995, J BIOL CHEM, V270, P14477, DOI 10.1074/jbc.270.24.14477; Bajzar L, 1996, BLOOD, V88, P2093, DOI 10.1182/blood.V88.6.2093.bloodjournal8862093; Boffa MB, 1998, J BIOL CHEM, V273, P2127, DOI 10.1074/jbc.273.4.2127; Broze GJ, 1996, BLOOD, V88, P3815, DOI 10.1182/blood.V88.10.3815.bloodjournal88103815; CARDIN AD, 1989, ARTERIOSCLEROSIS, V9, P21, DOI 10.1161/01.ATV.9.1.21; EATON DL, 1991, J BIOL CHEM, V266, P21833; HASS GM, 1981, METHOD ENZYMOL, V80, P778; HENDRIKS D, 1990, BIOCHIM BIOPHYS ACTA, V1034, P86, DOI 10.1016/0304-4165(90)90157-R; HIRSH J, 1994, CIRCULATION, V89, P1449, DOI 10.1161/01.CIR.89.3.1449; HOYLAERTS M, 1982, J BIOL CHEM, V257, P2913; JORDAN SP, 1992, BIOCHEMISTRY-US, V31, P5374, DOI 10.1021/bi00138a019; Kluszynski BA, 1997, J BIOL CHEM, V272, P13541, DOI 10.1074/jbc.272.21.13541; Lindahl U, 1998, J BIOL CHEM, V273, P24979, DOI 10.1074/jbc.273.39.24979; Nesheim M, 1997, THROMB HAEMOSTASIS, V78, P386; Plow EF, 1997, TRENDS CARDIOVAS MED, V7, P71, DOI 10.1016/S1050-1738(97)00012-1; PLUMMER TH, 1981, BIOCHEM BIOPH RES CO, V98, P448, DOI 10.1016/0006-291X(81)90860-3; PLUMMER TH, 1980, ANAL BIOCHEM, V108, P348, DOI 10.1016/0003-2697(80)90598-9; Sakharov DV, 1997, J BIOL CHEM, V272, P14477, DOI 10.1074/jbc.272.22.14477; SUENSON E, 1984, EUR J BIOCHEM, V140, P513, DOI 10.1111/j.1432-1033.1984.tb08132.x; Wang W, 1998, J BIOL CHEM, V273, P27176, DOI 10.1074/jbc.273.42.27176; WANG W, 1994, J BIOL CHEM, V269, P15937	22	100	106	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 3	1999	274	49					35046	35052		10.1074/jbc.274.49.35046	http://dx.doi.org/10.1074/jbc.274.49.35046			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	260XW	10574983	hybrid			2022-12-25	WOS:000083979600077
J	Gudi, T; Hong, GKP; Vaandrager, AB; Lohmann, SM; Pilz, RB				Gudi, T; Hong, GKP; Vaandrager, AB; Lohmann, SM; Pilz, RB			Nitric oxide and cGMP regulate gene expression in neuronal and glial cells by activating type II cGMP-dependent protein kinase	FASEB JOURNAL			English	Article						NO/cGMP signaling; nervous system; fos promoter	INDUCE C-FOS; TRANSMEMBRANE CONDUCTANCE REGULATOR; LONG-TERM POTENTIATION; NERVOUS-SYSTEM; INCREASES PHOSPHORYLATION; PC12 CELLS; RAT-BRAIN; TRANSCRIPTION; MEMBRANE; CAMP	Nitric oxide (NO) and cGMP have been implicated in many neuronal functions, including regulation of gene expression, but little is known about the downstream targets of NO/cGMP in the nervous system, We found that type II cGMP-dependent protein kinase (G-kinase), which is widely expressed in the brain, mediated NO- and cGMP-induced activation of the fos promoter in cells of neuronal and glial origin; the enzyme was ineffective in regulating gene expression in fibroblast-like cells, The effect of G-kinase II on gene expression did not require calcium uptake but was synergistically enhanced by calcium, G-kinase II was membrane associated and did not translocate to the nucleus; however, a soluble G-kinase II mutant translocated to the nucleus and regulated gene expression in fibroblast-like cells, Soluble G-kinase I also regulates fos promoter activity, but membrane targeting of G-kinase I prevented the enzyme from translocating to the nucleus and regulating transcription in multiple cell types, including glioma cells; this suggests that cell type-specific factor(s) that mediate the transcriptional effects of extranuclear G-kinase II are not regulated by G-kinase I, Our results suggest that G-kinase I and II control gene expression by different mechanisms and that NO effects on neuronal plasticity may involve G-kinase II regulation of gene expression.	Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA; Ctr Canc, La Jolla, CA 92093 USA; Erasmus Univ, NL-3000 DR Rotterdam, Netherlands; Univ Wurzburg, Med Klin, Inst Klin Biochem & Pathobiochem, D-97080 Wurzburg, Germany	University of California System; University of California San Diego; Erasmus University Rotterdam; University of Wurzburg	Pilz, RB (corresponding author), Univ Calif San Diego, Dept Med, 9500 Gilman Dr, La Jolla, CA 92093 USA.	rpilz@ucsd.edu		Vaandrager, Arie/0000-0001-9394-9239	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007233] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM055586] Funding Source: NIH RePORTER; NIDDK NIH HHS [2T32DK07233] Funding Source: Medline; NIGMS NIH HHS [1RO1-GM055586] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALBERTS AS, 1994, MOL CELL BIOL, V14, P4398, DOI 10.1128/MCB.14.7.4398; Amir S, 1997, NEUROSCIENCE, V77, P623; Belsham DD, 1996, EMBO J, V15, P538, DOI 10.1002/j.1460-2075.1996.tb00386.x; Blitzer RD, 1998, SCIENCE, V280, P1940, DOI 10.1126/science.280.5371.1940; Boerth NJ, 1997, J VASC RES, V34, P245, DOI 10.1159/000159231; BOSCOFELLEY E, 1994, AM J RESP CELL MOL B, V11, P159; BUTT E, 1993, NEUROCHEM RES, V18, P27, DOI 10.1007/BF00966920; Calabresi P, 1999, J NEUROSCI, V19, P2489; Chinery R, 1997, J BIOL CHEM, V272, P30356, DOI 10.1074/jbc.272.48.30356; Chu DM, 1997, J BIOL CHEM, V272, P31922, DOI 10.1074/jbc.272.50.31922; EIGENTHALER M, 1998, REV PHYSL BIOCH PHAR, V135, P174; El-Husseini AE, 1998, J NEUROCHEM, V71, P676; ELHUSSEINI AED, 1995, J NEUROCHEM, V64, P2814; Farinelli SE, 1996, J NEUROSCI, V16, P2325; FISCH TM, 1989, GENE DEV, V3, P198, DOI 10.1101/gad.3.2.198; Gambaryan S, 1996, J CLIN INVEST, V98, P662, DOI 10.1172/JCI118837; GAMM DM, 1995, J BIOL CHEM, V270, P27380, DOI 10.1074/jbc.270.45.27380; GARTHWAITE J, 1995, ANNU REV PHYSIOL, V57, P683, DOI 10.1146/annurev.ph.57.030195.003343; GHOSH A, 1995, SCIENCE, V268, P239, DOI 10.1126/science.7716515; Gudi T, 1996, J BIOL CHEM, V271, P4597; Gudi T, 1997, MOL CELL BIOL, V17, P5244, DOI 10.1128/MCB.17.9.5244; HABY C, 1994, J NEUROCHEM, V62, P496; Idriss SD, 1999, J BIOL CHEM, V274, P9489, DOI 10.1074/jbc.274.14.9489; JARCHAU T, 1994, P NATL ACAD SCI USA, V91, P9426, DOI 10.1073/pnas.91.20.9426; JOHNSTON HM, 1995, MOL BRAIN RES, V31, P141, DOI 10.1016/0169-328X(95)00046-U; JOHNSTON HM, 1994, J NEUROCHEM, V63, P379; Kleppisch T, 1999, J NEUROSCI, V19, P48, DOI 10.1523/JNEUROSCI.19-01-00048.1999; LevRam V, 1997, NEURON, V18, P1025, DOI 10.1016/S0896-6273(00)80340-2; Lewin MR, 1999, NAT NEUROSCI, V2, P18, DOI 10.1038/4520; Li H, 1996, MOL CELL ENDOCRINOL, V122, P159, DOI 10.1016/0303-7207(96)03881-6; Lincoln Thomas M., 1995, P51, DOI 10.1016/B978-012721985-1/50006-X; Lohmann SM, 1997, TRENDS BIOCHEM SCI, V22, P307, DOI 10.1016/S0968-0004(97)01086-4; MARKERT T, 1995, J CLIN INVEST, V96, P822, DOI 10.1172/JCI118128; MEINECKE M, 1994, MOL PHARMACOL, V46, P283; METZ R, 1991, GENE DEV, V5, P1754, DOI 10.1101/gad.5.10.1754; MORRIS BJ, 1995, J BIOL CHEM, V270, P24740; Murphy BJ, 1998, TRENDS CARDIOVAS MED, V8, P89, DOI 10.1016/S1050-1738(97)00131-X; NAKAZAWA K, 1993, NEUROREPORT, V4, P1275, DOI 10.1097/00001756-199309000-00017; OHKI K, 1995, BRAIN RES, V696, P140, DOI 10.1016/0006-8993(95)00914-C; Orstavik S, 1997, GENOMICS, V42, P311, DOI 10.1006/geno.1997.4743; PEUNOVA N, 1995, NATURE, V375, P68, DOI 10.1038/375068a0; PEUNOVA N, 1993, NATURE, V364, P450, DOI 10.1038/364450a0; PILZ RB, 1995, FASEB J, V9, P552, DOI 10.1096/fasebj.9.7.7737465; POHLER D, 1995, FEBS LETT, V374, P419, DOI 10.1016/0014-5793(95)01168-E; Qian YF, 1996, J NEUROSCI, V16, P3130; SCHONTHAL A, 1991, ONCOGENE, V6, P423; SHENG M, 1990, NEURON, V4, P571, DOI 10.1016/0896-6273(90)90115-V; SNYDER GL, 1992, J NEUROSCI, V12, P3071, DOI 10.1523/JNEUROSCI.12-08-03071.1992; Snyder SH, 1998, BRAIN RES REV, V26, P167, DOI 10.1016/S0165-0173(97)00032-5; Son H, 1996, CELL, V87, P1015, DOI 10.1016/S0092-8674(00)81796-1; THELEN M, 1991, NATURE, V351, P320, DOI 10.1038/351320a0; Thiriet N, 1997, NEUROREPORT, V8, P399, DOI 10.1097/00001756-199701200-00003; UHLER MD, 1993, J BIOL CHEM, V268, P13586; Vaandrager AB, 1996, J BIOL CHEM, V271, P7025, DOI 10.1074/jbc.271.12.7025; Vaandrager AB, 1998, P NATL ACAD SCI USA, V95, P1466, DOI 10.1073/pnas.95.4.1466; Vaandrager AB, 1997, J BIOL CHEM, V272, P11816, DOI 10.1074/jbc.272.18.11816; Vo NK, 1998, BIOCHEM BIOPH RES CO, V246, P831, DOI 10.1006/bbrc.1998.8722; Wang X, 1997, J NEUROCHEM, V68, P443; ZHUO M, 1994, NATURE, V368, P635, DOI 10.1038/368635a0	59	64	64	0	2	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	1999	13	15					2143	2152		10.1096/fasebj.13.15.2143	http://dx.doi.org/10.1096/fasebj.13.15.2143			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	266QN	10593861				2022-12-25	WOS:000084310800005
J	Tejpar, S; Nollet, F; Li, C; Wunder, JS; Michils, G; dal Cin, P; Van Cutsem, E; Bapat, B; van Roy, F; Cassiman, JJ; Alman, BA				Tejpar, S; Nollet, F; Li, C; Wunder, JS; Michils, G; dal Cin, P; Van Cutsem, E; Bapat, B; van Roy, F; Cassiman, JJ; Alman, BA			Predominance of beta-catenin mutations and beta-catenin dysregulation in sporadic aggressive fibromatosis (desmoid tumor)	ONCOGENE			English	Article						beta-catenin; aggressive fibromatosis; mutational analysis; immunohistochemistry; tyrosine phosphorylation	ADENOMATOUS POLYPOSIS; COLORECTAL-CANCER; HEPATOCELLULAR CARCINOMAS; FUNCTIONAL INTERACTION; APC GENE; PHOSPHORYLATION; ACTIVATION; RECEPTOR; UNCOMMON; PROTEIN	Aggressive fibromatosis (also called desmoid tumor) occurs as a sporadic lesion or as part of Familial Adenomatous Polyposis, which is caused by germ line mutations in the Adenomatous polyposis Coli (APC) gene. APC is involved in the regulation of the cellular level of beta-catenin, which is a mediator in Wnt signaling, Mutational analysis of the beta-catenin and APC genes was performed in 42 sporadic aggressive fibromatoses. Nine tumors had mutations in APC, and 22 had a point mutation in beta-catenin at either codon 45 or codon 41 (producing a stabilized beta-catenin protein product). Immunohistochemistry showed an elevated beta-catenin protein level in all tumors, regardless of mutational status. Beta-catenin localized to the nucleus, and was not tyrosine phosphorylated in the six tumors in which this was tested. The demonstration of mutations in two mediators in the Wnt-APC-beta-catenin pathway implicates beta-catenin stabilization as the key factor in the pathogenesis of aggressive fibromatosis. This is the first demonstration of somatic beta-catenin mutations in a locally invasive, but non metastatic lesion composed of spindle cells, illustrating the importance of beta-catenin stabilization in a variety of cell types and neoplastic processes. Moreover, this tumor has one of the highest reported frequencies of beta-catenin mutations of any tumor type.	Hosp Sick Children, Div Orthopaed Surg, Programme Dev Biol, Toronto, ON M5G 1X8, Canada; Katholieke Univ Leuven, Ctr Human Genet, B-3000 Louvain, Belgium; VIB Univ Ghent, Dept Mol Biol, Mol Cell Biol Unit, B-9000 Ghent, Belgium; Mt Sinai Hosp, Dept Surg, Div Orthopaed Surg, Toronto, ON M5G 1X5, Canada; Univ Toronto, Toronto, ON M5G 1X5, Canada; Katholieke Univ Leuven, Dept Gastroenterol, B-3000 Louvain, Belgium; Mt Sinai Hosp, Dept Lab Med & Pathobiol, Toronto, ON M5G 1X5, Canada; Hosp Sick Children, Dept Surg, Div Orthopaed Surg, Toronto, ON M5G 1X8, Canada; Univ Toronto, Toronto, ON M5G 1X8, Canada	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); KU Leuven; Flanders Institute for Biotechnology (VIB); Ghent University; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; University of Toronto; KU Leuven; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto	Alman, BA (corresponding author), Hosp Sick Children, Div Orthopaed Surg, Programme Dev Biol, 555 Univ Ave, Toronto, ON M5G 1X8, Canada.		Van+Cutsem, Eric/ABE-1762-2021; Bapat, Bharati/B-5839-2014; van Roy, Frans M/C-6123-2009	van Roy, Frans M/0000-0003-4358-1039				Alman BA, 1997, AM J PATHOL, V151, P329; Alman BA, 1997, DIAGN MOL PATHOL, V6, P98, DOI 10.1097/00019606-199704000-00005; Behrens J, 1998, SCIENCE, V280, P596, DOI 10.1126/science.280.5363.596; Behrens J, 1996, NATURE, V382, P638, DOI 10.1038/382638a0; BOSMAN FT, 1992, J CLIN PATHOL, V45, P120, DOI 10.1136/jcp.45.2.120; Chan EF, 1999, NAT GENET, V21, P410, DOI 10.1038/7747; de La Coste A, 1998, P NATL ACAD SCI USA, V95, P8847; Eccles DM, 1996, AM J HUM GENET, V59, P1193; Fukuchi T, 1998, CANCER RES, V58, P3526; Garcia-Rostan G, 1999, CANCER RES, V59, P1811; Giarola M, 1998, BRIT J CANCER, V78, P582, DOI 10.1038/bjc.1998.544; Iwao K, 1998, CANCER RES, V58, P1021; KINZLER KW, 1991, SCIENCE, V253, P661, DOI 10.1126/science.1651562; Kitaeva MN, 1997, CANCER RES, V57, P4478; Koch A, 1999, CANCER RES, V59, P269; Li C, 1998, AM J PATHOL, V153, P709, DOI 10.1016/S0002-9440(10)65614-3; Li MM, 1996, HUM PATHOL, V27, P939, DOI 10.1016/S0046-8177(96)90221-X; Liu D, 1997, LAB INVEST, V77, P557; Miyoshi Y, 1998, CANCER RES, V58, P2524; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; MUNEMITSU S, 1995, P NATL ACAD SCI USA, V92, P3046, DOI 10.1073/pnas.92.7.3046; Orford K, 1997, J BIOL CHEM, V272, P24735, DOI 10.1074/jbc.272.40.24735; Papkoff J, 1996, MOL CELL BIOL, V16, P2128; PLUKKER JT, 1995, BRIT J SURG, V82, P510, DOI 10.1002/bjs.1800820424; POWELL SM, 1993, NEW ENGL J MED, V329, P1982, DOI 10.1056/NEJM199312303292702; Rimm DL, 1999, AM J PATHOL, V154, P325, DOI 10.1016/S0002-9440(10)65278-9; Rubinfeld B, 1997, SCIENCE, V275, P1790, DOI 10.1126/science.275.5307.1790; Sparks AB, 1998, CANCER RES, V58, P1130; Takayama T, 1998, BRIT J CANCER, V77, P605, DOI 10.1038/bjc.1998.97; vanDiest PJ, 1997, J CLIN PATHOL, V50, P801, DOI 10.1136/jcp.50.10.801; vanDiest PJ, 1996, ANAL QUANT CYTOL, V18, P351; Voeller HJ, 1998, CANCER RES, V58, P2520; Zurawel RH, 1998, CANCER RES, V58, P896	33	237	248	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 11	1999	18	47					6615	6620		10.1038/sj.onc.1203041	http://dx.doi.org/10.1038/sj.onc.1203041			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	256CW	10597266				2022-12-25	WOS:000083709200026
J	Laliberte, RE; Eggler, J; Gabel, CA				Laliberte, RE; Eggler, J; Gabel, CA			ATP treatment of human monocytes promotes caspase-1 maturation and externalization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTERLEUKIN-1-BETA CONVERTING-ENZYME; CYTOPLASMIC GROUND SUBSTANCE; PROGRAMMED CELL-DEATH; IL-1-BETA-CONVERTING ENZYME; EXTRACELLULAR ATP; (ACYLOXY)METHYL KETONES; IL-1-BETA PRODUCTION; CYSTEINE PROTEASE; 45-KDA PRECURSOR; MATURE IL-1-BETA	Mechanisms that regulate conversion of prointerleukin-1 beta (pro-IL-1 beta) to its mature form by the cysteine protease caspase-1 are not well understood. In this study, we demonstrate that mature caspase-1 subunits are produced when human monocytes are treated with ATP and, like mature IL-1 beta, are released extracellularly. Characterization of the pharmacological sensitivity of this stimulus coupled response revealed that some caspase-1 inhibitors allow pro-IL-1 beta secretion, whereas others do not. Two nonselective alkylating agents, N-ethylmaleimide and phenylarsine oxide, also blocked maturation and release of pro-IL-1 beta. Two inhibitors of anion transport, glyburide and ethacrynic acid, blocked maturation of both caspase-1 and pro-IL-1 beta and prevented release of the propolypeptides, Procaspase-3 was detected in monocyte extracts, but its proteolytic activation was not efficient in the presence of ATP, Maturation of procaspase-1 and release of the mature enzyme subunits therefore accompany stimulus-coupled human monocyte IL-1 post-translational processing. Agents that appear to selectively inhibit mature caspase-1 do not prevent ATP-treated cells from releasing their cytosolic components, On the other hand, anion transport inhibitors and alkylating agents arrest ATP-treated monocytes in a state where membrane latency is maintained. The data provided support the hypothesis that stimulus-coupled IL-1 post-translational processing involves a commitment to cell death.	Pfizer Inc, Dept Resp Allergy Immunol Inflammat & Infect Dis, Groton, CT 06340 USA	Pfizer	Gabel, CA (corresponding author), Pfizer Inc, Dept Resp Allergy Immunol Inflammat & Infect Dis, Eastern Point Rd, Groton, CT 06340 USA.							AYALA JM, 1994, J IMMUNOL, V153, P2592; BHAKDI S, 1990, J CLIN INVEST, V85, P1746, DOI 10.1172/JCI114631; BOUDREAU N, 1995, SCIENCE, V267, P891, DOI 10.1126/science.7531366; Buell G, 1998, BLOOD, V92, P3521, DOI 10.1182/blood.V92.10.3521.422k50_3521_3528; CARRUTH LM, 1991, J BIOL CHEM, V266, P12162; CERRETTI DP, 1992, SCIENCE, V256, P97, DOI 10.1126/science.1373520; Cheneval D, 1998, J BIOL CHEM, V273, P17846, DOI 10.1074/jbc.273.28.17846; CHIN J, 1993, J IMMUNOL, V151, P5574; Chow SC, 1999, EXP CELL RES, V246, P491, DOI 10.1006/excr.1998.4333; Cohen GM, 1997, BIOCHEM J, V326, P1, DOI 10.1042/bj3260001; Dinarello C A, 1998, Int Rev Immunol, V16, P457, DOI 10.3109/08830189809043005; DIVIRGILIO F, 1995, IMMUNOL TODAY, V16, P524, DOI 10.1016/0167-5699(95)80045-X; Ferrari D, 1997, J IMMUNOL, V159, P1451; Ferrari D, 1999, FEBS LETT, V447, P71, DOI 10.1016/S0014-5793(99)00270-7; FROST SC, 1990, BIOCHEM J, V269, P589, DOI 10.1042/bj2690589; Gitler C, 1997, ANAL BIOCHEM, V252, P48, DOI 10.1006/abio.1997.2294; GU Y, 1995, EMBO J, V14, P1923, DOI 10.1002/j.1460-2075.1995.tb07184.x; Hamon Y, 1997, BLOOD, V90, P2911, DOI 10.1182/blood.V90.8.2911; HOGQUIST KA, 1991, J IMMUNOL, V147, P2181; HOGQUIST KA, 1991, P NATL ACAD SCI USA, V88, P8485, DOI 10.1073/pnas.88.19.8485; HOWARD AD, 1991, J IMMUNOL, V147, P2964; Jacobson MD, 1996, J CELL BIOL, V133, P1041, DOI 10.1083/jcb.133.5.1041; KRANTZ A, 1991, BIOCHEMISTRY-US, V30, P4678, DOI 10.1021/bi00233a007; KUIDA K, 1995, SCIENCE, V267, P2000, DOI 10.1126/science.7535475; LALIBERTE R, 1994, J IMMUNOL, V153, P2168; Laliberte RE, 1997, J LEUKOCYTE BIOL, V62, P227, DOI 10.1002/jlb.62.2.227; LI P, 1995, CELL, V80, P401, DOI 10.1016/0092-8674(95)90490-5; Livingston DJ, 1997, J CELL BIOCHEM, V64, P19, DOI 10.1002/(SICI)1097-4644(199701)64:1<19::AID-JCB4>3.0.CO;2-2; MAJNO G, 1995, AM J PATHOL, V146, P3; MARCH CJ, 1985, NATURE, V315, P641, DOI 10.1038/315641a0; Martin SJ, 1996, EMBO J, V15, P2407, DOI 10.1002/j.1460-2075.1996.tb00598.x; MILLER BE, 1995, J IMMUNOL, V154, P1331; MILLER DK, 1993, J BIOL CHEM, V268, P18062; Miossec C, 1996, EUR J IMMUNOL, V26, P1032, DOI 10.1002/eji.1830260512; MIURA M, 1993, CELL, V75, P653, DOI 10.1016/0092-8674(93)90486-A; MOSLEY B, 1987, J BIOL CHEM, V262, P2941; NettFiordalisi M, 1995, J LEUKOCYTE BIOL, V58, P717, DOI 10.1002/jlb.58.6.717; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; Ozaki I, 1999, J BIOL CHEM, V274, P5310, DOI 10.1074/jbc.274.9.5310; PERREGAUX D, 1992, J IMMUNOL, V149, P1294; PERREGAUX D, 1994, J BIOL CHEM, V269, P15195; Perregaux DG, 1998, AM J PHYSIOL-CELL PH, V275, pC1538, DOI 10.1152/ajpcell.1998.275.6.C1538; Perregaux DG, 1996, J BIOL CHEM, V271, P29830, DOI 10.1074/jbc.271.47.29830; Perregaux DG, 1998, J IMMUNOL, V160, P2469; PLOEMEN JHTM, 1994, CANCER RES, V54, P915; Polverino AJ, 1997, J BIOL CHEM, V272, P7013, DOI 10.1074/jbc.272.11.7013; RUBARTELLI A, 1990, EMBO J, V9, P1503, DOI 10.1002/j.1460-2075.1990.tb08268.x; SINGER II, 1995, J EXP MED, V182, P1447, DOI 10.1084/jem.182.5.1447; SINGER II, 1988, J EXP MED, V167, P389, DOI 10.1084/jem.167.2.389; Surprenant A, 1996, SCIENCE, V272, P735, DOI 10.1126/science.272.5262.735; THORNBERRY NA, 1992, NATURE, V356, P768, DOI 10.1038/356768a0; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; THORNBERRY NA, 1994, BIOCHEMISTRY-US, V33, P3934, DOI 10.1021/bi00179a020; WALEV I, 1995, EMBO J, V14, P1607, DOI 10.1002/j.1460-2075.1995.tb07149.x; Walev I, 1996, INFECT IMMUN, V64, P2974, DOI 10.1128/IAI.64.8.2974-2979.1996; WALKER NPC, 1994, CELL, V78, P343, DOI 10.1016/0092-8674(94)90303-4; WANG SY, 1992, IMMUNOLOGY, V77, P298; Warny M, 1999, AM J PHYSIOL-CELL PH, V276, pC717, DOI 10.1152/ajpcell.1999.276.3.C717; Watanabe N, 1998, CYTOKINE, V10, P645, DOI 10.1006/cyto.1998.0341; WILSON KP, 1994, NATURE, V370, P270, DOI 10.1038/370270a0; Yamin TT, 1996, J BIOL CHEM, V271, P13273, DOI 10.1074/jbc.271.22.13273; YUAN JY, 1993, CELL, V75, P641, DOI 10.1016/0092-8674(93)90485-9; ZHENG LM, 1991, J CELL BIOL, V112, P279, DOI 10.1083/jcb.112.2.279; ZYCHLINSKY A, 1991, J IMMUNOL, V146, P393	64	106	107	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 24	1999	274	52					36944	36951		10.1074/jbc.274.52.36944	http://dx.doi.org/10.1074/jbc.274.52.36944			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	267WR	10601248	hybrid			2022-12-25	WOS:000084382700019
J	Tengholm, A; Hellman, B; Gylfe, E				Tengholm, A; Hellman, B; Gylfe, E			Glucose regulation of free Ca2+ in the endoplasmic reticulum of mouse pancreatic beta cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INSULIN-SECRETING CELLS; K-ATP CHANNELS; INOSITOL 1,4,5-TRISPHOSPHATE; INTRACELLULAR STORES; CYTOPLASMIC CA2+; CALCIUM RELEASE; CYTOSOLIC CA2+; RAT INSULINOMA; CA-2+ RELEASE; STEADY-STATE	Free Ca2+ was measured in organelles of individual mouse pancreatic beta cells loaded with the low affinity indicator furaptra. After removal of cytoplasmic indicator by controlled digitonin permeabilization the organelle Ca2+ was located essentially in the endoplasmic reticulum (ER), >90% being sensitive to inhibition of sarco(endo)plasmic reticulum Ca2+-ATPases. The Ca2+ accumulation in the ER of intact beta cells depended in a hyperbolic fashion on the glucose concentration with half-maximal and maximal filling at 5.5 and >20 mM, respectively. Also elevation of cytoplasmic Ca2+ by K+ depolarization significantly enhanced the Ca2+ accumulation. In permeabilized beta cells 1-3 mM ATP caused rapid Ca2+ filling of the ER reaching almost 500 mu M, At 50 nM, Ca2+ ER became half-maximally filled at 45 mu M ATP, whereas only 3.5 mu M ATP was required at 200 nM Ca2+ Inositol 1,4,5-trisphosphate induced a rapid release of about 65% of the ER Ca2+, and its precursor phosphatidylinositol 4,5-bisphosphate was found to slowly mobilize 75% by another mechanism. It is concluded that glucose is an efficient stimulator of Ca2+ uptake in the ER of pancreatic beta cells both by increasing ATP and cytoplasmic Ca2+. Because physiological concentrations of cytoplasmic ATP are in the mM range, Ca2+ sequestration can be anticipated to be modulated by factors reducing its ATP sensitivity.	Univ Uppsala, Biomedicum, Dept Med Cell Biol, SE-75123 Uppsala, Sweden	Uppsala University	Gylfe, E (corresponding author), Univ Uppsala, Biomedicum, Dept Med Cell Biol, Box 571, SE-75123 Uppsala, Sweden.			Gylfe, Erik/0000-0002-8414-2107				ASHCROFT FM, 1989, PROG BIOPHYS MOL BIO, V54, P87, DOI 10.1016/0079-6107(89)90013-8; Ashcroft FM, 1998, SCIENCE, V282, P1059, DOI 10.1126/science.282.5391.1059; Baukrowitz T, 1998, SCIENCE, V282, P1141, DOI 10.1126/science.282.5391.1141; BERS DM, 1994, METHOD CELL BIOL, V40, P3; BERTRAM R, 1995, BIOPHYS J, V68, P2323, DOI 10.1016/S0006-3495(95)80414-5; BERTS A, 1995, BIOCHEM BIOPH RES CO, V208, P644, DOI 10.1006/bbrc.1995.1387; BIDEN TJ, 1984, BIOCHEM J, V223, P467, DOI 10.1042/bj2230467; COLCA JR, 1983, BIOCHIM BIOPHYS ACTA, V729, P176, DOI 10.1016/0005-2736(83)90483-2; ERECINSKA M, 1992, BIOCHIM BIOPHYS ACTA, V1101, P273, DOI 10.1016/0167-4838(92)90555-R; Favre CJ, 1996, J BIOL CHEM, V271, P14925, DOI 10.1074/jbc.271.25.14925; Guest PC, 1997, BIOCHEM J, V323, P445, DOI 10.1042/bj3230445; GYLFE E, 1990, BIOCHIM BIOPHYS ACTA, V1055, P82, DOI 10.1016/0167-4889(90)90094-T; GYLFE E, 1991, PFLUG ARCH EUR J PHY, V419, P639, DOI 10.1007/BF00370308; GYLFE E, 1988, J BIOL CHEM, V263, P13750; Hajnoczky G, 1999, J BIOL CHEM, V274, P14157, DOI 10.1074/jbc.274.20.14157; Hajnoczky G, 1997, EMBO J, V16, P3533, DOI 10.1093/emboj/16.12.3533; HELLMAN B, 1965, ANN NY ACAD SCI, V131, P541, DOI 10.1111/j.1749-6632.1965.tb34819.x; HELLMAN B, 1992, BIOCHIM BIOPHYS ACTA, V1113, P295, DOI 10.1016/0304-4157(92)90003-S; HELLMAN B, 1986, BIOCHEM INT, V13, P383; Hellman B., 1986, CALCIUM CELL FUNCTIO, P253; Hellman B., 1992, NUTR REGULATION INSU, P213; Hofer AM, 1996, FASEB J, V10, P302, DOI 10.1096/fasebj.10.2.8641563; Hofer AM, 1998, J CELL BIOL, V140, P325, DOI 10.1083/jcb.140.2.325; HOFER AM, 1993, P NATL ACAD SCI USA, V90, P2598, DOI 10.1073/pnas.90.7.2598; INESI G, 1989, J BIOL CHEM, V264, P5929; ISLAM MS, 1993, BIOCHEM J, V293, P423, DOI 10.1042/bj2930423; Kennedy ED, 1996, J CLIN INVEST, V98, P2524, DOI 10.1172/JCI119071; Kennedy HJ, 1999, J BIOL CHEM, V274, P13281, DOI 10.1074/jbc.274.19.13281; LENZEN S, 1991, DIABETES, V40, P323, DOI 10.2337/diabetes.40.3.323; LERNMARK A, 1974, DIABETOLOGIA, V10, P431, DOI 10.1007/BF01221634; Levy J, 1998, METABOLISM, V47, P185, DOI 10.1016/S0026-0495(98)90218-9; Liu YJ, 1998, J PHYSIOL-LONDON, V508, P471, DOI 10.1111/j.1469-7793.1998.471bq.x; Maechler P, 1998, J BIOL CHEM, V273, P20770, DOI 10.1074/jbc.273.33.20770; Maechler P, 1999, J BIOL CHEM, V274, P12583, DOI 10.1074/jbc.274.18.12583; Meldolesi J, 1998, TRENDS BIOCHEM SCI, V23, P10, DOI 10.1016/S0968-0004(97)01143-2; Mogami H, 1998, EMBO J, V17, P435, DOI 10.1093/emboj/17.2.435; NAKAMURA Y, 1987, ENDOCRINOLOGY, V120, P2302, DOI 10.1210/endo-120-6-2302; NILSSON T, 1987, BIOCHEM J, V248, P329, DOI 10.1042/bj2480329; OHO C, 1986, J BIOCHEM-TOKYO, V100, P911, DOI 10.1093/oxfordjournals.jbchem.a121804; POZZAN T, 1994, PHYSIOL REV, V74, P595, DOI 10.1152/physrev.1994.74.3.595; PRALONG WF, 1994, J BIOL CHEM, V269, P27310; PRENTKI M, 1985, J BIOL CHEM, V260, P9185; PRENTKI M, 1984, J BIOL CHEM, V259, P118; RAJU B, 1989, AM J PHYSIOL, V256, P540; ROE MW, 1994, J BIOL CHEM, V269, P18279; RUTTER GA, 1994, CELL CALCIUM, V16, P71, DOI 10.1016/0143-4160(94)90002-7; Shyng SL, 1998, SCIENCE, V282, P1138, DOI 10.1126/science.282.5391.1138; Tengholm A, 1998, DIABETES, V47, P1224, DOI 10.2337/diabetes.47.8.1224; TRUBE G, 1986, PFLUG ARCH EUR J PHY, V407, P493, DOI 10.1007/BF00657506; Varadi A, 1996, BIOCHEM J, V319, P521, DOI 10.1042/bj3190521; WOLF BA, 1985, BIOCHEM J, V227, P965, DOI 10.1042/bj2270965; WOLF BA, 1986, J BIOL CHEM, V261, P6284; WOLLHEIM CB, 1981, PHYSIOL REV, V61, P914, DOI 10.1152/physrev.1981.61.4.914; WORLEY JF, 1994, J BIOL CHEM, V269, P14359	54	49	49	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 24	1999	274	52					36883	36890		10.1074/jbc.274.52.36883	http://dx.doi.org/10.1074/jbc.274.52.36883			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	267WR	10601240	hybrid			2022-12-25	WOS:000084382700011
J	Chabes, A; Domkin, V; Thelander, L				Chabes, A; Domkin, V; Thelander, L			Yeast Sml1, a protein inhibitor of ribonucleotide reductase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMALL-SUBUNIT; SACCHAROMYCES-CEREVISIAE; RECOMBINANT MOUSE; CALF THYMUS; DNA; IDENTIFICATION; PURIFICATION; GENES; RNA; R1	Ribonucleotide reductase (RNR) catalyzes the reduction of ribonucleotides to deoxyribonucleotides; this step is rate-limiting in DNA precursor synthesis. A number of regulatory mechanisms ensure optimal deoxyribonucleotide pools, which are essential for cell viability. The best studied mechanisms are transcriptional regulation of the RNR genes during the cell cycle and in the response to DNA damage, and the allosteric regulation of ribonucleotide reductase by nucleoside triphosphates, Recently, another mode of RNR regulation has been hypothesized in yeast. A novel protein, Sml1, was shown to bind to the Rnr1 protein of the yeast ribonucleotide reductase; this interaction was proposed to inhibit ribonucleotide reductase activity when DNA synthesis is not required (Zhao, X,, Muller, E.G.D,, and Rothstein, R. (1998) Mol. Cell 2, 329-340). Here, we use highly purified recombinant proteins to directly demonstrate that the Sml1 protein is a strong inhibitor of yeast RNR, The Sml1p specifically binds to the yeast Rnr1p in a 1:1 ratio with a dissociation constant of 0.4 mu M. Interestingly, Sml1p also specifically binds to the mouse ribonucleotide reductase R1 protein. However, the inhibition observed in an in vitro mouse ribonucleotide reductase assay is less pronounced than the inhibition in yeast and probably occurs via a different mechanism.	Umea Univ, Dept Med Biosci Med Biochem, SE-90187 Umea, Sweden	Umea University	Chabes, A (corresponding author), Umea Univ, Dept Med Biosci Med Biochem, SE-90187 Umea, Sweden.			Chabes, Andrei/0000-0003-1708-8259				BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHANCE B, 1950, BIOCHEM J, V46, P402, DOI 10.1042/bj0460402; DAVIS R, 1994, J BIOL CHEM, V269, P23171; Desany BA, 1998, GENE DEV, V12, P2956, DOI 10.1101/gad.12.18.2956; ELLEDGE SJ, 1990, GENE DEV, V4, P740, DOI 10.1101/gad.4.5.740; ELLEDGE SJ, 1987, MOL CELL BIOL, V7, P2783, DOI 10.1128/MCB.7.8.2783; ENGSTROM Y, 1979, BIOCHEMISTRY-US, V18, P2941, DOI 10.1021/bi00581a004; Huang MX, 1997, MOL CELL BIOL, V17, P6105, DOI 10.1128/MCB.17.10.6105; HURD HK, 1987, MOL CELL BIOL, V7, P3673, DOI 10.1128/MCB.7.10.3673; Ingemarson R, 1996, BIOCHEMISTRY-US, V35, P8603, DOI 10.1021/bi960184n; JONSSON U, 1991, BIOTECHNIQUES, V11, P620; LIUZZI M, 1994, NATURE, V372, P695, DOI 10.1038/372695a0; LYCKSELL PO, 1994, BIOCHEMISTRY-US, V33, P2838, DOI 10.1021/bi00176a013; MANN GJ, 1991, BIOCHEMISTRY-US, V30, P1939, DOI 10.1021/bi00221a030; REICHARD P, 1988, ANNU REV BIOCHEM, V57, P349, DOI 10.1146/annurev.bi.57.070188.002025; REICHARD P, 1993, SCIENCE, V260, P1773, DOI 10.1126/science.8511586; ROVA U, 1995, BIOCHEMISTRY-US, V34, P4267, DOI 10.1021/bi00013a016; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; THELANDER L, 1980, J BIOL CHEM, V255, P7426; Thelander Lars, 1994, V30, P109; Wang PJ, 1997, MOL CELL BIOL, V17, P6114, DOI 10.1128/MCB.17.10.6114; Zhao XL, 1998, MOL CELL, V2, P329, DOI 10.1016/S1097-2765(00)80277-4	22	110	114	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 17	1999	274	51					36679	36683		10.1074/jbc.274.51.36679	http://dx.doi.org/10.1074/jbc.274.51.36679			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	266AV	10593972	hybrid			2022-12-25	WOS:000084279200091
J	Planas, JV; Cummings, DE; Idzerda, RL; McKnight, GS				Planas, JV; Cummings, DE; Idzerda, RL; McKnight, GS			Mutation of the RII beta subunit of protein kinase A differentially affects lipolysis but not gene induction in white adipose tissue	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HORMONE-SENSITIVE LIPASE; OB MESSENGER-RNA; A MUTANT MICE; RAT ADIPOCYTES; TARGETED DISRUPTION; LIPOGENIC ENZYME; BODY-WEIGHT; FOOD-INTAKE; LEAN MICE; EXPRESSION	Targeted disruption of the RII beta subunit of protein kinase A (PKA) produces lean mice that resist diet-induced obesity. In this report we examine the effects of the RII beta knockout on white adipose tissue physiology, Loss of RII beta is compensated by an increase in the RI alpha isoform, generating an isoform switch from a type II to a type I PKA, Type I holoenzyme binds cAMP more avidly and is more easily activated than the type II enzyme. These alterations are associated with increases in both basal kinase activity and the basal rate of lipolysis, possibly contributing to the lean phenotype, However, the ability of both beta(3)-selective and nonspecific beta-adrenergic agonists to stimulate lipolysis is markedly compromised in mutant white adipose tissue. This defect was found in vitro and in vivo and does not result from reduced expression of beta-adrenergic receptor or hormone-sensitive lipase genes. In contrast, beta-adrenergic stimulated gene transcription remains intact, and the expression of key genes involved in lipid metabolism is normal under both fasted and fed conditions. We suggest that the R subunit isoform switch disrupts the subcellular localization of PHA that is required for efficient transduction of signals that modulate lipolysis but not for those that mediate gene expression.	Univ Washington, Dept Pharmacol, Sch Med, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle	McKnight, GS (corresponding author), Univ Washington, Dept Pharmacol, Sch Med, Box 357750, Seattle, WA 98195 USA.	mcknight@u.washington.edu		Planas, Josep/0000-0002-6525-9617	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K12DK001964] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK01964] Funding Source: Medline; NIGMS NIH HHS [GM82375] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adams MR, 1997, P NATL ACAD SCI USA, V94, P12157, DOI 10.1073/pnas.94.22.12157; ALLEN DO, 1988, J PHARMACOL EXP THER, V244, P852; ALLEN DO, 1986, J PHARMACOL EXP THER, V238, P659; Amieux PS, 1997, J BIOL CHEM, V272, P3993, DOI 10.1074/jbc.272.7.3993; Anthonsen MW, 1998, J BIOL CHEM, V273, P215, DOI 10.1074/jbc.273.1.215; ANTRAS J, 1991, MOL CELL ENDOCRINOL, V82, P183, DOI 10.1016/0303-7207(91)90030-V; Auwerx J, 1998, LANCET, V351, P737, DOI 10.1016/S0140-6736(97)06348-4; BLOOM JD, 1992, J MED CHEM, V35, P3081, DOI 10.1021/jm00094a025; Brandon EP, 1998, J NEUROSCI, V18, P3639; Campfield LA, 1996, HORM METAB RES, V28, P619, DOI 10.1055/s-2007-979867; CLEGG CH, 1987, J BIOL CHEM, V262, P13111; Colledge M, 1999, TRENDS CELL BIOL, V9, P216, DOI 10.1016/S0962-8924(99)01558-5; COLLINS S, 1994, MOL ENDOCRINOL, V8, P518, DOI 10.1210/me.8.4.518; Collins S, 1996, J BIOL CHEM, V271, P9437, DOI 10.1074/jbc.271.16.9437; Considine RV, 1997, INT J BIOCHEM CELL B, V29, P1255, DOI 10.1016/S1357-2725(97)00050-2; Cummings DE, 1996, NATURE, V382, P622, DOI 10.1038/382622a0; Degerman E, 1998, METHODS, V14, P43, DOI 10.1006/meth.1997.0564; DOSKELAND SO, 1988, METHOD ENZYMOL, V159, P147; EGAN JJ, 1992, P NATL ACAD SCI USA, V89, P8537, DOI 10.1073/pnas.89.18.8537; FAIN JN, 1973, MOL PHARMACOL, V9, P595; FOUFELLE F, 1994, EUR J BIOCHEM, V223, P893, DOI 10.1111/j.1432-1033.1994.tb19066.x; FREDERICH RC, 1995, J CLIN INVEST, V96, P1658, DOI 10.1172/JCI118206; Friedman JM, 1998, NUTR REV, V56, pS38; Gettys TW, 1996, ENDOCRINOLOGY, V137, P4054, DOI 10.1210/en.137.9.4054; GIRARD J, 1994, FASEB J, V8, P36, DOI 10.1096/fasebj.8.1.7905448; GOODRIDGE AG, 1987, ANNU REV NUTR, V7, P157, DOI 10.1146/annurev.nu.07.070187.001105; Guthrie CR, 1997, J BIOL CHEM, V272, P29560, DOI 10.1074/jbc.272.47.29560; HIRSCH AH, 1984, J LIPID RES, V25, P665; HOLLENGA C, 1991, EUR J PHARMACOL, V200, P325, DOI 10.1016/0014-2999(91)90590-M; HONNOR RC, 1985, J BIOL CHEM, V260, P5122; KAESTNER KH, 1991, P NATL ACAD SCI USA, V88, P1933, DOI 10.1073/pnas.88.5.1933; KIM KH, 1989, FASEB J, V3, P2250, DOI 10.1096/fasebj.3.11.2570725; Krebs E G, 1972, Curr Top Cell Regul, V5, P99; LABARCA C, 1980, ANAL BIOCHEM, V102, P344, DOI 10.1016/0003-2697(80)90165-7; LANGIN D, 1992, BIOCHIM BIOPHYS ACTA, V1135, P349, DOI 10.1016/0167-4889(92)90242-4; LEIBEL RL, 1995, NEW ENGL J MED, V332, P621, DOI 10.1056/NEJM199503093321001; Lester LB, 1997, P NATL ACAD SCI USA, V94, P14942, DOI 10.1073/pnas.94.26.14942; LITOSCH I, 1982, MOL PHARMACOL, V22, P109; MACDOUGALD OA, 1995, P NATL ACAD SCI USA, V92, P9034, DOI 10.1073/pnas.92.20.9034; Mantzoros CS, 1996, DIABETES, V45, P909, DOI 10.2337/diabetes.45.7.909; McKnight GS, 1991, CURR OPIN CELL BIOL, V3, P213; MCKNIGHT GS, 1980, J BIOL CHEM, V255, P144; MCKNIGHT GS, 1996, SIGNAL TRANSDUCTION, P95; Mizuno TM, 1996, P NATL ACAD SCI USA, V93, P3434, DOI 10.1073/pnas.93.8.3434; Moxham CM, 1996, NATURE, V379, P840, DOI 10.1038/379840a0; MURPHY GJ, 1993, BIOCHEM PHARMACOL, V46, P575, DOI 10.1016/0006-2952(93)90540-D; ROSENMUND C, 1994, NATURE, V368, P853, DOI 10.1038/368853a0; RUBIN CS, 1994, BBA-MOL CELL RES, V1224, P467; SALADIN R, 1995, NATURE, V377, P527, DOI 10.1038/377527a0; SCHWABE U, 1973, N-S ARCH PHARMACOL, V276, P133, DOI 10.1007/BF00501186; Shih ML, 1999, J BIOL CHEM, V274, P1588, DOI 10.1074/jbc.274.3.1588; Slieker LJ, 1996, J BIOL CHEM, V271, P5301, DOI 10.1074/jbc.271.10.5301; STRALFORS P, 1983, J BIOL CHEM, V258, P5146; STRALFORS P, 1984, P NATL ACAD SCI-BIOL, V81, P3317, DOI 10.1073/pnas.81.11.3317; SUSULIC VS, 1995, J BIOL CHEM, V270, P29483, DOI 10.1074/jbc.270.49.29483; SZTALRYD C, 1995, METABOLISM, V44, P1391, DOI 10.1016/0026-0495(95)90135-3; SZTALRYD C, 1994, AM J PHYSIOL, V266, pE179, DOI 10.1152/ajpendo.1994.266.2.E179; UHLE, 1986, P NATL ACAD SCI USA, V83, P1300; Westphal RS, 1999, SCIENCE, V285, P93, DOI 10.1126/science.285.5424.93	59	52	53	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 17	1999	274	51					36281	36287		10.1074/jbc.274.51.36281	http://dx.doi.org/10.1074/jbc.274.51.36281			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	266AV	10593917	hybrid			2022-12-25	WOS:000084279200036
J	Smicun, Y; Campbell, SD; Chen, MA; Gu, H; Rudnick, G				Smicun, Y; Campbell, SD; Chen, MA; Gu, H; Rudnick, G			The role of external loop regions in serotonin transport - Loop scanning mutagenesis of the serotonin transporter external domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOPAMINE-NOREPINEPHRINE TRANSPORTERS; STRUCTURAL DOMAINS; RAT-BRAIN; SUBSTRATE; TOPOLOGY; RESIDUES; CLONING; BINDING; SITE; ANTIDEPRESSANTS	Chimeric transporters were constructed in which the predicted external loops of the serotonin transporter (SERT) were replaced one at a time with a corresponding sequence from the norepinephrine transporter (NET). All of the chimeric transporters were expressed at levels equal to or greater than those of wild type SERT, but the transport and binding activity of the mutants varied greatly. In particular, mutants in which the NET sequence replaced external loops 4 or 6 of SERT had transport activity 5% or less than that of wild type, and the loop 5 replacement was essentially inactive, In some of these mutants, binding of a high affinity cocaine analog was less affected than transport, suggesting that the mutation had less effect on the initial binding steps in transport than on subsequent conformational changes. The more severely affected mutants also displayed an altered response to Na+. In contrast to the dramatic reduction in transport and binding, the specificity of ligand binding was essentially unchanged. Chimeric transporters did not gain affinity for dopamine, a NET substrate, or desipramine, an inhibitor, at the expense of affinity for serotonin or paroxetine, a selective SERT inhibitor. The results suggest that external loops are not the primary determinants of substrate and inhibitor binding sites. However, they are not merely passive structures connecting transmembrane segments but rather active elements responsible for maintaining the stability and conformational flexibility of the transporter.	Yale Univ, Sch Med, Dept Pharmacol, New Haven, CT 06510 USA	Yale University	Rudnick, G (corresponding author), Yale Univ, Sch Med, Dept Pharmacol, 333 Cedar St, New Haven, CT 06510 USA.	gary.rudnick@yale.edu						BALKOVETZ DF, 1989, J BIOL CHEM, V264, P2195; Bennett ER, 1997, J BIOL CHEM, V272, P1203, DOI 10.1074/jbc.272.2.1203; BLAKELY RD, 1993, SOC GEN PHY, V48, P283; BLAKELY RD, 1991, ANAL BIOCHEM, V194, P302, DOI 10.1016/0003-2697(91)90233-J; BLAKELY RD, 1991, NATURE, V354, P66, DOI 10.1038/354066a0; Buck KJ, 1995, MOL PHARMACOL, V48, P1030; BUCK KJ, 1994, P NATL ACAD SCI USA, V91, P12584, DOI 10.1073/pnas.91.26.12584; BUCK KJ, 1993, SOC NEUR ABSTR, V19; Cao YW, 1998, J NEUROSCI, V18, P7739; Chen JG, 1997, BIOCHEMISTRY-US, V36, P1479, DOI 10.1021/bi962256g; Chen JG, 1997, J BIOL CHEM, V272, P28321, DOI 10.1074/jbc.272.45.28321; Chen JG, 1998, J BIOL CHEM, V273, P12675, DOI 10.1074/jbc.273.20.12675; GIROS B, 1994, J BIOL CHEM, V269, P15985; GOTTARDI CJ, 1995, AM J PHYSIOL-RENAL, V268, pF285, DOI 10.1152/ajprenal.1995.268.2.F285; Greenberg BD, 1998, MOL PSYCHIATR, V3, P186, DOI 10.1038/sj.mp.4000415; HEISLER S, 1972, ACTA PHYSIOL SCAND, V86, P145, DOI 10.1111/j.1748-1716.1972.tb05321.x; HOFFMAN BJ, 1991, SCIENCE, V254, P579, DOI 10.1126/science.1948036; HUMPHREYS CJ, 1994, BIOCHEMISTRY-US, V33, P9118, DOI 10.1021/bi00197a014; MITCHELL P, 1990, RES MICROBIOL, V141, P286, DOI 10.1016/0923-2508(90)90002-8; MOORE KR, 1994, BIOTECHNIQUES, V17, P130; Olivares L, 1997, J BIOL CHEM, V272, P1211, DOI 10.1074/jbc.272.2.1211; Rudnick G, 1997, NEUROTRANSMITTER TRA, P73; RUDNICK G, 1986, PLATELET FUNCTION ME, V2, P119; Stephan MM, 1997, BIOCHEMISTRY-US, V36, P1322, DOI 10.1021/bi962150l; TAMURA S, 1995, J BIOL CHEM, V270, P28712, DOI 10.1074/jbc.270.48.28712; TATE CG, 1994, J BIOL CHEM, V269, P26303	26	53	55	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 17	1999	274	51					36058	36064		10.1074/jbc.274.51.36058	http://dx.doi.org/10.1074/jbc.274.51.36058			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	266AV	10593887	hybrid			2022-12-25	WOS:000084279200006
J	Fraaije, MW; van den Heuvel, RHH; van Berkel, WJH; Mattevi, A				Fraaije, MW; van den Heuvel, RHH; van Berkel, WJH; Mattevi, A			Covalent flavinylation is essential for efficient redox catalysis in vanillyl-alcohol oxidase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OXIDATION-REDUCTION POTENTIALS; X-RAY ANALYSIS; PENICILLIUM-SIMPLICISSIMUM; BOUND FAD; TRIMETHYLAMINE DEHYDROGENASE; ESCHERICHIA-COLI; BREVIBACTERIUM-STEROLICUM; HETEROLOGOUS EXPRESSION; SUBSTRATE-SPECIFICITY; CHOLESTEROL OXIDASE	By mutating the target residue of covalent flavinylation in vanillyl-alcohol oxidase, the functional role of the histidyl-FAD bond was studied. Three His(422) mutants (H422A, H422T, and H422C) were purified, which all contained tightly but noncovalently bound FAD. Steady state kinetics revealed that the mutants have retained enzyme activity, although the turnover rates have decreased by 1 order of magnitude. Stopped-flow analysis showed that the H422A mutant is still able to form a stable binary complex of reduced enzyme and a quinone methide product intermediate, a crucial step during vanillyl-alcohol oxidase-mediated catalysis, The only significant change in the catalytic cycle of the H422A mutant is a marked decrease in reduction rate. Redox potentials of both wild type and H422A vanillyl-alcohol oxidase have been determined. During reduction of H422A, a large portion of the neutral flavin semiquinone is observed. Using suitable reference dyes, the redox potentials for the two one-electron couples have been determined: -17 and -113 mV. Reduction of wild type enzyme did not result in any formation of flavin semiquinone and revealed a remarkably high redox potential of +55 mV, The marked decrease in redox potential caused by the missing covalent histidyl-FAD bond is reflected in the reduced rate of substrate-mediated flavin reduction limiting the turnover rate. Elucidation of the crystal structure of the H422A mutant established that deletion of the histidyl-FAD bond did not result in any significant structural changes. These results clearly indicate that covalent interaction of the isoalloxazine ring with the protein moiety can markedly increase the redox potential of the flavin cofactor, thereby facilitating redox catalysis, Thus, formation of a histidyl-EAD bond in specific flavoenzymes might have evolved as a way to contribute to the enhancement of their oxidative power.	Univ Pavia, Dept Genet & Microbiol, I-27100 Pavia, Italy; Wageningen Univ, Biochem Lab, Dept Biomol Sci, NL-6703 HA Wageningen, Netherlands	University of Pavia; Wageningen University & Research	Fraaije, MW (corresponding author), Univ Groningen, Biochem Lab, Nijenborgh 4, NL-9747 AG Groningen, Netherlands.	M.W.Fraaije@chem.rug.nl	mattevi, andrea/K-5464-2012; Fraaije, Marco/E-8421-2014; van Berkel, Willem J.H./O-2431-2014; Mattevi, Andrea/R-4469-2019	mattevi, andrea/0000-0002-9523-7128; van Berkel, Willem J.H./0000-0002-6551-2782; Mattevi, Andrea/0000-0002-9523-7128; Fraaije, Marco/0000-0001-6346-5014				Ackrell B. A.C, 1992, CHEM BIOCH FLAVOPROT, V3, P229; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BARBER MJ, 1988, BIOCHEM J, V256, P657, DOI 10.1042/bj2560657; Benen JAE, 1998, J BIOL CHEM, V273, P7865, DOI 10.1074/jbc.273.14.7865; BLAUT M, 1989, J BIOL CHEM, V264, P13599; Clark W.M., 1960, OXIDATION REDUCTION, P184; Croteau N, 1996, J STRUCT BIOL, V116, P317, DOI 10.1006/jsbi.1996.0047; DECKER KF, 1994, NUTR BIOCH, P443; DEJONG E, 1992, EUR J BIOCHEM, V208, P651; EDMONDSON DE, 1977, PHOTOCHEM PHOTOBIOL, V25, P445, DOI 10.1111/j.1751-1097.1977.tb09169.x; EDMONDSON DE, 1973, J BIOL CHEM, V248, P8144; EDMONDSON DE, 1991, CHEM BIOCH FLAVOENZY, V1, P73; Fraaije MW, 1998, EUR J BIOCHEM, V253, P712, DOI 10.1046/j.1432-1327.1998.2530712.x; FRAAIJE MW, 1995, EUR J BIOCHEM, V234, P271, DOI 10.1111/j.1432-1033.1995.271_c.x; Fraaije MW, 1997, APPL ENVIRON MICROB, V63, P435, DOI 10.1128/AEM.63.2.435-439.1997; Fraaije MW, 1997, J BIOL CHEM, V272, P18111, DOI 10.1074/jbc.272.29.18111; Fraaije MW, 1997, FEBS LETT, V402, P33, DOI 10.1016/S0014-5793(96)01494-9; Fraaije MW, 1998, TRENDS BIOCHEM SCI, V23, P206, DOI 10.1016/S0968-0004(98)01210-9; Fraaije MW, 1998, FEBS LETT, V422, P65, DOI 10.1016/S0014-5793(97)01605-0; Gadda G, 1998, BIOCHEMISTRY-US, V37, P6154, DOI 10.1021/bi973085y; Gadda G, 1997, EUR J BIOCHEM, V250, P369, DOI 10.1111/j.1432-1033.1997.0369a.x; GIBSON T, 1984, THESIS U CAMBRIDGE U; GOMEZMORENO C, 1979, J BIOL CHEM, V254, P7630; GUTMAN M, 1980, BIOCHIM BIOPHYS ACTA, V591, P400, DOI 10.1016/0005-2728(80)90171-1; Hiro I, 1996, J BIOCHEM-TOKYO, V120, P759; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KEARNEY EB, 1955, BIOCHIM BIOPHYS ACTA, V17, P596, DOI 10.1016/0006-3002(55)90432-7; KENNEY WC, 1976, J BIOL CHEM, V251, P5386; Kim J, 1995, J BIOL CHEM, V270, P31202, DOI 10.1074/jbc.270.52.31202; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMZIN VS, 1993, ACTA CRYSTALLOGR D, V49, P129, DOI 10.1107/S0907444992008886; Massey V, 1990, FLAVINS FLAVOPROTEIN, P59; Mattevi A, 1997, STRUCTURE, V5, P907, DOI 10.1016/S0969-2126(97)00245-1; Mattevi A, 1997, PROTEINS, V27, P601, DOI 10.1002/(SICI)1097-0134(199704)27:4<601::AID-PROT12>3.0.CO;2-O; MAUCH L, 1989, FEBS LETT, V257, P86, DOI 10.1016/0014-5793(89)81792-2; MAYHEW SG, 1969, J BIOL CHEM, V244, P803; Mewies M, 1998, PROTEIN SCI, V7, P7, DOI 10.1002/pro.5560070102; Mewies M, 1997, BIOCHEMISTRY-US, V36, P7162, DOI 10.1021/bi970621d; MINNAERT K, 1965, BIOCHIM BIOPHYS ACTA, V110, P42, DOI 10.1016/S0926-6593(65)80093-5; MOORE EG, 1979, J BIOL CHEM, V254, P8173; MORRIS AL, 1992, PROTEINS, V12, P345, DOI 10.1002/prot.340120407; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; NISHIKIMI M, 1994, BIOCHEM MOL BIOL INT, V33, P313; Parsonage D, 1998, J BIOL CHEM, V273, P23812, DOI 10.1074/jbc.273.37.23812; ROBINSON KM, 1994, EUR J BIOCHEM, V222, P983, DOI 10.1111/j.1432-1033.1994.tb18949.x; SCHILLING B, 1995, MOL GEN GENET, V247, P430, DOI 10.1007/BF00293144; SCRUTTON NS, 1994, J BIOL CHEM, V269, P13942; Stankovich M.T., 1991, CHEM BIOCH FLAVOENZY, V1, P401; STANKOVICH MT, 1978, J BIOL CHEM, V253, P4971; van den Heuvel RHH, 1998, J BACTERIOL, V180, P5646, DOI 10.1128/JB.180.21.5646-5651.1998; VANBERKEL WJH, 1991, CHEM BIOCH FLAVOENZY, V1, P261; WILLIAMSON G, 1985, BIOCHEMISTRY-US, V24, P7790, DOI 10.1021/bi00347a043; WOODCOCK DM, 1989, NUCLEIC ACIDS RES, V17, P3469, DOI 10.1093/nar/17.9.3469	54	97	99	1	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 10	1999	274	50					35514	35520		10.1074/jbc.274.50.35514	http://dx.doi.org/10.1074/jbc.274.50.35514			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	264NG	10585424	Green Published, hybrid			2022-12-25	WOS:000084187900036
J	Frick, DN; Kumar, S; Richardson, CC				Frick, DN; Kumar, S; Richardson, CC			Interaction of ribonucleoside triphosphates with the gene 4 primase of bacteriophage T7	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACID REPLICATION INVITRO; STRAND DNA-SYNTHESIS; NUCLEOSIDE 5'-TRIPHOSPHATASE ACTIVITY; ESCHERICHIA-COLI PRIMASE; DEOXYRIBONUCLEIC-ACID; TEMPLATE RECOGNITION; HELICASE ACTIVITY; PRIMER SYNTHESIS; RNA-POLYMERASE; TRANSCRIPTION INITIATION	The primase fragment of bacteriophage T7 gene 4 protein catalyzes the synthesis of oligoribonucleotides in the presence of ATP, CTP, Mg2+ (or Mn2+), and DNA containing a primase recognition site. During chain initiation, ATP binds with a K-m of 0.32 mM, and CTP binds with a K-m of 0.85 mM. Synthesis of the dinucleotides proceeds at a rate of 3.8/s. The dinucleotide either dissociates or is extended to a tetranucleotide. The primase preferentially inserts ribonucleotides forming Watson-Crick base pairs with the DNA template >200-fold more rapidly than other ribo- or deoxynucleotides. 3'-dCTP binds the primase with a similar affinity as CTP and is incorporated as a chain terminator at a rate 1/100 that of CTP. ATP analogues alpha,beta-methylene ATP, beta,gamma-methylene ATP, and beta,gamma-imido ATP are incorporated by the primase fragment at the 5'-ends of the oligoribonucleotides but not at the 3'-ends. A model is presented in which the primase fragment utilizes two nucleotide-binding sites, one for the initiating ATP and one for the nucleoside triphosphate which elongates the primer on the 3'-end, The initiation site binds ATP or oligoribonucleotides, whereas the elongation site binds ATP or CTP as directed by the template.	Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA; Amersham Pharmacia Biotech, Nucle Acid Chem, Piscataway, NJ 08855 USA	Harvard University; Harvard Medical School	Richardson, CC (corresponding author), Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, 240 Longwood Ave, Boston, MA 02115 USA.			Frick, David/0000-0002-2434-7223	NIAID NIH HHS [AI-06045] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI006045, R01AI006045] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BERNSTEIN JA, 1988, J BIOL CHEM, V263, P14891; BERNSTEIN JA, 1989, J BIOL CHEM, V264, P13066; BERNSTEIN JA, 1988, P NATL ACAD SCI USA, V85, P396, DOI 10.1073/pnas.85.2.396; DEBYSER Z, 1994, CELL, V77, P157, DOI 10.1016/0092-8674(94)90243-7; DUNN JJ, 1983, J MOL BIOL, V166, P477, DOI 10.1016/S0022-2836(83)80282-4; EGELMAN EH, 1995, P NATL ACAD SCI USA, V92, P3869, DOI 10.1073/pnas.92.9.3869; Frick DN, 1999, J BIOL CHEM, V274, P35889, DOI 10.1074/jbc.274.50.35889; Frick DN, 1998, P NATL ACAD SCI USA, V95, P7957, DOI 10.1073/pnas.95.14.7957; Hacker KJ, 1997, BIOCHEMISTRY-US, V36, P14080, DOI 10.1021/bi971644v; Hernandez A, 1998, BIOINFORMATICS, V14, P227, DOI 10.1093/bioinformatics/14.2.227; HINTON DM, 1987, J BIOL CHEM, V262, P10873; HORI K, 1979, J BIOL CHEM, V254, P1598; HORI K, 1979, J BIOL CHEM, V254, P1591; ILYINA TV, 1992, J MOL EVOL, V34, P351, DOI 10.1007/BF00160243; Jia YP, 1997, BIOCHEMISTRY-US, V36, P4223, DOI 10.1021/bi9630467; KIM YT, 1993, P NATL ACAD SCI USA, V90, P10173, DOI 10.1073/pnas.90.21.10173; KOLODNER R, 1977, P NATL ACAD SCI USA, V74, P1525, DOI 10.1073/pnas.74.4.1525; Kusakabe T, 1999, P NATL ACAD SCI USA, V96, P4295, DOI 10.1073/pnas.96.8.4295; Kusakabe T, 1997, J BIOL CHEM, V272, P12446, DOI 10.1074/jbc.272.19.12446; LECHNER RL, 1983, J BIOL CHEM, V258, P1185; Lee J, 1998, MOL CELL, V1, P1001, DOI 10.1016/S1097-2765(00)80100-8; MARTIN CT, 1987, BIOCHEMISTRY-US, V26, P2690, DOI 10.1021/bi00384a006; MARTIN CT, 1988, BIOCHEMISTRY-US, V27, P3966, DOI 10.1021/bi00411a012; MATSON SW, 1985, J BIOL CHEM, V260, P2281; MATSON SW, 1983, J BIOL CHEM, V258, P4017; MATSON SW, 1983, J BIOL CHEM, V258, P4009; MENDELMAN LV, 1994, EMBO J, V13, P3909, DOI 10.1002/j.1460-2075.1994.tb06702.x; MENDELMAN LV, 1995, BIOCHEMISTRY-US, V34, P10187, DOI 10.1021/bi00032a012; MENDELMAN LV, 1992, P NATL ACAD SCI USA, V89, P10638, DOI 10.1073/pnas.89.22.10638; MENDELMAN LV, 1991, J BIOL CHEM, V266, P23240; MODRICH P, 1975, J BIOL CHEM, V250, P5515; MUSTAEV A, 1993, J BIOL CHEM, V268, P19185; MUSTAEV AA, 1995, J BIOL CHEM, V270, P15711, DOI 10.1074/jbc.270.26.15711; NAKAI H, 1986, J BIOL CHEM, V261, P5208; NOTARNICOLA SM, 1995, J BIOL CHEM, V270, P20215, DOI 10.1074/jbc.270.34.20215; Park K, 1998, J BIOL CHEM, V273, P5260, DOI 10.1074/jbc.273.9.5260; PATEL SS, 1993, J BIOL CHEM, V268, P10668; RICHARDSON CC, 1983, CELL, V33, P315, DOI 10.1016/0092-8674(83)90411-7; ROMANO LJ, 1979, J BIOL CHEM, V254, P476; ROMANO LJ, 1979, J BIOL CHEM, V254, P483; SCHERZINGER E, 1977, NUCLEIC ACIDS RES, V4, P4151, DOI 10.1093/nar/4.12.4151; SHEAFF RJ, 1993, BIOCHEMISTRY-US, V32, P3027, DOI 10.1021/bi00063a014; SOUSA R, 1992, J MOL BIOL, V224, P319, DOI 10.1016/0022-2836(92)90997-X; Swart JR, 1995, BIOCHEMISTRY-US, V34, P16097, DOI 10.1021/bi00049a025; TABOR S, 1981, P NATL ACAD SCI-BIOL, V78, P205, DOI 10.1073/pnas.78.1.205; TABOR S, 1987, J BIOL CHEM, V262, P16212; Washington MT, 1998, J BIOL CHEM, V273, P7880, DOI 10.1074/jbc.273.14.7880	47	33	33	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 10	1999	274	50					35899	35907		10.1074/jbc.274.50.35899	http://dx.doi.org/10.1074/jbc.274.50.35899			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	264NG	10585475	hybrid, Green Published			2022-12-25	WOS:000084187900087
J	Kim, SO; Houtman, JCD; Jiang, J; Ruppert, JI; Bertics, PJ; Frank, SJ				Kim, SO; Houtman, JCD; Jiang, J; Ruppert, JI; Bertics, PJ; Frank, SJ			Growth hormone-induced alteration in ErbB-2 phosphorylation status in 3T3-F442A fibroblasts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; JAK2 TYROSINE KINASE; NEU DIFFERENTIATION FACTOR; FACTOR-RECEPTOR; EXTRACELLULAR DOMAIN; TRANSCRIPTION FACTOR; SIGNAL-TRANSDUCTION; PHOSPHATASE SHP-2; INTERFERON-GAMMA; GH RECEPTOR	The growth hormone receptor (GHR), a cytokine receptor superfamily member, requires the JAK2 tyrosine kinase for signaling. We now examine functional interactions between growth hormone (GH) and epidermal growth factor (EGF) in 3T3-F442A fibroblasts. Although EGF enhanced ErbB-2 tyrosine phosphorylation, GH, while causing retardation of its migration on SDS-polyacrylamide gel electrophoresis, decreased ErbE-2's tyrosine phosphorylation, GH-induced retardation was reversed by treatment of anti-ErbB-2 precipitates with both alkaline phosphatase and protein phosphatase 2A suggesting that GH induced serine/threonine phosphorylation of ErbB-2. Both GH-induced shift in ErbB-2 migration and GH-induced MAP kinase activation were unaffected by a protein kinase C inhibitor but were blocked by the mitogen-activated protein kinase/extracellular signal-regulated kinase kinase 1 (MEK1) inhibitor, PD98059. Notably, leukemia inhibitory factor, but not interferon-gamma, also promoted ErbB-2 shift and mitogen-activated protein kinase activation. Cotreatment with EGF and GH versus EGF alone resulted in a 35% decline in acute ErbB-2 tyrosine 1248 autophosphorylation, a marked decline (approximately 50%) in DNA synthesis, and substantially decreased cyclin D1 expression. We conclude that in 3T3-F442A cells, 1) the GH-induced decrease in ErbB-2 tyrosine phosphorylation correlates with MEK1/mitogen-activated protein kinase activity and 2) GH antagonizes EGF induced DNA synthesis and cyclin D1 expression in a pattern consistent with its alteration in ErbB-2 phosphorylation status.	Univ Alabama Birmingham, Dept Med, Div Endocrinol & Metab, Birmingham, AL 35294 USA; Univ Alabama Birmingham, Dept Med, Div Hematol Oncol, Birmingham, AL 35294 USA; Univ Alabama Birmingham, Dept Cell Biol, Birmingham, AL 35294 USA; Vet Adm Med Ctr, Birmingham, AL 35294 USA; Univ Wisconsin, Sch Med, Dept Biomol Chem, Madison, WI 53706 USA	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; US Department of Veterans Affairs; Veterans Health Administration (VHA); University of Wisconsin System; University of Wisconsin Madison	Frank, SJ (corresponding author), Univ Alabama Birmingham, Dept Med, Div Endocrinol & Metab, Rm 756,DREB,UAB Stn, Birmingham, AL 35294 USA.	frank@endo.dom.uab.edu		Houtman, Jon/0000-0002-5307-9854	NATIONAL CANCER INSTITUTE [R01CA065686, R29CA065686] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK046395, R56DK046395, R01DK046395] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM053271] Funding Source: NIH RePORTER; NCI NIH HHS [CA65686] Funding Source: Medline; NIDDK NIH HHS [DK46395] Funding Source: Medline; NIGMS NIH HHS [GM53271] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AKIYAMA T, 1991, MOL CELL BIOL, V11, P833, DOI 10.1128/MCB.11.2.833; Alaoui-Jamali MA, 1997, BIOCHEM CELL BIOL, V75, P315, DOI 10.1139/bcb-75-4-315; ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; ANDERSON NG, 1992, BIOCHEM J, V284, P649, DOI 10.1042/bj2840649; ARGETSINGER LS, 1995, J BIOL CHEM, V270, P14685, DOI 10.1074/jbc.270.24.14685; ARGETSINGER LS, 1993, CELL, V74, P237, DOI 10.1016/0092-8674(93)90415-M; Argetsinger LS, 1996, J BIOL CHEM, V271, P29415, DOI 10.1074/jbc.271.46.29415; BAZAN JF, 1990, P NATL ACAD SCI USA, V87, P6934, DOI 10.1073/pnas.87.18.6934; BEERLI RR, 1995, MOL CELL BIOL, V15, P6496; BERGER MS, 1988, CANCER RES, V48, P1238; Bole-Feysot C, 1998, ENDOCR REV, V19, P225, DOI 10.1210/edrv.19.3.0334; CAMPBELL GS, 1992, J BIOL CHEM, V267, P6074; CAMPBELL GS, 1995, J BIOL CHEM, V270, P3974, DOI 10.1074/jbc.270.8.3974; CARRAWAY KL, 1994, CELL, V78, P5, DOI 10.1016/0092-8674(94)90564-9; CarterSu C, 1996, ANNU REV PHYSIOL, V58, P187, DOI 10.1146/annurev.ph.58.030196.001155; CUNNINGHAM BC, 1991, SCIENCE, V254, P821, DOI 10.1126/science.1948064; DEVOS AM, 1992, SCIENCE, V255, P306, DOI 10.1126/science.1549776; EPSTEIN RJ, 1992, P NATL ACAD SCI USA, V89, P10435, DOI 10.1073/pnas.89.21.10435; EPSTEIN RJ, 1990, J BIOL CHEM, V265, P10746; Fenton SE, 1997, EXP CELL RES, V236, P285, DOI 10.1006/excr.1997.3727; Frank SJ, 1999, ADV MOL CELL ENDOCR, V3, P1; FRANK SJ, 1994, ENDOCRINOLOGY, V135, P2228, DOI 10.1210/en.135.5.2228; FRANK SJ, 1995, J BIOL CHEM, V270, P14776, DOI 10.1074/jbc.270.24.14776; Fujioka Y, 1996, MOL CELL BIOL, V16, P6887; GrausPorta D, 1997, EMBO J, V16, P1647, DOI 10.1093/emboj/16.7.1647; GRAUSPORTA D, 1995, MOL CELL BIOL, V15, P1182; GREEN H, 1976, CELL, V7, P105, DOI 10.1016/0092-8674(76)90260-9; GURLAND G, 1990, ENDOCRINOLOGY, V127, P3187, DOI 10.1210/endo-127-6-3187; HAZAN R, 1990, CELL GROWTH DIFFER, V1, P3; Hodge C, 1998, J BIOL CHEM, V273, P31327, DOI 10.1074/jbc.273.47.31327; ISAKSSON OGP, 1985, ANNU REV PHYSIOL, V47, P483, DOI 10.1146/annurev.ph.47.030185.002411; Jiang J, 1998, BIOCHEM BIOPH RES CO, V253, P774, DOI 10.1006/bbrc.1998.9793; Karunagaran D, 1996, EMBO J, V15, P254, DOI 10.1002/j.1460-2075.1996.tb00356.x; Kharitonenkov A, 1997, NATURE, V386, P181, DOI 10.1038/386181a0; Kim SO, 1998, J BIOL CHEM, V273, P2344, DOI 10.1074/jbc.273.4.2344; LEUNG DW, 1987, NATURE, V330, P537, DOI 10.1038/330537a0; Love DW, 1998, ENDOCRINOLOGY, V139, P1965, DOI 10.1210/en.139.4.1965; MEYER DJ, 1994, J BIOL CHEM, V269, P4701; MOLLER C, 1992, J BIOL CHEM, V267, P23403; Morrison P, 1996, J BIOL CHEM, V271, P12891, DOI 10.1074/jbc.271.22.12891; Qiu Y, 1998, NATURE, V393, P83, DOI 10.1038/30012; Quijano VJ, 1998, J BIOL CHEM, V273, P1200, DOI 10.1074/jbc.273.2.1200; SEGATTO O, 1992, ONCOGENE, V7, P1339; SILVENNOINEN O, 1993, P NATL ACAD SCI USA, V90, P8429, DOI 10.1073/pnas.90.18.8429; Smit LS, 1996, MOL ENDOCRINOL, V10, P519, DOI 10.1210/me.10.5.519; SOTIROPOULOS A, 1994, ENDOCRINOLOGY, V135, P1292, DOI 10.1210/en.135.4.1292; STERN DF, 1988, MOL CELL BIOL, V8, P3969, DOI 10.1128/MCB.8.9.3969; Stofega MR, 1998, J BIOL CHEM, V273, P7112, DOI 10.1074/jbc.273.12.7112; TANNER JW, 1995, J BIOL CHEM, V270, P6523, DOI 10.1074/jbc.270.12.6523; TOULLEC D, 1991, J BIOL CHEM, V266, P15771; Vanderkuur JA, 1997, ENDOCRINOLOGY, V138, P4301, DOI 10.1210/en.138.10.4301; VANDERKUUR JA, 1994, J BIOL CHEM, V269, P21709; Wiepz GJ, 1997, J CELL PHYSIOL, V173, P44, DOI 10.1002/(SICI)1097-4652(199710)173:1<44::AID-JCP6>3.0.CO;2-J; Winston LA, 1995, J BIOL CHEM, V270, P30837, DOI 10.1074/jbc.270.52.30837; WINSTON LA, 1992, J BIOL CHEM, V267, P4747; Yamauchi T, 1997, NATURE, V390, P91, DOI 10.1038/36369; Yamauchi T, 1998, ENDOCR J, V45, pS27, DOI 10.1507/endocrj.45.Suppl_S27; ZHAO YM, 1995, J BIOL CHEM, V270, P13814, DOI 10.1074/jbc.270.23.13814	58	46	47	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 10	1999	274	50					36015	36024		10.1074/jbc.274.50.36015	http://dx.doi.org/10.1074/jbc.274.50.36015			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	264NG	10585492	hybrid			2022-12-25	WOS:000084187900104
J	Malek, RL; Nie, ZZ; Ramkumar, V; Lee, NH				Malek, RL; Nie, ZZ; Ramkumar, V; Lee, NH			Adenosine A(2A) receptor mRNA regulation by nerve growth factor is TrkA-, Src-, and Ras-dependent via extracellular regulated kinase and stress-activated protein kinase/c-Jun NH2-terminal kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA EXPRESSION; NIH 3T3 CELLS; PC12 CELLS; MAP KINASE; DOWN-REGULATION; NEURONAL DIFFERENTIATION; TYROSINE PHOSPHORYLATION; NEUROTROPHIN RECEPTOR; SIGNALING PATHWAYS; GENE-EXPRESSION	We have shown previously that nerve growth factor (NGF) down-regulates adenosine A(2A) receptor (A(2A)AR) mRNA in PC12 cells, To define cellular mechanisms that modulate A(2A)AR expression, A(2A)AR mRNA and protein levels were examined in three PC12 sublines: i) PC12nnr5 cells, which lack the high affinity NGF receptor TrkA, ii) srcDN2 cells, which overexpress kinase-defective Src, and iii) 17.26 cells, which overexpress a dominant-inhibitory Ras, In the absence of functional TrkA, Src, or Ras, NGF-induced down-regulation of A(2A)AR mRNA and protein was significantly impaired. However, regulation of A(2A)AR expression was reconstituted in PC12nnr5 cells stably transfected with TrkA. Whereas NGF stimulated the mitogen-activated protein kinases p38, extracellular regulated kinase 1 and 2 (ERK1/ERK2), and stress-activated protein kinase/c-Jun NH2-terminal kinase (SAPK/JNK) in PC12 cells, these kinases were activated only partially or not at all in srcDN2 and 17.26 cells. Inhibiting ERK1/ERK2 with PD98059 or inhibiting SAPK/JNK by transfecting cells with a dominant-negative SAPK beta/JNK3 mutant partially blocked NGF-induced down-regulation of A(2A)AR expression in PC12 cells, In contrast, inhibiting p38 with SB203580 had no effect on the regulation of A(2A)AR mRNA and protein levels. Treating SAPK beta/JNK3 mutant-transfected PC12 cells with PD98059 completely abolished the NGF-induced decrease in A(2A)AR mRNA and protein levels, These results reveal a role for ERK1/ERK2 and SAPK/JNK in regulating A(2A)AR expression.	Inst Genom Res, Dept Mol & Cellular Biol, Rockville, MD 20850 USA; So Illinois Univ, Sch Med, Dept Pharmacol, Springfield, IL 62794 USA	J. Craig Venter Institute; Southern Illinois University System; Southern Illinois University	Lee, NH (corresponding author), Inst Genom Res, Dept Mol & Cellular Biol, 9712 Med Ctr Dr, Rockville, MD 20850 USA.	nhlee@tigr.org			NHLBI NIH HHS [HL56316] Funding Source: Medline; NINDS NIH HHS [NS352321] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL056316] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Arslan G, 1997, NEUROPHARMACOLOGY, V36, P1319, DOI 10.1016/S0028-3908(97)00090-7; Carter BD, 1996, SCIENCE, V272, P542, DOI 10.1126/science.272.5261.542; COLLIS MG, 1993, TRENDS PHARMACOL SCI, V14, P360; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; CUENDA A, 1995, FEBS LETT, V364, P229, DOI 10.1016/0014-5793(95)00357-F; DARCANGELO G, 1993, MOL CELL BIOL, V13, P3146, DOI 10.1128/MCB.13.6.3146; DAVAL JL, 1991, LIFE SCI, V49, P1435, DOI 10.1016/0024-3205(91)90043-B; Dean JLE, 1999, J BIOL CHEM, V274, P264, DOI 10.1074/jbc.274.1.264; DENT P, 1992, SCIENCE, V257, P1404, DOI 10.1126/science.1326789; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; DOBROWSKY RT, 1994, SCIENCE, V265, P1596, DOI 10.1126/science.8079174; FREDHOLM BB, 1994, PHARMACOL REV, V46, P143; Goodman MN, 1998, J NEUROBIOL, V36, P537, DOI 10.1002/(SICI)1097-4695(19980915)36:4<537::AID-NEU7>3.0.CO;2-X; GREEN SH, 1986, J CELL BIOL, V102, P830, DOI 10.1083/jcb.102.3.830; HALEGOUA S, 1991, CURR TOP MICROBIOL, V165, P119; Johansson B, 1997, NEUROSCIENCE, V80, P1187, DOI 10.1016/S0306-4522(97)00143-7; Kita Y, 1998, J CELL SCI, V111, P907; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; LANGECARTER CA, 1993, SCIENCE, V260, P315, DOI 10.1126/science.8385802; Lazarovici P, 1997, J BIOL CHEM, V272, P11026, DOI 10.1074/jbc.272.17.11026; Lee NH, 1998, J BIOL CHEM, V273, P22317, DOI 10.1074/jbc.273.35.22317; LEE NH, 1995, P NATL ACAD SCI USA, V92, P8303, DOI 10.1073/pnas.92.18.8303; LEE NH, 1994, J BIOL CHEM, V269, P4291; LIN AN, 1995, SCIENCE, V268, P286, DOI 10.1126/science.7716521; Liu HL, 1997, J BIOL CHEM, V272, P6038, DOI 10.1074/jbc.272.9.6038; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; Morooka T, 1998, J BIOL CHEM, V273, P24285, DOI 10.1074/jbc.273.38.24285; Nie ZZ, 1997, MOL PHARMACOL, V52, P456, DOI 10.1124/mol.52.3.456; OSHIMA M, 1991, J BIOL CHEM, V266, P23753; PANG L, 1995, J BIOL CHEM, V270, P13585, DOI 10.1074/jbc.270.23.13585; QIU MS, 1991, NEURON, V7, P937, DOI 10.1016/0896-6273(91)90339-2; Ridley SH, 1998, FEBS LETT, V439, P75, DOI 10.1016/S0014-5793(98)01342-8; Rossner S, 1998, J NEUROCHEM, V71, P757; Rusanescu G, 1995, NEURON, V15, P1415, DOI 10.1016/0896-6273(95)90019-5; Sadot E, 1998, J NEUROCHEM, V70, P428; SAITOH O, 1994, NEUROREPORT, V5, P1317, DOI 10.1097/00001756-199406000-00005; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; Segal RA, 1996, ANNU REV NEUROSCI, V19, P463, DOI 10.1146/annurev.ne.19.030196.002335; Shibutani M, 1998, J BIOL CHEM, V273, P6878, DOI 10.1074/jbc.273.12.6878; Smith MA, 1997, J BIOL CHEM, V272, P15675, DOI 10.1074/jbc.272.25.15675; Swantek JL, 1997, MOL CELL BIOL, V17, P6274, DOI 10.1128/MCB.17.11.6274; SZEBERENYI J, 1990, MOL CELL BIOL, V10, P5324, DOI 10.1128/MCB.10.10.5324; THOMAS SM, 1991, MOL CELL BIOL, V11, P4739, DOI 10.1128/MCB.11.9.4739; THOMAS SM, 1992, CELL, V68, P1031, DOI 10.1016/0092-8674(92)90075-N; WEAVER DR, 1993, MOL BRAIN RES, V20, P313, DOI 10.1016/0169-328X(93)90058-W; WOOD KW, 1992, CELL, V68, P1041, DOI 10.1016/0092-8674(92)90076-O; YAN MH, 1994, NATURE, V372, P798	47	25	25	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 10	1999	274	50					35499	35504		10.1074/jbc.274.50.35499	http://dx.doi.org/10.1074/jbc.274.50.35499			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	264NG	10585422	hybrid			2022-12-25	WOS:000084187900034
J	Ram, PA; Waxman, DJ				Ram, PA; Waxman, DJ			SOCS/CIS protein inhibition of growth hormone-stimulated STAT5 signaling by multiple mechanisms	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE PHOSPHORYLATION; GH RECEPTOR; RAT-LIVER; ACTIVATION; GENE; CIS; KINASE; JAK2; INTERLEUKIN-3; REQUIREMENT	The inhibition of growth hormone (GH) signaling by five members of the GH-inducible suppressor of cytokine signaling (SOCS/CIS) family was investigated in transfected COS cells. Complete inhibition of GH activation of the signal transducer STAT5b and STAT5b-dependent transcriptional activity was observed upon expression of SOCS-1 or SOCS-3, while partial inhibition (CIS, SOCS-2) or no inhibition (SOCS-6) was seen with other SOCS/CIS family members. SOCS-1, SOCS-2, SOCS-3, and CIS each strongly inhibited the GH receptor (GHR)-dependent tyrosine phosphorylation of JAK2 seen at low levels of transfected JAK2; however, only SOCS-1 strongly inhibited the GHR-independent tyrosine phosphorylation of JAK2 seen at higher JAK2 levels. To probe for interactions with GHR, in vitro binding assays were carried out using glutathione S-transferase-GHR fusion proteins containing variable lengths of GHR's COOH-terminal cytoplasmic domain. CIS and SOCS-2 bound to fusions containing as few as 80 COOH-terminal GHR residues, provided the fusion protein was tyrosine-phosphorylated. By contrast, SOCS-3 binding required tyrosine-phosphorylated GHR membrane-proximal sequences, SOCS-1 binding was tyrosine phosphorylation-independent, and SOCS-6 did not bind the GHR fusion proteins at all. Mutation of GHR's membrane-proximal tyrosine residues 333 and 338 to phenylalanine suppressed the inhibition by SOCS-3, but not by CIS, of GH signaling to STAT5b. SOCS/CIS proteins can thus inhibit GH signaling to STAT5b by three distinct mechanisms, distinguished by their molecular targets within the GHR-JAK2 signaling complex, as exemplified by SOCS-1 (direct JAK2 kinase inhibition), SOCS-3 (inhibition of JAK2 signaling via membrane-proximal GHR tyrosines 333 and 338), and CIS and SOCS-2 (inhibition via membrane-distal tyrosine(s)).	Boston Univ, Dept Biol, Div Cell & Mol Biol, Boston, MA 02215 USA	Boston University	Waxman, DJ (corresponding author), Boston Univ, Dept Biol, Div Cell & Mol Biol, 5 Cummington St, Boston, MA 02215 USA.			Waxman, David/0000-0001-7982-9206	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK033765, R56DK033765] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01 DK033765, DK33765] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ARGETSINGER LS, 1993, CELL, V74, P237, DOI 10.1016/0092-8674(93)90415-M; Argetsinger LS, 1996, PHYSIOL REV, V76, P1089, DOI 10.1152/physrev.1996.76.4.1089; BILLESTRUP N, 1990, P NATL ACAD SCI USA, V87, P7210, DOI 10.1073/pnas.87.18.7210; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CUNNINGHAM BC, 1991, SCIENCE, V254, P821, DOI 10.1126/science.1948064; Ganguly TC, 1997, J CLIN INVEST, V99, P2906, DOI 10.1172/JCI119485; Gebert CA, 1997, MOL ENDOCRINOL, V11, P400, DOI 10.1210/me.11.4.400; Hackett RH, 1997, J BIOL CHEM, V272, P11128; Hansen JA, 1997, J MOL ENDOCRINOL, V18, P213, DOI 10.1677/jme.0.0180213; Hilton DJ, 1998, P NATL ACAD SCI USA, V95, P114, DOI 10.1073/pnas.95.1.114; LOBIE PE, 1995, J BIOL CHEM, V270, P21745, DOI 10.1074/jbc.270.37.21745; Matsumoto A, 1997, BLOOD, V89, P3148, DOI 10.1182/blood.V89.9.3148; Moutoussamy S, 1998, EUR J BIOCHEM, V255, P1, DOI 10.1046/j.1432-1327.1998.2550001.x; MUI ALF, 1995, EMBO J, V14, P1166, DOI 10.1002/j.1460-2075.1995.tb07100.x; Naka T, 1997, NATURE, V387, P924, DOI 10.1038/43219; Narazaki M, 1998, P NATL ACAD SCI USA, V95, P13130, DOI 10.1073/pnas.95.22.13130; Ram PA, 1996, J BIOL CHEM, V271, P5929, DOI 10.1074/jbc.271.10.5929; Ram PA, 1997, J BIOL CHEM, V272, P17694, DOI 10.1074/jbc.272.28.17694; REEDIJK M, 1992, EMBO J, V11, P1365, DOI 10.1002/j.1460-2075.1992.tb05181.x; SHAPIRO BH, 1995, INT J BIOCHEM CELL B, V27, P9, DOI 10.1016/1357-2725(94)00056-5; Smit LS, 1997, ENDOCRINOLOGY, V138, P3426, DOI 10.1210/en.138.8.3426; Starr R, 1997, NATURE, V387, P917, DOI 10.1038/43206; TANNENBAUM GS, 1976, ENDOCRINOLOGY, V98, P562, DOI 10.1210/endo-98-3-562; Udy GB, 1997, P NATL ACAD SCI USA, V94, P7239, DOI 10.1073/pnas.94.14.7239; VANDERKUUR JA, 1995, J BIOL CHEM, V270, P21738, DOI 10.1074/jbc.270.37.21738; Verdier F, 1998, J BIOL CHEM, V273, P28185, DOI 10.1074/jbc.273.43.28185; Verdier F, 1998, MOL CELL BIOL, V18, P5852, DOI 10.1128/MCB.18.10.5852; Yin TG, 1997, J BIOL CHEM, V272, P1032, DOI 10.1074/jbc.272.2.1032; YOSHIMURA A, 1995, EMBO J, V14, P2816, DOI 10.1002/j.1460-2075.1995.tb07281.x	29	279	295	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 10	1999	274	50					35553	35561		10.1074/jbc.274.50.35553	http://dx.doi.org/10.1074/jbc.274.50.35553			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	264NG	10585430	hybrid			2022-12-25	WOS:000084187900042
J	Wragg, S; Drickamer, K				Wragg, S; Drickamer, K			Identification of amino acid residues that determine pH dependence of ligand binding to the asialoglycoprotein receptor during endocytosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARBOHYDRATE-RECOGNITION DOMAIN; CA2+-DEPENDENT ANIMAL LECTINS; SITE-DIRECTED MUTAGENESIS; MANNOSE-BINDING; SUGAR LIGANDS; PROTEIN; RAT	The rat hepatic asialoglycoprotein receptor mediates clearance of galactose- and N-acetylgalactosamine-terminated glycoproteins by endocytosis, binding ligands through a C-type, Ca2+ dependent carbohydrate-recognition domain (CRD) at extracellular pH and releasing them at lower PEI in endosomes. At physiological Ca2+ concentrations, the midpoint for ligand release from the CRD of the major subunit of the receptor is pH 7.1. In contrast, the midpoint is pH 5.0 for a galactose-binding derivative of the homologous C-type CRD of serum mannose-binding protein, which would thus not efficiently release ligand at an endosomal pH of 5.4. Site-directed mutagenesis of the CRD from the major subunit of the asialoglycoprotein receptor has been used to identify residues that are essential for efficient release of ligand at endosomal pH, The effects of changes to residues His(256), Asp(266) and Arg(270) singly and in combination indicate that these residues reduce the affinity of the CRD for Ca2+, so that ligands are released at physioloscal Ca2+ concentrations. The proximity of these three residues to the ligand-binding site at Ca2+ site 2 of the domain suggests that they form a pH-sensitive switch for Ca2+ and ligand binding. Introduction of histidine and aspartic acid residues into the mannose-binding protein CRD at positions equivalent to His(256) and Asp(266) raises the pH for half-maximal binding of ligand to 6.1. The results, as well as sequence comparisons with other C-type CRDs, confirm the importance of these residues in conferring appropriate pH dependence in this family of domains.	Univ Oxford, Dept Biochem, Glycobiol Inst, Oxford OX1 3QU, England	University of Oxford								BRAITERMAN LT, 1989, J BIOL CHEM, V264, P1682; DOMER K, 1998, BIOCHEMISTRY-US, V37, P17016; EISENBERG SP, 1990, NATURE, V343, P341, DOI 10.1038/343341a0; FORNSTEDT N, 1975, FEBS LETT, V57, P187, DOI 10.1016/0014-5793(75)80713-7; Gerasimenko JV, 1998, CURR BIOL, V8, P1335, DOI 10.1016/S0960-9822(07)00565-9; GREENWOOD FC, 1963, BIOCHEM J, V89, P114, DOI 10.1042/bj0890114; HALBERG DF, 1987, J BIOL CHEM, V262, P9828; HUDGIN RL, 1974, J BIOL CHEM, V249, P5536; IOBST ST, 1994, J BIOL CHEM, V269, P15512; Iobst ST, 1996, J BIOL CHEM, V271, P6686, DOI 10.1074/jbc.271.12.6686; IOBST ST, 1994, J BIOL CHEM, V269, P15505; Kolatkar AR, 1996, J BIOL CHEM, V271, P6679, DOI 10.1074/jbc.271.12.6679; Kolatkar AR, 1998, J BIOL CHEM, V273, P19502, DOI 10.1074/jbc.273.31.19502; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LI M, 1990, J BIOL CHEM, V265, P11295; LOEB JA, 1988, J BIOL CHEM, V263, P9752; MELLMAN I, 1986, ANNU REV BIOCHEM, V55, P663, DOI 10.1146/annurev.biochem.55.1.663; Miroux B, 1996, J MOL BIOL, V260, P289, DOI 10.1006/jmbi.1996.0399; MULLIN NP, 1994, J BIOL CHEM, V269, P28405; Ng KKS, 1998, BIOCHEMISTRY-US, V37, P17977, DOI 10.1021/bi9819733; Roberts DL, 1998, CELL, V93, P639, DOI 10.1016/S0092-8674(00)81192-7; SPIESS M, 1990, BIOCHEMISTRY-US, V29, P10008; WEIS WI, 1991, J BIOL CHEM, V266, P20678; WEIS WI, 1992, NATURE, V360, P127, DOI 10.1038/360127a0	24	38	43	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 10	1999	274	50					35400	35406		10.1074/jbc.274.50.35400	http://dx.doi.org/10.1074/jbc.274.50.35400			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	264NG	10585409	hybrid			2022-12-25	WOS:000084187900021
J	Chiang, CW; Carter, N; Sullivan, WJ; Donald, RGK; Roos, DS; Naguib, FNM; el Kouni, MH; Ullman, B; Wilson, CM				Chiang, CW; Carter, N; Sullivan, WJ; Donald, RGK; Roos, DS; Naguib, FNM; el Kouni, MH; Ullman, B; Wilson, CM			The adenosine transporter of Toxoplasma gondii - Identification by insertional mutagenesis, cloning, and recombinant expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GIARDIA-INTESTINALIS TROPHOZOITES; NA+-NUCLEOSIDE COTRANSPORTER; GLUT1 GLUCOSE TRANSPORTER; FUNCTIONAL EXPRESSION; LEISHMANIA-DONOVANI; PARASITOPHOROUS VACUOLE; PROTOZOAN PARASITE; PLASMA-MEMBRANE; RESISTANT; MARKER	Purine transport into the protozoan parasite Toxoplasma gondii plays an indispensable nutritional function for this pathogen, To facilitate genetic and biochemical characterization of the adenosine transporter of the parasite, T, gondii tachyzoites were transfected with an insertional mutagenesis vector, and clonal mutants were selected for resistance to the cytotoxic adenosine analog adenine arabinoside (Ara-A), Whereas some Ara-A-resistant clones exhibited disruption of the adenosine kinase (AK) locus, others displayed normal AK activity, suggesting that a second locus had been tagged by the insertional mutagenesis plasmid, These Ara-A(r) AK+ mutants displayed reduced adenosine uptake capability, implying a defect in adenosine transport, Sequences flanking the transgene integration point in one mutant were rescued from a genomic library of Ara-A(r) AK+ DNA, and Southern blot analysis revealed that all Ara-A(r) AK+ mutants were disrupted at the same locus. Probes derived from this locus, designated TgAT, were employed to isolate genomic and cDNA clones from wild-type libraries. Conceptual translation of the TgAT cDNA open reading frame predicts a 462 amino acid protein containing II transmembrane domains, a primary structure and membrane topology similar to members of the mammalian equilibrative nucleoside transporter family. Expression of TgAT cRNA in Xenopus laevis oocytes increased adenosine uptake capacity in a saturable manner, with an apparent K-m value of 114 mu M. Uptake was inhibited by various nucleosides, nucleoside analogs, hypoxanthine, guanine, and dipyridamole. The combination of genetic and biochemical studies demonstrates that TgAT is the sole functional adenosine transporter in T, gondii and a rational target for therapeutic intervention.	Univ Alabama Birmingham, Div Geog Med, Birmingham, AL 35294 USA; Univ Alabama Birmingham, Dept Biol, Birmingham, AL 35294 USA; Oregon Hlth & Sci Univ, Dept Biochem & Mol Biol, Portland, OR 97201 USA; Univ Penn, Dept Biol, Philadelphia, PA 19104 USA; Univ Alabama Birmingham, Dept Pharmacol & Toxicol, Birmingham, AL 35294 USA	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; Oregon Health & Science University; University of Pennsylvania; University of Alabama System; University of Alabama Birmingham	Wilson, CM (corresponding author), Univ Alabama Birmingham, Div Geog Med, 845 19th St S,BBRB 203, Birmingham, AL 35294 USA.	cwilson@uab.edu	Donald, Robert George Konrad/GNP-4958-2022	Roos, David Siker/0000-0001-6725-4089; Wilson, Craig/0000-0001-6869-1053	NIAID NIH HHS [P30-AI-27767, AI-29848, AI-31808] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI031808, U19AI031808, R01AI029848, P30AI027767] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ARONOW B, 1987, MOL BIOCHEM PARASIT, V22, P29, DOI 10.1016/0166-6851(87)90066-1; ASAI T, 1995, J BIOL CHEM, V270, P11391, DOI 10.1074/jbc.270.19.11391; BAUM KF, 1993, J EUKARYOT MICROBIOL, V40, P643, DOI 10.1111/j.1550-7408.1993.tb06122.x; Berens Randolph L., 1995, P89, DOI 10.1016/B978-012473345-9/50007-6; BERMUDES D, 1994, J BIOL CHEM, V269, P29252; BOOTHROYD JC, 1995, METHODS MOL GENET, V6, P1; CARTER NS, 1993, NATURE, V361, P173, DOI 10.1038/361173a0; CHE MX, 1995, J BIOL CHEM, V270, P13596, DOI 10.1074/jbc.270.23.13596; CRAIG JE, 1994, MOL MICROBIOL, V11, P1159, DOI 10.1111/j.1365-2958.1994.tb00392.x; DAVEY RA, 1992, BIOCHIM BIOPHYS ACTA, V1109, P172, DOI 10.1016/0005-2736(92)90080-6; DAVEY RA, 1991, MOL BIOCHEM PARASIT, V48, P163, DOI 10.1016/0166-6851(91)90112-J; Donald RGK, 1996, J BIOL CHEM, V271, P14010, DOI 10.1074/jbc.271.24.14010; DONALD RGK, 1995, P NATL ACAD SCI USA, V92, P5749, DOI 10.1073/pnas.92.12.5749; DONALD RGK, 1993, P NATL ACAD SCI USA, V90, P11703, DOI 10.1073/pnas.90.24.11703; ELKOUNI MH, 1999, IN PRESS ANTIMICROB, V43; FAIRLAMB AH, 1992, MOL BIOCHEM PARASIT, V53, P213, DOI 10.1016/0166-6851(92)90023-D; FENG DF, 1987, J MOL EVOL, V25, P351, DOI 10.1007/BF02603120; FINLEY RW, 1988, MOL BIOCHEM PARASIT, V31, P133, DOI 10.1016/0166-6851(88)90164-8; FISCHBARG J, 1995, AM J PHYSIOL-CELL PH, V268, pC1077, DOI 10.1152/ajpcell.1995.268.5.C1077; GARCIA JC, 1992, J BIOL CHEM, V267, P7770; Griffiths M, 1997, NAT MED, V3, P89, DOI 10.1038/nm0197-89; HANSEN SEW, 1987, EUR J BIOCHEM, V168, P385, DOI 10.1111/j.1432-1033.1987.tb13431.x; HARRIS DI, 1988, MOL BIOCHEM PARASIT, V29, P105, DOI 10.1016/0166-6851(88)90065-5; HOFMANN K, 1993, BIOL CHEM HOPPESEYLE, V374, P166, DOI DOI 10.1515/BCHM3.1993.374.1-6.143; HUANG QQ, 1994, J BIOL CHEM, V269, P17757; KATAGIRI H, 1993, BIOCHEM J, V291, P861, DOI 10.1042/bj2910861; KRIEG PA, 1984, NUCLEIC ACIDS RES, V12, P7057, DOI 10.1093/nar/12.18.7057; KRUG EC, 1989, J BIOL CHEM, V264, P10601; LUFT BJ, 1988, J INFECT DIS, V157, P1, DOI 10.1093/infdis/157.1.1; NEEDLEMAN SB, 1970, J MOL BIOL, V48, P443, DOI 10.1016/0022-2836(70)90057-4; OGBUNUDE POJ, 1991, EXP PARASITOL, V73, P369, DOI 10.1016/0014-4894(91)90109-A; PAJOR AM, 1992, J BIOL CHEM, V267, P3557; PFEFFERKORN ER, 1977, EXP PARASITOL, V42, P44, DOI 10.1016/0014-4894(77)90060-1; PFEFFERKORN ER, 1977, EXP PARASITOL, V41, P95, DOI 10.1016/0014-4894(77)90134-5; PFEFFERKORN ER, 1976, J PARASITOL, V62, P993, DOI 10.2307/3279197; PLAGEMANN PGW, 1988, BIOCHIM BIOPHYS ACTA, V947, P405, DOI 10.1016/0304-4157(88)90002-0; ROIZEN N, 1995, PEDIATRICS, V95, P11; ROOS DS, 1994, METHOD CELL BIOL, V45, P27; ROOS DS, 1993, J BIOL CHEM, V268, P6269; Roos DS, 1997, METHODS, V13, P112, DOI 10.1006/meth.1997.0504; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SCHWAB JC, 1995, MOL BIOCHEM PARASIT, V70, P59, DOI 10.1016/0166-6851(95)00005-L; SCHWAB JC, 1994, P NATL ACAD SCI USA, V91, P509, DOI 10.1073/pnas.91.2.509; SCHWARTZMAN JD, 1982, EXP PARASITOL, V53, P77, DOI 10.1016/0014-4894(82)90094-7; Seyfang A, 1997, J BIOL CHEM, V272, P24210, DOI 10.1074/jbc.272.39.24210; Sullivan WJ, 1999, MOL BIOCHEM PARASIT, V103, P1, DOI 10.1016/S0166-6851(99)00114-0; Sundaram M, 1998, J BIOL CHEM, V273, P21519, DOI 10.1074/jbc.273.34.21519; TAMORI Y, 1994, J BIOL CHEM, V269, P2982; Vasudevan G, 1998, P NATL ACAD SCI USA, V95, P9873, DOI 10.1073/pnas.95.17.9873; VONHEIJNE G, 1992, J MOL BIOL, V225, P487, DOI 10.1016/0022-2836(92)90934-C; Wang J, 1997, J BIOL CHEM, V272, P28845, DOI 10.1074/jbc.272.46.28845; Wang J, 1999, J BIOL CHEM, V274, P2298, DOI 10.1074/jbc.274.4.2298; Yao SYM, 1997, J BIOL CHEM, V272, P28423, DOI 10.1074/jbc.272.45.28423	53	57	64	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 3	1999	274	49					35255	35261		10.1074/jbc.274.49.35255	http://dx.doi.org/10.1074/jbc.274.49.35255			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	260XW	10575012	hybrid			2022-12-25	WOS:000083979600106
J	Chien, YT; Manna, AC; Projan, SJ; Cheung, AL				Chien, YT; Manna, AC; Projan, SJ; Cheung, AL			SarA, a global regulator of virulence determinants in Staphylococcus aureus, binds to a conserved motif essential for sar-dependent gene regulation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-A; LOCUS SAR; AGR; RNA; TRANSCRIPTION; EXPRESSION; TRANSDUCTION; PROMOTERS; SEQUENCE; SIGNAL	The expression of many virulence determinants in Staphylococcus aureus including alpha-hemolysin-, protein A-, and fibronectin-binding proteins is controlled by global regulatory loci such as sar and agr. In addition to controlling target gene expression via agr (e.g. alpha-hemolysin), the sar locus can also regulate target gene transcription via agr-independent mechanisms. In particular, we have found that SarA, the major regulatory protein encoded within sar, binds to a conserved sequence, homologous to the SarA-binding site on the agr promoter, upstream of the -35 promoter boxes of several target genes including hla (alpha-hemolysin gene), spa (protein A gene), fnb (fibronectin-binding protein genes), and sec (enterotoxin C gene). Deletion of the SarA recognition motif in the promoter regions of agr and hla in shuttle plasmids rendered the transcription of these genes undetectable in agr and hla mutants, respectively. Likewise, the transcription activity of spa (a gene normally repressed by sar), as measured by a XylE reporter fusion assay, became derepressed in a wild type strain containing a shuttle plasmid in which the SarA recognition site had been deleted from the spa promoter region. However, DNase I footprinting assays demonstrated that the SarA-binding region on the spa and hla promoter is more extensive than the predicted consensus sequence, thus raising the possibility that the consensus sequence is an activation site within a larger binding region. Because the sar and agr regulate an assortment of virulence factors in S. aureus, we propose, based on our data, a unifying hypothesis for virulence gene activation in S. aureus whereby SarA is a regulatory protein that binds to its consensus SarA recognition motif to activate (e.g. hla) or repress (e.g. spa) the transcription of sar target genes, thus accounting for both agr-dependent and agr-independent mode of regulation.	Rockefeller Univ, Lab Bacterial Pathogenesis & Immunol, New York, NY 10021 USA; Amer Cyanamid Co, Lederle Labs, Wyeth Ayerst Res, Pearl River, NY 10965 USA	Rockefeller University; Pfizer	Chien, YT (corresponding author), Dartmouth Coll, Sch Med, Dept Microbiol, Hanover, NH 03755 USA.				NIAID NIH HHS [AI37142, AI30061] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI037142, R29AI030061] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Bayer MG, 1996, J BACTERIOL, V178, P4563, DOI 10.1128/jb.178.15.4563-4570.1996; BOYCE JM, 1997, STAPHYLOCOCCI HUMAN, V12, P309; Chan PF, 1998, J BACTERIOL, V180, P6232; CHEUNG AL, 1994, J BACTERIOL, V176, P580, DOI 10.1128/jb.176.3.580-585.1994; CHEUNG AL, 1992, P NATL ACAD SCI USA, V89, P6462, DOI 10.1073/pnas.89.14.6462; Cheung AL, 1997, J BACTERIOL, V179, P3963, DOI 10.1128/jb.179.12.3963-3971.1997; Cheung AL, 1997, INFECT IMMUN, V65, P2243, DOI 10.1128/IAI.65.6.2243-2249.1997; CHEUNG AL, 1994, J CLIN INVEST, V94, P1815, DOI 10.1172/JCI117530; CHEUNG AL, 1994, ANAL BIOCHEM, V222, P511, DOI 10.1006/abio.1994.1528; CHEUNG AL, 1997, 37 ANN M ICAAC TOR S; Chien YT, 1998, MOL MICROBIOL, V30, P991, DOI 10.1046/j.1365-2958.1998.01126.x; Chien YT, 1998, J BIOL CHEM, V273, P2645, DOI 10.1074/jbc.273.5.2645; Deora R, 1997, J BACTERIOL, V179, P6355, DOI 10.1128/jb.179.20.6355-6359.1997; GASKILL ME, 1988, J BIOL CHEM, V263, P6276; GRAY GS, 1984, INFECT IMMUN, V46, P615, DOI 10.1128/IAI.46.2.615-618.1984; Ji GY, 1995, P NATL ACAD SCI USA, V92, P12055, DOI 10.1073/pnas.92.26.12055; Ji GY, 1997, SCIENCE, V276, P2027, DOI 10.1126/science.276.5321.2027; Kornblum J., 1990, MOL BIOL STAPHYLOCOC, P373; Manna AC, 1998, J BACTERIOL, V180, P3828, DOI 10.1128/JB.180.15.3828-3836.1998; MORFELDT E, 1995, EMBO J, V14, P4569, DOI 10.1002/j.1460-2075.1995.tb00136.x; NOVICK RP, 1995, MOL GEN GENET, V248, P446, DOI 10.1007/BF02191645; NOVICK RP, 1993, EMBO J, V12, P3967, DOI 10.1002/j.1460-2075.1993.tb06074.x; NOVICK RP, 1991, METHOD ENZYMOL, V204, P587; PATEL AH, 1992, GENE, V114, P25, DOI 10.1016/0378-1119(92)90703-R; PATEL AH, 1987, INFECT IMMUN, V55, P3103, DOI 10.1128/IAI.55.12.3103-3110.1987; PROJAN SJ, 1997, MOL BASIS PATHOGENIC, V3, P55; ROSS W, 1993, SCIENCE, V262, P1407, DOI 10.1126/science.8248780; Sambrook J., 1989, MOL CLONING LAB MANU, V2nd, ed.; SCHENK S, 1992, FEMS MICROBIOL LETT, V94, P133; SHUTTLEWORTH HL, 1987, GENE, V58, P283, DOI 10.1016/0378-1119(87)90383-0; VANDENESCH F, 1991, J BACTERIOL, V173, P6313, DOI 10.1128/jb.173.20.6313-6320.1991; Wolz C, 1996, INFECT IMMUN, V64, P3142, DOI 10.1128/IAI.64.8.3142-3147.1996; ZUKOWSKI MM, 1983, P NATL ACAD SCI-BIOL, V80, P1101, DOI 10.1073/pnas.80.4.1101	33	183	192	4	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 24	1999	274	52					37169	37176		10.1074/jbc.274.52.37169	http://dx.doi.org/10.1074/jbc.274.52.37169			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	267WR	10601279	hybrid			2022-12-25	WOS:000084382700050
J	Goodman, SD; Kay, O				Goodman, SD; Kay, O			Replacement of integration host factor protein-induced DNA bending by flexible regions of DNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-SPECIFIC RECOMBINATION; ESCHERICHIA-COLI; BACTERIOPHAGE-LAMBDA; IHF PROTEIN; HU PROTEIN; BINDING; FLEXIBILITY; SEQUENCES; COMPLEX; INCREASE	The Escherichia coli integration host factor (IHF) protein is required for site-specific recombination of bacteriophage A DNA. Previously, we had shown that alternative modules of static DNA curvature could partially replace IHF in recombination. Now we use regions of single-stranded DNA as a flexible tether to address whether the function of IHF in recombination is simply to reduce persistence length. Although we find that these modules clearly enhance recombination in the absence of IHF, they are not perfect replacements. In addition, evidence is presented that the efficacy of a flexibility swap is specific to a particular IHF site. This may indicate that additional functions beyond simple deformation of DNA are required of IHF. During the course of these experiments we discovered that these flexible sequences are still specific sites for IHF binding and function.	Univ So Calif, Sch Dent, Dept Basic Sci, Los Angeles, CA 90089 USA	University of Southern California	Goodman, SD (corresponding author), Univ So Calif, Sch Dent, Dept Basic Sci, 925 W 34th St, Los Angeles, CA 90089 USA.		Goodman, Steven/C-5732-2013		NIGMS NIH HHS [GM55392] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM055392] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BHATTACHARYYA A, 1989, NUCLEIC ACIDS RES, V17, P6821, DOI 10.1093/nar/17.17.6821; BRACCO L, 1989, EMBO J, V8, P4289, DOI 10.1002/j.1460-2075.1989.tb08615.x; CANN JR, 1989, J BIOL CHEM, V264, P17032; CASTAING B, 1995, J BIOL CHEM, V270, P10291, DOI 10.1074/jbc.270.17.10291; Chalmers R, 1998, CELL, V93, P897, DOI 10.1016/S0092-8674(00)81449-X; GARDNER JF, 1986, J MOL BIOL, V191, P181, DOI 10.1016/0022-2836(86)90255-X; GARTENBERG MR, 1991, J MOL BIOL, V219, P217, DOI 10.1016/0022-2836(91)90563-L; GILADI H, 1992, J MOL BIOL, V227, P985, DOI 10.1016/0022-2836(92)90514-K; Goodman SD, 1999, J BACTERIOL, V181, P3246, DOI 10.1128/JB.181.10.3246-3255.1999; GOODMAN SD, 1989, NATURE, V341, P251, DOI 10.1038/341251a0; GOODMAN SD, 1992, P NATL ACAD SCI USA, V89, P11910, DOI 10.1073/pnas.89.24.11910; Grove A, 1998, J MOL BIOL, V282, P731, DOI 10.1006/jmbi.1998.2058; HSU PL, 1984, NATURE, V311, P721, DOI 10.1038/311721a0; KAHN JD, 1994, NATURE, V368, P163, DOI 10.1038/368163a0; KIM SH, 1990, CELL, V63, P773, DOI 10.1016/0092-8674(90)90143-3; LUETKE KH, 1995, J MOL BIOL, V251, P493, DOI 10.1006/jmbi.1995.0451; Mills JB, 1999, J MOL BIOL, V285, P245, DOI 10.1006/jmbi.1998.2287; MILLS JB, 1994, BIOCHEMISTRY-US, V33, P1797, DOI 10.1021/bi00173a024; NASH HA, 1989, EMBO J, V8, P3523, DOI 10.1002/j.1460-2075.1989.tb08518.x; NUNESDUBY SE, 1995, J MOL BIOL, V253, P228, DOI 10.1006/jmbi.1995.0548; PATSEY RL, 1995, J MOL BIOL, V252, P47, DOI 10.1006/jmbi.1995.0474; RAMSTEIN J, 1988, P NATL ACAD SCI USA, V85, P7231, DOI 10.1073/pnas.85.19.7231; Rice PA, 1996, CELL, V87, P1295, DOI 10.1016/S0092-8674(00)81824-3; Rice PA, 1997, CURR OPIN STRUC BIOL, V7, P86, DOI 10.1016/S0959-440X(97)80011-5; RICHET E, 1988, CELL, V52, P9, DOI 10.1016/0092-8674(88)90526-0; Segall AM, 1996, GENES CELLS, V1, P453, DOI 10.1046/j.1365-2443.1996.d01-254.x; SEGALL AM, 1994, EMBO J, V13, P4536, DOI 10.1002/j.1460-2075.1994.tb06775.x; TRAVERS AA, 1990, CELL, V60, P177, DOI 10.1016/0092-8674(90)90729-X; Travers AA, 1991, CURR OPIN STRUC BIOL, V1, P114, DOI 10.1016/0959-440X(91)90019-P; Yang SW, 1995, EMBO J, V14, P6292, DOI 10.1002/j.1460-2075.1995.tb00319.x	30	7	11	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 24	1999	274	52					37004	37011		10.1074/jbc.274.52.37004	http://dx.doi.org/10.1074/jbc.274.52.37004			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	267WR	10601256	hybrid			2022-12-25	WOS:000084382700027
J	Fernandez-Salas, E; Sagar, M; Cheng, C; Yuspa, SH; Weinberg, WC				Fernandez-Salas, E; Sagar, M; Cheng, C; Yuspa, SH; Weinberg, WC			p53 and tumor necrosis factor alpha regulate the expression of a mitochondrial chloride channel protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL-KERATINOCYTES; MOLECULAR-CLONING; INDUCED APOPTOSIS; SKIN-CANCER; CELL-LINES; P64; ONCOGENE; GROWTH; PROGRESSION; DATABASE	A novel chloride intracellular channel (CLIC) gene, clone mc3s5/mtCLIC, has been identified from differential display analysis of differentiating mouse keratinocytes from p53+/+ and p53-/- mice. The 4.2-kilobase pair cDNA contains an open reading frame of 762 base pairs encoding a 253-amino acid protein with two putative transmembrane domains. mc3s5/mtCLIC protein shares extensive homology with a family of intracellular organelle chloride channels but is the first shown to be differentially regulated. mc3s5/mtCLIC mRNA is expressed to the greatest extent in vivo in heart, lung, liver, kidney, and skin, with reduced levels in some organs from p53-/- mice, mc3s5/mtCLIC mRNA and protein are higher in p53+/+ compared with p53-/- basal keratinocytes in culture, and both increase in differentiating keratinocytes independent of genotype. Overexpression of p53 in keratinocytes induces mc3s5/mtCLIC mRNA and protein. Exogenous human recombinant tumor necrosis factor alpha also up-regulates mc3s5/mtCLIC mRNA and protein in keratinocytes, Subcellular fractionation of keratinocytes indicates that both the green fluorescent protein-mc3s5 fusion protein and the endogenous mc3s5/mtCLIC are localized to the cytoplasm and mitochondria. Similarly, mc3s5/mtCLIC was localized to mitochondria and cytoplasmic fractions of rat liver homogenates. Furthermore, mc3s5/mtCLIC colocalized with cytochrome oxidase in keratinocyte mitochondria by immunofluorescence and was also detected in the cytoplasmic compartment. Sucrose gradient-purified mitochondria from rat liver confirmed this mitochondrial localization. This represents the first report of localization of a CLIC type chloride channel in mitochondria and the first indication that expression of an organellular chloride channel can be regulated by p53 and tumor necrosis factor alpha.	NCI, Cellular Carcinogenesis & Tumor Promot Lab, NIH, Bethesda, MD 20892 USA; NIDCR, Oral & Pharyngeal Canc Branch, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR)	Fernandez-Salas, E (corresponding author), NCI, Cellular Carcinogenesis & Tumor Promot Lab, NIH, 37 Convent Dr,MSC 4255,Bldg 37,Rm 3B16, Bethesda, MD 20892 USA.		Weinberg, Wendy/A-8920-2009	Sagar, Manish/0000-0001-9803-6594				Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Azzoli CG, 1998, MOL CARCINOGEN, V21, P50, DOI 10.1002/(SICI)1098-2744(199801)21:1<50::AID-MC7>3.0.CO;2-T; Bairoch A, 1997, NUCLEIC ACIDS RES, V25, P217, DOI 10.1093/nar/25.1.217; Cai ZZ, 1997, ONCOGENE, V15, P2817, DOI 10.1038/sj.onc.1201445; Chuang JZ, 1999, J NEUROSCI, V19, P2919; Darley-Usmar V.M., 1987, MITOCHONDRIA PRACTIC, P4; DLUGOSZ AA, 1995, METHOD ENZYMOL, V254, P3; Donato NJ, 1998, J BIOL CHEM, V273, P5067, DOI 10.1074/jbc.273.9.5067; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; Duncan RR, 1997, J BIOL CHEM, V272, P23880, DOI 10.1074/jbc.272.38.23880; Durell SR, 1998, J STRUCT BIOL, V121, P263, DOI 10.1006/jsbi.1998.3962; Edwards JC, 1998, J MEMBRANE BIOL, V163, P119; Edwards JC, 1999, AM J PHYSIOL-RENAL, V276, pF398, DOI 10.1152/ajprenal.1999.276.3.F398; GORDON HM, 1992, J IMMUNOL, V148, P4021; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; GURNEY EG, 1980, J VIROL, V34, P752, DOI 10.1128/JVI.34.3.752-763.1980; Heiss NS, 1997, GENOMICS, V45, P224, DOI 10.1006/geno.1997.4922; Hermeking H, 1997, MOL CELL, V1, P3, DOI 10.1016/S1097-2765(00)80002-7; Jentsch TJ, 1997, BIOESSAYS, V19, P117, DOI 10.1002/bies.950190206; Katayose D, 1995, CLIN CANCER RES, V1, P889; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; KOZAK M, 1980, CELL, V22, P7, DOI 10.1016/0092-8674(80)90148-8; Kraemer KH, 1997, P NATL ACAD SCI USA, V94, P11, DOI 10.1073/pnas.94.1.11; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LANDRY D, 1993, J BIOL CHEM, V268, P14948; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; Qian ZJ, 1999, J BIOL CHEM, V274, P1621, DOI 10.1074/jbc.274.3.1621; Redhead C, 1997, MOL BIOL CELL, V8, P691, DOI 10.1091/mbc.8.4.691; Rickwood D., 1997, SUBCELLULAR FRACTION, P71; SANES JR, 1986, EMBO J, V5, P3133, DOI 10.1002/j.1460-2075.1986.tb04620.x; SCHWARZ A, 1995, J INVEST DERMATOL, V104, P922, DOI 10.1111/1523-1747.ep12606202; SELIVANOVA G, 1995, ADV CANCER RES, V66, P143, DOI 10.1016/S0065-230X(08)60253-5; STRICKLAND JE, 1988, CANCER RES, V48, P165; Trounce I A, 1996, Methods Enzymol, V264, P484, DOI 10.1016/S0076-6879(96)64044-0; TULK BM, 1998, AM J PHYSIOL, V274, pF1140; Valenzuela SM, 1997, J BIOL CHEM, V272, P12575, DOI 10.1074/jbc.272.19.12575; VanderHeiden MG, 1997, CELL, V91, P627, DOI 10.1016/S0092-8674(00)80450-X; WEINBERG WC, 1995, ONCOGENE, V10, P2271; WEINBERG WC, 1994, CANCER RES, V54, P5584; WU HY, 1994, J BIOL CHEM, V269, P20067; Yeung MC, 1998, J BIOL CHEM, V273, P25198, DOI 10.1074/jbc.273.39.25198; ZIEGLER A, 1994, NATURE, V372, P773, DOI 10.1038/372773a0	44	116	121	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 17	1999	274	51					36488	36497		10.1074/jbc.274.51.36488	http://dx.doi.org/10.1074/jbc.274.51.36488			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	266AV	10593946	hybrid			2022-12-25	WOS:000084279200065
J	Yu, CJ; Chen, J; Lin, S; Liu, J; Chang, CCY; Chang, TY				Yu, CJ; Chen, J; Lin, S; Liu, J; Chang, CCY; Chang, TY			Human acyl-CoA : cholesterol acyltransferase-1 is a homotetrameric enzyme in intact cells and in vitro	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; HAMSTER OVARY CELLS; COENZYME-A; RADIATION INACTIVATION; COOPERATIVITY; PATHWAY; LIVER; SIZE; PHOSPHATIDYLSERINE; CHROMATOGRAPHY	Acyl-CoA:cholesterol acyltransferase (ACAT) is a key enzyme in cellular cholesterol homeostasis and in atherosclerosis. ACAT-1 may function as an allosteric enzyme, We took a multifaceted approach to investigate the subunit composition of ACAT-1, When ACAT-1 with two different tags were co-expressed in the same Chinese hamster ovary cells, antibody specific to one tag caused co-immunoprecipitation of both types of ACAT-1 proteins. Radioimmunoprecipitations of cells expressing the untagged ACAT-1 or the 6-histidine-tagged ACAT-1 yielded a single radiolabeled band of predicted size on SDS-polyacrylamide gel electrophoresis. These results show that ACAT-1 exists as homo-oligomers in intact Chinese hamster ovary cells. We solubilized HisACAT-1 with the detergent deoxycholate or CHAPS (3-[(3-cholamidopropyl)-dimethylammoniol]-1-propane-sulfonic acid), performed gel filtration chromatography and sucrose density gradient centrifugations in H2O and D2O, and determined the Stokes radii and sedimentation coefficients of the HisACAT1-detergent complexes, The estimated molecular mass of HisACAT-1 is 263 kDa, which is 4 times that of the HisACAT-1 monomer (69 kDa), Finally, cross-linking experiments in intact cells and in vitro show that the increase in cross-linker concentrations causes an increase in size of the HisACAT-1-positive signals, forming material(s) 4 times the size of the monomer, supporting the conclusion that ACAT-I is a homotetrameric enzyme.	Dartmouth Med Sch, Dept Biochem, Hanover, NH 03755 USA	Dartmouth College	Chang, TY (corresponding author), Dartmouth Med Sch, Dept Biochem, Hanover, NH 03755 USA.	ta.yuan.chang@dartmouth.edu	Yu, Chunjiang/E-9419-2012	Liu, Jay/0000-0002-4230-1843; Chang, Ta-Yuan/0000-0002-3249-0468	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL060306] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 60306] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Anderson RA, 1998, J BIOL CHEM, V273, P26747, DOI 10.1074/jbc.273.41.26747; BILLHEIMER JT, 1990, J BIOL CHEM, V265, P8632; Brown MS, 1997, CELL, V89, P331, DOI 10.1016/S0092-8674(00)80213-5; CADIGAN KM, 1990, J CELL BIOL, V110, P295, DOI 10.1083/jcb.110.2.295; CADIGAN KM, 1988, J BIOL CHEM, V263, P274; Cases S, 1998, J BIOL CHEM, V273, P26755, DOI 10.1074/jbc.273.41.26755; CHANG CCY, 1995, J BIOL CHEM, V270, P29532; CHANG CCY, 1986, BIOCHEMISTRY-US, V25, P1693, DOI 10.1021/bi00355a038; Chang CCY, 1998, J BIOL CHEM, V273, P35132, DOI 10.1074/jbc.273.52.35132; CHANG CCY, 1993, J BIOL CHEM, V268, P20747; Chang TY, 1997, ANNU REV BIOCHEM, V66, P613, DOI 10.1146/annurev.biochem.66.1.613; CHENG D, 1995, J BIOL CHEM, V270, P685, DOI 10.1074/jbc.270.2.685; CLARKE S, 1989, METHOD ENZYMOL, V172, P696; DIETSCHY JM, 1993, J LIPID RES, V34, P1637; ERICKSON SK, 1994, J LIPID RES, V35, P763; FORSEN S, 1995, TRENDS BIOCHEM SCI, V20, P495, DOI 10.1016/S0968-0004(00)89115-X; GODAR DE, 1988, BIOCHEMISTRY-US, V22, P2181; GOLDSTEIN JL, 1990, NATURE, V343, P425, DOI 10.1038/343425a0; HJELMELAND LM, 1983, ANAL BIOCHEM, V130, P72, DOI 10.1016/0003-2697(83)90651-6; Kawasaki T, 1998, BIOCHEM BIOPH RES CO, V244, P347, DOI 10.1006/bbrc.1998.8268; LAURENT TC, 1964, J CHROMATOGR, V14, P317, DOI 10.1016/S0021-9673(00)86637-6; Lee O, 1998, J LIPID RES, V39, P1722; LEMAIRE M, 1986, ANAL BIOCHEM, V154, P525, DOI 10.1016/0003-2697(86)90025-4; Li BL, 1999, J BIOL CHEM, V274, P11060, DOI 10.1074/jbc.274.16.11060; Lin S, 1999, J BIOL CHEM, V274, P23276, DOI 10.1074/jbc.274.33.23276; MCMEEKIN TL, 1952, SCIENCE, V116, P142, DOI 10.1126/science.116.3006.142; MEUNIER JC, 1972, FEBS LETT, V24, P63, DOI 10.1016/0014-5793(72)80827-5; NEWTON AC, 1995, J BIOL CHEM, V270, P28495, DOI 10.1074/jbc.270.48.28495; NEWTON AC, 1989, J BIOL CHEM, V264, P14909; OBRIEN RD, 1978, ANAL BIOCHEM, V86, P602, DOI 10.1016/0003-2697(78)90788-1; Oelkers P, 1998, J BIOL CHEM, V273, P26765, DOI 10.1074/jbc.273.41.26765; ORR JW, 1992, BIOCHEMISTRY-US, V31, P4667, DOI 10.1021/bi00134a019; ORR JW, 1992, BIOCHEMISTRY-US, V31, P4661, DOI 10.1021/bi00134a018; Perutz MF, 1998, ANNU REV BIOPH BIOM, V27, P1, DOI 10.1146/annurev.biophys.27.1.1; POTSCHKA M, 1987, ANAL BIOCHEM, V162, P47, DOI 10.1016/0003-2697(87)90009-1; SOBER HA, 1968, HDB BIOCH, pC20; TABAS I, 1995, CURR OPIN LIPIDOL, V6, P260, DOI 10.1097/00041433-199510000-00004; TANFORD C, 1974, BIOCHEMISTRY-US, V13, P2369, DOI 10.1021/bi00708a021; WILSON MD, 1994, J LIPID RES, V35, P943	39	63	64	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 17	1999	274	51					36139	36145		10.1074/jbc.274.51.36139	http://dx.doi.org/10.1074/jbc.274.51.36139			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	266AV	10593897	hybrid			2022-12-25	WOS:000084279200016
J	Davey, HW; Park, SH; Grattan, DR; McLachlan, MJ; Waxman, DJ				Davey, HW; Park, SH; Grattan, DR; McLachlan, MJ; Waxman, DJ			STAT5b-deficient mice are growth hormone pulse-resistant - Role of STAT5b in sex-specific liver P450 expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR FACTOR; TYROSINE PHOSPHORYLATION; MAMMARY TISSUE; MOUSE-LIVER; RAT-LIVER; TRANSCRIPTION; STIMULATION; DIMORPHISM; SECRETION; PROTEINS	The signal transducer and transcriptional activator STAT5b is required to maintain the adult male pattern of liver gene expression and whole body pubertal growth rates, as demonstrated by the loss of these growth hormone (GH) pulse-dependent responses in mice with a targeted disruption of the STAT5b gene, The present study investigates whether these phenotypes of STAT5b-deficient mice result from impaired intracellular GH signaling associated with a loss of GH pulse responsiveness, as contrasted with a feminization of the pituitary GH secretory profile leading to the observed feminization of body growth and liver gene expression. Pulsatile GH replacement in hypophysectomized mice stimulated body weight gain in wild-type but not in STAT5b-deficient mice. Expression of the male-specific liver P450 enzyme CYP2D9, which is reduced to female levels in hypophysectomized male mice, was restored to male levels by GH pulse replacement in wild-type but not in STAT5b-deficient mice. Similarly, a female-specific liver CYP2B P450 enzyme that was up-regulated to female levels following hypophysectomy of males was suppressed to normal basal male levels by GH pulses only in wild-type hypophysectomized mice. Finally, urinary excretion of the male-specific, GH pulse-induced major urinary protein was restored to normal male levels following pulsatile GH treatment only in the case of wild-type hypophysectomized mice. STAT5b-deficient mice are thus GH pulse-resistant, supporting the proposed role of STAT5b as a key intracellular mediator of the stimulatory effects of plasma GH pulses on the male pattern of liver gene expression.	AgResearch, Ruakura Res Ctr, Hamilton, New Zealand; Boston Univ, Dept Biol, Div Cell & Mol Biol, Boston, MA 02215 USA; Univ Otago, Sch Med Sci, Dept Anat & Struct Biol, Dunedin, New Zealand	AgResearch - New Zealand; Boston University; University of Otago	Davey, HW (corresponding author), AgResearch, Ruakura Res Ctr, Private Bag 3123, Hamilton, New Zealand.	daveyh@agresearch.cri.nz; djw@bio.bu.edu	Grattan, David/M-4307-2019	Grattan, David/0000-0001-5606-2559	NIDDK NIH HHS [DK33765, R01 DK033765] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK033765, R56DK033765] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AVERILL RLW, 1991, ENDOCRINOLOGY, V128, P704, DOI 10.1210/endo-128-2-705; AZAM M, 1995, EMBO J, V14, P1402, DOI 10.1002/j.1460-2075.1995.tb07126.x; BENNETT KL, 1982, P NATL ACAD SCI-BIOL, V79, P1220, DOI 10.1073/pnas.79.4.1220; BISHOP JO, 1982, EMBO J, V1, P615, DOI 10.1002/j.1460-2075.1982.tb01217.x; Bluet-Pajot MT, 1998, CELL MOL NEUROBIOL, V18, P101, DOI 10.1023/A:1022579327647; Carter-Su C, 1998, RECENT PROG HORM RES, V53, P61; Choi HK, 1999, ENDOCRINOLOGY, V140, P5126, DOI 10.1210/en.140.11.5126; Davey HW, 1999, AM J HUM GENET, V65, P959, DOI 10.1086/302599; Gebert CA, 1997, MOL ENDOCRINOL, V11, P400, DOI 10.1210/me.11.4.400; HARADA N, 1984, J BIOL CHEM, V259, P2285; Hurst JL, 1998, ANIM BEHAV, V55, P1289, DOI 10.1006/anbe.1997.0650; ISAKSSON OGP, 1985, ANNU REV PHYSIOL, V47, P483, DOI 10.1146/annurev.ph.47.030185.002411; JANSSON JO, 1985, ENDOCR REV, V6, P128, DOI 10.1210/edrv-6-2-128; JOHNSON D, 1995, J MOL ENDOCRINOL, V14, P35, DOI 10.1677/jme.0.0140035; JOHNSON D, 1995, J MOL ENDOCRINOL, V14, P21, DOI 10.1677/jme.0.0140021; KNOPF JL, 1983, MOL CELL BIOL, V3, P2232, DOI 10.1128/MCB.3.12.2232; Lin JX, 1996, J BIOL CHEM, V271, P10738, DOI 10.1074/jbc.271.18.10738; LIU XW, 1995, P NATL ACAD SCI USA, V92, P8831, DOI 10.1073/pnas.92.19.8831; LUCKMAN SM, 1998, ANN M SOC NEUR NOV 7; LYNCH KR, 1982, CELL, V28, P185, DOI 10.1016/0092-8674(82)90388-9; MACLEOD JN, 1991, J ENDOCRINOL, V131, P395, DOI 10.1677/joe.0.1310395; Minami S, 1998, ENDOCR J, V45, pS19, DOI 10.1507/endocrj.45.Suppl_S19; MUI ALF, 1995, EMBO J, V14, P1166, DOI 10.1002/j.1460-2075.1995.tb07100.x; NORSTEDT G, 1984, CELL, V36, P805, DOI 10.1016/0092-8674(84)90030-8; NOSHIRO M, 1986, J BIOL CHEM, V261, P5923; PAMPORI NA, 1991, ACTA ENDOCRINOL-COP, V124, P283, DOI 10.1530/acta.0.1240283; Park SH, 1999, J BIOL CHEM, V274, P7421, DOI 10.1074/jbc.274.11.7421; Ram PA, 1996, J BIOL CHEM, V271, P5929, DOI 10.1074/jbc.271.10.5929; SCHMITT-NEY M, 1992, P NATL ACAD SCI USA, V89, P3130, DOI 10.1073/pnas.89.7.3130; SCHMITT-NEY M, 1992, MOL ENDOCRINOL, V6, P1988, DOI 10.1210/me.6.12.1988; SHAPIRO BH, 1995, INT J BIOCHEM CELL B, V27, P9, DOI 10.1016/1357-2725(94)00056-5; Sharma MC, 1998, BIOCHEM PHARMACOL, V56, P1251, DOI 10.1016/S0006-2952(98)00247-0; Subramanian A, 1998, NUCLEIC ACIDS RES, V26, P2173, DOI 10.1093/nar/26.9.2173; Sueyoshi T, 1999, MOL PHARMACOL, V56, P473, DOI 10.1124/mol.56.3.473; Udy GB, 1997, P NATL ACAD SCI USA, V94, P7239, DOI 10.1073/pnas.94.14.7239; Verdier F, 1998, MOL CELL BIOL, V18, P5852, DOI 10.1128/MCB.18.10.5852; WAKAO H, 1992, J BIOL CHEM, V267, P16365; WAKAO H, 1994, EMBO J, V13, P2182, DOI 10.1002/j.1460-2075.1994.tb06495.x; Waxman David J., 1995, P391; WAXMAN DJ, 1982, J BIOL CHEM, V257, P446; WAXMAN DJ, 1995, J BIOL CHEM, V270, P13262, DOI 10.1074/jbc.270.22.13262; WAXMAN DJ, 1991, P NATL ACAD SCI USA, V88, P6868, DOI 10.1073/pnas.88.15.6868; Yamashita H, 1998, J BIOL CHEM, V273, P30218, DOI 10.1074/jbc.273.46.30218	43	77	78	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 10	1999	274	50					35331	35336		10.1074/jbc.274.50.35331	http://dx.doi.org/10.1074/jbc.274.50.35331			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	264NG	10585399	hybrid			2022-12-25	WOS:000084187900011
J	Akiyoshi, S; Inoue, H; Hanai, J; Kusanagi, K; Nemoto, N; Miyazono, K; Kawabata, M				Akiyoshi, S; Inoue, H; Hanai, J; Kusanagi, K; Nemoto, N; Miyazono, K; Kawabata, M			c-Ski acts as a transcriptional co-repressor in transforming growth factor-beta signaling through interaction with Smads	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TGF-BETA; DNA-BINDING; MUSCLE DIFFERENTIATION; V-SKI; GENE; PROTEIN; ACTIVATION; ONCOGENE; PROMOTER; COACTIVATOR	Smads are intracellular signaling mediators of the transforming growth factor-beta (TGF-beta) superfamily that regulates a wide variety of biological processes. Among them, Smads 2 and 3 are activated specifically by TGF-beta. We identified c-Ski as a Smad2 interacting protein. c-Ski is the cellular homologue of the v-ski oncogene product and has been shown to repress transcription by recruiting histone deacetylase (HDAC). Smad2/3 interacts with c-Ski through its C-terminal MH2 domain in a TGF-beta-dependent manner. c-Ski contains two distinct Smad-binding sites with different binding properties. c-Ski strongly inhibits transactivation of various reporter genes by TGF-beta. c-Ski is incorporated in the Smad DNA binding complex, interferes with the interaction of Smads with a transcriptional co-activator, p300, and in turn recruits HDAC. c-Ski is thus a transcriptional corepressor that links Smads to HDAC in TGF-beta signaling.	Japanese Fdn Canc Res, Inst Canc, Dept Biochem, Toshima Ku, Tokyo 1708455, Japan; Japan Soc Promot Sci, Res Future Program, Dept Biochem, Toshima Ku, Tokyo 1708455, Japan; Toyama Med & Pharmaceut Univ, Fac Pharmaceut Sci, Dept Toxicol, Toyama 9300194, Japan	Japanese Foundation for Cancer Research; Japan Society for the Promotion of Science; University of Toyama	Miyazono, K (corresponding author), Japanese Fdn Canc Res, Inst Canc, Dept Biochem, Toshima Ku, 1-37-1 Kami Ikebukuro, Tokyo 1708455, Japan.							Bannister AJ, 1996, NATURE, V384, P641, DOI 10.1038/384641a0; Bertolino E, 1995, J BIOL CHEM, V270, P31178, DOI 10.1074/jbc.270.52.31178; Campbell G, 1999, CELL, V96, P553, DOI 10.1016/S0092-8674(00)80659-5; CHEN RH, 1995, J BIOL CHEM, V270, P12235, DOI 10.1074/jbc.270.20.12235; Chen X, 1996, NATURE, V383, P691, DOI 10.1038/383691a0; Cohen SB, 1998, ONCOGENE, V17, P2505, DOI 10.1038/sj.onc.1202177; COLMENARES C, 1989, CELL, V59, P293, DOI 10.1016/0092-8674(89)90291-2; Dahl R, 1998, P NATL ACAD SCI USA, V95, P11187, DOI 10.1073/pnas.95.19.11187; Datto MB, 1999, MOL CELL BIOL, V19, P2495; Dennler S, 1998, EMBO J, V17, P3091, DOI 10.1093/emboj/17.11.3091; Dennler S, 1999, ONCOGENE, V18, P1643, DOI 10.1038/sj.onc.1202729; Derynck R, 1998, CELL, V95, P737, DOI 10.1016/S0092-8674(00)81696-7; Derynck R, 1997, BBA-REV CANCER, V1333, pF105, DOI 10.1016/S0304-419X(97)00017-6; ENGERT JC, 1995, NUCLEIC ACIDS RES, V23, P2988, DOI 10.1093/nar/23.15.2988; Feng XH, 1998, GENE DEV, V12, P2153, DOI 10.1101/gad.12.14.2153; Goto D, 1998, FEBS LETT, V430, P201, DOI 10.1016/S0014-5793(98)00658-9; Grozinger CM, 1999, P NATL ACAD SCI USA, V96, P4868, DOI 10.1073/pnas.96.9.4868; Hayashi H, 1997, CELL, V89, P1165, DOI 10.1016/S0092-8674(00)80303-7; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; HEYMAN HC, 1994, J BIOL CHEM, V269, P26996; Huse M, 1999, CELL, V96, P425, DOI 10.1016/S0092-8674(00)80555-3; Iavarone A, 1999, MOL CELL BIOL, V19, P916; Ichikawa K, 1997, BIOCHEM J, V328, P607, DOI 10.1042/bj3280607; Imamura T, 1997, NATURE, V389, P622, DOI 10.1038/39355; Janknecht R, 1998, GENE DEV, V12, P2114, DOI 10.1101/gad.12.14.2114; Jazwinska A, 1999, CELL, V96, P563, DOI 10.1016/S0092-8674(00)80660-1; Jonk LJC, 1998, J BIOL CHEM, V273, P21145, DOI 10.1074/jbc.273.33.21145; Kawabata M, 1998, EMBO J, V17, P4056, DOI 10.1093/emboj/17.14.4056; KAWABATA M, 1995, J BIOL CHEM, V270, P5625, DOI 10.1074/jbc.270.10.5625; Kim J, 1997, NATURE, V388, P304, DOI 10.1038/40906; Laherty CD, 1997, CELL, V89, P349, DOI 10.1016/S0092-8674(00)80215-9; LEDAI J, 1998, CANCER RES, V58, P4592; LeSuer JA, 1999, DEVELOPMENT, V126, P137; LI Y, 1986, J VIROL, V57, P1065, DOI 10.1128/JVI.57.3.1065-1072.1986; Liu F, 1996, NATURE, V381, P620, DOI 10.1038/381620a0; Mannervik M, 1999, SCIENCE, V284, P606, DOI 10.1126/science.284.5414.606; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; Masuyama N, 1999, J BIOL CHEM, V274, P12163, DOI 10.1074/jbc.274.17.12163; MATRISIAN LM, 1986, MOL CELL BIOL, V6, P1679, DOI 10.1128/MCB.6.5.1679; Mauviel A, 1996, J BIOL CHEM, V271, P10917, DOI 10.1074/jbc.271.18.10917; Minami M, 1999, NATURE, V398, P242, DOI 10.1038/18451; NAGASE T, 1993, J BIOL CHEM, V268, P13710; NAGASE T, 1990, NUCLEIC ACIDS RES, V18, P337, DOI 10.1093/nar/18.2.337; Nakao A, 1997, NATURE, V389, P631, DOI 10.1038/39369; Nakashima K, 1999, SCIENCE, V284, P479, DOI 10.1126/science.284.5413.479; Nicol R, 1998, J BIOL CHEM, V273, P3588, DOI 10.1074/jbc.273.6.3588; Nicol R, 1999, CELL GROWTH DIFFER, V10, P243; Nishihara A, 1998, GENES CELLS, V3, P613, DOI 10.1046/j.1365-2443.1998.00217.x; NOMURA N, 1989, NUCLEIC ACIDS RES, V17, P5489, DOI 10.1093/nar/17.14.5489; Nomura T, 1999, GENE DEV, V13, P412, DOI 10.1101/gad.13.4.412; PEARSONWHITE S, 1993, NUCLEIC ACIDS RES, V21, P4632, DOI 10.1093/nar/21.19.4632; PearsonWhite S, 1997, NUCLEIC ACIDS RES, V25, P2930, DOI 10.1093/nar/25.14.2930; PIETENPOL JA, 1991, P NATL ACAD SCI USA, V88, P10227, DOI 10.1073/pnas.88.22.10227; Pouponnot C, 1998, J BIOL CHEM, V273, P22865, DOI 10.1074/jbc.273.36.22865; RICCIO A, 1985, NUCLEIC ACIDS RES, V13, P2759, DOI 10.1093/nar/13.8.2759; Ritter SJ, 1998, J BIOL CHEM, V273, P12798, DOI 10.1074/jbc.273.21.12798; ROBERTS SGE, 1995, NATURE, V375, P105, DOI 10.1038/375105a0; Shen X, 1998, MOL BIOL CELL, V9, P3309, DOI 10.1091/mbc.9.12.3309; Shi XM, 1999, J BIOL CHEM, V274, P13711, DOI 10.1074/jbc.274.19.13711; STAVNEZER E, 1989, MOL CELL BIOL, V9, P4038, DOI 10.1128/MCB.9.9.4038; STEVENSON BJ, 1986, NUCLEIC ACIDS RES, V14, P8307, DOI 10.1093/nar/14.21.8307; SUTRAVE P, 1989, MOL CELL BIOL, V9, P4046, DOI 10.1128/MCB.9.9.4046; Tang SJ, 1998, DEVELOPMENT, V125, P1877; Tokitou F, 1999, J BIOL CHEM, V274, P4485, DOI 10.1074/jbc.274.8.4485; Topper JN, 1998, P NATL ACAD SCI USA, V95, P9506, DOI 10.1073/pnas.95.16.9506; Verschueren K, 1999, J BIOL CHEM, V274, P20489, DOI 10.1074/jbc.274.29.20489; Wotton D, 1999, CELL, V97, P29, DOI 10.1016/S0092-8674(00)80712-6; Yagi K, 1999, J BIOL CHEM, V274, P703, DOI 10.1074/jbc.274.2.703; Yanagisawa J, 1999, SCIENCE, V283, P1317, DOI 10.1126/science.283.5406.1317; Zawel L, 1998, MOL CELL, V1, P611, DOI 10.1016/S1097-2765(00)80061-1; Zheng GX, 1997, J BIOL CHEM, V272, P31855, DOI 10.1074/jbc.272.50.31855	71	319	339	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 3	1999	274	49					35269	35277		10.1074/jbc.274.49.35269	http://dx.doi.org/10.1074/jbc.274.49.35269			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	260XW	10575014	hybrid			2022-12-25	WOS:000083979600108
J	Billy, E; Hess, D; Hofsteenge, J; Filipowicz, W				Billy, E; Hess, D; Hofsteenge, J; Filipowicz, W			Characterization of the adenylation site in the RNA 3 '-terminal phosphate cyclase from Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HELA-CELL EXTRACT; WHEAT-GERM; 3',5'-PHOSPHODIESTER LINKAGE; LIGASE; PROTEIN; PURIFICATION; MECHANISM; LIGATION; SIGNAL; URIDYLYLTRANSFERASE	RNA 3'-terminal phosphate cyclases are a family of evolutionarily conserved enzymes that catalyze ATP-dependent conversion of the 3'-phosphate to the 2',3'-cyclic phosphodiester at the end of RNA. The precise function of cyclases is not known, but they may be responsible for generating or regenerating cyclic phosphate RNA ends required by eukaryotic and prokaryotic RNA ligases, Previous work carried out with human and Escherichia coli enzymes demonstrated that the initial step of the cyclization reaction involves adenylation of the protein. The AMP group is then transferred to the 3'-phosphate in RNA,yielding an RNA-N(3')pp(5')A (N is any nucleoside) intermediate, which finally undergoes cyclization. In this work, by using different protease digestions and mass spectrometry, we assign the site of adenylation in the E, coli cyclase to His-309. This histidine is conserved in all members of the class I subfamily of cyclases identified by phylogenetic analysis. Replacement of His-309 with asparagine or alanine abrogates both enzyme-adenylate formation and cyclization of the 3'-terminal phosphate in a model RNA substrate. The cyclase is the only known protein undergoing adenylation on a histidine residue. Sequences flanking the adenylated histidine in cyclases do not resemble those found in other proteins modified by nucleotidylation.	Friedrich Miescher Inst, CH-4002 Basel, Switzerland	Friedrich Miescher Institute for Biomedical Research	Filipowicz, W (corresponding author), Friedrich Miescher Inst, Maubeerstr 66, CH-4058 Basel, Switzerland.	Filipowi@FMI.CH		Billy, Eric/0000-0002-8859-0089				Arn EA, 1998, COLD SPRING HARBOR M, P695; Arn EA, 1996, J BIOL CHEM, V271, P31145, DOI 10.1074/jbc.271.49.31145; BLANC A, 1994, MOL CELL BIOL, V14, P2664, DOI 10.1128/MCB.14.4.2664; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brons-Poulsen J, 1998, MOL CELL PROBE, V12, P345, DOI 10.1006/mcpr.1998.0187; Cartwright JL, 1999, ARCH BIOCHEM BIOPHYS, V361, P101, DOI 10.1006/abbi.1998.0970; CRESTFIELD AM, 1963, J BIOL CHEM, V238, P622; Egger LA, 1997, GENES CELLS, V2, P167, DOI 10.1046/j.1365-2443.1997.d01-311.x; FILIPOWICZ W, 1985, P NATL ACAD SCI USA, V82, P1316, DOI 10.1073/pnas.82.5.1316; FILIPOWICZ W, 1990, METHOD ENZYMOL, V181, P499; FILIPOWICZ W, 1984, TRENDS BIOCHEM SCI, V9, P68, DOI 10.1016/0968-0004(84)90186-5; FILIPOWICZ W, 1983, CELL, V32, P547, DOI 10.1016/0092-8674(83)90474-9; FILIPOWICZ W, 1983, NUCLEIC ACIDS RES, V11, P1405, DOI 10.1093/nar/11.5.1405; FREY PA, 1982, METHOD ENZYMOL, V87, P20; FRUCHTER RG, 1967, J BIOL CHEM, V242, P5807; FURNEAUX H, 1983, P NATL ACAD SCI-BIOL, V80, P3933, DOI 10.1073/pnas.80.13.3933; Genschik P, 1998, J BIOL CHEM, V273, P25516, DOI 10.1074/jbc.273.39.25516; Genschik P, 1997, EMBO J, V16, P2955, DOI 10.1093/emboj/16.10.2955; GREER CL, 1983, CELL, V33, P899, DOI 10.1016/0092-8674(83)90032-6; GREER CL, 1983, CELL, V32, P537, DOI 10.1016/0092-8674(83)90473-7; Gu J, 1997, J BIOL CHEM, V272, P21989, DOI 10.1074/jbc.272.35.21989; GUMPORT RI, 1980, NUCLEIC ACIDS RES S, V7, P167; HINTON DM, 1982, NUCLEIC ACIDS RES, V10, P1877, DOI 10.1093/nar/10.6.1877; Kirby A.J., 1967, ORGANIC CHEM PHOSPHO; KONARSKA M, 1982, P NATL ACAD SCI-BIOL, V79, P1474, DOI 10.1073/pnas.79.5.1474; KONARSKA M, 1981, NATURE, V293, P112, DOI 10.1038/293112a0; Krieg J, 1998, MOL BIOL CELL, V9, P301, DOI 10.1091/mbc.9.2.301; LUND E, 1992, SCIENCE, V255, P327, DOI 10.1126/science.1549778; LUTHY R, 1992, NATURE, V356, P83, DOI 10.1038/356083a0; PERKINS KK, 1985, P NATL ACAD SCI USA, V82, P684, DOI 10.1073/pnas.82.3.684; PHIZICKY EM, 1993, TRENDS BIOCHEM SCI, V18, P31; PHIZICKY EM, 1986, J BIOL CHEM, V261, P2978; PICK L, 1986, J BIOL CHEM, V261, P6694; REINBERG D, 1985, J BIOL CHEM, V260, P6088; SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHWARTZ RC, 1983, J BIOL CHEM, V258, P8374; SHUMAN S, 1995, MOL MICROBIOL, V17, P405, DOI 10.1111/j.1365-2958.1995.mmi_17030405.x; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; VICENTE O, 1988, EUR J BIOCHEM, V176, P431, DOI 10.1111/j.1432-1033.1988.tb14300.x; Wedekind JE, 1996, BIOCHEMISTRY-US, V35, P11560, DOI 10.1021/bi9612677; Wilm M, 1996, ANAL CHEM, V68, P1, DOI 10.1021/ac9509519	42	22	22	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 3	1999	274	49					34955	34960		10.1074/jbc.274.49.34955	http://dx.doi.org/10.1074/jbc.274.49.34955			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	260XW	10574971	hybrid			2022-12-25	WOS:000083979600065
J	Feldman, MF; Marolda, CL; Monteiro, MA; Perry, MB; Parodi, AJ; Valvano, MA				Feldman, MF; Marolda, CL; Monteiro, MA; Perry, MB; Parodi, AJ; Valvano, MA			The activity of a putative polyisoprenol-linked sugar translocase (Wzx) involved in Escherichia coli O antigen assembly is independent of the chemical structure of the O repeat	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RFB GENE-CLUSTER; GRAM-NEGATIVE BACTERIA; WATER-SOLUBLE ANALOG; SALMONELLA-TYPHIMURIUM; ENDOPLASMIC-RETICULUM; BIOSYNTHESIS REGION; MOLECULAR-WEIGHT; OUTER-MEMBRANE; LIPOPOLYSACCHARIDE; K-12	During O antigen lipopolysaccharide (LPS) synthesis in bacteria, transmembrane migration of undecaprenylpyrophosphate (Und-P-P)-bound O antigen subunits occurs before their polymerization and ligation to the rest of the LPS molecule, Despite the general nature of the translocation process, putative O-antigen translocases display a low level of amino acid sequence similarity, In this work, we investigated whether complete O antigen subunits are required for translocation, We demonstrate that a single sugar, GlcNAc, can be incorporated to LPS of Escherichia coli K-12, This incorporation required the functions of two O antigen synthesis genes, wecA (UDP-GlcNAc:Und-P GlcNAc-1-P transferase) and wzx (O-antigen translocase). Complementation experiments with putative O-antigen translocases from E. coli O7 and Salmonella enterica indicated that translocation of O antigen subunits is independent of the chemical structure of the saccharide moiety, Furthermore, complementation with putative translocases involved in synthesis of exopolysaccharides demonstrated that these proteins could not participate in O antigen assembly. Our data indicate that recognition of a complete Und-P-P-bound O antigen subunit is not required for translocation and suggest a model for O antigen synthesis involving recognition of Und-P-P-linked sugars by a putative complex made of Wzx translocase and other proteins involved in the processing of O antigen.	Univ Western Ontario, Dept Microbiol & Immunol, London, ON N6A 5C1, Canada; Fdn Campomar, Inst Invest Bioquim, RA-1405 Buenos Aires, DF, Argentina; Natl Res Council Canada, Inst Biol Sci, Ottawa, ON K1A 0R6, Canada	Western University (University of Western Ontario); Leloir Institute; National Research Council Canada	Valvano, MA (corresponding author), Univ Western Ontario, Dept Microbiol & Immunol, London, ON N6A 5C1, Canada.	mvalvano@julian.uwo.ca	Feldman, Mario/A-2637-2014; Valvano, Miguel A/G-8759-2012	Feldman, Mario/0000-0003-4497-0976; Valvano, Miguel A/0000-0001-8229-3641				ABEIJON C, 1992, TRENDS BIOCHEM SCI, V17, P32, DOI 10.1016/0968-0004(92)90424-8; ALLEN AK, 1973, BIOCHEM J, V131, P155, DOI 10.1042/bj1310155; BRONNER D, 1994, MOL MICROBIOL, V14, P505, DOI 10.1111/j.1365-2958.1994.tb02185.x; BUGG TDH, 1994, FEMS MICROBIOL LETT, V119, P255; Burda P, 1999, BBA-GEN SUBJECTS, V1426, P239, DOI 10.1016/S0304-4165(98)00127-5; CIUCANU I, 1984, CARBOHYD RES, V131, P209, DOI 10.1016/0008-6215(84)85242-8; CLARKE BR, 1995, J BACTERIOL, V177, P5411, DOI 10.1128/jb.177.19.5411-5418.1995; DELL A, 1990, CARBOHYD RES, V200, P59, DOI 10.1016/0008-6215(90)84182-T; DUBOIS M, 1956, ANAL CHEM, V28, P350, DOI 10.1021/ac60111a017; Dykxhoorn DM, 1996, GENE, V177, P133, DOI 10.1016/0378-1119(96)00289-2; Gonzalez JE, 1998, P NATL ACAD SCI USA, V95, P13477, DOI 10.1073/pnas.95.23.13477; Guan S, 1999, MICROBIOL-UK, V145, P1263, DOI 10.1099/13500872-145-5-1263; HANOVER JA, 1979, J BIOL CHEM, V254, P9237; Heinrichs DE, 1998, MOL MICROBIOL, V30, P221, DOI 10.1046/j.1365-2958.1998.01063.x; Heinrichs DE, 1999, ENDOTOXIN IN HEALTH AND DISEASE, P305; HIGGINS CF, 1994, CELL, V79, P393, DOI 10.1016/0092-8674(94)90248-8; HIRSCHBERG CB, 1987, ANNU REV BIOCHEM, V56, P63, DOI 10.1146/annurev.bi.56.070187.000431; HOLST O, 1991, CARBOHYD RES, V215, P323, DOI 10.1016/0008-6215(91)84031-9; JACKSON BJ, 1989, ARCH BIOCHEM BIOPHYS, V272, P203, DOI 10.1016/0003-9861(89)90211-7; Keenleyside WJ, 1999, ENDOTOXIN IN HEALTH AND DISEASE, P331; KLENA JD, 1993, MOL MICROBIOL, V9, P393, DOI 10.1111/j.1365-2958.1993.tb01700.x; Liu D, 1996, J BACTERIOL, V178, P2102, DOI 10.1128/jb.178.7.2102-2107.1996; LIU D, 1994, MICROBIOL-UK, V140, P49, DOI 10.1099/13500872-140-1-49; MALOY SR, 1981, J BACTERIOL, V145, P1110, DOI 10.1128/JB.145.2.1110-1111.1981; MARINO PA, 1991, J BACTERIOL, V173, P3128, DOI 10.1128/JB.173.10.3128-3133.1991; Marolda CL, 1999, MICROBIOL-UK, V145, P2485, DOI 10.1099/00221287-145-9-2485; MAROLDA CL, 1990, J BACTERIOL, V172, P3590, DOI 10.1128/jb.172.7.3590-3599.1990; MAROLDA CL, 1993, J BACTERIOL, V175, P148, DOI 10.1128/JB.175.1.148-158.1993; MCCLOSKEY MA, 1980, BIOCHEMISTRY-US, V19, P2061, DOI 10.1021/bi00551a009; MCGRATH BC, 1991, J BACTERIOL, V173, P649, DOI 10.1128/jb.173.2.649-654.1991; MEIERDIETER U, 1990, J BIOL CHEM, V265, P13490; METCALF WW, 1994, GENE, V138, P1, DOI 10.1016/0378-1119(94)90776-5; MILLER VL, 1988, J BACTERIOL, V170, P2575, DOI 10.1128/JB.170.6.2575-2583.1988; MULFORD CA, 1983, P NATL ACAD SCI-BIOL, V80, P1159, DOI 10.1073/pnas.80.5.1159; Nassau PM, 1996, J BACTERIOL, V178, P1047, DOI 10.1128/jb.178.4.1047-1052.1996; NEUHARD J, 1976, J BACTERIOL, V126, P999, DOI 10.1128/JB.126.2.999-1001.1976; NIKAIDO H, 1996, ESCHERICHIA COLI SAL, P29; OSBORN MJ, 1963, P NATL ACAD SCI USA, V50, P499, DOI 10.1073/pnas.50.3.499; OWEN RJ, 1987, NUCLEIC ACIDS RES, V15, P3631, DOI 10.1093/nar/15.8.3631; Paulsen IT, 1997, MICROBIOL-SGM, V143, P2685, DOI 10.1099/00221287-143-8-2685; Provence David L., 1994, P317; RAETZ CRH, 1996, ESCHERICHIA COLI SAL, P1035; Rick P, 1996, ESCHERICHIA COLI SAL, P104; RICK PD, 1994, J BACTERIOL, V176, P2877, DOI 10.1128/JB.176.10.2877-2884.1994; RIED JL, 1987, GENE, V57, P239, DOI 10.1016/0378-1119(87)90127-2; RUSH JS, 1995, J CELL BIOL, V130, P529, DOI 10.1083/jcb.130.3.529; Rush JS, 1998, GLYCOBIOLOGY, V8, P1195, DOI 10.1093/glycob/8.12.1195; SAWARDEKER JS, 1965, ANAL CHEM, V37, P1602, DOI 10.1021/ac60231a048; STEVENSON G, 1994, J BACTERIOL, V176, P4144, DOI 10.1128/JB.176.13.4144-4156.1994; VALVANO MA, 1989, INFECT IMMUN, V57, P937, DOI 10.1128/IAI.57.3.937-943.1989; Wang L, 1996, J BACTERIOL, V178, P2598, DOI 10.1128/jb.178.9.2598-2604.1996; Wang L, 1998, INFECT IMMUN, V66, P3545, DOI 10.1128/IAI.66.8.3545-3551.1998; Westphal O., 1965, METHODS CARBOHYDRATE, V5, P83, DOI DOI 10.1016/J.WATRES.2010.04.030; Whitfield C, 1999, MOL MICROBIOL, V31, P1307, DOI 10.1046/j.1365-2958.1999.01276.x; WHITFIELD C, 1993, ADV MICROB PHYSIOL, V35, P135, DOI 10.1016/S0065-2911(08)60099-5; WHITFIELD C, 1995, TRENDS MICROBIOL, V3, P178, DOI 10.1016/S0966-842X(00)88917-9; YAO ZJ, 1994, J BACTERIOL, V176, P4133, DOI 10.1128/JB.176.13.4133-4143.1994; YAO ZJ, 1992, J BACTERIOL, V174, P7500, DOI 10.1128/JB.174.23.7500-7508.1992; [No title captured]	59	172	180	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 3	1999	274	49					35129	35138		10.1074/jbc.274.49.35129	http://dx.doi.org/10.1074/jbc.274.49.35129			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	260XW	10574995	hybrid			2022-12-25	WOS:000083979600089
J	Reszka, AA; Halasy-Nagy, JM; Masarachia, PJ; Rodan, GA				Reszka, AA; Halasy-Nagy, JM; Masarachia, PJ; Rodan, GA			Bisphosphonates act directly on the osteoclast to induce caspase cleavage of Mst1 kinase during apoptosis - A link between inhibition of the mevalonate pathway and regulation of an apoptosis-promoting kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE; MOLECULAR MECHANISMS; MEDIATED ACTIVATION; BONE-RESORPTION; IN-VITRO; ALENDRONATE; PRENYLATION; CELLS; MACROPHAGES; CLODRONATE	Bisphosphonates (BPs) include potent inhibitors of bone resorption used to treat osteoporosis and other bone diseases. BPs directly or indirectly induce apoptosis in osteoclasts, the bone resorbing cells, and this mag play a role in inhibition of bone resorption, Little is known about downstream mediators of apoptosis in osteoclasts, which are difficult to culture. Using purified osteoclasts, we examined the effects of alendronate, risedronate, pamidronate, etidronate, and clodronate on apoptosis and signaling kinases, All BPs induce caspase-dependent formation of pyknotic nuclei and cleavage of Mammalian Sterile 20-like (Mst) kinase 1 to form the active 34-kDa species associated with apoptosis. Withdrawal of serum and of macrophage colony stimulating factor, necessary for survival of purified osteoclasts, or treatment with staurosporine also induce apoptosis and caspase cleavage of Mst1, Consistent with their inhibition of the mevalonate pathway, apoptosis and cleavage of Mst1 kinase induced by alendronate, risedronate, and lovastatin, but not clodronate, are blocked by geranylgeraniol, a precursor of geranylgeranyl diphosphate. Together these findings suggest that BPs act directly on the osteoclast to induce apoptosis and that caspase cleavage of Mst1 kinase is part of the apoptotic pathway, For alendronate and risedronate, these events seem to be downstream of inhibition of geranylgeranylation.	Merck Res Labs, Dept Bone Biol & Osteoporosis Res, W Point, PA 19486 USA	Merck & Company	Reszka, AA (corresponding author), Merck Res Labs, Dept Bone Biol & Osteoporosis Res, W Point, PA 19486 USA.							Auriola S, 1997, J CHROMATOGR B, V704, P187, DOI 10.1016/S0378-4347(97)00490-8; Coxon FP, 1998, MOL PHARMACOL, V54, P631; Creasy CL, 1996, J BIOL CHEM, V271, P21049, DOI 10.1074/jbc.271.35.21049; David P, 1996, J BONE MINER RES, V11, P1498, DOI 10.1002/jbmr.5650111017; Fisher JE, 1999, P NATL ACAD SCI USA, V96, P133, DOI 10.1073/pnas.96.1.133; Fleisch H, 1998, ENDOCR REV, V19, P80, DOI 10.1210/er.19.1.80; Frith JC, 1997, J BONE MINER RES, V12, P1358, DOI 10.1359/jbmr.1997.12.9.1358; GOTOH Y, 1990, EUR J BIOCHEM, V193, P661, DOI 10.1111/j.1432-1033.1990.tb19384.x; Graves JD, 1998, EMBO J, V17, P2224, DOI 10.1093/emboj/17.8.2224; HUGHES DE, 1995, J BONE MINER RES, V10, P1478; Kakeya H, 1998, CANCER RES, V58, P4888; KAMESHITA I, 1989, ANAL BIOCHEM, V183, P139, DOI 10.1016/0003-2697(89)90181-4; Lee KK, 1998, J BIOL CHEM, V273, P19160, DOI 10.1074/jbc.273.30.19160; Luckman SP, 1998, J BONE MINER RES, V13, P581, DOI 10.1359/jbmr.1998.13.4.581; Luckman SP, 1998, J BONE MINER RES, V13, P1668, DOI 10.1359/jbmr.1998.13.11.1668; Mortensen L, 1998, J CLIN ENDOCR METAB, V83, P396, DOI 10.1210/jc.83.2.396; Opas EE, 1997, BIOCHEM PHARMACOL, V54, P721, DOI 10.1016/S0006-2952(97)00225-6; Peter CP, 1998, DIGEST DIS SCI, V43, P1009, DOI 10.1023/A:1018826600877; Peter CP, 1998, DIGEST DIS SCI, V43, P1998, DOI 10.1023/A:1018894827961; Rodan GA, 1998, ANNU REV PHARMACOL, V38, P375, DOI 10.1146/annurev.pharmtox.38.1.375; SATO M, 1991, J CLIN INVEST, V88, P2095, DOI 10.1172/JCI115539; Schmidt A, 1996, P NATL ACAD SCI USA, V93, P3068, DOI 10.1073/pnas.93.7.3068; Sebti Said, 1997, Current Opinion in Oncology, V9, P557, DOI 10.1097/00001622-199711000-00011; Selander KS, 1996, MOL PHARMACOL, V50, P1127; TEITELBAUM SL, 1995, J CELL BIOCHEM, V59, P1, DOI 10.1002/jcb.240590102; van Beek E, 1999, BIOCHEM BIOPH RES CO, V255, P491, DOI 10.1006/bbrc.1999.0224; WESOLOWSKI G, 1995, EXP CELL RES, V219, P679, DOI 10.1006/excr.1995.1279; Zhang FL, 1996, ANNU REV BIOCHEM, V65, P241, DOI 10.1146/annurev.bi.65.070196.001325	28	213	218	1	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 3	1999	274	49					34967	34973		10.1074/jbc.274.49.34967	http://dx.doi.org/10.1074/jbc.274.49.34967			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	260XW	10574973	hybrid			2022-12-25	WOS:000083979600067
J	Woldin, CN; Hing, FS; Lee, J; Pilch, PF; Shipley, GG				Woldin, CN; Hing, FS; Lee, J; Pilch, PF; Shipley, GG			Structural studies of the detergent-solubilized and vesicle-reconstituted insulin receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL GROWTH-FACTOR; FIRST 3 DOMAINS; CRYSTAL-STRUCTURE; TYROSINE KINASE; ELECTRON-MICROSCOPY; BETA-SUBUNIT; SIGNAL TRANSDUCTION; DISULFIDE BONDS; PROTEIN-KINASE; ECTODOMAIN	Insulin binding to the insulin receptor initiates a cascade of cellular events that are responsible for regulating cell metabolism, proliferation, and growth. We have investigated the structure of the purified functionally active, human insulin receptor using negative stain and cryo-electron microscopy. Visualization of the detergent-solubilized and vesicle-reconstituted receptor shows the alpha(2)beta(2) heterotetrameric insulin receptor to be a three-armed pinwheel-like complex that exhibits considerable variability among individual receptors. The alpha-subunit of the receptor was labeled with an insulin analogue streptavidin gold conjugate, which facilitated the identification of the receptor arm responsible for insulin binding. The gold label was localized to the tip of a single receptor arm of the three-armed complex. The beta-subunit of the insulin receptor was labeled with a maleimide-gold conjugate, which allowed orientation of the receptor complex in the membrane bilayer. The model derived from electron microscopic studies displays a "Y"-like morphology representing the predominant species identified in the reconstituted receptor images. The insulin receptor dimensions are approximately 12.2 nm by 20.0 nm, extending 9.7 nm above the membrane surface. The beta-subunit-containing arm is approximately 13.9 nn, and each alpha-subunit-containing arm is 8.6 nm in length. The model presented is the first description of the insulin receptor visualized in a fully hydrated state using cryo-electron microscopy.	Boston Univ, Sch Med, Dept Biophys, Ctr Adv Biomed Res, Boston, MA 02118 USA; Boston Univ, Sch Med, Dept Biochem, Ctr Adv Biomed Res, Boston, MA 02118 USA	Boston University; Boston University	Shipley, GG (corresponding author), Boston Univ, Sch Med, Dept Biophys, Ctr Adv Biomed Res, 80 E Concord St, Boston, MA 02118 USA.		Lee, Jongsoon/AAG-1674-2020	Shipley, G./0000-0001-9603-5555; Pilch, Paul/0000-0003-1997-0499; Lee, Jongsoon/0000-0002-0891-5059	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL057405, T32HL007429] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK036424] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 57405, HL 07429] Funding Source: Medline; NIDDK NIH HHS [DK 36424] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BAJAJ M, 1987, BIOCHIM BIOPHYS ACTA, V916, P220, DOI 10.1016/0167-4838(87)90112-9; CHEATHAM B, 1992, J BIOL CHEM, V267, P7108; CHEATHAM B, 1995, ENDOCR REV, V16, P117, DOI 10.1210/er.16.2.117; CHRISTIANSEN K, 1991, P NATL ACAD SCI USA, V88, P249, DOI 10.1073/pnas.88.1.249; DEVOS AM, 1992, SCIENCE, V255, P306, DOI 10.1126/science.1549776; DUBOCHET J, 1988, Q REV BIOPHYS, V21, P129, DOI 10.1017/S0033583500004297; EBINA Y, 1985, CELL, V40, P747, DOI 10.1016/0092-8674(85)90334-4; Eck MJ, 1996, CELL, V85, P695, DOI 10.1016/S0092-8674(00)81236-2; EYTAN GD, 1982, BIOCHIM BIOPHYS ACTA, V694, P185, DOI 10.1016/0304-4157(82)90024-7; Frank J, 1996, J STRUCT BIOL, V116, P190, DOI 10.1006/jsbi.1996.0030; FRATTALI AL, 1992, J BIOL CHEM, V267, P19521; Garrett TPJ, 1998, NATURE, V394, P395, DOI 10.1038/28668; HAINFELD JF, 1992, J HISTOCHEM CYTOCHEM, V40, P177, DOI 10.1177/40.2.1552162; HARRIS WJ, 1962, NATURE, V196, P499, DOI 10.1038/196499b0; HOLLENBERG MD, 1976, METHODS RECEPTOR R 2, P429; HOPE MJ, 1985, BIOCHIM BIOPHYS ACTA, V812, P55, DOI 10.1016/0005-2736(85)90521-8; Hubbard SR, 1997, EMBO J, V16, P5572, DOI 10.1093/emboj/16.18.5572; HUBBARD SR, 1994, NATURE, V372, P746, DOI 10.1038/372746a0; JOHNSON JD, 1988, P NATL ACAD SCI USA, V85, P7516, DOI 10.1073/pnas.85.20.7516; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lee J, 1997, BIOCHEMISTRY-US, V36, P2701, DOI 10.1021/bi961815g; LEE JS, 1993, J BIOL CHEM, V268, P4092; LEE JS, 1994, AM J PHYSIOL, V266, pC319, DOI 10.1152/ajpcell.1994.266.2.C319; Lu KH, 1996, MOL BIOL CELL, V7, P679, DOI 10.1091/mbc.7.5.679; MASSAGUE J, 1982, J BIOL CHEM, V257, P6729; McKern NM, 1997, PROTEIN SCI, V6, P2663; OHARE T, 1989, J BIOL CHEM, V264, P602; RIDGE KD, 1988, P NATL ACAD SCI USA, V85, P9489, DOI 10.1073/pnas.85.24.9489; SCHAEFER EM, 1992, J BIOL CHEM, V267, P23393; Shepherd PR, 1998, BIOCHEM J, V333, P471, DOI 10.1042/bj3330471; SHIA MA, 1983, BIOCHEMISTRY-US, V22, P717, DOI 10.1021/bi00273a001; SHIA MA, 1983, J BIOL CHEM, V258, P4450; SHOELSON SE, 1993, J BIOL CHEM, V268, P4085; Sparrow LG, 1997, J BIOL CHEM, V272, P29460, DOI 10.1074/jbc.272.47.29460; SWEET LJ, 1985, BIOCHEMISTRY-US, V24, P6571, DOI 10.1021/bi00344a040; TRANUMJENSEN J, 1994, J MEMBRANE BIOL, V140, P215; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; ULLRICH A, 1985, NATURE, V313, P756, DOI 10.1038/313756a0; VANOBBERGHEN E, 1981, P NATL ACAD SCI-BIOL, V78, P1052; WARD CW, 1995, PROTEINS, V22, P141, DOI 10.1002/prot.340220207; WHITE MF, 1994, J BIOL CHEM, V269, P1; WILDEN PA, 1986, BIOCHEMISTRY-US, V25, P4381, DOI 10.1021/bi00363a031	42	23	24	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 3	1999	274	49					34981	34992		10.1074/jbc.274.49.34981	http://dx.doi.org/10.1074/jbc.274.49.34981			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	260XW	10574975	hybrid			2022-12-25	WOS:000083979600069
J	Hans, MA; Muller, M; Meyer-Ficca, M; Burkle, A; Kupper, JH				Hans, MA; Muller, M; Meyer-Ficca, M; Burkle, A; Kupper, JH			Overexpression of dominant negative PARP interferes with tumor formation of HeLa cells in nude mice: Evidence for increased tumor cell apoptosis in vivo	ONCOGENE			English	Article						apoptosis; DNA damage; PARP; transfection; tumorigenesis	HUMAN POLY(ADP-RIBOSE) POLYMERASE; DNA-BINDING DOMAIN; TRANSDOMINANT INHIBITION; GAMMA-IRRADIATION; MAMMALIAN-CELLS; HAMSTER-CELLS; CLEAVAGE; PROTEASE; REPAIR; MUTANT	Poly(ADP-ribose) polymerase (PARP(4)) catalyzes the formation of ADP-ribose polymers covalently attached to proteins by using NAD(+) as substrate. PARP is strongly activated by DNA single- or double-strand breaks and is thought to be involved in cellular responses to DNA damage. We characterized a dominant negative PARP mutant, i.e, the DNA-binding domain of this enzyme, whose overexpression in cells leads to increased genetic instability following DNA damage. In order to study whether PARP activity is also implicated in the process of tumorigenesis, me generated stably transfected HeLa cell clones with constitutive overexpression of dominant negative PARP and investigated tumor formation of these clones in nude mice. We found that inhibition of PARP activity dramatically reduces tumor forming ability of HeLa cells. Moreover, me provide strong evidence that the observed reduction in tumor forming ability is due to increased tumor cell apoptosis in viva. Viewed together, our data and those from other groups show that inhibition of PARP enzyme activity interferes with DNA base excision repair and leads to increased genetic instability and recombination but, on the other hand, can sensitize cells to apoptotic stimuli and by this mechanism may prevent tumor formation.	Univ Tubingen, Dept Mol Pathol, D-72076 Tubingen, Germany; German Canc Res Ctr, Dept Tumorvirol, D-69120 Heidelberg, Germany	Eberhard Karls University of Tubingen; Helmholtz Association; German Cancer Research Center (DKFZ)	Kupper, JH (corresponding author), Univ Tubingen, Dept Mol Pathol, Liebermeisterstr 8, D-72076 Tubingen, Germany.		Meyer-Ficca, Mirella/P-1771-2014	Meyer-Ficca, Mirella/0000-0002-9949-8157				Butler AJ, 1999, MOL CELL BIOL, V19, P296; Jeggo PA, 1998, CURR BIOL, V8, pR49, DOI 10.1016/S0960-9822(98)70032-6; KAUFMANN SH, 1993, CANCER RES, V53, P3976; Kawamitsu H, 1983, Princess Takamatsu Symp, V13, P41; KORSMEYER SJ, 1995, TRENDS GENET, V11, P101, DOI 10.1016/S0168-9525(00)89010-1; Kupper JH, 1996, CANCER RES, V56, P2715; KUPPER JH, 1990, J BIOL CHEM, V265, P18721; Kupper JH, 1996, CYTOTECHNOLOGY, V21, P225, DOI 10.1007/BF00365345; KUPPER JH, 1995, MOL CELL BIOL, V15, P3154; LAMARRE D, 1988, BIOCHIM BIOPHYS ACTA, V950, P147, DOI 10.1016/0167-4781(88)90007-3; LINDAHL T, 1995, TRENDS BIOCHEM SCI, V20, P405, DOI 10.1016/S0968-0004(00)89089-1; MOLINETE M, 1993, EMBO J, V12, P2109, DOI 10.1002/j.1460-2075.1993.tb05859.x; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; Oei SL, 1998, BIOCHEMISTRY-US, V37, P1465, DOI 10.1021/bi9727390; Oliver FJ, 1998, J BIOL CHEM, V273, P33533, DOI 10.1074/jbc.273.50.33533; SATOH MS, 1993, J BIOL CHEM, V268, P5480; SCHREIBER V, 1995, P NATL ACAD SCI USA, V92, P4753, DOI 10.1073/pnas.92.11.4753; Simbulan-Rosenthal CM, 1998, J BIOL CHEM, V273, P13703, DOI 10.1074/jbc.273.22.13703; Song QZ, 1996, EMBO J, V15, P3238, DOI 10.1002/j.1460-2075.1996.tb00688.x; Teraoka H, 1996, FEBS LETT, V393, P1, DOI 10.1016/0014-5793(96)00842-3; TEWARI M, 1995, CELL, V81, P801, DOI 10.1016/0092-8674(95)90541-3; VanGool L, 1997, EUR J BIOCHEM, V244, P15; Wang ZQ, 1997, GENE DEV, V11, P2347, DOI 10.1101/gad.11.18.2347; WHITAKER JR, 1980, ANAL BIOCHEM, V109, P156, DOI 10.1016/0003-2697(80)90024-X	24	20	23	2	7	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 25	1999	18	50					7010	7015		10.1038/sj.onc.1203178	http://dx.doi.org/10.1038/sj.onc.1203178			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	259PH	10597301	Bronze			2022-12-25	WOS:000083901900007
J	Lu, YL; Lin, YZ; LaPushin, R; Cuevas, B; Fang, XJ; Yu, SX; Davies, MA; Khan, H; Furui, T; Mao, ML; Zinner, R; Hung, MC; Steck, P; Siminovitch, K; Mills, GB				Lu, YL; Lin, YZ; LaPushin, R; Cuevas, B; Fang, XJ; Yu, SX; Davies, MA; Khan, H; Furui, T; Mao, ML; Zinner, R; Hung, MC; Steck, P; Siminovitch, K; Mills, GB			The PTEN/MMAC1/TEP tumor suppressor gene decreases cell growth and induces apoptosis and anoikis in breast cancer cells	ONCOGENE			English	Article						PTEN/MMAC1; PI3-K (phosphatidylinositol 3-kinase); breast cancer; apoptosis; anoikis; cell cycle arrest	GLYCOGEN-SYNTHASE KINASE-3; IN-VITRO; PHOSPHATASE-ACTIVITY; GLIOBLASTOMA CELLS; GLIOMA-CELLS; PTEN; PHOSPHORYLATION; ACTIVATION; SURVIVAL; DEATH	The PTEN/MMAC1/TEP (PTEN) tumor suppressor gene at 10q23.3 is mutated in multiple types of sporadic tumors including breast cancers and also in the germline of patients with the Cowden's breast cancer predisposition syndrome. The PTEN gene encodes a multifunctional phosphatase capable of dephosphorylating the same sites in membrane phosphatidylinositols phosphorylated by phosphatidylinositol 3'-kinase (PI3K). We demonstrate herein that loss of PTEN function in breast cancer cells results in an increase in basal levels of phosphorylation of multiple components of the PI3K signaling cascade as web as an increase in duration of ligand-induced signaling through the PI3K cascade. These alterations are reversed by wild-type but not phosphatase inactive PTEN. In the presence of high concentrations of serum, enforced expression of PTEN induces a predominant G1 arrest consistent with the capacity of PTEN to evoke increases in the expression of the p27Kip1 cyclin dependent kinase inhibitor. In the presence of low concentrations of serum, enforced PTEN expression results in a marked increase in cellular apoptosis, a finding which is consistent with the capacity of PTEN to alter the phosphorylation, and presumably function, of the AKT, BAD, p70S6 kinase and GSK3 alpha apoptosis regulators. Under anchorage-independent conditions, PTEN also induces anoikis, a form of apoptosis that occurs when cells are dissociated from the extracellular matrix, which is enhanced in conjunction with low serum culture conditions. Together, these data suggest that PTEN effects on the PI3K signaling cascade are influenced by the cell stimulatory context, and that depending on the exposure to growth factors and other exogenous stimuli such as integrin ligation, PTEN can induce cell cycle arrest, apoptosis or anoikis in breast cancer cells.	Univ Texas, MD Anderson Canc Ctr, Dept Mol Oncol, Div Med, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Neurooncol, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Canc Biol, Houston, TX 77030 USA; Univ Toronto, Dept Med Immunol & Mol & Med Genet, Toronto, ON M5G 1X5, Canada	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Toronto	Mills, GB (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Mol Oncol, Div Med, 1515 Holcombe Blvd,Box 092, Houston, TX 77030 USA.		Siminovitch, Katherine/K-1475-2013; Hung, Mien-Chie/ABD-5911-2021; Davies, Michael/GWV-2527-2022	Hung, Mien-Chie/0000-0003-4317-4740; 	NATIONAL CANCER INSTITUTE [R01CA071418] Funding Source: NIH RePORTER; NCI NIH HHS [CA71418] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BATES SE, 1990, ENDOCRINOLOGY, V126, P596, DOI 10.1210/endo-126-1-596; Cardone MH, 1998, SCIENCE, V282, P1318, DOI 10.1126/science.282.5392.1318; Cheney IW, 1998, CANCER RES, V58, P2331; Cheyney IW, 1999, CANCER RES, V59, P2318; CHOU MM, 1995, CURR OPIN CELL BIOL, V7, P806, DOI 10.1016/0955-0674(95)80064-6; Coffer PJ, 1998, BIOCHEM J, V335, P1; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; Davies MA, 1999, CANCER RES, V59, P2551; Davies MA, 1998, CANCER RES, V58, P5285; Delcommenne M, 1998, P NATL ACAD SCI USA, V95, P11211, DOI 10.1073/pnas.95.19.11211; DICRISTOFANO A, 1998, LEUKEMIA, V12, P1277; Downward J, 1998, CURR OPIN GENET DEV, V8, P49, DOI 10.1016/S0959-437X(98)80061-0; Dumont FJ, 1995, LIFE SCI, V58, P373, DOI 10.1016/0024-3205(95)02233-3; Frisch SM, 1997, CURR OPIN CELL BIOL, V9, P701, DOI 10.1016/S0955-0674(97)80124-X; Furnari FB, 1998, CANCER RES, V58, P5002; FURNARI FB, 1997, CANCER RES, V57, P4997; Haas-Kogan D, 1998, CURR BIOL, V8, P1195, DOI 10.1016/S0960-9822(07)00493-9; HANSEN MB, 1989, J IMMUNOL METHODS, V119, P203, DOI 10.1016/0022-1759(89)90397-9; Howe A, 1998, CURR OPIN CELL BIOL, V10, P220, DOI 10.1016/S0955-0674(98)80144-0; Koester SK, 1997, CYTOMETRY, V29, P306; Li DM, 1997, CANCER RES, V57, P2124; Li DM, 1998, P NATL ACAD SCI USA, V95, P15406, DOI 10.1073/pnas.95.26.15406; Li J, 1998, CANCER RES, V58, P5667; LI J, 1997, NAT GENET, V15, P356; LIAW D, 1997, CANCER RES, V57, P2124; Liu TJ, 1999, CANCER GENE THER, V6, P163, DOI 10.1038/sj.cgt.7700007; Maehama T, 1998, J BIOL CHEM, V273, P13375, DOI 10.1074/jbc.273.22.13375; MARSH DJ, 1997, HUM MOL GENET, V6, P1383; Myers MP, 1997, P NATL ACAD SCI USA, V94, P9052, DOI 10.1073/pnas.94.17.9052; Myers MP, 1998, P NATL ACAD SCI USA, V95, P13513, DOI 10.1073/pnas.95.23.13513; Pap M, 1998, J BIOL CHEM, V273, P19929, DOI 10.1074/jbc.273.32.19929; PARSONS R, 1998, ONCOGENE, V16, P89; Pepper C, 1998, LEUKEMIA RES, V22, P439, DOI 10.1016/S0145-2126(98)00013-7; Podsypanina K, 1999, P NATL ACAD SCI USA, V96, P1563, DOI 10.1073/pnas.96.4.1563; Pullen N, 1997, FEBS LETT, V410, P78, DOI 10.1016/S0014-5793(97)00323-2; Ramaswamy S, 1999, P NATL ACAD SCI USA, V96, P2110, DOI 10.1073/pnas.96.5.2110; SCHULTZ RM, 1995, ANTICANCER RES, V15, P1135; Shayesteh L, 1999, NAT GENET, V21, P99, DOI 10.1038/5042; SHI YF, 1995, CANCER RES, V55, P1982; Stambolic V, 1998, CELL, V95, P29, DOI 10.1016/S0092-8674(00)81780-8; STECK PA, 1997, NAT GENET, V16, P64; Sun H, 1999, P NATL ACAD SCI USA, V96, P6199, DOI 10.1073/pnas.96.11.6199; Suzuki A, 1998, CURR BIOL, V8, P1169, DOI 10.1016/S0960-9822(07)00488-5; Tamura M, 1999, CANCER RES, V59, P442; TAMURA M, 1998, CANCER RES, V58, P2331; Teng DHF, 1997, CANCER RES, V57, P5221; Tian XX, 1999, J NEUROPATH EXP NEUR, V58, P472, DOI 10.1097/00005072-199905000-00006; VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241; Werner H, 1997, CRIT REV ONCOGENESIS, V8, P71, DOI 10.1615/CritRevOncog.v8.i1.40; Wu XY, 1998, P NATL ACAD SCI USA, V95, P15587, DOI 10.1073/pnas.95.26.15587; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326	51	260	289	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 25	1999	18	50					7034	7045		10.1038/sj.onc.1203183	http://dx.doi.org/10.1038/sj.onc.1203183			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	259PH	10597304				2022-12-25	WOS:000083901900010
J	Qiu, SG; Krishnan, S; El-Guendy, N; Rangnekar, VM				Qiu, SG; Krishnan, S; El-Guendy, N; Rangnekar, VM			Negative regulation of Par-4 by oncogenic Ras is essential for cellular transformation	ONCOGENE			English	Article						Ras; Par-4; ERK; transformation	PROTEIN-KINASE-C; MAMMALIAN-CELL; GROWTH ARREST; GENE; PHOSPHORYLATION; APOPTOSIS; ACTIVATION; SURVIVAL; INHIBITION; EXPRESSION	Oncogenic variants of the cellular Ras protein are often associated with different types of human cancers. However, the mechanisms by which oncogenic Ras induces transformation are not fully established. Expression of the transcriptional repressor Par-4 was downregulated by oncogenic Ras via the Raf-MEK-ERK pathway. Restoration of Par-4 levels by abrogation of the Raf-MEK-ERK pathway with the MEK-inhibitor PD98059 or by ectopic Par-4, that acted to inhibit ERK expression and activation, was sufficient to suppress oncogenic Ras-induced transformation. These findings identify Par-4 as a novel target that has to be downmodulated by oncogenic Ras for successful transformation.	Univ Kentucky, Dept Surg, Lexington, KY 40536 USA; Univ Kentucky, Lucille P Markey Canc Ctr, Lexington, KY 40536 USA	University of Kentucky; University of Kentucky	Rangnekar, VM (corresponding author), Univ Kentucky, Dept Surg, Combs Res Bldg,Room 303,800 Rose St, Lexington, KY 40536 USA.			El-Guendy, Nadia/0000-0002-0770-3740	NCI NIH HHS [R01 CA60872] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA060872] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bergmann A, 1998, CELL, V95, P331, DOI 10.1016/S0092-8674(00)81765-1; Berra E, 1997, MOL CELL BIOL, V17, P4346, DOI 10.1128/MCB.17.8.4346; Berra E, 1998, J BIOL CHEM, V273, P10792, DOI 10.1074/jbc.273.17.10792; Boghaert ER, 1997, CELL GROWTH DIFFER, V8, P881; BOS JL, 1989, CANCER RES, V49, P4682; Cardone MH, 1998, SCIENCE, V282, P1318, DOI 10.1126/science.282.5392.1318; Clerk A, 1998, FEBS LETT, V426, P93, DOI 10.1016/S0014-5793(98)00324-X; Cook J, 1999, ONCOGENE, V18, P1205, DOI 10.1038/sj.onc.1202416; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; delPeso L, 1997, SCIENCE, V278, P687; Denhardt DT, 1996, BIOCHEM J, V318, P729, DOI 10.1042/bj3180729; DER CJ, 1982, P NATL ACAD SCI-BIOL, V79, P3637, DOI 10.1073/pnas.79.11.3637; DiazMeco MT, 1996, CELL, V86, P777, DOI 10.1016/S0092-8674(00)80152-X; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; Finco TS, 1997, J BIOL CHEM, V272, P24113, DOI 10.1074/jbc.272.39.24113; GALANG CK, 1994, ONCOGENE, V9, P2913; GALLEGO C, 1992, P NATL ACAD SCI USA, V89, P7355, DOI 10.1073/pnas.89.16.7355; Guo Q, 1998, NAT MED, V4, P957, DOI 10.1038/nm0898-957; Johnstone RW, 1996, MOL CELL BIOL, V16, P6945; KISS Z, 1995, FEBS LETT, V357, P279, DOI 10.1016/0014-5793(94)01371-7; Kurada P, 1998, CELL, V95, P319, DOI 10.1016/S0092-8674(00)81764-X; LIN XY, 1995, MOL CELL BIOL, V15, P2754; MARSHALL MS, 1995, FASEB J, V9, P1311, DOI 10.1096/fasebj.9.13.7557021; Marte BM, 1997, TRENDS BIOCHEM SCI, V22, P355, DOI 10.1016/S0968-0004(97)01097-9; Mayo MW, 1997, SCIENCE, V278, P1812, DOI 10.1126/science.278.5344.1812; Meier P, 1998, CELL, V95, P295, DOI 10.1016/S0092-8674(00)81760-2; Muthukkumar S, 1996, J BIOL CHEM, V271, P5733, DOI 10.1074/jbc.271.10.5733; PARK M, 1998, GENETIC BASIS HUMAN, P205; Qiu GF, 1999, ONCOGENE, V18, P623, DOI 10.1038/sj.onc.1202344; RANGNEKAR VV, 1992, J BIOL CHEM, V267, P6240; Robinson MJ, 1998, CURR BIOL, V8, P1141, DOI 10.1016/S0960-9822(07)00485-X; Sells SF, 1997, MOL CELL BIOL, V17, P3823, DOI 10.1128/MCB.17.7.3823; SELLS SF, 1994, CELL GROWTH DIFFER, V5, P457; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WHITE MA, 1995, CELL, V80, P533, DOI 10.1016/0092-8674(95)90507-3	35	53	54	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 25	1999	18	50					7115	7123		10.1038/sj.onc.1203199	http://dx.doi.org/10.1038/sj.onc.1203199			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	259PH	10597313				2022-12-25	WOS:000083901900019
J	Yoon, Y; Ao, ZH; Cheng, Y; Schlossman, SF; Prasad, KVS				Yoon, Y; Ao, ZH; Cheng, Y; Schlossman, SF; Prasad, KVS			Murine Siva-1 and Siva-2, alternate splice forms of the mouse Siva gene, both bind to CD27 but differentially transduce apoptosis	ONCOGENE			English	Article						Siva; CD27; apoptosis; alternate splice forms; murine Siva gene; TNFR family	NECROSIS-FACTOR RECEPTOR; NF-KAPPA-B; DOMAIN-CONTAINING RECEPTOR; T-CELL ACTIVATION; RING FINGER PROTEIN; DEATH-DOMAIN; CYTOPLASMIC DOMAIN; SIGNAL-TRANSDUCTION; KINASE RIP; FAMILY	CD27, a member of the TNFR family known to provide essential co-stimulatory signals for T cell growth and B cell Ig synthesis, can also mediate cell death. Using the CD27 cytoplasmic tail as the bait in yeast two hybrid assay, me previously cloned human Siva, a pro-apoptotic molecule. Here me report the characterization of the mouse Siva gene as a 4 kb sequence containing 4 exons and 3 introns. RT-PCR has revealed the presence of two forms of mouse Siva mRNA, the longer full length form Siva-1 and the shorter Siva-2 lacking the sequence coded by exon 2. Immunoblotting with anti-Siva (human) antibodies clearly demonstrate the presence of both Siva-1 and Siva-2. Cotransfection experiments in 293T cells reveal that mouse CD27 receptor can interact with both forms of Siva. Although mouse Siva-1 can trigger apoptosis in Rat-1 cells and in some of the mouse cell lines in transient transfection experiments, similar to the observation made with human Siva, intriguingly its alternate splice form, Siva-2 appears to be much less toxic. It is therefore likely that Siva-2 could regulate the function of Siva-1.	Dana Farber Canc Inst, Div Tumor Immunol, Dept Canc Immunol & Aids, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Med, Boston, MA 02115 USA	Harvard University; Dana-Farber Cancer Institute; Harvard University; Harvard Medical School	Prasad, KVS (corresponding author), Dana Farber Canc Inst, Div Tumor Immunol, Dept Canc Immunol & Aids, M552,44 Binney St, Boston, MA 02115 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM056706] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM56706] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AGEMATSU K, 1994, J IMMUNOL, V153, P1421; Akiba H, 1998, J BIOL CHEM, V273, P13353, DOI 10.1074/jbc.273.21.13353; Baker SJ, 1996, ONCOGENE, V12, P1; Bodmer JL, 1997, IMMUNITY, V6, P79, DOI 10.1016/S1074-7613(00)80244-7; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; CAMERINI D, 1991, J IMMUNOL, V147, P3165; CHENG GH, 1995, SCIENCE, V267, P1494, DOI 10.1126/science.7533327; Cheng GH, 1996, GENE DEV, V10, P963, DOI 10.1101/gad.10.8.963; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; Chinnaiyan AM, 1996, SCIENCE, V274, P990, DOI 10.1126/science.274.5289.990; CORY S, 1995, ANNU REV IMMUNOL, V13, P513, DOI 10.1146/annurev.iy.13.040195.002501; Gedrich RW, 1996, J BIOL CHEM, V271, P12852, DOI 10.1074/jbc.271.22.12852; GRAVESTEIN LA, 1993, EUR J IMMUNOL, V23, P943, DOI 10.1002/eji.1830230427; HINTZEN RQ, 1995, J IMMUNOL, V154, P2612; HSU HL, 1995, CELL, V81, P495, DOI 10.1016/0092-8674(95)90070-5; Hsu HL, 1996, IMMUNITY, V4, P387, DOI 10.1016/S1074-7613(00)80252-6; Hsu HL, 1996, CELL, V84, P299, DOI 10.1016/S0092-8674(00)80984-8; HU HM, 1994, J BIOL CHEM, V269, P30069; ITOH N, 1993, J BIOL CHEM, V268, P10932; Jacquot S, 1997, J IMMUNOL, V159, P2652; Kelliher MA, 1998, IMMUNITY, V8, P297, DOI 10.1016/S1074-7613(00)80535-X; Kitson J, 1996, NATURE, V384, P372, DOI 10.1038/384372a0; KOBATA T, 1995, P NATL ACAD SCI USA, V92, P11249, DOI 10.1073/pnas.92.24.11249; KOBATA T, 1994, J IMMUNOL, V153, P5422; Lee SY, 1996, J EXP MED, V183, P669, DOI 10.1084/jem.183.2.669; Lee SY, 1996, P NATL ACAD SCI USA, V93, P9699, DOI 10.1073/pnas.93.18.9699; MCDONALD NQ, 1993, CELL, V73, P421, DOI 10.1016/0092-8674(93)90127-C; MOSIALOS G, 1995, CELL, V80, P389, DOI 10.1016/0092-8674(95)90489-1; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; Nakano H, 1996, J BIOL CHEM, V271, P14661, DOI 10.1074/jbc.271.25.14661; Nocentini G, 1997, P NATL ACAD SCI USA, V94, P6216, DOI 10.1073/pnas.94.12.6216; Padanilam BJ, 1998, KIDNEY INT, V54, P1967, DOI 10.1046/j.1523-1755.1998.00197.x; Pan GH, 1997, SCIENCE, V276, P111, DOI 10.1126/science.276.5309.111; Prasad KVS, 1997, P NATL ACAD SCI USA, V94, P6346, DOI 10.1073/pnas.94.12.6346; REGNIER CH, 1995, J BIOL CHEM, V270, P25715, DOI 10.1074/jbc.270.43.25715; ROTHE M, 1995, SCIENCE, V269, P1424, DOI 10.1126/science.7544915; ROTHE M, 1994, CELL, V78, P681, DOI 10.1016/0092-8674(94)90532-0; SATO T, 1995, FEBS LETT, V358, P113, DOI 10.1016/0014-5793(94)01406-Q; Screaton GR, 1997, P NATL ACAD SCI USA, V94, P4615, DOI 10.1073/pnas.94.9.4615; SMITH CA, 1994, CELL, V76, P959, DOI 10.1016/0092-8674(94)90372-7; SONG HY, 1995, BIOCHEM J, V309, P825, DOI 10.1042/bj3090825; STANGER BZ, 1995, CELL, V81, P513, DOI 10.1016/0092-8674(95)90072-1; TARTAGLIA LA, 1993, CELL, V74, P845, DOI 10.1016/0092-8674(93)90464-2; Ting AT, 1996, EMBO J, V15, P6189, DOI 10.1002/j.1460-2075.1996.tb01007.x; Walsh CM, 1998, IMMUNITY, V8, P439, DOI 10.1016/S1074-7613(00)80549-X; Yang E, 1996, BLOOD, V88, P386, DOI 10.1182/blood.V88.2.386.bloodjournal882386; Yang XL, 1997, CELL, V89, P1067, DOI 10.1016/S0092-8674(00)80294-9; Zhang JK, 1998, NATURE, V392, P296, DOI 10.1038/32681	49	42	46	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 25	1999	18	50					7174	7179		10.1038/sj.onc.1203144	http://dx.doi.org/10.1038/sj.onc.1203144			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	259PH	10597319				2022-12-25	WOS:000083901900025
J	Furth, PA; Bar-Peled, U; Li, ML; Lewis, A; Laucirica, R; Jager, R; Weiher, H; Russell, RG				Furth, PA; Bar-Peled, U; Li, ML; Lewis, A; Laucirica, R; Jager, R; Weiher, H; Russell, RG			Loss of anti-mitotic effects of Bcl-2 with retention of anti-apoptotic activity during tumor progression in a mouse model	ONCOGENE			English	Article						Bcl-2; cancer progression; mitosis; apoptosis; mouse model	DEPENDENT PROTEIN-KINASES; CELL-CYCLE PROGRESSION; LYMPH-NODE METASTASES; LARGE-T-ANTIGEN; BREAST-CANCER; MAMMARY-GLAND; REDUCES PROLIFERATION; TRANSGENE EXPRESSION; SUPPRESSION; FAMILY	Bcl-2 is an anti-apoptotic and anti-proliferative protein over-expressed in several different human cancers including breast, Gain of Bcl-2 function in mammary epithelial cells was superimposed on the WAP-TAg transgenic mouse model of breast cancer progression to determine its effect on epithelial cell survival and proliferation at three key stages in oncogenesis: the initial proliferative process, hyperplasia, and cancer. During the initial proliferative process, Bcl-2 strongly inhibited both apoptosis and mitotic activity. However as tumorigenesis progressed to hyperplasia and adenocarcinoma, the inhibitory effects on mitotic activity were lost. In contrast, anti-apoptotic activity persisted in both hyperplasias and adenocarcinomas. These results demonstrate that the inhibitory effect of Bcl-2 on epithelial cell proliferation and apoptosis can separate during cancer progression. In this model, retention of anti-apoptotic activity with loss of anti-proliferative action resulted in earlier tumor presentation.	Univ Maryland, Ctr Med Biotechnol, Inst Human Virol, Sch Med,Dept Med,Div Infect Dis, Baltimore, MD 21201 USA; Baltimore Vet Affairs Med Ctr, Baltimore, MD 21201 USA; Univ Maryland, Sch Med, Dept Physiol, Baltimore, MD 21201 USA; Baylor Coll Med, Houston, TX 77030 USA; Methodist Hosp, Houston, TX 77030 USA; Forschungszentrum Karlsruhe, Inst Genet, D-76021 Karlsruhe, Germany; Inst Diabet Forsch, D-80804 Munich, Germany	University System of Maryland; University of Maryland Baltimore; US Department of Veterans Affairs; Veterans Health Administration (VHA); Baltimore VA Medical Center; University System of Maryland; University of Maryland Baltimore; Baylor College of Medicine; The Methodist Hospital System; The Methodist Hospital - Houston; Helmholtz Association; Karlsruhe Institute of Technology	Furth, PA (corresponding author), Univ Maryland, Ctr Med Biotechnol, Inst Human Virol, Sch Med,Dept Med,Div Infect Dis, 725 W Lombard St,Room N545, Baltimore, MD 21201 USA.		Jager, Richard/B-9478-2009	Jager, Richard/0000-0002-1623-1917	NATIONAL CANCER INSTITUTE [R29CA068033] Funding Source: NIH RePORTER; NCI NIH HHS [CA-68033] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; BASOLO F, 1994, INT J CANCER, V56, P736, DOI 10.1002/ijc.2910560521; Bonetti A, 1998, CLIN CANCER RES, V4, P2331; Borner C, 1996, J BIOL CHEM, V271, P12695, DOI 10.1074/jbc.271.22.12695; Bottinger EP, 1997, CANCER RES, V57, P5564; Castano E, 1998, MOL CELL BIOL, V18, P5380, DOI 10.1128/MCB.18.9.5380; Coats S, 1999, CURR BIOL, V9, P163, DOI 10.1016/S0960-9822(99)80086-4; DeLuca A, 1997, J BIOL CHEM, V272, P20971, DOI 10.1074/jbc.272.34.20971; DEMERIL D, 1996, CANCER, V77, P1494; FRANCH HA, 1995, J CELL BIOL, V129, P245, DOI 10.1083/jcb.129.1.245; Frankfurt OS, 1997, CLIN CANCER RES, V3, P465; GASPARINI G, 1995, CLIN CANCER RES, V1, P189; Gil-Gomez G, 1998, EMBO J, V17, P7209, DOI 10.1093/emboj/17.24.7209; Hakem A, 1999, J EXP MED, V189, P957, DOI 10.1084/jem.189.6.957; Huang DCS, 1997, EMBO J, V16, P4628, DOI 10.1093/emboj/16.15.4628; Jager R, 1997, ONCOGENE, V15, P1787, DOI 10.1038/sj.onc.1201353; JERRY DJ, 1994, MOL CARCINOGEN, V9, P175, DOI 10.1002/mc.2940090309; Kitada S, 1998, AM J PATHOL, V152, P51; KORSMEYER SJ, 1992, BLOOD, V80, P879; Li ML, 1996, CELL GROWTH DIFFER, V7, P3; Li ML, 1996, CELL GROWTH DIFFER, V7, P13; Lind EF, 1999, J IMMUNOL, V162, P5374; Linette GP, 1996, P NATL ACAD SCI USA, V93, P9545, DOI 10.1073/pnas.93.18.9545; Meikrantz W, 1996, J BIOL CHEM, V271, P10205, DOI 10.1074/jbc.271.17.10205; MEIKRANTZ W, 1994, P NATL ACAD SCI USA, V91, P3754, DOI 10.1073/pnas.91.9.3754; MOSES HL, 1992, MOL REPROD DEV, V32, P179, DOI 10.1002/mrd.1080320215; OReilly LA, 1997, J IMMUNOL, V159, P2301; OReilly LA, 1997, INT IMMUNOL, V9, P1291, DOI 10.1093/intimm/9.9.1291; PIERCE DF, 1995, P NATL ACAD SCI USA, V92, P4254, DOI 10.1073/pnas.92.10.4254; PIETENPOL JA, 1994, CANCER RES, V54, P3714; Pillai MR, 1996, CANCER EPIDEM BIOMAR, V5, P329; Ravaioli A, 1998, CELL PROLIFERAT, V31, P113; SAEGUSA M, 1995, CANCER, V76, P2297, DOI 10.1002/1097-0142(19951201)76:11<2297::AID-CNCR2820761118>3.0.CO;2-B; Schorr K, 1999, CANCER RES, V59, P2541; Schorr K, 1999, J MAMMARY GLAND BIOL, V4, P153, DOI 10.1023/A:1018773123899; SCHWARZ JK, 1995, P NATL ACAD SCI USA, V92, P483, DOI 10.1073/pnas.92.2.483; SHANKEY TV, 1993, CYTOMETRY, V14, P472, DOI 10.1002/cyto.990140503; Shiyanov P, 1996, MOL CELL BIOL, V16, P737; Sierra A, 1996, CLIN CANCER RES, V2, P1887; Strom DK, 1998, CELL GROWTH DIFFER, V9, P59; Theodorakis P, 1996, ONCOGENE, V12, P1707; TSUJIMOTO Y, 1984, SCIENCE, V226, P1097, DOI 10.1126/science.6093263; TZENG YJ, 1993, ONCOGENE, V8, P1965; Uhlmann EJ, 1996, CANCER RES, V56, P2506; VINDELOV LL, 1983, CYTOMETRY, V3, P323, DOI 10.1002/cyto.990030503; Zalvide J, 1998, MOL CELL BIOL, V18, P1408, DOI 10.1128/MCB.18.3.1408; Zapata JM, 1998, BREAST CANCER RES TR, V47, P129, DOI 10.1023/A:1005940832123; Zhang GJ, 1998, ONCOL REP, V5, P1211	48	42	42	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 11	1999	18	47					6589	6596		10.1038/sj.onc.1203073	http://dx.doi.org/10.1038/sj.onc.1203073			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	256CW	10597263				2022-12-25	WOS:000083709200023
J	Haribabu, B; Zhelev, DV; Pridgen, BC; Richardson, RM; Ali, H; Snyderman, R				Haribabu, B; Zhelev, DV; Pridgen, BC; Richardson, RM; Ali, H; Snyderman, R			Chemoattractant receptors activate distinct pathways for chemotaxis and secretion - Role of G-protein usage	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE REGULATORY PROTEIN; CHEMOKINE RECEPTORS; SIGNAL-TRANSDUCTION; HUMAN NEUTROPHILS; COUPLED RECEPTOR; CARBOXYL-TERMINUS; ACTIN; PHOSPHORYLATION; MOTILITY; CDC42	Human leukocyte chemoattractant receptors activate chemotactic and cytotoxic pathways to varying degrees and also activate different G-proteins depending on the receptor and the cell-type. To determine the relationship between G-protein usage and the biological and biochemical responses activated, receptors for the chemoattractants formyl peptides (FR), platelet-activating factor (PAFR), and leukotriene B-4 (BLTR) were transfected into RBL-2H3 cells. Pertussis toxin (Ptx) served as a G alpha(i) inhibitor. These receptors were chosen to represent the spectrum of G(i) usage as Ptx had differential effects on their ability to induce calcium mobilization, phosphoinositide hydrolysis, and exocytosis with complete inhibition of all responses by FR, intermediate effects on BLTR, and little effect on PAFR, Ptx did not affect ligand-induced phosphorylation of PAFR and BLTR but inhibited phosphorylation of FR. In contrast, chemotaxis to formylmethionylleucylphenylalanine, leukotriene B-4, and platelet-activating factor was completely blocked by Ptx. Wortmannin, a phosphotidylinositol 3-kinase inhibitor, also completely blocked ligand-induced chemotaxis by all receptors but did not affect calcium mobilization or phosphoinositide hydrolysis; however, it partially blocked the exocytosis response to formylmethionylleucylphenylalanine and the platelet-activating factor. Membrane ruffling and pseudopod extension via the BLTR was also completely inhibited by both Ptx and wortmannin. These data suggest that of the chemoattractant receptors studied, G-protein usage varies with FR being totally dependent on G(i), whereas BLTR and PAFR utilize both G(i) and a Ptx-insensitive G-protein. Both Ptx-sensitive and -insensitive G-protein usage can mediate the activation of phospholipase C, mobilization of intracellular calcium, and exocytosis by chemoattractant receptors, Chemotaxis, however, had an absolute requirement for a G(i)-mediated pathway.	Duke Univ, Med Ctr, Dept Med, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Immunol, Durham, NC 27710 USA; Duke Univ, Dept Mech Engn & Mat Sci, Durham, NC 27708 USA	Duke University; Duke University; Duke University	Haribabu, B (corresponding author), Duke Univ, Med Ctr, Dept Med, Box 3680, Durham, NC 27710 USA.		Bodduluri, Haribabu/A-2584-2010	Bodduluri, Haribabu/0000-0002-8261-3294	NIAID NIH HHS [AI-43184] Funding Source: Medline; NIAMS NIH HHS [AR-39162] Funding Source: Medline; NIDCR NIH HHS [DE-03738] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R29AI043184] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P50AR039162] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE003738] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		ALI H, 1994, J BIOL CHEM, V269, P24557; ALI H, 1993, J BIOL CHEM, V268, P24247; Alteraifi AM, 1997, J CELL SCI, V110, P1967; AMATRUDA TT, 1993, J BIOL CHEM, V268, P10139; Arai H, 1997, P NATL ACAD SCI USA, V94, P14495, DOI 10.1073/pnas.94.26.14495; Arai H, 1996, J BIOL CHEM, V271, P21814, DOI 10.1074/jbc.271.36.21814; BAGGIOLINI M, 1991, BIOCHEM SOC T, V19, P55, DOI 10.1042/bst0190055; BENBARUCH A, 1995, J BIOL CHEM, V270, P9121, DOI 10.1074/jbc.270.16.9121; GERARD C, 1994, CURR OPIN IMMUNOL, V6, P140, DOI 10.1016/0952-7915(94)90045-0; Haribabu B, 1997, J BIOL CHEM, V272, P28726, DOI 10.1074/jbc.272.45.28726; HARTWIG JH, 1995, CELL, V82, P643, DOI 10.1016/0092-8674(95)90036-5; Keely PJ, 1997, NATURE, V390, P632, DOI 10.1038/37656; Knall C, 1997, P NATL ACAD SCI USA, V94, P3052, DOI 10.1073/pnas.94.7.3052; Kuang YN, 1996, J BIOL CHEM, V271, P3975; LINDER ME, 1990, J BIOL CHEM, V265, P8243; Neptune ER, 1999, J BIOL CHEM, V274, P2824, DOI 10.1074/jbc.274.5.2824; Neptune ER, 1997, P NATL ACAD SCI USA, V94, P14489, DOI 10.1073/pnas.94.26.14489; Niggli V, 1997, EUR J PHARMACOL, V335, P43, DOI 10.1016/S0014-2999(97)01169-2; Pitcher JA, 1998, ANNU REV BIOCHEM, V67, P653, DOI 10.1146/annurev.biochem.67.1.653; PROSSNITZ ER, 1995, J BIOL CHEM, V270, P1130, DOI 10.1074/jbc.270.3.1130; Prossnitz ER, 1999, BIOCHEMISTRY-US, V38, P2240, DOI 10.1021/bi982274t; SAMUELSSON B, 1987, SCIENCE, V237, P1171, DOI 10.1126/science.2820055; SNYDERMAN R, 1986, J LEUKOCYTE BIOL, V40, P785, DOI 10.1002/jlb.40.6.785; SNYDERMAN R, 1999, INFLAMMATION BASIC P, P607; Tapon N, 1997, CURR OPIN CELL BIOL, V9, P86, DOI 10.1016/S0955-0674(97)80156-1; TRUETT AP, 1988, P NATL ACAD SCI USA, V85, P1549, DOI 10.1073/pnas.85.5.1549; VERGHESE MW, 1987, J IMMUNOL, V138, P4374; WU DQ, 1993, SCIENCE, V261, P101, DOI 10.1126/science.8316840; Yokomizo T, 1997, NATURE, V387, P620, DOI 10.1038/42506; Zhelev DV, 1996, CELL MOTIL CYTOSKEL, V35, P331; Zigmond SH, 1997, J CELL BIOL, V138, P363, DOI 10.1083/jcb.138.2.363; Zigmond SH, 1996, CURR OPIN CELL BIOL, V8, P66, DOI 10.1016/S0955-0674(96)80050-0	32	92	93	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 24	1999	274	52					37087	37092		10.1074/jbc.274.52.37087	http://dx.doi.org/10.1074/jbc.274.52.37087			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	267WR	10601267	hybrid			2022-12-25	WOS:000084382700038
J	He, B; Kemppainen, JA; Voegel, JJ; Gronemeyer, H; Wilson, EM				He, B; Kemppainen, JA; Voegel, JJ; Gronemeyer, H; Wilson, EM			Activation function 2 in the human androgen receptor ligand binding domain mediates interdomain communication with the NH2-terminal domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESTROGEN-RECEPTOR; NUCLEAR RECEPTORS; TRANSCRIPTIONAL ACTIVATION; COACTIVATOR TIF2; HORMONE RECEPTORS; GENE-MUTATIONS; INSENSITIVITY; SPECIFICITY; ENHANCEMENT; REGION	Activation function 2 in the ligand binding domain of nuclear receptors forms a hydrophobic cleft that binds the LXXLL motif of p160 transcriptional coactivators. Here we provide evidence that activation function 2 in the androgen receptor serves as the contact site for the androgen dependent NH2- and carboxyl-terminal interaction of the androgen receptor and only weakly interacts with p160 coactivators in an LXXLL-dependent manner. Mutagenesis studies indicate that it is the NH2-/ carboxyl-terminal interaction that is required by activation function 2 to stabilize helix 12 and slow androgen dissociation critical for androgen receptor activity in vice. The androgen receptor recruits p160 coactivators through its NH2-terminal and DNA binding domains in an LXXLL motif-independent manner. The results suggest a novel function for activation function 2 and a unique mechanism of nuclear receptor transactivation.	Univ N Carolina, Dept Pediat, Labs Reprod Biol, Chapel Hill, NC 27599 USA; Univ N Carolina, Dept Biochem & Biophys, Chapel Hill, NC 27599 USA; Univ Strasbourg 1, Coll France, CNRS, INSERM,Inst Genet & Biol Mol & Cellulaire, F-67404 Illkirch Graffenstaden, France	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; PSL Research University Paris; College de France; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Wilson, EM (corresponding author), Univ N Carolina, Dept Pediat, Labs Reprod Biol, Med Sci Res Bldg,Rm 374,CB 7500, Chapel Hill, NC 27599 USA.	emw@med.unc.edu	Gronemeyer, Hinrich/G-6240-2011; Gronemeyer, Hinrich/AAH-5575-2019; Gronemeyer, Hinrich/H-7002-2016	Gronemeyer, Hinrich/0000-0001-9454-2449; Gronemeyer, Hinrich/0000-0001-9454-2449; Gronemeyer, Hinrich/0000-0001-9454-2449	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R37HD016910, R01HD016910, U54HD035041] Funding Source: NIH RePORTER; NICHD NIH HHS [U54-HD-35041, HD-16910] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Alen P, 1999, MOL ENDOCRINOL, V13, P117, DOI 10.1210/me.13.1.117; Berrevoets CA, 1998, MOL ENDOCRINOL, V12, P1172, DOI 10.1210/me.12.8.1172; Bjorklund S, 1999, CELL, V96, P759, DOI 10.1016/S0092-8674(00)80586-3; Brzozowski AM, 1997, NATURE, V389, P753, DOI 10.1038/39645; DANIELIAN PS, 1992, EMBO J, V11, P1025, DOI 10.1002/j.1460-2075.1992.tb05141.x; Darimont BD, 1998, GENE DEV, V12, P3343, DOI 10.1101/gad.12.21.3343; DEBELLIS A, 1994, J CLIN ENDOCR METAB, V78, P513, DOI 10.1210/jc.78.3.513; Ding XF, 1998, MOL ENDOCRINOL, V12, P302, DOI 10.1210/me.12.2.302; Feng WJ, 1998, SCIENCE, V280, P1747, DOI 10.1126/science.280.5370.1747; Fondell JD, 1999, P NATL ACAD SCI USA, V96, P1959, DOI 10.1073/pnas.96.5.1959; Freedman LP, 1999, CELL, V97, P5, DOI 10.1016/S0092-8674(00)80708-4; Gee AC, 1999, MOL ENDOCRINOL, V13, P1912, DOI 10.1210/me.13.11.1912; Gottlieb B, 1998, NUCLEIC ACIDS RES, V26, P234, DOI 10.1093/nar/26.1.234; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; Heery DM, 1997, NATURE, V387, P733, DOI 10.1038/42750; Henttu PMA, 1997, MOL CELL BIOL, V17, P1832, DOI 10.1128/MCB.17.4.1832; Hiort O, 1998, J PEDIATR-US, V132, P939, DOI 10.1016/S0022-3476(98)70387-7; Hong H, 1999, J BIOL CHEM, V274, P3496, DOI 10.1074/jbc.274.6.3496; Ikonen T, 1997, J BIOL CHEM, V272, P29821, DOI 10.1074/jbc.272.47.29821; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; Kemppainen JA, 1999, MOL ENDOCRINOL, V13, P440, DOI 10.1210/me.13.3.440; KLEINERMAN DI, 1996, J UROLOGY, V155, P624; Langley E, 1998, J BIOL CHEM, V273, P92, DOI 10.1074/jbc.273.1.92; LANGLEY E, 1995, J BIOL CHEM, V270, P29983; LeDouarin B, 1996, EMBO J, V15, P6701, DOI 10.1002/j.1460-2075.1996.tb01060.x; Leers J, 1998, MOL CELL BIOL, V18, P6001, DOI 10.1128/MCB.18.10.6001; McInerney EM, 1996, P NATL ACAD SCI USA, V93, P10069, DOI 10.1073/pnas.93.19.10069; Moilanen A, 1997, FEBS LETT, V412, P355, DOI 10.1016/S0014-5793(97)00791-6; Moras D, 1998, CURR OPIN CELL BIOL, V10, P384, DOI 10.1016/S0955-0674(98)80015-X; Nolte RT, 1998, NATURE, V395, P137, DOI 10.1038/25931; Norris JD, 1998, J BIOL CHEM, V273, P6679, DOI 10.1074/jbc.273.12.6679; Onate SA, 1998, J BIOL CHEM, V273, P12101, DOI 10.1074/jbc.273.20.12101; ONATE SA, 1995, SCIENCE, V270, P1354; PARER MG, 1999, P STER REC SUP IND W; QUIGLEY CA, 1995, ENDOCR REV, V16, P271, DOI 10.1210/er.16.3.271; Shao DL, 1998, NATURE, V396, P377, DOI 10.1038/24634; Shiau AK, 1998, CELL, V95, P927, DOI 10.1016/S0092-8674(00)81717-1; SIMENTAL JA, 1991, J BIOL CHEM, V266, P510; Tan J, 1997, MOL ENDOCRINOL, V11, P450, DOI 10.1210/me.11.4.450; Tetel MJ, 1999, MOL ENDOCRINOL, V13, P910, DOI 10.1210/me.13.6.910; Torchia J, 1998, CURR OPIN CELL BIOL, V10, P373, DOI 10.1016/S0955-0674(98)80014-8; Voegel JJ, 1998, EMBO J, V17, P507, DOI 10.1093/emboj/17.2.507; Webb P, 1998, MOL ENDOCRINOL, V12, P1605, DOI 10.1210/me.12.10.1605; Williams SP, 1998, NATURE, V393, P392, DOI 10.1038/30775; Wurtz JM, 1996, NAT STRUCT BIOL, V3, P87, DOI 10.1038/nsb0196-87; ZHOU ZX, 1995, MOL ENDOCRINOL, V9, P208, DOI 10.1210/me.9.2.208	46	276	291	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 24	1999	274	52					37219	37225		10.1074/jbc.274.52.37219	http://dx.doi.org/10.1074/jbc.274.52.37219			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	267WR	10601285	Green Published, hybrid			2022-12-25	WOS:000084382700056
J	Blair, AS; Hajduch, E; Litherland, GJ; Hundal, HS				Blair, AS; Hajduch, E; Litherland, GJ; Hundal, HS			Regulation of glucose transport and glycogen synthesis in L6 muscle cells during oxidative stress - Evidence for cross-talk between the insulin and SAPK2/p38 mitogen-activated protein kinase signaling pathways	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN SKELETAL-MUSCLE; PHOSPHOINOSITIDE 3-KINASE; SYNTHASE KINASE-3; GLUCOSE-TRANSPORTER-4 TRANSLOCATION; 3T3-L1 ADIPOCYTES; MAPKAP KINASE-2; HEAT-SHOCK; EXERCISE; PHOSPHORYLATION; INHIBITION	We have investigated the cellular mechanisms that participate in reducing insulin sensitivity in response to increased oxidant stress in skeletal muscle. Measurement of glucose transport and glycogen synthesis in L6 myotubes showed that insulin stimulated both processes, by 2- and 5-fold, respectively. Acute (30 min) exposure of muscle cells to hydrogen peroxide (H2O2) blocked the hormonal activation of both these processes. Immunoblot analyses of cell lysates prepared after an acute oxidant challenge using phospho-specific antibodies against c-Jun N-terminal kinase (JNK), p38, protein kinase B (PKB), and p42 and p44 mitogen-activated protein (MAP) kinases established that H2O2 induced a dose dependent activation of all five protein kinases, In vitro kinase analyses revealed that 1 mM H2O2 stimulated the activity of JNK by similar to 8-fold, MAP-KAP-K2 (the downstream target of p38 MAP kinase) by similar to 12-fold and that of PKB by up to 34-fold. PKB activation was associated with a concomitant inactivation of glycogen synthase kinase-3, Stimulation of the p38 pathway, but not that of JNK, was blocked by SE 202190 or 8B203580, while that of p42/p44 MAP kinases and PKB was inhibited by PD 98059 and wortmannin respectively. However, of the kinases assayed, only p38 MAP kinase was activated at H2O2 concentrations (50 mu M) that caused an inhibition of insulin-stimulated glucose transport and glycogen synthesis. Strikingly, inhibiting the activation of p38 MAP kinase using either SE 202190 or SE 203580 prevented the loss in insulin-stimulated glucose transport, but not that of glycogen synthesis, by oxidative stress, Our data indicate that activation of the p38 MAP kinase pathway plays a central role in the oxidant-induced inhibition of insulin-regulated glucose transport, and unveils an important biochemical link between the classical stress-activated and insulin signaling pathways in skeletal muscle.	Univ Dundee, Dept Anat & Physiol, Inst Med Sci, Dundee DD1 5EH, Scotland	University of Dundee	Hundal, HS (corresponding author), Univ Dundee, Dept Anat & Physiol, Inst Med Sci, Wellcome Trust Bioctr Complex, Dundee DD1 5EH, Scotland.		Hajduch, Eric/B-7332-2008; Hundal, Hari/A-8990-2008; Litherland, Gary J/K-9755-2015	Hajduch, Eric/0000-0002-0125-7751; Hundal, Hari/0000-0002-7621-4932; Litherland, Gary/0000-0001-5264-0219				ASP S, 1995, J PHYSIOL-LONDON, V482, P705, DOI 10.1113/jphysiol.1995.sp020553; Baynes JW, 1999, DIABETES, V48, P1, DOI 10.2337/diabetes.48.1.1; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Clerk A, 1998, J BIOL CHEM, V273, P7228, DOI 10.1074/jbc.273.13.7228; Clifton AD, 1996, FEBS LETT, V392, P209, DOI 10.1016/0014-5793(96)00816-2; Cohen P, 1999, CURR OPIN CHEM BIOL, V3, P459, DOI 10.1016/S1367-5931(99)80067-2; Cohen P, 1997, TRENDS CELL BIOL, V7, P353, DOI 10.1016/S0962-8924(97)01105-7; CROSS DAE, 1994, BIOCHEM J, V303, P21, DOI 10.1042/bj3030021; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; Deak M, 1998, EMBO J, V17, P4426, DOI 10.1093/emboj/17.15.4426; DEFRONZO RA, 1991, DIABETES CARE, V14, P173, DOI 10.2337/diacare.14.3.173; DEFRONZO RA, 1992, DIABETES CARE, V15, P318, DOI 10.2337/diacare.15.3.318; DENT P, 1990, NATURE, V348, P302, DOI 10.1038/348302a0; Duranteau J, 1998, J BIOL CHEM, V273, P11619, DOI 10.1074/jbc.273.19.11619; FERRARI P, 1990, J HYPERTENS, V8, P491, DOI 10.1097/00004872-199006000-00001; Frantz B, 1998, BIOCHEMISTRY-US, V37, P13846, DOI 10.1021/bi980832y; Galuska D, 1998, ADV EXP MED BIOL, V441, P73; Goodyear LJ, 1996, AM J PHYSIOL-ENDOC M, V271, pE403, DOI 10.1152/ajpendo.1996.271.2.E403; Hajduch E, 1998, DIABETES, V47, P1006, DOI 10.2337/diabetes.47.7.1006; Hansen LL, 1999, J BIOL CHEM, V274, P25078, DOI 10.1074/jbc.274.35.25078; Heidenreich KA, 1996, J BIOL CHEM, V271, P9891, DOI 10.1074/jbc.271.17.9891; Holman GD, 1997, DIABETOLOGIA, V40, P991, DOI 10.1007/s001250050780; Igarashi M, 1999, J CLIN INVEST, V103, P185, DOI 10.1172/JCI3326; Ihara Y, 1999, DIABETES, V48, P927, DOI 10.2337/diabetes.48.4.927; Kahn BB, 1996, DIABETES, V45, P1644, DOI 10.2337/diabetes.45.11.1644; KIRWAN JP, 1992, J APPL PHYSIOL, V72, P2197, DOI 10.1152/jappl.1992.72.6.2197; Kitamura T, 1998, MOL CELL BIOL, V18, P3708, DOI 10.1128/MCB.18.7.3708; Kohn AD, 1996, J BIOL CHEM, V271, P31372, DOI 10.1074/jbc.271.49.31372; Kozlovsky N, 1997, J BIOL CHEM, V272, P33367, DOI 10.1074/jbc.272.52.33367; Kramer RM, 1996, J BIOL CHEM, V271, P27723, DOI 10.1074/jbc.271.44.27723; LAWRENCE JC, 1977, J BIOL CHEM, V252, P444; Marte BM, 1997, TRENDS BIOCHEM SCI, V22, P355, DOI 10.1016/S0968-0004(97)01097-9; McDowell HE, 1998, FEBS LETT, V441, P15, DOI 10.1016/S0014-5793(98)01508-7; Moxham CM, 1996, J BIOL CHEM, V271, P30765, DOI 10.1074/jbc.271.48.30765; New L, 1998, EMBO J, V17, P3372, DOI 10.1093/emboj/17.12.3372; Parik T, 1996, J Cardiovasc Risk, V3, P49, DOI 10.1097/00043798-199602000-00007; PARKER PJ, 1983, EUR J BIOCHEM, V130, P227; ROUSE J, 1994, CELL, V78, P1027, DOI 10.1016/0092-8674(94)90277-1; Rudich A, 1997, AM J PHYSIOL-ENDOC M, V272, pE935, DOI 10.1152/ajpendo.1997.272.5.E935; SEN CK, 1995, J APPL PHYSIOL, V79, P675, DOI 10.1152/jappl.1995.79.3.675; Shaw M, 1998, BIOCHEM J, V336, P241, DOI 10.1042/bj3360241; Shepherd PR, 1998, BIOCHEM J, V333, P471, DOI 10.1042/bj3330471; Sweeney G, 1999, J BIOL CHEM, V274, P10071, DOI 10.1074/jbc.274.15.10071; Tanti JF, 1997, ENDOCRINOLOGY, V138, P2005, DOI 10.1210/en.138.5.2005; TAYLOR DE, 1995, J CRIT CARE, V10, P122, DOI 10.1016/0883-9441(95)90003-9; Tirosh A, 1999, J BIOL CHEM, V274, P10595, DOI 10.1074/jbc.274.15.10595; Ushio-Fukai M, 1999, J BIOL CHEM, V274, P22699, DOI 10.1074/jbc.274.32.22699; Wang QH, 1999, MOL CELL BIOL, V19, P4008; Wang XT, 1998, BIOCHEM J, V333, P291, DOI 10.1042/bj3330291; Waskiewicz AJ, 1997, EMBO J, V16, P1909, DOI 10.1093/emboj/16.8.1909; Widegren U, 1998, FASEB J, V12, P1379, DOI 10.1096/fasebj.12.13.1379	51	151	155	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 17	1999	274	51					36293	36299		10.1074/jbc.274.51.36293	http://dx.doi.org/10.1074/jbc.274.51.36293			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	266AV	10593919	hybrid			2022-12-25	WOS:000084279200038
J	Kang, YK; Park, JS; Lee, CS; Il Yeom, Y; Chung, AS; Lee, KK				Kang, YK; Park, JS; Lee, CS; Il Yeom, Y; Chung, AS; Lee, KK			Efficient integration of short interspersed element-flanked foreign DNA via homologous recombination	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAMMALIAN-CELLS; MOUSE GENOME; CHROMOSOME BANDS; GAMMA-GLOBIN; SEQUENCES; GENES; PROMOTER; FEATURES; DUPLICATION; EXPRESSION	We investigated whether mouse short interspersed elements (SINEs) could influence the recombination frequency of foreign DNA. Vectors harboring a reporter gene in combinations of SINEs B1 and/or B2 or a portion of long interspersed element-1 were prepared and tested in vitro by a colony assay using HC11 murine mammary epithelial cells and in, vivo by microinjection into fetilized mouse eggs. In transfected HC11 cells, the number of colonies surviving G418 selection increased by 3.5-fold compared with control when the reporter was flanked by fused B1-B2 sequences. Similar results were obtained from microinjection study; in fetuses 11.5 days post coitum, transgene positives in control and SINE-flanked vectors were 16 and 53%, respectively. Individual B1- and B2-harboring vectors showed equivalent activities with each other, as determined by the colony assay (2.8-fold versus 3.2-fold compared with control). We determined the contribution of homologous recombination to the SINE-mediated increase in integration frequency through a polymerase chain reaction-based strategy; in more than half of embryos transgenes underwent homologous recombinations involving B1 sequences. These results demonstrate that the SINE sequences can increase the integration rate of foreign DNA and that such an increase is most likely due to the enhancement of homologous recombination.	Korea Res Inst Biosci & Biotechnol, Anin Dev Biol Res Unit, Taejon 305600, South Korea; Korea Adv Inst Sci & Technol, Dept Sci Biol, Taejon 305701, South Korea	Korea Research Institute of Bioscience & Biotechnology (KRIBB); Korea Advanced Institute of Science & Technology (KAIST)	Lee, KK (corresponding author), POB 115 Yusong, Taejon 305600, South Korea.							ALLEN ND, 1988, NATURE, V333, P852, DOI 10.1038/333852a0; AYARES D, 1986, P NATL ACAD SCI USA, V83, P5199, DOI 10.1073/pnas.83.14.5199; BARSH GS, 1983, NUCLEIC ACIDS RES, V11, P3939, DOI 10.1093/nar/11.12.3939; BENNETT KL, 1984, MOL CELL BIOL, V4, P1561, DOI 10.1128/MCB.4.8.1561; BERG DE, 1989, MOBILE DNA, P593; BOYLE AL, 1990, P NATL ACAD SCI USA, V87, P7757, DOI 10.1073/pnas.87.19.7757; CHEN CM, 1995, TRANSGENIC RES, V4, P52, DOI 10.1007/BF01976502; CRAIG JM, 1993, BIOESSAYS, V15, P349, DOI 10.1002/bies.950150510; CROSS M, 1990, EMBO J, V9, P1283, DOI 10.1002/j.1460-2075.1990.tb08237.x; DOPPLER W, 1989, P NATL ACAD SCI USA, V86, P104, DOI 10.1073/pnas.86.1.104; Edgell M H, 1987, Prog Clin Biol Res, V251, P107; FRIEDRICH G, 1991, GENE DEV, V5, P1513, DOI 10.1101/gad.5.9.1513; HOGAN B, 1994, MANIPULATING MOUSE E, P226; HOLMQUIST GP, 1992, AM J HUM GENET, V51, P17; JAGADEESWARAN P, 1982, NATURE, V296, P469, DOI 10.1038/296469a0; KATO S, 1986, MOL CELL BIOL, V6, P1787, DOI 10.1128/MCB.6.5.1787; KRAMEROV DA, 1979, NUCLEIC ACIDS RES, V6, P697, DOI 10.1093/nar/6.2.697; KRAYEV AS, 1982, NUCLEIC ACIDS RES, V10, P7461, DOI 10.1093/nar/10.23.7461; KRISHER RL, 1994, TRANSGENIC RES, V3, P226, DOI 10.1007/BF02336775; LEHRMAN MA, 1987, CELL, V48, P827, DOI 10.1016/0092-8674(87)90079-1; LIN HJ, 1987, J CLIN INVEST, V80, P374, DOI 10.1172/JCI113082; LOEB DD, 1986, MOL CELL BIOL, V6, P168, DOI 10.1128/MCB.6.1.168; MARAIA RJ, 1991, NUCLEIC ACIDS RES, V19, P5695, DOI 10.1093/nar/19.20.5695; MARCHUK D, 1991, NUCLEIC ACIDS RES, V19, P1154, DOI 10.1093/nar/19.5.1154; MARTIN DIK, 1989, NATURE, V338, P435, DOI 10.1038/338435a0; Mcfarlane M, 1996, TRANSGENIC RES, V5, P171, DOI 10.1007/BF01969706; MURNANE JP, 1990, NUCLEIC ACIDS RES, V18, P2733, DOI 10.1093/nar/18.9.2733; NICHOLLS RD, 1987, CELL, V49, P369, DOI 10.1016/0092-8674(87)90289-3; OTTOLENGHI S, 1982, NATURE, V300, P770, DOI 10.1038/300770a0; PAVAN WJ, 1991, P NATL ACAD SCI USA, V88, P7788, DOI 10.1073/pnas.88.17.7788; SAMBROOK J, 1989, MOL CLONING LABORATO, V2, P16; SANES JR, 1986, EMBO J, V5, P3133, DOI 10.1002/j.1460-2075.1986.tb04620.x; SHEN MR, 1992, ANAL BIOCHEM, V205, P83; WALDMAN AS, 1988, MOL CELL BIOL, V8, P5350, DOI 10.1128/MCB.8.12.5350; WALLENBURG JC, 1987, NUCLEIC ACIDS RES, V15, P7849, DOI 10.1093/nar/15.19.7849; Watson JEV, 1995, GENOME RES, V5, P444, DOI 10.1101/gr.5.5.444; WEINER AM, 1986, ANNU REV BIOCHEM, V55, P631, DOI 10.1146/annurev.bi.55.070186.003215	37	23	24	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 17	1999	274	51					36585	36591		10.1074/jbc.274.51.36585	http://dx.doi.org/10.1074/jbc.274.51.36585			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	266AV	10593959	hybrid			2022-12-25	WOS:000084279200078
J	Kuznetsova, N; Leikin, S				Kuznetsova, N; Leikin, S			Does the triple helical domain of type I collagen encode molecular recognition and fiber assembly while telopeptides serve as catalytic domains? Effect of proteolytic cleavage on fibrillogenesis and on collagen-collagen interaction in fibers	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							X-RAY-DIFFRACTION; FIBRIL FORMATION; INVITRO; FORCES; SEQUENCE; DRIVEN; CHAIN; CDNA	Over the last several decades, it has been established that proteolytic removal of short, non-helical terminal peptides (telopeptides) from type I collagen significantly alters the kinetics of in vitro fibrillogenesis. However, it has also been observed that the protein is still capable of forming fibers even after complete removal of telopeptides. This study focuses on the characterization of this fibrillogenesis competency of collagen, We have combined traditional kinetic and thermodynamic assays of fibrillogenesis efficacy with direct measurements of interaction between collagen molecules in fibers by osmotic stress and x-ray diffraction. We found that telopeptide cleavage by pepsin or by up to 20 h of Pronase treatment altered fiber assembly kinetics, but the same fraction of the protein still assembled into fibers. Small-angle x-ray diffraction showed that these fibers have normal, native-like D-stagger. Force measurements indicated that collagen-collagen interactions in fibers were not affected by either pepsin or Pronase treatment, In contrast, prolonged (>20 h) Pronase treatment resulted in cleavage of the triple helical domain as indicated by SDS-polyacrylamide gel electrophoresis. The triple-helix cleavage correlated with the observed decrease in the fraction of protein capable of forming fibers and with the measured loss of attraction between helices in fibers, These data suggest that telopeptides play a catalytic role, whereas the information necessary for proper molecular recognition and fiber assembly is encoded in the triple helical domain of collagen.	NICHD, Lab Phys & Struct Biol, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)	Leikin, S (corresponding author), NICHD, Lab Phys & Struct Biol, NIH, Bldg 12A,Rm 2041, Bethesda, MD 20892 USA.		Leikin, Sergey/A-5518-2008	Leikin, Sergey/0000-0001-7095-0739	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [ZIAHD000256] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [Z01HD000256, Z01HD000241] Funding Source: NIH RePORTER	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		BRODSKY B, 1982, METHOD ENZYMOL, V82, P127; BRODSKY B, 1982, BIOPOLYMERS, V21, P935, DOI 10.1002/bip.360210507; BRODSKY B, 1978, BIOCHIM BIOPHYS ACTA, P25; BRODSKY B, 1988, COLLAGEN, V1, P95; CHANDRAKASAN G, 1976, J BIOL CHEM, V251, P6062; COMPER WD, 1977, BIOPOLYMERS, V16, P2113, DOI 10.1002/bip.1977.360161004; COMPER WD, 1977, BIOPOLYMERS, V16, P2133, DOI 10.1002/bip.1977.360161005; DAVISON PF, 1966, BIOCHEMISTRY-US, V5, P313, DOI 10.1021/bi00865a040; DRAKE MP, 1966, BIOCHEMISTRY-US, V5, P301, DOI 10.1021/bi00865a039; EDELHOCH H, 1967, BIOCHEMISTRY-US, V6, P1948, DOI 10.1021/bi00859a010; EIKENBERRY EF, 1980, J MOL BIOL, V144, P397, DOI 10.1016/0022-2836(80)90098-4; EYRE DR, 1984, ANNU REV BIOCHEM, V53, P717, DOI 10.1146/annurev.bi.53.070184.003441; Fraser R.D.B., 1973, CONFORMATION FIBROUS; GELMAN RA, 1979, J BIOL CHEM, V254, P1741; GHOSH SK, 1975, BIOCHIM BIOPHYS ACTA, V405, P340, DOI 10.1016/0005-2795(75)90099-9; HELSETH DL, 1981, J BIOL CHEM, V256, P7118; KADLER K, 1994, PROTEIN PROFILE, V1, P519; Kuznetsova N, 1998, BIOCHEMISTRY-US, V37, P11888, DOI 10.1021/bi980089+; Kuznetsova N, 1997, BIOPHYS J, V72, P353, DOI 10.1016/S0006-3495(97)78674-0; LEIBOVICH SJ, 1970, BIOCHIM BIOPHYS ACTA, V214, P445, DOI 10.1016/0005-2795(70)90303-X; LEIKIN S, 1995, NAT STRUCT BIOL, V2, P205, DOI 10.1038/nsb0395-205; LEIKIN S, 1994, P NATL ACAD SCI USA, V91, P276, DOI 10.1073/pnas.91.1.276; LI SW, 1995, MATRIX BIOL, V14, P593, DOI 10.1016/S0945-053X(05)80009-5; MILLER EJ, 1982, METHOD ENZYMOL, V82, P33; MUDD CP, 1987, REV SCI INSTRUM, V58, P2110, DOI 10.1063/1.1139472; NA GC, 1988, COLLAGEN REL RES, V8, P315; PARSEGIAN VA, 1986, METHOD ENZYMOL, V127, P400; PHILLIPS CL, 1992, GENOMICS, V13, P1345, DOI 10.1016/0888-7543(92)90065-Z; PROCKOP DJ, 1995, ANNU REV BIOCHEM, V64, P403, DOI 10.1146/annurev.biochem.64.1.403; Prockop DJ, 1998, J STRUCT BIOL, V122, P111, DOI 10.1006/jsbi.1998.3976; Prockop DJ, 1998, J BIOL CHEM, V273, P15598, DOI 10.1074/jbc.273.25.15598; RAU DC, 1984, P NATL ACAD SCI-BIOL, V81, P2621, DOI 10.1073/pnas.81.9.2621; Veis A, 1988, COLLAGEN, V1, P113; Weiss J B, 1976, Int Rev Connect Tissue Res, V7, P101; WILLIAMS BR, 1978, J BIOL CHEM, V253, P6578; Yamauchi M, 1988, COLLAGEN, P157	36	94	95	1	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 17	1999	274	51					36083	36088		10.1074/jbc.274.51.36083	http://dx.doi.org/10.1074/jbc.274.51.36083			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	266AV	10593890	hybrid			2022-12-25	WOS:000084279200009
J	Pettitt, TR; Wakelam, MJO				Pettitt, TR; Wakelam, MJO			Diacylglycerol kinase epsilon, but not zeta selectively removes polyunsaturated diacylglycerol, inducing altered protein kinase C distribution in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR-CLONING; PHOSPHOLIPASE-C; GENERATION; ACTIVATION; SYNTHASE; GENE	Porcine aortic endothelial cells have previously been shown to contain particularly high basal levels of polyunsaturated diacylglycerol (DAG) together with a very high degree of membrane associated protein kinase C (PBC), which is largely insensitive to further activation (Pettitt, T. R., Martin, A. Horton, T., Liossis, C., Lord, J. M., and Wakelam, M. J. O. (1997) J. Biol. Chem. 272, 17354-17359), To investigate the possibility that the high polyunsaturated DAG levels were constitutively activating PKC, we transfected porcine aortic endothelial cells with two different forms of human diacylglycerol kinase, epsilon and zeta, In vitro, the former is specific for polyunsaturated structures, whereas the latter shows no apparent selectivity, Overexpression of DAGK epsilon specifically reduced the level of polyunsaturated DAG in the transfected cells while having little effect on the more saturated structures. It also caused the redistribution of PKC alpha and epsilon from the membrane to the cytosol, Overexpression of DAGK zeta caused a general reduction in DAG levels but had little effect on PKC distribution. These results for the first time show that DAGK epsilon specifically phosphorylates polyunsaturated DAG in vivo and that in so doing it regulates PKC localization and activity, This provides support for the proposal that it is the polyunsaturated DAGs that function as messengers and convincing evidence for DAGK epsilon being a physiological terminator of DAG second messenger signaling.	Univ Birmingham, Inst Canc Studies, Birmingham B15 2TA, W Midlands, England	University of Birmingham	Wakelam, MJO (corresponding author), Univ Birmingham, Inst Canc Studies, Birmingham B15 2TA, W Midlands, England.	M.J.O.Wakelam@bham.ac.uk		Wakelam, Michael/0000-0003-4059-9276				Bunting M, 1996, J BIOL CHEM, V271, P10230, DOI 10.1074/jbc.271.17.10230; Ding L, 1997, P NATL ACAD SCI USA, V94, P5519, DOI 10.1073/pnas.94.11.5519; Ding L, 1998, FEBS LETT, V429, P109, DOI 10.1016/S0014-5793(98)00490-6; Exton JH, 1997, PHYSIOL REV, V77, P303, DOI 10.1152/physrev.1997.77.2.303; Flores I, 1996, J BIOL CHEM, V271, P10334, DOI 10.1074/jbc.271.17.10334; Goto K, 1996, P NATL ACAD SCI USA, V93, P11196, DOI 10.1073/pnas.93.20.11196; Hodgkin MN, 1998, TRENDS BIOCHEM SCI, V23, P200, DOI 10.1016/S0968-0004(98)01200-6; Lykidis A, 1997, J BIOL CHEM, V272, P33402, DOI 10.1074/jbc.272.52.33402; Mellor H, 1998, BIOCHEM J, V332, P281, DOI 10.1042/bj3320281; Newton AC, 1998, BBA-REV BIOMEMBRANES, V1376, P155, DOI 10.1016/S0304-4157(98)00003-3; Olivier AR, 1996, BIOCHEM J, V318, P519, DOI 10.1042/bj3180519; Pettitt TR, 1997, J BIOL CHEM, V272, P17354, DOI 10.1074/jbc.272.28.17354; PETTITT TR, 1993, BIOCHEM J, V289, P487, DOI 10.1042/bj2890487; PETTITT TR, 1994, BIOCHEM J, V298, P655, DOI 10.1042/bj2980655; Saito S, 1997, J BIOL CHEM, V272, P9503; Sakane F, 1997, INT J BIOCHEM CELL B, V29, P1139, DOI 10.1016/S1357-2725(97)00037-X; Tang W, 1996, J BIOL CHEM, V271, P10237, DOI 10.1074/jbc.271.17.10237; Topham MK, 1998, NATURE, V394, P697, DOI 10.1038/29337; WAKELAM MJO, 1986, NATURE, V323, P68, DOI 10.1038/323068a0; Wakelam MJO, 1998, BBA-MOL CELL BIOL L, V1436, P117, DOI 10.1016/S0005-2760(98)00123-4; WALSH JP, 1995, J BIOL CHEM, V270, P28647, DOI 10.1074/jbc.270.48.28647	21	54	56	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 17	1999	274	51					36181	36186		10.1074/jbc.274.51.36181	http://dx.doi.org/10.1074/jbc.274.51.36181			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	266AV	10593903	hybrid			2022-12-25	WOS:000084279200022
J	Teuchert, M; Berghofer, S; Klenk, HD; Garten, W				Teuchert, M; Berghofer, S; Klenk, HD; Garten, W			Recycling of furin from the plasma membrane - Functional importance of the cytoplasmic tail sorting signals and interaction with the AP-2 adaptor medium chain subunit	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANS-GOLGI NETWORK; KINASE-II PHOSPHORYLATION; TYROSINE-BASED MOTIF; CELL-SURFACE; INTRACELLULAR TRAFFICKING; PROPROTEIN CONVERTASE; COFACTOR PROTEIN; LOCALIZATION; CLATHRIN; DOMAIN	The predominant intracellular localization of the eukaryotic subtilisin-like endoprotease furin is the trans-Golgi network (TGN), but a small fraction is also found on the cell surface. Furin on the cell surface is internalized and delivered to the TGN, The identification of three endocytosis motifs, a tyrosine (YKGL(765)) motif, a leucine-isoleucine (LI760) motif, and a phenylalanine (Phe(790)) signal, in the furin cytoplasmic domain suggested that endocytosis of furin occurs via an AP-2/clathrin-dependent pathway. Since little is known about proteins containing multiple sorting components in their cytoplasmic domain, the combination of diverse internalization signals in the furin tail raised the question of their individual role, Here we present data showing that the furin tail interacts with the medium (mu 2) subunit of the AP-2 plasma membrane specific adaptor complex in vitro and that this interaction primarily depends on recognition of the tyrosine-based sorting signal and to less extent on the leucine-isoleucine motif, We further provide evidence that the three endocytosis signals are of different functional importance for furin internalization and retrieval to the TGN in vivo, with the tyrosine-based motif being the major determinant, followed by the phenylalanine signal, whereas the leucine-isoleucine motif is only a minor component, Finally, we report that phosphorylation of the furin tail by casein kinase II is not only important for efficient interaction with mu 2 and internalization from the plasma membrane but also determines fast retrieval of the protein from the plasma membrane to the TGN.	Univ Marburg, Inst Virol, D-35037 Marburg, Germany	Philipps University Marburg	Garten, W (corresponding author), Univ Marburg, Inst Virol, Robert Koch Str 17, D-35037 Marburg, Germany.							Alconada A, 1996, EMBO J, V15, P6096, DOI 10.1002/j.1460-2075.1996.tb00998.x; Alconada A, 1999, J VIROL, V73, P377, DOI 10.1128/JVI.73.1.377-387.1999; BENNETT G, 1981, J CELL BIOL, V88, P1, DOI 10.1083/jcb.88.1.1; Berlioz-Torrent C, 1999, J VIROL, V73, P1350, DOI 10.1128/JVI.73.2.1350-1361.1999; Boll W, 1996, EMBO J, V15, P5789, DOI 10.1002/j.1460-2075.1996.tb00965.x; BOSSHART H, 1994, J CELL BIOL, V126, P1157, DOI 10.1083/jcb.126.5.1157; CHAPMAN RE, 1994, EMBO J, V13, P2305, DOI 10.1002/j.1460-2075.1994.tb06514.x; Dittie AS, 1997, EMBO J, V16, P4859, DOI 10.1093/emboj/16.16.4859; Ghosh RN, 1998, J CELL BIOL, V142, P923, DOI 10.1083/jcb.142.4.923; HIGUCHI R, 1988, NUCLEIC ACIDS RES, V16, P7351, DOI 10.1093/nar/16.15.7351; Hirst J, 1998, BBA-MOL CELL RES, V1404, P173, DOI 10.1016/S0167-4889(98)00056-1; JIN M, 1989, J BIOL CHEM, V264, P7675; JONES BG, 1995, EMBO J, V14, P5869, DOI 10.1002/j.1460-2075.1995.tb00275.x; Kirchhausen T, 1997, CURR OPIN CELL BIOL, V9, P488, DOI 10.1016/S0955-0674(97)80024-5; KYHSEANDERSEN J, 1984, J BIOCHEM BIOPH METH, V10, P203, DOI 10.1016/0165-022X(84)90040-X; Le Borgne R, 1998, BBA-MOL CELL RES, V1404, P195, DOI 10.1016/S0167-4889(98)00057-3; Le Borgne R, 1998, CURR OPIN CELL BIOL, V10, P499; LISZEWSKI MK, 1992, CURR TOP MICROBIOL, V178, P45; Maisner A, 1997, J BIOL CHEM, V272, P20793, DOI 10.1074/jbc.272.33.20793; Mallard F, 1998, J CELL BIOL, V143, P973, DOI 10.1083/jcb.143.4.973; Marks MS, 1997, TRENDS CELL BIOL, V7, P124, DOI 10.1016/S0962-8924(96)10057-X; Mellman I, 1996, ANNU REV CELL DEV BI, V12, P575, DOI 10.1146/annurev.cellbio.12.1.575; MOLLOY SS, 1994, EMBO J, V13, P18, DOI 10.1002/j.1460-2075.1994.tb06231.x; MOLLOY SS, 1992, J BIOL CHEM, V267, P16396; Molloy SS, 1998, J CELL BIOL, V142, P1399, DOI 10.1083/jcb.142.6.1399; Nakayama K, 1997, BIOCHEM J, V327, P625, DOI 10.1042/bj3270625; Ohno H, 1996, J BIOL CHEM, V271, P29009, DOI 10.1074/jbc.271.46.29009; OHNO H, 1995, SCIENCE, V269, P1872, DOI 10.1126/science.7569928; Rapoport I, 1998, EMBO J, V17, P2148, DOI 10.1093/emboj/17.8.2148; Rapoport I, 1997, EMBO J, V16, P2240, DOI 10.1093/emboj/16.9.2240; REAVES B, 1993, MOL BIOL CELL, V4, P93, DOI 10.1091/mbc.4.1.93; Rodionov DG, 1998, J BIOL CHEM, V273, P6005, DOI 10.1074/jbc.273.11.6005; ROTH J, 1985, CELL, V43, P287, DOI 10.1016/0092-8674(85)90034-0; SCHAFER W, 1995, EMBO J, V14, P2424, DOI 10.1002/j.1460-2075.1995.tb07240.x; STEINER DF, 1992, J BIOL CHEM, V267, P23435; STOH A, 1999, EUR J CELL BIOL, V78, P151; TAKAHASHI S, 1995, J BIOL CHEM, V270, P28397; Teuchert M, 1999, J BIOL CHEM, V274, P8199, DOI 10.1074/jbc.274.12.8199; VOORHEES P, 1995, EMBO J, V14, P4961, DOI 10.1002/j.1460-2075.1995.tb00179.x; Wan L, 1998, CELL, V94, P205, DOI 10.1016/S0092-8674(00)81420-8	40	48	49	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 17	1999	274	51					36781	36789		10.1074/jbc.274.51.36781	http://dx.doi.org/10.1074/jbc.274.51.36781			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	266AV	10593987	hybrid			2022-12-25	WOS:000084279200106
J	Canard, B; Chowdhury, K; Sarfati, R; Doublie, S; Richardson, CC				Canard, B; Chowdhury, K; Sarfati, R; Doublie, S; Richardson, CC			The motif D loop of human immunodeficiency virus type 1 reverse transcriptase is critical for nucleoside 5 '-triphosphate selectivity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-POLYMERASE-I; ESCHERICHIA-COLI; 3'-AZIDO-3'-DEOXYTHYMIDINE AZT; CRYSTAL-STRUCTURE; RNA-POLYMERASES; STEADY-STATE; WILD-TYPE; BINDING; RESISTANCE; MECHANISM	Human immunodeficiency virus type 1 reverse transcriptase (RT) has limited homology with DNA and RNA polymerases. The conserved Lys-220 of motif D is a signature of RNA-dependent polymerases. Motif D is located in the "palm" domain and forms a small loop from Thr-215 to Lys-223. This loop is absent from the polymerase I family of DNA-dependent polymerases. Analysis of RT structures in comparison with other polymerases reveals that the motif D loop has the potential to undergo a conformational change upon binding a nucleotide. We find that amino acid changes in motif D affect the interaction of RT with the incoming nucleotide. A chimeric RT in which the loop of motif D is substituted by the corresponding amino acid segment from Tag DNA polymerase lacking this loop has a decreased affinity for incoming nucleotides. We have also constructed a mutant RT where the conserved lysine at position 220 within the motif D is substituted with glutamine. Both RT(K220Q) and the chimeric RT are resistant in vitro to 3'-deoxy S'-azidothymidine 5'-triphosphate (AZTTP). These results suggest that motif D is interacting with the incoming nucleotide and a determinant of the sensitivity of reverse transcriptases to AZTTP. We do not observe any interaction of motif D with the template primer.	Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA; Ecole Super Ingn Luminy, CNRS, F-13288 Marseille 9, France; Inst Pasteur, F-75724 Paris 15, France	Harvard University; Harvard Medical School; Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	Richardson, CC (corresponding author), Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA.			Canard, Bruno/0000-0003-4924-1991; Doublie, Sylvie/0000-0002-6294-5304	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI006045, R37AI006045] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-06045] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Arion D, 1998, BIOCHEMISTRY-US, V37, P15908, DOI 10.1021/bi981200e; BEESE LS, 1993, SCIENCE, V260, P352, DOI 10.1126/science.8469987; BOYER PL, 1994, P NATL ACAD SCI USA, V91, P4882, DOI 10.1073/pnas.91.11.4882; BRAITHWAITE DK, 1993, NUCLEIC ACIDS RES, V21, P787, DOI 10.1093/nar/21.4.787; Canard B, 1998, J BIOL CHEM, V273, P14596, DOI 10.1074/jbc.273.23.14596; Canard B, 1997, P NATL ACAD SCI USA, V94, P11279, DOI 10.1073/pnas.94.21.11279; CARROLL SS, 1994, BIOCHEMISTRY-US, V33, P2113, DOI 10.1021/bi00174a018; CHENG YC, 1987, J BIOL CHEM, V262, P2187; Counter CM, 1998, ONCOGENE, V16, P1217, DOI 10.1038/sj.onc.1201882; DELARUE M, 1990, PROTEIN ENG, V3, P461, DOI 10.1093/protein/3.6.461; Doublie S, 1998, NATURE, V391, P251, DOI 10.1038/34593; Eom SH, 1996, NATURE, V382, P278, DOI 10.1038/382278a0; ESNOUF R, 1995, NAT STRUCT BIOL, V2, P303, DOI 10.1038/nsb0495-303; GEORGIADIS MM, 1995, STRUCTURE, V3, P879, DOI 10.1016/S0969-2126(01)00223-4; Harrigan PR, 1996, J VIROL, V70, P5930, DOI 10.1128/JVI.70.9.5930-5934.1996; Huang HF, 1998, SCIENCE, V282, P1669, DOI 10.1126/science.282.5394.1669; HUBER HE, 1989, J BIOL CHEM, V264, P4669; JOYCE CM, 1994, ANNU REV BIOCHEM, V63, P777, DOI 10.1146/annurev.bi.63.070194.004021; KATI WM, 1992, J BIOL CHEM, V267, P25988; Kerr SG, 1997, BIOCHEMISTRY-US, V36, P14064, DOI 10.1021/bi9713862; Krebs R, 1997, BIOCHEMISTRY-US, V36, P10292, DOI 10.1021/bi970512z; LACEY SF, 1992, J BIOL CHEM, V267, P15789; LARDER B, 1987, EMBO J, V6, P3133, DOI 10.1002/j.1460-2075.1987.tb02623.x; LARDER B, 1992, REVERSE TRANSCRIPTAS, P205; Li Y, 1998, EMBO J, V17, P7514, DOI 10.1093/emboj/17.24.7514; OLLIS DL, 1985, NATURE, V313, P762, DOI 10.1038/313762a0; PAINTER GR, 1991, J BIOL CHEM, V266, P19362; PATRA D, 1992, J MOL BIOL, V224, P307, DOI 10.1016/0022-2836(92)90996-W; REARDON JE, 1990, J BIOL CHEM, V265, P20302; REARDON JE, 1992, BIOCHEMISTRY-US, V31, P4473, DOI 10.1021/bi00133a013; ROUSSEL A, 1991, SILICON GRAPHICS DIR, P97; SOUSA R, 1993, NATURE, V364, P593, DOI 10.1038/364593a0; Sousa R, 1996, TRENDS BIOCHEM SCI, V21, P186, DOI 10.1016/S0968-0004(96)10023-2; STEITZ TA, 1994, SCIENCE, V266, P2022, DOI 10.1126/science.7528445; TANTILLO C, 1994, J MOL BIOL, V243, P369, DOI 10.1006/jmbi.1994.1665; WU J, 1993, J BIOL CHEM, V268, P9980; YADAV PNS, 1994, J BIOL CHEM, V269, P716	37	16	16	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 10	1999	274	50					35768	35776		10.1074/jbc.274.50.35768	http://dx.doi.org/10.1074/jbc.274.50.35768			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	264NG	10585459	Green Published, hybrid			2022-12-25	WOS:000084187900071
J	Engelman, JA; Berg, AH; Lewis, RY; Lin, AN; Lisanti, MP; Scherer, PE				Engelman, JA; Berg, AH; Lewis, RY; Lin, AN; Lisanti, MP; Scherer, PE			Constitutively active mitogen-activated protein kinase kinase 6 (MIKK6) or salicylate induces spontaneous 3T3-L1 adipogenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; FLOW CYTOMETRIC DETECTION; P38 MAP KINASE; SODIUM-SALICYLATE; PPAR-GAMMA; ANNEXIN-V; PHOSPHATIDYLSERINE EXPRESSION; ADIPOCYTE DIFFERENTIATION; TRANSCRIPTION FACTOR; ADIPOSE CONVERSION	Although much has been learned regarding the importance of p38 mitogen-activated protein kinase in inflammatory and stress responses, relatively little is known concerning its role in differentiation processes. Recently, we demonstrated that p38 mitogen-activated protein kinase activity is necessary for the differentiation of 3T3-L1 fibroblasts into adipocytes (Engelman, J. A, Lisanti, M. P., and Scherer, P. E. (1998) J. Biol. Chem. 273, 32111-32120), p38 activity is high during the initial stages of differentiation but decreases drastically as the fibroblasts undergo terminal differentiation into adipocytes. However, it remains unknown whether activation of p38 is sufficient to stimulate adipogenesis and whether the down-regulation of p38 activity in mature adipocytes is critical for maintaining adipocyte homeostasis. In this report, we have directly addressed these questions by analyzing 3T3-L1 cell lines harboring a specific upstream activator of p38 (a constitutively active mitogen-activated protein kinase kinase 6 (MKX6) mutant, MKK6(Glu)) under the control of an inducible promoter. Induction of MKK6(Glu) in 3T3-L1 fibroblasts spurs adipocyte conversion in the absence of the hormonal mixture normally required for efficient differentiation of wild-type cells. However, activation of p38 in adipocytes leads to cell death. Furthermore, treatment of 3T3-L1 fibroblasts with salicylate, a potent stimulator of p38, produces adipocyte-specific changes consistent with those observed with induction of MKK6(Glu). Expression of MKK6(Glu) in NIH-3T3 fibroblasts (cells that do not differentiate into adipocytes under normal conditions) is capable of converting these fibroblasts into lipid-laden fat cells following hormonal stimulation. Thus, p38 activation has pro-adipogenic effects in multiple fibroblast cell lines.	Yeshiva Univ Albert Einstein Coll Med, Dept Cell Biol, Bronx, NY 10461 USA; Yeshiva Univ Albert Einstein Coll Med, Dept Mol Pharmacol, Bronx, NY 10461 USA; Univ Alabama, Dept Pathol, Birmingham, AL 35294 USA	Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; University of Alabama System; University of Alabama Birmingham	Scherer, PE (corresponding author), Yeshiva Univ Albert Einstein Coll Med, Dept Cell Biol, 1300 Morris Pk Ave, Bronx, NY 10461 USA.		Lisanti, Michael P/C-6866-2013; Lisanti, Michael/B-6131-2018; Scherer, Philipp E/K-7819-2012	Lisanti, Michael/0000-0003-2034-1382; Scherer, Philipp E/0000-0003-0680-3392	NCI NIH HHS [R01-CA-80250] Funding Source: Medline; NIGMS NIH HHS [T32-GM07491, T32-GM07288] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA080250] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007491, T32GM007288] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AKIRA S, 1990, EMBO J, V9, P1897, DOI 10.1002/j.1460-2075.1990.tb08316.x; Arita Y, 1999, BIOCHEM BIOPH RES CO, V257, P79, DOI 10.1006/bbrc.1999.0255; BENITO M, 1991, SCIENCE, V253, P565, DOI 10.1126/science.1857988; Beyaert R, 1996, EMBO J, V15, P1914, DOI 10.1002/j.1460-2075.1996.tb00542.x; Brun RP, 1996, CURR OPIN CELL BIOL, V8, P826, DOI 10.1016/S0955-0674(96)80084-6; Chen KD, 1998, J BIOL CHEM, V273, P749, DOI 10.1074/jbc.273.2.749; CORNELIUS P, 1994, ANNU REV NUTR, V14, P99, DOI 10.1146/annurev.nu.14.070194.000531; Cuenda A, 1997, EMBO J, V16, P295, DOI 10.1093/emboj/16.2.295; Cuenda A, 1999, J BIOL CHEM, V274, P4341, DOI 10.1074/jbc.274.7.4341; Darlington GJ, 1998, J BIOL CHEM, V273, P30057, DOI 10.1074/jbc.273.46.30057; deMora JF, 1997, MOL CELL BIOL, V17, P6068, DOI 10.1128/MCB.17.10.6068; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; Engelman JA, 1998, FEBS LETT, V428, P205, DOI 10.1016/S0014-5793(98)00470-0; Engelman JA, 1998, J BIOL CHEM, V273, P32111, DOI 10.1074/jbc.273.48.32111; FREYTAG SO, 1994, GENE DEV, V8, P1654, DOI 10.1101/gad.8.14.1654; Graves JD, 1996, P NATL ACAD SCI USA, V93, P13814, DOI 10.1073/pnas.93.24.13814; GREEN H, 1976, CELL, V7, P105, DOI 10.1016/0092-8674(76)90260-9; GREEN H, 1975, CELL, V5, P19, DOI 10.1016/0092-8674(75)90087-2; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; Han JH, 1996, J BIOL CHEM, V271, P2886, DOI 10.1074/jbc.271.6.2886; Hanson RW, 1998, J BIOL CHEM, V273, P28543, DOI 10.1074/jbc.273.44.28543; HOMBURG CHE, 1995, BLOOD, V85, P532; Hu E, 1996, J BIOL CHEM, V271, P10697, DOI 10.1074/jbc.271.18.10697; KASTURI I, 1982, J BIOL CHEM, V257, P12224; KOOPMAN G, 1994, BLOOD, V84, P1415, DOI 10.1182/blood.V84.5.1415.1415; Lekstrom-Himes J, 1998, J BIOL CHEM, V273, P28545, DOI 10.1074/jbc.273.44.28545; LIN AN, 1995, SCIENCE, V268, P286, DOI 10.1126/science.7716521; Loftus TM, 1997, CURR OPIN GENET DEV, V7, P603, DOI 10.1016/S0959-437X(97)80006-8; Maeda K, 1996, BIOCHEM BIOPH RES CO, V221, P286, DOI 10.1006/bbrc.1996.0587; Mandrup S, 1997, J BIOL CHEM, V272, P5367, DOI 10.1074/jbc.272.9.5367; Morooka T, 1998, J BIOL CHEM, V273, P24285, DOI 10.1074/jbc.273.38.24285; Mueller E, 1998, MOL CELL, V1, P465, DOI 10.1016/S1097-2765(00)80047-7; Nagata Y, 1998, BLOOD, V92, P1859, DOI 10.1182/blood.V92.6.1859.418k37_1859_1869; PESTELL RG, 1994, J BIOL CHEM, V269, P31090; POLL V, 1990, CELL, V63, P643; Porras A, 1998, MOL ENDOCRINOL, V12, P825, DOI 10.1210/me.12.6.825; PORRAS A, 1992, J BIOL CHEM, V267, P21124; Raingeaud J, 1996, MOL CELL BIOL, V16, P1247; Sarraf P, 1998, NAT MED, V4, P1046, DOI 10.1038/2030; SCHAFFER JE, 1994, CELL, V79, P427, DOI 10.1016/0092-8674(94)90252-6; Scherer PE, 1997, J BIOL CHEM, V272, P29337, DOI 10.1074/jbc.272.46.29337; SCHERER PE, 1994, J CELL BIOL, V127, P1233, DOI 10.1083/jcb.127.5.1233; SCHERER PE, 1995, J BIOL CHEM, V270, P26746, DOI 10.1074/jbc.270.45.26746; Schwenger P, 1996, J BIOL CHEM, V271, P8089, DOI 10.1074/jbc.271.14.8089; Schwenger P, 1998, MOL CELL BIOL, V18, P78, DOI 10.1128/MCB.18.1.78; Schwenger P, 1997, P NATL ACAD SCI USA, V94, P2869, DOI 10.1073/pnas.94.7.2869; Spiegelman BM, 1998, CELL, V93, P153, DOI 10.1016/S0092-8674(00)81567-6; Sterneck E, 1998, J NEUROCHEM, V70, P2424; STUDENT AK, 1980, J BIOL CHEM, V255, P4745; TONTONOZ P, 1994, CELL, V79, P1147, DOI 10.1016/0092-8674(94)90006-X; VERMES I, 1995, J IMMUNOL METHODS, V184, P39, DOI 10.1016/0022-1759(95)00072-I; Wang XZ, 1996, SCIENCE, V272, P1347, DOI 10.1126/science.272.5266.1347; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Yamanaka R, 1998, INT J MOL MED, V1, P213; Yang D, 1997, P NATL ACAD SCI USA, V94, P3004, DOI 10.1073/pnas.94.7.3004; YEH WC, 1995, GENE DEV, V9, P168, DOI 10.1101/gad.9.2.168; Zechner D, 1997, J CELL BIOL, V139, P115, DOI 10.1083/jcb.139.1.115	57	93	98	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 10	1999	274	50					35630	35638		10.1074/jbc.274.50.35630	http://dx.doi.org/10.1074/jbc.274.50.35630			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	264NG	10585441				2022-12-25	WOS:000084187900053
J	Feng, YH; Karnik, SS				Feng, YH; Karnik, SS			Role of transmembrane helix IV in G-protein specificity of the angiotensin II type 1 receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COUPLED RECEPTORS; AT(1) RECEPTOR; ACTIVATION; RHODOPSIN; DOMAINS; SITE; PHOSPHATASE; ANTAGONISTS; INHIBITION; MECHANISMS	G-protein activation by G-protein coupled receptors (GPCRs) is accomplished through proper interaction with the cytoplasmic loops rather than through sequence-specific interactions. However, the mechanism by which a specific G-protein is selected by a GPCR is not known. In the current model of GPCR activation, agonist binding modulates helix-helix interactions, which is necessary for fully determining G-protein specificity and stimulation of GDP/GTP exchange. In this study, we report that a single-residue deletion in transmembrane helix IV leads the ansotensin II type 1 (AT,) receptor chimera CR17 to retain GTP-sensitive high affinity for the agonist angiotensin II but results in complete inactivation of intracellular inositol phosphate production. The agonist dissociation profile of CR17 in the presence of guanosine 5'-3-O-(thio)triphosphate suggests that the activation-induced conformational changes of the chimeric receptor itself remain intact. Insertion of an alanine at position 149 (CR17 del 149A) in this chimera rescued the inactive phenotype, restoring intracellular inositol phosphate production by the chimera. This finding suggests that in the wild-type AT(1) receptor the orientation of transmembrane helix TV-residues following Cys(149) is a key determinant for effectively distinguishing among various structurally similar G-proteins. The results emphasize that the contacts within the membrane-embedded portion of transmembrane helix TV in the AT(1) receptor is important for specific G-protein selection.	Cleveland Clin Fdn, Dept Mol Cardiol NB50, Lerner Res Inst, Cleveland, OH 44195 USA	Cleveland Clinic Foundation	Karnik, SS (corresponding author), Cleveland Clin Fdn, Dept Mol Cardiol NB50, Lerner Res Inst, 9500 Euclid Ave, Cleveland, OH 44195 USA.		Karnik, Sadashiva/Y-2477-2019	Karnik, Sadashiva/0000-0003-0746-2753	NATIONAL EYE INSTITUTE [R01EY009704] Funding Source: NIH RePORTER; NEI NIH HHS [EY09704] Funding Source: Medline; NHLBI NIH HHS [R01 HL064845, R01 HL057470, HL5648] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Altenbach C, 1996, BIOCHEMISTRY-US, V35, P12470, DOI 10.1021/bi960849l; BALDWIN JM, 1993, EMBO J, V12, P1693, DOI 10.1002/j.1460-2075.1993.tb05814.x; Bedecs K, 1997, BIOCHEM J, V325, P449, DOI 10.1042/bj3250449; CATT KJ, 1994, RENIN ANGIOTENSIN SY, P121; FARAHBAKHSH ZT, 1995, BIOCHEMISTRY-US, V34, P8812, DOI 10.1021/bi00027a033; FENG YH, 1995, J BIOL CHEM, V270, P12846, DOI 10.1074/jbc.270.21.12846; Feng YH, 1998, BIOCHEMISTRY-US, V37, P15791, DOI 10.1021/bi980863t; Hunyady L, 1996, TRENDS PHARMACOL SCI, V17, P135, DOI 10.1016/0165-6147(96)81588-4; Ji TH, 1998, J BIOL CHEM, V273, P17299, DOI 10.1074/jbc.273.28.17299; Kai H, 1998, BIOCHEM J, V332, P781, DOI 10.1042/bj3320781; KAMBAYASHI Y, 1993, J BIOL CHEM, V268, P24543; KOBILKA BK, 1988, SCIENCE, V240, P1310, DOI 10.1126/science.2836950; LIGGETT SB, 1991, J BIOL CHEM, V266, P4816; Miura S, 1999, J BIOL CHEM, V274, P7103, DOI 10.1074/jbc.274.11.7103; MUKOYAMA M, 1993, J BIOL CHEM, V268, P24539; NAHMIAS C, 1995, TRENDS PHARMACOL SCI, V16, P223, DOI 10.1016/S0165-6147(00)89030-6; NODA K, 1995, J BIOL CHEM, V270, P28511, DOI 10.1074/jbc.270.48.28511; NODA K, 1995, J BIOL CHEM, V270, P2284, DOI 10.1074/jbc.270.5.2284; Noda K, 1996, BIOCHEMISTRY-US, V35, P16435, DOI 10.1021/bi961593m; Sano T, 1997, J BIOL CHEM, V272, P23631, DOI 10.1074/jbc.272.38.23631; SCHERTLER GFX, 1993, NATURE, V362, P770, DOI 10.1038/362770a0; TIMMERMANS PBMWM, 1993, PHARMACOL REV, V45, P205; Wess J, 1997, FASEB J, V11, P346, DOI 10.1096/fasebj.11.5.9141501; WONG SKF, 1990, J BIOL CHEM, V265, P6219; Zhu MY, 1998, J NEUROSCI, V18, P679	25	21	22	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 10	1999	274	50					35546	35552		10.1074/jbc.274.50.35546	http://dx.doi.org/10.1074/jbc.274.50.35546			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	264NG	10585429	hybrid			2022-12-25	WOS:000084187900041
J	Kline, JB; Roehrs, H; Clevenger, CV				Kline, JB; Roehrs, H; Clevenger, CV			Functional characterization of the intermediate isoform of the human prolactin receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RIBONUCLEIC-ACID; POLYMERASE CHAIN-REACTION; TYROSINE KINASE P59(FYN); GROWTH-HORMONE RECEPTOR; SIGNAL-TRANSDUCTION; CELL-PROLIFERATION; PROTEIN-KINASE; CYTOPLASMIC REGIONS; GENE-EXPRESSION; PRL RECEPTOR	Prolactin-dependent signaling occurs as the result of ligand-induced dimerization of the prolactin receptor (PRLr), While three PRLr isoforms have been characterized in the rat, studies have suggested the existence of several human isoforms in breast carcinoma species and normal tissues. Reverse transcription polymerase chain reaction was performed on mRNA isolated from the breast carcinoma cell line T47D, revealing two predominant receptor isoforms: the previously described long PRLr and a novel human intermediate PRLr, The nucleotide sequence of the intermediate isoform was found to be identical to the long isoform except for a 573-base pair deletion occurring at a consensus splice site, resulting in a frameshift and truncated intracytoplasmic domain. Scatchard analysis of the intermediate PRLr revealed an affinity for PRL comparable with the long PRLr, While Ba/F3 transfectants expressing the long PRLr proliferated in response to PRL, intermediate PRLr transfectants exhibited modest incorporation of [H-3]thymidine, Significantly, however, both the long and intermediate PRLr were equivalent in their inhibition of apoptosis of the Ba/F3 transfectants after PRL treatment. The activation of proximal signaling molecules also differed between isoforms, Upon ligand binding, Jak2 and Fyn were activated in CHO-K1 cells transiently transfected with the long PRLr, In contrast, the intermediate PRLr transfectants showed equivalent levels of Jak2 activation but only minimal activation of Fyn Last, Northern analysis revealed variable tissue expression of intermediate PRLr transcript that differed from that of the long PRLr, Taken together, differences in signaling and tissue expression suggest that the human intermediate PRLr differs from the long PRLr in physiological function.	Univ Penn, Med Ctr, Dept Pathol & Lab Med, Sch Med, Philadelphia, PA 19104 USA	University of Pennsylvania	Clevenger, CV (corresponding author), Univ Penn, Med Ctr, Dept Pathol & Lab Med, Sch Med, 509 Stellar Chance Labs,422 Curie Blvd, Philadelphia, PA 19104 USA.	clevengc@mail.med.upenn.edu			NATIONAL CANCER INSTITUTE [R01CA069294] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [F32DK009727] Funding Source: NIH RePORTER; NCI NIH HHS [2RO1CA69294] Funding Source: Medline; NIDDK NIH HHS [1F32DK09727] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALI S, 1991, J BIOL CHEM, V266, P20110; ALI S, 1991, ENDOCR SOC P, V73, P245; Anderson SM, 1997, J BIOL CHEM, V272, P739, DOI 10.1074/jbc.272.2.739; ANTHONY RV, 1995, ENDOCRINE, V3, P291, DOI 10.1007/BF03021408; BAZAN JF, 1990, IMMUNOL TODAY, V11, P350, DOI 10.1016/0167-5699(90)90139-Z; BAZAN JF, 1990, P NATL ACAD SCI USA, V87, P6934, DOI 10.1073/pnas.87.18.6934; BERLANGA J, 1997, MOL ENDOCRINOL, V344; BOISE LH, 1995, CURR TOP MICROBIOL I, V200, P171; BOUTIN JM, 1988, CELL, V53, P69, DOI 10.1016/0092-8674(88)90488-6; BOUTIN JM, 1989, MOL ENDOCRINOL, V3, P1455, DOI 10.1210/mend-3-9-1455; Buteau H, 1998, MOL ENDOCRINOL, V12, P544, DOI 10.1210/me.12.4.544; Chang WP, 1996, P NATL ACAD SCI USA, V93, P5947, DOI 10.1073/pnas.93.12.5947; Chang WP, 1998, MOL CELL BIOL, V18, P896, DOI 10.1128/MCB.18.2.896; Chaturvedi P, 1998, ONCOGENE, V16, P1749, DOI 10.1038/sj.onc.1201972; CHEN XJ, 1994, ENDOCRINOLOGY, V135, P269, DOI 10.1210/en.135.1.269; CHOW LML, 1993, NATURE, V365, P156, DOI 10.1038/365156a0; CLARKE DL, 1993, ENDOCRINOLOGY, V133, P224, DOI 10.1210/en.133.1.224; CLEVENGER CV, 1990, P NATL ACAD SCI USA, V87, P6460, DOI 10.1073/pnas.87.16.6460; CLEVENGER CV, 1992, ENDOCRINOLOGY, V130, P3216, DOI 10.1210/en.130.6.3216; CLEVENGER CV, 1995, AM J PATHOL, V146, P695; CLEVENGER CV, 1994, MOL ENDOCRINOL, V8, P674, DOI 10.1210/me.8.6.674; Clevenger CV, 1997, MOL ENDOCRINOL, V11, P608, DOI 10.1210/me.11.5.608; DASILVA L, 1994, J BIOL CHEM, V269, P18267; DAVIS JA, 1989, MOL ENDOCRINOL, V3, P674, DOI 10.1210/mend-3-4-674; DONATSCH P, 1975, J ENDOCRINOL, V66, P101, DOI 10.1677/joe.0.0660101; DORATO A, 1992, ENDOCRINOLOGY, V131, P1734, DOI 10.1210/en.131.4.1734; EMMANOUEL DS, 1981, AM J PHYSIOL, V240, pF437, DOI 10.1152/ajprenal.1981.240.5.F437; FIELDS K, 1993, LAB INVEST, V68, P354; FREEMARK M, 1993, ENDOCRINOLOGY, V133, P1830, DOI 10.1210/en.133.4.1830; GILMOUR KC, 1994, P NATL ACAD SCI USA, V91, P6850, DOI 10.1073/pnas.91.15.6850; Glasow A, 1996, J CLIN ENDOCR METAB, V81, P3103, DOI 10.1210/jc.81.8.3103; Goffin V, 1997, J MAMMARY GLAND BIOL, V2, P7, DOI 10.1023/A:1026313211704; GOUJON L, 1994, P NATL ACAD SCI USA, V91, P957, DOI 10.1073/pnas.91.3.957; GRONER B, 1994, MOL CELL ENDOCRINOL, V100, P109, DOI 10.1016/0303-7207(94)90288-7; GU Y, 1992, ENDOCRINOLOGY, V131, P1321, DOI 10.1210/en.131.3.1321; HARTMANN DP, 1989, FASEB J, V3, P2194, DOI 10.1096/fasebj.3.10.2787766; Horseman ND, 1997, EMBO J, V16, P6926, DOI 10.1093/emboj/16.23.6926; KAGNOFF MF, 1993, GASTROENTEROLOGY, V105, P1275, DOI 10.1016/0016-5085(93)90128-Y; KELLY PA, 1993, RECENT PROG HORM RES, V48, P123; KELLY PA, 1991, ENDOCR REV, V12, P235, DOI 10.1210/edrv-12-3-235; Kline JB, 1996, INFECT IMMUN, V64, P861, DOI 10.1128/IAI.64.3.861-869.1996; KRISHNAN KA, 1991, COMP BIOCHEM PHYS B, V100, P769, DOI 10.1016/0305-0491(91)90288-O; Leav I, 1999, AM J PATHOL, V154, P863, DOI 10.1016/S0002-9440(10)65333-3; LEBRUN JJ, 1994, J BIOL CHEM, V269, P14021; Maaskant RA, 1996, J CLIN ENDOCR METAB, V81, P396, DOI 10.1210/jc.81.1.396; Mao JNC, 1999, ENDOCRINOLOGY, V140, P1165, DOI 10.1210/en.140.3.1165; NAGANO M, 1994, J BIOL CHEM, V269, P13337; NAGANO M, 1995, AM J PHYSIOL-GASTR L, V268, pG431, DOI 10.1152/ajpgi.1995.268.3.G431; NICOLL CS, 1980, CTR PERIPHERAL REGUL; ONEAL KD, 1994, J BIOL CHEM, V269, P26076; ONEAL KD, 1992, MOL CELL ENDOCRINOL, V87, pR19, DOI 10.1016/0303-7207(92)90251-Z; OUHTIT A, 1993, ENDOCRINOLOGY, V133, P135, DOI 10.1210/en.133.1.135; PELLEGRINI I, 1992, MOL ENDOCRINOL, V6, P1023, DOI 10.1210/me.6.7.1023; PLATT JE, 1977, GEN COMP ENDOCR, V31, P243, DOI 10.1016/0016-6480(77)90023-5; PostelVinay MC, 1996, HORM RES, V45, P178, DOI 10.1159/000184783; Quelle FW, 1996, MOL CELL BIOL, V16, P1622; QUELLE FW, 1995, MOL CELL BIOL, V15, P3336; RAJANIEMI H, 1974, HORM RES, V5, P6, DOI 10.1159/000178614; REED JC, 1994, J CELL BIOL, V124, P1, DOI 10.1083/jcb.124.1.1; Reynolds C, 1997, ENDOCRINOLOGY, V138, P5555, DOI 10.1210/en.138.12.5555; Riddle O, 1933, AM J PHYSIOL, V105, P191, DOI 10.1152/ajplegacy.1933.105.1.191; ROYSTER M, 1995, ENDOCRINOLOGY, V136, P3892, DOI 10.1210/en.136.9.3892; RUI H, 1992, J BIOL CHEM, V267, P24076; RUI H, 1994, J BIOL CHEM, V269, P5364; RUI H, 1994, ENDOCRINOLOGY, V135, P1299, DOI 10.1210/en.135.4.1299; RUSSELL DH, 1996, PROLACTIN GENE FAMIL, P155; Sakai I, 1997, J BIOL CHEM, V272, P12350, DOI 10.1074/jbc.272.19.12350; Sakai Y, 1999, KIDNEY INT, V55, P833, DOI 10.1046/j.1523-1755.1999.055003833.x; SATO N, 1993, EMBO J, V12, P4181, DOI 10.1002/j.1460-2075.1993.tb06102.x; Schuler LA, 1997, ENDOCRINOLOGY, V138, P3187, DOI 10.1210/en.138.8.3187; SETH A, 1992, J BIOL CHEM, V267, P24796; SHIROTA M, 1990, MOL ENDOCRINOL, V4, P1136, DOI 10.1210/mend-4-8-1136; Simon HU, 1997, EUR J IMMUNOL, V27, P3536, DOI 10.1002/eji.1830271256; TANAKA M, 1992, BIOCHEM BIOPH RES CO, V188, P490, DOI 10.1016/0006-291X(92)91082-2; VEILLETTE A, 1992, ONCOGENE, V7, P971; VENKITARAMAN AR, 1992, P NATL ACAD SCI USA, V89, P12083, DOI 10.1073/pnas.89.24.12083; WAKAO H, 1994, EMBO J, V13, P2182, DOI 10.1002/j.1460-2075.1994.tb06495.x; WITORSCH RJ, 1993, P SOC EXP BIOL MED, V203, P454, DOI 10.3181/00379727-203-43622; YETTER A, 1995, J BIOL CHEM, V270, P18179, DOI 10.1074/jbc.270.31.18179	79	107	111	1	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 10	1999	274	50					35461	35468		10.1074/jbc.274.50.35461	http://dx.doi.org/10.1074/jbc.274.50.35461			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	264NG	10585417	hybrid			2022-12-25	WOS:000084187900029
J	MacMillan, LB; Bass, MA; Cheng, N; Howard, EF; Tamura, M; Strack, S; Wadzinski, BE; Colbran, RJ				MacMillan, LB; Bass, MA; Cheng, N; Howard, EF; Tamura, M; Strack, S; Wadzinski, BE; Colbran, RJ			Brain actin-associated protein phosphatase 1 holoenzymes containing spinophilin, neurabin, and selected catalytic subunit isoforms	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FILAMENT-BINDING PROTEIN; POSTSYNAPTIC DENSITY; KINASE-II; TARGETING SUBUNITS; DENDRITIC SPINES; RAT LIN-10; RECEPTORS; DOMAIN; PROTEIN-PHOSPHATASE-1; PHOSPHORYLATION	We previously characterized PP1bp134 and PP1bp175, two neuronal proteins that bind the protein phosphatase 1 catalytic subunit (PPI). Here we purify from rat brain actin-cytoskeletal extracts PP1(A) holoenzymes selectively enriched in PP1 gamma(1) over PP1 beta isoforms and also containing PP1bp134 and PP1bp175. PP1bp134 and PP1bp175 were identified as the synapse-localized F-actin-binding proteins spinophilin (Allen, P. B., Ouimet, C. C., and Greengard, P. (1997) Proc. Natl. Acad. Sci. U.S.A. 94, 9956-9561; Satoh, A., Nakanishi, H., Obaishi, H., Wada, M., Takahashi, K., Satoh, K., Hirao, K., Nishioka, H., Hata, Y., Mizoguchi, A., and Takai, Y. (1998) J. Biol. Chem. 273, 3470-3475) and neurabin (Nakanishi, H., Obaishi, H., Satoh, A., Wada, M., Mandai, K., Satoh, K., Nishioka, H., Matsuura, Y., Mizoguchi, A., and Takai, Y. (1997) J. Cell Biol. 139, 951-961), respectively. Recombinant spinophilin and neurabin interacted with endogenous PP1 and also with each other when co-expressed in HEK293 cells. Spinophilin residues 427-470, or homologous neurabin residues 436-479, were sufficient to bind PPI in gel overlay assays, and selectively bound PP1 gamma(1), from a mixture of brain protein phosphatase catalytic subunits; additional N- and C-terminal sequences were required for potent inhibition of PPI. Immunoprecipitation of spinophilin or neurabin from crude brain extracts selectively coprecipitated PP1 gamma(1), over PP1 beta. Moreover, immunoprecipitation of PP1 gamma(1), from brain extracts efficiently coprecipitated spinophilin and neurabin, whereas PP1 beta immunoprecipitation did not. Thus, PP1(A) holoenzymes containing spinophilin and/or neurabin target specific neuronal PP1 isoforms, facilitating efficient regulation of synaptic phosphoproteins.	Vanderbilt Univ, Sch Med, Dept Physiol & Mol Biophys, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Dept Biochem, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Dept Pharmacol, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Ctr Mol Neurosci, Nashville, TN 37232 USA	Vanderbilt University; Vanderbilt University; Vanderbilt University; Vanderbilt University	Colbran, RJ (corresponding author), Vanderbilt Univ, Sch Med, Dept Physiol & Mol Biophys, Rm 702,Light Hall, Nashville, TN 37232 USA.		Colbran, Roger/AAU-7708-2021	Colbran, Roger/0000-0001-7401-8244; Strack, Stefan/0000-0002-6175-7280; Tamura, Masaaki/0000-0003-4863-3379	NIGMS NIH HHS [GM47973, GM51366] Funding Source: Medline; NINDS NIH HHS [NS37508] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R56GM051366, R29GM047973, R01GM051366] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS037508] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Allen PB, 1997, P NATL ACAD SCI USA, V94, P9956, DOI 10.1073/pnas.94.18.9956; Allen PB, 1998, J BIOL CHEM, V273, P4089, DOI 10.1074/jbc.273.7.4089; Barria A, 1997, SCIENCE, V276, P2042, DOI 10.1126/science.276.5321.2042; BOLLEN M, 1992, CRIT REV BIOCHEM MOL, V27, P227, DOI 10.3109/10409239209082564; Burnett PE, 1998, P NATL ACAD SCI USA, V95, P8351, DOI 10.1073/pnas.95.14.8351; Colbran RJ, 1997, J NEUROCHEM, V69, P920; Connor JH, 1998, J BIOL CHEM, V273, P27716, DOI 10.1074/jbc.273.42.27716; Egloff MP, 1997, EMBO J, V16, P1876, DOI 10.1093/emboj/16.8.1876; Endo S, 1996, BIOCHEMISTRY-US, V35, P5220, DOI 10.1021/bi952940f; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; Greengard P, 1998, BRAIN RES REV, V26, P274, DOI 10.1016/S0165-0173(97)00057-X; Hsieh-Wilson LC, 1999, BIOCHEMISTRY-US, V38, P4365, DOI 10.1021/bi982900m; HUBBARD MJ, 1993, TRENDS BIOCHEM SCI, V18, P172, DOI 10.1016/0968-0004(93)90109-Z; Ide N, 1998, BIOCHEM BIOPH RES CO, V244, P258, DOI 10.1006/bbrc.1998.8243; Ide N, 1998, BIOCHEM BIOPH RES CO, V243, P634, DOI 10.1006/bbrc.1998.8142; Johnson DF, 1996, EUR J BIOCHEM, V239, P317, DOI 10.1111/j.1432-1033.1996.0317u.x; Kennedy M B, 1993, Curr Opin Neurobiol, V3, P732, DOI 10.1016/0959-4388(93)90145-O; KLAUCK TM, 1995, CELL SIGNAL, V7, P747, DOI 10.1016/0898-6568(95)02003-9; Kwon YG, 1997, P NATL ACAD SCI USA, V94, P3536, DOI 10.1073/pnas.94.8.3536; Lee HK, 1998, NEURON, V21, P1151, DOI 10.1016/S0896-6273(00)80632-7; LEVILLIERS N, 1984, BIOCHIMIE, V66, P531, DOI 10.1016/0300-9084(84)90147-0; LOVINGER DM, 1995, J PHARMACOL EXP THER, V274, P164; MALENKA RC, 1994, CELL, V78, P535, DOI 10.1016/0092-8674(94)90517-7; MULKEY RM, 1994, NATURE, V369, P486, DOI 10.1038/369486a0; Nakanishi H, 1997, J CELL BIOL, V139, P951, DOI 10.1083/jcb.139.4.951; OUIMET CC, 1995, P NATL ACAD SCI USA, V92, P3396, DOI 10.1073/pnas.92.8.3396; Satoh A, 1998, J BIOL CHEM, V273, P3470, DOI 10.1074/jbc.273.6.3470; SHENOLIKAR S, 1994, ANNU REV CELL BIOL, V10, P55, DOI 10.1146/annurev.cellbio.10.1.55; SILVA EFDE, 1995, J NEUROSCI, V15, P3375; SIM ATR, 1994, J NEUROCHEM, V62, P1552; Smith FD, 1999, J BIOL CHEM, V274, P19894, DOI 10.1074/jbc.274.28.19894; Strack S, 1999, J COMP NEUROL, V413, P373; Strack S, 1997, J BIOL CHEM, V272, P13467, DOI 10.1074/jbc.272.21.13467; Strack S, 1997, J NEUROCHEM, V68, P2119; Strack S, 1998, J BIOL CHEM, V273, P20689, DOI 10.1074/jbc.273.33.20689; WADZINSKI BE, 1993, MOL CELL BIOL, V13, P2822, DOI 10.1128/MCB.13.5.2822; Whitfield CW, 1999, MOL BIOL CELL, V10, P2087, DOI 10.1091/mbc.10.6.2087; Wu J, 1998, FEBS LETT, V439, P185, DOI 10.1016/S0014-5793(98)01371-4; Yan Z, 1999, NAT NEUROSCI, V2, P13, DOI 10.1038/4516; Zhao SM, 1997, J BIOL CHEM, V272, P28368, DOI 10.1074/jbc.272.45.28368	40	85	89	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 10	1999	274	50					35845	35854		10.1074/jbc.274.50.35845	http://dx.doi.org/10.1074/jbc.274.50.35845			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	264NG	10585469	hybrid			2022-12-25	WOS:000084187900081
J	Nantel, A; Huber, M; Thomas, DY				Nantel, A; Huber, M; Thomas, DY			Localization of endogenous Grb10 to the mitochondria and its interaction with the mitochondrial-associated Raf-1 pool	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR RECEPTOR; INSULIN-RECEPTOR; ESOPHAGEAL-CARCINOMA; BINDING-PROTEIN; KINASE-ACTIVITY; TUMOR-CELLS; APOPTOSIS; DOMAINS; CLONING; RAS	Grb10 belongs to a small family of adapter proteins that are known to interact with a number of receptor tyrosine kinases and signaling molecules. We have recently demonstrated that the Grb10 SH2 domain interacts with both the Raf-1 and MEK1 kinases. Overexpression of Grb10 genes with mutations in their SH2 domains promotes apoptosis in cultured cells, a phenotype that is reversed by concomitant overexpression of the wild type gene. Using immunofluorescence microscopy and subcellular fractionation we now show that most of the Grb10 molecules are peripherally associated with mitochondria. Following insulin-like growth factor I or serum treatment, small pools of Grb10 can also be found at the plasma membrane and in actin-rich membrane ruffles, whereas overexpression of Grb10 leads to its mislocalization to the cytosol. Two-hybrid analysis shows that the Grb10-binding site on Raf-1 co-localizes with its Ras-binding domain. Finally, we show that the endogenous Grb10 and Raf-1 proteins can be co-immunoprecipitated from a partially purified mitochondrial extract, an interaction that is enhanced following the activation of Raf-1 by ultraviolet radiation. Thus, we infer that Grb10 may regulate signaling between plasma membrane receptors and the apoptosis-inducing machinery on the mitochondrial outer membrane by modulating the anti-apoptotic activity of mitochondrial Raf-1.	Natl Res Council Canada, Biotechnol Res Inst, Eukaryot Genet Grp, Dept Anat & Cell Biol, Montreal, PQ H4P 2R2, Canada; McGill Univ, Dept Biol, Montreal, PQ H3A 2B2, Canada	National Research Council Canada; McGill University	Nantel, A (corresponding author), Natl Res Council Canada, Biotechnol Res Inst, Eukaryot Genet Grp, Dept Anat & Cell Biol, 6100 Royalmount Ave, Montreal, PQ H4P 2R2, Canada.		Thomas, David/M-7661-2017	Thomas, David/0000-0002-8854-762X				AKAO Y, 1994, CANCER RES, V54, P2468; Ali ST, 1997, BIOCHEM J, V325, P321, DOI 10.1042/bj3250321; BARSAGI D, 1993, CELL, V74, P83, DOI 10.1016/0092-8674(93)90296-3; BOTHMER J, 1992, BIOCHEM BIOPH RES CO, V187, P1077, DOI 10.1016/0006-291X(92)91307-C; CATLING AD, 1995, MOL CELL BIOL, V15, P5214; Chen H, 1998, CELL GROWTH DIFFER, V9, P939; CLAYTON DA, 1997, CELLS LAB MANUAL, V1; CLEM RJ, 1991, SCIENCE, V254, P1388, DOI 10.1126/science.1962198; Daly RJ, 1998, CELL SIGNAL, V10, P613, DOI 10.1016/S0898-6568(98)00022-9; Daly RJ, 1996, J BIOL CHEM, V271, P12502, DOI 10.1074/jbc.271.21.12502; Dong LQ, 1997, J BIOL CHEM, V272, P29104, DOI 10.1074/jbc.272.46.29104; Drugan JK, 1996, J BIOL CHEM, V271, P233, DOI 10.1074/jbc.271.1.233; Frantz JD, 1997, J BIOL CHEM, V272, P2659, DOI 10.1074/jbc.272.5.2659; GOLEMIS EA, 1994, CURRENT PROTOCOLS MO; Goping IS, 1998, J CELL BIOL, V143, P207, DOI 10.1083/jcb.143.1.207; Green D, 1998, TRENDS CELL BIOL, V8, P267, DOI 10.1016/S0962-8924(98)01273-2; HACKENBROCK CR, 1981, TRENDS BIOCHEM SCI, V6, P151, DOI 10.1016/0968-0004(81)90056-6; HALL A, 1994, SCIENCE, V264, P1413, DOI 10.1126/science.8197454; He WM, 1998, J BIOL CHEM, V273, P6860, DOI 10.1074/jbc.273.12.6860; Kasid U, 1996, NATURE, V382, P813, DOI 10.1038/382813a0; Kasus-Jacobi A, 1998, J BIOL CHEM, V273, P26026, DOI 10.1074/jbc.273.40.26026; Kim B, 1998, ENDOCRINOLOGY, V139, P4881, DOI 10.1210/en.139.12.4881; KNAPPIK A, 1994, BIOTECHNIQUES, V17, P754; Kroemer G, 1998, ANNU REV PHYSIOL, V60, P619, DOI 10.1146/annurev.physiol.60.1.619; Lau QC, 1998, ONCOGENE, V16, P1899, DOI 10.1038/sj.onc.1201709; Lewis TS, 1998, ADV CANCER RES, V74, P49, DOI 10.1016/S0065-230X(08)60765-4; LIU F, 1995, P NATL ACAD SCI USA, V92, P10287, DOI 10.1073/pnas.92.22.10287; Majewski M, 1999, CANCER RES, V59, P2815; MARGOLIS B, 1992, P NATL ACAD SCI USA, V89, P8894, DOI 10.1073/pnas.89.19.8894; Morrione A, 1997, J BIOL CHEM, V272, P26382, DOI 10.1074/jbc.272.42.26382; Morrison DK, 1997, CURR OPIN CELL BIOL, V9, P174, DOI 10.1016/S0955-0674(97)80060-9; Moutoussamy S, 1998, J BIOL CHEM, V273, P15906, DOI 10.1074/jbc.273.26.15906; Nagase T., 1996, DNA RES, V3; Nantel A, 1998, J BIOL CHEM, V273, P10475, DOI 10.1074/jbc.273.17.10475; OConnor R, 1997, MOL CELL BIOL, V17, P427, DOI 10.1128/MCB.17.1.427; Oliviero R, 1997, BIOCHEM J, V324, P75, DOI 10.1042/bj3240075; OOI J, 1995, ONCOGENE, V10, P1621; Pritchard C, 1997, NAT GENET, V16, P214, DOI 10.1038/ng0797-214; Rasouli-Nia A, 1998, CLIN CANCER RES, V4, P1111; Rebecchi MJ, 1998, ANNU REV BIOPH BIOM, V27, P503, DOI 10.1146/annurev.biophys.27.1.503; RIPARBELLI MG, 1995, EXP CELL RES, V221, P363, DOI 10.1006/excr.1995.1386; Robinson MJ, 1997, CURR OPIN CELL BIOL, V9, P180, DOI 10.1016/S0955-0674(97)80061-0; Salomoni P, 1998, J EXP MED, V187, P1995, DOI 10.1084/jem.187.12.1995; STANCATO LF, 1993, J BIOL CHEM, V268, P21711; Stein E, 1996, J BIOL CHEM, V271, P23588, DOI 10.1074/jbc.271.38.23588; Susin SA, 1998, BBA-BIOENERGETICS, V1366, P151, DOI 10.1016/S0005-2728(98)00110-8; Tanaka S, 1997, CANCER RES, V57, P28; Tanaka S, 1998, J CLIN INVEST, V102, P821, DOI 10.1172/JCI2921; Therrien M, 1998, CELL, V95, P343, DOI 10.1016/S0092-8674(00)81766-3; TRAN D, 1993, CELL SIGNAL, V5, P565, DOI 10.1016/0898-6568(93)90052-N; Tzivion G, 1998, NATURE, V394, P88, DOI 10.1038/27938; Wang HG, 1996, CELL, V87, P629, DOI 10.1016/S0092-8674(00)81383-5; Winkler DG, 1998, J BIOL CHEM, V273, P21578, DOI 10.1074/jbc.273.34.21578; Wojcik J, 1999, BIOCHEM BIOPH RES CO, V259, P113, DOI 10.1006/bbrc.1999.0727; Xing HM, 1997, CURR BIOL, V7, P294, DOI 10.1016/S0960-9822(06)00152-7; Ziogas A, 1998, J BIOL CHEM, V273, P24108, DOI 10.1074/jbc.273.37.24108	56	73	73	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 10	1999	274	50					35719	35724		10.1074/jbc.274.50.35719	http://dx.doi.org/10.1074/jbc.274.50.35719			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	264NG	10585452	hybrid			2022-12-25	WOS:000084187900064
J	Srinivasan, S; Alexander, H; Alexander, S				Srinivasan, S; Alexander, H; Alexander, S			The prespore vesicles of Dictyostelium discoideum - Purification, characterization, and developmental regulation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SPORE COAT PROTEINS; SACCHAROMYCES-CEREVISIAE; GLYCOPROTEIN COMPLEX; MEMBRANE-PROTEINS; PLASMA-MEMBRANE; CELL; GENE; ORGANIZATION; LOCALIZATION; PATHWAYS	The coordinate fusion of the prespore vesicles (PSVs) with the plasma membrane at the terminal stage of spore differentiation in Dictyostelium discoideum is an important example of developmentally regulated protein secretion, However, little is known about the composition of the vesicles, the molecular signals regulating secretion, or the mechanics of the membrane fusion, Taking a biochemical approach, we purified PSVs from different developmental stages. These preparations are highly enriched for their specific cargo of spore coat proteins while devoid of markers for other cellular compartments. Electron microscopic observations show that the PSV preparations are homogenous, with the soluble spore coat protein PsB/SP85 distributed throughout the lumen and the acid mucopolysaccharide localized in the central core. During development the PSVs increase in size and density concomitant with an increase in their protein cargo. The PSVs contain approximately 80 proteins, and we have identified a PSV-specific GTP-binding protein that may be involved in regulating vesicle fusion, The PSVs are not clathrin-coated and do not contain the SpiA spore coat protein. The PSV preparations are ideal for a global proteome analysis to identify proteins involved in signal reception, vesicle movement, docking, and fusion in this developmentally regulated organelle.	Univ Missouri, Div Biol Sci, Columbia, MO 65211 USA	University of Missouri System; University of Missouri Columbia	Alexander, S (corresponding author), Univ Missouri, Div Biol Sci, Columbia, MO 65211 USA.							ADESSI C, 1995, J CELL SCI, V108, P3331; ALEXANDER S, 1988, DIFFERENTIATION, V38, P82, DOI 10.1111/j.1432-0436.1988.tb00201.x; Alexander S., 1992, P29; ALEXANDER S, 1992, DIFFERENTIATION, V51, P149, DOI 10.1111/j.1432-0436.1992.tb00691.x; ALEXANDER S, 1983, CELL, V34, P467, DOI 10.1016/0092-8674(83)90380-X; ALEXANDER S, 1997, DICTYOSTELIUM MODEL, P349; Aunis D, 1998, INT REV CYTOL, V181, P213, DOI 10.1016/S0074-7696(08)60419-2; BORDIER C, 1981, J BIOL CHEM, V256, P1604; BORTS RH, 1981, DEV BIOL, V87, P185, DOI 10.1016/0012-1606(81)90071-3; CHAMPION A, 1995, MICROBIOL-UK, V141, P785, DOI 10.1099/13500872-141-4-785; CHAMPION A, 1991, J GEN MICROBIOL, V137, P2431, DOI 10.1099/00221287-137-10-2431; DECAMILLI P, 1990, ANNU REV PHYSIOL, V52, P625, DOI 10.1146/annurev.ph.52.030190.003205; DEVINE KM, 1982, P NATL ACAD SCI-BIOL, V79, P7361, DOI 10.1073/pnas.79.23.7361; DEVINE KM, 1983, DEV BIOL, V99, P437, DOI 10.1016/0012-1606(83)90293-2; ERDOS GW, 1989, EXP MYCOL, V13, P169, DOI 10.1016/0147-5975(89)90022-4; ERDOS GW, 1985, MYCOLOGIA, V77, P308, DOI 10.2307/3793083; FOSNAUGH KL, 1991, DEV GENET, V12, P123, DOI 10.1002/dvg.1020120120; GLOMP I, 1985, HISTOCHEMISTRY, V83, P251, DOI 10.1007/BF00953993; Gracz LM, 1996, BBA-PROTEIN STRUCT M, V1292, P293, DOI 10.1016/0167-4838(95)00222-7; GREEN AA, 1974, BIOCHEM J, V140, P313, DOI 10.1042/bj1400313; GREEN N, 1982, CELL, V28, P477, DOI 10.1016/0092-8674(82)90202-1; GRIFFITHS KR, 1996, THESIS MACQUARIE U S; HOHL HR, 1969, J ULTRA MOL STRUCT R, V26, P442, DOI 10.1016/S0022-5320(69)90050-1; HOPPER NA, 1993, EMBO J, V12, P2459, DOI 10.1002/j.1460-2075.1993.tb05900.x; IKEDA T, 1981, BIOCHIM BIOPHYS ACTA, V675, P69, DOI 10.1016/0304-4165(81)90070-2; IKEDA T, 1971, DEV GROWTH DIFFER, V13, P221; KHYSEANDERSON J, 1984, J BIOCHEM BIOPH METH, V10, P203; Kraemer J, 1999, EUR J CELL BIOL, V78, P265, DOI 10.1016/S0171-9335(99)80060-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lang JC, 1999, EUR J BIOCHEM, V259, P3, DOI 10.1046/j.1432-1327.1999.00043.x; LENHARD JM, 1989, EXP CELL RES, V182, P242, DOI 10.1016/0014-4827(89)90295-4; LENHARD JM, 1990, J CELL BIOL, V1, P2761; LIVI GP, 1985, DEV BIOL, V110, P514, DOI 10.1016/0012-1606(85)90110-1; Loomis WF, 1998, MICROBIOL MOL BIOL R, V62, P684, DOI 10.1128/MMBR.62.3.684-694.1998; LOOMIS WF, 1969, J BACTERIOL, V100, P417, DOI 10.1128/JB.100.1.417-422.1969; LOOMIS WF, 1970, J BACTERIOL, V103, P375, DOI 10.1128/JB.103.2.375-381.1970; Lupashin VV, 1997, SCIENCE, V276, P1255, DOI 10.1126/science.276.5316.1255; MAEDA Y, 1969, DEV GROWTH DIFFER, V11, P232; McGuire V, 1996, J BIOL CHEM, V271, P14596, DOI 10.1074/jbc.271.24.14596; MCGUIRE V, 1996, THESIS U MISSOURI CO; Mellman I, 1996, ANNU REV CELL DEV BI, V12, P575, DOI 10.1146/annurev.cellbio.12.1.575; MIERENDORF RC, 1985, J CELL BIOL, V100, P1777, DOI 10.1083/jcb.100.5.1777; NEWELL PC, 1969, BIOCHIM BIOPHYS ACTA, V177, P610, DOI 10.1016/0304-4165(69)90326-2; Novick P, 1997, CURR OPIN CELL BIOL, V9, P496, DOI 10.1016/S0955-0674(97)80025-7; ORLOWSKI M, 1979, DEV BIOL, V71, P297, DOI 10.1016/0012-1606(79)90171-4; RATNER D, 1983, EXP CELL RES, V143, P1, DOI 10.1016/0014-4827(83)90103-9; RICHARDSON DL, 1992, GENE DEV, V6, P1058, DOI 10.1101/gad.6.6.1058; RICHARDSON DL, 1991, DEV BIOL, V144, P269, DOI 10.1016/0012-1606(91)90421-X; Rothman JE, 1997, SCIENCE, V276, P1212, DOI 10.1126/science.276.5316.1212; Rybin V, 1996, NATURE, V383, P266, DOI 10.1038/383266a0; Sack S, 1999, EUR J BIOCHEM, V262, P1, DOI 10.1046/j.1432-1327.1999.00341.x; SALMINEN A, 1987, CELL, V49, P527, DOI 10.1016/0092-8674(87)90455-7; SAXE SA, 1990, MOL CELL BIOL, V10, P2367, DOI 10.1128/MCB.10.5.2367; Schmid SL, 1997, ANNU REV BIOCHEM, V66, P511, DOI 10.1146/annurev.biochem.66.1.511; Shaulsky G, 1996, P NATL ACAD SCI USA, V93, P15260, DOI 10.1073/pnas.93.26.15260; SHAULSKY G, 1995, GENE DEV, V9, P1111, DOI 10.1101/gad.9.9.1111; SMITH E, 1989, GENETICS, V122, P59; SUSSMAN M, 1987, METHOD CELL BIOL, V28, P9; SUSSMAN R, 1971, ARCH BIOCHEM BIOPHYS, V144, P127, DOI 10.1016/0003-9861(71)90462-0; TAKEUCHI I, 1970, EXP CELL RES, V61, P183, DOI 10.1016/0014-4827(70)90272-7; Tapon N, 1997, CURR OPIN CELL BIOL, V9, P86, DOI 10.1016/S0955-0674(97)80156-1; VATER CA, 1992, J CELL BIOL, V119, P773, DOI 10.1083/jcb.119.4.773; Wang N, 1996, EMBO J, V15, P3890, DOI 10.1002/j.1460-2075.1996.tb00763.x; WATSON N, 1993, J BIOL CHEM, V268, P22634; WATSON N, 1994, J CELL SCI, V107, P2567; WEST CM, 1990, DEV GENET, V11, P492, DOI 10.1002/dvg.1020110526; WILKINSON DG, 1983, BIOCHEM J, V216, P567, DOI 10.1042/bj2160567; YAN JX, 1997, DICTYOSTELIUM MODEL, P455; Zhang YY, 1998, BIOCHEMISTRY-US, V37, P10766, DOI 10.1021/bi9808013	69	17	17	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 10	1999	274	50					35823	35831		10.1074/jbc.274.50.35823	http://dx.doi.org/10.1074/jbc.274.50.35823			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	264NG	10585466	hybrid			2022-12-25	WOS:000084187900078
J	Stockand, JD; Spier, BJ; Worrell, RT; Yue, G; Al-Baldawi, N; Eaton, DC				Stockand, JD; Spier, BJ; Worrell, RT; Yue, G; Al-Baldawi, N; Eaton, DC			Regulation of Na+ reabsorption by the aldosterone-induced small G protein K-Ras2A	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAS-RELATED PROTEINS; CARBOXYL METHYLATION; SODIUM-TRANSPORT; SURFACE EXPRESSION; APICAL MEMBRANE; CHANNELS; EPITHELIA; A6	Xenopus laevis A6 cells were used as model epithelia to test the hypothesis that K-Ras2A is an aldosterone-induced protein necessary for steroid-regulated Na+ transport. The possibility that increased K-Ras2A alone is sufficient to mimic aldosterone action on Na+ transport also was tested. Aldosterone treatment increased K-Ras2A protein expression 2.8 fold within 4 h, Active Ras is membrane associated. After aldosterone treatment, 75% of K-Ras was localized to the plasma membrane compared with 25% in the absence of steroid. Aldosterone also increased the amount of active (phosphorylated) mitogen-activated protein kinase kinase likely through K-Ras2A signaling. Steroid-induced K-Ras2A protein levels and Na+ transport were decreased with antisense K-ras2A oligonucleotides, showing that K-Ras2A is necessary for the natriferic actions of aldosterone, Aldosterone-induced Na+ channel activity, was decreased from 0.40 to 0.09 by pretreatment with antisense ras oligonucleotide, implicating the luminal Na+ channel as one final effector of Ras signaling. Overexpression of K-Ras2A increased Na+ transport approximately 2.2-foId in the absence of aldosterone. These results suggest that aldosterone signals to the luminal Naf channel via multiple pathways and that K-Ras2A levels are limiting for a portion of the aldosterone-sensitive Na+ transport.	Emory Univ, Sch Med, Dept Physiol, Ctr Cell & Mol Signaling, Atlanta, GA 30322 USA	Emory University	Stockand, JD (corresponding author), Emory Univ, Sch Med, Dept Physiol, Ctr Cell & Mol Signaling, 1648 Pierce Dr, Atlanta, GA 30322 USA.	jstocka@emory.edu		Eaton, Douglas/0000-0002-2686-6692; Stockand, James/0000-0002-3817-4319	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK037963, R01DK037963, F32DK009729] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK09729, DK37963] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		CANTIELLO HF, 1990, J BIOL CHEM, V265, P21624; EATON DC, 1995, KIDNEY INT, V48, P941, DOI 10.1038/ki.1995.375; Garty H, 1997, PHYSIOL REV, V77, P359, DOI 10.1152/physrev.1997.77.2.359; ISMAILOV II, 1994, J BIOL CHEM, V269, P22193; KEMENDY AE, 1992, AM J PHYSIOL, V263, pC825, DOI 10.1152/ajpcell.1992.263.4.C825; KLEYMAN TR, 1989, J BIOL CHEM, V264, P11995; KLEYMAN TR, 1992, J BIOL CHEM, V267, P9622; Mastroberardino L, 1998, MOL BIOL CELL, V9, P3417, DOI 10.1091/mbc.9.12.3417; Pells S, 1997, ONCOGENE, V15, P1781, DOI 10.1038/sj.onc.1201354; PHILIPS MR, 1993, SCIENCE, V259, P977, DOI 10.1126/science.8438158; PRAT AG, 1993, AM J PHYSIOL, V265, pC224, DOI 10.1152/ajpcell.1993.265.1.C224; Rokaw MD, 1998, J BIOL CHEM, V273, P28746, DOI 10.1074/jbc.273.44.28746; SARIBANSOHRABY S, 1995, AM J PHYSIOL-CELL PH, V268, pC557, DOI 10.1152/ajpcell.1995.268.3.C557; SARIBANSOHRABY S, 1993, J BIOL CHEM, V268, P26613; SARIBANSOHRABY S, 1984, SCIENCE, V225, P745, DOI 10.1126/science.6463652; Spindler B, 1997, PFLUG ARCH EUR J PHY, V434, P323, DOI 10.1007/s004240050403; Stockand JD, 1999, J BIOL CHEM, V274, P26912, DOI 10.1074/jbc.274.38.26912; Stockand JD, 1999, J BIOL CHEM, V274, P3842, DOI 10.1074/jbc.274.6.3842; VERREY F, 1995, J MEMBRANE BIOL, V144, P93; VOLKER C, 1995, METHOD ENZYMOL, V255, P65; WIESMANN WP, 1985, AM J PHYSIOL, V248, pF43, DOI 10.1152/ajprenal.1985.248.1.F43	21	72	73	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 10	1999	274	50					35449	35454		10.1074/jbc.274.50.35449	http://dx.doi.org/10.1074/jbc.274.50.35449			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	264NG	10585415	hybrid			2022-12-25	WOS:000084187900027
J	Sudharshan, E; Rao, AGA				Sudharshan, E; Rao, AGA			Involvement of cysteine residues and domain interactions in the reversible unfolding of lipoxygenase-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SOYBEAN LIPOXYGENASE-1; MAMMALIAN LIPOXYGENASES; TRYPTOPHAN SYNTHASE; PLANT LIPOXYGENASE; ALPHA-SUBUNIT; FATTY-ACID; UREA; 15-LIPOXYGENASE; INACTIVATION; DENATURATION	Urea-induced unfolding of lipoxygenase-1 (LOX1) at pH 7.0 was followed by enzyme activity, spectroscopic measurements, and limited proteolysis experiments. Complete unfolding of LOX1 in 9 M urea in the presence of thiol reducing or thiol modifying reagents was observed. The aggregation and oxidative reactions prevented the reversible unfolding of the molecule. The loss of enzyme activity was much earlier than the structural loss of the molecule during the course of unfolding, with the midpoint concentrations being 4.5 and 7.0 M for activity and spectroscopic measurements, respectively. The equilibrium unfolding transition could be adequately fitted to a three-state, two-step model (N <-> I <-> U) and the intermediate fraction was maximally populated at 6.3 M urea. The free energy change (Delta G(H2O)) for the unfolding of native (N) to intermediate (I) was 14.2 +/- 0.28 kcal/mol and for the intermediate to the unfolded state (U) was 11.9 +/- 0.12 kcal/mol. The ANS binding measurements as a function of urea concentration indicated that the maximum binding of ANS was in 6.3 M urea due to the exposure of hydrophobic groups; this intermediate showed significant amount of tertiary structure and retained nearly 60% of secondary structure. The limited proteolysis measurements showed that the initiation of unfolding was from the C-terminal domain. Thus, the stable intermediate observed could be the C-terminal domain unfolded with exposed hydrophobic domain-domain interface, Limited proteolysis experiments during refolding process suggested that the intermediate refolded prior to completely unfolded LOX1, These results confirmed the role of cysteine residues and domain-domain interactions in the reversible unfolding of LOX1, This is the first report of the reversible unfolding of a very large monomeric, multi-domain protein, which also has a prosthetic group.	Cent Food Technol Res Inst, Dept Prot Chem & Technol, Mysore 570013, Karnataka, India	Council of Scientific & Industrial Research (CSIR) - India; CSIR - Central Food Technological Research Institute (CFTRI)	Rao, AGA (corresponding author), Cent Food Technol Res Inst, Dept Prot Chem & Technol, Mysore 570013, Karnataka, India.							ANDRE JC, 1986, ANAL BIOCHEM, V158, P316, DOI 10.1016/0003-2697(86)90556-7; Axelrod B., 1981, METH ENZYMOL, V441, P451, DOI [10.1016/0076-6879(81)71055-3, DOI 10.1016/0076-6879(81)71055-3]; BANASZAK L, 1994, ADV PROTEIN CHEM, V45, P89; BEASTY AM, 1986, BIOCHEMISTRY-US, V25, P2965, DOI 10.1021/bi00358a035; BOYINGTON JC, 1993, SCIENCE, V260, P1482, DOI 10.1126/science.8502991; Finkelman R.B., 1995, ENER ENVIORNM SER, V2, P24; Funk CD, 1996, BBA-LIPID LIPID MET, V1304, P65, DOI 10.1016/S0005-2760(96)00107-5; Gaffney BJ, 1996, ANNU REV BIOPH BIOM, V25, P431, DOI 10.1146/annurev.bb.25.060196.002243; Gillmor SA, 1997, NAT STRUCT BIOL, V4, P1003, DOI 10.1038/nsb1297-1003; Goldenberg D.P, 1989, PROTEIN STRUCTURE PR, P225; Grechkin A, 1998, PROG LIPID RES, V37, P317, DOI 10.1016/S0163-7827(98)00014-9; Jaenicke R, 1999, PROG BIOPHYS MOL BIO, V71, P155, DOI 10.1016/S0079-6107(98)00032-7; Jaenicke R, 1989, PROTEIN STRUCTURE PR, P191; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MATTHEWS CR, 1981, BIOCHEMISTRY-US, V20, P784, DOI 10.1021/bi00507a021; Minor W, 1996, BIOCHEMISTRY-US, V35, P10687, DOI 10.1021/bi960576u; Pace C N, 1986, Methods Enzymol, V131, P266; Prigge ST, 1996, PROTEINS, V24, P275; Privalov PL, 1996, J MOL BIOL, V258, P707, DOI 10.1006/jmbi.1996.0280; RAMACHANDRAN S, 1992, BIOCHEMISTRY-US, V31, P7700, DOI 10.1021/bi00148a034; RIDDLES PW, 1983, METHOD ENZYMOL, V91, P49; SAMUELSSON B, 1987, SCIENCE, V237, P1171, DOI 10.1126/science.2820055; SIEDOW JN, 1991, ANNU REV PLANT PHYS, V42, P145, DOI 10.1146/annurev.pp.42.060191.001045; SIGAL E, 1991, AM J PHYSIOL, V260, P13; SkrzypczakJankun E, 1997, PROTEINS, V29, P15, DOI [10.1002/(SICI)1097-0134(199709)29:1&lt;15::AID-PROT2&gt;3.0.CO;2-E, 10.1002/(SICI)1097-0134(199709)29:1<15::AID-PROT2>3.3.CO;2-F]; Srinivasulu S, 1996, BBA-PROTEIN STRUCT M, V1294, P115, DOI 10.1016/0167-4838(95)00263-4; STECZKO J, 1992, BIOCHEMISTRY-US, V31, P4053, DOI 10.1021/bi00131a022; Sudharshan E, 1997, FEBS LETT, V406, P184, DOI 10.1016/S0014-5793(97)00268-8; TSOU CL, 1995, BBA-PROTEIN STRUCT M, V1253, P151, DOI 10.1016/0167-4838(95)00172-5; Wu Y, 1998, BBA-PROTEIN STRUCT M, V1388, P325, DOI 10.1016/S0167-4838(98)00182-4; YAMAMOTO S, 1992, BIOCHIM BIOPHYS ACTA, V1128, P117, DOI 10.1016/0005-2760(92)90297-9; ZARDENETA G, 1994, ANAL BIOCHEM, V223, P1, DOI 10.1006/abio.1994.1537	32	22	22	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 10	1999	274	50					35351	35358		10.1074/jbc.274.50.35351	http://dx.doi.org/10.1074/jbc.274.50.35351			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	264NG	10585402	hybrid			2022-12-25	WOS:000084187900014
J	Tschantz, WR; Zhang, LL; Casey, PJ				Tschantz, WR; Zhang, LL; Casey, PJ			Cloning, expression, and cellular localization of a human prenylcysteine lyase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PALMITOYL-PROTEIN THIOESTERASE; NEURONAL CEROID-LIPOFUSCINOSIS; MULTIDRUG-RESISTANCE; P-GLYCOPROTEIN; BOVINE BRAIN; PRENYLATION; RAS; BIOCHEMISTRY; TRANSPORTER; ENZYMES	Prenylated proteins contain either a 15-carbon farnesyl or 20-carbon geranylgeranyl isoprenoid covalently attached to cysteine residues at or near their C terminus. These proteins constitute up to 2% of total cellular protein in eukaryotic cells. The degradation of prenylated proteins raises a metabolic challenge to the cell, because the thioether bond of the modified cysteine is quite stable. We recently identified and isolated an enzyme termed prenylcysteine lyase that cleaves the prenylcysteine to free cysteine and an isoprenoid product (Zhang, L., Tschantz, W, R,, and Casey, P, J, (1997) J. Biol. Chem. 272, 23354-23359), To facilitate the molecular characterization of this enzyme, its cloning was undertaken. Overlapping cDNA clones encoding the complete coding sequence of this enzyme were obtained from a human cDNA library. The open reading frame of the gene encoding prenylcysteine lyase is 1515 base pairs and has a nearly ubiquitous expression pattern with a message size of 6 kilobase pairs. Recombinant prenylcysteine lyase was produced in a baculovirus-Sf9 expression system. Analysis of both the recombinant and native enzyme revealed that the enzyme is glycosylated and contains a signal peptide that is cleaved during processing. Additionally, the subcellular localization of this enzyme was determined to be lysosomal. These findings strengthen the notion that prenylcysteine lyase plays an important role in the final step in the degradation of prenylated proteins and will allow further physiological and biochemical characterization of this enzyme.	Duke Univ, Med Ctr, Dept Pharmacol & Canc Biol, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Biochem, Durham, NC 27710 USA	Duke University; Duke University	Casey, PJ (corresponding author), Duke Univ, Med Ctr, Dept Pharmacol & Canc Biol, Durham, NC 27710 USA.	casey006@mc.duke.edu		Casey, Patrick/0000-0002-7366-9309	NIGMS NIH HHS [GM46372, GM18069] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM046372, F32GM018069] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ashby MN, 1998, CURR OPIN LIPIDOL, V9, P99, DOI 10.1097/00041433-199804000-00004; BABA T, 1991, BIOCHEMISTRY-US, V30, P500, DOI 10.1021/bi00216a028; CAMP LA, 1994, J BIOL CHEM, V269, P23212; CASEY PJ, 1989, P NATL ACAD SCI USA, V86, P8323, DOI 10.1073/pnas.86.21.8323; CASEY PJ, 1995, SCIENCE, V268, P221, DOI 10.1126/science.7716512; CHEN JW, 1985, J CELL BIOL, V101, P85, DOI 10.1083/jcb.101.1.85; DING JB, 1994, J BIOL CHEM, V269, P16837; ENDICOTT JA, 1989, ANNU REV BIOCHEM, V58, P137, DOI 10.1146/annurev.bi.58.070189.001033; EPSTEIN WW, 1991, P NATL ACAD SCI USA, V88, P9668, DOI 10.1073/pnas.88.21.9668; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; GLOMSET JA, 1994, ANNU REV CELL BIOL, V10, P181, DOI 10.1146/annurev.cellbio.10.1.181; GOTTESMAN MM, 1993, ANNU REV BIOCHEM, V62, P385, DOI 10.1146/annurev.bi.62.070193.002125; Graham John M., 1993, V19, P51; Haklai R, 1998, BIOCHEMISTRY-US, V37, P1306, DOI 10.1021/bi972032d; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; Lu JY, 1996, P NATL ACAD SCI USA, V93, P10046, DOI 10.1073/pnas.93.19.10046; MARSHALL CJ, 1993, SCIENCE, V259, P1865, DOI 10.1126/science.8456312; MOOMAW JF, 1995, METHOD ENZYMOL, V250, P12; MUNRO S, 1987, CELL, V48, P899, DOI 10.1016/0092-8674(87)90086-9; PHILIPS MR, 1993, SCIENCE, V259, P977, DOI 10.1126/science.8438158; Sambrook J., 1990, MOL CLONING LAB MANU, V2nd; SCHAFER WR, 1992, ANNU REV GENET, V26, P209, DOI 10.1146/annurev.ge.26.120192.001233; STORRIE B, 1990, METHOD ENZYMOL, V182, P203; VESA J, 1995, NATURE, V376, P584, DOI 10.1038/376584a0; VONHEIJNE G, 1990, J MEMBRANE BIOL, V115, P195, DOI 10.1007/BF01868635; Zhang FL, 1996, ANNU REV BIOCHEM, V65, P241, DOI 10.1146/annurev.bi.65.070196.001325; ZHANG L, 1994, J BIOL CHEM, V269, P15973; ZHANG LL, 1995, J BIOL CHEM, V270, P22859, DOI 10.1074/jbc.270.39.22859; Zhang LL, 1997, J BIOL CHEM, V272, P23354, DOI 10.1074/jbc.272.37.23354	29	27	31	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 10	1999	274	50					35802	35808		10.1074/jbc.274.50.35802	http://dx.doi.org/10.1074/jbc.274.50.35802			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	264NG	10585463	hybrid			2022-12-25	WOS:000084187900075
J	Xu, SB; Ladak, R; Swanson, DA; Soltyk, A; Sun, H; Ploder, L; Vidgen, D; Duncan, AMV; Garami, E; Valle, D; McInnes, RR				Xu, SB; Ladak, R; Swanson, DA; Soltyk, A; Sun, H; Ploder, L; Vidgen, D; Duncan, AMV; Garami, E; Valle, D; McInnes, RR			PHR1 encodes an abundant, pleckstrin homology domain-containing integral membrane protein in the photoreceptor outer segments	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-GAMMA-SUBUNITS; BRUTONS-TYROSINE-KINASE; OXYSTEROL-BINDING PROTEIN; HETEROTRIMERIC G-PROTEINS; RETINITIS-PIGMENTOSA; MOLECULAR-CLONING; ALPHA-SUBUNIT; CGMP PHOSPHODIESTERASE; PHOSPHOINOSITIDE BINDING; SIGNAL-TRANSDUCTION	We cloned human and murine cDNAs of a gene (designated PHR1), expressed preferentially in retina and brain. In both species, PHR1 utilizes two promoters and alternative splicing to produce four PHR1 transcripts, encoding isoforms of 243, 224, 208, and 189 amino acids, each with a pleckstrin homology domain at their N terminus and a transmembrane domain at their C terminus. Transcript 1 originates from a 5'-photoreceptor-specific promoter with at least three Crx elements ((C/T)TAATCC). Transcript 2 originates from the same promoter but lacks exon 7, which encodes 35 amino acids immediately C-terminal to the pleckstrin homology domain. Transcripts 3 and 4 originate from an internal promoter in intron 2 and either include or lack exon 7, respectively. In situ hybridization shows that PHR1 is highly expressed in photoreceptors, with lower expression in retinal ganglion cells. Immunohistochemistry localizes the PHR1 protein to photoreceptor outer segments where chemical extraction studies confirm it is an integral membrane protein. Using a series of PHR1 glutathione S-transferase fusion proteins to perform in vitro binding assays, we found PHR1 binds transducin beta gamma subunits but not inositol phosphates. This activity and subcellular location suggests that PHR1 may function as a previously unrecognized modulator of the phototransduction pathway.	Johns Hopkins Univ, Sch Med, Howard Hughes Med Inst, Dept Pediat, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Predoctoral Training Program Human Genet, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Mol Biol & Genet, Baltimore, MD 21205 USA; Hosp Sick Children, Res Inst, Program Dev Biol, Toronto, ON M5G 1X8, Canada; Hosp Sick Children, Res Inst, Genet Program, Toronto, ON M5G 1X8, Canada; McGill Univ, Ctr Hosp, Dept Pathol & Human Genet, Toronto, ON M5G 1X8, Canada	Howard Hughes Medical Institute; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); McGill University	Valle, D (corresponding author), Johns Hopkins Univ, Sch Med, Howard Hughes Med Inst, Dept Pediat, PCTB 802,725 N Wolfe St, Baltimore, MD 21205 USA.	dvalle@jhmi.edu		Garami, Elizabeth/0000-0003-1295-4007				ABE T, 1990, GENE, V91, P209, DOI 10.1016/0378-1119(90)90090-E; Allikmets R, 1997, NAT GENET, V17, P122, DOI 10.1038/ng0997-122b; Ausubel FM, 1991, CURRENT PROTOCOLS MO; BASCOM RA, 1993, HUM MOL GENET, V2, P385, DOI 10.1093/hmg/2.4.385; Bauer PH, 1998, J BIOL CHEM, V273, P9465, DOI 10.1074/jbc.273.16.9465; BAUER PH, 1992, NATURE, V358, P73, DOI 10.1038/358073a0; BELLACOSA A, 1991, SCIENCE, V254, P274, DOI 10.1126/science.1833819; Bence K, 1997, NATURE, V389, P296, DOI 10.1038/38520; Bottomley MJ, 1999, CURR BIOL, V9, pR301, DOI 10.1016/S0960-9822(99)80184-5; Chardin P, 1996, NATURE, V384, P481, DOI 10.1038/384481a0; Chen SM, 1997, NEURON, V19, P1017, DOI 10.1016/S0896-6273(00)80394-3; COFFER PJ, 1991, EUR J BIOCHEM, V201, P475, DOI 10.1111/j.1432-1033.1991.tb16305.x; CRANE DI, 1994, J BIOL CHEM, V269, P21835; Danner S, 1996, P NATL ACAD SCI USA, V93, P10145, DOI 10.1073/pnas.93.19.10145; DAWSON PA, 1989, J BIOL CHEM, V264, P16798; DEJUAN E, 1994, RETINA, P2499; DIATLOFFZITO C, 1995, GENE, V163, P301, DOI 10.1016/0378-1119(95)00275-B; DRYJA TP, 1990, NATURE, V343, P364, DOI 10.1038/343364a0; DRYJA TP, 1995, HUM MOL GENET, V4, P1739, DOI 10.1093/hmg/4.suppl_1.1739; Franke TF, 1997, SCIENCE, V275, P665, DOI 10.1126/science.275.5300.665; Freund CL, 1998, NAT GENET, V18, P311, DOI 10.1038/ng0498-311; Fukuda M, 1996, J BIOL CHEM, V271, P30303, DOI 10.1074/jbc.271.48.30303; Furukawa T, 1997, CELL, V91, P531, DOI 10.1016/S0092-8674(00)80439-0; Gregory-Evans K, 1998, TRENDS GENET, V14, P103, DOI 10.1016/S0168-9525(98)01402-4; HARLAN JE, 1994, NATURE, V371, P168, DOI 10.1038/371168a0; Haske TN, 1996, J BIOL CHEM, V271, P2941, DOI 10.1074/jbc.271.6.2941; HASLAM RJ, 1993, NATURE, V363, P309, DOI 10.1038/363309b0; He W, 1998, NEURON, V20, P95, DOI 10.1016/S0896-6273(00)80437-7; HUANG SH, 1995, NAT GENET, V11, P468, DOI 10.1038/ng1295-468; Illing M, 1997, J BIOL CHEM, V272, P10303, DOI 10.1074/jbc.272.15.10303; INGLEY E, 1994, J CELL BIOCHEM, V56, P436, DOI 10.1002/jcb.240560403; Jiang Y, 1998, NATURE, V395, P808, DOI 10.1038/27454; JONES PF, 1991, P NATL ACAD SCI USA, V88, P4171, DOI 10.1073/pnas.88.10.4171; KAJIWARA K, 1994, SCIENCE, V264, P1604, DOI 10.1126/science.8202715; KAJIWARA K, 1991, NATURE, V354, P480, DOI 10.1038/354480a0; Kasai K, 1999, J BIOCHEM, V125, P780, DOI 10.1093/oxfordjournals.jbchem.a022349; KHRAMTSOV NV, 1993, FEBS LETT, V327, P275, DOI 10.1016/0014-5793(93)81003-I; Klarlund JK, 1997, SCIENCE, V275, P1927, DOI 10.1126/science.275.5308.1927; Klein DE, 1998, J BIOL CHEM, V273, P27725, DOI 10.1074/jbc.273.42.27725; Klippel A, 1997, MOL CELL BIOL, V17, P338, DOI 10.1128/MCB.17.1.338; KOCH WJ, 1993, J BIOL CHEM, V268, P8256; KONISHI H, 1995, BIOCHEM BIOPH RES CO, V216, P526, DOI 10.1006/bbrc.1995.2654; KOZAK M, 1983, MICROBIOL REV, V47, P1; Krappa R, 1999, P NATL ACAD SCI USA, V96, P4633, DOI 10.1073/pnas.96.8.4633; KUBO M, 1991, FEBS LETT, V291, P245, DOI 10.1016/0014-5793(91)81294-I; KUHN H, 1982, METHOD ENZYMOL, V81, P556; Kutay Ulrike, 1993, Trends in Cell Biology, V3, P72, DOI 10.1016/0962-8924(93)90066-A; LANGHANSRAJASEKARAN SA, 1995, P NATL ACAD SCI USA, V92, P8601, DOI 10.1073/pnas.92.19.8601; LEE RH, 1987, BIOCHEMISTRY-US, V26, P3983, DOI 10.1021/bi00387a036; LEE RH, 1984, BIOCHEMISTRY-US, V23, P1972, DOI 10.1021/bi00304a014; LEE RH, 1992, J BIOL CHEM, V267, P25104; Lemmon MA, 1996, CELL, V85, P621, DOI 10.1016/S0092-8674(00)81022-3; Levine TP, 1998, CURR BIOL, V8, P729, DOI 10.1016/S0960-9822(98)70296-9; LIU L, 1992, BIOCHIM BIOPHYS ACTA, V1132, P75, DOI 10.1016/0167-4781(92)90055-5; LOLLEY RN, 1992, NEUROCHEM RES, V17, P81, DOI 10.1007/BF00966868; MAHADEVAN D, 1995, BIOCHEMISTRY-US, V34, P9111, DOI 10.1021/bi00028a021; Makino ER, 1999, P NATL ACAD SCI USA, V96, P1947, DOI 10.1073/pnas.96.5.1947; MAYER BJ, 1993, CELL, V73, P629, DOI 10.1016/0092-8674(93)90244-K; MCLAUGHLIN ME, 1993, NAT GENET, V4, P130, DOI 10.1038/ng0693-130; MUSACCHIO A, 1993, TRENDS BIOCHEM SCI, V18, P343, DOI 10.1016/0968-0004(93)90071-T; NATHANS J, 1984, P NATL ACAD SCI-BIOL, V81, P4851, DOI 10.1073/pnas.81.15.4851; PAPERMASTER DS, 1982, METHOD ENZYMOL, V81, P48; Peng YW, 1997, P NATL ACAD SCI USA, V94, P1995, DOI 10.1073/pnas.94.5.1995; PITTLER SJ, 1990, GENOMICS, V6, P272, DOI 10.1016/0888-7543(90)90567-E; Rameh LE, 1997, J BIOL CHEM, V272, P22059, DOI 10.1074/jbc.272.35.22059; Salim K, 1996, EMBO J, V15, P6241, DOI 10.1002/j.1460-2075.1996.tb01014.x; SCHAERENWIEMERS N, 1993, HISTOCHEMISTRY, V100, P431, DOI 10.1007/BF00267823; Shaw G, 1996, BIOESSAYS, V18, P35, DOI 10.1002/bies.950180109; SMITH DE, 1984, J CELL BIOL, V99, P20, DOI 10.1083/jcb.99.1.20; Soucy E, 1998, NEURON, V21, P481, DOI 10.1016/S0896-6273(00)80560-7; Srinivasan N, 1996, BIOCHEM BIOPH RES CO, V220, P697, DOI 10.1006/bbrc.1996.0467; Sun H, 1997, NAT GENET, V17, P15, DOI 10.1038/ng0997-15; Swanson DA, 1997, GENOME RES, V7, P513, DOI 10.1101/gr.7.5.513; Tanaka M, 1999, BIOCHEM BIOPH RES CO, V255, P169, DOI 10.1006/bbrc.1999.0162; Toker A, 1997, NATURE, V387, P673, DOI 10.1038/42648; TOUHARA K, 1994, J BIOL CHEM, V271, P2941; TRAVIS GH, 1991, GENOMICS, V10, P733, DOI 10.1016/0888-7543(91)90457-P; TSUKADA S, 1994, P NATL ACAD SCI USA, V91, P11256, DOI 10.1073/pnas.91.23.11256; TYERS M, 1988, NATURE, V333, P470, DOI 10.1038/333470a0; VANDERBLIEK AM, 1993, J CELL BIOL, V122, P553, DOI 10.1083/jcb.122.3.553; VANDOP C, 1989, NUCLEIC ACIDS RES, V17, P4887, DOI 10.1093/nar/17.12.4887; WATANABE Y, 1990, BIOCHEM BIOPH RES CO, V170, P951, DOI 10.1016/0006-291X(90)92183-Z; Watson AJ, 1996, J BIOL CHEM, V271, P28154, DOI 10.1074/jbc.271.45.28154; WATSON AJ, 1994, J BIOL CHEM, V269, P22150; WELL D, 1995, NATURE, V374, P60, DOI 10.1038/374060a0; Wilkins JF, 1996, J BIOL CHEM, V271, P19232, DOI 10.1074/jbc.271.32.19232; YOSHIDA T, 1994, J BIOL CHEM, V269, P24050	87	18	22	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 10	1999	274	50					35676	35685		10.1074/jbc.274.50.35676	http://dx.doi.org/10.1074/jbc.274.50.35676			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	264NG	10585447	hybrid			2022-12-25	WOS:000084187900059
J	Pei, XH; Nakanishi, Y; Takayama, K; Bai, F; Hara, N				Pei, XH; Nakanishi, Y; Takayama, K; Bai, F; Hara, N			Benzo[a]pyrene activates the human p53 gene through induction of nuclear factor kappa B activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							WILD-TYPE P53; TUMOR-NECROSIS-FACTOR; CELL-CYCLE CONTROL; PROTEIN-KINASE-C; DNA-DAMAGE; INTERLEUKIN-8 PROMOTER; SUPPRESSOR GENES; G(1) ARREST; CANCER; TRANSCRIPTION	p53 is known to be recruited in response to DNA-damaging genotoxic stress and plays an important role in maintaining the integrity of the genome. In the present study, the effect of a potent lung cancer carcinogen, benzo[a]pyrene (B[a]P) on p53 expression was investigated. We showed that exposure of A549 and NIH 3T3 cells to B[a]P resulted in an increase in p53 mRNA levels and in p53 promoter activation, indicating that B[a]P-induced p53 expression is partly regulated at the transcriptional level. The p53 promoter region which extends from -58 to -43, overlapping the kappa B motif, is essential for both the p53 basal promoter activity and p53 promoter activation induced by B[a]P, Nuclear factor kappa B (NF-kappa B) proteins have been revealed to be activated in B[a]P-induced p53 expression. Activated NF-kappa B complexes were shown to contain predominantly p50 and p65 subunit components in A549 cells and p65 subunit in NIH 3T3 cells. In addition, the overexpression of I kappa B alpha completely inhibited NF-kappa B activation, p53 promoter transactivation and the stimulatory effect on p53 transcription induced by B[a]P, We therefore conclude that B[a]P transcriptionally activates the human p53 gene through the induction of NF-kappa B activity.	Kyushu Univ, Grad Sch Med Sci, Res Inst Dis Chest, Higashi Ku, Fukuoka 8128582, Japan	Kyushu University	Nakanishi, Y (corresponding author), Kyushu Univ, Grad Sch Med Sci, Res Inst Dis Chest, Higashi Ku, 3-1-1 Maidashi, Fukuoka 8128582, Japan.		Pei, Xin-Hai/P-1812-2014	pei, xin-hai/0000-0001-6441-1691				Bender K, 1998, EMBO J, V17, P5170, DOI 10.1093/emboj/17.17.5170; Boland MP, 1997, J BIOL CHEM, V272, P12952, DOI 10.1074/jbc.272.20.12952; Das KC, 1997, J BIOL CHEM, V272, P14914, DOI 10.1074/jbc.272.23.14914; Denissenko MF, 1996, SCIENCE, V274, P430, DOI 10.1126/science.274.5286.430; DIPPLE A, 1994, ADDUCTS IDENTIFICATI, P107; Durant JL, 1996, MUTAT RES-GENET TOX, V371, P123, DOI 10.1016/S0165-1218(96)90103-2; ELDEIRY WS, 1994, CANCER RES, V54, P1169; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FRITSCHE M, 1993, ONCOGENE, V8, P307; Furlong EEM, 1996, MOL CELL BIOL, V16, P5933; Giri DK, 1998, J BIOL CHEM, V273, P14008, DOI 10.1074/jbc.273.22.14008; GRANA X, 1995, ONCOGENE, V11, P211; Harvey R. G., 1991, POLYCYCLIC AROMATIC; Hellin AC, 1998, ONCOGENE, V16, P1187, DOI 10.1038/sj.onc.1201638; HOFFMAN B, 1994, ONCOGENE, V9, P1807; IWAMOTO A, 1985, JPN J EXP MED, V55, P129; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KASTAN MB, 1991, CANCER RES, V51, P6304; Khan QA, 1997, CARCINOGENESIS, V18, P2313, DOI 10.1093/carcin/18.12.2313; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; KUIPERS OP, 1991, NUCLEIC ACIDS RES, V19, P4558, DOI 10.1093/nar/19.16.4558; KUNSCH C, 1993, MOL CELL BIOL, V13, P6137, DOI 10.1128/MCB.13.10.6137; Lakshminarayanan V, 1998, J BIOL CHEM, V273, P32670, DOI 10.1074/jbc.273.49.32670; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; LIN RT, 1995, J BIOL CHEM, V270, P3123, DOI 10.1074/jbc.270.7.3123; Liu L, 1998, MOL CELL BIOL, V18, P4221, DOI 10.1128/MCB.18.7.4221; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; MALTZMAN W, 1984, MOL CELL BIOL, V4, P1689, DOI 10.1128/MCB.4.9.1689; MEEK DW, 1994, SEMIN CANCER BIOL, V5, P203; NELSON WG, 1994, MOL CELL BIOL, V14, P1815, DOI 10.1128/MCB.14.3.1815; OHMORI Y, 1995, J IMMUNOL, V154, P5235; RAMET M, 1995, CARCINOGENESIS, V16, P2117, DOI 10.1093/carcin/16.9.2117; RONEN D, 1991, P NATL ACAD SCI USA, V88, P4128, DOI 10.1073/pnas.88.10.4128; RYSECK RP, 1992, MOL CELL BIOL, V12, P674, DOI 10.1128/MCB.12.2.674; Sancar A, 1995, ANNU REV GENET, V29, P69, DOI 10.1146/annurev.ge.29.120195.000441; SUN XG, 1995, MOL CELL BIOL, V15, P4489; TAKAYAMA K, 1994, J BIOCHEM-TOKYO, V116, P193, DOI 10.1093/oxfordjournals.jbchem.a124493; Takayama K, 1998, GENE THER, V5, P361, DOI 10.1038/sj.gt.3300608; TOKIWA H, 1993, CARCINOGENESIS, V14, P1933, DOI 10.1093/carcin/14.9.1933; TUCK SP, 1989, MOL CELL BIOL, V9, P2163, DOI 10.1128/MCB.9.5.2163; Vaziri C, 1997, J BIOL CHEM, V272, P2762, DOI 10.1074/jbc.272.5.2762; Venkatachalam S, 1997, ONCOGENE, V14, P801, DOI 10.1038/sj.onc.1200890; VERMA IM, 1995, GENE DEV, V9, P2723, DOI 10.1101/gad.9.22.2723; WINGO PA, 1995, CA-CANCER J CLIN, V45, P8, DOI 10.3322/canjclin.45.1.8; WU HY, 1994, J BIOL CHEM, V269, P20067; YIN YX, 1992, CELL, V70, P937, DOI 10.1016/0092-8674(92)90244-7; ZAKUTHOURI R, 1983, NATURE, V306, P594, DOI 10.1038/306594a0	48	82	87	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 3	1999	274	49					35240	35246		10.1074/jbc.274.49.35240	http://dx.doi.org/10.1074/jbc.274.49.35240			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	260XW	10575010	hybrid			2022-12-25	WOS:000083979600104
J	van Vlijmen, BJM; Rohlmann, A; Page, ST; Bensadoun, A; Bos, IST; van Berkel, TJC; Havekes, LM; Herz, J				van Vlijmen, BJM; Rohlmann, A; Page, ST; Bensadoun, A; Bos, IST; van Berkel, TJC; Havekes, LM; Herz, J			An extrahepatic receptor-associated protein-sensitive mechanism is involved in the metabolism of triglyceride-rich lipoproteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPARAN-SULFATE PROTEOGLYCANS; LIPOLYSIS-STIMULATED RECEPTOR; APOLIPOPROTEIN-E; LDL RECEPTOR; IN-VIVO; ALPHA-2-MACROGLOBULIN RECEPTOR; CHYLOMICRON REMNANTS; PLASMA-LIPOPROTEINS; HEPATIC LIPASE; BINDING	We have used adenovirus-mediated gene transfer in mice to investigate low density lipoprotein receptor (LDLR) and LDLR-related protein (LRP)-independent mechanisms that control the metabolism of chylomicron and very low density lipoprotein (VLDL) remnants in vivo. Overexpression of receptor-associated protein (RAP) in mice that lack both LRP and LDLR (MX1cre(+)LRP(flox/flox)LDLR(-/-)) in their livers elicited a marked hypertriglyceridemia in addition to the pre-existing hypercholesterolemia in these animals, resulting in a shift in the distribution of plasma lipids from LDL-sized lipoproteins to large VLDL-sized particles. This dramatic increase in plasma lipids was not due to a RAP-mediated inhibition of a unknown hepatic high affinity binding site involved in lipoprotein metabolism, because no RAP binding could be detected in livers of MX1cre(+)LRP(flox/flox)LDLR(-/-) mice using both membrane binding studies and ligand blotting experiments. Remarkably, RAP overexpression also resulted in a 7-fold increase (from 13.6 to 95.6 ng/ml) of circulating, but largely inactive, lipoprotein lipase (LPL), In contrast, plasma hepatic lipase levels and activity were unaffected. In vitro studies showed that RAP binds to LPL with high affinity (K-d = 5 nM) but does not affect its catalytic activity, in vitro or in vivo. Our findings suggest that an extrahepatic RAP-sensitive process that is independent of the LDLR or LRP is involved in metabolism of triglyceride-rich lipoproteins. There, RAP may affect the functional maturation of LPL, thus causing the accumulation of triglyceride-rich lipoproteins in the circulation.	Univ Texas, SW Med Ctr, Dept Mol Genet, Dallas, TX 75235 USA; Cornell Univ, Div Nutr Sci, Ithaca, NY 14853 USA; Leiden Univ, Med Ctr, Dept Cardiol, NL-2300 RA Leiden, Netherlands; Leiden Univ, Med Ctr, Dept Internal Med, NL-2300 RA Leiden, Netherlands; Lieden Amsterdam Ctr Drug Res, Dept Biopharmaceut, NL-2300 RA Leiden, Netherlands; TNO, Prevetn & Hlth, Gaubius Lab, NL-2300 RA Leiden, Netherlands	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Cornell University; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Netherlands Organization Applied Science Research	Herz, J (corresponding author), Univ Texas, SW Med Ctr, Dept Mol Genet, 5323 Harry Hines Blvd, Dallas, TX 75235 USA.	herz@utsw.swmed.edu	Page, Shallee/AAA-6855-2019; Van Berkel, Theo/ABD-7677-2021	Page, Shallee/0000-0002-3557-4122; Rohlmann, Astrid/0000-0003-0869-6893	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL014990, R37HL063762, P01HL020948] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007158] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL20948, HL14990, R37 HL063762] Funding Source: Medline; NIDDK NIH HHS [DK07158] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ARGRAVES KM, 1995, J BIOL CHEM, V270, P26550, DOI 10.1074/jbc.270.44.26550; BEISIEGEL U, 1991, P NATL ACAD SCI USA, V88, P8342, DOI 10.1073/pnas.88.19.8342; BELFRAGE P, 1969, J LIPID RES, V10, P341; Bensadoun A, 1999, METH MOL B, V109, P145; Bensadoun A, 1999, METH MOL B, V109, P151; CHAPPELL DA, 1992, J BIOL CHEM, V267, P25764; CHOI SY, 1993, J BIOL CHEM, V268, P15804; CISAR LA, 1985, J LIPID RES, V26, P380; CISAR LA, 1989, J BIOL CHEM, V264, P1767; de Man FHAF, 1997, J LIPID RES, V38, P2465; FRAKER PJ, 1978, BIOCHEM BIOPH RES CO, V80, P849, DOI 10.1016/0006-291X(78)91322-0; FRYKMAN PK, 1995, P NATL ACAD SCI USA, V92, P8453, DOI 10.1073/pnas.92.18.8453; Goldstein J.L., 1989, METABOLIC BASIS INHE, P1215; HAMILTON RL, 1990, J LIPID RES, V31, P1589; HERZ J, 1993, CELL, V73, P428, DOI 10.1016/0092-8674(93)90130-I; HERZ J, 1992, CELL, V71, P411, DOI 10.1016/0092-8674(92)90511-A; HERZ J, 1991, J BIOL CHEM, V266, P21232; ISHIBASHI S, 1993, J CLIN INVEST, V92, P883, DOI 10.1172/JCI116663; JI ZS, 1994, J BIOL CHEM, V269, P2764; JI ZS, 1994, J BIOL CHEM, V269, P13429; KIRCHGESSNER TG, 1987, J BIOL CHEM, V262, P8463; KOWAL RC, 1989, P NATL ACAD SCI USA, V86, P5810, DOI 10.1073/pnas.86.15.5810; KOWAL RC, 1990, J BIOL CHEM, V265, P10771; KUHN R, 1995, SCIENCE, V269, P1427, DOI 10.1126/science.7660125; Mahley RW, 1999, J LIPID RES, V40, P1; Nielsen MS, 1999, J BIOL CHEM, V274, P8832, DOI 10.1074/jbc.274.13.8832; OLIVECRONA G, 1995, CURR OPIN LIPIDOL, V6, P291, DOI 10.1097/00041433-199510000-00009; OTWAY S, 1967, J PHYSIOL-LONDON, V190, P321, DOI 10.1113/jphysiol.1967.sp008211; REDGRAVE TG, 1975, ANAL BIOCHEM, V65, P42, DOI 10.1016/0003-2697(75)90488-1; Rensen PCN, 1996, J BIOL CHEM, V271, P14791, DOI 10.1074/jbc.271.25.14791; Rohlmann A, 1996, NAT BIOTECHNOL, V14, P1562, DOI 10.1038/nbt1196-1562; Rohlmann A, 1998, J CLIN INVEST, V101, P689, DOI 10.1172/JCI1240; Sendak RA, 1998, J LIPID RES, V39, P633; SHAFI S, 1994, J LIPID RES, V35, P709; TAKAHASHI S, 1995, J BIOL CHEM, V270, P15747, DOI 10.1074/jbc.270.26.15747; TROUSSARD AA, 1995, J BIOL CHEM, V270, P17068, DOI 10.1074/jbc.270.29.17068; van Dijk KW, 1999, J LIPID RES, V40, P336; VANDIJK MCM, 1992, J BIOL CHEM, V267, P17732; Veniant MM, 1998, J CLIN INVEST, V102, P1559, DOI 10.1172/JCI4164; WILLNOW TE, 1994, SCIENCE, V264, P1471, DOI 10.1126/science.7515194; WILLNOW TE, 1995, P NATL ACAD SCI USA, V92, P4537, DOI 10.1073/pnas.92.10.4537; YEN FT, 1994, BIOCHEMISTRY-US, V33, P1172, DOI 10.1021/bi00171a017	42	36	36	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 3	1999	274	49					35219	35226		10.1074/jbc.274.49.35219	http://dx.doi.org/10.1074/jbc.274.49.35219			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	260XW	10575007	Green Published, hybrid			2022-12-25	WOS:000083979600101
J	Jakubowski, H				Jakubowski, H			Protein homocysteinylation: possible mechanism underlying pathological consequences of elevated homocysteine levels	FASEB JOURNAL			English	Article						homocysteine thiolactone; atherosclerosis	TRANSFER-RNA-SYNTHETASES; ESCHERICHIA-COLI; PROOFREADING INVIVO; THIOLACTONE; DISEASE; INHIBITION; PATHWAYS	Homocysteine thiolactone, a cyclic thioester, is synthesized by certain aminoacyl-tRNA synthetases in editing or proofreading reactions that prevent translational incorporation of homocysteine into proteins. Although homocysteine thiolactone is expected to acylate amino groups in proteins, virtually nothing is known regarding reactivity of the thiolactone. Here it is shown that reactions of the thiolactone with protein lysine residues were robust under physiological conditions. In human serum incubated with homocysteine thiolactone, protein homocysteinylation was a major reaction that could be observed with as little as 10 nM thiolactone, Individual proteins were homocysteinylated at rates proportional to their lysine contents. Homocysteinylation led to protein damage, manifested as multimerization and precipitation of extensively modified proteins. Model enzymes, such as methionyl-tRNA synthetase and trypsin, were inactivated by homocysteinylation, Metabolic conversion of homocysteine to the thiolactone, protein homocysteinylation, and resulting protein damage may underlie involvement of Hey in the pathology of vascular disease.	Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Microbiol & Mol Genet, Newark, NJ 07103 USA	Rutgers State University New Brunswick; Rutgers State University Medical Center	Jakubowski, H (corresponding author), Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Microbiol & Mol Genet, 185 S Orange Ave, Newark, NJ 07103 USA.		Jakubowski, Hieronim/A-2510-2017; Jakubowski, Hieronim/AAA-6834-2019	Jakubowski, Hieronim/0000-0001-5845-4409; 				AUSUBEL FM, 1990, CURRENT PROTOCOLS MO, V2; Baernstein HD, 1934, J BIOL CHEM, V106, P451; Bergmeyer H.U., 1974, METHOD ENZYMAT AN, V1, P515; Booth AA, 1997, J BIOL CHEM, V272, P5430, DOI 10.1074/jbc.272.9.5430; DUDMAN NPB, 1991, ARTERIOSCLER THROMB, V11, P663, DOI 10.1161/01.ATV.11.3.663; Ferguson E, 1998, J LIPID RES, V39, P925; GAO WW, 1994, BIOCHEMISTRY-US, V33, P11528, DOI 10.1021/bi00204a015; HARRINGTON CR, 1994, NATURE, V370, P247, DOI 10.1038/370247a0; HAWKINS D, 1969, J CLIN INVEST, V48, P536, DOI 10.1172/JCI106011; HOLVOET P, 1995, J CLIN INVEST, V95, P2611, DOI 10.1172/JCI117963; Jacobsen DW, 1998, CLIN CHEM, V44, P1833; Jakubowski H, 1997, J BIOL CHEM, V272, P1935; JAKUBOWSKI H, 1995, J BIOL CHEM, V270, P17672, DOI 10.1074/jbc.270.30.17672; JAKUBOWSKI H, 1991, EMBO J, V10, P593, DOI 10.1002/j.1460-2075.1991.tb07986.x; JAKUBOWSKI H, 1990, P NATL ACAD SCI USA, V87, P4504, DOI 10.1073/pnas.87.12.4504; JAKUBOWSKI H, 1981, NUCLEIC ACIDS RES, V9, P3105, DOI 10.1093/nar/9.13.3105; Jakubowski H, 1997, BIOCHEMISTRY-US, V36, P11077, DOI 10.1021/bi970589n; JAKUBOWSKI H, 1993, FEBS LETT, V317, P593; Liu GM, 1997, J BIOL CHEM, V272, P32370, DOI 10.1074/jbc.272.51.32370; YVON M, 1988, FEBS LETT, V239, P237, DOI 10.1016/0014-5793(88)80924-4	20	317	322	1	16	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	DEC	1999	13	15					2277	2283		10.1096/fasebj.13.15.2277	http://dx.doi.org/10.1096/fasebj.13.15.2277			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	266QN	10593875				2022-12-25	WOS:000084310800019
J	Tchou, WW; Yie, TA; Tan, TH; Rom, WN; Tchou-Wong, KM				Tchou, WW; Yie, TA; Tan, TH; Rom, WN; Tchou-Wong, KM			Role of c-Jun N-terminal kinase 1 (JNK1) in cell cycle checkpoint activated by the protease inhibitor N-acetyl-leucinyl-leucinyl-norleucinal	ONCOGENE			English	Article						JNK; LLnL; cell cycle arrest	SPINDLE ASSEMBLY CHECKPOINT; MAP KINASE; INDUCED APOPTOSIS; GAMMA-RADIATION; MAMMALIAN-CELLS; ARREST; PATHWAY; REQUIREMENT; DEGRADATION; INDUCTION	The cysteine protease inhibitor N-acetyl-leucinyl-leucinyl-norleucinal (LLnL) inhibited the growth of the Calu-1 lung carcinoma cells and induced a prolonged cell cycle arrest in the S phase, c-Jun N-terminal kinases (JNKs) participate in cellular responses to mitogenic stimuli, environmental stresses, and apoptotic signals but its role in cell cycle checkpoint control has not been elucidated. In this report, me examined the role of JNK in LLnL-induced S phase checkpoint by overexpression of a dominant-negative mutant of JNK1 (JNK1-APF) in Calu-1 cells. Expression of high levels of JNK1-APF blocked the growth-inhibitory effects of LLnL and abrogated S phase arrest induced by LLnL. These results support the role of JNK in the activation of cell cycle checkpoint induced by LLnL.	NYU, Med Ctr, Div Hematol & Oncol, New York, NY 10016 USA; NYU, Med Ctr, Div Pulm & Crit Care Med, New York, NY 10016 USA; NYU, Med Ctr, Dept Med, New York, NY 10016 USA; NYU, Med Ctr, Dept Microbiol, New York, NY 10016 USA; NYU, Med Ctr, Dept Environm Med, New York, NY 10016 USA; Baylor Coll Med, Dept Microbiol & Immunol, Houston, TX 77030 USA	New York University; New York University; New York University; New York University; New York University; Baylor College of Medicine	Tchou-Wong, KM (corresponding author), NYU, Med Ctr, Div Hematol & Oncol, 550 1st Ave,MSB 147, New York, NY 10016 USA.		Tan, Tse-Hua/E-3983-2010; Tan, Tse-Hua/ABD-7080-2021	Tan, Tse-Hua/0000-0003-4969-3170; Tan, Tse-Hua/0000-0003-4969-3170; Rom, William/0000-0002-8793-7028	NHLBI NIH HHS [R01 HL59832] Funding Source: Medline; NIAID NIH HHS [R01 AI38649] Funding Source: Medline; PHS HHS [M0100096] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL059832] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI038649] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Chen YR, 1996, J BIOL CHEM, V271, P31929, DOI 10.1074/jbc.271.50.31929; Chen YR, 1996, J BIOL CHEM, V271, P631, DOI 10.1074/jbc.271.2.631; COBB MH, 1995, J BIOL CHEM, V270, P14843, DOI 10.1074/jbc.270.25.14843; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; Dietrich C, 1996, P NATL ACAD SCI USA, V93, P10815, DOI 10.1073/pnas.93.20.10815; Elledge SJ, 1996, SCIENCE, V274, P1664, DOI 10.1126/science.274.5293.1664; GUPTA S, 1995, SCIENCE, V267, P389, DOI 10.1126/science.7824938; HACCARD O, 1993, SCIENCE, V262, P1262, DOI 10.1126/science.8235656; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; HUNTER T, 1995, CELL, V80, P225, DOI 10.1016/0092-8674(95)90405-0; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; Jiang Y, 1996, J BIOL CHEM, V271, P17920, DOI 10.1074/jbc.271.30.17920; KOSAKO H, 1994, EMBO J, V13, P2131, DOI 10.1002/j.1460-2075.1994.tb06489.x; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MINSHULL J, 1994, CELL, V79, P475, DOI 10.1016/0092-8674(94)90256-9; Nasmyth K, 1996, SCIENCE, V274, P1643, DOI 10.1126/science.274.5293.1643; PAGANO M, 1995, SCIENCE, V269, P682, DOI 10.1126/science.7624798; PALOMBELLA VJ, 1994, CELL, V78, P773, DOI 10.1016/S0092-8674(94)90482-0; Patel R, 1998, J CELL SCI, V111, P2247; Paulovich AG, 1997, CELL, V88, P315, DOI 10.1016/S0092-8674(00)81870-X; ROCK KL, 1994, CELL, V78, P761, DOI 10.1016/S0092-8674(94)90462-6; SHERWOOD SW, 1993, P NATL ACAD SCI USA, V90, P3353, DOI 10.1073/pnas.90.8.3353; Shim J, 1996, NATURE, V381, P804, DOI 10.1038/381804a0; Takenaka K, 1997, J CELL BIOL, V136, P1091, DOI 10.1083/jcb.136.5.1091; Takenaka K, 1998, SCIENCE, V280, P599, DOI 10.1126/science.280.5363.599; Verheij M, 1996, NATURE, V380, P75, DOI 10.1038/380075a0; VISNITSKY A, 1992, BIOCHEMISTRY-US, V31, P9421; WHITMARSH AJ, 1995, SCIENCE, V269, P403, DOI 10.1126/science.7618106; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326	32	13	14	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 25	1999	18	50					6974	6980		10.1038/sj.onc.1203195	http://dx.doi.org/10.1038/sj.onc.1203195			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	259PH	10597296				2022-12-25	WOS:000083901900002
J	Duval, A; Iacopetta, B; Ranzani, GN; Lothe, RA; Thomas, G; Hamelin, R				Duval, A; Iacopetta, B; Ranzani, GN; Lothe, RA; Thomas, G; Hamelin, R			Variable mutation frequencies in coding repeats of TCF-4 and other target genes in colon, gastric and endometrial carcinoma showing microsatellite instability	ONCOGENE			English	Article						TCF-4; coding repeat; stomach; endometrium; colon; microsatellite instability	REPLICATION ERROR PHENOTYPE; II RECEPTOR GENE; BETA-CATENIN; COLORECTAL-CANCER; SOMATIC MUTATIONS; HOMOLOG; APC; ACTIVATION; TUMORS; DNA	Frameshift mutations in genes containing mononucleotide repeats are often observed in cancers exhibiting a high frequency of microsatellite instability (MSI-H). Several tumor types, including colorectal, gastric, and endometrial carcinomas, display this phenotype in a significant proportion of cases. We recently showed in a large series of MSI-H colorectal tumors that approximately 40% of them exhibited frameshift mutations in an (A)9 tract within the coding region of the TCF-4 gene, a crucial member of the APC/beta-catenin/TCF pathway. In the present study, we have examined MSI-H cancers from other primary tumor sites for mutations in this new target gene. Two of 22 (9%) MSI-H primary gastric cancers and none of 23 MSI-H endometrial primary tumors and cell lines were found to have a 1 bp deletion in the TCF-4 repeat. In the same series of tumors we also looked for frameshift mutations in other coding repeats localized within the TGF beta-RII, BAX, IGFIIR, hMSH3 and hMSH6 genes. Our results suggest that the TCF-4 gene, in a similar manner to some of these latter genes, is differentially altered in MSI-H tumors from different primary sites.	INSERM, U434, CEPH, F-75010 Paris, France; Univ Western Australia, Dept Surg, Nedlands, WA 6009, Australia; Univ Pavia, Dept Genet & Microbiol, I-27100 Pavia, Italy; Norwegian Radium Hosp, Inst Canc Res, Dept Genet, Oslo, Norway	Institut National de la Sante et de la Recherche Medicale (Inserm); University of Western Australia; University of Pavia; University of Oslo	Hamelin, R (corresponding author), INSERM, U434, CEPH, 27 Rue Juliette Dodu, F-75010 Paris, France.			Lothe, Ragnhild A./0000-0002-1693-1032; Ranzani, Guglielmina/0000-0002-3080-6473				AALTONEN LA, 1993, SCIENCE, V260, P812, DOI 10.1126/science.8484121; BRONNER CE, 1994, NATURE, V368, P258, DOI 10.1038/368258a0; Candidus S, 1996, CANCER RES, V56, P49; Duval A, 1999, CANCER RES, V59, P4213; FISHEL R, 1993, CELL, V75, P1027, DOI 10.1016/0092-8674(93)90546-3; Fukuchi T, 1998, CANCER RES, V58, P3526; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; Hoang JM, 1997, CANCER RES, V57, P300; HORII A, 1992, CANCER RES, V52, P5231; IONOV Y, 1993, NATURE, V363, P558, DOI 10.1038/363558a0; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; LEACH FS, 1993, CELL, V75, P1215, DOI 10.1016/0092-8674(93)90330-S; Malkhosyan S, 1996, NATURE, V382, P499, DOI 10.1038/382499a0; MARKOWITZ S, 1995, SCIENCE, V268, P1336, DOI 10.1126/science.7761852; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; MYEROFF LL, 1995, CANCER RES, V55, P5545; OGASAWARA S, 1994, VIRCHOWS ARCH, V424, P607, DOI 10.1007/BF01069740; PAPADOPOULOS N, 1994, SCIENCE, V263, P1625, DOI 10.1126/science.8128251; PARSONS R, 1995, CANCER RES, V55, P5548; Rampino N, 1997, SCIENCE, V275, P967, DOI 10.1126/science.275.5302.967; Souza RF, 1996, NAT GENET, V14, P255, DOI 10.1038/ng1196-255; TAMURA G, 1994, CANCER RES, V54, P1149; THIBODEAU SN, 1993, SCIENCE, V260, P816, DOI 10.1126/science.8484122; Wu MS, 1998, CANCER RES, V58, P1494; Yamamoto H, 1997, CANCER RES, V57, P4420; Zhou XP, 1998, GENE CHROMOSOME CANC, V21, P101, DOI 10.1002/(SICI)1098-2264(199802)21:2<101::AID-GCC4>3.0.CO;2-4	26	55	60	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 18	1999	18	48					6806	6809		10.1038/sj.onc.1203287	http://dx.doi.org/10.1038/sj.onc.1203287			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	257QA	10597289				2022-12-25	WOS:000083792000023
J	Jordan, P; Brazao, R; Boavida, MG; Gespach, C; Chastre, E				Jordan, P; Brazao, R; Boavida, MG; Gespach, C; Chastre, E			Cloning of a novel human Rac1b splice variant with increased expression in colorectal tumors	ONCOGENE			English	Article						Rac1; Ras; GTPase; colorectal cancer; alternative splicing	CELL-CELL ADHESION; SMALL GTPASES; CRYSTAL-STRUCTURE; GROWTH-FACTOR; EXTRACELLULAR-MATRIX; SIGNALING PATHWAY; GTP ANALOG; RHO; CDC42; PROTEINS	Rac1 is a member of the Ras superfamily of small GTPases involved in signal transduction pathways that induce the formation of lamellipodia, stimulate cell proliferation and activate the JNK/SAPK protein kinase cascade, Here we describe that amplification by RT-PCR of the entire Rac1 coding sequence from a series of human adult and fetal tissues revealed beside the expected Rac1 cDNA, a variant product which contained additional 57 nucleotides between codons 75 and 76. This variant resulted in an in-frame insertion of 19 new amino acids immediately behind the switch II region, including two potential threonine phosphorylation sites for casein kinase II and protein kinase C, Primers designed within and downstream of the inserted nucleotide sequence allowed isolation of a genomic clone with intronic consensus sequences demonstrating that the insertion corresponds to a novel, yet undescribed exon 3b, This Rac1 splice variant, designated Rac1b, was predominantly identified in skin and epithelial tissues from the intestinal tract. Most notably, the expression of rac1b versus rad was found to be elevated in colorectal tumors at various stages of neoplastic progression, as compared to their respective adjacent tissues. We suggest that the 19 amino acid-insertion following the switch II region may create a novel effector binding site in rac1b, and thus participate in signaling pathways related to the normal or neoplastic growth of the intestinal mucosa.	Inst Nacl Saude Dr Ricardo Jorge, Ctr Genet Humana, Lab Oncobiol, P-1649 Lisbon, Portugal; Hop St Antoine, INSERM, U482, F-75571 Paris 12, France	Instituto Nacional de Saude Dr. Ricardo Jorge; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Antoine - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite	Jordan, P (corresponding author), Inst Nacl Saude Dr Ricardo Jorge, Ctr Genet Humana, Lab Oncobiol, Ave Padre Cruz, P-1649 Lisbon, Portugal.		Jordan, Peter/G-9335-2012; CHASTRE, Eric/L-8446-2018	Jordan, Peter/0000-0002-1425-9211; CHASTRE, Eric/0000-0002-8993-1228				Allen WE, 1997, J CELL SCI, V110, P707; Anand-Apte B, 1997, J BIOL CHEM, V272, P30688, DOI 10.1074/jbc.272.49.30688; Atfi A, 1997, J BIOL CHEM, V272, P1429, DOI 10.1074/jbc.272.3.1429; Braga VMM, 1997, J CELL BIOL, V137, P1421, DOI 10.1083/jcb.137.6.1421; Chabot B, 1996, TRENDS GENET, V12, P472, DOI 10.1016/0168-9525(96)10037-8; Cooper TA, 1997, AM J HUM GENET, V61, P259, DOI 10.1086/514856; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; Courjal F, 1997, GENOMICS, V44, P242, DOI 10.1006/geno.1997.4871; Gayther SA, 1998, CANCER RES, V58, P4086; Guilford P, 1998, NATURE, V392, P402, DOI 10.1038/32918; HALL A, 1994, ANNU REV CELL BIOL, V10, P31, DOI 10.1146/annurev.cb.10.110194.000335; Hirshberg M, 1997, NAT STRUCT BIOL, V4, P147, DOI 10.1038/nsb0297-147; Hordijk PL, 1997, SCIENCE, V278, P1464, DOI 10.1126/science.278.5342.1464; Hotchin NA, 1995, J CELL BIOL, V131, P1857, DOI 10.1083/jcb.131.6.1857; Ihara K, 1998, J BIOL CHEM, V273, P9656, DOI 10.1074/jbc.273.16.9656; Jou TS, 1998, J CELL BIOL, V142, P101, DOI 10.1083/jcb.142.1.101; Jou TS, 1998, J CELL BIOL, V142, P85, DOI 10.1083/jcb.142.1.85; Keely PJ, 1997, NATURE, V390, P632, DOI 10.1038/37656; KINSELLA BT, 1991, J BIOL CHEM, V266, P9786; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; Klemke RL, 1998, J CELL BIOL, V140, P961, DOI 10.1083/jcb.140.4.961; Kuroda S, 1998, SCIENCE, V281, P832, DOI 10.1126/science.281.5378.832; Macara IG, 1996, FASEB J, V10, P625, DOI 10.1096/fasebj.10.5.8621061; Machesky LM, 1997, J CELL BIOL, V138, P913, DOI 10.1083/jcb.138.4.913; MICHIELS F, 1995, NATURE, V375, P338, DOI 10.1038/375338a0; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; Miranti CK, 1998, CURR BIOL, V8, P1289, DOI 10.1016/S0960-9822(07)00559-3; Missy K, 1998, J BIOL CHEM, V273, P30279, DOI 10.1074/jbc.273.46.30279; Moore KA, 1997, BIOCHEM J, V326, P17, DOI 10.1042/bj3260017; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; Nassar N, 1998, NAT STRUCT BIOL, V5, P1047, DOI 10.1038/4156; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; OLSON MF, 1995, SCIENCE, V269, P1270, DOI 10.1126/science.7652575; Price LS, 1998, MOL BIOL CELL, V9, P1863, DOI 10.1091/mbc.9.7.1863; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; Rittinger K, 1997, NATURE, V388, P693, DOI 10.1038/41805; Scheffzek K, 1997, SCIENCE, V277, P333, DOI 10.1126/science.277.5324.333; Schneider TD, 1997, NUCLEIC ACIDS RES, V25, P4408, DOI 10.1093/nar/25.21.4408; Shaw LM, 1997, CELL, V91, P949, DOI 10.1016/S0092-8674(00)80486-9; Takaishi K, 1997, J CELL BIOL, V139, P1047, DOI 10.1083/jcb.139.4.1047; Vider BZ, 1996, ONCOGENE, V12, P153; Wittinghofer A, 1996, TRENDS BIOCHEM SCI, V21, P488, DOI 10.1016/S0968-0004(96)10064-5; Zohn IM, 1998, ONCOGENE, V17, P1415, DOI 10.1038/sj.onc.1202181	43	184	188	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 18	1999	18	48					6835	6839		10.1038/sj.onc.1203233	http://dx.doi.org/10.1038/sj.onc.1203233			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	257QA	10597294				2022-12-25	WOS:000083792000028
J	Hansen, GM; Justice, MJ				Hansen, GM; Justice, MJ			Activation of Hex and mEg5 by retroviral insertion may contribute to mouse B-cell leukemia	ONCOGENE			English	Article						leukemia or lymphoma; hematopoiesis; homeobox; mouse; retrovirus	ACUTE MYELOGENOUS LEUKEMIAS; PROTEIN-CODING REGIONS; HOMEOBOX GENE PRH; INSITU HYBRIDIZATION; MYELOID-LEUKEMIA; MULTIPLE GENES; LYMPHOMAS; IDENTIFICATION; DNA; LOCUS	AKXD recombinant inbred mice develop a variety of leukemias and lymphomas due to retrovirally mediated insertional activation of cellular proto-oncogenes. We describe a new retroviral insertion site that is the most frequent genetic alteration in AKXD B-cell leukemias. Multiple genes flank the site of viral insertion, but the expression of just two, Hex and mEg5, is significantly upregulated. Hex is a divergent homeobox gene that is transiently expressed in many hematopoietic lineages, suggesting an involvement in cellular differentiation. mEp5 is a member of the bim-C subfamily of kinesin related proteins that are necessary for spindle formation and stabilization during mitosis. Our data provide the first genetic evidence for the activation of these genes in leukemia, and suggest that unscheduled expression of Hex and mEg5 contributes to the development of B-cell leukemia. In addition, this work highlights the use of genomic approaches for the study of position effect mutations.	Baylor Coll Med, Dept Mol & Hum Genet, Houston, TX 77030 USA	Baylor College of Medicine	Justice, MJ (corresponding author), Baylor Coll Med, Dept Mol & Hum Genet, 1 Baylor Plaza, Houston, TX 77030 USA.				NATIONAL CANCER INSTITUTE [R29CA063229] Funding Source: NIH RePORTER; NCI NIH HHS [R29CA63229] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AFFHOLTER JA, 1990, MOL ENDOCRINOL, V4, P1125, DOI 10.1210/mend-4-8-1125; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Barr FG, 1998, NAT GENET, V19, P121, DOI 10.1038/475; BARTHOLOMEW C, 1991, MOL CELL BIOL, V11, P1820, DOI 10.1128/MCB.11.4.1820; Barton NR, 1996, P NATL ACAD SCI USA, V93, P1735, DOI 10.1073/pnas.93.5.1735; BEDFORD FK, 1993, NUCLEIC ACIDS RES, V21, P1245, DOI 10.1093/nar/21.5.1245; Beeman RW, 1997, INSECT MOL BIOL, V6, P83, DOI 10.1046/j.1365-2583.1997.00159.x; Blangy A, 1995, CELL, V83, P1159, DOI 10.1016/0092-8674(95)90142-6; Borrow J, 1996, NAT GENET, V12, P159, DOI 10.1038/ng0296-159; CHATTOPADHYAY SK, 1980, P NATL ACAD SCI-BIOL, V77, P5774, DOI 10.1073/pnas.77.10.5774; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; CLAVERIE JM, 1994, GENOMICS, V23, P575, DOI 10.1006/geno.1994.1545; CROMPTON MR, 1992, NUCLEIC ACIDS RES, V20, P5661, DOI 10.1093/nar/20.21.5661; Deloukas P, 1998, SCIENCE, V282, P744, DOI 10.1126/science.282.5389.744; DUBE ID, 1991, BLOOD, V78, P2996; GILBERT DJ, 1993, J VIROL, V67, P2083, DOI 10.1128/JVI.67.4.2083-2090.1993; GISH W, 1993, NAT GENET, V3, P266, DOI 10.1038/ng0393-266; Hansen GM, 1999, GENOMICS, V56, P228, DOI 10.1006/geno.1998.5708; Hawley RG, 1997, CANCER RES, V57, P337; HECK MMS, 1993, J CELL BIOL, V123, P665, DOI 10.1083/jcb.123.3.665; Heng H H, 1994, Methods Mol Biol, V33, P35; HENG HHQ, 1993, CHROMOSOMA, V102, P325, DOI 10.1007/BF00661275; HENG HHQ, 1992, P NATL ACAD SCI USA, V89, P9509, DOI 10.1073/pnas.89.20.9509; HROMAS R, 1993, BIOCHEM BIOPH RES CO, V195, P976, DOI 10.1006/bbrc.1993.2140; IHLE JN, 1990, PROG CLIN BIOL RES, V352, P329; Jacobs JJL, 1999, NATURE, V397, P164, DOI 10.1038/16476; Kee Y, 1997, P NATL ACAD SCI USA, V94, P14438, DOI 10.1073/pnas.94.26.14438; KENNEDY MA, 1991, P NATL ACAD SCI USA, V88, P8900, DOI 10.1073/pnas.88.20.8900; KERE J, 1992, GENOMICS, V14, P241, DOI 10.1016/S0888-7543(05)80212-5; LAMMIE GA, 1992, ONCOGENE, V7, P2381; LEVY ER, 1994, BLOOD, V83, P1348; LIAO XB, 1995, J VIROL, V69, P7132, DOI 10.1128/JVI.69.11.7132-7137.1995; Look AT, 1997, SCIENCE, V278, P1059, DOI 10.1126/science.278.5340.1059; MANFIOLETTI G, 1995, BLOOD, V85, P1237, DOI 10.1182/blood.V85.5.1237.bloodjournal8551237; MONK RJ, 1981, CELL, V24, P301, DOI 10.1016/0092-8674(81)90319-6; MORISHITA K, 1992, P NATL ACAD SCI USA, V89, P3937, DOI 10.1073/pnas.89.9.3937; *MOUS GEN DAT, 1999, MOUS GEN INF; MUCENSKI ML, 1986, MOL CELL BIOL, V6, P4236, DOI 10.1128/MCB.6.12.4236; MUCENSKI ML, 1988, MOL CELL BIOL, V8, P301, DOI 10.1128/MCB.8.1.301; MUELLER PR, 1989, SCIENCE, V246, P780, DOI 10.1126/science.2814500; Nakagawa T, 1997, P NATL ACAD SCI USA, V94, P9654, DOI 10.1073/pnas.94.18.9654; Nakamura T, 1996, NAT GENET, V12, P154, DOI 10.1038/ng0296-154; Nakamura T, 1996, NAT GENET, V12, P149, DOI 10.1038/ng0296-149; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Sarkar G, 1993, PCR Methods Appl, V2, P318; SAWIN KE, 1992, NATURE, V359, P540, DOI 10.1038/359540a0; SPEAKS SL, 1992, GENE CHROMOSOME CANC, V5, P239, DOI 10.1002/gcc.2870050311; SUZUKAWA K, 1994, BLOOD, V84, P2681; TSICHLIS PN, 1990, J VIROL, V64, P2236, DOI 10.1128/JVI.64.5.2236-2244.1990; TSICHLIS PN, 1989, P NATL ACAD SCI USA, V86, P5487, DOI 10.1073/pnas.86.14.5487; UBERBACHER EC, 1991, P NATL ACAD SCI USA, V88, P11261, DOI 10.1073/pnas.88.24.11261; VANLOHUIZEN M, 1990, BIOCHIM BIOPHYS ACTA, V1032, P213, DOI 10.1016/0304-419X(90)90005-L; VARMUS HE, 1982, SCIENCE, V216, P812, DOI 10.1126/science.6177038; White JA, 1998, GENOMICS, V48, P270, DOI 10.1006/geno.1997.5157	54	50	56	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 11	1999	18	47					6531	6539		10.1038/sj.onc.1203023	http://dx.doi.org/10.1038/sj.onc.1203023			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	256CW	10597256				2022-12-25	WOS:000083709200016
J	Campbell, IG; Manolitsas, T				Campbell, IG; Manolitsas, T			Absence of PPP2R1B gene alterations in primary ovarian cancers	ONCOGENE			English	Article						ovarian cancer; PPP2R1B; loss of heterozygosity; chromosome 11q23; mutation analysis	MOLECULAR-CLONING; REGION; HETEROZYGOSITY; FREQUENT; PROTEIN; TUMORS; REFINEMENT; CARCINOMA; DELETIONS; 11Q23	The PPP2R1B gene has recently been implicated as a tumor suppressor based on the finding of somatic alterations in lung and colon cancers. PPP2R1B is located on chromosome 11q22-24 which coincides with the site of frequent loss of heterozygosity (LOH) in ovarian cancer. We investigated if the PPP2R1B gene was inactivated in ovarian cancer by single strand conformational polymorphism (SSCP) and heteroduplex (HD) analysis of 99% of the coding region. LOH at the PPP2R1B locus was detected in 32% of the malignant tumors but no somatic alterations were detected in any of 65 malignant, five borderline or six benign tumors. A germline G>A transition (GGC>GAC) in codon 90 was detected in 4/76 tumors. This alteration has previously been described as a mutation but on further investigation we found that the frequency of this variant among 167 ovarian cancers (4.2%) was not statistically significantly different from that observed in 247 noncancer random controls (2.4%). We conclude that the PPP2R1B gene is not involved in the pathogenesis of ovarian cancer. The codon 90 Gly>Asp alteration may represent a non-pathological polymorphism and consequently the mutation frequency reported in lung cancers may have been overstated and the designation of PPP2R1B as a tumor suppressor gene should be regarded with caution.	Univ Southampton, Princess Anne Hosp, Dept Obstet & Gynaecol, Southampton SO16 5YA, Hants, England; Peter MacCallum Canc Inst, E Melbourne, Vic 3002, Australia	University of Southampton; Peter Maccallum Cancer Center	Campbell, IG (corresponding author), Peter MacCallum Canc Inst, Sir Donald & Lady Trescowthick Res Labs, Locked Bag 1,A Beckett St, Melbourne, Vic 3000, Australia.		campbell, Ian G/F-6006-2011	Campbell, Ian/0000-0002-7773-4155				Baysal BE, 1998, GENE, V217, P107, DOI 10.1016/S0378-1119(98)00350-3; CAMPBELL IG, 1994, HUM MOL GENET, V3, P589, DOI 10.1093/hmg/3.4.589; Davis M, 1996, CANCER RES, V56, P741; Evans MF, 1998, ONCOGENE, V16, P2557, DOI 10.1038/sj.onc.1202039; Gabra H, 1996, CANCER RES, V56, P950; Gayther SA, 1997, ONCOGENE, V15, P2119, DOI 10.1038/sj.onc.1201591; Herbst RA, 1999, INT J CANCER, V80, P205, DOI 10.1002/(SICI)1097-0215(19990118)80:2<205::AID-IJC8>3.0.CO;2-J; Hui ABY, 1996, CANCER RES, V56, P3225; Koreth J, 1997, ONCOGENE, V14, P431, DOI 10.1038/sj.onc.1200847; Monaco C, 1998, GENOMICS, V52, P358, DOI 10.1006/geno.1998.5419; Monaco C, 1997, GENOMICS, V46, P217, DOI 10.1006/geno.1997.5036; Murakami Y, 1998, P NATL ACAD SCI USA, V95, P8153, DOI 10.1073/pnas.95.14.8153; Obata K, 1998, CANCER RES, V58, P2095; Skomedal H, 1997, J PATHOL, V181, P158; Wang L, 1998, ONCOGENE, V16, P635, DOI 10.1038/sj.onc.1201576; Wang SS, 1998, SCIENCE, V282, P284, DOI 10.1126/science.282.5387.284	16	19	20	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 4	1999	18	46					6367	6369		10.1038/sj.onc.1203070	http://dx.doi.org/10.1038/sj.onc.1203070			3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	260DK	10597236				2022-12-25	WOS:000083934100021
J	Kirksey, TJ; Pogue-Caley, RR; Frelinger, JA; Collins, EJ				Kirksey, TJ; Pogue-Caley, RR; Frelinger, JA; Collins, EJ			The structural basis for the increased immunogenicity of two HIV-reverse transcriptase peptide variant/class I major histocompatibility complexes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							T-CELL RECEPTOR; PROTEIN CRYSTALLOGRAPHY; MHC MOLECULES; AMINO; REFINEMENT; STABILITY; HLA-A2.1; BINDING	Designing altered peptide ligands to generate specific immunological reactivity when bound to class I major histocompatibility complexes is important for both therapeutic and prophylactic reasons. We have previously shown that two altered peptides, derived from human immunodeficiency virus (HIV)-reverse transcriptase (RT) residues 309-317, are more immunogenic in vitro than the wild-type peptide. One peptide variant, I1Y, was able to stimulate RT-specific cytotoxic T cells from the blood of three HIV-infected individuals better than the wild-type BT peptide. Both I1Y and I1F peptide variants increase the cell surface half-life of the peptide-class I complex approximately 3-fold over that of the RT peptide but have different immunological activities. These peptides are candidates for the design of vaccines for HN due to their increased immunogenicity, To understand the basis for the increased cell surface stability compared with wild-type peptide and to understand the differences in T cell recognition between I1Y and I1F, we determined the x-ray crystal structures of the two class I MHC-peptide complexes, These structures indicate that the increased cell surface half-life is due to pi-pi stacking interactions between Trp-167 of HLA-A2.1 and the aromatic P1 residues of I1F and I1Y, Comparison of the structures and modeling potential T cell receptor (TCR) interactions suggests that T cell interactions and immunogenicity are different between I1Y and I1F for two reasons. First, subtle changes in the steric and polar properties of the I1Y peptide affect TCR engagement. Second, water-mediated hydrogen bond interactions between the P1-Tyr and the P4-Glu peptide residues increase peptide side chain rigidity of residues critical for TCR engagement.	Univ N Carolina, Dept Microbiol & Immunol, Chapel Hill, NC 27599 USA; Univ N Carolina, Dept Biochem & Biophys, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill	Collins, EJ (corresponding author), Univ N Carolina, Dept Microbiol & Immunol, CB 7290,804 ME Jones Bldg, Chapel Hill, NC 27599 USA.		Frelinger, Jeffrey A/F-2448-2014	Frelinger, Jeffrey A/0000-0002-2503-6267	NIAID NIH HHS [AI20288, AI29324] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI029324, R37AI020288, R01AI020288] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Batalia MA, 1997, BIOPOLYMERS, V43, P281, DOI 10.1002/(SICI)1097-0282(1997)43:4<281::AID-BIP3>3.0.CO;2-R; BOUVIER M, 1994, SCIENCE, V265, P398, DOI 10.1126/science.8023162; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; BRUNGER AT, 1992, XPLOR SYSTEM XRAY CR; BURLEY SK, 1985, SCIENCE, V229, P23, DOI 10.1126/science.3892686; Cowtan K., 1994, JOINT CCP4 ESF EACBM, V31, P34; Ding YH, 1998, IMMUNITY, V8, P403, DOI 10.1016/S1074-7613(00)80546-4; Dodson EJ, 1997, METHOD ENZYMOL, V277, P620, DOI 10.1016/S0076-6879(97)77034-4; DOHERTY PC, 1992, ANNU REV IMMUNOL, V10, P123; FALK K, 1991, NATURE, V351, P290, DOI 10.1038/351290a0; Garboczi DN, 1996, NATURE, V384, P134, DOI 10.1038/384134a0; GARBOCZI DN, 1992, P NATL ACAD SCI USA, V89, P3429, DOI 10.1073/pnas.89.8.3429; Garcia KC, 1998, SCIENCE, V279, P1166, DOI 10.1126/science.279.5354.1166; HUNT DF, 1992, SCIENCE, V255, P1261, DOI 10.1126/science.1546328; JARDETZKY TS, 1991, NATURE, V353, P326, DOI 10.1038/353326a0; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Lamzin VS, 1997, METHOD ENZYMOL, V277, P269, DOI 10.1016/S0076-6879(97)77016-2; MADDEN DR, 1993, CELL, V75, P693, DOI 10.1016/0092-8674(93)90490-H; Morgan CS, 1997, PROTEIN SCI, V6, P1771, DOI 10.1002/pro.5560060819; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; POGUE RR, 1995, P NATL ACAD SCI USA, V92, P8166, DOI 10.1073/pnas.92.18.8166; RUPPERT J, 1993, CELL, V74, P929, DOI 10.1016/0092-8674(93)90472-3; Schmitz JE, 1999, SCIENCE, V283, P857, DOI 10.1126/science.283.5403.857; ZINKERNA.RM, 1974, NATURE, V248, P701, DOI 10.1038/248701a0	25	46	48	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 24	1999	274	52					37259	37264		10.1074/jbc.274.52.37259	http://dx.doi.org/10.1074/jbc.274.52.37259			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	267WR	10601290	Green Published, hybrid			2022-12-25	WOS:000084382700061
J	Sayas, CL; Moreno-Flores, MT; Avila, J; Wandosell, F				Sayas, CL; Moreno-Flores, MT; Avila, J; Wandosell, F			The neurite retraction induced by lysophosphatidic acid increases Alzheimer's disease-like Tau phosphorylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCOGEN-SYNTHASE KINASE-3; PC12 CELLS; ANTISENSE OLIGONUCLEOTIDES; ABNORMAL PHOSPHORYLATION; PROTEIN; INHIBITION; RHO; LITHIUM; FIBROBLASTS; PATHOLOGY	The bioactive phospholipid lysophosphatidic acid (LPA) causes growth cone collapse and neurite retraction in neuronal cells. These changes are brought about by the action of a cell surface receptor coupled to specific G proteins that control morphology and motility through the action of a group of small GTPases, the Rho family of proteins. Many studies have focused on actin reorganization modulated by Rho-GTPases, but almost no information has been obtained concerning microtubular network reorganization after LPA-induced neurite retraction. In the present study, we demonstrate an increase in site-specific Alzheimer's disease-like Talc phosphorylation during LPA-induced neurite retraction in differentiated SY-SH5Y human neuroblastoma cells. The phosphorylation state of Tau was inferred from its immunoreactivity with antibodies that recognize phosphorylation-sensitive epitopes. The effects of specific kinase inhibitors indicate that this phosphorylation is mediated by glycogen synthase kinase-3 (GSK-3). In support of this idea, we observed an increase of GSK-3 activity upon growth cone collapse. Our results are consistent with the hypothesis that activation of GSK-3 occurs in the Rho pathway and may represent an important link between microtubules and microfilaments dynamics during neuritogenesis and in pathological situations such as Alzheimer's disease.	Univ Autonoma Madrid, CSIC, Ctr Biol Mol Severo Ochoa, E-28049 Madrid, Spain	Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Biologia Molecular Severo Ochoa (CBM)	Wandosell, F (corresponding author), Univ Autonoma Madrid, CSIC, Ctr Biol Mol Severo Ochoa, E-28049 Madrid, Spain.		Wandosell, Francisco/AAV-6391-2020; Sayas Casanova, Carmen Laura/AAD-9270-2022; Avila, Jesus/I-2610-2015; Moreno-Flores, M. Teresa/E-8949-2018; Moreno-Flores, M. Teresa/ABH-9655-2020; Wandosell, Francisco/G-6105-2015	Sayas Casanova, Carmen Laura/0000-0001-8594-0322; Avila, Jesus/0000-0002-6288-0571; Moreno-Flores, M. Teresa/0000-0002-8494-8143; Moreno-Flores, M. Teresa/0000-0002-8494-8143; Wandosell, Francisco/0000-0001-6537-2321				AVILA J, 1994, INT J DEV BIOL, V38, P13; BRAMBLETT GT, 1993, NEURON, V10, P1089, DOI 10.1016/0896-6273(93)90057-X; CACERES A, 1991, J NEUROSCI, V11, P1515; CACERES A, 1990, NATURE, V343, P461, DOI 10.1038/343461a0; Chen FS, 1998, J NEUROCHEM, V71, P248; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Chuprun JK, 1997, J BIOL CHEM, V272, P773, DOI 10.1074/jbc.272.2.773; Cook D, 1996, EMBO J, V15, P4526, DOI 10.1002/j.1460-2075.1996.tb00830.x; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; DELALONSO CA, 1996, NAT MED, V2, P783; DRECHSEL DN, 1992, MOL BIOL CELL, V3, P1147; Fischer DJ, 1998, MOL PHARMACOL, V54, P979, DOI 10.1124/mol.54.6.979; GLASS DB, 1978, ANAL BIOCHEM, V87, P566, DOI 10.1016/0003-2697(78)90707-8; GOEDERT M, 1993, P NATL ACAD SCI USA, V90, P5066, DOI 10.1073/pnas.90.11.5066; Goetzl EJ, 1998, FASEB J, V12, P1589, DOI 10.1096/fasebj.12.15.1589; GREENBERG SG, 1992, J BIOL CHEM, V267, P564; GREENBERG SG, 1990, P NATL ACAD SCI USA, V87, P5827, DOI 10.1073/pnas.87.15.5827; GRUNDKEIQBAL I, 1986, P NATL ACAD SCI USA, V83, P4913, DOI 10.1073/pnas.83.13.4913; HALL A, 1994, ANNU REV CELL BIOL, V10, P31, DOI 10.1146/annurev.cb.10.110194.000335; Hecht JH, 1996, J CELL BIOL, V135, P1071, DOI 10.1083/jcb.135.4.1071; Hong M, 1997, J BIOL CHEM, V272, P25326, DOI 10.1074/jbc.272.40.25326; ISHIGURO K, 1996, BRAIN MICROTUBULES A, P73; JALINK K, 1994, J CELL BIOL, V126, P801, DOI 10.1083/jcb.126.3.801; JALINK K, 1990, J BIOL CHEM, V265, P12232; KAPFHAMMER JP, 1987, J NEUROSCI, V7, P201; Klein PS, 1996, P NATL ACAD SCI USA, V93, P8455, DOI 10.1073/pnas.93.16.8455; Lesort M, 1999, J NEUROCHEM, V72, P576, DOI 10.1046/j.1471-4159.1999.0720576.x; Lewin GR, 1996, ANNU REV NEUROSCI, V19, P289, DOI 10.1146/annurev.ne.19.030196.001445; MANDELL J, 1996, NEUROBIOL AGING, V16, P229; MATSUO ES, 1994, NEURON, V13, P989, DOI 10.1016/0896-6273(94)90264-X; Moolenaar WH, 1997, CURR OPIN CELL BIOL, V9, P168, DOI 10.1016/S0955-0674(97)80059-2; Munoz-Montano JR, 1999, J NEUROSCI RES, V55, P278, DOI 10.1002/(SICI)1097-4547(19990201)55:3<278::AID-JNR2>3.0.CO;2-2; MunozMontano JR, 1997, FEBS LETT, V411, P183, DOI 10.1016/S0014-5793(97)00688-1; OLSON MF, 1995, SCIENCE, V269, P1270, DOI 10.1126/science.7652575; OTVOS L, 1994, J NEUROSCI RES, V39, P669, DOI 10.1002/jnr.490390607; SMALHEISER NR, 1994, BRAIN RES, V660, P309, DOI 10.1016/0006-8993(94)91304-8; STAHL B, 1990, NEURON, V5, P733; STAMBOLIC V, 1994, BIOCHEM J, V303, P701, DOI 10.1042/bj3030701; SturchlerPierrat C, 1997, P NATL ACAD SCI USA, V94, P13287, DOI 10.1073/pnas.94.24.13287; TAKASHIMA A, 1993, P NATL ACAD SCI USA, V90, P7789, DOI 10.1073/pnas.90.16.7789; TANAKA E, 1995, CELL, V83, P171, DOI 10.1016/0092-8674(95)90158-2; Tigyi G, 1996, J NEUROCHEM, V66, P549; Tigyi G, 1996, J NEUROCHEM, V66, P537; VanAelst L, 1997, GENE DEV, V11, P2295, DOI 10.1101/gad.11.18.2295; Welsh GI, 1997, ANAL BIOCHEM, V244, P16, DOI 10.1006/abio.1996.9838	45	143	149	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 24	1999	274	52					37046	37052		10.1074/jbc.274.52.37046	http://dx.doi.org/10.1074/jbc.274.52.37046			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	267WR	10601262	hybrid			2022-12-25	WOS:000084382700033
J	Washington, MT; Johnson, RE; Prakash, S; Prakash, L				Washington, MT; Johnson, RE; Prakash, S; Prakash, L			Fidelity and processivity of Saccharomyces cerevisiae DNA polymerase eta	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PIGMENTOSUM VARIANT CELLS; ESCHERICHIA-COLI DINB; REPLICATION; DIMER; HYPERMUTABILITY; EFFICIENCIES; PROTEINS; HOMOLOG; GENE	The yeast RAD30 gene functions in error-free replication of UV-damaged DNA, and RAD30 encodes a DNA polymerase, pol eta, that has the ability to efficiently and correctly replicate past a cis-syn-thymine-thymine dimer in template DNA. To better understand the role of pol eta in damage bypass, we examined its fidelity and processivity on nondamaged DNA templates. Steady-state kinetic analyses of deoxynucleotide incorporation indicate that pol eta has a low fidelity, misincorporating deoxynucleotides with a frequency of about 10(-2) to 10(-3) Also pol eta has a low processivity, incorporating only a Pew nucleotides before dissociating. We suggest that pol eta's low fidelity reflects a flexibility in its active site rendering it more tolerant of DNA damage, while its low processivity limits its activity to reduce errors.	Univ Texas, Med Branch, Sealy Ctr Mol Sci, Galveston, TX 77555 USA	University of Texas System; University of Texas Medical Branch Galveston	Prakash, L (corresponding author), Univ Texas, Med Branch, Sealy Ctr Mol Sci, 6-104 Med Res Bldg,11th & Mech St, Galveston, TX 77555 USA.		Prakash, Satya/C-6420-2013	Prakash, Satya/0000-0001-7228-1444; Washington, Todd/0000-0001-8680-2992; Prakash, Louise/0000-0001-9143-6261	NIGMS NIH HHS [GM19261] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM019261] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bailly V, 1997, J BIOL CHEM, V272, P23360, DOI 10.1074/jbc.272.37.23360; Bambara RA, 1995, METHOD ENZYMOL, V262, P270; Bloom LB, 1997, J BIOL CHEM, V272, P27919, DOI 10.1074/jbc.272.44.27919; CIARROCCHI G, 1982, J MOL BIOL, V155, P177, DOI 10.1016/0022-2836(82)90445-4; Creighton S, 1995, METHOD ENZYMOL, V262, P232; CREIGHTON S, 1995, J BIOL CHEM, V270, P4759, DOI 10.1074/jbc.270.9.4759; ECHOLS H, 1991, ANNU REV BIOCHEM, V60, P477, DOI 10.1146/annurev.biochem.60.1.477; Fersht A., 1984, ENZYME STRUCTURE MEC; Goodman MF, 1998, GENETICS, V148, P1475; GOODMAN MF, 1993, CRIT REV BIOCHEM MOL, V28, P83, DOI 10.3109/10409239309086792; Johnson RE, 1999, SCIENCE, V283, P1001, DOI 10.1126/science.283.5404.1001; Johnson RE, 1999, SCIENCE, V285, P263, DOI 10.1126/science.285.5425.263; Johnson RE, 1999, J BIOL CHEM, V274, P15975, DOI 10.1074/jbc.274.23.15975; KEMMINK J, 1987, NUCLEIC ACIDS RES, V15, P4645, DOI 10.1093/nar/15.11.4645; KIM JK, 1995, PHOTOCHEM PHOTOBIOL, V62, P44, DOI 10.1111/j.1751-1097.1995.tb05236.x; Masutani C, 1999, NATURE, V399, P700, DOI 10.1038/21447; McDonald JP, 1997, GENETICS, V147, P1557; Osheroff WP, 1999, J BIOL CHEM, V274, P3642, DOI 10.1074/jbc.274.6.3642; Roush AA, 1998, MOL GEN GENET, V257, P686; Steitz TA, 1999, J BIOL CHEM, V274, P17395, DOI 10.1074/jbc.274.25.17395; THOMAS DC, 1991, BIOCHEMISTRY-US, V30, P11751, DOI 10.1021/bi00115a003; VONHIPPEL PH, 1994, ANN NY ACAD SCI, V726, P118; WANG CI, 1991, P NATL ACAD SCI USA, V88, P9072, DOI 10.1073/pnas.88.20.9072; WANG YC, 1993, MOL CELL BIOL, V13, P4276, DOI 10.1128/MCB.13.7.4276; WATERS HL, 1993, J INVEST DERMATOL, V101, P744, DOI 10.1111/1523-1747.ep12371686	25	155	160	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 24	1999	274	52					36835	36838		10.1074/jbc.274.52.36835	http://dx.doi.org/10.1074/jbc.274.52.36835			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	267WR	10601233	hybrid			2022-12-25	WOS:000084382700004
J	Yang, ZH; Hong, SH; Privalsky, ML				Yang, ZH; Hong, SH; Privalsky, ML			Transcriptional anti-repression - Thyroid hormone receptor beta-2 recruits SMRT corepressor but interferes with subsequent assembly of a functional corepressor complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HISTONE DEACETYLASE; CO-REPRESSOR; N-COR; RESPONSE ELEMENT; DOMAIN; IDENTIFICATION; ACTIVATION; EXPRESSION; ISOFORM; ALPHA	Thyroid hormone receptors (TSRs) are hormone-regulated transcription factors. Different T3R isoforms are expressed in a tissue-specific and developmentally regulated manner. The T3R alpha-1, beta-0, and beta-1 isoforms typically repress target gene expression in the absence of hormone and activate transcription in the presence of hormone, intriguingly, however, the T3R beta-2 isoform fails to repress, and instead is able to activate transcription in both the absence and presence of hormone. We investigated the molecular mechanism behind this absence of repression by T3R beta-2. Repression by T3R alpha-1, beta-0, and beta-1 is mediated by the ability of these isoforms to physically recruit a SMRT/N-CoR corepressor complex. We determined that the unliganded T3R beta-2 also recruits the SMRT corepressor; in contrast to the alpha-1, beta-0, and beta-1 isoforms, however, the T3R beta-2 protein interacts not only with the C-terminal "receptor-interaction domain" of SMRT, but also makes additional contacts with the N-terminal "silencing domain" of the SMRT corepressor. These additional, T3R beta-2-specific contacts interfere with the subsequent association of SMRT with mSin3, a crucial second subunit of the corepressor holocomplex. Our results suggest that T3R beta-2 regulates transcription through a novel anti-repression mechanism, recruiting SMRT, but preventing the subsequent formation of a functional corepressor complex.	Univ Calif Davis, Div Biol Sci, Microbiol Sect, Davis, CA 95616 USA	University of California System; University of California Davis	Privalsky, ML (corresponding author), Univ Calif Davis, Div Biol Sci, Microbiol Sect, Davis, CA 95616 USA.			Hong, Suk-Hyun/0000-0001-7541-4847	NCI NIH HHS [R37 CA053394, R37 CA053394-06S1, R37 CA-53394] Funding Source: Medline; NIDDK NIH HHS [R01 DK053528, R01 DK053528-02, R01 DK-53528] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R37CA053394] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK053528] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Alland L, 1997, NATURE, V387, P49, DOI 10.1038/387049a0; BAGY L, 1997, CELL, V89, P373; BANIAHMAD A, 1995, MOL CELL BIOL, V15, P76, DOI 10.1128/MCB.15.1.76; BEATO M, 1995, CELL, V83, P851, DOI 10.1016/0092-8674(95)90201-5; BIGLER J, 1988, MOL CELL BIOL, V8, P4155, DOI 10.1128/MCB.8.10.4155; CASANOVA J, 1994, MOL CELL BIOL, V14, P5756, DOI 10.1128/MCB.14.9.5756; Chen JD, 1996, P NATL ACAD SCI USA, V93, P7567, DOI 10.1073/pnas.93.15.7567; CHEN JD, 1995, NATURE, V377, P454, DOI 10.1038/377454a0; DAMM K, 1989, NATURE, V339, P593, DOI 10.1038/339593a0; Dhordain P, 1997, P NATL ACAD SCI USA, V94, P10762, DOI 10.1073/pnas.94.20.10762; FORREST D, 1990, EMBO J, V9, P1519, DOI 10.1002/j.1460-2075.1990.tb08270.x; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; Hassig CA, 1997, CELL, V89, P341, DOI 10.1016/S0092-8674(00)80214-7; Heinzel T, 1997, NATURE, V387, P43, DOI 10.1038/387043a0; HODIN RA, 1989, SCIENCE, V244, P76, DOI 10.1126/science.2539642; Hollenberg AN, 1996, J BIOL CHEM, V271, P28516, DOI 10.1074/jbc.271.45.28516; Hong SH, 1997, P NATL ACAD SCI USA, V94, P9028, DOI 10.1073/pnas.94.17.9028; HORLEIN AJ, 1995, NATURE, V377, P397, DOI 10.1038/377397a0; Horwitz KB, 1996, MOL ENDOCRINOL, V10, P1167, DOI 10.1210/me.10.10.1167; KASTNER P, 1995, CELL, V83, P859, DOI 10.1016/0092-8674(95)90202-3; Laherty CD, 1997, CELL, V89, P349, DOI 10.1016/S0092-8674(00)80215-9; Langlois MF, 1997, J BIOL CHEM, V272, P24927, DOI 10.1074/jbc.272.40.24927; LAZAR MA, 1993, ENDOCR REV, V14, P184, DOI 10.1210/er.14.2.184; LECHAN RM, 1994, ENDOCRINOLOGY, V135, P92, DOI 10.1210/en.135.1.92; LECHAN RM, 1993, ENDOCRINOLOGY, V132, P2461, DOI 10.1210/en.132.6.2461; Li H, 1997, MOL ENDOCRINOL, V11, P2025, DOI 10.1210/me.11.13.2025; Li M, 1997, BRAIN RES, V773, P125, DOI 10.1016/S0006-8993(97)00917-7; Lin BC, 1997, MOL CELL BIOL, V17, P6131, DOI 10.1128/MCB.17.10.6131; MANGELSDORF DJ, 1995, CELL, V83, P841, DOI 10.1016/0092-8674(95)90200-7; MANGELSDORF DJ, 1995, CELL, V83, P335; Muscat GEO, 1998, NUCLEIC ACIDS RES, V26, P2899, DOI 10.1093/nar/26.12.2899; Pazin MJ, 1997, CELL, V89, P325, DOI 10.1016/S0092-8674(00)80211-1; RIBEIRO RC, 1993, ANN NY ACAD SCI, V758, P366; Safer JD, 1997, MOL ENDOCRINOL, V11, P16, DOI 10.1210/me.11.1.16; Sande S, 1996, MOL ENDOCRINOL, V10, P813, DOI 10.1210/me.10.7.813; SAP J, 1989, NATURE, V340, P242, DOI 10.1038/340242a0; Schulman IG, 1996, MOL CELL BIOL, V16, P3807; SCHWARTZ HL, 1994, J BIOL CHEM, V269, P24777; Seol W, 1996, MOL ENDOCRINOL, V10, P1646, DOI 10.1210/me.10.12.1646; SHOWERS MO, 1991, DNA CELL BIOL, V10, P211, DOI 10.1089/dna.1991.10.211; SJOBERG M, 1995, MOL CELL BIOL, V15, P4718; SJOBERG M, 1992, DEVELOPMENT, V114, P39; TSAI MJ, 1994, ANNU REV BIOCHEM, V63, P451, DOI 10.1146/annurev.biochem.63.1.451; WAGNER RL, 1995, NATURE, V378, P690, DOI 10.1038/378690a0; Wolffe AP, 1997, NATURE, V387, P16, DOI 10.1038/387016a0; Wong CW, 1998, MOL CELL BIOL, V18, P5724, DOI 10.1128/MCB.18.10.5724; Wong CW, 1998, MOL CELL BIOL, V18, P5500, DOI 10.1128/MCB.18.9.5500; Yoh SM, 1997, MOL ENDOCRINOL, V11, P470, DOI 10.1210/me.11.4.470; Zamir I, 1997, GENE DEV, V11, P835, DOI 10.1101/gad.11.7.835; Zamir I, 1996, MOL CELL BIOL, V16, P5458; Zhang JS, 1997, MOL CELL BIOL, V17, P6887, DOI 10.1128/MCB.17.12.6887; Zhang Y, 1997, CELL, V89, P357, DOI 10.1016/S0092-8674(00)80216-0	52	38	38	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 24	1999	274	52					37131	37138		10.1074/jbc.274.52.37131	http://dx.doi.org/10.1074/jbc.274.52.37131			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	267WR	10601274	hybrid, Green Accepted			2022-12-25	WOS:000084382700045
J	Balboa, MA; Balsinde, J; Johnson, CA; Dennis, EA				Balboa, MA; Balsinde, J; Johnson, CA; Dennis, EA			Regulation of arachidonic acid mobilization in lipopolysaccharide-activated P388D(1) macrophages by adenosine triphosphate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOLIPASE A(2) ENZYMES; EXPRESSION; RECEPTOR; ATP; CELLS; MODULATION; P2X(7); PROSTAGLANDIN-E(2); INHIBITION; DEATH	Murine P388D, macrophages exhibit a delayed prostaglandin biosynthetic response when exposed to bacterial lipopolysaccharide (LPS) for prolonged periods of time that is dependent on induction of the genes coding for Group V secretory phospholipase A(2) and cyclooxygenase-2, We herein report that LPS-induced arachidonic acid (AA) metabolite release in P388D(1) macrophages is strongly attenuated by the P2X(7) purinergic receptor antagonists periodate-oxidized ATP and pyridoxal-phosphate-6-azophenyl-2',4'-disulfonic acid, and this is accompanied by suppression of the expression of both Group V secretory phospholipase A(2) and cyclooxygenase-2, The effect appears to be specific for LPS, because the P2X(7) purinergic receptor antagonists do not affect P388D, cell stimulation by other stimuli such as platelet-activating factor or the Ca2+ ionophore A23187. Moreover, extracellular nucleotides are found to stimulate macrophage AA mobilization with a pharmacological profile that implicates the participation of the P2X(7) receptor and that is inhibited by periodate-oxidized ATP. Collectively these results demonstrate coupling of the P2X(7) receptor to the AA cascade in P388D, macrophages and implicate the participation of this type of receptor in LPS-induced AA mobilization.	Univ Calif San Diego, Dept Biochem & Chem, La Jolla, CA 92093 USA	University of California System; University of California San Diego	Dennis, EA (corresponding author), Univ Calif San Diego, Dept Biochem & Chem, 4080 BSB M-C 0601,9500 Gilman Dr, La Jolla, CA 92093 USA.	edennis@ucsd.edu	Balboa, María A./V-9493-2018; Balsinde, Jesús/C-7833-2018; Dennis, Edward A./M-5554-2019	Balboa, María A./0000-0002-2130-5298; Balsinde, Jesús/0000-0002-4157-6714; Dennis, Edward A./0000-0003-3738-3140	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD026171] Funding Source: NIH RePORTER; NICHD NIH HHS [HD26171] Funding Source: Medline; NIGMS NIH HHS [GM2051] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ASMIS R, 1994, BIOCHEM J, V298, P543, DOI 10.1042/bj2980543; Balsinde J, 1999, ANNU REV PHARMACOL, V39, P175, DOI 10.1146/annurev.pharmtox.39.1.175; Balsinde J, 1997, BIOCHEM J, V321, P805, DOI 10.1042/bj3210805; BALSINDE J, 1994, P NATL ACAD SCI USA, V91, P11060, DOI 10.1073/pnas.91.23.11060; Balsinde J, 1999, J BIOL CHEM, V274, P25967, DOI 10.1074/jbc.274.37.25967; Balsinde J, 1996, J BIOL CHEM, V271, P6758, DOI 10.1074/jbc.271.12.6758; BARBOUR SE, 1993, J BIOL CHEM, V268, P21875; DIVIRGILIO F, 1995, IMMUNOL TODAY, V16, P524, DOI 10.1016/0167-5699(95)80045-X; DUBYAK GR, 1993, AM J PHYSIOL, V265, pC577, DOI 10.1152/ajpcell.1993.265.3.C577; ELMOATASSIM C, 1993, J BIOL CHEM, V268, P15571; Ferrari D, 1999, J BIOL CHEM, V274, P13205, DOI 10.1074/jbc.274.19.13205; Ferrari D, 1997, J EXP MED, V185, P579, DOI 10.1084/jem.185.3.579; Ferrari D, 1997, J CELL BIOL, V139, P1635, DOI 10.1083/jcb.139.7.1635; GLASER KB, 1990, J BIOL CHEM, V265, P8658; Hu Y, 1998, J BIOL CHEM, V273, P27170, DOI 10.1074/jbc.273.42.27170; Humphreys BD, 1998, J LEUKOCYTE BIOL, V64, P265, DOI 10.1002/jlb.64.2.265; Lammas DA, 1997, IMMUNITY, V7, P433, DOI 10.1016/S1074-7613(00)80364-7; Lio YC, 1996, BBA-LIPID LIPID MET, V1302, P55, DOI 10.1016/0005-2760(96)00002-1; MATSUURA K, 1994, J EXP MED, V179, P1671, DOI 10.1084/jem.179.5.1671; MURGIA M, 1993, J BIOL CHEM, V268, P8199; NUTTLE LC, 1993, MOL PHARMACOL, V44, P93; PROCTOR RA, 1994, P NATL ACAD SCI USA, V91, P6017, DOI 10.1073/pnas.91.13.6017; Rassendren F, 1997, J BIOL CHEM, V272, P5482, DOI 10.1074/jbc.272.9.5482; Shinohara H, 1999, J BIOL CHEM, V274, P12263, DOI 10.1074/jbc.274.18.12263; Sperlagh B, 1998, NEUROCHEM INT, V33, P209, DOI 10.1016/S0197-0186(98)00025-4; Surprenant A, 1996, SCIENCE, V272, P735, DOI 10.1126/science.272.5262.735; Ulevitch RJ, 1999, CURR OPIN IMMUNOL, V11, P19, DOI 10.1016/S0952-7915(99)80004-1	27	29	29	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 17	1999	274	51					36764	36768		10.1074/jbc.274.51.36764	http://dx.doi.org/10.1074/jbc.274.51.36764			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	266AV	10593984	Green Published, hybrid			2022-12-25	WOS:000084279200103
J	Barroso, JB; Corpas, FJ; Carreras, A; Sandalio, LM; Valderrama, R; Palma, JM; Lupianez, JA; del Rio, LA				Barroso, JB; Corpas, FJ; Carreras, A; Sandalio, LM; Valderrama, R; Palma, JM; Lupianez, JA; del Rio, LA			Localization of nitric-oxide synthase in plant peroxisomes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PISUM-SATIVUM-L; SUPEROXIDE-DISMUTASE; MOLECULAR-CLONING; DISEASE RESISTANCE; DEHYDROGENASE; MITOCHONDRIA; EXPRESSION; RAT; GLYOXYSOMES; COTYLEDONS	The presence of nitric-oxide synthase (NOS) in peroxisomes from leaves of pea plants (Pisum sativum L.) was studied. Plant organelles were purified by differential and sucrose density gradient centrifugation. In purified intact peroxisomes a Ca2+-dependent NOS activity of 5.61 nmol of L-[H-3]citrulline mg(-1) protein min(-1) was measured while no activity was detected in mitochondria. The peroxisomal NOS activity was clearly inhibited (60-90%) by different well characterized inhibitors of mammalian NO synthases. The immunoblot analysis of peroxisomes with a polyclonal antibody against the C terminus region of murine iNOS revealed an immunoreactive protein of 130 kDa. Electron microscopy immuno-gold-labeling confirmed the subcellular localization of NOS in the matrix of peroxisomes as well as in chloroplasts. The presence of NOS in peroxisomes suggests that these oxidative organelles are a cellular source of nitric oxide (NO) and implies new roles for peroxisomes in the cellular signal transduction mechanisms.	CSIC, Estac Expt Zaidin, Dept Bioquim Biol Celular & Mol Plantas, E-18080 Granada, Spain; Univ Jaen, Fac Ciencias Expt, Dept Bioquim & Biol Mol, E-23071 Jaen, Spain; Univ Granada, Ctr Ciencias Biol, Dept Bioquim & Biol Mol, E-18001 Granada, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Estacion Experimental del Zaidin (EEZ); Universidad de Jaen; University of Granada	Lupianez, JA (corresponding author), CSIC, Estac Expt Zaidin, Dept Bioquim Biol Celular & Mol Plantas, Apartado 419, E-18080 Granada, Spain.	javier.corpas@eez.csic.es	Barroso, Juan B./G-8041-2014; Albarracín, Juan Bautista Barroso/ABC-2908-2020; Valderrama, Raquel/H-5937-2015; Sandalio, Luisa M/H-7673-2015; Corpas, Francisco J/A-4447-2008; Lupiáñez, José A./M-6664-2015; Palma, Jose M/L-3803-2014	Albarracín, Juan Bautista Barroso/0000-0002-9477-9195; Sandalio, Luisa M/0000-0002-8550-7577; Corpas, Francisco J/0000-0002-1814-9212; Lupiáñez, José A./0000-0001-9095-7145; Palma, Jose M/0000-0001-6673-3571; Carreras Egana, Alfonso Maria/0000-0003-2312-6602; Valderrama Rodriguez, Raquel/0000-0003-2253-0101				AEBI H, 1984, METHOD ENZYMOL, V105, P121; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BREDT DS, 1989, P NATL ACAD SCI USA, V86, P9030, DOI 10.1073/pnas.86.22.9030; BREDT DS, 1991, NATURE, V351, P714, DOI 10.1038/351714a0; Corpas FJ, 1998, BIOCHEM J, V330, P777; CORPAS FJ, 1994, EUR J CELL BIOL, V65, P280; Corpas FJ, 1998, NEW PHYTOL, V138, P307, DOI 10.1046/j.1469-8137.1998.00899.x; Cueto M, 1996, FEBS LETT, V398, P159, DOI 10.1016/S0014-5793(96)01232-X; Dangl J, 1998, NATURE, V394, P525, DOI 10.1038/28958; del Rio LA, 1998, PHYSIOL PLANTARUM, V104, P673, DOI 10.1034/j.1399-3054.1998.1040422.x; Delledonne M, 1998, NATURE, V394, P585, DOI 10.1038/29087; DELRIO LA, 1985, J INORG BIOCHEM, V24, P25; Distefano S, 1997, BIOCHEM J, V327, P399, DOI 10.1042/bj3270399; Finkel T, 1998, CURR OPIN CELL BIOL, V10, P248, DOI 10.1016/S0955-0674(98)80147-6; Ghafourifar P, 1997, FEBS LETT, V418, P291, DOI 10.1016/S0014-5793(97)01397-5; HUANG AHC, 1983, PLANT PEROXIDSOMES; Jimenez A, 1997, PLANT PHYSIOL, V114, P275, DOI 10.1104/pp.114.1.275; Knowles RG, 1996, BIOCHEM SOC T, V24, P875, DOI 10.1042/bst0240875; KNOWLES RG, 1994, BIOCHEM J, V298, P249, DOI 10.1042/bj2980249; Leshem YY, 1996, J PLANT PHYSIOL, V148, P258, DOI 10.1016/S0176-1617(96)80251-3; LEVINE A, 1994, CELL, V79, P583, DOI 10.1016/0092-8674(94)90544-4; LopezHuertas E, 1997, FREE RADICAL RES, V26, P497, DOI 10.3109/10715769709097820; LOPEZHUERTAS E, 1995, PLANT PHYSIOL BIOCH, V33, P295; LOPEZHUERTAS E, 1989, BIOOCH J, V337, P531; LYONS CR, 1992, J BIOL CHEM, V267, P6370; MARSDEN PA, 1992, FEBS LETT, V307, P287, DOI 10.1016/0014-5793(92)80697-F; McMillan K, 1996, METHOD ENZYMOL, V268, P460; Mullen RT, 1996, TRENDS PLANT SCI, V1, P389, DOI 10.1016/S1360-1385(96)80314-1; Ninnemann H, 1996, PHOTOCHEM PHOTOBIOL, V64, P393, DOI 10.1111/j.1751-1097.1996.tb02477.x; Noritake T, 1996, PLANT CELL PHYSIOL, V37, P113, DOI 10.1093/oxfordjournals.pcp.a028908; Ribeiro EA, 1999, FEBS LETT, V445, P283, DOI 10.1016/S0014-5793(99)00138-6; RIVEROSMORENO V, 1993, EUR J BIOCHEM, V215, P801, DOI 10.1111/j.1432-1033.1993.tb18095.x; Sakuma S, 1997, BIOCHEM BIOPH RES CO, V230, P476, DOI 10.1006/bbrc.1996.5983; SANDALIO LM, 1987, PLANT SCI, V51, P1, DOI 10.1016/0168-9452(87)90213-5; SANDALIO LM, 1988, PLANT PHYSIOL, V87, P1, DOI 10.1104/pp.87.1.1; SESSA WC, 1992, J BIOL CHEM, V267, P15274; SHEPHARD EA, 1992, ARCH BIOCHEM BIOPHYS, V294, P168, DOI 10.1016/0003-9861(92)90152-M; Shirasu K, 1996, CURR OPIN IMMUNOL, V8, P3, DOI 10.1016/S0952-7915(96)80097-5; Tatoyan A, 1998, J BIOL CHEM, V273, P11044, DOI 10.1074/jbc.273.18.11044; Uttenthal LO, 1998, MICROSC RES TECHNIQ, V43, P75, DOI 10.1002/(SICI)1097-0029(19981001)43:1<75::AID-JEMT11>3.0.CO;2-0; Van Camp W, 1998, TRENDS PLANT SCI, V3, P330, DOI 10.1016/S1360-1385(98)01297-7; VANDENBOSCH H, 1992, ANNU REV BIOCHEM, V61, P157, DOI 10.1146/annurev.bi.61.070192.001105; WALK RA, 1977, PLANTA, V134, P277, DOI 10.1007/BF00384194; XIE QW, 1992, SCIENCE, V256, P225, DOI 10.1126/science.1373522	44	255	303	2	31	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 17	1999	274	51					36729	36733		10.1074/jbc.274.51.36729	http://dx.doi.org/10.1074/jbc.274.51.36729			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	266AV	10593979	hybrid			2022-12-25	WOS:000084279200098
J	Bielicki, J; Crawley, AC; Davey, RCA; Varnai, JC; Hopwood, JJ				Bielicki, J; Crawley, AC; Davey, RCA; Varnai, JC; Hopwood, JJ			Advantages of using same species enzyme for replacement therapy in a feline model of mucopolysaccharidosis type VI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAROTEAUX-LAMY SYNDROME; N-ACETYLGALACTOSAMINE 4-SULFATASE; LYSOSOMAL-ENZYMES; GAUCHER-DISEASE; CANINE MODEL; LONG-TERM; EXPRESSION; PURIFICATION; FIBROBLASTS; PROTEINS	In a feline model of mucopolysaccharidosis type VI (IMPS VI), recombinant feline N-acetylgalactosamine-4-sulfatase (rf4S) administered at a dose of 1 mg/kg of body weight, altered the clinical course of the disease in two affected cats treated from birth. After 170 days of therapy, both cats were physically indistinguishable from normal cats with the exception of mild corneal clouding. Feline N-acetylgalactosamine-4-sulfatase was effective in reducing urinary glycosaminoglycan levels and lysosomal storage in all cell types examined except for corneal keratocytes and cartilage chondrocytes. In addition, skeletal pathology was nearly normalized as assessed by radiographic evidence and bone morphometric analysis. Comparison of results with a previous study in which recombinant human 4S (rh4S) was used at an equivalent dose and one 5 times higher indicated that rf4S had a more pronounced effect on reducing pathology than the same dose of rh4S, and in some instances such as bone pathology and lysosomal storage in aorta smooth muscle cells, it was as good as, or better than, the higher dose of rh4S. We conclude that in the feline MPS VI model the use of native or same species enzyme for enzyme replacement therapy has significant benefits.	Womens & Childrens Hosp, Lysosomal Dis Res Unit, Dept Chem Pathol, Adelaide, SA 5006, Australia; Univ New S Wales, Dept Biotechnol, Sydney, NSW 2052, Australia	Womens & Childrens Hospital Australia; University of New South Wales Sydney	Hopwood, JJ (corresponding author), Womens & Childrens Hosp, Lysosomal Dis Res Unit, Dept Chem Pathol, 72 King William Rd, Adelaide, SA 5006, Australia.	jhopwood@medicine.adelaide.edu.au						ANSON DS, 1992, BIOCHEM J, V284, P789, DOI 10.1042/bj2840789; BARTON NW, 1990, P NATL ACAD SCI USA, V87, P1913, DOI 10.1073/pnas.87.5.1913; Bielicki J, 1998, BIOCHEM J, V329, P145, DOI 10.1042/bj3290145; BIELICKI J, 1993, BIOCHEM J, V289, P241, DOI 10.1042/bj2890241; BIELICKI J, 1995, BIOCHEM J, V311, P333, DOI 10.1042/bj3110333; BLUMENKR.N, 1973, ANAL BIOCHEM, V54, P484, DOI 10.1016/0003-2697(73)90377-1; BROOKS DA, 1994, BIOCHEM MED METAB B, V53, P58, DOI 10.1006/bmmb.1994.1058; Brooks DA, 1997, BBA-MOL BASIS DIS, V1361, P203, DOI 10.1016/S0925-4439(97)00036-7; Byers S, 1997, BONE, V21, P425, DOI 10.1016/S8756-3282(97)00175-0; CHANG PL, 1988, EXP CELL RES, V176, P258, DOI 10.1016/0014-4827(88)90329-1; Crawley AC, 1997, J CLIN INVEST, V99, P651, DOI 10.1172/JCI119208; Crawley AC, 1996, J CLIN INVEST, V97, P1864, DOI 10.1172/JCI118617; DORNER AJ, 1989, J BIOL CHEM, V264, P20602; FREEMAN C, 1992, ADV EXP MED BIOL, V313, P121; Genetic Computer Group, 1994, PROGR MAN WISC PACK; GIBSON GJ, 1987, BIOCHEM J, V248, P755, DOI 10.1042/bj2480755; GOLD EW, 1979, ANAL BIOCHEM, V99, P183, DOI 10.1016/0003-2697(79)90061-7; Hopwood J. J., 1989, HEPARIN CHEM BIOL PR, P191; HOPWOOD JJ, 1982, ANAL BIOCHEM, V119, P120, DOI 10.1016/0003-2697(82)90674-1; HOPWOOD JJ, 1993, J INHERIT METAB DIS, V16, P1024, DOI 10.1007/BF00711520; JACKSON CE, 1992, GENOMICS, V14, P403, DOI 10.1016/S0888-7543(05)80233-2; JEZYK PF, 1977, SCIENCE, V198, P834, DOI 10.1126/science.144321; JOSHI L, 1995, ENDOCRINOLOGY, V136, P3839, DOI 10.1210/en.136.9.3839; Kakkis ED, 1996, BIOCHEM MOL MED, V58, P156, DOI 10.1006/bmme.1996.0044; KORNFELD S, 1987, FASEB J, V1, P462, DOI 10.1096/fasebj.1.6.3315809; KRIVIT W, 1984, NEW ENGL J MED, V311, P1606, DOI 10.1056/NEJM198412203112504; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Litjens T, 1997, BIOCHEM J, V327, P89, DOI 10.1042/bj3270089; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MORRELL AG, 1971, J BIOL CHEM, V246, P1461; Neufeld EF, 1995, METABOLIC MOL BASES, P2465; PARFITT AM, 1987, J BONE MINER RES, V2, P595, DOI 10.1002/jbmr.5650020617; Ponce E, 1997, BLOOD, V90, P43; Recker RR., 1983, BONE HISTOMORPHOMETR; SHULL RM, 1994, P NATL ACAD SCI USA, V91, P12937, DOI 10.1073/pnas.91.26.12937; TURNBULL JE, 1997, LAB GUIDE GLYCOCONJU, P261; VOGLER C, 1993, PEDIATR RES, V34, P837, DOI 10.1203/00006450-199312000-00028; YANAGISHITA M, 1984, J BIOL CHEM, V259, P270; Yogalingam G, 1996, J BIOL CHEM, V271, P27259, DOI 10.1074/jbc.271.44.27259	39	28	36	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 17	1999	274	51					36335	36343		10.1074/jbc.274.51.36335	http://dx.doi.org/10.1074/jbc.274.51.36335			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	266AV	10593925	hybrid			2022-12-25	WOS:000084279200044
J	Fuglsang, AT; Visconti, S; Drumm, K; Jahn, T; Stensballe, A; Mattei, B; Jensen, ON; Aducci, P; Palmgren, MG				Fuglsang, AT; Visconti, S; Drumm, K; Jahn, T; Stensballe, A; Mattei, B; Jensen, ON; Aducci, P; Palmgren, MG			Binding of 14-3-3 protein to the plasma membrane H+-ATPase AHA2 involves the three C-terminal residues Tyr(946)-Thr-Val and requires phosphorylation of Thr(947)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYACRYLAMIDE GELS; NITRATE REDUCTASE; KINASE-ACTIVITY; SPINACH LEAVES; FUSICOCCIN; 14-3-3-PROTEINS; DOMAIN; IDENTIFICATION; ASSOCIATION; TRANSPORT	14-3-3 proteins play a regulatory role in a diverse array of cellular functions such as apoptosis, regulation of the cell cycle, and regulation of gene transcription. The phytotoxin fusicoccin specifically induces association of virtually any 14-3-3 protein to plant plasma membrane Hf-ATPase. The 14-3-3 binding site in the Arabidopsis plasma membrane H+-ATPase AHA2 was localized to the three C-terminal residues of the enzyme (Tyr(946)-Thr-Val). finding of 14-3-3 protein to this target was induced by phosphorylation of Thr(947) (K-D = 88 nM) and was in practice irreversible in the presence of fusicoccin (K-D = 7 nM). Mass spectrometry analysis demonstrated that AHA2 expressed in yeast was phosphorylated at Thr(947). We conclude that the extreme end of AHA2 contains an unusual high-affinity binding site for 14-3-3 protein.	Royal Vet & Agr Univ, Dept Plant Biol, DK-1871 Frederiksberg, Copenhagen, Denmark; Univ Roma Tor Vergata, Dept Biol, I-00133 Rome, Italy; Odense Univ, Univ So Denmark, Dept Biol Mol, Prot Res Grp, DK-5230 Odense, Denmark; Univ Rome La Sapienza, Dept Plant Biol, I-00185 Rome, Italy	University of Copenhagen; University of Rome Tor Vergata; University of Southern Denmark; Sapienza University Rome	Palmgren, MG (corresponding author), Royal Vet & Agr Univ, Dept Plant Biol, Thorvaldsensvej 40, DK-1871 Frederiksberg, Copenhagen, Denmark.		Mattei, Benedetta/F-1504-2015; Stensballe, Allan/K-6756-2019; fuglsang, anja thoe t/E-1683-2012; Palmgren, Michael/A-9808-2013; Fuglsang, Anja Thoe/A-6733-2015; Jensen, Ole N/J-1763-2012; Mattei, Benedetta/C-3013-2019	Mattei, Benedetta/0000-0003-2927-6329; Stensballe, Allan/0000-0002-9888-1955; fuglsang, anja thoe t/0000-0003-1153-8394; Palmgren, Michael/0000-0002-9982-6114; Fuglsang, Anja Thoe/0000-0003-1153-8394; Jensen, Ole N/0000-0003-1862-8528; Mattei, Benedetta/0000-0003-2927-6329				Aitken A, 1996, TRENDS CELL BIOL, V6, P341, DOI 10.1016/0962-8924(96)10029-5; ANDERSSON L, 1986, ANAL BIOCHEM, V154, P250, DOI 10.1016/0003-2697(86)90523-3; Andrews RK, 1998, BIOCHEMISTRY-US, V37, P638, DOI 10.1021/bi970893g; Axelsen KB, 1999, BIOCHEMISTRY-US, V38, P7227, DOI 10.1021/bi982482l; Bachmann M, 1996, FEBS LETT, V387, P127, DOI 10.1016/0014-5793(96)00478-4; BALLIO A, 1980, PLANT SCI LETT, V18, P39, DOI 10.1016/0304-4211(80)90019-X; BALLIO A, 1968, Annali dell'Istituto Superiore di Sanita, V4, P317; Baunsgaard L, 1998, PLANT J, V13, P661, DOI 10.1046/j.1365-313X.1998.00083.x; CHANG A, 1991, J CELL BIOL, V115, P289, DOI 10.1083/jcb.115.2.289; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; Ferl RJ, 1996, ANNU REV PLANT PHYS, V47, P49, DOI 10.1146/annurev.arplant.47.1.49; FU H, 1993, P NATL ACAD SCI USA, V90, P2320, DOI 10.1073/pnas.90.6.2320; Fullone MR, 1998, J BIOL CHEM, V273, P7698, DOI 10.1074/jbc.273.13.7698; Gobom J, 1999, J MASS SPECTROM, V34, P105, DOI 10.1002/(SICI)1096-9888(199902)34:2<105::AID-JMS768>3.0.CO;2-4; Gu MY, 1998, J BIOL CHEM, V273, P33465, DOI 10.1074/jbc.273.50.33465; ICHIMURA T, 1988, P NATL ACAD SCI USA, V85, P7084, DOI 10.1073/pnas.85.19.7084; Jahn T, 1997, PLANT CELL, V9, P1805, DOI 10.1105/tpc.9.10.1805; Liu YC, 1997, J BIOL CHEM, V272, P9979, DOI 10.1074/jbc.272.15.9979; LU GH, 1994, PLANT MOL BIOL, V25, P659, DOI 10.1007/BF00029604; MattoYelin M, 1997, MOL BIOL CELL, V8, P1889, DOI 10.1091/mbc.8.10.1889; MEYER C, 1993, Z NATURFORSCH C, V48, P595; Miyawaki A, 1997, NATURE, V388, P882, DOI 10.1038/42264; Moore BE, 1967, PHYSL BIOCH ASPECTS, P343; Moorhead G, 1996, CURR BIOL, V6, P1104, DOI 10.1016/S0960-9822(02)70677-5; Morsomme P, 1998, J BIOL CHEM, V273, P34837, DOI 10.1074/jbc.273.52.34837; Muslin AJ, 1996, CELL, V84, P889, DOI 10.1016/S0092-8674(00)81067-3; Oecking C, 1997, PLANT J, V12, P441, DOI 10.1046/j.1365-313X.1997.12020441.x; Olsson A, 1998, PLANT PHYSIOL, V118, P551, DOI 10.1104/pp.118.2.551; Palmgren M.G., 1998, EXP BIOL ONLINE, V3, P1; Palmgren MG, 1998, ADV BOT RES, V28, P1; PALMGREN MG, 1991, J BIOL CHEM, V266, P20470; Piotrowski M, 1998, J BIOL CHEM, V273, P30018, DOI 10.1074/jbc.273.45.30018; REGENBERG B, 1995, PLANT CELL, V7, P1655, DOI 10.1105/tpc.7.10.1655; Sehnke PC, 1996, CURR BIOL, V6, P1403, DOI 10.1016/S0960-9822(96)00742-7; Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h; Thorson JA, 1998, MOL CELL BIOL, V18, P5229, DOI 10.1128/MCB.18.9.5229; Tzivion G, 1998, NATURE, V394, P88, DOI 10.1038/27938; Wakui H, 1997, J BIOL CHEM, V272, P8153, DOI 10.1074/jbc.272.13.8153; Wang HN, 1998, J BIOL CHEM, V273, P16297, DOI 10.1074/jbc.273.26.16297; Wang WF, 1996, J MOL EVOL, V43, P384; Waterman MJF, 1998, NAT GENET, V19, P175, DOI 10.1038/542; Wilm M, 1996, NATURE, V379, P466, DOI 10.1038/379466a0; Yaffe MB, 1997, CELL, V91, P961, DOI 10.1016/S0092-8674(00)80487-0; Zhang LX, 1997, J BIOL CHEM, V272, P13717, DOI 10.1074/jbc.272.21.13717	44	265	282	1	44	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 17	1999	274	51					36774	36780		10.1074/jbc.274.51.36774	http://dx.doi.org/10.1074/jbc.274.51.36774			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	266AV	10593986	Green Published, hybrid			2022-12-25	WOS:000084279200105
J	Roberts, BJ; Whitelaw, ML				Roberts, BJ; Whitelaw, ML			Degradation of the basic helix-loop-helix/Per-ARNT-Sim homology domain dioxin receptor via the ubiquitin/proteasome pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ARYL-HYDROCARBON RECEPTOR; UBIQUITIN-PROTEASOME PATHWAY; NUCLEAR TRANSLOCATOR PROTEIN; INDUCIBLE FACTOR 1-ALPHA; AH RECEPTOR; IN-VIVO; C-JUN; CELLS; 2,3,7,8-TETRACHLORODIBENZO-P-DIOXIN; PHOSPHORYLATION	The basic helix-loop-helix/Per-ARNT-Sim homology domain dioxin receptor (DR) translocates to the nucleus upon binding of aromatic hydrocarbon ligands typified by dioxin, whereupon it partners the Ah receptor nuclear translocator and initiates transcription. Concurrently, ligand binding down-regulates receptor levels via an unknown mechanism. In this study we show that receptor levels are dependent upon cellular compartmentalization, with entry into the nucleus leading to the rapid destruction of the DR. Ligand-induced DR translocation was bypassed by adding a heterologous nuclear localization signal to the DR, creating a constitutively nuclear form of the dioxin receptor (DRNLS). The DRNLS protein was shown to be unstable with a half-life of less than or equal to 1 h whether partnering ARNT or HSP90. Thus, the structural changes induced by ligand binding have no inherent effect on DR stability but are critical in transporting the receptor prior to degradation. The proteolytic pathway that degrades the nuclear receptor is suggested to involve ubiquitination as it was inhibited by the proteasome inhibitor MG132 or co-expression of DRNLS with the ubiquitin mutant UbK48R. Incubation of cells expressing DRNLS with the phosphatase inhibitor calyculin resulted in the rapid phosphorylation and ubiquitination of DRNLS, suggesting that a nuclear kinase is required to trigger receptor proteolysis. Overall, this study demonstrates a novel mechanism of proteolysis whereby the simple relocation of a transcription factor from cytoplasm to nucleus initiates its rapid destruction.	Univ Adelaide, Dept Biochem, Adelaide, SA 5005, Australia	University of Adelaide	Roberts, BJ (corresponding author), Univ Adelaide, Dept Biochem, Adelaide, SA 5005, Australia.	broberts@biochem.adelaide.edu.au						Aberle H, 1997, EMBO J, V16, P3797, DOI 10.1093/emboj/16.13.3797; Abu Hatoum O, 1998, MOL CELL BIOL, V18, P5670, DOI 10.1128/MCB.18.10.5670; ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; Breitschopf K, 1998, EMBO J, V17, P5964, DOI 10.1093/emboj/17.20.5964; Carver LA, 1997, J BIOL CHEM, V272, P11452; Carver LA, 1998, J BIOL CHEM, V273, P33580, DOI 10.1074/jbc.273.50.33580; CHAU V, 1989, SCIENCE, V243, P1576, DOI 10.1126/science.2538923; Chen ZJ, 1996, CELL, V84, P853, DOI 10.1016/S0092-8674(00)81064-8; Cole CN, 1998, CURR BIOL, V8, pR368, DOI 10.1016/S0960-9822(98)70239-8; Crews ST, 1998, GENE DEV, V12, P607, DOI 10.1101/gad.12.5.607; Eguchi H, 1997, J BIOL CHEM, V272, P17640, DOI 10.1074/jbc.272.28.17640; FINLEY D, 1994, MOL CELL BIOL, V14, P5501, DOI 10.1128/MCB.14.8.5501; Gorlich D, 1998, EMBO J, V17, P2721, DOI 10.1093/emboj/17.10.2721; HODGINS RRW, 1992, J BIOL CHEM, V267, P8807; HOFFMAN EC, 1991, SCIENCE, V252, P954, DOI 10.1126/science.1852076; Huang LE, 1998, P NATL ACAD SCI USA, V95, P7987, DOI 10.1073/pnas.95.14.7987; Ikuta T, 1998, J BIOL CHEM, V273, P2895, DOI 10.1074/jbc.273.5.2895; Kallio PJ, 1998, EMBO J, V17, P6573, DOI 10.1093/emboj/17.22.6573; Kazlauskas A, 1999, J BIOL CHEM, V274, P13519, DOI 10.1074/jbc.274.19.13519; Kim TK, 1996, SCIENCE, V273, P1717, DOI 10.1126/science.273.5282.1717; Lahvis GP, 1998, BIOCHEM PHARMACOL, V56, P781, DOI 10.1016/S0006-2952(98)00134-8; LEES M, 1999, IN PRESS MOL CELL BI; Ma Q, 1997, J BIOL CHEM, V272, P8878; Mattaj IW, 1998, ANNU REV BIOCHEM, V67, P265, DOI 10.1146/annurev.biochem.67.1.265; Meyer BK, 1998, MOL CELL BIOL, V18, P978, DOI 10.1128/MCB.18.2.978; Mimura J, 1999, GENE DEV, V13, P20, DOI 10.1101/gad.13.1.20; Musti AM, 1997, SCIENCE, V275, P400, DOI 10.1126/science.275.5298.400; Nigg EA, 1997, NATURE, V386, P779, DOI 10.1038/386779a0; OKEY AB, 1994, TRENDS PHARMACOL SCI, V15, P226, DOI 10.1016/0165-6147(94)90316-6; POLLENZ RS, 1994, MOL PHARMACOL, V45, P428; Pollenz RS, 1996, MOL PHARMACOL, V49, P391; PROKIPCAK RD, 1991, CAN J PHYSIOL PHARM, V69, P1204, DOI 10.1139/y91-176; Ptashne M, 1998, CURR BIOL, V8, pR812, DOI 10.1016/S0960-9822(07)00508-8; Salceda S, 1997, J BIOL CHEM, V272, P22642, DOI 10.1074/jbc.272.36.22642; Schmidt JV, 1996, ANNU REV CELL DEV BI, V12, P55, DOI 10.1146/annurev.cellbio.12.1.55; Song A, 1998, MOL CELL BIOL, V18, P4994, DOI 10.1128/MCB.18.9.4994; SWANSON HI, 1993, ARCH BIOCHEM BIOPHYS, V302, P167, DOI 10.1006/abbi.1993.1195; TREIER M, 1994, CELL, V78, P787, DOI 10.1016/S0092-8674(94)90502-9; TSURUMI C, 1995, MOL CELL BIOL, V15, P5682; WANG GL, 1995, P NATL ACAD SCI USA, V92, P5510, DOI 10.1073/pnas.92.12.5510; Whitlock JP, 1996, FASEB J, V10, P809, DOI 10.1096/fasebj.10.8.8666157; WILKINSON KD, 1995, BIOCHEMISTRY-US, V34, P14535, DOI 10.1021/bi00044a032	42	100	102	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 17	1999	274	51					36351	36356		10.1074/jbc.274.51.36351	http://dx.doi.org/10.1074/jbc.274.51.36351			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	266AV	10593927	hybrid			2022-12-25	WOS:000084279200046
J	Rogerson, FM; Dimopoulos, N; Sluka, P; Chu, S; Curtis, AJ; Fuller, PJ				Rogerson, FM; Dimopoulos, N; Sluka, P; Chu, S; Curtis, AJ; Fuller, PJ			Structural determinants of aldosterone binding selectivity in the mineralocorticoid receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PIG GLUCOCORTICOID RECEPTOR; 11-BETA-HYDROXYSTEROID DEHYDROGENASE; PROGESTERONE RECEPTORS; CORTISOL RESISTANCE; CRYSTAL-STRUCTURE; TRANSACTIVATION; SPECIFICITY; DOMAIN; SALT; HYPERTENSION	The structural determinants of aldosterone binding specificity in the mineralocorticoid receptor (MR) have not been determined. The MR has greatest sequence identity with the better characterized glucocorticoid receptor (GR), which is reflected in their overlapping ligand binding specificities. There must be subtle sequence differences that can account for the MR-specific binding of aldosterone and the shared binding of cortisol. To characterize ligand binding specificity, chimeras were made between the human MR and GR ligand-binding domains (LBDs). Three points were chosen as break points to generate a total of 16 different constructs, These chimeric LBDs were placed in a human Cat expression vector containing the GR RNA-binding and N-terminal domains and assayed by co-transfection into CV-1 cells with the mouse mammary tumor virus-luciferase reporter plasmid, Binding of [(3)H]aldosterone and [(3)H]dexamethasone was also measured. All of the constructs that are potently activated by aIdosterone contain amino acids 804-874 of the MR. The results of the Ligand binding experiments using [(3)H]aldosterone were consistent with the transactivation assay. Cortisol activation of the chimeras was surprisingly complex. Constructs that are activated by cortisol contain either amino acids 804-874 and 932-984 of the MR or amino acids 598-668 and 726-777 of the GR. However, all of the chimeras retained the ability to bind the synthetic glucocorticoid [(3)H]dexamethasone, and cortisol was able to displace [(3)H]dexamethasone binding, suggesting that the differential effects of cortisol on transcriptional activation are caused by an effect that occurs downstream of ligand binding. These results identify a subregion of the MR LED that confers specificity of aldosterone binding, which contrasts with cortisol binding where differential effects between chimeras appear to be mediated by interactions distal to ligand binding.	Prince Henrys Inst Med Res, Clayton, Vic 3168, Australia	Prince Henry's Institute of Medical Research	Rogerson, FM (corresponding author), Prince Henrys Inst Med Res, POB 5152, Clayton, Vic 3168, Australia.	fraser.rogerson@med.monash.edu.au	Sluka, Pavel/ABH-5049-2020; Chu, Simon/AAJ-7802-2020; Sluka, Pavel/I-1443-2013	Sluka, Pavel/0000-0002-6043-0809; Chu, Simon/0000-0003-4658-215X; Sluka, Pavel/0000-0002-6043-0809; Curtis, Andrea/0000-0003-2407-770X; Fuller, Peter/0000-0002-0948-2072				ARRIZA JL, 1987, SCIENCE, V237, P268, DOI 10.1126/science.3037703; ARRIZA JL, 1988, NEURON, V1, P887, DOI 10.1016/0896-6273(88)90136-5; ARRIZA JL, 1991, COLLOQ INSE, V215, P13; BENHAMOU B, 1992, SCIENCE, V255, P206, DOI 10.1126/science.1372753; BOURGUET W, 1995, NATURE, V375, P377, DOI 10.1038/375377a0; Brzozowski AM, 1997, NATURE, V389, P753, DOI 10.1038/39645; CATO ACB, 1991, COLLOQ INSE, V215, P23; Chang SS, 1996, NAT GENET, V12, P248, DOI 10.1038/ng0396-248; EISEN LP, 1986, ENDOCRINOLOGY, V119, P1419, DOI 10.1210/endo-119-4-1419; Fagart J, 1998, EMBO J, V17, P3317, DOI 10.1093/emboj/17.12.3317; Fuller P.J, 1997, CURR OPIN ENDOCRINOL, V4, P218; FUNDER JW, 1988, SCIENCE, V242, P583, DOI 10.1126/science.2845584; Geller DS, 1998, NAT GENET, V19, P279, DOI 10.1038/966; GomezSanchez EP, 1996, STEROIDS, V61, P184, DOI 10.1016/0039-128X(96)00010-4; GOMEZSANCHEZ EP, 1990, AM J PHYSIOL, V258, pE649, DOI 10.1152/ajpendo.1990.258.4.E649; Govindan MV, 1998, J BIOL CHEM, V273, P24439, DOI 10.1074/jbc.273.38.24439; JAMIESON A, 1993, J MOL ENDOCRINOL, V10, P3, DOI 10.1677/jme.0.0100003; KEIGHTLEY MC, 1995, STEROIDS, V60, P87, DOI 10.1016/0039-128X(94)00014-4; Keightley MC, 1998, ENDOCRINOLOGY, V139, P2479, DOI 10.1210/en.139.5.2479; KEIGHTLEY MC, 1994, MOL ENDOCRINOL, V8, P431, DOI 10.1210/me.8.4.431; Lim-Tio SS, 1998, ENDOCRINOLOGY, V139, P1653, DOI 10.1210/en.139.4.1653; LimTio SS, 1997, ENDOCRINOLOGY, V138, P2537, DOI 10.1210/en.138.6.2537; LOMBES M, 1994, ENDOCRINOLOGY, V135, P834, DOI 10.1210/en.135.3.834; Lupo B, 1998, BIOCHEMISTRY-US, V37, P12153, DOI 10.1021/bi980593e; MCPHERSON GA, 1983, J PHARMACOL METHOD, V10, P231, DOI 10.1016/0160-5402(83)90017-7; NEMOTO T, 1993, J BIOCHEM-TOKYO, V113, P769; RENAUD JP, 1995, NATURE, V378, P681, DOI 10.1038/378681a0; RUPPRECHT R, 1993, MOL ENDOCRINOL, V7, P597, DOI 10.1210/me.7.4.597; Shiau AK, 1998, CELL, V95, P927, DOI 10.1016/S0092-8674(00)81717-1; Vivat V, 1997, J MOL ENDOCRINOL, V18, P147, DOI 10.1677/jme.0.0180147; Wagner BL, 1999, ENDOCRINOLOGY, V140, P1449, DOI 10.1210/en.140.3.1449; White PC, 1997, ENDOCR REV, V18, P135, DOI 10.1210/er.18.1.135; Williams SP, 1998, NATURE, V393, P392, DOI 10.1038/30775; Wurtz JM, 1996, NAT STRUCT BIOL, V3, P87, DOI 10.1038/nsb0196-87; Young MJ, 1996, STEROIDS, V61, P233, DOI 10.1016/0039-128X(96)00020-7	35	53	54	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 17	1999	274	51					36305	36311		10.1074/jbc.274.51.36305	http://dx.doi.org/10.1074/jbc.274.51.36305			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	266AV	10593921	hybrid			2022-12-25	WOS:000084279200040
J	Thomas, JW; Cooley, MA; Broome, JM; Salgia, R; Griffin, JD; Lombardo, CR; Schaller, MD				Thomas, JW; Cooley, MA; Broome, JM; Salgia, R; Griffin, JD; Lombardo, CR; Schaller, MD			The role of focal adhesion kinase binding in the regulation of tyrosine phosphorylation of paxillin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SRC HOMOLOGY-2 DOMAIN; CELL-ADHESION; HIGH-AFFINITY; SH3 DOMAIN; LIM DOMAIN; V-SRC; DIRECT ASSOCIATION; DEPENDENT BINDING; FAMILY KINASES; PROTEIN BINDS	Focal adhesion kinase (FAK) and paxillin are focal adhesion-associated phosphotyrosine-containing proteins that physically interact. A previous study has demonstrated that paxillin contains two binding sites for FAB Ne have further characterized these two binding sites and have demonstrated that the binding affinity of the carboxyl-terminal domain of FAR is the same for each of the two binding sites. The presence of both binding sites increases the affinity for FAR by 5-10-fold. A conserved paxillin sequence called the LD motif has been implicated in FAK binding. We show that mutations in the LD motifs in both FAK-binding sites are required to dramatically impair FAR binding in vitro. A paxillin mutant containing point mutations in both FAK-binding sites was characterized. The mutant exhibited reduced levels of phosphotyrosine relative to wild type paxillin in subconfluent cells growing in culture, following cell adhesion to fibronectin and in src-transformed fibroblasts. These results suggest that paxillin must bind FAK for maximal phosphorylation in response to cell adhesion and that FAK may function to direct tyrosine phosphorylation of paxillin in the process of transformation by the src oncogene.	Univ N Carolina, Dept Cell Biol & Anat, Chapel Hill, NC 27599 USA; Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA; Univ N Carolina, Macromol Interact Facil, Chapel Hill, NC 27599 USA; Dana Farber Canc Inst, Div Hematol Malignancies, Boston, MA 02115 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; Harvard University; Dana-Farber Cancer Institute	Schaller, MD (corresponding author), Univ N Carolina, Dept Cell Biol & Anat, Taylor Hall CB 7090, Chapel Hill, NC 27599 USA.			Cooley, Marion A./0000-0002-4286-745X	NCI NIH HHS [1F32CA74490] Funding Source: Medline; NIGMS NIH HHS [GM53668] Funding Source: Medline; NATIONAL CANCER INSTITUTE [F32CA074490] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALBELDA SM, 1990, FASEB J, V4, P2868, DOI 10.1096/fasebj.4.11.2199285; Angers-Loustau A, 1999, J CELL BIOL, V144, P1019, DOI 10.1083/jcb.144.5.1019; BELLIS SL, 1995, J BIOL CHEM, V270, P17437, DOI 10.1074/jbc.270.29.17437; BERGMAN M, 1995, MOL CELL BIOL, V15, P711; BIRGE RB, 1993, MOL CELL BIOL, V13, P4648, DOI 10.1128/MCB.13.8.4648; Brown MC, 1996, J CELL BIOL, V135, P1109, DOI 10.1083/jcb.135.4.1109; CALALB MB, 1995, MOL CELL BIOL, V15, P954; Cary LA, 1996, J CELL SCI, V109, P1787; CHAN PY, 1994, J BIOL CHEM, V269, P20567; CHAREST A, 1995, BIOCHEM J, V308, P425, DOI 10.1042/bj3080425; CHEN HC, 1995, J BIOL CHEM, V270, P16995, DOI 10.1074/jbc.270.28.16995; Cote JF, 1999, J BIOL CHEM, V274, P20550, DOI 10.1074/jbc.274.29.20550; CousinsWasti RC, 1996, BIOCHEMISTRY-US, V35, P16746, DOI 10.1021/bi9620868; EIDE BL, 1995, MOL CELL BIOL, V15, P2819; Frisch SM, 1996, J CELL BIOL, V134, P793, DOI 10.1083/jcb.134.3.793; Fujita H, 1998, J BIOL CHEM, V273, P26516, DOI 10.1074/jbc.273.41.26516; Gilmore AP, 1996, MOL BIOL CELL, V7, P1209, DOI 10.1091/mbc.7.8.1209; GLENNEY JR, 1989, J CELL BIOL, V108, P2401, DOI 10.1083/jcb.108.6.2401; HILDEBRAND JD, 1993, J CELL BIOL, V123, P993, DOI 10.1083/jcb.123.4.993; HILDEBRAND JD, 1995, MOL BIOL CELL, V6, P637, DOI 10.1091/mbc.6.6.637; Hungerford JE, 1996, J CELL BIOL, V135, P1383, DOI 10.1083/jcb.135.5.1383; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; KAELIN WG, 1992, CELL, V70, P351, DOI 10.1016/0092-8674(92)90108-O; KANNER SB, 1990, P NATL ACAD SCI USA, V87, P3328, DOI 10.1073/pnas.87.9.3328; Kim E, 1998, J BIOL CHEM, V273, P1591, DOI 10.1074/jbc.273.3.1591; LADBURY JE, 1995, P NATL ACAD SCI USA, V92, P3199, DOI 10.1073/pnas.92.8.3199; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE CH, 1995, EMBO J, V14, P5006, DOI 10.1002/j.1460-2075.1995.tb00183.x; LEMMON MA, 1994, BIOCHEMISTRY-US, V33, P5070, DOI 10.1021/bi00183a010; Lewis JM, 1998, J BIOL CHEM, V273, P14225, DOI 10.1074/jbc.273.23.14225; Lipsky BP, 1998, J BIOL CHEM, V273, P11709, DOI 10.1074/jbc.273.19.11709; Matsuya M, 1998, J BIOL CHEM, V273, P1003, DOI 10.1074/jbc.273.2.1003; Mosser EA, 1998, BIOCHEMISTRY-US, V37, P13686, DOI 10.1021/bi981310l; Nishiya N, 1999, J BIOL CHEM, V274, P9847, DOI 10.1074/jbc.274.14.9847; Owen JD, 1999, MOL CELL BIOL, V19, P4806; PAYNE G, 1993, P NATL ACAD SCI USA, V90, P4902, DOI 10.1073/pnas.90.11.4902; POLTE TR, 1995, P NATL ACAD SCI USA, V92, P10678, DOI 10.1073/pnas.92.23.10678; Reiske HR, 1999, J BIOL CHEM, V274, P12361, DOI 10.1074/jbc.274.18.12361; REYNOLDS AB, 1989, MOL CELL BIOL, V9, P629, DOI 10.1128/MCB.9.2.629; Richardson A, 1996, NATURE, V380, P538, DOI 10.1038/380538a0; SABE H, 1994, P NATL ACAD SCI USA, V91, P3984, DOI 10.1073/pnas.91.9.3984; SAKAI R, 1994, EMBO J, V13, P3748, DOI 10.1002/j.1460-2075.1994.tb06684.x; SALGIA R, 1995, ONCOGENE, V11, P1149; SALGIA R, 1995, J BIOL CHEM, V270, P5039, DOI 10.1074/jbc.270.10.5039; SASTRY L, 1995, ONCOGENE, V11, P1107; SCHALLER MD, 1993, MOL CELL BIOL, V13, P785, DOI 10.1128/MCB.13.2.785; SCHALLER MD, 1995, MOL CELL BIOL, V15, P2635; SCHALLER MD, 1994, MOL CELL BIOL, V14, P1680, DOI 10.1128/MCB.14.3.1680; SCHALLER MD, 1992, P NATL ACAD SCI USA, V89, P5192, DOI 10.1073/pnas.89.11.5192; SCHMEICHEL KL, 1994, CELL, V79, P211, DOI 10.1016/0092-8674(94)90191-0; Schwartz MA, 1995, ANNU REV CELL DEV BI, V11, P549, DOI 10.1146/annurev.cellbio.11.1.549; Shen Y, 1999, MOL BIOL CELL, V10, P2507, DOI 10.1091/mbc.10.8.2507; Shen Y, 1998, J BIOL CHEM, V273, P6474, DOI 10.1074/jbc.273.11.6474; SHIBANUMA M, 1994, J BIOL CHEM, V269, P26767; Sudol M, 1998, ONCOGENE, V17, P1469, DOI 10.1038/sj.onc.1202182; TACHIBANA K, 1995, J EXP MED, V182, P1089, DOI 10.1084/jem.182.4.1089; Thomas JW, 1998, J BIOL CHEM, V273, P577, DOI 10.1074/jbc.273.1.577; Thomas SM, 1999, J CELL SCI, V112, P181; Thomas SM, 1997, ANNU REV CELL DEV BI, V13, P513, DOI 10.1146/annurev.cellbio.13.1.513; THOMAS SM, 1995, NATURE, V376, P267, DOI 10.1038/376267a0; Tong X, 1997, J BIOL CHEM, V272, P33373, DOI 10.1074/jbc.272.52.33373; Turner CE, 1999, J CELL BIOL, V145, P851, DOI 10.1083/jcb.145.4.851; TURNER CE, 1994, J CELL SCI, V107, P1583; Vande Pol SB, 1998, ONCOGENE, V16, P43, DOI 10.1038/sj.onc.1201504; WENG ZG, 1993, J BIOL CHEM, V268, P14956; Wu RY, 1996, J BIOL CHEM, V271, P15934, DOI 10.1074/jbc.271.27.15934; XING Z, 1994, MOL BIOL CELL, V5, P413, DOI 10.1091/mbc.5.4.413; Zhang X, 1999, P NATL ACAD SCI USA, V96, P9021, DOI 10.1073/pnas.96.16.9021; Zhao JH, 1998, J CELL BIOL, V143, P1997, DOI 10.1083/jcb.143.7.1997	69	119	120	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 17	1999	274	51					36684	36692		10.1074/jbc.274.51.36684	http://dx.doi.org/10.1074/jbc.274.51.36684			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	266AV	10593973	Green Published, hybrid			2022-12-25	WOS:000084279200092
J	Berg, KL; Siminovitch, KA; Stanley, ER				Berg, KL; Siminovitch, KA; Stanley, ER			SHP-1 regulation of p62(DOK) tyrosine phosphorylation in macrophages	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STIMULATING FACTOR-I; HEMATOPOIETIC-CELL PHOSPHATASE; GTPASE-ACTIVATING PROTEIN; M-CSF RECEPTOR; SIGNAL-TRANSDUCTION; INHIBITORY RECEPTORS; MOTH-EATEN; BCR-ABL; B-CELLS; C-CBL	SHP-1 plays key roles in the modulation of hematopoietic cell signaling. To ascertain the impact of SHP-1 on colony-stimulating factor-1 (CSF-1)-mediated survival and proliferative signaling, we compared the CSF-1 responses of primary bone marrow macrophages (BMM) from wild-type and SHP-1-deficient motheaten (me/me) mice. CSF-1-induced protein tyrosine phosphorylation levels were similar in wild-type and me/me BMM, except for the constitutive hyperphosphoryIation of a 62-kDa phosphoprotein (pp62) in me/me macrophages. pp62 was identified as the RASGAP-associated p62(DOK) and was shown to be the major CSF-1R-associated tyrosine-phosphorylated protein in CSF-1-treated BMM, p62DOK was found to be constitutively associated with SHP-1 in BMM and in 293T cells, co-expressing p62(dok) and either wild-type or catalytically inert SHP-1 (SHP-1 C453S). In both cell types, the interaction of SHP-1 with p62DOK occurred independently of p62(DOK) tyrosine phosphorylation, but only the tyrosine-phosphorylated p62DOK was bound by SHP-1 C4535 in a far Western analysis. These findings suggest a constitutive association of SHP-1 and p62DOK that is either conformation-dependent or indirect as well as a direct, inducible association of the SHP-1 catalytic domain with tyrosine-phosphorylated p62(DOK). P62(DOK) hyperphosphorylation is not associated with altered CSF-1-induced RAS signaling or proliferation. However, whereas wild-type macrophages undergo cell death following CSF-1 removal, me/me macrophages exhibit prolonged survival in the absence of growth factor. Thus, p62(DOK) is a major SHP-1 substrate whose tyrosine phosphorylation correlates with growth factor-independent survival in macrophages.	Yeshiva Univ Albert Einstein Coll Med, Dept Dev & Mol Biol, Bronx, NY 10461 USA; Univ Toronto, Dept Med & Immunol, Toronto, ON M5G 1X5, Canada; Univ Toronto, Dept Mol & Med Genet, Toronto, ON M5G 1X5, Canada; Mt Sinai Hosp, Samuel Lunenfeld Res Inst, Toronto, ON M5G 1X5, Canada	Yeshiva University; Albert Einstein College of Medicine; University of Toronto; University of Toronto; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute	Stanley, ER (corresponding author), Yeshiva Univ Albert Einstein Coll Med, Dept Dev & Mol Biol, 1300 Morris Pk Ave, Bronx, NY 10461 USA.		Siminovitch, Katherine/K-1475-2013; Stanley, Evan R/J-9154-2013	Stanley, Evan R/0000-0002-2910-2065	NCI NIH HHS [5T32 CA90173, CA26504, P30-CA13330] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA013330, R01CA026504, R37CA026504] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BEDI A, 1994, BLOOD, V83, P2038; Berg KL, 1998, ONCOGENE, V17, P2535, DOI 10.1038/sj.onc.1202203; BIGNON JS, 1994, CLIN IMMUNOL IMMUNOP, V73, P168, DOI 10.1006/clin.1994.1185; Binstadt BA, 1998, J BIOL CHEM, V273, P27518, DOI 10.1074/jbc.273.42.27518; Black DS, 1997, EMBO J, V16, P2730, DOI 10.1093/emboj/16.10.2730; Blery M, 1998, P NATL ACAD SCI USA, V95, P2446, DOI 10.1073/pnas.95.5.2446; Bourette RP, 1998, EMBO J, V17, P7273, DOI 10.1093/emboj/17.24.7273; Bourette RP, 1997, EMBO J, V16, P5880, DOI 10.1093/emboj/16.19.5880; BUSCHER D, 1995, MOL CELL BIOL, V15, P466; BUSCHER D, 1993, ONCOGENE, V8, P3323; Carpino N, 1997, CELL, V88, P197, DOI 10.1016/S0092-8674(00)81840-1; Chen HE, 1996, MOL CELL BIOL, V16, P3685, DOI 10.1128/mcb.16.7.3685; DAVID M, 1995, MOL CELL BIOL, V15, P7050; Dong Q, 1999, J IMMUNOL, V162, P3220; Dustin LB, 1999, J IMMUNOL, V162, P2717; ELLIS C, 1990, NATURE, V343, P377, DOI 10.1038/343377a0; Frearson JA, 1997, BIOESSAYS, V19, P417, DOI 10.1002/bies.950190509; GERLACH MS, 1995, J BIOL CHEM, V270, P24635, DOI 10.1074/jbc.270.42.24635; Hamilton JA, 1997, J LEUKOCYTE BIOL, V62, P145, DOI 10.1002/jlb.62.2.145; Hayami K, 1997, J BIOL CHEM, V272, P7320, DOI 10.1074/jbc.272.11.7320; HEIDARAN MA, 1992, ONCOGENE, V7, P147; HOSOMI Y, 1994, J BIOL CHEM, V269, P11498; Hua CT, 1998, J BIOL CHEM, V273, P28332, DOI 10.1074/jbc.273.43.28332; Jiao HY, 1997, EXP HEMATOL, V25, P592; Kanagasundaram V, 1996, BIOCHEM J, V320, P69, DOI 10.1042/bj3200069; Kharitonenkov A, 1997, NATURE, V386, P181, DOI 10.1038/386181a0; KINOSHITA T, 1995, EMBO J, V14, P266, DOI 10.1002/j.1460-2075.1995.tb07000.x; Kubagawa H, 1997, P NATL ACAD SCI USA, V94, P5261, DOI 10.1073/pnas.94.10.5261; LIOUBIN MN, 1994, MOL CELL BIOL, V14, P5682, DOI 10.1128/MCB.14.9.5682; Lioubin MN, 1996, GENE DEV, V10, P1084, DOI 10.1101/gad.10.9.1084; Lock P, 1996, CELL, V84, P23, DOI 10.1016/S0092-8674(00)80989-7; Maeda A, 1998, J EXP MED, V187, P1355, DOI 10.1084/jem.187.8.1355; MCGAHON A, 1994, BLOOD, V83, P1179, DOI 10.1182/blood.V83.5.1179.bloodjournal8351179; Mizuno K, 1996, J EXP MED, V184, P457, DOI 10.1084/jem.184.2.457; MORAN MF, 1991, MOL CELL BIOL, V11, P1304; Neel BG, 1997, CURR OPIN CELL BIOL, V9, P193, DOI 10.1016/S0955-0674(97)80063-4; Noguchi T, 1999, EMBO J, V18, P1748, DOI 10.1093/emboj/18.7.1748; REEDIJK M, 1992, EMBO J, V11, P1365, DOI 10.1002/j.1460-2075.1992.tb05181.x; Roach TIA, 1998, CURR BIOL, V8, P1035, DOI 10.1016/S0960-9822(07)00426-5; Rohrschneider LR, 1997, MOL REPROD DEV, V46, P96; Siminovitch KA, 1998, SEMIN IMMUNOL, V10, P329, DOI 10.1006/smim.1998.0125; Somani AK, 1997, J BIOL CHEM, V272, P21113, DOI 10.1074/jbc.272.34.21113; Stanley ER, 1997, MOL REPROD DEV, V46, P4, DOI 10.1002/(SICI)1098-2795(199701)46:1<4::AID-MRD2>3.0.CO;2-V; STANLEY ER, 1990, METHOD MOL BIOL, P299; Stein-Gerlach M, 1998, INT J BIOCHEM CELL B, V30, P559, DOI 10.1016/S1357-2725(98)00002-8; TANAKA S, 1995, J BIOL CHEM, V270, P14347, DOI 10.1074/jbc.270.24.14347; Timms JF, 1998, MOL CELL BIOL, V18, P3838, DOI 10.1128/MCB.18.7.3838; Unkeless JC, 1997, CURR OPIN IMMUNOL, V9, P338, DOI 10.1016/S0952-7915(97)80079-9; VANDERGEER P, 1993, EMBO J, V12, P5161, DOI 10.1002/j.1460-2075.1993.tb06211.x; Veillette A, 1998, J BIOL CHEM, V273, P22719, DOI 10.1074/jbc.273.35.22719; Vuica M, 1997, J EXP MED, V186, P259, DOI 10.1084/jem.186.2.259; Wang Y, 1996, J BIOL CHEM, V271, P17, DOI 10.1074/jbc.271.1.17; WISNIEWSKI D, 1994, LEUKEMIA, V8, P688; Wu YJ, 1998, CURR BIOL, V8, P1009, DOI 10.1016/S0960-9822(07)00421-6; Yamanashi Y, 1997, CELL, V88, P205, DOI 10.1016/S0092-8674(00)81841-3; YEUNG YG, 1992, J BIOL CHEM, V267, P23447; Yeung YG, 1998, J BIOL CHEM, V273, P30638, DOI 10.1074/jbc.273.46.30638; YI TL, 1993, MOL CELL BIOL, V13, P3350, DOI 10.1128/MCB.13.6.3350; Yokoyama WM, 1997, J EXP MED, V186, P1803, DOI 10.1084/jem.186.11.1803	59	41	41	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 10	1999	274	50					35855	35865		10.1074/jbc.274.50.35855	http://dx.doi.org/10.1074/jbc.274.50.35855			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	264NG	10585470	hybrid			2022-12-25	WOS:000084187900082
J	Chung, HO; Yang, Q; Catt, KJ; Arora, KK				Chung, HO; Yang, Q; Catt, KJ; Arora, KK			Expression and function of the gonadotropin-releasing hormone receptor are dependent on a conserved apolar amino acid in the third intracellular loop	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTORS; SIGNAL-TRANSDUCTION PATHWAYS; AT(1) ANGIOTENSIN RECEPTOR; 3RD CYTOPLASMIC LOOP; LIGAND-BINDING; MOLECULAR-BASIS; ACTIVATION; INTERNALIZATION; MUTAGENESIS; DOMAINS	The coupling of agonist-activated heptahelical receptors to; their cognate G proteins is often dependent on the amino-terminal region of the third intracellular loop. Like many G protein coupled receptors, the gonadotropin-releasing hormone (GnRH) receptor contains an apolar amino acid in this region at a constant distance fi om conserved Pro and Tyr/Asn residues in the fifth transmembrane domain (TM V). An analysis of the role of this conserved residue (Leu(237)) in GnRH receptor function revealed that the binding affinities of the L237I and L237V mutant receptors were unchanged, but their abilities to mediate GnRH-induced inositol phosphate signaling, G; protein coupling, and agonist-induced internalization were significantly impaired. Receptor expression at the cell surface was reduced by replacement of LeU(237) With Val, and abolished by replacement with Ala, Arg, or Asp residues, These results are consistent with molecular modeling of the TM V and VI regions of the GnRH receptor, which predicts that LeU(237) is caged by several apolar amino acids (Ile(233), Ile(234), and Val(240) in TM V, and LeU(262), LeU(265), and Val(269) in TM VI) to form a tight hydrophobic cluster. These findings indicate that the conserved apolar residue (LeU(237)) in the third intracellular loop is an important determinant of GnRH receptor expression and activation, and possibly that of other G protein-coupled receptors.	NICHD, Endocrinol & Reprod Res Branch, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)	Arora, KK (corresponding author), NICHD, Endocrinol & Reprod Res Branch, NIH, Bldg 49,Rm 6A36, Bethesda, MD 20892 USA.				EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [ZIAHD000184] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [Z01HD000184] Funding Source: NIH RePORTER	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Arora KK, 1998, J BIOL CHEM, V273, P25581, DOI 10.1074/jbc.273.40.25581; Arora KK, 1999, MOL ENDOCRINOL, V13, P890, DOI 10.1210/me.13.6.890; Arora KK, 1997, MOL ENDOCRINOL, V11, P1203, DOI 10.1210/me.11.9.1203; ARORA KK, 1995, J BIOL CHEM, V270, P22820, DOI 10.1074/jbc.270.39.22820; Baldwin JM, 1997, J MOL BIOL, V272, P144, DOI 10.1006/jmbi.1997.1240; BALDWIN JM, 1993, EMBO J, V12, P1693, DOI 10.1002/j.1460-2075.1993.tb05814.x; CHEUNG AH, 1992, MOL PHARMACOL, V41, P1061; CLARK CD, 1994, J BIOL CHEM, V269, P8831; CLAYTON RN, 1981, ENDOCR REV, V2, P186, DOI 10.1210/edrv-2-2-186; CLAYTON RN, 1989, J ENDOCRINOL, V120, P11, DOI 10.1677/joe.0.1200011; DAngelo DD, 1996, J BIOL CHEM, V271, P6233, DOI 10.1074/jbc.271.11.6233; DOHLMAN HG, 1991, ANNU REV BIOCHEM, V60, P653, DOI 10.1146/annurev.biochem.60.1.653; DUNBRACK RL, 1993, J MOL BIOL, V230, P543, DOI 10.1006/jmbi.1993.1170; FRANKE RR, 1990, SCIENCE, V250, P123, DOI 10.1126/science.2218504; Gomeza J, 1996, J BIOL CHEM, V271, P2199, DOI 10.1074/jbc.271.4.2199; Grosse R, 1997, MOL ENDOCRINOL, V11, P1305, DOI 10.1210/me.11.9.1305; HAWES BE, 1994, J BIOL CHEM, V269, P15776; HEDIN KE, 1993, CELL SIGNAL, V5, P505, DOI 10.1016/0898-6568(93)90046-O; Huang ZM, 1996, J BIOL CHEM, V271, P33382, DOI 10.1074/jbc.271.52.33382; HUNYADY L, 1995, J BIOL CHEM, V270, P9702, DOI 10.1074/jbc.270.17.9702; HUNYADY L, 1994, J BIOL CHEM, V269, P31378; HUNYADY L, 1994, J BIOL CHEM, V269, P24798; Hunyady L, 1996, P NATL ACAD SCI USA, V93, P10040, DOI 10.1073/pnas.93.19.10040; KJELSBERG MA, 1992, J BIOL CHEM, V267, P1430; KOSUGI S, 1993, MOL ENDOCRINOL, V7, P1009, DOI 10.1210/me.7.8.1009; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LAMEH J, 1992, J BIOL CHEM, V267, P13406; LECHLEITER J, 1990, EMBO J, V9, P4381, DOI 10.1002/j.1460-2075.1990.tb07888.x; LEE C, 1994, J MOL BIOL, V236, P918, DOI 10.1006/jmbi.1994.1198; Lin XW, 1998, BIOL REPROD, V59, P1470, DOI 10.1095/biolreprod59.6.1470; Lin ZL, 1997, PROTEIN ENG, V10, P501, DOI 10.1093/protein/10.5.501; Mathi SK, 1997, MOL ENDOCRINOL, V11, P424, DOI 10.1210/me.11.4.424; MCCLUE SJ, 1994, EUR J PHARM-MOLEC PH, V267, P185, DOI 10.1016/0922-4106(94)90170-8; MORO O, 1993, J BIOL CHEM, V268, P22273; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; OHYAMA K, 1992, BIOCHEM BIOPH RES CO, V189, P677, DOI 10.1016/0006-291X(92)92254-U; OKAMOTO T, 1992, J BIOL CHEM, V267, P8342; PROBST WC, 1992, DNA CELL BIOL, V11, P1, DOI 10.1089/dna.1992.11.1; PROSSNITZ ER, 1993, BIOCHEM J, V294, P581, DOI 10.1042/bj2940581; Qian A, 1998, CELL SIGNAL, V10, P101, DOI 10.1016/S0898-6568(97)00097-1; SANKARARAMAKRISHNAN R, 1993, PROTEINS, V15, P26, DOI 10.1002/prot.340150105; SAVARESE TM, 1992, BIOCHEM J, V283, P1; Sealfon SC, 1997, ENDOCR REV, V18, P180, DOI 10.1210/er.18.2.180; STOJILKOVIC SS, 1994, ENDOCR REV, V15, P462, DOI 10.1210/er.15.4.462; STRADER CD, 1994, ANNU REV BIOCHEM, V63, P101, DOI 10.1146/annurev.bi.63.070194.000533; Ulloa-Aguirre A, 1998, ENDOCRINOLOGY, V139, P2472, DOI 10.1210/en.139.5.2472; WEINER JL, 1993, J BIOL CHEM, V268, P8070; WESS J, 1993, TRENDS PHARMACOL SCI, V14, P308, DOI 10.1016/0165-6147(93)90049-P; Wess J, 1998, PHARMACOL THERAPEUT, V80, P231, DOI 10.1016/S0163-7258(98)00030-8; Yang K, 1996, BIOCHEMISTRY-US, V35, P12464, DOI 10.1021/bi960848t	50	15	16	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 10	1999	274	50					35756	35762		10.1074/jbc.274.50.35756	http://dx.doi.org/10.1074/jbc.274.50.35756			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	264NG	10585457	hybrid			2022-12-25	WOS:000084187900069
J	Janzen, DM; Torgov, MY; Reddy, MK				Janzen, DM; Torgov, MY; Reddy, MK			In vitro reconstitution of the bacteriophage T4 clamp loader complex (gp44/62)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYMERASE ACCESSORY PROTEIN; REPLICATION FACTOR-C; ONE HOLOENZYME PARTICLE; 2 DNA-POLYMERASES; SLIDING CLAMP; ATP HYDROLYSIS; BACTERIAL LUCIFERASE; STRUCTURAL-ANALYSES; ESCHERICHIA-COLI; GENE-CLUSTER	The clamp loader complex (CLC) of bacteriophage T4 is essential for viability and has analogs in both prokaryotes and eukaryotes. The gp44 and gp62 subunits of the T4 CLC, in a 4:1 ratio, tightly associate such that the two proteins co-purify. Using transformed Escherichia coli, we were able to demonstrate for the first time purification of the unique protein gp62 in the absence of gp44. We experimentally determined the isoelectric point for the individual subunits. An in vitro physical interaction could be observed between the native subunits, which resulted in a reconstituted CLC that displayed the signature pattern of the ATPase functions of native CLC. Thus we demonstrate that the CLC forms via a self-assembly pathway rather than through a translational capture mechanism.	Univ Wisconsin, Dept Chem, Milwaukee, WI 53201 USA	University of Wisconsin System; University of Wisconsin Milwaukee	Reddy, MK (corresponding author), Univ Wisconsin, Dept Chem, POB 413, Milwaukee, WI 53201 USA.							BARRY J, 1972, P NATL ACAD SCI USA, V69, P2717, DOI 10.1073/pnas.69.9.2717; Berdis AJ, 1997, BIOCHEMISTRY-US, V36, P2733, DOI 10.1021/bi962139l; Berdis AJ, 1996, BIOCHEMISTRY-US, V35, P9253, DOI 10.1021/bi952569w; Bertram JG, 1998, J BIOL CHEM, V273, P24564, DOI 10.1074/jbc.273.38.24564; Bloom LB, 1996, J BIOL CHEM, V271, P30699, DOI 10.1074/jbc.271.48.30699; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Cai JS, 1996, P NATL ACAD SCI USA, V93, P12896, DOI 10.1073/pnas.93.23.12896; CULLMANN G, 1995, MOL CELL BIOL, V15, P4661; GERALD WL, 1984, GENETICS, V107, P537; GOGOL EP, 1992, J MOL BIOL, V224, P395, DOI 10.1016/0022-2836(92)91003-8; GUZMAN LM, 1995, J BACTERIOL, V177, P4121, DOI 10.1128/jb.177.14.4121-4130.1995; HSU T, 1990, J BIOL CHEM, V265, P5303; Janzen DM, 1999, VIROLOGY, V260, P64, DOI 10.1006/viro.1999.9785; JARVIS TC, 1989, J BIOL CHEM, V264, P12717; JARVIS TC, 1989, J BIOL CHEM, V264, P12709; Kaboord BF, 1996, BIOCHEMISTRY-US, V35, P1084, DOI 10.1021/bi9520747; KABOORD BF, 1995, CURR BIOL, V5, P149, DOI 10.1016/S0960-9822(95)00036-4; KARAM J, 1979, VIROLOGY, V94, P192, DOI 10.1016/0042-6822(79)90449-5; Kroutil LC, 1998, J MOL BIOL, V278, P135, DOI 10.1006/jmbi.1998.1676; Latham GJ, 1997, J BIOL CHEM, V272, P31677, DOI 10.1074/jbc.272.50.31677; LEE SH, 1991, J BIOL CHEM, V266, P594; MACE DC, 1984, J MOL BIOL, V177, P279, DOI 10.1016/0022-2836(84)90457-1; MORRIS CF, 1979, J BIOL CHEM, V254, P6787; NOSSAL NG, 1992, FASEB J, V6, P871, DOI 10.1096/fasebj.6.3.1310946; ODONNELL M, 1993, NUCLEIC ACIDS RES, V21, P1, DOI 10.1093/nar/21.1.1; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; ONRUST R, 1995, J BIOL CHEM, V270, P13366, DOI 10.1074/jbc.270.22.13366; ONRUST R, 1995, J BIOL CHEM, V270, P13348, DOI 10.1074/jbc.270.22.13348; Pietroni P, 1997, J BIOL CHEM, V272, P31666, DOI 10.1074/jbc.272.50.31666; PIPERNO JR, 1978, J BIOL CHEM, V253, P5174; REDDY MK, 1993, P NATL ACAD SCI USA, V90, P3211, DOI 10.1073/pnas.90.8.3211; Reddy MK, 1995, METHOD ENZYMOL, V262, P466; RUSH J, 1989, J BIOL CHEM, V264, P10943; Sexton DJ, 1996, J BIOL CHEM, V271, P28045, DOI 10.1074/jbc.271.45.28045; SINCLAIR JF, 1993, BIOCHEMISTRY-US, V32, P5036, DOI 10.1021/bi00070a010; SPICER EK, 1984, J BIOL CHEM, V259, P5425; Torgov MY, 1998, J BACTERIOL, V180, P4339, DOI 10.1128/JB.180.17.4339-4343.1998; TROJANOWSKA M, 1984, NUCLEIC ACIDS RES, V12, P5979, DOI 10.1093/nar/12.15.5979; TSURIMOTO T, 1991, J BIOL CHEM, V266, P1950; Uhlmann F, 1996, P NATL ACAD SCI USA, V93, P6521, DOI 10.1073/pnas.93.13.6521; WADDLE JJ, 1987, BIOCHEMISTRY-US, V26, P4917, DOI 10.1021/bi00390a004; Yeh LS, 1998, J BACTERIOL, V180, P2005, DOI 10.1128/JB.180.8.2005-2013.1998; YOUNG MC, 1992, BIOCHEMISTRY-US, V31, P8675, DOI 10.1021/bi00152a001	43	4	6	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 10	1999	274	50					35938	35943		10.1074/jbc.274.50.35938	http://dx.doi.org/10.1074/jbc.274.50.35938			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	264NG	10585481	hybrid			2022-12-25	WOS:000084187900093
J	Smith, ER; Storch, J				Smith, ER; Storch, J			The adipocyte fatty acid-binding protein binds to membranes by electrostatic interactions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOLIPID-MEMBRANES; COLLISIONAL TRANSFER; CYTOCHROME-C; CARDIOLIPIN; MECHANISM; REVERSIBILITY; PURIFICATION; LIVER; NMR	The adipocyte fatty acid-binding protein (AFABP) is believed to transfer unesterified fatty acids (FA) to phospholipid membranes via a collisional mechanism that involves ionic interactions between lysine residues on the protein surface and phospholipid headgroups, This hypothesis is derived largely from kinetic analysis of FA transfer from AFABP to membranes. In this study, we examined directly the binding of AFABP to large unilamellar vesicles (LUV) of differing phospholipid compositions, AFABP bound LW containing either cardiolipin or phosphatidic acid, and the amount of protein bound depended upon the mol % anionic phospholipid. The K-a for CL or PA in LUV containing 25 mol % of these anionic phospholipids was approximately 2 x 10(3) M-1 No detectable binding occurred when AFABP was mixed with zwitterionic membranes, nor when acetylated AFABP in which surface lysines had been chemically neutralized was mixed with anionic membranes. The binding of AFABP to acidic membranes depended upon the ionic strength of the incubation buffer: greater than or equal to 200 mM NaCl reduced protein-lipid complex formation in parallel with a decrease in the rate of FA transfer from AFABP to negatively charged membranes. It was further found that AFABP, but not acetylated AFABP, prevented cytochrome c, a well characterized peripheral membrane protein, from binding to membranes. These results directly demonstrate that AFABP binds to anionic phospholipid membranes and suggest that, although generally described as a cytosolic protein, AFABP may behave as a peripheral membrane protein to help target fatty acids to and/or from intracellular sites of utilization.	Rutgers State Univ, Dept Nutr Sci, New Brunswick, NJ 08901 USA	Rutgers State University New Brunswick	Storch, J (corresponding author), Rutgers State Univ, Dept Nutr Sci, 96 Lipman Dr, New Brunswick, NJ 08901 USA.			Storch, Judith/0000-0001-5482-1777	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK038389, R29DK038389] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK38389, R01 DK038389, DK09303] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ames B. N., 1966, METHOD ENZYMOL, P115, DOI DOI 10.1016/0076-6879(66)08014-5; ANANTHARAMAIAH GM, 1993, AMPHIPATHIC HELIX, P110; BERCLAZ T, 1984, BIOCHEMISTRY-US, V23, P4033, DOI 10.1021/bi00313a004; BUSER CA, 1994, BIOCHEMISTRY-US, V33, P13093, DOI 10.1021/bi00248a019; Corsico B, 1998, P NATL ACAD SCI USA, V95, P12174, DOI 10.1073/pnas.95.21.12174; FAUCON JF, 1976, BIOCHIM BIOPHYS ACTA, V435, P283; Gericke A, 1997, BIOCHEMISTRY-US, V36, P8311, DOI 10.1021/bi970679s; Herr FM, 1996, BIOCHEMISTRY-US, V35, P1296, DOI 10.1021/bi952204b; HERR FM, 1995, BIOCHEMISTRY-US, V34, P11840, DOI 10.1021/bi00037a023; HOVIUS R, 1990, BIOCHIM BIOPHYS ACTA, V1021, P217, DOI 10.1016/0005-2736(90)90036-N; Hsu KT, 1996, J BIOL CHEM, V271, P13317, DOI 10.1074/jbc.271.23.13317; Huang C, 1974, Methods Enzymol, V32, P485; KAIKAUS RM, 1990, EXPERIENTIA, V46, P617, DOI 10.1007/BF01939701; KIM HK, 1992, J BIOL CHEM, V267, P20051; KIM HK, 1992, J BIOL CHEM, V269, P10517; Liou HL, 1998, FASEB J, V12, pA514; MATARESE V, 1988, J BIOL CHEM, V263, P14544; MOSIOR M, 1995, J BIOL CHEM, V270, P25526, DOI 10.1074/jbc.270.43.25526; NARAYANAN V, 1988, J BIOL CHEM, V263, P8332; OCKNER RK, 1974, J CLIN INVEST, V54, P326, DOI 10.1172/JCI107768; PINHEIRO TJT, 1994, BIOCHEMISTRY-US, V33, P4896, DOI 10.1021/bi00182a018; POWELL GL, 1985, BIOCHEMISTRY-US, V24, P2902, DOI 10.1021/bi00333a013; REBECCHI M, 1992, BIOCHEMISTRY-US, V31, P12742, DOI 10.1021/bi00166a005; RIETVELD A, 1983, EMBO J, V2, P907, DOI 10.1002/j.1460-2075.1983.tb01520.x; RODRIGUEZVICO F, 1989, ANAL BIOCHEM, V183, P275, DOI 10.1016/0003-2697(89)90479-X; RYTOMAA M, 1995, J BIOL CHEM, V270, P3197, DOI 10.1074/jbc.270.7.3197; Sankaram M.B., 1993, NEW COMPREHENSIVE BI, VVolume 25, P127; SCHLAME M, 1993, EUR J BIOCHEM, V212, P727, DOI 10.1111/j.1432-1033.1993.tb17711.x; SCHLAME M, 1990, BIOCHEM J, V265, P79, DOI 10.1042/bj2650079; STRUCK DK, 1981, BIOCHEMISTRY-US, V20, P4093, DOI 10.1021/bi00517a023; TRAPP BD, 1984, J NEUROCHEM, V43, P944, DOI 10.1111/j.1471-4159.1984.tb12828.x; UYEMURA K, 1977, J NEUROCHEM, V29, P61, DOI 10.1111/j.1471-4159.1977.tb03924.x; WESSEL D, 1984, ANAL BIOCHEM, V138, P141, DOI 10.1016/0003-2697(84)90782-6; WOOTAN MG, 1993, BIOCHEMISTRY-US, V32, P8622, DOI 10.1021/bi00084a033; WOOTAN MG, 1994, J BIOL CHEM, V269, P10517; XU ZH, 1991, J BIOL CHEM, V266, P14367	36	27	30	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 10	1999	274	50					35325	35330		10.1074/jbc.274.50.35325	http://dx.doi.org/10.1074/jbc.274.50.35325			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	264NG	10585398	hybrid			2022-12-25	WOS:000084187900010
J	Weinberger, M; Trabold, PA; Lu, M; Sharma, K; Huberman, JA; Burhans, WC				Weinberger, M; Trabold, PA; Lu, M; Sharma, K; Huberman, JA; Burhans, WC			Induction by adozelesin and hydroxyurea of origin recognition complex-dependent DNA damage and DNA replication checkpoints in Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-CYCLE PROGRESSION; S-PHASE; BUDDING YEAST; CHROMOSOMAL REPLICATION; PROTEIN-KINASE; ORC; PATHWAY; AGENTS; REPAIR	DNA damaging agents induce a conserved intra-S-phase checkpoint that inhibits DNA replication in eukaryotic cells. To better understand this checkpoint and its role in determining the efficacy of antitumor drugs that damage DNA, we examined the effects of adozelesin, a DNA-alkylating antitumor agent that has a profound inhibitory effect on initiation of DNA replication in mammals, on the replication of Saccharomyces cerevisiae chromosomes. Adozelesin inhibited initiation of S, cerevisiae DNA replication by inducing an intra-S-phase DNA damage checkpoint. This inhibitory effect was abrogated in orc2-1 cells containing a temperature-sensitive mutation in a component of the origin recognition complex (ORC) that also causes a defect in initiation. The orc2-1 mutation also caused a defect in a checkpoint that regulates the activation of origins in late S phase in cells treated with hydroxyurea, Defects in both initiation and checkpoint regulation in the orc2-1 strain were suppressed by deletion of a gene encoding a putative acetyltransferase, SAS2, Adozelesin also induced a cellular response that requires a function of ORC in G(1). A similar G(1)-specific response in mammals may contribute to the cytotoxic and antitumor properties of this and other DNA-damaging drugs.	Roswell Pk Canc Inst, Dept Canc Genet, Buffalo, NY 14263 USA	Roswell Park Cancer Institute	Burhans, WC (corresponding author), Roswell Pk Canc Inst, Dept Canc Genet, Buffalo, NY 14263 USA.	wburhans@sc3101.med.buffalo.edu			NATIONAL CANCER INSTITUTE [P30CA016056] Funding Source: NIH RePORTER; NCI NIH HHS [P30 CA16056-24] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALLEN JB, 1994, GENE DEV, V8, P2401, DOI 10.1101/gad.8.20.2401; BHUYAN BK, 1992, CANCER CHEMOTH PHARM, V30, P348, DOI 10.1007/BF00689961; BHUYAN BK, 1992, CANCER RES, V52, P5687; Boger DL, 1996, ANGEW CHEM INT EDIT, V35, P1438, DOI 10.1002/anie.199614381; BREWER BJ, 1987, CELL, V51, P463, DOI 10.1016/0092-8674(87)90642-8; BRUNBORG G, 1978, MOL GEN GENET, V162, P277, DOI 10.1007/BF00268853; Desany BA, 1998, GENE DEV, V12, P2956, DOI 10.1101/gad.12.18.2956; Diffley TFX, 1996, GENE DEV, V10, P2819, DOI 10.1101/gad.10.22.2819; Dillin A, 1998, SCIENCE, V279, P1733, DOI 10.1126/science.279.5357.1733; DONALDSON KL, 1994, INT J CANCER, V57, P847, DOI 10.1002/ijc.2910570614; DUBEY DD, 1991, MOL CELL BIOL, V11, P5346, DOI 10.1128/MCB.11.10.5346; Dutta A, 1997, ANNU REV CELL DEV BI, V13, P293, DOI 10.1146/annurev.cellbio.13.1.293; EhrenhoferMurray AE, 1997, GENETICS, V145, P923; FERGUSON BM, 1991, CELL, V65, P507, DOI 10.1016/0092-8674(91)90468-E; Foiani M, 1998, BIOL CHEM, V379, P1019; FOSS M, 1993, SCIENCE, V262, P1838, DOI 10.1126/science.8266071; FOX CA, 1995, GENE DEV, V9, P911, DOI 10.1101/gad.9.8.911; GUARENTE L, 1993, TRENDS GENET, V9, P362, DOI 10.1016/0168-9525(93)90042-G; GUTHRIE C, 1991, METHOD ENZYMOL, V194, P294; HEIGERBERNAYS WJ, 1990, BIOCHEMISTRY-US, V29, P8461, DOI 10.1021/bi00488a037; Huberman JA, 1999, PROG NUCLEIC ACID RE, V62, P369; HUBERMAN JA, 1987, CELL, V51, P473, DOI 10.1016/0092-8674(87)90643-X; Iizuka M, 1999, J BIOL CHEM, V274, P23027, DOI 10.1074/jbc.274.33.23027; Kaufmann WK, 1996, FASEB J, V10, P238, DOI 10.1096/fasebj.10.2.8641557; Longhese MP, 1996, NUCLEIC ACIDS RES, V24, P3533, DOI 10.1093/nar/24.18.3533; LOO S, 1995, MOL BIOL CELL, V6, P741, DOI 10.1091/mbc.6.6.741; MAINE GT, 1984, GENETICS, V106, P365; Marini F, 1997, EMBO J, V16, P639, DOI 10.1093/emboj/16.3.639; PAULOVICH AG, 1995, CELL, V82, P841, DOI 10.1016/0092-8674(95)90481-6; RIVIN CJ, 1980, J CELL BIOL, V85, P96, DOI 10.1083/jcb.85.1.96; Santocanale C, 1998, NATURE, V395, P615, DOI 10.1038/27001; Santocanale C, 1999, GENE DEV, V13, P2360, DOI 10.1101/gad.13.18.2360; Santocanale C, 1996, EMBO J, V15, P6671, DOI 10.1002/j.1460-2075.1996.tb01057.x; Shirahige K, 1998, NATURE, V395, P618, DOI 10.1038/27007; SIEDE W, 1994, GENETICS, V138, P271; SIEDE W, 1990, MUTAT RES, V245, P287, DOI 10.1016/0165-7992(90)90158-G; Stillman B, 1996, SCIENCE, V274, P1659, DOI 10.1126/science.274.5293.1659; Sugimoto K, 1997, MOL CELL BIOL, V17, P5905, DOI 10.1128/MCB.17.10.5905; Tannock I, 1998, BASIC SCI ONCOLOGY; Vujcic M, 1999, MOL CELL BIOL, V19, P6098; WEINERT TA, 1994, GENE DEV, V8, P652, DOI 10.1101/gad.8.6.652; Williams GH, 1998, P NATL ACAD SCI USA, V95, P14932, DOI 10.1073/pnas.95.25.14932	42	32	32	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 10	1999	274	50					35975	35984		10.1074/jbc.274.50.35975	http://dx.doi.org/10.1074/jbc.274.50.35975			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	264NG	10585487	hybrid			2022-12-25	WOS:000084187900099
J	Caride, AJ; Elwess, NL; Verma, AK; Filoteo, AG; Enyedi, A; Bajzer, Z; Penniston, JT				Caride, AJ; Elwess, NL; Verma, AK; Filoteo, AG; Enyedi, A; Bajzer, Z; Penniston, JT			The rate of activation by calmodulin of isoform 4 of the plasma membrane Ca2+ pump is slow and is changed by alternative splicing	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE; CALCIUM-PUMP; ERYTHROCYTE-MEMBRANES; BINDING DOMAIN; ANTIBODIES; MECHANISM; REGION; ATPASE	A reconstitution system allowed us to measure the ATPase activity of specific isoforms of the plasma membrane Ca2+ pump continuously, and to measure the effects of adding or removing calmodulin, The rate of activation by calmodulin of isoform 4b was found to be very slow, with a half-time (at 235 nM calmodulin and 0.5 mu M free Ca2+) of about 1 min. The rate of inactivation of isoform 4b when calmodulin was removed was even slower, with a half-time of about 20 min. Isoform 4a has a lower apparent affinity for calmodulin than 4b, but its activation rate was surprisingly faster (half time about 20 s), This was coupled with a much faster inactivation rate, consistent with its low affinity. A truncated mutant of isoform 4b also had a more rapid activation rate, indicating that the downstream inhibitory region of full-length 4b contributed to its slow activation. The results indicate that the slow activation is due to occlusion of the calmodulin-binding domain of 4b, caused by its strong interaction with the catalytic core. Since the activation of 4b occurs on a time scale comparable to that of many Ca2+ spikes, this phenomenon is important to the function of the pump in living cells, The slow response of 4b indicates that this isoform may be the appropriate one for cells which respond slowly to Ca2+ signals.	Mayo Clin & Mayo Fdn, Dept Biochem & Mol Biol, Rochester, MN 55905 USA; Natl Inst Haematol & Immunol, H-1113 Budapest, Hungary	Mayo Clinic	Penniston, JT (corresponding author), Mayo Clin & Mayo Fdn, Dept Biochem & Mol Biol, 200 1st St SW, Rochester, MN 55905 USA.		Enyedi, Agnes/N-9742-2013	Enyedi, Agnes/0000-0002-7366-9376	NIGMS NIH HHS [GM55514, GM28835] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM055514, R01GM028835] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bautista DM, 1999, BIOPHYS J, V76, pA379; Caride AJ, 1996, BIOCHEM J, V316, P353, DOI 10.1042/bj3160353; Enyedi A, 1997, J BIOL CHEM, V272, P27525, DOI 10.1074/jbc.272.44.27525; Enyedi A, 1996, J BIOL CHEM, V271, P32461, DOI 10.1074/jbc.271.50.32461; ENYEDI A, 1994, J BIOL CHEM, V269, P41; Filoteo AG, 1997, J BIOL CHEM, V272, P23741, DOI 10.1074/jbc.272.38.23741; GRAF E, 1980, ARCH BIOCHEM BIOPHYS, V203, P719, DOI 10.1016/0003-9861(80)90231-3; GRAF E, 1981, ARCH BIOCHEM BIOPHYS, V210, P257, DOI 10.1016/0003-9861(81)90187-9; GRAF E, 1982, BIOCHEMISTRY-US, V21, P4511, DOI 10.1021/bi00261a049; JARRETT HW, 1979, J BIOL CHEM, V254, P8237; Klishin A, 1998, AM J PHYSIOL-CELL PH, V274, pC1117, DOI 10.1152/ajpcell.1998.274.4.C1117; MEYER T, 1992, SCIENCE, V256, P1199, DOI 10.1126/science.256.5060.1199; SCHARFF O, 1994, CELL CALCIUM, V16, P455, DOI 10.1016/0143-4160(94)90075-2; SCHARFF O, 1982, BIOCHIM BIOPHYS ACTA, V691, P133, DOI 10.1016/0005-2736(82)90222-X; STREHLER EE, 1990, J BIOL CHEM, V265, P2835; TOROK K, 1994, BIOCHEMISTRY-US, V33, P12807, DOI 10.1021/bi00209a012; Verma AK, 1996, J BIOL CHEM, V271, P3714; Verma AK, 1999, J BIOL CHEM, V274, P527, DOI 10.1074/jbc.274.1.527; VERMA AK, 1994, J BIOL CHEM, V269, P1687; Wang J H, 1980, Ann N Y Acad Sci, V356, P190, DOI 10.1111/j.1749-6632.1980.tb29611.x; WEBB MR, 1992, P NATL ACAD SCI USA, V89, P4884, DOI 10.1073/pnas.89.11.4884	21	62	63	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 3	1999	274	49					35227	35232		10.1074/jbc.274.49.35227	http://dx.doi.org/10.1074/jbc.274.49.35227			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	260XW	10575008	hybrid			2022-12-25	WOS:000083979600102
J	Tamura, K; Rice, RL; Wipf, P; Lazo, JS				Tamura, K; Rice, RL; Wipf, P; Lazo, JS			Dual G1 and G2/M phase inhibition by SC-alpha alpha delta 9, a combinatorially derived Cdc25 phosphatase inhibitor	ONCOGENE			English	Article						Cdc25 phosphatase inhibitor; cell cycle arrest; Cdc2; Cdk2; Cdk4; tsFT210	CELL-CYCLE; SMALL-MOLECULE; C-MYC; TYROSINE PHOSPHATASE; PROTEIN-KINASE; PHOSPHORYLATION; ACTIVATION; MITOSIS; LIBRARY; OVEREXPRESSION	The Cdc25 dual specificity phosphatase family has a central role in controlling cell cycle progression and has been implicated in the etiology of cancer. One compound, 4-(benzyl-(2-[(2, 5-diphenyl-oxazole-4-carbonyl)-amino]-ethyl)-carbamoyl) -2-decanoylamino butyric acid (SC-alpha alpha delta 9), was previously identified as the most potent reported synthetic inhibitor of Cdc25 phosphatases in vitro. In the present study, we demonstrate that SC-alpha alpha delta 9 inhibited Cdc25-dependent cell cycle progression at both G1 and G2/M phase using tsFT210 cells, which express a temperature-sensitive Cdc2 mutant, SC-alpha alpha delta 9 blocked both G2/M transition and dephosphorylation of Cdc2 in a concentration-dependent manner. SC-alpha alpha delta 9 also enhanced tyrosine phosphorylation of both Cdk2 and Cdk4, and decreased Cdk4 kinase activity. Both of the kinases are potent regulators of G1 transition. Furthermore, closely related chemical analogs that lacked Cdc25 inhibitory activity failed to block cell cycle progression at both G1 and G2/M, and did not affect Cdc2 phosphorylation or Cdk4 kinase activity. SC-alpha alpha delta 9 did not alter p53, p21 or p16 levels, Our results support the hypothesis that the disruption in cell cycle transition caused by SC-alpha alpha delta 9 was due to intracellular Cdc25 inhibition. We propose that the SC-alpha alpha delta 9 pharmacophore could be useful in further clarifying the role of Cdc25 phosphatase-dependent pathways in checkpoint control, oncogenesis, and apoptosis.	Univ Pittsburgh, Dept Pharmacol, Pittsburgh, PA 15261 USA; Univ Pittsburgh, Dept Chem, Pittsburgh, PA 15261 USA; Hiroshima Univ, Sch Med, Dept Internal Med 2, Minami Ku, Hiroshima 734, Japan	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Hiroshima University	Lazo, JS (corresponding author), Univ Pittsburgh, Dept Pharmacol, Biomed Sci Tower E-1340, Pittsburgh, PA 15261 USA.		Wipf, Peter/AAG-1771-2021	Wipf, Peter/0000-0001-7693-5863	NATIONAL CANCER INSTITUTE [P01CA078039, R01CA039745] Funding Source: NIH RePORTER; NCI NIH HHS [CA-78039, CA-39745] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BARATTE B, 1992, ANTICANCER RES, V12, P873; GALAKTIONOV K, 1991, CELL, V67, P1181, DOI 10.1016/0092-8674(91)90294-9; Galaktionov K, 1996, NATURE, V382, P511, DOI 10.1038/382511a0; GALAKTIONOV K, 1995, GENE DEV, V9, P1046, DOI 10.1101/gad.9.9.1046; GALAKTIONOV K, 1995, SCIENCE, V269, P1575, DOI 10.1126/science.7667636; Garner-Hamrick PA, 1998, INT J CANCER, V76, P720, DOI 10.1002/(SICI)1097-0215(19980529)76:5<720::AID-IJC18>3.0.CO;2-7; Gasparotto D, 1997, CANCER RES, V57, P2366; Gunasekera SP, 1996, J AM CHEM SOC, V118, P8759, DOI 10.1021/ja961961+; HAMAGUCHI T, 1995, FEBS LETT, V372, P54, DOI 10.1016/0014-5793(95)00953-7; Hermeking H, 1997, MOL CELL, V1, P3, DOI 10.1016/S1097-2765(00)80002-7; Hernandez S, 1998, CANCER RES, V58, P1762; HOFFMANN I, 1993, EMBO J, V12, P53, DOI 10.1002/j.1460-2075.1993.tb05631.x; HOFFMANN I, 1994, EMBO J, V13, P4302, DOI 10.1002/j.1460-2075.1994.tb06750.x; HORIGUCHI T, 1994, BIOCHEM PHARMACOL, V48, P2139, DOI 10.1016/0006-2952(94)90516-9; HUNTER T, 1994, CELL, V79, P537; IZUMI T, 1993, MOL BIOL CELL, V4, P1337, DOI 10.1091/mbc.4.12.1337; JINNO S, 1994, EMBO J, V13, P1549, DOI 10.1002/j.1460-2075.1994.tb06417.x; Jinno S, 1999, ONCOGENE, V18, P565, DOI 10.1038/sj.onc.1202347; Kakeya H, 1998, CANCER RES, V58, P704; Lammer C, 1998, J CELL SCI, V111, P2445; MILLAR JBA, 1991, P NATL ACAD SCI USA, V88, P10500, DOI 10.1073/pnas.88.23.10500; NAGATA A, 1991, NEW BIOL, V3, P959; Peng HR, 1998, J MED CHEM, V41, P4677, DOI 10.1021/jm980500r; Rice RL, 1997, BIOCHEMISTRY-US, V36, P15965, DOI 10.1021/bi971338h; RICE RL, 1998, P AM ASSOC CANC RES, V39, P1208; SADHU K, 1990, P NATL ACAD SCI USA, V87, P5139, DOI 10.1073/pnas.87.13.5139; SEBASTIAN B, 1993, P NATL ACAD SCI USA, V90, P3521, DOI 10.1073/pnas.90.8.3521; STRAUSFELD U, 1994, J BIOL CHEM, V269, P5989; TERADA Y, 1995, NATURE, V376, P358, DOI 10.1038/376358a0; THNG JPH, 1990, CELL, V63, P313, DOI 10.1016/0092-8674(90)90164-A; Vogt A, 1998, J PHARMACOL EXP THER, V287, P806; Wipf P, 1997, BIOORGAN MED CHEM, V5, P165, DOI 10.1016/S0968-0896(96)00199-X; Wu WG, 1998, CANCER RES, V58, P4082	33	25	25	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 25	1999	18	50					6989	6996		10.1038/sj.onc.1203179	http://dx.doi.org/10.1038/sj.onc.1203179			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	259PH	10597298				2022-12-25	WOS:000083901900004
J	Konishi, Y; Tominaga, M; Watanabe, Y; Imamura, F; Goldfarb, A; Maki, R; Blum, H; De Robertis, EM; Tominaga, A				Konishi, Y; Tominaga, M; Watanabe, Y; Imamura, F; Goldfarb, A; Maki, R; Blum, H; De Robertis, EM; Tominaga, A			GOOSECOID inhibits erythrocyte differentiation by competing with Rb for PU.1 binding in murine cells	ONCOGENE			English	Article						goosecoid; PU.1; Rb	TRANSCRIPTION FACTOR PU.1; RETINOBLASTOMA PROTEIN; ERYTHROLEUKEMIA-CELLS; POSITIVE REGULATOR; GENE-PRODUCT; ETS ONCOGENE; LEUKEMIA; EXPRESSION; SCL; HEMATOPOIESIS	Misexpression of the dorsal mesodermal patterning factor goosecoid on the ventral side of amphibian embryos results in inhibition of blood formation in early embryogenesis, To investigate the mechanism of this inhibition, we ectopically expressed goosecoid in erythroleukemia cells. While erythroid differentiation of these cells can be induced by activin, goosecoid expressing cells were unresponsive to activin, We demonstrate an in vitro interaction between the oncogene PU.1, an ets family transcription factor thought to play a role in erythropoiesis, and the goosecoid protein (GSC). Interaction with PU.1 was specific as GSC did not bind to the ets family members, Fli-1 or Ets-2, The ability of goosecoid expressing erythroleukemia cells to differentiate in response to activin was rescued by coexpression of the GSC-binding N-terminal portion of PU.1. The N-terminal portion of PU.1 was coimmunoprecipitated with anti-GSC antibodies as well. The N-terminal domain of PU.1 is the region recognized by the retinoblastoma protein (Rb), a tumor suppressor gene presumably involved in erythroid differentiation. We show that GSC competitively inhibits binding of Rb to PU.1, Our data suggest that the suppression of blood formation by GSC could, at least in part, be mediated by binding to PU.1.	Kochi Med Sch, Med Res Ctr, Nankoku, Kochi 7838505, Japan; Kumamoto City Hosp, Div Pulm Dis, Kumamoto 8620808, Japan; Univ Virginia, Dept Pathol, Charlottesville, VA 22908 USA; Burnham Inst, La Jolla, CA 92037 USA; Forschungszentrum Karlsruhe, Inst Genet, D-76021 Karlsruhe, Germany; Univ Calif Los Angeles, Sch Med, HHMI, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Sch Med, Dept Biol Chem, Los Angeles, CA 90095 USA	Kochi University; University of Virginia; Sanford Burnham Prebys Medical Discovery Institute; Helmholtz Association; Karlsruhe Institute of Technology; Howard Hughes Medical Institute; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Tominaga, A (corresponding author), Kochi Med Sch, Med Res Ctr, Okoh Cho, Nankoku, Kochi 7838505, Japan.							APLAN PD, 1992, EMBO J, V11, P4073, DOI 10.1002/j.1460-2075.1992.tb05500.x; BEGLEY CG, 1989, P NATL ACAD SCI USA, V86, P10128, DOI 10.1073/pnas.86.24.10128; BENDAVID Y, 1991, GENE DEV, V5, P908, DOI 10.1101/gad.5.6.908; BERNARDS R, 1989, P NATL ACAD SCI USA, V86, P6474, DOI 10.1073/pnas.86.17.6474; BLUM M, 1992, CELL, V69, P1097, DOI 10.1016/0092-8674(92)90632-M; BLUMBERG B, 1991, SCIENCE, V253, P194, DOI 10.1126/science.1677215; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; CHO KWY, 1991, CELL, V67, P1111, DOI 10.1016/0092-8674(91)90288-A; CLARKE AR, 1992, NATURE, V359, P328, DOI 10.1038/359328a0; DEROBERTIS EM, 1992, DEVELOPMENT, P167; DOWDY SF, 1993, CELL, V73, P499, DOI 10.1016/0092-8674(93)90137-F; ETO Y, 1987, BIOCHEM BIOPH RES CO, V142, P1095, DOI 10.1016/0006-291X(87)91528-2; GOLDFARB AN, 1992, BLOOD, V80, P2858; GU W, 1993, CELL, V72, P309, DOI 10.1016/0092-8674(93)90110-C; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; HAGEMEIER C, 1993, P NATL ACAD SCI USA, V90, P1580, DOI 10.1073/pnas.90.4.1580; HROMAS R, 1993, BLOOD, V82, P2998; IKAWA Y, 1976, GANN, V67, P767; JACKS T, 1992, NATURE, V359, P295, DOI 10.1038/359295a0; KLEMSZ MJ, 1990, CELL, V61, P113, DOI 10.1016/0092-8674(90)90219-5; Klemsz MJ, 1996, MOL CELL BIOL, V16, P390; KULESSA H, 1995, GENE DEV, V9, P1250, DOI 10.1101/gad.9.10.1250; LEE EYHP, 1992, NATURE, V359, P288, DOI 10.1038/359288a0; MATSUSHIME H, 1992, CELL, V71, P323, DOI 10.1016/0092-8674(92)90360-O; McKercher SR, 1996, EMBO J, V15, P5647, DOI 10.1002/j.1460-2075.1996.tb00949.x; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; MoreauGachelin F, 1996, MOL CELL BIOL, V16, P2453; NIEHRS C, 1994, SCIENCE, V263, P817, DOI 10.1126/science.7905664; NIEHRS C, 1993, CELL, V72, P491, DOI 10.1016/0092-8674(93)90069-3; Rao G, 1997, ONCOGENE, V14, P123, DOI 10.1038/sj.onc.1200807; SCHUETZE S, 1992, MOL CELL BIOL, V12, P2967, DOI 10.1128/MCB.12.7.2967; SCHUETZE S, 1993, MOL CELL BIOL, V13, P5670, DOI 10.1128/MCB.13.9.5670; Scott EW, 1997, IMMUNITY, V6, P437, DOI 10.1016/S1074-7613(00)80287-3; SCOTT EW, 1994, SCIENCE, V265, P1573, DOI 10.1126/science.8079170; Shivdasani RA, 1996, BLOOD, V87, P4025, DOI 10.1182/blood.V87.10.4025.bloodjournal87104025; Spemann H., 1924, FDN EXPT EMBRYOLOGY, P144; TSAI FY, 1994, NATURE, V371, P221, DOI 10.1038/371221a0; TSAI SF, 1991, GENE DEV, V5, P919, DOI 10.1101/gad.5.6.919; WATSON DK, 1988, P NATL ACAD SCI USA, V85, P7862, DOI 10.1073/pnas.85.21.7862; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0; Yamada T, 1997, BLOOD, V89, P1383, DOI 10.1182/blood.V89.4.1383; YU J, 1987, NATURE, V330, P765, DOI 10.1038/330765a0	42	17	17	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 18	1999	18	48					6795	6805		10.1038/sj.onc.1203118	http://dx.doi.org/10.1038/sj.onc.1203118			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	257QA	10597288				2022-12-25	WOS:000083792000022
J	Schulz, RA; Gajewski, K				Schulz, RA; Gajewski, K			Ventral neuroblasts and the Heartless FGF receptor are required for muscle founder cell specification in Drosophila	ONCOGENE			English	Article						D-mef2; heartless; muscle founder cells; signal transduction; ventral neuroblasts	GROWTH-FACTOR RECEPTOR; CENTRAL-NERVOUS-SYSTEM; SINGLE-MINDED GENE; MESODERM; EXPRESSION; MIGRATION; HOMOLOG; EMBRYO; TINMAN; BREATHLESS	Muscle founder cells are uniquely specified cells that fuse with neighboring myoblasts to generate the complex pattern of body wall muscles in the Drosophila embryo. We have investigated the positional specification of founder cells for ventral oblique muscles, marked by the restricted expression of tinman RNA and the activity of a D-mef2 enhancer. The formation of these ventral myoblasts requires the function of the Heartless FGF receptor in the mesoderm and the presence of ventral neuroblasts in the central nervous system. Overproduction of ventral neuroblasts due to the forced expression of the homeodomain protein Vnd leads to increased numbers of founder cells. These results suggest the use of a neuroectoderm-to-mesoderm signaling pathway in the specification of ventral muscle precursors.	Univ Texas, MD Anderson Canc Ctr, Dept Biochem & Mol Biol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center	Schulz, RA (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Biochem & Mol Biol, 1515 Holcombe Blvd, Houston, TX 77030 USA.				NHLBI NIH HHS [HL59151] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL059151] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AZPIAZU N, 1993, GENE DEV, V7, P1325, DOI 10.1101/gad.7.7b.1325; BAKER R, 1995, DEVELOPMENT, V121, P1387; Bate M, 1996, SEMIN CELL DEV BIOL, V7, P103, DOI 10.1006/scdb.1996.0015; Bate Michael, 1993, P1013; BAYLIES MK, 1995, DEVELOPMENT, V121, P3829; Baylies MK, 1996, SCIENCE, V272, P1481, DOI 10.1126/science.272.5267.1481; Baylies MK, 1998, CELL, V93, P921, DOI 10.1016/S0092-8674(00)81198-8; Beiman M, 1996, GENE DEV, V10, P2993, DOI 10.1101/gad.10.23.2993; BODMER R, 1993, DEVELOPMENT, V118, P719; BRAND AH, 1993, DEVELOPMENT, V118, P401; Buff E, 1998, DEVELOPMENT, V125, P2075; Chu H, 1998, GENE DEV, V12, P3613, DOI 10.1101/gad.12.22.3613; FRASCH M, 1995, NATURE, V374, P464, DOI 10.1038/374464a0; Gajewski K, 1997, EMBO J, V16, P515, DOI 10.1093/emboj/16.3.515; Gajewski K, 1998, DEV GENES EVOL, V208, P382, DOI 10.1007/s004270050194; Gisselbrecht S, 1996, GENE DEV, V10, P3003, DOI 10.1101/gad.10.23.3003; Grass S, 1996, DEVELOPMENT, V122, P141; HILLIKER AJ, 1981, DROS INFORM SERV, V56, P65; Ingham P. W., 1997, The molecular biology of insect disease vectors: a methods manual., P268; JIMENEZ F, 1990, NEURON, V5, P81, DOI 10.1016/0896-6273(90)90036-F; LEWIS JO, 1994, MECH DEVELOP, V48, P81, DOI 10.1016/0925-4773(94)90018-3; LILLY B, 1995, SCIENCE, V267, P688, DOI 10.1126/science.7839146; McDonald JA, 1998, GENE DEV, V12, P3603, DOI 10.1101/gad.12.22.3603; Michelson AM, 1998, DEV GENET, V22, P212, DOI 10.1002/(SICI)1520-6408(1998)22:3<212::AID-DVG4>3.0.CO;2-9; NAMBU JR, 1990, CELL, V63, P63, DOI 10.1016/0092-8674(90)90288-P; Nguyen HT, 1998, DEV BIOL, V204, P550, DOI 10.1006/dbio.1998.9081; Ranganayakulu G, 1996, DEV BIOL, V176, P143, DOI 10.1006/dbio.1996.9987; REICHMANFRIED M, 1995, MECH DEVELOP, V52, P265, DOI 10.1016/0925-4773(95)00407-R; REICHMANFRIED M, 1994, GENE DEV, V8, P428, DOI 10.1101/gad.8.4.428; RUSHTON E, 1995, DEVELOPMENT, V121, P1979; Shishido E, 1997, DEVELOPMENT, V124, P2119; Sutherland D, 1996, CELL, V87, P1091, DOI 10.1016/S0092-8674(00)81803-6; VOLK T, 1994, DEVELOPMENT, V120, P59; Xu X, 1998, GENE DEV, V12, P2354, DOI 10.1101/gad.12.15.2354	34	7	7	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 18	1999	18	48					6818	6823		10.1038/sj.onc.1203081	http://dx.doi.org/10.1038/sj.onc.1203081			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	257QA	10597291				2022-12-25	WOS:000083792000025
J	Wouters, BG; Denko, NC; Giaccia, AJ; Brown, JM				Wouters, BG; Denko, NC; Giaccia, AJ; Brown, JM			A p53 and apoptotic independent role for p21(waf1) in tumour response to radiation therapy	ONCOGENE			English	Article						apoptosis; cancer-therapy; radiosensitivity; cyclin-dependent; kinase inhibitor; xenografts	CYCLIN-DEPENDENT KINASE; CLONOGENIC SURVIVAL; CANCER-THERAPY; CELL-DEATH; IONIZING-RADIATION; SOLID TUMORS; BCL-2; P21; DELAYS; RESISTANCE	Loss of p21 in human cancer cells results in checkpoint failure, induction of polyploidy and subsequent apoptosis following DNA damage. Tumours in immunodeficient mice derived from cells lacking p21 are also more sensitive to ionizing radiation than their wild-type counterparts. Abrogation of p53 in the p21(+/+) parental cells results in an in vitro phenotype that is indistinguishable from that of the p21 knockout cells. Thus, the in vitro phenotype resulting from loss of p21 is consistent with its well-established role in the p53/p21 damage response pathway. However, despite the similar in vitro phenotype, p21(+/+) cells with abrogated p53 show no evidence of the sensitivity observed in the p21(-/-) cells when grown as tumours in immunodeficient mice. The increased radio-sensitization stabilization of p21(-/-) tumours is also unrelated to the increase in apoptosis observed in these tumours following radiation treatment. Apoptosis in the p21(-/-) tumours was significantly reduced by expression of bcl-2 without any corresponding change in the overall response of the tumour. Similarly, abrogation of p53 in the p21(+/+) tumours substantially increased radiation-induced apoptosis within the tumours without increasing their radiation sensitivity. Dissociation of these in vivo and in vitro phenotypes indicates that p21 participates in a novel in vivo specific damage response pathway that is distinct from its role in the p53 pathway, and therefore that it may be an effective therapeutic target for cancer therapy.	Stanford Univ, Sch Med, Dept Radiat Oncol, Stanford, CA 94305 USA	Stanford University	Wouters, BG (corresponding author), Ottawa Reg Canc Ctr, Canc Res Grp, 3rd Floor,501 Smyth Rd, Ottawa, ON K1H 8L6, Canada.		Wouters, Bradly/T-1525-2017; denko, nicholas/F-8444-2010	Wouters, Bradly/0000-0002-8187-592X; 	NATIONAL CANCER INSTITUTE [R01CA064489, R01CA015201] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA15201, CA 64489, CA 09302] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BHATIA K, 1995, CANCER RES, V55, P1431; BIGGS JR, 1995, J MOL MED-JMM, V73, P509; Brizel DM, 1996, CANCER RES, V56, P941; Brown JM, 1996, NAT MED, V2, P1055, DOI 10.1038/nm1096-1055b; Brown JM, 1998, CANCER RES, V58, P1408; Fan SJ, 1997, ONCOGENE, V14, P2127, DOI 10.1038/sj.onc.1201052; FISHER DE, 1994, CELL, V78, P539, DOI 10.1016/0092-8674(94)90518-5; GJERSET RA, 1997, ENCY CANC, P1785; Graeber TG, 1996, NATURE, V379, P88, DOI 10.1038/379088a0; HALBERT CL, 1992, J VIROL, V66, P2125, DOI 10.1128/JVI.66.4.2125-2134.1992; Han JW, 1997, CANCER RES, V57, P176; HARTWELL LH, 1994, SCIENCE, V266, P1821, DOI 10.1126/science.7997877; Hockel M, 1996, CANCER RES, V56, P4509; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; Huang H, 1996, INT J RADIAT BIOL, V70, P151, DOI 10.1080/095530096145148; Kyprianou N, 1997, INT J CANCER, V70, P341, DOI 10.1002/(SICI)1097-0215(19970127)70:3<341::AID-IJC16>3.0.CO;2-I; Lock RB, 1996, CANCER RES, V56, P4006; SCHEFFNER M, 1993, CELL, V75, P495, DOI 10.1016/0092-8674(93)90384-3; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; Waldman T, 1997, NAT MED, V3, P1034, DOI 10.1038/nm0997-1034; WALDMAN T, 1995, CANCER RES, V55, P5187; Waldman T, 1996, NATURE, V381, P713, DOI 10.1038/381713a0; Wang YA, 1997, P NATL ACAD SCI USA, V94, P14590, DOI 10.1073/pnas.94.26.14590; Westphal CH, 1997, NAT GENET, V16, P397, DOI 10.1038/ng0897-397; Wouters BG, 1997, CANCER RES, V57, P4703; YIN DX, 1995, CANCER RES, V55, P4922	26	43	45	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 11	1999	18	47					6540	6545		10.1038/sj.onc.1203053	http://dx.doi.org/10.1038/sj.onc.1203053			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	256CW	10597257				2022-12-25	WOS:000083709200017
J	Zhan, Y; van de Water, B; Wang, YP; Stevens, JL				Zhan, Y; van de Water, B; Wang, YP; Stevens, JL			The roles of caspase-3 and bcl-2 in chemically-induced apoptosis but not necrosis of renal epithelial cells	ONCOGENE			English	Article						kidney; bcl-2; apoptosis; caspase; glutathione	C-MYC; OXIDATIVE STRESS; CATHEPSIN-B; GRANZYME-B; DEATH; PROTEASE; ACTIVATION; EXPRESSION; MECHANISM; CA2+	The kidney is a target for toxicants including cisplatin and S-(1,2-dichlorovinyl)-L-cysteine (DCVC), a metabolite of the environmental contaminant, trichloroethylene. Necrosis is well characterized in kidney cells, but pathways leading to apoptosis are less clear. Cysteine conjugates are useful toxicants because they induce either necrosis or apoptosis depending on chemical structure or antioxidant status. Herein, we show that in the renal epithelial cell line LLC-PK1, activation of caspase3 (CPP32/Yama/apopain) is crucial for apoptosis, but not necrosis. Apoptosis was blocked by zVAD.fmk, and partially by a cathepsin inhibitor. Caspase-3 activity and cleavage of poly(ADP-ribose) polymerase (PARP) was detected only during apoptosis. S-(1,1,2,2-Tetrafluoroethyl)-1-cysteine (TFEC), a metabolite of tetrafluoroethylene, kills cells only by necrosis, and did not activate caspases under any conditions. Apoptosis and activation of caspase3 by cisplatin, but not DCVC, was prevented by bcl-2. Thus, caspase-3 activation by bcl-2-dependent and -independent mechanisms is a terminal event in chemical-apoptosis of renal epithelial cells.	Univ Vermont, Coll Med, Dept Pathol, Burlington, VT 05405 USA; Adirondack Biomed Res Inst, New York, NY 12946 USA	University of Vermont	Stevens, JL (corresponding author), Univ Vermont, Coll Med, Dept Pathol, A249 Med Alumni Bldg, Burlington, VT 05405 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK046267] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES007847] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK46267] Funding Source: Medline; NIEHS NIH HHS [ES07847] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; Antoku K, 1997, LEUKEMIA, V11, P1665, DOI 10.1038/sj.leu.2400805; Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; BARRETT AJ, 1982, BIOCHEM J, V201, P189, DOI 10.1042/bj2010189; BISSONNETTE RP, 1992, NATURE, V359, P552, DOI 10.1038/359552a0; BONFOCO E, 1995, P NATL ACAD SCI USA, V92, P7162, DOI 10.1073/pnas.92.16.7162; Brunk UT, 1997, FREE RADICAL BIO MED, V23, P616, DOI 10.1016/S0891-5849(97)00007-5; BUTTKE TM, 1994, IMMUNOL TODAY, V15, P7, DOI 10.1016/0167-5699(94)90018-3; CHEN Q, 1990, J BIOL CHEM, V265, P21603; Cohen GM, 1997, BIOCHEM J, V326, P1, DOI 10.1042/bj3260001; CRONIN RE, 1995, KIDNEY, P1680; Darmon AJ, 1996, J BIOL CHEM, V271, P21709, DOI 10.1074/jbc.271.36.21709; Datta R, 1997, J BIOL CHEM, V272, P1965, DOI 10.1074/jbc.272.3.1965; Deiss LP, 1996, EMBO J, V15, P3861, DOI 10.1002/j.1460-2075.1996.tb00760.x; Distelhorst CW, 1996, ONCOGENE, V12, P2051; Edelstein CL, 1997, KIDNEY INT, V51, P1341, DOI 10.1038/ki.1997.183; Eguchi Y, 1997, CANCER RES, V57, P1835; Emoto Y, 1995, EMBO J, V14, P6148, DOI 10.1002/j.1460-2075.1995.tb00305.x; Evan G, 1998, SCIENCE, V281, P1317, DOI 10.1126/science.281.5381.1317; FANIDI A, 1992, NATURE, V359, P554, DOI 10.1038/359554a0; GOLDSTEIN RS, 1996, TOXICOLOGY, P417; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Gregoli PA, 1999, J CELL PHYSIOL, V178, P133, DOI 10.1002/(SICI)1097-4652(199902)178:2<133::AID-JCP2>3.3.CO;2-X; GUENETTE RS, 1994, EUR J BIOCHEM, V226, P311, DOI 10.1111/j.1432-1033.1994.tb20055.x; Jacobson MD, 1996, TRENDS BIOCHEM SCI, V21, P83, DOI 10.1016/0968-0004(96)20008-8; Kagaya S, 1997, MOL CELL BIOL, V17, P6736, DOI 10.1128/MCB.17.11.6736; KANE DJ, 1995, J NEUROSCI RES, V40, P269, DOI 10.1002/jnr.490400216; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; Kroemer G, 1997, NAT MED, V3, P614, DOI 10.1038/nm0697-614; Leist M, 1997, J EXP MED, V185, P1481, DOI 10.1084/jem.185.8.1481; Lieberthal W, 1996, AM J PHYSIOL-RENAL, V271, pF477, DOI 10.1152/ajprenal.1996.271.3.F477; LOCK EA, 1989, TOXICOL LETT, V46, P93, DOI 10.1016/0378-4274(89)90120-3; Lotem J, 1996, P NATL ACAD SCI USA, V93, P12507, DOI 10.1073/pnas.93.22.12507; MAJNO G, 1995, AM J PATHOL, V146, P3; MARTIN SJ, 1995, CELL, V82, P349, DOI 10.1016/0092-8674(95)90422-0; Martin SJ, 1996, EMBO J, V15, P2407, DOI 10.1002/j.1460-2075.1996.tb00598.x; McGowan AJ, 1996, FEBS LETT, V392, P299, DOI 10.1016/0014-5793(96)00838-1; MOALLEM SA, 1995, TERATOLOGY, V52, P3, DOI 10.1002/tera.1420520103; PACKHAM G, 1995, BBA-REV CANCER, V1242, P11, DOI 10.1016/0304-419X(94)00015-T; Reed JC, 1997, NATURE, V387, P773, DOI 10.1038/42867; REED JC, 1994, J CELL BIOL, V124, P1, DOI 10.1083/jcb.124.1.1; Roberts LR, 1997, GASTROENTEROLOGY, V113, P1714, DOI 10.1053/gast.1997.v113.pm9352877; Shimizu S, 1996, ONCOGENE, V12, P2251; SimboliCampbell M, 1997, BREAST CANCER RES TR, V42, P31, DOI 10.1023/A:1005772432465; STEVENS JL, 1986, J BIOL CHEM, V261, P5529; Susin SA, 1996, J EXP MED, V184, P1331, DOI 10.1084/jem.184.4.1331; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Trudel M, 1997, J EXP MED, V186, P1873, DOI 10.1084/jem.186.11.1873; VAMVAKAS S, 1989, MUTAT RES, V222, P329, DOI 10.1016/0165-1218(89)90108-0; van de Water B, 1999, J BIOL CHEM, V274, P13328, DOI 10.1074/jbc.274.19.13328; VANDEWATER B, 1994, J BIOL CHEM, V269, P14546; VanDeWater B, 1996, AM J PHYSIOL-RENAL, V270, pF593, DOI 10.1152/ajprenal.1996.270.4.F593; WAGNER AJ, 1993, MOL CELL BIOL, V13, P2432, DOI 10.1128/MCB.13.4.2432; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; Zhan Y, 1997, MOL CELL BIOL, V17, P6755, DOI 10.1128/MCB.17.11.6755; ZORNIG M, 1995, ONCOGENE, V11, P2165	56	66	74	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 11	1999	18	47					6505	6512		10.1038/sj.onc.1203060	http://dx.doi.org/10.1038/sj.onc.1203060			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	256CW	10597253				2022-12-25	WOS:000083709200013
J	Wo, ZG; Chohan, KK; Chen, HY; Sutcliffe, MJ; Oswald, RE				Wo, ZG; Chohan, KK; Chen, HY; Sutcliffe, MJ; Oswald, RE			Cysteine mutagenesis and homology modeling of the ligand-binding site of a kainate-binding protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLUTAMATE-RECEPTOR-CHANNEL; GATED ION CHANNELS; 3-DIMENSIONAL MODELS; TETRAMERIC STRUCTURE; ESCHERICHIA-COLI; AMPA RECEPTORS; ACID RECEPTORS; NR1 SUBUNIT; DOMAIN; IDENTIFICATION	Glutamate receptors comprise the most abundant group of neurotransmitter receptors in the vertebrate central nervous system. Cysteine mutagenesis in combination with homology modeling has been used to study the determinants of kainate binding in a glutamate receptor subtype, a low molecular weight goldfish kainate-binding protein, GFKAR beta. A construct of GFKAR beta with no cysteines in the extracellular domain was produced, and single cysteine residues were introduced at selected positions. N Ethylmaleimide or derivatized methanethiosulfonate reagents (neutral or charged) were used to modify the introduced cysteines covalently, and the effect on [H-3]kainate binding was determined. In addition, cysteine mutants of GFKAR beta transiently expressed in HEK293 cells were labeled with a membrane-impermeable biotinylating reagent followed by precipitation with streptavidin beads and specific detection of GFKAR beta by Western blot analysis. The results are consistent with the proposal that the energy driving kainate binding is contributed both from residues within the binding site and from interactions between two regions (i.e, two lobes) of the protein that are brought into contact upon ligand binding in a manner analogous to that seen in bacterial amino acid-binding proteins.	Cornell Univ, Coll Vet Med, Dept Mol Med, Ithaca, NY 14853 USA; Univ Leicester, Dept Chem, Leicester LE1 7RH, Leics, England	Cornell University; University of Leicester	Oswald, RE (corresponding author), Cornell Univ, Coll Vet Med, Dept Mol Med, Ithaca, NY 14853 USA.			Sutcliffe, Mike/0000-0003-0414-1700	NIGMS NIH HHS [T32 GM8210] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008210] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abele R, 1998, J BIOL CHEM, V273, P25132, DOI 10.1074/jbc.273.39.25132; AKABAS MH, 1992, SCIENCE, V258, P307, DOI 10.1126/science.1384130; Armstrong N, 1998, NATURE, V395, P913, DOI 10.1038/27692; Arvola M, 1996, J BIOL CHEM, V271, P15527, DOI 10.1074/jbc.271.26.15527; BARTON GJ, 1993, PROTEIN ENG, V6, P37, DOI 10.1093/protein/6.1.37; Basiry SS, 1999, J NEUROSCI, V19, P644; Chen GQ, 1997, P NATL ACAD SCI USA, V94, P13431, DOI 10.1073/pnas.94.25.13431; Dingledine R, 1999, PHARMACOL REV, V51, P7; Dong HL, 1997, NATURE, V386, P279, DOI 10.1038/386279a0; Hall RA, 1997, J NEUROCHEM, V68, P625; HOLLMANN M, 1994, ANNU REV NEUROSCI, V17, P31, DOI 10.1146/annurev.ne.17.030194.000335; Ivanovic A, 1998, J BIOL CHEM, V273, P19933, DOI 10.1074/jbc.273.32.19933; KORNAU HC, 1995, SCIENCE, V269, P1737, DOI 10.1126/science.7569905; Kuner T, 1996, NEURON, V17, P343, DOI 10.1016/S0896-6273(00)80165-8; Kuusinen A, 1995, EMBO J, V14, P6327, DOI 10.1002/j.1460-2075.1995.tb00323.x; Lampinen M, 1998, EMBO J, V17, P4704, DOI 10.1093/emboj/17.16.4704; Laube B, 1997, NEURON, V18, P493, DOI 10.1016/S0896-6273(00)81249-0; Laube B, 1998, J NEUROSCI, V18, P2954; Mano I, 1996, J BIOL CHEM, V271, P15299, DOI 10.1074/jbc.271.26.15299; Mano I, 1998, NEUROREPORT, V9, P327, DOI 10.1097/00001756-199801260-00027; MONAGHAN DT, 1989, ANNU REV PHARMACOL, V29, P365, DOI 10.1146/annurev.pa.29.040189.002053; NAKANISHI N, 1990, NEURON, V5, P569, DOI 10.1016/0896-6273(90)90212-X; Nishimune A, 1998, NEURON, V21, P87, DOI 10.1016/S0896-6273(00)80517-6; OHARA PJ, 1993, NEURON, V11, P41, DOI 10.1016/0896-6273(93)90269-W; Paas Y, 1996, NEURON, V17, P979, DOI 10.1016/S0896-6273(00)80228-7; Paas Y, 1996, EMBO J, V15, P1548, DOI 10.1002/j.1460-2075.1996.tb00499.x; Premkumar LS, 1997, J GEN PHYSIOL, V110, P485, DOI 10.1085/jgp.110.5.485; RAYMOND LA, 1993, NATURE, V361, P637, DOI 10.1038/361637a0; Rosenmund C, 1998, SCIENCE, V280, P1596, DOI 10.1126/science.280.5369.1596; SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626; STERNBACH Y, 1994, NEURON, V13, P1345, DOI 10.1016/0896-6273(94)90420-0; Sutcliffe MJ, 1996, BIOPHYS J, V70, P1575, DOI 10.1016/S0006-3495(96)79724-2; Sutcliffe MJ, 1998, BIOCHEM SOC T, V26, P450, DOI 10.1042/bst0260450; Sutcliffe MJ, 1998, METHOD ENZYMOL, V293, P589; Swanson GT, 1997, NEURON, V19, P913, DOI 10.1016/S0896-6273(00)80972-1; TINGLEY WG, 1993, NATURE, V364, P70, DOI 10.1038/364070a0; UCHINO S, 1992, FEBS LETT, V308, P253, DOI 10.1016/0014-5793(92)81286-U; WAFFORD KA, 1995, MOL PHARMACOL, V47, P374; WALLACE AC, 1995, PROTEIN ENG, V8, P127, DOI 10.1093/protein/8.2.127; WANG LY, 1993, SCIENCE, V259, P1173, DOI 10.1126/science.8382377; WO ZG, 1995, TRENDS NEUROSCI, V18, P161; WO ZG, 1994, P NATL ACAD SCI USA, V91, P7154, DOI 10.1073/pnas.91.15.7154; Wo ZG, 1996, MOL PHARMACOL, V50, P770; WO ZGL, 1995, J BIOL CHEM, V270, P2000, DOI 10.1074/jbc.270.5.2000; WOOD MW, 1995, P NATL ACAD SCI USA, V92, P4882, DOI 10.1073/pnas.92.11.4882	45	11	11	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 24	1999	274	52					37210	37218		10.1074/jbc.274.52.37210	http://dx.doi.org/10.1074/jbc.274.52.37210			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	267WR	10601284	hybrid			2022-12-25	WOS:000084382700055
J	Coe, NR; Smith, AJ; Frohnert, BI; Watkins, PA; Bernlohr, DA				Coe, NR; Smith, AJ; Frohnert, BI; Watkins, PA; Bernlohr, DA			The fatty acid transport protein (FATP1) is a very long chain acyl-CoA synthetase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COENZYME-A SYNTHETASE; ESCHERICHIA-COLI; PHOSPHOLIPID-BILAYERS; GAMMA ACTIVATORS; PLASMA-MEMBRANE; EXPRESSION; GENE; ADIPOCYTES; INSULIN; PURIFICATION	The primary sequence of the murine fatty acid transport protein (FATP1) is very similar to the multigene family of very long chain (C20-C26) acyl-CoA synthetases, To determine if FATP1 is a long chain acyl coenzyme A synthetase, FATP1-Myc/His fusion protein was expressed in COS1 cells, and its enzymatic activity was analyzed. In addition, mutations were generated in two domains conserved in acyl-CoA synthetases: a 6-amino acid substitution into the putative active site (amino acids 249-254) generating mutant M1 and a 59-amino acid deletion into a conserved C-terminal domain (amino acids 464-523) generating mutant M2. Immunolocalization revealed that the FATP1-Myc/His forms were distributed between the COS1 cell plasma membrane and intracellular membranes. COS1 cells expressing wild type FATP1-Myc/His exhibited a 8-fold increase in the ratio of lignoceroyl-CoA synthetase activity (C24:0) to palmitoyl-CoA synthetase activity (C16:0), characteristic of very long chain acyl-CoA synthetases, whereas both mutant M1 and M2 were catalytically inactive. Detergent-solubilized FATP1-Myc/His was partially purified using nickel-based affinity chromatography and demonstrated a 10-fold increase in very long chain acyl-CoA specific activity (C24:0/C16:0). These results indicate that FATP1 is a very long chain acyl-CoA synthetase and suggest that a potential mechanism for facilitating mammalian fatty acid uptake is via esterification coupled influx.	Univ Minnesota, Dept Biochem Mol Biol & Biophys, St Paul, MN 55108 USA; Kennedy Krieger Res Inst, Baltimore, MD 21205 USA	University of Minnesota System; University of Minnesota Twin Cities; Kennedy Krieger Institute	Bernlohr, DA (corresponding author), Univ Minnesota, Dept Biochem Mol Biol & Biophys, 1479 Gortner Ave, St Paul, MN 55108 USA.			Frohnert, Brigitte/0000-0002-6636-4048; Watkins, Paul A./0000-0002-3246-1405	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [P01HD010981] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK049807] Funding Source: NIH RePORTER; NICHD NIH HHS [HD10981] Funding Source: Medline; NIDDK NIH HHS [DK49807] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ABUMRAD NA, 1984, J BIOL CHEM, V259, P8945; Allgood VE, 1997, BIOCHEMISTRY-US, V36, P224, DOI 10.1021/bi961125c; Berk PD, 1996, P SOC EXP BIOL MED, V212, P1; Berk PD, 1997, J BIOL CHEM, V272, P8830, DOI 10.1074/jbc.272.13.8830; Bernlohr DA, 1999, SEMIN CELL DEV BIOL, V10, P43, DOI 10.1006/scdb.1998.0271; BLACK PN, 1994, BBA-LIPID LIPID MET, V1210, P123, DOI 10.1016/0005-2760(94)90113-9; BLACK PN, 1992, J BIOL CHEM, V267, P25513; Black PN, 1997, J BIOL CHEM, V272, P4896, DOI 10.1074/jbc.272.8.4896; Choi JY, 1999, J BIOL CHEM, V274, P4671, DOI 10.1074/jbc.274.8.4671; Faergeman NJ, 1997, J BIOL CHEM, V272, P8531, DOI 10.1074/jbc.272.13.8531; Fitscher BA, 1996, P SOC EXP BIOL MED, V212, P15; Frohnert BI, 1999, J BIOL CHEM, V274, P3970, DOI 10.1074/jbc.274.7.3970; Gargiulo CE, 1999, J LIPID RES, V40, P881; GOSWITZ VC, 1995, PROTEIN SCI, V4, P534; Hirsch D, 1998, P NATL ACAD SCI USA, V95, P8625, DOI 10.1073/pnas.95.15.8625; Hui T.Y., 1997, FRONT BIOSCI, V2, P222; Hui TY, 1998, J BIOL CHEM, V273, P27420, DOI 10.1074/jbc.273.42.27420; KAMEDA K, 1987, BIOCHEM INT, V14, P227; KAMEDA K, 1986, BIOCHEM INT, V13, P343; KAMP F, 1993, BIOCHEMISTRY-US, V32, P11074, DOI 10.1021/bi00092a017; KAMP F, 1995, BIOCHEMISTRY-US, V34, P11928, DOI 10.1021/bi00037a034; Man MZ, 1996, MOL ENDOCRINOL, V10, P1021, DOI 10.1210/me.10.8.1021; MANGROO D, 1993, BIOCHEM CELL BIOL, V71, P51, DOI 10.1139/o93-008; Martin G, 1997, J BIOL CHEM, V272, P28210, DOI 10.1074/jbc.272.45.28210; Motojima K, 1998, J BIOL CHEM, V273, P16710, DOI 10.1074/jbc.273.27.16710; SCHAFFER JE, 1994, CELL, V79, P427, DOI 10.1016/0092-8674(94)90252-6; Steinberg SJ, 1999, BIOCHEM BIOPH RES CO, V257, P615, DOI 10.1006/bbrc.1999.0510; Stuhlsatz-Krouper SM, 1998, J BIOL CHEM, V273, P28642, DOI 10.1074/jbc.273.44.28642; Trigatti BL, 1996, BIOCHEM J, V313, P487, DOI 10.1042/bj3130487; Uchida Y, 1996, J BIOCHEM, V119, P565; Watkins PA, 1998, J BIOL CHEM, V273, P18210, DOI 10.1074/jbc.273.29.18210; Zakim D, 1996, P SOC EXP BIOL MED, V212, P5	32	185	195	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 17	1999	274	51					36300	36304		10.1074/jbc.274.51.36300	http://dx.doi.org/10.1074/jbc.274.51.36300			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	266AV	10593920	hybrid			2022-12-25	WOS:000084279200039
J	Lin, HB; Jurk, M; Gulick, T; Cooper, GM				Lin, HB; Jurk, M; Gulick, T; Cooper, GM			Identification of COUP-TF as a transcriptional repressor of the c-mos proto-oncogene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ORPHAN NUCLEAR RECEPTOR; THYROID-HORMONE; XENOPUS OOCYTES; SARCOMA-VIRUS; MOUSE-TISSUES; SOMATIC-CELLS; GERM-CELLS; MEIOSIS-II; EXPRESSION; PROMOTER	The c-mos proto-oncogene is specifically expressed in the male and female germ cells of the mouse and other vertebrates. We previously identified a 15-base pair sequence element (B2) as the binding site of a candidate repressor of c-mos transcription in somatic cells. In the present study, we used the yeast one-hybrid system to isolate HeLa cell cDNAs encoding proteins that specifically bound to the c-mos B2 element. Nucleotide sequencing identified several of the clones isolated in this screen as the orphan nuclear receptors COUP-TFI and COUP-TFII. A COUP-TF-binding site was then identified within the B2 sequence. Complexes formed between purified COUP-TFs and the c-mos B2 probe comigrated in electrophoretic mobility shift assays with those formed using whole nuclear extracts of NIH 3T3 or HeLa cells. Moreover, the complexes formed with NIH 3T3 nuclear extracts and B2 probe were supershifted with antibody against COUP-TF, identifying COUP-TF as the candidate repressor previously detected in these somatic cell extracts. Substitution of a consensus COUP-TF-binding site for the c-mos negative regulatory element suppressed expression from the c-mos promoter in transfected somatic cells, demonstrating the functional activity of COUP-TF as a repressor of c-mos transcription.	Boston Univ, Dept Biol, Boston, MA 02215 USA; Massachusetts Gen Hosp, Diabet Res Lab, Charlestown, MA 02129 USA; Massachusetts Gen Hosp, Med Serv, Charlestown, MA 02129 USA	Boston University; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital	Cooper, GM (corresponding author), Boston Univ, Dept Biol, 5 Cummington St, Boston, MA 02215 USA.	gmcooper@bu.edu			NICHD NIH HHS [R01-HD35685, R01-HD26594] Funding Source: Medline; NIDDK NIH HHS [K02-DK02461] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD026594] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K02DK002461] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bauer UM, 1998, FEBS LETT, V439, P208, DOI 10.1016/S0014-5793(98)01327-1; CARTER ME, 1994, MOL CELL BIOL, V14, P4360, DOI 10.1128/MCB.14.7.4360; CHEN F, 1994, MOL ENDOCRINOL, V8, P1434, DOI 10.1210/me.8.10.1434; COLLEDGE WH, 1994, NATURE, V370, P65, DOI 10.1038/370065a0; COONEY AJ, 1992, MOL CELL BIOL, V12, P4153, DOI 10.1128/MCB.12.9.4153; GOLDMAN DS, 1987, P NATL ACAD SCI USA, V84, P4509, DOI 10.1073/pnas.84.13.4509; HASHIMOTO N, 1994, NATURE, V370, P68, DOI 10.1038/370068a0; Higgy NA, 1997, BBA-GENE STRUCT EXPR, V1351, P313, DOI 10.1016/S0167-4781(96)00221-7; HUANG HC, 1990, GENE DEV, V4, P287, DOI 10.1101/gad.4.2.287; Hummelke GC, 1998, MOL REPROD DEV, V50, P396, DOI 10.1002/(SICI)1098-2795(199808)50:4<396::AID-MRD3>3.0.CO;2-D; JONK LJC, 1994, MECH DEVELOP, V47, P81, DOI 10.1016/0925-4773(94)90098-1; KANKI JP, 1991, P NATL ACAD SCI USA, V88, P5794, DOI 10.1073/pnas.88.13.5794; Katz D, 1997, ENDOCRINOLOGY, V138, P4364, DOI 10.1210/en.138.10.4364; LI JJ, 1993, SCIENCE, V262, P1870, DOI 10.1126/science.8266075; MANGELSDORF DJ, 1995, CELL, V83, P841, DOI 10.1016/0092-8674(95)90200-7; MUTTER GL, 1987, P NATL ACAD SCI USA, V84, P5301, DOI 10.1073/pnas.84.15.5301; NAKSHATRI H, 1994, J BIOL CHEM, V269, P890; OKEEFE SJ, 1989, P NATL ACAD SCI USA, V86, P7038, DOI 10.1073/pnas.86.18.7038; OSKARSSON M, 1980, SCIENCE, V207, P1222, DOI 10.1126/science.6243788; PAL SK, 1991, MOL CELL BIOL, V11, P5190, DOI 10.1128/MCB.11.10.5190; PAL SK, 1994, FERTIL STERIL, V61, P496; PAPKOFF J, 1982, CELL, V29, P417, DOI 10.1016/0092-8674(82)90158-1; PAULES RS, 1988, ONCOGENE, V3, P59; PEREIRA FA, 1995, J STEROID BIOCHEM, V53, P503, DOI 10.1016/0960-0760(95)00097-J; PROPST F, 1985, NATURE, V315, P516, DOI 10.1038/315516a0; PROPST F, 1987, MOL CELL BIOL, V7, P1629, DOI 10.1128/MCB.7.5.1629; Qiu YH, 1997, GENE DEV, V11, P1925, DOI 10.1101/gad.11.15.1925; SAGATA N, 1989, NATURE, V342, P512, DOI 10.1038/342512a0; SAGATA N, 1988, NATURE, V335, P519, DOI 10.1038/335519a0; Sagata N, 1997, BIOESSAYS, V19, P13, DOI 10.1002/bies.950190105; SCHMIDT M, 1988, MOL CELL BIOL, V8, P923, DOI 10.1128/MCB.8.2.923; Shibata H, 1997, MOL ENDOCRINOL, V11, P714, DOI 10.1210/me.11.6.714; Tsai SY, 1997, ENDOCR REV, V18, P229, DOI 10.1210/er.18.2.229; VANDERHOORN FA, 1991, ONCOGENE, V6, P929; WANG LH, 1989, NATURE, V340, P163, DOI 10.1038/340163a0; WANG MM, 1993, NATURE, V364, P121, DOI 10.1038/364121a0; XU WH, 1995, MOL CELL BIOL, V15, P5369; ZINKEL SS, 1992, MOL CELL BIOL, V12, P2029, DOI 10.1128/MCB.12.5.2029	38	7	7	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 17	1999	274	51					36796	36800		10.1074/jbc.274.51.36796	http://dx.doi.org/10.1074/jbc.274.51.36796			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	266AV	10593989	hybrid			2022-12-25	WOS:000084279200108
J	Seshagiri, S; Vucic, D; Lee, J; Dixit, VM				Seshagiri, S; Vucic, D; Lee, J; Dixit, VM			Baculovirus-based genetic screen for antiapoptotic genes identifies a novel IAP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INDUCED APOPTOSIS; CELL-DEATH; INHIBITION; P35; CLEAVAGE; PROTEASE	The prototype baculovirus, Autographa californica multiple nuclear polyhedrosis virus (AcMNPV) expresses p35, a potent anti cell-death gene that promotes the propagation of the virus by blocking host cell. apoptosis. Infection of insect Sf-21 cells with AcMNPV lacking p35 induces apoptosis. We have used this pro-apoptotic property of the p35 null virus to screen for genes encoding inhibitors of apoptosis that rescue cells infected with the p35 defective virus. We report here the identification of Tn-IAP1, a novel member of the IAP family of cell. death inhibitors. Tn-IAP1 blocks cell death induced by p35 null AcMNPV, actinomycin D, and Drosophila cell-death inducers KID and GRIM. Given the conserved nature of the cell death pathway, this genetic screen can be used for rapid identification of novel inhibitors of apoptosis from diverse sources.	Genentech Inc, Dept Mol Oncol, S San Francisco, CA 94080 USA; Genentech Inc, Dept Biol Mol, S San Francisco, CA 94080 USA	Roche Holding; Genentech; Roche Holding; Genentech	Dixit, VM (corresponding author), Genentech Inc, Dept Mol Oncol, 1 DNA Way, S San Francisco, CA 94080 USA.		dixit, vishva m/A-4496-2012	dixit, vishva m/0000-0001-6983-0326; Seshagiri, Somasekar/0000-0003-4272-6443				Bertin J, 1996, J VIROL, V70, P6251, DOI 10.1128/JVI.70.9.6251-6259.1996; BIRNBAUM MJ, 1994, J VIROL, V68, P2521, DOI 10.1128/JVI.68.4.2521-2528.1994; BUMP NJ, 1995, SCIENCE, V269, P1885, DOI 10.1126/science.7569933; CLEM JR, 1997, BACULOVIRUSES, P237; CLEM RJ, 1991, SCIENCE, V254, P1388, DOI 10.1126/science.1962198; CLEM RJ, 1993, J VIROL, V67, P3730, DOI 10.1128/JVI.67.7.3730-3738.1993; CLEM RJ, 1994, MOL CELL BIOL, V14, P5212, DOI 10.1128/MCB.14.8.5212; Clem RJ, 1996, CELL DEATH DIFFER, V3, P9; Deveraux QL, 1999, GENE DEV, V13, P239, DOI 10.1101/gad.13.3.239; LASKY LA, 1986, SCIENCE, V233, P209, DOI 10.1126/science.3014647; Miller LK, 1999, TRENDS CELL BIOL, V9, P323, DOI 10.1016/S0962-8924(99)01609-8; Peter ME, 1997, P NATL ACAD SCI USA, V94, P12736, DOI 10.1073/pnas.94.24.12736; Seshagiri S, 1997, P NATL ACAD SCI USA, V94, P13606, DOI 10.1073/pnas.94.25.13606; SHEN YQ, 1995, CURR OPIN GENET DEV, V5, P105, DOI 10.1016/S0959-437X(95)90061-6; STELLER H, 1995, SCIENCE, V267, P1445, DOI 10.1126/science.7878463; VAUGHN JL, 1977, IN VITRO CELL DEV B, V13, P213; Vucic D, 1998, J BIOL CHEM, V273, P33915, DOI 10.1074/jbc.273.51.33915; Vucic D, 1997, P NATL ACAD SCI USA, V94, P10183, DOI 10.1073/pnas.94.19.10183; Vucic D, 1998, MOL CELL BIOL, V18, P3300, DOI 10.1128/MCB.18.6.3300; Vucic D, 1997, MOL CELL BIOL, V17, P667, DOI 10.1128/MCB.17.2.667; White E, 1996, GENE DEV, V10, P1, DOI 10.1101/gad.10.1.1; XUE D, 1995, NATURE, V377, P248, DOI 10.1038/377248a0	22	29	33	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 17	1999	274	51					36769	36773		10.1074/jbc.274.51.36769	http://dx.doi.org/10.1074/jbc.274.51.36769			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	266AV	10593985	hybrid			2022-12-25	WOS:000084279200104
J	Richter, NJ; Rogers, GW; Hensold, JO; Merrick, WC				Richter, NJ; Rogers, GW; Hensold, JO; Merrick, WC			Further biochemical and kinetic characterization of human eukaryotic initiation factor 4H	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-BINDING DOMAIN; TRANSLATION INITIATION; MESSENGER-RNA; CRYSTAL-STRUCTURE; NMR-SPECTROSCOPY; ALPHA-HELIX; SEX-LETHAL; PROTEIN; SEQUENCE; ASSIGNMENTS	A cDNA encoding human eukaryotic initiation factor (eIF) 4H was subcloned into a bacterial expression plasmid for purification of recombinant protein. Recombinant human eIF4H (heIF4H) was purified to greater than 95% homogeneity and shown to have similar physical characteristics to eIF4H purified from rabbit reticulocyte lysate as described previously. Functional studies have revealed that recombinant heIF4H functions identically to rabbit eIF4H in stimulating protein synthesis, and the ATP hydrolysis and helicase activities of eIF4A, More detailed enzymatic studies revealed that eIF4H increases the affinity of eLF4A for RNA by a-fold, but has no effect on the binding of ATP by eIF4A, eIF4H stimulates the helicase activity of eIF4A at least 4-fold, and it is postulated that this stimulation occurs through increasing the processivity of eIF4A Northern blot analysis shows that eIF4H is expressed ubiquitously in human tissues, and displays different levels of expression in given tissues relative to eIF4B. Secondary structure analysis of heIF4H by circular dichroism suggest that eIF4H has a mostly beta-sheet structure, which appears similar to other RNA recognition motif-containing proteins. Finally, it is suggested that eIF4H functions in translation initiation through protein-protein interactions that possibly stabilize conformational changes that occur in eIF4A during RNA binding, ATP hydrolysis, and RNA duplex unwinding.	Case Western Reserve Univ, Dept Biochem, Cleveland, OH 44106 USA; Case Western Reserve Univ, Vet Affairs Med Ctr, Cleveland, OH 44106 USA; Case Western Reserve Univ, Dept Med, Cleveland, OH 44106 USA	Case Western Reserve University; US Department of Veterans Affairs; Veterans Health Administration (VHA); Case Western Reserve University; Louis Stokes Cleveland Veterans Affairs Medical Center; Case Western Reserve University	Merrick, WC (corresponding author), Case Western Reserve Univ, Dept Biochem, 10900 Euclid Ave, Cleveland, OH 44106 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM026796] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 07319, DK 43414] Funding Source: Medline; NIGMS NIH HHS [GM 26796] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABRAMSON RD, 1988, J BIOL CHEM, V263, P6016; ABRAMSON RD, 1987, J BIOL CHEM, V262, P3826; Benz J, 1999, STRUCTURE, V7, P671, DOI 10.1016/S0969-2126(99)80088-4; Chen JJ, 1996, NUCLEIC ACIDS RES, V24, P1727, DOI 10.1093/nar/24.9.1727; Cho HS, 1998, J BIOL CHEM, V273, P15045, DOI 10.1074/jbc.273.24.15045; Cho HS, 1996, PROTEIN SCI, V5, P262; Fletcher CM, 1998, BIOCHEMISTRY-US, V37, P9, DOI 10.1021/bi972494r; Fletcher CM, 1998, PROTEIN SCI, V7, P1639, DOI 10.1002/pro.5560070720; FLINTA C, 1986, EUR J BIOCHEM, V154, P193, DOI 10.1111/j.1432-1033.1986.tb09378.x; Gallie DR, 1998, GENE, V216, P1, DOI 10.1016/S0378-1119(98)00318-7; Gradi A, 1998, MOL CELL BIOL, V18, P334, DOI 10.1128/MCB.18.1.334; GRIFO JA, 1983, J BIOL CHEM, V258, P5804; GRIFO JA, 1984, J BIOL CHEM, V259, P8648; Gulbis JM, 1996, CELL, V87, P297, DOI 10.1016/S0092-8674(00)81347-1; HOFFMAN DW, 1991, P NATL ACAD SCI USA, V88, P2495, DOI 10.1073/pnas.88.6.2495; Horiuchi M, 1997, J BIOCHEM-TOKYO, V122, P711; HUANG S, 1987, BIOCHEMISTRY-US, V26, P8242, DOI 10.1021/bi00399a033; Inoue M, 1997, J MOL BIOL, V272, P82, DOI 10.1006/jmbi.1997.1213; Kurihara Y, 1997, GENE, V186, P21, DOI 10.1016/S0378-1119(96)00673-7; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE AL, 1994, BIOCHEMISTRY-US, V33, P13775, DOI 10.1021/bi00250a031; Lee JH, 1999, P NATL ACAD SCI USA, V96, P4342, DOI 10.1073/pnas.96.8.4342; Lorsch JR, 1998, BIOCHEMISTRY-US, V37, P2180, DOI 10.1021/bi972430g; LU JR, 1995, J MOL BIOL, V247, P739, DOI 10.1016/S0022-2836(05)80152-4; Merrick W C, 1979, Methods Enzymol, V60, P101, DOI 10.1016/S0076-6879(79)60010-1; Merrick W C, 1979, Methods Enzymol, V60, P108, DOI 10.1016/S0076-6879(79)60011-3; MERRICK WC, 1996, PATHWAY MECH EUKARYO; METHOT N, 1994, MOL CELL BIOL, V14, P2307, DOI 10.1128/MCB.14.4.2307; MILBURN SC, 1990, EMBO J, V9, P2783, DOI 10.1002/j.1460-2075.1990.tb07466.x; NAGAI K, 1990, NATURE, V348, P515, DOI 10.1038/348515a0; NARANDA T, 1994, J BIOL CHEM, V269, P14465; NIELSEN PJ, 1988, EMBO J, V7, P2097, DOI 10.1002/j.1460-2075.1988.tb03049.x; Nomura N, 1994, DNA Res, V1, P27, DOI 10.1093/dnares/1.1.27; Nomura N, 1994, DNA Res, V1, P47, DOI 10.1093/dnares/1.1.47; Penkett CJ, 1997, J MOL BIOL, V274, P152, DOI 10.1006/jmbi.1997.1369; PERSSON B, 1985, EUR J BIOCHEM, V152, P523, DOI 10.1111/j.1432-1033.1985.tb09227.x; Plaxco KW, 1997, NATURE, V386, P657, DOI 10.1038/386657a0; Richter-Cook NJ, 1998, J BIOL CHEM, V273, P7579, DOI 10.1074/jbc.273.13.7579; Rogers GW, 1999, J BIOL CHEM, V274, P12236, DOI 10.1074/jbc.274.18.12236; Sachs AB, 1997, CELL, V89, P831, DOI 10.1016/S0092-8674(00)80268-8; Sambrook J, 1989, MOL CLONING LAB MANU, V1-3; Uesugi M, 1997, SCIENCE, V277, P1310, DOI 10.1126/science.277.5330.1310; VanGilst MR, 1997, J MOL BIOL, V274, P160, DOI 10.1006/jmbi.1997.1389; WITTEKIND M, 1992, BIOCHEMISTRY-US, V31, P6254, DOI 10.1021/bi00142a013	44	60	63	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 10	1999	274	50					35415	35424		10.1074/jbc.274.50.35415	http://dx.doi.org/10.1074/jbc.274.50.35415			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	264NG	10585411				2022-12-25	WOS:000084187900023
J	Borjigin, J; Deng, J; Wang, MM; Li, XD; Blackshaw, S; Snyder, SH				Borjigin, J; Deng, J; Wang, MM; Li, XD; Blackshaw, S; Snyder, SH			Circadian rhythm of patched1 transcription in the pineal regulated by adrenergic stimulation and cAMP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-A; N-ACETYLTRANSFERASE ACTIVITY; DROSOPHILA IMAGINAL DISKS; SONIC-HEDGEHOG; SIGNALING PATHWAY; HUMAN HOMOLOG; NEURAL-TUBE; GENE; INDUCTION; EXPRESSION	The tumor suppressor patched1 (PTC1), a product of the mammalian homologue of the Drosophila segment polarity gene patched, is a receptor for hedgehog (HH) and is crucial for embryonic development. Although little is known about the signal transduction pathways leading to the activation of pfc1, increased ptc1 transcription has always been associated with elevated HH activity and decreased activity of cAMP-dependent protein kinase A. Here, we demonstrate that in the mammalian pineal gland, ptc1 expression exhibits a dramatic diurnal rhythm with peak expression at midnight. ptc1 mRNA expression in the pineal is regulated by a clock mechanism mediated by the superior cervical ganglion. Most importantly, ptc1 transcription can be induced by agents activating the cAMP signal transduction pathway both in vivo and in vitro and appears to be independent of HH signaling.	Johns Hopkins Univ, Sch Med, Dept Neurosci, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Neurol, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Pharmacol & Mol Sci, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Psychiat, Baltimore, MD 21205 USA; Carnegie Inst Washington, Dept Embryol, Baltimore, MD 21210 USA	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Carnegie Institution for Science	Snyder, SH (corresponding author), Johns Hopkins Univ, Sch Med, Dept Neurosci, 725 N Wolfe St, Baltimore, MD 21205 USA.		Borjigin, Jimo/GXA-3484-2022		NATIONAL INSTITUTE OF MENTAL HEALTH [R03MH057299] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [P50DA000266] Funding Source: NIH RePORTER; NIDA NIH HHS [DA-00266] Funding Source: Medline; NIMH NIH HHS [MH57299] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Blackshaw S, 1997, J NEUROSCI, V17, P8074; Borjigin J, 1999, ANNU REV PHARMACOL, V39, P53, DOI 10.1146/annurev.pharmtox.39.1.53; Borjigin J, 1999, J NEUROSCI, V19, P1018; BORJIGIN J, 1995, NATURE, V378, P7833; CAPDEVILA J, 1994, EMBO J, V13, P4459, DOI 10.1002/j.1460-2075.1994.tb06768.x; Concordet JP, 1996, DEVELOPMENT, V122, P2835; ECHELARD Y, 1993, CELL, V75, P1417, DOI 10.1016/0092-8674(93)90627-3; Epstein DJ, 1996, DEVELOPMENT, V122, P2885; Ericson J, 1996, CELL, V87, P661, DOI 10.1016/S0092-8674(00)81386-0; FAN CM, 1995, CELL, V81, P457, DOI 10.1016/0092-8674(95)90398-4; Goodrich LV, 1996, GENE DEV, V10, P301, DOI 10.1101/gad.10.3.301; Hahn H, 1996, CELL, V85, P841, DOI 10.1016/S0092-8674(00)81268-4; Hammerschmidt M, 1996, GENE DEV, V10, P647, DOI 10.1101/gad.10.6.647; HOOPER JE, 1989, CELL, V59, P751, DOI 10.1016/0092-8674(89)90021-4; Huang Z, 1996, CELL, V86, P411, DOI 10.1016/S0092-8674(00)80114-2; Ingham PW, 1998, CURR OPIN GENET DEV, V8, P88, DOI 10.1016/S0959-437X(98)80067-1; JIANG J, 1995, CELL, V80, P563, DOI 10.1016/0092-8674(95)90510-3; Johnson RL, 1996, SCIENCE, V272, P1668, DOI 10.1126/science.272.5268.1668; LEPAGE T, 1995, NATURE, V373, P711, DOI 10.1038/373711a0; LI W, 1995, CELL, V80, P553, DOI 10.1016/0092-8674(95)90509-X; Marigo V, 1996, P NATL ACAD SCI USA, V93, P9346, DOI 10.1073/pnas.93.18.9346; Marigo V, 1996, DEVELOPMENT, V122, P1225; MARIGO V, 1996, NATURE, V384, P76; NAKANO Y, 1989, NATURE, V341, P508, DOI 10.1038/341508a0; NUSSLEINVOLHARD C, 1980, NATURE, V287, P795, DOI 10.1038/287795a0; Ohlmeyer JT, 1997, GENE DEV, V11, P2250, DOI 10.1101/gad.11.17.2250; PAN DJ, 1995, CELL, V80, P543, DOI 10.1016/0092-8674(95)90508-1; PARFITT A, 1976, NEUROPHARMACOLOGY, V15, P353, DOI 10.1016/0028-3908(76)90083-6; Stone DM, 1996, NATURE, V384, P129, DOI 10.1038/384129a0; STRUTT DI, 1995, NATURE, V373, P705, DOI 10.1038/373705a0; TABATA T, 1994, CELL, V76, P89, DOI 10.1016/0092-8674(94)90175-9; Vortkamp A, 1996, SCIENCE, V273, P613, DOI 10.1126/science.273.5275.613; YUWILER A, 1983, J NEUROCHEM, V41, P146, DOI 10.1111/j.1471-4159.1983.tb11826.x	33	16	16	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 3	1999	274	49					35012	35015		10.1074/jbc.274.49.35012	http://dx.doi.org/10.1074/jbc.274.49.35012			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	260XW	10574978	hybrid			2022-12-25	WOS:000083979600072
J	Devoto, A; Piffanelli, P; Nilsson, I; Wallin, E; Panstruga, R; von Heijne, G; Schulze-Lefert, P				Devoto, A; Piffanelli, P; Nilsson, I; Wallin, E; Panstruga, R; von Heijne, G; Schulze-Lefert, P			Topology, subcellular localization, and sequence diversity of the Mlo family in plants	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTORS; MEMBRANE-PROTEINS; ENDOPLASMIC-RETICULUM; ARABIDOPSIS-THALIANA; LEADER PEPTIDASE; POWDERY MILDEW; SIGNAL PEPTIDE; RESISTANCE; GENE; IDENTIFICATION	Barley Mlo defines the founder of a novel class of plant integral membrane proteins. Lack of the wild type protein leads to broad spectrum disease resistance against the pathogenic powdery mildew fungus and deregulated leaf cell death. Scanning N-glycosylation mutagenesis and Mlo-Lep fusion proteins demonstrated that Mlo is membrane-anchored by 7 transmembrane (TM) helices such that the N terminus is located extracellularly and the C terminus intracellularly. Fractionation of leaf cells and immunoblotting localized the protein to the plant plasma membrane. A genome-wide search for Mlo sequence-related genes in Arabidopsis thaliana revealed approximately 35 family members, the only abundant gene family encoding 7 TM proteins in higher plants. The sequence variability of Mlo family members within a single species, their topology and subcellular localization are reminiscent of the most abundant class of metazoan 7 TM receptors, the G-protein-coupled receptors.	John Innes Ctr Plant Sci Res, Sainsbury Lab, Norwich NR4 7UH, Norfolk, England; Univ Stockholm, Dept Biochem, S-10691 Stockholm, Sweden	UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); John Innes Center; Stockholm University	Schulze-Lefert, P (corresponding author), John Innes Ctr Plant Sci Res, Sainsbury Lab, Colney Lane, Norwich NR4 7UH, Norfolk, England.	schlef@bbsrc.ac.uk	Schulze-Lefert, Paul/B-6707-2011; von Heijne, Gunnar/F-5576-2011; Panstruga, Ralph/F-3340-2011; Schulze-Lefert, Paul/A-7746-2008; von Heijne, Gunnar/AAH-9389-2019	von Heijne, Gunnar/0000-0002-4490-8569; Panstruga, Ralph/0000-0002-3756-8957; 				Aarts N, 1998, P NATL ACAD SCI USA, V95, P10306, DOI 10.1073/pnas.95.17.10306; Arase S, 1997, J PHYTOPATHOL, V145, P31, DOI 10.1111/j.1439-0434.1997.tb00338.x; Baker B, 1997, SCIENCE, V276, P726, DOI 10.1126/science.276.5313.726; BALDWIN JM, 1993, EMBO J, V12, P1693, DOI 10.1002/j.1460-2075.1993.tb05814.x; Bevan M, 1999, BIOESSAYS, V21, P110, DOI 10.1002/(SICI)1521-1878(199902)21:2&lt;110::AID-BIES5&gt;3.0.CO;2-V; BEVAN M, 1998, NATURE, V391, P485; BILGIN N, 1990, EMBO J, V9, P2717, DOI 10.1002/j.1460-2075.1990.tb07458.x; BLOBEL G, 1980, P NATL ACAD SCI-BIOL, V77, P1496, DOI 10.1073/pnas.77.3.1496; Bockaert J, 1999, EMBO J, V18, P1723, DOI 10.1093/emboj/18.7.1723; Bourne HR, 1997, CURR OPIN CELL BIOL, V9, P134, DOI 10.1016/S0955-0674(97)80054-3; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Buschges R, 1997, CELL, V88, P695, DOI 10.1016/S0092-8674(00)81912-1; C elegans Sequencing Consortium, 1998, SCIENCE, V282, P2012, DOI 10.1126/science.282.5396.2012; CALVIN NM, 1988, J BACTERIOL, V170, P2796, DOI 10.1128/jb.170.6.2796-2801.1988; CAPLAN MJ, 1991, CURR TOP MEMBR, V39, P37; CLAROS MG, 1994, COMPUT APPL BIOSCI, V10, P685; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DIETRICH RA, 1994, CELL, V77, P565, DOI 10.1016/0092-8674(94)90218-6; Erickson B. W., 1976, PROTEINS, VII, P255; Freialdenhoven A, 1996, PLANT CELL, V8, P5, DOI 10.1105/tpc.8.1.5; Frye CA, 1998, PLANT CELL, V10, P947, DOI 10.1105/tpc.10.6.947; FUJIKI Y, 1982, J CELL BIOL, V93, P97, DOI 10.1083/jcb.93.1.97; Gafvelin G, 1997, J BIOL CHEM, V272, P6119, DOI 10.1074/jbc.272.10.6119; HEDIN KE, 1993, CELL SIGNAL, V5, P505, DOI 10.1016/0898-6568(93)90046-O; Horn F, 1998, NUCLEIC ACIDS RES, V26, P275, DOI 10.1093/nar/26.1.275; HORN F, 1988, RECEPTOR CHANNEL, V5, P305; HORTON RM, 1989, GENE, V77, P61, DOI 10.1016/0378-1119(89)90359-4; Jabs T, 1996, PLANT PHYSIOL, V111, P76; Jones DA, 1997, ADV BOT RES, V24, P89; Josefsson LG, 1997, EUR J BIOCHEM, V249, P415, DOI 10.1111/j.1432-1033.1997.t01-1-00415.x; KAPLAN HA, 1987, BIOCHIM BIOPHYS ACTA, V906, P161, DOI 10.1016/0304-4157(87)90010-4; Kehoe DM, 1999, TRENDS PLANT SCI, V4, P38, DOI 10.1016/S1360-1385(98)01354-5; KOZAK M, 1989, MOL CELL BIOL, V9, P5134, DOI 10.1128/MCB.9.11.5134; LARSSON C, 1984, FEBS LETT, V171, P271, DOI 10.1016/0014-5793(84)80502-5; MA H, 1990, P NATL ACAD SCI USA, V87, P3821, DOI 10.1073/pnas.87.10.3821; MADDY AH, 1976, J THEOR BIOL, V62, P315, DOI 10.1016/0022-5193(76)90123-5; MELANCON P, 1986, EMBO J, V5, P1551, DOI 10.1002/j.1460-2075.1986.tb04396.x; NAPIER RM, 1995, J EXP BOT, V46, P1603, DOI 10.1093/jxb/46.10.1603; Nielsen H, 1997, PROTEIN ENG, V10, P1, DOI 10.1093/protein/10.1.1; NILSSON I, 1994, J CELL BIOL, V126, P1127, DOI 10.1083/jcb.126.5.1127; NILSSON I, 1993, J BIOL CHEM, V268, P5798; NILSSON I, 1992, FEBS LETT, V299, P243, DOI 10.1016/0014-5793(92)80124-Y; PARETSSOLER A, 1990, PLANT PHYSIOL, V93, P1654, DOI 10.1104/pp.93.4.1654; Plakidou-Dymock S, 1998, CURR BIOL, V8, P315, DOI 10.1016/S0960-9822(98)70131-9; Popov M, 1997, J BIOL CHEM, V272, P18325, DOI 10.1074/jbc.272.29.18325; PRYER NK, 1992, ANNU REV BIOCHEM, V61, P471; Sandelius A. S., 1990, The plant plasma membrane., P44; SERRANO R, 1989, ANNU REV PLANT PHYS, V40, P61; Shirasu K, 1999, PLANT J, V17, P293, DOI 10.1046/j.1365-313X.1999.00376.x; Sonnhammer E L, 1998, Proc Int Conf Intell Syst Mol Biol, V6, P175; TAM JP, 1988, P NATL ACAD SCI USA, V85, P5409, DOI 10.1073/pnas.85.15.5409; Teasdale RD, 1996, ANNU REV CELL DEV BI, V12, P27, DOI 10.1146/annurev.cellbio.12.1.27; van Geest M, 1999, J BIOL CHEM, V274, P2816, DOI 10.1074/jbc.274.5.2816; van Neuren AS, 1999, J RECEPT SIGNAL TR R, V19, P341, DOI 10.3109/10799899909036656; von Heijne G, 1998, NATURE, V396, P111, DOI 10.1038/24036; Von Heijne G, 1998, ACTA PHYSIOL SCAND, V163, P17; VonHeijne G, 1996, PROG BIOPHYS MOL BIO, V66, P113, DOI 10.1016/S0079-6107(97)85627-1; Wallin E, 1998, PROTEIN SCI, V7, P1029, DOI 10.1002/pro.5560070420; Wess J, 1997, FASEB J, V11, P346, DOI 10.1096/fasebj.11.5.9141501; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9	60	218	252	0	36	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 3	1999	274	49					34993	35004		10.1074/jbc.274.49.34993	http://dx.doi.org/10.1074/jbc.274.49.34993			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	260XW	10574976	hybrid			2022-12-25	WOS:000083979600070
J	Hi, R; Osada, S; Yumoto, N; Osumi, T				Hi, R; Osada, S; Yumoto, N; Osumi, T			Characterization of the amino-terminal activation domain of peroxisome proliferator-activated receptor alpha - Importance of alpha-helical structure in the transactivating function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KINASE-MEDIATED PHOSPHORYLATION; PPAR-GAMMA; TRANSCRIPTIONAL ACTIVATION; NUCLEAR RECEPTOR; PROTEIN-KINASE; RETINOIC ACID; OXIDIZED LDL; BINDING; VP16; ELEMENTS	The transactivating function of the A/B region of mouse peroxisome proliferator-activated receptor alpha (PPAR alpha; NR1C1) was characterized. The truncated version of PPAR alpha lacking the A/B region had 60-70% lower transactivating function than full-length PPAR alpha in both the presence and absence of the peroxisome proliferator ciprofibrate. When tethered to the yeast Gal4 DNA-binding domain, the A/B region exhibited the significant ligand-independent transactivating function, AF-1 activity. The first 44 amino acid residues were necessary for maximal transactivation, and the minimally essential region was further delimited to amino acids 15-44. This region is highly enriched with acidic residues, but mutational analyses showed that the protein structure, rather than the negative charge itself, was important for the AF-1 activity. An alpha-helical configuration was predicted for this region, and a CD spectrum analysis of the synthetic peptides showed that mutant sequences with higher AF-1 activity have higher helical contents and vice versa. The most active mutant, in which Met(31) was replaced with Leu, was similar to 5-fold more potent than the wild-type A/B region. These findings indicate that the AF-1 region of PPAR alpha is an acidic activation domain and that the helix-forming property is implicated in the transactivating function.	Himeji Inst Technol, Fac Sci, Dept Life Sci, Kamigori, Hyogo 6781297, Japan; Osaka Natl Res Inst, Dept Organ Mat, Ikeda, Osaka 5638577, Japan	University of Hyogo; National Institute of Advanced Industrial Science & Technology (AIST)	Osumi, T (corresponding author), Himeji Inst Technol, Fac Sci, Dept Life Sci, 3-2-1 Koto, Kamigori, Hyogo 6781297, Japan.							Adams M, 1997, J BIOL CHEM, V272, P5128, DOI 10.1074/jbc.272.8.5128; Auwerx J, 1999, CELL, V97, P161; BERRY M, 1990, EMBO J, V9, P2811, DOI 10.1002/j.1460-2075.1990.tb07469.x; Camp HS, 1999, ENDOCRINOLOGY, V140, P392, DOI 10.1210/en.140.1.392; Camp HS, 1997, J BIOL CHEM, V272, P10811; CHEN YH, 1974, BIOCHEMISTRY-US, V13, P3350, DOI 10.1021/bi00713a027; CHOU PY, 1978, ANNU REV BIOCHEM, V47, P251, DOI 10.1146/annurev.bi.47.070178.001343; CRESS WD, 1991, SCIENCE, V251, P87, DOI 10.1126/science.1846049; DOIG AJ, 1994, BIOCHEMISTRY-US, V33, P3396, DOI 10.1021/bi00177a033; FOLKERS GE, 1995, J BIOL CHEM, V270, P23552, DOI 10.1074/jbc.270.40.23552; Gelman L, 1999, J BIOL CHEM, V274, P7681, DOI 10.1074/jbc.274.12.7681; Green VJ, 1998, J BIOL CHEM, V273, P29950, DOI 10.1074/jbc.273.45.29950; Hu ED, 1996, SCIENCE, V274, P2100, DOI 10.1126/science.274.5295.2100; Ijpenberg A, 1997, J BIOL CHEM, V272, P20108, DOI 10.1074/jbc.272.32.20108; Ikonen T, 1997, J BIOL CHEM, V272, P29821, DOI 10.1074/jbc.272.47.29821; ISSEMANN I, 1990, NATURE, V347, P645, DOI 10.1038/347645a0; Jiang CY, 1998, NATURE, V391, P82, DOI 10.1038/34184; Juge-Aubry CE, 1999, J BIOL CHEM, V274, P10505, DOI 10.1074/jbc.274.15.10505; JugeAubry C, 1997, J BIOL CHEM, V272, P25252, DOI 10.1074/jbc.272.40.25252; KLIEWER SA, 1992, NATURE, V358, P771, DOI 10.1038/358771a0; Kraus WL, 1995, P NATL ACAD SCI USA, V92, P12314, DOI 10.1073/pnas.92.26.12314; Kussie PH, 1996, SCIENCE, V274, P948, DOI 10.1126/science.274.5289.948; Lim H, 1999, GENE DEV, V13, P1561, DOI 10.1101/gad.13.12.1561; MACGREGOR GR, 1989, NUCLEIC ACIDS RES, V17, P2365, DOI 10.1093/nar/17.6.2365; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; Munoz V, 1997, BIOPOLYMERS, V41, P495, DOI 10.1002/(SICI)1097-0282(19970415)41:5<495::AID-BIP2>3.3.CO;2-6; Nagy L, 1998, CELL, V93, P229, DOI 10.1016/S0092-8674(00)81574-3; Osada S, 1997, GENES CELLS, V2, P315, DOI 10.1046/j.1365-2443.1997.1220319.x; OSUMI T, 1991, BIOCHEM BIOPH RES CO, V175, P866, DOI 10.1016/0006-291X(91)91645-S; PALMER CNA, 1995, J BIOL CHEM, V270, P16114, DOI 10.1074/jbc.270.27.16114; SAMBROOK J, 1989, MOL CLONING LABORATO, V2, P16; SCHIFFER M, 1967, BIOPHYS J, V7, P121, DOI 10.1016/S0006-3495(67)86579-2; Shalev A, 1996, ENDOCRINOLOGY, V137, P4499, DOI 10.1210/en.137.10.4499; Shao DL, 1998, NATURE, V396, P377, DOI 10.1038/24634; Sullivan SM, 1998, NUCLEIC ACIDS RES, V26, P4487, DOI 10.1093/nar/26.19.4487; TONTONOZ P, 1994, CELL, V79, P1147, DOI 10.1016/0092-8674(94)90006-X; Tontonoz P, 1998, CELL, V93, P241, DOI 10.1016/S0092-8674(00)81575-5; Tremblay A, 1999, MOL CELL, V3, P513, DOI 10.1016/S1097-2765(00)80479-7; Uesugi M, 1997, SCIENCE, V277, P1310, DOI 10.1126/science.277.5330.1310; Werman A, 1997, J BIOL CHEM, V272, P20230, DOI 10.1074/jbc.272.32.20230; Zhang B, 1996, J BIOL CHEM, V271, P31771, DOI 10.1074/jbc.271.50.31771	41	40	43	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 3	1999	274	49					35152	35158		10.1074/jbc.274.49.35152	http://dx.doi.org/10.1074/jbc.274.49.35152			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	260XW	10574998	hybrid			2022-12-25	WOS:000083979600092
J	Bounpheng, MA; Dimas, JJ; Dodds, SG; Christy, BA				Bounpheng, MA; Dimas, JJ; Dodds, SG; Christy, BA			Degradation of Id proteins by the ubiquitin-proteasome pathway	FASEB JOURNAL			English	Article						helix-loop-helix; dominant-negative regulators; 26S proteasome	CELL-CYCLE; TRANSCRIPTION FACTORS; 3T3 CELLS; IN-VIVO; APOPTOSIS; MECHANISM; LACTACYSTIN; PROTEOLYSIS; EXPRESSION; THREONINE	Id proteins act as negative regulators of bHLH transcription factors by forming; transcriptionally inactive protein complexes. The proposed function of these proteins includes promotion of cell growth and cell cycle progression, induction of apoptosis, and inhibition of cellular differentiation. We investigated the role of the ubiquitin-mediated proteolytic pathway in the degradation of the Id3 protein. We found Id3 to be a short-lived protein and estimated the half-life to be similar to 20 min in 293 cells, Using specific inhibitors of the 26S proteasome and mutant fibroblast cells with a temperature-sensitive defect in the essential El ubiquitin-activating enzyme, we show that Id3 and the related Idl and Id2 proteins are degraded through the ubiquitin-proteasome pathway. We found the Id4 protein to be much less sensitive to inhibitors of the 26S proteasome, but its degradation was dependent on the El enzyme. In addition, we observed that coexpression of the bHLH protein E47 with Id3 significantly reduced the rate of degradation of Id3, suggesting that Id3 is less susceptible to degradation by the 26S proteasome when complexed to a bHLH protein.	Univ Texas, Hlth Sci Ctr, Inst Biotechnol, Dept Mol Med, San Antonio, TX 78245 USA; Univ Texas, Hlth Sci Ctr, Inst Biotechnol, Dept Struct & Cellular Biol, San Antonio, TX 78245 USA	University of Texas System; University of Texas Health San Antonio; University of Texas System; University of Texas Health San Antonio	Christy, BA (corresponding author), Univ Texas, Hlth Sci Ctr, Inst Biotechnol, Dept Mol Med, 15355 Lambda Dr, San Antonio, TX 78245 USA.	christy@uthscsa.edu		Dodds, Sherry/0000-0002-7987-9542	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R29HD029850] Funding Source: NIH RePORTER; NICHD NIH HHS [R29HD29850] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Abu Hatoum O, 1998, MOL CELL BIOL, V18, P5670, DOI 10.1128/MCB.18.10.5670; Anand G, 1997, J BIOL CHEM, V272, P19140, DOI 10.1074/jbc.272.31.19140; BARONE MV, 1994, P NATL ACAD SCI USA, V91, P4985, DOI 10.1073/pnas.91.11.4985; Bogyo M, 1997, P NATL ACAD SCI USA, V94, P6629, DOI 10.1073/pnas.94.13.6629; Breitschopf K, 1998, EMBO J, V17, P5964, DOI 10.1093/emboj/17.20.5964; Campanero MR, 1997, P NATL ACAD SCI USA, V94, P2221, DOI 10.1073/pnas.94.6.2221; CHOWDARY DR, 1994, MOL CELL BIOL, V14, P1997, DOI 10.1128/MCB.14.3.1997; CHRISTY BA, 1991, P NATL ACAD SCI USA, V88, P1815, DOI 10.1073/pnas.88.5.1815; Claret FX, 1996, NATURE, V383, P453, DOI 10.1038/383453a0; DEED RW, 1994, BBA-GENE STRUCT EXPR, V1219, P160, DOI 10.1016/0167-4781(94)90261-5; DEED RW, 1993, ONCOGENE, V8, P599; Deed RW, 1996, J BIOL CHEM, V271, P23603, DOI 10.1074/jbc.271.39.23603; Dick LR, 1996, J BIOL CHEM, V271, P7273, DOI 10.1074/jbc.271.13.7273; FENTEANY G, 1995, SCIENCE, V268, P726, DOI 10.1126/science.7732382; Florio M, 1998, MOL CELL BIOL, V18, P5435, DOI 10.1128/MCB.18.9.5435; Geier E, 1999, SCIENCE, V283, P978, DOI 10.1126/science.283.5404.978; Glas R, 1998, NATURE, V392, P618, DOI 10.1038/33443; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; Hershko A, 1997, CURR OPIN CELL BIOL, V9, P788, DOI 10.1016/S0955-0674(97)80079-8; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; IAVARONE A, 1994, GENE DEV, V8, P1270, DOI 10.1101/gad.8.11.1270; Kho CJ, 1997, J BIOL CHEM, V272, P3845, DOI 10.1074/jbc.272.6.3845; King RW, 1996, SCIENCE, V274, P1652, DOI 10.1126/science.274.5293.1652; Loveys DA, 1996, NUCLEIC ACIDS RES, V24, P2813, DOI 10.1093/nar/24.14.2813; Martinsen BJ, 1998, SCIENCE, V281, P988, DOI 10.1126/science.281.5379.988; Melnikova IN, 1996, CELL GROWTH DIFFER, V7, P1067; Nakajima T, 1998, P NATL ACAD SCI USA, V95, P10590, DOI 10.1073/pnas.95.18.10590; Norton JD, 1998, TRENDS CELL BIOL, V8, P58, DOI 10.1016/S0962-8924(97)01183-5; Norton JD, 1998, MOL CELL BIOL, V18, P2371, DOI 10.1128/MCB.18.4.2371; Oyama F, 1998, NEUROSCI RES, V31, P1, DOI 10.1016/S0168-0102(98)00020-0; Pagano M, 1997, FASEB J, V11, P1067, DOI 10.1096/fasebj.11.13.9367342; Pickart CM, 1997, FASEB J, V11, P1055, DOI 10.1096/fasebj.11.13.9367341; Spataro V, 1997, J BIOL CHEM, V272, P30470, DOI 10.1074/jbc.272.48.30470; SUN XH, 1994, CELL, V79, P893, DOI 10.1016/0092-8674(94)90078-7; Tanaka K, 1998, J BIOL CHEM, V273, P25922, DOI 10.1074/jbc.273.40.25922; TREIER M, 1994, CELL, V78, P787, DOI 10.1016/S0092-8674(94)90502-9; Yokota Y, 1999, NATURE, V397, P702, DOI 10.1038/17812; ZENG GC, 1984, MOL CELL BIOL, V4, P1815, DOI 10.1128/MCB.4.9.1815	38	105	106	0	2	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	1999	13	15					2257	2264		10.1096/fasebj.13.15.2257	http://dx.doi.org/10.1096/fasebj.13.15.2257			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	266QN	10593873				2022-12-25	WOS:000084310800017
J	Kikyo, M; Tanaka, K; Kamei, T; Ozaki, K; Fujiwara, T; Inoue, E; Takita, Y; Ohya, Y; Takai, Y				Kikyo, M; Tanaka, K; Kamei, T; Ozaki, K; Fujiwara, T; Inoue, E; Takita, Y; Ohya, Y; Takai, Y			An FH domain-containing Bnr1p is a multifunctional protein interacting with a variety of cytoskeletal proteins in Saccharomyces cerevisiae	ONCOGENE			English	Article						Rho; formin-like protein; septins	GTP-BINDING PROTEIN; ACTIN CYTOSKELETON; EXCHANGE PROTEINS; ESCHERICHIA-COLI; SHUTTLE VECTORS; CELL DIVISION; BUD SITE; YEAST; BNI1P; CYTOKINESIS	Proteins containing formin homology domains, FH1 and FH2, are involved in cytokinesis or establishment of cell polarity in a variety of organisms. Bni1p and Bnr1p are FPF proteins and potential targets of the Rho family small GTP-binding proteins in S. cerevisiae. We have shown that Bnr1p is localized at the bud neck to interact with Hof1p, involved in cytokinesis. We report here that the overexpression of BNR1 causes a cytokinesis deficiency which is similar to the phenotypes of the septin mutants, including cdc3, cdc10, cdc11, and cdc12. The region required for the septin mutant phenotypes was mapped to Bnr1p (35-500), which coincided,vith the region required for the bud-neck localization. To further isolate a gene interacting with BNI1 or BNR1, a multicopy suppressor of the bni1 bnr1 mutant was isolated. This gene encoded Smy1p, a kinesin-related protein. Bnr1p, but not Bni1p, directly interacted with the C-terminal region of Smy1p. The Smy1p-interacting region of Bnr1p was mapped to a region containing the FH2 domain. Bnr1p also directly interacted with Bud6p, a novel actin-binding protein. Bnr1p is thus a multifunctional protein which interacts with the septin system, a microtubule-dependent motor protein, and the actin system, to regulate cytoskeletal functions in S. cerevisiae.	Osaka Univ, Grad Sch Med, Fac Med, Dept Biochem & Mol Biol, Suita, Osaka 5650871, Japan; Univ Tokyo, Grad Sch Frontier Sci, Dept Integrated Biosci, Bunkyo Ku, Tokyo 1130033, Japan	Osaka University; University of Tokyo	Takai, Y (corresponding author), Osaka Univ, Grad Sch Med, Fac Med, Dept Biochem & Mol Biol, 2-2 Yamadaoka, Suita, Osaka 5650871, Japan.		Kuroda, Kumi O/A-3312-2013; Yashiroda, Yoko/C-8769-2014	Kuroda, Kumi O./0000-0001-7037-1753				BARTEL P, 1993, BIOTECHNIQUES, V14, P920; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Carroll CW, 1998, J CELL BIOL, V143, P709, DOI 10.1083/jcb.143.3.709; CID VJ, 1995, MICROBIOL REV, V59, P345, DOI 10.1128/MMBR.59.3.345-386.1995; DIGUAN C, 1988, GENE, V67, P21, DOI 10.1016/0378-1119(88)90004-2; Evangelista M, 1997, SCIENCE, V276, P118, DOI 10.1126/science.276.5309.118; FLESCHER EG, 1993, J CELL BIOL, V122, P373, DOI 10.1083/jcb.122.2.373; FRAZIER JA, 1997, CURR BIOL, V7, P414; Fujiwara T, 1998, MOL BIOL CELL, V9, P1221, DOI 10.1091/mbc.9.5.1221; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; Giot L, 1997, MOL BIOL CELL, V8, P987, DOI 10.1091/mbc.8.6.987; GUARENTE L, 1983, METHOD ENZYMOL, V101, P181; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; HALL A, 1994, ANNU REV CELL BIOL, V10, P31, DOI 10.1146/annurev.cb.10.110194.000335; HARTWELL LH, 1971, EXP CELL RES, V69, P265, DOI 10.1016/0014-4827(71)90223-0; HILL JE, 1986, YEAST, V2, P163, DOI 10.1002/yea.320020304; Imamura H, 1997, EMBO J, V16, P2745, DOI 10.1093/emboj/16.10.2745; Kamei T, 1998, J BIOL CHEM, V273, P28341, DOI 10.1074/jbc.273.43.28341; KIKUCHI A, 1992, J BIOL CHEM, V267, P14611; Kohno H, 1996, EMBO J, V15, P6060, DOI 10.1002/j.1460-2075.1996.tb00994.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lillie SH, 1998, J CELL BIOL, V140, P873, DOI 10.1083/jcb.140.4.873; LILLIE SH, 1992, NATURE, V356, P358, DOI 10.1038/356358a0; Longtine MS, 1996, CURR OPIN CELL BIOL, V8, P106, DOI 10.1016/S0955-0674(96)80054-8; Longtine MS, 1998, J CELL BIOL, V143, P719, DOI 10.1083/jcb.143.3.719; Mino A, 1998, BIOCHEM BIOPH RES CO, V251, P732, DOI 10.1006/bbrc.1998.9541; NAKATSURU S, 1994, BIOCHEM BIOPH RES CO, V202, P82, DOI 10.1006/bbrc.1994.1896; Ozaki K, 1996, EMBO J, V15, P2196, DOI 10.1002/j.1460-2075.1996.tb00573.x; PRINGLE JR, 1991, METHOD ENZYMOL, V194, P732; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SANDERS SL, 1994, CURR BIOL, V4, P907, DOI 10.1016/S0960-9822(00)00201-3; Sherman F., 1986, METHODS YEAST GENETI; SIKORSKI RS, 1989, GENETICS, V122, P19; TAKAI Y, 1995, TRENDS BIOCHEM SCI, V20, P227, DOI 10.1016/S0968-0004(00)89022-2; Tanaka K, 1998, CURR OPIN CELL BIOL, V10, P112, DOI 10.1016/S0955-0674(98)80093-8; Umikawa M, 1998, ONCOGENE, V16, P2011, DOI 10.1038/sj.onc.1201724; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; Wasserman S, 1998, TRENDS CELL BIOL, V8, P111, DOI 10.1016/S0962-8924(97)01217-8; YAMOCHI W, 1994, J CELL BIOL, V125, P1077, DOI 10.1083/jcb.125.5.1077	39	47	47	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 25	1999	18	50					7046	7054		10.1038/sj.onc.1203184	http://dx.doi.org/10.1038/sj.onc.1203184			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	259PH	10597305				2022-12-25	WOS:000083901900011
J	Crusius, K; Kaszkin, M; Kinzel, V; Alonso, A				Crusius, K; Kaszkin, M; Kinzel, V; Alonso, A			The human papillomavirus type 16 E5 protein modulates phospholipase C-gamma-1 activity and phosphatidyl inositol turnover in mouse fibroblasts	ONCOGENE			English	Article						phospholipids; phospholipases; membranes; kinases	EPIDERMAL-GROWTH-FACTOR; EPITHELIAL-CELL LINE; KINASE-C ACTIVATION; SIGNAL-TRANSDUCTION; FACTOR RECEPTOR; A431 CELLS; KERATINOCYTES; HYDROLYSIS; GENE; COMMUNICATION	The human papillomavirus type 16 E5 (HPV16-E5) protein is a membrane protein that has been associated with malignant growth. The protein affects growth factor-mediated signal transduction in a ligand-dependent manner. We show now that E5 expression in A31 fibroblasts results in an increased level of diacylglycerol (DAG) and inositol phosphates. Immunoprecipitation of phospholipase C-gamma-1 (PLC-gamma-1) with specific antibodies and immunoblotting with anti-phosphotyrosine antibodies reveal a large increase in tyrosine phosphorylation of the enzyme in ES-expressing cells compared to control vector-transfected cells. This activation of tyrosine phosphorylation is growth factor independent. In addition, an enhanced formation of phosphatidic acid (PA) was observed in E5 cells. This increase did not result from activation of phospholipase D (PLD), although the enzyme was activatable by treatment with phorbol ester. Thus, a phosphohydrolase-mediated DAG synthesis from PLD-produced PA can be excluded. The observed effects were not further enhanced by EGF showing that the presence of the growth factor is not necessary for maintaining permanent activation of PLC-gamma-1 in E5-expressing cells. The DAG- and inositol phosphate-mediated signal cascade within the cells is thus effectively uncoupled from external control via EGF and its receptor in the presence of E5 protein.	Deutsch Krebsforschungszentrum, D-69120 Heidelberg, Germany	Helmholtz Association; German Cancer Research Center (DKFZ)	Alonso, A (corresponding author), Deutsch Krebsforschungszentrum, Neuenheimer Feld 242, D-69120 Heidelberg, Germany.							Auvinen E, 1997, INT J ONCOL, V11, P1297; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BOUVARD V, 1994, VIROLOGY, V203, P73, DOI 10.1006/viro.1994.1456; CONRAD M, 1993, J VIROL, V67, P6170, DOI 10.1128/JVI.67.10.6170-6178.1993; Crusius K, 1998, EXP CELL RES, V241, P76, DOI 10.1006/excr.1998.4024; Crusius K, 1997, ONCOGENE, V15, P1437, DOI 10.1038/sj.onc.1201312; DIVECHA N, 1995, CELL, V80, P269, DOI 10.1016/0092-8674(95)90409-3; Exton JH, 1998, BBA-MOL CELL BIOL L, V1436, P105, DOI 10.1016/S0005-2760(98)00124-6; Faccini AM, 1996, J VIROL, V70, P9041, DOI 10.1128/JVI.70.12.9041-9045.1996; FAULKNERVALLE G, 1995, J GEN VIROL, V76, P1239; HAUSEN HZ, 1991, VIROLOGY, V184, P9, DOI 10.1016/0042-6822(91)90816-T; HAUSEN HZ, 1989, CANCER RES, V49, P4677; HOKIN LE, 1985, ANNU REV BIOCHEM, V54, P205, DOI 10.1146/annurev.biochem.54.1.205; Homma MK, 1996, CELL GROWTH DIFFER, V7, P281; Kaszkin M, 1996, BIOCHEM J, V314, P129, DOI 10.1042/bj3140129; KASZKIN M, 1992, BIOCHEM J, V287, P51, DOI 10.1042/bj2870051; Katan M, 1996, CANCER SURV, V27, P199; Khare S, 1997, J CLIN INVEST, V99, P1831, DOI 10.1172/JCI119350; Kiss Z, 1998, BBA-LIPID LIPID MET, V1392, P109, DOI 10.1016/S0005-2760(98)00030-7; KOBAYASHI M, 1987, J NEUROCHEM, V48, P1597, DOI 10.1111/j.1471-4159.1987.tb05707.x; Lambeth JD., 1996, NEW COMPREHENSIVE BI, P237; LEECHANACHAI P, 1992, ONCOGENE, V7, P19; LEPTAK C, 1991, J VIROL, V65, P7078, DOI 10.1128/JVI.65.12.7078-7083.1991; Liscovitch M, 1996, J LIPID MEDIAT CELL, V14, P215, DOI 10.1016/0929-7855(96)00528-7; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; OELZE I, 1995, J VIROL, V69, P4489, DOI 10.1128/JVI.69.7.4489-4494.1995; PIM D, 1992, ONCOGENE, V7, P27; Rahimi N, 1996, CELL GROWTH DIFFER, V7, P263; REYNOLDS NJ, 1993, BIOCHEM J, V294, P535, DOI 10.1042/bj2940535; Sakane F, 1997, INT J BIOCHEM CELL B, V29, P1139, DOI 10.1016/S1357-2725(97)00037-X; Schmidt M, 1998, J BIOL CHEM, V273, P7413, DOI 10.1074/jbc.273.13.7413; Singer WD, 1997, ANNU REV BIOCHEM, V66, P475, DOI 10.1146/annurev.biochem.66.1.475; STRAIGHT SW, 1993, J VIROL, V67, P4521, DOI 10.1128/JVI.67.8.4521-4532.1993; WAGNER H, 1962, J LIPID RES, V3, P177; WAHL M, 1988, J BIOL CHEM, V263, P7581; YEO EJ, 1995, J BIOL CHEM, V270, P3980, DOI 10.1074/jbc.270.8.3980	36	21	22	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 18	1999	18	48					6714	6718		10.1038/sj.onc.1203075	http://dx.doi.org/10.1038/sj.onc.1203075			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	257QA	10597278				2022-12-25	WOS:000083792000012
J	Hori, T; Osaka, F; Chiba, T; Miyamoto, C; Okabayashi, K; Shimbara, N; Kato, S; Tanaka, K				Hori, T; Osaka, F; Chiba, T; Miyamoto, C; Okabayashi, K; Shimbara, N; Kato, S; Tanaka, K			Covalent modification of all members of human cullin family proteins by NEDD8	ONCOGENE			English	Article						cullin; NEDD8; SCF; ubiquitin; ubiquitin-like protein	UBIQUITIN-LIKE PROTEIN; F-BOX PROTEIN; CELL-CYCLE; LIGASE COMPLEX; HUMAN CUL-1; PATHWAY; GENE; PROTEOLYSIS; SUMO-1; SYSTEM	Recently we found that NEDD8, a ubiquitin-like protein, was linked covalently to human cullin-4A (abbreviated Cul-4A) by a new ubiquitin-related pathway that is analogous to but distinct from the ligating system for SUMO1, another ubiquitin-like protein. However, it remained unknown whether the other five members of the family of human cullin/Cdc53 proteins are modified by NEDD8, Here we report that all Hs-Cul family proteins, such as Cul-1, Cul-2, Cul-3, Cul-4B, and Cul-5, in addition to Cul-4A, were modified by covalent attachment of NEDD8 in rabbit reticulocyte lysates, Moreover, by comprehensive Northern-blot analyses, we examined multiple tissue distributions of the messages for all Cul-family proteins, NEDD8, and the NEDD8-ligating system consisting of APP-BP1/hUba3, and hUbc12, which function as E1- and E2-like enzymes, respectively, The expressions of Cul-1, Cul-2, and Cul-3 resembled each other and were apparently correlated to those of NEDD8 and the NEDD8-ligating system in various human cells and tissues. However, the mRNA levels of Cul-4A, Cul-4B, and Cul-5 differed considerably from each other as well as from other Cul-family proteins. The enhanced expression of all Cul-family proteins except Cul-5 was observed in a variety of tumor cell lines.	Tokyo Metropolitan Inst Med Sci, Bunkyo Ku, Tokyo 1130021, Japan; Hoffmann La Roche Inc, Nutley, NJ 07110 USA; Japan Sci & Technol Corp, Sagami Chem Res Ctr, ERATO, Kato Cytoprot Network Project, Kanagawa 2290012, Japan; Sumitomo Elect Ind Ltd, Biomed R&D Dept, Sakae Ku, Yokohama, Kanagawa 2448588, Japan	Tokyo Metropolitan Institute of Medical Science; Roche Holding; Japan Science & Technology Agency (JST); Sumitomo Electric Industries	Tanaka, K (corresponding author), Tokyo Metropolitan Inst Med Sci, Bunkyo Ku, 3-18-22 Honkomagome, Tokyo 1130021, Japan.							Chen LC, 1998, CANCER RES, V58, P3677; Desterro JMP, 1998, MOL CELL, V2, P233, DOI 10.1016/S1097-2765(00)80133-1; Drury LS, 1997, EMBO J, V16, P5966, DOI 10.1093/emboj/16.19.5966; Du M, 1998, J BIOL CHEM, V273, P24289, DOI 10.1074/jbc.273.38.24289; Elledge SJ, 1998, BBA-REV CANCER, V1377, pM61, DOI 10.1016/S0304-419X(98)00005-5; Feldman RMR, 1997, CELL, V91, P221, DOI 10.1016/S0092-8674(00)80404-3; HANDELI S, 1992, CELL, V71, P599, DOI 10.1016/0092-8674(92)90594-3; Harper JW, 1999, NAT CELL BIOL, V1, pE5, DOI 10.1038/8952; Hart M, 1999, CURR BIOL, V9, P207, DOI 10.1016/S0960-9822(99)80091-8; Hatakeyama S, 1999, P NATL ACAD SCI USA, V96, P3859, DOI 10.1073/pnas.96.7.3859; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Hochstrasser M, 1996, ANNU REV GENET, V30, P405, DOI 10.1146/annurev.genet.30.1.405; Hochstrasser M, 1998, GENE DEV, V12, P901, DOI 10.1101/gad.12.7.901; Johnson ES, 1997, EMBO J, V16, P5509, DOI 10.1093/emboj/16.18.5509; Kamitani T, 1997, J BIOL CHEM, V272, P28557, DOI 10.1074/jbc.272.45.28557; Kipreos ET, 1996, CELL, V85, P829, DOI 10.1016/S0092-8674(00)81267-2; Kitagawa M, 1999, EMBO J, V18, P2401, DOI 10.1093/emboj/18.9.2401; KUMAR S, 1993, BIOCHEM BIOPH RES CO, V195, P393, DOI 10.1006/bbrc.1993.2056; Lammer D, 1998, GENE DEV, V12, P914, DOI 10.1101/gad.12.7.914; Latres E, 1999, ONCOGENE, V18, P849, DOI 10.1038/sj.onc.1202653; Li FN, 1997, EMBO J, V16, P5629, DOI 10.1093/emboj/16.18.5629; Liakopoulos D, 1999, P NATL ACAD SCI USA, V96, P5510, DOI 10.1073/pnas.96.10.5510; Liakopoulos D, 1998, EMBO J, V17, P2208, DOI 10.1093/emboj/17.8.2208; Lisztwan J, 1998, EMBO J, V17, P368, DOI 10.1093/emboj/17.2.368; Lyapina SA, 1998, P NATL ACAD SCI USA, V95, P7451, DOI 10.1073/pnas.95.13.7451; Margottin F, 1998, MOL CELL, V1, P565, DOI 10.1016/S1097-2765(00)80056-8; Marti A, 1999, NAT CELL BIOL, V1, P14, DOI 10.1038/8984; Michel JJ, 1998, CELL GROWTH DIFFER, V9, P435; Osaka F, 1998, GENE DEV, V12, P2263, DOI 10.1101/gad.12.15.2263; Patton EE, 1998, GENE DEV, V12, P692, DOI 10.1101/gad.12.5.692; Patton EE, 1998, TRENDS GENET, V14, P236, DOI 10.1016/S0168-9525(98)01473-5; Russell A, 1999, ONCOGENE, V18, P1983, DOI 10.1038/sj.onc.1202511; Saitoh H, 1997, TRENDS BIOCHEM SCI, V22, P374, DOI 10.1016/S0968-0004(97)01102-X; Schwarz SE, 1998, P NATL ACAD SCI USA, V95, P560, DOI 10.1073/pnas.95.2.560; Skowyra D, 1997, CELL, V91, P209, DOI 10.1016/S0092-8674(00)80403-1; Spencer E, 1999, GENE DEV, V13, P284, DOI 10.1101/gad.13.3.284; Suzuki H, 1999, BIOCHEM BIOPH RES CO, V256, P127, DOI 10.1006/bbrc.1999.0289; Tanaka K, 1998, MOL CELLS, V8, P503; Winston JT, 1999, GENE DEV, V13, P270, DOI 10.1101/gad.13.3.270; Yaron A, 1998, NATURE, V396, P590, DOI 10.1038/25159	40	242	257	2	10	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 18	1999	18	48					6829	6834		10.1038/sj.onc.1203093	http://dx.doi.org/10.1038/sj.onc.1203093			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	257QA	10597293				2022-12-25	WOS:000083792000027
J	Kamei, T; Matozaki, T; Sakisaka, T; Kodama, A; Yokoyama, S; Peng, YF; Nakano, K; Takaishi, K; Takai, Y				Kamei, T; Matozaki, T; Sakisaka, T; Kodama, A; Yokoyama, S; Peng, YF; Nakano, K; Takaishi, K; Takai, Y			Coendocytosis of cadherin and c-Met coupled to disruption of cell-cell adhesion in MDCK cells - regulation by Rho, Rac and Rab small G proteins	ONCOGENE			English	Article						c-Met; E-cadherin; endocytosis; small G proteins	EPIDERMAL GROWTH-FACTOR; CANINE KIDNEY-CELLS; FACTOR RECEPTOR; PHOSPHATIDYLINOSITOL 3-KINASE; ENDOCYTIC PATHWAY; KINASE; ACTIVATION; TRANSPORT; SITES; MORPHOGENESIS	Both E-cadherin, a cell-cell adhesion molecule, and c-Met, the hepatocyte growth factor (HGF)/scatter factor (SF) receptor, were colocalized at cell-cell adhesion sites of MDCK cells. HGF/SF or a phorbol ester, 12-O-tetradecanoylphorbol-13-acetate (TPA), induced disruption of cell-cell adhesion, which was accompanied by endocytosis of both E-cadherin and c-Met. Reduction of medium Ca2+ to a micromolar range showed the same effects. Re-increase in medium Ca2+ to a millimolar range formed cell-cell adhesion, which was accompanied by exocytosis of E-cadherin and c-Met, followed by their re-colocalization at the cell-cell adhesion sites. These results suggest that E-cadherin and c-Met are colocalized at cell-cell adhesion sites and undergo co-endo-exocytosis. We have previously shown that TPA does not induce disruption of cell-cell adhesion and subsequent scattering of MDCK cells stably expressing a dominant active mutant of RhoA or Rac1 small G protein or a dominant negative mutant of Rab5 small G protein. In these cell lines, the HGF- or TPA-induced coendocytosis of E-cadherin and c-Met was inhibited, but the coendocytosis of E-cadherin and c-Met in response to reduction of medium Ca2+ was not affected. Wortmannin, an inhibitor of phosphoinositide (PI) 3-kinase, inhibited the HGF-induced disruption of cell-cell junction and endocytosis of E-cadherin and c-Met, but not the TPA-induced ones. These results suggest that disruption of cell-cell adhesion is involved in the HGF- or TPA-induced coendocytosis of E-cadherin and c-Met in MDCK cells, and that the Rho and Rab family members indirectly regulate this coendocytosis. In addition, coendocytosis of E-cadherin and c-Met in response to HGF is partly mediated by PI 3-kinase. The cross-talk between cell-cell and cell-matrix adherens junctions is discussed.	Osaka Univ, Grad Sch Med, Fac Med, Dept Mol Biol & Biochem, Suita, Osaka 5650871, Japan	Osaka University	Takai, Y (corresponding author), Osaka Univ, Grad Sch Med, Fac Med, Dept Mol Biol & Biochem, 2-2 Yamadaoka, Suita, Osaka 5650871, Japan.							BALDA MS, 1993, J CELL BIOL, V123, P293, DOI 10.1083/jcb.123.2.293; BOTTARO DP, 1991, SCIENCE, V251, P802, DOI 10.1126/science.1846706; Braga VMM, 1997, J CELL BIOL, V137, P1421, DOI 10.1083/jcb.137.6.1421; BUCCI C, 1992, CELL, V70, P715, DOI 10.1016/0092-8674(92)90306-W; CARPENTER G, 1987, ANNU REV BIOCHEM, V56, P881, DOI 10.1146/annurev.biochem.56.1.881; CHANG CP, 1993, J BIOL CHEM, V268, P19312; CREPALDI T, 1994, J CELL BIOL, V125, P313, DOI 10.1083/jcb.125.2.313; Gumbiner BM, 1996, CELL, V84, P345, DOI 10.1016/S0092-8674(00)81279-9; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; HALL A, 1994, ANNU REV CELL BIOL, V10, P31, DOI 10.1146/annurev.cb.10.110194.000335; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; Imamura H, 1998, MOL BIOL CELL, V9, P2561, DOI 10.1091/mbc.9.9.2561; JOLY M, 1995, J BIOL CHEM, V270, P13225, DOI 10.1074/jbc.270.22.13225; JOLY M, 1994, SCIENCE, V263, P684, DOI 10.1126/science.8303278; Jou TS, 1998, J CELL BIOL, V142, P85, DOI 10.1083/jcb.142.1.85; KARTENBECK J, 1991, J CELL BIOL, V113, P881, DOI 10.1083/jcb.113.4.881; LAMAZE C, 1995, J CELL BIOL, V129, P47, DOI 10.1083/jcb.129.1.47; MARATOSFLIER E, 1987, J CELL BIOL, V105, P1595, DOI 10.1083/jcb.105.4.1595; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; Novick P, 1997, CURR OPIN CELL BIOL, V9, P496, DOI 10.1016/S0955-0674(97)80025-7; Potempa S, 1998, MOL BIOL CELL, V9, P2185, DOI 10.1091/mbc.9.8.2185; ROYAL I, 1995, J BIOL CHEM, V270, P27780, DOI 10.1074/jbc.270.46.27780; Sakisaka T, 1999, ONCOGENE, V18, P1609, DOI 10.1038/sj.onc.1202451; Schwartz MA, 1995, ANNU REV CELL DEV BI, V11, P549, DOI 10.1146/annurev.cellbio.11.1.549; Seaman MNJ, 1996, CURR OPIN CELL BIOL, V8, P549, DOI 10.1016/S0955-0674(96)80034-2; Shpetner H, 1996, J CELL BIOL, V132, P595, DOI 10.1083/jcb.132.4.595; SIMONS K, 1993, NEURON, V11, P789, DOI 10.1016/0896-6273(93)90109-5; STENMARK H, 1994, EMBO J, V13, P1287, DOI 10.1002/j.1460-2075.1994.tb06381.x; Takai Y, 1996, GENES CELLS, V1, P615, DOI 10.1046/j.1365-2443.1996.00257.x; TAKAI Y, 1995, TRENDS BIOCHEM SCI, V20, P227, DOI 10.1016/S0968-0004(00)89022-2; TAKAISHI K, 1995, ONCOGENE, V11, P39; Takaishi K, 1997, J CELL BIOL, V139, P1047, DOI 10.1083/jcb.139.4.1047; TAKEICHI M, 1988, DEVELOPMENT, V102, P639; TAKEICHI M, 1991, SCIENCE, V251, P1451, DOI 10.1126/science.2006419; TAKEICHI M, 1995, CURR OPIN CELL BIOL, V7, P619, DOI 10.1016/0955-0674(95)80102-2; Tanimura S, 1998, ONCOGENE, V17, P57, DOI 10.1038/sj.onc.1201905; Tsukita Shoichiro, 1992, Current Opinion in Cell Biology, V4, P834, DOI 10.1016/0955-0674(92)90108-O	37	171	178	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 18	1999	18	48					6776	6784		10.1038/sj.onc.1203114	http://dx.doi.org/10.1038/sj.onc.1203114			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	257QA	10597286				2022-12-25	WOS:000083792000020
J	Abdollahi, A; Bao, R; Hamilton, TC				Abdollahi, A; Bao, R; Hamilton, TC			LOT1 is a growth suppressor gene down-regulated by the epidermal growth factor receptor ligands and encodes a nuclear zinc-finger protein	ONCOGENE			English	Article						LOT1; ovary; epidermal growth factor; EGFR; TGF-alpha; cancer	SURFACE EPITHELIAL-CELLS; HUMAN-BREAST-CANCER; OVARIAN-CANCER; OKADAIC ACID; TRANSCRIPTIONAL ACTIVATION; SPONTANEOUS TRANSFORMATION; TYROSINE PHOSPHORYLATION; MYELOID DIFFERENTIATION; INCESSANT OVULATION; SIGNAL-TRANSDUCTION	We previously reported cloning the rLot1 gene, and its human homolog (hLOT1), through analysis of differential gene expression in normal and malignant rat ovarian surface epithelial cells. Both human and rat ovarian carcinoma cell lines exhibited lost or decreased expression of this gene. Interestingly, the LOT1 gene localized at band q25 of human chromosome 6 which is a frequent site for LOH in many solid tumors including ovarian cancer. In this report we have further characterized the potential role of LOT1 in malignant transformation and developed evidence that the gene is a novel target of growth factor signaling pathway. Assays using transient transfections showed that LOT1 is a nuclear protein and may act as a transcription factor. In vitro and lit vivo studies involving ovarian cancer cell lines revealed that expression of LOT1 is directly associated with inhibition of cellular proliferation and induction of morphological transformations. Additionally, we show that in normal rat ovarian surface epithelial cells Lot1 gene expression is responsive to growth factor stimulation. Its mRNA is strongly down-regulated by epidermal growth factor receptor (EGFR) ligands, namely EGF and TGF-alpha. Blocking the ligand-activated EGFR signal transduction pathway by the specific EGF receptor inhibitor, tyrphostin AG1478, and the MEK inhibitor, PD098059, restores the normal level of Lot1 gene expression. It appears that the regulation of Lot1 gene is unique to these ligands, as well as the growth promoting agent TPA, since other factors either did not affect Lot1 expression, or the effect was modest and transient. Altogether, the results suggest that Lot1 expression is primarily mediated via EGF receptor or a related pathway and it may regulate the growth promoting signals as a zinc-finger motif containing nuclear transcription factor.	Fox Chase Canc Ctr, Dept Med Oncol, Ovarian Canc Program, Philadelphia, PA 19111 USA	Fox Chase Cancer Center	Abdollahi, A (corresponding author), Fox Chase Canc Ctr, Dept Med Oncol, Ovarian Canc Program, 7701 Burholme Ave, Philadelphia, PA 19111 USA.				NCI NIH HHS [CA56916] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA056916] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AARONSON SA, 1991, SCIENCE, V254, P1146, DOI 10.1126/science.1659742; ABDOLLAHI A, 1991, ONCOGENE, V6, P165; Abdollahi A, 1997, CANCER RES, V57, P2029; Abdollahi A, 1999, J SOC GYNECOL INVEST, V6, P32, DOI 10.1016/S1071-5576(98)00048-3; Abdollahi A, 1997, ONCOGENE, V14, P1973, DOI 10.1038/sj.onc.1201034; AHARONOV A, 1978, J BIOL CHEM, V253, P3970; AHN NG, 1990, J BIOL CHEM, V265, P11487; ALESSANDRINI A, 1992, P NATL ACAD SCI USA, V89, P8200, DOI 10.1073/pnas.89.17.8200; AMES BN, 1990, P NATL ACAD SCI USA, V87, P7772, DOI 10.1073/pnas.87.19.7772; ARENDS MJ, 1991, INT REV EXP PATHOL, V32, P223; Batt DB, 1998, J BIOL CHEM, V273, P3408, DOI 10.1074/jbc.273.6.3408; BAUKNECHT T, 1986, CANCER RES, V46, P2614; BERCHUCK A, 1990, OBSTET GYNECOL, V75, P255; BRENT R, 1985, CELL, V43, P729, DOI 10.1016/0092-8674(85)90246-6; CANO E, 1994, MOL CELL BIOL, V14, P7352, DOI 10.1128/MCB.14.11.7352; CARPENTER G, 1976, J CELL PHYSIOL, V88, P227, DOI 10.1002/jcp.1040880212; CARPENTER G, 1981, HDB EXPT PHARM, V57, P90; CASAGRANDE JT, 1979, LANCET, V2, P170; CASILLAS AM, 1993, BIOCHEM J, V290, P545, DOI 10.1042/bj2900545; Cheng AY, 1998, CANCER RES, V58, P3611; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COHEN P, 1990, TRENDS BIOCHEM SCI, V15, P98, DOI 10.1016/0968-0004(90)90192-E; Colitti CV, 1998, ONCOGENE, V16, P555, DOI 10.1038/sj.onc.1201523; COUGHLIN SR, 1985, CELL, V43, P243, DOI 10.1016/0092-8674(85)90029-7; COURNEY A, 1988, CELL, V55, P741; DERYNCK R, 1988, CELL, V54, P593, DOI 10.1016/S0092-8674(88)80001-1; DINGWALL C, 1982, CELL, V30, P449, DOI 10.1016/0092-8674(82)90242-2; DOWNWARD J, 1984, NATURE, V307, P521, DOI 10.1038/307521a0; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; Emkey R, 1997, J BIOL CHEM, V272, P31172, DOI 10.1074/jbc.272.49.31172; ESKRAND A, 1994, ONCOGENE, V9, P2313; FATHALLA MF, 1971, LANCET, V2, P163; FRY DW, 1994, SCIENCE, V265, P1093, DOI 10.1126/science.8066447; Fujii H, 1996, GENE CHROMOSOME CANC, V16, P35, DOI 10.1002/(SICI)1098-2264(199605)16:1<35::AID-GCC5>3.0.CO;2-4; GODWIN AK, 1992, J NATL CANCER I, V84, P592, DOI 10.1093/jnci/84.8.592; GONZALEZ FA, 1991, J BIOL CHEM, V266, P22159; GOTOH N, 1994, P NATL ACAD SCI USA, V91, P167, DOI 10.1073/pnas.91.1.167; Grimes HL, 1996, MOL CELL BIOL, V16, P6263; Hazzalin CA, 1998, MOL CELL BIOL, V18, P1844, DOI 10.1128/MCB.18.4.1844; HENDERSON BE, 1991, SCIENCE, V254, P1131, DOI 10.1126/science.1957166; HOWE LR, 1992, CELL, V71, P335, DOI 10.1016/0092-8674(92)90361-F; HUNTER T, 1995, CELL, V80, P225, DOI 10.1016/0092-8674(95)90405-0; HUNTER T, 1984, NATURE, V311, P414, DOI 10.1038/311414a0; Ilekis JV, 1997, GYNECOL ONCOL, V65, P36, DOI 10.1006/gyno.1996.4526; Jans DA, 1998, BIOESSAYS, V20, P400, DOI 10.1002/(SICI)1521-1878(199805)20:5<400::AID-BIES7>3.0.CO;2-R; Kampfer S, 1998, EMBO J, V17, P4046, DOI 10.1093/emboj/17.14.4046; Kas K, 1998, J BIOL CHEM, V273, P23026, DOI 10.1074/jbc.273.36.23026; Kas K, 1997, NAT GENET, V15, P170, DOI 10.1038/ng0297-170; KOMMOSS F, 1990, J PATHOL, V162, P223, DOI 10.1002/path.1711620308; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; Li S, 1998, J BIOL CHEM, V273, P6183, DOI 10.1074/jbc.273.11.6183; LIBERMANN TA, 1985, NATURE, V313, P144, DOI 10.1038/313144a0; LORD KA, 1990, CELL GROWTH DIFFER, V1, P637; LORD KA, 1993, MOL CELL BIOL, V13, P841, DOI 10.1128/MCB.13.2.841; MASSAGUE J, 1983, J BIOL CHEM, V258, P3614; MELLON K, 1995, J UROLOGY, V153, P919, DOI 10.1016/S0022-5347(01)67604-3; MERMOD N, 1989, CELL, V58, P741, DOI 10.1016/0092-8674(89)90108-6; MOON SO, 1984, P NATL ACAD SCI-BIOL, V81, P2298, DOI 10.1073/pnas.81.8.2298; MORENO S, 1990, CELL, V61, P549, DOI 10.1016/0092-8674(90)90463-O; MORISHIGE KI, 1991, CANCER RES, V51, P5322; MOSCATELLO DK, 1995, CANCER RES, V55, P5536; Nomura N, 1994, DNA Res, V1, P223, DOI 10.1093/dnares/1.5.223; PARDEE AB, 1989, SCIENCE, V246, P603, DOI 10.1126/science.2683075; PETCH LA, 1990, MOL CELL BIOL, V10, P2973, DOI 10.1128/MCB.10.6.2973; PONTECORVI A, 1988, EMBO J, V7, P1489, DOI 10.1002/j.1460-2075.1988.tb02967.x; PRESTONMARTIN S, 1990, CANCER RES, V50, P7415; Rani CSS, 1997, J BIOL CHEM, V272, P10777; ROBERTS D, 1999, UNPUB; RODRIGUEZ GC, 1991, AM J OBSTET GYNECOL, V164, P745, DOI 10.1016/0002-9378(91)90508-O; SAINSBURY JRC, 1985, LANCET, V1, P364; Sambrook J., 1989, MOL CLONING LAB MANU, V2nd, ed.; SCAMBIA G, 1992, J CLIN ONCOL, V10, P529, DOI 10.1200/JCO.1992.10.4.529; SHECHTER Y, 1978, P NATL ACAD SCI USA, V75, P5788, DOI 10.1073/pnas.75.12.5788; Spengler D, 1997, EMBO J, V16, P2814, DOI 10.1093/emboj/16.10.2814; SUGANUMA M, 1988, P NATL ACAD SCI USA, V85, P1768, DOI 10.1073/pnas.85.6.1768; TANAKA K, 1989, CANCER GENET CYTOGEN, V43, P1, DOI 10.1016/0165-4608(89)90122-2; TESTA JR, 1994, CANCER RES, V54, P2778; THRASHBINGHAM CA, 1995, CANCER RES, V55, P6189; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WEINBERG RA, 1991, SCIENCE, V254, P1138, DOI 10.1126/science.1659741; WILLIAMSON MP, 1994, BIOCHEM J, V297, P249, DOI 10.1042/bj2970249; XU YH, 1984, NATURE, V309, P806, DOI 10.1038/309806a0; YAMAMOTO T, 1986, CANCER RES, V46, P414; ZHENG CF, 1993, J BIOL CHEM, V268, P11435; ZHOU L, 1988, CELL, V55, P1005	85	47	50	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 11	1999	18	47					6477	6487		10.1038/sj.onc.1203067	http://dx.doi.org/10.1038/sj.onc.1203067			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	256CW	10597250				2022-12-25	WOS:000083709200010
J	Schnackerz, KD; Tai, CH; Potsch, RKW; Cook, PF				Schnackerz, KD; Tai, CH; Potsch, RKW; Cook, PF			Substitution of pyridoxal 5 '-phosphate in D-serine dehydratase from Escherichia coli by cofactor analogues provides information on cofactor binding and catalysis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							O-ACETYLSERINE SULFHYDRYLASE; ALPHA-AMINOACRYLATE INTERMEDIATE; BIOSYNTHETIC THREONINE DEAMINASE; SYNTHASE ALPHA(2)BETA(2) COMPLEX; TIME-RESOLVED FLUORESCENCE; TRYPTOPHAN SYNTHASE; SALMONELLA-TYPHIMURIUM; 3-DIMENSIONAL STRUCTURE; ACTIVE-SITES; ASPARTATE-AMINOTRANSFERASE	D-Serine dehydratase (DSD) is a pyridoxal 5'-phosphate-dependent enzyme that catalyzes the conversion of D-serine to pyruvate and ammonia. Spectral studies of enzyme species where the natural cofactor was substituted by pyridoxal 5'-sulfate (PLS), pyridoxal 5-deoxymethylene phosphonate (PDMP), and pyridoxal 5'-phosphate monomethyl ester (PLPMe) were used to gain insight into the structural basis for binding of cofactor and substrate analogues. PDMP-DSD exhibits 35% of the activity of the native enzyme, whereas PLS-DSD and PLPMe-DSD are catalytically inactive. The emission spectrum of native DSD when excited at 280 nm shows maxima at 335 and 530 nm, The energy transfer band at 530 nm is very likely generated as a result of the proximity of Trp-197 to the protonated internal Schiff base, The cofactor analogue-reconstituted DSD species exhibit emission intensities decreasing from PLS-DSD, to PLPMe-DSD, and PDMP-DSD, when excited at 415 nm. Large increases in fluorescence intensity at 530 (540) nm can be observed for cofactor analogue-reconstituted DSD in the presence of substrate analogues when excited at 415 nm, In the absence and presence of substrate analogues, virtually identical far UV CD spectra were obtained for all DSD species. The visible CD spectra of native DSD, PDMP-DSD, and PLS-DSD exhibit a band centered on the visible absorption maximum with nearly identical intensity. Addition of substrate analogues to native and cofactor analogue-reconstituted DSD species results in most cases in a decrease or elimination of ellipticity. The results are interpreted in terms of local conformational changes and/or changes in the orientation of the bound cofactor (analogue).	Univ Wurzburg, Biozentrum, Theodor Boveri Inst Biowissensch, D-97074 Wurzburg, Germany; Univ Oklahoma, Dept Chem & Biochem, Norman, OK 73072 USA	University of Wurzburg; University of Oklahoma System; University of Oklahoma - Norman	Schnackerz, KD (corresponding author), Univ Wurzburg, Biozentrum, Theodor Boveri Inst Biowissensch, Am Hubland, D-97074 Wurzburg, Germany.							AHMED SA, 1985, J BIOL CHEM, V260, P3716; ALEXANDER FW, 1994, EUR J BIOCHEM, V219, P953, DOI 10.1111/j.1432-1033.1994.tb18577.x; ARRIODUPONT M, 1971, BIOCHEM BIOPH RES CO, V44, P653, DOI 10.1016/S0006-291X(71)80133-X; ARRIODUPONT M, 1970, PHOTOCHEM PHOTOBIOL, V12, P297, DOI 10.1111/j.1751-1097.1970.tb06062.x; BALK H, 1981, BIOCHEMISTRY-US, V20, P6391, DOI 10.1021/bi00525a017; Benci S, 1997, BIOCHEMISTRY-US, V36, P15419, DOI 10.1021/bi970464i; Burkhard P, 1999, J MOL BIOL, V291, P941, DOI 10.1006/jmbi.1999.3002; Burkhard P, 1998, J MOL BIOL, V283, P121, DOI 10.1006/jmbi.1998.2037; BURSTEIN EA, 1973, PHOTOCHEM PHOTOBIOL, V18, P263, DOI 10.1111/j.1751-1097.1973.tb06422.x; BYRNE CR, 1988, J BACTERIOL, V170, P3150, DOI 10.1128/jb.170.7.3150-3157.1988; Cook PF, 1996, J BIOL CHEM, V271, P25842, DOI 10.1074/jbc.271.42.25842; COOK PF, 1992, BIOCHEMISTRY-US, V31, P2295; DOWHAN W, 1970, J BIOL CHEM, V245, P4629; DOWHAN W, 1970, J BIOL CHEM, V245, P4618; EHRLICH JH, 1973, H-S Z PHYSIOL CHEM, V354, P1183; EISENSTEIN E, 1994, J BIOL CHEM, V269, P29423; EISENSTEIN E, 1994, J BIOL CHEM, V269, P29416; FEDERIUK CS, 1983, J BIOL CHEM, V258, P5372; Gallagher DT, 1998, STRUCTURE, V6, P465, DOI 10.1016/S0969-2126(98)00048-3; GOLDBERG ME, 1968, BIOCHEMISTRY-US, V7, P3662, DOI 10.1021/bi00850a045; GOLDBERG ME, 1967, BIOCHEMISTRY-US, V6, P2113, DOI 10.1021/bi00859a032; GRISHIN NV, 1995, PROTEIN SCI, V4, P1291, DOI 10.1002/pro.5560040705; GROMAN E, 1977, P NATL ACAD SCI USA, V69, P3297; HUANG YZ, 1972, J BIOL CHEM, V247, P7358; HYDE CC, 1988, J BIOL CHEM, V263, P17857; ISOM HC, 1975, BIOCHEMISTRY-US, V14, P4291, DOI 10.1021/bi00690a024; KAYASTHA AM, 1991, INDIAN J BIOCHEM BIO, V28, P352; KURODA T, 1963, BITUMEN, V28, P21; LAKOWICZ JR, 1983, PRINCIPLES FLUORESCE, P303; MARCEAU M, 1988, J BIOL CHEM, V263, P16926; MCCLURE GD, 1994, BIOCHEMISTRY-US, V33, P1674, DOI 10.1021/bi00173a009; MILES EW, 1977, J BIOL CHEM, V252, P6594; MIURA R, 1989, ARCH BIOCHEM BIOPHYS, V270, P526, DOI 10.1016/0003-9861(89)90535-3; MOSKOWITZ A, 1961, TETRAHEDRON, V13, P48; OH KJ, 1973, J BIOL CHEM, V248, P7370; PFEUFFER T, 1972, BIOCHEMISTRY-US, V11, P2125, DOI 10.1021/bi00761a020; Rhee S, 1997, BIOCHEMISTRY-US, V36, P7664, DOI 10.1021/bi9700429; Rhee S, 1996, BIOCHEMISTRY-US, V35, P4211, DOI 10.1021/bi952506d; SCHILTZ E, 1976, EUR J BIOCHEM, V71, P109, DOI 10.1111/j.1432-1033.1976.tb11095.x; SCHILTZ E, 1981, FEBS LETT, V134, P57, DOI 10.1016/0014-5793(81)80550-9; SCHIRCH V, 1978, BIOCHEM BIOPH RES CO, V85, P99; SCHNACKERZ KD, 1989, EUR J BIOCHEM, V185, P525, DOI 10.1111/j.1432-1033.1989.tb15145.x; SCHNACKERZ KD, 1979, BIOCHEMISTRY-US, V18, P1536, DOI 10.1021/bi00575a023; SCHNACKERZ KD, 1995, BIOCHEMISTRY-US, V34, P12152, DOI 10.1021/bi00038a008; SCHNACKERZ KD, 1979, BIOCHEMISTRY-US, V18, P3557, DOI 10.1021/bi00583a019; SCHNACKERZ KD, 1972, Z PHYSL CHEM, V353, P1565; Schneider TR, 1998, BIOCHEMISTRY-US, V37, P5394, DOI 10.1021/bi9728957; SHALTIEL S, 1970, BIOCHEM BIOPH RES CO, V41, P594, DOI 10.1016/0006-291X(70)90054-9; STRAMBINI GB, 1992, BIOCHEMISTRY-US, V31, P7527, DOI 10.1021/bi00148a013; Strambini GB, 1996, BIOCHEMISTRY-US, V35, P8392, DOI 10.1021/bi952919e; TOKUSHIGE M, 1980, BIOCHEM BIOPH RES CO, V96, P863, DOI 10.1016/0006-291X(80)91435-7; TORCHINSKY YM, 1986, PYRIDOXAL PHOSPHATE, P163; Vaccari S, 1996, BIOPHYS CHEM, V61, P9, DOI 10.1016/0301-4622(96)00020-8; Woehl EU, 1996, BIOCHEMISTRY-US, V35, P4776, DOI 10.1021/bi952938o; YORK SS, 1972, BIOCHEMISTRY-US, V11, P2733, DOI 10.1021/bi00764a029	55	13	13	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 24	1999	274	52					36935	36943		10.1074/jbc.274.52.36935	http://dx.doi.org/10.1074/jbc.274.52.36935			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	267WR	10601247	hybrid			2022-12-25	WOS:000084382700018
J	Segui, B; Andrieu-Abadie, N; Adam-Klages, S; Meilhac, O; Kreder, D; Garcia, V; Bruno, AP; Jaffrezou, JP; Salvayre, R; Kronke, M; Levade, T				Segui, B; Andrieu-Abadie, N; Adam-Klages, S; Meilhac, O; Kreder, D; Garcia, V; Bruno, AP; Jaffrezou, JP; Salvayre, R; Kronke, M; Levade, T			CD40 signals apoptosis through FAN-regulated activation of the sphingomyelin-ceramide pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NECROSIS-FACTOR-ALPHA; NEUTRAL SPHINGOMYELINASE; FACTOR RECEPTOR; B-CELLS; PROTEIN-KINASES; CYTOPLASMIC DOMAIN; GROWTH-INHIBITION; PHOSPHOLIPASE-C; DENDRITIC CELLS; LYMPHOMA-CELLS	The possibility that the sphingomyelin (SM)-ceramide pathway is activated by CD40, a transmembrane glycoprotein belonging to the tumor necrosis factor receptor superfamily and that plays a critical role in the regulation of immune responses has been investigated. We demonstrate that incubation of Epstein-Barr virus-transformed lymphoid cells with an anti-CD40 antibody acting as an agonist results in the stimulation of a neutral sphingomyelinase, hydrolysis of cellular SM, and concomitant ceramide generation. In addition, SM degradation was observed in acid sphingomyelinase-deficient cells, as well as after ligation by soluble CD40 ligand. The anti-CD40 antibody, as well as the soluble CD40 ligand induced a decrease in thymidine incorporation and morphological features of apoptosis, which were mimicked by cell-permeant or bacterial sphingomyelinase-produced ceramides, Stable expression of a dominant-negative form of the FAN protein (factor associated with neutral sphingomyelinase activation), which has been reported to mediate tumor necrosis factor-induced activation of neutral sphingomyelinase, significantly inhibited CD40 ligand-induced sphingomyelinase stimulation and apoptosis of transformed human fibroblasts, Transformed fibroblasts from FAN knockout mice were also protected from CD40-mediated cell death. Finally, anti-CD40 antibodies were able to coimmunoprecipitate FAN in control fibroblasts but not in cells expressing the dominant-negative form of FAN, indicating interaction between CD40 and FAN. Altogether, these results strongly suggest that CD40 ligation can activate via FAN a neutral sphingomyelinase-mediated ceramide pathway that is involved in the cell growth inhibitory effects of CD40.	CHU Rangueil, Inst Louis Bugnard, Biochim Lab, INSERM,U466, F-31403 Toulouse 4, France; Univ Kiel, Inst Immunol, D-24105 Kiel, Germany; Roche Biosci, Neurobiol Unit, Palo Alto, CA 94304 USA; Inst Claudius Regaud, INSERM, E9910, F-31052 Toulouse, France; Univ Cologne, Inst Med Mikrobiol & Hyg, D-50935 Cologne, Germany	CHU de Toulouse; Institut National de la Sante et de la Recherche Medicale (Inserm); University of Kiel; Roche Holding; Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Institut Claudius Regaud; University of Cologne	Levade, T (corresponding author), CHU Rangueil, Inst Louis Bugnard, Biochim Lab, INSERM,U466, Batiment L3,1 Ave Jean Poulhes, F-31403 Toulouse 4, France.		Adam-Klages, Sabine/E-9761-2010; Meilhac, Olivier/N-4385-2017; Levade, Thierry/O-8948-2014; GARCIA, Virginie/W-8313-2019; Ségui, Bruno/O-8957-2014; Andrieu-Abadie, Nathalie/N-6793-2013	GARCIA, Virginie/0000-0002-9761-7036; Ségui, Bruno/0000-0002-6119-1889; Andrieu-Abadie, Nathalie/0000-0003-2698-1970; Meilhac, Olivier/0000-0002-3740-7539				Adam D, 1996, J BIOL CHEM, V271, P14617, DOI 10.1074/jbc.271.24.14617; AdamKlages S, 1996, CELL, V86, P937, DOI 10.1016/S0092-8674(00)80169-5; Ames B. N., 1966, METHOD ENZYMOL, P115, DOI DOI 10.1016/0076-6879(66)08014-5; ANDRIEU N, 1994, BIOCHEM J, V303, P341, DOI 10.1042/bj3030341; Baker MP, 1998, BLOOD, V92, P2830, DOI 10.1182/blood.V92.8.2830.420k10_2830_2843; Ballou LR, 1996, BBA-LIPID LIPID MET, V1301, P273, DOI 10.1016/0005-2760(96)00004-5; Berberich I, 1996, EMBO J, V15, P92, DOI 10.1002/j.1460-2075.1996.tb00337.x; Bergamo A, 1997, BRIT J HAEMATOL, V97, P652, DOI 10.1046/j.1365-2141.1997.1032919.x; Chatelut M, 1997, CLIN CHIM ACTA, V262, P61, DOI 10.1016/S0009-8981(97)06527-3; Chung TW, 1997, J BIOL CHEM, V272, P3064, DOI 10.1074/jbc.272.5.3064; CIFONE MG, 1995, EMBO J, V14, P5859, DOI 10.1002/j.1460-2075.1995.tb00274.x; CUADRADO A, 1993, ONCOGENE, V8, P2959; DOBROWSKY RT, 1994, SCIENCE, V265, P1596, DOI 10.1126/science.8079174; Eliopoulos AG, 1996, ONCOGENE, V13, P2243; FARIS M, 1994, J EXP MED, V179, P1923, DOI 10.1084/jem.179.6.1923; Foy TM, 1996, ANNU REV IMMUNOL, V14, P591, DOI 10.1146/annurev.immunol.14.1.591; FUNAKOSHI S, 1994, BLOOD, V83, P2787, DOI 10.1182/blood.V83.10.2787.2787; Goldstein MD, 1996, J IMMUNOL, V157, P2837; GRAVIELI Y, 1992, J CELL BIOL, V119, P493; Grell M, 1999, EMBO J, V18, P3034, DOI 10.1093/emboj/18.11.3034; Grewal IS, 1996, IMMUNOL TODAY, V17, P410, DOI 10.1016/0167-5699(96)10030-X; Gulbins E, 1996, J IMMUNOL, V157, P2844; GULBINS E, 1995, IMMUNITY, V2, P1; Hanissian SH, 1997, IMMUNITY, V6, P379, DOI 10.1016/S1074-7613(00)80281-2; Hannun YA, 1996, SCIENCE, V274, P1855, DOI 10.1126/science.274.5294.1855; HEATH AW, 1994, EUR J IMMUNOL, V24, P1828, DOI 10.1002/eji.1830240816; HEATH AW, 1993, CELL IMMUNOL, V152, P468, DOI 10.1006/cimm.1993.1305; Hess S, 1996, J EXP MED, V183, P159, DOI 10.1084/jem.183.1.159; Hostager BS, 1996, J IMMUNOL, V157, P1047; HU HM, 1994, J BIOL CHEM, V269, P30069; INOKUCHI JI, 1987, J LIPID RES, V28, P565; INUI S, 1990, EUR J IMMUNOL, V20, P1747, DOI 10.1002/eji.1830200819; Ishida T, 1996, P NATL ACAD SCI USA, V93, P9437, DOI 10.1073/pnas.93.18.9437; Jaffrezou JP, 1996, EMBO J, V15, P2417, DOI 10.1002/j.1460-2075.1996.tb00599.x; KIM MY, 1991, J BIOL CHEM, V266, P484; Kolesnick RN, 1998, ANNU REV PHYSIOL, V60, P643, DOI 10.1146/annurev.physiol.60.1.643; Kreder D, 1999, EMBO J, V18, P2472, DOI 10.1093/emboj/18.9.2472; Lee HH, 1999, P NATL ACAD SCI USA, V96, P1421, DOI 10.1073/pnas.96.4.1421; LEVADE T, 1991, J BIOL CHEM, V266, P13519; LEVADE T, 1984, BIOCHIM BIOPHYS ACTA, V793, P321, DOI 10.1016/0005-2760(84)90337-0; Mathias S, 1998, BIOCHEM J, V335, P465, DOI 10.1042/bj3350465; OKAZAKI T, 1994, J BIOL CHEM, V269, P4070; Pullen SS, 1998, BIOCHEMISTRY-US, V37, P11836, DOI 10.1021/bi981067q; REN CL, 1994, J EXP MED, V179, P673, DOI 10.1084/jem.179.2.673; Sakata N, 1995, J BIOL CHEM, V270, P30823, DOI 10.1074/jbc.270.51.30823; Sallusto F, 1996, J EXP MED, V184, P2411, DOI 10.1084/jem.184.6.2411; Sambrook J., 2002, MOL CLONING LAB MANU; SCHUTZE S, 1992, CELL, V71, P765, DOI 10.1016/0092-8674(92)90553-O; Spiegel S, 1996, FASEB J, V10, P1388, DOI 10.1096/fasebj.10.12.8903509; STAMENKOVIC I, 1989, EMBO J, V8, P1403, DOI 10.1002/j.1460-2075.1989.tb03521.x; Sutherland CL, 1996, J IMMUNOL, V157, P3381; TEPPER CG, 1995, P NATL ACAD SCI USA, V92, P8443, DOI 10.1073/pnas.92.18.8443; Testi R, 1996, TRENDS BIOCHEM SCI, V21, P468, DOI 10.1016/S0968-0004(96)10056-6; Tsukamoto N, 1999, P NATL ACAD SCI USA, V96, P1234, DOI 10.1073/pnas.96.4.1234; UCKUN FM, 1991, J BIOL CHEM, V266, P17478; vanKooten C, 1997, CURR OPIN IMMUNOL, V9, P330, DOI 10.1016/S0952-7915(97)80078-7; VANVELDHOVEN PP, 1992, BIOCHEM BIOPH RES CO, V187, P209, DOI 10.1016/S0006-291X(05)81480-9; WIEGMANN K, 1994, CELL, V78, P1005, DOI 10.1016/0092-8674(94)90275-5; YANAGA F, 1992, FEBS LETT, V314, P297, DOI 10.1016/0014-5793(92)81493-6	59	58	58	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 24	1999	274	52					37251	37258		10.1074/jbc.274.52.37251	http://dx.doi.org/10.1074/jbc.274.52.37251			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	267WR	10601289	hybrid			2022-12-25	WOS:000084382700060
J	Kroog, GS; Jian, XY; Chen, L; Northup, JK; Battey, JF				Kroog, GS; Jian, XY; Chen, L; Northup, JK; Battey, JF			Phosphorylation uncouples the gastrin-releasing peptide receptor from G(q)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-ADRENERGIC-RECEPTOR; MUSCARINIC CHOLINERGIC RECEPTORS; PROTEIN-KINASE-C; SF9 INSECT CELLS; BETA-2-ADRENERGIC RECEPTOR; DEPENDENT PHOSPHORYLATION; BOMBESIN RECEPTORS; 48-KDA PROTEIN; LIGAND-BINDING; ARRESTIN	Previous work on the desensitization of G protein-coupled receptors has focused on the role of arrestin binding following receptor phosphorylation. We have examined the hypothesis that phosphorylation alone contributes to desensitization. In this study we demonstrate that for the G(q)-coupled gastrin-releasing peptide receptor (GRP-R), phosphorylation by GRK2 to a stoichiometry of similar to 1 mol PO4/mol GRP-R is sufficient in the absence of arrestin to reduce the rate of receptor catalyzed G protein activation by approximately 80%. Furthermore, GRP-Rs exposed in vivo to agonist are rapidly phosphorylated to a similar stoichiometry and are desensitized to a similar degree. Finally, the molecular mechanism for both in vitro GRK2-induced and in vivo agonist-induced desensitization is primarily a decrease in the maximum velocity (V-max) for the catalysis of guanine nucleotide exchange by the GRP-R rather than a change in the affinity of the receptor for the alpha(q) or beta(gamma) subunits. Based on these results, we suggest that, for some G protein-coupled receptors, phosphorylation has a role in desensitization that is independent of arrestin.	NIDCD, Mol Biol Lab, NIH, Rockville, MD 20850 USA; NIDCD, Lab Cellular Biol, NIH, Rockville, MD 20850 USA	National Institutes of Health (NIH) - USA; NIH National Institute on Deafness & Other Communication Disorders (NIDCD); National Institutes of Health (NIH) - USA; NIH National Institute on Deafness & Other Communication Disorders (NIDCD)	Battey, JF (corresponding author), NIDCD, Mol Biol Lab, NIH, 5 Res Ct, Rockville, MD 20850 USA.	batteyj@nidcd.nih.gov						ATTRAMADAL H, 1992, J BIOL CHEM, V267, P17882; BENOVIC JL, 1988, ANNU REV CELL BIOL, V4, P405, DOI 10.1146/annurev.cb.04.110188.002201; BENOVIC JL, 1987, P NATL ACAD SCI USA, V84, P8879, DOI 10.1073/pnas.84.24.8879; DEBBURMAN SK, 1995, MOL PHARMACOL, V47, P224; DEBBURMAN SK, 1995, J BIOL CHEM, V270, P5742, DOI 10.1074/jbc.270.11.5742; Dicker F, 1999, P NATL ACAD SCI USA, V96, P5476, DOI 10.1073/pnas.96.10.5476; DUA HS, 1992, EYE, V6, P594, DOI 10.1038/eye.1992.128; FAWZI AB, 1991, J BIOL CHEM, V266, P12194; Ferguson SSG, 1996, SCIENCE, V271, P363, DOI 10.1126/science.271.5247.363; Fredericks ZL, 1996, J BIOL CHEM, V271, P13796, DOI 10.1074/jbc.271.23.13796; Freedman NJ, 1997, J BIOL CHEM, V272, P17734, DOI 10.1074/jbc.272.28.17734; Grady EF, 1997, AM J PHYSIOL-GASTR L, V273, pG586, DOI 10.1152/ajpgi.1997.273.3.G586; HAGA K, 1992, J BIOL CHEM, V267, P2222; HARGRAVE PA, 1992, FASEB J, V6, P2323, DOI 10.1096/fasebj.6.6.1544542; Hartman JL, 1996, J BIOL CHEM, V271, P22591, DOI 10.1074/jbc.271.37.22591; Hellmich MR, 1997, P NATL ACAD SCI USA, V94, P751, DOI 10.1073/pnas.94.2.751; Jian XY, 1999, J BIOL CHEM, V274, P11573, DOI 10.1074/jbc.274.17.11573; KEENAN AK, 1987, FEBS LETT, V217, P287, DOI 10.1016/0014-5793(87)80680-4; KIM CM, 1993, RECEPTOR, V3, P39; KROOG GS, 1995, MED RES REV, V15, P389, DOI 10.1002/med.2610150502; Kroog GS, 1998, RESP PHARM & PHARMAC, P143; KROOG GS, 1995, J BIOL CHEM, V270, P8217, DOI 10.1074/jbc.270.14.8217; Krupnick JG, 1997, J BIOL CHEM, V272, P18125, DOI 10.1074/jbc.272.29.18125; KUSUI T, 1995, BIOCHEMISTRY-US, V34, P8061, DOI 10.1021/bi00025a012; LEBACQVERHEYDEN AM, 1990, HDB EXPT PHARM, V95, P71; Lefkowitz R J, 1998, Adv Pharmacol, V42, P416; LOHSE MJ, 1992, J BIOL CHEM, V267, P8558; LOHSE MJ, 1990, SCIENCE, V248, P1547, DOI 10.1126/science.2163110; Luttrell LM, 1999, SCIENCE, V283, P655, DOI 10.1126/science.283.5402.655; MANTEY S, 1993, MOL PHARMACOL, V43, P762; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; NEER EJ, 1995, CELL, V80, P249, DOI 10.1016/0092-8674(95)90407-7; NORTHUP JK, 1982, J BIOL CHEM, V257, P1416; OHGURO H, 1993, BIOCHEMISTRY-US, V32, P5718, DOI 10.1021/bi00072a030; PITCHER J, 1992, BIOCHEMISTRY-US, V31, P3193, DOI 10.1021/bi00127a021; POTTINGER JDD, 1991, BIOCHEM J, V279, P323, DOI 10.1042/bj2790323; PREMONT RT, 1995, FASEB J, V9, P175, DOI 10.1096/fasebj.9.2.7781920; RICHARDSON RM, 1993, J BIOL CHEM, V268, P13650; RICHARDSON RM, 1992, J BIOL CHEM, V267, P22249; SPINDEL ER, 1990, MOL ENDOCRINOL, V4, P1956, DOI 10.1210/mend-4-12-1956; STERNEMARR R, 1993, J BIOL CHEM, V268, P15640; STERNWEIS PC, 1984, J BIOL CHEM, V259, P3806; WILDEN U, 1986, P NATL ACAD SCI USA, V83, P1174, DOI 10.1073/pnas.83.5.1174; Zhang J, 1996, J BIOL CHEM, V271, P18302, DOI 10.1074/jbc.271.31.18302	44	14	14	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 17	1999	274	51					36700	36706		10.1074/jbc.274.51.36700	http://dx.doi.org/10.1074/jbc.274.51.36700			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	266AV	10593975	hybrid			2022-12-25	WOS:000084279200094
J	Moncalian, G; Cabezon, E; Alkorta, I; Valle, M; Moro, F; Valpuesta, JM; Goni, FM; de la Cruz, F				Moncalian, G; Cabezon, E; Alkorta, I; Valle, M; Moro, F; Valpuesta, JM; Goni, FM; de la Cruz, F			Characterization of ATP and DNA binding activities of TrwB, the coupling protein essential in plasmid R388 conjugation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; ADENOSINE 5'-TRIPHOSPHATE; BACTERIAL CONJUGATION; BACILLUS-SUBTILIS; INCW PLASMID-R388; RNA-POLYMERASE; GENE-PRODUCT; CLONED GENES; PURIFICATION; ORGANIZATION	TrwB is the conjugative coupling protein of plasmid R388, TrwB Delta N70 contains the soluble domain of TrwB, It was constructed by deletion of trwB sequences containing TrwB N-proximal transmembrane segments. Purified TrwB Delta N70 protein bound tightly the fluorescent ATP analogue TNP-ATP (K-s = 8.7 mu M) but did not show measurable ATPase or GTPase activity. A single ATP binding site was found per TrwB monomer, An intact ATP-binding site was essential for R388 conjugation, since a TrwB mutant with a single amino acid alteration in the ATP-binding signature (K136T) was transfer-deficient, TrwB Delta N70 also bound DNA nonspecifically. DNA binding enhanced TrwC nic cleavage, providing the first evidence that directly links TrwB with conjugative DNA processing. Since DNA bound by TrwB Delta N70 also showed increased negative superhelicity las shown by increased sensitivity to topoisomerase I), nic cleavage enhancement was assumed to be a consequence of the increased single-stranded nature of DNA around nic, The mutant protein TrwB(K136T)Delta N70 was indistinguishable from TrwB Delta N70 with respect to the above properties, indicating that TrwB ATP binding activity is not required for them. The reported properties of TrwB suggest potential functions for conjugative coupling proteins, both as triggers of conjugative DNA processing and as motors in the transport process.	Univ Cantabria, Dept Biol Mol, Unidad Asociada Ctr Invest Biol, Santander 39011, Spain; Univ Basque Country, Euskal Herriko Unibersitatea, Unidad Biofis, Ctr Mixto,CSIC, E-48080 Bilbao, Spain; Univ Basque Country, Euskal Herriko Unibersitatea, Dept Bioquim, E-48080 Bilbao, Spain; CSIC, Ctr Nacl Biotecnol, E-28049 Madrid, Spain	Universidad de Cantabria; Consejo Superior de Investigaciones Cientificas (CSIC); University of Basque Country; CSIC - UPV EHU - Instituto Biofisika; University of Basque Country; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro Nacional de Biotecnologia (CNB)	de la Cruz, F (corresponding author), Univ Cantabria, Dept Biol Mol, Unidad Asociada Ctr Invest Biol, C Herrera Oria S-N, Santander 39011, Spain.	delacruz@medi.unican.es	Valpuesta, José M/T-1977-2017; Alkorta, Itziar/Y-6267-2019; Moncalian, Gabriel/K-3493-2014; de la Cruz, Fernando/L-2812-2014; Valle, Mikel/F-7598-2011; Valpuesta, Jose M/AAA-6002-2019; Moro Pérez, Fernando/P-3891-2015; Goni, Felix M/M-5425-2015; Alkorta, Itziar/N-4374-2014; Cabezon, Elena/K-5874-2014	Valpuesta, José M/0000-0001-7468-8053; Moncalian, Gabriel/0000-0002-3007-6490; de la Cruz, Fernando/0000-0003-4758-6857; Valle, Mikel/0000-0001-8268-6912; Moro Pérez, Fernando/0000-0002-3568-3388; Goni, Felix M/0000-0001-6270-9216; Alkorta, Itziar/0000-0002-1976-8904; Cabezon, Elena/0000-0002-6177-5016; ALCORTA CALVO, MIREN ITZIAR/0000-0001-6978-389X				BARTOLOME B, 1991, GENE, V102, P75, DOI 10.1016/0378-1119(91)90541-I; BOLLAND S, 1990, J BACTERIOL, V172, P5795, DOI 10.1128/jb.172.10.5795-5802.1990; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Byrd DR, 1997, MOL MICROBIOL, V25, P1011, DOI 10.1046/j.1365-2958.1997.5241885.x; Cabezon E, 1997, MOL GEN GENET, V254, P400, DOI 10.1007/s004380050432; CABEZON E, 1994, J BACTERIOL, V176, P4455, DOI 10.1128/jb.176.14.4455-4458.1994; CAMILLONI G, 1988, NUCLEIC ACIDS RES, V16, P7071, DOI 10.1093/nar/16.14.7071; CLEWELL DB, 1993, BACTERIAL CONJUGATIO; DATTA N, 1972, J GEN MICROBIOL, V72, P349, DOI 10.1099/00221287-72-2-349; Dayan G, 1996, J BIOL CHEM, V271, P11652, DOI 10.1074/jbc.271.20.11652; DELACRUZ F, 1982, J BACTERIOL, V151, P222, DOI 10.1128/JB.151.1.222-228.1982; DisqueKochem C, 1997, J BACTERIOL, V179, P6133, DOI 10.1128/jb.179.19.6133-6137.1997; DIVITA G, 1993, J BIOL CHEM, V268, P13178; DOWER WJ, 1988, NUCLEIC ACIDS RES, V16, P6127, DOI 10.1093/nar/16.13.6127; DRI AM, 1992, GENE, V120, P11, DOI 10.1016/0378-1119(92)90003-8; DUPONT Y, 1982, BIOCHEM BIOPH RES CO, V106, P1272, DOI 10.1016/0006-291X(82)91250-5; GRANDOSO G, 1994, EUR J BIOCHEM, V226, P403, DOI 10.1111/j.1432-1033.1994.tb20065.x; GRANT SGN, 1990, P NATL ACAD SCI USA, V87, P4645, DOI 10.1073/pnas.87.12.4645; GUTFREUND H, 1972, ENZYMES PHYSICAL PRI, P71; HIRATSUKA T, 1973, BIOCHIM BIOPHYS ACTA, V320, P635, DOI 10.1016/0304-4165(73)90143-8; Hopwood D.A., 1993, BACTERIAL CONJUGATIO, P293, DOI DOI 10.1007/978-1-4757-9357-4_11; INOUYE S, 1991, DIRECTED MUTAGENESIS, P71; KINGSMAN A, 1978, J MOL BIOL, V122, P287, DOI 10.1016/0022-2836(78)90191-2; KROGH S, 1991, NUCLEIC ACIDS RES, V19, P1235, DOI 10.1093/nar/19.6.1235; LANKA E, 1995, ANNU REV BIOCHEM, V64, P141, DOI 10.1146/annurev.bi.64.070195.001041; LLOSA M, 1994, J MOL BIOL, V235, P448, DOI 10.1006/jmbi.1994.1005; LLOSA M, 1995, J MOL BIOL, V246, P54, DOI 10.1006/jmbi.1994.0065; LLOSA M, 1994, J BACTERIOL, V176, P3210, DOI 10.1128/jb.176.11.3210-3217.1994; Llosa M, 1996, J MOL BIOL, V264, P56, DOI 10.1006/jmbi.1996.0623; LOHMAN TM, 1989, J BIOL CHEM, V264, P10139; Moncalian G, 1997, J MOL BIOL, V270, P188, DOI 10.1006/jmbi.1997.1082; Moncalian G, 1999, MOL MICROBIOL, V31, P1643, DOI 10.1046/j.1365-2958.1999.01288.x; NELSON WC, 1995, J BIOL CHEM, V270, P28374; PANICKER MM, 1992, J BIOL CHEM, V267, P12761; Pansegrau W, 1996, PROG NUCLEIC ACID RE, V54, P197, DOI 10.1016/S0079-6603(08)60364-5; Rivas S, 1997, J BIOL CHEM, V272, P25583, DOI 10.1074/jbc.272.41.25583; Sambrook J., 2002, MOL CLONING LAB MANU; Santini JM, 1998, J BACTERIOL, V180, P4093, DOI 10.1128/JB.180.16.4093-4101.1998; Sastre JI, 1998, J BACTERIOL, V180, P6039, DOI 10.1128/JB.180.22.6039-6042.1998; SCHERZINGER E, 1992, NUCLEIC ACIDS RES, V20, P41, DOI 10.1093/nar/20.1.41; Steiner W, 1999, MOL MICROBIOL, V31, P579, DOI 10.1046/j.1365-2958.1999.01198.x; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; VIEIRA J, 1982, GENE, V19, P259, DOI 10.1016/0378-1119(82)90015-4; VOLOGODSKII AV, 1992, J MOL BIOL, V227, P1224, DOI 10.1016/0022-2836(92)90533-P; WATANABE T, 1982, J BIOL CHEM, V257, P1510; Weber J, 1996, J BIOL CHEM, V271, P3474; WILKINS BM, 1998, NATO ASI SER H, V103, P43; WU LJ, 1995, GENE DEV, V9, P1316, DOI 10.1101/gad.9.11.1316; Wu LJ, 1998, MOL MICROBIOL, V27, P777, DOI 10.1046/j.1365-2958.1998.00724.x; Wu LJ, 1997, EMBO J, V16, P2161, DOI 10.1093/emboj/16.8.2161; Zhang SY, 1997, MOL MICROBIOL, V25, P509, DOI 10.1046/j.1365-2958.1997.4861849.x	52	86	89	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 17	1999	274	51					36117	36124		10.1074/jbc.274.51.36117	http://dx.doi.org/10.1074/jbc.274.51.36117			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	266AV	10593894	hybrid			2022-12-25	WOS:000084279200013
J	Sengupta, PK; Ehrlich, M; Smith, BD				Sengupta, PK; Ehrlich, M; Smith, BD			A methylation-responsive MDBP/RFX site is in the first exon of the collagen alpha 2(I) promoter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING PROTEIN; B VIRUS ENHANCER; CHICK-EMBRYO FIBROBLASTS; NUCLEAR ANTIGEN PROMOTER; MESSENGER-RNA LEVELS; TRANSCRIPTION FACTORS; REGULATORY REGIONS; CELL-CYCLE; GENE; REPRESSION	DNA methylation inhibits transcription driven by the collagen alpha 2(I) promoter and the 5' end of the gene in transient transfection and in vitro transcription assays. DNA-binding proteins in a unique family of ubiquitously expressed proteins, methylated DNA-binding protein (MDBP)/regulatory factor for X box (RFX), form specific complexes with a sequence overlapping the transcription start site of the collagen alpha 2(I) gene. Complex formation increased when the CPG site at +7 base pairs from the transcription start site was methylated, The identity of the protein was demonstrated by co-migration and cross-competition for a characteristic slowly migrating doublet complex formed on MDBP/RFX recognition sequences and the collagen sequences by band shift assays. A RFX1-specific antibody supershifted the collagen DNA-protein complexes. Furthermore, in vitro translated REX1 protein formed a specific complex with the collagen sequence that was also supershifted with the RFX1 antibody, MDBP/RFX displayed a higher affinity binding to the collagen sequence if the CPG at +7 was mutated in a manner similar to TpG. This same mutation within reporter constructs inhibited transcription in transfection and in vitro transcription assay. These results support the hypothesis that DNA methylation-induced inactivation of collagen alpha 2(I) gene transcription is mediated, in part, by increased binding of MDBP/RFX to the first exon in response to methylation in this region.	Boston Univ, Sch Med, Dept Biochem, Boston, MA 02118 USA; Boston Dept Vet Affairs Med Ctr, Boston, MA 02118 USA; Tulane Univ, Sch Med, Dept Biochem, New Orleans, LA 70112 USA; Tulane Univ, Sch Med, Human Genet Program, New Orleans, LA 70112 USA	Boston University; Tulane University; Tulane University	Smith, BD (corresponding author), Boston Univ, Sch Med, Dept Biochem, 715 Albany St, Boston, MA 02118 USA.	smith@biochem.bumc.bu.edu		Smith, Barbara/0000-0002-5375-7627	NCI NIH HHS [R01-CA23540] Funding Source: Medline; NHLBI NIH HHS [P5-HL56386] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA023540] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL056386] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ADAMS SL, 1977, P NATL ACAD SCI USA, V74, P3399, DOI 10.1073/pnas.74.8.3399; Agami R, 1998, ONCOGENE, V16, P1779, DOI 10.1038/sj.onc.1201708; Blake C, 1996, INTERNET WORLD, V7, P70; DIGNAM JD, 1983, METHOD ENZYMOL, V101, P582; Emery P, 1996, NUCLEIC ACIDS RES, V24, P803, DOI 10.1093/nar/24.5.803; GHAZAL P, 1987, P NATL ACAD SCI USA, V84, P3658, DOI 10.1073/pnas.84.11.3658; GUENETTE DK, 1992, BIOCHEM J, V283, P699, DOI 10.1042/bj2830699; HORNSTRA IK, 1994, MOL CELL BIOL, V14, P1419, DOI 10.1128/MCB.14.2.1419; HUANG LH, 1984, NATURE, V308, P293, DOI 10.1038/308293a0; Huang MX, 1998, CELL, V94, P595, DOI 10.1016/S0092-8674(00)81601-3; Iannello RC, 1997, MOL CELL BIOL, V17, P612, DOI 10.1128/MCB.17.2.612; KARPEN S, 1988, MOL CELL BIOL, V8, P5159, DOI 10.1128/MCB.8.12.5159; Katan Y, 1997, NUCLEIC ACIDS RES, V25, P3621, DOI 10.1093/nar/25.18.3621; Katan-Khaykovich Y, 1998, J BIOL CHEM, V273, P24504, DOI 10.1074/jbc.273.38.24504; Kirillov A, 1996, NAT GENET, V13, P435, DOI 10.1038/ng0895-435; KUDO S, 1995, J BIOL CHEM, V270, P13298, DOI 10.1074/jbc.270.22.13298; KUROKAWA R, 1995, NATURE, V377, P451, DOI 10.1038/377451a0; LABRIE C, 1995, NUCLEIC ACIDS RES, V23, P3732, DOI 10.1093/nar/23.18.3732; Lee BH, 1998, J VIROL, V72, P1138, DOI 10.1128/JVI.72.2.1138-1145.1998; LEHMING N, 1994, NATURE, V371, P175, DOI 10.1038/371175a0; LEWIS JD, 1992, CELL, V69, P905, DOI 10.1016/0092-8674(92)90610-O; Liu MS, 1999, J BIOL CHEM, V274, P15433, DOI 10.1074/jbc.274.22.15433; MAHESWARAN S, 1993, P NATL ACAD SCI USA, V90, P5100, DOI 10.1073/pnas.90.11.5100; Nan XS, 1998, CIBA F SYMP, V214, P6; Nan XS, 1998, NATURE, V393, P386, DOI 10.1038/30764; Okuse K, 1997, MOL BRAIN RES, V46, P197, DOI 10.1016/S0169-328X(96)00302-6; OSTAPCHUK P, 1989, MOL CELL BIOL, V9, P2787, DOI 10.1128/MCB.9.7.2787; REINHOLD W, 1995, MOL CELL BIOL, V15, P3041; REITH W, 1994, MOL CELL BIOL, V14, P1230, DOI 10.1128/MCB.14.2.1230; ROWE DW, 1978, BIOCHEMISTRY-US, V17, P1581, DOI 10.1021/bi00602a001; Samac S, 1998, BIOL CHEM, V379, P541; SANCHEZ CH, 1992, MOL CELL BIOL, V12, P4076, DOI 10.1128/MCB.12.9.4076; SANDMEYER S, 1981, CANCER RES, V41, P830; Schwarz S, 1997, NUCLEIC ACIDS RES, V25, P5052, DOI 10.1093/nar/25.24.5052; Sengupta PK, 1998, BBA-GENE STRUCT EXPR, V1443, P75, DOI 10.1016/S0167-4781(98)00188-2; SHI Y, 1991, CELL, V67, P377, DOI 10.1016/0092-8674(91)90189-6; SIEGRIST CA, 1993, MOL CELL BIOL, V13, P6375, DOI 10.1128/MCB.13.10.6375; Singal R, 1997, P NATL ACAD SCI USA, V94, P13724, DOI 10.1073/pnas.94.25.13724; SMITH BD, 1980, BIOCHEMISTRY-US, V19, P1820, DOI 10.1021/bi00550a014; SMITH BD, 1988, BIOCHEM J, V253, P269, DOI 10.1042/bj2530269; Smith KJ, 1998, AM J DERMATOPATH, V20, P22, DOI 10.1097/00000372-199802000-00005; TONY Y, 1995, CURR BIOL, V5, P1; TREITEL MA, 1995, P NATL ACAD SCI USA, V92, P3132, DOI 10.1073/pnas.92.8.3132; Umezawa A, 1997, MOL CELL BIOL, V17, P4885, DOI 10.1128/MCB.17.9.4885; Wolff GL, 1998, FASEB J, V12, P949, DOI 10.1096/fasebj.12.11.949; WU SY, 1995, MOL CELL BIOL, V15, P1479; ZHANG XY, 1991, VIROLOGY, V182, P865, DOI 10.1016/0042-6822(91)90631-K; ZHANG XY, 1990, CANCER RES, V50, P6865; ZHANG XY, 1993, MOL CELL BIOL, V13, P6810, DOI 10.1128/MCB.13.11.6810; ZHANG XY, 1989, NUCLEIC ACIDS RES, V17, P1459, DOI 10.1093/nar/17.4.1459; ZHANG XY, 1990, NUCLEIC ACIDS RES, V18, P6253, DOI 10.1093/nar/18.21.6253; ZHANG XY, 1995, NUCLEIC ACIDS RES, V23, P3026, DOI 10.1093/nar/23.15.3026	52	38	39	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 17	1999	274	51					36649	36655		10.1074/jbc.274.51.36649	http://dx.doi.org/10.1074/jbc.274.51.36649			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	266AV	10593968	hybrid			2022-12-25	WOS:000084279200087
J	Kosa, JL; Sweasy, JB				Kosa, JL; Sweasy, JB			The E249K mutator mutant of DNA polymerase beta extends mispaired termini	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BASE-EXCISION-REPAIR; HIV-1 REVERSE-TRANSCRIPTASE; CRYSTAL-STRUCTURES; NUCLEAR EXTRACT; HIGH FIDELITY; REPLICATION; MECHANISM; EXTENSION; SUBSTITUTE; SEQUENCE	The DNA polymerase beta mutant enzyme, which is altered from glutamic acid to lysine at position 249, exhibits a mutator phenotype in primer extension assays and in the herpes simplex virus-thymidine kinase (HSV-tk) forward mutation assay. The basis for this loss of accuracy was investigated by measurement of misincorporation fidelity in single turnover conditions. For the four misincorporation reactions investigated, the fidelity of the E249K mutant was not significantly different from wild type, implying that the mutator phenotype was not caused by a general inability to distinguish between correct and incorrect bases during the incorporation reaction. However, the discrimination between correct and incorrect substrates by the E249K enzyme occurred less during the conformational change and chemical steps and more during the initial binding step, compared with pol beta wild type. This implies that the E249R mutation alters the kinetic mechanism of nucleotide discrimination without reducing misincorporation fidelity. In a missing base primer extension assay, we observed that the mutant enzyme produced mispairs and extended them. This indicates that the altered fidelity of E249K could be due to loss of discrimination against mispaired primer termini, This was supported by the finding that the E249K enzyme extended a G:A mispair 8-fold more efficiently than wild type and a C:T mispair 4-fold more efficiently. These results demonstrate that an enhanced ability to extend mispairs can produce a mutator phenotype and that the Glu-249 side chain of DNA polymerase beta is critical for mispair extension fidelity.	Yale Univ, Sch Med, Dept Therapeut Radiol, New Haven, CT 06520 USA; Yale Univ, Sch Med, Dept Genet, New Haven, CT 06520 USA	Yale University; Yale University	Sweasy, JB (corresponding author), Yale Univ, Sch Med, Dept Therapeut Radiol, 333 Cedar St, New Haven, CT 06520 USA.				NATIONAL CANCER INSTITUTE [R01CA080830] Funding Source: NIH RePORTER; NCI NIH HHS [CA 80830, R01 CA080830] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ahn J, 1997, BIOCHEMISTRY-US, V36, P1100, DOI 10.1021/bi961653o; Andersen T, 1987, APPL GEOCHEM, V2, P163, DOI DOI 10.1016/0883-2927(87)90031-X; Beard WA, 1998, CHEM BIOL, V5, pR7, DOI 10.1016/S1074-5521(98)90081-3; Bennett RAO, 1997, P NATL ACAD SCI USA, V94, P7166, DOI 10.1073/pnas.94.14.7166; CARSON M, 1991, J APPL CRYSTALLOGR, V24, P958, DOI 10.1107/S0021889891007240; Chagovetz AM, 1997, J BIOL CHEM, V272, P27501, DOI 10.1074/jbc.272.44.27501; Clairmont CA, 1996, J BACTERIOL, V178, P656, DOI 10.1128/jb.178.3.656-661.1996; DIANOV G, 1994, CURR BIOL, V4, P1069, DOI 10.1016/S0960-9822(00)00245-1; ECHOLS H, 1991, ANNU REV BIOCHEM, V60, P477, DOI 10.1146/annurev.biochem.60.1.477; Eckert KA, 1997, NUCLEIC ACIDS RES, V25, P1450, DOI 10.1093/nar/25.7.1450; GU H, 1994, SCIENCE, V265, P103, DOI 10.1126/science.8016642; JENKINS TM, 1992, SCIENCE, V258, P475, DOI 10.1126/science.1411545; JOHNSON KA, 1995, METHOD ENZYMOL, V249, P38; KOHLSTAEDT LA, 1992, SCIENCE, V256, P1783, DOI 10.1126/science.1377403; Kosa JL, 1999, J BIOL CHEM, V274, P3851, DOI 10.1074/jbc.274.6.3851; KUCHTA RD, 1988, BIOCHEMISTRY-US, V27, P6716, DOI 10.1021/bi00418a012; Li SX, 1999, BIOCHEMISTRY-US, V38, P4800, DOI 10.1021/bi9827058; MATSUKAGE A, 1987, J BIOL CHEM, V262, P8960; MATSUMOTO Y, 1995, SCIENCE, V269, P699, DOI 10.1126/science.7624801; MENDELMAN LV, 1990, J BIOL CHEM, V265, P2338; Opresko PL, 1998, BIOCHEMISTRY-US, V37, P2111, DOI 10.1021/bi9722711; Pelletier H, 1996, BIOCHEMISTRY-US, V35, P12742, DOI 10.1021/bi952955d; PERRINO FW, 1989, P NATL ACAD SCI USA, V86, P8343, DOI 10.1073/pnas.86.21.8343; PERRINO FW, 1989, J BIOL CHEM, V264, P2898; Plug AW, 1997, P NATL ACAD SCI USA, V94, P1327, DOI 10.1073/pnas.94.4.1327; Sawaya MR, 1997, BIOCHEMISTRY-US, V36, P11205, DOI 10.1021/bi9703812; SINGHAL RK, 1993, J BIOL CHEM, V268, P15906; SINGHAL RK, 1995, J BIOL CHEM, V270, P949, DOI 10.1074/jbc.270.2.949; Sobol RW, 1996, NATURE, V379, P183, DOI 10.1038/379183a0; Srivastava DK, 1998, J BIOL CHEM, V273, P21203, DOI 10.1074/jbc.273.33.21203; STEIN CA, 1994, J MED VIROL, V44, P115, DOI 10.1002/jmv.1890440203; Suzuki M, 1997, J BIOL CHEM, V272, P11228; SWEASY JB, 1992, J BIOL CHEM, V267, P1407; SWEASY JB, 1995, J BACTERIOL, V177, P2923, DOI 10.1128/jb.177.10.2923-2925.1995; TANTILLO C, 1994, J MOL BIOL, V243, P369, DOI 10.1006/jmbi.1994.1665	35	30	30	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 10	1999	274	50					35866	35872		10.1074/jbc.274.50.35866	http://dx.doi.org/10.1074/jbc.274.50.35866			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	264NG	10585471	hybrid			2022-12-25	WOS:000084187900083
J	Shiyanov, P; Nag, A; Raychaudhuri, P				Shiyanov, P; Nag, A; Raychaudhuri, P			Cullin 4A associates with the UV-damaged DNA-binding protein DDB	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PIGMENTOSUM GROUP-E; REPAIR PROTEIN; PURIFICATION; GENE; CELL; TRANSCRIPTION; INTERACTS; ELEGANS; DEFECT; FAMILY	The damaged DNA-binding protein (DDB) is believed to be involved in DNA repair, and it has been linked to the repair deficiency disease xeroderma pigmentosum. DDB also exhibits transcriptional activities. DDE binds to the activation domain of E2F1 and stimulates E2F1-activated transcription. Here we provide evidence that DDB or DDB-associated proteins are targets of cullin 4A (CUL-4A). CUL-4A is a member of the cullin family of proteins, which are believed to be ubiquitin-protein isopeptide ligases (type E3). The CUL-4A gene has been shown to be amplified and up-regulated in breast carcinomas. In this study, we identify CUL-4A as one of the DDB-associated proteins. CUL-4A co-immunoprecipitates with DDE, but not with a naturally occurring mutant of DDB, Moreover, CUL-4A in HeLa nuclear extracts co-purifies with DDB, suggesting they are parts of the same complex. The observation provides insights how CUL-4A, through an interaction with DDB, might be playing a role in the development of breast carcinomas.	Univ Illinois, Dept Biochem & Mol Biophys MC 536, Chicago, IL 60612 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Raychaudhuri, P (corresponding author), Univ Illinois, Dept Biochem & Mol Biophys MC 536, Chicago, IL 60612 USA.	pradip@uic.edu			NCI NIH HHS [CA76276] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA076276] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Chen LC, 1998, CANCER RES, V58, P3677; CHU G, 1988, SCIENCE, V242, P564, DOI 10.1126/science.3175673; de Weerd-Kastelein E A, 1974, Mutat Res, V22, P87, DOI 10.1016/0165-1218(74)90056-1; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DUALAN R, 1995, GENOMICS, V29, P62, DOI 10.1006/geno.1995.1215; Feldman RMR, 1997, CELL, V91, P221, DOI 10.1016/S0092-8674(00)80404-3; Hayes S, 1998, MOL CELL BIOL, V18, P240, DOI 10.1128/MCB.18.1.240; Honda R, 1997, FEBS LETT, V420, P25, DOI 10.1016/S0014-5793(97)01480-4; HWANG BJ, 1993, BIOCHEMISTRY-US, V32, P1657, DOI 10.1021/bi00057a033; Hwang BJ, 1998, MOL CELL BIOL, V18, P4391, DOI 10.1128/MCB.18.7.4391; Hwang BJ, 1999, P NATL ACAD SCI USA, V96, P424, DOI 10.1073/pnas.96.2.424; KADONAGA JT, 1986, P NATL ACAD SCI USA, V83, P5889, DOI 10.1073/pnas.83.16.5889; Kazantsev A, 1996, P NATL ACAD SCI USA, V93, P5014, DOI 10.1073/pnas.93.10.5014; KEENEY S, 1994, P NATL ACAD SCI USA, V91, P4053, DOI 10.1073/pnas.91.9.4053; Kipreos ET, 1996, CELL, V85, P829, DOI 10.1016/S0092-8674(00)81267-2; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Krishnamoorthy RR, 1997, BIOCHEMISTRY-US, V36, P960, DOI 10.1021/bi961407c; LEE TH, 1995, J VIROL, V69, P1107, DOI 10.1128/JVI.69.2.1107-1114.1995; Lin GY, 1998, VIROLOGY, V249, P189, DOI 10.1006/viro.1998.9317; Martelli F, 1999, P NATL ACAD SCI USA, V96, P2858, DOI 10.1073/pnas.96.6.2858; Mathias N, 1996, MOL CELL BIOL, V16, P6634; Michel JJ, 1998, CELL GROWTH DIFFER, V9, P435; Nichols AF, 1996, J BIOL CHEM, V271, P24317, DOI 10.1074/jbc.271.40.24317; Ohta T, 1999, MOL CELL, V3, P535, DOI 10.1016/S1097-2765(00)80482-7; Otrin VR, 1998, MOL CELL BIOL, V18, P3182, DOI 10.1128/MCB.18.6.3182; Shiyanov P, 1999, MOL CELL BIOL, V19, P4935; Thut CJ, 1997, GENE DEV, V11, P1974, DOI 10.1101/gad.11.15.1974; VANASSENDELFT GB, 1993, NUCLEIC ACIDS RES, V21, P3399, DOI 10.1093/nar/21.15.3399; Watanabe T, 1999, J NEUROCHEM, V72, P549, DOI 10.1046/j.1471-4159.1999.0720549.x; Willems AR, 1996, CELL, V86, P453, DOI 10.1016/S0092-8674(00)80118-X	30	137	142	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 10	1999	274	50					35309	35312		10.1074/jbc.274.50.35309	http://dx.doi.org/10.1074/jbc.274.50.35309			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	264NG	10585395	hybrid			2022-12-25	WOS:000084187900007
J	Rich, JN; Zhang, M; Datto, MB; Bigner, DD; Wang, XF				Rich, JN; Zhang, M; Datto, MB; Bigner, DD; Wang, XF			Transforming growth factor-beta-mediated p15(INK4B) induction and growth inhibition in astrocytes is SMAD3-dependent and a pathway prominently altered in human glioma cell lines	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN BRAIN-TUMORS; TGF-BETA; MALIGNANT GLIOMA; RECEPTOR EXPRESSION; ANTISENSE GENE; IN-VITRO; PROLIFERATION; FACTOR-BETA-1; TGF-BETA-1; RESISTANCE	We sought to characterize the pathway by which the multifunctional cytokine transforming growth factor-beta (TGF-beta) inhibits the proliferation of normal astrocytes, and we analyzed the alterations in the TGF-beta pathway in human glioma cell lines. Upon TGF-beta treatment, primary rat astrocytes showed a significant decrease in DNA synthesis upon thymidine incorporation with a cell cycle arrest in the G(1) phase. Western analysis of the astrocytes revealed that the expression of the cyclin-dependent kinase inhibitor (CdkI) p15(INK4B) was significantly up-regulated upon TGF-beta treatment without a change in other CdkI levels. The retinoblastoma protein (Rb) became hypophosphorylated, and Cdk2 activity decreased. Analysis of Smad3 null mouse astrocytes showed a significant loss of both TGF-beta-mediated growth inhibition and p15(INK4B) induction compared with wild-type mouse astrocytes. Infection of rat astrocytes by SMAD3 and SMAD4 adenoviruses failed to induce increased expression of p15(INK4B), implying indirect transcriptional regulation of p15(INK4B) by SMAD3, High-grade human gliomas secrete TGF-beta, yet are resistant to its growth inhibitory effects. Analysis of the effects of TGF-beta on 12 human glioma cell lines showed that TGF-beta mildly inhibited the growth of six lines, had no effect on four lines, and stimulated the growth of two lines. The majority of glioma lines had homozygous deletions of the p15(INK4B) gene, except for two lines that expressed p15(INK4B) protein, which was induced further upon TGF-beta treatment. Three lines mildly induced CdkI p21(WAF1) expression in response to TGF-beta. Most tumor lines retained other TGF-beta-mediated responses, including extracellular matrix protein and angiogenic factor secretion, which may contribute to increased malignant behavior. This suggests that the loss of p15(INK4B) may explain, in part, the selective loss of growth inhibition by TGF-beta in gliomas to form a more aggressive tumor phenotype.	Duke Univ, Med Ctr, Div Neurol, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Pharmacol & Canc Biol, Durham, NC USA; Duke Univ, Med Ctr, Dept Pathol, Durham, NC 27710 USA	Duke University; Duke University; Duke University	Rich, JN (corresponding author), Duke Univ, Med Ctr, Div Neurol, Durham, NC 27710 USA.		Rich, Jeremy/AAM-1445-2021		NATIONAL CANCER INSTITUTE [R01CA075368] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [K08NS002055] Funding Source: NIH RePORTER; NCI NIH HHS [CA75368] Funding Source: Medline; NINDS NIH HHS [NS02055-02] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ALEXANDROW MG, 1995, P NATL ACAD SCI USA, V92, P3239, DOI 10.1073/pnas.92.8.3239; Arap W, 1997, ONCOGENE, V15, P2013, DOI 10.1038/sj.onc.1201389; BARNETT S, 1994, CULTURE ANIMAL CELLS, P337; Behzadian MA, 1998, GLIA, V24, P216, DOI 10.1002/(SICI)1098-1136(199810)24:2<216::AID-GLIA6>3.3.CO;2-D; BINDAL AK, 1994, J NEURO-ONCOL, V22, P101, DOI 10.1007/BF01052886; CHANG HL, 1993, CANCER RES, V53, P4391; CHEN RH, 1993, SCIENCE, V260, P1335, DOI 10.1126/science.8388126; CONSTAM DB, 1992, J IMMUNOL, V148, P1404; Cui W, 1996, CELL, V86, P531, DOI 10.1016/S0092-8674(00)80127-0; Datto MB, 1999, MOL CELL BIOL, V19, P2495; DATTO MB, 1995, P NATL ACAD SCI USA, V92, P5545, DOI 10.1073/pnas.92.12.5545; Fakhrai H, 1996, P NATL ACAD SCI USA, V93, P2909, DOI 10.1073/pnas.93.7.2909; Feng XH, 1998, GENE DEV, V12, P2153, DOI 10.1101/gad.12.14.2153; Flanders KC, 1998, PROG NEUROBIOL, V54, P71, DOI 10.1016/S0301-0082(97)00066-X; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; HELSETH E, 1988, J NEURO-ONCOL, V6, P269, DOI 10.1007/BF00163712; HELSETH E, 1988, CANCER IMMUNOL IMMUN, V26, P273; Herman JG, 1996, CANCER RES, V56, P722; Isoe S, 1998, J NEUROSURG, V88, P529, DOI 10.3171/jns.1998.88.3.0529; Izumoto S, 1997, CANCER LETT, V112, P251, DOI 10.1016/S0304-3835(96)04583-1; Jachimczak P, 1996, INT J CANCER, V65, P332, DOI 10.1002/(SICI)1097-0215(19960126)65:3<332::AID-IJC10>3.3.CO;2-X; JEN J, 1994, CANCER RES, V54, P6353; Jennings MT, 1998, J NEURO-ONCOL, V36, P123, DOI 10.1023/A:1005863419880; JENNINGS MT, 1991, INT J CANCER, V49, P129, DOI 10.1002/ijc.2910490124; KALKHOVEN E, 1995, CELL GROWTH DIFFER, V6, P1151; LAIHO M, 1991, MOL CELL BIOL, V11, P972, DOI 10.1128/MCB.11.2.972; Liau LM, 1998, NEUROL RES, V20, P742; MARUSHIGE K, 1994, ANTICANCER RES, V14, P2419; Massague J, 1996, CELL, V85, P947, DOI 10.1016/S0092-8674(00)81296-9; MERZAK A, 1994, BRIT J CANCER, V70, P199, DOI 10.1038/bjc.1994.280; Moustakas A, 1998, P NATL ACAD SCI USA, V95, P6733, DOI 10.1073/pnas.95.12.6733; PAULUS W, 1995, J NEUROPATH EXP NEUR, V54, P236, DOI 10.1097/00005072-199503000-00010; Piek E, 1999, INT J CANCER, V80, P756, DOI 10.1002/(SICI)1097-0215(19990301)80:5<756::AID-IJC21>3.0.CO;2-N; Reuning U, 1998, INT J ONCOL, V13, P893; Riggins GJ, 1997, CANCER RES, V57, P2578; SAMOTO K, 1995, CANCER RES, V55, P1189; Shen X, 1998, MOL BIOL CELL, V9, P3309, DOI 10.1091/mbc.9.12.3309; SONODA Y, 1995, ONCOGENE, V11, P2145; Stiles JD, 1997, J NEUROPATH EXP NEUR, V56, P435, DOI 10.1097/00005072-199704000-00012; SUN LZ, 1994, J BIOL CHEM, V269, P26449; Sun PQ, 1998, SCIENCE, V282, P2270, DOI 10.1126/science.282.5397.2270; TENAN M, 1995, BIOCHEM BIOPH RES CO, V217, P195, DOI 10.1006/bbrc.1995.2763; TORUDELBAUFFE D, 1990, J NEUROCHEM, V54, P1056, DOI 10.1111/j.1471-4159.1990.tb02357.x; VERGELLI M, 1995, J NEUROSCI RES, V40, P127, DOI 10.1002/jnr.490400114; VICK WW, 1987, ACTA CYTOL, V31, P815; Weller M, 1995, BRAIN RES REV, V21, P128, DOI 10.1016/0165-0173(95)00010-0; WRANA JL, 1992, CELL, V71, P1003, DOI 10.1016/0092-8674(92)90395-S; Zhang SJ, 1996, JPN J CANCER RES, V87, P900, DOI 10.1111/j.1349-7006.1996.tb02118.x	48	87	94	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 3	1999	274	49					35053	35058		10.1074/jbc.274.49.35053	http://dx.doi.org/10.1074/jbc.274.49.35053			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	260XW	10574984	hybrid			2022-12-25	WOS:000083979600078
J	Ito, K; Okamoto, I; Araki, N; Kawano, Y; Nakao, M; Fujiyama, S; Tomita, K; Mimori, T; Saya, H				Ito, K; Okamoto, I; Araki, N; Kawano, Y; Nakao, M; Fujiyama, S; Tomita, K; Mimori, T; Saya, H			Calcium influx triggers the sequential proteolysis of extracellular and cytoplasmic domains of E-cadherin, leading to loss of beta-catenin from cell-cell contacts	ONCOGENE			English	Article						metalloprotease; mechanical stimulation; calcium ionophore; E-cadherin; beta-catenin	BREAST-CARCINOMA CELLS; SOLUBLE E-CADHERIN; CANCER-PATIENTS; ADHESION; RECEPTORS; CLEAVAGE; TISSUE; GROWTH; METALLOPROTEINASES; IDENTIFICATION	Cadherins are major cell-cell adhesion molecules in both tumor and normal tissues. Although serum levels of soluble E-cadherin have been shown to be higher in the cancer patients than in healthy volunteers, the detail mechanism regulating release of soluble E-cadherin remains to be elucidated. Here we show that the ectodomain of E-cadherin is proteolytically cleaved from some cancer cells by a membrane-bound metalloprotease to yield soluble form, and the residual membrane-tethered cleavage product is subsequently degraded by intracellular proteolytic pathway. Futhermore, we show that extracellular calcium influx, that is induced by mechanical scraping of cells or ionomycin treatment, enhances the metalloprotease-mediated E-cadherin cleavage and the subsequent degradation of the cytoplasmic domain. Immunocytochemical analysis demonstrates that the sequential proteolysis of E-cadherin triggered by the calcium influx results in translocation of beta-catenin from the cell-cell contacts to cytoplasm. Our data suggest that calcium influx-induced proteolysis of E-cadherin not only disrupts the cell-cell adhesion but also activates beta-catenin-mediated intracellular signaling pathway, potentially leading to alterations in motility and proliferation activity of cells.	Kumamoto Univ, Sch Med, Dept Tumor Genet & Biol, Kumamoto 8600811, Japan; Kumamoto Univ, Sch Med, Dept Internal Med 3, Kumamoto 8600811, Japan	Kumamoto University; Kumamoto University	Saya, H (corresponding author), Kumamoto Univ, Sch Med, Dept Tumor Genet & Biol, 2-2-1 Honjo, Kumamoto 8600811, Japan.		Saya, Hideyuki/J-4325-2013					ABERLE H, 1994, J CELL SCI, V107, P3655; Berridge MJ, 1998, NATURE, V395, P645, DOI 10.1038/27094; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Codony-Servat J, 1999, CANCER RES, V59, P1196; COOMBER BL, 1990, ARTERIOSCLEROSIS, V10, P215, DOI 10.1161/01.ATV.10.2.215; DAMSKY CH, 1983, CELL, V34, P455, DOI 10.1016/0092-8674(83)90379-3; Dethlefsen SM, 1998, J CELL BIOCHEM, V69, P143, DOI 10.1002/(SICI)1097-4644(19980501)69:2<143::AID-JCB5>3.0.CO;2-S; DIFIORE PP, 1987, SCIENCE, V237, P178, DOI 10.1126/science.2885917; FEIGNER PL, 1987, P NATL ACAD SCI USA, V84, P7413, DOI DOI 10.1073/PNAS.84.21.7413; Gofuku J, 1998, BRIT J CANCER, V78, P1095, DOI 10.1038/bjc.1998.634; GORDON MY, 1991, CANCER CELL-MON REV, V3, P127; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; Herren B, 1998, MOL BIOL CELL, V9, P1589, DOI 10.1091/mbc.9.6.1589; Hirohashi S, 1998, AM J PATHOL, V153, P333, DOI 10.1016/S0002-9440(10)65575-7; Hooper NM, 1997, BIOCHEM J, V321, P265, DOI 10.1042/bj3210265; Huber O, 1996, MECH DEVELOP, V59, P3, DOI 10.1016/0925-4773(96)00597-7; HULSKEN J, 1994, J CELL BIOL, V127, P2061, DOI 10.1083/jcb.127.6.2061; ITO A, 1995, BRIT J CANCER, V71, P1039, DOI 10.1038/bjc.1995.200; Jeffers M, 1997, MOL CELL BIOL, V17, P799, DOI 10.1128/MCB.17.2.799; KATAYAMA M, 1994, BRIT J CANCER, V69, P580, DOI 10.1038/bjc.1994.106; LIN YZJ, 1991, ONCOGENE, V6, P639; Lochter A, 1997, J CELL BIOL, V139, P1861, DOI 10.1083/jcb.139.7.1861; Lombard MA, 1998, CANCER RES, V58, P4001; Murphy Andrew J. M., 1992, Methods (Orlando), V4, P111, DOI 10.1016/1046-2023(92)90044-9; Okamoto I, 1999, ONCOGENE, V18, P1435, DOI 10.1038/sj.onc.1202447; OZAWA M, 1989, EMBO J, V8, P1711, DOI 10.1002/j.1460-2075.1989.tb03563.x; PANDIELLA A, 1992, J BIOL CHEM, V267, P24028; Polakis P, 1999, CURR OPIN GENET DEV, V9, P15, DOI 10.1016/S0959-437X(99)80003-3; REIDY MA, 1990, TOXICOL PATHOL, V18, P547; Sadot E, 1998, P NATL ACAD SCI USA, V95, P15339, DOI 10.1073/pnas.95.26.15339; SATO H, 1992, ONCOGENE, V7, P77; TAKEICHI M, 1991, SCIENCE, V251, P1451, DOI 10.1126/science.2006419; Takeichi M, 1993, CURR OPIN CELL BIOL, V5, P806, DOI 10.1016/0955-0674(93)90029-P; Talbot DC, 1996, EUR J CANCER, V32A, P2528; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; TODARO GJ, 1965, J CELL COMPAR PHYSL, V66, P325, DOI 10.1002/jcp.1030660310; Tran POT, 1999, EXP CELL RES, V246, P319, DOI 10.1006/excr.1998.4239; YEE NS, 1993, J BIOL CHEM, V268, P14189; ZABRECKY JR, 1991, J BIOL CHEM, V266, P1716	39	111	120	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 25	1999	18	50					7080	7090		10.1038/sj.onc.1203191	http://dx.doi.org/10.1038/sj.onc.1203191			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	259PH	10597309				2022-12-25	WOS:000083901900015
J	Balana, ME; Lupu, R; Labriola, L; Charreau, EH; Elizalde, PV				Balana, ME; Lupu, R; Labriola, L; Charreau, EH; Elizalde, PV			Interactions between progestins and heregulin (HRG) signaling pathways: HRG acts as mediator of progestins proliferative effects in mouse mammary adenocarcinomas	ONCOGENE			English	Article						progestin; heregulin; mouse mammary tumors; type I insulin-like growth factor receptor	BREAST-CANCER CELLS; NEU DIFFERENTIATION FACTOR; EPIDERMAL GROWTH-FACTOR; FACTOR-I RECEPTOR; MEDROXYPROGESTERONE ACETATE; TRANSDUCTION PATHWAYS; ESTROGEN-RECEPTOR; EPITHELIAL-CELLS; TUMOR-CELLS; EXPRESSION	The present study addressed links between progestin and heregulin (HRG) signaling pathways in mammary tumors. An experimental model of hormonal carcinogenesis, in which the synthetic progestin medroxyprogesterone acetate (MPA) induced mammary adenocarcinomas in female Balb/c mice, was used. MPA induced an in vivo up-regulation of HRG mRNA expression in progestin-dependent (HD) tumor lines. Mammary tumor progression to a progestin-independent (HI) phenotype was accompanied by a high constitutive expression of HRG. The HRG message arose from the tumor epithelial cells. Primary cultures of malignant epithelial cells from a HD tumor line were used to investigate HRG involvement on cell proliferation. HRG induced a potent proliferative effect on these cells and potentiated MPA mitogenic effects. Blocking endogenous HRG synthesis by antisense oligodeoxynucleotides (ASODNs) to HRG mRNA inhibited MPA-induced cell growth, indicating that HRG acts as a mediator of MPA-induced growth. High levels of ErbB-2 and ErbB-3 expression and low ErbB-4 levels mere found in HD cells. Treatment of these cells with either MPA or HRG resulted in tyrosine phosphorylation of both ErbB-2 and ErbB-3. Furthermore, both HRG and MPA proliferative effects mere abolished when cells were treated with ASODNs to ErbB-2 mRNA, providing evidence for a critical role of ErbB-2 in HRG-induced growth. Finally, blocking type I insulin-like growth factor receptor (IGF-IR) expression with ASODN resulted in the complete inhibition of HRG proliferative effect, demonstrating that a functional IGF-IR is required for HRG mitogenic activity. These results provide the first evidence of interactions between progestins and HRB/ErbB signal transduction pathways in mammary cancer and the first demonstration that IGF-IR is required for HRG proliferative effects.	Inst Biol & Med Expt, RA-1428 Buenos Aires, DF, Argentina; Univ Calif Berkeley, Lawrence Berkeley Natl Labs, Berkeley, CA 94710 USA	Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET); Institute of Biology & Experimental Medicine; United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley	Elizalde, PV (corresponding author), Inst Biol & Med Expt, Obligado 2490, RA-1428 Buenos Aires, DF, Argentina.		Labriola, Leticia/E-9059-2012; Labriola, Leticia/ABF-9079-2020	Labriola, Leticia/0000-0003-3899-6088; Labriola, Leticia/0000-0003-3899-6088; Elizalde, Patricia V./0000-0002-5923-9898				Amundadottir LT, 1998, ONCOGENE, V16, P737, DOI 10.1038/sj.onc.1201829; BACKER JM, 1993, J BIOL CHEM, V268, P8204; BACUS SS, 1993, CANCER RES, V53, P5251; BARONE MV, 1995, NATURE, V378, P509, DOI 10.1038/378509a0; BERLII R, 1995, MOL CELL BIOL, V15, P6496; CARRAWAY KL, 1994, CELL, V78, P5, DOI 10.1016/0092-8674(94)90564-9; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COLOMER R, 1994, BRIT J CANCER, V70, P819, DOI 10.1038/bjc.1994.405; COPPOLA D, 1994, MOL CELL BIOL, V14, P4588, DOI 10.1128/MCB.14.7.4588; CULOUSCOU JM, 1993, J BIOL CHEM, V268, P18407; DRAN G, 1995, BREAST CANCER RES TR, V35, P173, DOI 10.1007/BF00668207; Elizalde PV, 1998, J STEROID BIOCHEM, V67, P305, DOI 10.1016/S0960-0760(98)00123-X; FEDI P, 1994, MOL CELL BIOL, V14, P492, DOI 10.1128/MCB.14.1.492; GrausPorta D, 1997, EMBO J, V16, P1647, DOI 10.1093/emboj/16.7.1647; GRAUSPORTA D, 1995, MOL CELL BIOL, V15, P1182; GRUNT TW, 1995, INT J CANCER, V63, P560, DOI 10.1002/ijc.2910630417; Guerra FK, 1996, INT J CANCER, V65, P812, DOI 10.1002/(SICI)1097-0215(19960315)65:6<812::AID-IJC18>3.3.CO;2-5; HAMBURGER AW, 1997, MOL CELL ENDOCRINOL, V138, P163; HOLMES WE, 1992, SCIENCE, V256, P1205, DOI 10.1126/science.256.5060.1205; Krane IM, 1996, ONCOGENE, V12, P1781; LANARI C, 1989, INT J CANCER, V43, P845, DOI 10.1002/ijc.2910430518; Lewis GD, 1996, CANCER RES, V56, P1457; Lowe WL, 1997, ENDOCRINOLOGY, V138, P2219, DOI 10.1210/en.138.6.2219; LUPU R, 1993, BREAST CANCER RES TR, V27, P83, DOI 10.1007/BF00683195; MARTE BM, 1995, MOL ENDOCRINOL, V9, P14, DOI 10.1210/me.9.1.14; MARTE BM, 1995, ONCOGENE, V10, P167; MOLINOLO AA, 1987, J NATL CANCER I, V79, P1341; NORMANNO N, 1995, BREAST CANCER RES TR, V35, P293, DOI 10.1007/BF00665981; NORMANNO N, 1993, INT J ONCOL, V2, P903; PELES E, 1993, BIOESSAYS, V15, P815, DOI 10.1002/bies.950151207; PELES E, 1992, CELL, V69, P205, DOI 10.1016/0092-8674(92)90131-U; PIETRAS RJ, 1995, ONCOGENE, V10, P2435; Pinkas-Kramarski R, 1997, J MAMMARY GLAND BIOL, V2, P97, DOI 10.1023/A:1026343528967; RAM TG, 1995, J CELL PHYSIOL, V163, P589, DOI 10.1002/jcp.1041630320; Saceda M, 1996, ENDOCRINOLOGY, V137, P4322, DOI 10.1210/en.137.10.4322; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SELL C, 1994, MOL CELL BIOL, V14, P3604, DOI 10.1128/MCB.14.6.3604; SeppLorenzino L, 1996, ONCOGENE, V12, P1679; Tang CK, 1996, CANCER RES, V56, P3350; WEN DZ, 1994, MOL CELL BIOL, V14, P1909, DOI 10.1128/MCB.14.3.1909; WEN DZ, 1992, CELL, V69, P559, DOI 10.1016/0092-8674(92)90456-M; YANG YM, 1995, J CELL BIOL, V131, P215, DOI 10.1083/jcb.131.1.215; YOUNG JAT, 1985, NUCLEIC ACIDS RES, V13, P8883, DOI 10.1093/nar/13.24.8883	43	50	50	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 4	1999	18	46					6370	6379		10.1038/sj.onc.1203028	http://dx.doi.org/10.1038/sj.onc.1203028			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	260DK	10597237				2022-12-25	WOS:000083934100022
J	Mollenhauer, J; Holmskov, U; Wiemann, S; Krebs, I; Herbertz, S; Madsen, J; Kioschis, P; Coy, JF; Poustka, A				Mollenhauer, J; Holmskov, U; Wiemann, S; Krebs, I; Herbertz, S; Madsen, J; Kioschis, P; Coy, JF; Poustka, A			The genomic structure of the DMBT1 gene: evidence for a region with susceptibility to genomic instability	ONCOGENE			English	Article						DMBT1; tumour suppressor; scavenger-receptor cysteine-rich; exon-intron structure; genomic instability	TUMOR-SUPPRESSOR GENES; PROSTATE-CANCER; IDENTIFICATION; CHROMOSOME-10; RECOMBINATION; PROGRESSION; GLIOMAS; MEMBER; BRAIN; LOCI	Increasing evidence has accumulated for an involvement of the inactivation of tumour suppressor genes at chromosome 10q in the carcinogenesis of brain tumours, melanomas, and carcinomas of the lung, the prostate, the pancreas, and the endometrium. The gene DMBT1 (Deleted in Malignant Brain Tumours 1) is located at chromosome 10q25.3-q26.1, within one of the putative intervals for tumour suppressor genes. DMBT1 is a member of the scavenger-receptor cysteine-rich (SRCR) superfamily and displays homozygous deletions or lack of expression in glioblastoma multiforme, medulloblastoma, and in gastrointestinal and lung cancers. Based on these properties, DMBT1 has been proposed to be a candidate tumour suppressor gene. We have determined the genomic sequence of DMBT1 to allow analyses of mutations. The gene has at least 54 exons that span a genomic region of about 80 kb, We have identified a putative exon with coding potential for a transmembrane domain. Our data further suggest that alternative splicing gives rise to isoforms of DMBT1 with a differential utilization of SRCR domains and SRCR interspersed domains. The major part of the gene harbours locus specific repeats. These repeats may point to the DMBT1 locus as a region susceptible to chromosomal instability.	Deutsch Krebsforschungszentrum, Dept Mol Genome Anal, D-69120 Heidelberg, Germany; Odense Univ, Univ So Denmark, Inst Med Biol, DK-5000 Odense C, Denmark	Helmholtz Association; German Cancer Research Center (DKFZ); University of Southern Denmark	Mollenhauer, J (corresponding author), Deutsch Krebsforschungszentrum, Dept Mol Genome Anal, Neuenheimer Feld 280, D-69120 Heidelberg, Germany.		Madsen, Jens/N-8082-2013; Mollenhauer, Jan/G-4452-2012; Wiemann, Stefan/E-4424-2013; Holmskov, Uffe/AAA-3056-2022	Madsen, Jens/0000-0003-1664-7645; Wiemann, Stefan/0000-0003-4683-3174; Holmskov, Uffe/0000-0002-2391-9445				Albarosa R, 1996, AM J HUM GENET, V58, P1260; Chen KS, 1997, NAT GENET, V17, P154, DOI 10.1038/ng1097-154; Cheng H, 1996, ANAT REC, V244, P327; HAHN SA, 1995, CANCER RES, V55, P4670; Healy E, 1996, CANCER RES, V56, P589; Hogger P, 1998, J IMMUNOL, V161, P1883; HOLMSKOV V, 1999, IN PRESS P NATL ACAD; Kim SK, 1998, ONCOGENE, V17, P1749, DOI 10.1038/sj.onc.1202073; Komiya A, 1996, GENE CHROMOSOME CANC, V17, P245; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; LI XJ, 1995, J BIOL CHEM, V270, P17674, DOI 10.1074/jbc.270.30.17674; LOUIS DN, 1995, TRENDS GENET, V11, P412, DOI 10.1016/S0168-9525(00)89125-8; Mollenhauer J, 1997, NAT GENET, V17, P32, DOI 10.1038/ng0997-32; Mori M, 1999, BRIT J CANCER, V79, P211, DOI 10.1038/sj.bjc.6690035; Nagase S, 1996, BRIT J CANCER, V74, P1979, DOI 10.1038/bjc.1996.663; O'Keeffe MA, 1999, IMMUNOGENETICS, V49, P45, DOI 10.1007/s002510050462; PENTAO L, 1992, NAT GENET, V2, P292, DOI 10.1038/ng1292-292; RASHEED BKA, 1995, ONCOGENE, V10, P2243; Scheurlen WG, 1997, GENE CHROMOSOME CANC, V18, P50, DOI 10.1002/(SICI)1098-2264(199701)18:1<50::AID-GCC6>3.0.CO;2-0; Somerville RPT, 1998, ONCOGENE, V17, P1755, DOI 10.1038/sj.onc.1202066; Steck PA, 1997, NAT GENET, V15, P356, DOI 10.1038/ng0497-356; Teng DHF, 1997, CANCER RES, V57, P5221; WHITNEY GS, 1995, J BIOL CHEM, V270, P18187, DOI 10.1074/jbc.270.31.18187; Wu WG, 1999, CANCER RES, V59, P1846	24	71	75	0	6	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 4	1999	18	46					6233	6240		10.1038/sj.onc.1203071	http://dx.doi.org/10.1038/sj.onc.1203071			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	260DK	10597221				2022-12-25	WOS:000083934100006
J	Kang, F; Purich, DL; Southwick, FS				Kang, F; Purich, DL; Southwick, FS			Profilin promotes barbed-end actin filament assembly without lowering the critical concentration	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACANTHAMOEBA-PROFILIN; F-ACTIN; POLYMORPHONUCLEAR LEUKOCYTES; SEQUESTERING PEPTIDE; THYMOSIN-BETA-4; MOTILITY; CELLS; POLYMERIZATION; INTERACTS; COMPLEXES	The mechanism of profilin-promoted actin polymerization has been systematically reinvestigated. Rates of barbed-end elongation onto Spectrin . 4.1 . Actin seeds were measured by right angle light scattering to avoid confounding effects of pyrenyl-actin, and KINSIM was used to analyze elongation progress curves. Without thymosin-beta 4, both actin and Profilin . Actin (P . A) are competent in barbed-end polymerization, and kinetic simulations yielded the same bimolecular rate constant (similar to 10 x 10(6) M-1 S-1) for actin monomer or Profilin . Actin. When measured in the absence of profilin, actin assembly curves over a 0.7-4 mu M, thymosin-beta 4 concentration range fit a simple monomer sequestering model (1 mu M K-D for Thymosin-beta 4 . Actin). The corresponding constant for Thymosin-beta 4 . pyrenyl-Actin, however, was significantly higher (similar to 9-10 mu M), suggesting that the fluorophore markedly weakens binding to thymosin-beta 4. With solutions of actin (2 mu M) and thymosin-beta 4 (2 or 4 mu M), the barbed-end assembly rate rose with increasing profilin concentration (0.7-2 mu M). Actin assembly in presence of thymosin-beta 4 and profilin fit a simple thermodynamic energy cycle, thereby disproving an earlier claim (D. Pantaloni and M. F. Carlier (1993) Cell 75, 1007-1014) that profilin promotes nonequilibrium filament assembly by accelerating hydrolysis of filament-bound ATP. Our findings indicate that profilin serves as a polymerization catalyst that captures actin monomers from Thymosin-beta 4 . Actin and ushers actin as a Profilin . Actin complex onto growing barbed filament ends.	Univ Florida, Coll Med, Dept Med, Gainesville, FL 32610 USA; Univ Florida, Coll Med, Dept Biochem & Mol Biol, Gainesville, FL 32610 USA	State University System of Florida; University of Florida; State University System of Florida; University of Florida	Purich, DL (corresponding author), Univ Florida, Hlth Sci Ctr, Dept Biochem & Mol Biol, POB 100245, Gainesville, FL 32610 USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI034276, R01AI023262] Funding Source: NIH RePORTER; NIAID NIH HHS [R01 AI023262, R01 AI034276, R01-AI23262, R01-AI24276] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BARSHOP BA, 1983, ANAL BIOCHEM, V130, P134, DOI 10.1016/0003-2697(83)90660-7; BERNE B J, 1974, Journal of Molecular Biology, V89, P755, DOI 10.1016/0022-2836(74)90049-7; Carlier MF, 1996, J BIOL CHEM, V271, P9231, DOI 10.1074/jbc.271.16.9231; CARLSSON L, 1977, J MOL BIOL, V115, P465, DOI 10.1016/0022-2836(77)90166-8; CASSIMERIS L, 1992, J CELL BIOL, V119, P1261, DOI 10.1083/jcb.119.5.1261; COOPER JA, 1982, METHOD ENZYMOL, V82, P198; GOLDSCHMIDTCLERMONT PJ, 1991, J CELL BIOL, V113, P1081, DOI 10.1083/jcb.113.5.1081; HANNAPPEL E, 1986, ANAL BIOCHEM, V156, P390, DOI 10.1016/0003-2697(86)90270-8; KAISER DA, 1986, J CELL BIOL, V102, P221, DOI 10.1083/jcb.102.1.221; Kang F, 1997, BIOCHEMISTRY-US, V36, P8384, DOI 10.1021/bi970065n; KOUYAMA T, 1981, EUR J BIOCHEM, V114, P33; Laine RO, 1997, J CELL BIOL, V138, P1255, DOI 10.1083/jcb.138.6.1255; LAL AA, 1985, J BIOL CHEM, V260, P132; LIN DC, 1978, J BIOL CHEM, V253, P1415; LINDBERG U, 1988, BIOCHIM BIOPHYS ACTA, V967, P391, DOI 10.1016/0304-4165(88)90102-X; MOCKRIN SC, 1980, BIOCHEMISTRY-US, V19, P5359, DOI 10.1021/bi00564a033; PANTALONI D, 1993, CELL, V75, P1007, DOI 10.1016/0092-8674(93)90544-Z; Perelroizen I, 1996, J BIOL CHEM, V271, P12302, DOI 10.1074/jbc.271.21.12302; POLLARD TD, 1984, BIOCHEMISTRY-US, V23, P6631, DOI 10.1021/bi00321a054; PRING M, 1992, BIOCHEMISTRY-US, V31, P1827, DOI 10.1021/bi00121a035; PURICH DL, 1999, HDB BIOCH KINETICS, P247; SAFER D, 1991, J BIOL CHEM, V266, P4029; SAFER D, 1990, P NATL ACAD SCI USA, V87, P2536, DOI 10.1073/pnas.87.7.2536; SAFER D, 1994, BIOESSAYS, V16, P473, DOI 10.1002/bies.950160706; SOUTHWICK FS, 1994, BIOESSAYS, V16, P885, DOI 10.1002/bies.950161206; SOUTHWICK FS, 1990, J CELL BIOL, V110, P1965, DOI 10.1083/jcb.110.6.1965; SPUDICH JA, 1971, J BIOL CHEM, V246, P4865; STOSSEL TP, 1993, SCIENCE, V260, P1086, DOI 10.1126/science.8493552; TANAKA M, 1985, EUR J BIOCHEM, V151, P291, DOI 10.1111/j.1432-1033.1985.tb09099.x; THERIOT JA, 1994, CELL, V76, P505, DOI 10.1016/0092-8674(94)90114-7; TILNEY LG, 1983, J CELL BIOL, V97, P112, DOI 10.1083/jcb.97.1.112; TOBACMAN LS, 1983, J BIOL CHEM, V258, P8806; TSENG PCH, 1984, J CELL BIOL, V98, P214, DOI 10.1083/jcb.98.1.214; Vinson VK, 1998, BIOCHEMISTRY-US, V37, P10871, DOI 10.1021/bi980093l; WEBER A, 1992, BIOCHEMISTRY-US, V31, P6179, DOI 10.1021/bi00142a002; WEGNER A, 1975, BIOPHYS CHEM, V3, P215, DOI 10.1016/0301-4622(75)80013-5; WEGNER A, 1982, J MOL BIOL, V161, P607, DOI 10.1016/0022-2836(82)90411-9; YOUNG CL, 1994, J BIOL CHEM, V269, P13997; YU FX, 1993, J BIOL CHEM, V268, P502; Zeile WL, 1998, P NATL ACAD SCI USA, V95, P13917, DOI 10.1073/pnas.95.23.13917; ZIMMERLE CT, 1989, BIOCHEM J, V258, P381, DOI 10.1042/bj2580381	41	144	147	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 24	1999	274	52					36963	36972		10.1074/jbc.274.52.36963	http://dx.doi.org/10.1074/jbc.274.52.36963			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	267WR	10601251	hybrid			2022-12-25	WOS:000084382700022
J	Perkins, KJ; Byers, S; Yogalingam, G; Weber, B; Hopwood, JJ				Perkins, KJ; Byers, S; Yogalingam, G; Weber, B; Hopwood, JJ			Expression and characterization of wild type and mutant recombinant human sulfamidase - Implications for Sanfilippo (mucopolysaccharidosis IIIA) syndrome	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SYNDROME TYPE-A; N-ACETYLGALACTOSAMINE 4-SULFATASE; MOLECULAR DEFECTS; IDENTIFICATION; MUTATIONS; PURIFICATION; GENE; VI	Mucopolysaccharidosis IIIA (MPS-IIIA) is an autosomal recessive lysosomal storage disorder caused by the deficiency of sulfamidase (NS; EC 3.10.1.1), resulting in defective degradation and storage of heparan sulfate. This paper reports the production and characterization of monoclonal and polyclonal antibodies against recombinant human sulfamidase (rhNS) to quantitate and characterize normal and mutant sulfamidase produced from the wild type NS expression vector. Glycosylation and phosphorylation studies of immunoprecipitated rhNS show that all five potential glycosylation sites are utilized, with three high mannose/hybrid oligosaccharides and two simpler chains, with at least one functional mannose B-phosphate group. An NS quantification system was developed to determine the effect of the three most common and severe patient mutations: S66W (Italy), R74C (Poland), and R245H (The Netherlands), The quantity and specific activity of expressed mutant rhNS was significantly lower than expressed normal rhNS, with 0.3, 0.2, and 0.05% of normal rhNS produced and 15, 17, and 83% of normal specific activity for S66W, R74C, and R245H observed, respectively. The recent structural elucidation of N-acetylgalactosamine-4-sulfatase was utilized to postulate the effect on the structure-function relationship of NS, The characterization of normal and mutated rhNS has relevance for efficient diagnosis and therapeutic developments for MPS-IIIA patients.	Womens & Childrens Hosp, Dept Chem Pathol, Lysosomal Disorders Res Unit, N Adelaide, SA 5006, Australia		Hopwood, JJ (corresponding author), Womens & Childrens Hosp, Dept Chem Pathol, Lysosomal Disorders Res Unit, 72 King William Rd, N Adelaide, SA 5006, Australia.			Byers, Sharon/0000-0001-5576-3636				ANSON DS, 1992, BIOCHEM J, V284, P789, DOI 10.1042/bj2840789; Bielicki J, 1998, BIOCHEM J, V329, P145, DOI 10.1042/bj3290145; Blanch L, 1997, HUM MOL GENET, V6, P787, DOI 10.1093/hmg/6.5.787; Bond CS, 1997, STRUCTURE, V5, P277, DOI 10.1016/S0969-2126(97)00185-8; BROOKS DA, 1990, J INHERIT METAB DIS, V13, P108, DOI 10.1007/BF01799338; Bunge S, 1997, HUM MUTAT, V10, P479, DOI 10.1002/(SICI)1098-1004(1997)10:6<479::AID-HUMU10>3.0.CO;2-X; CLEMENTS PR, 1985, EUR J BIOCHEM, V152, P21, DOI 10.1111/j.1432-1033.1985.tb09158.x; Di Natale P, 1998, HUM MUTAT, V11, P313, DOI 10.1002/(SICI)1098-1004(1998)11:4<313::AID-HUMU9>3.0.CO;2-P; FREEMAN C, 1986, BIOCHEM J, V234, P83, DOI 10.1042/bj2340083; HOPWOOD JJ, 1982, CLIN CHIM ACTA, V123, P241, DOI 10.1016/0009-8981(82)90168-1; HOPWOOD JJ, 1983, BIOCHEM INT, V6, P831; Karageorgos L E, 1996, DNA Res, V3, P269, DOI 10.1093/dnares/3.4.269; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lukatela G, 1998, BIOCHEMISTRY-US, V37, P3654, DOI 10.1021/bi9714924; Meikle PJ, 1999, JAMA-J AM MED ASSOC, V281, P249, DOI 10.1001/jama.281.3.249; Montfort M, 1998, HUM MUTAT, V12, P274, DOI 10.1002/(SICI)1098-1004(1998)12:4<274::AID-HUMU9>3.3.CO;2-Y; Neufeld EF, 1995, METABOLIC MOL BASES, P2465; Sambrook J., 1990, MOL CLONING LAB MANU, V2nd; SCOTT HS, 1995, NAT GENET, V11, P465, DOI 10.1038/ng1295-465; VANDEKAMP JJP, 1981, CLIN GENET, V20, P152; Weber B, 1998, J INHERIT METAB DIS, V21, P416, DOI 10.1023/A:1005362826552; Weber B, 1997, HUM MOL GENET, V6, P1573, DOI 10.1093/hmg/6.9.1573; Yogalingam G, 1996, J BIOL CHEM, V271, P27259, DOI 10.1074/jbc.271.44.27259	23	33	35	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 24	1999	274	52					37193	37199		10.1074/jbc.274.52.37193	http://dx.doi.org/10.1074/jbc.274.52.37193			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	267WR	10601282	hybrid			2022-12-25	WOS:000084382700053
J	Pongracz, J; Webb, P; Wang, KQ; Deacon, E; Lunn, OJ; Lord, JM				Pongracz, J; Webb, P; Wang, KQ; Deacon, E; Lunn, OJ; Lord, JM			Spontaneous neutrophil apoptosis involves caspase 3-mediated activation of protein kinase C-delta	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-DEATH; PROTEOLYTIC ACTIVATION; EXPRESSION; ISOZYME; U937; BETA; DIFFERENTIATION; INVOLVEMENT; BCL-2; ALPHA	Neutrophils are short-lived leukocytes that die by apoptosis, Whereas stress-induced apoptosis is mediated by the p38 mitogen-activated protein (MAP) kinase pathway (Frasch, S, C., Nick, J, A., Fadok, V, A, Bratton, D, L,, Worthen, G, S., and Henson, P, M, (1998) J, Biol. Chem. 273, 8389-8397), signals regulating spontaneous neutrophil apoptosis have not been fully determined. In this study we found increased activation of protein kinase C (PKC)-beta and -delta in neutrophils undergoing spontaneous apoptosis, but we show that only activation of PKC-delta was directly involved in the induction of apoptosis, PKC-delta can be proteolytically activated by caspase 3, We detected the 40-kDa caspase-generated fragment of PKC-delta in apoptotic neutrophils and showed that the caspase 3: inhibitor Asp-Glu-Val-Asp-fluoromethylketone prevented generation of the 40-kDa PKC-delta fragment and delayed neutrophil apoptosis, In a cell-free system, removal of PKC-delta by immunoprecipitation reduced DNA fragmentation, whereas loss of PKC-alpha, -beta, or -zeta had no significant effect. Rottlerin and LY379196 inhibit PRC-delta and PKC-beta, respectively. Only Rottlerin was able to delay neutrophil apoptosis, Inhibitors of MAP-ERK-kinase 1 (PD98059) or p38 MAP kinase (SB202190) had no effect on neutrophil apoptosis, and activation of p42/44 and p38 MAP kinase did not increase in apoptotic neutrophils, We conclude that spontaneous neutrophil apoptosis involves activation of PKC-delta but is MAP kinase-independent.	Univ Birmingham, Sch Med, MRC, Ctr Immune Regulat,Div Immun & Infect, Birmingham B15 2TT, W Midlands, England	University of Birmingham	Lord, JM (corresponding author), Univ Birmingham, Sch Med, MRC, Ctr Immune Regulat,Div Immun & Infect, Birmingham B15 2TT, W Midlands, England.		Webb, Paul/C-3285-2011; Pongracz, Judit E/N-7927-2018; Pongracz, Judit E/J-7517-2019	Pongracz, Judit E/0000-0002-0278-5556; Pongracz, Judit E/0000-0002-0278-5556; Lord, Janet/0000-0003-1030-6786				AFFORD SC, 1992, J BIOL CHEM, V267, P21612; Bharti A, 1998, MOL CELL BIOL, V18, P6719, DOI 10.1128/MCB.18.11.6719; Brown SB, 1999, J IMMUNOL, V162, P480; BUNCE CM, 1988, ANAL BIOCHEM, V175, P67, DOI 10.1016/0003-2697(88)90362-4; DANG PMC, 1994, FEBS LETT, V349, P338, DOI 10.1016/0014-5793(94)00700-4; Deacon EM, 1997, J CLIN PATHOL-MOL PA, V50, P124, DOI 10.1136/mp.50.3.124; Edwards S.L., 1994, BIOCH PHYSL NEUTROPH; Emoto Y, 1995, EMBO J, V14, P6148, DOI 10.1002/j.1460-2075.1995.tb00305.x; Enari M, 1998, NATURE, V393, P396, DOI 10.1038/30782; EVANS CA, 1995, J CELL SCI, V108, P2591; Frasch SC, 1998, J BIOL CHEM, V273, P8389, DOI 10.1074/jbc.273.14.8389; Frutos S, 1999, J BIOL CHEM, V274, P10765, DOI 10.1074/jbc.274.16.10765; Ghayur T, 1996, J EXP MED, V184, P2399, DOI 10.1084/jem.184.6.2399; Griffiths G, 1996, BIOCHEM BIOPH RES CO, V222, P802, DOI 10.1006/bbrc.1996.0830; GSCWENDT M, 1994, BIOCHEM BIOPH RES CO, V199, P93; HALLETT MB, 1995, IMMUNOL TODAY, V16, P264, DOI 10.1016/0167-5699(95)80178-2; HOGG JC, 1987, PHYSIOL REV, V67, P1249, DOI 10.1152/physrev.1987.67.4.1249; IWAI K, 1994, BLOOD, V84, P1201; Janicke RU, 1998, J BIOL CHEM, V273, P15540, DOI 10.1074/jbc.273.25.15540; Jirousek MR, 1996, J MED CHEM, V39, P2664, DOI 10.1021/jm950588y; KNOX KA, 1993, EXP CELL RES, V207, P68, DOI 10.1006/excr.1993.1164; LEE A, 1993, J LEUKOCYTE BIOL, V54, P283, DOI 10.1002/jlb.54.4.283; Lee JY, 1996, J BIOL CHEM, V271, P13169, DOI 10.1074/jbc.271.22.13169; MACFARLANE DE, 1994, J BIOL CHEM, V269, P4327; MAJUMDAR S, 1991, J BIOL CHEM, V266, P9285; Mashima T, 1999, ONCOGENE, V18, P2423, DOI 10.1038/sj.onc.1202558; NAIRN AC, 1994, SEMIN CANCER BIOL, V5, P295; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; Parmer TG, 1997, CELL GROWTH DIFFER, V8, P327; PONGRACZ J, 1995, EXP CELL RES, V218, P430, DOI 10.1006/excr.1995.1176; Pongracz J, 1996, LEUKEMIA RES, V20, P319, DOI 10.1016/0145-2126(95)00074-7; SAVILL JS, 1989, J CLIN INVEST, V83, P865, DOI 10.1172/JCI113970; Scheel-Toellner D, 1999, EUR J IMMUNOL, V29, P2603, DOI 10.1002/(SICI)1521-4141(199908)29:08<2603::AID-IMMU2603>3.0.CO;2-L; SMALLWOOD JI, 1992, J LEUKOCYTE BIOL, V51, P84, DOI 10.1002/jlb.51.1.84; Stringer RE, 1996, BRIT J HAEMATOL, V92, P169, DOI 10.1046/j.1365-2141.1996.00307.x; TSUTSUMI A, 1993, J IMMUNOL, V150, P1746; WEISS SJ, 1989, NEW ENGL J MED, V320, P365; Whelan RDH, 1998, ONCOGENE, V16, P1939, DOI 10.1038/sj.onc.1201725	38	164	169	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 24	1999	274	52					37329	37334		10.1074/jbc.274.52.37329	http://dx.doi.org/10.1074/jbc.274.52.37329			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	267WR	10601300	hybrid			2022-12-25	WOS:000084382700071
J	Garrison, TR; Zhang, YN; Pausch, M; Apanovitch, D; Aebersold, R; Dohlman, HG				Garrison, TR; Zhang, YN; Pausch, M; Apanovitch, D; Aebersold, R; Dohlman, HG			Feedback phosphorylation of an RGS protein by MAP kinase in yeast	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE REQUIRES; SIGNAL-TRANSDUCTION PATHWAY; PHEROMONE RESPONSE PATHWAY; ALPHA-SUBUNIT; MASS-SPECTROMETRY; POINT MUTATION; KSS1; GENE; DESENSITIZATION; SST2	Regulators of G protein signaling (RGS proteins) are well. known to accelerate G protein GTPase activity in vitro and to promote G protein desensitization in vivo. Less is known about how RGS proteins are themselves regulated. To address this question we purified the RGS in yeast, Sst2, and used electrospray ionization mass spectrometry to identify post-translational modifications. This analysis revealed that Sst2 is phosphorylated at Ser-539 and that phosphorylation occurs in response to pheromone stimulation. Ser-539 lies within a consensus mitogen-activated protein (MAP) kinase phosphorylation site, Pro-X-Ser-Pro. Phosphorylation is blocked by mutations in the MAP kinase genes (FUS3, KSS1), as well as by mutations in components needed for MAP kinase activation (STE11, STE7, STE4, STE18). Phosphorylation is also blocked by replacing Ser-539 with Ala, Asp, or Glu (but not Thr). These point mutations do not alter pheromone sensitivity, as determined by growth arrest and reporter transcription assays. However, phosphorylation appears to slow the rate of Sst2 degradation. These findings indicate that the G protein-regulated MAP kinase in yeast can act as a feedback regulator of Sst2, itself a regulator of G protein signaling.	Yale Univ, Sch Med, Dept Pharmacol, Boyer Ctr Mol Med, New Haven, CT 06536 USA; Univ Washington, Dept Mol Biotechnol, Seattle, WA 98195 USA; Wyeth Ayerst Res, Princeton, NJ 08543 USA	Yale University; University of Washington; University of Washington Seattle; Pfizer	Dohlman, HG (corresponding author), Yale Univ, Sch Med, Dept Pharmacol, Boyer Ctr Mol Med, 295 Congress Ave,Room 436,POB 9812, New Haven, CT 06536 USA.	henrik.dohlman@yale.edu		Dohlman, Henrik/0000-0003-2443-0729	NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR011823] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM055316, R29GM055316, R01GM059167] Funding Source: NIH RePORTER; NCRR NIH HHS [RR11823] Funding Source: Medline; NIGMS NIH HHS [R01 GM059167, GM59167, GM55316, R01 GM055316] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Apanovitch DM, 1998, J BIOL CHEM, V273, P28597, DOI 10.1074/jbc.273.44.28597; Apanovitch DM, 1998, BIOCHEMISTRY-US, V37, P4815, DOI 10.1021/bi9729965; Berman DM, 1998, J BIOL CHEM, V273, P1269, DOI 10.1074/jbc.273.3.1269; CHAN RK, 1982, MOL CELL BIOL, V2, P11, DOI 10.1128/MCB.2.1.11; Cook JG, 1997, NATURE, V390, P85, DOI 10.1038/36355; Cook JG, 1996, GENE DEV, V10, P2831, DOI 10.1101/gad.10.22.2831; DAVIS JL, 1992, MOL CELL BIOL, V12, P1879, DOI 10.1128/MCB.12.4.1879; DiBello PR, 1998, J BIOL CHEM, V273, P5780, DOI 10.1074/jbc.273.10.5780; DIETZEL C, 1987, MOL CELL BIOL, V7, P4169, DOI 10.1128/MCB.7.12.4169; DOHLMAN HG, 1995, MOL CELL BIOL, V15, P3635; Dohlman HG, 1996, MOL CELL BIOL, V16, P5194; Dohlman HG, 1997, J BIOL CHEM, V272, P3871, DOI 10.1074/jbc.272.7.3871; ELION EA, 1993, MOL BIOL CELL, V4, P495, DOI 10.1091/mbc.4.5.495; Figeys D, 1996, NAT BIOTECHNOL, V14, P1579, DOI 10.1038/nbt1196-1579; Figeys D, 1998, ELECTROPHORESIS, V19, P2338, DOI 10.1002/elps.1150191314; GARTNER A, 1992, GENE DEV, V6, P1280, DOI 10.1101/gad.6.7.1280; HASSON MS, 1994, MOL CELL BIOL, V14, P1054, DOI 10.1128/MCB.14.2.1054; Kim E, 1999, P NATL ACAD SCI USA, V96, P6371, DOI 10.1073/pnas.96.11.6371; Lan KL, 1998, J BIOL CHEM, V273, P12794, DOI 10.1074/jbc.273.21.12794; Lefkowitz RJ, 1998, J BIOL CHEM, V273, P18677, DOI 10.1074/jbc.273.30.18677; Lin FT, 1999, J BIOL CHEM, V274, P15971, DOI 10.1074/jbc.274.23.15971; MA D, 1995, MOL BIOL CELL, V6, P889, DOI 10.1091/mbc.6.7.889; Madhani HD, 1997, CELL, V91, P673, DOI 10.1016/S0092-8674(00)80454-7; Pausch Mark H., 1998, P196; PETER M, 1993, CELL, V73, P747, DOI 10.1016/0092-8674(93)90254-N; RAMER SW, 1993, P NATL ACAD SCI USA, V90, P452, DOI 10.1073/pnas.90.2.452; Rechsteiner M, 1996, TRENDS BIOCHEM SCI, V21, P267, DOI 10.1016/S0968-0004(96)10031-1; SEGER R, 1995, FASEB J, V9, P726, DOI 10.1096/fasebj.9.9.7601337; SPRAGUE GF, 1991, METHOD ENZYMOL, V194, P77; Sprague GF, 1998, GENE DEV, V12, P2817, DOI 10.1101/gad.12.18.2817; Tesmer JJG, 1997, CELL, V89, P251, DOI 10.1016/S0092-8674(00)80204-4; TYERS M, 1993, MOL CELL BIOL, V13, P5659, DOI 10.1128/MCB.13.9.5659; YATES JR, 1995, ANAL CHEM, V67, P1426, DOI 10.1021/ac00104a020; ZHANG H, 1994, GENE DEV, V8, P1750, DOI 10.1101/gad.8.15.1750; ZHOU ZQ, 1993, MOL CELL BIOL, V13, P2069, DOI 10.1128/MCB.13.4.2069	35	64	65	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 17	1999	274	51					36387	36391		10.1074/jbc.274.51.36387	http://dx.doi.org/10.1074/jbc.274.51.36387			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	266AV	10593933	hybrid			2022-12-25	WOS:000084279200052
J	Harris, CM; Molla, G; Pilone, MS; Pollegioni, L				Harris, CM; Molla, G; Pilone, MS; Pollegioni, L			Studies on the reaction mechanism of Rhodotorula gracilis D-amino-acid oxidase - Role of the highly conserved Tyr-223 on substrate binding and catalysis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVE-SITE; 3-DIMENSIONAL STRUCTURE; KINETIC MECHANISM; CEPHALOSPORIN-C; RESOLUTION; ENZYME; COLI	We have studied D-amino-acid oxidase from Rhodotorula gracilis by site-directed mutagenesis for the purpose of determining the presence or absence of residues having a possible role in acid/base catalysis, Tyr-223, one of the very few conserved residues among D-amino-acid oxidases, has been mutated to phenylalanine and to serine, Both mutants are active catalysts in turnover with D-alanine, and they are reduced by D-alanine slightly faster than wild type enzyme. The Tyr-223 -> Phe mutant is virtually identical to the wild-type enzyme, whereas the Tyr-223 -> Ser mutant exhibits 60-fold slower substrate binding and at least 800-fold slower rate of product release relative to wild-type. These data eliminate Tyr-223 as an active site acid/base catalyst. These results underline the importance of Tyr-223 for substrate binding and exemplify the importance of steric interactions in RgDAAO catalysis.	Univ Insubria, Dept Biol Strutturale & Funz, I-21100 Varese, Italy	University of Insubria	Pollegioni, L (corresponding author), Univ Insubria, Dept Biol Strutturale & Funz, Via JH Dunant 3, I-21100 Varese, Italy.			Molla, Gianluca/0000-0003-3688-3397; POLLEGIONI, LOREDANO/0000-0003-1733-7243				CURTI B, 1992, CHEM BIOCH FLAVOENZY, P69; DALZIEL K, 1969, BIOCHEM J, V114, P547, DOI 10.1042/bj1140547; FAOTTO L, 1995, BIOTECHNOL LETT, V17, P193, DOI 10.1007/BF00127987; GIBSON QH, 1964, J BIOL CHEM, V239, P3927; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LINDQVIST Y, 1989, J BIOL CHEM, V264, P3624; MASSEY V, 1978, BIOCHEMISTRY-US, V17, P9, DOI 10.1021/bi00594a002; MASSEY V, 1964, FED PROC, V23, P18; MASSEY V, 1991, FLAVINS AND FLAVOPROTEINS 1990, P59; Mattevi A, 1996, P NATL ACAD SCI USA, V93, P7496, DOI 10.1073/pnas.93.15.7496; Mattevi A, 1997, CURR OPIN STRUC BIOL, V7, P804, DOI 10.1016/S0959-440X(97)80150-9; MINNAERT K, 1965, BIOCHIM BIOPHYS ACTA, V110, P42, DOI 10.1016/S0926-6593(65)80093-5; MIURA R, 1988, BIOORG CHEM, V16, P97, DOI 10.1016/0045-2068(88)90039-9; Mizutani H, 1996, J BIOCHEM-TOKYO, V120, P14; Molla G, 1998, PROTEIN EXPRES PURIF, V14, P289, DOI 10.1006/prep.1998.0956; MUH U, 1994, J BIOL CHEM, V269, P7994; PILONE MS, 1995, BIOTECHNOL LETT, V17, P199, DOI 10.1007/BF00127988; PILONE MS, 1998, RRD BIOTECH BIOENG 2, V1, P285; Pollegioni L, 1997, J BIOL CHEM, V272, P4924, DOI 10.1074/jbc.272.8.4924; Pollegioni L, 1997, J BIOTECHNOL, V58, P115, DOI 10.1016/S0168-1656(97)00142-9; POLLEGIONI L, 1994, J BIOL CHEM, V269, P31666; POLLEGIONI L, 1993, J BIOL CHEM, V268, P13850; POLLEGIONI L, 1992, BIOCHIM BIOPHYS ACTA, V1120, P11, DOI 10.1016/0167-4838(92)90418-D; PORTER DJT, 1977, J BIOL CHEM, V252, P4464; ROUVIEREFOURMY N, 1994, BIOCHEMISTRY-US, V33, P798, DOI 10.1021/bi00169a022; Sambrook J., 2002, MOL CLONING LAB MANU; Stegman LD, 1998, HUM GENE THER, V9, P185, DOI 10.1089/hum.1998.9.2-185; STRICKLAND S, 1975, J BIOL CHEM, V250, P4048; Todone F, 1997, BIOCHEMISTRY-US, V36, P5853, DOI 10.1021/bi9630570; WALSH CT, 1971, J BIOL CHEM, V246, P6855; XIA ZX, 1987, P NATL ACAD SCI USA, V84, P2629, DOI 10.1073/pnas.84.9.2629	31	53	55	2	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 17	1999	274	51					36233	36240		10.1074/jbc.274.51.36233	http://dx.doi.org/10.1074/jbc.274.51.36233			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	266AV	10593911	hybrid			2022-12-25	WOS:000084279200030
J	Sargent, F; Stanley, NR; Berks, BC; Palmer, T				Sargent, F; Stanley, NR; Berks, BC; Palmer, T			Sec-independent protein translocation in Escherichia coli - A distinct and pivotal role for the TatB protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE-SEQUENCE; HYDROGENASE ISOENZYMES; FORMATE DEHYDROGENASE; MUTATIONAL ANALYSIS; EXPORT PATHWAY; MEMBRANE; OPERON; GENE; REDUCTASE; EXPRESSION	In Escherichia coli, transmembrane translocation of proteins can proceed by a number of routes. A subset of periplasmic proteins are exported via the Tat pathway to which proteins are directed by N-terminal "transfer peptides" bearing the consensus (S/T)RRXFLK "twin-arginine" motif, The Tat system involves the integral membrane proteins TatA, TatB, TatC, and TatE, Of these, TatA, TatB, and TatE are homologues of the Hcf106 component of the Delta pH-dependent protein import system of plant thylakoids, Deletion of the tatB gene alone is sufficient to block the export of seven endogenous Tat substrates, including hydrogenase-g. Complementation analysis indicates that while TatA and TatE are functionally interchangeable, the TatB protein is functionally distinct. This conclusion is supported by the observation that Helicobacter pylori tatA will complement an E. coli tatA mutant, but not a tatB mutant. Analysis of Tat component stability in various tot deletion backgrounds shows that TatC is rapidly degraded in the absence of TatB suggesting that TatC complexes, and is stabilized by, TatB.	John Innes Ctr, Dept Mol Microbiol, Norwich NR4 7UH, Norfolk, England; Univ E Anglia, Sch Biol Sci, Ctr Metalloprot Spect & Biol, Norwich NR4 7TJ, Norfolk, England	UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); John Innes Center; University of East Anglia	Palmer, T (corresponding author), John Innes Ctr, Dept Mol Microbiol, Norwich NR4 7UH, Norfolk, England.	tracy.palmer@bbsrc.ac.uk		Sargent, Frank/0000-0002-6841-3624; Stanley-Wall, Nicola/0000-0002-5936-9721; Berks, Ben/0000-0001-9685-4067; Palmer, Tracy/0000-0001-9043-2592				ATLUNG T, 1989, J BACTERIOL, V171, P1683, DOI 10.1128/jb.171.3.1683-1691.1989; BALLANTINE SP, 1986, EUR J BIOCHEM, V156, P277, DOI 10.1111/j.1432-1033.1986.tb09578.x; BALLANTINE SP, 1985, J BACTERIOL, V163, P454, DOI 10.1128/JB.163.2.454-459.1985; BARTOLOME B, 1991, GENE, V102, P75, DOI 10.1016/0378-1119(91)90541-I; BERG BL, 1991, J BIOL CHEM, V266, P22380; Berks BC, 1996, MOL MICROBIOL, V22, P393, DOI 10.1046/j.1365-2958.1996.00114.x; Bernhard M, 1997, EUR J BIOCHEM, V248, P179, DOI 10.1111/j.1432-1033.1997.00179.x; Bernhard M, 1996, J BACTERIOL, V178, P4522, DOI 10.1128/jb.178.15.4522-4529.1996; BILOUS PT, 1988, MOL MICROBIOL, V2, P785, DOI 10.1111/j.1365-2958.1988.tb00090.x; BILOUS PT, 1985, J BACTERIOL, V162, P1151, DOI 10.1128/JB.162.3.1151-1155.1985; Bogsch EG, 1998, J BIOL CHEM, V273, P18003, DOI 10.1074/jbc.273.29.18003; CASADABAN MJ, 1979, P NATL ACAD SCI USA, V76, P4530, DOI 10.1073/pnas.76.9.4530; Chanal A, 1998, MOL MICROBIOL, V30, P674, DOI 10.1046/j.1365-2958.1998.01095.x; COHEN N, 1956, ANN I PASTEUR PARIS, V91, P693; Cristobal S, 1999, EMBO J, V18, P2982, DOI 10.1093/emboj/18.11.2982; Dalbey RE, 1999, TRENDS BIOCHEM SCI, V24, P17, DOI 10.1016/S0968-0004(98)01333-4; Danese PN, 1998, ANNU REV GENET, V32, P59, DOI 10.1146/annurev.genet.32.1.59; GRAHAM A, 1980, FEMS MICROBIOL LETT, V7, P145, DOI 10.1111/j.1574-6941.1980.tb01595.x; Gross R, 1998, ARCH MICROBIOL, V170, P50, DOI 10.1007/s002030050614; HAMILTON CM, 1989, J BACTERIOL, V171, P4617, DOI 10.1128/jb.171.9.4617-4622.1989; JAYARAMAN PS, 1987, J MOL BIOL, V196, P781, DOI 10.1016/0022-2836(87)90404-9; LIU JD, 1989, J BACTERIOL, V171, P1254, DOI 10.1128/jb.171.3.1254-1261.1989; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MEJEAN V, 1994, MOL MICROBIOL, V11, P1169, DOI 10.1111/j.1365-2958.1994.tb00393.x; MENON NK, 1994, J BACTERIOL, V176, P4416, DOI 10.1128/jb.176.14.4416-4423.1994; MENON NK, 1990, J BACTERIOL, V172, P1969, DOI 10.1128/jb.172.4.1969-1977.1990; Miller J.H., 1992, SHORT COURSE BACTERI, P150; OSBORN MJ, 1972, J BIOL CHEM, V247, P3973; PUGSLEY AP, 1993, MICROBIOL REV, V57, P50, DOI 10.1128/MMBR.57.1.50-108.1993; Rodrigue A, 1996, FEBS LETT, V392, P81, DOI 10.1016/0014-5793(96)00788-0; Rodrigue A, 1999, J BIOL CHEM, V274, P13223, DOI 10.1074/jbc.274.19.13223; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Santini CL, 1998, EMBO J, V17, P101, DOI 10.1093/emboj/17.1.101; Sargent F, 1998, EMBO J, V17, P3640, DOI 10.1093/emboj/17.13.3640; Sargent F, 1998, EUR J BIOCHEM, V255, P746, DOI 10.1046/j.1432-1327.1998.2550746.x; SAUTER M, 1992, MOL MICROBIOL, V6, P1523, DOI 10.1111/j.1365-2958.1992.tb00873.x; SAWERS G, 1994, ANTON LEEUW INT J G, V66, P57, DOI 10.1007/BF00871633; SAWERS RG, 1985, J BACTERIOL, V164, P1324, DOI 10.1128/JB.164.3.1324-1331.1985; Settles AM, 1998, TRENDS CELL BIOL, V8, P494, DOI 10.1016/S0962-8924(98)01387-7; Settles AM, 1997, SCIENCE, V278, P1467, DOI 10.1126/science.278.5342.1467; SILVESTRO A, 1988, BIOCHIM BIOPHYS ACTA, V954, P1, DOI 10.1016/0167-4838(88)90049-0; TABOR S, 1985, P NATL ACAD SCI USA, V82, P1074, DOI 10.1073/pnas.82.4.1074; Tomb JF, 1997, NATURE, V388, P539, DOI 10.1038/41483; VONHEIJNE G, 1986, EMBO J, V5, P3021, DOI 10.1002/j.1460-2075.1986.tb04601.x; VONHEIJNE G, 1985, J MOL BIOL, V184, P99, DOI 10.1016/0022-2836(85)90046-4; Wanner B.L., 1996, ESCHERICHIA COLI SAL; Weiner JH, 1998, CELL, V93, P93, DOI 10.1016/S0092-8674(00)81149-6; WU LF, 1993, FEMS MICROBIOL LETT, V104, P243	48	247	254	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 17	1999	274	51					36073	36082		10.1074/jbc.274.51.36073	http://dx.doi.org/10.1074/jbc.274.51.36073			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	266AV	10593889	hybrid			2022-12-25	WOS:000084279200008
J	Teng-umnuay, P; van der Wel, H; West, CM				Teng-umnuay, P; van der Wel, H; West, CM			Identification of a UDP-GlcNAc : Skp1-hydroxyproline GlcNAc-transferase in the cytoplasm of Dictyostelium	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-ACETYLGLUCOSAMINYLTRANSFERASE; TETRATRICOPEPTIDE REPEATS; CYTOSOLIC GLYCOPROTEIN; ENDOPLASMIC-RETICULUM; GLYCOSYLATION; PROTEINS; GLYCOSYLTRANSFERASES; NUCLEAR; FP21; PURIFICATION	Skp1 is a cytoplasmic and nuclear protein required for the ubiquitination of cell cycle regulatory proteins and transcriptional factors. In Dictyostelium, Skp1 is modified by a linear pentasaccharide, Gal alpha 1-6Gal alpha 1-Fuc alpha 1-2Gal beta 1-3GlcNAc, attached to a hydroxyproline (HyPro) residue at position 143. To study the formation of the GlcNAc-HyPro Linkage, an assay was developed for the transfer of [H-3]GlcNAc from UDP-[H-3]GlcNAc to Skp1-HyPro-143 or a synthetic Skp1 4-HyPro peptide. The cytosolic but not the particulate fraction of the cell mediated transfer in a time-, concentration-, and HyProdependent fashion. Incorporated radioactivity was alkali-resistant and was recovered as GlcNH(2) after acid hydrolysis, consistent with Linkage of GlcNAc to HyPro. The GlcNAc-transferase activity was purified 130,000-fold as a single component with a recovery of 5%. Key to the purification was the synthesis of a novel affinity resin linking UDP-GlcNAc at its 5-uridyl position. The purified activity had an apparent M-r of similar to 45,000 by gel filtration, required dithiothreitol and a divalent cation, and consisted predominantly of a M-r 51,000 band after SDS-polyacrylamide gel electrophoresis that was photoaffinity labeled with 5-I-125-[3-(p-azidosalicylamido)-1-propenyl-UDP-GlcNAc in a UDP-GlcNAc-sensitive fashion. Its apparent IL, values for UDP-GlcNAc and Skp1 were submicromolar. The presence of the enzyme in the cytosolic fraction, its dependence on a reducing environment, and its high affinity for UDP-GlcNAc strongly suggest that Skp1 is glycosylated by a HyPro GlcNAc-transferase that resides in the cytoplasm.	Univ Florida, Coll Med, Dept Anat & Cell Biol, Gainesville, FL 32610 USA	State University System of Florida; University of Florida	West, CM (corresponding author), Box 100235,1600 SW Archer Rd, Gainesville, FL 32610 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM037539] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01-GM37539] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABEIJON C, 1992, TRENDS BIOCHEM SCI, V17, P32, DOI 10.1016/0968-0004(92)90424-8; BENDIAK B, 1987, J BIOL CHEM, V262, P5784; Busch C, 1998, J BIOL CHEM, V273, P19566, DOI 10.1074/jbc.273.31.19566; DALE RMK, 1975, BIOCHEMISTRY-US, V14, P2447, DOI 10.1021/bi00682a027; FIELD MC, 1995, GLYCOBIOLOGY, V5, P463, DOI 10.1093/glycob/5.5.463; GONZALEZYANES B, 1992, J BIOL CHEM, V267, P9595; HALTIWANGER RS, 1992, J BIOL CHEM, V267, P9005; Harlow E., 1999, USING ANTIBODIES LAB; Hart GW, 1997, ANNU REV BIOCHEM, V66, P315, DOI 10.1146/annurev.biochem.66.1.315; HOLMES EH, 1990, J BIOL CHEM, V265, P13150; Ingram GC, 1997, EMBO J, V16, P6521, DOI 10.1093/emboj/16.21.6521; Kivirikko KI, 1998, ADV ENZYMOL RAMB, V72, P325; Koepp DM, 1999, CELL, V97, P431, DOI 10.1016/S0092-8674(00)80753-9; KOZAROV E, 1995, J BIOL CHEM, V270, P3022, DOI 10.1074/jbc.270.7.3022; Kreppel LK, 1997, J BIOL CHEM, V272, P9308; Laney JD, 1999, CELL, V97, P427, DOI 10.1016/S0092-8674(00)80752-7; Li FN, 1997, EMBO J, V16, P5629, DOI 10.1093/emboj/16.18.5629; Lubas WA, 1997, J BIOL CHEM, V272, P9316; MACLEAN N, 1984, EXPERIENTIA, V40, P1207, DOI 10.1007/BF01946648; PAULSON JC, 1989, J BIOL CHEM, V264, P17615; ROQUEMORE EP, 1994, METHOD ENZYMOL, V230, P443; SEDMAK JJ, 1977, ANAL BIOCHEM, V79, P544, DOI 10.1016/0003-2697(77)90428-6; Selzer J, 1996, J BIOL CHEM, V271, P25173, DOI 10.1074/jbc.271.41.25173; Suzuki T, 1998, J BIOL CHEM, V273, P10083, DOI 10.1074/jbc.273.17.10083; Teng-umnuay P, 1998, J BIOL CHEM, V273, P18242, DOI 10.1074/jbc.273.29.18242; West CM, 1996, J BIOL CHEM, V271, P12024, DOI 10.1074/jbc.271.20.12024; West CM, 1997, GENE, V200, P1, DOI 10.1016/S0378-1119(97)00194-7; WRAY W, 1981, ANAL BIOCHEM, V118, P197, DOI 10.1016/0003-2697(81)90179-2; Zeng Y, 1996, ANAL BIOCHEM, V239, P99, DOI 10.1006/abio.1996.0296	29	28	30	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 17	1999	274	51					36392	36402		10.1074/jbc.274.51.36392	http://dx.doi.org/10.1074/jbc.274.51.36392			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	266AV	10593934	hybrid			2022-12-25	WOS:000084279200053
J	Yamasaki, R; Koshino, H; Kurono, S; Nishinaka, Y; McQuillen, DP; Kume, A; Gulati, S; Rice, PA				Yamasaki, R; Koshino, H; Kurono, S; Nishinaka, Y; McQuillen, DP; Kume, A; Gulati, S; Rice, PA			Structural and immunochemical characterization of a Neisseria gonorrhoeae epitope defined by a monoclonal antibody 2C7; the antibody recognizes a conserved epitope on specific lipo-oligosaccharides in spite of the presence of human carbohydrate epitopes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-SERUM; GONOCOCCAL LIPOOLIGOSACCHARIDE; 2-DIMENSIONAL NMR; NEURAMINIC ACID; BLOOD-CELLS; BETA-CHAIN; LIPOPOLYSACCHARIDE; MENINGITIDIS; RESISTANCE; EXPRESSION	Lipo-oligosaccharides (LOS) produced by Neisseria gonorrhoeae are important antigenic and immunogenic components of the outer membrane complex. Previously, we showed that murine monoclonal antibody (mAb) 2C7 did not cross-react with human glycosphingolipids but identified the LOS epitope that is widely expressed in vivo and in vitro (Gulati, S., McQuillen, D. P., Mandrell, R. E., Jani, D. E,, and Rice, P. A. (1996) J. Infect. Dis. 174, 1223-1237). In the present study, we analyzed the structure of gonococcal strain WG LOS containing the 2C7 epitope and investigated the structural requirements for expression of the epitope, We determined that the WG LOS components are Hep[1]-elongated forms of 15253 LOS that have a lactose on both Hep[1] and Hep[2] (Yamasaki, a, Kerwood, D. E., Schneider, H., Quinn, a P., Griffiss, J. M., and Mandrell, a E, (1994) J. Biol. Chem. 269, 30345-30351). In addition, we found that expression of the 2C7 epitope within the LOS is blocked when the Hep[2]-lactose is elongated. Eased on the structural data of these LOS and the results obtained from immunochemical analyses, we conclude the following: 1) mAb 2C7 requires both the 15253 OS minimum structure and the N-linked fatty acids in the lipoidal moiety for expression of the epitope; 2) mAb 2C7 binds to the LOS that elongates the lactose on Hep[1] of the 15253 OS, but not the one on Hep[2]; and 3) the 2C7 epitope is expressed on gonococcal LOS despite the presence of human carbohydrate epitopes such as a lactosamine or its N-acetylgalactosaminylated (globo) form. Our study shows that the conserved epitope defined by mAb 2C7 could potentially be used as a safe site for the development of a vaccine candidate.	Tottori Univ, Dept Biochem & Biotechnol, Tottori 6808553, Japan; Inst Phys & Chem Res, Wako, Saitama 3510198, Japan; Boston Univ, Maxwell Finland Lab Infect Dis, Evans Mem Dept Clin Res, Boston, MA 02118 USA; Boston Univ, Dept Med, Boston, MA 02118 USA	Tottori University; RIKEN; Boston University; Boston University	Yamasaki, R (corresponding author), Tottori Univ, Dept Biochem & Biotechnol, Koyama Minami 4-101, Tottori 6808553, Japan.	yamasaki@muses.tottori-u.ac.jp	Koshino, Hiroyuki/N-7948-2015; Koshino, Hiroyuki/ABF-4899-2021	Koshino, Hiroyuki/0000-0002-0954-9839; Koshino, Hiroyuki/0000-0002-0954-9839	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI032725, R01AI032725, R56AI032725] Funding Source: NIH RePORTER; NIAID NIH HHS [AI32725, AI01061] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		APICELLA MA, 1981, INFECT IMMUN, V34, P751, DOI 10.1128/IAI.34.3.751-756.1981; Banerjee A, 1998, P NATL ACAD SCI USA, V95, P10872, DOI 10.1073/pnas.95.18.10872; BOSLEGO JW, 1991, VACCINE, V9, P154, DOI 10.1016/0264-410X(91)90147-X; Brinton C., 1978, IMMUNOBIOLOGY NEISER, P155; BROOKS GF, 1989, CLIN MICROBIOL REV, V2, pS5, DOI 10.1128/CMR.2.Suppl.S5-10.1989; Erwin AL, 1996, J EXP MED, V184, P1233, DOI 10.1084/jem.184.4.1233; GIBSON BW, 1989, P NATL ACAD SCI USA, V86, P17, DOI 10.1073/pnas.86.1.17; GOTSCHLICH EC, 1994, J EXP MED, V180, P2181, DOI 10.1084/jem.180.6.2181; Gulati S, 1996, J INFECT DIS, V174, P1238, DOI 10.1093/infdis/174.6.1238; Gulati S, 1996, J INFECT DIS, V174, P1223, DOI 10.1093/infdis/174.6.1223; GUYMON LF, 1982, INFECT IMMUN, V36, P541, DOI 10.1128/IAI.36.2.541-547.1982; HAISHIMA Y, 1992, EUR J BIOCHEM, V203, P127, DOI 10.1111/j.1432-1033.1992.tb19837.x; HOLST O, 1993, EUR J BIOCHEM, V214, P703, DOI 10.1111/j.1432-1033.1993.tb17971.x; HOOK EW, 1984, INFECT IMMUN, V43, P706, DOI 10.1128/IAI.43.2.706-709.1984; KERWOOD DE, 1992, BIOCHEMISTRY-US, V31, P12760, DOI 10.1021/bi00166a008; Kurono S, 1998, J MASS SPECTROM, V33, P35, DOI 10.1002/(SICI)1096-9888(199801)33:1<35::AID-JMS607>3.0.CO;2-I; MANDRELL R, 1986, INFECT IMMUN, V54, P63, DOI 10.1128/IAI.54.1.63-69.1986; MANDRELL RE, 1990, J EXP MED, V171, P1649, DOI 10.1084/jem.171.5.1649; MANDRELL RE, 1994, METHOD ENZYMOL, V236, P231; MANDRELL RE, 1988, J EXP MED, V168, P107, DOI 10.1084/jem.168.1.107; Muhlecker W, 1999, GLYCOBIOLOGY, V9, P157, DOI 10.1093/glycob/9.2.157; NAIRN CA, 1988, J GEN MICROBIOL, V134, P3295; PARSONS NJ, 1988, MICROB PATHOGENESIS, V5, P303, DOI 10.1016/0882-4010(88)90103-9; Rice P.A., 1994, NEISSERIA 94, P483; RICE PA, 1982, J CLIN INVEST, V70, P157, DOI 10.1172/JCI110589; SCHNEIDER H, 1984, INFECT IMMUN, V45, P544, DOI 10.1128/IAI.45.3.544-549.1984; Tamura J, 1997, CARBOHYD RES, V305, P43, DOI 10.1016/S0008-6215(97)00225-5; YAMASAKI R, 1991, BIOCHEMISTRY-US, V30, P851, DOI 10.1021/bi00217a039; YAMASAKI R, 1988, MOL IMMUNOL, V25, P799, DOI 10.1016/0161-5890(88)90116-2; YAMASAKI R, 1993, J BACTERIOL, V175, P4565, DOI 10.1128/JB.175.14.4565-4568.1993; YAMASAKI R, 1991, MOL IMMUNOL, V28, P1233, DOI 10.1016/0161-5890(91)90010-H; YAMASAKI R, 1994, J BIOL CHEM, V269, P30345; YAMASAKI R, 1991, BIOCHEMISTRY-US, V30, P10566, DOI 10.1021/bi00107a028; ZHAO M, 1995, J BIOL CHEM, V270, P26657, DOI 10.1074/jbc.270.44.26657; ZHOU DG, 1994, J BIOL CHEM, V269, P11162	35	40	42	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 17	1999	274	51					36550	36558		10.1074/jbc.274.51.36550	http://dx.doi.org/10.1074/jbc.274.51.36550			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	266AV	10593954	hybrid			2022-12-25	WOS:000084279200073
J	Yan, F; Polk, DB				Yan, F; Polk, DB			Aminosalicylic acid inhibits I kappa B kinase alpha phosphorylation of I kappa B alpha in mouse intestinal epithelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; IKK-ALPHA; TRANSCRIPTION FACTOR; ULCERATIVE-COLITIS; TNF-ALPHA; BETA; ACTIVATION; DISEASE; SULFASALAZINE; MACROPHAGES	Tumor necrosis factor alpha (TNF alpha)-stimulated nuclear factor (NF) kappa B activation plays a key role in the pathogenesis of inflammatory bowel disease (IBD). Phosphorylation of NF kappa B inhibitory protein (I kappa B) leading to its degradation and NF kappa B activation, is regulated by the multimeric I kappa B kinase complex, including IKK alpha and IKK beta. We recently reported that 5-aminosalicylic acid (5-ASA) inhibits TNF alpha-regulated I kappa B degradation and NF kappa B activation. To determine the mechanism of Q-ASA inhibition of I kappa B degradation, we studied young adult mouse colon (YAMC) cells by immunodetection and in vitro kinase assays. We show 5-ASA inhibits TNF alpha-stimulated phosphorylation of I kappa B alpha in intact YAMC cells. Phosphorylation of a glutathione S-transferase-I kappa B alpha fusion protein by cellular extracts or immunoprecipitated IKK alpha isolated from cells treated with TNF alpha is inhibited by 5-ASA. Recombinant IKK alpha and IKK beta autophosphorylation and their phosphorylation of glutathione S-transferase-I kappa B alpha: are inhibited by 5-ASA. However, IKK alpha serine phosphorylation by its upstream kinase in either intact cells or cellular extracts is not blocked by 5-ASA. Surprisingly, immunodepletion of cellular extracts suggests IKK alpha is predominantly responsible for I kappa B alpha phosphorylation in intestinal epithelial cells. In summary, 5-ASA inhibits TNF alpha-stimulated IKK alpha kinase activity toward I kappa B alpha in intestinal epithelial cells. These findings suggest a novel role for 5-ASA in the management of IBD by disrupting TNF alpha activation of NF kappa B.	Vanderbilt Univ, Sch Med, Dept Pediat, Div Gastroenterol & Nutr, Nashville, TN 37232 USA	Vanderbilt University	Polk, DB (corresponding author), Vanderbilt Univ, Sch Med, Dept Pediat, Div Gastroenterol & Nutr, S4322 MCN,21st & Garland Ave, Nashville, TN 37232 USA.	d-brent.polk@mcmail.vanderbilt.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007673, K08DK002212] Funding Source: NIH RePORTER; NIDDK NIH HHS [T32 DK07673, DK02212, DK56008] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Abbott DW, 1999, J BIOL CHEM, V274, P2732, DOI 10.1074/jbc.274.5.2732; AZADKHAN AK, 1977, LANCET, V2, P892; Barnes PJ, 1997, NEW ENGL J MED, V336, P1066, DOI 10.1056/NEJM199704103361506; CASELLAS F, 1994, CLIN SCI, V87, P453, DOI 10.1042/cs0870453; CHEN ZJ, 1995, GENE DEV, V9, P1586, DOI 10.1101/gad.9.13.1586; CRONSTEIN BN, 1994, INFLAMMATION, V18, P323, DOI 10.1007/BF01534273; Delhase M, 1999, SCIENCE, V284, P309, DOI 10.1126/science.284.5412.309; DIAZMECO MT, 1994, EMBO J, V13, P2842, DOI 10.1002/j.1460-2075.1994.tb06578.x; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; ETTEHADI P, 1994, CLIN EXP IMMUNOL, V96, P146, DOI 10.1111/j.1365-2249.1994.tb06244.x; FIOCCHI C, 1995, FALK SYMP, V76, P252; Hu YL, 1999, SCIENCE, V284, P316, DOI 10.1126/science.284.5412.316; JAMES SP, 1994, INFLAMM BOWEL DIS, P65; Kaiser GC, 1997, GASTROENTEROLOGY, V112, P1231, DOI 10.1016/S0016-5085(97)70135-5; Kaiser GC, 1999, GASTROENTEROLOGY, V116, P602, DOI 10.1016/S0016-5085(99)70182-4; Kontoyiannis D, 1999, IMMUNITY, V10, P387, DOI 10.1016/S1074-7613(00)80038-2; KOPP E, 1994, SCIENCE, V265, P956, DOI 10.1126/science.8052854; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Larrea E, 1996, HEPATOLOGY, V23, P210, DOI 10.1002/hep.510230203; Li J, 1998, J BIOL CHEM, V273, P30736, DOI 10.1074/jbc.273.46.30736; Ling L, 1998, P NATL ACAD SCI USA, V95, P3792, DOI 10.1073/pnas.95.7.3792; Mercurio F, 1997, SCIENCE, V278, P860, DOI 10.1126/science.278.5339.860; Nakano H, 1998, P NATL ACAD SCI USA, V95, P3537, DOI 10.1073/pnas.95.7.3537; Nemoto S, 1998, MOL CELL BIOL, V18, P7336, DOI 10.1128/MCB.18.12.7336; Neurath MF, 1998, GUT, V43, P856, DOI 10.1136/gut.43.6.856; PEPPERCORN MA, 1973, GASTROENTEROLOGY, V64, P240; PESKAR BM, 1987, DIG DIS SCI S, V32, P51; PINALS RS, 1988, SEMIN ARTHRITIS RHEU, V17, P246, DOI 10.1016/0049-0172(88)90010-8; Rogler G, 1998, GASTROENTEROLOGY, V115, P357, DOI 10.1016/S0016-5085(98)70202-1; SARTOR RB, 1995, GASTROENTEROL CLIN N, V24, P475; Schreiber S, 1998, GUT, V42, P477, DOI 10.1136/gut.42.4.477; SHANAHAN F, 1990, IMMUNOPHARMACOLOGY, V20, P217, DOI 10.1016/0162-3109(90)90037-F; Takeda K, 1999, SCIENCE, V284, P313, DOI 10.1126/science.284.5412.313; TAN XD, 1993, AM J PATHOL, V142, P1858; THANOS D, 1995, CELL, V80, P529, DOI 10.1016/0092-8674(95)90506-5; Wahl C, 1998, J CLIN INVEST, V101, P1163, DOI 10.1172/JCI992; WHITEHEAD RH, 1993, P NATL ACAD SCI USA, V90, P587, DOI 10.1073/pnas.90.2.587; Wilson L, 1999, GASTROENTEROLOGY, V117, P106, DOI 10.1016/S0016-5085(99)70556-1; Woronicz JD, 1997, SCIENCE, V278, P866, DOI 10.1126/science.278.5339.866; Yin MJ, 1998, NATURE, V396, P77, DOI 10.1038/23948; Zandi E, 1997, CELL, V91, P243, DOI 10.1016/S0092-8674(00)80406-7; Zandi E, 1998, SCIENCE, V281, P1360, DOI 10.1126/science.281.5381.1360; Zhao Q, 1999, J BIOL CHEM, V274, P8355, DOI 10.1074/jbc.274.13.8355; Zhong HH, 1997, CELL, V89, P413, DOI 10.1016/S0092-8674(00)80222-6	44	63	66	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 17	1999	274	51					36631	36636		10.1074/jbc.274.51.36631	http://dx.doi.org/10.1074/jbc.274.51.36631			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	266AV	10593965	hybrid			2022-12-25	WOS:000084279200084
J	Anderson, VE; Zaniewski, RP; Kaczmarek, FS; Gootz, TD; Osheroff, N				Anderson, VE; Zaniewski, RP; Kaczmarek, FS; Gootz, TD; Osheroff, N			Quinolones inhibit DNA religation mediated by Staphylococcus aureus topoisomerase IV - Changes in drug mechanism across evolutionary boundaries	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EUKARYOTIC TOPOISOMERASE; ESCHERICHIA-COLI; STREPTOCOCCUS-PNEUMONIAE; ANTINEOPLASTIC DRUGS; PRIMARY TARGET; ENZYME MECHANISM; NALIDIXIC-ACID; GYRASE GENES; IN-VITRO; II-ALPHA	Quinolones are the most active oral antibacterials in clinical use and act by increasing DNA cleavage mediated by prokaryotic type II topoisomerases. Although topoisomerase TV appears to be the primary cytotoxic target for most quinolones in Gram-positive bacteria, interactions between the enzyme and these drugs are poorly understood. Therefore, the effects of ciprofloxacin on the DNA cleavage and religation reactions of Staphylococcus aureus topoisomerase TV were characterized. Ciprofloxacin doubled DNA scission at 150 nM drug and increased cleavage similar to 9-fold at 5 mu M. Furthermore, it dramatically inhibited rates of DNA religation mediated by S. aureus topoisomerase TV. This inhibition of religation is in marked contrast to the effects of antineoplastic quinolones on eukaryotic topoisomerase II, and suggests that the mechanistic basis for quinolone action against type II topoisomerases has not been maintained across evolutionary boundaries. The apparent change in quinolone mechanism was not caused by an overt difference in the drug interaction domain on topoisomerase TV. Therefore, we propose that the mechanistic basis for quinolone action is regulated by subtle changes in drug orientation within the enzyme drug DNA ternary complex rather than gross differences in the site of drug binding.	Vanderbilt Univ, Sch Med, Dept Biochem, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Dept Med Hematol Oncol, Nashville, TN 37232 USA; Pfizer Inc, Pfizer Cent Res, Dept Canc Immunol & Infect Dis, Groton, CT 06340 USA	Vanderbilt University; Vanderbilt University; Pfizer	Osheroff, N (corresponding author), Vanderbilt Univ, Sch Med, Dept Biochem, 654 Med Res Bldg 1, Nashville, TN 37232 USA.				NCI NIH HHS [5 T32 CA09385] Funding Source: Medline; NIGMS NIH HHS [GM33944] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA009385] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM033944] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Anderson VE, 1998, J BIOL CHEM, V273, P17879, DOI 10.1074/jbc.273.28.17879; BARRETT JF, 1989, ANTIMICROB AGENTS CH, V33, P1697, DOI 10.1128/AAC.33.10.1697; BERGERAT A, 1994, J BIOL CHEM, V269, P27663; Borde V, 1998, NUCLEIC ACIDS RES, V26, P2042, DOI 10.1093/nar/26.9.2042; Burden DA, 1996, J BIOL CHEM, V271, P29238, DOI 10.1074/jbc.271.46.29238; Burden DA, 1998, BBA-GENE STRUCT EXPR, V1400, P139, DOI 10.1016/S0167-4781(98)00132-8; Capranico G, 1998, BBA-GENE STRUCT EXPR, V1400, P185, DOI 10.1016/S0167-4781(98)00135-3; Champoux J J, 1994, Adv Pharmacol, V29A, P71; CLEMENT JJ, 1995, CANCER RES, V55, P830; CORBETT AH, 1991, J BIOL CHEM, V266, P19666; CORBETT AH, 1993, ANTIMICROB AGENTS CH, V37, P2599, DOI 10.1128/AAC.37.12.2599; CORBETT AH, 1993, CHEM RES TOXICOL, V6, P585, DOI 10.1021/tx00035a001; COUGHLIN SA, 1995, BIOCHEM PHARMACOL, V50, P111, DOI 10.1016/0006-2952(95)00016-S; Cove ME, 1997, NUCLEIC ACIDS RES, V25, P2716, DOI 10.1093/nar/25.14.2716; Drlica K, 1997, MICROBIOL MOL BIOL R, V61, P377, DOI 10.1128/.61.3.377-392.1997; Elsea SH, 1997, BIOCHEMISTRY-US, V36, P2919, DOI 10.1021/bi962488f; ELSEA SH, 1993, ANTIMICROB AGENTS CH, V37, P2179, DOI 10.1128/AAC.37.10.2179; ELSEA SH, 1995, J BIOL CHEM, V270, P1913, DOI 10.1074/jbc.270.4.1913; ELSEA SH, 1992, J BIOL CHEM, V267, P13150; FERRERO L, 1994, MOL MICROBIOL, V13, P641, DOI 10.1111/j.1365-2958.1994.tb00458.x; Fitzgibbon JE, 1998, ANTIMICROB AGENTS CH, V42, P2122, DOI 10.1128/AAC.42.8.2122; FREUDENREICH CH, 1994, P NATL ACAD SCI USA, V91, P11007, DOI 10.1073/pnas.91.23.11007; FROELICHAMMON SJ, 1995, J BIOL CHEM, V270, P21429, DOI 10.1074/jbc.270.37.21429; GELLERT M, 1976, P NATL ACAD SCI USA, V73, P3872, DOI 10.1073/pnas.73.11.3872; GELLERT M, 1977, P NATL ACAD SCI USA, V74, P4772, DOI 10.1073/pnas.74.11.4772; Gootz TD, 1996, ANTIMICROB AGENTS CH, V40, P2691, DOI 10.1128/AAC.40.12.2691; Gootz TD, 1996, MED RES REV, V16, P433, DOI 10.1002/(SICI)1098-1128(199609)16:5<433::AID-MED3>3.0.CO;2-W; Gootz Thomas D., 1993, P139; GOSS WA, 1965, J BACTERIOL, V89, P1068, DOI 10.1128/JB.89.4.1068-1074.1965; HALLETT P, 1990, GENE, V93, P139, DOI 10.1016/0378-1119(90)90148-K; HANDE KR, 1993, BIOCHIM BIOPHYS ACTA, V1400, P173; HIROTA Y, 1968, COLD SPRING HARB SYM, V33, P677, DOI 10.1101/SQB.1968.033.01.077; Hooper D., 1993, QUINOLONE ANTIMICROB, Vsecond; Hooper DC, 1998, BBA-GENE STRUCT EXPR, V1400, P45, DOI 10.1016/S0167-4781(98)00127-4; HOOPER DC, 1991, NEW ENGL J MED, V324, P384, DOI 10.1056/NEJM199102073240606; Hooper DC, 1998, CLIN INFECT DIS, V27, pS54, DOI 10.1086/514923; HOPEWELL R, 1990, J BACTERIOL, V172, P3481, DOI 10.1128/jb.172.6.3481-3484.1990; HSIUNG YC, 1995, J BIOL CHEM, V270, P20359, DOI 10.1074/jbc.270.35.20359; KATO J, 1990, CELL, V63, P393, DOI 10.1016/0092-8674(90)90172-B; KATO JI, 1988, J BACTERIOL, V170, P3967, DOI 10.1128/jb.170.9.3967-3977.1988; KHODURSKY AB, 1995, P NATL ACAD SCI USA, V92, P11801, DOI 10.1073/pnas.92.25.11801; Khodursky AB, 1998, J BIOL CHEM, V273, P27668, DOI 10.1074/jbc.273.42.27668; Kingma PS, 1997, BIOCHEMISTRY-US, V36, P5934, DOI 10.1021/bi970507v; Kingma PS, 1997, J BIOL CHEM, V272, P1148, DOI 10.1074/jbc.272.2.1148; Kingma PS, 1998, BBA-GENE STRUCT EXPR, V1400, P223, DOI 10.1016/S0167-4781(98)00138-9; Kingma PS, 1998, J BIOL CHEM, V273, P17999, DOI 10.1074/jbc.273.29.17999; KNAB AM, 1993, J BIOL CHEM, V268, P22322; KREUZER KN, 1979, J BACTERIOL, V140, P424, DOI 10.1128/JB.140.2.424-435.1979; LEVINE C, 1998, BIOCHIM BIOPHYS ACTA, V1998, P29; LIU LF, 1983, J BIOL CHEM, V258, P5365; LUTTINGER A, 1995, MOL MICROBIOL, V15, P601, DOI 10.1111/j.1365-2958.1995.tb02369.x; Marians KJ, 1997, J BIOL CHEM, V272, P9401; MAXWELL A, 1992, J ANTIMICROB CHEMOTH, V30, P409, DOI 10.1093/jac/30.4.409; Maxwell A, 1997, TRENDS MICROBIOL, V5, P102, DOI 10.1016/S0966-842X(96)10085-8; Munoz R, 1996, ANTIMICROB AGENTS CH, V40, P2252, DOI 10.1128/AAC.40.10.2252; Ng EY, 1996, ANTIMICROB AGENTS CH, V40, P1881, DOI 10.1128/AAC.40.8.1881; Pan XS, 1996, ANTIMICROB AGENTS CH, V40, P2321, DOI 10.1128/AAC.40.10.2321; Pechere JC, 1998, EUR J CLIN MICROBIOL, V17, P405, DOI 10.1007/BF01691573; PENG H, 1993, J BIOL CHEM, V268, P24481; Pommier Y, 1998, BBA-GENE STRUCT EXPR, V1400, P83, DOI 10.1016/S0167-4781(98)00129-8; Pommier Y., 1996, CANC CHEMOTHERAPY BI, P435; PRUSS GJ, 1982, CELL, V31, P35, DOI 10.1016/0092-8674(82)90402-0; REECE RJ, 1991, CRIT REV BIOCHEM MOL, V26, P335, DOI 10.3109/10409239109114072; ROBINSON MJ, 1992, ANTIMICROB AGENTS CH, V36, P751, DOI 10.1128/AAC.36.4.751; ROBINSON MJ, 1991, BIOCHEMISTRY-US, V30, P1807, DOI 10.1021/bi00221a012; ROBINSON MJ, 1991, J BIOL CHEM, V266, P14585; Sambrook J., 2002, MOL CLONING LAB MANU; SANDER M, 1983, J BIOL CHEM, V258, P8421; SPITZNER JR, 1995, MOL PHARMACOL, V48, P238; SUGINO A, 1977, P NATL ACAD SCI USA, V74, P4767, DOI 10.1073/pnas.74.11.4767; Wang JC, 1996, ANNU REV BIOCHEM, V65, P635, DOI 10.1146/annurev.bi.65.070196.003223; WASSERMAN RA, 1993, CANCER RES, V53, P3591; YAMASHITA Y, 1992, CANCER RES, V52, P2818	73	35	38	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 10	1999	274	50					35927	35932		10.1074/jbc.274.50.35927	http://dx.doi.org/10.1074/jbc.274.50.35927			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	264NG	10585479	hybrid			2022-12-25	WOS:000084187900091
J	Mensenkamp, AR; Jong, MC; van Goor, H; van Luyn, MJA; Bloks, V; Havinga, R; Voshol, PJ; Hofker, MH; van Dijk, KW; Havekes, LM; Kuipers, F				Mensenkamp, AR; Jong, MC; van Goor, H; van Luyn, MJA; Bloks, V; Havinga, R; Voshol, PJ; Hofker, MH; van Dijk, KW; Havekes, LM; Kuipers, F			Apolipoprotein E participates in the regulation of very low density lipoprotein-triglyceride secretion by the liver	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPARAN-SULFATE PROTEOGLYCANS; LIPASE-MEDIATED LIPOLYSIS; SERUM PLANT STEROLS; E-DEFICIENT MOUSE; CHOLESTEROL ABSORPTION; TRANSGENIC MICE; MESSENGER-RNA; IN-VIVO; METABOLISM; HEPATOCYTES	ApoE-deficient mice on low fat diet show hepatic triglyceride accumulation and a reduced very low density lipoprotein (VLDL) triglyceride production rate. To establish the role of apoE in the regulation of hepatic VLDL production, the human APOE3 gene was introduced into apoE-deficient mice by cross-breeding with APOE3 transgenics (APOE3/apoe-/- mice) or by adenoviral transduction, APOE3 was expressed in the liver and, to a lesser extent, in brain, spleen, and lung of transgenic APOE3/apoe-/- mice similar to endogenous apoe, Plasma cholesterol levels in APOE/apoe-/- mice (3.4 +/- 0.5 mM) were reduced when compared with apoe-/- mice (12.6 +/- 1.4 mM) but still elevated when compared with wild type control values (1.9 +/- 0.1 mar). Hepatic triglyceride accumulation in apoE-deficient mice was completely reversed by introduction of the APOE3 transgene, The in vivo hepatic VLDL-triglyceride production rate was reduced to 36% of control values in apoE-deficient mice but normalized in APOE3/ apoe-/- mice. Hepatic secretion of apoB was not affected in either of the strains. Secretion of H-3-labeled triglycerides synthesized from [H-3]glycerol by cultured hepatocytes from apoE-deficient mice was four times lower than by APOE3/apoe-/- or control hepatocytes. The average size of secreted VLDL particles produced by cultured apoE-deficient hepatocytes was significantly reduced when compared with those of APOE3/ apoe-/- and wild type mice. Hepatic expression of human APOE3 cDNA via adenovirus-mediated gene transfer in apoE-deficient mice resulted in a reduction of plasma cholesterol depending on plasma apoE3 levels. The in vivo VLDL-triglyceride production rate in these mice was increased up to 500% compared with LacZ-injected controls and correlated with the amount of apoE3 per particle. These findings indicate a regulatory role of apoE in hepatic VLDL-triglyceride secretion, independent from its role in lipoprotein clearance.	Univ Groningen Hosp, Ctr Liver Digest & Metab Dis, Groningen Inst Drug Studies, Dept Pediat, NL-9713 GZ Groningen, Netherlands; Univ Groningen Hosp, Groningen Inst Drug Studies, Dept Pathol, NL-9713 GZ Groningen, Netherlands; TNO Prevent & Hlth, Gaubius Lab, NL-2301 CE Leiden, Netherlands; Leiden Univ, Ctr Med, Dept Human Genet, NL-2300 RA Leiden, Netherlands; Leiden Univ, Ctr Med, Dept Cardiol, NL-2300 RA Leiden, Netherlands; Leiden Univ, Ctr Med, Dept Internal Med, NL-2300 RA Leiden, Netherlands; Univ Groningen, Fac Med Sci, Lab Cell Biol & Biomat, NL-9712 KZ Groningen, Netherlands	University of Groningen; University of Groningen; Netherlands Organization Applied Science Research; Leiden University; Leiden University - Excl LUMC; Leiden University; Leiden University - Excl LUMC; Leiden University; Leiden University - Excl LUMC; University of Groningen	Kuipers, F (corresponding author), Univ Groningen Hosp, Ctr Liver Digest & Metab Dis, Groningen Inst Drug Studies, Dept Pediat, Rm Y2115,CMC IV,Hanzeplein 1, NL-9713 GZ Groningen, Netherlands.		van Dijk, Ko Willems/AAT-4681-2021; van Dijk, Ko Willems/A-1798-2008; Mensenkamp, Arjen/L-4520-2015; Bloks, Vincent/A-7609-2012	van Dijk, Ko Willems/0000-0002-2172-7394; van Dijk, Ko Willems/0000-0002-2172-7394; Mensenkamp, Arjen/0000-0003-3805-877X; Bloks, Vincent/0000-0001-6493-7482; Kuipers, Folkert/0000-0003-2518-737X; van Goor, Harry/0000-0002-6670-1577				BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Bottcher CJF, 1961, ANAL CHIM ACTA, V24, P203; CHOI SSY, 1994, J LIPID RES, V35, P848; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; FAZIO S, 1995, ARTERIOSCL THROM VAS, V15, P593, DOI 10.1161/01.ATV.15.5.593; FORT P, 1985, NUCLEIC ACIDS RES, V13, P1431, DOI 10.1093/nar/13.5.1431; GOMEZCORONADO D, 1993, BIOCHIM BIOPHYS ACTA, V1167, P70, DOI 10.1016/0005-2760(93)90219-Y; HAMILTON RL, 1991, J LIPID RES, V32, P529; HAMILTON RL, 1990, J LIPID RES, V31, P1589; HERZ J, 1993, P NATL ACAD SCI USA, V90, P2812, DOI 10.1073/pnas.90.7.2812; HOGAN B, 1986, MANIPULATING MOUSE E; Huang YD, 1998, J BIOL CHEM, V273, P17483, DOI 10.1074/jbc.273.28.17483; Huang YD, 1998, J BIOL CHEM, V273, P26388, DOI 10.1074/jbc.273.41.26388; JI ZS, 1994, J BIOL CHEM, V269, P2764; JIALAL I, 1995, ARTERIOSCL THROM VAS, V15, P190, DOI 10.1161/01.ATV.15.2.190; Jong MC, 1996, J CLIN INVEST, V98, P2259, DOI 10.1172/JCI119036; KASHYAP VS, 1995, J CLIN INVEST, V96, P1612, DOI 10.1172/JCI118200; KLAUNIG JE, 1981, IN VITRO CELL DEV B, V17, P913; Kuipers F, 1996, HEPATOLOGY, V24, P241; Kuipers F, 1997, J CLIN INVEST, V100, P2915, DOI 10.1172/JCI119841; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Li XH, 1996, J LIPID RES, V37, P210; LOMBARDI P, 1993, J BIOL CHEM, V268, P26113; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LUSIS AJ, 1987, J BIOL CHEM, V262, P7594; MAHLEY RW, 1988, SCIENCE, V240, P622, DOI 10.1126/science.3283935; MIETTINEN TA, 1990, AM J EPIDEMIOL, V131, P20, DOI 10.1093/oxfordjournals.aje.a115479; PIETZSCH J, 1995, BBA-LIPID LIPID MET, V1254, P77, DOI 10.1016/0005-2760(94)00171-T; PLUMP AS, 1995, ANNU REV NUTR, V15, P495, DOI 10.1146/annurev.nu.15.070195.002431; QUARFORDT SH, 1995, J LIPID RES, V36, P1227; Rensen PCN, 1996, J BIOL CHEM, V271, P14791, DOI 10.1074/jbc.271.25.14791; REUE KL, 1984, J BIOL CHEM, V259, P2100; SCHWIEGELSHOHN B, 1995, J BIOL CHEM, V270, P1761, DOI 10.1074/jbc.270.4.1761; Srivastava RAK, 1996, BIOCHEM MOL BIOL INT, V38, P91; TILVIS RS, 1986, AM J CLIN NUTR, V43, P92, DOI 10.1093/ajcn/43.1.92; van Dijk KW, 1999, J LIPID RES, V40, P336; VANREE JH, 1994, ATHEROSCLEROSIS, V111, P25, DOI 10.1016/0021-9150(94)90188-0; vanVlijmen BJM, 1996, J CLIN INVEST, V97, P1184, DOI 10.1172/JCI118532; Williams KJ, 1997, CURR OPIN LIPIDOL, V8, P253; WOLTHERS BG, 1991, J LIPID RES, V32, P603; Woollett LA, 1995, P NATL ACAD SCI USA, V92, P12500, DOI 10.1073/pnas.92.26.12500; ZANNIS VI, 1984, J BIOL CHEM, V259, P5495; ZHANG SH, 1992, SCIENCE, V258, P468, DOI 10.1126/science.1411543	43	105	109	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 10	1999	274	50					35711	35718		10.1074/jbc.274.50.35711	http://dx.doi.org/10.1074/jbc.274.50.35711			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	264NG	10585451	hybrid, Green Published			2022-12-25	WOS:000084187900063
J	Katagiri, YU; Mori, T; Nakajima, H; Katagiri, C; Taguchi, T; Takeda, T; Kiyokawa, N; Fujimoto, J				Katagiri, YU; Mori, T; Nakajima, H; Katagiri, C; Taguchi, T; Takeda, T; Kiyokawa, N; Fujimoto, J			Activation of Src family kinase Yes induced by Shiga toxin binding to globotriaosyl ceramide (Gb3/CD77) in low density, detergent-insoluble microdomains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BURKITTS-LYMPHOMA CELLS; MELANOMA B16 CELLS; ESCHERICHIA-COLI; APOPTOSIS; MEMBRANE; CAVEOLAE; PURIFICATION; RECEPTOR; PROTEIN; TRANSPORT	Shiga toxin (Stx) is an enterotoxin produced by Shigella dysenteriae serotype 1 and enterohemorrhagic Escherichia coli, which binds specifically to globotriao-sylceramide, Gb3, on the cell surface and causes cell death. We previously demonstrated that Stx induced apoptosis in human renal tubular cell line ACHN cells (Taguchi, T,, Uchida, H,, Kiyokawa, N., Mori, T,, Sate, N,, Horie, H., Takeda, T and Fujimoto, J, (1998) Kidney Int. 53, 1681-1688), To study the early signal transduction after Stx addition, Gb3-enriched microdomains were prepared from ACHN cells by sucrose density gradient centrifugation of Triton X-100 lysate as buoyant, detergent-insoluble microdomains (DIM), Gb3 was only recovered in DIM and was associated with Src family kinase Yes. Phosphorylation of tyrosine residues of proteins in the DIM fraction increased by 10 min and returned to the resting level by 30 min after the addition of Stx, Since the kinase activity of Yes changed with the same kinetics, Yes was thought to be responsible for the hyperphosphorylation observed in DIM proteins. Unexpectedly, however, all of the Yes kinase activity was obtained in the high density, detergent-soluble fraction. Yes was assumed to be activated and show increased Triton X-100 solubility in the early phase of retrograde endocytosis of Stx-Gb3 complex. Since Yes activation by the Stx addition was suppressed by filipin pretreatment, Gb3-enriched microdomains containing cholesterol were deeply involved in Stx signal transduction.	Natl Childrens Med Res Ctr, Dept Pathol, Setagaya Ku, Tokyo 1548509, Japan; Natl Childrens Med Res Ctr, Dept Infect Dis Res, Setagaya Ku, Tokyo 1548509, Japan; Hokkaido Univ, Inst Low Temp Sci, Biochem Lab, Sapporo, Hokkaido 0600819, Japan	National Center for Child Health & Development - Japan; National Center for Child Health & Development - Japan; Hokkaido University	Fujimoto, J (corresponding author), Natl Childrens Med Res Ctr, Dept Pathol, Setagaya Ku, 3-35-31 Taisido, Tokyo 1548509, Japan.	jfujimoto@nch.go.jp						ANDERSON RGW, 1992, SCIENCE, V255, P410, DOI 10.1126/science.1310359; [Anonymous], 1977, Lipids, V12, P455; ENDO Y, 1988, EUR J BIOCHEM, V171, P45, DOI 10.1111/j.1432-1033.1988.tb13756.x; GHISLAIN J, 1994, J IMMUNOL, V153, P3655; HANAI N, 1988, J BIOL CHEM, V263, P10915; INWARD CD, 1995, J INFECTION, V30, P213, DOI 10.1016/S0163-4453(95)90693-2; Iwabuchi K, 1998, J BIOL CHEM, V273, P9130, DOI 10.1074/jbc.273.15.9130; Iwabuchi K, 1998, J BIOL CHEM, V273, P33766, DOI 10.1074/jbc.273.50.33766; KARLSSON KA, 1992, APMIS, V100, P71; Karpman D, 1998, INFECT IMMUN, V66, P636, DOI 10.1128/IAI.66.2.636-644.1998; Kasahara K, 1997, J BIOL CHEM, V272, P29947, DOI 10.1074/jbc.272.47.29947; Khine AA, 1998, J CELL PHYSIOL, V176, P281, DOI 10.1002/(SICI)1097-4652(199808)176:2<281::AID-JCP6>3.0.CO;2-K; Kiyokawa N, 1998, J INFECT DIS, V178, P178, DOI 10.1086/515592; LINGWOOD CA, 1987, J BIOL CHEM, V262, P8834; LISANTI MP, 1995, METHOD ENZYMOL, V250, P655; MANGENEY M, 1993, CANCER RES, V53, P5314; MUTOH T, 1995, P NATL ACAD SCI USA, V92, P5087, DOI 10.1073/pnas.92.11.5087; NODA M, 1987, MICROB PATHOGENESIS, V2, P339, DOI 10.1016/0882-4010(87)90076-3; Park H, 1998, J BIOL CHEM, V273, P32304, DOI 10.1074/jbc.273.48.32304; RESH MD, 1994, CELL, V76, P411, DOI 10.1016/0092-8674(94)90104-X; SARGIACOMO M, 1993, J CELL BIOL, V122, P789, DOI 10.1083/jcb.122.4.789; Schapiro FB, 1998, AM J PHYSIOL-CELL PH, V274, pC319, DOI 10.1152/ajpcell.1998.274.2.C319; Song KS, 1996, J BIOL CHEM, V271, P9690, DOI 10.1074/jbc.271.16.9690; STROCKBINE NA, 1985, INFECT IMMUN, V50, P695, DOI 10.1128/IAI.50.3.695-700.1985; SVENNERHOLM L, 1964, J LIPID RES, V5, P145; Taga S, 1997, BLOOD, V90, P2757, DOI 10.1182/blood.V90.7.2757.2757_2757_2767; Taguchi T, 1998, KIDNEY INT, V53, P1681, DOI 10.1046/j.1523-1755.1998.00939.x; TAKI T, 1994, ANAL BIOCHEM, V221, P312, DOI 10.1006/abio.1994.1418; Williams JM, 1999, TOXICOL LETT, V105, P47, DOI 10.1016/S0378-4274(98)00383-X	29	146	151	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 3	1999	274	49					35278	35282		10.1074/jbc.274.49.35278	http://dx.doi.org/10.1074/jbc.274.49.35278			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	260XW	10575015	hybrid			2022-12-25	WOS:000083979600109
J	Ryder, JW; Kawano, Y; Galuska, D; Fahlman, R; Wallberg-Henriksson, H; Charron, MJ; Zierath, JR				Ryder, JW; Kawano, Y; Galuska, D; Fahlman, R; Wallberg-Henriksson, H; Charron, MJ; Zierath, JR			Postexercise glucose uptake and glycogen synthesis in skeletal muscle from GLUT4-deficient mice	FASEB JOURNAL			English	Article						metabolism; glucose transport; glycogen synthase; electrical stimulation; physical exercise	TRANSGENIC MICE; INSULIN ACTION; DIABETIC RATS; ENDURANCE EXERCISE; TRANSPORTER GLUT4; METABOLISM; ACCUMULATION; CONTRACTION; DISTINCT; COMPLEMENTATION	To determine the role of GLUT4 on postexercise glucose transport and glycogen resynthesis in skeletal muscle, GLUT4-deficient and wild-type mice were studied after a 3 h swim exercise. In wildtype mice, insulin and swimming each increased 2-deoxyglucose uptake by twofold in extensor digitorum longus muscle. In contrast, insulin did not increase 2-deoxyglucose glucose uptake in muscle from GLUT4-null mice. Swimming increased glucose transport twofold in muscle from fed GLUT4-null mice, with no effect noted in fasted GLUT4-null mice. This exercise-associated 2-deoxyglucose glucose uptake was not accompanied by increased cell surface GLUT1 content. Glucose transport in GLUT4-null muscle was increased 1.6-fold over basal levels after electrical stimulation. Contraction-induced glucose transport activity was fourfold greater in wild-type vs. GLUT4-null muscle. Glycogen content in gastrocnemius muscle was similar between wild-type and GLUT4-null mice and was reduced similar to 50% after exercise. After 5 h carbohydrate refeeding, muscle glycogen content was fully restored in wild-type, with no change in GLUT4-null mice. After 24 h carbohydrate refeeding, muscle glycogen in GLUT4-null mice was restored to fed levels. In conclusion, GLUT4 is the major transporter responsible for exercise-induced glucose transport. Also, postexercise glycogen resynthesis in muscle was greatly delayed; unlike wild-type mice, glycogen supercompensation was not found. GLUT4 it is not essential for glycogen repletion since muscle glycogen levels in previously exercised GLUT4-null mice were totally restored after 24 h carbohydrate refeeding.	Karolinska Hosp, Dept Clin Physiol, King Gustaf V Res Inst, S-17176 Stockholm, Sweden; Karolinska Inst, Dept Physiol & Pharmacol, S-17177 Stockholm, Sweden; Albert Einstein Coll Med, Dept Biochem, Bronx, NY 10461 USA	Karolinska Institutet; Karolinska University Hospital; Karolinska Institutet; Yeshiva University; Albert Einstein College of Medicine	Zierath, JR (corresponding author), Karolinska Hosp, Dept Clin Physiol, King Gustaf V Res Inst, S-17176 Stockholm, Sweden.			Zierath, Juleen/0000-0001-6891-7497	NHLBI NIH HHS [HL58119] Funding Source: Medline; NIDDK NIH HHS [DK47425] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL058119] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK047425] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANDREASSON K, 1991, ACTA PHYSIOL SCAND, V142, P255, DOI 10.1111/j.1748-1716.1991.tb09154.x; Aslesen R, 1998, AM J PHYSIOL-ENDOC M, V275, pE448, DOI 10.1152/ajpendo.1998.275.3.E448; BERGSTROM J, 1966, NATURE, V210, P309, DOI 10.1038/210309a0; BONADONNA RC, 1993, J CLIN INVEST, V92, P486, DOI 10.1172/JCI116592; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CARTEE GD, 1991, J APPL PHYSIOL, V70, P1593, DOI 10.1152/jappl.1991.70.4.1593; CARTEE GD, 1989, AM J PHYSIOL, V256, pE494, DOI 10.1152/ajpendo.1989.256.4.E494; CHARRON MJ, 1989, P NATL ACAD SCI USA, V86, P2535, DOI 10.1073/pnas.86.8.2535; CONSTABLE SH, 1988, J APPL PHYSIOL, V64, P2329, DOI 10.1152/jappl.1988.64.6.2329; DEFRONZO RA, 1981, DIABETES, V30, P1000, DOI 10.2337/diab.30.12.1000; DOUEN AG, 1990, J BIOL CHEM, V265, P13427; FRIEDMAN JE, 1991, DIABETES, V40, P150, DOI 10.2337/diabetes.40.1.150; FUKUMOTO H, 1988, P NATL ACAD SCI USA, V85, P5435; Guillam MT, 1997, NAT GENET, V17, P327, DOI 10.1038/ng1197-327; GULVE EA, 1990, AM J PHYSIOL, V259, pE685, DOI 10.1152/ajpendo.1990.259.5.E685; GUMA A, 1995, AM J PHYSIOL-ENDOC M, V268, pE613, DOI 10.1152/ajpendo.1995.268.4.E613; HANDBERG A, 1992, AM J PHYSIOL, V262, pE721, DOI 10.1152/ajpendo.1992.262.5.E721; HANSEN P, 1995, AM J PHYSIOL-CELL PH, V268, pC30, DOI 10.1152/ajpcell.1995.268.1.C30; HANSEN PA, 1995, J BIOL CHEM, V270, P1679; Hickner RC, 1997, J APPL PHYSIOL, V83, P897, DOI 10.1152/jappl.1997.83.3.897; HIRSHMAN MF, 1990, J BIOL CHEM, V265, P987; JAMES DE, 1985, AM J PHYSIOL, V248, pE567, DOI 10.1152/ajpendo.1985.248.5.E567; JAMES DE, 1989, NATURE, V338, P83, DOI 10.1038/338083a0; JUE T, 1989, P NATL ACAD SCI USA, V92, P8535; KAHN BB, 1991, J CLIN INVEST, V87, P2197, DOI 10.1172/JCI115254; KATZ A, 1988, AM J PHYSIOL, V255, pE942, DOI 10.1152/ajpendo.1988.255.6.E942; KATZ EB, 1995, NATURE, V377, P151, DOI 10.1038/377151a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE AD, 1995, FEBS LETT, V361, P54; LIU ML, 1993, P NATL ACAD SCI USA, V90, P11346, DOI 10.1073/pnas.90.23.11346; Lowery OH, 1972, FLEXIBLE SYSTEM ENZY; LUND S, 1994, AM J PHYSIOL, V267, pE461, DOI 10.1152/ajpendo.1994.267.3.E461; LUND S, 1993, FEBS LETT, V330, P312, DOI 10.1016/0014-5793(93)80895-2; LUND S, 1995, P NATL ACAD SCI USA, V92, P5817, DOI 10.1073/pnas.92.13.5817; Manchester J, 1996, P NATL ACAD SCI USA, V93, P10707, DOI 10.1073/pnas.93.20.10707; Nakatani A, 1997, J APPL PHYSIOL, V82, P711, DOI 10.1152/jappl.1997.82.2.711; Ogawa W, 1998, MOL CELL BIOCHEM, V182, P13, DOI 10.1023/A:1006862807598; Ploug T, 1998, J CELL BIOL, V142, P1429, DOI 10.1083/jcb.142.6.1429; REN JM, 1993, J BIOL CHEM, V268, P16113; RICHTER EA, 1984, AM J PHYSIOL, V246, pE476, DOI 10.1152/ajpendo.1984.246.6.E476; Rincon J, 1996, DIABETES, V45, P615, DOI 10.2337/diabetes.45.5.615; Ryder JW, 1999, BIOCHEM J, V342, P321, DOI 10.1042/0264-6021:3420321; Stenbit AE, 1996, J CLIN INVEST, V98, P629, DOI 10.1172/JCI118833; THOMAS JA, 1968, ANAL BIOCHEM, V25, P486, DOI 10.1016/0003-2697(68)90127-9; Tsao TS, 1997, J CLIN INVEST, V100, P671, DOI 10.1172/JCI119579; Tsao TS, 1996, DIABETES, V45, P28, DOI 10.2337/diabetes.45.1.28; WALLBERGHENRIKSSON H, 1986, ACTA PHYSIOL SCAND, V127, P39, DOI 10.1111/j.1748-1716.1986.tb07873.x; WALLBERGHENRIKSSON H, 1987, J BIOL CHEM, V262, P7665; WALLBERGHENRIKSSON H, 1984, J APPL PHYSIOL, V57, P1045, DOI 10.1152/jappl.1984.57.4.1045; WALLBERGHENRIKSSON H, 1988, J APPL PHYSIOL, V65, P909, DOI 10.1152/jappl.1988.65.2.909; WALLBERGHENRIKSSON H, 1985, AM J PHYSIOL, V249, pC233, DOI 10.1152/ajpcell.1985.249.3.C233; White MF, 1998, MOL CELL BIOCHEM, V182, P3, DOI 10.1023/A:1006806722619; YEH JI, 1995, J BIOL CHEM, V270, P2107, DOI 10.1074/jbc.270.5.2107; ZIEL FH, 1988, DIABETES, V37, P885, DOI 10.2337/diabetes.37.7.885; Zierath JR, 1996, DIABETOLOGIA, V39, P1180, DOI 10.1007/BF02658504; Zierath JR, 1998, J BIOL CHEM, V273, P20910, DOI 10.1074/jbc.273.33.20910	56	58	59	0	8	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	DEC	1999	13	15					2246	2256		10.1096/fasebj.13.15.2246	http://dx.doi.org/10.1096/fasebj.13.15.2246			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	266QN	10593872				2022-12-25	WOS:000084310800016
J	Vrana, JA; Decker, RH; Johnson, CR; Wang, Z; Jarvis, WD; Richon, VM; Ehinger, M; Fisher, PB; Grant, S				Vrana, JA; Decker, RH; Johnson, CR; Wang, Z; Jarvis, WD; Richon, VM; Ehinger, M; Fisher, PB; Grant, S			Induction of apoptosis in U937 human leukemia cells by suberoylanilide hydroxamic acid (SAHA) proceeds through pathways that are regulated by Bcl-2/Bcl-X-L, c-Jun, and p21(CIP1), but independent of p53	ONCOGENE			English	Article						SAHA; HMBA; apoptosis; differentiation; leukemia; p53	HISTONE DEACETYLASE INHIBITORS; DOMINANT-NEGATIVE MUTANT; RETINOBLASTOMA PROTEIN; TRICHOSTATIN-A; CYCLE ARREST; HL-60 CELLS; DNA-DAMAGE; DIFFERENTIATION; KINASE; EXPRESSION	Determinants of differentiation and apoptosis in myelomonocytic leukemia cells (U937) exposed to the novel hybrid polar compound SAHA. (suberoylanilide hydroxamic acid) have been examined, In contrast to hexamethylenbisacetamide (HMBA), SAHA-related maturation was limited and accompanied by marked cytoxicity. SAHA-mediated apoptosis occurred within the G(0)G(1) and S phase populations, and,vas associated with decreased mitochondrial membrane potential, caspase-3 activation, PARP degradation, hypophosphorylation/cleavage of pRB, and down-regulation of c-Myc, c-Myb, and B-Myb. Enforced expression of Bcl-2 or Bcl-x(L), inhibited SAHA-induced apoptosis, but only modestly potentiated differentiation. While SAHA induced the cyclin-dependent kinase inhibitor p21(CIP1), antisense ablation of this CDKI increased, rather than decreased, SAHA-related lethality, In contrast, conditional expression of mild-type p53 failed to modify SAHA actions, but markedly potentiated HMBA-induced apoptosis. Finally, SAHA modestly increased expression/activation of the stress-activated protein kinase (SAPK/JNK); moreover, SAHA-related lethality was partially attenuated by a dominant-negative c-jun mutant protein (TAM67). SAHA did not stimulate mitogen-activated protein kinase (MAPK), nor was Lethality diminished by the specific MEK/MAPK inhibitor PD98059. These findings indicate that SAHA potently induces apoptosis in human leukemia cells via a pathway that is p53-independent but at least partially regulated by Bcl-2/Bcl-x(L), p21(CIP1), and the c-Jun/AP-1 signaling cascade.	Virginia Commonwealth Univ, Med Coll Virginia, Dept Med, Richmond, VA 23298 USA; Virginia Commonwealth Univ, Med Coll Virginia, Dept Pharmacol, Richmond, VA 23298 USA; Virginia Commonwealth Univ, Med Coll Virginia, Dept Biochem, Richmond, VA 23298 USA; Virginia Commonwealth Univ, Med Coll Virginia, Dept Microbiol, Richmond, VA 23298 USA; Mem Sloan Kettering Canc Ctr, Dept Dev Cell Biol & Genet, New York, NY 10021 USA; Univ Lund Hosp, Res Dept 2, S-22185 Lund, Sweden; Columbia Univ Coll Phys & Surg, Dept Pathol, New York, NY 10032 USA; Columbia Univ Coll Phys & Surg, Dept Urol, New York, NY 10032 USA	Virginia Commonwealth University; Virginia Commonwealth University; Virginia Commonwealth University; Virginia Commonwealth University; Memorial Sloan Kettering Cancer Center; Lund University; Skane University Hospital; Columbia University; Columbia University	Grant, S (corresponding author), Virginia Commonwealth Univ, Med Coll Virginia, Dept Med, MCV Stn Box 230, Richmond, VA 23298 USA.		Ehinger, Mats/H-8457-2016	Ehinger, Mats/0000-0003-2342-1679	NATIONAL CANCER INSTITUTE [R03CA077141, R01CA063753, P01CA072955] Funding Source: NIH RePORTER; NCI NIH HHS [CA77141, CA72955, CA63753] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDREEFF M, 1992, BLOOD, V80, P2604; Archer SY, 1998, P NATL ACAD SCI USA, V95, P6791, DOI 10.1073/pnas.95.12.6791; BROWN PH, 1994, ONCOGENE, V9, P791; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; COLLINS SJ, 1977, NATURE, V270, P347, DOI 10.1038/270347a0; Dangond F, 1998, BIOCHEM BIOPH RES CO, V247, P833, DOI 10.1006/bbrc.1998.8891; DEVENTE J, 1995, CELL GROWTH DIFFER, V6, P371; Dong ZG, 1997, MOL CARCINOGEN, V19, P204, DOI 10.1002/(SICI)1098-2744(199707)19:3<204::AID-MC8>3.0.CO;2-D; DUNAIEF JL, 1994, CELL, V79, P119, DOI 10.1016/0092-8674(94)90405-7; Ehinger M, 1996, BLOOD, V87, P1064, DOI 10.1182/blood.V87.3.1064.bloodjournal8731064; Franklin CC, 1995, ONCOGENE, V11, P2365; Gervais JLM, 1998, J BIOL CHEM, V273, P19207, DOI 10.1074/jbc.273.30.19207; Grant S, 1996, EXP CELL RES, V228, P65, DOI 10.1006/excr.1996.0300; Grant S, 1996, CELL GROWTH DIFFER, V7, P603; HASS R, 1991, CELL GROWTH DIFFER, V2, P541; JIANG HP, 1994, ONCOGENE, V9, P3397; KHARBANDA S, 1994, J BIOL CHEM, V269, P872; MARTIN SJ, 1990, CLIN EXP IMMUNOL, V79, P448; McBain JA, 1997, BIOCHEM PHARMACOL, V53, P1357, DOI 10.1016/S0006-2952(96)00904-5; Medina V, 1997, CANCER RES, V57, P3697; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; NAUMOVSKI L, 1994, BLOOD, V83, P2261; Ogryzko VV, 1996, MOL CELL BIOL, V16, P5210; OHTA H, 1995, CANCER RES, V55, P691; RAFF MC, 1992, NATURE, V356, P397, DOI 10.1038/356397a0; Richon VM, 1996, P NATL ACAD SCI USA, V93, P5705, DOI 10.1073/pnas.93.12.5705; Richon VM, 1998, P NATL ACAD SCI USA, V95, P3003, DOI 10.1073/pnas.95.6.3003; Salminen A, 1998, MOL BRAIN RES, V61, P203, DOI 10.1016/S0169-328X(98)00210-1; SELVAKUMARAN M, 1994, BLOOD, V84, P1036; STEINMAN RA, 1994, ONCOGENE, V9, P3389; SUGIMOTO K, 1992, BLOOD, V79, P2378, DOI 10.1182/blood.V79.9.2378.2378; SUNDSTROM C, 1976, INT J CANCER, V17, P565, DOI 10.1002/ijc.2910170504; Tang H, 1998, J BIOL CHEM, V273, P29156, DOI 10.1074/jbc.273.44.29156; Thompson MA, 1998, CANCER RES, V58, P5168; Vaziri C, 1998, CELL GROWTH DIFFER, V9, P465; Verheij M, 1996, NATURE, V380, P75, DOI 10.1038/380075a0; Vrana JA, 1998, DIFFERENTIATION, V63, P33, DOI 10.1046/j.1432-0436.1998.6310033.x; Wang J, 1996, SCIENCE, V273, P359, DOI 10.1126/science.273.5273.359; Wang SJ, 1997, MOL PHARMACOL, V52, P1000, DOI 10.1124/mol.52.6.1000; Wang ZL, 1998, EXP CELL RES, V244, P105, DOI 10.1006/excr.1998.4191; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Yen A, 1998, CANCER RES, V58, P3163	42	255	284	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 25	1999	18	50					7016	7025		10.1038/sj.onc.1203176	http://dx.doi.org/10.1038/sj.onc.1203176			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	259PH	10597302				2022-12-25	WOS:000083901900008
J	Okada-Ban, M; Moens, G; Thiery, JP; Jouanneau, J				Okada-Ban, M; Moens, G; Thiery, JP; Jouanneau, J			Nuclear 24 kD fibroblast growth factor (FGF)-2 confers metastatic properties on rat bladder carcinoma cells	ONCOGENE			English	Article						FGF-2; nuclear localization; tumor progression; lung metastasis	MOLECULAR-WEIGHT FORMS; IN-VIVO; TRANSCRIPTION; PROLIFERATION; TRANSLATION; TRANSITION; EXPRESSION; PHENOTYPE; BINDING; FAMILY	The tumorigenic and metastatic properties of rat bladder carcinoma NET-II cells transfected with a cDNA encoding the 24 kD nuclear isoform of human fibroblast growth factor-2 (FGF-2) were analysed and compared with those cells producing the 18 kD cytoplasmic isoform FGF-2. In transfected clones, 24 kD FGF-2 was found in the nucleus, and no FGF-2 was secreted. RT-PCR analysis shelved no upregulation of FGF-2-specific receptor FGFR2c expression in these proliferating transfected cells. A shorter latency period for in vivo tumor formation and abundant spontaneous lung metastases were only seen if nuclear FGF-2-producing cells were injected subcutaneously into nude mice. Intravenous injection of 24 kD FGF-2-producing cells led to extensive experimental lung metastases whereas injection of control NET-II cells or 18 kD FGF-a-producing cells did not. As FGF-2-producing cells have no specific FGF-2 receptors, our results suggest that the 24 kD FGF-2 has nuclear targets, and activates metastatic property of carcinoma cells via a mechanism other than the conventional FGF receptor-mediated signaling pathway.	Inst Curie, CNRS, UMR144, Sect Rech, F-75248 Paris 05, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Sorbonne Universite	Okada-Ban, M (corresponding author), Inst Curie, CNRS, UMR144, Sect Rech, 26 Rue Ulm, F-75248 Paris 05, France.		Thiery, Jean Paul/M-9387-2019; Thiery, Jean Paul/H-1550-2011	Thiery, Jean Paul/0000-0003-0478-5020				Arnaud E, 1999, MOL CELL BIOL, V19, P505; BASILICO C, 1992, ADV CANCER RES, V59, P115, DOI 10.1016/S0065-230X(08)60305-X; BELLUSCI S, 1994, ONCOGENE, V9, P1091; BIKFALVI A, 1995, J CELL BIOL, V129, P233, DOI 10.1083/jcb.129.1.233; Bonnet H, 1996, J BIOL CHEM, V271, P24781, DOI 10.1074/jbc.271.40.24781; BOUCHE G, 1987, P NATL ACAD SCI USA, V84, P6770, DOI 10.1073/pnas.84.19.6770; BUGLER B, 1991, MOL CELL BIOL, V11, P573, DOI 10.1128/MCB.11.1.573; BURGESS WH, 1989, ANNU REV BIOCHEM, V58, P575, DOI 10.1146/annurev.bi.58.070189.003043; COLTRINI D, 1995, CANCER RES, V55, P4729; COUDERC B, 1991, CELL REGUL, V2, P709, DOI 10.1091/mbc.2.9.709; ESTIVAL A, 1993, CANCER RES, V53, P1182; Fernig David G., 1994, Progress in Growth Factor Research, V5, P353, DOI 10.1016/0955-2235(94)00007-8; Florkiewicz RZ, 1991, GROWTH FACTORS, V4, P265, DOI 10.3109/08977199109043912; FLORKIEWICZ RZ, 1989, P NATL ACAD SCI USA, V86, P3978, DOI 10.1073/pnas.86.11.3978; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GUALANDRIS A, 1993, GROWTH FACTORS, V8, P49, DOI 10.3109/08977199309029134; Hill DJ, 1992, GROWTH FACTORS, V7, DOI 10.3109/08977199209046926; Jouanneau J, 1997, ONCOGENE, V14, P671, DOI 10.1038/sj.onc.1200883; JOUANNEAU J, 1994, P NATL ACAD SCI USA, V91, P286, DOI 10.1073/pnas.91.1.286; JOUANNEAU J, 1995, GROWTH FACTORS, V12, P37, DOI 10.3109/08977199509003212; Joy A, 1997, ONCOGENE, V14, P171, DOI 10.1038/sj.onc.1200823; Levine JE, 1995, NEUROIMMUNOMODULAT, V2, P290, DOI 10.1159/000097208; MASON IJ, 1994, CELL, V78, P547, DOI 10.1016/0092-8674(94)90520-7; NAKANISHI Y, 1992, P NATL ACAD SCI USA, V89, P5216, DOI 10.1073/pnas.89.12.5216; PASUMARTHI K, 1995, CIRC RES, V78, P126; Pintucci G, 1996, MOL BIOL CELL, V7, P1249, DOI 10.1091/mbc.7.8.1249; PRATS H, 1989, P NATL ACAD SCI USA, V86, P1836, DOI 10.1073/pnas.86.6.1836; QUARTO N, 1991, CELL REGUL, V2, P699, DOI 10.1091/mbc.2.9.699; RENCO M, 1990, J CELL PHYSL, V144, P108; SAVAGNER P, 1994, MOL BIOL CELL, V5, P851, DOI 10.1091/mbc.5.8.851; Sidransky D, 1997, SCIENCE, V278, P1054, DOI 10.1126/science.278.5340.1054; TESSLER S, 1990, J CELL PHYSIOL, V145, P310, DOI 10.1002/jcp.1041450216; TOSHIMA K, 1971, J NATL CANCER I, V47, P979	33	34	34	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 18	1999	18	48					6719	6724		10.1038/sj.onc.1203092	http://dx.doi.org/10.1038/sj.onc.1203092			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	257QA	10597279				2022-12-25	WOS:000083792000013
J	Murphy, KL; Kittrell, FS; Gay, JP; Jager, R; Medina, D; Rosen, JM				Murphy, KL; Kittrell, FS; Gay, JP; Jager, R; Medina, D; Rosen, JM			Bcl-2 expression delays mammary tumor development in dimethylbenz(a)anthracene-treated transgenic mice	ONCOGENE			English	Article						Bcl-2; mammary tumorigenesis; DMBA; transgenic mice	CELL-DEATH; EPITHELIAL-CELLS; DNA-DAMAGE; MUTANT P53; APOPTOSIS; TUMORIGENESIS; OVEREXPRESSION; GLAND; PROLIFERATION; MORPHOGENESIS	Bcl-2 is known to have dual antiproliferative and antiapoptotic roles. Overexpression of Bcl-2 in the mammary gland using a whey acidic protein (WAP) promoter-driven Bcl-2 transgene inhibits apoptosis in the mammary gland during pregnancy, lactation, and involution, and also counteracts apoptosis induced by overexpression of a mutant p53 transgene (WAP-p53 172 R-L), WAP-Bcl-2 mice and nontransgenic controls were treated with the carcinogen dimethylbenz(a)anthracene (DMBA), Surprisingly, the nontransgenic mice developed mammary tumors with decreased latency. Tumors arising in WAP-Bcl-2 mice displayed substantially reduced levels of proliferation relative to those seen in nontransgenic mice (P<0.015), perhaps resulting in the observed increase in tumor latency following carcinogen treatment. This WAP-Bcl-2 mouse tumor model reflects the situation seen in some human breast cancers overexpressing Bcl-2, where expression of Bcl-2 has been shown to correlate with a lower proliferative index in tumors.	Baylor Coll Med, Dept Cell Biol, Houston, TX 77030 USA; Baylor Coll Med, Cell & Mol Biol Program, Houston, TX 77030 USA; Forschungszentrum Karlsruhe, Inst Genet, D-76021 Karlsruhe, Germany	Baylor College of Medicine; Baylor College of Medicine; Helmholtz Association; Karlsruhe Institute of Technology	Rosen, JM (corresponding author), Baylor Coll Med, Dept Cell Biol, 1 Baylor Plaza, Houston, TX 77030 USA.		Jager, Richard/B-9478-2009	Jager, Richard/0000-0002-1623-1917	NATIONAL CANCER INSTITUTE [R01CA016303, R37CA016303] Funding Source: NIH RePORTER; NCI NIH HHS [CA16303] Funding Source: Medline; NIGMS NIH HHS [GM08231] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Beham A, 1997, ONCOGENE, V15, P2767, DOI 10.1038/sj.onc.1201464; Borner C, 1996, J BIOL CHEM, V271, P12695, DOI 10.1074/jbc.271.22.12695; CHRISTOV K, 1993, CARCINOGENESIS, V14, P2019, DOI 10.1093/carcin/14.10.2019; Friedrich K, 1995, PATHOL RES PRACT, V191, P1114, DOI 10.1016/S0344-0338(11)80656-4; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; HERMEKING H, 1994, SCIENCE, V265, P2091, DOI 10.1126/science.8091232; Humphreys RC, 1996, DEVELOPMENT, V122, P4013; Jager R, 1997, ONCOGENE, V15, P1787, DOI 10.1038/sj.onc.1201353; Kroemer G, 1997, NAT MED, V3, P614, DOI 10.1038/nm0697-614; LI BL, 1994, CELL GROWTH DIFFER, V5, P711; LI BL, 1995, MOL CARCINOGEN, V14, P75, DOI 10.1002/mc.2940140203; LU PJ, 1995, J CELL BIOL, V129, P1363, DOI 10.1083/jcb.129.5.1363; LunaMore S, 1996, PATHOL RES PRACT, V192, P27, DOI 10.1016/S0344-0338(96)80126-9; MARIN MC, 1994, ONCOGENE, V9, P3107; MEDINA D, 1974, J NATL CANCER I, V53, P213, DOI 10.1093/jnci/53.1.213; Merlo GR, 1997, CELL GROWTH DIFFER, V8, P251; Naumovski L, 1996, MOL CELL BIOL, V16, P3884; OReilly LA, 1996, EMBO J, V15, P6979, DOI 10.1002/j.1460-2075.1996.tb01090.x; PIETENPOL JA, 1994, CANCER RES, V54, P3714; Rodriguez-Villanueva J, 1998, ONCOGENE, V16, P853, DOI 10.1038/sj.onc.1201610; Siziopikou KP, 1996, CANCER, V77, P499, DOI 10.1002/(SICI)1097-0142(19960201)77:3<499::AID-CNCR11>3.0.CO;2-#; STRASSER A, 1994, CELL, V79, P329, DOI 10.1016/0092-8674(94)90201-1; TEIXEIRA C, 1995, CANCER RES, V55, P3902	23	47	48	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 11	1999	18	47					6597	6604		10.1038/sj.onc.1203099	http://dx.doi.org/10.1038/sj.onc.1203099			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	256CW	10597264				2022-12-25	WOS:000083709200024
J	Tamura, T; Mancini, A; Joos, H; Koch, A; Hakim, C; Dumanski, J; Weidner, KM; Niemann, H				Tamura, T; Mancini, A; Joos, H; Koch, A; Hakim, C; Dumanski, J; Weidner, KM; Niemann, H			FMIP, a novel Fms-interacting protein, affects granulocyte/macrophage differentiation	ONCOGENE			English	Article						novel c-Fms-interacting protein; M-CSF-receptor; granulocyte/macrophage differentiation; lineage control	COLONY-STIMULATING FACTOR; M-CSF RECEPTOR; SIGNAL-TRANSDUCTION; TYROSINE KINASE; ONCOGENE PRODUCT; PROGENITOR CELLS; BINDING-SITE; SH2 DOMAINS; GM-CSF; ACTIVATION	Hematopoietic cell growth, differentiation, and commitment to a restricted lineage are guided by a set of cytokines acting exclusively on cells expressing the corresponding cytokine receptor. The macrophage colony stimulating factor (M-CSF, also termed CSF-1) and its cognate receptor, the tyrosine kinase c-Fms, are essential for monocyte and macrophage development. The underlying molecular mechanism, however, is poorly understood. Here we identified a novel Fms-interacting protein (FMIP, MW 78 kDa) which binds transiently via its N-terminal 144 residues to the cytoplasmic domain of activated Fms-molecules. Binding of FMIP was paralleled by rapid tyrosine phosphorylation within the binding domain which drastically reduced its ability to associate with Fms. Binding was specific as evidenced by co-immunoprecipitation and association with recombinant GST-Fms fusion proteins. No binding was observed with the tyrosine phosphorylated cytoplasmic domains of c-Kit, TrkA, c-Met, and the insulin receptor. The role of FMIP in hematopoietic differentiation was studied in the bipotential myeloid progenitor cell line, FDC-P1Mac11. Overexpression of FMIP prevented M-CSF induced macrophage differentiation. Instead, cells differentiated into granulocytes. Our data suggest that the level of FMIP expression could form a threshold that decides about differentiation either into macrophages or into granulocytes.	Hannover Med Sch, Inst Biochem, D-30623 Hannover, Germany; Karolinska Inst, Dept Mol Med, S-17176 Stockholm, Sweden; Roche Pharma Res Werk Penzberg, D-82372 Penzberg, Germany	Hannover Medical School; Karolinska Institutet	Tamura, T (corresponding author), Hannover Med Sch, Inst Biochem, OE 4310,Carl-Neuberg-Str 1, D-30623 Hannover, Germany.			Dumanski, Jan Piotr/0000-0002-1489-1452				Bourette RP, 1997, EMBO J, V16, P5880, DOI 10.1093/emboj/16.19.5880; Broudy VC, 1997, BLOOD, V90, P1345, DOI 10.1182/blood.V90.4.1345.1345_1345_1364; COURTNEIDGE SA, 1993, EMBO J, V12, P943, DOI 10.1002/j.1460-2075.1993.tb05735.x; CROSS MA, 1997, CIBA F SYMP, P3; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; GLINIAK BC, 1990, CELL, V63, P1073, DOI 10.1016/0092-8674(90)90510-L; Helftenbein G, 1996, ONCOGENE, V12, P931; Joos H, 1996, J BIOL CHEM, V271, P24476, DOI 10.1074/jbc.271.40.24476; JUST U, 1993, GROWTH FACTORS, V9, P291, DOI 10.3109/08977199308991589; Lioubin MN, 1996, GENE DEV, V10, P1084, DOI 10.1101/gad.10.9.1084; Mancini A, 1997, ONCOGENE, V15, P1565, DOI 10.1038/sj.onc.1201518; Novak U, 1996, ONCOGENE, V13, P2607; Pawson T, 1997, SCIENCE, V278, P2075, DOI 10.1126/science.278.5346.2075; Pierce A, 1998, J CELL BIOL, V140, P1511, DOI 10.1083/jcb.140.6.1511; QUELLE FW, 1994, MOL CELL BIOL, V14, P4335, DOI 10.1128/MCB.14.7.4335; REEDIJK M, 1992, EMBO J, V11, P1365, DOI 10.1002/j.1460-2075.1992.tb05181.x; TAMURA T, 1986, MOL CELL BIOL, V6, P4745, DOI 10.1128/MCB.6.12.4745; TROULIARIS S, 1995, J VIROL, V69, P6010, DOI 10.1128/JVI.69.10.6010-6020.1995; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VANDERGEER P, 1993, EMBO J, V12, P5161, DOI 10.1002/j.1460-2075.1993.tb06211.x; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; Weidner KM, 1996, NATURE, V384, P173, DOI 10.1038/384173a0; WHETTON AD, 1994, J CELL BIOL, V125, P651, DOI 10.1083/jcb.125.3.651; XIE YG, 1993, HUM MOL GENET, V2, P1361; YASUKAWA T, 1995, J BIOL CHEM, V270, P25328, DOI 10.1074/jbc.270.43.25328; Yokouchi M, 1997, ONCOGENE, V15, P7, DOI 10.1038/sj.onc.1201163; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	27	41	43	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 11	1999	18	47					6488	6495		10.1038/sj.onc.1203062	http://dx.doi.org/10.1038/sj.onc.1203062			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	256CW	10597251				2022-12-25	WOS:000083709200011
J	Roshan, B; Kjelsberg, C; Spokes, K; Eldred, A; Crovello, CS; Cantley, LG				Roshan, B; Kjelsberg, C; Spokes, K; Eldred, A; Crovello, CS; Cantley, LG			Activated ERK2 interacts with and phosphorylates the docking protein GAB1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR RECEPTOR; TYROSINE PHOSPHORYLATION; SIGNAL-TRANSDUCTION; PTB DOMAIN; KINASE; SHC; ASSOCIATION; PHOSPHOTYROSINE; MODULATION; RESIDUES	Grb2-associated binder 1 (GAB1) is a docking protein found to associate with the activated c-MET receptor via the MET-binding domain (MBD) and appears to be critical for the tubulogenic actions of this receptor. Pull-down experiments with bacterially expressed MBD and fall-length GAB1 revealed the presence of c-MET as web as phosphorylated ERK2 (pERK2). By using purified pERK2 and non-pERK2, we found that GAB1 associates exclusively with the phosphorylated form of the enzyme and that this association does not require mediation by a third protein. When epitope-tagged GAB1 was cotransfected with constitutively active MEK1 into A293 cells, co-immunoprecipitation of GAB1 and pERK2 was observed, demonstrating that this interaction can occur in intact cells. In vitro, both the MBD and full-length GAB1 were found to be substrates for activated ERK2. In intact cells, epitope-tagged GAB1 was found to be basally phosphorylated on serine with an increase following co-transfection with constitutively active MEK1 and the appearance of novel phosphorylation sites detected by phosphopeptide mapping. Thus, it appears that GAB1 can associate directly with phosphorylated ERK2 via the MET-binding domain and that GAB1 then acts as a substrate for the enzyme.	Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Div Nephrol, Boston, MA 02215 USA; Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Div Signal Transduct, Boston, MA 02215 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School	Roshan, B (corresponding author), Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Div Nephrol, 330 Brookline Ave,Dana 517, Boston, MA 02215 USA.		Eldred, A./AAS-3702-2021		NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK054911, R01DK048871] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK48871, DK54911] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BARROS EJG, 1995, P NATL ACAD SCI USA, V92, P4412, DOI 10.1073/pnas.92.10.4412; Cantley LG, 1996, AM J PHYSIOL-RENAL, V271, pF1103, DOI 10.1152/ajprenal.1996.271.6.F1103; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; DeFea K, 1997, J BIOL CHEM, V272, P31400, DOI 10.1074/jbc.272.50.31400; Ferrell JE, 1997, J BIOL CHEM, V272, P19008, DOI 10.1074/jbc.272.30.19008; Gu HH, 1998, MOL CELL, V2, P729, DOI 10.1016/S1097-2765(00)80288-9; Hanazono Y, 1996, BIOCHEM BIOPH RES CO, V222, P330, DOI 10.1006/bbrc.1996.0744; HARRISONFINDIK D, 1995, ONCOGENE, V10, P1385; HolgadoMadruga M, 1996, NATURE, V379, P560, DOI 10.1038/379560a0; Jacque JM, 1998, EMBO J, V17, P2607, DOI 10.1093/emboj/17.9.2607; Khokhlatchev AV, 1998, CELL, V93, P605, DOI 10.1016/S0092-8674(00)81189-7; Kjelsberg C, 1997, AM J PHYSIOL-RENAL, V272, pF222, DOI 10.1152/ajprenal.1997.272.2.F222; LoGrasso PV, 1996, P NATL ACAD SCI USA, V93, P12165, DOI 10.1073/pnas.93.22.12165; Maroun CR, 1999, MOL CELL BIOL, V19, P1784; Milia E, 1996, ONCOGENE, V13, P767; MORRISON P, 1993, J BIOL CHEM, V268, P15536; Nguyen L, 1997, J BIOL CHEM, V272, P20811, DOI 10.1074/jbc.272.33.20811; NORTHWOOD IC, 1991, J BIOL CHEM, V266, P15266; Pratt JC, 1996, J BIOL CHEM, V271, P12137, DOI 10.1074/jbc.271.21.12137; TRUB T, 1995, J BIOL CHEM, V270, P18205; vanderGeer P, 1996, CURR BIOL, V6, P1435, DOI 10.1016/S0960-9822(96)00748-8; Weidner KM, 1996, NATURE, V384, P173, DOI 10.1038/384173a0	22	32	32	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 17	1999	274	51					36362	36368		10.1074/jbc.274.51.36362	http://dx.doi.org/10.1074/jbc.274.51.36362			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	266AV	10593929	hybrid			2022-12-25	WOS:000084279200048
J	Shin, OH; Ross, AH; Mihai, I; Exton, JH				Shin, OH; Ross, AH; Mihai, I; Exton, JH			Identification of arfophilin, a target protein for GTP-bound class II ADP-ribosylation factors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GOLGI MEMBRANES; NUCLEOTIDE EXCHANGE; ACTIVATING PROTEIN; MAMMALIAN-CELLS; PLASMA-MEMBRANE; ARF PROTEINS; EXPRESSION; FAMILY	Yeast two-hybrid screening of a human kidney cDNA library using the GTP-bound form of a class II ADP-ribosylation factor (ARF5) identified a novel ARF5-binding protein with a calculated molecular mass of 82.4 kDa, which was named arfophilin, Northern hybridization analysis showed high level arfophilin mRNA expression in human heart and skeletal muscle. Arfophilin bound only to the active, GTP-bound form of ARF5 and did not bind to GTP-ARF3, which is a class I ARF. The N terminus of ARF5 (1-17 amino acids) was essential for binding to arfophilin. The GTP-bound form of ARF5 with amino acid residues in the N terminus mutated to those in ARF4 (another class II ARF) also bound to arfophilin, suggesting it is a target protein for GTP-bound forms of class II ARFs. The binding site for ARF on arfophilin was localized to the C terminus (residues 612-756), which contains putative coiled-coil structures. Recombinant arfophilin overexpressed in CHO-K1 cells was localized in the cytosol and translocated to a membrane fraction in association with GTP-bound ARF5. ARF5 containing the N terminus of ARF3 did not promote translocation indicating that class II ARFs are specific carriers for arfophilin.	Vanderbilt Univ, Howard Hughes Med Inst, Sch Med, Nashville, TN 37232 USA; Vanderbilt Univ, Dept Physiol & Mol Biophys, Sch Med, Nashville, TN 37232 USA	Howard Hughes Medical Institute; Vanderbilt University; Vanderbilt University	Exton, JH (corresponding author), Vanderbilt Univ, Howard Hughes Med Inst, Sch Med, 221 Kirkland Hall, Nashville, TN 37232 USA.							BALCH WE, 1992, J BIOL CHEM, V267, P13053; Brown MT, 1998, MOL CELL BIOL, V18, P7038, DOI 10.1128/MCB.18.12.7038; Cavenagh MM, 1996, J BIOL CHEM, V271, P21767, DOI 10.1074/jbc.271.36.21767; Chardin P, 1996, NATURE, V384, P481, DOI 10.1038/384481a0; Claude A, 1999, J CELL BIOL, V146, P71, DOI 10.1083/jcb.146.1.71; CUKIERMAN E, 1995, SCIENCE, V270, P1999, DOI 10.1126/science.270.5244.1999; D'SOUZA-SCHOREY C, 1995, SCIENCE, V267, P1175, DOI 10.1126/science.7855600; Deitz SB, 1996, MOL CELL BIOL, V16, P3275; FRANGIONI JV, 1993, ANAL BIOCHEM, V210, P179, DOI 10.1006/abio.1993.1170; Galas MC, 1997, J BIOL CHEM, V272, P2788, DOI 10.1074/jbc.272.5.2788; Gaschet J, 1999, J BIOL CHEM, V274, P20040, DOI 10.1074/jbc.274.28.20040; Goldberg J, 1998, CELL, V95, P237, DOI 10.1016/S0092-8674(00)81754-7; Gress TM, 1996, ONCOGENE, V13, P1819; KAHN RA, 1991, J BIOL CHEM, V266, P2606; KAHN RA, 1995, J BIOL CHEM, V270, P143, DOI 10.1074/jbc.270.1.143; Kanoh H, 1997, J BIOL CHEM, V272, P5421, DOI 10.1074/jbc.272.9.5421; Liang JO, 1997, J BIOL CHEM, V272, P4141, DOI 10.1074/jbc.272.7.4141; Mansour SJ, 1999, P NATL ACAD SCI USA, V96, P7968, DOI 10.1073/pnas.96.14.7968; MOSS J, 1995, J BIOL CHEM, V270, P12327, DOI 10.1074/jbc.270.21.12327; Moss J, 1998, J BIOL CHEM, V273, P21431, DOI 10.1074/jbc.273.34.21431; Peyroche A, 1996, NATURE, V384, P479, DOI 10.1038/384479a0; Radhakrishna H, 1997, J CELL BIOL, V139, P49, DOI 10.1083/jcb.139.1.49; Roth MG, 1999, CELL, V97, P149, DOI 10.1016/S0092-8674(00)80723-0; Sata M, 1999, P NATL ACAD SCI USA, V96, P2752, DOI 10.1073/pnas.96.6.2752; SUDHOF TC, 1995, NATURE, V375, P645, DOI 10.1038/375645a0; TSAI SC, 1992, P NATL ACAD SCI USA, V89, P9272, DOI 10.1073/pnas.89.19.9272; TSUCHIYA M, 1991, J BIOL CHEM, V266, P2772	27	51	52	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 17	1999	274	51					36609	36615		10.1074/jbc.274.51.36609	http://dx.doi.org/10.1074/jbc.274.51.36609			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	266AV	10593962	hybrid			2022-12-25	WOS:000084279200081
J	Sorgen, PL; Bubb, MR; Cain, BD				Sorgen, PL; Bubb, MR; Cain, BD			Lengthening the second stalk of F1F0 ATP synthase in Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							B-SUBUNIT; DELTA-SUBUNIT; SUPPRESSOR MUTATIONS; MUTAGENIC ANALYSIS; GAMMA-SUBUNIT; F-0 PARTS; 2ND STALK; F1-ATPASE; EPSILON; SECTOR	In Escherichia coli F1F0 ATP synthase, the two b subunits dimerize forming the peripheral second stalk linking the membrane F-0 sector to F-1. Previously, we have demonstrated that the enzyme could accommodate relatively large deletions in the b subunits while retaining function (Sorgen, P, L., Caviston, T, L., Perry, R. C., and Cain, B. D. (1998) J. Biol. Chem. 273, 27873-27878). The manipulations of b subunit length have been extended by construction of insertion mutations into the uncF(b) gene adding amino acids to the second stalk Mutants with insertions of seven amino acids were essentially identical to wild type strains, and mutants with insertions of up to 14 amino acids retained biologically significant levels of activity. Membranes prepared from these strains had readily detectable levels of F1F0-ATPase activity and proton pumping activity. However, the larger insertions resulted in decreasing levels of activity, and immunoblot analysis indicated that these reductions in activity correlated with reduced levels of b subunit in the membranes. Addition of 18 amino acids was sufficient to result in the loss of F1F0 ATP synthase function. Assuming the predicted alpha-helical structure for this area of the b subunit, the 14-amino acid insertion would result in the addition of enough material to lengthen the b subunit by as much as 20 Angstrom. The results of both insertion and deletion experiments support a model in which the second stalk is a flexible feature of the enzyme rather than a rigid rod-like structure.	Univ Florida, Dept Biochem & Mol Biol, Gainesville, FL 32610 USA; Univ Florida, Dept Med, Gainesville, FL 32610 USA	State University System of Florida; University of Florida; State University System of Florida; University of Florida	Cain, BD (corresponding author), Univ Florida, Dept Biochem & Mol Biol, Box 100245, Gainesville, FL 32610 USA.	bcain@biochem.med.ufl.edu			NIGMS NIH HHS [GM43495] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM043495] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABRAHAMS JP, 1994, NATURE, V370, P621, DOI 10.1038/370621a0; ARIS JP, 1985, J BIOL CHEM, V260, P1207; Bulygin VV, 1998, J BIOL CHEM, V273, P31765, DOI 10.1074/jbc.273.48.31765; CAIN BD, 1986, J BIOL CHEM, V261, P43; CAIN BD, 1989, J BIOL CHEM, V264, P3292; CAPALDI RA, 1994, TRENDS BIOCHEM SCI, V19, P284, DOI 10.1016/0968-0004(94)90006-X; Caviston TL, 1998, FEBS LETT, V429, P201, DOI 10.1016/S0014-5793(98)00597-3; Cherepanov DA, 1999, FEBS LETT, V449, P1, DOI 10.1016/S0014-5793(99)00386-5; DECKERSHEBESTREIT G, 1992, J BIOL CHEM, V267, P12364; Dimroth P, 1999, P NATL ACAD SCI USA, V96, P4924, DOI 10.1073/pnas.96.9.4924; Dmitriev O, 1999, J BIOL CHEM, V274, P15598, DOI 10.1074/jbc.274.22.15598; DUNCAN TM, 1995, P NATL ACAD SCI USA, V92, P10964, DOI 10.1073/pnas.92.24.10964; DUNN SD, 1992, J BIOL CHEM, V267, P7630; Dunn SD, 1998, J BIOL CHEM, V273, P8646, DOI 10.1074/jbc.273.15.8646; Fillingame RH, 1998, BBA-BIOENERGETICS, V1365, P135, DOI 10.1016/S0005-2728(98)00053-X; HARTZOG PE, 1994, J BIOL CHEM, V269, P32313; Hermolin J, 1999, J BIOL CHEM, V274, P17011, DOI 10.1074/jbc.274.24.17011; HERMOLIN J, 1983, J BIOL CHEM, V258, P4550; Junge W, 1997, TRENDS BIOCHEM SCI, V22, P420, DOI 10.1016/S0968-0004(97)01129-8; MARKWELL MAK, 1978, ANAL BIOCHEM, V87, P206, DOI 10.1016/0003-2697(78)90586-9; MCCORMICK KA, 1993, J BIOL CHEM, V268, P24683; MCCORMICK KA, 1991, J BACTERIOL, V173, P7240, DOI 10.1128/jb.173.22.7240-7248.1991; McLachlin DT, 1998, J BIOL CHEM, V273, P15162, DOI 10.1074/jbc.273.24.15162; McLachlin DT, 1997, J BIOL CHEM, V272, P21233, DOI 10.1074/jbc.272.34.21233; Nakamoto RK, 1999, ANNU REV BIOPH BIOM, V28, P205, DOI 10.1146/annurev.biophys.28.1.205; Noji H, 1997, NATURE, V386, P299, DOI 10.1038/386299a0; Ogilvie I, 1997, J BIOL CHEM, V272, P16652, DOI 10.1074/jbc.272.26.16652; PERLIN DS, 1983, J BIOL CHEM, V258, P9793; PORTER ACG, 1985, J BIOL CHEM, V260, P8182; Rodgers AJW, 1997, J BIOL CHEM, V272, P31058, DOI 10.1074/jbc.272.49.31058; ROGERS AJW, 1998, J BIOL CHEM, V273, P29406; Sabbert D, 1997, P NATL ACAD SCI USA, V94, P4401, DOI 10.1073/pnas.94.9.4401; Sawada K, 1997, J BIOL CHEM, V272, P30047, DOI 10.1074/jbc.272.48.30047; Sorgen PL, 1998, BIOCHEMISTRY-US, V37, P923, DOI 10.1021/bi972309+; Sorgen PL, 1998, J BIOL CHEM, V273, P27873, DOI 10.1074/jbc.273.43.27873; WATTS SD, 1995, FEBS LETT, V368, P235, DOI 10.1016/0014-5793(95)00658-V; Watts SD, 1996, J BIOL CHEM, V271, P28341, DOI 10.1074/jbc.271.45.28341; Wilkens S, 1998, NATURE, V393, P29, DOI 10.1038/29908; Yamane Y, 1998, J BIOL CHEM, V273, P7375, DOI 10.1074/jbc.273.13.7375; ZHANG Y, 1995, J BIOL CHEM, V270, P24609, DOI 10.1074/jbc.270.41.24609; ZHANG Y, 1994, J BIOL CHEM, V269, P10221	41	56	58	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 17	1999	274	51					36261	36266		10.1074/jbc.274.51.36261	http://dx.doi.org/10.1074/jbc.274.51.36261			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	266AV	10593914	hybrid			2022-12-25	WOS:000084279200033
J	Vadas, A; Monbouquette, HG; Johnson, E; Schroder, I				Vadas, A; Monbouquette, HG; Johnson, E; Schroder, I			Identification and characterization of a novel ferric reductase from the hyperthermophilic Archaeon Archaeoglobus fulgidus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SULFATE-REDUCING ARCHAEBACTERIUM; ESCHERICHIA-COLI; IRON REDUCTASE; SACCHAROMYCES-CEREVISIAE; MOLECULAR CHARACTERIZATION; DEDUCED FUNCTIONS; PLASMA-MEMBRANE; SP-NOV; GENES; CLONING	Archaeoglobus fulgidus, a hyperthermophilic sulfate-reducing Archaeon, contains high Fe3+-EDTA reductase activity in its soluble protein fraction. The corresponding enzyme, which constitutes about 0.75% of the soluble protein, was purified 175-fold to homogeneity, Based on SDS-polyacrylamide gel electrophoresis, the ferric reductase consists of a single subunit with a M-r of 18,000, The M-r of the native enzyme was determined by size exclusion chromatography to be 40,000 suggesting that the native ferric reductase is a homodimer, The enzyme uses both NADH and NADPH as electron donors to reduce Fe3+-EDTA. Other Fe3+ complexes and dichlorophenolindophenol serve as alternative electron accepters, but uncomplexed Fe3+ is not utilized. The purified enzyme strictly requires FMN or FAD as a catalytic intermediate for Fe3+ reduction. Ferric reductase also reduces FMN and FAD, but not riboflavin, with NAD(P)H which classifies the enzyme as a NAD(P)H:flavin oxidoreductase. The enzyme exhibits a temperature optimum of 88 degrees C. When incubated at 85 degrees C, the enzyme activity half-life was 2 h, N-terminal sequence analysis of the purified ferric reductase resulted in the identification of the hypothetical gene, AF0830, of the A. fulgidus genomic sequence. The A. fulgidus ferric reductase shares amino acid sequence similarity with a family of NAD(P)H:FMN oxidoreductases but not with any ferric reductases suggesting that the A. fulgidus ferric reductase is a novel enzyme.	Univ Calif Los Angeles, Dept Microbiol & Mol Genet, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Dept Chem Engn, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles	Schroder, I (corresponding author), Univ Calif Los Angeles, Dept Microbiol & Mol Genet, 1602 Mol Sci Bldg, Los Angeles, CA 90095 USA.		Monbouquette, Harold/GNW-3860-2022	Monbouquette, Harold/0000-0001-8144-8189	NHLBI NIH HHS [HL-16251] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL016251] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Aalen N, 1997, ARCH MICROBIOL, V168, P536, DOI 10.1007/s002030050533; AIBA H, 1996, DNA RES, V3, P137; Aubert C, 1998, APPL ENVIRON MICROB, V64, P1308; Barchini E, 1996, ARCH MICROBIOL, V166, P51, DOI 10.1007/s002030050354; Beltrametti F, 1997, APPL ENVIRON MICROB, V63, P2232, DOI 10.1128/AEM.63.6.2232-2239.1997; BERCZI A, 1995, ARCH BIOCHEM BIOPHYS, V320, P65, DOI 10.1006/abbi.1995.1343; BIBB MJ, 1994, GENE, V142, P31, DOI 10.1016/0378-1119(94)90351-4; BLANC V, 1995, J BACTERIOL, V177, P5206, DOI 10.1128/jb.177.18.5206-5214.1995; BRIAT JF, 1992, J GEN MICROBIOL, V138, P2475, DOI 10.1099/00221287-138-12-2475; BRUGGEMANN W, 1990, PHYSIOL PLANTARUM, V79, P339; CACCAVO F, 1994, APPL ENVIRON MICROB, V60, P3752, DOI 10.1128/AEM.60.10.3752-3759.1994; COVES J, 1993, EUR J BIOCHEM, V211, P635, DOI 10.1111/j.1432-1033.1993.tb17591.x; DAHL C, 1993, J GEN MICROBIOL, V139, P1817, DOI 10.1099/00221287-139-8-1817; DANCIS A, 1992, P NATL ACAD SCI USA, V89, P3869, DOI 10.1073/pnas.89.9.3869; ESCHENBRENNER M, 1994, BIOCHEM BIOPH RES CO, V198, P127, DOI 10.1006/bbrc.1994.1018; FERNANDEZMORENO MA, 1992, J BIOL CHEM, V267, P19278; FONTECAVE M, 1987, J BIOL CHEM, V262, P12325; FONTECAVE M, 1994, BIOMETALS, V7, P3; Gibello A, 1997, ARCH MICROBIOL, V167, P160, DOI 10.1007/s002030050429; GORBY YA, 1991, APPL ENVIRON MICROB, V57, P867, DOI 10.1128/AEM.57.3.867-870.1991; GUERINOT ML, 1994, ANNU REV MICROBIOL, V48, P743, DOI 10.1146/annurev.mi.48.100194.003523; HUYER M, 1989, J BACTERIOL, V171, P4031, DOI 10.1128/jb.171.7.4031-4037.1989; KENDREW SG, 1995, J BIOL CHEM, V270, P17339, DOI 10.1074/jbc.270.29.17339; Klenk HP, 1997, NATURE, V390, P364, DOI 10.1038/37052; Knobel HR, 1996, J BACTERIOL, V178, P6123, DOI 10.1128/jb.178.21.6123-6132.1996; Langelandsvik AS, 1997, ARCH MICROBIOL, V168, P59, DOI 10.1007/s002030050470; LEFAOU AE, 1991, BIOL MET, V4, P126; LESUISSE E, 1990, BIOCHIM BIOPHYS ACTA, V1038, P253, DOI 10.1016/0167-4838(90)90213-Y; LOVLEY DR, 1993, ANNU REV MICROBIOL, V47, P263, DOI 10.1146/annurev.mi.47.100193.001403; MOODY MD, 1985, J BACTERIOL, V163, P1120, DOI 10.1128/JB.163.3.1120-1125.1985; ODOM JM, 1984, ANNU REV MICROBIOL, V38, P551, DOI 10.1146/annurev.mi.38.100184.003003; Prieto MA, 1996, J BACTERIOL, V178, P111, DOI 10.1128/jb.178.1.111-120.1996; SCHRODER I, 1994, J BACTERIOL, V176, P4985, DOI 10.1128/jb.176.16.4985-4992.1994; Seeliger S, 1998, J BACTERIOL, V180, P3686, DOI 10.1128/JB.180.14.3686-3691.1998; Shatwell KP, 1996, J BIOL CHEM, V271, P14240, DOI 10.1074/jbc.271.24.14240; Slobodkin A, 1997, INT J SYST BACTERIOL, V47, P541, DOI 10.1099/00207713-47-2-541; Sparla F, 1997, FEBS LETT, V414, P571, DOI 10.1016/S0014-5793(97)01073-9; SPEICH N, 1988, J GEN MICROBIOL, V134, P1419; SPYROU G, 1991, J BACTERIOL, V173, P3673, DOI 10.1128/JB.173.12.3673-3679.1991; Steen IH, 1997, ARCH MICROBIOL, V168, P412, DOI 10.1007/s002030050516; UETZ T, 1992, J BACTERIOL, V174, P1179, DOI 10.1128/jb.174.4.1179-1188.1992; Vargas M, 1998, NATURE, V395, P65, DOI 10.1038/25720; Wasserfallen A, 1998, EUR J BIOCHEM, V254, P325, DOI 10.1046/j.1432-1327.1998.2540325.x; Xu YR, 1997, J BACTERIOL, V179, P1112, DOI 10.1128/jb.179.4.1112-1116.1997; ZELLNER G, 1989, SYST APPL MICROBIOL, V11, P151, DOI 10.1016/S0723-2020(89)80055-4	45	50	53	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 17	1999	274	51					36715	36721		10.1074/jbc.274.51.36715	http://dx.doi.org/10.1074/jbc.274.51.36715			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	266AV	10593977	hybrid			2022-12-25	WOS:000084279200096
J	Chen, F; Demers, LM; Vallyathan, V; Lu, YJ; Castranova, V; Shi, XL				Chen, F; Demers, LM; Vallyathan, V; Lu, YJ; Castranova, V; Shi, XL			Involvement of 5 '-flanking kappa B-like sites within bcl-x gene in silica-induced Bcl-x expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-DEATH; HL-60 CELLS; ACTIVATION; APOPTOSIS; MACROPHAGES; SURVIVAL; RECEPTOR; FAMILY; INHIBITOR; PROTEIN	The present study investigated the involvement of the transcription factor NF-kappa B in the expression of an antiapoptotic gene, bcl-x, using a murine macrophage cell line and peritoneal macrophages from both wild type (p50(+/+)) and NF-kappa B p50 gene knockout (p50(-/-)) mice. Increased expression of Bcl-x protein was observed in native and silica-exposed p50-/- macrophages in which the NF-kappa B p65-containing complex was predominantly induced. Co-transfection experiment using a bcl-x promoter reporter construct and an expression vector for NF-kappa B p50 or p65 indicates that p65, but not p50, upregulates the promoter activity of the bcl-x gene. DNA sequence analysis revealed that there are several kappa B-like sites within the 5'-flanking region of the bcl-x: gene. Electrophoretic mobility shift assay suggested differences in binding of the NF-kappa B complexes to these putative NF-kappa B binding sites of the bcl-x gene.	NIOSH, Pathol & Physiol Res Branch, Hlth Effects Lab Div, Morgantown, WV 26505 USA; Penn State Univ, Coll Med, Dept Pathol, Hershey, PA 17033 USA	Centers for Disease Control & Prevention - USA; National Institute for Occupational Safety & Health (NIOSH); Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health	Shi, XL (corresponding author), NIOSH, Pathol & Physiol Res Branch, Hlth Effects Lab Div, 1095 Willowdale Rd, Morgantown, WV 26505 USA.		Shi, Xianglin/B-8588-2012					Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; Arriola EL, 1999, ONCOGENE, V18, P1457, DOI 10.1038/sj.onc.1202420; BARGOU RC, 1995, INT J CANCER, V60, P854, DOI 10.1002/ijc.2910600622; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; BESSHO R, 1994, BIOCHEM PHARMACOL, V48, P1883, DOI 10.1016/0006-2952(94)90586-X; BOISE LH, 1993, CELL, V74, P597, DOI 10.1016/0092-8674(93)90508-N; CASANO FJ, 1994, GENOMICS, V20, P474, DOI 10.1006/geno.1994.1203; Chan H, 1999, MOL CELL BIOL, V19, P2098, DOI 10.1128/mcb.19.3.2098; Chen F, 1999, CLIN CHEM, V45, P7; CHEN F, 1995, BIOCHEM BIOPH RES CO, V214, P985, DOI 10.1006/bbrc.1995.2383; Chen F, 1997, ARCH BIOCHEM BIOPHYS, V342, P383, DOI 10.1006/abbi.1997.0132; Clifton DR, 1998, P NATL ACAD SCI USA, V95, P4646, DOI 10.1073/pnas.95.8.4646; DING AH, 1988, J IMMUNOL, V141, P2407; Dixon EP, 1997, BRAIN RES, V776, P222, DOI 10.1016/S0006-8993(97)01040-8; DRISCOLL KE, 1995, EXP LUNG RES, V21, P941, DOI 10.3109/01902149509031772; Erl W, 1999, CIRC RES, V84, P668, DOI 10.1161/01.RES.84.6.668; Fang W, 1998, IMMUNITY, V9, P35, DOI 10.1016/S1074-7613(00)80586-5; FITZGERALD MJ, 1995, CELL GROWTH DIFFER, V6, P417; Gao HL, 1997, CANCER LETT, V112, P65, DOI 10.1016/S0304-3835(96)04546-6; GHOSH G, 1995, NATURE, V373, P303, DOI 10.1038/373303a0; GOLDFELD AE, 1991, J EXP MED, V174, P73, DOI 10.1084/jem.174.1.73; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Grillot DAM, 1997, J IMMUNOL, V158, P4750; Grumont RJ, 1999, GENE DEV, V13, P400, DOI 10.1101/gad.13.4.400; Hu YM, 1998, J BIOL CHEM, V273, P33489, DOI 10.1074/jbc.273.50.33489; Karin M, 1998, CANCER J SCI AM, V4, pS92; KESSLER DJ, 1992, ONCOGENE, V7, P2447; LaCasse EC, 1998, ONCOGENE, V17, P3247, DOI 10.1038/sj.onc.1202569; Lee HH, 1999, P NATL ACAD SCI USA, V96, P9136, DOI 10.1073/pnas.96.16.9136; Marinovich M, 1996, EXP CELL RES, V226, P98, DOI 10.1006/excr.1996.0207; McDonnell TJ, 1996, EXPERIENTIA, V52, P1008, DOI 10.1007/BF01920110; Michaelidis TM, 1996, NEURON, V17, P75, DOI 10.1016/S0896-6273(00)80282-2; MOTOYAMA N, 1995, SCIENCE, V267, P1506, DOI 10.1126/science.7878471; MULLER CW, 1995, NATURE, V373, P311, DOI 10.1038/373311a0; Okada S, 1998, J IMMUNOL, V160, P2590; Pan GH, 1998, J BIOL CHEM, V273, P5841, DOI 10.1074/jbc.273.10.5841; Reed JC, 1998, ONCOGENE, V17, P3225, DOI 10.1038/sj.onc.1202591; SARMA V, 1995, J BIOL CHEM, V270, P12343, DOI 10.1074/jbc.270.21.12343; SCHULZEOSTHOFF K, 1994, EMBO J, V13, P4587, DOI 10.1002/j.1460-2075.1994.tb06780.x; Shu HB, 1996, P NATL ACAD SCI USA, V93, P13973, DOI 10.1073/pnas.93.24.13973; Stehlik C, 1998, J EXP MED, V188, P211, DOI 10.1084/jem.188.1.211; Tamatani M, 1999, J BIOL CHEM, V274, P8531, DOI 10.1074/jbc.274.13.8531; WU HY, 1994, J BIOL CHEM, V269, P20067; Wu MX, 1998, SCIENCE, V281, P998, DOI 10.1126/science.281.5379.998; Xerri L, 1996, BRIT J HAEMATOL, V92, P900, DOI 10.1046/j.1365-2141.1996.423958.x; Yamit-Hezi A, 1998, EMBO J, V17, P5161, DOI 10.1093/emboj/17.17.5161; Zong WX, 1999, GENE DEV, V13, P382, DOI 10.1101/gad.13.4.382	47	50	50	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 10	1999	274	50					35591	35595		10.1074/jbc.274.50.35591	http://dx.doi.org/10.1074/jbc.274.50.35591			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	264NG	10585435	hybrid			2022-12-25	WOS:000084187900047
J	Ho, GY; MacKenzie, RG				Ho, GY; MacKenzie, RG			Functional characterization of mutations in melanocortin-4 receptor associated with human obesity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTOR; MOLECULAR-CLONING; FRAMESHIFT MUTATION; TRUNCATION MUTANTS; PLASMA-MEMBRANE; MSH RECEPTOR; V2 RECEPTOR; FOOD-INTAKE; LEPTIN; EXPRESSION	Melanocortin-4 receptor (MC4R) is a G protein-coupled receptor implicated in the regulation of body weight. Genetic studies in humans have identified two frameshift mutations of MC4R associated with a dominantly inherited form of obesity. We have generated and expressed the corresponding MC4R mutants in 293T cells and found that cells transfected with the truncation mutants failed to exhibit agonist binding or responsiveness despite retention of structural motifs potentially sufficient for binding and signaling. Immunofluorescence studies showed that the mutant proteins were expressed and localized in the intracellular compartment but absent from the plasma membrane, suggesting that these mutations disrupted the proper cellular transport of MC4R. Further studies identified a sequence in the cytoplasmic tail of MC4R necessary for the cell surface targeting. We further investigated a possible dominant-negative activity of the mutants on wildtype receptor function. Co-transfection studies showed that the mutants affected neither signaling nor cell surface expression of wild-type MC4R. We also characterized three human sequence variants of MC4R, but these exhibited identical affinities for peptide ligands and identical agonist responsiveness. Thus, unlike the obesity-associated MC4R truncation mutants, the polymorphisms of MC4R are unlikely to be contributors to human obesity.	Parke Davis Pharmaceut Res, Dept Cell Biol, Ann Arbor, MI 48105 USA	Pfizer	MacKenzie, RG (corresponding author), Parke Davis Pharmaceut Res, Dept Cell Biol, 2800 Plymouth Rd, Ann Arbor, MI 48105 USA.	Robert.MacKenzie@wl.com						Bockaert J, 1999, EMBO J, V18, P1723, DOI 10.1093/emboj/18.7.1723; Chen WB, 1997, CELL, V91, P789, DOI 10.1016/S0092-8674(00)80467-5; Clement K, 1998, NATURE, V392, P398, DOI 10.1038/32911; Comuzzie AG, 1997, NAT GENET, V15, P273, DOI 10.1038/ng0397-273; Dohlman HG, 1997, J BIOL CHEM, V272, P3871, DOI 10.1074/jbc.272.7.3871; Fan W, 1997, NATURE, V385, P165, DOI 10.1038/385165a0; GANTZ I, 1993, J BIOL CHEM, V268, P15174; GANTZ I, 1994, BIOCHEM BIOPH RES CO, V200, P1214, DOI 10.1006/bbrc.1994.1580; GANTZ I, 1993, J BIOL CHEM, V268, P8246; Gotoda T, 1997, DIABETOLOGIA, V40, P976, DOI 10.1007/s001250050777; GRIFFON N, 1994, BIOCHEM BIOPH RES CO, V200, P1007, DOI 10.1006/bbrc.1994.1550; Gu W, 1999, DIABETES, V48, P635, DOI 10.2337/diabetes.48.3.635; Hebert TE, 1996, J BIOL CHEM, V271, P16384, DOI 10.1074/jbc.271.27.16384; Hebert TE, 1998, BIOCHEM CELL BIOL, V76, P1, DOI 10.1139/bcb-76-1-1; Heymann JAW, 1997, P NATL ACAD SCI USA, V94, P4966, DOI 10.1073/pnas.94.10.4966; Hinney A, 1999, J CLIN ENDOCR METAB, V84, P1483, DOI 10.1210/jc.84.4.1483; HO GY, 1995, J BIOL CHEM, V270, P27977, DOI 10.1074/jbc.270.46.27977; Huszar D, 1997, CELL, V88, P131, DOI 10.1016/S0092-8674(00)81865-6; Jackson RS, 1997, NAT GENET, V16, P303, DOI 10.1038/ng0797-303; Ji TH, 1998, J BIOL CHEM, V273, P17299, DOI 10.1074/jbc.273.28.17299; Jones KA, 1998, NATURE, V396, P674, DOI 10.1038/25348; Jordan BA, 1999, NATURE, V399, P697, DOI 10.1038/21441; Kask A, 1998, EUR J PHARMACOL, V360, P15, DOI 10.1016/S0014-2999(98)00699-2; Kaupmann K, 1998, NATURE, V396, P683, DOI 10.1038/25360; Krude H, 1998, NAT GENET, V19, P155, DOI 10.1038/509; Kuner R, 1999, SCIENCE, V283, P74, DOI 10.1126/science.283.5398.74; LABBE O, 1994, BIOCHEMISTRY-US, V33, P4543, DOI 10.1021/bi00181a015; Ling K, 1999, P NATL ACAD SCI USA, V96, P7922, DOI 10.1073/pnas.96.14.7922; Montague CT, 1997, NATURE, V387, P903, DOI 10.1038/43185; MOUNTJOY KG, 1992, SCIENCE, V257, P1248, DOI 10.1126/science.1325670; MOUNTJOY KG, 1994, MOL ENDOCRINOL, V8, P1298, DOI 10.1210/me.8.10.1298; Nimchinsky EA, 1997, J BIOL CHEM, V272, P29229, DOI 10.1074/jbc.272.46.29229; Ollmann MM, 1997, SCIENCE, V278, P135, DOI 10.1126/science.278.5335.135; ROBBINS LS, 1993, CELL, V72, P827, DOI 10.1016/0092-8674(93)90572-8; Romano C, 1996, J BIOL CHEM, V271, P28612, DOI 10.1074/jbc.271.45.28612; SCHONEBERG T, 1995, J BIOL CHEM, V270, P18000; Schulein R, 1998, MOL PHARMACOL, V54, P525, DOI 10.1124/mol.54.3.525; Schulein R, 1996, BIOCHEM J, V313, P611, DOI 10.1042/bj3130611; Seeley RJ, 1997, NATURE, V390, P349, DOI 10.1038/37016; Shutter JR, 1997, GENE DEV, V11, P593, DOI 10.1101/gad.11.5.593; Strobel A, 1998, NAT GENET, V18, P213, DOI 10.1038/ng0398-213; UNSON CG, 1995, J BIOL CHEM, V270, P27720, DOI 10.1074/jbc.270.46.27720; Vaisse C, 1998, NAT GENET, V20, P113, DOI 10.1038/2407; White JH, 1998, NATURE, V396, P679, DOI 10.1038/25354; Woods SC, 1998, SCIENCE, V280, P1378, DOI 10.1126/science.280.5368.1378; XIONG X, 1995, CURR OPIN CELL BIOL, V7, P523; Yang YK, 1997, J BIOL CHEM, V272, P23000, DOI 10.1074/jbc.272.37.23000; Yeo GSH, 1998, NAT GENET, V20, P111, DOI 10.1038/2404; Zhu XY, 1998, BIOCHEMISTRY-US, V37, P15773, DOI 10.1021/bi981162z	49	104	117	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 10	1999	274	50					35816	35822		10.1074/jbc.274.50.35816	http://dx.doi.org/10.1074/jbc.274.50.35816			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	264NG	10585465	hybrid			2022-12-25	WOS:000084187900077
J	Nakajima, T; Cheng, T; Rohrwasser, A; Bloem, LJ; Pratt, JH; Inoue, I; Lalouel, JM				Nakajima, T; Cheng, T; Rohrwasser, A; Bloem, LJ; Pratt, JH; Inoue, I; Lalouel, JM			Functional analysis of a mutation occurring between the two in-frame AUG codons of human angiotensinogen	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOPLASMIC-RETICULUM MEMBRANE; SITE-DIRECTED MUTAGENESIS; SIGNAL PEPTIDE; ESSENTIAL-HYPERTENSION; TRANSLATIONAL CONTROL; ESCHERICHIA-COLI; INVARIANT CHAIN; PROTEIN; GENE; TRANSLOCATION	Angiotensinogen (ANG) is the specific substrate of the renin-angiotensin system, a major participant in blood pressure control, We have identified a natural mutation at the -30 amino acid position of the angiotensinogen signal peptide, in which an arginine is replaced by a proline (R-30P), Heterozygous individuals with R-30P showed a tendency to lowered plasma angiotensinogen level (1563 ng of ANG I/ml (range 1129-1941)) compared with normal individuals in the family (1892 ng of ANG I/ml (range 1603-2072)). Human angiotensinogen mRNA has two in-phase translation initiation codons (AUG) starting upstream 39 and 66 nucleotides from the cap site. R-30P occurs in a cluster of basic residues adjacent to the first AUG codon that may affect intracellular sorting of the nascent protein, Pulse-chase experiments in transiently transfected cultured cells revealed that the R-30P mutation was associated with reduced amounts of both intra- and extracellular protein, In a cell-free system, we found that two forms of native angiotensinogen were generated by alternative initiation of translation at either AUG codon, Alteration of either the first or second AUG codons abolished the synthesis of the longer and the shorter form of native angiotensinogen, respectively, Furthermore, the rate of secretion of the shorter form was lower than that of the longer form. By transplanting angiotensinogen signal peptide onto green fluorescence protein, however, we found that both forms of the signal peptide could target green fluorescence protein, normally localized in the cytoplasm, to the secretory pathway, Although the R-30P mutation may not affect intracellular sorting of angiotensinogen in a qualitative manner, it leads to a quantitative reduction in the net secretion of mature angiotensinogen through decreased translocation or increased residence time in the endoplasmic reticulum.	Univ Utah, Howard Hughes Med Inst, Eccles Inst Human Genet, Salt Lake City, UT 84112 USA; Univ Utah, Howard Hughes Med Inst, Dept Human Genet, Salt Lake City, UT 84112 USA; Indiana Univ, Med Ctr, Dept Med, Indianapolis, IN 46202 USA	Howard Hughes Medical Institute; Utah System of Higher Education; University of Utah; Howard Hughes Medical Institute; Utah System of Higher Education; University of Utah; Indiana University System; Indiana University-Purdue University Indianapolis	Lalouel, JM (corresponding author), Univ Utah, Howard Hughes Med Inst, Eccles Inst Human Genet, 6th Floor, Salt Lake City, UT 84112 USA.				NHLBI NIH HHS [HL-3579, HL-45325] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL045325, Z01HL003579] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BLOEM LJ, 1995, J CLIN INVEST, V95, P948, DOI 10.1172/JCI117803; CLOUSTON W M, 1988, Genomics, V2, P240, DOI 10.1016/0888-7543(88)90008-0; DEVRIJE T, 1988, NATURE, V334, P173, DOI 10.1038/334173a0; FUKAMIZU A, 1990, J BIOL CHEM, V265, P7576; GAILLARD I, 1989, DNA-J MOLEC CELL BIO, V8, P87, DOI 10.1089/dna.1.1989.8.87; Gimenez-Roqueplo AP, 1998, J BIOL CHEM, V273, P21232, DOI 10.1074/jbc.273.33.21232; Harlow E., 1988, ANTIBODIES LAB MANUA; HATA A, 1994, J CLIN INVEST, V93, P1285, DOI 10.1172/JCI117083; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; INOUE I, 1995, J BIOL CHEM, V270, P11430, DOI 10.1074/jbc.270.19.11430; Inoue I, 1997, J CLIN INVEST, V99, P1786, DOI 10.1172/JCI119343; INOUYE S, 1982, P NATL ACAD SCI-BIOL, V79, P3438, DOI 10.1073/pnas.79.11.3438; IZARD JW, 1994, MOL MICROBIOL, V13, P765, DOI 10.1111/j.1365-2958.1994.tb00469.x; JEUNEMAITRE X, 1992, CELL, V71, P169, DOI 10.1016/0092-8674(92)90275-H; KARAPLIS AC, 1995, J BIOL CHEM, V270, P1629, DOI 10.1074/jbc.270.4.1629; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KOZAK M, 1995, P NATL ACAD SCI USA, V92, P2662, DOI 10.1073/pnas.92.7.2662; Kozak M, 1997, EMBO J, V16, P2482, DOI 10.1093/emboj/16.9.2482; KOZAK M, 1991, J CELL BIOL, V115, P887, DOI 10.1083/jcb.115.4.887; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; LIN FT, 1993, P NATL ACAD SCI USA, V90, P9606, DOI 10.1073/pnas.90.20.9606; LOTTEAU V, 1990, NATURE, V348, P600, DOI 10.1038/348600a0; LYNCH KR, 1991, HYPERTENSION, V17, P263, DOI 10.1161/01.HYP.17.3.263; MILLER PF, 1989, GENE DEV, V3, P1217, DOI 10.1101/gad.3.8.1217; MURALIDHAR S, 1994, J VIROL, V68, P170, DOI 10.1128/JVI.68.1.170-176.1994; OHKUBO H, 1983, P NATL ACAD SCI-BIOL, V80, P2196, DOI 10.1073/pnas.80.8.2196; RACCHI M, 1993, J BIOL CHEM, V268, P5735; SANDERS SL, 1992, J BIOL CHEM, V267, P13791; SCHUTZE MP, 1994, EMBO J, V13, P1696, DOI 10.1002/j.1460-2075.1994.tb06434.x; Seppen J, 1996, FEBS LETT, V390, P294, DOI 10.1016/0014-5793(96)00677-1; SLUSHER LB, 1991, P NATL ACAD SCI USA, V88, P9789, DOI 10.1073/pnas.88.21.9789; STRUBIN M, 1986, CELL, V47, P619, DOI 10.1016/0092-8674(86)90626-4; TAMURA K, 1992, JPN HEART J, V33, P113; TANAKA T, 1984, J BIOL CHEM, V259, P8063; VLASUK GP, 1983, J BIOL CHEM, V258, P7141; VONHEIJNE G, 1990, J MEMBRANE BIOL, V115, P195, DOI 10.1007/BF01868635	36	15	18	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 10	1999	274	50					35749	35755		10.1074/jbc.274.50.35749	http://dx.doi.org/10.1074/jbc.274.50.35749			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	264NG	10585456	hybrid			2022-12-25	WOS:000084187900068
J	Stolowich, N; Frolov, A; Petrescu, AD; Scott, AI; Billheimer, JT; Schroeder, F				Stolowich, N; Frolov, A; Petrescu, AD; Scott, AI; Billheimer, JT; Schroeder, F			Holo-sterol carrier protein-2 - C-13 NMR investigation of cholesterol and fatty acid binding sites	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIPID-TRANSFER PROTEIN; BRUSH-BORDER MEMBRANE; ACYL-COENZYME-A; PLASMA-MEMBRANE; ENDOPLASMIC-RETICULUM; LIVER; RAT; EXPRESSION; TRANSPORT; BILE	Although sterol carrier protein-2 (SCP-2) stimulates sterol transfer in vitro, almost nothing is known regarding the identity of the putative cholesterol binding site. Furthermore, the interrelationship(s) between this SCP-2 ligand binding site and the recently reported SCP-2 long chain fatty acid (LCFA) and long chain fatty acyl-CoA (LCFA-CoA) binding site(s) remains to be established. In the present work, two SCP-2 ligand binding sites were identified, First, both [4-C-13]cholesterol and 22-(N-(7-nitrobenz-2-oxa-1,3-diazol-4-yl)amino)-23,24-bisnor-5-cholen-3 beta-ol (NBD-cholesterol) binding assays were consistent with a single cholesterol binding site in SCP-S. This ligand binding site had high affinity for NBD-cholesterol, K-d = 4.15 +/- 0.71 nm. C-13 NMR-labeled ligand competition studies demonstrated that the SCP-2 high affinity cholesterol binding site also bound LCFA or LCFA-CoA, However, only the LCFA-CoA was able to effectively displace the SCP-2-bound [4-C-13]Cholesterol, Thus, the ligand affinities at this SCP-2 binding site were in the relative order cholesterol = LCFA-CoA > LCFA. Second, C-13 NMR studies demonstrated the presence of another ligand binding site on SCP-2 that bound either LCFA or LCFA-CoA but not cholesterol, Photon correlation spectroscopy was consistent with SCP-2 being monomeric in both liganded and unliganded states. In summary, both C-13 NMR and fluorescence techniques demonstrated for the first time that SCP-2 had a single high affinity binding site that bound cholesterol, LCFA, or LCFA-CoA, Furthermore, results with C-13 NMR supported the presence of a second SCP-2 ligand binding site that bound either LCFA or LCFA-CoA but not cholesterol, These data contribute to our understanding of a role for SCP-2 in both cellular cholesterol and LCFA metabolism.	Texas A&M Univ, Dept Physiol & Pharmacol, TVMC, College Stn, TX 77843 USA; Texas A&M Univ, Dept Chem, College Stn, TX 77843 USA; Dupont Merck Pharmaceut Co, Cardiovasc Dept, Expt Stn, Wilmington, DE 19898 USA	Texas A&M University System; Texas A&M University College Station; Texas A&M University System; Texas A&M University College Station; DuPont	Schroeder, F (corresponding author), Texas A&M Univ, Dept Physiol & Pharmacol, TVMC, College Stn, TX 77843 USA.	fschroeder@cvm.tamu.edu			NIDDK NIH HHS [DK41405] Funding Source: Medline; NIGMS NIH HHS [GM31651] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM031651] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Antonenkov VD, 1997, J BIOL CHEM, V272, P26023, DOI 10.1074/jbc.272.41.26023; Atshaves BP, 1999, J LIPID RES, V40, P610; Avdulov NA, 1997, J NEUROCHEM, V69, P1746; Babitt J, 1997, J BIOL CHEM, V272, P13242, DOI 10.1074/jbc.272.20.13242; BATENBURG JJ, 1994, BIOCHEM J, V298, P223, DOI 10.1042/bj2980223; Baum CL, 1997, J BIOL CHEM, V272, P6490, DOI 10.1074/jbc.272.10.6490; Berk PD, 1997, J BIOL CHEM, V272, P8830, DOI 10.1074/jbc.272.13.8830; Billheimer J T, 1990, Subcell Biochem, V16, P301; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Bun-ya M, 1998, J BIOCHEM-TOKYO, V123, P347; CHANDERBHAN R, 1982, J BIOL CHEM, V257, P8928; CHANDERBHAN RF, 1986, ENDOCR RES, V12, P351, DOI 10.3109/07435808609035445; CISTOLA DP, 1988, BIOCHEMISTRY-US, V27, P711, DOI 10.1021/bi00402a033; COLLES SM, 1995, LIPIDS, V30, P795, DOI 10.1007/BF02533954; FIELDING CJ, 1995, J LIPID RES, V36, P211; Fielding CJ, 1997, J LIPID RES, V38, P1503; Frolov A, 1997, BIOCHEMISTRY-US, V36, P6545, DOI 10.1021/bi970205t; Frolov A, 1997, LIPIDS, V32, P1201, DOI 10.1007/s11745-997-0154-5; Frolov A, 1996, J BIOL CHEM, V271, P31878, DOI 10.1074/jbc.271.50.31878; Fuchs M, 1997, FASEB J, V11, pA1060; Fuchs M, 1998, BIOCHEM J, V336, P33, DOI 10.1042/bj3360033; GADELLA TWJ, 1991, BIOCHEMISTRY-US, V30, P5555, DOI 10.1021/bi00236a031; GAVEY KL, 1981, J BIOL CHEM, V256, P2993; Gossett RE, 1996, LIPIDS, V31, P895, DOI 10.1007/BF02522684; Gurd F R, 1973, Methods Enzymol, V27, P836; Hertz R, 1998, NATURE, V392, P512, DOI 10.1038/33185; HIGAKI T, 1991, BIOCHEMISTRY-US, V30, P2519, DOI 10.1021/bi00223a032; HIRAI A, 1994, J CLIN INVEST, V94, P2215, DOI 10.1172/JCI117583; JOHNSON LF, 1972, CARBON 13 NMR SPECTR; Jolly CA, 1997, ARCH BIOCHEM BIOPHYS, V341, P112, DOI 10.1006/abbi.1997.9957; JUGUELIN H, 1991, BIOCHIM BIOPHYS ACTA, V1068, P41, DOI 10.1016/0005-2736(91)90058-G; Kallen CB, 1998, J BIOL CHEM, V273, P26285, DOI 10.1074/jbc.273.41.26285; KAWATA S, 1991, CLIN CHIM ACTA, V197, P201, DOI 10.1016/0009-8981(91)90140-8; KLEIN U, 1995, BIOCHEMISTRY-US, V34, P13784, DOI 10.1021/bi00042a009; Kocsis MG, 1996, LIPIDS, V31, P785, DOI 10.1007/BF02522974; KRISANS SK, 1996, ANN NY ACAD SCI, V142, P142; LIPKA G, 1995, J BIOL CHEM, V270, P5917, DOI 10.1074/jbc.270.11.5917; LISCUM L, 1995, J BIOL CHEM, V270, P15443, DOI 10.1074/jbc.270.26.15443; MATSUURA JE, 1993, BIOCHEMISTRY-US, V32, P567, DOI 10.1021/bi00053a023; McArthur MJ, 1999, J LIPID RES, V40, P1371; MCLEAN MP, 1995, ENDOCRINOLOGY, V136, P3360, DOI 10.1210/en.136.8.3360; Moncecchi D, 1996, BBA-LIPID LIPID MET, V1302, P110, DOI 10.1016/0005-2760(96)00044-6; MONCECCHI D, 1991, J BIOL CHEM, V266, P9885; Monier S, 1996, FEBS LETT, V388, P143, DOI 10.1016/0014-5793(96)00519-4; MURATA M, 1995, P NATL ACAD SCI USA, V92, P10339, DOI 10.1073/pnas.92.22.10339; Murphy EJ, 1997, BBA-LIPID LIPID MET, V1345, P283, DOI 10.1016/S0005-2760(97)00003-9; NOLAND BJ, 1980, J BIOL CHEM, V255, P4282; Ohvo H, 1996, BIOCHEMISTRY-US, V35, P8018, DOI 10.1021/bi9528816; Okamoto T, 1998, J BIOL CHEM, V273, P5419, DOI 10.1074/jbc.273.10.5419; Paulussen R J, 1990, Subcell Biochem, V16, P175; PFEIFER SM, 1993, ARCH BIOCHEM BIOPHYS, V304, P287, DOI 10.1006/abbi.1993.1351; PFEIFER SM, 1993, J STEROID BIOCHEM, V47, P167, DOI 10.1016/0960-0760(93)90071-4; POORTHUIS BJHM, 1982, BIOCHIM BIOPHYS ACTA, V710, P99, DOI 10.1016/0005-2760(82)90195-3; Puglielli L, 1996, BIOCHEM J, V317, P681, DOI 10.1042/bj3170681; PUGLIELLI L, 1995, J BIOL CHEM, V270, P18723, DOI 10.1074/jbc.270.32.18723; Richieri GV, 1996, J BIOL CHEM, V271, P31068, DOI 10.1074/jbc.271.49.31068; SAMS GH, 1991, COMP BIOCHEM PHYS B, V99, P213, DOI 10.1016/0305-0491(91)90032-9; SCALLEN TJ, 1985, J BIOL CHEM, V260, P4733; SCHROEDER F, 1990, J BIOL CHEM, V265, P151; Schroeder F, 1996, P SOC EXP BIOL MED, V213, P150, DOI 10.3181/00379727-213-44047; Schroeder F, 1998, INTRACELLULAR CHOLESTEROL TRAFFICKING, P213; SCHROEDER F, 1995, BIOCHEMISTRY-US, V34, P11919, DOI 10.1021/bi00037a033; SCHROEDER F, 1991, P SOC EXP BIOL MED, V196, P235; Schroeder F, 1998, CHEM PHYS LIPIDS, V92, P1, DOI 10.1016/S0009-3084(98)00003-6; SCHULTHESS G, 1994, BIOCHEMISTRY-US, V33, P4500, DOI 10.1021/bi00181a009; SEEDORF U, 1994, J BIOL CHEM, V269, P2613; Seedorf U, 1998, GENE DEV, V12, P1189, DOI 10.1101/gad.12.8.1189; SMALL DM, 1986, PHYSICAL CHEM LIPIDS; Smart EJ, 1996, J BIOL CHEM, V271, P29427, DOI 10.1074/jbc.271.46.29427; Stolowich NJ, 1997, BIOCHEMISTRY-US, V36, P1719, DOI 10.1021/bi962317a; Thompson J, 1997, J BIOL CHEM, V272, P7140, DOI 10.1074/jbc.272.11.7140; Thumser AEA, 1996, BIOCHEM J, V320, P729, DOI 10.1042/bj3200729; TRIGATTI BL, 1991, J BIOL CHEM, V266, P22621; TRZASKOS JM, 1983, BIOCHIM BIOPHYS ACTA, V751, P52, DOI 10.1016/0005-2760(83)90256-4; Uittenbogaard A, 1998, J BIOL CHEM, V273, P6525, DOI 10.1074/jbc.273.11.6525; VANDENBOSCH H, 1992, ANNU REV BIOCHEM, V61, P157, DOI 10.1146/annurev.bi.61.070192.001105; WOODFORD JK, 1995, CHEM PHYS LIPIDS, V76, P73, DOI 10.1016/0009-3084(95)02436-M; YAMAMOTO R, 1991, P NATL ACAD SCI USA, V88, P463, DOI 10.1073/pnas.88.2.463	78	60	61	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 10	1999	274	50					35425	35433		10.1074/jbc.274.50.35425	http://dx.doi.org/10.1074/jbc.274.50.35425			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	264NG	10585412	hybrid			2022-12-25	WOS:000084187900024
J	Zhou, B; Zhang, ZY				Zhou, B; Zhang, ZY			Mechanism of mitogen-activated protein kinase phosphatase-3 activation by ERK2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DUAL-SPECIFICITY PHOSPHATASE; TRANSITION-STATE STRUCTURES; PRE-STEADY-STATE; TYROSINE-PHOSPHATASE; CRYSTAL-STRUCTURE; MAP KINASE; CATALYZED REACTION; KINETIC-ANALYSIS; VHR; STABILIZATION	The mitogen-activated protein kinase phosphatase 3 (MKP3)-catalyzed hydrolysis of aryl phosphates in the absence and presence of extracellular signal-regulated kinase 2 (ERK2) was investigated in order to provide insights into the molecular basis of the ERK2-induced MKP3 activation. In the absence of ERK2, the MKP3-catalyzed hydrolysis of simple aryl phosphates does not display any dependence on pH, viscosity, and the nature of the leaving group. Increased catalytic activity and enhanced affinity for oxyanions are observed for MKP3 in the presence of ERK2, In addition, normal bell-shaped pH dependence on the reaction catalyzed by MKP3 is restored in the presence of ERK2, Collectively, these results suggest that the rate-limiting step in the absence of ERK2 for the MKP3 reaction corresponds to a substrate-induced conformational change in MKP3 involving active site rearrangement and general acid loop closure. The binding of ERK2 to the N-terminal domain of MKP3 facilitates the repositioning of active site residues and speeds up the loop closure in MKP3 such that chemistry becomes rate-limiting in the presence of ERK2, Remarkably, it is found that the extent of ERK2-induced MKP3 activation is substrate dependent, with smaller activation observed for bulkier substrates. Unlike simple aryl phosphates, the MKP3-catalyzed hydrolysis of bulky polycyclic substrates exhibits bell-shaped pH rate profiles in the absence of ERK2. Furthermore, it is found that glycerol can also activate the MKP3-catalyzed reaction, increase the affinity of MKP3 for oxyanion, and restore the bell-shaped pH rate profile for the MKP3-catalyzed reaction. Thus, the rate of repositioning of catalytic groups and the reorienting of the electrostatic environment in the MKP3 active site can be enhanced not only by ERK2 but also by high affinity substrates or by glycerol.	Albert Einstein Coll Med, Dept Mol Pharmacol, Bronx, NY 10461 USA	Yeshiva University; Albert Einstein College of Medicine	Zhang, ZY (corresponding author), Albert Einstein Coll Med, Dept Mol Pharmacol, 1300 Morris Pk Ave, Bronx, NY 10461 USA.				NATIONAL CANCER INSTITUTE [R01CA069202] Funding Source: NIH RePORTER; NCI NIH HHS [CA69202] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AHN NG, 1991, J BIOL CHEM, V266, P4220; ALESSI DR, 1995, CURR BIOL, V5, P283, DOI 10.1016/S0960-9822(95)00059-5; Alhambra C, 1998, J AM CHEM SOC, V120, P3858, DOI 10.1021/ja972578n; Camps M, 1998, SCIENCE, V280, P1262, DOI 10.1126/science.280.5367.1262; Canagarajah BJ, 1997, CELL, V90, P859, DOI 10.1016/S0092-8674(00)80351-7; Chen L, 1996, BIOCHEMISTRY-US, V35, P9349, DOI 10.1021/bi960700+; DENU JM, 1995, J BIOL CHEM, V270, P3796, DOI 10.1074/jbc.270.8.3796; DENU JM, 1995, BIOCHEMISTRY-US, V34, P3396, DOI 10.1021/bi00010a031; Denu JM, 1996, P NATL ACAD SCI USA, V93, P2493, DOI 10.1073/pnas.93.6.2493; Fauman EB, 1998, CELL, V93, P617, DOI 10.1016/S0092-8674(00)81190-3; GEKKO K, 1981, BIOCHEMISTRY-US, V20, P4667, DOI 10.1021/bi00519a023; GEKKO K, 1981, BIOCHEMISTRY-US, V20, P4677, DOI 10.1021/bi00519a024; Gottlin EB, 1996, J BIOL CHEM, V271, P27445, DOI 10.1074/jbc.271.44.27445; Groom LA, 1996, EMBO J, V15, P3621, DOI 10.1002/j.1460-2075.1996.tb00731.x; HENGGE AC, 1995, BIOCHEMISTRY-US, V34, P13982, DOI 10.1021/bi00043a003; Hengge AC, 1996, BIOCHEMISTRY-US, V35, P7084, DOI 10.1021/bi960255i; JIA ZC, 1995, SCIENCE, V268, P1754, DOI 10.1126/science.7540771; Juszczak LJ, 1997, BIOCHEMISTRY-US, V36, P2227, DOI 10.1021/bi9622130; Keng YF, 1999, EUR J BIOCHEM, V259, P809, DOI 10.1046/j.1432-1327.1999.00090.x; Keyse SM, 1998, SEMIN CELL DEV BIOL, V9, P143, DOI 10.1006/scdb.1997.0219; Mourey RJ, 1996, J BIOL CHEM, V271, P3795; Muda M, 1996, J BIOL CHEM, V271, P27205, DOI 10.1074/jbc.271.44.27205; Muda M, 1996, J BIOL CHEM, V271, P4319; Muda M, 1998, J BIOL CHEM, V273, P9323, DOI 10.1074/jbc.273.15.9323; Pannifer ADB, 1998, J BIOL CHEM, V273, P10454, DOI 10.1074/jbc.273.17.10454; PAYNE DM, 1991, EMBO J, V10, P885, DOI 10.1002/j.1460-2075.1991.tb08021.x; Pulido R, 1998, EMBO J, V17, P7337, DOI 10.1093/emboj/17.24.7337; SCHUBERT HL, 1995, PROTEIN SCI, V4, P1904, DOI 10.1002/pro.5560040924; Stewart AE, 1999, NAT STRUCT BIOL, V6, P174; STOKOE D, 1992, EMBO J, V11, P3985, DOI 10.1002/j.1460-2075.1992.tb05492.x; STUCKEY JA, 1994, NATURE, V370, P571, DOI 10.1038/370571a0; SUN H, 1993, CELL, V75, P487, DOI 10.1016/0092-8674(93)90383-2; Tanoue T, 1999, J BIOL CHEM, V274, P19949, DOI 10.1074/jbc.274.28.19949; Wang J, 1997, BIOCHEMISTRY-US, V36, P2993, DOI 10.1021/bi9611873; Widmann C, 1999, PHYSIOL REV, V79, P143, DOI 10.1152/physrev.1999.79.1.143; Wiland AM, 1996, J BIOL CHEM, V271, P33486, DOI 10.1074/jbc.271.52.33486; Wu L, 1996, BIOCHEMISTRY-US, V35, P5426, DOI 10.1021/bi952885a; Yuvaniyama J, 1996, SCIENCE, V272, P1328, DOI 10.1126/science.272.5266.1328; Zhang M, 1997, BIOCHEMISTRY-US, V36, P15, DOI 10.1021/bi961804n; Zhang YL, 1999, BIOCHEMISTRY-US, V38, P12111, DOI 10.1021/bi990836i; Zhang YL, 1998, ANAL BIOCHEM, V261, P139, DOI 10.1006/abio.1998.2738; ZHANG ZY, 1994, J BIOL CHEM, V269, P8140; Zhang ZY, 1995, BIOCHEMISTRY-US, V34, P16088, DOI 10.1021/bi00049a024; ZHANG ZY, 1995, J BIOL CHEM, V270, P11199, DOI 10.1074/jbc.270.19.11199; ZHANG ZY, 1994, P NATL ACAD SCI USA, V91, P1624, DOI 10.1073/pnas.91.5.1624; Zhang ZY, 1998, CRIT REV BIOCHEM MOL, V33, P1, DOI 10.1080/10409239891204161; ZHANG ZY, 1994, BIOCHEMISTRY-US, V33, P15266, DOI 10.1021/bi00255a007; ZHANG ZY, 1991, J BIOL CHEM, V266, P1516; Zhao Y, 1998, J BIOL CHEM, V273, P5484, DOI 10.1074/jbc.273.10.5484; ZHENG CF, 1993, J BIOL CHEM, V268, P16116	50	57	58	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 10	1999	274	50					35526	35534		10.1074/jbc.274.50.35526	http://dx.doi.org/10.1074/jbc.274.50.35526			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	264NG	10585426	hybrid			2022-12-25	WOS:000084187900038
J	Rey, O; Lee, S; Park, NH				Rey, O; Lee, S; Park, NH			Impaired nucleotide excision repair in UV-irradiated human oral keratinocytes immortalized with type 16 human papillomavirus genome	ONCOGENE			English	Article						HPV; p53; oral cancer; DNA repair	TRANSCRIPTION-COUPLED REPAIR; HUMAN FIBROBLASTS; MOUSE CELLS; DNA-BINDING; P53; PROTEIN; E6; DEGRADATION; INTEGRITY; DEFICIENT	We previously reported that 'high risk' human papillomaviruses (HPV) induce genetic instability in human oral keratinocytes. To understand the mechanisms of HPV-induced genetic instability, we determined the nucleotide excision repair (NER) capacity of normal (NHOK) and human papillomavirus type-16 immortalized oral keratinocytes HOK-16B) by strand-specific removal of UV-induced cyclobutane pyrimidine diners (CPDs) from a 16 Kb fragment of the p53 gene. In NHOK the NER activity was initiated in both DNA strands immediately, although the process in the non-transcribed strand was notably slower than that of the transcribed strand. In HOK-16B cells the initiation of CPDs removal was delayed for at least 8h in both DNA strands, and the process was significantly slower than that in NHOK. UV-irradiation enhanced the p53 protein level more than 30-fold in NHOK(, but it did not significantly alter the protein level in the HOK-16B cells. UV-irradiation also increased the p21(WAF1/CIP1) protein level only in NHOK. These data indicate that 'high risk' HPV induces genetic instability by impairing NER capacity of cells. Impaired NER activity of HOK-16B cells may be implicated with their inability to enhance active p53 when challenged by genotoxic stress.	Univ Calif Los Angeles, Sch Dent, Los Angeles, CA 90095 USA; Inst Dent Res, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles	Park, NH (corresponding author), Univ Calif Los Angeles, Sch Dent, Los Angeles, CA 90095 USA.			Rey, Osvaldo/0000-0003-1575-9864	NIDCR NIH HHS [DE11229, DE10598] Funding Source: Medline; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [P50DE010598, P20DE010598, R01DE011229] Funding Source: NIH RePORTER	NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		ABOUSSEKHRA A, 1994, CURR OPIN GENET DEV, V4, P212, DOI 10.1016/S0959-437X(05)80047-4; ANDROPHY EJ, 1987, EMBO J, V6, P989, DOI 10.1002/j.1460-2075.1987.tb04849.x; BAKALKIN G, 1994, P NATL ACAD SCI USA, V91, P413, DOI 10.1073/pnas.91.1.413; BAND V, 1993, EMBO J, V12, P1847, DOI 10.1002/j.1460-2075.1993.tb05833.x; BOHR VA, 1985, CELL, V40, P359, DOI 10.1016/0092-8674(85)90150-3; COVERLEY D, 1992, NUCLEIC ACIDS RES, V20, P3873, DOI 10.1093/nar/20.15.3873; DUTTA A, 1993, NATURE, V365, P79, DOI 10.1038/365079a0; El-Deiry WS, 1998, CURR TOP MICROBIOL, V227, P121; ELDEIRY WS, 1994, CANCER RES, V54, P1169; Ford JM, 1998, CANCER RES, V58, P599; FORD JM, 1995, P NATL ACAD SCI USA, V92, P8876, DOI 10.1073/pnas.92.19.8876; FOSTER SA, 1994, J VIROL, V68, P5698, DOI 10.1128/JVI.68.9.5698-5705.1994; FRITSCHE M, 1993, ONCOGENE, V8, P307; HUBBERT NL, 1992, J VIROL, V66, P6237, DOI 10.1128/JVI.66.10.6237-6241.1992; ISHIZAKI K, 1994, INT J CANCER, V58, P254, DOI 10.1002/ijc.2910580218; LI SL, 1992, ORAL ONCOL, V28B, P129, DOI 10.1016/0964-1955(92)90041-X; Liu X, 1997, ONCOGENE, V14, P2347, DOI 10.1038/sj.onc.1201078; PARK NH, 1991, CARCINOGENESIS, V12, P1627, DOI 10.1093/carcin/12.9.1627; REY O, 1992, J VIROL, V66, P5815, DOI 10.1128/JVI.66.10.5815-5824.1992; Rey O, 1999, ONCOGENE, V18, P827, DOI 10.1038/sj.onc.1202328; SANCAR A, 1993, PHOTOCHEM PHOTOBIOL, V57, P905, DOI 10.1111/j.1751-1097.1993.tb09233.x; SANCAR A, 1994, SCIENCE, V266, P1954, DOI 10.1126/science.7801120; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; Shin KH, 1996, ONCOGENE, V12, P1089; TOMMASINO M, 1993, ONCOGENE, V8, P195; vanderHorst GTJ, 1997, CELL, V89, P425, DOI 10.1016/S0092-8674(00)80223-8; WANG XW, 1994, P NATL ACAD SCI USA, V91, P2230, DOI 10.1073/pnas.91.6.2230; WANG XW, 1995, NAT GENET, V10, P188, DOI 10.1038/ng0695-188; WHITE AE, 1994, GENE DEV, V8, P666, DOI 10.1101/gad.8.6.666	29	25	27	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 25	1999	18	50					6997	7001		10.1038/sj.onc.1203180	http://dx.doi.org/10.1038/sj.onc.1203180			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	259PH	10597299				2022-12-25	WOS:000083901900005
J	Siegel, J; Li, Y; Whyte, P				Siegel, J; Li, Y; Whyte, P			SHIP-mediated inhibition of K562 erythroid differentiation requires an intact catalytic domain and Shc binding site	ONCOGENE			English	Article						SHIP; erythroid differentiation; K562 cells	INOSITOL POLYPHOSPHATE 5-PHOSPHATASE; TYROSINE-PHOSPHORYLATED PROTEIN; FULL-LENGTH CDNA; CELL-LINE K562; FC-GAMMA-RIIB; PHOSPHATASE SHIP; MEGAKARYOCYTIC DIFFERENTIATION; ERYTHROLEUKEMIA-CELLS; SIGNAL-TRANSDUCTION; NEGATIVE REGULATION	Growing evidence supports a role for the SHIP inositol 5'-phosphatase in the negative regulation of a variety of receptor-mediated signaling pathways in hematopoietic cells. SHIP expression among cultured cell lines was examined and found to be restricted to cells of hematopoietic origin, with the exception of the K562 erythroleukemia cell line, in which SHIP protein and mRNA were undetectable. The absence of endogenous SHIP in K562 cells provided a useful system to study the role of SHIP in growth and differentiation. When stably expressed in K562 cells, SHIP was found to be constitutively tyrosine phosphorylated and associated with endogenous Shc and Grb-2. Stable expression of SHIP did not affect growth of the cells but resulted in decreased synthesis of hemoglobin protein and E-globin mRNA in response to hemin, an inducer of erythroid differentiation. This effect was not due to increased cell death in the SHIP-expressing lines following hemin stimulation, but was likely the result of an impaired differentiation program in these cells. Mutational analysis indicated that SHIP must retain both an intact catalytic domain and Shc binding site to efficiently inhibit K562 erythroid differentiation.	McMaster Univ, Inst Mol Biol & Biotechnol, Ctr Hlth Sci, Dept Pathol, Hamilton, ON L8N 3Z5, Canada; McMaster Univ, Dept Pathol & Mol Med, Hamilton, ON L8N 3Z5, Canada	McMaster University; McMaster University	Whyte, P (corresponding author), McMaster Univ, Inst Mol Biol & Biotechnol, Ctr Hlth Sci, Dept Pathol, 1200 Main St W, Hamilton, ON L8N 3Z5, Canada.							BARALLE FE, 1980, CELL, V21, P621, DOI 10.1016/0092-8674(80)90425-0; Benito A, 1996, BLOOD, V87, P3837, DOI 10.1182/blood.V87.9.3837.bloodjournal8793837; Bolland S, 1998, IMMUNITY, V8, P509, DOI 10.1016/S1074-7613(00)80555-5; Chacko GW, 1996, J IMMUNOL, V157, P2234; CHARNAY P, 1983, SCIENCE, V220, P1281, DOI 10.1126/science.6574602; DAmbrosio D, 1996, IMMUNOL LETT, V54, P77, DOI 10.1016/S0165-2478(96)02653-3; Damen JE, 1996, P NATL ACAD SCI USA, V93, P1689, DOI 10.1073/pnas.93.4.1689; DAMEN JE, 1993, BLOOD, V82, P2296; FEINSTEIN E, 1992, ONCOGENE, V7, P1853; Fong DC, 1996, IMMUNOL LETT, V54, P83, DOI 10.1016/S0165-2478(96)02654-5; GROSVELD G, 1986, MOL CELL BIOL, V6, P607, DOI 10.1128/MCB.6.2.607; GUNNING P, 1983, MOL CELL BIOL, V3, P787, DOI 10.1128/MCB.3.5.787; HARLOW E, 1986, MOL CELL BIOL, V6, P1579, DOI 10.1128/MCB.6.5.1579; Harlow E., 1988, ANTIBODIES LAB MANUA; Helgason CD, 1998, GENE DEV, V12, P1610, DOI 10.1101/gad.12.11.1610; HENSOLD JO, 1991, BLOOD, V77, P1362; Huber M, 1998, EMBO J, V17, P7311, DOI 10.1093/emboj/17.24.7311; Jefferson AB, 1996, BIOCHEMISTRY-US, V35, P7890, DOI 10.1021/bi9602627; Jefferson AB, 1997, J BIOL CHEM, V272, P5983, DOI 10.1074/jbc.272.9.5983; KAVANAUGH WM, 1994, SCIENCE, V266, P1862, DOI 10.1126/science.7527937; Kavanaugh WM, 1996, CURR BIOL, V6, P438, DOI 10.1016/S0960-9822(02)00511-0; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; Kubota Y, 1996, LEUKEMIA, V10, P720; Lamkin TD, 1997, J BIOL CHEM, V272, P10396; LEIBOWITZ D, 1991, LEUKEMIA RES, V15, P65, DOI 10.1016/0145-2126(91)90146-K; Lioubin MN, 1996, GENE DEV, V10, P1084, DOI 10.1101/gad.10.9.1084; LIU L, 1994, MOL CELL BIOL, V14, P6926, DOI 10.1128/MCB.14.10.6926; Liu L, 1997, J BIOL CHEM, V272, P8983; Liu QR, 1998, J EXP MED, V188, P1333, DOI 10.1084/jem.188.7.1333; Liu QR, 1998, BLOOD, V91, P2753, DOI 10.1182/blood.V91.8.2753.2753_2753_2759; LUCKHOFF A, 1992, NATURE, V355, P356, DOI 10.1038/355356a0; MASONGARCIA M, 1991, FASEB J, V5, P2958, DOI 10.1096/fasebj.5.14.1752362; MATSUGUCHI T, 1994, J BIOL CHEM, V269, P5016; NISHIMURA J, 1988, LEUKEMIA RES, V12, P875, DOI 10.1016/0145-2126(88)90014-8; OKABEKADO J, 1986, CANCER RES, V46, P1239; OKAYAMA H, 1982, MOL CELL BIOL, V2, P161, DOI 10.1128/MCB.2.2.161; Ono M, 1996, NATURE, V383, P263, DOI 10.1038/383263a0; Ono M, 1997, CELL, V90, P293, DOI 10.1016/S0092-8674(00)80337-2; Osborne MA, 1996, J BIOL CHEM, V271, P29271, DOI 10.1074/jbc.271.46.29271; Paulus W, 1996, J VIROL, V70, P62, DOI 10.1128/JVI.70.1.62-67.1996; Racke FK, 1997, J BIOL CHEM, V272, P23366, DOI 10.1074/jbc.272.37.23366; Rivero JA, 1996, BIOCHEM BIOPH RES CO, V224, P796, DOI 10.1006/bbrc.1996.1102; SALCINI AE, 1994, ONCOGENE, V9, P2827; Sattler M, 1997, ONCOGENE, V15, P2379, DOI 10.1038/sj.onc.1201422; SAXTON TM, 1994, J IMMUNOL, V153, P623; Schaefer A, 1997, CELL SIGNAL, V9, P483, DOI 10.1016/S0898-6568(97)00094-6; Scharenberg AM, 1998, EMBO J, V17, P1961, DOI 10.1093/emboj/17.7.1961; Tilbrook PA, 1996, J BIOL CHEM, V271, P3453; TORTI M, 1992, J BIOL CHEM, V267, P8293; Tridandapani S, 1997, IMMUNOL TODAY, V18, P424, DOI 10.1016/S0167-5699(97)01112-2; Tridandapani S, 1997, MOL CELL BIOL, V17, P4305, DOI 10.1128/MCB.17.8.4305; Ware MD, 1996, BLOOD, V88, P2833, DOI 10.1182/blood.V88.8.2833.bloodjournal8882833; Whalen AM, 1997, MOL CELL BIOL, V17, P1947, DOI 10.1128/MCB.17.4.1947; WU H, 1995, CELL, V83, P59, DOI 10.1016/0092-8674(95)90234-1	54	10	12	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 25	1999	18	50					7135	7148		10.1038/sj.onc.1203212	http://dx.doi.org/10.1038/sj.onc.1203212			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	259PH	10597315				2022-12-25	WOS:000083901900021
J	Takao, N; Kato, H; Mori, R; Morrison, C; Sonada, E; Sun, XG; Shimizu, H; Yoshioka, K; Takeda, S; Yamamoto, K				Takao, N; Kato, H; Mori, R; Morrison, C; Sonada, E; Sun, XG; Shimizu, H; Yoshioka, K; Takeda, S; Yamamoto, K			Disruption of ATM in p53-null cells causes multiple functional abnormalities in cellular response to ionizing radiation	ONCOGENE			English	Article						ATM disruption; p53; cell cycle checkpoint; DNA repair	ATAXIA-TELANGIECTASIA GENE; STRAND-BREAK REPAIR; CYCLE CHECKPOINTS; HOMOLOGOUS RECOMBINATION; VERTEBRATE CELLS; DNA-DAMAGE; NUCLEOTIDE-SEQUENCE; DEFICIENT MICE; P53; DEFECTS	ATM is a member of the large phosphatidylinositol-3 kinase family and plays an important role in cellular response to DNA damage. To further define the physiological roles of ATM at the cellular level, me created an isogenic set of stable cell lines differing only in their ATM status from the chicken B cell line DT40 by targeted integration. These stable DT40 cell lines, as most of transformed chicken cell lines, do not express p53. However, ATM(-/-) DT40 cells displayed retarded cellular proliferation, defective G(2)/M checkpoint control and radio-resistant DNA synthesis. Furthermore, ATM(-/-) DT40 cells were sensitive to ionizing radiation and showed highly elevated frequencies of both spontaneous and radiation-induced chromosomal aberrations. In addition, a slight but significant reduction in targeted integration frequency was observed in,ATM(-/-) DT40 cells. These results suggest that ATM has multiple p53-independent functions in cell cycle checkpoint control and in maintenance of chromosomal DNA. These ATM deficient DT40 clones therefore provide a useful model system for analysing p53-independent ATM functions.	Kanazawa Univ, Fac Med, Canc Res Inst, Dept Mol Pathol, Kanazawa, Ishikawa 9200934, Japan; Kanazawa Univ, Fac Med, Kanazawa, Ishikawa 9200934, Japan; Kyoto Univ, Fac Med, Dept Radiat Genet, Kyoto 6068501, Japan	Kanazawa University; Kanazawa University; Kyoto University	Yamamoto, K (corresponding author), Kanazawa Univ, Fac Med, Canc Res Inst, Dept Mol Pathol, Kanazawa, Ishikawa 9200934, Japan.		Morrison, Ciaran/B-6568-2008; Morrison, Ciaran/AAH-2034-2019	Morrison, Ciaran/0000-0003-2401-7029; Morrison, Ciaran/0000-0003-2401-7029; Mori, Ryoichi/0000-0002-7596-9620; Takeda, Shunichi/0000-0002-7924-7991				AGARWAL ML, 1995, P NATL ACAD SCI USA, V92, P8493, DOI 10.1073/pnas.92.18.8493; Banin S, 1998, SCIENCE, V281, P1674, DOI 10.1126/science.281.5383.1674; Barlow C, 1996, CELL, V86, P159, DOI 10.1016/S0092-8674(00)80086-0; Beamish H, 1996, J BIOL CHEM, V271, P20486, DOI 10.1074/jbc.271.34.20486; BEAMISH H, 1994, INT J RADIAT BIOL, V65, P175, DOI 10.1080/09553009414550211; Bezzubova O, 1997, CELL, V89, P185, DOI 10.1016/S0092-8674(00)80198-1; BUERSTEDDE JM, 1991, CELL, V82, P685; Canman CE, 1998, SCIENCE, V281, P1677, DOI 10.1126/science.281.5383.1677; Cliby WA, 1998, EMBO J, V17, P159, DOI 10.1093/emboj/17.1.159; CORNFORTH MN, 1987, RADIAT RES, V111, P385, DOI 10.2307/3576926; CROSS SM, 1995, SCIENCE, V267, P1353, DOI 10.1126/science.7871434; Elson A, 1996, P NATL ACAD SCI USA, V93, P13084, DOI 10.1073/pnas.93.23.13084; Foray N, 1997, INT J RADIAT BIOL, V72, P271, DOI 10.1080/095530097143266; GATTI RA, 1991, MEDICINE, V70, P99, DOI 10.1097/00005792-199103000-00003; GATTI RA, 1988, NATURE, V336, P577, DOI 10.1038/336577a0; Hermeking H, 1997, MOL CELL, V1, P3, DOI 10.1016/S1097-2765(00)80002-7; *ISCN1985, 1985, REP STAND COMM HUM C; Jeggo PA, 1998, TRENDS GENET, V14, P312, DOI 10.1016/S0168-9525(98)01511-X; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KEITH CT, 1995, SCIENCE, V270, P50, DOI 10.1126/science.270.5233.50; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; KOST TA, 1983, NUCLEIC ACIDS RES, V11, P8287, DOI 10.1093/nar/11.23.8287; Laderoute MP, 1996, ANTICANCER RES, V16, P2825; Lavin MF, 1997, ANNU REV IMMUNOL, V15, P177, DOI 10.1146/annurev.immunol.15.1.177; LEHMANN AR, 1995, TRENDS GENET, V11, P375, DOI 10.1016/S0168-9525(00)89112-X; Matsuoka S, 1998, SCIENCE, V282, P1893, DOI 10.1126/science.282.5395.1893; MEYN MS, 1995, CANCER RES, V55, P5991; PAINTER RB, 1980, P NATL ACAD SCI-BIOL, V77, P7315, DOI 10.1073/pnas.77.12.7315; PAULES RS, 1995, CANCER RES, V55, P1763; Sanchez Y, 1997, SCIENCE, V277, P1497, DOI 10.1126/science.277.5331.1497; SAVITSKY K, 1995, SCIENCE, V268, P1749, DOI 10.1126/science.7792600; SAVITSKY K, 1995, HUM MOL GENET, V4, P2025, DOI 10.1093/hmg/4.11.2025; Shiloh Y, 1997, ANNU REV GENET, V31, P635, DOI 10.1146/annurev.genet.31.1.635; Sonoda E, 1998, EMBO J, V17, P598, DOI 10.1093/emboj/17.2.598; SOUSSI T, 1988, NUCLEIC ACIDS RES, V16, P11383, DOI 10.1093/nar/16.23.11383; Takata M, 1998, EMBO J, V17, P5497, DOI 10.1093/emboj/17.18.5497; TAYLOR AMR, 1976, NATURE, V260, P441, DOI 10.1038/260441a0; Taylor SS, 1997, CELL, V89, P727, DOI 10.1016/S0092-8674(00)80255-X; ULRICH E, 1992, GENE DEV, V6, P876, DOI 10.1101/gad.6.5.876; Uziel T, 1996, GENOMICS, V33, P317, DOI 10.1006/geno.1996.0201; WEAVER DT, 1995, TRENDS GENET, V11, P388, DOI 10.1016/S0168-9525(00)89121-0; WESTPHAL CH, 1997, CANCER RES, V57, P164; Xu Y, 1998, MOL CELL BIOL, V18, P4385, DOI 10.1128/MCB.18.7.4385; Xu Y, 1996, GENE DEV, V10, P2401, DOI 10.1101/gad.10.19.2401; Yamaguchi-Iwai Y, 1998, MOL CELL BIOL, V18, P6430, DOI 10.1128/MCB.18.11.6430; ZAKIAN VA, 1995, CELL, V82, P685, DOI 10.1016/0092-8674(95)90463-8	46	92	95	1	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 25	1999	18	50					7002	7009		10.1038/sj.onc.1203172	http://dx.doi.org/10.1038/sj.onc.1203172			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	259PH	10597300				2022-12-25	WOS:000083901900006
J	Ohta, T; Michel, JJ; Xiong, Y				Ohta, T; Michel, JJ; Xiong, Y			Association with cullin partners protects ROC proteins from proteasome-dependent degradation	ONCOGENE			English	Article						ROC family; cullins; proteasome-dependent degradation	CELL-CYCLE; UBIQUITIN-LIGASE; S-PHASE; F-BOX; COMPLEX; PROTEOLYSIS; FAMILY; KINASE; IDENTIFICATION; CONJUGATION	Cullin 1/CDC53 represents a multigene family and has been linked to the ubiquitin-mediated proteolysis of several different proteins. We recently identified two closely related RING finger proteins, ROC1 and ROC2, that share considerable sequence similarity to an APC subunit, APC11, and demonstrated ROC1 as an essential subunit of CUL1 and CDC53 ubiquitin ligases. We report here that the expression of ROC1, ROC2 and APC11 genes are induced by mitogens and remain constant during the cell cycle. Unlike other subunits of SCF and APC E3 ligases, ectopically expressed ROC family proteins are degraded by a proteasome-inhibitor sensitive pathway and are stabilized by associating with cullins. Mutations at the conserved Phe79 and His80 residues in the RING finger of ROC1 diminish its binding with cullins, resulting in a loss of cullin protection and ubiquitin ligase activity. These results suggest a potential mechanism for regulating the activity of ROC-cullin ligases through complex assembly and ROC/APC11 subunit ubiquitination.	Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA; Univ N Carolina, Curriculum Genet & Mol Biol, Chapel Hill, NC 27599 USA; Univ N Carolina, Dept Biochem & Biophys, Chapel Hill, NC 27599 USA; Univ N Carolina, Program Mol Biol & Biotechnol, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill	Xiong, Y (corresponding author), Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA.			Ohta, Tomohiko/0000-0002-9700-7342	NCI NIH HHS [CA68377, CA65572] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA068377, R01CA065572] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bai C, 1996, CELL, V86, P263, DOI 10.1016/S0092-8674(00)80098-7; Feldman RMR, 1997, CELL, V91, P221, DOI 10.1016/S0092-8674(00)80404-3; Hershko A, 1997, CURR OPIN CELL BIOL, V9, P788, DOI 10.1016/S0955-0674(97)80079-8; Hochstrasser M, 1996, ANNU REV GENET, V30, P405, DOI 10.1146/annurev.genet.30.1.405; HUIBREGTSE JM, 1995, P NATL ACAD SCI USA, V92, P2563, DOI 10.1073/pnas.92.7.2563; JENKINS CW, 1995, CELL CYCLE MAT METHO, P250; JENTSCH S, 1992, ANNU REV GENET, V26, P179, DOI 10.1146/annurev.ge.26.120192.001143; Kamura T, 1999, SCIENCE, V284, P657, DOI 10.1126/science.284.5414.657; KING RW, 1995, CELL, V81, P279, DOI 10.1016/0092-8674(95)90338-0; King RW, 1996, SCIENCE, V274, P1652, DOI 10.1126/science.274.5293.1652; Kipreos ET, 1996, CELL, V85, P829, DOI 10.1016/S0092-8674(00)81267-2; Laney JD, 1999, CELL, V97, P427, DOI 10.1016/S0092-8674(00)80752-7; LI Y, 1994, ONCOGENE, V9, P2261; Maniatis T, 1999, GENE DEV, V13, P505, DOI 10.1101/gad.13.5.505; Marti A, 1999, NAT CELL BIOL, V1, P14, DOI 10.1038/8984; Mathias N, 1996, MOL CELL BIOL, V16, P6634; Mathias N, 1999, MOL CELL BIOL, V19, P1759; Michel JJ, 1998, CELL GROWTH DIFFER, V9, P435; Ohta T, 1999, MOL CELL, V3, P535, DOI 10.1016/S1097-2765(00)80482-7; Patton EE, 1998, TRENDS GENET, V14, P236, DOI 10.1016/S0168-9525(98)01473-5; SCHWOB E, 1994, CELL, V79, P233, DOI 10.1016/0092-8674(94)90193-7; Seol JH, 1999, GENE DEV, V13, P1614, DOI 10.1101/gad.13.12.1614; Skowyra D, 1997, CELL, V91, P209, DOI 10.1016/S0092-8674(00)80403-1; Skowyra D, 1999, SCIENCE, V284, P662, DOI 10.1126/science.284.5414.662; SUDAKIN V, 1995, MOL BIOL CELL, V6, P185, DOI 10.1091/mbc.6.2.185; Tan PL, 1999, MOL CELL, V3, P527, DOI 10.1016/S1097-2765(00)80481-5; Verma R, 1997, SCIENCE, V278, P455, DOI 10.1126/science.278.5337.455; Willems AR, 1996, CELL, V86, P453, DOI 10.1016/S0092-8674(00)80118-X; Yaron A, 1998, NATURE, V396, P590, DOI 10.1038/25159; Yu HT, 1998, SCIENCE, V279, P1219, DOI 10.1126/science.279.5354.1219; Zachariae W, 1998, SCIENCE, V279, P1216, DOI 10.1126/science.279.5354.1216; ZHANG H, 1995, CELL, V82, P915, DOI 10.1016/0092-8674(95)90271-6; Zhou PB, 1998, MOL CELL, V2, P571, DOI 10.1016/S1097-2765(00)80156-2	33	42	43	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 18	1999	18	48					6758	6766		10.1038/sj.onc.1203115	http://dx.doi.org/10.1038/sj.onc.1203115			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	257QA	10597284				2022-12-25	WOS:000083792000018
J	Liu, JF; Chevet, E; Kebache, S; Lemaitre, G; Barritault, D; Larose, L; Crepin, M				Liu, JF; Chevet, E; Kebache, S; Lemaitre, G; Barritault, D; Larose, L; Crepin, M			Functional Rac-1 and Nck signaling networks are required for FGF-2-induced DNA synthesis in MCF-7 cells	ONCOGENE			English	Article						FGF-2; MCF-7; DNA synthesis	FIBROBLAST-GROWTH-FACTOR; BREAST-CANCER CELLS; PROTEIN-KINASE PATHWAY; TYROSINE PHOSPHATASE; RECEPTOR ACTIVATION; STIMULATED CELLS; FACTOR FAMILY; MAP KINASE; RAS; SHC	The effects of Fibroblast Growth Factor-2 (FGF-2) on breast cancer cell DNA synthesis are controversial. To elucidate the mechanisms by which FGF-2 stimulates or inhibits DNA synthesis, we analysed FGF-2 signaling pathways in breast cancer MCF-7 and MCF-7 cells overexpressing Ha-Ras (MCF-7ras), We found that FGF-2-induction of DNA synthesis correlates with Ras transient activation, FRS-2 tyrosine phosphorylation and low level of expression of p66(She). In addition, Nck-associated proteins are highly tyrosine phosphorylated and JNK reaches a higher level of activation when FGF-2 triggers DNA synthesis. Interestingly upon FGF-2 treatment, JNK activation and DNA synthesis are dependent on Rac-1 activity. These results confirm that in MCF-7 cells, induction of DNA synthesis by FGF-2 requires a transient activation of the Ras/MAPK cascade and demonstrates for the first time that intact Rac-1 and Nck signaling networks are required.	McGill Univ, Dept Anat & Cell Biol, Montreal, PQ H3A 2B2, Canada; McGill Univ, Dept Expt Med, Montreal, PQ H3A 2B2, Canada; Univ Paris 13, UFR Leonard de Vinci, Lab Rech Oncol Mol Humaine, EA 445, F-93012 Bobigny, France; Univ Paris 13, Lab CRRET, F-94010 Creteil, France	McGill University; McGill University; Universite Paris 13; Universite Paris 13; Universite Paris-Est-Creteil-Val-de-Marne (UPEC)	Chevet, E (corresponding author), McGill Univ, Dept Anat & Cell Biol, 3640 Univ St, Montreal, PQ H3A 2B2, Canada.		Liu, Jianfeng/E-2786-2012; chevet, eric/E-4992-2016; Lemaître, Gilles/AAL-5889-2021	chevet, eric/0000-0001-5855-4522; Lemaitre, Gilles/0000-0002-0898-1582				Alblas J, 1998, ONCOGENE, V16, P131, DOI 10.1038/sj.onc.1201485; Bikfalvi A, 1997, ENDOCR REV, V18, P26, DOI 10.1210/er.18.1.26; BLAIKIE P, 1994, J BIOL CHEM, V269, P32031; Cantrell D, 1998, TRENDS CELL BIOL, V8, P180, DOI 10.1016/S0962-8924(98)01264-1; DIGUGLIELMO GM, 1994, EMBO J, V13, P4269, DOI 10.1002/j.1460-2075.1994.tb06747.x; Fenig E, 1997, CLIN CANCER RES, V3, P135; GELMANN EP, 1992, INT J CANCER, V50, P665, DOI 10.1002/ijc.2910500431; Goh KC, 1996, J BIOL CHEM, V271, P5832, DOI 10.1074/jbc.271.10.5832; GOMM JJ, 1991, CANCER RES, V51, P4685; Hadari YR, 1998, MOL CELL BIOL, V18, P3966, DOI 10.1128/MCB.18.7.3966; JAYE M, 1986, SCIENCE, V233, P541, DOI 10.1126/science.3523756; Kanai M, 1997, J BIOL CHEM, V272, P6621, DOI 10.1074/jbc.272.10.6621; KAREY KP, 1988, CANCER RES, V48, P4083; KAVANAUGH WM, 1994, SCIENCE, V266, P1862, DOI 10.1126/science.7527937; Kerkhoff E, 1998, ONCOGENE, V16, P211, DOI 10.1038/sj.onc.1201520; KLINT P, 1995, J BIOL CHEM, V270, P23337, DOI 10.1074/jbc.270.40.23337; Kouhara H, 1997, CELL, V89, P693, DOI 10.1016/S0092-8674(00)80252-4; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Liu JF, 1998, EUR J BIOCHEM, V258, P271, DOI 10.1046/j.1432-1327.1998.2580271.x; MARAIS R, 1995, EMBO J, V14, P3136, DOI 10.1002/j.1460-2075.1995.tb07316.x; MCLESKEY SW, 1994, CANCER RES, V54, P523; MEDEMA RH, 1993, MOL CELL BIOL, V13, P155, DOI 10.1128/MCB.13.1.155; Migliaccio E, 1997, EMBO J, V16, P706, DOI 10.1093/emboj/16.4.706; MIYAMOTO M, 1993, MOL CELL BIOL, V13, P4251, DOI 10.1128/MCB.13.7.4251; Mohammadi M, 1996, CELL, V86, P577, DOI 10.1016/S0092-8674(00)80131-2; Mohammadi M, 1996, MOL CELL BIOL, V16, P977; Ohbayashi N, 1998, J BIOL CHEM, V273, P18161, DOI 10.1074/jbc.273.29.18161; Okada S, 1997, J BIOL CHEM, V272, P28042, DOI 10.1074/jbc.272.44.28042; Olson MF, 1998, NATURE, V394, P295, DOI 10.1038/28425; Ong SH, 1997, BIOCHEM BIOPH RES CO, V238, P261, DOI 10.1006/bbrc.1997.7272; Ong SH, 1996, BIOCHEM BIOPH RES CO, V225, P1021, DOI 10.1006/bbrc.1996.1288; QIU RG, 1995, NATURE, V374, P457, DOI 10.1038/374457a0; RABIN SJ, 1993, MOL CELL BIOL, V13, P2203, DOI 10.1128/MCB.13.4.2203; Roche S, 1996, EMBO J, V15, P4940, DOI 10.1002/j.1460-2075.1996.tb00874.x; Rockow S, 1996, ONCOGENE, V12, P2351; Rodrigues GA, 1997, EMBO J, V16, P2634, DOI 10.1093/emboj/16.10.2634; Roof RW, 1998, MOL CELL BIOL, V18, P7052, DOI 10.1128/MCB.18.12.7052; SOMMERS CL, 1990, CANCER RES, V50, P67; Stein E, 1998, J BIOL CHEM, V273, P1303, DOI 10.1074/jbc.273.3.1303; STEWART AJ, 1992, BRIT J CANCER, V66, P640, DOI 10.1038/bjc.1992.330; VAINIKKA S, 1994, J BIOL CHEM, V269, P18320; Wang HS, 1997, CANCER RES, V57, P1750; Wang JK, 1996, ONCOGENE, V13, P721; Yamasaki M, 1996, J BIOL CHEM, V271, P15918, DOI 10.1074/jbc.271.27.15918; YAYON A, 1991, CELL, V64, P841, DOI 10.1016/0092-8674(91)90512-W; Yiangou C, 1997, BRIT J CANCER, V75, P28, DOI 10.1038/bjc.1997.5; Zhang WG, 1998, CELL, V92, P83, DOI 10.1016/S0092-8674(00)80901-0	47	29	31	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 11	1999	18	47					6425	6433		10.1038/sj.onc.1203027	http://dx.doi.org/10.1038/sj.onc.1203027			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	256CW	10597244				2022-12-25	WOS:000083709200004
J	Barnouin, K; Fredersdorf, S; Eddaoudi, A; Mittnacht, S; Pan, LX; Du, MQ; Lu, X				Barnouin, K; Fredersdorf, S; Eddaoudi, A; Mittnacht, S; Pan, LX; Du, MQ; Lu, X			Antiproliferative function of p27(kip1) is frequently inhibited in highly malignant Burkitt's lymphoma cells	ONCOGENE			English	Article						D-type cyclin; cyclin dependant kinase; p27(kip1); cell cycle; Birkitt's lymphoma	DEPENDENT KINASE INHIBITOR; RETINOBLASTOMA PROTEIN; CDK INHIBITORS; MICE LACKING; CYCLE ARREST; TGF-BETA; INACTIVATION; EXPRESSION; GROWTH; HYPERPLASIA	Lack of detectable expression of p27(kip1) cyclin dependent kinase inhibitor has previously been correlated with high degree of malignancy in human breast, colorectal, gastric and smalt cell lung carcinomas. Here me demonstrate that an inverse correlation between p27(kip1) expression and tumour malignancy also exists in most types of human B cell lymphomas examined. A clear exception was Burkitt's lymphoma (BL), a highly malignant tumour which often expresses high levels of p27(kip1). Analysis of p27(kip1) derived from Burkitt's lymphoma cell lines expressing high levels of p27(kip1), BL40 and BL41, in a cyclin E/cdk2 kinase inhibition assay demonstrated that p27(kip1) is not permanently inactivated since heat treatment can restore the inhibitory activity of p27(kip1). However, p27(kip1) expressed in these two cell lines is largely sequestered in inactive complexes and me have no evidence that c-myc or Epstein-Barr virus are responsible for the sequestration of p27(kip1) in these two cell lines although c-myc and EBV are two oncogenic agents often associated with Burkitt's lymphomas. Interestingly, we observed that high level p27(kip1) expression often correlated,vith cyclin D3 overexpression both in vivo and in BL cell lines. The majority of p27(kip1) in BL40 cells was complexed with cyclin D3 indicating that overexpressed cyclin D3 may at least be part of the sequestering activity for the inhibitory function of p27(kip1). Furthermore, cyclinD3/cdk4 complex could sequester p27(kip1) in a cyclin E/cdk2 kinase assay in vitro. Finally, me show that cyclin D3 transfected into an inducible p27(kip1) cell line could overcome the G1 arrest mediated by p27(kip1). These results argue that in addition to down-regulation of p27(kip1) expression, some tumour cells can sequester and tolerate the antiproliferative function of p27(kip1), They also suggest a novel role for the overexpression of D-type cyclins as one pathway allowing tumour cells to overcome the antiproliferative function of p27(kip1).	St Marys Hosp, Imperial Coll, Sch Med, Ludwig Inst Canc Res, London W2 1PG, England; UCL, Sch Med, Dept Histopathol, London WC1E 6JJ, England; Inst Canc Res, London SW3 6JB, England; St Marys Hosp, Imperial Coll, Sch Med, Dept Med Microbiol, London W2 1PG, England	Imperial College London; Ludwig Institute for Cancer Research; University of London; University College London; UCL Medical School; Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK; Imperial College London	Lu, X (corresponding author), St Marys Hosp, Imperial Coll, Sch Med, Ludwig Inst Canc Res, Norfolk Pl, London W2 1PG, England.			Lu, Xin/0000-0002-6587-1152; Du, Ming-Qing/0000-0002-1017-5045; Eddaoudi, Ayad/0000-0001-5272-6426				Bartkova J, 1996, INT J CANCER, V65, P323, DOI 10.1002/(SICI)1097-0215(19960126)65:3<323::AID-IJC8>3.0.CO;2-1; Cheng MG, 1999, EMBO J, V18, P1571, DOI 10.1093/emboj/18.6.1571; ELLEDGE SJ, 1994, CURR OPIN CELL BIOL, V6, P847, DOI 10.1016/0955-0674(94)90055-8; Fero ML, 1996, CELL, V85, P733, DOI 10.1016/S0092-8674(00)81239-8; Fero ML, 1998, NATURE, V396, P177, DOI 10.1038/24179; FIRPO EJ, 1994, MOL CELL BIOL, V14, P4889, DOI 10.1128/MCB.14.7.4889; Fredersdorf S, 1997, P NATL ACAD SCI USA, V94, P6380, DOI 10.1073/pnas.94.12.6380; GoddenKent D, 1997, J VIROL, V71, P4193, DOI 10.1128/JVI.71.6.4193-4198.1997; Harlow E., 1988, ANTIBODIES LAB MANUA; Hsieh JK, 1997, GENE DEV, V11, P1840, DOI 10.1101/gad.11.14.1840; KATO JY, 1994, CELL, V79, P487, DOI 10.1016/0092-8674(94)90257-7; Kiyokawa H, 1996, CELL, V85, P721, DOI 10.1016/S0092-8674(00)81238-6; Lloyd RV, 1999, AM J PATHOL, V154, P313, DOI 10.1016/S0002-9440(10)65277-7; Mal A, 1996, NATURE, V380, P262, DOI 10.1038/380262a0; MATSUSHIME H, 1992, CELL, V71, P323, DOI 10.1016/0092-8674(92)90360-O; Muller D, 1997, ONCOGENE, V15, P2561, DOI 10.1038/sj.onc.1201440; Nakayama K, 1996, CELL, V85, P707, DOI 10.1016/S0092-8674(00)81237-4; NOURSE J, 1994, NATURE, V372, P570, DOI 10.1038/372570a0; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; Porter PL, 1997, NAT MED, V3, P222, DOI 10.1038/nm0297-222; REYNISDOTTIR I, 1995, GENE DEV, V9, P1831, DOI 10.1101/gad.9.15.1831; SanchezBeato M, 1997, AM J PATHOL, V151, P151; Sheaff RJ, 1997, GENE DEV, V11, P1464, DOI 10.1101/gad.11.11.1464; SINCLAIR AJ, 1995, METH MOL G, V7, P89; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; Vlach J, 1996, EMBO J, V15, P6595, DOI 10.1002/j.1460-2075.1996.tb01050.x; ZerfassThome K, 1996, ONCOGENE, V13, P2323	28	30	30	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 4	1999	18	46					6388	6397		10.1038/sj.onc.1203162	http://dx.doi.org/10.1038/sj.onc.1203162			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	260DK	10597239				2022-12-25	WOS:000083934100024
J	Corre, I; Baumann, H; Hermouet, S				Corre, I; Baumann, H; Hermouet, S			Regulation by G(i2) proteins of v-fms-induced proliferation and transformation via Src-kinase and STAT3	ONCOGENE			English	Article						CSF-1R; receptor tyrosine-kinases; G(i2); Src-kinase; ERK-MAPK; STAT3	TYROSINE KINASES; COUPLED RECEPTORS; PERTUSSIS TOXIN; CELL-PROLIFERATION; MEDIATED ACTIVATION; DIRECT STIMULATION; BINDING-PROTEIN; GROWTH-FACTORS; ALPHA-SUBUNIT; TGF-BETA	We previously showed that G(i2) proteins interfere with the transduction of CSF-1 receptor (CSF-1R) proliferation signals (Corre and Hermouet, 1995). To identify CSF-1R pathways controlled by G(i2), we transfected nu-fms, the oncogenic equivalent of CSF-IR, in NIH3T3 cells in which G(i2) proteins were inactivated by stably expressing a dominant negative mutant form of the alpha subunit of G(i2) (alpha(i2)-G204A). Expression of alpha(i2)-G204A resulted in decreased Src-kinase activity, delayed activation of p42 ERK-MAPK, decreased cyclin D1 expression and reduced proliferation in response to serum. In alpha(i2)-G204A cells transfected with nu-fms, Src-kinase activity remained deficient but p42 MAPK activity and cyclin D1 expression were similar to those of vector/nu-fms cells, suggesting that nu-fms bypasses Src to activate the ERK-MAPK cascade. However, DNA synthesis and focus formation were inhibited by up to 80% in alpha(i2)-G204A/nu-fms cells compared to vector/nu-fms cells. We found that tyrosine phosphorylation of STAT3, also activated by CSP-1R/nu-fms, was inhibited in alpha(i2)-G204A/nu-fms cells; in addition, expression of an 85 kDa, C-terminal truncated form of STAT3 (STAT3 Delta) was constitutively increased. Both the inhibition of v-fms-induced STAT3 tyrosine phosphorylation and the increased expression of STAT3 Delta were reproduced by transfecting a dominant negative mutant of Src. Last, we show that expression of STAT3 Delta 55C, a mutant form of STAT3 lacking the last 55 C-terminal amino acids, is sufficient to inhibit DNA synthesis and nu-fms-induced transformation in NIH3T3 cells. In summary, adequate regulation by G(i2) proteins of the activity of both Src-kinase and STAT3 is required for optimal cell proliferation in response to CSF-1R/nu-fms.	Inst Biol, INSERM, U463, Grp Cytokines Recepteurs & Transduct Signal, F-44093 Nantes, France; Roswell Pk Canc Inst, Dept Mol & Cellular Biol, Buffalo, NY 14263 USA	Institut National de la Sante et de la Recherche Medicale (Inserm); Roswell Park Cancer Institute	Hermouet, S (corresponding author), Inst Biol, INSERM, U463, Grp Cytokines Recepteurs & Transduct Signal, 9 Quai Moncousu, F-44093 Nantes, France.		Corre, Isabelle/L-2583-2015	CORRE, Isabelle/0000-0001-6444-1145				ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; BELKA C, 1995, LEUKEMIA, V9, P754; Bence K, 1997, NATURE, V389, P296, DOI 10.1038/38520; Campbell GS, 1997, J BIOL CHEM, V272, P2591, DOI 10.1074/jbc.272.5.2591; Cao XM, 1996, MOL CELL BIOL, V16, P1595; Chaturvedi P, 1998, ONCOGENE, V16, P1749, DOI 10.1038/sj.onc.1201972; CHEN YH, 1994, J BIOL CHEM, V269, P27372; Corre I, 1999, EXP HEMATOL, V27, P28, DOI 10.1016/S0301-472X(98)00032-0; CORRE I, 1995, BLOOD, V86, P1776, DOI 10.1182/blood.V86.5.1776.bloodjournal8651776; COURTNEIDGE SA, 1993, EMBO J, V12, P943, DOI 10.1002/j.1460-2075.1993.tb05735.x; CRESPO P, 1994, NATURE, V369, P418, DOI 10.1038/369418a0; Dhanasekaran N, 1998, ONCOGENE, V17, P1383, DOI 10.1038/sj.onc.1202242; Dikic I, 1996, NATURE, V383, P547, DOI 10.1038/383547a0; Fukada T, 1996, IMMUNITY, V5, P449, DOI 10.1016/S1074-7613(00)80501-4; Gutkind JS, 1998, J BIOL CHEM, V273, P1839, DOI 10.1074/jbc.273.4.1839; Gutkind JS, 1998, ONCOGENE, V17, P1331, DOI 10.1038/sj.onc.1202186; HE YX, 1988, BLOOD, V71, P1187; HERMOUET S, 1991, P NATL ACAD SCI USA, V88, P10455, DOI 10.1073/pnas.88.23.10455; IMAMURA K, 1988, J BIOL CHEM, V263, P14093; Kim HK, 1997, J BIOL CHEM, V272, P14571, DOI 10.1074/jbc.272.23.14571; KOYASU S, 1989, CELL STRUCT FUNCT, V14, P459; Kranenburg O, 1997, EMBO J, V16, P3097, DOI 10.1093/emboj/16.11.3097; LALLEMAIN G, 1991, CELL REGUL, V2, P675, DOI 10.1091/mbc.2.8.675; Lavoie JN, 1996, J BIOL CHEM, V271, P20608, DOI 10.1074/jbc.271.34.20608; Luttrell LM, 1996, J BIOL CHEM, V271, P19443, DOI 10.1074/jbc.271.32.19443; MAESTRONI GJM, 1994, EXP HEMATOL, V22, P313; MARRERO MB, 1995, NATURE, V375, P247, DOI 10.1038/375247a0; MAYANI H, 1995, EXP HEMATOL, V23, P422; MILLER BA, 1991, BLOOD, V77, P486; NOVAK U, 1995, BLOOD, V86, P2948, DOI 10.1182/blood.V86.8.2948.bloodjournal8682948; PAGES G, 1993, P NATL ACAD SCI USA, V90, P8319, DOI 10.1073/pnas.90.18.8319; ROCHE S, 1995, SCIENCE, V269, P1567, DOI 10.1126/science.7545311; ROCHE S, 1995, MOL CELL BIOL, V15, P1102; ROUSSEL MF, 1994, J CELL SCI, P105; TANIGUCHI T, 1995, SCIENCE, V268, P251, DOI 10.1126/science.7716517; VANBIESEN T, 1995, NATURE, V376, P781, DOI 10.1038/376781a0; Wan Y, 1996, NATURE, V380, P541, DOI 10.1038/380541a0; Wan Y, 1997, J BIOL CHEM, V272, P17209, DOI 10.1074/jbc.272.27.17209; WANG Y, IN PRESS HEPATOLOGY; WEN ZL, 1995, CELL, V82, P241, DOI 10.1016/0092-8674(95)90311-9; YEUNG YG, 1992, J BIOL CHEM, V267, P23447	41	33	34	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 4	1999	18	46					6335	6342		10.1038/sj.onc.1203010	http://dx.doi.org/10.1038/sj.onc.1203010			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	260DK	10597233				2022-12-25	WOS:000083934100018
J	Darbinian, N; Gallia, GL; Kundu, M; Shcherbik, N; Tretiakova, A; Giordano, A; Khalili, K				Darbinian, N; Gallia, GL; Kundu, M; Shcherbik, N; Tretiakova, A; Giordano, A; Khalili, K			Association of Pur alpha and E2F-1 suppresses transcriptional activity of E2F-1	ONCOGENE			English	Article						single-stranded DNA binding protein; Pur alpha; E2F-1; protein-protein interaction	SINGLE-STRANDED-DNA; CELLULAR PROTEINS YB-1; BINDING PROTEIN; RETINOBLASTOMA PROTEIN; CONTROL ELEMENT; TUMOR-ANTIGEN; CYCLE CONTROL; GENE; REPLICATION; COMPONENTS	Protein-protein interaction can play an important role in the control of several biological events including gene transcription, replication and cell proliferation. E2F-1 is a DNA-binding transcription factor which, upon interaction with its target DNA sequence, induces expression of several S phase specific genes allowing progression of the cell cycle. Evidently, the activity of this protein is modulated by its cellular partner, pRb, which in the hypophosphorylated form, binds to E2F-1 and inactivates its transcriptional ability. In this study, we have demonstrated that expression of a sequence-specific single-stranded DNA binding protein, Pur alpha, in cells decreases the ability of E2F-1 to exert its transcriptional activity upon the responsive promoter derived from DHFR, Results from band shift experiments revealed that while Pur alpha does not recognize the double-stranded DNA fragment containing the E2F-1 binding site, it has the ability to inhibit E2F-1 interaction with its target DNA sequence. Results from GST pull-down assays and the combined immunoprecipitation/Western blot analysis of nuclear extracts revealed a direct association of E2F-1 with Pur alpha in the absence of the DNA molecule containing the E2F-1 binding site, The association of Pur alpha with E2F-1 may increase the stability of E2F-1, as a higher level of E2F-1 was detected in cells coexpressing Pur alpha and E2F-1, The importance of these observations with respect to the role of Pur alpha in the control of cell cycle progression is discussed.	Med Coll Penn & Hahnemann Univ, Sch Med, Ctr Neurovirol & Neurooncol, Philadelphia, PA 19102 USA; Thomas Jefferson Univ, Dept Pathol Anat & Cell Biol, Sbarro Inst Canc Res, Philadelphia, PA 19107 USA	Drexel University; Jefferson University	Khalili, K (corresponding author), Med Coll Penn & Hahnemann Univ, Sch Med, Ctr Neurovirol & Neurooncol, 245 N 15th St,MS 406, Philadelphia, PA 19102 USA.		Kundu, Mondira/N-8139-2018; Giordano, Antonio/F-1927-2010	Kundu, Mondira/0000-0001-9946-2472; Giordano, Antonio/0000-0002-5959-016X				BERGEMANN AD, 1992, MOL CELL BIOL, V12, P1257, DOI 10.1128/MCB.12.3.1257; BERGEMANN AD, 1992, MOL CELL BIOL, V12, P5673, DOI 10.1128/MCB.12.12.5673; CHEN NN, 1995, P NATL ACAD SCI USA, V92, P1087, DOI 10.1073/pnas.92.4.1087; CHEN NN, 1995, J VIROL, V69, P5843, DOI 10.1128/JVI.69.9.5843-5848.1995; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; Du Q, 1997, J BIOL CHEM, V272, P14990, DOI 10.1074/jbc.272.23.14990; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HAAS S, 1995, J CELL BIOL, V130, P1171, DOI 10.1083/jcb.130.5.1171; JOHNSON EM, 1995, J BIOL CHEM, V270, P24352, DOI 10.1074/jbc.270.41.24352; Kelm RJ, 1997, J BIOL CHEM, V272, P26727, DOI 10.1074/jbc.272.42.26727; Krachmarov CP, 1996, P NATL ACAD SCI USA, V93, P14112, DOI 10.1073/pnas.93.24.14112; Kundu M, 1997, J BIOL CHEM, V272, P29468, DOI 10.1074/jbc.272.47.29468; LATHANGUE NB, 1994, CURR OPIN CELL BIOL, V6, P443, DOI 10.1016/0955-0674(94)90038-8; MA ZW, 1994, GENE, V149, P311, DOI 10.1016/0378-1119(94)90167-8; NEVINS JR, 1992, SCIENCE, V258, P424; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; Zambrano N, 1997, BIOCHEM J, V328, P293, DOI 10.1042/bj3280293	17	49	49	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 4	1999	18	46					6398	6402		10.1038/sj.onc.1203011	http://dx.doi.org/10.1038/sj.onc.1203011			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	260DK	10597240				2022-12-25	WOS:000083934100025
J	Bellocq, A; Doublier, S; Suberville, S; Perez, J; Escoubet, B; Fouqueray, B; Puyol, DR; Baud, L				Bellocq, A; Doublier, S; Suberville, S; Perez, J; Escoubet, B; Fouqueray, B; Puyol, DR; Baud, L			Somatostatin increases glucocorticoid binding and signaling in macrophages by blocking the calpain-specific cleavage of Hsp 90	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NITRIC-OXIDE SYNTHASE; HEAT-SHOCK PROTEINS; FACTOR NF-KAPPA; RECEPTOR EXPRESSION; MESSENGER-RNA; TERMINAL REGION; DNA-BINDING; TNF-ALPHA; IN-VIVO; ACTIVATION	Somatostatin has direct anti-inflammatory actions and participates in the anti-inflammatory actions of glucocorticoids, but the mechanisms underlying this regulation remain poorly understood, The objective of this study was to evaluate whether somatostatin increases glucocorticoid responsiveness by up-regulating glucocorticoid receptor (GR) expression and signaling. Somatostatin promoted a time- and dose-dependent increase in [H-3]dexamethasone binding to RAW 264.7 macrophages. Cell exposure to 10 nM somatostatin for 18 h promoted a 2-fold increase in the number of GR sites per cell without significant modification of the affinity. Analysis of GR heterocomplex components demonstrated that somatostatin increased the level of heat shock protein (Hsp) 90, whereas the level of GR remained almost unchanged. The increase in Hsp 90 was associated with a decrease in the cleavage of its carboxyl-terminal domain. Evidence for the involvement of calpain inhibition in this process was obtained by the demonstration that 1) somatostatin induced a dose-dependent decrease in calpain activity and 2) calpain inhibitors, calpain inhibitor I and calpain, both abolished the cleavage of Hsp 90 and induced a dose-dependent increase in [H-3]dexamethasone binding. Increases in glucocorticoid binding after somatostatin treatment were associated with similar increases in the ability of GR to transactivate a minimal promoter containing two glucocorticoid response elements (GRE) and to interfere with the activation of nuclear factor-kappa B (NF-kappa B), Thus, the present findings indicate that somatostatin increases glucocorticoid binding and signaling by limiting the calpain-specific cleavage of GR-associated Hsp 90, This mechanism may represent a novel target for intervention to increase glucocorticoid responsiveness.	Hop Tenon, INSERM, U489, F-75020 Paris, France; Univ Paris 07, INSERM, U426, Paris, France; Univ Alcala de Henares, Madrid, Spain; Hosp Principe Asturias, Madrid, Spain	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Tenon - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Universidad de Alcala; Prince of Asturias University Hospital	Baud, L (corresponding author), Hop Tenon, INSERM, U489, 4 Rue Chine, F-75020 Paris, France.	laurent.baud@tnn.ap-hop-paris.fr	Puyol, Diego Rodriguez/AAG-9752-2020	Puyol, Diego Rodriguez/0000-0002-9125-9311; BELLOCQ, Agnes/0000-0002-9297-7534				ADEYEMI EO, 1990, PEPTIDES, V11, P869, DOI 10.1016/0196-9781(90)90206-K; Ahmed AA, 1998, SCAND J IMMUNOL, V48, P79; Bellocq A, 1998, J BIOL CHEM, V273, P5086, DOI 10.1074/jbc.273.9.5086; BERMUDEZ LE, 1990, LYMPHOKINE RES, V9, P137; BERTRAND F, 1995, J BIOL CHEM, V270, P24435, DOI 10.1074/jbc.270.41.24435; BLUM AM, 1992, J IMMUNOL, V149, P3621; BRONK SF, 1993, AM J PHYSIOL, V264, pG744, DOI 10.1152/ajpgi.1993.264.4.G744; Bronnegard M, 1996, AM J RESP CRIT CARE, V154, pS28; CADEPOND F, 1991, J BIOL CHEM, V266, P5834; Cong M, 1998, J BIOL CHEM, V273, P660, DOI 10.1074/jbc.273.1.660; Costas M, 1996, J CLIN INVEST, V98, P1409, DOI 10.1172/JCI118928; CROALL DE, 1991, PHYSIOL REV, V71, P813, DOI 10.1152/physrev.1991.71.3.813; DESHPANDE RV, 1995, J BIOL CHEM, V270, P2497, DOI 10.1074/jbc.270.6.2497; Dittmar KD, 1997, J BIOL CHEM, V272, P21213, DOI 10.1074/jbc.272.34.21213; DONG Y, 1989, J BIOL CHEM, V264, P13679; Elliott DE, 1998, J IMMUNOL, V160, P3997; Escoubet B, 1996, AM J PHYSIOL-CELL PH, V270, pC1343, DOI 10.1152/ajpcell.1996.270.5.C1343; Griscavage JM, 1996, P NATL ACAD SCI USA, V93, P3308, DOI 10.1073/pnas.93.8.3308; HONG DH, 1995, MOL CELL ENDOCRINOL, V108, P199, DOI 10.1016/0303-7207(95)03476-N; KAM JC, 1993, J IMMUNOL, V151, P3460; Kang KI, 1999, P NATL ACAD SCI USA, V96, P1439, DOI 10.1073/pnas.96.4.1439; KARALIS K, 1994, J CLIN INVEST, V93, P2000, DOI 10.1172/JCI117193; KARALIS K, 1995, ENDOCRINOLOGY, V136, P4133, DOI 10.1210/en.136.9.4133; Karin M, 1998, CELL, V93, P487, DOI 10.1016/S0092-8674(00)81177-0; Kimura Y, 1998, NAT MED, V4, P915, DOI 10.1038/nm0898-915; KRAMER TH, 1989, J PHARMACOL EXP THER, V249, P544; LEROMANCER M, 1994, J BIOL CHEM, V269, P17464; MINAMI Y, 1994, MOL CELL BIOL, V14, P1459, DOI 10.1128/MCB.14.2.1459; MINAMI Y, 1993, J BIOL CHEM, V268, P9604; MOORE SK, 1989, J BIOL CHEM, V264, P5343; Patel YC, 1997, TRENDS ENDOCRIN MET, V8, P398, DOI 10.1016/S1043-2760(97)00168-9; PRATT WB, 1993, J BIOL CHEM, V268, P21455; Pratt WB, 1997, ENDOCR REV, V18, P306, DOI 10.1210/er.18.3.306; REICHLIN S, 1983, NEW ENGL J MED, V309, P1495, DOI 10.1056/NEJM198312153092406; REICHLIN S, 1983, NEW ENGL J MED, V309, P1556, DOI 10.1056/NEJM198312223092506; SALKOWSKI CA, 1992, J IMMUNOL, V149, P4041; SCHEINMAN RI, 1995, SCIENCE, V270, P283, DOI 10.1126/science.270.5234.283; SELDEN RF, 1996, CURRENT PROTOCOLS MO; Spahn JD, 1996, J IMMUNOL, V157, P2654; SQUIER MKT, 1994, J CELL PHYSIOL, V159, P229, DOI 10.1002/jcp.1041590206; SREEDHARAN SP, 1989, J BIOL CHEM, V264, P949; Tanaka Y, 1995, CURR EYE RES, V14, P1125, DOI 10.3109/02713689508995819; Verheggen MM, 1996, EUR RESPIR J, V9, P2036, DOI 10.1183/09031936.96.09102036; Walker G, 1997, J BIOL CHEM, V272, P16679, DOI 10.1074/jbc.272.26.16679; WANG KKW, 1989, BIOCHEM J, V262, P693, DOI 10.1042/bj2620693; Warriar N, 1996, J BIOL CHEM, V271, P18662, DOI 10.1074/jbc.271.31.18662; ZABEL U, 1991, J BIOL CHEM, V266, P252	47	39	41	0	3	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 24	1999	274	52					36891	36896		10.1074/jbc.274.52.36891	http://dx.doi.org/10.1074/jbc.274.52.36891			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	267WR	10601241	hybrid			2022-12-25	WOS:000084382700012
J	Teng, KK; Esposito, DK; Schwartz, GD; Lander, HM; Hempstead, BL				Teng, KK; Esposito, DK; Schwartz, GD; Lander, HM; Hempstead, BL			Activation of c-Ha-Ras by nitric oxide modulates survival responsiveness in neuronal PC12 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NERVE GROWTH-FACTOR; KINASE PHOSPHORYLATION; PHEOCHROMOCYTOMA CELLS; REDOX REGULATION; DIFFERENTIATION; PROTEIN; PATHWAY; APOPTOSIS; P21(RAS); SUPPRESSION	p21(c-Ha-Ras) (Bas) can be activated by the guanine nucleotide exchange factor mSOS1 or by S-nitrosylation of cysteine 118 via nitric oxide (NO), To determine whether these two Ras-activating mechanisms modulate distinct biological effects, a NO-nonresponsive Ras mutant (Ras(C118S)) was stably expressed in the PC12 cells, a cell line that generates NO upon nerve growth-factor treatment, We report here that RasC118S functions indistinguishably from wild type Ras in activating and maintaining the mSOS1- and Raf-1-dependent mitogen-activated protein kinase cascade necessary for neuronal differentiation. However, continuous (>5 days) exposure to nerve growth factor reveals that, in contrast to parental or wild-type Ras-overexpressing PC12 cells, Ras(C118S)-expressing PC12 cells cannot sustain the basal interaction between Ras and phosphatidylinositol 3-kinase, This results in spontaneous apoptosis of these cells despite the presence of nerve growth factor and serum. Thus unique downstream effector interactions and biological outcomes can be differentially modulated by distinct modes of Bas activation.	Cornell Univ, Weill Med Coll, Dept Med, Div Hematol & Oncol, New York, NY 10021 USA; Cornell Univ, Weill Med Coll, Dept Biochem, New York, NY 10021 USA	Cornell University; Cornell University	Hempstead, BL (corresponding author), Cornell Univ, Weill Med Coll, Dept Med, Div Hematol Oncol, Rm C-606,1300 York Ave, New York, NY 10021 USA.	blhempst@mail.med.cornell.edu		Teng, Kenneth/0000-0002-9392-2172	PHS HHS [N530687] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Aleryani S, 1998, J BIOL CHEM, V273, P6041, DOI 10.1074/jbc.273.11.6041; BARSAGI D, 1985, CELL, V42, P841, DOI 10.1016/0092-8674(85)90280-6; BORASIO GD, 1993, J CELL BIOL, V121, P665, DOI 10.1083/jcb.121.3.665; Bos JL, 1998, EMBO J, V17, P6776, DOI 10.1093/emboj/17.23.6776; BREDT DS, 1994, ANNU REV BIOCHEM, V63, P175, DOI 10.1146/annurev.bi.63.070194.001135; BUDAY L, 1995, ONCOGENE, V11, P1327; CorbalanGarcia S, 1996, MOL CELL BIOL, V16, P5674; DAWSON TM, 1991, P NATL ACAD SCI USA, V88, P7797, DOI 10.1073/pnas.88.17.7797; Denhardt DT, 1996, BIOCHEM J, V318, P729, DOI 10.1042/bj3180729; Deora AA, 1998, J BIOL CHEM, V273, P29923, DOI 10.1074/jbc.273.45.29923; Dudek H, 1997, SCIENCE, V275, P661, DOI 10.1126/science.275.5300.661; Duhe RJ, 1998, P NATL ACAD SCI USA, V95, P126, DOI 10.1073/pnas.95.1.126; Foschi M, 1997, EMBO J, V16, P6439, DOI 10.1093/emboj/16.21.6439; GarciaCardena G, 1997, J BIOL CHEM, V272, P25437, DOI 10.1074/jbc.272.41.25437; GREENE LA, 1978, J CELL BIOL, V78, P747, DOI 10.1083/jcb.78.3.747; GREENE LA, 1995, CURR OPIN NEUROBIOL, V5, P579, DOI 10.1016/0959-4388(95)80062-X; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; HEMPSTEAD BL, 1992, NEURON, V9, P883, DOI 10.1016/0896-6273(92)90241-5; Irani K, 1997, SCIENCE, V275, P1649, DOI 10.1126/science.275.5306.1649; KauffmanZeh A, 1997, NATURE, V385, P544, DOI 10.1038/385544a0; Kim YM, 1998, J BIOL CHEM, V273, P31437, DOI 10.1074/jbc.273.47.31437; Kjeldgaard M, 1996, FASEB J, V10, P1347, DOI 10.1096/fasebj.10.12.8903506; Lander HM, 1996, NATURE, V381, P380, DOI 10.1038/381380a0; LANDER HM, 1995, J BIOL CHEM, V270, P21195, DOI 10.1074/jbc.270.36.21195; Lewin GR, 1996, ANNU REV NEUROSCI, V19, P289, DOI 10.1146/annurev.ne.19.030196.001445; LIPTON SA, 1993, NATURE, V364, P626, DOI 10.1038/364626a0; Mott HR, 1997, BIOCHEMISTRY-US, V36, P3640, DOI 10.1021/bi962790o; MUTOH T, 1988, J BIOL CHEM, V263, P15853; NODA M, 1985, NATURE, V318, P73, DOI 10.1038/318073a0; PAN ZH, 1993, J NEUROCHEM, V61, P1713, DOI 10.1111/j.1471-4159.1993.tb09808.x; PEUNOVA N, 1995, NATURE, V375, P68, DOI 10.1038/375068a0; Poluha W, 1997, J BIOL CHEM, V272, P24002, DOI 10.1074/jbc.272.38.24002; QIU MS, 1992, NEURON, V9, P705, DOI 10.1016/0896-6273(92)90033-A; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; RodriguezViciana P, 1996, EMBO J, V15, P2442, DOI 10.1002/j.1460-2075.1996.tb00602.x; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; RYDEL RE, 1987, J NEUROSCI, V7, P3639; Segal RA, 1996, ANNU REV NEUROSCI, V19, P463, DOI 10.1146/annurev.ne.19.030196.002335; Song KS, 1996, J BIOL CHEM, V271, P9690, DOI 10.1074/jbc.271.16.9690; Stamler J S, 1995, Curr Top Microbiol Immunol, V196, P19; Stamler JS, 1997, NEURON, V18, P691, DOI 10.1016/S0896-6273(00)80310-4; SUNDARESAN M, 1995, SCIENCE, V270, P296, DOI 10.1126/science.270.5234.296; SZEBERENYI J, 1990, MOL CELL BIOL, V10, P5324, DOI 10.1128/MCB.10.10.5324; TENG KK, 1995, J BIOL CHEM, V270, P20677, DOI 10.1074/jbc.270.35.20677; Therrien M, 1998, CELL, V95, P343, DOI 10.1016/S0092-8674(00)81766-3; Vojtek AB, 1998, J BIOL CHEM, V273, P19925, DOI 10.1074/jbc.273.32.19925; WARNE PH, 1993, NATURE, V364, P352, DOI 10.1038/364352a0; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; YAO RJ, 1995, SCIENCE, V267, P2003, DOI 10.1126/science.7701324; Yun HY, 1998, P NATL ACAD SCI USA, V95, P5773, DOI 10.1073/pnas.95.10.5773	50	42	42	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 24	1999	274	52					37315	37320		10.1074/jbc.274.52.37315	http://dx.doi.org/10.1074/jbc.274.52.37315			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	267WR	10601298	hybrid			2022-12-25	WOS:000084382700069
J	Bilcock, DT; Daniels, LE; Bath, AJ; Halford, SE				Bilcock, DT; Daniels, LE; Bath, AJ; Halford, SE			Reactions of type II restriction endonucleases with 8-base pair recognition sites	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA CLEAVAGE; SUPERCOILED DNA; SFII; ECORII; SEQUENCES; RECOMBINATION; RESOLVASE; SYSTEMS	Type II restriction endonucleases usually recognize 4-6-base pair (bp) sites on DNA and cleave each site in a separate reaction. A few type II endonucleases have 8-bp recognition sites, but these seem unsuited for restriction, since their sites are rare on most DNA. Moreover, only one endonuclease that recognizes a target containing 8 bp has been examined to date, and this enzyme, SfiI, needs two copies of this site for its DNA cleavage reaction. In this study, several endonucleases with 8-bp sites were tested on plasmids that have either one or two copies of the relevant sequence to determine if they also need two sites. SgfI, SrfI, FseI, PacI, PmeI, Sse8781I, and SdaI all acted through equal and independent reactions at each site. Asci cleaved the DNA with one site at the same rate as that with two sites but acted processively on the latter. In contrast, SgrAI. showed a marked preference for the plasmid with two sites and cleaved both sites on this DNA in a concerted manner, like SfiI. Endonucleases that require two copies of an 8-bp sequence may be widespread in nature, where, despite this seemingly inappropriate requirement, they may function in DNA restriction.	Univ Bristol, Sch Med Sci, Dept Biochem, Bristol BS8 1TD, Avon, England	University of Bristol	Halford, SE (corresponding author), Univ Bristol, Sch Med Sci, Dept Biochem, Univ Walk, Bristol BS8 1TD, Avon, England.	s.halford@bris.ac.uk						Baldwin GS, 1999, J MOL BIOL, V288, P87, DOI 10.1006/jmbi.1999.2672; BAXTER BK, 1993, BIOCHEMISTRY-US, V32, P8291, DOI 10.1021/bi00083a033; Bilcock DT, 1999, MOL MICROBIOL, V31, P1243, DOI 10.1046/j.1365-2958.1999.01266.x; Bozic D, 1996, J MOL BIOL, V255, P176, DOI 10.1006/jmbi.1996.0015; Cao WG, 1999, BIOCHEMISTRY-US, V38, P8080, DOI 10.1021/bi9903796; CONRAD M, 1992, NUCLEIC ACIDS RES, V20, P5127, DOI 10.1093/nar/20.19.5127; Dorner LF, 1999, J MOL BIOL, V285, P1515, DOI 10.1006/jmbi.1998.2408; Embleton ML, 1999, J MOL BIOL, V289, P785, DOI 10.1006/jmbi.1999.2822; Erskine SG, 1997, BIOCHEMISTRY-US, V36, P7567, DOI 10.1021/bi970155s; GABBARA S, 1992, J BIOL CHEM, V267, P18623; GRASBY JA, 1992, BIOCHEMISTRY-US, V31, P7855, DOI 10.1021/bi00149a016; Gutfreund H, 1995, KINETICS LIFE SCI; Halford S E, 1994, Methods Mol Biol, V30, P385; HALFORD SE, 1980, BIOCHEM J, V191, P581, DOI 10.1042/bj1910581; Hallet B, 1997, FEMS MICROBIOL REV, V21, P157, DOI 10.1016/S0168-6445(97)00055-7; Horton JR, 1998, J MOL BIOL, V284, P1491, DOI 10.1006/jmbi.1998.2269; Jian HM, 1998, J MOL BIOL, V284, P287, DOI 10.1006/jmbi.1998.2170; KELLEHER JE, 1994, J BACTERIOL, V176, P5888, DOI 10.1128/jb.176.19.5888-5896.1994; KOBAYASHI I, 1996, EPIGENETIC MECH GENE, P155; KRUGER DH, 1988, NUCLEIC ACIDS RES, V16, P3997; MAXWELL A, 1980, BIOCHEM J, V203, P85; MEISEL A, 1992, NATURE, V355, P467, DOI 10.1038/355467a0; Mizuuchi K, 1999, BIOCHEMISTRY-US, V38, P4640, DOI 10.1021/bi990054p; NAITO T, 1995, SCIENCE, V267, P897, DOI 10.1126/science.7846533; Nobbs TJ, 1998, BIOL CHEM, V379, P599; NOBBS TJ, 1995, J MOL BIOL, V252, P399, DOI 10.1006/jmbi.1995.0506; Nobbs TJ, 1998, J MOL BIOL, V281, P419, DOI 10.1006/jmbi.1998.1966; Oram M, 1997, J MOL BIOL, V270, P396, DOI 10.1006/jmbi.1997.1109; Panne D, 1999, J MOL BIOL, V290, P49, DOI 10.1006/jmbi.1999.2894; PEIN CD, 1991, NUCLEIC ACIDS RES, V19, P5139, DOI 10.1093/nar/19.19.5139; QIANG BQ, 1987, METHOD ENZYMOL, V155, P15; QIANG BQ, 1984, NUCLEIC ACIDS RES, V12, P4507, DOI 10.1093/nar/12.11.4507; Reuter M, 1998, J BIOL CHEM, V273, P8294, DOI 10.1074/jbc.273.14.8294; RIPPE K, 1995, TRENDS BIOCHEM SCI, V20, P500, DOI 10.1016/S0968-0004(00)89117-3; Roberts R, 1993, NUCLEASES, P35; Roberts RJ, 1999, NUCLEIC ACIDS RES, V27, P312, DOI 10.1093/nar/27.1.312; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Sasnauskas G, 1999, BIOCHEMISTRY-US, V38, P4028, DOI 10.1021/bi982456n; Siksnys V, 1999, J MOL BIOL, V291, P1105, DOI 10.1006/jmbi.1999.2977; Szczelkun MD, 1996, EMBO J, V15, P6335, DOI 10.1002/j.1460-2075.1996.tb01023.x; Szczelkun MD, 1996, EMBO J, V15, P1460, DOI 10.1002/j.1460-2075.1996.tb00488.x; TAYLOR JD, 1992, BIOCHEMISTRY-US, V28, P6198; Terry B J, 1987, Gene Amplif Anal, V5, P103; TERRY BJ, 1985, J BIOL CHEM, V260, P3130; THOMAS M, 1975, J MOL BIOL, V91, P315, DOI 10.1016/0022-2836(75)90383-6; TWIGG AJ, 1980, NATURE, V283, P216, DOI 10.1038/283216a0; WENTZELL LM, 1995, J MOL BIOL, V248, P581, DOI 10.1006/jmbi.1995.0244; Wentzell LM, 1998, J MOL BIOL, V281, P433, DOI 10.1006/jmbi.1998.1967; WILSON GG, 1991, ANNU REV GENET, V25, P585, DOI 10.1146/annurev.ge.25.120191.003101; YANG CC, 1992, BIOCHEMISTRY-US, V31, P9657, DOI 10.1021/bi00155a019; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9	51	49	57	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 17	1999	274	51					36379	36386		10.1074/jbc.274.51.36379	http://dx.doi.org/10.1074/jbc.274.51.36379			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	266AV	10593932	hybrid			2022-12-25	WOS:000084279200051
J	Akamatsu, M; Aota, S; Suwa, A; Ueda, K; Amachi, T; Yamada, KM; Akiyama, SK; Kioka, N				Akamatsu, M; Aota, S; Suwa, A; Ueda, K; Amachi, T; Yamada, KM; Akiyama, SK; Kioka, N			Vinexin forms a signaling complex with Sos and modulates epidermal growth factor-induced c-Jun N-terminal kinase/stress-activated protein kinase activities	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR TYROSINE KINASES; GUANINE-NUCLEOTIDE EXCHANGE; PDGF-BETA-RECEPTORS; INSULIN-RECEPTOR; SH3 DOMAIN; CELL-ADHESION; STRESS FIBERS; EGF RECEPTOR; FACTOR HSOS1; RAS	Vinexin, a novel protein that plays a hey role in cell spreading and cytoskeletal organization, contains three SH3 domains and binds to vinculin through its first and second SH3 domains. We show here that the third SH3 domain binds to Sos, a guanine nucleotide exchange factor for Pas and Pac, both in vitro and in vivo. Point mutations in the third SH3 domain abolished the vinexin-Sos interaction. Stimulation of NIH/3T3 cells with serum, epidermal growth factor (EGF), or platelet derived growth factor (PDGF) decreased the electro phoretic mobility of Sos and concomitantly inhibited formation of the vinexin-Sos complex. Phosphatase treatment of lysates restored the binding of Sos to vinexin, suggesting that signaling from serum, EGF, or PDGF regulates the vinexin-Sos complex through the Sos phosphorylation. To evaluate the function of vinexin downstream of growth factors, we examined the effects of wild-type and mutant vinexin expression on extracellular signal-regulated kinase (Erk) and c-Jun N-terminal kinase/stress activated protein kinase (JNK/SAPK) activation in response to EGF. Exogenous expression of vinexin beta in NIH/3T3 cells enhanced JNK/SAPK activation but did not affect Erk activation. Moreover mutations in the third SH3 domain abolished EGF activation of JNK/SAPK in a dominant-negative fashion, whereas they slightly stimulated Erk. Together these results suggest that vinexin can selectively modulate EGF-induced signal transduction pathways leading to JNK/SAPK kinase activation.	Kyoto Univ, Grad Sch Agr, Div Appl Life Sci, Sakyo Ku, Kyoto 6068502, Japan; Biomol Engn Res Inst, Suita, Osaka 565, Japan; NIDCR, Craniofacial Dev Biol & Regenerat Branch, NIH, Bethesda, MD 20892 USA; NIEHS, Mol Carcinogenesis Lab, NIH, Res Triangle Pk, NC 27709 USA	Kyoto University; National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR); National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)	Kioka, N (corresponding author), Kyoto Univ, Grad Sch Agr, Div Appl Life Sci, Sakyo Ku, Kyoto 6068502, Japan.	nkioka@kais.kyoto-u.ac.jp		Kioka, Noriyuki/0000-0002-2708-537X; Ueda, Kazumitsu/0000-0003-2980-6078; Yamada, Kenneth/0000-0003-1512-6805	NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [ZIADE000525, ZIADE000524] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [Z01DE000525, Z01DE000524] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [ZIAES023025, Z01ES023025] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Atfi A, 1997, J BIOL CHEM, V272, P1429, DOI 10.1074/jbc.272.3.1429; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; BURRIDGE K, 1989, BIOESSAYS, V10, P104, DOI 10.1002/bies.950100403; CHARDIN P, 1993, SCIENCE, V260, P1338, DOI 10.1126/science.8493579; Chen D, 1996, J BIOL CHEM, V271, P6328, DOI 10.1074/jbc.271.11.6328; CHERNIACK AD, 1995, J BIOL CHEM, V270, P1485, DOI 10.1074/jbc.270.4.1485; CorbalanGarcia S, 1996, MOL CELL BIOL, V16, P5674; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; CREWS CM, 1993, CELL, V74, P215, DOI 10.1016/0092-8674(93)90411-I; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; FEIG LA, 1993, SCIENCE, V260, P767, DOI 10.1126/science.8484117; FELLER SM, 1994, TRENDS BIOCHEM SCI, V19, P453, DOI 10.1016/0968-0004(94)90129-5; FELLER SM, 1995, ONCOGENE, V10, P1465; GALE NW, 1993, NATURE, V363, P88, DOI 10.1038/363088a0; Gu JG, 1998, J CELL BIOL, V143, P1375, DOI 10.1083/jcb.143.5.1375; HU QJ, 1995, MOL CELL BIOL, V15, P1169; Kioka N, 1999, J CELL BIOL, V144, P59, DOI 10.1083/jcb.144.1.59; KLEMKE RL, 1994, J CELL BIOL, V127, P859, DOI 10.1083/jcb.127.3.859; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; LIM WA, 1994, NAT STRUCT BIOL, V1, P221, DOI 10.1038/nsb0494-221; Lin TH, 1997, J BIOL CHEM, V272, P8849; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; Mainiero F, 1996, J CELL BIOL, V134, P241, DOI 10.1083/jcb.134.1.241; Mandai K, 1999, J CELL BIOL, V144, P1001, DOI 10.1083/jcb.144.5.1001; MATSUDA M, 1994, MOL CELL BIOL, V14, P5495, DOI 10.1128/MCB.14.8.5495; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; MIYAMOTO S, 1995, J CELL BIOL, V131, P791, DOI 10.1083/jcb.131.3.791; Miyamoto S, 1996, J CELL BIOL, V135, P1633, DOI 10.1083/jcb.135.6.1633; Moro L, 1998, EMBO J, V17, P6622, DOI 10.1093/emboj/17.22.6622; Nimnual AS, 1998, SCIENCE, V279, P560, DOI 10.1126/science.279.5350.560; Okada S, 1996, J BIOL CHEM, V271, P25533, DOI 10.1074/jbc.271.41.25533; PLOPPER GE, 1995, MOL BIOL CELL, V6, P1349, DOI 10.1091/mbc.6.10.1349; Porfiri E, 1996, J BIOL CHEM, V271, P5871, DOI 10.1074/jbc.271.10.5871; Renshaw MW, 1997, EMBO J, V16, P5592, DOI 10.1093/emboj/16.18.5592; Ribon V, 1998, MOL CELL BIOL, V18, P872, DOI 10.1128/MCB.18.2.872; Ribon V, 1998, J BIOL CHEM, V273, P4073, DOI 10.1074/jbc.273.7.4073; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; SAKAI R, 1994, EMBO J, V13, P3748, DOI 10.1002/j.1460-2075.1994.tb06684.x; Schneller M, 1997, EMBO J, V16, P5600, DOI 10.1093/emboj/16.18.5600; SKOLNIK EY, 1993, SCIENCE, V260, P1953, DOI 10.1126/science.8316835; Soldi R, 1999, EMBO J, V18, P882, DOI 10.1093/emboj/18.4.882; Sparks AB, 1996, NAT BIOTECHNOL, V14, P741, DOI 10.1038/nbt0696-741; Sundberg C, 1996, J CELL BIOL, V132, P741, DOI 10.1083/jcb.132.4.741; VUORI K, 1994, SCIENCE, V266, P1576, DOI 10.1126/science.7527156; Wang BL, 1997, J BIOL CHEM, V272, P17542, DOI 10.1074/jbc.272.28.17542; WATERS SB, 1995, MOL CELL BIOL, V15, P2791; Yamada KM, 1997, CURR OPIN CELL BIOL, V9, P76, DOI 10.1016/S0955-0674(97)80155-X; Zhao H, 1998, J BIOL CHEM, V273, P12061, DOI 10.1074/jbc.273.20.12061	48	43	44	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 10	1999	274	50					35933	35937		10.1074/jbc.274.50.35933	http://dx.doi.org/10.1074/jbc.274.50.35933			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	264NG	10585480	hybrid			2022-12-25	WOS:000084187900092
J	Delfino, FJ; Walker, WH				Delfino, FJ; Walker, WH			NF-kappa B induces cAMP-response element-binding protein gene transcription in Sertoli cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FOLLICLE-STIMULATING-HORMONE; NECROSIS-FACTOR-ALPHA; V-REL ONCOGENE; SPERMATOGENIC CELLS; CREB; EXPRESSION; ACTIVATION; APOPTOSIS; TESTIS; P65	Spermatogenesis is dependent upon Sertoli cells, which relay hormonal signals and provide factors required for the differentiation and proliferation of germ cells. NF-kappa B transcription factors are constitutively expressed in the nuclei of Sertoli cells in rodent testis. Electrophoretic mobility shift assays demonstrated that Sertoli NF-kappa B proteins specifically bind to kappa B enhancer motifs within the promoter of the cAMP-response element-binding protein (CREB) gene, an important mediator of hormonal signals that control spermatogenesis. Overexpression of NF-kappa B proteins in primary Sertoli and NIH 3T3 fibroblast cells induced the CREB promoter in transient transfection assays. Stimulation of Sertoli cells with tumor necrosis factor-alpha, an NF-kappa B-activating cytokine produced by round spermatids located adjacent to Sertoli cells, stimulated the elimination of I kappa B, the translocation of additional NF-kappa B to the nucleus, and increased NF-kappa B binding to CREB promoter kappa B enhancer elements. Tumor necrosis factor-alpha also stimulated transcription from the CREB promoter. These data demonstrate that NF-kappa B contributes to the up-regulation of CREB expression in Sertoli cells and raises the possibility that MF-kappa B may induce other Sertoli genes required for spermatogenesis. Furthermore, the CREB promoter is also inducible by NF-kappa B in MH 3T3 cells suggesting that NF-kappa B may be a general regulator of CREB in non-testis tissues.	Univ Pittsburgh, Dept Cell Biol & Physiol, Pittsburgh, PA 15261 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Walker, WH (corresponding author), Univ Pittsburgh, Dept Cell Biol & Physiol, S333 Biomed Sci Tower, Pittsburgh, PA 15261 USA.				EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [K02HD001206, R29HD034913] Funding Source: NIH RePORTER; NICHD NIH HHS [K02-HD01206, R29-HD34913] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ANDERSSON S, 1989, J BIOL CHEM, V264, P822; ANTWERP DJV, 1996, SCIENCE, V274, P787; BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; BALLARD DW, 1990, CELL, V63, P803, DOI 10.1016/0092-8674(90)90146-6; BALLARD DW, 1992, P NATL ACAD SCI USA, V89, P1875, DOI 10.1073/pnas.89.5.1875; BARTKE A, 1995, ENDOCRINOLOGY, V136, P3, DOI 10.1210/en.136.1.3; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; BELLVE AR, 1977, J HISTOCHEM CYTOCHEM, V25, P480, DOI 10.1177/25.7.893996; CHAPIN RE, 1987, J ANDROL, V8, P155; CHEN WJ, 1991, CELL, V66, P327, DOI 10.1016/0092-8674(91)90622-6; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; DE SK, 1993, ENDOCRINOLOGY, V133, P389, DOI 10.1210/en.133.1.389; DEKRETSER DM, 1995, ENDORNINOLOGY, V3, P2307; Delfino F, 1998, MOL ENDOCRINOL, V12, P1696, DOI 10.1210/me.12.11.1696; Gerritsen ME, 1997, P NATL ACAD SCI USA, V94, P2927, DOI 10.1073/pnas.94.7.2927; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; Mauduit C, 1996, BIOCHEM BIOPH RES CO, V224, P631, DOI 10.1006/bbrc.1996.1077; NAUMANN M, 1994, EMBO J, V13, P4597, DOI 10.1002/j.1460-2075.1994.tb06781.x; Rodriguez I, 1997, EMBO J, V16, P2262, DOI 10.1093/emboj/16.9.2262; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; Sharpe Richard M., 1994, P1363; SIEBENLIST U, 1994, ANNU REV CELL BIOL, V10, P405, DOI 10.1146/annurev.cb.10.110194.002201; STEIN B, 1993, EMBO J, V12, P3879, DOI 10.1002/j.1460-2075.1993.tb06066.x; STEIN B, 1993, MOL CELL BIOL, V13, P3964, DOI 10.1128/MCB.13.7.3964; THOMPSON JE, 1995, CELL, V80, P573, DOI 10.1016/0092-8674(95)90511-1; VERMA IM, 1995, GENE DEV, V9, P2723, DOI 10.1101/gad.9.22.2723; WAEBER G, 1991, MOL ENDOCRINOL, V5, P1418, DOI 10.1210/mend-5-10-1418; WALKER WH, 1995, ENDOCRINOLOGY, V136, P3534, DOI 10.1210/en.136.8.3534; WALKER WH, 1992, J VIROL, V66, P5018, DOI 10.1128/JVI.66.8.5018-5029.1992; Walker WH, 1996, TRENDS ENDOCRIN MET, V7, P133, DOI 10.1016/1043-2760(96)00035-5; Walker WH, 1998, MOL CELL ENDOCRINOL, V143, P167, DOI 10.1016/S0303-7207(98)00082-3; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; WEST AP, 1994, BIOL REPROD, V50, P869, DOI 10.1095/biolreprod50.4.869; Zhong HH, 1998, MOL CELL, V1, P661, DOI 10.1016/S1097-2765(00)80066-0	36	34	36	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 10	1999	274	50					35607	35613		10.1074/jbc.274.50.35607	http://dx.doi.org/10.1074/jbc.274.50.35607			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	264NG	10585438	hybrid			2022-12-25	WOS:000084187900050
J	Martins, LO; Empadinhas, N; Marugg, JD; Miguel, C; Ferreira, C; da Costa, MS; Santos, H				Martins, LO; Empadinhas, N; Marugg, JD; Miguel, C; Ferreira, C; da Costa, MS; Santos, H			Biosynthesis of mannosylglycerate in the thermophilic bacterium Rhodothermus marinus - Biochemical and genetic characterization of a mannosylglycerate synthase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MYO-INOSITOL-PHOSPHATE; HYPERTHERMOPHILIC ARCHAEA; ESCHERICHIA-COLI; GLUCOSYLGLYCEROL SYNTHESIS; COMPATIBLE SOLUTES; PYROCOCCUS-WOESEI; DI-MYO-INOSITOL-1,1'-PHOSPHATE; SEQUENCE; PROTEIN; 2,3-CYCLOPYROPHOSPHOGLYCERATE	The biosynthetic reaction scheme for the compatible solute mannosylglycerate in Rhodothermus marinus is proposed based on measurements of the relevant enzymatic activities in cell-free extracts and in vivo C-13 labeling experiments. The synthesis of mannosylglycerate proceeded via two alternative pathways; in one of them, GDP mannose was condensed with D-glycerate to produce mannosylglycerate in a single reaction catalyzed by mannosylglycerate synthase, in the other pathway, a mannosyl-3-phosphoglycerate synthase catalyzed the conversion of GDP mannose and D-3-phosphoglycerate into a phosphorylated intermediate, which was subsequently converted to mannosylglycerate by the action of a phosphatase. The enzyme activities committed to the synthesis of mannosylglycerate were not influenced by the NaCl concentration in the growth medium, However, the combined mannosyl-3-phosphoglycerate synthase/phosphatase system required the addition of NaCl or KCl to the assay mixture for optimal activity. The mannosylglycerate synthase enzyme was purified and characterized. Based on partial sequence information, the corresponding mgs gene was identified from a genomic library of R. marinus, In addition, the mgs gene was overexpressed in Escherichia coli with a high yield, The enzyme had a molecular mass of 46,125 Da, and was specific for GDP mannose and D-glycerate. This is the first report of the characterization of a mannosylglycerate synthase.	Univ Nova Lisboa, Inst Tecnol Quim & Biol, P-2780 Oeiras, Portugal; Univ Coimbra, Dept Bioquim, P-3000 Coimbra, Portugal; Univ Coimbra, Ctr Neurociencias Coimbra, P-3000 Coimbra, Portugal	Universidade Nova de Lisboa; Universidade de Coimbra; Universidade de Coimbra	Santos, H (corresponding author), Univ Nova Lisboa, Inst Tecnol Quim & Biol, Rua Quinta Grande 6,Apartado 127, P-2780 Oeiras, Portugal.	santos@itqb.unl.pt	Empadinhas, Nuno/G-3118-2011; Martins, Lígia O./C-2513-2009; Santos, Helena/B-9141-2011; Ferreira, Célia/A-3271-2012	Empadinhas, Nuno/0000-0001-8938-7560; Martins, Lígia O./0000-0003-0082-9591; Santos, Helena/0000-0002-8050-9485; Ferreira, Célia/0000-0003-1190-4323; da Costa, Milton/0000-0003-4027-4412; Marugg, John/0000-0003-2657-6692				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; APPERT HE, 1986, BIOCHEM BIOPH RES CO, V138, P224, DOI 10.1016/0006-291X(86)90269-X; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Chen LJ, 1998, J BACTERIOL, V180, P3785, DOI 10.1128/JB.180.15.3785-3792.1998; CIULLA RA, 1994, APPL ENVIRON MICROB, V60, P3660, DOI 10.1128/AEM.60.10.3660-3664.1994; da Costa M. S., 1998, V61, P117; DELMER DP, 1972, J BIOL CHEM, V247, P3822; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; EDMAN P, 1967, EUR J BIOCHEM, V1, P80, DOI 10.1111/j.1432-1033.1967.tb00047.x; EVANS JNS, 1985, BIOCHEMISTRY-US, V24, P5693, DOI 10.1021/bi00342a001; FUJITAYAMAGUCHI Y, 1981, J BIOL CHEM, V256, P2701; GIAEVER HM, 1988, J BACTERIOL, V170, P2841, DOI 10.1128/jb.170.6.2841-2849.1988; Ginsburg V, 1978, Prog Clin Biol Res, V23, P595; GRANT WD, 1970, J BACTERIOL, V103, P89, DOI 10.1128/JB.103.1.89-96.1970; Hagemann M, 1996, J PLANT PHYSIOL, V149, P746, DOI 10.1016/S0176-1617(96)80101-5; HAGEMANN M, 1994, MICROBIOL-SGM, V140, P1427, DOI 10.1099/00221287-140-6-1427; HENSEL R, 1988, FEMS MICROBIOL LETT, V49, P75, DOI 10.1111/j.1574-6968.1988.tb02685.x; JACIN H, 1965, J CHROMATOGR, V18, P170, DOI 10.1016/S0021-9673(01)80341-1; KARSTEN U, 1994, PLANT PHYSIOL BIOCH, V32, P669; KAUSS H, 1971, FEBS LETT, V19, P131, DOI 10.1016/0014-5793(71)80496-9; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lamosa P, 1998, APPL ENVIRON MICROB, V64, P3591; LECHMACHER A, 1990, FEBS LETT, V272, P94; Louis P, 1997, MICROBIOL-UK, V143, P1141, DOI 10.1099/00221287-143-4-1141; MARMUR J, 1961, J MOL BIOL, V3, P208, DOI 10.1016/S0022-2836(61)80047-8; MARTINS LO, 1995, APPL ENVIRON MICROB, V61, P3299, DOI 10.1128/AEM.61.9.3299-3303.1995; Martins LO, 1996, J BACTERIOL, V178, P5644, DOI 10.1128/jb.178.19.5644-5651.1996; Martins LO, 1997, APPL ENVIRON MICROB, V63, P896, DOI 10.1128/AEM.63.3.896-902.1997; MUNCHPETERSEN A, 1956, ACTA CHEM SCAND, V10, P928, DOI 10.3891/acta.chem.scand.10-0928; NORVAL M, 1973, EUR J BIOCHEM, V35, P209, DOI 10.1111/j.1432-1033.1973.tb02827.x; NUNES OC, 1992, SYST APPL MICROBIOL, V15, P92, DOI 10.1016/S0723-2020(11)80144-X; NUNES OC, 1995, APPL ENVIRON MICROB, V61, P2351, DOI 10.1128/AEM.61.6.2351-2357.1995; PEARSON WR, 1990, METHOD ENZYMOL, V183, P63; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; PETERS P, 1990, FEMS MICROBIOL LETT, V71, P157; PINDAR DF, 1975, BIOCHEM J, V152, P617, DOI 10.1042/bj1520617; Ramos A, 1997, APPL ENVIRON MICROB, V63, P4020, DOI 10.1128/AEM.63.10.4020-4025.1997; ROGERS MJ, 1988, GENE, V62, P197; SACORREIA I, 1987, J BACTERIOL, V169, P3224, DOI 10.1128/jb.169.7.3224-3231.1987; SALVUCCI ME, 1990, ARCH BIOCHEM BIOPHYS, V281, P212, DOI 10.1016/0003-9861(90)90434-Z; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Scholz S, 1998, FEMS MICROBIOL LETT, V168, P37, DOI 10.1111/j.1574-6968.1998.tb13252.x; SCHOLZ S, 1992, FEBS LETT, V306, P239, DOI 10.1016/0014-5793(92)81008-A; Selig M, 1997, ARCH MICROBIOL, V167, P217, DOI 10.1007/BF03356097; Silva Z, 1999, EXTREMOPHILES, V3, P163, DOI 10.1007/s007920050112; SLEIN MW, 1955, METHOD ENZYMOL, V1, P299, DOI 10.1016/0076-6879(55)01041-0; STROM AR, 1993, MOL MICROBIOL, V8, P205, DOI 10.1111/j.1365-2958.1993.tb01564.x; THORBJARNARDOTT.SH, 1995, GENE, V6, P1; TOLMAN CJ, 1986, BIOCHIM BIOPHYS ACTA, V886, P345, DOI 10.1016/0167-4889(86)90169-2	49	56	60	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 10	1999	274	50					35407	35414		10.1074/jbc.274.50.35407	http://dx.doi.org/10.1074/jbc.274.50.35407			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	264NG	10585410	hybrid			2022-12-25	WOS:000084187900022
J	Pearce, LL; Pitt, BR; Peterson, J				Pearce, LL; Pitt, BR; Peterson, J			The peroxynitrite reductase activity of cytochrome c oxidase involves a two-electron redox reaction at the heme a(3)-Cu-B site	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NITRIC-OXIDE; MITOCHONDRIAL RESPIRATION; INHIBITION; MECHANISM; PROTEINS; OXYGEN; ENZYME; HEART; METABOLISM; SUPEROXIDE	Fully and partially reduced forms of isolated bovine cytochrome c oxidase undergo a two-electron oxidation-reduction process with added peroxynitrite, leading to catalytic oxidation of ferrocytochrome c to ferricytochrome c, The other major reaction product is nitrite ion, 86% of the added peroxynitrite being measurably converted to this species. The reaction is inhibited in the presence of cyanide, implicating the heme alpha(3)-Cu-B binuclear pair as the active site. Moreover, provided peroxynitrite is not added to excess, the reductase activity of the enzyme toward this oxidant efficiently protects other protein and detergent molecules in vitro from nitration of tyrosine residues and oxidative damage. If the enzyme is exposed to similar to 10(2)-fold excesses of peroxynitrite, then significant irreversible loss of electron transfer activity results, and the heme alpha(3)-Cu-B binuclear pair no longer undergo a characteristic carbon monoxide-driven reduction. The accompanying rather small changes in the observed electronic absorption spectrum are suggestive of a modification in the vicinity of one or both hemes but probably not to the cofactors themselves.	Carnegie Mellon Univ, Dept Chem, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Sch Med, Dept Pharmacol, Pittsburgh, PA 15261 USA	Carnegie Mellon University; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Peterson, J (corresponding author), Carnegie Mellon Univ, Dept Chem, 4400 5th Ave, Pittsburgh, PA 15213 USA.			Peterson, James/0000-0002-7300-5887; Pearce, Linda/0000-0002-0940-965X	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007563] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P50GM053789] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL32155, HL07563] Funding Source: Medline; NIGMS NIH HHS [GM53789] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Beckman JS, 1996, CHEM RES TOXICOL, V9, P836, DOI 10.1021/tx9501445; BECKMAN JS, 1994, METHOD ENZYMOL, V233, P229; BECKMAN JS, 1996, NITRIC OXIDE PRINCIP, P1, DOI DOI 10.1016/B978-012435555-2/50002-4; BECKMANN JS, 1994, BIOL CHEM H-S, V375, P81, DOI 10.1515/bchm3.1994.375.2.81; BICKAR D, 1984, J BIOL CHEM, V259, P777; Bonaventura C, 1999, J BIOL CHEM, V274, P5499, DOI 10.1074/jbc.274.9.5499; BROWN GC, 1994, FEBS LETT, V356, P295, DOI 10.1016/0014-5793(94)01290-3; Brown GC, 1997, BIOCHEM SOC T, V25, P901, DOI 10.1042/bst0250901; Cai JY, 1998, J BIOL CHEM, V273, P11401, DOI 10.1074/jbc.273.19.11401; Cassina A, 1996, ARCH BIOCHEM BIOPHYS, V328, P309, DOI 10.1006/abbi.1996.0178; CLEETER MWJ, 1994, FEBS LETT, V345, P50, DOI 10.1016/0014-5793(94)00424-2; Cooper CE, 1997, FEBS LETT, V414, P281, DOI 10.1016/S0014-5793(97)01009-0; GADSBY PMA, 1987, BIOCHEM J, V246, P43, DOI 10.1042/bj2460043; Giuffre A, 1996, J BIOL CHEM, V271, P33404, DOI 10.1074/jbc.271.52.33404; Giulivi C, 1998, BIOCHEM J, V332, P673, DOI 10.1042/bj3320673; Giulivi C, 1998, J BIOL CHEM, V273, P11038, DOI 10.1074/jbc.273.18.11038; Granger Donald L., 1995, Methods (Orlando), V7, P78, DOI 10.1006/meth.1995.1011; Hill BC, 1998, ARCH BIOCHEM BIOPHYS, V350, P273, DOI 10.1006/abbi.1997.0528; Holm DE, 1996, COMP BIOCHEM PHYS B, V114, P345, DOI 10.1016/0305-0491(96)00031-4; HOLM DE, 1995, FEBS LETT, V370, P53, DOI 10.1016/0014-5793(95)00791-7; HUIE RE, 1993, FREE RADICAL RES COM, V18, P195, DOI 10.3109/10715769309145868; JONES MG, 1984, BIOCHEM J, V220, P57, DOI 10.1042/bj2200057; Knowles RG, 1997, BIOCHEM SOC T, V25, P895, DOI 10.1042/bst0250895; Koivisto A, 1997, FEBS LETT, V417, P75, DOI 10.1016/S0014-5793(97)01258-1; Lizasoain I, 1996, BIOCHEM J, V314, P877, DOI 10.1042/bj3140877; MARGOLIASH E, 1959, BIOCHEM J, V71, P570, DOI 10.1042/bj0710570; Narula P, 1998, AM J PHYSIOL-LUNG C, V274, pL411, DOI 10.1152/ajplung.1998.274.3.L411; PALMER G, 1993, J BIOENERG BIOMEMBR, V25, P145, DOI 10.1007/BF00762856; PETERSON J, 1995, BIOCHEM J, V305, P871, DOI 10.1042/bj3050871; Poderoso JJ, 1998, AM J PHYSIOL-CELL PH, V274, pC112, DOI 10.1152/ajpcell.1998.274.1.C112; RADI R, 1994, ARCH BIOCHEM BIOPHYS, V308, P89, DOI 10.1006/abbi.1994.1013; Sarti P, 1999, FASEB J, V13, P191, DOI 10.1096/fasebj.13.1.191; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; Schmidt K, 1998, FREE RADICAL BIO MED, V24, P859, DOI 10.1016/S0891-5849(97)00366-3; Sharpe MA, 1998, J BIOL CHEM, V273, P30961, DOI 10.1074/jbc.273.47.30961; SINJORGO KMC, 1987, BIOCHIM BIOPHYS ACTA, V893, P251, DOI 10.1016/0005-2728(87)90046-6; Tatoyan A, 1998, J BIOL CHEM, V273, P11044, DOI 10.1074/jbc.273.18.11044; Torres J, 1997, J INORG BIOCHEM, V66, P207, DOI 10.1016/S0162-0134(96)00206-1; TORRES J, 1995, BIOCHEM J, V312, P169, DOI 10.1042/bj3120169; TURRENS JF, 1991, FREE RADICAL RES COM, V12-3, P681, DOI 10.3109/10715769109145847; VANGELDER BF, 1966, BIOCHIM BIOPHYS ACTA, V118, P36, DOI 10.1016/S0926-6593(66)80142-X; WILSON MT, 1981, P NATL ACAD SCI-BIOL, V78, P7115, DOI 10.1073/pnas.78.11.7115; Wilson MT, 1997, BIOCHEM SOC T, V25, P905, DOI 10.1042/bst0250905; Wolin MS, 1997, BIOCHEM SOC T, V25, P934, DOI 10.1042/bst0250934; YOUNG LJ, 1987, J BIOL CHEM, V262, P15019	45	41	41	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 10	1999	274	50					35763	35767		10.1074/jbc.274.50.35763	http://dx.doi.org/10.1074/jbc.274.50.35763			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	264NG	10585458	hybrid			2022-12-25	WOS:000084187900070
J	Van der Kaay, J; Beck, M; Gray, A; Downes, CP				Van der Kaay, J; Beck, M; Gray, A; Downes, CP			Distinct phosphatidylinositol 3-kinase lipid products accumulate upon oxidative and osmotic stress and lead to different cellular responses	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; PLECKSTRIN-HOMOLOGY DOMAINS; HEAT-SHOCK; SIGNAL-TRANSDUCTION; IN-VIVO; INSULIN; AKT; 3,4,5-TRISPHOSPHATE; PTDINS(3,4,5)P-3; 3-PHOSPHATE	Signaling by phosphatidylinositol (PI) 3-kinases is mediated by S-phosphoinositides, which bind to Pleckstrin homology (PH) domains that are present in a wide spectrum of proteins. PH domains can be classified into three groups based on their different lipid binding specificities. Distinct 3-phosphoinositides can accumulate upon PI 3-kinase activation in cells in response to different stimuli and mediate specific cellular responses. In Swiss 3T3 mouse fibroblasts, oxidative stress induced by I mM H2O2 caused almost exclusive accumulation of phosphatidylinositol 3,4-bisphosphate (PtdIns(3,4)P-2), whereas osmotic stress increased both phosphatidylinositol 3,4,5-trisphosphate (PtdIns(3,4,5)P-3) and PtdIns(3,4)P-2 levels. The increase in PtdIns(3,4)P-2 levels, caused by oxidative stress, correlated with the activation of protein kinase B, which has a promiscuous PH domain that binds both PtdIns(3,4,5)P-3 and PtdIns(3,4)P-2. p70 S6 kinase, another signaling component downstream of PI 3-kinase, however, was not activated by this oxidative stress-induced increase in PtdIns(3,4)P-2 levels. Increased PtdIns(3,4,5)P-3 and PtdIns(3,4)P-2 levels in response to osmotic stress did not correlate with protein kinase B activation, because of concomitant activation of an inhibitory pathway, but p70 S6 kinase was activated by osmotic stress. These results demonstrate that PtdIns(3,4)P-2 can accumulate independently of PtdIns(3,4,5)P-3 and exerts a pattern of cellular responses that is distinct from that induced by accumulation of PtdIns(3,4,5)P-3.	Univ Dundee, Dept Biochem, Dundee DD1 5EH, Scotland; Free Univ Berlin, Inst Biochem, D-14195 Berlin, Germany; Inst Med Sci, Div Signal Transduct Therapy, Dundee DD1 5EH, Scotland	University of Dundee; Free University of Berlin; University of Dundee	Van der Kaay, J (corresponding author), Univ Dundee, Dept Biochem, Dundee DD1 5EH, Scotland.	jvdkaay@bad.dundee.ac.uk		Gray, Alexander/0000-0001-9227-0363				Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; Alessi DR, 1998, CURR BIOL, V8, P69, DOI 10.1016/S0960-9822(98)70037-5; Balendran A, 1999, CURR BIOL, V9, P393, DOI 10.1016/S0960-9822(99)80186-9; Banfic H, 1998, J BIOL CHEM, V273, P13, DOI 10.1074/jbc.273.1.13; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; Chou MM, 1996, CELL, V85, P573, DOI 10.1016/S0092-8674(00)81257-X; CLARKE NG, 1981, BIOCHEM J, V195, P301, DOI 10.1042/bj1950301; Cohen P, 1997, TRENDS CELL BIOL, V7, P353, DOI 10.1016/S0962-8924(97)01105-7; Cooke FT, 1998, CURR BIOL, V8, P1219, DOI 10.1016/S0960-9822(07)00513-1; Currie RA, 1999, BIOCHEM J, V337, P575, DOI 10.1042/0264-6021:3370575; CZECH MP, 1974, P NATL ACAD SCI USA, V71, P4173, DOI 10.1073/pnas.71.10.4173; Franke TF, 1997, SCIENCE, V275, P665, DOI 10.1126/science.275.5300.665; Gaullier JM, 1998, NATURE, V394, P432, DOI 10.1038/28767; Guyton KZ, 1996, J BIOL CHEM, V271, P4138, DOI 10.1074/jbc.271.7.3604; Han SJ, 1998, J BIOL CHEM, V273, P369, DOI 10.1074/jbc.273.1.369; HELDIN CH, 1995, CELL, V80, P213, DOI 10.1016/0092-8674(95)90404-2; Joyal JL, 1997, J BIOL CHEM, V272, P28183, DOI 10.1074/jbc.272.45.28183; Kavran JM, 1998, J BIOL CHEM, V273, P30497, DOI 10.1074/jbc.273.46.30497; Klarlund JK, 1998, J BIOL CHEM, V273, P1859, DOI 10.1074/jbc.273.4.1859; Kohn AD, 1998, J BIOL CHEM, V273, P11937, DOI 10.1074/jbc.273.19.11937; Konishi H, 1996, P NATL ACAD SCI USA, V93, P7639, DOI 10.1073/pnas.93.15.7639; Lemmon MA, 1997, TRENDS CELL BIOL, V7, P237, DOI 10.1016/S0962-8924(97)01065-9; Lin RZ, 1997, J BIOL CHEM, V272, P31196, DOI 10.1074/jbc.272.49.31196; Meier R, 1998, EMBO J, V17, P7294, DOI 10.1093/emboj/17.24.7294; Patki V, 1998, NATURE, V394, P433, DOI 10.1038/28771; Peterson RT, 1999, P NATL ACAD SCI USA, V96, P4438, DOI 10.1073/pnas.96.8.4438; Pullen N, 1998, SCIENCE, V279, P707, DOI 10.1126/science.279.5351.707; Qin SF, 1997, J BIOL CHEM, V272, P2098; Rameh LE, 1999, J BIOL CHEM, V274, P8347, DOI 10.1074/jbc.274.13.8347; Shaw M, 1998, BIOCHEM J, V336, P241, DOI 10.1042/bj3360241; Stephens L, 1998, SCIENCE, V279, P710, DOI 10.1126/science.279.5351.710; STEPHENS LR, 1993, BIOCHIM BIOPHYS ACTA, V1179, P27, DOI 10.1016/0167-4889(93)90072-W; Tanaka K, 1999, J BIOL CHEM, V274, P3919, DOI 10.1074/jbc.274.7.3919; van der Kaay J, 1998, Methods Mol Biol, V105, P109; vanderKaay J, 1997, J BIOL CHEM, V272, P5477, DOI 10.1074/jbc.272.9.5477; Vanhaesebroeck B, 1997, TRENDS BIOCHEM SCI, V22, P267, DOI 10.1016/S0968-0004(97)01061-X	36	104	105	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 10	1999	274	50					35963	35968		10.1074/jbc.274.50.35963	http://dx.doi.org/10.1074/jbc.274.50.35963			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	264NG	10585485	hybrid			2022-12-25	WOS:000084187900097
J	Wissmann, R; Baukrowitz, T; Kalbacher, H; Kalbitzer, HR; Ruppersberg, JP; Pongs, O; Antz, C; Fakler, B				Wissmann, R; Baukrowitz, T; Kalbacher, H; Kalbitzer, HR; Ruppersberg, JP; Pongs, O; Antz, C; Fakler, B			NMR structure and functional characteristics of the hydrophilic N terminus of the potassium channel beta-subunit Kv beta 1.1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED K+ CHANNELS; BALL PEPTIDE; INACTIVATION; SPECTROSCOPY; ALPHA; MODULATION; BINDING; SPECTRA; PORE; GATE	Rapid N-type inactivation of voltage-dependent potassium (Kv) channels controls membrane excitability and signal propagation in central neurons and is mediated by protein domains (inactivation gates) occluding the open channel pore from the cytoplasmic side, Inactivation domains (ID) are donated either by the pore-forming alpha-subunit or certain auxiliary beta-subunits. Upon coexpression, Kv beta 1.1 was found to endow non-inactivating members of the Kv1 alpha family with fast inactivation via its unique N terminus, Here we investigated structure and functional properties of the Kv beta 1.1 N terminus (amino acids 1-62, beta N-(1-62)) using NMR spectroscopy and patch clamp recordings, beta N-(1-62) showed all hallmarks of N-type inactivation: it inactivated non-inactivating Kv1.1 channels when applied to the cytoplasmic side as a synthetic peptide, and its interaction with the cu-subunit was competed with tetraethylammonium and displayed an affinity in the lower micromolar range. In aequous and physiological salt solution, beta N-(1-62) showed no well defined three-dimensional structure, it rather existed in a fast equilibrium of multiple weakly structured states. These structural and functional properties of beta N-(1-62) closely resemble those of the "unstructured" ID from Shaker B, but differ markedly from those of the compactly folded ID of the Kv3.4 alpha-subunit.	Otogene AG, D-72074 Tubingen, Germany; Univ Tubingen, Dept Physiol 2, D-72074 Tubingen, Germany; Univ Tubingen, Inst Physiol Chem, D-72074 Tubingen, Germany; Univ Regensburg, Dept Biophys & Phys Biochem, D-93053 Regensburg, Germany; Zentrum Mol Neurobiol Hamburg, D-20251 Hamburg, Germany	Eberhard Karls University of Tubingen; Eberhard Karls University of Tubingen; University of Regensburg; University of Hamburg; University Medical Center Hamburg-Eppendorf	Antz, C (corresponding author), Otogene AG, Vor Kreuzberg 17, D-72074 Tubingen, Germany.			Kalbitzer, Hans Robert/0000-0002-6514-2355; Baukrowitz, Thomas/0000-0003-4562-0505				ALDRICH RW, 1990, COLD SPRING HARB SYM, V55, P19; Antz C, 1999, NAT STRUCT BIOL, V6, P146; Antz C, 1997, NATURE, V385, P272, DOI 10.1038/385272a0; ARMSTRONG CM, 1977, J GEN PHYSIOL, V70, P567, DOI 10.1085/jgp.70.5.567; AUE WP, 1976, J CHEM PHYS, V64, P2229, DOI 10.1063/1.432450; Baukrowitz T, 1996, P NATL ACAD SCI USA, V93, P13357, DOI 10.1073/pnas.93.23.13357; BUNDI A, 1979, BIOPOLYMERS, V18, P185; DAVIS DG, 1985, J AM CHEM SOC, V107, P2820, DOI 10.1021/ja00295a052; DEMO SD, 1991, NEURON, V7, P743, DOI 10.1016/0896-6273(91)90277-7; ENGLAND SK, 1995, J BIOL CHEM, V270, P28531, DOI 10.1074/jbc.270.48.28531; FAKLER B, 1995, CELL, V80, P149, DOI 10.1016/0092-8674(95)90459-X; FERNANDEZBALLESTER G, 1995, BIOPHYS J, V68, P858, DOI 10.1016/S0006-3495(95)80262-6; FRANK R, 1988, MODERN METHODS PROTE; Heinemann SH, 1996, J PHYSIOL-LONDON, V493, P625, DOI 10.1113/jphysiol.1996.sp021409; Hille B, 1992, IONIC CHANNELS EXCIT, P127; HOSHI T, 1990, SCIENCE, V250, P533, DOI 10.1126/science.2122519; JEENER J, 1979, J CHEM PHYS, V71, P4546, DOI 10.1063/1.438208; Jing J, 1997, J BIOL CHEM, V272, P14021, DOI 10.1074/jbc.272.22.14021; Jing J, 1999, EMBO J, V18, P1245, DOI 10.1093/emboj/18.5.1245; MACKINNON R, 1990, SCIENCE, V250, P276, DOI 10.1126/science.2218530; MCCORMACK K, 1995, FEBS LETT, V370, P32, DOI 10.1016/0014-5793(95)00785-8; MCCORMACK T, 1994, CELL, V79, P1133, DOI 10.1016/0092-8674(94)90004-3; MURRELLLAGNADO RD, 1993, J GEN PHYSIOL, V102, P977, DOI 10.1085/jgp.102.6.977; MURRELLLAGNADO RD, 1993, J GEN PHYSIOL, V102, P949, DOI 10.1085/jgp.102.6.949; NEIDIG KP, 1995, J BIOMOL NMR, V6, P255, DOI 10.1007/BF00197807; Oliver D, 1998, BIOPHYS J, V74, P2318, DOI 10.1016/S0006-3495(98)77941-X; RETTIG J, 1994, NATURE, V369, P289, DOI 10.1038/369289a0; RUPPERSBERG JP, 1991, NATURE, V353, P657, DOI 10.1038/353657a0; Schott MK, 1998, EUR BIOPHYS J BIOPHY, V27, P99, DOI 10.1007/s002490050115; Sewing S, 1996, NEURON, V16, P455, DOI 10.1016/S0896-6273(00)80063-X; STEPHENS GJ, 1995, J PHYSIOL-LONDON, V484, P1; Stephens GJ, 1996, FEBS LETT, V378, P250, DOI 10.1016/0014-5793(95)01469-1; WISHART DS, 1995, J BIOMOL NMR, V5, P67, DOI 10.1007/BF00227471; WUTHRICH K, 1993, METHOD ENZYMOL, V177, P125; Yu WF, 1996, NEURON, V16, P441, DOI 10.1016/S0896-6273(00)80062-8; ZAGOTTA WN, 1990, SCIENCE, V250, P568, DOI 10.1126/science.2122520	36	35	36	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 10	1999	274	50					35521	35525		10.1074/jbc.274.50.35521	http://dx.doi.org/10.1074/jbc.274.50.35521			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	264NG	10585425	hybrid, Green Published			2022-12-25	WOS:000084187900037
J	Jacobsen, H; Reinhardt, D; Brockhaus, M; Bur, D; Kocyba, C; Kurt, H; Grim, MG; Baumeister, R; Loetscher, H				Jacobsen, H; Reinhardt, D; Brockhaus, M; Bur, D; Kocyba, C; Kurt, H; Grim, MG; Baumeister, R; Loetscher, H			The influence of endoproteolytic processing of familial Alzheimer's disease presenilin 2 on A beta 42 amyloid peptide formation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IN-VIVO; CAENORHABDITIS-ELEGANS; MISSENSE MUTATIONS; TRANSFECTED CELLS; BETA-PROTEIN; CLEAVAGE; GENE; CHROMOSOME-1; DERIVATIVES; FRAGMENTS	Mutant presenilins (PS) contribute to the pathogenesis of familial Alzheimer's disease (FAD) by enhancing the production of A beta 42 from beta-amyloid precursor protein. Presenilins are endoproteolytically processed to N-terminal and C-terminal fragments, which together form a stable 1:1 complex. We have mapped the cleavage site in the PS2 protein by direct sequencing of its C-terminal fragment isolated from mouse liver. Three different N-terminal residues were identified starting at Val-299, Thr-301, and Leu-307 that correspond closely to the previously described N termini of the C-terminal fragment of human PS1, Mutational analysis of the PS2 cleavage site indicates that the principal endoproteolytic cleavage occurs at residues Met-298/Val-299 and that the N terminus is subsequently modified by secondary proteolytic cleavages. We have generated cleavage defective PS2 constructs, which accumulate exclusively as full-length polypeptides in transfected Neuro2a cells. Functional analysis of such cleavage defective PS2 carrying the FAD mutation Asn-141 --> Ile showed that its A beta 42 producing activity was strongly reduced compared with cleavage-competent FAD PS2, In contrast, cleavage defective PS2 was active in rescuing the egg-laying defect of a sel-12 mutant in Caenorhabditis elegans. We conclude that PS2 endoproteolytic cleavage is not an absolute requirement for its activities but may rather selectively enhance or stabilize its functions.	F Hoffmann La Roche & Co Ltd, Div Pharma, Preclin Cent Nervous Syst Res, CH-4070 Basel, Switzerland; F Hoffmann La Roche & Co Ltd, Mol Design, CH-4070 Basel, Switzerland; Genzentrum, D-81377 Munich, Germany	Roche Holding; Roche Holding; University of Munich	Jacobsen, H (corresponding author), F Hoffmann La Roche & Co Ltd, Div Pharma, Preclin Cent Nervous Syst Res, B93-314, CH-4070 Basel, Switzerland.		Kurt, Halil/HCH-8226-2022					Baumeister R, 1997, Genes Funct, V1, P149; Borchelt DR, 1996, NEURON, V17, P1005, DOI 10.1016/S0896-6273(00)80230-5; Brockhaus M, 1998, NEUROREPORT, V9, P1481, DOI 10.1097/00001756-199805110-00043; Capell A, 1998, J BIOL CHEM, V273, P3205, DOI 10.1074/jbc.273.6.3205; Citron M, 1997, NAT MED, V3, P67, DOI 10.1038/nm0197-67; De Strooper B, 1999, NATURE, V398, P518, DOI 10.1038/19083; De Strooper B, 1998, NATURE, V391, P387, DOI 10.1038/34910; DeStrooper B, 1997, J BIOL CHEM, V272, P3590, DOI 10.1074/jbc.272.6.3590; Doan A, 1996, NEURON, V17, P1023, DOI 10.1016/S0896-6273(00)80232-9; Duff K, 1996, NATURE, V383, P710, DOI 10.1038/383710a0; Haass C, 1997, NEURON, V18, P687, DOI 10.1016/S0896-6273(00)80309-8; Haass Christian, 1999, Trends in Cell Biology, V9, P241, DOI 10.1016/S0962-8924(99)01576-7; Kim TW, 1997, SCIENCE, V277, P373, DOI 10.1126/science.277.5324.373; Levitan D, 1996, P NATL ACAD SCI USA, V93, P14940, DOI 10.1073/pnas.93.25.14940; LEVITAN D, 1995, NATURE, V377, P351, DOI 10.1038/377351a0; LEVYLAHAD E, 1995, SCIENCE, V269, P970, DOI 10.1126/science.7638621; Loetscher H, 1997, J BIOL CHEM, V272, P20655, DOI 10.1074/jbc.272.33.20655; Podlisny MB, 1997, NEUROBIOL DIS, V3, P325, DOI 10.1006/nbdi.1997.0129; Ratovitski T, 1997, J BIOL CHEM, V272, P24536, DOI 10.1074/jbc.272.39.24536; ROGAEV EI, 1995, NATURE, V376, P775, DOI 10.1038/376775a0; Saura CA, 1999, J BIOL CHEM, V274, P13818, DOI 10.1074/jbc.274.20.13818; Scheuner D, 1996, NAT MED, V2, P864, DOI 10.1038/nm0896-864; SHERRINGTON R, 1995, NATURE, V375, P754, DOI 10.1038/375754a0; Shirotani K, 1997, BIOCHEM BIOPH RES CO, V240, P728, DOI 10.1006/bbrc.1997.7730; Steiner H, 1999, J BIOL CHEM, V274, P7615, DOI 10.1074/jbc.274.12.7615; Steiner H, 1998, J BIOL CHEM, V273, P32322, DOI 10.1074/jbc.273.48.32322; Struhl G, 1999, NATURE, V398, P522, DOI 10.1038/19091; Thinakaran G, 1998, NEUROBIOL DIS, V4, P438, DOI 10.1006/nbdi.1998.0171; Thinakaran G, 1996, NEURON, V17, P181, DOI 10.1016/S0896-6273(00)80291-3; Walter J, 1999, P NATL ACAD SCI USA, V96, P1391, DOI 10.1073/pnas.96.4.1391; Walter J, 1996, MOL MED, V2, P673, DOI 10.1007/BF03401652; Wisniewski T, 1997, AM J PATHOL, V151, P601; Wolfe MS, 1999, NATURE, V398, P513, DOI 10.1038/19077; Ye YH, 1999, NATURE, V398, P525, DOI 10.1038/19096; Zhang JM, 1998, J BIOL CHEM, V273, P12436, DOI 10.1074/jbc.273.20.12436	35	34	34	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 3	1999	274	49					35233	35239		10.1074/jbc.274.49.35233	http://dx.doi.org/10.1074/jbc.274.49.35233			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	260XW	10575009	hybrid			2022-12-25	WOS:000083979600103
J	Meyer, D; Liu, A; Margolis, B				Meyer, D; Liu, A; Margolis, B			Interaction of c-Jun amino-terminal kinase interacting protein-1 with p190 rhoGEF and its localization in differentiated neurons	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOTYROSINE-BINDING DOMAIN; SIGNAL-TRANSDUCTION PATHWAY; PC12 CELL-DIFFERENTIATION; NEURITE RETRACTION; SHC; ACTIVATION; RECEPTOR; IDENTIFICATION; GROWTH; MOTIF	c-Jun amino-terminal kinase (JNK) interacting protein-1 (JIP-1) was originally identified as a cytoplasmic inhibitor of JNK, More recently, JIP-1 was proposed to function as a scaffold protein by complexing specific components of the JNK signaling pathway, namely JNK, mitogen-activated protein kinase kinase 7, and mixed lineage kinase 3, We have identified the human homologue of JIP-1 that contains a phosphotyrosine binding (PTB) domain in addition to a JNK binding domain and an Src homology 3 domain. To identify binding targets for the hJIP-1 PTB domain, a mouse embryo cDNA library was screened using the yeast two-hybrid system. One clone encoded a 191-amino acid region of the neuronal protein rhoGEF, an exchange factor for rhoA, Overexpression of rhoGEF promotes cytoskeletal rearrangement and cell rounding in NIE-115 neuronal cells. The interaction of JIP-1 with rhoGEF was confirmed by coimmunoprecipitation of these proteins from lysates of transiently transfected HEK 293 cells. Using glutathione S-transferase rhoGEF fusion proteins containing deletion or point mutations, we identified a putative PTB binding site within rhoGEF, This binding site does not contain tyrosine, indicating that the JIP PTB domain, like that of Xll alpha and Numb, binds independently of phosphotyrosine, Several forms of endogenous JIP-1 protein can be detected in neuronal cell lines. Indirect immunofluorescence analysis localized endogenous JIP-1 to the tip of the neurites in differentiated NIE-115 and PC12 cells. The interaction of JIP-1 with rhoGEF and its subcellular localization suggests that JIP-1 may function to specifically localize a signaling complex in neuronal cells.	Univ Michigan, Med Ctr, Howard Hughes Med Inst, Sch Med, Ann Arbor, MI 48109 USA; Univ Michigan, Sch Med, Dept Biol Chem, Ann Arbor, MI 48109 USA; Univ Michigan, Sch Med, Dept Internal Med, Ann Arbor, MI 48109 USA	Howard Hughes Medical Institute; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Margolis, B (corresponding author), Univ Michigan, Med Ctr, Howard Hughes Med Inst, Sch Med, 4570 MSRB 2,Box 0650,1150 W Med Ctr Dr, Ann Arbor, MI 48109 USA.							Alberts AS, 1998, EMBO J, V17, P4075, DOI 10.1093/emboj/17.14.4075; BATZER AG, 1995, MOL CELL BIOL, V15, P4403; BLAIKIE P, 1994, J BIOL CHEM, V269, P32031; Bonny C, 1998, J BIOL CHEM, V273, P1843, DOI 10.1074/jbc.273.4.1843; Borg JP, 1996, MOL CELL BIOL, V16, P6229; BORK P, 1995, CELL, V80, P693, DOI 10.1016/0092-8674(95)90347-X; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; Chien CT, 1998, MOL CELL BIOL, V18, P598, DOI 10.1128/MCB.18.1.598; Dho SE, 1998, J BIOL CHEM, V273, P9179, DOI 10.1074/jbc.273.15.9179; Dickens M, 1997, SCIENCE, V277, P693, DOI 10.1126/science.277.5326.693; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; Gebbink MFBG, 1997, J CELL BIOL, V137, P1603, DOI 10.1083/jcb.137.7.1603; Glaven JA, 1999, J BIOL CHEM, V274, P2279, DOI 10.1074/jbc.274.4.2279; GUSTAFSON TA, 1995, MOL CELL BIOL, V15, P2500; HARPER JW, 1993, CELL, V75, P805; Heasley LE, 1996, MOL CELL BIOL, V16, P648; JALINK K, 1994, J CELL BIOL, V126, P801, DOI 10.1083/jcb.126.3.801; JALINK K, 1993, CELL GROWTH DIFFER, V4, P247; KAVANAUGH WM, 1994, SCIENCE, V266, P1862, DOI 10.1126/science.7527937; Kita Y, 1998, J CELL SCI, V111, P907; Kobayashi M, 1997, J BIOL CHEM, V272, P16089, DOI 10.1074/jbc.272.26.16089; Kranenburg O, 1997, J CELL SCI, V110, P2417; Kuhn TB, 1999, J NEUROSCI, V19, P1965; Leppa S, 1998, EMBO J, V17, P4404, DOI 10.1093/emboj/17.15.4404; Machesky LM, 1997, J CELL BIOL, V138, P913, DOI 10.1083/jcb.138.4.913; Mooser V, 1999, GENOMICS, V55, P202, DOI 10.1006/geno.1998.5641; Postma FR, 1996, EMBO J, V15, P2388, DOI 10.1002/j.1460-2075.1996.tb00595.x; Symons M, 1996, TRENDS BIOCHEM SCI, V21, P178, DOI 10.1016/S0968-0004(96)10022-0; Threadgill R, 1997, NEURON, V19, P625, DOI 10.1016/S0896-6273(00)80376-1; VanAelst L, 1997, GENE DEV, V11, P2295, DOI 10.1101/gad.11.18.2295; vanderGeer P, 1996, P NATL ACAD SCI USA, V93, P963, DOI 10.1073/pnas.93.3.963; VOJTEK AB, 1995, METHOD ENZYMOL, V255, P331; Whitmarsh AJ, 1998, SCIENCE, V281, P1671, DOI 10.1126/science.281.5383.1671; Yaich L, 1998, J BIOL CHEM, V273, P10381, DOI 10.1074/jbc.273.17.10381; Yajnik V, 1996, J BIOL CHEM, V271, P1813, DOI 10.1074/jbc.271.4.1813; Yao RJ, 1997, J BIOL CHEM, V272, P18261, DOI 10.1074/jbc.272.29.18261; ZHOU MM, 1995, NATURE, V378, P584, DOI 10.1038/378584a0	37	115	120	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 3	1999	274	49					35113	35118		10.1074/jbc.274.49.35113	http://dx.doi.org/10.1074/jbc.274.49.35113			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	260XW	10574993	hybrid			2022-12-25	WOS:000083979600087
J	Shen, GJ; Datta, AK; Izumi, M; Koeller, KM; Wong, CH				Shen, GJ; Datta, AK; Izumi, M; Koeller, KM; Wong, CH			Expression of alpha 2,8/2,9-polysialyltransferase from Escherichia coli K92 - Characterization of the enzyme and its reaction products	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-GALACTOSIDE ALPHA-2,6-SIALYLTRANSFERASE; CELL-ADHESION MOLECULE; GROUP-C MENINGOCOCCI; POLYSIALIC ACID; NEISSERIA-MENINGITIDIS; GROUP-B; SURFACE POLYMERS; K1; SIALYLTRANSFERASE; POLYSACCHARIDE	The capsular polysaccharide of Escherichia coli K92 contains alternating -8-NeuAc alpha 2- and -9-NeuAc alpha 2- linkages. The enzyme catalyzing this polymerizing reaction has been cloned from the genomic DNA of E. coli K92. The 1.2-kilobase polymerase chain reaction fragment was subcloned in pRSET vector and the protein was expressed in the BL21(DE3) strain of E. coli with a hexameric histidine at its N-terminal end, The enzyme was isolated in the supernatant after lysis of the cells and fractionated by ultracentrifugation. Western blotting using anti-histidine antibody showed the presence of a band that migrated at about 47.5 kDa on both reducing and nonreducing SDS-polyacrylamide gel electrophoresis, indicating a monomeric enzyme. Among the carbohydrate accepters tested, N-acetylneuraminic acid and the gangliosides G(D3) and G(Q1b) were preferred substrates. The cell-free enzyme reaction products obtained were characterized by NMR and mass spectrometry, which indicated the presence of both alpha 2,9- and alpha 2,8-linked polysialyl structure. The K92 neuS gene was used to transform the K1 strain of E. coli, the capsule of which contains only -8-NeuAc alpha 2- linkages. Analysis of the polysaccharides isolated from these transformed cells is consistent with the presence of both -8-NeuAc alpha 2- and -9-NeuAc alpha 2- linkages. Our results suggest that the neuS gene product of E. coli K92 catalyzes the synthesis of polysialic acid with alpha 2,9- and alpha 2,8-linkages in vitro and in vivo.	Scripps Res Inst, Dept Chem, La Jolla, CA 92037 USA; Scripps Res Inst, Skaggs Inst Chem Biol, La Jolla, CA 92037 USA	Scripps Research Institute; Scripps Research Institute	Wong, CH (corresponding author), Scripps Res Inst, Dept Chem, 10666 N Torrey Pines Rd,BCC 338, San Diego, CA 92037 USA.	wong@scripps.edu	Izumi, Masayuki/C-6230-2008	Izumi, Masayuki/0000-0001-6486-9678	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM044154, R01GM044154] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM44154] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BARRY GT, 1962, J GEN MICROBIOL, V29, P335, DOI 10.1099/00221287-29-2-335; BARRY GT, 1965, B SOC CHIM BIOL, V47, P529; Chao CF, 1999, J BIOL CHEM, V274, P18206, DOI 10.1074/jbc.274.26.18206; Cheng MC, 1999, ANGEW CHEM INT EDIT, V38, P686, DOI 10.1002/(SICI)1521-3773(19990301)38:5<686::AID-ANIE686>3.0.CO;2-P; CLEMENTZ T, 1991, J BIOL CHEM, V266, P9687; CORFIELD AP, 1982, CELL BIOL MONOGR, V10, P77; CUNNINGHAM BA, 1987, SCIENCE, V236, P799, DOI 10.1126/science.3576199; Datta AK, 1998, J BIOL CHEM, V273, P9608, DOI 10.1074/jbc.273.16.9608; DEVI SJN, 1991, P NATL ACAD SCI USA, V88, P7175, DOI 10.1073/pnas.88.16.7175; EDELMAN GM, 1985, COLD SPRING HARB SYM, V50, P877, DOI 10.1101/SQB.1985.050.01.105; EGAN W, 1977, BIOCHEMISTRY-US, V16, P3687, DOI 10.1021/bi00635a028; Gilbert M, 1997, EUR J BIOCHEM, V249, P187, DOI 10.1111/j.1432-1033.1997.t01-1-00187.x; GLODE MP, 1977, J INFECT DIS, V135, P94, DOI 10.1093/infdis/135.1.94; HARLOW E, 1988, ANTIGODIES; HOPP TP, 1981, P NATL ACAD SCI-BIOL, V78, P3824, DOI 10.1073/pnas.78.6.3824; KASPER DL, 1973, J IMMUNOL, V110, P262; KUNDIG FD, 1971, J BIOL CHEM, V246, P2543; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; Lee YL, 1997, BIOCHEM BIOPH RES CO, V231, P452, DOI 10.1006/bbrc.1997.5797; LIU JLC, 1992, J AM CHEM SOC, V114, P3901, DOI 10.1021/ja00036a044; LIU TY, 1971, J BIOL CHEM, V246, P4703; PELKONEN S, 1990, CURR MICROBIOL, V21, P23, DOI 10.1007/BF02090095; ROHR TE, 1980, J BIOL CHEM, V255, P2332; SAMBROOK J, 1991, MOL CLINING LAB MANU; Schauer R, 1995, BIOL SIALIC ACIDS, DOI [10.1007/978-1-4757-9504-2, DOI 10.1007/978-1-4757-9504-2]; STEENBERGEN SM, 1990, MOL MICROBIOL, V4, P603, DOI 10.1111/j.1365-2958.1990.tb00629.x; STEENBERGEN SM, 1992, J BACTERIOL, V174, P1099, DOI 10.1128/jb.174.4.1099-1108.1992; STEENBERGEN SM, 1991, GLYCOCONJUGATE JJ, V8, P145; TROY FA, 1992, GLYCOBIOLOGY, V2, P5, DOI 10.1093/glycob/2.1.5; TROY FA, 1979, J BIOL CHEM, V254, P7377; TROY FA, 1990, TRENDS GLYCOSCI GLYC, V2, P430; Tsuji S, 1996, GLYCOBIOLOGY, V6, pR5; VANHOOF G, 1995, FASEB J, V9, P736, DOI 10.1096/fasebj.9.9.7601338; VANN WF, 1978, J BACTERIOL, V133, P1300, DOI 10.1128/JB.133.3.1300-1306.1978; VIMR ER, 1992, J BACTERIOL, V174, P5127, DOI 10.1128/JB.174.15.5127-5131.1992; WEINSTEIN J, 1987, J BIOL CHEM, V262, P17735; WEISGERBER C, 1990, J BIOL CHEM, V265, P1578; WEISGERBER C, 1991, Glycobiology, V1, P357, DOI 10.1093/glycob/1.4.357; WILLIAMS MA, 1995, GLYCOCONJUGATE J, V12, P755, DOI 10.1007/BF00731235; Yamamoto T, 1998, J BIOCHEM-TOKYO, V123, P94; Zhang Y, 1999, J BIOL CHEM, V274, P6183, DOI 10.1074/jbc.274.10.6183	41	46	54	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 3	1999	274	49					35139	35146		10.1074/jbc.274.49.35139	http://dx.doi.org/10.1074/jbc.274.49.35139			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	260XW	10574996	hybrid			2022-12-25	WOS:000083979600090
J	Haase, H; Podzuweit, T; Lutsch, G; Hohaus, A; Kostka, S; Lindschau, C; Kott, M; Kraft, R; Morano, I				Haase, H; Podzuweit, T; Lutsch, G; Hohaus, A; Kostka, S; Lindschau, C; Kott, M; Kraft, R; Morano, I			Signaling from beta-adrenoceptor to L-type calcium channel: identification of a novel cardiac protein kinase A target possessing similarities to AHNAK	FASEB JOURNAL			English	Article						cAMP kinase; protein phosphorylation; cardiomyocytes	HUMAN GENE AHNAK; CAMP-DEPENDENT PHOSPHORYLATION; SUBUNIT HETEROGENEITY; FUNCTIONAL EXPRESSION; PLASMA-MEMBRANE; CA2+ CHANNELS; MUSCLE; HEART; BRAIN; RAT	A novel calcium channel-associated protein of similar to 700 kDa has been identified in mammalian cardiomyocytes that undergoes substantial cAMP-dependent protein kinase (PKA) phosphorylation. It was therefore designated as phosphoprotein 700 (pp700). The pp700 interacts specifically with the beta(2) subunit of cardiac L-type calcium channels as revealed by coprecipitation experiments using affinity-purified antibodies against different calcium channel subunits. It is surprising that amino acid sequence analysis of pig pp700 revealed homology to AHNAK-encoded protein, which was originally identified in human cell lines of neural crest origin as 700-kDa phosphoprotein. Cardiac AHNAK expression was assessed on mRNA level by reverse transcriptase-polymerase chain reaction. Sequence-directed antibodies raised against human AHNAK recognized pp700 in immunoblotting and immunoprecipitation experiments, confirming the homology between both proteins. Anti-AHNAK antibodies labeled preferentially the plasma membrane of cardiomyocytes in cryosections of rat cardiac tissue and isolated cardiomyocytes. Sarcolemmal pp700/AHNAK localization was not influenced by stimulation of either the PKA or the protein kinase C pathway. In back-phosphorylation studies with cardiac biopsies, we identified distinct pp700 pools. The membrane-associated fraction of pp700 underwent substantial in vivo phosphorylation on beta-adrenergic receptor stimulation by isoproterenol, whereas the cytoplasmic fraction of pp700 was not accessible to endogenous PKA. It is important that in vivo phosphorylation occurred in that pp700 fraction which coprecipitated with the calcium channel beta subunit. We hypothesize that both phosphorylation of pp700 and its coupling to the beta subunit play a physiological role in cardiac beta-adrenergic signal transduction.	Max Delbruck Ctr Mol Med, D-13092 Berlin, Germany; Max Planck Inst Physiol & Clin Res, D-6350 Bad Nauheim, Germany; Humboldt Univ, Franz Volhard Clin, Max Delbruck Ctr Mol Med, Berlin, Germany; Humboldt Univ, Inst Physiol, Berlin, Germany	Helmholtz Association; Max Delbruck Center for Molecular Medicine; Max Planck Society; Franz-Volhard Clinical Research Center; Helmholtz Association; Max Delbruck Center for Molecular Medicine; Humboldt University of Berlin; Humboldt University of Berlin	Morano, I (corresponding author), Max Delbruck Ctr Mol Med, Robert Rossle Str 10, D-13092 Berlin, Germany.	imorano@mdc-berlin.de	Lindschau, Carsten/G-1798-2011; Lindschau, Carsten/AAE-6721-2020	Lindschau, Carsten/0000-0003-1960-099X; 				CALOVINI T, 1995, J CELL BIOCHEM, V59, P69, DOI 10.1002/jcb.240590109; Charnet P, 1995, BIOCHIMIE, V77, P957, DOI 10.1016/0300-9084(95)80008-5; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Dai SP, 1999, FEBS LETT, V442, P70, DOI 10.1016/S0014-5793(98)01632-9; DeJongh KS, 1996, BIOCHEMISTRY-US, V35, P10392, DOI 10.1021/bi953023c; Gao TY, 1997, NEURON, V19, P185, DOI 10.1016/S0896-6273(00)80358-X; Gerster U, 1999, J PHYSIOL-LONDON, V517, P353, DOI 10.1111/j.1469-7793.1999.0353t.x; Gollasch M, 1998, FASEB J, V12, P593, DOI 10.1096/fasebj.12.7.593; HAASE H, 1993, FEBS LETT, V335, P217, DOI 10.1016/0014-5793(93)80733-B; Haase H, 1996, J MOL MED-JMM, V74, P99; HARTZELL HC, 1991, NATURE, V351, P573, DOI 10.1038/351573a0; Hase H, 1996, MOL CELL BIOCHEM, V164, P99, DOI 10.1007/BF00408645; HASHIMOTO T, 1993, J CELL SCI, V105, P275; HASHIMOTO T, 1995, EXP CELL RES, V217, P258, DOI 10.1006/excr.1995.1085; Hoch B, 1998, J CELL BIOCHEM, V68, P259, DOI 10.1002/(SICI)1097-4644(19980201)68:2<259::AID-JCB12>3.0.CO;2-A; Hosey MM, 1996, TRENDS CARDIOVAS MED, V6, P265, DOI 10.1016/S1050-1738(96)00109-0; HULLIN R, 1992, EMBO J, V11, P885, DOI 10.1002/j.1460-2075.1992.tb05126.x; Kameyama A, 1996, J BIOCHEM-TOKYO, V120, P170; KENNELLY PJ, 1991, J BIOL CHEM, V266, P15555; KLOCKNER U, 1992, PFLUG ARCH EUR J PHY, V420, P413, DOI 10.1007/BF00374479; Kraft R, 1997, SPRING LAB MAN, P61; Lutsch G, 1997, CIRCULATION, V96, P3466; MIKAMI A, 1989, NATURE, V340, P230, DOI 10.1038/340230a0; PEREZREYES E, 1994, FEBS LETT, V342, P119, DOI 10.1016/0014-5793(94)80484-2; Pichler M, 1997, J BIOL CHEM, V272, P13877, DOI 10.1074/jbc.272.21.13877; PODZUWEIT T, 1980, BASIC RES CARDIOL, V75, P772, DOI 10.1007/BF01910455; PODZUWEIT T, 1982, EARLY ARRHYTHMIAS RE, P171; PRAGNELL M, 1991, FEBS LETT, V291, P253, DOI 10.1016/0014-5793(91)81296-K; REUTER H, 1974, J PHYSIOL-LONDON, V242, P429, DOI 10.1113/jphysiol.1974.sp010716; SCULPTOREANU A, 1993, P NATL ACAD SCI USA, V90, P10135, DOI 10.1073/pnas.90.21.10135; SHTIVELMAN E, 1993, J CELL BIOL, V120, P625, DOI 10.1083/jcb.120.3.625; SHTIVELMAN E, 1992, P NATL ACAD SCI USA, V89, P5472, DOI 10.1073/pnas.89.12.5472; Sonnhammer E L, 1998, Proc Int Conf Intell Syst Mol Biol, V6, P175; TOKUYASU KT, 1986, J MICROSC-OXFORD, V143, P139, DOI 10.1111/j.1365-2818.1986.tb02772.x; TRAUTWEIN W, 1990, ANNU REV PHYSIOL, V52, P257, DOI 10.1146/annurev.ph.52.030190.001353; TSIEN RW, 1986, J MOL CELL CARDIOL, V18, P691, DOI 10.1016/S0022-2828(86)80941-5; Vance CL, 1998, J BIOL CHEM, V273, P14495, DOI 10.1074/jbc.273.23.14495; Vetter R, 1998, MOL CELL BIOCHEM, V188, P177, DOI 10.1023/A:1006850724830; Vogt AM, 1996, BASIC RES CARDIOL, V91, P389; YOSHIDA A, 1992, FEBS LETT, V309, P343, DOI 10.1016/0014-5793(92)80804-P; ZONG XG, 1995, PFLUG ARCH EUR J PHY, V430, P340, DOI 10.1007/BF00373908	41	60	65	0	1	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	1999	13	15					2161	2172		10.1096/fasebj.13.15.2161	http://dx.doi.org/10.1096/fasebj.13.15.2161			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	266QN	10593863				2022-12-25	WOS:000084310800007
J	Jorquera, R; Tanguay, RM				Jorquera, R; Tanguay, RM			Cyclin B-dependent kinase and caspase-1 activation precedes mitochondrial dysfunction in fumarylacetoacetate-induced apoptosis	FASEB JOURNAL			English	Article						cell cycle; caspase; cytochrome c; glutathione; cell death	TYROSINEMIA TYPE-I; DNA-DAMAGE CHECKPOINT; CELL-CYCLE; HEREDITARY TYROSINEMIA; CYTOCHROME-C; FLOW-CYTOMETRY; GLUTATHIONE; P34(CDC2); INDUCTION; ENZYME	Hereditary tyrosinemia type I is the most severe metabolic disease of the tyrosine catabolic pathway mainly affecting the liver. It is caused by deficiency of fumarylacetoacetate hydrolase, which prevents degradation of the toxic metabolite fumarylacetoacetate (FAA). We report here that FAA induces common effects (i.e., cell cycle arrest and apoptosis) in both human (HepG2) and rodent (Chinese hamster V79) cells, effects that seem to be temporally related. Both the antiproliferative and apoptosis-inducing activities of FAA are dose dependent and enhanced by glutathione (GSH) depletion with L-buthionine-(S,R)-sulfoximine (BSO). Short treatment (2 h) with 35 mu M FAA/+BSO or 100 mu M FAA/-BSO induced a transient cell cycle arrest at the G2/M transition (20% and 37%, respectively) 24 h post-treatment. In cells treated with 100 mu M FAA/-BSO, an inactivation, followed by a rapid over-induction of cyclin B-dependent kinase occurred, which peaked 24 h post-treatment. Maximum levels of caspase-1 and caspase-3 activation were detected at 3 h and 32 h, respectively, whereas release of mitochondrial cytochrome c was maximal at 24-32 h post-treatment. The G2/M peak declined 24 h later, concomitantly with the appearance of a sub-G I, apoptotic population showing typical nucleosomal-sized DNA fragmentation and reduced mitochondrial transmembrane potential (Delta psi(m)). These events were prevented by the general caspase inhibitor z-VAD-fmk, whereas G2/M arrest and subsequent apoptosis were abolished by GSH-monoethylester or N-acetylcysteine. Other tyrosine metabolites, maleylacetoacetate and succinylacetone, had no antiproliferative effects and induced only very low levels of apoptosis. These results suggest a modulator role of GSH in FAA-induced cell cycle disturbance and apoptosis Ft here activation of cyclin B-dependent kinase and caspase-1 are early events preceding mitochondrial cytochrome c release, caspase-3 activation, and Delta psi(m) loss.	Univ Laval, Lab Cell & Dev Genet, Dept Med, St Foy, PQ G1K 7P4, Canada; CHU Laval, Res Ctr, St Foy, PQ G1K 7P4, Canada	Laval University; Laval University	Tanguay, RM (corresponding author), Univ Laval, Lab Cell & Dev Genet, Dept Med, Pav CE Marchand, St Foy, PQ G1K 7P4, Canada.							Borgne A, 1996, J BIOL CHEM, V271, P27847, DOI 10.1074/jbc.271.44.27847; Bossy-Wetzel E, 1998, EMBO J, V17, P37, DOI 10.1093/emboj/17.1.37; DARZYNKIEWICZ Z, 1992, CYTOMETRY, V13, P795, DOI 10.1002/cyto.990130802; DAVIS FM, 1983, P NATL ACAD SCI-BIOL, V80, P2926, DOI 10.1073/pnas.80.10.2926; DECKWERTH TL, 1993, J CELL BIOL, V123, P1207, DOI 10.1083/jcb.123.5.1207; DEMARCQ C, 1994, CELL GROWTH DIFFER, V5, P983; DUKE RC, 1992, CURR PROT IMMUNOL, V1; EDGREN M, 1981, INT J RADIAT BIOL, V40, P355, DOI 10.1080/09553008114551311; EDWARDS SW, 1955, METHOD ENZYMOL, V2, P292; Endo F, 1997, J BIOL CHEM, V272, P24426, DOI 10.1074/jbc.272.39.24426; FAURE R, 1995, J CELL BIOCHEM, V59, P389, DOI 10.1002/jcb.240590310; Furnari B, 1997, SCIENCE, V277, P1495, DOI 10.1126/science.277.5331.1495; GONG JP, 1994, ANAL BIOCHEM, V218, P314, DOI 10.1006/abio.1994.1184; GORCZYCA W, 1993, CANCER RES, V53, P3186; Harvey KJ, 1998, MOL CELL BIOL, V18, P2912, DOI 10.1128/MCB.18.5.2912; Jorquera R, 1997, BIOCHEM BIOPH RES CO, V232, P42, DOI 10.1006/bbrc.1997.6220; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; Kluck RM, 1997, EMBO J, V16, P4639, DOI 10.1093/emboj/16.15.4639; KOHN KW, 1994, J CELL BIOCHEM, V54, P440, DOI 10.1002/jcb.240540411; Kubo S, 1998, P NATL ACAD SCI USA, V95, P9552, DOI 10.1073/pnas.95.16.9552; Laberge C., 1986, Essential nutrients in carcinogenesis, P209; LALANDE M, 1990, EXP CELL RES, V186, P332, DOI 10.1016/0014-4827(90)90313-Y; LAZEBNIK YA, 1994, NATURE, V371, P346, DOI 10.1038/371346a0; LINDBLAD B, 1977, P NATL ACAD SCI USA, V74, P4641, DOI 10.1073/pnas.74.10.4641; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; Margolin N, 1997, J BIOL CHEM, V272, P7223, DOI 10.1074/jbc.272.11.7223; Medema JP, 1997, EMBO J, V16, P2794, DOI 10.1093/emboj/16.10.2794; Mitchell G, 1995, METABOLIC MOL BASES, P1077; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; OCONNOR PM, 1992, CELL GROWTH DIFFER, V3, P43; PETIT PX, 1990, EUR J BIOCHEM, V194, P389, DOI 10.1111/j.1432-1033.1990.tb15632.x; PHANEUF D, 1992, J CLIN INVEST, V90, P1185, DOI 10.1172/JCI115979; Poon RYC, 1997, CANCER RES, V57, P5168; Prieto-Alamo MJ, 1998, P NATL ACAD SCI USA, V95, P12614, DOI 10.1073/pnas.95.21.12614; RUPPERT S, 1992, GENE DEV, V6, P1430, DOI 10.1101/gad.6.8.1430; SHI L, 1994, SCIENCE, V263, P1143, DOI 10.1126/science.8108732; SHIMIZU T, 1995, CANCER RES, V55, P228; Slee EA, 1999, J CELL BIOL, V144, P281, DOI 10.1083/jcb.144.2.281; Slee EA, 1996, BIOCHEM J, V315, P21, DOI 10.1042/bj3150021; StLouis M, 1997, HUM MUTAT, V9, P291, DOI 10.1002/(SICI)1098-1004(1997)9:4<291::AID-HUMU1>3.0.CO;2-9; STONER E, 1984, PEDIATR RES, V18, P1332, DOI 10.1203/00006450-198412000-00023; TANGUAY RM, 1990, AM J HUM GENET, V47, P308; Tanguay RM, 1996, ACTA BIOCHIM POL, V43, P209; Ueda S, 1998, J IMMUNOL, V161, P6689; Voehringer DW, 1998, P NATL ACAD SCI USA, V95, P2956, DOI 10.1073/pnas.95.6.2956; Wang XW, 1999, P NATL ACAD SCI USA, V96, P3706, DOI 10.1073/pnas.96.7.3706; WEINBERG AG, 1976, J PEDIATR-US, V88, P434, DOI 10.1016/S0022-3476(76)80259-4; WHITACRE CM, 1995, CANCER RES, V55, P3697; Yao SL, 1996, CANCER RES, V56, P4551	49	52	53	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	DEC	1999	13	15					2284	2298		10.1096/fasebj.13.15.2284	http://dx.doi.org/10.1096/fasebj.13.15.2284			15	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	266QN	10593876				2022-12-25	WOS:000084310800020
J	Knecht, H; Berger, C; McQuain, C; Rothenberger, S; Bachmann, E; Martin, J; Esslinger, C; Drexler, HG; Cai, YC; Quesenberry, PJ; Odermatt, BF				Knecht, H; Berger, C; McQuain, C; Rothenberger, S; Bachmann, E; Martin, J; Esslinger, C; Drexler, HG; Cai, YC; Quesenberry, PJ; Odermatt, BF			Latent membrane protein 1 associated signaling pathways are important in tumor cells of Epstein-Barr virus negative Hodgkin's disease	ONCOGENE			English	Article						LMP1; Reed-Sternberg cells; TRAF2; JNK pathway	NF-KAPPA-B; NECROSIS-FACTOR RECEPTOR; REED-STERNBERG CELLS; TERMINAL KINASE; MEDIATED TRANSCRIPTION; TRANSFORMING PROTEIN; CYTOPLASMIC DOMAIN; GENE-EXPRESSION; LMP1 ONCOGENE; ACTIVATION	The latent membrane protein 1 (LMP1) oncogene of Epstein-Barr virus (EBV) is selectively expressed in the Reed-Sternberg (RS) cells of EBV-associated Hodgkin's disease (HD). However, no differences in clinical presentation and course are found between EBV positive and EBV negative forms of HD suggesting a common pathogenetic mechanism. We have studied the LMP1 associated signaling pathways and their dominant negative inhibition in the myelomonocytic HD-MyZ and the B-lymphoid L-428 HD cell lines. In both EBV negative cell lines expression of LMP1 is associated with the formation of multinuclear RS cells. Dominant negative inhibition of NF-kappa B mediated signaling at the step of I kappa B-alpha phosphorylation results in increased cell death with only a few typical RS cells resistant to overexpression of the dominant negative inhibitor I kappa B-alpha-N Delta 54. However, dominant negative inhibition of NF-kappa B mediated signaling at the early step of TRAF2 interaction results in the formation of multinuclear cells in both cell lines and, in addition, in clusters of small mononuclear cells in the HD-MyZ cell line. In HD-MyZ cells overexpression of the powerful JBD-inhibitor of the JNK signal transduction pathway is restricted to small cells and never observed in RS cells. These small cells undergo apoptosis as shown by the TUNEL technique. Apoptosis of small cells is still observed after cotransfection of JBD and LMP1 but in addition a few apoptotic HD-MyZ cells with large fused nuclear masses are identified suggesting that specific inhibition of JNK leads also to apoptosis of LMP1. induced RS cells. Thus, activation of the JNK signaling pathway is also important in the formation of Reed-Sternberg cells. Our findings are consistent with a model where all three LMP1 associated functions, i.e. NF-kappa B mediated transcription, TRAF2 dependent signaling, and c-Jun activation act as a common pathogenetic denominator of both EBV negative and EBV positive HD.	Univ Massachusetts, Ctr Canc, LIMK Labs, Worcester, MA 01605 USA; Univ Lausanne, Inst Pharmacol & Toxicol, CH-1015 Lausanne, Switzerland; Univ Colorado, MCD Biol, Boulder, CO 80309 USA; LICR, Lausanne, Switzerland; DSMZ, Braunschweig, Germany; Univ Zurich Hosp, Lab Immunohistochem, CH-8091 Zurich, Switzerland	University of Massachusetts System; University of Massachusetts Worcester; University of Lausanne; University of Colorado System; University of Colorado Boulder; Leibniz Institut fur Deutsche Sammlung von Mikroorganismen und Zellkulturen (DSMZ); University of Zurich; University Zurich Hospital	Knecht, H (corresponding author), Viollier Inst, Div Hematol, Spalenring 145, CH-4002 Basel, Switzerland.			Rothenberger, Sylvia/0000-0001-8633-2994				Baeuerle PA, 1998, CURR BIOL, V8, pR19, DOI 10.1016/S0960-9822(98)70010-7; BAICHWAL VR, 1988, ONCOGENE, V2, P461; Baker SJ, 1996, ONCOGENE, V12, P1; Bargou RC, 1997, J CLIN INVEST, V100, P2961, DOI 10.1172/JCI119849; BARGOU RC, 1993, J EXP MED, V177, P1257, DOI 10.1084/jem.177.5.1257; Bargou RC, 1996, BLOOD, V87, P4340, DOI 10.1182/blood.V87.10.4340.bloodjournal87104340; Brodeur SR, 1997, J BIOL CHEM, V272, P19777, DOI 10.1074/jbc.272.32.19777; Cao ZD, 1996, NATURE, V383, P443, DOI 10.1038/383443a0; CARBONE A, 1995, BLOOD, V85, P780, DOI 10.1182/blood.V85.3.780.bloodjournal853780; Devergne O, 1996, MOL CELL BIOL, V16, P7098; Dickens M, 1997, SCIENCE, V277, P693, DOI 10.1126/science.277.5326.693; DREXLER HG, 1994, LEUKEMIA LYMPHOMA, V3, P201; Duckett CS, 1997, MOL CELL BIOL, V17, P1535, DOI 10.1128/MCB.17.3.1535; DURKOP H, 1992, CELL, V68, P421, DOI 10.1016/0092-8674(92)90180-K; Eliopoulos AG, 1996, ONCOGENE, V13, P2243; Eliopoulos AG, 1998, ONCOGENE, V16, P1731, DOI 10.1038/sj.onc.1201694; Floettmann JE, 1997, ONCOGENE, V15, P1851, DOI 10.1038/sj.onc.1201359; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; Gires O, 1997, EMBO J, V16, P6131, DOI 10.1093/emboj/16.20.6131; Glaser SL, 1997, INT J CANCER, V70, P375, DOI 10.1002/(SICI)1097-0215(19970207)70:4&lt;375::AID-IJC1&gt;3.0.CO;2-T; HALUSKA FG, 1994, BLOOD, V84, P1005, DOI 10.1182/blood.V84.4.1005.bloodjournal8441005; HAMMARSKJOLD ML, 1992, J VIROL, V66, P6496; HENDERSON S, 1991, CELL, V65, P1107, DOI 10.1016/0092-8674(91)90007-L; HERBST H, 1991, P NATL ACAD SCI USA, V88, P4766, DOI 10.1073/pnas.88.11.4766; HERRERO JA, 1995, J VIROL, V69, P2168, DOI 10.1128/JVI.69.4.2168-2174.1995; HUEN DS, 1995, ONCOGENE, V10, P549; Izumi KM, 1999, MOL CELL BIOL, V19, P5759; Izumi KM, 1997, P NATL ACAD SCI USA, V94, P12592, DOI 10.1073/pnas.94.23.12592; JOSKE DJL, 1992, BLOOD, V80, P2610; Kadin Marshall E., 1994, Current Opinion in Oncology, V6, P456, DOI 10.1097/00001622-199409000-00002; Kanzler H, 1996, J EXP MED, V184, P1495, DOI 10.1084/jem.184.4.1495; Karin M, 1997, CURR OPIN CELL BIOL, V9, P240, DOI 10.1016/S0955-0674(97)80068-3; Kaye KM, 1996, P NATL ACAD SCI USA, V93, P11085, DOI 10.1073/pnas.93.20.11085; Kieser A, 1999, EMBO J, V18, P2511, DOI 10.1093/emboj/18.9.2511; Kieser A, 1997, EMBO J, V16, P6478, DOI 10.1093/emboj/16.21.6478; Kilger E, 1998, EMBO J, V17, P1700, DOI 10.1093/emboj/17.6.1700; KNECHT H, 1993, BLOOD, V82, P2937; Knecht H, 1996, ONCOGENE, V13, P947; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; MARTIN JM, 1993, J VIROL, V67, P5269, DOI 10.1128/JVI.67.9.5269-5278.1993; Messineo C, 1998, BLOOD, V91, P2443, DOI 10.1182/blood.V91.7.2443.2443_2443_2451; MITCHELL T, 1995, J VIROL, V69, P2968, DOI 10.1128/JVI.69.5.2968-2976.1995; MOORTHY RK, 1993, J VIROL, V67, P1638, DOI 10.1128/JVI.67.3.1638-1646.1993; MOSIALOS G, 1995, CELL, V80, P389, DOI 10.1016/0092-8674(95)90489-1; PALLESEN G, 1991, LANCET, V337, P320, DOI 10.1016/0140-6736(91)90943-J; REGNIER CH, 1995, J BIOL CHEM, V270, P25715, DOI 10.1074/jbc.270.43.25715; Reinhard C, 1997, EMBO J, V16, P1080, DOI 10.1093/emboj/16.5.1080; Rothe M, 1996, P NATL ACAD SCI USA, V93, P8241, DOI 10.1073/pnas.93.16.8241; Rothe M, 1995, CELL, V83, P1243, DOI 10.1016/0092-8674(95)90149-3; ROTHE M, 1995, SCIENCE, V269, P1424, DOI 10.1126/science.7544915; ROTHE M, 1994, CELL, V78, P681, DOI 10.1016/0092-8674(94)90532-0; Rothenberger S, 1997, ONCOGENE, V14, P2123, DOI 10.1038/sj.onc.1201032; Sandberg M, 1997, J VIROL, V71, P4649, DOI 10.1128/JVI.71.6.4649-4656.1997; SCHAADT M, 1979, BLUT, V38, P185, DOI 10.1007/BF01007965; STEIN H, 1985, BLOOD, V66, P848; Takeuchi M, 1996, J BIOL CHEM, V271, P19935, DOI 10.1074/jbc.271.33.19935; URBA WJ, 1992, NEW ENGL J MED, V326, P678, DOI 10.1056/NEJM199203053261006; Van Antwerp DJ, 1998, TRENDS CELL BIOL, V8, P107, DOI 10.1016/S0962-8924(97)01215-4; WANG D, 1985, CELL, V43, P831, DOI 10.1016/0092-8674(85)90256-9; Whitmarsh AJ, 1996, J MOL MED-JMM, V74, P589, DOI 10.1007/s001090050063	60	17	19	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 25	1999	18	50					7161	7167		10.1038/sj.onc.1203177	http://dx.doi.org/10.1038/sj.onc.1203177			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	259PH	10597317				2022-12-25	WOS:000083901900023
J	Blagosklonny, MV; An, WG; Melillo, G; Nguyen, P; Trepel, JB; Neckers, LM				Blagosklonny, MV; An, WG; Melillo, G; Nguyen, P; Trepel, JB; Neckers, LM			Regulation of BRCA1 by protein degradation	ONCOGENE			English	Article						BRCA1; protein degradation; proteasome; acidic proteases; cathepsin; calpain	SUSCEPTIBILITY GENE-PRODUCT; BREAST-CANCER CELLS; NUCLEAR EXPORT; P53 PROTEIN; TRANSCRIPTIONAL ACTIVATION; PROTEOLYTIC CLEAVAGE; MUTATED P53; DNA-DAMAGE; IN-VIVO; EXPRESSION	BRCA1, a tumor suppressor protein implicated in hereditary forms of breast and ovarian cancer, is transcriptionally regulated in a proliferation-dependent manner. In this study, we demonstrate a substantial role for proteolysis in regulating the BRCA1 steady-state protein level in several cell lines. N-acetyl-leu-leu-norleucinal (ALLN), an inhibitor of the proteasome, calpain, and cathepsins, caused BRCA1 protein to accumulate in the nucleus of several human breast, prostate, and melanoma cell lines which express low or undetectable basal levels of BRCA1 protein, but not in cells with high basal expression of BRCA1. Protease inhibition did not increase BRCA1 synthesis, nor change its mRNA level, but it dramatically prolonged the protein's half-life. In contrast to ALLN, lactacystin and PS341, two specific proteasome inhibitors, as well as calpastatin peptide and PD150606, two selective calpain inhibitors, had no effect on BRCA1 stability, whereas ALLM, an effective calpain and cathepsin inhibitor but weak proteasome inhibitor, did stimulate accumulation of BRCA1. Moreover, three inhibitors of acidic cysteine proteases, chloroquine, ammonium chloride and bafilomycin, were as effective as ALLN. These results demonstrate that degradation by a cathepsin-like protease in fine balance with BRCA1 transcription is responsible for maintaining the low steady-state level of BRCA1 protein seen in many cancer cells.	NCI, Med Branch, Dept Therapeut, NIH, Rockville, MD 20850 USA; NCI, Dept Cell & Canc Biol, Med Branch, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Neckers, LM (corresponding author), NCI, Med Branch, Dept Therapeut, NIH, 9610 Med Ctr Dr,Suite 300, Rockville, MD 20850 USA.				NATIONAL CANCER INSTITUTE [ZIASC010074, Z01SC010074] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		An WG, 1998, NATURE, V392, P405, DOI 10.1038/32925; Andres JL, 1998, ONCOGENE, V16, P2229, DOI 10.1038/sj.onc.1201752; ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; Aniento F, 1996, FEBS LETT, V390, P47, DOI 10.1016/0014-5793(96)00625-4; Aprelikova O, 1996, ONCOGENE, V13, P2487; Bishop DT, 1997, SEMIN CANCER BIOL, V8, P45, DOI 10.1006/scbi.1997.0053; Blackwood MA, 1998, J CLIN ONCOL, V16, P1969, DOI 10.1200/JCO.1998.16.5.1969; Blagosklonny MV, 1997, ONCOGENE, V15, P1889, DOI 10.1038/sj.onc.1201374; BLAGOSKLONNY MV, 1995, ONCOGENE, V11, P933; Brugarolas J, 1997, NAT MED, V3, P721, DOI 10.1038/nm0797-721; Carafoli E, 1998, BIOCHEM BIOPH RES CO, V247, P193, DOI 10.1006/bbrc.1998.8378; Chai YL, 1999, ONCOGENE, V18, P263, DOI 10.1038/sj.onc.1202323; Chapman MS, 1996, NATURE, V382, P678, DOI 10.1038/382678a0; Fan S, 1999, SCIENCE, V284, P1354, DOI 10.1126/science.284.5418.1354; Fenteany G, 1998, J BIOL CHEM, V273, P8545, DOI 10.1074/jbc.273.15.8545; Fornerod M, 1997, CELL, V90, P1051, DOI 10.1016/S0092-8674(00)80371-2; Freedman DA, 1998, MOL CELL BIOL, V18, P7288, DOI 10.1128/MCB.18.12.7288; Fu YHF, 1998, FEBS LETT, V421, P89, DOI 10.1016/S0014-5793(97)01541-X; Fukuda M, 1997, NATURE, V390, P308, DOI 10.1038/36894; Gonen H, 1997, FEBS LETT, V406, P17, DOI 10.1016/S0014-5793(97)00225-1; Grisham MB, 1999, METHOD ENZYMOL, V300, P345; GUDAS JM, 1995, CANCER RES, V55, P4561; Gudas JM, 1996, CELL GROWTH DIFFER, V7, P717; Holaska JM, 1998, P NATL ACAD SCI USA, V95, P14739, DOI 10.1073/pnas.95.25.14739; Holt JT, 1996, NAT GENET, V12, P298, DOI 10.1038/ng0396-298; INOUE S, 1991, J BIOL CHEM, V266, P13311; Jin Y, 1997, P NATL ACAD SCI USA, V94, P12075, DOI 10.1073/pnas.94.22.12075; KASTAN MB, 1991, CANCER RES, V51, P6304; Kubbutat MHG, 1997, MOL CELL BIOL, V17, P460, DOI 10.1128/MCB.17.1.460; Kudo N, 1998, EXP CELL RES, V242, P540, DOI 10.1006/excr.1998.4136; Lain S, 1999, EXP CELL RES, V248, P457, DOI 10.1006/excr.1999.4433; Maki CG, 1996, CANCER RES, V56, P2649; MELILLO G, 1995, J EXP MED, V182, P1683, DOI 10.1084/jem.182.6.1683; MERCER WE, 1985, EXP CELL RES, V160, P31, DOI 10.1016/0014-4827(85)90233-2; Monteiro ANA, 1996, P NATL ACAD SCI USA, V93, P13595, DOI 10.1073/pnas.93.24.13595; Nagaya T, 1998, J BIOL CHEM, V273, P33166, DOI 10.1074/jbc.273.50.33166; NELSON WG, 1994, MOL CELL BIOL, V14, P1815, DOI 10.1128/MCB.14.3.1815; NISHI K, 1994, J BIOL CHEM, V269, P6320; Nishinaka T, 1997, BBA-GENE STRUCT EXPR, V1351, P274, DOI 10.1016/S0167-4781(96)00210-2; Ouchi T, 1998, P NATL ACAD SCI USA, V95, P2302, DOI 10.1073/pnas.95.5.2302; Paoletti F, 1997, J CELL PHYSIOL, V172, P63, DOI 10.1002/(SICI)1097-4652(199707)172:1<63::AID-JCP7>3.3.CO;2-F; Pariat M, 1997, MOL CELL BIOL, V17, P2806, DOI 10.1128/MCB.17.5.2806; REICH NC, 1984, NATURE, V308, P199, DOI 10.1038/308199a0; ROCK KL, 1994, CELL, V78, P761, DOI 10.1016/S0092-8674(94)90462-6; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; Scheffner M, 1998, PHARMACOL THERAPEUT, V78, P129, DOI 10.1016/S0163-7258(98)00003-5; Scully R, 1997, CELL, V88, P265, DOI 10.1016/S0092-8674(00)81847-4; Somasundaram K, 1997, NATURE, V389, P187, DOI 10.1038/38291; Stommel JM, 1999, EMBO J, V18, P1660, DOI 10.1093/emboj/18.6.1660; THOMPSON ME, 1995, NAT GENET, V9, P444, DOI 10.1038/ng0495-444; Wang KKW, 1996, P NATL ACAD SCI USA, V93, P6687, DOI 10.1073/pnas.93.13.6687; Whitesell L, 1997, ONCOGENE, V14, P2809, DOI 10.1038/sj.onc.1201120; Zhang HB, 1998, ONCOGENE, V16, P1713, DOI 10.1038/sj.onc.1201932; Zhang WL, 1997, ONCOGENE, V14, P255, DOI 10.1038/sj.onc.1200841	54	58	59	1	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 11	1999	18	47					6460	6468		10.1038/sj.onc.1203068	http://dx.doi.org/10.1038/sj.onc.1203068			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	256CW	10597248				2022-12-25	WOS:000083709200008
J	Li, WQ; Zhang, JC; Flechner, L; Hyun, T; Yam, A; Franke, TF; Pierce, JH				Li, WQ; Zhang, JC; Flechner, L; Hyun, T; Yam, A; Franke, TF; Pierce, JH			Protein kinase C-alpha overexpression stimulates Akt activity and suppresses apoptosis induced by interleukin 3 withdrawal	ONCOGENE			English	Article						apoptosis; Akt/protein kinase B; protein; kinase C-alpha	MYC-INDUCED APOPTOSIS; SIGNAL-TRANSDUCTION; PHOSPHATIDYLINOSITOL 3-KINASE; PROTEOLYTIC ACTIVATION; MOLECULAR-CLONING; LEUKEMIA-CELLS; BETA-II; DELTA; FAMILY; TARGET	To investigate the role of protein kinase C (PKC) in apoptotic signaling induced by cytokine withdrawal, we expressed PKC-alpha, -delta and -epsilon individually in the 32D myeloid progenitor cells. The parental and PKC-delta- and PKC-epsilon- transfected 32D cells underwent apoptosis within 24 h in the absence of interleukin 3. In contrast, expression of PKC-alpha inhibited the onset of apoptosis as determined by genomic DNA fragmentation and flow cytometric analysis. Correlating with the inhibition of apoptosis, PKC-alpha transfectants exhibited increased activity of the endogenous Akt serine/threonine kinase. Furthermore, PKC-alpha, but not PKC-delta or -epsilon, specifically activated overexpressed Akt. PKC-alpha-induced Akt activity was partially dependent on phosphoinositol 3' kinase (PI 3'K) since a PI 3'K inhibitor was able to suppress PKC-alpha-induced Akt activation. Both basal and interleukin 3-stimulated phosphorylation of Akt on serine 473 was enhanced in the PKC-alpha and Akt contransfectants. Coexpression of wild type Akt and PKC-alpha resulted in greater suppression of apoptosis than PKC-alpha expression alone. Together, our results demonstrate that suppression of apoptosis by PKC-alpha correlates with its ability of activating endogenous Akt. Furthermore, activation of overexpressed Akt by PKC-alpha is consistent with their synergistic effect on suppressing apoptosis, providing the strong evidence of cross talk between Akt and PKC-alpha.	NCI, Cellular & Mol Biol Lab, Bethesda, MD 20892 USA; Columbia Univ, Dept Pharmacol, New York, NY 10032 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Columbia University	Li, WQ (corresponding author), Georgetown Univ, Med Ctr, Vincent T Lombardi Canc Res Ctr, Stem Cell Res Lab, 3970 Reservoir Rd NW,NRB W309, Washington, DC 20007 USA.		Roszak, Joanna/F-4003-2010	Hyun, Teresa/0000-0002-9350-2733				Ahmed NN, 1997, P NATL ACAD SCI USA, V94, P3627, DOI 10.1073/pnas.94.8.3627; Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; Andjelkovic M, 1997, J BIOL CHEM, V272, P31515, DOI 10.1074/jbc.272.50.31515; Barr LF, 1997, CELL GROWTH DIFFER, V8, P381; BELLACOSA A, 1991, SCIENCE, V254, P274, DOI 10.1126/science.1833819; Berra E, 1997, MOL CELL BIOL, V17, P4346, DOI 10.1128/MCB.17.8.4346; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; CORY S, 1995, ANNU REV IMMUNOL, V13, P513, DOI 10.1146/annurev.iy.13.040195.002501; DATTA K, 1995, MOL CELL BIOL, V15, P2304; Datta R, 1997, J BIOL CHEM, V272, P20317, DOI 10.1074/jbc.272.33.20317; delPeso L, 1997, SCIENCE, V278, P687; DiazMeco MT, 1996, CELL, V86, P777, DOI 10.1016/S0092-8674(00)80152-X; Downward J, 1998, SCIENCE, V279, P673, DOI 10.1126/science.279.5351.673; Emoto Y, 1996, BLOOD, V87, P1990; Emoto Y, 1995, EMBO J, V14, P6148, DOI 10.1002/j.1460-2075.1995.tb00305.x; Eves EM, 1998, MOL CELL BIOL, V18, P2143, DOI 10.1128/MCB.18.4.2143; FAIRBAIRN LJ, 1993, CELL, V74, P823, DOI 10.1016/0092-8674(93)90462-Y; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; Franke TF, 1997, CELL, V88, P435, DOI 10.1016/S0092-8674(00)81883-8; Ghayur T, 1996, J EXP MED, V184, P2399, DOI 10.1084/jem.184.6.2399; Hemmings BA, 1997, SCIENCE, V277, P534, DOI 10.1126/science.277.5325.534; JOHANNES FJ, 1994, J BIOL CHEM, V269, P6140; JONES PF, 1991, P NATL ACAD SCI USA, V88, P4171, DOI 10.1073/pnas.88.10.4171; KauffmanZeh A, 1997, NATURE, V385, P544, DOI 10.1038/385544a0; Kelly ML, 1998, BLOOD, V92, P416, DOI 10.1182/blood.V92.2.416.414k01_416_424; Kennedy SG, 1997, GENE DEV, V11, P701, DOI 10.1101/gad.11.6.701; KORSMEYER SJ, 1995, TRENDS GENET, V11, P101, DOI 10.1016/S0168-9525(00)89010-1; Le Good JA, 1998, SCIENCE, V281, P2042, DOI 10.1126/science.281.5385.2042; LI WQ, 1995, J BIOL CHEM, V270, P8311, DOI 10.1074/jbc.270.14.8311; LI WQ, 1994, MOL CELL BIOL, V14, P6727, DOI 10.1128/MCB.14.10.6727; MISCHAK H, 1993, J BIOL CHEM, V268, P20110; Mizuno K, 1997, EUR J BIOCHEM, V250, P7, DOI 10.1111/j.1432-1033.1997.00007.x; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; O'Brian CA, 1998, ONCOL REP, V5, P305; OHNO S, 1991, ADV ENZYME REGUL, V31, P287, DOI 10.1016/0065-2571(91)90018-H; Peter ME, 1997, P NATL ACAD SCI USA, V94, P12736, DOI 10.1073/pnas.94.24.12736; Pullen N, 1998, SCIENCE, V279, P707, DOI 10.1126/science.279.5351.707; Saini KS, 1998, MOL CELL BIOCHEM, V178, P9, DOI 10.1023/A:1006891430596; Stephens L, 1998, SCIENCE, V279, P710, DOI 10.1126/science.279.5351.710; Stokoe D, 1997, SCIENCE, V277, P567, DOI 10.1126/science.277.5325.567; VALVERDE AM, 1994, P NATL ACAD SCI USA, V91, P8572, DOI 10.1073/pnas.91.18.8572; Vanhaesebroeck B, 1997, TRENDS BIOCHEM SCI, V22, P267, DOI 10.1016/S0968-0004(97)01061-X; Whelan RDH, 1998, ONCOGENE, V16, P1939, DOI 10.1038/sj.onc.1201725; Whitman SP, 1997, J BIOL CHEM, V272, P23481, DOI 10.1074/jbc.272.38.23481; Zhou SY, 1997, P NATL ACAD SCI USA, V94, P11345, DOI 10.1073/pnas.94.21.11345	45	93	94	1	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 11	1999	18	47					6564	6572		10.1038/sj.onc.1203065	http://dx.doi.org/10.1038/sj.onc.1203065			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	256CW	10597260				2022-12-25	WOS:000083709200020
J	Majumder, S; Ghoshal, K; Li, ZL; Bo, Y; Jacob, ST				Majumder, S; Ghoshal, K; Li, ZL; Bo, Y; Jacob, ST			Silencing of metallothionein-I gene in mouse lymphosarcoma cells by methylation	ONCOGENE			English	Article						metallothionein; methylation; lymphosarcoma; thymus; bisulfite sequencing	CCAAT-HOMOLOGOUS SEQUENCES; TRANSCRIPTION FACTOR MTF-1; DNA METHYLATION; BINDING-SITES; HEAVY-METALS; PROMOTER; INDUCTION; PROTEIN; METHYLTRANSFERASE; HYPERMETHYLATION	Metallothionein-I (MT-I) gene is silenced by methylation of CpG islands in mouse lymphosarcoma P1798 cells but not in the thymus, the cell type from which the tumor was derived. Bisulfite genomic sequencing revealed that all 21 CpG dinucleotides present within -216 bp to +1 bp with respect to transcription start site are methylated in the tumor cell line, but none is methylated in the thymus. The lymphosarcoma cells induced MT-I in response to heavy metals only after demethylation with 5-azacytidine (5-AsaC). The electrophoretic mobility shift assay using specific oligonucleotide probes showed that the key transcription factors regulating MT-I gene (e.g., MTF-1, Sp 1 and MLTF/USF) are active in P1798 cells. In vivo footprinting of the proximal promoter region showed that none of the metal regulatory elements (MREs) or MLTF/USF are occupied in response to heavy metals. Demethylation of the lymphosarcoma cells with 5-AzaC resulted in constitutive footprinting at MLTF/ARE, and zinc-inducible footprinting at MRE-c, MRE-d and MRE-e sites. Demethylation of just 10-20% of the CpG islands was sufficient to render the gene inducible by cadmium or zinc. The MT-I induction persisted in the cancer cells for several generations even after withdrawal of 5-AzaC from the culture medium.	Ohio State Univ, Coll Med, Dept Med Biochem, Columbus, OH 43210 USA; Ohio State Univ, Ctr Comprehens Canc, Columbus, OH 43210 USA	University System of Ohio; Ohio State University; James Cancer Hospital & Solove Research Institute; University System of Ohio; Ohio State University	Jacob, ST (corresponding author), Ohio State Univ, Coll Med, Dept Med Biochem, 333 Hamilton Hall,1645 Neil Ave, Columbus, OH 43210 USA.		Jacob, Samson/H-3135-2011; bo, yu/AAB-3064-2019		NATIONAL CANCER INSTITUTE [R01CA061321] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA061321-05, CA61321] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aniskovitch LP, 1997, ARCH BIOCHEM BIOPHYS, V341, P337, DOI 10.1006/abbi.1997.9976; Aniskovitch LP, 1998, ONCOGENE, V16, P1475, DOI 10.1038/sj.onc.1201659; Aschner M, 1997, TOXICOL APPL PHARM, V142, P229, DOI 10.1006/taap.1996.8054; Baylin SB, 1998, ADV CANCER RES, V72, P141; Baylin SB, 1997, SCIENCE, V277, P1948, DOI 10.1126/science.277.5334.1948; Cameron EE, 1999, NAT GENET, V21, P103, DOI 10.1038/5047; CARTHEW RW, 1987, GENE DEV, V1, P973, DOI 10.1101/gad.1.9.973; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHUBATSU LS, 1993, BIOCHEM J, V291, P193, DOI 10.1042/bj2910193; CLARK SJ, 1995, NAT GENET, V10, P20, DOI 10.1038/ng0595-20; CLARK SJ, 1994, NUCLEIC ACIDS RES, V22, P2990, DOI 10.1093/nar/22.15.2990; COMPERE SJ, 1981, CELL, V25, P233, DOI 10.1016/0092-8674(81)90248-8; DATTA PK, 1993, CELL MOL BIOL RES, V39, P439; Datta PK, 1997, BIOCHEM BIOPH RES CO, V230, P159, DOI 10.1006/bbrc.1996.5655; Deng J, 1998, J BIOL CHEM, V273, P22869, DOI 10.1074/jbc.273.36.22869; FEINBERG AP, 1988, CANCER RES, V48, P1159; FROMMER M, 1992, P NATL ACAD SCI USA, V89, P1827, DOI 10.1073/pnas.89.5.1827; Ghoshal K, 1998, P NATL ACAD SCI USA, V95, P10390, DOI 10.1073/pnas.95.18.10390; Ghoshal K, 1996, BIOCHEM J, V317, P689, DOI 10.1042/bj3170689; Ghoshal K, 1998, J BIOL CHEM, V273, P27904, DOI 10.1074/jbc.273.43.27904; Harrison J, 1998, ANAL BIOCHEM, V264, P129, DOI 10.1006/abio.1998.2833; HEUCHEL R, 1994, EMBO J, V13, P2870, DOI 10.1002/j.1460-2075.1994.tb06581.x; Jaenisch R, 1997, TRENDS GENET, V13, P323, DOI 10.1016/S0168-9525(97)01180-3; KAGI JHR, 1991, METHOD ENZYMOL, V205, P613; Kass SU, 1997, TRENDS GENET, V13, P444, DOI 10.1016/S0168-9525(97)01268-7; KELLEY SL, 1988, SCIENCE, V241, P1813, DOI 10.1126/science.3175622; Klein CB, 1997, MUTAT RES-REV MUTAT, V386, P163, DOI 10.1016/S1383-5742(96)00052-X; KNIGHT SJL, 1993, CELL, V74, P127, DOI 10.1016/0092-8674(93)90300-F; Lengauer C, 1997, P NATL ACAD SCI USA, V94, P2545, DOI 10.1073/pnas.94.6.2545; Lewin B, 1998, CELL, V93, P301, DOI 10.1016/S0092-8674(00)81154-X; LI E, 1993, COLD SPRING HARB SYM, V58, P297, DOI 10.1101/SQB.1993.058.01.035; Li QW, 1998, NUCLEIC ACIDS RES, V26, P5182, DOI 10.1093/nar/26.22.5182; MUELLER PR, 1989, SCIENCE, V246, P780, DOI 10.1126/science.2814500; Nan XS, 1997, CELL, V88, P471, DOI 10.1016/S0092-8674(00)81887-5; Ng MHL, 1997, BLOOD, V89, P2500, DOI 10.1182/blood.V89.7.2500; NORRIS DP, 1994, CELL, V77, P41, DOI 10.1016/0092-8674(94)90233-X; Palmiter R D, 1987, Experientia Suppl, V52, P63; Ping DS, 1996, IMMUNITY, V4, P455, DOI 10.1016/S1074-7613(00)80412-4; Pitt BR, 1997, AM J PHYSIOL-LUNG C, V273, pL856, DOI 10.1152/ajplung.1997.273.4.L856; QUAIFE CJ, 1994, BIOCHEMISTRY-US, V33, P7250, DOI 10.1021/bi00189a029; RADTKE F, 1993, EMBO J, V12, P1355, DOI 10.1002/j.1460-2075.1993.tb05780.x; Radtke F, 1996, BIOL CHEM H-S, V377, P47, DOI 10.1515/bchm3.1996.377.1.47; ROBERTSON KD, 1995, MOL CELL BIOL, V15, P6150; SANTI DV, 1984, P NATL ACAD SCI-BIOL, V81, P6993, DOI 10.1073/pnas.81.22.6993; SANTI DV, 1983, CELL, V33, P9, DOI 10.1016/0092-8674(83)90327-6; SCHWARZ MA, 1995, P NATL ACAD SCI USA, V92, P4452, DOI 10.1073/pnas.92.10.4452; Szyf M, 1996, PHARMACOL THERAPEUT, V70, P1, DOI 10.1016/0163-7258(96)00002-2; Warnecke PM, 1997, NUCLEIC ACIDS RES, V25, P4422, DOI 10.1093/nar/25.21.4422; WATT F, 1990, PHILOS T R SOC LON B, V326, P267; WOOD KM, 1984, MOL CELL ENDOCRINOL, V37, P169, DOI 10.1016/0303-7207(84)90049-2; YAGLE MK, 1985, MOL CELL BIOL, V5, P291, DOI 10.1128/MCB.5.2.291	51	39	39	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 4	1999	18	46					6287	6295		10.1038/sj.onc.1203004	http://dx.doi.org/10.1038/sj.onc.1203004			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	260DK	10597227	Green Accepted			2022-12-25	WOS:000083934100012
J	Drake, RR; Wilbert, TN; Hinds, TA; Gilbert, KM				Drake, RR; Wilbert, TN; Hinds, TA; Gilbert, KM			Differential ganciclovir-mediated cell killing by glutamine 125 mutants of herpes simplex virus type 1 thymidine kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SUICIDE-GENE-THERAPY; IN-VITRO; TUMOR; CANCER; DEATH; PHASE; LYMPHOCYTES; METABOLISM; REGRESSION; EXPRESSION	The therapeutic combination of the herpesvirus simplex virus type 1 (HSV-1) thymidine kinase (TK) gene and the prodrug, ganciclovir (GCV), has found great utility for the treatment of many types of cancer. After initial phosphorylation of GCV by HSV-1 TK, cellular kinases generate the toxic GCV-triphosphate metabolite that is incorporated into DNA and eventually leads to tumor cell death, The cellular and pharmacological mechanisms by which metabolites of GCV lead to cell death are still poorly defined. To bean to address these mechanisms, different mutated forms of HSV-1 TK at residue Gln-125 that have distinct substrate properties were expressed in mammalian cell lines. It was found that expression of the Asn-125 HSV-1 TK mutant in two cell lines, NIH3T3 and HCT-116, was equally effective as wild-type HSV-1 TK for metabolism and sensitivity to GCV, bystander effect killing and induction of apoptosis. The major difference between the two enzymes was the lack of deoxypyrimidine metabolism in the Asn-125 TK-expressing cells. In HCT-116 cells expressing the Glu-125 TK mutant, GCV metabolism was greatly attenuated, yet at higher GCV concentrations, cell sensitivity to the drug and bystander effect killing were diminished but still effective. Cell cycle analysis, 4',6'-diamidine-2'-phenylindoledihydrochloride staining, and caspase 3 activation assays indicated different cell death responses in the Glu-125 TK-expressing cells as compared with the wild-type HSV-1 TK or Asn-125 TK-expressing cells. A mechanistic hypothesis to explain these results based on the differences in GCV-triphosphate metabolite levels is presented.	Univ Arkansas Med Sci, Dept Biochem & Mol Biol, Little Rock, AR 72205 USA; Univ Arkansas Med Sci, Dept Microbiol & Immunol, Little Rock, AR 72205 USA	University of Arkansas System; University of Arkansas Medical Sciences; University of Arkansas System; University of Arkansas Medical Sciences	Drake, RR (corresponding author), Univ Arkansas Med Sci, Dept Biochem, Slot 516,4301 W Markham, Little Rock, AR 72205 USA.				NCI NIH HHS [CA77938-01] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R41CA077938] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADAM L, 1995, CANCER RES, V55, P5156; BI WL, 1993, HUM GENE THER, V4, P725, DOI 10.1089/hum.1993.4.6-725; Bi WL, 1997, CANCER GENE THER, V4, P246; Bonini C, 1997, SCIENCE, V276, P1719, DOI 10.1126/science.276.5319.1719; CULVER KW, 1992, SCIENCE, V256, P1550, DOI 10.1126/science.1317968; Denning C, 1997, HUM GENE THER, V8, P1825, DOI 10.1089/hum.1997.8.15-1825; Drake RR, 1997, ANTIVIR RES, V35, P177, DOI 10.1016/S0166-3542(97)00027-2; FREEMAN SM, 1993, CANCER RES, V53, P5274; Freeman SM, 1997, LANCET, V349, P2, DOI 10.1016/S0140-6736(97)22001-5; Freeman SM, 1996, SEMIN ONCOL, V23, P31; Hall SJ, 1998, CANCER RES, V58, P3221; Halloran PJ, 1998, CANCER RES, V58, P3855; Hamel W, 1996, CANCER RES, V56, P2697; ILSLEY DD, 1995, BIOCHEMISTRY-US, V34, P2504, DOI 10.1021/bi00008a014; KANEKO Y, 1995, CANCER LETT, V96, P105, DOI 10.1016/0304-3835(95)03919-N; Kianmanesh AR, 1997, HUM GENE THER, V8, P1807, DOI 10.1089/hum.1997.8.15-1807; KIM YG, 1999, IN PRESS CANC GENE T; Klatzmann D, 1998, HUM GENE THER, V9, P2595, DOI 10.1089/hum.1998.9.17-2595; McMasters RA, 1998, HUM GENE THER, V9, P2253, DOI 10.1089/hum.1998.9.15-2253; Melcher A, 1998, NAT MED, V4, P581, DOI 10.1038/nm0598-581; Mullen CA, 1998, HUM GENE THER, V9, P2019, DOI 10.1089/hum.1998.9.14-2019; Rubsam LZ, 1999, CANCER RES, V59, P669; Rubsam LZ, 1998, CANCER RES, V58, P3873; Rudel T, 1997, SCIENCE, V276, P1571, DOI 10.1126/science.276.5318.1571; SMEE DF, 1985, BIOCHEM PHARMACOL, V34, P1049, DOI 10.1016/0006-2952(85)90608-2; Sterman DH, 1998, HUM GENE THER, V9, P1083, DOI 10.1089/hum.1998.9.7-1083; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Vile RG, 1997, INT J CANCER, V71, P267; WEI MX, 1998, CANCER RES, V58, P3221; Wei SJ, 1998, EXP CELL RES, V241, P66, DOI 10.1006/excr.1998.4005	30	22	23	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 24	1999	274	52					37186	37192		10.1074/jbc.274.52.37186	http://dx.doi.org/10.1074/jbc.274.52.37186			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	267WR	10601281	hybrid			2022-12-25	WOS:000084382700052
J	Szegedy, MA; Maguire, ME				Szegedy, MA; Maguire, ME			The CorA Mg2+ transport protein of Salmonella typhimurium - Mutagenesis of conserved residues in the second membrane domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAGNESIUM TRANSPORT; ESCHERICHIA-COLI; REGULATORY CATION; MG-2+ TRANSPORT; RIBONUCLEASE-H; ION; BINDING; SYSTEM; METALLOBIOCHEMISTRY; ACTIVATION	Salmonella typhimurium CorA is the archetypal member of the largest family of Mg2+ transporters of the Bacteria and Archaea, It contains three transmembrane segments. There are no conserved charged residues within these segments indicating electrostatic interactions are not used in Mg2+ transport through CorA, Previous mutagenesis studies of CorA revealed a single face of the third transmembrane segment that is important for Mg2+ transport. In this study, we mutated hydroxyl-bearing and other conserved residues in the second transmembrane segment to identify residues involved in transport. Residues Ser(260), Thr(270) and Ser(274) appear to be important for transport and are oriented such that they would also line a face of an alpha-helix, In addition, the sequence (276)YGMNF(280), found in virtually all CorA homologues, is critical for CorA function because even conservative mutations are not tolerated at these residues. Finally, mutations of residues in the second transmembrane segment, unlike those in the third transmembrane segment, revealed cooperative behavior for the influx of Mg2+. We conclude that the second transmembrane segment forms a major part of the Mg2+ pore with the third transmembrane segment of CorA.	Case Western Reserve Univ, Sch Med, Dept Pharmacol, Cleveland, OH 44106 USA	Case Western Reserve University	Szegedy, MA (corresponding author), Case Western Reserve Univ, Sch Med, Dept Pharmacol, 10900 Euclid Ave, Cleveland, OH 44106 USA.	mxs100@po.cwru.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM039447] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM08056, GM39447] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bui DM, 1999, J BIOL CHEM, V274, P20438, DOI 10.1074/jbc.274.29.20438; Chang G, 1998, SCIENCE, V282, P2220, DOI 10.1126/science.282.5397.2220; Cowan JA, 1998, CHEM REV, V98, P1067, DOI 10.1021/cr960436q; COWAN JA, 1991, INORG CHEM, V30, P2740, DOI 10.1021/ic00013a008; Doyle DA, 1998, SCIENCE, V280, P69, DOI 10.1126/science.280.5360.69; GIBSON MM, 1991, MOL MICROBIOL, V5, P2753, DOI 10.1111/j.1365-2958.1991.tb01984.x; GROISMAN EA, 1989, P NATL ACAD SCI USA, V86, P7077, DOI 10.1073/pnas.86.18.7077; GRUBBS RD, 1989, METHOD ENZYMOL, V173, P546; GRUBBS RD, 1987, MAGNESIUM, V6, P113; HMIEL SP, 1989, J BACTERIOL, V171, P4742, DOI 10.1128/jb.171.9.4742-4751.1989; HMIEL SP, 1986, J BACTERIOL, V168, P1444, DOI 10.1128/jb.168.3.1444-1450.1986; HUANG HW, 1994, EUR J BIOCHEM, V219, P253, DOI 10.1111/j.1432-1033.1994.tb19936.x; INESI G, 1980, J BIOL CHEM, V255, P3025; JOU RW, 1991, J AM CHEM SOC, V113, P6685, DOI 10.1021/ja00017a056; KEENAN D, 1995, CIRC RES, V77, P973, DOI 10.1161/01.RES.77.5.973; Kehres D G, 1998, Microb Comp Genomics, V3, P151, DOI 10.1089/omi.1.1998.3.151; MacDiarmid CW, 1998, J BIOL CHEM, V273, P1727, DOI 10.1074/jbc.273.3.1727; MAGUIRE ME, 1990, MET IONS BIOL SYST, V26, P135; MAGUIRE ME, 1980, J BIOL CHEM, V255, P1030; MILLER SI, 1989, P NATL ACAD SCI USA, V86, P5054, DOI 10.1073/pnas.86.13.5054; NELSON DL, 1971, J BIOL CHEM, V246, P3042; QUIGLEY GJ, 1978, P NATL ACAD SCI USA, V75, P64, DOI 10.1073/pnas.75.1.64; ROMANI A, 1993, CIRC RES, V72, P1139, DOI 10.1161/01.RES.72.6.1139; ROMANI A, 1990, NATURE, V346, P841, DOI 10.1038/346841a0; ROMANI A, 1990, FEBS LETT, V269, P37, DOI 10.1016/0014-5793(90)81113-3; Smith RL, 1998, J BACTERIOL, V180, P2788, DOI 10.1128/JB.180.10.2788-2791.1998; SMITH RL, 1993, J BIOL CHEM, V268, P14071; Smith RL, 1998, J BIOL CHEM, V273, P28663, DOI 10.1074/jbc.273.44.28663; Smith RL, 1998, MICROBIOL-SGM, V144, P1835, DOI 10.1099/00221287-144-7-1835; Smith RL, 1998, MOL MICROBIOL, V28, P217, DOI 10.1046/j.1365-2958.1998.00810.x; SMITH RL, 1995, J BACTERIOL, V177, P1638, DOI 10.1128/jb.177.6.1638-1640.1995; SNAVELY MD, 1989, J BACTERIOL, V171, P4761, DOI 10.1128/jb.171.9.4761-4766.1989; SNAVELY MD, 1991, J BIOL CHEM, V266, P824; SNAVELY MD, 1989, J BACTERIOL, V171, P4752, DOI 10.1128/jb.171.9.4752-4760.1989; Tepperman K, 1997, AM J PHYSIOL-CELL PH, V273, pC2065, DOI 10.1152/ajpcell.1997.273.6.C2065; Vescovi EG, 1996, CELL, V84, P165, DOI 10.1016/S0092-8674(00)81003-X	36	57	65	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 24	1999	274	52					36973	36979		10.1074/jbc.274.52.36973	http://dx.doi.org/10.1074/jbc.274.52.36973			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	267WR	10601252	hybrid			2022-12-25	WOS:000084382700023
J	Thanos, CD; Faham, S; Goodwill, KE; Cascio, D; Phillips, M; Bowie, JU				Thanos, CD; Faham, S; Goodwill, KE; Cascio, D; Phillips, M; Bowie, JU			Monomeric structure of the human EphB2 sterile alpha motif domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR TYROSINE KINASE; PROTEIN-KINASE; IN-VITRO; LIGAND; BINDING; SAM; EXPRESSION; GUIDANCE; SYSTEM; ELF-1	The sterile a motif (SAM) domain is a protein module found in many diverse signaling proteins. SAM domains in some systems have been shown to self-associate. Previous crystal structures of an EphA4-SAM domain dimer (Stapleton, D,, Balan, I., Pawson, T,, and Sicheri, F, (1999) Not, Struct. Biol. 6, 44-49) and a possible EphB2-SAM oligomer (Thanos, C, D,, Goodwill, K, E,, and Bowie, J, U, (1999) Science 283, 833-836) both revealed large interfaces comprising an exchange of N-terminal peptide arms. Within the arm, a conserved hydrophobic residue (Tyr-8 in the EphB2-SAM structure or Phe-910 in the EphA4-SAM structure) is anchored into a hydrophobic cleft on a neighboring molecule. Here we have solved a new crystal form of the human EphB2-SAM domain that has the same overall SARI domain fold yet has no substantial intermolecular contacts. In the new structure, the N-terminal peptide arm of the EphB2-SAM domain protrudes out from the core of the molecule, leaving both the arm (including Tyr-8) and the hydrophobic cleft solvent-exposed, To verify that Tyr-8 is solvent-exposed in solution, we made a Tyr-8 to Ala-8 mutation and found that the EphB2-SAM domain structure and stability were only slightly altered. These results suggest that Tyr-8 is not part of the hydrophobic core of the EphB2-SAM domain and is conserved for functional reasons. Cystallographic evidence suggests a possible role for the N-terminal arm in oligomerization, In the absence of a direct demonstration of biological relevance, however, the functional role of the N-terminal arm remains an open question.	Univ Calif Los Angeles, DOE Lab Struct Biol & Mol Med, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Dept Chem & Biochem, Los Angeles, CA 90095 USA	United States Department of Energy (DOE); University of California System; University of California Los Angeles; University of California System; University of California Los Angeles	Bowie, JU (corresponding author), Univ Calif Los Angeles, DOE Lab Struct Biol & Mol Med, Los Angeles, CA 90095 USA.							Barr MM, 1996, MOL CELL BIOL, V16, P5597; BOWIE JU, 1990, SCIENCE, V247, P1306, DOI 10.1126/science.2315699; Bruckner K, 1999, NEURON, V22, P511, DOI 10.1016/S0896-6273(00)80706-0; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Buchert M, 1999, J CELL BIOL, V144, P361, DOI 10.1083/jcb.144.2.361; CHENG HJ, 1995, CELL, V82, P371, DOI 10.1016/0092-8674(95)90426-3; Chi SW, 1999, EMBO J, V18, P4438, DOI 10.1093/emboj/18.16.4438; Cohn E. J., 1943, PROTEINS AMINO ACIDS, P370; Donoghue MJ, 1996, MOL CELL NEUROSCI, V8, P185, DOI 10.1006/mcne.1996.0056; DRESCHER U, 1995, CELL, V82, P359, DOI 10.1016/0092-8674(95)90425-5; ERIKSSON AE, 1992, SCIENCE, V255, P178, DOI 10.1126/science.1553543; Henkemeyer M, 1996, CELL, V86, P35, DOI 10.1016/S0092-8674(00)80075-6; Hock B, 1998, P NATL ACAD SCI USA, V95, P9779, DOI 10.1073/pnas.95.17.9779; Hsueh YP, 1998, NEURON, V21, P1227, DOI 10.1016/S0896-6273(00)80641-8; Jousset C, 1997, EMBO J, V16, P69, DOI 10.1093/emboj/16.1.69; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Kyba M, 1998, DEV GENET, V22, P74, DOI 10.1002/(SICI)1520-6408(1998)22:1<74::AID-DVG8>3.3.CO;2-V; Laue T.M., 1992, ANAL ULTRACENTRIFUGA, P90; Lin D, 1999, J BIOL CHEM, V274, P3726, DOI 10.1074/jbc.274.6.3726; Nakamoto M, 1996, CELL, V86, P755, DOI 10.1016/S0092-8674(00)80150-6; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; Otwinowski Z., 1993, DATA COLLECTION PROC, P56; PANDEY A, 1995, SCIENCE, V268, P567, DOI 10.1126/science.7536959; PONTING CP, 1995, PROTEIN SCI, V4, P1928, DOI 10.1002/pro.5560040927; Remy I, 1999, SCIENCE, V283, P990, DOI 10.1126/science.283.5404.990; SATOW Y, 1986, J MOL BIOL, V190, P593, DOI 10.1016/0022-2836(86)90245-7; Schultz J, 1997, PROTEIN SCI, V6, P249; SERRAPAGES C, 1995, EMBO J, V14, P2827, DOI 10.1002/j.1460-2075.1995.tb07282.x; Slupsky CM, 1998, P NATL ACAD SCI USA, V95, P12129, DOI 10.1073/pnas.95.21.12129; Stapleton D, 1999, NAT STRUCT BIOL, V6, P44; Stein E, 1996, J BIOL CHEM, V271, P23588, DOI 10.1074/jbc.271.38.23588; Stein E, 1998, GENE DEV, V12, P667, DOI 10.1101/gad.12.5.667; Thanos CD, 1999, SCIENCE, V283, P833, DOI 10.1126/science.283.5403.833; Torres R, 1998, NEURON, V21, P1453, DOI 10.1016/S0896-6273(00)80663-7; Tu H, 1997, MOL CELL BIOL, V17, P5876, DOI 10.1128/MCB.17.10.5876; WINSLOW JW, 1995, NEURON, V14, P973, DOI 10.1016/0896-6273(95)90335-6; Xu QL, 1996, NATURE, V381, P319, DOI 10.1038/381319a0; Xu QL, 1995, DEVELOPMENT, V121, P4005	41	35	36	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 24	1999	274	52					37301	37306		10.1074/jbc.274.52.37301	http://dx.doi.org/10.1074/jbc.274.52.37301			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	267WR	10601296	hybrid			2022-12-25	WOS:000084382700067
J	Hudrisier, D; Riond, J; Mazarguil, H; Oldstone, MBA; Gairin, JE				Hudrisier, D; Riond, J; Mazarguil, H; Oldstone, MBA; Gairin, JE			Genetically encoded and post-translationally modified forms of a major histocompatibility complex class I-restricted antigen bearing a glycosylation motif are independently processed and co-presented to cytotoxic T lymphocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHORIOMENINGITIS VIRUS; ENDOPLASMIC-RETICULUM; VIRAL-INFECTION; GLYCOPROTEIN EPITOPE; MEMBRANE-PROTEIN; ANCHOR RESIDUES; CELL RESPONSE; PEPTIDES; H-2D(B); RECOGNITION	The mechanisms by which antigenic peptides bearing a glycosylation site may be processed from viral glycoproteins, post-translationally modified, and presented by major histocompatibility complex class I molecules remain poorly understood. With the aim of exploring these processes, we have dissected the structural and functional properties of the MHC-restricted peptide GP92-101 (CSANNSHHYI) generated from the lymphocytic choriomeningitis virus (LCMV) GP1 glycoprotein. LCMV GP92-101 bears a glycosylation motif -NXS- that is naturally N-glycosylated in the mature viral glycoprotein, displays high affinity for H-2D(b) molecules, and elicits a CD8(+) cytotoxic T lymphocyte response. By analyzing the functional. properties of natural and synthetic peptides and by identifying the viral sequence(s) from the pool of naturally occurring peptides, we demonstrated that multiple forms of LCMV GP92-101 were generated hom the viral glycoprotein and co-presented at the surface of LCMV-infected cells. They corresponded to non-glycosylated and post-translationally modified sequences (conversion of Asn-95 to Asp or alteration of Cys-92). The glycosylated form, despite its potential immunogenicity, was not detected. These data illustrate that distinct, non-mutually exclusive antigen presentation pathways may occur simultaneously within a cell to generate structurally and functionally different peptides from a single genetically encoded sequence, thus contributing to increasing the diversity of the T cell repertoire.	CNRS, Inst Pharmacol & Biol Struct, UPR 9062, F-31400 Toulouse, France; Scripps Res Inst, Dept Neuropharmacol, La Jolla, CA 92037 USA	Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Centre National de la Recherche Scientifique (CNRS); Scripps Research Institute	Hudrisier, D (corresponding author), CNRS, Inst Pharmacol & Biol Struct, UPR 9062, 205 Route Narbonne, F-31400 Toulouse, France.		Riond, Joelle/R-6414-2016	Riond, Joelle/0000-0002-6281-2376; Hudrisier, Denis/0000-0002-3631-9561				Anton LC, 1998, J IMMUNOL, V160, P4859; Bacik I, 1997, J EXP MED, V186, P479, DOI 10.1084/jem.186.4.479; Carson RT, 1999, J IMMUNOL, V162, P1; Chen WS, 1999, J EXP MED, V189, P1757, DOI 10.1084/jem.189.11.1757; CHICZ RM, 1993, J EXP MED, V178, P27, DOI 10.1084/jem.178.1.27; Craiu A, 1997, P NATL ACAD SCI USA, V94, P10850, DOI 10.1073/pnas.94.20.10850; DUDLER T, 1995, EUR J IMMUNOL, V25, P538, DOI 10.1002/eji.1830250235; Elliott T, 1997, ADV IMMUNOL, V65, P47, DOI 10.1016/S0065-2776(08)60741-5; ELLIOTT T, 1995, J EXP MED, V181, P1481, DOI 10.1084/jem.181.4.1481; Ferris RL, 1996, J IMMUNOL, V156, P834; Ferris RL, 1999, J IMMUNOL, V162, P1324; GAIRIN JE, 1995, J VIROL, V69, P2297, DOI 10.1128/JVI.69.4.2297-2305.1995; Gallimore A, 1998, EUR J IMMUNOL, V28, P3301, DOI 10.1002/(SICI)1521-4141(199810)28:10<3301::AID-IMMU3301>3.0.CO;2-Q; Geier E, 1999, SCIENCE, V283, P978, DOI 10.1126/science.283.5404.978; Glithero A, 1999, IMMUNITY, V10, P63, DOI 10.1016/S1074-7613(00)80007-2; Groettrup M, 1996, IMMUNOL TODAY, V17, P429, DOI 10.1016/0167-5699(96)10051-7; HAURUM JS, 1994, J EXP MED, V180, P739, DOI 10.1084/jem.180.2.739; Haurum JS, 1995, EUR J IMMUNOL, V25, P3270, DOI 10.1002/eji.1830251211; HUDRISIER D, 1995, MOL IMMUNOL, V32, P895, DOI 10.1016/0161-5890(95)00043-E; Hudrisier D, 1996, J BIOL CHEM, V271, P17829, DOI 10.1074/jbc.271.30.17829; Hudrisier D, 1998, J IMMUNOL, V161, P553; HUDRISIER D, 1996, THESIS P SABATIER U; JAMESON SC, 1993, J EXP MED, V177, P1541, DOI 10.1084/jem.177.6.1541; Kessler B, 1998, J IMMUNOL, V161, P6939; KLAVINSKIS LS, 1990, VIROLOGY, V178, P393, DOI 10.1016/0042-6822(90)90336-P; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; Meadows L, 1997, IMMUNITY, V6, P273, DOI 10.1016/S1074-7613(00)80330-1; Mosse CA, 1998, J EXP MED, V187, P37, DOI 10.1084/jem.187.1.37; Murali-Krishna K, 1998, IMMUNITY, V8, P177, DOI 10.1016/S1074-7613(00)80470-7; OLDSTONE MBA, 1988, J EXP MED, V168, P559, DOI 10.1084/jem.168.2.559; OLDSTONE MBA, 1995, J VIROL, V69, P7423, DOI 10.1128/JVI.69.12.7423-7429.1995; RAMMENSEE HG, 1995, IMMUNOGENETICS, V41, P178, DOI 10.1007/BF00172063; SCHULZ M, 1989, EUR J IMMUNOL, V19, P1657, DOI 10.1002/eji.1830190921; Selby M, 1999, J IMMUNOL, V162, P669; Skipper JCA, 1996, J EXP MED, V183, P527, DOI 10.1084/jem.183.2.527; SNYDER HL, 1994, J EXP MED, V180, P2389, DOI 10.1084/jem.180.6.2389; Speir JA, 1999, IMMUNITY, V10, P51, DOI 10.1016/S1074-7613(00)80006-0; SUZUKI T, 1994, J BIOL CHEM, V269, P17611; van der Most RG, 1998, VIROLOGY, V240, P158, DOI 10.1006/viro.1997.8934; WIDMANN C, 1992, J IMMUNOL METHODS, V155, P95, DOI 10.1016/0022-1759(92)90275-X; Wiertz EJHJ, 1996, CELL, V84, P769, DOI 10.1016/S0092-8674(00)81054-5; Wiertz EJHJ, 1996, NATURE, V384, P432, DOI 10.1038/384432a0; Wood P, 1998, J EXP MED, V188, P773, DOI 10.1084/jem.188.4.773; WRIGHT KE, 1990, VIROLOGY, V177, P175, DOI 10.1016/0042-6822(90)90471-3; Yewdell JW, 1996, J IMMUNOL, V157, P1823; YOUNG ACM, 1994, CELL, V76, P39, DOI 10.1016/0092-8674(94)90171-6	47	18	19	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 17	1999	274	51					36274	36280		10.1074/jbc.274.51.36274	http://dx.doi.org/10.1074/jbc.274.51.36274			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	266AV	10593916	hybrid			2022-12-25	WOS:000084279200035
J	Kuhns, JJ; Batalia, MA; Yan, SQ; Collins, EJ				Kuhns, JJ; Batalia, MA; Yan, SQ; Collins, EJ			Poor binding of a HER-2/neu epitope (GP2) to HLA-A2.1 is due to a lack of interactions with the center of the peptide	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOTOXIC T-LYMPHOCYTES; CLASS-I; HIGH-AFFINITY; HER2/NEU-DERIVED PEPTIDE; ANTIGEN PRESENTATION; MAXIMUM-LIKELIHOOD; OVARIAN-CANCER; MHC; MOLECULES; AMINO	Class I major histocompatibility complex (MHC) molecules bind short peptides derived from proteins synthesized within the cell. These complexes of peptide and class I MHC (pMHC) are transported from the endoplasmic reticulum to the cell surface. If a clonotypic T cell receptor expressed on a circulating T cell binds to the pMHC complex, the cell presenting the pMHC is killed. In this manner, some tumor cells expressing aberrant proteins are recognized and removed by the immune system. However, not all tumors are recognized efficiently. One reason hypothesized for poor T cell recognition of tumor-associated peptides is poor binding of those peptides to class I MHC molecules. Many peptides, derived from the proto-oncogene HER-2/neu have been shown to be recognized by cytotoxic T cells derived from HLA-A2(+) patients with breast cancer and other adenocarcinomas. Seven of these peptides were found to bind with intermediate to poor affinity. In particular, GP2 (HER-2/neu residues 654-662) binds very poorly even though it is predicted to bind web based upon the presence of the correct HLA-A2.1 peptide-binding motif. Altering the anchor residues to those most favored by HLA-A2.1 did not significantly improve binding affinity. The crystallographic structure shows that unlike other class I-peptide structures, the center of the peptide does not assume one specific conformation and does not make stabilizing contacts with the peptide-binding cleft.	Univ N Carolina, Dept Microbiol & Immunol, Chapel Hill, NC 27599 USA; Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA; Univ N Carolina, Dept Biochem & Biophys, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill	Collins, EJ (corresponding author), Univ N Carolina, Dept Microbiol & Immunol, CB 7290,804 M E Jones Bldg, Chapel Hill, NC 27599 USA.				NATIONAL CANCER INSTITUTE [P50CA058223] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI029324] Funding Source: NIH RePORTER; NCI NIH HHS [CA 58223] Funding Source: Medline; NIAID NIH HHS [AI 29324] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Adams PD, 1997, P NATL ACAD SCI USA, V94, P5018, DOI 10.1073/pnas.94.10.5018; Batalia MA, 1997, BIOPOLYMERS, V43, P281, DOI 10.1002/(SICI)1097-0282(1997)43:4<281::AID-BIP3>3.0.CO;2-R; BOUVIER M, 1994, SCIENCE, V265, P398, DOI 10.1126/science.8023162; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; BRUNGER AT, 1992, XPLOR VERSION 3 1; Chan S, 1998, IMMUNOL REV, V165, P195, DOI 10.1111/j.1600-065X.1998.tb01240.x; CHEN Y, 1994, J IMMUNOL, V152, P2874; COLBERT RA, 1994, IMMUNITY, V1, P121, DOI 10.1016/1074-7613(94)90105-8; Dodson EJ, 1997, METHOD ENZYMOL, V277, P620, DOI 10.1016/S0076-6879(97)77034-4; FALL K, 1991, NATURE, V351, P290; Fisk B, 1995, J IMMUNOTHER, V18, P197, DOI 10.1097/00002371-199511000-00001; FISK B, 1995, J EXP MED, V181, P2109, DOI 10.1084/jem.181.6.2109; GARBOCZI DN, 1992, P NATL ACAD SCI USA, V89, P3429, DOI 10.1073/pnas.89.8.3429; GARRETT TPJ, 1989, NATURE, V342, P692, DOI 10.1038/342692a0; GUO HC, 1992, NATURE, V360, P364, DOI 10.1038/360364a0; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kono K, 1998, INT J CANCER, V78, P202, DOI 10.1002/(SICI)1097-0215(19981005)78:2<202::AID-IJC14>3.0.CO;2-C; Lamzin VS, 1997, METHOD ENZYMOL, V277, P269, DOI 10.1016/S0076-6879(97)77016-2; Lanzavecchia A, 1999, CELL, V96, P1, DOI 10.1016/S0092-8674(00)80952-6; Lehner PJ, 1998, CURR BIOL, V8, pR605, DOI 10.1016/S0960-9822(98)70387-2; MADDEN DR, 1992, CELL, V70, P1035, DOI 10.1016/0092-8674(92)90252-8; MADDEN DR, 1993, CELL, V75, P693, DOI 10.1016/0092-8674(93)90490-H; Morgan CS, 1997, PROTEIN SCI, V6, P1771, DOI 10.1002/pro.5560060819; Navaza J, 1997, METHOD ENZYMOL, V276, P581, DOI 10.1016/S0076-6879(97)76079-8; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Overwijk WW, 1998, J EXP MED, V188, P277, DOI 10.1084/jem.188.2.277; Pannu NS, 1996, ACTA CRYSTALLOGR A, V52, P659, DOI 10.1107/S0108767396004370; PARHAM P, 1981, HUM IMMUNOL, V3, P277, DOI 10.1016/0198-8859(81)90065-3; PEOPLES GE, 1995, P NATL ACAD SCI USA, V92, P432, DOI 10.1073/pnas.92.2.432; Ploegh HL, 1998, SCIENCE, V280, P248, DOI 10.1126/science.280.5361.248; POGUE RR, 1995, P NATL ACAD SCI USA, V92, P8166, DOI 10.1073/pnas.92.18.8166; RAMMENSEE HG, 1995, IMMUNOGENETICS, V41, P178, DOI 10.1007/BF00172063; Romero P, 1997, J IMMUNOL, V159, P2366; Ross JS, 1998, STEM CELLS, V16, P413, DOI 10.1002/stem.160413; RUPPERT J, 1993, CELL, V74, P929, DOI 10.1016/0092-8674(93)90472-3; TSOMIDES TJ, 1991, P NATL ACAD SCI USA, V88, P11276, DOI 10.1073/pnas.88.24.11276; YOSHINO I, 1994, CANCER RES, V54, P3387; Zhao R, 1999, J EXP MED, V189, P359, DOI 10.1084/jem.189.2.359	38	58	90	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 17	1999	274	51					36422	36427		10.1074/jbc.274.51.36422	http://dx.doi.org/10.1074/jbc.274.51.36422			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	266AV	10593938	Green Published, hybrid			2022-12-25	WOS:000084279200057
J	Ro, HS; Miles, EW				Ro, HS; Miles, EW			Structure and function of the tryptophan synthase alpha(2)beta(2) complex - Roles of beta subunit histidine 86	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID AMINOTRANSFERASE; D-SERINE DEHYDRATASE; INDUCED CONFORMATIONAL-CHANGES; NUCLEAR MAGNETIC-RESONANCE; ESCHERICHIA-COLI; PYRIDOXAL 5'-PHOSPHATE; SALMONELLA-TYPHIMURIUM; CRYSTAL-STRUCTURES; INTERSUBUNIT COMMUNICATION; CATALYTIC MECHANISM	To probe the structural and functional roles of active-site residues in the tryptophan synthase alpha(2)beta(2) complex from Salmonella typhimurium, we have determined the effects of mutation of His(86) in the beta subunit. His(86) is located adjacent to beta subunit Lys(87), which forms an internal aldimine with the pyridoxal phosphate and catalyzes the abstraction of the alpha-proton of L-serine. The replacement of His(86) by leucine (H86L) weakened pyridoxal phosphate binding similar to 20-fold and abolished the circular dichroism signals of the bound coenzyme and of a reaction intermediate. Correlation of these results with previous crystal structures indicates that beta-His(86) plays a structural role in binding pyridoxal phosphate and in stabilizing the correct orientation of pyridoxal phosphate in the active site of the beta subunit. The H86L mutation also altered the pH profiles of absorbance and fluorescence signals and shifted the pH optimum for the synthesis of L-tryptophan from pH 7.5 to 8.8. We propose that the interaction of His(86) with the phosphate of pyridoxal phosphate and with Lys(87) lowers the pK(a) of Lys(87) in the wild-type alpha(2)beta(2) complex and thereby facilitates catalysis by Lys(87) in the physiological pH range.	NIDDK, Lab Biochem & Genet, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	Miles, EW (corresponding author), NIDDK, Lab Biochem & Genet, NIH, Bldg 8,Rm 225,8 Ctr Dr,MSC 0830, Bethesda, MD 20892 USA.	EdithM@intra.niddk.nih.gov	Ro, Hyeon-Su/V-7023-2019		NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [ZIADK034002, Z01DK024140, ZIHDK034002, Z01DK034002] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Adams E, 1979, Methods Enzymol, V62, P407; AHMED SA, 1991, J BIOL CHEM, V266, P21548; AHMED SA, 1994, J BIOL CHEM, V269, P16486; Ahmed SA, 1996, J BIOL CHEM, V271, P29100, DOI 10.1074/jbc.271.46.29100; ALEXANDER FW, 1994, EUR J BIOCHEM, V219, P953, DOI 10.1111/j.1432-1033.1994.tb18577.x; ANDERSON KS, 1991, J BIOL CHEM, V266, P8020; BALK H, 1981, BIOCHEMISTRY-US, V20, P6391, DOI 10.1021/bi00525a017; BANIK U, 1995, J BIOL CHEM, V270, P7944, DOI 10.1074/jbc.270.14.7944; BARTHOLMES P, 1976, BIOCHEMISTRY-US, V15, P4712, DOI 10.1021/bi00666a027; BORK P, 1990, BIOCHEM BIOPH RES CO, V171, P1319, DOI 10.1016/0006-291X(90)90830-G; BRZOVIC PS, 1992, BIOCHEMISTRY-US, V31, P3831, DOI 10.1021/bi00130a014; Burkhard P, 1998, J MOL BIOL, V283, P121, DOI 10.1006/jmbi.1998.2037; CRAWFORD IP, 1964, P NATL ACAD SCI USA, V51, P390, DOI 10.1073/pnas.51.3.390; Fan YX, 1999, BIOCHEMISTRY-US, V38, P7881, DOI 10.1021/bi990307e; Gallagher DT, 1998, STRUCTURE, V6, P465, DOI 10.1016/S0969-2126(98)00048-3; GOLDBERG ME, 1968, BIOCHEMISTRY-US, V7, P3662, DOI 10.1021/bi00850a045; GRISHIN NV, 1995, PROTEIN SCI, V4, P1291, DOI 10.1002/pro.5560040705; Hur O, 1996, BIOCHEMISTRY-US, V35, P7378, DOI 10.1021/bi960240k; HYDE CC, 1988, J BIOL CHEM, V263, P17857; Jansonius J.N., 1987, BIOL MACROMOLECULES, P187; Jhee KH, 1998, J BIOL CHEM, V273, P11417, DOI 10.1074/jbc.273.19.11417; Jhee KH, 1998, BIOCHEMISTRY-US, V37, P14591, DOI 10.1021/bi981325j; JOHNSON GF, 1970, J BIOL CHEM, V245, P5560; JUDD CT, 1978, J THEOR BIOL, V75, P503, DOI 10.1016/0022-5193(78)90359-4; KAWASAKI H, 1987, J BIOL CHEM, V262, P10678; KAYASTHA AM, 1991, INDIAN J BIOCHEM BIO, V28, P352; KISHIMOTO K, 1995, J BIOCHEM-TOKYO, V117, P691, DOI 10.1093/oxfordjournals.jbchem.a124765; LANE AN, 1984, EMBO J, V3, P279, DOI 10.1002/j.1460-2075.1984.tb01797.x; LANE AN, 1983, EUR J BIOCHEM, V129, P571; MARCEAU M, 1988, J BIOL CHEM, V263, P16934; MARCEAU M, 1988, J BIOL CHEM, V263, P16926; Miles E W, 1995, Subcell Biochem, V24, P207; Miles E W, 1979, Adv Enzymol Relat Areas Mol Biol, V49, P127; MILES EW, 1991, ADV ENZYMOL RAMB, V64, P93; MILES EW, 1987, METHOD ENZYMOL, V142, P398; MILES EW, 1989, J BIOL CHEM, V264, P6280; MILES EW, 1977, J BIOL CHEM, V252, P6594; Miles EW, 1999, J BIOL CHEM, V274, P12193, DOI 10.1074/jbc.274.18.12193; Pan P, 1997, TRENDS BIOCHEM SCI, V22, P22, DOI 10.1016/S0968-0004(96)10066-9; Peracchi A, 1996, BIOCHEMISTRY-US, V35, P1872, DOI 10.1021/bi951889c; Rhee S, 1998, BIOCHEMISTRY-US, V37, P10653, DOI 10.1021/bi980779d; Rhee S, 1997, BIOCHEMISTRY-US, V36, P7664, DOI 10.1021/bi9700429; Ro HS, 1999, J BIOL CHEM, V274, P31189, DOI 10.1074/jbc.274.44.31189; ROY M, 1988, BIOCHEMISTRY-US, V27, P8661, DOI 10.1021/bi00423a023; RUVINOV SB, 1995, J BIOL CHEM, V270, P17333, DOI 10.1074/jbc.270.29.17333; SCHIRCH L, 1975, J BIOL CHEM, V250, P1939; SCHNACKERZ KD, 1983, BIOCHEM BIOPH RES CO, V111, P817, DOI 10.1016/0006-291X(83)91372-4; SCHNACKERZ KD, 1979, BIOCHEMISTRY-US, V18, P1536, DOI 10.1021/bi00575a023; Schneider TR, 1998, BIOCHEMISTRY-US, V37, P5394, DOI 10.1021/bi9728957; SHALTIEL S, 1970, BIOCHEM BIOPH RES CO, V41, P594, DOI 10.1016/0006-291X(70)90054-9; SUGIO S, 1995, BIOCHEMISTRY-US, V34, P9661, DOI 10.1021/bi00030a002; Sugio S, 1998, PROTEIN ENG, V11, P613, DOI 10.1093/protein/11.8.613; TONEY MD, 1995, J MOL BIOL, V245, P151, DOI 10.1006/jmbi.1994.0014; Yang LH, 1997, J BIOL CHEM, V272, P7859, DOI 10.1074/jbc.272.12.7859; Yang LH, 1996, PROTEIN EXPRES PURIF, V8, P126, DOI 10.1006/prep.1996.0082; YANG XJ, 1993, J BIOL CHEM, V268, P22269	56	8	8	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 17	1999	274	51					36439	36445		10.1074/jbc.274.51.36439	http://dx.doi.org/10.1074/jbc.274.51.36439			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	266AV	10593940	hybrid			2022-12-25	WOS:000084279200059
J	Sevrioukova, IF; Hazzard, JT; Tollin, G; Poulos, TL				Sevrioukova, IF; Hazzard, JT; Tollin, G; Poulos, TL			The FMN to heme electron transfer in cytochrome P450BM-3 - Effect of chemical modification of cysteines engineered at the FMN-heme domain interaction site	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LASER FLASH-PHOTOLYSIS; FLAVOCYTOCHROME P-450 BM3; C PEROXIDASE; METHYLAMINE DEHYDROGENASE; BACILLUS-MEGATERIUM; FLAVOPROTEIN DOMAIN; TRANSIENT KINETICS; CRYSTAL-STRUCTURE; TRANSFER COMPLEX; DIRECTED MUTAGENESIS	The crystal structure of the complex between the heme and FMN-containing domains of Bacillus megaterium cytochrome P450BM-3 (Sevrioukova, I. F., Li, H., Zhang, H., Peterson, J. A., and Poulos, T. L. (1999) Proc. Natl, Acad, Sci, U. S. A. 96, 1863-1868) indicates that the proximal side of the heme domain molecule is the docking site for the FMN domain and that the Pro(382)-Gln(387) peptide may provide an electron transfer (ET) path from the FMN to the heme iron. In order to evaluate whether ET complexes formed in solution by the heme and FMN domains are structurally relevant to that seen in the crystal structure, we utilized site-directed mutagenesis to introduce Cys residues at positions 104 and 387, which are sites of close contact between the domains in the crystal structure and at position 372 as a control. Cys residues were modified with a bulky sulfhydryl reagent, 1-dimethylamino-naphthalene-5-sulfonate-L-cystine (dansylcystine (DC)), to prevent the FMN domain from binding at the site seen in the crystal structure. The DC modification of Cys(372) and Cys(387) resulted in a S fold decrease in the rates of interdomain ET in the reconstituted system consisting of the separate heme and FMN domains and had no effect on heme reduction in the intact heme/FMN-binding fragment of P450BM-3. DC modification of Cys(104) caused a 10-20-fold decrease in the interdomain ET reaction rate in both the reconstituted system and the intact heme/FMN domain. This indicates that the proximal side of the heme domain molecule represents the FMN domain binding site in both the crystallized and solution complexes, with the area around residue 104 being the most critical for the redox partner docking.	Univ Calif Irvine, Dept Mol Biol & Biochem, Irvine, CA 92697 USA; Univ Calif Irvine, Program Macromol Struct, Irvine, CA 92697 USA; Univ Arizona, Dept Biochem, Tucson, AZ 85721 USA	University of California System; University of California Irvine; University of California System; University of California Irvine; University of Arizona	Poulos, TL (corresponding author), Univ Calif Irvine, Dept Mol Biol & Biochem, Irvine, CA 92697 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM042614, R01GM033688] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM33688, GM19749, GM42614] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BODDUPALLI SS, 1992, J BIOL CHEM, V267, P10375; CHEN LY, 1992, BIOCHEMISTRY-US, V31, P4959, DOI 10.1021/bi00136a006; CHEN LY, 1994, SCIENCE, V264, P86, DOI 10.1126/science.8140419; CHEN ZW, 1994, SCIENCE, V266, P430, DOI 10.1126/science.7939681; CORIN AF, 1993, BIOCHEMISTRY-US, V32, P2756, DOI 10.1021/bi00062a004; CORRELL CC, 1992, SCIENCE, V2, P2112; Daff SN, 1997, BIOCHEMISTRY-US, V36, P13816, DOI 10.1021/bi971085s; DALY TJ, 1986, BIOCHEMISTRY-US, V25, P5468, DOI 10.1021/bi00367a018; DARWISH K, 1991, PROTEIN ENG, V4, P701, DOI 10.1093/protein/4.6.701; Davidson VL, 1997, BIOCHEMISTRY-US, V36, P12733, DOI 10.1021/bi971353m; DAVIDSON VL, 1995, J BIOL CHEM, V270, P23941, DOI 10.1074/jbc.270.41.23941; DEISENHOFER J, 1984, J MOL BIOL, V180, P385, DOI 10.1016/S0022-2836(84)80011-X; EDMONDSO.DE, 1972, BIOCHEMISTRY-US, V11, P1133, DOI 10.1021/bi00757a003; Erman JE, 1997, BIOCHEMISTRY-US, V36, P4054, DOI 10.1021/bi962632x; GONVINDARAJ S, 1994, BIOCHEM BIOPH RES CO, V203, P1745, DOI 10.1006/bbrc.1994.2388; Govindaraj S, 1997, J BIOL CHEM, V272, P7915, DOI 10.1074/jbc.272.12.7915; Hazzard JT, 1997, J BIOL CHEM, V272, P7922, DOI 10.1074/jbc.272.12.7922; HURLEY JK, 1994, ARCH BIOCHEM BIOPHYS, V312, P480, DOI 10.1006/abbi.1994.1335; Iwata S, 1998, SCIENCE, V281, P64, DOI 10.1126/science.281.5373.64; KNAFF DB, 1981, BIOCHEMISTRY-US, V20, P4333, DOI 10.1021/bi00518a015; LAVIS PC, 1974, BIOCHEMISTRY-US, V13, P3042; Li HY, 1997, NAT STRUCT BIOL, V4, P140, DOI 10.1038/nsb0297-140; LI HY, 1991, J BIOL CHEM, V266, P11909; LI HY, 1995, ACTA CRYSTALLOGR D, V51, P21, DOI 10.1107/S0907444994009194; MASSEY V, 1966, BIOCHEMISTRY-US, V5, P3181, DOI 10.1021/bi00874a016; Merli A, 1996, J BIOL CHEM, V271, P9177, DOI 10.1074/jbc.271.16.9177; MEYER TE, 1995, ARCH BIOCHEM BIOPHYS, V318, P457, DOI 10.1006/abbi.1995.1254; MEYER TE, 1993, BIOCHEMISTRY-US, V32, P4552, DOI 10.1021/bi00068a010; MEYER TE, 1993, BIOCHEMISTRY-US, V32, P622, DOI 10.1021/bi00053a030; MILES CS, 1992, BIOCHEM J, V285, P187, DOI 10.1042/bj2850187; Miller MA, 1996, BIOCHEMISTRY-US, V35, P667, DOI 10.1021/bi952557a; MOSER CC, 1992, NATURE, V355, P796, DOI 10.1038/355796a0; Munro AW, 1996, EUR J BIOCHEM, V239, P403, DOI 10.1111/j.1432-1033.1996.0403u.x; Murataliev MB, 1997, BIOCHEMISTRY-US, V36, P8401, DOI 10.1021/bi970026b; NARHI LO, 1986, J BIOL CHEM, V261, P7160; OMURA T, 1964, J BIOL CHEM, V239, P2370; OSTER T, 1991, J BIOL CHEM, V266, P22718; Pacheco A, 1999, J BIOL INORG CHEM, V4, P390, DOI 10.1007/s007750050325; Pappa HS, 1996, BIOCHEMISTRY-US, V35, P4837, DOI 10.1021/bi952935b; PELLETIER H, 1992, SCIENCE, V258, P1748, DOI 10.1126/science.1334573; PORTER TD, 1991, TRENDS BIOCHEM SCI, V16, P154, DOI 10.1016/0968-0004(91)90059-5; POULOS TL, 1980, J BIOL CHEM, V255, P322; RAVICHANDRAN KG, 1993, SCIENCE, V261, P731, DOI 10.1126/science.8342039; RUETTINGER RT, 1989, J BIOL CHEM, V264, P10987; Sevrioukova I, 1996, BIOCHEMISTRY-US, V35, P7058, DOI 10.1021/bi960060a; Sevrioukova I, 1996, BIOCHIMIE, V78, P744, DOI 10.1016/S0300-9084(97)82532-1; Sevrioukova I, 1997, ARCH BIOCHEM BIOPHYS, V340, P231, DOI 10.1006/abbi.1997.9895; Sevrioukova I, 1996, BIOCHEMISTRY-US, V35, P7528, DOI 10.1021/bi960330p; SEVRIOUKOVA IF, 1995, BIOCHIMIE, V77, P562, DOI 10.1016/0300-9084(96)88172-7; SEVRIOUKOVA IF, 1995, ARCH BIOCHEM BIOPHYS, V317, P397, DOI 10.1006/abbi.1995.1180; Sevrioukova IF, 1999, P NATL ACAD SCI USA, V96, P1863, DOI 10.1073/pnas.96.5.1863; SHARP RE, 1994, BIOCHEMISTRY-US, V33, P5115, DOI 10.1021/bi00183a015; SULLIVAN EP, 1993, BIOCHEMISTRY-US, V32, P12465, DOI 10.1021/bi00097a026; TOLLIN G, 1993, BIOPHYS CHEM, V48, P259, DOI 10.1016/0301-4622(93)85014-9; TOMLINSON G, 1989, BIOCHEM CELL BIOL, V67, P337, DOI 10.1139/o89-053; WALKER MC, 1992, BIOCHEMISTRY-US, V31, P2798, DOI 10.1021/bi00125a021; WALKER MC, 1990, ARCH BIOCHEM BIOPHYS, V281, P76, DOI 10.1016/0003-9861(90)90415-U; WHITE P, 1993, BIOCHEM J, V291, P89, DOI 10.1042/bj2910089; WU C, 1972, P NATL ACAD SCI USA, V69, P1104, DOI 10.1073/pnas.69.5.1104; XIA ZX, 1990, J MOL BIOL, V212, P837, DOI 10.1016/0022-2836(90)90240-M	60	39	40	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 17	1999	274	51					36097	36106		10.1074/jbc.274.51.36097	http://dx.doi.org/10.1074/jbc.274.51.36097			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	266AV	10593892	hybrid			2022-12-25	WOS:000084279200011
J	Azpiazu, I; Cruzblanca, H; Li, P; Linder, M; Zhuo, M; Gautam, N				Azpiazu, I; Cruzblanca, H; Li, P; Linder, M; Zhuo, M; Gautam, N			A G protein gamma subunit-specific peptide inhibits muscarinic receptor signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT SYMPATHETIC NEURONS; HETEROTRIMERIC G-PROTEINS; PHOSPHOLIPASE-C; ACETYLCHOLINE-RECEPTORS; CALCIUM CHANNELS; ADENYLYL-CYCLASE; CA2+ CURRENT; ACTIVATION; EXPRESSION; MODULATION	Muscarinic acetylcholine receptors modulate the function of a variety of effecters through heterotrimeric G proteins. A prenylated peptide specific to the G protein gamma 5 subunit type inhibits G protein activation by the M2 muscarinic receptor in a reconstitution assay. Scrambling the amino acid sequence of the peptide significantly reduces the efficacy of the peptide. The peptide does not disrupt the G protein heterotrimer. In cultured sympathetic neurons, the gamma 5 peptide inhibits modulation of Ca2+ current by the M4 receptor. Peptide activity is specific, the scrambled peptide and peptides specific to two other members of the G protein gamma subunit family are significantly less effective. The gamma 5 peptide has no effect on Ca2+ current modulation by the alpha 2-adrenergic and somatostatin receptors. In addition, the gamma 5 peptide inhibits muscarinic receptor signaling in spinal cord slices with specificity. These results support a specific role for G protein gamma subunit types in signal transduction, most likely at the receptor-G protein interface.	Washington Univ, Sch Med, Dept Anesthesiol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Physiol & Cell Biol, St Louis, MO 63110 USA; Univ Washington, Dept Physiol & Biophys, Seattle, WA 98195 USA	Washington University (WUSTL); Washington University (WUSTL); University of Washington; University of Washington Seattle	Gautam, N (corresponding author), Washington Univ, Sch Med, Dept Anesthesiol, Box 8054, St Louis, MO 63110 USA.		Zhuo, Min/A-2072-2008	Zhuo, Min/0000-0001-9062-3241	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM046963, R01GM051466] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS008174, R37NS008174] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM046963, GM46963, GM51466] Funding Source: Medline; NINDS NIH HHS [NS08174] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ASHKENAZI A, 1989, CELL, V56, P487, DOI 10.1016/0092-8674(89)90251-1; BEECH DJ, 1992, NEURON, V8, P97, DOI 10.1016/0896-6273(92)90111-P; BERNHEIM L, 1992, P NATL ACAD SCI USA, V89, P9544, DOI 10.1073/pnas.89.20.9544; CAULFIELD MP, 1994, J PHYSIOL-LONDON, V477, P415, DOI 10.1113/jphysiol.1994.sp020203; DELLACQUA ML, 1993, J BIOL CHEM, V268, P5676; Delmas P, 1998, EUR J NEUROSCI, V10, P1654, DOI 10.1046/j.1460-9568.1998.00170.x; FUNG BKK, 1983, J BIOL CHEM, V258, P495; Gautam N, 1998, CELL SIGNAL, V10, P447, DOI 10.1016/S0898-6568(98)00006-0; HANSEN CA, 1995, J MOL CELL CARDIOL, V27, P471, DOI 10.1016/S0022-2828(08)80043-0; Herlitze S, 1996, NATURE, V380, P258, DOI 10.1038/380258a0; HULME EC, 1990, ANNU REV PHARMACOL, V30, P633, DOI 10.1146/annurev.pa.30.040190.003221; HUNT TW, 1994, J BIOL CHEM, V269, P29565; Ikeda SR, 1996, NATURE, V380, P255, DOI 10.1038/380255a0; KISSELEV O, 1995, P NATL ACAD SCI USA, V92, P9102, DOI 10.1073/pnas.92.20.9102; KISSELEV O, 1995, J BIOL CHEM, V270, P25356, DOI 10.1074/jbc.270.43.25356; KISSELEV O, 1993, J BIOL CHEM, V268, P24519; KISSELEV OG, 1994, J BIOL CHEM, V269, P21399; KLEUSS C, 1993, SCIENCE, V259, P832, DOI 10.1126/science.8094261; KOZASA T, 1995, J BIOL CHEM, V270, P1734, DOI 10.1074/jbc.270.4.1734; Li P, 1998, NATURE, V393, P695, DOI 10.1038/31496; Li P, 1999, NATURE, V397, P161, DOI 10.1038/16469; MUMBY SM, 1994, METHOD ENZYMOL, V237, P254; PERALTA EG, 1987, SCIENCE, V236, P600, DOI 10.1126/science.3107123; PERALTA EG, 1987, EMBO J, V6, P3923, DOI 10.1002/j.1460-2075.1987.tb02733.x	24	37	37	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 10	1999	274	50					35305	35308		10.1074/jbc.274.50.35305	http://dx.doi.org/10.1074/jbc.274.50.35305			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	264NG	10585394	hybrid			2022-12-25	WOS:000084187900006
J	Sawada, J; Simizu, N; Suzuki, F; Sawa, C; Goto, M; Hasegawa, M; Imai, T; Watanabe, H; Handa, H				Sawada, J; Simizu, N; Suzuki, F; Sawa, C; Goto, M; Hasegawa, M; Imai, T; Watanabe, H; Handa, H			Synergistic transcriptional activation by hGABP and select members of the activation transcription factor/cAMP response element-binding protein family	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR E4TF1; HUMAN-CHROMOSOME; 2 SUBUNITS; FACTOR ATF; KINASE-II; RB GENE; ETS; COMPLEX; IDENTIFICATION; EXPRESSION	The Ets-related DNA-binding protein human GA-binding protein (hGABP) alpha interacts with the four ankyrin-type repeats of hGABP beta to form an hGABP tetrameric complex that stimulates transcription through the adenovirus early 4 (E4) promoter. Using co-transfection assays, this study demonstrated that the hGABP complex mediated efficient activation of transcription from E4 promoter synergistically with activating transcription factor (ATF) 1 or cAMP response element-binding protein (CREB), but not ATF2/CRE-BP1. This synergy also partially occurred when hGABP alpha was used alone in place of the combination of hGABP alpha and hGABP beta. hGABP activated an artificial promoter containing only ATF/CREB-binding sites under coexistence of ATF1 or CREB. Consistent with these results, physical interactions of hGABP alpha with ATF1 or CREB were observed in vitro. Functional domain analyses of the physical interactions revealed that the amino-terminal region of hGABP alpha bound to the DNA-binding domain of ATF1, which resulted in the formation of ternary complexes composed of ATF1, hGABP alpha, and hGABP beta. In contrast to hGABP alpha, hGABP beta did not significantly interact with ATF1 and CREB. Taken together, these results indicate that hGABP functionally interacts with selective members of the ATF/CREB family, and also suggest that synergy results from multiple interactions which mediate stabilization of large complexes within the regulatory elements of the promoter region, including DNA-binding and non-DNA-binding factors.	Tokyo Inst Technol, Frontier Collaborat Res Ctr, Res Funct Biotechnol, Midori Ku, Yokohama, Kanagawa 2268501, Japan; Tokyo Inst Technol, Grad Sch Biosci & Biotechnol, Dept Biol Informat, Midori Ku, Yokohama, Kanagawa 2268501, Japan	Tokyo Institute of Technology; Tokyo Institute of Technology	Handa, H (corresponding author), Tokyo Inst Technol, Frontier Collaborat Res Ctr, Res Funct Biotechnol, Midori Ku, 4259 Nagatsuta Cho, Yokohama, Kanagawa 2268501, Japan.		WATANABE, Hajime/AAJ-8904-2021; Watanabe, Hajime/S-8957-2019	Imai, Takeshi/0000-0002-9503-7353; Watanabe, Hajime/0000-0001-9657-6554				Bannert N, 1999, P NATL ACAD SCI USA, V96, P1541, DOI 10.1073/pnas.96.4.1541; BOLWIG GM, 1992, NUCLEIC ACIDS RES, V20, P6555, DOI 10.1093/nar/20.24.6555; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; GIESE K, 1995, GENE DEV, V9, P995, DOI 10.1101/gad.9.8.995; GONZALEZ GA, 1989, NATURE, V337, P749, DOI 10.1038/337749a0; Goto M, 1995, GENE, V166, P337, DOI 10.1016/0378-1119(95)00575-7; GUGNEJA S, 1995, MOL CELL BIOL, V15, P102, DOI 10.1128/MCB.15.1.102; HAI T, 1988, CELL, V54, P1043, DOI 10.1016/0092-8674(88)90119-5; HAI TW, 1989, GENE DEV, V3, P2083, DOI 10.1101/gad.3.12b.2083; HURST HC, 1991, NUCLEIC ACIDS RES, V19, P4601, DOI 10.1093/nar/19.17.4601; INOMATA Y, 1992, ANAL BIOCHEM, V206, P109, DOI 10.1016/S0003-2697(05)80018-1; JANKNECHT R, 1993, BIOCHIM BIOPHYS ACTA, V1155, P346, DOI 10.1016/0304-419X(93)90014-4; LAI JS, 1992, P NATL ACAD SCI USA, V89, P6958, DOI 10.1073/pnas.89.15.6958; LAMARCO K, 1991, SCIENCE, V253, P789, DOI 10.1126/science.1876836; MAEKAWA T, 1989, EMBO J, V8, P2023, DOI 10.1002/j.1460-2075.1989.tb03610.x; MARCHIONI M, 1993, MOL CELL BIOL, V13, P6479, DOI 10.1128/MCB.13.10.6479; NIWA H, 1991, GENE, V108, P193, DOI 10.1016/0378-1119(91)90434-D; OOYAMA S, 1989, EMBO J, V8, P863, DOI 10.1002/j.1460-2075.1989.tb03447.x; SAUER F, 1995, SCIENCE, V270, P1783, DOI 10.1126/science.270.5243.1783; SAVOYSKY E, 1994, ONCOGENE, V9, P1839; Sawa C, 1996, NUCLEIC ACIDS RES, V24, P4954, DOI 10.1093/nar/24.24.4954; SAWADA J, 1994, EMBO J, V13, P1396, DOI 10.1002/j.1460-2075.1994.tb06393.x; SAWADA J, 1995, JPN J CANCER RES, V86, P10, DOI 10.1111/j.1349-7006.1995.tb02981.x; SCHNEIDER I, 1972, J EMBRYOL EXP MORPH, V27, P353; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; Shikama N, 1997, TRENDS CELL BIOL, V7, P230, DOI 10.1016/S0962-8924(97)01048-9; Shimomura A, 1996, J BIOL CHEM, V271, P17957, DOI 10.1074/jbc.271.30.17957; Sieweke MH, 1996, CELL, V85, P49, DOI 10.1016/S0092-8674(00)81081-8; Sowa Y, 1997, CANCER RES, V57, P3145; Suzuki F, 1998, J BIOL CHEM, V273, P29302, DOI 10.1074/jbc.273.45.29302; Thanos D, 1995, CELL, V83, P1091, DOI 10.1016/0092-8674(95)90136-1; THOMPSON CC, 1991, SCIENCE, V253, P762, DOI 10.1126/science.1876833; TREIER M, 1995, CELL, V83, P753, DOI 10.1016/0092-8674(95)90188-4; VIRBASIUS JV, 1993, GENE DEV, V7, P380, DOI 10.1101/gad.7.3.380; Wada T, 1996, NUCLEIC ACIDS RES, V24, P876, DOI 10.1093/nar/24.5.876; WASYLYK B, 1993, EUR J BIOCHEM, V211, P7, DOI 10.1111/j.1432-1033.1993.tb19864.x; WATANABE H, 1990, EMBO J, V9, P841, DOI 10.1002/j.1460-2075.1990.tb08181.x; WATANABE H, 1993, MOL CELL BIOL, V13, P1385, DOI 10.1128/MCB.13.3.1385; WATANABE H, 1988, MOL CELL BIOL, V8, P1290, DOI 10.1128/MCB.8.3.1290	40	26	26	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 10	1999	274	50					35475	35482		10.1074/jbc.274.50.35475	http://dx.doi.org/10.1074/jbc.274.50.35475			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	264NG	10585419	hybrid			2022-12-25	WOS:000084187900031
J	Liu, DX; Wen, J; Liu, J; Li, LP				Liu, DX; Wen, J; Liu, J; Li, LP			The roles of free radicals in amyotrophic lateral sclerosis: reactive oxygen species and elevated oxidation of protein, DNA, and membrane phospholipids	FASEB JOURNAL			English	Article						mutation of Cu,Zn-superoxide dismutase gene; transgenic mouse; hydrogen peroxide; hydroxyl radical; superoxide anion	CU,ZN SUPEROXIDE-DISMUTASE; RAT SPINAL-CORD; PERFORMANCE LIQUID-CHROMATOGRAPHY; MODEL COMBINING MICRODIALYSIS; METAL-CATALYZED OXIDATION; TRANSGENIC MOUSE MODEL; IN-VIVO; ELECTROCHEMICAL DETECTION; HYDROGEN-PEROXIDE; SALICYLATE HYDROXYLATION	TO explore whether reactive oxygen species (ROS) play a role in the pathogenesis of amyotrophic lateral sclerosis (ALS), a unique microdialysis or microcannula sampling technique was used in mice transfected with a mutant Cu,Zn-superoxide dismutase (SOD1) gene from humans with familial ALS, mice transfected with the normal human SOD1 gene, and normal mice. We demonstrate for the first time that the levels of hydrogen peroxide (H2O2) and the hydroxyl radical ((OH)-O-.) are significantly higher, and the level of the superoxide anion (O-2(.-)) is significantly lower in ALS mutant mice than in controls, supporting; by in vivo evidence the hypothesis that the mutant enzyme catalyzes (OH)-O-. formation by the sequence: O-2(.-) --> H2O2 --> (OH)-O-.. This removes doubts regarding the relevance of elevated ROS in FALS raised by in vitro experiments. The levels of oxidation products are also significantly higher in the mutant mice than in controls, consistent with some previous reports. Only the superoxide concentration differs between two controls among all the measurements. Our findings correlate in vivo a gene mutation to both elevated H2O2 and (OH)-O-. and increased oxidation of cellular constituents. The elevated H2O2 in mutant mice indicates impairment of its detoxification pathways, perhaps by changed interactions between SOD1 and H2O2 detoxification enzymes.	Univ Texas, Med Branch, Dept Neurol, Galveston, TX 77555 USA; Univ Texas, Med Branch, Dept Human Biol Chem & Genet, Galveston, TX 77555 USA	University of Texas System; University of Texas Medical Branch Galveston; University of Texas System; University of Texas Medical Branch Galveston	Liu, DX (corresponding author), Univ Texas, Med Branch, Dept Neurol, Gail Borden Bldg,Route 0653, Galveston, TX 77555 USA.	DLiu@utmb.edu		liu, danxia/0000-0001-8172-2344				Aguirre T, 1998, ANN NEUROL, V43, P452, DOI 10.1002/ana.410430407; AMICI A, 1989, J BIOL CHEM, V264, P3341; Andrus PK, 1998, J NEUROCHEM, V71, P2041; BELAND FA, 1979, J CHROMATOGR, V174, P177, DOI 10.1016/S0021-9673(00)87048-X; BELLEROCHE J, 1996, J NEUROPATHOL EXP NE, V55, P747; BERGERON C, 1994, BRAIN RES, V659, P272, DOI 10.1016/0006-8993(94)90892-3; Bogdanov MB, 1998, J NEUROCHEM, V71, P1321; BOWLING AC, 1993, J NEUROCHEM, V61, P2322, DOI 10.1111/j.1471-4159.1993.tb07478.x; Bruijn LI, 1997, P NATL ACAD SCI USA, V94, P7606, DOI 10.1073/pnas.94.14.7606; Bruijn LI, 1998, SCIENCE, V281, P1851, DOI 10.1126/science.281.5384.1851; DENG HX, 1993, SCIENCE, V261, P1047, DOI 10.1126/science.8351519; Ferrante RJ, 1997, ANN NEUROL, V42, P326, DOI 10.1002/ana.410420309; Ferrante RJ, 1997, J NEUROCHEM, V69, P2064; Fitzmaurice PS, 1996, MUSCLE NERVE, V19, P797; FLOYD R A, 1986, Journal of Free Radicals in Biology and Medicine, V2, P13, DOI 10.1016/0748-5514(86)90118-2; FLOYD RA, 1992, ANN NEUROL, V32, pS22, DOI 10.1002/ana.410320706; FLOYD RA, 1986, BIOCHEM BIOPH RES CO, V137, P841, DOI 10.1016/0006-291X(86)91156-3; FLOYD RA, 1988, ARCH BIOCHEM BIOPHYS, V262, P266, DOI 10.1016/0003-9861(88)90188-9; FLOYD RA, 1984, J BIOCHEM BIOPH METH, V10, P221, DOI 10.1016/0165-022X(84)90042-3; GUPTA RC, 1984, P NATL ACAD SCI-BIOL, V81, P6943, DOI 10.1073/pnas.81.22.6943; GURNEY ME, 1994, SCIENCE, V264, P1772, DOI 10.1126/science.8209258; Gurney ME, 1996, ANN NEUROL, V39, P147, DOI 10.1002/ana.410390203; Hall ED, 1998, J NEUROSCI RES, V53, P66, DOI 10.1002/(SICI)1097-4547(19980701)53:1<66::AID-JNR7>3.3.CO;2-K; HALLIWELL B, 1989, ACTA NEUROL SCAND, V80, P23, DOI 10.1111/j.1600-0404.1989.tb01779.x; Halliwell B, 1997, FREE RADICAL RES, V27, P239, DOI 10.3109/10715769709065762; HALLIWELL B, 1987, FASEB J, V1, P358, DOI 10.1096/fasebj.1.5.2824268; IMLAY JA, 1988, SCIENCE, V240, P1302, DOI 10.1126/science.3287616; INGELMANSUNDBERG M, 1991, BIOCHEM J, V276, P753, DOI 10.1042/bj2760753; IWASAKI Y, 1993, LANCET, V342, P1118, DOI 10.1016/0140-6736(93)92104-2; Kaur H, 1997, FREE RADICAL RES, V26, P71, DOI 10.3109/10715769709097786; LEVINE RL, 1990, METHOD ENZYMOL, V186, P464; LIU D, 1997, J NEUROTRAUM, V14, P785; LIU D, FREE RAD BIOL MED, V27, P478; LIU DX, 1993, BRAIN RES, V609, P293, DOI 10.1016/0006-8993(93)90885-Q; LIU DX, 1995, FREE RADICAL BIO MED, V18, P861, DOI 10.1016/0891-5849(94)00214-5; LIU DX, 1994, J NEUROCHEM, V62, P37; LIU DX, 1993, J BIOCHEM BIOPH METH, V27, P281, DOI 10.1016/0165-022X(93)90009-D; LIU DX, 1993, J NEUROTRAUM, V10, P349, DOI 10.1089/neu.1993.10.349; LIU DX, 1995, FREE RADICAL BIO MED, V18, P571, DOI 10.1016/0891-5849(94)00154-C; LIU DX, 1994, MOL CHEM NEUROPATHOL, V23, P77, DOI 10.1007/BF02815402; Liu DX, 1998, J NEUROCHEM, V70, pS7; Liu DX, 1998, FREE RADICAL BIO MED, V25, P298, DOI 10.1016/S0891-5849(98)00055-0; Liu RG, 1998, ANN NEUROL, V44, P763, DOI 10.1002/ana.410440510; Marklund SL, 1997, J NEUROCHEM, V69, P675; Marsala M, 1995, J NEUROSCI METH, V62, P43, DOI 10.1016/0165-0270(95)00053-4; Narayan M, 1997, FREE RADICAL RES, V27, P63, DOI 10.3109/10715769709097839; OHKAWA H, 1979, ANAL BIOCHEM, V95, P351, DOI 10.1016/0003-2697(79)90738-3; OLANOW CW, 1993, TRENDS NEUROSCI, V16, P439, DOI 10.1016/0166-2236(93)90070-3; PARDO CA, 1995, P NATL ACAD SCI USA, V92, P954, DOI 10.1073/pnas.92.4.954; Przedborski S, 1996, NEURODEGENERATION, V5, P57; Qian H, 1997, NEUROCHEM RES, V22, P1231, DOI 10.1023/A:1021980929422; ROBBERECHT W, 1994, J NEUROCHEM, V62, P384; ROSEN DR, 1993, NATURE, V362, P59, DOI 10.1038/362059a0; Rowland L. P., 1995, MERRITTS TXB NEUROLO, P742; SHIGENAGA MK, 1994, METHOD ENZYMOL, V234, P16; SHIGENAGA MK, 1990, METHOD ENZYMOL, V186, P521; Siddique T, 1996, HUM MOL GENET, V5, P1465, DOI 10.1093/hmg/5.Supplement_1.1465; Singh RJ, 1998, P NATL ACAD SCI USA, V95, P6675, DOI 10.1073/pnas.95.12.6675; STADTMAN ER, 1991, J BIOL CHEM, V266, P2005; UCHIYAMA M, 1978, ANAL BIOCHEM, V86, P271, DOI 10.1016/0003-2697(78)90342-1; WATSON BD, 1989, ANN NY ACAD SCI, V559, P269; WiedauPazos M, 1996, SCIENCE, V271, P515, DOI 10.1126/science.271.5248.515; Yim HS, 1997, J BIOL CHEM, V272, P8861; YIM MB, 1993, J BIOL CHEM, V268, P4099; YIM MB, 1990, P NATL ACAD SCI USA, V87, P5006, DOI 10.1073/pnas.87.13.5006; Yim MB, 1996, P NATL ACAD SCI USA, V93, P5709, DOI 10.1073/pnas.93.12.5709	66	158	162	0	24	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	1999	13	15					2318	2328		10.1096/fasebj.13.15.2318	http://dx.doi.org/10.1096/fasebj.13.15.2318			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	266QN	10593879				2022-12-25	WOS:000084310800023
J	Nesbit, M; Nesbit, HKE; Bennett, J; Andl, T; Hsu, MY; Dejesus, E; McBrian, M; Gupta, AR; Eck, SL; Herlyn, M				Nesbit, M; Nesbit, HKE; Bennett, J; Andl, T; Hsu, MY; Dejesus, E; McBrian, M; Gupta, AR; Eck, SL; Herlyn, M			Basic fibroblast growth factor induces a transformed phenotype in normal human melanocytes	ONCOGENE			English	Article						melanocytes; bFGF; adenovirus; transformation	FACTOR MESSENGER-RNA; MELANOMA CELL-LINES; MALIGNANT-MELANOMA; FACTOR RECEPTORS; 3T3 CELLS; EXPRESSION; BFGF; GENE; FGF; PROLIFERATION	Basic fibroblast growth factor (bFGF or FGF-2) is produced by nearly all melanomas in vitro and in viva but not by normal melanocytes, which require exogenous bFGF for growth, In this study, we transduced normal human melanocytes to overexpress two forms of bFGF: (bFGF-Long and bFGF-Short) using replication-deficient adenovirus 5 vectors. bFGF-Long induced the 17.8, 22.5, 23.1 and 24.2 kDa forms of bFGF, whereas bFGF-Short induced only the 17.8 kDa mature form. Growth of cultured melanocytes transduced with either vector was similar to that of nevus and melanoma cells and was independent of exogenous bFGF and of insulin/insulin-like growth factor 1, and cyclic AMP enhancers, requiring only phorbol ester as an exogenous mitogen, Like primary melanoma cells, transduced normal melanocytes grew anchorage independently in soft agar, When injected into the dermis of human skin grafted to mice, bFGF-transduced melanocytes proliferated for at least 20 days, whereas cells from control cultures showed poor survival and no proliferation. These results demonstrate that bFGF upregulation is a component in melanoma progression.	Wistar Inst Anat & Biol, Philadelphia, PA 19104 USA; Univ Penn, Dept Ophthalmol, Philadelphia, PA 19104 USA; Univ Penn, Dept Med, Philadelphia, PA 19104 USA	The Wistar Institute; University of Pennsylvania; University of Pennsylvania	Herlyn, M (corresponding author), Wistar Inst Anat & Biol, 3601 Spruce St, Philadelphia, PA 19104 USA.			Hsu, Mei-Yu/0000-0002-4628-0808; Andl, Thomas/0000-0002-5555-468X	NCI NIH HHS [CA25874, CA47159, CA76674] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA025874, R01CA047159, R01CA076674] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABDELMALEK Z, 1992, J CELL PHYSIOL, V150, P416, DOI 10.1002/jcp.1041500226; Ahmed NU, 1997, MELANOMA RES, V7, P299, DOI 10.1097/00008390-199708000-00004; AlAlousi S, 1996, J CUTAN PATHOL, V23, P506, DOI 10.1111/j.1600-0560.1996.tb01442.x; AlAlousi S, 1996, J CUTAN PATHOL, V23, P118, DOI 10.1111/j.1600-0560.1996.tb01284.x; ALBINO AP, 1991, CANCER RES, V51, P4815; AMALRIC F, 1994, BIOCHEM PHARMACOL, V47, P111, DOI 10.1016/0006-2952(94)90443-X; BALDIN V, 1990, EMBO J, V9, P1511, DOI 10.1002/j.1460-2075.1990.tb08269.x; BECKER D, 1992, ONCOGENE, V7, P2303; BECKER D, 1989, EMBO J, V8, P3685, DOI 10.1002/j.1460-2075.1989.tb08543.x; BOUCHE G, 1994, CELL MOL BIOL RES, V40, P547; Care A, 1996, MOL CELL BIOL, V16, P4842; CohenJonathan E, 1997, CANCER RES, V57, P1364; Coleman AB, 1998, J INVEST DERMATOL, V110, P793, DOI 10.1046/j.1523-1747.1998.00166.x; Czubayko F, 1997, NAT MED, V3, P1137, DOI 10.1038/nm1097-1137; DAVOL P, 1995, J INVEST DERMATOL, V104, P916, DOI 10.1111/1523-1747.ep12606193; DELUCA M, 1993, J CELL SCI, V105, P1079; deOliveira AR, 1996, BRAZ J MED BIOL RES, V29, P1743; DOTTO GP, 1989, J CELL BIOL, V109, P3115, DOI 10.1083/jcb.109.6.3115; Florkiewicz RZ, 1998, J BIOL CHEM, V273, P544, DOI 10.1074/jbc.273.1.544; FLORKIEWICZ RZ, 1989, P NATL ACAD SCI USA, V86, P3978, DOI 10.1073/pnas.86.11.3978; GUALANDRIS A, 1994, J CELL PHYSIOL, V161, P149, DOI 10.1002/jcp.1041610118; HALABAN R, 1988, ONCOGENE RES, V3, P177; HERLYN M, 1988, EXP CELL RES, V179, P322, DOI 10.1016/0014-4827(88)90271-6; HERLYN M, 1994, PIGM CELL RES, V7, P81, DOI 10.1111/j.1600-0749.1994.tb00025.x; HERLYN M, 1994, CANCER RES, V45, P5670; Horikawa T, 1996, PIGM CELL RES, V9, P58, DOI 10.1111/j.1600-0749.1996.tb00089.x; Hsu MY, 1999, HUMAN CELL CULTURE, V1, P259; Hsu MY, 1998, AM J PATHOL, V153, P1435, DOI 10.1016/S0002-9440(10)65730-6; JUHASZ I, 1993, AM J PATHOL, V143, P528; KOZARSKY KF, 1993, CURR OPIN GENET DEV, V3, P499, DOI 10.1016/0959-437X(93)90126-A; MANCIANTI ML, 1993, J INVEST DERMATOL, V100, pS281, DOI 10.1111/1523-1747.ep12470161; Nakazawa K, 1996, PIGM CELL RES, V9, P28, DOI 10.1111/j.1600-0749.1996.tb00083.x; Nelson JE, 1997, J VIROL, V71, P8902, DOI 10.1128/JVI.71.11.8902-8907.1997; PRATS AC, 1992, MOL CELL BIOL, V12, P4796, DOI 10.1128/MCB.12.10.4796; QUARTO N, 1991, CELL REGUL, V2, P699, DOI 10.1091/mbc.2.9.699; QUARTO N, 1989, ONCOGENE RES, V5, P101; REED JA, 1994, AM J PATHOL, V144, P329; RODECK U, 1987, INT J CANCER, V40, P687, DOI 10.1002/ijc.2910400520; Satyamoorthy K, 1997, MELANOMA RES, V7, pS35; SATYAMOORTHY K, 1996, IMMUNOLOGY HUMAN MEL, P71; SCOTT G, 1991, J INVEST DERMATOL, V96, P318, DOI 10.1111/1523-1747.ep12465203; Seno M, 1998, CYTOKINE, V10, P290, DOI 10.1006/cyto.1997.0286; UEDA M, 1994, BRIT J DERMATOL, V130, P320, DOI 10.1111/j.1365-2133.1994.tb02927.x; VALYINAGY IT, 1993, LAB INVEST, V69, P152; Wang YP, 1997, NAT MED, V3, P887, DOI 10.1038/nm0897-887; WEITZMAN MD, 1995, CNAC THERAPEUTICS; YAN HC, 1993, J CLIN INVEST, V91, P986, DOI 10.1172/JCI116320; Yayon A, 1997, ONCOGENE, V14, P2999, DOI 10.1038/sj.onc.1201159	48	95	100	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 11	1999	18	47					6469	6476		10.1038/sj.onc.1203066	http://dx.doi.org/10.1038/sj.onc.1203066			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	256CW	10597249				2022-12-25	WOS:000083709200009
J	Cho, HP; Nakamura, M; Clarke, SD				Cho, HP; Nakamura, M; Clarke, SD			Cloning, expression, and fatty acid regulation of the human Delta-5 desaturase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AUTOSOMAL GENOMIC SCAN; ARACHIDONIC-ACID; DOCOSAHEXAENOIC ACID; PRETERM INFANTS; PIMA-INDIANS; RAT-LIVER; GENE; METABOLISM; BRAIN; N-3	Arachidonic (20:4(n-6)), eicosapentaenoic (20:5(n-3)), and docosahexaenoic (22:6(n-3)) acids are major components of brain and retina phospholipids, substrates for eicosanoid production, and regulators of nuclear transcription factors. One of the two rate-limiting steps in the production of these polyenoic fatty acids is the desaturation of 20:3(n-6) and 20:4(n-3) by Delta-5 desaturase, This report describes the cloning and expression of the human Delta-5 desaturase, and it compares the structural characteristics and nutritional regulation of the Delta-5 and Delta-6 desaturases, The open reading frame of the human Delta-5 desaturase encodes a 444-amino acid peptide which is identical in size to the Delta-6 desaturase and which shares 61% identity with the human Delta-6 desaturase, The Delta-5 desaturase contains two membrane-spanning domains, three histidine-rich regions, and a cytochrome b(5) domain that all align perfectly with the same domains located in the Delta-6 desaturase. Expression of the open reading frame in Chinese hamster ovary cells instilled the ability:to convert 20:3(n-6) to 20:4(n-6), Northern analysis revealed that many human tissues including skeletal muscle, lung, placenta, kidney, and pancreas expressed Delta-5 desaturase mRNA, but Delta-5 desaturase was most abundant in the liver, brain, and heart. However, in all tissues, the abundance of Delta-5 desaturase mRNA was much lower than that observed for the Delta-6 desaturase. When rats were fed a diet containing 10% safflower oil or menhaden fish oil, the level of hepatic mRNA for Delta-5 and Delta-6 desaturase was only 25% of that found in the liver of rats fed a fat-free diet or a diet containing triolein, Finally, a BLAST and Genemap search of the human genome revealed that the Delta-5 and Delta-6 desaturase genes reside in reverse orientation on chromosome 11 and that they are separated by <11,000 base pairs.	Univ Texas, Nutr Sci Program, Austin, TX 78712 USA; Univ Texas, Inst Mol & Cellular Biol, Austin, TX 78712 USA	University of Texas System; University of Texas Austin; University of Texas System; University of Texas Austin	Clarke, SD (corresponding author), Univ Texas, Nutr Sci Program, 117 CEA, Austin, TX 78712 USA.	stevedclarke@mail.utexas.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK053872] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 53872] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Birch EE, 1998, PEDIATR RES, V44, P201, DOI 10.1203/00006450-199808000-00011; BOURRE JM, 1990, LIPIDS, V25, P354, DOI 10.1007/BF02544347; BRENNER RR, 1989, ROLE FATS HUMAN NUTR, P45; CARLSON SE, 1993, P NATL ACAD SCI USA, V90, P1073, DOI 10.1073/pnas.90.3.1073; Cho HP, 1999, J BIOL CHEM, V274, P471, DOI 10.1074/jbc.274.1.471; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHRISTIANSEN EN, 1991, BIOCHIM BIOPHYS ACTA, V1082, P57, DOI 10.1016/0005-2760(91)90299-W; Clarke SD, 1997, ANN NY ACAD SCI, V827, P178, DOI 10.1111/j.1749-6632.1997.tb51833.x; Crawford MA, 1997, AM J CLIN NUTR, V66, P1032, DOI 10.1093/ajcn/66.4.1032S; Forman BM, 1997, P NATL ACAD SCI USA, V94, P4312, DOI 10.1073/pnas.94.9.4312; GOETZL EJ, 1995, FASEB J, V9, P1051, DOI 10.1096/fasebj.9.11.7649404; Hanson RL, 1998, AM J HUM GENET, V63, P1130, DOI 10.1086/302061; HOLMAN RT, 1983, P NATL ACAD SCI-BIOL, V80, P2375, DOI 10.1073/pnas.80.8.2375; Horrobin DF, 1997, DIABETES, V46, pS90, DOI 10.2337/diab.46.2.S90; IGAL RA, 1991, MOL CELL ENDOCRINOL, V77, P217, DOI 10.1016/0303-7207(91)90077-6; Jump DB, 1999, ANNU REV NUTR, V19, P63, DOI 10.1146/annurev.nutr.19.1.63; Lim H, 1999, GENE DEV, V13, P1561, DOI 10.1101/gad.13.12.1561; MARTINEZ M, 1992, J PEDIATR-US, V120, pS129, DOI 10.1016/S0022-3476(05)81247-8; Marzo I, 1996, BBA-LIPID LIPID MET, V1301, P263, DOI 10.1016/0005-2760(96)00051-3; Michaelson LV, 1998, FEBS LETT, V439, P215, DOI 10.1016/S0014-5793(98)01385-4; Michaelson LV, 1998, J BIOL CHEM, V273, P19055, DOI 10.1074/jbc.273.30.19055; MITCHELL AG, 1995, J BIOL CHEM, V270, P29766; NEURINGER M, 1994, J PEDIATR-US, V125, pS39, DOI 10.1016/S0022-3476(06)80735-3; Norman RA, 1998, AM J HUM GENET, V62, P659, DOI 10.1086/301758; Pan DA, 1995, J CLIN INVEST, V96, P2802, DOI 10.1172/JCI118350; PELUFFO RO, 1976, BIOCHIM BIOPHYS ACTA, V441, P25, DOI 10.1016/0005-2760(76)90277-0; Piomelli D, 1993, CURR OPIN CELL BIOL, V5, P274, DOI 10.1016/0955-0674(93)90116-8; POISSON JPG, 1991, J NUTR BIOCHEM, V2, P60, DOI 10.1016/0955-2863(91)90030-9; SAMUELSSON B, 1983, BIOSCIENCE REP, V3, P791, DOI 10.1007/BF01133779; SCOTT BL, 1989, P NATL ACAD SCI USA, V86, P2903, DOI 10.1073/pnas.86.8.2903; SHANKLIN J, 1994, BIOCHEMISTRY-US, V33, P12787, DOI 10.1021/bi00209a009; Spiegelman BM, 1996, CELL, V87, P377, DOI 10.1016/S0092-8674(00)81359-8; SPRECHER H, 1981, Progress in Lipid Research, V20, P13, DOI 10.1016/0163-7827(81)90009-6; STRITTMATTER P, 1974, P NATL ACAD SCI USA, V71, P4565, DOI 10.1073/pnas.71.11.4565; Stuhlmeier KM, 1997, J BIOL CHEM, V272, P24679, DOI 10.1074/jbc.272.39.24679; Tsuboyama-Kasaoka N, 1999, BIOCHEM BIOPH RES CO, V257, P879, DOI 10.1006/bbrc.1999.0555; UAUY R, 1992, J PEDIATR-US, V120, pS168, DOI 10.1016/S0022-3476(05)81252-1; Werkman SH, 1996, LIPIDS, V31, P91, DOI 10.1007/BF02522417; WOLF BA, 1986, J BIOL CHEM, V261, P3501; Xu J, 1999, J BIOL CHEM, V274, P23577, DOI 10.1074/jbc.274.33.23577	40	407	438	0	20	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 24	1999	274	52					37335	37339		10.1074/jbc.274.52.37335	http://dx.doi.org/10.1074/jbc.274.52.37335			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	267WR	10601301	hybrid			2022-12-25	WOS:000084382700072
J	Iakhiaev, A; Pendurthi, UR; Voigt, J; Ezban, M; Rao, LVM				Iakhiaev, A; Pendurthi, UR; Voigt, J; Ezban, M; Rao, LVM			Catabolism of factor VIIa bound to tissue factor in fibroblasts in the presence and absence of tissue factor pathway inhibitor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR-RELATED PROTEIN; VEIN ENDOTHELIAL-CELLS; LUNG-CANCER CELLS; FACTOR-XA; IN-VIVO; ENDOCYTOSIS; THROMBOMODULIN; DEGRADATION; MECHANISM; SURFACES	Vascular injury leads to the exposure of blood to fibroblasts and smooth muscle cells within the vessel wall. These cells constitutively express tissue factor (TF), the cellular receptor for plasma clotting factor VIIa (FVIIa). Formation of TF . FVIIa complexes on cell surfaces triggers the blood coagulation cascade. In the present study, we have investigated the fate of TF . FVIIa complexes formed on the cell surface of fibroblasts in the presence and absence of plasma inhibitor, tissue factor pathway inhibitor (TFPI), FVIIa bound to TF on the cell surface was internalized and degraded without depleting the cell surface TF antigen and activity. TFPI significantly enhanced the TF-specific internalization and degradation of FVIIa, TFPI-enhanced internalization and degradation of FVIIa requires the C-terminal domain of TFPI and factor Xa, TFPI . Xa-mediated internalization of FVIIa was associated with the depletion of TF from the cell surface. A majority of the internalized FVIIa was degraded, but a small portion of the internalized FVIIa recycles back to the cell surface as an intact protein. In addition to TF, other cell surface components, such as low density lipoprotein receptor-related protein (LRP) and heparan sulfates, are essential for TFPI . Xa-induced internalization of FVIIa, Acidification of cytosol, which selectively inhibits the endocytotic pathway via coated pits, inhibited TFPI . Xa-mediated internalization but not the basal internalization of FVIIa, Overall, our data support the concept that FVIIa bound to cell surface TF was endocytosed by two different pathways. FVIIa complexed with TF in the absence of the inhibitor was internalized via a LRP-independent and probably noncoated pit pathway, whereas FVIIa complexed with TF along with the inhibitor was internalized via LRP-dependent coated pit pathway.	Univ Texas, Ctr Hlth, Dept Biochem, Tyler, TX 75708 USA; Univ Texas, Ctr Hlth, Dept Mol Biol, Tyler, TX 75708 USA; Novo Nordisk AS, DK-2760 Malov, Denmark	University of Texas System; University of Texas at Tyler; University of Texas-Health Sciences Center at Tyler (UTHSCT); University of Texas System; University of Texas at Tyler; University of Texas-Health Sciences Center at Tyler (UTHSCT); Novo Nordisk	Rao, LVM (corresponding author), Univ Texas, Ctr Hlth, Dept Biochem, 11937 US Hwy 271, Tyler, TX 75708 USA.	rao@uthct.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL058869] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL58869] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Bach RR, 1997, BLOOD, V89, P3270, DOI 10.1182/blood.V89.9.3270; BAJAJ SP, 1981, PREP BIOCHEM, V11, P397, DOI 10.1080/00327488108065531; CALLANDER NS, 1992, J BIOL CHEM, V267, P876; CHANG GTG, 1995, THROMB HAEMOSTASIS, V73, P231; DRAKE TA, 1989, AM J PATHOL, V134, P1087; FLECK RA, 1990, THROMB RES, V59, P421, DOI 10.1016/0049-3848(90)90148-6; Hamik A, 1999, J BIOL CHEM, V274, P4962, DOI 10.1074/jbc.274.8.4962; HEUSER J, 1989, J CELL BIOL, V108, P401, DOI 10.1083/jcb.108.2.401; Kojima T, 1996, J BIOL CHEM, V271, P5914, DOI 10.1074/jbc.271.10.5914; LE DT, 1992, J BIOL CHEM, V267, P15447; MARUYAMA I, 1985, J BIOL CHEM, V260, P5432; MARUYAMA I, 1987, BLOOD, V69, P1481; Mast AE, 1997, BIOCHEM J, V327, P577; MORRISSEY JH, 1988, THROMB RES, V52, P247, DOI 10.1016/0049-3848(88)90084-9; Mulder AB, 1996, BLOOD, V88, P1306, DOI 10.1182/blood.V88.4.1306.bloodjournal8841306; NARITA M, 1995, J BIOL CHEM, V270, P24800, DOI 10.1074/jbc.270.42.24800; RAO LVM, 1995, BLOOD, V85, P121, DOI 10.1182/blood.V85.1.121.bloodjournal851121; Rao LVM, 1998, BLOOD COAGUL FIBRIN, V9, pS27; RAO LVM, 1992, THROMB HAEMOSTASIS, V67, P654; RAO LVM, 1988, THROMB RES, V51, P373, DOI 10.1016/0049-3848(88)90373-8; RAPAPORT SI, 1995, THROMB HAEMOSTASIS, V74, P7; SANDVIG K, 1987, J CELL BIOL, V105, P679, DOI 10.1083/jcb.105.2.679; SCHWARTZ AL, 1995, PEDIATR RES, V38, P835, DOI 10.1203/00006450-199512000-00003; Semeraro N, 1997, THROMB HAEMOSTASIS, V78, P759; Sevinsky JR, 1996, J CELL BIOL, V133, P293, DOI 10.1083/jcb.133.2.293; Sorensen BB, 1997, J BIOL CHEM, V272, P11863, DOI 10.1074/jbc.272.18.11863; Sorensen BB, 1998, BLOOD COAGUL FIBRIN, V9, pS67; STRICKLAND DK, 1995, FASEB J, V9, P890, DOI 10.1096/fasebj.9.10.7615159; TEASDALE MS, 1994, IMMUNOL CELL BIOL, V72, P480, DOI 10.1038/icb.1994.72; THIM L, 1988, BIOCHEMISTRY-US, V27, P7785, DOI 10.1021/bi00420a030; WARSHAWSKY I, 1994, P NATL ACAD SCI USA, V91, P6664, DOI 10.1073/pnas.91.14.6664; WARSHAWSKY I, 1995, J CLIN INVEST, V95, P1773, DOI 10.1172/JCI117855; Warshawsky I, 1996, J BIOL CHEM, V271, P25873, DOI 10.1074/jbc.271.42.25873; WATTS C, 1985, J CELL BIOL, V100, P633, DOI 10.1083/jcb.100.2.633; WESSELSCHMIDT R, 1993, BLOOD COAGUL FIBRIN, V4, P661, DOI 10.1097/00001721-199304050-00001	35	45	45	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 24	1999	274	52					36995	37003		10.1074/jbc.274.52.36995	http://dx.doi.org/10.1074/jbc.274.52.36995			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	267WR	10601255	hybrid			2022-12-25	WOS:000084382700026
J	Komuro, A; Saeki, M; Kato, S				Komuro, A; Saeki, M; Kato, S			Association of two nuclear proteins, Npw38 and NpwBP, via the interaction between the WW domain and a novel proline-rich motif containing glycine and arginine	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPITHELIAL NA+ CHANNEL; LIDDLES-SYNDROME; BINDING PROTEIN; DYSTROPHIN; HOMOLOGY; NEDD4	We have previously reported a nuclear protein possessing a WW domain, Npw38 (Komuro, A., Saeki, M,, and Kato, S, (1999) Nucleic Acids Res. 27, 1957-1965), Here we report a Npw38-binding protein, NpwBP, isolated from HeLa cell nuclear extracts and its characterization using a cloned cDNA, NpwBP contains two proline-rich regions that are capable of binding to the WW domain of Npw38, The binding analysis using an oligopeptide-immobilized membrane revealed that the WW domain of Npw38 preferentially recognizes a short proline-rich sequence, PPGPPP, surrounded by an arginine residue, so we named it a PGR motif, Localization analysis using green fluorescent protein fusion protein and immunostaining showed that Npw38 and NpwBP are colocalized in the same subnuclear region. Coimmunoprecipitation experiments confirmed the association between Npw38 and NpwBP, which were expressed as epitope-tagged forms in COS7 cells. Furthermore, the N-terminal region of NpwBP has binding ability for poly(rG) and G-rich single-stranded DNA. These results suggest that NpwBP is a physiological ligand of Npw88 and that the Npw38NpwBP complex may function as a component of an mRNA factory in the nucleus.	Sagami Chem Res Ctr, Japan Sci & Technol Corp, Kato Cytoprot Network Project, Sagamihara, Kanagawa 2290012, Japan	Japan Science & Technology Agency (JST)	Kato, S (corresponding author), Sagami Chem Res Ctr, Japan Sci & Technol Corp, Kato Cytoprot Network Project, 4-4-1 Nishi Ohnuma, Sagamihara, Kanagawa 2290012, Japan.							ANDRE B, 1994, BIOCHEM BIOPH RES CO, V205, P1201, DOI 10.1006/bbrc.1994.2793; Bedford MT, 1998, P NATL ACAD SCI USA, V95, P10602, DOI 10.1073/pnas.95.18.10602; Bedford MT, 1997, EMBO J, V16, P2376, DOI 10.1093/emboj/16.9.2376; Bertolotti A, 1996, EMBO J, V15, P5022, DOI 10.1002/j.1460-2075.1996.tb00882.x; BORK P, 1994, TRENDS BIOCHEM SCI, V19, P531, DOI 10.1016/0968-0004(94)90053-1; Chan DC, 1996, EMBO J, V15, P1045, DOI 10.1002/j.1460-2075.1996.tb00442.x; CHEN HI, 1995, P NATL ACAD SCI USA, V92, P7819, DOI 10.1073/pnas.92.17.7819; Ermekova KS, 1997, J BIOL CHEM, V272, P32869, DOI 10.1074/jbc.272.52.32869; Espanel X, 1999, J BIOL CHEM, V274, P17284, DOI 10.1074/jbc.274.24.17284; Goulet CC, 1998, J BIOL CHEM, V273, P30012, DOI 10.1074/jbc.273.45.30012; Harvey KF, 1999, J BIOL CHEM, V274, P12525, DOI 10.1074/jbc.274.18.12525; HOFMANN K, 1995, FEBS LETT, V358, P153, DOI 10.1016/0014-5793(94)01415-W; KAELIN WG, 1992, CELL, V70, P351, DOI 10.1016/0092-8674(92)90108-O; Komuro A, 1999, NUCLEIC ACIDS RES, V27, P1957, DOI 10.1093/nar/27.9.1957; Lu PJ, 1999, SCIENCE, V283, P1325, DOI 10.1126/science.283.5406.1325; Macias MJ, 1996, NATURE, V382, P646, DOI 10.1038/382646a0; Rentschler S, 1999, BIOL CHEM, V380, P431, DOI 10.1515/BC.1999.057; Staub O, 1996, EMBO J, V15, P2371, DOI 10.1002/j.1460-2075.1996.tb00593.x; Sudol M, 1996, PROG BIOPHYS MOL BIO, V65, P113, DOI 10.1016/S0079-6107(96)00008-9; SUDOL M, 1995, FEBS LETT, V369, P67, DOI 10.1016/0014-5793(95)00550-S	20	71	74	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 17	1999	274	51					36513	36519		10.1074/jbc.274.51.36513	http://dx.doi.org/10.1074/jbc.274.51.36513			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	266AV	10593949	hybrid			2022-12-25	WOS:000084279200068
J	Michaely, P; Kamal, A; Anderson, RGW; Bennett, V				Michaely, P; Kamal, A; Anderson, RGW; Bennett, V			A requirement for ankyrin binding to clathrin during coated pit budding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ERYTHROCYTE ANKYRIN; ANION-EXCHANGER; ANNEXIN-VI; SPECTRIN; IDENTIFICATION; PROTEINS; RECEPTOR; REPEATS; DOMAIN; CELLS	Recent studies suggest that the mobility of clathrin-coated pits at the cell surface are restricted by an actin cytoskeleton and that there is an obligate reduction in the amount of spectrin on membranes during coated pit budding. The spectrin-actin cytoskeleton associates with membranes primarily through ankyrins, which interact with the cytoplasmic region of numerous integral membrane proteins. We now report that the fourth repeat domain (D4) of ankyrin, binds to the N-terminal domain of clathrin heavy chain with high affinity. Addition of peptides containing the D4 region inhibited clathrin-coated pit budding in vitro. In addition, microinjection of D4 containing peptides blocked the endocytosis of fluorescent low density lipoprotein (LDL). Ankyrin, peptides that contained repeat domains other than D4 had no effect on either in vitro budding or internalization of LDL. Finally, immunofluorescence shows that ankyrin is uniformly associated with endosomes that contain fluorescent LDL. These results suggest that ankyrin plays a role in the budding of clathrin-coated pits during endocytosis.	Univ Texas, SW Med Ctr, Dept Cell Biol & Neurosci, Dallas, TX 75235 USA; Duke Univ, Dept Cell Biol, Howard Hughes Med Inst, Durham, NC 27710 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Duke University; Howard Hughes Medical Institute	Michaely, P (corresponding author), Univ Texas, SW Med Ctr, Dept Cell Biol & Neurosci, 5323 Harry Hines Blvd, Dallas, TX 75235 USA.				NHLBI NIH HHS [HL20948] Funding Source: Medline; NIDDK NIH HHS [DK29808] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL020948] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK029808, R01DK029808] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Anderson R G, 1986, Methods Enzymol, V129, P201; Batchelor AH, 1998, SCIENCE, V279, P1037, DOI 10.1126/science.279.5353.1037; Beck KA, 1996, AM J PHYSIOL-CELL PH, V270, pC1263, DOI 10.1152/ajpcell.1996.270.5.C1263; BECK KA, 1994, J CELL BIOL, V127, P707, DOI 10.1083/jcb.127.3.707; BENNETT V, 1979, NATURE, V281, P597, DOI 10.1038/281597a0; BLACK JD, 1988, J CELL BIOL, V106, P97, DOI 10.1083/jcb.106.1.97; BORK P, 1993, PROTEINS, V17, P363, DOI 10.1002/prot.340170405; Butler MH, 1997, J CELL BIOL, V137, P1355, DOI 10.1083/jcb.137.6.1355; CONRADI S, 1969, ACTA PHYSIOL SCAND, P53; Devarajan P, 1996, J CELL BIOL, V133, P819, DOI 10.1083/jcb.133.4.819; FAIRBANKS G, 1971, BIOCHEMISTRY-US, V10, P2606, DOI 10.1021/bi00789a030; Gaidarov I, 1999, NAT CELL BIOL, V1, P1, DOI 10.1038/8971; GOLDSTEIN JL, 1983, METHOD ENZYMOL, V98, P241; Goodman OB, 1996, NATURE, V383, P447, DOI 10.1038/383447a0; Gorina S, 1996, SCIENCE, V274, P1001, DOI 10.1126/science.274.5289.1001; HEUSER J, 1980, J CELL BIOL, V84, P560, DOI 10.1083/jcb.84.3.560; Kamal A, 1998, J CELL BIOL, V142, P937, DOI 10.1083/jcb.142.4.937; KARLSSON U, 1967, J ULTRA MOL STRUCT R, V17, P137, DOI 10.1016/S0022-5320(67)80026-1; Kibbey RG, 1998, J CELL BIOL, V142, P59, DOI 10.1083/jcb.142.1.59; KORDELI E, 1995, J BIOL CHEM, V270, P2352, DOI 10.1074/jbc.270.5.2352; LIN HC, 1992, CELL, V70, P283, DOI 10.1016/0092-8674(92)90102-I; LUX SE, 1989, P NATL ACAD SCI USA, V86, P9089, DOI 10.1073/pnas.86.23.9089; MICHAELY P, 1993, J BIOL CHEM, V268, P22703; MICHAELY P, 1995, J BIOL CHEM, V270, P22050, DOI 10.1074/jbc.270.37.22050; Michaely P, 1995, J BIOL CHEM, V270, P31298, DOI 10.1074/jbc.270.52.31298; MOORE MS, 1987, SCIENCE, V236, P558, DOI 10.1126/science.2883727; OTTO E, 1991, J CELL BIOL, V114, P241, DOI 10.1083/jcb.114.2.241; PETERS LL, 1993, SEMIN HEMATOL, V30, P85; RODMAN JS, 1986, EUR J CELL BIOL, V42, P319; UNGEWICKELL E, 1981, NATURE, V289, P420, DOI 10.1038/289420a0; VIGERS GPA, 1986, EMBO J, V5, P2079, DOI 10.1002/j.1460-2075.1986.tb04469.x	31	47	48	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 10	1999	274	50					35908	35913		10.1074/jbc.274.50.35908	http://dx.doi.org/10.1074/jbc.274.50.35908			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	264NG	10585476	hybrid			2022-12-25	WOS:000084187900088
J	Palmer, RH; Fessler, LI; Edeen, PT; Madigan, SJ; McKeown, M; Hunter, T				Palmer, RH; Fessler, LI; Edeen, PT; Madigan, SJ; McKeown, M; Hunter, T			DFak56 is a novel Drosophila melanogaster focal adhesion kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE KINASE; TISSUE-SPECIFIC EXPRESSION; SWISS 3T3 CELLS; WING MORPHOGENESIS; MOLECULAR-CLONING; TERMINAL DOMAIN; PS INTEGRINS; C-SRC; BETA; PHOSPHORYLATION	The mammalian focal adhesion kinase (FAK) family of nonreceptor protein-tyrosine kinases have been implicated in controlling a multitude of cellular responses to the engagement of cell surface integrins and G protein-coupled receptors. We describe here a Drosophila melanogaster FAK homologue, DFak56, which maps to band 56D on the right arm of the second chromosome. Full-length DFak56 cDNA encodes a phosphoprotein of 140 kDa, which shares strong sequence similarity not only with mammalian p125(FAK) but also with the more recently described mammalian Pyk2 (also known as CAR beta, RAFTK, FAK2, and CADTK) FAK family member. DFak56 has intrinsic tyrosine kinase activity and is phosphorylated on tyrosine in vivo. As is the case for FAK, tyrosine phosphorylation of DFak56 is increased upon plating Drosophila embryo cells on extracellular matrix proteins. In situ hybridization and immunofluorescence staining analysis showed that DFak56 is ubiquitously expressed with particularly high levels within the developing central nervous system, We utilized the UAS-GAIA expression system to express DFak56 and analyze its function in vivo. Overexpression of DFak56 in the wing imaginal disc results in wing blistering in adults, a phenotype also observed with both position-specific integrin loss of function and position-specific integrin overexpression. Our results imply a role for DFak56 in adhesion-dependent signaling pathways in viva during D. melanogaster development.	Salk Inst Biol Studies, Mol Biol & Virol Lab, La Jolla, CA 92037 USA; Univ Calif Los Angeles, Dept Biol, Inst Mol Cell & Dev Biol, Los Angeles, CA 90095 USA	Salk Institute; University of California System; University of California Los Angeles	Hunter, T (corresponding author), Salk Inst Biol Studies, Mol Biol & Virol Lab, 10010 N Torrey Pines Rd, La Jolla, CA 92037 USA.				NATIONAL CANCER INSTITUTE [R35CA039780] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM057689] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH057460] Funding Source: NIH RePORTER; NCI NIH HHS [CA39780] Funding Source: Medline; NIGMS NIH HHS [GM57689] Funding Source: Medline; NIMH NIH HHS [MH57460] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; AVRAHAM S, 1995, J BIOL CHEM, V270, P27742, DOI 10.1074/jbc.270.46.27742; BOGAERT T, 1987, CELL, V51, P929, DOI 10.1016/0092-8674(87)90580-0; BRABANT MC, 1993, DEV BIOL, V157, P49, DOI 10.1006/dbio.1993.1111; Brabant MC, 1996, DEVELOPMENT, V122, P3307; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRAND AH, 1993, DEVELOPMENT, V118, P401; BROWN NH, 1993, BIOESSAYS, V15, P383, DOI 10.1002/bies.950150604; BROWN NH, 1994, DEVELOPMENT, V120, P1221; Bunch TA, 1998, DEVELOPMENT, V125, P1679; Burgaya F, 1996, MOL BRAIN RES, V37, P63, DOI 10.1016/0169-328X(95)00273-U; Cary LA, 1996, J CELL SCI, V109, P1787; CLARK EA, 1995, SCIENCE, V268, P233, DOI 10.1126/science.7716514; Dikic I, 1996, NATURE, V383, P547, DOI 10.1038/383547a0; DING D, 1993, P NATL ACAD SCI USA, V90, P2512, DOI 10.1073/pnas.90.6.2512; EMORI Y, 1994, J BIOL CHEM, V269, P25137; GEORGE EL, 1993, DEVELOPMENT, V119, P1079; Gilmore AP, 1996, MOL BIOL CELL, V7, P1209, DOI 10.1091/mbc.7.8.1209; GREGORY RJ, 1987, MOL CELL BIOL, V7, P2119, DOI 10.1128/MCB.7.6.2119; Grotewiel MS, 1998, NATURE, V391, P455, DOI 10.1038/35079; GUAN JL, 1992, NATURE, V358, P690, DOI 10.1038/358690a0; HANKS SK, 1992, P NATL ACAD SCI USA, V89, P8487, DOI 10.1073/pnas.89.18.8487; Herzog H, 1996, GENOMICS, V32, P484, DOI 10.1006/geno.1996.0149; HILDEBRAND JD, 1993, J CELL BIOL, V123, P993, DOI 10.1083/jcb.123.4.993; HILDEBRAND JD, 1995, MOL BIOL CELL, V6, P637, DOI 10.1091/mbc.6.6.637; Ito K, 1997, DEVELOPMENT, V124, P761; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAI C, 1991, NEURON, V6, P691, DOI 10.1016/0896-6273(91)90167-X; LAROCHELLE S, 1995, BBA-GENE STRUCT EXPR, V1261, P147, DOI 10.1016/0167-4781(95)00010-E; LEPTIN M, 1989, CELL, V56, P401, DOI 10.1016/0092-8674(89)90243-2; LEUNG J, 1991, J MOL BIOL, V219, P175, DOI 10.1016/0022-2836(91)90560-S; LEV S, 1995, NATURE, V376, P737, DOI 10.1038/376737a0; Li JZ, 1996, BLOOD, V88, P417, DOI 10.1182/blood.V88.2.417.bloodjournal882417; Li X, 1998, EMBO J, V17, P2574, DOI 10.1093/emboj/17.9.2574; Li X, 1998, J BIOL CHEM, V273, P9361, DOI 10.1074/jbc.273.16.9361; Ma EA, 1997, EUR J IMMUNOL, V27, P329, DOI 10.1002/eji.1830270147; MACKRELL AJ, 1988, P NATL ACAD SCI USA, V85, P2633, DOI 10.1073/pnas.85.8.2633; MARCK C, 1988, NUCLEIC ACIDS RES, V16, P1829, DOI 10.1093/nar/16.5.1829; PATEL NH, 1994, METHOD CELL BIOL, V44, P445, DOI 10.1016/S0091-679X(08)60927-9; Prout M, 1997, GENETICS, V146, P275; RANKIN S, 1994, J BIOL CHEM, V269, P704; Richardson A, 1997, BIOCHEM J, V324, P141, DOI 10.1042/bj3240141; RUBIN GM, 1982, SCIENCE, V218, P348, DOI 10.1126/science.6289436; SASAKI H, 1995, J BIOL CHEM, V270, P21206, DOI 10.1074/jbc.270.36.21206; Schaller MD, 1997, J BIOL CHEM, V272, P25319, DOI 10.1074/jbc.272.40.25319; SCHALLER MD, 1995, J CELL BIOL, V130, P1181, DOI 10.1083/jcb.130.5.1181; SCHALLER MD, 1992, P NATL ACAD SCI USA, V89, P5192, DOI 10.1073/pnas.89.11.5192; SCHEJTER ED, 1986, CELL, V46, P1091, DOI 10.1016/0092-8674(86)90709-9; Schneller M, 1997, EMBO J, V16, P5600, DOI 10.1093/emboj/16.18.5600; SIMON MA, 1985, CELL, V42, P831, DOI 10.1016/0092-8674(85)90279-X; Stark KA, 1997, DEVELOPMENT, V124, P4583; Takahashi F, 1996, GENE DEV, V10, P1645, DOI 10.1101/gad.10.13.1645; TAMKUN JW, 1992, CELL, V68, P561, DOI 10.1016/0092-8674(92)90191-E; THEOPOLD U, 1995, MOL CELL BIOL, V15, P824; WILCOX M, 1981, CELL, V25, P159, DOI 10.1016/0092-8674(81)90240-3; Yu H, 1996, J BIOL CHEM, V271, P29993, DOI 10.1074/jbc.271.47.29993; YUE L, 1992, GENE DEV, V6, P2443, DOI 10.1101/gad.6.12b.2443; ZACHARY I, 1992, J BIOL CHEM, V267, P19031	58	40	42	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 10	1999	274	50					35621	35629		10.1074/jbc.274.50.35621	http://dx.doi.org/10.1074/jbc.274.50.35621			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	264NG	10585440	Green Accepted, hybrid			2022-12-25	WOS:000084187900052
J	Chen, XZ; Peng, JB; Cohen, A; Nelson, H; Nelson, N; Hediger, MA				Chen, XZ; Peng, JB; Cohen, A; Nelson, H; Nelson, N; Hediger, MA			Yeast SMF1 mediates H+-coupled iron uptake with concomitant uncoupled cation currents	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GATED CHLORIDE CHANNEL; SACCHAROMYCES-CEREVISIAE; SEROTONIN TRANSPORTER; NATURAL-RESISTANCE; MICROCYTIC ANEMIA; TASTE BEHAVIOR; NRAMP GENE; PROTEIN; CANDIDATE; INFECTION	Yeast membrane proteins SMF1, SMF2, and SMF3 are homologues of the DCT1 metal ion transporter family. Their functional characteristics and the implications of these characteristics in vivo have not yet been reported. Here we show that SMF1 expressed in Xenopus oocytes mediates H+-dependent Fe2+ transport and uncoupled Na+ flux. SMF1-mediated Fe2+ transport exhibited saturation kinetics (K-m = 2.2 mu M), whereas the Na+ flux did not, although both processes mere electrogenic. SMF1 is also permeable to Li+, Rb+, K+, and Ca2+, which likely share the same uncoupled pathway. SMF2 (but not SMF3) mediated significant increases in both Fe2+ and Na+ transport compared with control oocytes. These data are consistent with the concept that uptake of divalent metal ions by SMF1 and SMF2 is essential to yeast cell growth. Na+ inhibited metal ion uptake mediated by SMF1 and SMF2 expressed in oocytes. Consistent with this, we found that increased sensitivity of yeast to EGTA in the high Na+ medium is due to inhibition of SMF1- and SMF2-mediated metal ion transport by uncoupled Na+ pathway. Interestingly, DCT1 also mediates Fe2+-activated uncoupled currents. We propose that uncoupled ion permeabilities in metal ion transporters protect cells from metal ion overload.	Harvard Univ, Brigham & Womens Hosp, Sch Med, Membrane Biol Program, Boston, MA 02115 USA; Harvard Univ, Brigham & Womens Hosp, Sch Med, Div Renal, Boston, MA 02115 USA; Tel Aviv Univ, Dept Biochem, IL-69978 Tel Aviv, Israel	Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard Medical School; Tel Aviv University	Hediger, MA (corresponding author), Harvard Univ, Inst Med, Div Renal, Rm 570, Boston, MA 02115 USA.			Hediger, Matthias/0000-0003-1946-027X	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK043171] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK43171] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Babcock M, 1997, SCIENCE, V276, P1709, DOI 10.1126/science.276.5319.1709; Cammack JN, 1996, P NATL ACAD SCI USA, V93, P723, DOI 10.1073/pnas.93.2.723; CHELLY J, 1993, NAT GENET, V3, P14, DOI 10.1038/ng0193-14; Chen XZ, 1998, J BIOL CHEM, V273, P20972, DOI 10.1074/jbc.273.33.20972; Chen XZ, 1995, BIOPHYS J, V69, P2405, DOI 10.1016/S0006-3495(95)80110-4; Cox D W, 1996, Prog Liver Dis, V14, P245; DIX DR, 1994, J BIOL CHEM, V269, P26092; ELBLE R, 1992, BIOTECHNIQUES, V13, P18; FAIRMAN WA, 1995, NATURE, V375, P599, DOI 10.1038/375599a0; Feder JN, 1996, NAT GENET, V13, P399, DOI 10.1038/ng0896-399; Fleming MD, 1997, NAT GENET, V16, P383, DOI 10.1038/ng0897-383; Fleming MD, 1998, P NATL ACAD SCI USA, V95, P1148, DOI 10.1073/pnas.95.3.1148; Galli A, 1997, J NEUROSCI, V17, P3401; Good PF, 1996, AM J PATHOL, V149, P21; GRUENHEID S, 1995, GENOMICS, V25, P514, DOI 10.1016/0888-7543(95)80053-O; Gunshin H, 1997, NATURE, V388, P482, DOI 10.1038/41343; Hartman KR, 1996, AM J HEMATOL, V51, P269, DOI 10.1002/(SICI)1096-8652(199604)51:4<269::AID-AJH4>3.0.CO;2-U; HIRSCH EC, 1994, MOL NEUROBIOL, V9, P135, DOI 10.1007/BF02816113; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; Lin F, 1996, BIOPHYS J, V71, P3126, DOI 10.1016/S0006-3495(96)79506-1; Liu XF, 1997, J BIOL CHEM, V272, P11763, DOI 10.1074/jbc.272.18.11763; Liu XF, 1999, J BIOL CHEM, V274, P4863, DOI 10.1074/jbc.274.8.4863; MAGER S, 1994, NEURON, V12, P845, DOI 10.1016/0896-6273(94)90337-9; NELSON H, 1990, P NATL ACAD SCI USA, V87, P3503, DOI 10.1073/pnas.87.9.3503; NOUMI T, 1991, P NATL ACAD SCI USA, V88, P1938, DOI 10.1073/pnas.88.5.1938; Orgad S, 1998, J EXP BIOL, V201, P115; Palmiter RD, 1996, P NATL ACAD SCI USA, V93, P14934, DOI 10.1073/pnas.93.25.14934; PICAUD SA, 1995, J NEUROPHYSIOL, V74, P1760, DOI 10.1152/jn.1995.74.4.1760; Pinner E, 1997, J BIOL CHEM, V272, P28933, DOI 10.1074/jbc.272.46.28933; RODRIGUES V, 1995, EMBO J, V14, P3007, DOI 10.1002/j.1460-2075.1995.tb07303.x; Rolfs A, 1999, J PHYSIOL-LONDON, V518, P1, DOI 10.1111/j.1469-7793.1999.0001r.x; Searle S, 1998, J CELL SCI, V111, P2855; Supek F, 1997, J EXP BIOL, V200, P321; Supek F, 1996, P NATL ACAD SCI USA, V93, P5105, DOI 10.1073/pnas.93.10.5105; VIDAL S, 1995, MAMM GENOME, V6, P224, DOI 10.1007/BF00352405; VIDAL SM, 1993, CELL, V73, P469, DOI 10.1016/0092-8674(93)90135-D; WEST AH, 1992, J BIOL CHEM, V267, P24625; Wood RJ, 1998, J NUTR, V128, P1841, DOI 10.1093/jn/128.11.1841	38	89	96	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 3	1999	274	49					35089	35094		10.1074/jbc.274.49.35089	http://dx.doi.org/10.1074/jbc.274.49.35089			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	260XW	10574989	hybrid			2022-12-25	WOS:000083979600083
J	Strassner, J; Furholz, A; Macheroux, P; Amrhein, N; Schaller, A				Strassner, J; Furholz, A; Macheroux, P; Amrhein, N; Schaller, A			A homolog of old yellow enzyme in tomato - Spectral properties and substrate specificity of the recombinant protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR-CLONING; ACTIVE-SITE; REDUCTASE; PURIFICATION; REACTIVITY; CLEAVAGE; BINDING; LIGAND; ACID	A cDNA was isolated and characterized from a tomato shoot cDNA library, the deduced amino acid sequence of which exhibited similarity with yeast Old Fellow Enzymes (OYEs) and related enzymes of bacterial and plant origin. Sequence identity was particularly high with 12-oxophytodienoate 10,11-reductase (OPR) from Arabidopsis thaliana. The cDNA-encoded protein was expressed as a glutathione S-transferase fusion protein in Escherichia coli and was purified from bacterial extracts. The protein was found to be a flavoprotein catalyzing the NADPH-dependent reduction of the olefinic bond of alpha,beta-unsaturated carbonyl compounds, including 12-oxophytodienoic acid. Thus, the tomato enzyme was termed LeOPR. The catalytic efficiency of LeOPR was highest with N-ethylmaleimide followed by 12-oxophytodienoic acid and maleic acid as substrates. Photoreduction of the LeOPR-bound FMN resulted in the formation of a red, anionic semiquinone prior to the formation of the fully reduced flavin dihydroquinone, Spectroscopic characterization of LeOPR revealed the formation of charge transfer complexes upon titration with para-substituted phenolic compounds, a distinctive feature of the enzymes of the OYE family. The ligand binding properties were compared between LeOPR and OYE, and the findings are discussed with respect to structural differences between the active sites of OYE and LeOPR.	Swiss Fed Inst Technol, Inst Plant Sci, CH-8092 Zurich, Switzerland	Swiss Federal Institutes of Technology Domain; ETH Zurich	Schaller, A (corresponding author), Swiss Fed Inst Technol, Inst Plant Sci, Univ Str 2, CH-8092 Zurich, Switzerland.		Macheroux, Peter/AAB-5157-2019; Schaller, Andreas/AAC-1940-2020	Macheroux, Peter/0000-0002-0242-454X; Schaller, Andreas/0000-0001-6872-9576				ABRAMOVITZ AS, 1976, J BIOL CHEM, V251, P5321; ABRAMOVITZ AS, 1976, J BIOL CHEM, V251, P5327; AUSUBEL FM, 1987, CURRENT PROTOCOLS MO, P247; Biesgen C, 1999, PLANTA, V208, P155, DOI 10.1007/s004250050545; Brown BJ, 1998, J BIOL CHEM, V273, P32753, DOI 10.1074/jbc.273.49.32753; Buckman J, 1998, BIOCHEMISTRY-US, V37, P14326, DOI 10.1021/bi981106y; FOX KM, 1994, STRUCTURE, V2, P1089, DOI 10.1016/S0969-2126(94)00111-1; FRANKLUND CV, 1993, J BACTERIOL, V175, P3002, DOI 10.1128/JB.175.10.3002-3012.1993; FRENCH CE, 1994, BIOCHEM J, V301, P97, DOI 10.1042/bj3010097; GHISLA S, 1989, EUR J BIOCHEM, V181, P1, DOI 10.1111/j.1432-1033.1989.tb14688.x; Gorlach J, 1996, GENE, V170, P145, DOI 10.1016/0378-1119(95)00825-X; HAUSCH C, 1991, CHEM REV, V91, P165; JAFFE HH, 1953, CHEM REV, V53, P191, DOI 10.1021/cr60165a003; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MASSEY V, 1986, J BIOL CHEM, V261, P1215; MASSEY V, 1979, J BIOL CHEM, V254, P9640; Massey V., 1984, FLAVINS FLAVOPROTEIN, P191; MATTHEWS RG, 1969, J BIOL CHEM, V244, P1779; MATTHEWS RG, 1975, J BIOL CHEM, V250, P9294; Miura K, 1997, BIOL PHARM BULL, V20, P110; PEARCE G, 1991, SCIENCE, V253, P895, DOI 10.1126/science.253.5022.895; Sambrook J., 2002, MOL CLONING LAB MANU; Schaller A, 1999, PLANT CELL, V11, P263, DOI 10.1105/tpc.11.2.263; Schaller F, 1998, PLANT PHYSIOL, V118, P1345, DOI 10.1104/pp.118.4.1345; Schaller F, 1997, EUR J BIOCHEM, V245, P294, DOI 10.1111/j.1432-1033.1997.t01-1-00294.x; Schaller F, 1997, J BIOL CHEM, V272, P28066, DOI 10.1074/jbc.272.44.28066; Schopfer L. M., 1991, STUDY ENZYMES, P247; STEWART RC, 1985, J BIOL CHEM, V260, P3639; STOTT K, 1993, J BIOL CHEM, V268, P6097; VAZ ADN, 1995, BIOCHEMISTRY-US, V34, P4246, DOI 10.1021/bi00013a014; Warburg O, 1933, BIOCHEM Z, V266, P377; WARBURG O, 1932, NATURWISSENSCHAFTEN, V20, P688; Weiler E.W., 1998, PHYTOCHEMICAL SIGNAL	33	83	102	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 3	1999	274	49					35067	35073		10.1074/jbc.274.49.35067	http://dx.doi.org/10.1074/jbc.274.49.35067			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	260XW	10574986	hybrid			2022-12-25	WOS:000083979600080
J	Frey, BM; Reber, BFX; Vishwanath, BS; Escher, G; Frey, FJ				Frey, BM; Reber, BFX; Vishwanath, BS; Escher, G; Frey, FJ			Annexin I modulates cell functions by controlling intracellular calcium release	FASEB JOURNAL			English	Article						phospholipase A; phospholipase C; E-cadherin; tumor; MCF-7; Ca2+; homeostasis	FOCAL ADHESION KINASE; BREAST-CANCER CELLS; E-CADHERIN FUNCTION; LIPOCORTIN-I; 11-BETA-HYDROXYSTEROID DEHYDROGENASE; U937 CELLS; PERITONEAL LEUKOCYTES; GROWTH FACTOR; PROTEIN; EXPRESSION	Annexin I is an intracellular protein in search of a function. Ex vivo it has calcium- and phospholipid-binding properties. To evaluate its role in vivo, MCF-7 cells were stably transfected with annexin I in sense or antisense orientations, In cells overexpressing annexin I, calcium release was abrogated on stimulation of purinergic or bradykinin receptors, whereas non-transfected cells or cells with down-regulated annexin I released calcium within seconds. Basal calcium and calcium stores were not affected, The impaired calcium release was paralleled by a down-regulation of the activities of phospholipase C, group II phospholipase A2, and E-cadherin with altered adhesion and enhanced tumor growth on soft agar, Significantly smaller tumors, with the histologically most differentiated cells, were observed in nude mice inoculated with cells transfected with the antisense rather than with the sense plasmid, These observations indicate that annexin I modulates cell functions by controlling intracellular calcium release.	Univ Bern, Div Nephrol & Hypertens, CH-3010 Bern, Switzerland; Univ Bern, Inst Pharmacol, CH-3010 Bern, Switzerland	University of Bern; University of Bern	Frey, BM (corresponding author), Inselspital Bern, Div Nephrol & Hypertens, CH-3010 Bern, Switzerland.	brigitte.frey@dkf2.unibe.ch		Escher, Genevieve/0000-0002-5125-2262				AGHIB DF, 1995, EXP CELL RES, V218, P359, DOI 10.1006/excr.1995.1167; ALBISTON AL, 1994, MOL CELL ENDOCRINOL, V105, pR11, DOI 10.1016/0303-7207(94)90176-7; BAZZI MD, 1993, CELL SIGNAL, V5, P357, DOI 10.1016/0898-6568(93)90075-W; BERRIDGE MJ, 1987, ANNU REV BIOCHEM, V56, P159, DOI 10.1146/annurev.bi.56.070187.001111; BERRIDGE MJ, 1982, BIOCHEM J, V206, P587, DOI 10.1042/bj2060587; BEZPROZVANNY I, 1991, NATURE, V351, P751, DOI 10.1038/351751a0; BIENKOWSKI MJ, 1989, J BIOL CHEM, V264, P6536; BLOBE GC, 1993, J BIOL CHEM, V268, P658; BRACKE ME, 1994, CANCER RES, V54, P4607; Brindle NPJ, 1996, BIOCHEM J, V318, P753, DOI 10.1042/bj3180753; BRONNEGARD M, 1988, MOL ENDOCRINOL, V2, P732, DOI 10.1210/mend-2-8-732; Brownawell AM, 1996, BIOCHEMISTRY-US, V35, P6839, DOI 10.1021/bi952585t; Buckingham JC, 1997, MOL MED TODAY, V3, P296, DOI 10.1016/S1357-4310(97)88908-3; Buckland AG, 1998, BIOCHEM J, V329, P369; BURGOYNE RD, 1988, NATURE, V331, P20, DOI 10.1038/331020a0; Cary LA, 1996, J CELL SCI, V109, P1787; Charlier C, 1996, EUR J PHARMACOL, V317, P413, DOI 10.1016/S0014-2999(96)00816-3; Chen HY, 1997, J CELL SCI, V110, P345; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COLL JL, 1995, P NATL ACAD SCI USA, V92, P9161, DOI 10.1073/pnas.92.20.9161; COMERA C, 1995, BRIT J PHARMACOL, V115, P1043, DOI 10.1111/j.1476-5381.1995.tb15916.x; CROXTALL JD, 1995, BIOCHEM PHARMACOL, V50, P465, DOI 10.1016/0006-2952(95)00156-T; Donnelly SR, 1998, BIOCHEM J, V332, P681, DOI 10.1042/bj3320681; Dubois T, 1996, BBA-MOL CELL RES, V1313, P290, DOI 10.1016/0167-4889(96)00102-4; Escher G, 1997, J EXP MED, V186, P189, DOI 10.1084/jem.186.2.189; FAIRCHILD CR, 1990, MOL PHARMACOL, V37, P801; FERNANDEZ JLR, 1992, J CELL BIOL, V119, P427, DOI 10.1083/jcb.119.2.427; FLOWER RJ, 1988, BRIT J PHARMACOL, V94, P987, DOI 10.1111/j.1476-5381.1988.tb11614.x; FREY BM, 1991, BIOCHEM J, V275, P219, DOI 10.1042/bj2750219; GEISOW MJ, 1986, NATURE, V320, P636, DOI 10.1038/320636a0; Gilmore AP, 1996, MOL BIOL CELL, V7, P1209, DOI 10.1091/mbc.7.8.1209; Graham ME, 1997, MOL BIOL CELL, V8, P431, DOI 10.1091/mbc.8.3.431; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; GUILLON G, 1989, CELL SIGNAL, V1, P541, DOI 10.1016/0898-6568(89)90062-4; GunteskiHamblin AM, 1996, AM J PHYSIOL-HEART C, V270, pH1091, DOI 10.1152/ajpheart.1996.270.3.H1091; HAYASHI J, 1993, BIOCHEM MOL BIOL INT, V31, P143; HOFFMAN R, 1979, Journal of the Biological Photographic Association, V47, P111; Hunt NCA, 1997, VIRCHOWS ARCH, V430, P285, DOI 10.1007/BF01092751; Jiang WG, 1996, BRIT J SURG, V83, P437, DOI 10.1002/bjs.1800830404; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; Krause KH, 1997, CELL, V88, P439, DOI 10.1016/S0092-8674(00)81884-X; LAKSHMI V, 1985, J STEROID BIOCHEM, V22, P331, DOI 10.1016/0022-4731(85)90435-2; MCLEOD JD, 1995, BIOCHEM PHARMACOL, V50, P1103, DOI 10.1016/0006-2952(95)00234-Q; MILLER SA, 1988, NUCLEIC ACIDS RES, V16, P1215, DOI 10.1093/nar/16.3.1215; MITCHELL RH, 1975, BIOCHIM BIOPHYS ACTA, V415, P81; MOSS SE, 1992, RES MONOGRAPH; MOSS SE, 1992, ANNEXINS RES MONOGRA; MOUILLAC B, 1989, BIOCHEM BIOPH RES CO, V159, P953, DOI 10.1016/0006-291X(89)92201-8; Nagar B, 1996, NATURE, V380, P360, DOI 10.1038/380360a0; OWENS LV, 1995, CANCER RES, V55, P2752; PARENTE L, 1992, Pharmacological Research, V26, P44, DOI 10.1016/1043-6618(92)90591-X; PEERS SH, 1993, BRIT J PHARMACOL, V108, P66, DOI 10.1111/j.1476-5381.1993.tb13441.x; PEPINSKY RB, 1986, NATURE, V321, P81, DOI 10.1038/321081a0; PERRETTI M, 1993, J IMMUNOL, V150, P992; PILTCH A, 1989, BIOCHEM J, V261, P395, DOI 10.1042/bj2610395; POKUTTA S, 1994, EUR J BIOCHEM, V223, P1019, DOI 10.1111/j.1432-1033.1994.tb19080.x; RAYNAL P, 1994, BBA-REV BIOMEMBRANES, V1197, P63, DOI 10.1016/0304-4157(94)90019-1; REBER BFX, 1991, J PHYSIOL-LONDON, V435, P145, DOI 10.1113/jphysiol.1991.sp018502; REINHARD M, 1992, EMBO J, V11, P2063, DOI 10.1002/j.1460-2075.1992.tb05264.x; ROYCHOUDHURY S, 1988, P NATL ACAD SCI USA, V85, P2014, DOI 10.1073/pnas.85.6.2014; SCHLAEPFER DD, 1987, J BIOL CHEM, V262, P6931; SCHLAEPFER DD, 1990, J CELL BIOL, V111, P229, DOI 10.1083/jcb.111.1.229; Solito E, 1998, BRIT J PHARMACOL, V124, P1675, DOI 10.1038/sj.bjp.0701991; TAIT JF, 1988, BIOCHEMISTRY-US, V27, P6268, DOI 10.1021/bi00417a011; Tharin S, 1996, J CELL PHYSIOL, V166, P547, DOI 10.1002/(SICI)1097-4652(199603)166:3<547::AID-JCP9>3.0.CO;2-P; VERMEULEN SJ, 1995, BRIT J CANCER, V72, P1447, DOI 10.1038/bjc.1995.528; VIOLETTE SM, 1990, J CELL PHYSIOL, V142, P70, DOI 10.1002/jcp.1041420110; VISHWANATH BS, 1992, ENDOCRINOLOGY, V130, P585, DOI 10.1210/en.130.2.585; VISHWANATH BS, 1993, J CLIN INVEST, V92, P1974, DOI 10.1172/JCI116791; WAYS DK, 1995, J CLIN INVEST, V95, P1906, DOI 10.1172/JCI117872; WEINER TM, 1993, LANCET, V342, P1024, DOI 10.1016/0140-6736(93)92881-S; White PC, 1997, ENDOCR REV, V18, P135, DOI 10.1210/er.18.1.135; Willmott NJ, 1997, BRIT J PHARMACOL, V122, P1055, DOI 10.1038/sj.bjp.0701490; WU CC, 1995, P NATL ACAD SCI USA, V92, P3473, DOI 10.1073/pnas.92.8.3473; Zschiesche W, 1997, ANTICANCER RES, V17, P561	75	35	36	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	1999	13	15					2235	2245		10.1096/fasebj.13.15.2235	http://dx.doi.org/10.1096/fasebj.13.15.2235			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	266QN	10593871				2022-12-25	WOS:000084310800015
J	Bruzzoni-Giovanelli, H; Faille, A; Linares-Cruz, G; Nemani, M; Le Deist, F; Germani, A; Chassoux, D; Millot, G; Roperch, JP; Amson, R; Telerman, A; Calvo, F				Bruzzoni-Giovanelli, H; Faille, A; Linares-Cruz, G; Nemani, M; Le Deist, F; Germani, A; Chassoux, D; Millot, G; Roperch, JP; Amson, R; Telerman, A; Calvo, F			SIAH-1 inhibits cell growth by altering the mitotic process	ONCOGENE			English	Article						SIAH-1; mitosis; multinucleated cell; cytokinesis; apoptosis; p21	DROSOPHILA EYE DEVELOPMENT; TUMOR SUPPRESSION; DNA-REPLICATION; HUMAN HOMOLOG; SINA GENE; APOPTOSIS; ABSENTIA; P21(WAF1/CIP1); CYTOKINESIS; ACTIVATION	SIAH-1, the human homologue of the drosophila seven in absentia gene, is a p53-p21(Waf-1) inducible gene. We report that stable transfection with SIAH-1 of the epithelial breast cancer cell line MCF-7 blocks its growth process. The transfectants show a redistribution of SIAH-1 protein within the nucleus, more specifically to the nuclear matrix, associated to dramatic changes in cell morphology and defective mitosis. Multinucleated giant cells (2-12 nuclei in more than 50% cells) were a most striking observation associated with tubulin spindle disorganization and defective cytokinesis, There were also present at high frequency abortive mitotic figures, DNA bridges and persistance of intercellular bridges and midbodies, along with an increased expression of p21(Waf-1) These results indicate that the mechanism of growth arrest induced by SIAH-1 in MCF-7 cells involves disorganization of the mitotic program, mainly during nuclei separation and cytokinesis.	Hop St Louis, Inst Genet Mol, Lab Pharmacol Expt, F-75010 Paris, France; Hop St Louis, Inst Genet Mol, Clin INSERM EP 9932, F-75010 Paris, France; CEPH, Fdn Jean Dausset, Paris, France; Hop Necker Enfants Malad, INSERM Unite 429, Paris, France; Hop Cochin, INSERM Unite 363, F-75674 Paris, France; Inst Curie, INRA, Unite 806, Paris, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Foundation Jean Dausset-CEPH; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; INRAE; UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie	Calvo, F (corresponding author), Hop St Louis, Inst Genet Mol, Lab Pharmacol Expt, 27 Rue Juliette Dodu, F-75010 Paris, France.			calvo, fabien/0000-0002-0298-7633; VARIN-BLANK, Nadine/0000-0003-2769-018X				Amson RB, 1996, P NATL ACAD SCI USA, V93, P3953, DOI 10.1073/pnas.93.9.3953; Bates S, 1998, ONCOGENE, V17, P1691, DOI 10.1038/sj.onc.1202104; Berezney R, 1996, J CELL BIOCHEM, V62, P223, DOI 10.1002/(SICI)1097-4644(199608)62:2<223::AID-JCB10>3.3.CO;2-M; BRUZZONIGIOVANE.H, 1998, ADV MOL TOXICOLOGY, P25; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; Carmena M, 1998, J CELL BIOL, V143, P659, DOI 10.1083/jcb.143.3.659; CARTHEW RW, 1990, CELL, V63, P561, DOI 10.1016/0092-8674(90)90452-K; CARTHEW RW, 1994, P NATL ACAD SCI USA, V91, P11689, DOI 10.1073/pnas.91.24.11689; DELLA NG, 1993, DEVELOPMENT, V117, P1333; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; Glover DM, 1996, J CELL BIOL, V135, P1681, DOI 10.1083/jcb.135.6.1681; Goodson HV, 1997, CURR OPIN CELL BIOL, V9, P18, DOI 10.1016/S0955-0674(97)80147-0; Hinchcliffe EH, 1999, SCIENCE, V283, P851, DOI 10.1126/science.283.5403.851; Hu G, 1997, GENE DEV, V11, P2701, DOI 10.1101/gad.11.20.2701; KOKEN MHM, 1994, EMBO J, V13, P1073, DOI 10.1002/j.1460-2075.1994.tb06356.x; Lacey KR, 1999, P NATL ACAD SCI USA, V96, P2817, DOI 10.1073/pnas.96.6.2817; Lai ZC, 1996, P NATL ACAD SCI USA, V93, P5025, DOI 10.1073/pnas.93.10.5025; LANDEGREN U, 1984, J IMMUNOL METHODS, V67, P379, DOI 10.1016/0022-1759(84)90477-0; Li SH, 1997, CELL, V90, P469, DOI 10.1016/S0092-8674(00)80507-3; Linares-Cruz G, 1998, P NATL ACAD SCI USA, V95, P1131, DOI 10.1073/pnas.95.3.1131; Lingle WL, 1998, P NATL ACAD SCI USA, V95, P2950, DOI 10.1073/pnas.95.6.2950; Madaule P, 1998, NATURE, V394, P491, DOI 10.1038/28873; Mandelkow E, 1999, CURR OPIN CELL BIOL, V11, P34, DOI 10.1016/S0955-0674(99)80005-2; Mantel C, 1999, BLOOD, V93, P1390, DOI 10.1182/blood.V93.4.1390.404k25_1390_1398; Matsumoto Y, 1999, CURR BIOL, V9, P429, DOI 10.1016/S0960-9822(99)80191-2; Matsumura I, 1997, MOL CELL BIOL, V17, P2933, DOI 10.1128/MCB.17.5.2933; Matsuzawa S, 1998, EMBO J, V17, P2736, DOI 10.1093/emboj/17.10.2736; Medema RH, 1998, ONCOGENE, V16, P431, DOI 10.1038/sj.onc.1201558; Nagata Y, 1997, J CELL BIOL, V139, P449, DOI 10.1083/jcb.139.2.449; Nemani M, 1996, P NATL ACAD SCI USA, V93, P9039, DOI 10.1073/pnas.93.17.9039; Neufeld TP, 1998, GENETICS, V148, P277; NEUFELD TP, 1994, CELL, V77, P371, DOI 10.1016/0092-8674(94)90152-X; NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O; Niculescu AB, 1998, MOL CELL BIOL, V18, P629, DOI 10.1128/MCB.18.1.629; SHEIKH MS, 1995, ONCOGENE, V11, P1899; Takayama S, 1997, EMBO J, V16, P4887, DOI 10.1093/emboj/16.16.4887; Tang AH, 1997, CELL, V90, P459, DOI 10.1016/S0092-8674(00)80506-1; Vitrat N, 1998, BLOOD, V91, P3711	38	41	42	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 25	1999	18	50					7101	7109		10.1038/sj.onc.1203187	http://dx.doi.org/10.1038/sj.onc.1203187			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	259PH	10597311				2022-12-25	WOS:000083901900017
J	Yamaguchi, M; Hirose, F; Inoue, YH; Shiraki, M; Hayashi, Y; Nishi, Y; Matsukage, A				Yamaguchi, M; Hirose, F; Inoue, YH; Shiraki, M; Hayashi, Y; Nishi, Y; Matsukage, A			Ectopic expression of human p53 inhibits entry into S phase and induces apoptosis in the Drosophila eye imaginal disc	ONCOGENE			English	Article						p53; Drosophila; cell cycle; apoptosis; P35	PROGRAMMED CELL-DEATH; WILD-TYPE P53; BACULOVIRUS P35; DNA-DAMAGE; CAENORHABDITIS-ELEGANS; PROTEIN P35; LUNG-CANCER; GENE; CYCLE; GROWTH	Transgenic flies in which ectopic expression of human p53 was targeted to the Drosophila eye imaginal disc were established. On sectioning of adult fly eyes which displayed a severe rough eye phenotype, most ommatidia were found to be fused and irregular shapes of rabdomeres were observed. In addition, many pigment cells were lost. In the developing eye imaginal disc, photoreceptor cell differentiation was initiated normally despite the ectopic expression of p53, However, expression of p53 inhibited cell cycle progression in eye imaginal disc cells and the S phase zone (the second mitotic wave) behind the morphogenetic furrow was almost completely abolished. Furthermore, expression of p53 induced extensive apoptosis of eye imaginal disc cells, and co-expression of baculovirus P35 in the eye imaginal disc suppressed the p53-induced rough eye phenotype, These results are consistent,vith the known functions of human p53 and indicate the existence of signaling systems with elements corresponding to human p53 in Drosophila eye imaginal disc cells. Genetic crosses of transgenic flies expressing p53 to a collection of Drosophila deficiency stocks allowed us to identify several genomic regions, deletions of which caused enhancement or suppression of the p53-induced rough eye phenotype, The transgenic flies established in this study should be useful to identify novel targets of p53 and its positive or negative regulators in Drosophila.	Aichi Canc Ctr, Res Inst, Cell Biol Lab, Chikusa Ku, Nagoya, Aichi 4648681, Japan; Aichi Canc Ctr, Res Inst, Biophys Unit, Chikusa Ku, Nagoya, Aichi 4648681, Japan	Aichi Cancer Center; Aichi Cancer Center	Yamaguchi, M (corresponding author), Aichi Canc Ctr, Res Inst, Cell Biol Lab, Chikusa Ku, Nagoya, Aichi 4648681, Japan.			Yamaguchi, Masamitsu/0000-0002-6321-9750; Hirose, Fumiko/0000-0003-4586-4892				Almog N, 1997, BBA-REV CANCER, V1333, pF1, DOI 10.1016/S0304-419X(97)00012-7; Bertin J, 1996, J VIROL, V70, P6251, DOI 10.1128/JVI.70.9.6251-6259.1996; BRAND AH, 1993, DEVELOPMENT, V118, P401; BUMP NJ, 1995, SCIENCE, V269, P1885, DOI 10.1126/science.7569933; Butler SJ, 1997, DEVELOPMENT, V124, P781; Chen P, 1996, GENE DEV, V10, P1773, DOI 10.1101/gad.10.14.1773; Chen XB, 1996, GENE DEV, V10, P2438, DOI 10.1101/gad.10.19.2438; CROOK NE, 1993, J VIROL, V67, P2168, DOI 10.1128/JVI.67.4.2168-2174.1993; deNooij JC, 1996, CELL, V87, P1237, DOI 10.1016/S0092-8674(00)81819-X; Du W, 1996, GENE DEV, V10, P1206, DOI 10.1101/gad.10.10.1206; Foley K, 1998, DEVELOPMENT, V125, P1075; Gallant P, 1996, SCIENCE, V274, P1523, DOI 10.1126/science.274.5292.1523; GRETHER ME, 1995, GENE DEV, V9, P1694, DOI 10.1101/gad.9.14.1694; HAY BA, 1994, DEVELOPMENT, V120, P2121; HENGARTNER MO, 1995, SCIENCE, V270, P931, DOI 10.1126/science.270.5238.931; Kaghad M, 1997, CELL, V90, P809, DOI 10.1016/S0092-8674(00)80540-1; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KASTAN MB, 1991, CANCER RES, V51, P6304; KIYONO T, 1994, J VIROL, V68, P4656, DOI 10.1128/JVI.68.7.4656-4661.1994; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LEE S, 1995, CELL, V81, P1013, DOI 10.1016/S0092-8674(05)80006-6; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; MALTZMAN W, 1984, MOL CELL BIOL, V4, P1689, DOI 10.1128/MCB.4.9.1689; McCall K, 1997, TRENDS GENET, V13, P222, DOI 10.1016/S0168-9525(97)01126-8; MOSES K, 1991, GENE DEV, V5, P583, DOI 10.1101/gad.5.4.583; Norimura T, 1996, NAT MED, V2, P577, DOI 10.1038/nm0596-577; ROBERTSON HM, 1988, GENETICS, V118, P461; Sakamuro D, 1997, ONCOGENE, V15, P887, DOI 10.1038/sj.onc.1201263; SANCHEZ Y, 1995, BIOESSAYS, V17, P545, DOI 10.1002/bies.950170611; SOUSSI T, 1990, ONCOGENE, V5, P945; Spradling AC, 1986, DROSOPHILA PRACTICAL, P175; TAKAHASHI T, 1992, CANCER RES, V52, P2340; TAKAHASHI T, 1990, J CLIN INVEST, V86, P363, DOI 10.1172/JCI114710; Wang XW, 1996, GENE DEV, V10, P1219, DOI 10.1101/gad.10.10.1219; WHITE K, 1994, SCIENCE, V264, P677, DOI 10.1126/science.8171319; WILDER EL, 1995, DEVELOPMENT, V121, P477; WOLFF T, 1991, DEVELOPMENT, V113, P825; Wolff Tanya, 1993, P1277; XUE D, 1995, NATURE, V377, P248, DOI 10.1038/377248a0; YAMAGUCHI M, 1994, EUR J BIOCHEM, V221, P227, DOI 10.1111/j.1432-1033.1994.tb18733.x; Zhou Q, 1998, BIOCHEMISTRY-US, V37, P10757, DOI 10.1021/bi980893w; Zhou XL, 1999, CANCER RES, V59, P843; Zhu JH, 1999, ONCOGENE, V18, P2149, DOI 10.1038/sj.onc.1202533	46	46	49	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 18	1999	18	48					6767	6775		10.1038/sj.onc.1203113	http://dx.doi.org/10.1038/sj.onc.1203113			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	257QA	10597285				2022-12-25	WOS:000083792000019
J	Baldassarre, G; Barone, MV; Belletti, B; Sandomenico, C; Bruni, P; Spiezia, S; Boccia, A; Vento, MT; Romano, A; Pepe, S; Fusco, A; Viglietto, G				Baldassarre, G; Barone, MV; Belletti, B; Sandomenico, C; Bruni, P; Spiezia, S; Boccia, A; Vento, MT; Romano, A; Pepe, S; Fusco, A; Viglietto, G			Key role of the cyclin-dependent kinase inhibitor p27(kip1) for embryonal carcinoma cell survival and differentiation	ONCOGENE			English	Article						embryonal carcinoma; p27; HMBA; differentiation; apoptosis	HEXAMETHYLENE BISACETAMIDE; NEURONAL DIFFERENTIATION; TERMINAL DIFFERENTIATION; POTENTIAL MEDIATOR; GENE-EXPRESSION; CDK INHIBITORS; RETINOIC ACID; G1 PHASE; APOPTOSIS; P21(CIP1/WAF1)	Hexamethylen-bisacetamide (HMBA) represents the prototype of a group of hybrid polar compounds, which induce differentiation in a variety of transformed cells including human embryonal carcinoma cells, Therefore, HMBA has been used in the differentiation therapy of cancer for patients with both hematological and solid malignancies. Upon HMBA treatment, the embryonal carcinoma cell line NTERA-2 clone D1 (NT2/D1) accumulates in G1 and undergoes terminal differentiation. Here we demonstrate that growth arrest and differentiation of NT2/D1 cells induced by HMBA involve increased expression of the cyclin-dependent kinase inhibitor p27, enhanced association of p27 with cyclin E/CDK2 complexes and suppression of kinase activity associated to cyclin E/CDK2 (but not to cyclin D3/CDK4), When HMBA differentiation was induced in the presence of p27 antisense oligonucleotides, NT2/D1 cells failed to arrest growth properly and, in parallel with the reduction of the anti-apoptotic Bcl-2 gene expression, cells underwent massive programmed cell death. Conversely, constitutive expression of p27 into NT2/D1 cells induced a marked reduction in the growth potential of these cells and partially reproduced HMBA-induced modification of surface antigen expression (down-regulation of SSEA-3 expression and up-regulation of VINIS-3 expression). Expression of p21 induced growth arrest but not differentiation. Likewise, inhibition of CDK2 by transfection of a dominant negative CDK2 in NT2/D1 cells or treatment with the kinase inhibitor olomucine induced growth arrest but not differentiation, Therefore, we propose that p27 represents a crucial molecule in HMBA signaling that cannot be replaced by p21, Furthermore, the results obtained with CDK2 inhibitors demonstrate that the block of CDK2; activity is sufficient for growth arrest but not for cell differentiation and suggest that, at least in these cells, growth arrest and differentiation are regulated by two overlapping but different pathways.	Ist Nazl Tumori, Serv Oncol Sperimentale E, I-80131 Naples, Italy; Univ Naples Federico II, Fac Med & Chirurg, Dipartimento Oncol & Endocrinol Mol & Clin, Cattedra Oncol Med, I-80131 Naples, Italy; Univ Reggio Calabria, Fac Med & Chirurg Catanzaro, Dipartimento Med Sperimentale & Clin, I-88100 Catanzaro, Italy	University of Naples Federico II; Magna Graecia University of Catanzaro; Universita Mediterranea di Reggio Calabria	Viglietto, G (corresponding author), Ist Nazl Tumori, Serv Oncol Sperimentale E, Via M Semmola, I-80131 Naples, Italy.		Belletti, Barbara/J-2028-2018; Baldassarre, Gustavo/K-1350-2016; Viglietto, Giuseppe/AAC-2852-2019	Belletti, Barbara/0000-0003-2249-0285; Baldassarre, Gustavo/0000-0002-9750-8825; Viglietto, Giuseppe/0000-0003-2327-7515; Fusco, Alfredo/0000-0003-3332-5197; Sandomenico, Claudia/0000-0003-3709-0807; BARONE, Maria Vittoria/0000-0001-6190-4917				Alessi F, 1998, EXP CELL RES, V245, P8, DOI 10.1006/excr.1998.4216; ANDREEFF M, 1992, BLOOD, V80, P2604; ANDREWS PW, 1984, DEV BIOL, V103, P285, DOI 10.1016/0012-1606(84)90316-6; ANDREWS PW, 1990, DIFFERENTIATION, V43, P131, DOI 10.1111/j.1432-0436.1990.tb00439.x; Baldassarre G, 1997, ONCOGENE, V15, P927, DOI 10.1038/sj.onc.1201260; CasacciaBonnefil P, 1997, GENE DEV, V11, P2335, DOI 10.1101/gad.11.18.2335; CHALFIE M, 1994, SCIENCE, V263, P802, DOI 10.1126/science.8303295; Coats S, 1996, SCIENCE, V272, P877, DOI 10.1126/science.272.5263.877; CONLEY BA, 1992, CANCER CHEMOTH PHARM, V31, P37, DOI 10.1007/BF00695992; Craig C, 1997, ONCOGENE, V14, P2283, DOI 10.1038/sj.onc.1201064; Di Cunto F, 1998, SCIENCE, V280, P1069, DOI 10.1126/science.280.5366.1069; DOBASHI Y, 1995, J BIOL CHEM, V270, P23031, DOI 10.1074/jbc.270.39.23031; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FIRPO EJ, 1994, MOL CELL BIOL, V14, P4889, DOI 10.1128/MCB.14.7.4889; Gil-Gomez G, 1998, EMBO J, V17, P7209, DOI 10.1093/emboj/17.24.7209; GUO K, 1995, MOL CELL BIOL, V15, P3823; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; KIYOKAWA H, 1994, MOL CELL BIOL, V14, P7195, DOI 10.1128/MCB.14.11.7195; Kiyokawa H, 1996, CELL, V85, P721, DOI 10.1016/S0092-8674(00)81238-6; KRANENBURG O, 1995, FEBS LETT, V367, P103, DOI 10.1016/0014-5793(95)00587-Y; Levkau B, 1998, MOL CELL, V1, P553, DOI 10.1016/S1097-2765(00)80055-6; Liu JB, 1997, J IMMUNOL, V159, P812; Liu M, 1996, GENE DEV, V10, P142, DOI 10.1101/gad.10.2.142; MARKS PA, 1987, CANCER RES, V47, P659; MIEKRANTZ W, 1995, J CELL BIOCHEM, V58, P160; Missero C, 1996, GENE DEV, V10, P3065, DOI 10.1101/gad.10.23.3065; OReilly LA, 1996, EMBO J, V15, P6979, DOI 10.1002/j.1460-2075.1996.tb01090.x; PAGANO M, 1995, SCIENCE, V269, P682, DOI 10.1126/science.7624798; Poluha W, 1996, MOL CELL BIOL, V16, P1335; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; Richon VM, 1996, P NATL ACAD SCI USA, V93, P5705, DOI 10.1073/pnas.93.12.5705; SAMBROOK J, 1992, MOL CLONING LAB MANU; Schutte B, 1997, EXP CELL RES, V236, P4, DOI 10.1006/excr.1997.3700; SENTMAN CL, 1991, CELL, V67, P879, DOI 10.1016/0092-8674(91)90361-2; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; SHEVINSKY LH, 1982, CELL, V30, P697, DOI 10.1016/0092-8674(82)90274-4; VANDENHEUVEL S, 1993, SCIENCE, V262, P2050, DOI 10.1126/science.8266103; Wang J, 1996, SCIENCE, V273, P359, DOI 10.1126/science.273.5273.359; Wang XT, 1997, ONCOGENE, V15, P2991, DOI 10.1038/sj.onc.1201450; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; White E, 1996, GENE DEV, V10, P1, DOI 10.1101/gad.10.1.1; YOUNG CW, 1988, CANCER RES, V48, P7304	43	45	45	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 4	1999	18	46					6241	6251		10.1038/sj.onc.1203031	http://dx.doi.org/10.1038/sj.onc.1203031			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	260DK	10597222				2022-12-25	WOS:000083934100007
J	Kim, YO; Koh, HJ; Kim, SH; Jo, SH; Huh, JW; Jeong, KS; Lee, IJ; Song, BJ; Huh, TL				Kim, YO; Koh, HJ; Kim, SH; Jo, SH; Huh, JW; Jeong, KS; Lee, IJ; Song, BJ; Huh, TL			Identification and functional characterization of a novel, tissue-specific NAD(+)-dependent isocitrate dehydrogenase beta subunit isoform	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRE-MESSENGER-RNA; SACCHAROMYCES-CEREVISIAE; OLIGONUCLEOTIDE PROBES; BINDING-SITES; BOVINE HEART; FATTY-ACIDS; PIG; PROTEIN; CLONING; PURIFICATION	To understand the interactions and functional role of each of the three mitochondrial NAD(+)-dependent isocitrate dehydrogenase (IDH) subunits (alpha, beta, and gamma), we have characterized human cDNAs encoding two beta isoforms (beta(1) and beta(2)) and the gamma subunit. Analysis of deduced amino acid sequences revealed that beta(1) and beta(2) encode 349 and 354 amino acids, respectively, and the two isoforms only differ in the most carboxyl 28 amino acids. The gamma cDNA encodes 354 amino acids and is almost identical to monkey IDH gamma. Northern analyses revealed that the smaller beta(2) transcript (1.3 kilobases) is primarily expressed in heart and skeletal muscle, whereas the larger beta(1) mRNA (1.6 kilobases) is prevalent in nonmuscle tissues. Sequence analysis of the IDH beta gene indicates that the difference in the C-terminal 28 amino acids between beta(1) and beta(2) proteins results from alternative splicing of a single transcript. Among the various combinations of human IDH subunits co-expressed in bacteria, alpha beta gamma, alpha beta, and alpha gamma combinations exhibited significant amounts of IDH activity, whereas subunits produced alone and beta gamma showed no detectable activity. These data suggest that the alpha is the catalytic subunit and that at least one of the other two subunits plays an essential supporting role for activity. Substitution of beta(1) with beta(2) in the co-expression system lowered the pH optimum for IDH activity from 8.0 to 7.6. This difference in optimal pH was analogous to what was observed in mouse kidney and brain (beta(1) prevalent; optimal pH 8.0) versus heart (beta(2) prevalent; pH 7.6) mitochondria, Experiments with a specially designed splicing reporter constrdct stably transfected into HT1080 cells indicate that acidic conditions favor a splicing pattern responsible for the muscle- and heart-specific beta(2) isoform. Taken together, these data indicate a regulatory role of IDH beta isoforms in determining the pH optimum for IDH activity through the tissue-specific alternative splicing.	Kyungpook Natl Univ, Coll Nat Sci, Dept Genet Engn, Taegu 702701, South Korea; Korea Green Cross Corp, Cent Res Inst, Yongin, South Korea; NIAAA, Lab Membrane Biochem & Biophys, Rockville, MD 20852 USA	Kyungpook National University; Green Cross Corporation; National Institutes of Health (NIH) - USA; NIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)	Huh, TL (corresponding author), Kyungpook Natl Univ, Coll Nat Sci, Dept Genet Engn, Taegu 702701, South Korea.			Kim, Yong-Ou/0000-0002-2040-2002				ANDREADIS A, 1987, ANNU REV CELL BIOL, V3, P207, DOI 10.1146/annurev.cellbio.3.1.207; AOGAICHI T, 1980, ARCH BIOCHEM BIOPHYS, V204, P350, DOI 10.1016/0003-9861(80)90043-0; APOSTOLAKOS D, 1982, CURR MICROBIOL, V7, P45, DOI 10.1007/BF01570979; BARNES LD, 1971, BIOCHEMISTRY-US, V10, P3939, DOI 10.1021/bi00797a022; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BREITBART RE, 1987, ANNU REV BIOCHEM, V56, P467, DOI 10.1146/annurev.bi.56.070187.002343; BREITBART RE, 1993, DEVELOPMENT, V118, P1095; COHEN PF, 1971, BIOCHIM BIOPHYS ACTA, V242, P325, DOI 10.1016/0005-2744(71)90224-5; CUPP JR, 1992, J BIOL CHEM, V267, P16417; CUPP JR, 1993, BIOCHEMISTRY-US, V32, P9323, DOI 10.1021/bi00087a010; CUPP JR, 1991, J BIOL CHEM, V266, P22199; DICKSON G, 1987, CELL, V50, P1119, DOI 10.1016/0092-8674(87)90178-4; EHRLICH RS, 1982, J BIOL CHEM, V257, P4769; EHRLICH RS, 1981, J BIOL CHEM, V256, P560; ELZINGA SDJ, 1993, NUCLEIC ACIDS RES, V21, P5328, DOI 10.1093/nar/21.23.5328; ENDO H, 1994, J BIOL CHEM, V269, P12488; GARNIER J, 1978, J MOL BIOL, V120, P97, DOI 10.1016/0022-2836(78)90297-8; GIORGIO NA, 1970, J BIOL CHEM, V245, P5469; Henke B, 1998, J BIOL CHEM, V273, P3702, DOI 10.1074/jbc.273.6.3702; HUANG YC, 1990, BIOCHEMISTRY-US, V29, P8266, DOI 10.1021/bi00488a010; HUH TL, 1993, BIOCHEM J, V292, P705, DOI 10.1042/bj2920705; Ichida M, 1998, J BIOL CHEM, V273, P8492, DOI 10.1074/jbc.273.14.8492; ILLINGWORTH JA, 1970, BIOCHEM J, V118, P253, DOI 10.1042/bj1180253; KIM YO, 1995, BIOCHEM J, V308, P63, DOI 10.1042/bj3080063; LAPORTE DC, 1985, J BIOL CHEM, V260, P563; LATHE R, 1985, J MOL BIOL, V183, P1, DOI 10.1016/0022-2836(85)90276-1; LOVERDE AW, 1973, J NEUROCHEM, V20, P441, DOI 10.1111/j.1471-4159.1973.tb12143.x; MATSUDA C, 1994, BIOCHEM BIOPH RES CO, V200, P671, DOI 10.1006/bbrc.1994.1503; NICHOLS BJ, 1995, BIOCHEM J, V310, P917, DOI 10.1042/bj3100917; PLAUT GWE, 1983, BIOCHIM BIOPHYS ACTA, V760, P300, DOI 10.1016/0304-4165(83)90177-0; PLAUT GWE, 1983, BIOCH METABOLIC PROC, P285; PLAUT GWE, 1970, CURR TOP CELL REGUL, V2, P1; RAMACHANDRAN N, 1980, J BIOL CHEM, V255, P8859; ROSENBERG HF, 1990, BIOTECHNIQUES, V8, P384; RUTTER GA, 1989, BIOCHEM J, V263, P445, DOI 10.1042/bj2630445; Sambrook J., 1989, MOL CLONING, pA1; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHARP PA, 1994, CELL, V77, P805, DOI 10.1016/0092-8674(94)90130-9; van Roermund CWT, 1998, EMBO J, V17, P677, DOI 10.1093/emboj/17.3.677; WANG YC, 1992, J BIOL CHEM, V267, P12004; YU YT, 1992, GENE DEV, V6, P1783, DOI 10.1101/gad.6.9.1783	41	38	63	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 24	1999	274	52					36866	36875		10.1074/jbc.274.52.36866	http://dx.doi.org/10.1074/jbc.274.52.36866			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	267WR	10601238	hybrid			2022-12-25	WOS:000084382700009
J	Kominato, Y; Hata, Y; Takizawa, H; Tsuchiya, T; Tsukada, J; Yamamoto, F				Kominato, Y; Hata, Y; Takizawa, H; Tsuchiya, T; Tsukada, J; Yamamoto, F			Expression of human histo-blood group ABO genes is dependent upon DNA methylation of the promoter region	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROUP-A; CARBOHYDRATE ANTIGENS; SUPPRESSOR GENE; BLADDER-TUMORS; CPG ISLAND; INACTIVATION; TRANSCRIPTION; CARCINOMAS; LUNG; DEACETYLASE	We have investigated the regulatory role of DNA methylation in the expression of the human histo-blood group ABO genes. The ABO gene promoter region contains a CpG island whose methylation status correlates well with gene expression in the cell lines tested. The CPG island was found hypomethylated in some cell lines that expressed ABO genes, whereas the other cell lines that did not express ABO genes were hypermethylated. Whereas constitutive transcriptional activity of the ABO gene promoter was demonstrated in both expressor and nonexpressor cell lines by transient transfection of reporter constructs containing the ABO gene promoter sequence, HhaI methylase-catalyzed in vitro methylation of the promoter region prior to DNA transfection suppressed the promoter activity when introduced into the expressor gastric cancer cell line KATOIII cells. On the other hand, in the nonexpressor gastric cancer cell line MKN28 cells, treatment with DNA methyltransferase inhibitor 5-aza-2'-deoxycytidine resulted in demethylation of the ABO:gene promoter and appearance of A-transferase messages, as well as A-antigens synthesized by A-transferase. Taken together, these studies suggest that DNA methylation of the ABO gene promoter may play an important role in the regulation of ABO gene expression.	Toyama Med & Pharmaceut Univ, Fac Med, Dept Legal Med, Toyama 9300194, Japan; Tokyo Med & Dent Univ, Med Res Inst, Tokyo 1130034, Japan; Univ Occupat & Environm Hlth, Sch Med, Kitakyushu, Fukuoka 8070804, Japan; Univ Occupat & Environm Hlth, Sch Hlth Sci, Dept Internal Med 1, Kitakyushu, Fukuoka 8070804, Japan; Burnham Inst, La Jolla, CA 92037 USA	University of Toyama; Tokyo Medical & Dental University (TMDU); University of Occupational & Environmental Health - Japan; University of Occupational & Environmental Health - Japan; Sanford Burnham Prebys Medical Discovery Institute	Kominato, Y (corresponding author), Toyama Med & Pharmaceut Univ, Fac Med, Dept Legal Med, 2630 Sugitani, Toyama 9300194, Japan.		Yamamoto, Fumiichiro/F-1478-2016	Yamamoto, Fumiichiro/0000-0001-9690-7034				ANTEQUERA F, 1993, P NATL ACAD SCI USA, V90, P11995, DOI 10.1073/pnas.90.24.11995; ANTEQUERA F, 1993, DNA METHYLATION MOL, P169; Baylin SB, 1998, ADV CANCER RES, V72, P141; Benvenuto G, 1996, MOL CELL BIOL, V16, P2736; BIRD A, 1992, CELL, V70, P5, DOI 10.1016/0092-8674(92)90526-I; BRANDEIS M, 1994, NATURE, V371, P435, DOI 10.1038/371435a0; Cameron EE, 1999, NAT GENET, V21, P103, DOI 10.1038/5047; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLARK SJ, 1994, NUCLEIC ACIDS RES, V22, P2990, DOI 10.1093/nar/22.15.2990; CORDONCARDO C, 1986, LAB INVEST, V55, P444; DABELSTEEN E, 1982, J INVEST DERMATOL, V79, P3, DOI 10.1111/1523-1747.ep12510411; DAVID L, 1993, CANCER RES, V53, P5494; DUVIC M, 1994, J INVEST DERMATOL, V102, P462, DOI 10.1111/1523-1747.ep12373021; EALSH CP, 1999, GENE DEV, V13, P26; EDLUND T, 1985, SCIENCE, V230, P912, DOI 10.1126/science.3904002; GINSBURG V, 1972, ADV ENZYMOL RAMB, V36, P131; GOZALEZULUETA M, 1995, CANCER RES, V55, P4531; Graff JR, 1997, J BIOL CHEM, V272, P22322, DOI 10.1074/jbc.272.35.22322; HAKOMORI S, 1984, ANNU REV IMMUNOL, V2, P103, DOI 10.1146/annurev.iy.02.040184.000535; Haslam DB, 1996, P NATL ACAD SCI USA, V93, P10697, DOI 10.1073/pnas.93.20.10697; Herman JG, 1996, CANCER RES, V56, P722; HERMAN JG, 1994, P NATL ACAD SCI USA, V91, P9700, DOI 10.1073/pnas.91.21.9700; Herman JG, 1997, CANCER RES, V57, P837; HERMAN JG, 1995, CANCER RES, V55, P4525; Jones PL, 1998, NAT GENET, V19, P187, DOI 10.1038/561; JUHL BR, 1986, CANCER, V57, P1768, DOI 10.1002/1097-0142(19860501)57:9<1768::AID-CNCR2820570910>3.0.CO;2-E; KABAT EA, 1973, CARBOHYDRATES SOLUTI, P334; Kominato Y, 1997, J BIOL CHEM, V272, P25890, DOI 10.1074/jbc.272.41.25890; KOMINATO Y, 1992, EUR J IMMUNOGENET, V19, P1, DOI 10.1111/j.1744-313X.1992.tb00042.x; Landsteiner K., 1900, ZBL BAKT, V27, P357; LEE JS, 1991, NEW ENGL J MED, V324, P1084, DOI 10.1056/NEJM199104183241603; Lu S, 1997, P NATL ACAD SCI USA, V94, P4692, DOI 10.1073/pnas.94.9.4692; MATSUMOTO H, 1993, CANCER-AM CANCER SOC, V72, P75, DOI 10.1002/1097-0142(19930701)72:1<75::AID-CNCR2820720116>3.0.CO;2-Z; MIYAKE M, 1992, NEW ENGL J MED, V327, P14, DOI 10.1056/NEJM199207023270103; MORGAN WTJ, 1969, BRIT MED BULL, V25, P30, DOI 10.1093/oxfordjournals.bmb.a070666; MUMMANENI P, 1995, J BIOL CHEM, V270, P788, DOI 10.1074/jbc.270.2.788; Nan XS, 1998, NATURE, V393, P386, DOI 10.1038/30764; Ngo V, 1996, MOL CELL BIOL, V16, P3245; Orlow I, 1998, INT J CANCER, V75, P819, DOI 10.1002/(SICI)1097-0215(19980316)75:6<819::AID-IJC1>3.0.CO;2-Y; Orntoft TF, 1996, CANCER RES, V56, P1031; ORNTOFT TF, 1990, APMIS S17, V98, P1; PATTNAIK AK, 1986, J VIROL, V60, P994, DOI 10.1128/JVI.60.3.994-1001.1986; RACE RR, 1975, BLOOD GROUPS MAN, P8; RIDEOUT WM, 1994, MOL CELL BIOL, V14, P6143, DOI 10.1128/MCB.14.9.6143; Salvatore P, 1998, FEBS LETT, V421, P152, DOI 10.1016/S0014-5793(97)01553-6; Shima M, 1992, JPN J TRANSFUSION ME, V38, P542; SHIMADA I, 1999, IN PRESS LEGAL MED; Singal R, 1997, P NATL ACAD SCI USA, V94, P13724, DOI 10.1073/pnas.94.25.13724; Warnecke PM, 1999, MOL CELL BIOL, V19, P164; Watkins W M, 1980, Adv Hum Genet, V10, P1; WHITE T, 1990, BIOCHEMISTRY-US, V29, P2740, DOI 10.1021/bi00463a017; YAMAMOTO F, 1990, J BIOL CHEM, V265, P19257; YAMAMOTO F, 1990, NATURE, V345, P229, DOI 10.1038/345229a0; YAMAMOTO F, 1995, GLYCOBIOLOGY, V5, P51, DOI 10.1093/glycob/5.1.51; YOSHIURA K, 1995, P NATL ACAD SCI USA, V92, P7416, DOI 10.1073/pnas.92.16.7416	55	69	77	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 24	1999	274	52					37240	37250		10.1074/jbc.274.52.37240	http://dx.doi.org/10.1074/jbc.274.52.37240			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	267WR	10601288	hybrid			2022-12-25	WOS:000084382700059
J	Schmidt, PJ; Ramos-Gomez, M; Culotta, VC				Schmidt, PJ; Ramos-Gomez, M; Culotta, VC			A gain of superoxide dismutase (SOD) activity obtained with CCS, the copper metallochaperone for SOD1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMYOTROPHIC-LATERAL-SCLEROSIS; CEREVISIAE LYS7 GENE; SACCHAROMYCES-CEREVISIAE; HYDROGEN-PEROXIDE; CU,ZN-SUPEROXIDE DISMUTASE; ATX1 GENE; K-M; YEAST; CHAPERONE; IDENTIFICATION	The incorporation of copper ions into the cytosolic superoxide dismutase (SOD1) is accomplished in vivo by the action of the copper metallochaperone CCS (popper chaperone for SOD1), Mammalian CCS is comprised of three distinct protein domains, with a central region exhibiting remarkable homology (approximately 50% identity) to SOD1 itself, Conserved in CCS are all the SOD1 zinc binding ligands and three of four histidine copper binding ligands, In CCS the fourth histidine is replaced by an aspartate (Asp(200)). Despite this conservation of sequence between SOD1 and CCS, CCS exhibited no detectable SOD activity, Surprisingly, however, a single D200H mutation, targeting the fourth potential copper ligand in CCS, granted significant superoxide scavenging activity to this metallochaperone that was readily detected with CCS expressed in yeast. This mutation did not inhibit the metallochaperone capacity of CCS, and in fact, D200H CCS appears to represent a bifunctional SOD that can self-activate itself with copper. The aspartate at CCS position 200 is well conserved among mammalian CCS molecules, and we propose that this residue has evolved to preclude deleterious reactions involving copper bound to CCS.	Johns Hopkins Univ, Sch Publ Hlth, Dept Environm Hlth Sci, Baltimore, MD 21205 USA	Johns Hopkins University	Culotta, VC (corresponding author), Johns Hopkins Univ, Sch Publ Hlth, Dept Environm Hlth Sci, 615 N Wolfe St,Room 7032, Baltimore, MD 21205 USA.	vculotta@jhsph.edu		Ramos-Gomez, Minerva/0000-0002-0763-4108	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM050016, R01GM050016] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 50016] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Amaravadi R, 1997, HUM GENET, V99, P329, DOI 10.1007/s004390050367; BatinicHaberle I, 1997, ARCH BIOCHEM BIOPHYS, V343, P225, DOI 10.1006/abbi.1997.0157; Beers J, 1997, J BIOL CHEM, V272, P33191, DOI 10.1074/jbc.272.52.33191; BILINSKI T, 1985, BIOCHEM BIOPH RES CO, V130, P533, DOI 10.1016/0006-291X(85)90449-8; BORCHELT DR, 1995, J BIOL CHEM, V270, P3234, DOI 10.1074/jbc.270.7.3234; BORCHELT DR, 1994, P NATL ACAD SCI USA, V91, P8292, DOI 10.1073/pnas.91.17.8292; BORDERS CL, 1985, ARCH BIOCHEM BIOPHYS, V241, P472, DOI 10.1016/0003-9861(85)90572-7; Casareno RLB, 1998, J BIOL CHEM, V273, P23625, DOI 10.1074/jbc.273.37.23625; Corson LB, 1998, P NATL ACAD SCI USA, V95, P6361, DOI 10.1073/pnas.95.11.6361; Culotta VC, 1997, J BIOL CHEM, V272, P23469, DOI 10.1074/jbc.272.38.23469; CULOTTA VC, 1995, J BIOL CHEM, V270, P29991; DEALVARE LR, 1976, BIOCHEM BIOPH RES CO, V69, P687, DOI 10.1016/0006-291X(76)90930-X; FLOHE L, 1984, METHOD ENZYMOL, V105, P93; Gamonet F, 1998, EUR J BIOCHEM, V251, P716, DOI 10.1046/j.1432-1327.1998.2510716.x; Glerum DM, 1996, J BIOL CHEM, V271, P14504, DOI 10.1074/jbc.271.24.14504; Goto JJ, 1998, J BIOL CHEM, V273, P30104, DOI 10.1074/jbc.273.46.30104; GRALLA EB, 1992, ADV GENET, V30, P251, DOI 10.1016/S0065-2660(08)60322-3; HORECKA J, 1995, GENE, V162, P87, DOI 10.1016/0378-1119(95)00325-Z; Hung IH, 1998, J BIOL CHEM, V273, P1749, DOI 10.1074/jbc.273.3.1749; Klomp LWJ, 1997, J BIOL CHEM, V272, P9221, DOI 10.1074/jbc.272.14.9221; Lamb AL, 1999, NAT STRUCT BIOL, V6, P724; LENGFELDER E, 1981, CLIN RES PROC, V17, P73; Lin SJ, 1996, MOL CELL BIOL, V16, P6303; LIN SJ, 1995, P NATL ACAD SCI USA, V92, P3784, DOI 10.1073/pnas.92.9.3784; Lin SJ, 1997, J BIOL CHEM, V272, P9215; Liochev SI, 1997, ARCH BIOCHEM BIOPHYS, V346, P263, DOI 10.1006/abbi.1997.0298; LIPPARD SJ, 1994, PRINCIPLES BIOINORGA, P45; LIU XF, 1992, J BIOL CHEM, V267, P18298; Lyons TJ, 1998, J BIOL INORG CHEM, V3, P650, DOI 10.1007/s007750050279; MCCORD JM, 1969, J BIOL CHEM, V244, P6049; Nishihara E, 1998, NEUROREPORT, V9, P3259, DOI 10.1097/00001756-199810050-00023; Pena MMO, 1999, J NUTR, V129, P1251, DOI 10.1093/jn/129.7.1251; Petrovic N, 1996, J BIOL CHEM, V271, P28331, DOI 10.1074/jbc.271.45.28331; Poulos TL, 1999, NAT STRUCT BIOL, V6, P709, DOI 10.1038/11464; Pufahl RA, 1997, SCIENCE, V278, P853, DOI 10.1126/science.278.5339.853; Rae TD, 1999, SCIENCE, V284, P805, DOI 10.1126/science.284.5415.805; ROSSI L, 1994, BIOCHEM BIOPH RES CO, V203, P1028, DOI 10.1006/bbrc.1994.2285; Rossi L, 1997, BIOMETALS, V10, P257, DOI 10.1023/A:1018364130807; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Schmidt PJ, 1999, J BIOL CHEM, V274, P23719, DOI 10.1074/jbc.274.34.23719; SHERMAN F, 1978, METHODS YEAST GENETI, P163; SIKORSKI RS, 1989, GENETICS, V122, P19; Srinivasan C, 1998, BIOCHEMISTRY-US, V37, P7572, DOI 10.1021/bi980418y; STEINKUHLER C, 1994, BIOCHEM J, V302, P687, DOI 10.1042/bj3020687; TAINER JA, 1982, J MOL BIOL, V160, P181, DOI 10.1016/0022-2836(82)90174-7; UCHIDA K, 1994, J BIOL CHEM, V269, P2405; Valentine JS, 1997, SCIENCE, V278, P817, DOI 10.1126/science.278.5339.817; WiedauPazos M, 1996, SCIENCE, V271, P515, DOI 10.1126/science.271.5248.515; Yim HS, 1997, J BIOL CHEM, V272, P8861; YIM MB, 1993, J BIOL CHEM, V268, P4099; YIM MB, 1990, P NATL ACAD SCI USA, V87, P5006, DOI 10.1073/pnas.87.13.5006; Yim MB, 1996, P NATL ACAD SCI USA, V93, P5709, DOI 10.1073/pnas.93.12.5709	52	62	66	2	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 24	1999	274	52					36952	36956		10.1074/jbc.274.52.36952	http://dx.doi.org/10.1074/jbc.274.52.36952			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	267WR	10601249	hybrid			2022-12-25	WOS:000084382700020
J	Yu, H; Kopito, RR				Yu, H; Kopito, RR			The role of multiubiquitination in dislocation and degradation of the alpha subunit of the T cell antigen receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UBIQUITIN-PROTEASOME PATHWAY; ENDOPLASMIC-RETICULUM DEGRADATION; I HEAVY-CHAINS; MEMBRANE-PROTEIN; 3-HYDROXY-3-METHYLGLUTARYL-COA REDUCTASE; SECRETORY PROTEIN; ER DEGRADATION; CYTOSOL; MUTANT; TRANSLOCATION	Unassembled alpha subunits of the T cell receptor (TCR alpha) are degraded by proteasomes following their dislocation from the endoplasmic reticulum membrane. We previously demonstrated that a variant of TCR alpha lacking lysines (K alpha R) is degraded by this pathway with kinetics indistinguishable from those of the wild type protein (Yu, H., Kaung, G., Kobayashi, S., and Kopito, R. R. (1997) J. Biol. Chem. 272, 20800-20804), demonstrating that ubiquitination on lysines is not required for TCR alpha degradation by the proteasome. Here, we show that dislocation and degradation of TCR alpha and K alpha R are sup pressed by dominant negative ubiquitin coexpression and by mutations in the ubiquitin activating enzyme, indicating that their degradation requires a functional ubiquitin pathway. A cytoplasmic TCR alpha variant that mimics a dislocated degradation intermediate was degraded 5 times more rapidly than full-length TCR alpha, suggesting that dislocation from the endoplasmic reticulum membrane is the rate-limiting step in TCR alpha degradation. We conclude that ubiquitination is required both for dislocation and for targeting TCR alpha chains to the proteasome.	Stanford Univ, Dept Biol Sci, Stanford, CA 94305 USA	Stanford University	Kopito, RR (corresponding author), Stanford Univ, Dept Biol Sci, Stanford, CA 94305 USA.				NIDDK NIH HHS [DK43994] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK043994] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BECKER MLB, 1989, CELL, V58, P911, DOI 10.1016/0092-8674(89)90943-4; Biederer T, 1997, SCIENCE, V278, P1806, DOI 10.1126/science.278.5344.1806; Biederer T, 1996, EMBO J, V15, P2069, DOI 10.1002/j.1460-2075.1996.tb00560.x; Bonifacino JS, 1998, ANNU REV CELL DEV BI, V14, P19, DOI 10.1146/annurev.cellbio.14.1.19; BONIFACINO JS, 1989, J CELL BIOL, V109, P73, DOI 10.1083/jcb.109.1.73; Breitschopf K, 1998, EMBO J, V17, P5964, DOI 10.1093/emboj/17.20.5964; CHAU V, 1989, SCIENCE, V243, P1576, DOI 10.1126/science.2538923; CHIEN Y, 1984, NATURE, V312, P31, DOI 10.1038/312031a0; Ciechanover A, 1998, EMBO J, V17, P7151, DOI 10.1093/emboj/17.24.7151; Corsi AK, 1996, J BIOL CHEM, V271, P30299, DOI 10.1074/jbc.271.48.30299; de Virgilio M, 1998, J BIOL CHEM, V273, P9734, DOI 10.1074/jbc.273.16.9734; Dick LR, 1996, J BIOL CHEM, V271, P7273, DOI 10.1074/jbc.271.13.7273; FINLEY D, 1994, MOL CELL BIOL, V14, P5501, DOI 10.1128/MCB.14.8.5501; Hampton RY, 1997, P NATL ACAD SCI USA, V94, P12944, DOI 10.1073/pnas.94.24.12944; Hampton RY, 1996, MOL BIOL CELL, V7, P2029, DOI 10.1091/mbc.7.12.2029; Hegde RS, 1997, CELL, V91, P575, DOI 10.1016/S0092-8674(00)80445-6; HERSHKO A, 1980, P NATL ACAD SCI-BIOL, V77, P1783, DOI 10.1073/pnas.77.4.1783; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Hiller MM, 1996, SCIENCE, V273, P1725, DOI 10.1126/science.273.5282.1725; Hughes EA, 1997, P NATL ACAD SCI USA, V94, P1896, DOI 10.1073/pnas.94.5.1896; Huppa JB, 1997, IMMUNITY, V7, P113, DOI 10.1016/S1074-7613(00)80514-2; JENSEN TJ, 1995, CELL, V83, P129, DOI 10.1016/0092-8674(95)90241-4; Johnston JA, 1998, J CELL BIOL, V143, P1883, DOI 10.1083/jcb.143.7.1883; Kopito RR, 1997, CELL, V88, P427, DOI 10.1016/S0092-8674(00)81881-4; KULKA RG, 1988, J BIOL CHEM, V263, P15726; LIPPINCOTTSCHWARTZ J, 1988, CELL, V54, P209, DOI 10.1016/0092-8674(88)90553-3; Mayer TU, 1998, EMBO J, V17, P3251, DOI 10.1093/emboj/17.12.3251; McCracken AA, 1996, J CELL BIOL, V132, P291, DOI 10.1083/jcb.132.3.291; Pilon M, 1997, EMBO J, V16, P4540, DOI 10.1093/emboj/16.15.4540; Plemper RK, 1997, NATURE, V388, P891, DOI 10.1038/42276; Plemper RK, 1998, J BIOL CHEM, V273, P32848, DOI 10.1074/jbc.273.49.32848; Qu DF, 1996, J BIOL CHEM, V271, P22791, DOI 10.1074/jbc.271.37.22791; Rapoport TA, 1996, ANNU REV BIOCHEM, V65, P271; ROTHMAN JE, 1977, NATURE, V269, P775, DOI 10.1038/269775a0; SAITO T, 1987, NATURE, V325, P125, DOI 10.1038/325125a0; Sommer T, 1997, FASEB J, V11, P1227, DOI 10.1096/fasebj.11.14.9409541; SOMMER T, 1993, NATURE, V365, P176, DOI 10.1038/365176a0; WARD CL, 1994, J BIOL CHEM, V269, P25710; WARD CL, 1995, CELL, V83, P121, DOI 10.1016/0092-8674(95)90240-6; Werner ED, 1996, P NATL ACAD SCI USA, V93, P13797, DOI 10.1073/pnas.93.24.13797; Wiertz EJHJ, 1996, CELL, V84, P769, DOI 10.1016/S0092-8674(00)81054-5; Wiertz EJHJ, 1996, NATURE, V384, P432, DOI 10.1038/384432a0; Xiong XM, 1999, J BIOL CHEM, V274, P2616, DOI 10.1074/jbc.274.5.2616; Yang M, 1998, J EXP MED, V187, P835, DOI 10.1084/jem.187.6.835; Yu H, 1997, J BIOL CHEM, V272, P20800, DOI 10.1074/jbc.272.33.20800	45	102	104	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 24	1999	274	52					36852	36858		10.1074/jbc.274.52.36852	http://dx.doi.org/10.1074/jbc.274.52.36852			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	267WR	10601236	hybrid			2022-12-25	WOS:000084382700007
J	Golovkin, M; Reddy, ASN				Golovkin, M; Reddy, ASN			An SC35-like protein and a novel serine/arginine-rich protein interact with Arabidopsis U1-70K protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRE-MESSENGER-RNA; SMALL NUCLEAR RIBONUCLEOPROTEIN; SPLICE-SITE SELECTION; SR-PROTEINS; INTRANUCLEAR DISTRIBUTION; DISTINCT FUNCTIONS; PREMESSENGER RNA; HIGHER-PLANTS; 70K PROTEIN; SERINE-RICH	The U1 small nuclear ribonucleoprotein 70-kDa protein, a U1 small nuclear ribonucleoprotein-specific protein, has been shown to have multiple roles in nuclear precursor mRNA processing in animals. By using the C-terminal arginine-rich region of Arabidopsis U1-'IOII protein in the yeast two-hybrid system, we have identified an SC35-like (SR33) and a novel plant serine/arginine-rich (SR) protein (SR45) that interact with the plant U1-70K The SR33 and SR45 proteins share several features with SR proteins including modular domains typical of splicing factors in the SR family of proteins. However, both plant SR proteins are rich in proline, and SR45, unlike most animal SR proteins, has two distinct arginine/serine-rich domains separated by an RNA recognition motif. By using coprecipitation assays we confirmed the interaction of plant U1-70K with SR33 and SR45 proteins. Furthermore, in vivo and in vitro protein-protein interaction experiments have shown that SR33 protein interacts with itself and with SR45 protein but not with two other members (SRZ21 and SRZ22) of the SR family that are known to interact with the Arabidopsis full-length U-70H only. A Clk/Sty protein kinase (AFC-8) from Arabidopsis phosphorylated four SR proteins (SR33, SR45, SRZ21, and SRZ22). Coprecipitation studies have confirmed the interaction of SR proteins with AFC2 kinase, and the interaction between AFC2 and SR33 is modulated by the phosphorylation status of these proteins. These and our previous results suggest that the plant U1-70B: interacts with at least four distinct members of the SR family including SR45 with its two arginine/serine-rich domains, and the interaction between the SR proteins and AFC2 is modulated by phosphorylation. The interaction of plant U1-70K with a novel set of proteins suggests the early stages of spliceosome assembly, and intron recognition in plants is likely to be different from animals.	Colorado State Univ, Dept Biol, Ft Collins, CO 80523 USA; Colorado State Univ, Cell & Mol Biol Program, Ft Collins, CO 80523 USA	Colorado State University; Colorado State University	Reddy, ASN (corresponding author), Colorado State Univ, Dept Biol, Ft Collins, CO 80523 USA.	reddy@lamar.colostate.edu		Reddy, Anireddy/0000-0002-4038-4091				AYANE M, 1991, NUCLEIC ACIDS RES, V19, P1273, DOI 10.1093/nar/19.6.1273; BENDER J, 1994, P NATL ACAD SCI USA, V91, P12105, DOI 10.1073/pnas.91.25.12105; BLACK DL, 1985, CELL, V42, P737, DOI 10.1016/0092-8674(85)90270-3; Blencowe BJ, 1998, GENE DEV, V12, P996, DOI 10.1101/gad.12.7.996; BRENDEL V, 1992, P NATL ACAD SCI USA, V89, P2002, DOI 10.1073/pnas.89.6.2002; Brown JWS, 1998, ANNU REV PLANT PHYS, V49, P77, DOI 10.1146/annurev.arplant.49.1.77; Brown JWS, 1996, PLANT MOL BIOL, V32, P531, DOI 10.1007/BF00019105; Burge CB, 1999, RNA WORLD, P525; CACERES JF, 1994, SCIENCE, V265, P1706, DOI 10.1126/science.8085156; Caceres JF, 1997, J CELL BIOL, V138, P225, DOI 10.1083/jcb.138.2.225; Cao WH, 1997, RNA, V3, P1456; Cao WH, 1998, J BIOL CHEM, V273, P20629, DOI 10.1074/jbc.273.32.20629; Colwill K, 1996, EMBO J, V15, P265, DOI 10.1002/j.1460-2075.1996.tb00357.x; Colwill K, 1996, J BIOL CHEM, V271, P24569, DOI 10.1074/jbc.271.40.24569; Domon C, 1998, J BIOL CHEM, V273, P34603, DOI 10.1074/jbc.273.51.34603; Duncan PI, 1998, EXP CELL RES, V241, P300, DOI 10.1006/excr.1998.4083; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; FU XD, 1995, RNA, V1, P663; FU XD, 1992, SCIENCE, V256, P535, DOI 10.1126/science.1373910; GE H, 1990, CELL, V62, P25, DOI 10.1016/0092-8674(90)90236-8; Gniadkowski M, 1996, NUCLEIC ACIDS RES, V24, P619, DOI 10.1093/nar/24.4.619; Golovkin M, 1996, PLANT CELL, V8, P1421, DOI 10.1105/tpc.8.8.1421; Golovkin M, 1998, PLANT CELL, V10, P1637, DOI 10.1105/tpc.10.10.1637; GOODALL GJ, 1989, CELL, V58, P473, DOI 10.1016/0092-8674(89)90428-5; Goodall GJ, 1991, OXFORD SURVEYS PLANT, V7, P255; GORALSKI TJ, 1989, CELL, V56, P1011, DOI 10.1016/0092-8674(89)90634-X; Graveley BR, 1998, MOL CELL, V1, P765, DOI 10.1016/S1097-2765(00)80076-3; Graveley BR, 1999, CURR BIOL, V9, pR6, DOI 10.1016/S0960-9822(99)80032-3; GUI JF, 1994, NATURE, V369, P678, DOI 10.1038/369678a0; GUI JF, 1994, P NATL ACAD SCI USA, V91, P10824, DOI 10.1073/pnas.91.23.10824; GUTHRIE C, 1991, SCIENCE, V253, P157, DOI 10.1126/science.1853200; Jumaa H, 1997, EMBO J, V16, P5077, DOI 10.1093/emboj/16.16.5077; Kanopka A, 1998, NATURE, V393, P185, DOI 10.1038/30277; Kanopka A, 1996, NATURE, V381, P535, DOI 10.1038/381535a0; Ko CH, 1998, PLANT MOL BIOL, V36, P573, DOI 10.1023/A:1005932620374; KOHTZ JD, 1994, NATURE, V368, P119, DOI 10.1038/368119a0; Kuroyanagi N, 1998, BIOCHEM BIOPH RES CO, V242, P357, DOI 10.1006/bbrc.1997.7913; LAVIGUEUR A, 1993, GENE DEV, V7, P2405, DOI 10.1101/gad.7.12a.2405; LAZAR G, 1995, P NATL ACAD SCI USA, V92, P7672, DOI 10.1073/pnas.92.17.7672; Lopato S, 1999, PLANT MOL BIOL, V39, P761, DOI 10.1023/A:1006129615846; Lopato S, 1999, GENE DEV, V13, P987, DOI 10.1101/gad.13.8.987; Lopato S, 1996, PLANT CELL, V8, P2255, DOI 10.1105/tpc.8.12.2255; LUEHRSEN KR, 1994, PLANT MOL BIOL, V24, P449, DOI 10.1007/BF00024113; LUEHRSEN KR, 1994, GENE DEV, V8, P1117, DOI 10.1101/gad.8.9.1117; MacMillan AM, 1997, P NATL ACAD SCI USA, V94, P133, DOI 10.1073/pnas.94.1.133; Manley JL, 1996, GENE DEV, V10, P1569, DOI 10.1101/gad.10.13.1569; MERMOUD JE, 1994, EMBO J, V13, P5679, DOI 10.1002/j.1460-2075.1994.tb06906.x; Misteli T, 1999, CURR BIOL, V9, pR198, DOI 10.1016/S0960-9822(99)80128-6; Misteli T, 1997, NATURE, V387, P523, DOI 10.1038/387523a0; Murray MV, 1999, GENE DEV, V13, P87, DOI 10.1101/gad.13.1.87; PAUTOT V, 1989, GENE, V77, P133, DOI 10.1016/0378-1119(89)90367-3; POPIELARZ M, 1995, J BIOL CHEM, V270, P17830, DOI 10.1074/jbc.270.30.17830; PUIG O, 1998, GENE DEV, V12, P569; RAMCHATESINGH J, 1995, MOL CELL BIOL, V15, P4898; Reddy ASN, 1996, J BIOL CHEM, V271, P7052, DOI 10.1074/jbc.271.12.7052; ROSBASH M, 1991, TRENDS BIOCHEM SCI, V16, P187, DOI 10.1016/0968-0004(91)90073-5; ROSCIGNO RF, 1995, RNA, V1, P692; ROTH MB, 1990, J CELL BIOL, V111, P2217, DOI 10.1083/jcb.111.6.2217; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Schneider S, 1996, BIOTECHNIQUES, V20, P960; Schuler MA, 1998, LOOK BEYOND TRANSCRIPTION, P1; SHARP PA, 1994, CELL, V77, P805, DOI 10.1016/0092-8674(94)90130-9; Simpson GG, 1996, PLANT MOL BIOL, V32, P1, DOI 10.1007/BF00039375; Staley JP, 1998, CELL, V92, P315, DOI 10.1016/S0092-8674(00)80925-3; Stark JM, 1998, P NATL ACAD SCI USA, V95, P2163, DOI 10.1073/pnas.95.5.2163; Tacke R, 1997, P NATL ACAD SCI USA, V94, P1148, DOI 10.1073/pnas.94.4.1148; Tacke R, 1998, CELL, V93, P139, DOI 10.1016/S0092-8674(00)81153-8; TARN WY, 1995, P NATL ACAD SCI USA, V92, P2504, DOI 10.1073/pnas.92.7.2504; Valcarcel J, 1996, TRENDS BIOCHEM SCI, V21, P296, DOI 10.1016/0968-0004(96)10039-6; Valcarcel J, 1996, SCIENCE, V273, P1706, DOI 10.1126/science.273.5282.1706; VANSANTEN VL, 1987, GENE, V56, P253, DOI 10.1016/0378-1119(87)90142-9; Wang HY, 1998, J CELL BIOL, V140, P737, DOI 10.1083/jcb.140.4.737; Wang J, 1998, GENE DEV, V12, P2222, DOI 10.1101/gad.12.14.2222; Will CL, 1997, CURR OPIN CELL BIOL, V9, P320, DOI 10.1016/S0955-0674(97)80003-8; WU JY, 1993, CELL, V75, P1061, DOI 10.1016/0092-8674(93)90316-I; Xiao SH, 1998, EMBO J, V17, P6359, DOI 10.1093/emboj/17.21.6359; Xiao SH, 1997, GENE DEV, V11, P334, DOI 10.1101/gad.11.3.334; Yeakley JM, 1999, J CELL BIOL, V145, P447, DOI 10.1083/jcb.145.3.447; ZAHLER AM, 1995, P NATL ACAD SCI USA, V92, P2642, DOI 10.1073/pnas.92.7.2642; ZAHLER AM, 1992, GENE DEV, V6, P837, DOI 10.1101/gad.6.5.837; ZAHLER AM, 1993, SCIENCE, V260, P219, DOI 10.1126/science.8385799; Zhang WJ, 1998, MOL CELL BIOL, V18, P676, DOI 10.1128/MCB.18.2.676	82	97	118	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 17	1999	274	51					36428	36438		10.1074/jbc.274.51.36428	http://dx.doi.org/10.1074/jbc.274.51.36428			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	266AV	10593939	hybrid			2022-12-25	WOS:000084279200058
J	Khwaja, A; Tatton, L				Khwaja, A; Tatton, L			Resistance to the cytotoxic effects of tumor necrosis factor alpha can be overcome by inhibition of a FADD/caspase-dependent signaling pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; CELL-DEATH INDUCTION; INDUCED APOPTOSIS; TNF-ALPHA; PERMEABILITY TRANSITION; SUPEROXIDE-DISMUTASE; TRANSCRIPTION FACTOR; CD95 FAS/APO-1; ACTIVATION; PROTEIN	Tumor necrosis factor (TNF) alpha initiates the activation of a pro-apoptotic pathway involving the recruitment of the death domain containing protein FADD and the subsequent activation of specific proteases (caspases). Many cells are resistant, however, to the cytotoxic effects of TNF alpha due to the concurrent activation of pro-survival pathways involving the transcription factor NP kappa B and TRAF2. Here we show that the TNF alpha-activated FADD/caspase pathway can also exert an unexpected pro-survival effect. Inhibition of this pathway in NIH3T3 fibroblasts or U937 leukemic cells by peptide caspase inhibitors or expression of dominant-negative FADD leads to rapid death following treatment with TNF alpha, whereas control cells are TNF alpha-resistant. FADD/caspase inhibited cells die by a non-apoptotic mechanism caused by increased production of reactive oxygen species which precedes loss of the mitochondrial membrane potential. Cytotoxicity can be prevented by preincubation with antioxidants including reduced glutathione or by expression of a dominant-negative Rac GTP-binding protein. These results indicate that caspase activation in response to TNF alpha as anti-necrotic as well as pro-apoptotic effects and extend our understanding of the biological role of these proteases.	UCL, Sch Med, Dept Haematol, London WC1E 6HX, England	University of London; University College London; UCL Medical School	Khwaja, A (corresponding author), UCL, Sch Med, Dept Haematol, 98 Chenies Mews, London WC1E 6HX, England.	a.khwaja@ucl.ac.uk	Khwaja, Asim/C-1509-2008					Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; BEUTLER B, 1989, ANNU REV IMMUNOL, V7, P625, DOI 10.1146/annurev.immunol.7.1.625; Bokoch G M, 1994, Curr Opin Hematol, V1, P53; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; Chinnaiyan AM, 1996, J BIOL CHEM, V271, P4961; Cohen GM, 1997, BIOCHEM J, V326, P1, DOI 10.1042/bj3260001; GOOSSENS V, 1995, P NATL ACAD SCI USA, V92, P8115, DOI 10.1073/pnas.92.18.8115; Higuchi M, 1998, ONCOGENE, V17, P2515, DOI 10.1038/sj.onc.1202485; HSU HL, 1995, CELL, V81, P495, DOI 10.1016/0092-8674(95)90070-5; Hsu HL, 1996, CELL, V84, P299, DOI 10.1016/S0092-8674(00)80984-8; Ichijo H, 1997, SCIENCE, V275, P90, DOI 10.1126/science.275.5296.90; Irani K, 1997, SCIENCE, V275, P1649, DOI 10.1126/science.275.5306.1649; Kelliher MA, 1998, IMMUNITY, V8, P297, DOI 10.1016/S1074-7613(00)80535-X; Khwaja A, 1997, EMBO J, V16, P2783, DOI 10.1093/emboj/16.10.2783; Kroemer G, 1998, ANNU REV PHYSIOL, V60, P619, DOI 10.1146/annurev.physiol.60.1.619; Kunstle G, 1997, IMMUNOL LETT, V55, P5, DOI 10.1016/S0165-2478(96)02642-9; Lee SY, 1998, J EXP MED, V188, P1381, DOI 10.1084/jem.188.7.1381; Lee SY, 1997, IMMUNITY, V7, P703, DOI 10.1016/S1074-7613(00)80390-8; Malinin NL, 1997, NATURE, V385, P540, DOI 10.1038/385540a0; Manna SK, 1998, J BIOL CHEM, V273, P13245, DOI 10.1074/jbc.273.21.13245; Marchetti P, 1996, J EXP MED, V184, P1155, DOI 10.1084/jem.184.3.1155; Medema JP, 1997, EMBO J, V16, P2794, DOI 10.1093/emboj/16.10.2794; Melcher A, 1998, NAT MED, V4, P581, DOI 10.1038/nm0598-581; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; Muzio M, 1997, J BIOL CHEM, V272, P2952, DOI 10.1074/jbc.272.5.2952; Newton K, 1998, EMBO J, V17, P706, DOI 10.1093/emboj/17.3.706; Nobel CSI, 1997, CHEM RES TOXICOL, V10, P1319, DOI 10.1021/tx970131m; Regnier CH, 1997, CELL, V90, P373, DOI 10.1016/S0092-8674(00)80344-X; RUFF MR, 1981, INFECT IMMUN, V31, P380, DOI 10.1128/IAI.31.1.380-385.1981; SCHRECK R, 1991, EMBO J, V10, P2247, DOI 10.1002/j.1460-2075.1991.tb07761.x; Sidoti-de Fraisse C, 1998, ONCOGENE, V17, P1639, DOI 10.1038/sj.onc.1202094; SUGARMAN BJ, 1985, SCIENCE, V230, P943, DOI 10.1126/science.3933111; Sundaresan M, 1996, BIOCHEM J, V318, P379, DOI 10.1042/bj3180379; Van Antwerp DJ, 1998, TRENDS CELL BIOL, V8, P107, DOI 10.1016/S0962-8924(97)01215-4; VanAntwerp DJ, 1996, SCIENCE, V274, P787, DOI 10.1126/science.274.5288.787; Vercammen D, 1998, J EXP MED, V187, P1477, DOI 10.1084/jem.187.9.1477; VICIANA PR, 1997, CELL, V89, P457; Wajant H, 1998, CURR BIOL, V8, P113, DOI 10.1016/S0960-9822(98)70042-9; Wallach D, 1997, TRENDS BIOCHEM SCI, V22, P107, DOI 10.1016/S0968-0004(97)01015-3; Wallach D, 1997, FEBS LETT, V410, P96, DOI 10.1016/S0014-5793(97)00553-X; Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680; WONG GHW, 1989, CELL, V58, P923, DOI 10.1016/0092-8674(89)90944-6; Wu MX, 1998, SCIENCE, V281, P998, DOI 10.1126/science.281.5379.998; Yang XL, 1997, CELL, V89, P1067, DOI 10.1016/S0092-8674(00)80294-9; Yeh WC, 1998, SCIENCE, V279, P1954, DOI 10.1126/science.279.5358.1954; Yeh WC, 1997, IMMUNITY, V7, P715, DOI 10.1016/S1074-7613(00)80391-X	46	77	84	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 17	1999	274	51					36817	36823		10.1074/jbc.274.51.36817	http://dx.doi.org/10.1074/jbc.274.51.36817			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	266AV	10593992	hybrid			2022-12-25	WOS:000084279200111
J	Mochizuki, Y; Takenawa, T				Mochizuki, Y; Takenawa, T			Novel inositol polyphosphate 5-phosphatase localizes at membrane ruffles	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							K-ATP CHANNELS; PHOSPHATIDYLINOSITOL 4,5-BISPHOSPHATE; MOLECULAR-CLONING; HUMAN-PLATELETS; PHOSPHOLIPASE-D; DOMAIN; POLYPHOSPHATE-5-PHOSPHATASE; IDENTIFICATION; SYNAPTOJANIN; ACTIVATION	We have cloned a novel inositol polyphosphate 5-phosphatase from the rat brain cDNA library. It contains two highly conserved 5-phosphatase motifs, both of which are essential for its enzymatic activity. Interestingly, the proline content of this protein is high and concentrated in its N- and C-terminal regions. One putative SH3-binding motif and six 14-3-3 zeta-binding motifs were found in the amino acid sequence. This enzyme hydrolyzed phosphate at the D-5 position of inositol 1,4,5-trisphosphate, inositol 1,3,4,5-tetrakisphosphate, and phosphatidylinositoI 4,5-bisphosphate, consistent with the substrate specificity of type II 5-phosphatase, OCRL, synaptojanin and synaptojanin 2, already characterized B-phosphatases. When the Myc-epitope-tagged enzyme was expressed in COS-7 cells and stained with anti-Myc polyclonal antibody, a signal was observed at ruffling membranes and in the cytoplasm. me prepared several deletion mutants and demonstrated that the 123 N-terminal amino acids (311-433) and a C-terminal proline-rich region containing 277 amino acids (725-1001) were essential for its localization to ruffling membranes. This enzyme might regulate the level of inositol and phosphatidylinositoI polyphosphates at membrane ruffles.	Univ Tokyo, Inst Med Sci, Dept Biochem, Minato Ku, Tokyo 1088639, Japan	University of Tokyo	Takenawa, T (corresponding author), Univ Tokyo, Inst Med Sci, Dept Biochem, Minato Ku, Tokyo 1088639, Japan.	takenawa@ims.u-tokyo.ac.jp						Alessi DR, 1998, CURR OPIN GENET DEV, V8, P55, DOI 10.1016/S0959-437X(98)80062-2; ATTREE O, 1992, NATURE, V358, P239, DOI 10.1038/358239a0; Auethavekiat V, 1997, J BIOL CHEM, V272, P1786, DOI 10.1074/jbc.272.3.1786; Baukrowitz T, 1998, SCIENCE, V282, P1141, DOI 10.1126/science.282.5391.1141; Campbell JK, 1997, BIOCHEMISTRY-US, V36, P15363, DOI 10.1021/bi9708085; Communi D, 1996, J BIOL CHEM, V271, P11676, DOI 10.1074/jbc.271.20.11676; CONNOLLY TM, 1985, J BIOL CHEM, V260, P7868; Damen JE, 1996, P NATL ACAD SCI USA, V93, P1689, DOI 10.1073/pnas.93.4.1689; FENG SB, 1994, SCIENCE, V266, P1241, DOI 10.1126/science.7526465; FUKAMI K, 1994, J BIOL CHEM, V269, P1518; Haffner C, 1997, FEBS LETT, V419, P175, DOI 10.1016/S0014-5793(97)01451-8; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; HEJNA JA, 1995, GENOMICS, V29, P285, DOI 10.1006/geno.1995.1247; Huang CL, 1998, NATURE, V391, P803, DOI 10.1038/35882; JANMEY PA, 1987, NATURE, V325, P362, DOI 10.1038/325362a0; Jefferson AB, 1996, BIOCHEMISTRY-US, V35, P7890, DOI 10.1021/bi9602627; Kavanaugh WM, 1996, CURR BIOL, V6, P438, DOI 10.1016/S0960-9822(02)00511-0; Khvotchev M, 1998, J BIOL CHEM, V273, P2306, DOI 10.1074/jbc.273.4.2306; KOZAK M, 1991, J CELL BIOL, V115, P887, DOI 10.1083/jcb.115.4.887; LASSING I, 1985, NATURE, V314, P472, DOI 10.1038/314472a0; LIM WA, 1994, NATURE, V372, P375, DOI 10.1038/372375a0; Lioubin MN, 1996, GENE DEV, V10, P1084, DOI 10.1101/gad.10.9.1084; LISCOVITCH M, 1994, J BIOL CHEM, V269, P21403; Ma AD, 1998, MOL CELL BIOL, V18, P4744, DOI 10.1128/MCB.18.8.4744; Majerus PW, 1999, J BIOL CHEM, V274, P10669, DOI 10.1074/jbc.274.16.10669; Matzaris M, 1998, J BIOL CHEM, V273, P8256, DOI 10.1074/jbc.273.14.8256; MATZARIS M, 1994, J BIOL CHEM, V269, P3397; McPherson PS, 1996, NATURE, V379, P353, DOI 10.1038/379353a0; Nemoto Y, 1997, J BIOL CHEM, V272, P30817, DOI 10.1074/jbc.272.49.30817; Oh ES, 1998, J BIOL CHEM, V273, P10624, DOI 10.1074/jbc.273.17.10624; Pappan K, 1997, J BIOL CHEM, V272, P7055, DOI 10.1074/jbc.272.11.7055; Pesesse X, 1998, FEBS LETT, V437, P301, DOI 10.1016/S0014-5793(98)01255-1; Pesesse X, 1997, BIOCHEM BIOPH RES CO, V239, P697, DOI 10.1006/bbrc.1997.7538; Randazzo PA, 1997, J BIOL CHEM, V272, P7688; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; ROSS TS, 1991, J BIOL CHEM, V266, P20283; SADLER I, 1992, J CELL BIOL, V119, P1573, DOI 10.1083/jcb.119.6.1573; Sakisaka T, 1997, MOL CELL BIOL, V17, P3841, DOI 10.1128/MCB.17.7.3841; Seet LF, 1998, BIOCHEM BIOPH RES CO, V247, P116, DOI 10.1006/bbrc.1998.8564; Shibasaki Y, 1997, J BIOL CHEM, V272, P7578, DOI 10.1074/jbc.272.12.7578; Shyng SL, 1998, SCIENCE, V282, P1138, DOI 10.1126/science.282.5391.1138; VERJANS B, 1994, BIOCHEM J, V300, P85, DOI 10.1042/bj3000085; Vollenweider P, 1999, MOL CELL BIOL, V19, P1081; Wisniewski D, 1999, BLOOD, V93, P2707, DOI 10.1182/blood.V93.8.2707.408k17_2707_2720; Woscholski R, 1998, FEBS LETT, V432, P5, DOI 10.1016/S0014-5793(98)00820-5; Woscholski R, 1997, J BIOL CHEM, V272, P9625; Zhang L, 1998, Methods Mol Biol, V105, P47; Zhang XL, 1998, J BIOL CHEM, V273, P1574, DOI 10.1074/jbc.273.3.1574; ZHANG XL, 1995, P NATL ACAD SCI USA, V92, P4853, DOI 10.1073/pnas.92.11.4853	49	48	52	3	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 17	1999	274	51					36790	36795		10.1074/jbc.274.51.36790	http://dx.doi.org/10.1074/jbc.274.51.36790			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	266AV	10593988	hybrid			2022-12-25	WOS:000084279200107
J	Roje, S; Wang, H; McNeil, SD; Raymond, RK; Appling, DR; Shachar-Hill, Y; Bohnert, HJ; Hanson, AD				Roje, S; Wang, H; McNeil, SD; Raymond, RK; Appling, DR; Shachar-Hill, Y; Bohnert, HJ; Hanson, AD			Isolation, characterization, and functional expression of cDNAs encoding NADH-dependent methylenetetrahydrofolate reductase from higher plants	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ONE-CARBON METABOLISM; MOLECULAR-BIOLOGY; PURIFICATION; MITOCHONDRIAL; BIOCHEMISTRY; EXTRACTION; LEAVES; BLOOD; CELLS; LIVER	Methylenetetrahydrofolate reductase (MTHFR) is the least understood enzyme of folate-mediated one-carbon metabolism in plants. Genomics-based approaches were used to identify one maize and two Arabidopsis cDNAs specifying proteins homologous to MTHFRs from other organisms. These cDNAs encode functional MTHFRs, as evidenced by their ability to complement a yeast met12 met13 mutant, and by the presence of MTHFR activity in extracts of complemented yeast cells. Deduced sequence analysis shows that the plant MTHFR polypeptides are of similar size (66 kDa) and domain structure to other eukaryotic MTHFRs, and lack obvious targeting sequences. Southern analyses and genomic evidence indicate that Arabidopsis has two MTHFR genes and that maize has at least two, A carboxyl terminal polyhistidine tag was added to one Arabidopsis MTHFR, and used to purify the enzyme 640-fold to apparent homogeneity, Size exclusion chromatography and denaturing gel electrophoresis of the recombinant enzyme indicate that it exists as a dimer of approximate to 66-kDa subunits, Unlike mammalian MTHFR, the plant enzymes strongly prefer NADH to NADPH, and are not inhibited by S-adenosylmethionine, An NADH-dependent MTHFR reaction could be reversible in plant cytosol, where the NADH/NAD ratio is 10(-3). Consistent with this, leaf tissues metabolized [methyl-C-14]methyltetrahydrofolate to serine, sugars, and starch. A reversible MTHFR reaction would obviate the need for inhibition by S-adenosylmethionine to prevent excessive conversion of methylene- to methyltetrahydrofolate.	Univ Florida, Dept Hort Sci, Gainesville, FL 32611 USA; Univ Arizona, Dept Biochem, Tucson, AZ 85721 USA; Univ Texas, Dept Chem & Biochem, Austin, TX 78712 USA; New Mexico State Univ, Dept Chem & Biochem, Las Cruces, NM 88003 USA	State University System of Florida; University of Florida; University of Arizona; University of Texas System; University of Texas Austin; New Mexico State University	Hanson, AD (corresponding author), Univ Florida, Dept Hort Sci, Gainesville, FL 32611 USA.		Bohnert, Hans J/A-7104-2009; Shachar-Hill, Yair/B-6165-2013	Shachar-Hill, Yair/0000-0001-8793-5084; Roje, Sanja/0000-0002-6302-5382	NCRR NIH HHS [RR09276] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [R01RR009276] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; APPLING DR, 1991, FASEB J, V5, P2645, DOI 10.1096/fasebj.5.12.1916088; ATKINS CA, 1971, CAN J BOTANY, V49, P1225, DOI 10.1139/b71-171; Bagley PJ, 1998, P NATL ACAD SCI USA, V95, P13217, DOI 10.1073/pnas.95.22.13217; BESSON V, 1995, PLANT PHYSIOL BIOCH, V33, P665; BOUDET AM, 1995, NEW PHYTOL, V129, P203, DOI 10.1111/j.1469-8137.1995.tb04292.x; Bourgis F, 1999, PLANT CELL, V11, P1485, DOI 10.1105/tpc.11.8.1485; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Chen LF, 1997, PLANT PHYSIOL, V115, P299, DOI 10.1104/pp.115.1.299; CLANDININ MT, 1972, BIOCHEM J, V128, P29, DOI 10.1042/bj1280029; Cossins E. A., 1980, The biochemistry of plants. A comprehensive treatise. Volume 2. Metabolism and respiration., P365; Cossins EA, 1997, PHYTOCHEMISTRY, V45, P437, DOI 10.1016/S0031-9422(96)00833-3; COSSINS EA, 1972, PHYTOCHEMISTRY, V11, P2481, DOI 10.1016/S0031-9422(00)88521-0; COSSINS EA, 1987, BIOCH PLANTS, V11, P317, DOI DOI 10.1016/B978-0-12-675411-7.50015-X; de Graef MR, 1999, J BACTERIOL, V181, P2351, DOI 10.1128/JB.181.8.2351-2357.1999; FEDEC P, 1976, PHYTOCHEMISTRY, V15, P359, DOI 10.1016/S0031-9422(00)86822-3; Goyette P, 1998, MAMM GENOME, V9, P652, DOI 10.1007/s003359900838; GOYETTE P, 1994, NAT GENET, V7, P196; GREGORY JF, 1984, J NUTR, V114, P341, DOI 10.1093/jn/114.2.341; Guenther BD, 1999, NAT STRUCT BIOL, V6, P359, DOI 10.1038/7594; GUSTINCICH S, 1991, BIOTECHNIQUES, V11, P298; HEINEKE D, 1991, PLANT PHYSIOL, V95, P1131, DOI 10.1104/pp.95.4.1131; Higgins DG, 1996, METHOD ENZYMOL, V266, P383; IMESON HC, 1988, J PLANT PHYSIOL, V132, P465, DOI 10.1016/S0176-1617(88)80064-6; JAMES F, 1995, J BIOL CHEM, V270, P22344, DOI 10.1074/jbc.270.38.22344; KUTCHAN TM, 1995, PLANT CELL, V7, P1059, DOI 10.2307/3870057; KUTZBACH C, 1971, BIOCHIM BIOPHYS ACTA, V250, P459, DOI 10.1016/0005-2744(71)90247-6; Lassner MW., 1989, PLANT MOL BIOL REP, V7, P116, DOI DOI 10.1007/BF02669627; MATTHEWS RG, 1986, METHOD ENZYMOL, V122, P372; Matthews RG, 1998, EUR J PEDIATR, V157, pS54, DOI 10.1007/PL00014305; Nuccio ML, 1999, CURR OPIN PLANT BIOL, V2, P128, DOI 10.1016/S1369-5266(99)80026-0; OLIVER DJ, 1994, ANNU REV PLANT PHYS, V45, P323, DOI 10.1146/annurev.pp.45.060194.001543; OSTREM JA, 1987, PLANT PHYSIOL, V84, P1271; RAYMOND RK, 1999, IN PRESS ARCH BIOCH, V372; Sambrook J., 2002, MOL CLONING LAB MANU; Sheppard CA, 1999, J BACTERIOL, V181, P718, DOI 10.1128/JB.181.3.718-725.1999; VANONI MA, 1984, BIOCHEMISTRY-US, V23, P5272, DOI 10.1021/bi00317a027; VERNET T, 1987, GENE, V52, P225, DOI 10.1016/0378-1119(87)90049-7; WOHLFARTH G, 1991, ARCH MICROBIOL, V155, P378; Zhao WN, 1997, J BIOL CHEM, V272, P21811, DOI 10.1074/jbc.272.35.21811; ZHOU JM, 1990, BIOCHEM MED METAB B, V43, P234, DOI 10.1016/0885-4505(90)90029-Z	41	59	63	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 17	1999	274	51					36089	36096		10.1074/jbc.274.51.36089	http://dx.doi.org/10.1074/jbc.274.51.36089			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	266AV	10593891	hybrid			2022-12-25	WOS:000084279200010
J	Whittaker, MM; Kersten, PJ; Cullen, D; Whittaker, JW				Whittaker, MM; Kersten, PJ; Cullen, D; Whittaker, JW			Identification of catalytic residues in glyoxal oxidase by targeted mutagenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MANGANESE SUPEROXIDE-DISMUTASE; GALACTOSE-OXIDASE; ACTIVE-SITE; PHANEROCHAETE-CHRYSOSPORIUM; APOGALACTOSE OXIDASE; PICHIA-PASTORIS; ENZYME; EXPRESSION; MECHANISM; TYROSINE-495	Glyoxal oxidase is a copper metalloenzyme produced by the wood-rot fungus Phanerochaete chrysosporium as an essential component of its extracellular lignin degradation pathways. Previous spectroscopic studies on glyoxal oxidase have demonstrated that it contains a free radical-coupled copper active site remarkably similar to that found in another fungal metalloenzyme, galactose oxidase. Alignment of primary structures has allowed four catalytic residues of glyoxal oxidase to be targeted for site-directed mutagenesis in the recombinant protein. Three glyoxal oxidase mutants have been heterologously expressed in both a filamentous fungus (Aspergillus nidulans) and in a methylotrophic yeast (Pichia pastoris), the latter expression system producing as much as 2 g of protein per liter of culture medium under conditions of high density methanol-induced fermentation. Biochemical and spectroscopic characterization of the mutant enzymes supports structural correlation ions between galactose oxidase and glyoxal oxidase, clearly identifying the catalytically important residues in glyoxal oxidase and demonstrating the functions of each of these residues.	Oregon Grad Inst Sci & Technol, Dept Biochem & Mol Biol, Portland, OR USA; USDA, Forest Prod Lab, Madison, WI 53705 USA	United States Department of Agriculture (USDA); United States Forest Service	Whittaker, JW (corresponding author), Oregon Grad Inst Sci & Technol, Dept Biochem & Mol Biol, Portland, OR USA.	jim@mb.ogi.edu	Cullen, Daniel/AAN-5484-2020		NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM046749] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 46749] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; BARON AJ, 1994, J BIOL CHEM, V269, P25095; BORK P, 1994, J MOL BIOL, V236, P1277, DOI 10.1016/0022-2836(94)90056-6; CREGG JM, 1993, BIO-TECHNOL, V11, P905, DOI 10.1038/nbt0893-905; CULLEN D, 1987, NUCLEIC ACIDS RES, V15, P9163, DOI 10.1093/nar/15.22.9163; Frey PA, 1997, CURR OPIN CHEM BIOL, V1, P347, DOI 10.1016/S1367-5931(97)80072-5; Gerfen GJ, 1996, J PHYS CHEM-US, V100, P16739, DOI 10.1021/jp960709l; Higgins DR, 1998, METH MOL B, V103, P1; ITO N, 1994, J MOL BIOL, V238, P794, DOI 10.1006/jmbi.1994.1335; Itoh S, 1997, INORG CHEM, V36, P1407, DOI 10.1021/ic961144a; KERSTEN PJ, 1995, J BACTERIOL, V177, P6106, DOI 10.1128/jb.177.21.6106-6110.1995; KERSTEN PJ, 1987, J BACTERIOL, V169, P2195, DOI 10.1128/jb.169.5.2195-2201.1987; KERSTEN PJ, 1993, P NATL ACAD SCI USA, V90, P7411, DOI 10.1073/pnas.90.15.7411; Knowles P. F., 1994, PERSPECTIVES BIO INO, V2, P207; KUAN IC, 1993, P NATL ACAD SCI USA, V90, P1242, DOI 10.1073/pnas.90.4.1242; Kurland C, 1996, CURR OPIN BIOTECH, V7, P489, DOI 10.1016/S0958-1669(96)80050-4; LOWRY OH, 1951, J BIOL CHEM, V193, P265; PARAST CV, 1995, BIOCHEMISTRY-US, V34, P2393, DOI 10.1021/bi00008a001; Reynolds MP, 1997, J BIOL INORG CHEM, V2, P327, DOI 10.1007/s007750050139; Reynolds MP, 1995, BIOCHEM SOC T, V23, pS510, DOI 10.1042/bst023510s; Rogers MS, 1998, INORG CHIM ACTA, V276, P175; Stansfield I, 1998, J MOL BIOL, V282, P13, DOI 10.1006/jmbi.1998.1976; Stratton J, 1998, METH MOL B, V103, P107; Stubbe J, 1998, CHEM REV, V98, P705, DOI 10.1021/cr9400875; STUBBE JA, 1989, ANNU REV BIOCHEM, V58, P257; Tatusova TA, 1999, FEMS MICROBIOL LETT, V174, P247, DOI 10.1016/S0378-1097(99)00149-4; VANGERVEN L, 1963, PARAMAGNETIC RESONAN, V2, P905; Whittaker JW, 1998, PURE APPL CHEM, V70, P903, DOI 10.1351/pac199870040903; WHITTAKER JW, 1994, MET IONS BIOL SYST, V30, P315; WHITTAKER JW, 1991, J AM CHEM SOC, V113, P5528, DOI 10.1021/ja00015a003; WHITTAKER MM, 1988, J BIOL CHEM, V263, P6074; WHITTAKER MM, 1993, J AM CHEM SOC, V115, P10029, DOI 10.1021/ja00075a019; WHITTAKER MM, 1993, BIOPHYS J, V64, P762, DOI 10.1016/S0006-3495(93)81437-1; Whittaker MM, 1998, J BIOL CHEM, V273, P22188, DOI 10.1074/jbc.273.35.22188; Whittaker MM, 1996, J BIOL CHEM, V271, P681, DOI 10.1074/jbc.271.2.681; WHITTAKER MM, 1990, J BIOL CHEM, V265, P9610; Whittaker MM, 1998, BIOCHEMISTRY-US, V37, P8426, DOI 10.1021/bi980328t; Zurita D, 1997, J BIOL INORG CHEM, V2, P46, DOI 10.1007/s007750050105	38	90	91	5	25	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 17	1999	274	51					36226	36232		10.1074/jbc.274.51.36226	http://dx.doi.org/10.1074/jbc.274.51.36226			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	266AV	10593910	hybrid			2022-12-25	WOS:000084279200029
J	Yang, PR; Pimental, R; Lai, D; Marcus, S				Yang, PR; Pimental, R; Lai, D; Marcus, S			Direct activation of the fission yeast PAK Shk1 by the novel SH3 domain protein, Skb5	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							P21-ACTIVATED KINASE PAK1; XENOPUS OOCYTES; SCHIZOSACCHAROMYCES-POMBE; SACCHAROMYCES-CEREVISIAE; PHEROMONE RESPONSE; CELL POLARITY; FAMILY; GENE; HOMOLOG; INTERACTS	The pal-activated kinase (PAK) homolog Shk1 is essential for cell viability in the fission yeast Schizosaccharomyces pombe. Roles have been established for Shk1 in the regulation of cell morphology, sexual differentiation, and mitosis in S. pombe. In this report, we describe the genetic and molecular characterization of a novel SH3 domain protein, Skb5, identified as a result of a two-hybrid screen for Shk1 interacting proteins. S. pombe cells carrying a deletion of the skb5 gene exhibit no discernible phenotypic defects under normal growth conditions, but when subjected to hypertonic stress, become spheroidal in shape and growth impaired. Both of these defects can be suppressed by overexpression of the Shk1 modulator, Skb1. The growth inhibition that results from overexpression of Shk1 in S. pombe cells is markedly suppressed by a null mutation in the skb5 gene, suggesting that Skb5 contributes positively to the function of Shk1 in vivo. Consistent with this notion, we show that Skb5 stimulates Shk1 catalytic function in S. pombe cells. Furthermore, and perhaps most significantly, we show that bacterially expressed recombinant Skb5 protein directly stimulates the catalytic activity of recombinant Shk1 kinase in vitro. These and additional data described herein demonstrate that Skb5 is a direct activator of Shk1 in fission yeast.	Univ Texas, MD Anderson Canc Ctr, Dept Mol Genet, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center	Marcus, S (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Mol Genet, Houston, TX 77030 USA.				NATIONAL CANCER INSTITUTE [P30CA016672] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM053239] Funding Source: NIH RePORTER; NCI NIH HHS [P30CA16672] Funding Source: Medline; NIGMS NIH HHS [R01GM53239] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Allen KM, 1998, NAT GENET, V20, P25, DOI 10.1038/1675; Bagrodia S, 1998, J BIOL CHEM, V273, P23633, DOI 10.1074/jbc.273.37.23633; Bokoch GM, 1996, J BIOL CHEM, V271, P25746, DOI 10.1074/jbc.271.42.25746; CHANG EC, 1994, CELL, V79, P131, DOI 10.1016/0092-8674(94)90406-5; Daniels RH, 1999, J BIOL CHEM, V274, P6047, DOI 10.1074/jbc.274.10.6047; DORAI T, 1990, MOL CELL BIOL, V10, P4068, DOI 10.1128/MCB.10.8.4068; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; Faure S, 1997, EMBO J, V16, P5550, DOI 10.1093/emboj/16.18.5550; Frost JA, 1996, MOL CELL BIOL, V16, P3707, DOI 10.1128/mcb.16.7.3707; Gilbreth M, 1998, P NATL ACAD SCI USA, V95, P14781, DOI 10.1073/pnas.95.25.14781; Gilbreth M, 1996, P NATL ACAD SCI USA, V93, P13802, DOI 10.1073/pnas.93.24.13802; LEBERER E, 1992, EMBO J, V11, P4815, DOI 10.1002/j.1460-2075.1992.tb05587.x; LEEUW T, 1995, SCIENCE, V270, P1210, DOI 10.1126/science.270.5239.1210; Manser E, 1998, MOL CELL, V1, P183, DOI 10.1016/S1097-2765(00)80019-2; Manser E, 1997, MOL CELL BIOL, V17, P1129, DOI 10.1128/MCB.17.3.1129; MARCUS S, 1995, P NATL ACAD SCI USA, V92, P6180, DOI 10.1073/pnas.92.13.6180; MARCUS S, 1994, P NATL ACAD SCI USA, V91, P7762, DOI 10.1073/pnas.91.16.7762; MAUNDRELL K, 1990, J BIOL CHEM, V265, P10857; MILLER PJ, 1994, MOL CELL BIOL, V14, P1075, DOI 10.1128/MCB.14.2.1075; OTTILIE S, 1995, EMBO J, V14, P5908, DOI 10.1002/j.1460-2075.1995.tb00278.x; POLVERINO A, 1995, J BIOL CHEM, V270, P26067, DOI 10.1074/jbc.270.44.26067; RAMER SW, 1993, P NATL ACAD SCI USA, V90, P452, DOI 10.1073/pnas.90.2.452; Rose MD., 1990, METHODS YEAST GENETI; Rudel T, 1997, SCIENCE, V276, P1571, DOI 10.1126/science.276.5318.1571; Sells MA, 1997, CURR BIOL, V7, P202, DOI 10.1016/S0960-9822(97)70091-5; Sells MA, 1998, J BIOL CHEM, V273, P18490, DOI 10.1074/jbc.273.29.18490; Sells MA, 1997, TRENDS CELL BIOL, V7, P162, DOI 10.1016/S0962-8924(97)01003-9; SHIBUYA EK, 1992, P NATL ACAD SCI USA, V89, P9831, DOI 10.1073/pnas.89.20.9831; VANAELST L, 1993, P NATL ACAD SCI USA, V90, P6213, DOI 10.1073/pnas.90.13.6213; Verde F, 1998, P NATL ACAD SCI USA, V95, P7526, DOI 10.1073/pnas.95.13.7526; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; Yang PR, 1998, J BIOL CHEM, V273, P18481, DOI 10.1074/jbc.273.29.18481; ZHANG SJ, 1995, J BIOL CHEM, V270, P23934, DOI 10.1074/jbc.270.41.23934	33	22	27	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 17	1999	274	51					36052	36057		10.1074/jbc.274.51.36052	http://dx.doi.org/10.1074/jbc.274.51.36052			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	266AV	10593886	hybrid			2022-12-25	WOS:000084279200005
J	Abid, MR; Li, Y; Anthony, C; De Benedetti, A				Abid, MR; Li, Y; Anthony, C; De Benedetti, A			Translational regulation of ribonucleotide reductase by eukaryotic initiation factor 4E links protein synthesis to the control of DNA replication	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CAP-BINDING PROTEIN; MESSENGER-RNA; SACCHAROMYCES-CEREVISIAE; SMALL-SUBUNIT; MALIGNANT TRANSFORMATION; R2 COMPONENT; CELL-GROWTH; EXPRESSION; YEAST; IDENTIFICATION	Ribonucleotide reductase synthesizes dNDPs, a specific and limiting step in DNA synthesis, and can participate in neoplastic transformation when overexpressed, The small subunit (ribonucleotide reductase 2 (RNR2)) was cloned as a major product in a subtraction library from eukaryotic initiation factor 4E (eIF4E)-transformed cells (Chinese hamster ovary-4E (CHO-4E)), CHO-4E cells have 20-40-fold elevated RNR2 protein, reflecting an increased distribution of RNR2 mRNA to the heavy polysomes, CHO-4E cells display an altered cell cycle with shortened S phase, similar to cells selected for RNR2 overexpression with hydroxyurea, The function of ribonucleotide reductase as a checkpoint component of S progression was studied in yeast in which elevated eIF4E rescued S-arrested rnr2-68(ts) cells, by increasing recruitment of its mRNA to polysomes, Crosses between rnr2-68(ts) and mutant eIF4E (cdc33-1(ts)) engendered conditional synthetic lethality, with extreme sensitivity to hydroxyurea and the microtubule depolymerizing agent, benomyl. The double mutant (cdc33-1 rnr2-68) also identified a unique terminal phenotype, arrested with small bud and a randomly distributed single nucleus, which is distinct from those of both parental single mutants. This phenotype defines eIF4E and RNR2 as determinants in an important cell cycle checkpoint, in early/mid-S phase. These results also provide a link between protein and DNA synthesis and provide an explanation for cell cycle alterations induced by elevated eIF4E.	Louisiana State Univ, Med Ctr, Dept Biochem & Mol Biol, Shreveport, LA 71130 USA	Louisiana State University System; Louisiana State University Health Sciences Center at Shreveport	De Benedetti, A (corresponding author), Louisiana State Univ, Med Ctr, Dept Biochem & Mol Biol, 1501 Kings Highway, Shreveport, LA 71130 USA.	adeben@lsumc.edu		de benedetti, arrigo/0000-0002-4198-8647	NATIONAL CANCER INSTITUTE [R29CA069148] Funding Source: NIH RePORTER; NCI NIH HHS [CA69148] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADAMS A, 1997, METHODS YEAST GENETI, P193; ALI MA, 1991, P NATL ACAD SCI USA, V88, P8257, DOI 10.1073/pnas.88.18.8257; ALLEN JB, 1994, GENE DEV, V8, P2401, DOI 10.1101/gad.8.20.2401; ALTMANN M, 1987, MOL CELL BIOL, V7, P998, DOI 10.1128/MCB.7.3.998; AMARA FM, 1995, NUCLEIC ACIDS RES, V23, P1461, DOI 10.1093/nar/23.9.1461; BONNEAU AM, 1987, J BIOL CHEM, V262, P11134; BRENNER C, 1988, MOL CELL BIOL, V8, P3556, DOI 10.1128/MCB.8.8.3556; CHAUDHURI MM, 1992, BIOCHIM BIOPHYS ACTA, V1171, P117, DOI 10.1016/0167-4781(92)90151-O; De Benedetti A, 1999, INT J BIOCHEM CELL B, V31, P59, DOI 10.1016/S1357-2725(98)00132-0; De Benedetti Arrigo, 1994, Molecular and Cellular Differentiation, V2, P347; DEBENEDETTI A, 1990, P NATL ACAD SCI USA, V87, P8212, DOI 10.1073/pnas.87.21.8212; DEBENEDETTI A, 1991, MOL CELL BIOL, V11, P5435, DOI 10.1128/MCB.11.11.5435; DeFatta RJ, 1999, INT J CANCER, V80, P516, DOI 10.1002/(SICI)1097-0215(19990209)80:4<516::AID-IJC6>3.3.CO;2-Z; ELLEDGE SJ, 1990, GENE DEV, V4, P740, DOI 10.1101/gad.4.5.740; ELLEDGE SJ, 1992, TRENDS BIOCHEM SCI, V17, P119, DOI 10.1016/0968-0004(92)90249-9; ELLEDGE SJ, 1987, MOL CELL BIOL, V7, P2783, DOI 10.1128/MCB.7.8.2783; ERIKSSON S, 1984, ADV EXP MED BIOL, V165, P407; Fan HZ, 1998, CANCER RES, V58, P1650; Fan HZ, 1996, P NATL ACAD SCI USA, V93, P14036, DOI 10.1073/pnas.93.24.14036; GEBALLE AP, 1994, TRENDS BIOCHEM SCI, V19, P159, DOI 10.1016/0968-0004(94)90277-1; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; Graff JR, 1997, BIOCHEM BIOPH RES CO, V240, P15, DOI 10.1006/bbrc.1997.7592; Huang AP, 1997, CANCER RES, V57, P4876; Huang MX, 1997, MOL CELL BIOL, V17, P6105, DOI 10.1128/MCB.17.10.6105; JENSEN RA, 1994, P NATL ACAD SCI USA, V91, P9257, DOI 10.1073/pnas.91.20.9257; KEREKATTE V, 1995, INT J CANCER, V64, P27, DOI 10.1002/ijc.2910640107; Kevil CG, 1996, INT J CANCER, V65, P785, DOI 10.1002/(SICI)1097-0215(19960315)65:6<785::AID-IJC14>3.0.CO;2-3; KOHRER K, 1991, METHOD ENZYMOL, V194, P398; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; Kulsh J, 1997, MED HYPOTHESES, V49, P297, DOI 10.1016/S0306-9877(97)90193-6; LAZARISKARATZAS A, 1990, NATURE, V345, P544, DOI 10.1038/345544a0; LODISH HF, 1974, NATURE, V251, P385, DOI 10.1038/251385a0; MOORE SA, 1988, J BIOL CHEM, V263, P9674; MORLEY SJ, 1994, MOL BIOL REP, V19, P221, DOI 10.1007/BF00986964; Nathan CAO, 1997, ONCOGENE, V15, P579, DOI 10.1038/sj.onc.1201216; PELLETIER J, 1987, BIOCHEM CELL BIOL, V65, P576, DOI 10.1139/o87-074; RAUE HA, 1991, METHOD ENZYMOL, V194, P453; RHOADS RE, 1988, TRENDS BIOCHEM SCI, V13, P52, DOI 10.1016/0968-0004(88)90028-X; RHOADS RE, 1993, J BIOL CHEM, V268, P3017; Rhoads RE, 1991, CURR OPIN CELL BIOL, V3, P1019, DOI 10.1016/0955-0674(91)90123-G; ROZELL B, 1986, J ORAL PATHOL MED, V15, P261, DOI 10.1111/j.1600-0714.1986.tb00619.x; Ruan HJ, 1996, J BIOL CHEM, V271, P29576, DOI 10.1074/jbc.271.47.29576; SARABIA MJF, 1993, MOL GEN GENET, V238, P241, DOI 10.1007/BF00279553; SHERMAN F, 1991, METHOD ENZYMOL, V194, P3; Sonenberg N, 1998, CURR OPIN CELL BIOL, V10, P268, DOI 10.1016/S0955-0674(98)80150-6; SORELLS DL, 1998, HEAD NECK-J SCI SPEC, V21, P60; STANDART N, 1986, J CELL BIOL, V103, P2129, DOI 10.1083/jcb.103.6.2129; THELANDER L, 1986, MOL CELL BIOL, V6, P3433, DOI 10.1128/MCB.6.10.3433; Wang PJ, 1997, MOL CELL BIOL, V17, P6114, DOI 10.1128/MCB.17.10.6114; Wells SE, 1998, MOL CELL, V2, P135, DOI 10.1016/S1097-2765(00)80122-7; YEN TJ, 1988, MOL CELL BIOL, V8, P1224, DOI 10.1128/MCB.8.3.1224; Zhao XL, 1998, MOL CELL, V2, P329, DOI 10.1016/S1097-2765(00)80277-4; ZHOU BS, 1995, CANCER RES, V55, P1328	54	39	41	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 10	1999	274	50					35991	35998		10.1074/jbc.274.50.35991	http://dx.doi.org/10.1074/jbc.274.50.35991			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	264NG	10585489	hybrid			2022-12-25	WOS:000084187900101
J	Daniels, GM; Amara, SG				Daniels, GM; Amara, SG			Regulated trafficking of the human dopamine transporter - Clathrin-mediated internalization and lysosomal degradation in response to phorbol esters	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; CELL-SURFACE EXPRESSION; DOWN-REGULATION; FUNCTIONAL REGULATION; NOREPINEPHRINE TRANSPORTER; RECEPTOR INTERNALIZATION; STRIATAL SYNAPTOSOMES; DILEUCINE MOTIF; XENOPUS-OOCYTES; COATED PITS	The dopamine transporter plays an essential role in the modulation of dopaminergic neurotransmission by mediating the reuptake of dopamine into presynaptic neurons. In cells expressing the dopamine transporter, activation of protein kinase C by phorbol esters results in a significant reduction in dopamine uptake. This phorbol ester-mediated inhibition of dopamine transport is associated with a decrease in V-max although the apparent affinity of the transporter for dopamine remains unchanged. Using a green fluorescent protein-tagged dopamine transporter stably expressed in Madin-Darby canine kidney cells, we show in live cells that the decrease in transporter activity is caused by the rapid internalization of carriers from the plasma membrane. This redistribution of the transporter is specific to phorbol ester activation and is unaffected by the presence of either substrates or inhibitors of the carrier. Upon the addition of phorbol esters, transporters at the cell surface are rapidly endocytosed through a clathrin-mediated and dynamin-dependent mechanism into early endosomes, where they colocalize with transferrin. The internalized carrier is targeted to the endosomal/lysosomal pathway and is completely degraded within 2 h of protein kinase C activation. Phorbol ester-mediated alterations in the trafficking of the dopamine transporter may serve as a mechanism for controlling extracellular dopamine levels in the central nervous system.	Oregon Hlth Sci Univ, Dept Cell & Dev Biol, Portland, OR 97201 USA; Oregon Hlth Sci Univ, Howard Hughes Med Inst, Portland, OR 97201 USA; Oregon Hlth Sci Univ, Vollum Inst, Portland, OR 97201 USA	Oregon Health & Science University; Howard Hughes Medical Institute; Oregon Health & Science University; Oregon Health & Science University	Amara, SG (corresponding author), 3181 SW Sam Jackson Pk Rd L-474, Portland, OR 97201 USA.			Amara, Susan/0000-0001-8914-1106				ACRES RB, 1986, J BIOL CHEM, V261, P6210; AIKEN C, 1994, CELL, V76, P853, DOI 10.1016/0092-8674(94)90360-3; Amara A, 1997, J EXP MED, V186, P139, DOI 10.1084/jem.186.1.139; Amara SG, 1998, DRUG ALCOHOL DEPEN, V51, P87, DOI 10.1016/S0376-8716(98)00068-4; Apparsundaram S, 1998, J PHARMACOL EXP THER, V287, P733; Apparsundaram S, 1998, J PHARMACOL EXP THER, V287, P744; BEGUINOT L, 1985, P NATL ACAD SCI USA, V82, P2774, DOI 10.1073/pnas.82.9.2774; Bernstein EM, 1999, J BIOL CHEM, V274, P889, DOI 10.1074/jbc.274.2.889; BOKMAN SH, 1981, BIOCHEM BIOPH RES CO, V101, P1372, DOI 10.1016/0006-291X(81)91599-0; BRANDSCH M, 1993, AM J PHYSIOL, V264, pG939, DOI 10.1152/ajpgi.1993.264.5.G939; Bresnahan PA, 1998, CURR BIOL, V8, P1235, DOI 10.1016/S0960-9822(07)00517-9; Carroll RC, 1999, NAT NEUROSCI, V2, P454, DOI 10.1038/8123; Chapell R, 1998, J BIOL CHEM, V273, P32595, DOI 10.1074/jbc.273.49.32595; COLLAWN JF, 1990, CELL, V63, P1061, DOI 10.1016/0092-8674(90)90509-D; Copeland BJ, 1996, J PHARMACOL EXP THER, V277, P1527; COREY JL, 1994, J BIOL CHEM, V269, P14759; Daniels GM, 1998, METHOD ENZYMOL, V296, P307; DArrigo A, 1997, EUR J CELL BIOL, V72, P95; GARCIA JV, 1991, NATURE, V350, P508, DOI 10.1038/350508a0; Giros B, 1996, NATURE, V379, P606, DOI 10.1038/379606a0; Goodman OB, 1996, NATURE, V383, P447, DOI 10.1038/383447a0; GUY B, 1987, NATURE, V330, P266, DOI 10.1038/330266a0; Henley JR, 1998, J CELL BIOL, V141, P85, DOI 10.1083/jcb.141.1.85; HERSKOVITS JS, 1993, J CELL BIOL, V122, P565, DOI 10.1083/jcb.122.3.565; HINSHAW JE, 1995, NATURE, V374, P190, DOI 10.1038/374190a0; HOXIE JA, 1986, J IMMUNOL, V137, P1194; Huff RA, 1997, J NEUROCHEM, V68, P225; KILTY JE, 1991, SCIENCE, V254, P578, DOI 10.1126/science.1948035; KITAYAMA S, 1994, EUR J PHARM-MOLEC PH, V268, P115, DOI 10.1016/0922-4106(94)90180-5; LILES WC, 1986, J BIOL CHEM, V261, P5307; MANDEL LJ, 1994, J CELL SCI, V107, P3315; Mellman I, 1996, ANNU REV CELL DEV BI, V12, P575, DOI 10.1146/annurev.cellbio.12.1.575; MYERS CL, 1989, AM J PHYSIOL, V257, pL253, DOI 10.1152/ajplung.1989.257.4.L253; NABI IR, 1991, J CELL BIOL, V115, P1573, DOI 10.1083/jcb.115.6.1573; Nguyen TT, 1996, J NEUROCHEM, V67, P645; Oh P, 1998, J CELL BIOL, V141, P101, DOI 10.1083/jcb.141.1.101; PELCHENMATTHEWS A, 1993, J EXP MED, V178, P1209, DOI 10.1084/jem.178.4.1209; PETERSEN CM, 1992, EXP CELL RES, V201, P160, DOI 10.1016/0014-4827(92)90360-K; Piguet V, 1999, CELL, V97, P63, DOI 10.1016/S0092-8674(00)80715-1; PODBILEWICZ B, 1990, EMBO J, V9, P3477, DOI 10.1002/j.1460-2075.1990.tb07556.x; Povlock SL, 1998, METHOD ENZYMOL, V296, P436; Pristupa ZB, 1998, SYNAPSE, V30, P79, DOI 10.1002/(SICI)1098-2396(199809)30:1<79::AID-SYN10>3.3.CO;2-I; Qian Y, 1997, J NEUROSCI, V17, P45, DOI 10.1523/JNEUROSCI.17-01-00045.1997; RITZ MC, 1987, SCIENCE, V237, P1219, DOI 10.1126/science.2820058; SATO K, 1995, J NEUROCHEM, V65, P1967; SCHNITZER JE, 1994, J CELL BIOL, V127, P1217, DOI 10.1083/jcb.127.5.1217; SHIMADA S, 1991, SCIENCE, V254, P576, DOI 10.1126/science.1948034; Shpetner HS, 1996, J BIOL CHEM, V271, P13, DOI 10.1074/jbc.271.1.13; SMART EJ, 1994, J CELL BIOL, V124, P307, DOI 10.1083/jcb.124.3.307; VANDERBLIEK AM, 1993, J CELL BIOL, V122, P553, DOI 10.1083/jcb.122.3.553; Vaughan RA, 1997, J BIOL CHEM, V272, P15541, DOI 10.1074/jbc.272.24.15541; VAUGHAN RA, 1993, MOL CELL NEUROSCI, V4, P209, DOI 10.1006/mcne.1993.1025; Vrindavanam NS, 1996, NEUROSCI LETT, V216, P133; Wright EM, 1997, J EXP BIOL, V200, P287; Zhang L, 1997, BIOCHEM PHARMACOL, V53, P677, DOI 10.1016/S0006-2952(96)00898-2; Zimmermann N, 1999, J BIOL CHEM, V274, P12611, DOI 10.1074/jbc.274.18.12611	56	277	279	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 10	1999	274	50					35794	35801		10.1074/jbc.274.50.35794	http://dx.doi.org/10.1074/jbc.274.50.35794			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	264NG	10585462	hybrid			2022-12-25	WOS:000084187900074
J	Davis, PK; Johnson, GVW				Davis, PK; Johnson, GVW			The microtubule binding of tau and high molecular weight tau in apoptotic PC12 cells is impaired because of altered phosphorylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NERVE GROWTH-FACTOR; PHOSPHOLIPASE C-GAMMA; HELICAL FILAMENT-TAU; ALZHEIMERS-DISEASE; SYMPATHETIC NEURONS; PROTEIN-KINASE; IN-SITU; DIFFERENTIAL PHOSPHORYLATION; PHEOCHROMOCYTOMA CELLS; DYNAMIC INSTABILITY	Although the importance of the microtubule network throughout cell life is well established, the dynamics of microtubules during apoptosis, a regulated cell death process, is unclear. In a previous study (Davis, P. K., and Johnson, G. V. (1999) Biochem. J. 340, 51-58) we demonstrated that the phosphorylation of the microtubule-associated protein tau was increased during neuronal PC12 cell apoptosis. The purpose of this study was to determine whether the increased tau phosphorylation that occurred during apoptosis impaired the microtubule binding capacity of tau. This study is the first demonstration that microtubule-binding by tau and high molecular weight tan is significantly impaired as a result of altered phosphorylation during a naturally occurring process, apoptosis. Furthermore, co-immunofluorescence studies reveal for the first time that tau populations within an apoptotic neuronal PC12 cell exhibit differential phosphorylation. In control PC12 cells, Tau-l staining (Tau-l recognizes an unphosphorylated epitope) is evident throughout the entire cell body. In contrast, Tau-l immunoreactivity in apoptotic PC12 cells is retained in the nuclear/perinuclear region but is significantly decreased in the cytoplasm up to the plasma membrane. The selective distribution of phosphorylated tau in apoptotic PC12 cells indicates that tau likely plays a significant role in the cytoskeletal changes that occur during apoptosis.	Univ Alabama, Dept Psychiat, Birmingham, AL 35294 USA; Univ Alabama, Dept Pharmacol, Birmingham, AL 35294 USA	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham	Johnson, GVW (corresponding author), Univ Alabama, Dept Psychiat, SC1061,1720 7th Ave S, Birmingham, AL 35294 USA.		Johnson, Gail V.W./K-4723-2012	Johnson, Gail V.W./0000-0003-3464-0404	NINDS NIH HHS [NS35060] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS035060] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BAAS PW, 1988, P NATL ACAD SCI USA, V85, P8335, DOI 10.1073/pnas.85.21.8335; BATISTATOU A, 1991, J CELL BIOL, V115, P461, DOI 10.1083/jcb.115.2.461; BINDER LI, 1985, J CELL BIOL, V101, P1371, DOI 10.1083/jcb.101.4.1371; Bonfoco E, 1996, J NEUROCHEM, V67, P2484; BRADY RM, 1995, NEUROBIOL AGING, V16, P479; BRAMBLETT GT, 1993, NEURON, V10, P1089, DOI 10.1016/0896-6273(93)90057-X; BRANDT R, 1995, J CELL BIOL, V131, P1327, DOI 10.1083/jcb.131.5.1327; Carmel G, 1996, J BIOL CHEM, V271, P32789, DOI 10.1074/jbc.271.51.32789; CAVIGELLI M, 1995, EMBO J, V14, P5957, DOI 10.1002/j.1460-2075.1995.tb00284.x; CLEVELAND DW, 1977, J MOL BIOL, V116, P207, DOI 10.1016/0022-2836(77)90213-3; CLEVELAND DW, 1977, J MOL BIOL, V116, P227, DOI 10.1016/0022-2836(77)90214-5; COUCHIE D, 1992, P NATL ACAD SCI USA, V89, P4378, DOI 10.1073/pnas.89.10.4378; Davis PK, 1997, J NEUROCHEM, V68, P2338; Davis PK, 1999, BIOCHEM J, V340, P51, DOI 10.1042/0264-6021:3400051; DECKWERTH TL, 1993, J CELL BIOL, V123, P1207, DOI 10.1083/jcb.123.5.1207; Deshmukh M, 1996, J CELL BIOL, V135, P1341, DOI 10.1083/jcb.135.5.1341; DREWES G, 1995, J BIOL CHEM, V270, P7679, DOI 10.1074/jbc.270.13.7679; DRUBIN D, 1988, J CELL BIOL, V106, P1583, DOI 10.1083/jcb.106.5.1583; DRUBIN DG, 1986, J CELL BIOL, V103, P2739, DOI 10.1083/jcb.103.6.2739; DRUBIN DG, 1985, J CELL BIOL, V101, P1799, DOI 10.1083/jcb.101.5.1799; ESMAELIAZAD B, 1994, J CELL SCI, V107, P869; Farschon DM, 1997, J CELL BIOL, V137, P1117, DOI 10.1083/jcb.137.5.1117; FLEMING LM, 1995, BIOCHEM J, V309, P41, DOI 10.1042/bj3090041; GAO CY, 1995, EXP CELL RES, V219, P612, DOI 10.1006/excr.1995.1271; Gervais FG, 1999, CELL, V97, P395, DOI 10.1016/S0092-8674(00)80748-5; GOEDERT M, 1992, P NATL ACAD SCI USA, V89, P1983, DOI 10.1073/pnas.89.5.1983; GOEDERT M, 1989, EMBO J, V8, P393, DOI 10.1002/j.1460-2075.1989.tb03390.x; GREENE LA, 1978, J CELL BIOL, V78, P747, DOI 10.1083/jcb.78.3.747; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; GREENWOOD JA, 1995, EXP CELL RES, V220, P332, DOI 10.1006/excr.1995.1323; Gu YJ, 1996, J NEUROCHEM, V67, P1235; Guenal I, 1997, J CELL SCI, V110, P489; Guo Q, 1998, NAT MED, V4, P957, DOI 10.1038/nm0898-957; GUSTKE N, 1992, FEBS LETT, V307, P199, DOI 10.1016/0014-5793(92)80767-B; Hanger DP, 1998, J NEUROCHEM, V71, P2465; Hwang SC, 1996, J BIOL CHEM, V271, P18342, DOI 10.1074/jbc.271.31.18342; JAMESON L, 1980, BIOCHEMISTRY-US, V19, P2472, DOI 10.1021/bi00552a027; Jenkins SM, 1998, NEUROREPORT, V9, P67, DOI 10.1097/00001756-199801050-00014; Johnson Gail V. W., 1998, Alzheimer's Disease Review, V3, P125; JOHNSON GVW, 1992, J NEUROCHEM, V59, P2056; Joshi HC, 1998, CURR OPIN CELL BIOL, V10, P35, DOI 10.1016/S0955-0674(98)80084-7; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; KNOPS J, 1991, J CELL BIOL, V114, P725, DOI 10.1083/jcb.114.4.725; KOLODNEY MS, 1995, P NATL ACAD SCI USA, V92, P10252, DOI 10.1073/pnas.92.22.10252; KROEMER G, 1995, FASEB J, V9, P1277, DOI 10.1096/fasebj.9.13.7557017; Lee G, 1998, J CELL SCI, V111, P3167; Levee MG, 1996, AM J PHYSIOL-CELL PH, V271, pC1981, DOI 10.1152/ajpcell.1996.271.6.C1981; LINDWALL G, 1984, J BIOL CHEM, V259, P5301; LINDWALL G, 1984, J BIOL CHEM, V259, P2241; LOO DT, 1993, P NATL ACAD SCI USA, V90, P7951, DOI 10.1073/pnas.90.17.7951; LOOMIS PA, 1990, P NATL ACAD SCI USA, V87, P8422, DOI 10.1073/pnas.87.21.8422; LU Q, 1993, J NEUROSCI, V13, P508; Mandell JW, 1996, J NEUROSCI, V16, P5727; Mashima T, 1997, ONCOGENE, V14, P1007, DOI 10.1038/sj.onc.1200919; Mills JC, 1998, J CELL SCI, V111, P625; MORISHIMAKAWASHIMA M, 1995, J BIOL CHEM, V270, P823, DOI 10.1074/jbc.270.2.823; Nuydens R, 1997, BIOCHEM BIOPH RES CO, V240, P687, DOI 10.1006/bbrc.1997.7721; OBLINGER MM, 1991, J NEUROSCI, V11, P2453; Park DS, 1996, J BIOL CHEM, V271, P21898, DOI 10.1074/jbc.271.36.21898; PITTMAN RN, 1993, J NEUROSCI, V13, P3669; Rao L, 1996, J CELL BIOL, V135, P1441, DOI 10.1083/jcb.135.6.1441; RIEDERER BM, 1995, J HISTOCHEM CYTOCHEM, V43, P1269, DOI 10.1177/43.12.8537643; SCOTT CW, 1993, BRAIN RES, V611, P237, DOI 10.1016/0006-8993(93)90508-K; SINCLAIR GI, 1988, BRAIN RES, V450, P60, DOI 10.1016/0006-8993(88)91544-2; SMALE G, 1995, EXP NEUROL, V133, P225, DOI 10.1006/exnr.1995.1025; SMITH CJ, 1995, FEBS LETT, V375, P243, DOI 10.1016/0014-5793(95)01221-Y; SU JH, 1994, NEUROREPORT, V5, P2358, DOI 10.1097/00001756-199411000-00037; SZENDREI GI, 1993, J NEUROSCI RES, V34, P243, DOI 10.1002/jnr.490340212; TALEGHANY N, 1992, J NEUROSCI RES, V33, P257, DOI 10.1002/jnr.490330209; Thurston VC, 1997, CELL MOTIL CYTOSKEL, V38, P100, DOI 10.1002/(SICI)1097-0169(1997)38:1<100::AID-CM9>3.0.CO;2-C; TRINCZEK B, 1995, MOL BIOL CELL, V6, P1887, DOI 10.1091/mbc.6.12.1887; vanEngeland M, 1997, EXP CELL RES, V235, P421, DOI 10.1006/excr.1997.3738; WEINGARTEN MD, 1975, P NATL ACAD SCI USA, V72, P1858, DOI 10.1073/pnas.72.5.1858; Wolozin B, 1996, SCIENCE, V274, P1710, DOI 10.1126/science.274.5293.1710; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; YOSHIDA H, 1993, J NEUROCHEM, V61, P1183, DOI 10.1111/j.1471-4159.1993.tb03642.x; [No title captured]	77	43	44	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 10	1999	274	50					35686	35692		10.1074/jbc.274.50.35686	http://dx.doi.org/10.1074/jbc.274.50.35686			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	264NG	10585448	hybrid			2022-12-25	WOS:000084187900060
J	Kusnetsov, V; Landsberger, M; Meurer, J; Oelmuller, R				Kusnetsov, V; Landsberger, M; Meurer, J; Oelmuller, R			The assembly of the CAAT-box binding complex at a photosynthesis gene promoter is regulated by light, cytokinin, and the stage of the plastids	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA LEVELS; FACTOR CBF/NF-Y; NF-Y; DNA-BINDING; IN-VIVO; TRANSCRIPTION FACTOR; NUCLEAR GENES; EXPRESSION; PROTEINS; ELEMENTS	A functionally important region in the promoter of the spinach photosynthesis gene AtpC, which encodes the subunit gamma of the chloroplast ATP synthase, is located immediately upstream of the CAAT-box, A single nucleotide exchange in this region (AAATTCAAT --> AAGATCAAT) uncouples the expression of an AtpC promoter::uidA gene fusion from the regulation by light, cytokinin, and functional plastids and results in a high constitutive expression of the reporter gene. By screening an Arabidopsis thaliana expression library with a double-stranded wild-type oligonucleotide from this promoter region, we have isolated cDNAs from Arabidopsis libraries that code for plant homologs of the CAAT-box binding factor (CBF)-C, Binding occurs only in the presence of nuclear extracts, consistent with reports from metazoa CBFs that the subunits A and B in addition to C are required for the formation of the CBF-DNA complex. At least eight genes with homologies to CBF-C are present in the Arabidopsis genome; one of them exhibits striking similarities to the gene for the human global transcriptional repressor Drap1, In gel mobility shift assays, low binding activity of CBF to the wild-type AtpC promoter sequence was observed with nuclear extracts from tissue with low AtpC expression levels, i.e. extracts from etiolated and photobleached seedlings, whereas high binding activity was detectable with extracts from tissues with high AtpC expression levels, i.e. extracts from light-grown seedlings and etiolated seedlings treated with cytokinin, Binding to the mutant sequence, which directs constitutive high level uidA expression in vivo, is significantly stronger than to the wild-type sequence. The data are consistent with the idea that the assembly of CBF at the AtpC promoter is regulated in response to light and cytokinin and that the low level of expression in etiolated and photobleached material is caused by an inhibitory effect. The structure/function relationships of the Arabidopsis CBFs are discussed in relation to their regulatory function in AtpC gene expression.	Univ Jena, Inst Allgemeine Bot, Lehrstuhl Pflanzenphysiol, D-07743 Jena, Germany; Russian Acad Sci, Inst Plant Physiol, Moscow 127276, Russia	Friedrich Schiller University of Jena; Russian Academy of Sciences; Timiryazev Institute of Plant Physiology	Oelmuller, R (corresponding author), Univ Jena, Inst Allgemeine Bot, Lehrstuhl Pflanzenphysiol, Dornburger Str 159, D-07743 Jena, Germany.	Ralf.Oelmueller@rz.uni-jena.de	Meurer, Jörg/F-8479-2010; Kusnetsov, Victor/P-9774-2016	Meurer, Jörg/0000-0003-2973-9514; Kusnetsov, Victor/0000-0003-4979-6137				ARCOT SS, 1989, J BIOL CHEM, V264, P2343; Bi WM, 1997, J BIOL CHEM, V272, P26562, DOI 10.1074/jbc.272.42.26562; BOLLE C, 1994, PLANT PHYSIOL, V105, P1355, DOI 10.1104/pp.105.4.1355; Bolle C, 1996, PLANT J, V9, P21, DOI 10.1046/j.1365-313X.1996.09010021.x; BROWN AM, 1993, J BIOL CHEM, V268, P26328; BUCHER P, 1990, J MOL BIOL, V212, P563, DOI 10.1016/0022-2836(90)90223-9; CHODOSH LA, 1988, CELL, V53, P11, DOI 10.1016/0092-8674(88)90483-7; CLAUSMEYER S, 1993, J BIOL CHEM, V268, P13869; DORN A, 1987, CELL, V50, P863, DOI 10.1016/0092-8674(87)90513-7; Fankhauser C, 1997, ANNU REV CELL DEV BI, V13, P203, DOI 10.1146/annurev.cellbio.13.1.203; FILATOV D, 1995, J BIOL CHEM, V270, P25239, DOI 10.1074/jbc.270.42.25239; FRAMSON P, 1993, J BIOL CHEM, V268, P4989; GOLDSMITH ME, 1993, J BIOL CHEM, V268, P5856; GUSTAFSON TA, 1989, P NATL ACAD SCI USA, V86, P2162, DOI 10.1073/pnas.86.7.2162; Hasegawa T, 1996, NUCLEIC ACIDS RES, V24, P3253, DOI 10.1093/nar/24.16.3253; HATAMOCHI A, 1988, J BIOL CHEM, V263, P5940; Herrmann R. G., 1991, Plant molecular biology 2. Proceedings of a NATO Advanced Study Institute, 14-23 May 1990, Elmau, Germany., P411; HSIAO KM, 1994, GENE DEV, V8, P1526, DOI 10.1101/gad.8.13.1526; Hung HL, 1996, J BIOL CHEM, V271, P2323, DOI 10.1074/jbc.271.4.2323; Isaacs RJ, 1996, J BIOL CHEM, V271, P16741, DOI 10.1074/jbc.271.28.16741; JACKSON SM, 1995, J BIOL CHEM, V270, P21445, DOI 10.1074/jbc.270.37.21445; Kim S, 1997, P NATL ACAD SCI USA, V94, P820, DOI 10.1073/pnas.94.3.820; Kusnetsov V, 1996, MOL GEN GENET, V252, P631, DOI 10.1007/BF02173968; KUSNETSOV VV, 1994, PLANTA, V194, P318, DOI 10.1007/BF00197531; LIWEBER M, 1994, J IMMUNOL, V153, P4122; LUBBERSTEDT T, 1994, MOL GEN GENET, V242, P602, DOI 10.1007/BF00285284; MAIRE P, 1989, SCIENCE, V244, P343, DOI 10.1126/science.2711183; MAITY SN, 1988, SCIENCE, V241, P582, DOI 10.1126/science.3399893; Maity SN, 1996, METHOD ENZYMOL, V273, P217; Maity SN, 1998, TRENDS BIOCHEM SCI, V23, P174, DOI 10.1016/S0968-0004(98)01201-8; MCNABB DS, 1995, GENE DEV, V9, P47, DOI 10.1101/gad.9.1.47; Mermelstein F, 1996, GENE DEV, V10, P1033, DOI 10.1101/gad.10.8.1033; OELMULLER R, 1995, MOL GEN GENET, V246, P478, DOI 10.1007/BF00290451; OELMULLER R, 1993, MOL GEN GENET, V237, P261, DOI 10.1007/BF00282808; Roy B, 1996, J BIOL CHEM, V271, P28995, DOI 10.1074/jbc.271.46.28995; SINHA S, 1995, P NATL ACAD SCI USA, V92, P1624, DOI 10.1073/pnas.92.5.1624; Tezuka KI, 1996, J BIOL CHEM, V271, P22713, DOI 10.1074/jbc.271.37.22713; WRIGHT KL, 1994, EMBO J, V13, P4042, DOI 10.1002/j.1460-2075.1994.tb06721.x; Yeung K, 1997, MOL CELL BIOL, V17, P36, DOI 10.1128/MCB.17.1.36; Zwicker J, 1997, TRENDS GENET, V13, P3, DOI 10.1016/S0168-9525(96)30112-1	40	79	91	0	20	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 10	1999	274	50					36009	36014		10.1074/jbc.274.50.36009	http://dx.doi.org/10.1074/jbc.274.50.36009			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	264NG	10585491	hybrid			2022-12-25	WOS:000084187900103
J	Tanner, KG; Kyte, J				Tanner, KG; Kyte, J			Dimerization of the extracellular domain of the receptor for epidermal growth factor containing the membrane-spanning segment in response to treatment with epidermal growth factor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEU ONCOGENE; POINT MUTATION; BINDING-DOMAIN; MIXED MICELLES; EGF RECEPTOR; ACTIVATION; AFFINITY; SPHINGOMYELIN; EXPRESSION; PROTEINS	A recombinant fragment of the human receptor for epidermal growth factor containing both its extracellular domain and its membrane-spanning segment, when dissolved with Triton X-100, was observed to dimerize in response to addition of epidermal growth factor (EGF) even at the lowest concentration of this fragment that could be assayed (4 nM). Consequently, the dissociation constant for the dimer of this fragment is at least 10,000-fold smaller than that for dimers of soluble, recombinant forms of the extracellular domain lacking the membrane-spanning segment. The second-order rate constant for dimerization of the fragment containing the extracellular domain and the membrane-spanning segment was estimated to be greater than 0.3 nM(-1) min(-1), more than 10-fold that of the native enzyme under the same conditions. This result suggests that the cytoplasmic domain of the intact enzyme sterically hinders its dimerization. When EGF is removed from the dimer of the fragment, the rate constant for its dissociation is greater than 0.2 min(-1), more than 40-fold that of the native enzyme. This result suggests that interfaces between cytoplasmic domains of intact EGF receptor impart significant stabilization to the dimer of the enzyme.	Univ Calif San Diego, Dept Chem 0506, La Jolla, CA 92093 USA	University of California System; University of California San Diego	Kyte, J (corresponding author), Univ Calif San Diego, Dept Chem 0506, 9500 Gilman Dr, La Jolla, CA 92093 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007233] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047968] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-07233] Funding Source: Medline; NIGMS NIH HHS [GM-47968] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BARGMANN CI, 1988, P NATL ACAD SCI USA, V85, P5394, DOI 10.1073/pnas.85.15.5394; BARGMANN CI, 1986, CELL, V45, P649, DOI 10.1016/0092-8674(86)90779-8; BLAKE MS, 1984, ANAL BIOCHEM, V136, P175, DOI 10.1016/0003-2697(84)90320-8; BROWN PM, 1994, EUR J BIOCHEM, V225, P223, DOI 10.1111/j.1432-1033.1994.00223.x; CADENA DL, 1993, PROTEIN EXPRES PURIF, V4, P177, DOI 10.1006/prep.1993.1024; CANALS F, 1992, BIOCHEMISTRY-US, V31, P4493, DOI 10.1021/bi00133a016; CHEN WS, 1989, CELL, V59, P33, DOI 10.1016/0092-8674(89)90867-2; Cohen BM, 1996, J BIOL CHEM, V271, P4813; GREENFIELD C, 1989, EMBO J, V8, P4115, DOI 10.1002/j.1460-2075.1989.tb08596.x; GUNTHER N, 1990, J BIOL CHEM, V265, P22082; HURWITZ DR, 1991, J BIOL CHEM, V266, P22035; KUSHNER LM, 1954, J PHYS CHEM-US, V58, P1163, DOI 10.1021/j150522a024; KYTE J, 1995, STRUCTURE PROTEIN CH, P521; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAX I, 1991, J BIOL CHEM, V266, P13828; Lemmon MA, 1997, EMBO J, V16, P281, DOI 10.1093/emboj/16.2.281; Philo JS, 1996, BIOCHEMISTRY-US, V35, P1681, DOI 10.1021/bi9524272; ROBSON RJ, 1979, BIOCHIM BIOPHYS ACTA, V573, P489, DOI 10.1016/0005-2760(79)90223-6; Sherrill JM, 1996, BIOCHEMISTRY-US, V35, P5705, DOI 10.1021/bi9602268; Siegel PM, 1996, P NATL ACAD SCI USA, V93, P8878, DOI 10.1073/pnas.93.17.8878; Tanford C, 1980, HYDROPHOBIC EFFECT, P42; Tanner KG, 1997, BIOCHEMISTRY-US, V36, P14889, DOI 10.1021/bi9706834; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; ULLRICH A, 1984, NATURE, V309, P418, DOI 10.1038/309418a0; WEDEGAERTNER PB, 1989, J BIOL CHEM, V264, P11346; WEINER DB, 1989, NATURE, V339, P230, DOI 10.1038/339230a0; YEDGAR S, 1974, BIOCHIM BIOPHYS ACTA, V363, P98, DOI 10.1016/0005-2736(74)90009-1	27	65	69	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 10	1999	274	50					35985	35990		10.1074/jbc.274.50.35985	http://dx.doi.org/10.1074/jbc.274.50.35985			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	264NG	10585488	hybrid			2022-12-25	WOS:000084187900100
J	Huang, QQ; Fisher, SA; Brozovich, FV				Huang, QQ; Fisher, SA; Brozovich, FV			Forced expression of essential myosin light chain isoforms demonstrates their role in smooth muscle force production	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article								The molecular determinants of the contractile properties of smooth muscle are poorly understood, and have been suggested to be controlled by splice variant expression of the myosin heavy chain near the 25/50-kDa junction (Kelley, C. A., Takahashi, M., Yu, J. H., and Adelstein, R. S. (1993) J. Biol. Chern. 268, 12848-12854) as well as by differences in the expression of an acidic (MLC17a) and a basic (MLC17b) isoform of the 17-kDa essential myosin light chain (Nabeshima, Y., Nonomura, Y., and Fujii-Kuriyama, Y. (1987) J. Biol. Chem. 262, 106508-10612). To investigate the molecular mechanism that regulates the mechanical properties of smooth muscle, we determined the effect of forced expression of MLC17a and MLC17b on the rate of force activation during agonist-stimulated contractions of single cultured chicken embryonic aortic and gizzard smooth muscle cells. Forced expression of MLC17a in aortic smooth muscle cells increased (p < 0.05) the rate of force activation, forced expression of MLC17b in gizzard smooth muscle cells decreased (p < 0.05) the rate of force activation, while forced expression of the endogenous MLC17 isoform had no effect on the rate of force activation. These results demonstrate that MLC17 is a molecular determinant of the contractile properties of smooth muscle. MLC17 could affect the contractile properties of smooth muscle by either changing the stiffness of the myosin lever arm or modulating the rate of a load-dependent step and/or transition in the actomyosin ATPase cycle.	Case Western Reserve Univ, Dept Med Cardiol, Cleveland, OH 44106 USA; Case Western Reserve Univ, Dept Physiol & Biophys, Cleveland, OH 44106 USA	Case Western Reserve University; Case Western Reserve University	Brozovich, FV (corresponding author), Case Western Reserve Univ, Dept Med Cardiol, Cleveland, OH 44106 USA.	fxb9@po.cwru.edu						BOWERS CW, 1993, AM J PHYSIOL, V264, pC229, DOI 10.1152/ajpcell.1993.264.1.C229; Fisher SA, 1997, CIRC RES, V80, P885; FULBRIGHT RM, 1998, BIOPHYS J, V72, pA278; HAI CM, 1999, AM J PHYSIOL, V254, pC99; HARTSHORNE DJ, 1987, PHYSL GASTROINTESTIN, P432; HASEGAWA Y, 1992, J BIOCHEM-TOKYO, V111, P798, DOI 10.1093/oxfordjournals.jbchem.a123839; HOMSHER E, 1993, ADV EXP MED BIOL, V332, P279; Huang QQ, 1999, GENE, V229, P1, DOI 10.1016/S0378-1119(99)00051-7; KELLEY CA, 1993, J BIOL CHEM, V268, P12848; Lauzon AM, 1998, J MUSCLE RES CELL M, V19, P825, DOI 10.1023/A:1005489501357; LOWEY S, 1993, J BIOL CHEM, V268, P20414; MALMQVIST U, 1991, PFLUG ARCH EUR J PHY, V418, P523, DOI 10.1007/BF00370566; Matthew JD, 1998, J BIOL CHEM, V273, P31289, DOI 10.1074/jbc.273.47.31289; NABESHIMA Y, 1987, J BIOL CHEM, V262, P10608; Ogut O, 1999, BIOPHYS J, V76, pA284; Rovner AS, 1997, J MUSCLE RES CELL M, V18, P103, DOI 10.1023/A:1018689102122; Shue GH, 1999, BIOPHYS J, V76, P2361, DOI 10.1016/S0006-3495(99)77393-5; SOMLYO AP, 1994, NATURE, V372, P231, DOI 10.1038/372231a0; SOMLYO AP, 1993, J MUSCLE RES CELL M, V14, P557, DOI 10.1007/BF00141552	19	27	28	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 3	1999	274	49					35095	35098		10.1074/jbc.274.49.35095	http://dx.doi.org/10.1074/jbc.274.49.35095			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	260XW	10574990	hybrid			2022-12-25	WOS:000083979600084
J	Veldhoen, N; Metcalfe, S; Milner, J				Veldhoen, N; Metcalfe, S; Milner, J			A novel exon within the mdm2 gene modulates translation initiation in vitro and disrupts the p53-binding domain of mdm2 protein	ONCOGENE			English	Article						mdm2; p53; regulatory exon; alternative splicing	P53 PROTEIN; ONCOPROTEIN MDM2; MESSENGER-RNAS; EXPRESSION; CELLS; TRANSCRIPTS; EFFICIENCY; MICE; TRANSACTIVATION; AMPLIFICATION	The mdm2 protein interacts with a number of proteins involved in cell growth control. Such interactions favour cell proliferation and may explain the oncogenic potential of mdm2 when over-expressed in cells. Interaction with the tumour suppressor p53 involves the N-terminus of mdm2 and targets p53 for rapid degradation by the ubiquitin pathway, We now describe a novel, highly conserved exon of mdm2 (exon alpha) which includes an in-frame UGA stop codon. Expression of exon alpha disrupts in vitro translation of the p53 binding domain of mdm2. We propose that exon alpha induces translation re-initiation at an internal AUG codon within the mdm2 alpha mRNA isoform. The putative mdm2 alpha protein lacks the N-terminus of mdm2 and shows little, if any, binding capacity for p53. Mdm2 alpha mRNA is expressed in a tissue-specific manner and is observed predominantly in testis and peripheral blood lymphocytes. We propose that mdm2 alpha expression may provide a mechanism for uncoupling mdm2-p53 interaction in certain cell types and/or under specific conditions of cell growth.	Univ York, Dept Biol, YCR Res Grp P53, York YO10 5DD, N Yorkshire, England; Univ Cambridge, Addenbrookes Hosp, Dept Surg, Cambridge CB2 2QQ, England	University of York - UK; Addenbrooke's Hospital; University of Cambridge	Milner, J (corresponding author), Univ York, Dept Biol, YCR Res Grp P53, York YO10 5DD, N Yorkshire, England.							ALMON E, 1993, DEV BIOL, V156, P107, DOI 10.1006/dbio.1993.1062; BARAK Y, 1994, GENE DEV, V8, P1739, DOI 10.1101/gad.8.15.1739; Bottger A, 1997, J MOL BIOL, V269, P744, DOI 10.1006/jmbi.1997.1078; Bruening W, 1996, J BIOL CHEM, V271, P8646, DOI 10.1074/jbc.271.15.8646; CAHILLYSNYDER L, 1987, SOMAT CELL MOLEC GEN, V13, P235, DOI 10.1007/BF01535205; CHEN JD, 1993, MOL CELL BIOL, V13, P4107, DOI 10.1128/MCB.13.7.4107; COOK A, 1990, BRIT J CANCER, V61, P548, DOI 10.1038/bjc.1990.123; Elenbaas B, 1996, MOL MED, V2, P439, DOI 10.1007/BF03401903; FAKHARZADEH SS, 1991, EMBO J, V10, P1565, DOI 10.1002/j.1460-2075.1991.tb07676.x; Freedman DA, 1997, MOL MED, V3, P248, DOI 10.1007/BF03401678; GAMBLE J, 1988, VIROLOGY, V162, P452, DOI 10.1016/0042-6822(88)90486-2; Gellersen B, 1997, MOL ENDOCRINOL, V11, P97, DOI 10.1210/me.11.1.97; GUDAS JM, 1995, CLIN CANCER RES, V1, P71; Haines DS, 1997, LEUKEMIA LYMPHOMA, V26, P227, DOI 10.3109/10428199709051772; HAINES DS, 1994, MOL CELL BIOL, V14, P1171, DOI 10.1128/MCB.14.2.1171; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Honda R, 1997, FEBS LETT, V420, P25, DOI 10.1016/S0014-5793(97)01480-4; Honda R, 1999, EMBO J, V18, P22, DOI 10.1093/emboj/18.1.22; Jones SN, 1996, GENE, V175, P209, DOI 10.1016/0378-1119(96)00151-5; Juven-Gershon T, 1998, MOL CELL BIOL, V18, P3974, DOI 10.1128/MCB.18.7.3974; KAUFMAN RJ, 1987, EMBO J, V6, P187, DOI 10.1002/j.1460-2075.1987.tb04737.x; Kraus A, 1999, INT J CANCER, V80, P930, DOI 10.1002/(SICI)1097-0215(19990315)80:6<930::AID-IJC20>3.3.CO;2-D; Kubbutat MHG, 1998, MOL MED TODAY, V4, P250, DOI 10.1016/S1357-4310(98)01260-X; Kussie PH, 1996, SCIENCE, V274, P948, DOI 10.1126/science.274.5289.948; LENG P, 1995, ONCOGENE, V10, P1275; LUNA RMD, 1995, NATURE, V378, P203; Luna RMDO, 1996, GENOMICS, V33, P352, DOI 10.1006/geno.1996.0210; Lundgren K, 1997, GENE DEV, V11, P714, DOI 10.1101/gad.11.6.714; LUUKKONEN BGM, 1995, J VIROL, V69, P4086, DOI 10.1128/JVI.69.7.4086-4094.1995; Marechal V, 1997, ONCOGENE, V14, P1427, DOI 10.1038/sj.onc.1200967; MARECHAL V, 1994, MOL CELL BIOL, V14, P7414, DOI 10.1128/MCB.14.11.7414; MARTIN K, 1995, NATURE, V375, P691, DOI 10.1038/375691a0; Matsumoto R, 1998, CANCER RES, V58, P609; MAXWELL SA, 1994, ANTICANCER RES, V14, P2541; MCCAUGHAN KK, 1995, P NATL ACAD SCI USA, V92, P5431, DOI 10.1073/pnas.92.12.5431; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; Momand J, 1997, J CELL BIOCHEM, V64, P343; Momand J, 1998, NUCLEIC ACIDS RES, V26, P3453, DOI 10.1093/nar/26.15.3453; OLINER JD, 1993, NATURE, V362, P857, DOI 10.1038/362857a0; OLINER JD, 1992, NATURE, V358, P80, DOI 10.1038/358080a0; OLSON DC, 1993, ONCOGENE, V8, P2353; PADGETT RA, 1986, ANNU REV BIOCHEM, V55, P1119, DOI 10.1146/annurev.bi.55.070186.005351; Piette J, 1997, ONCOGENE, V15, P1001, DOI 10.1038/sj.onc.1201432; Roth J, 1998, EMBO J, V17, P554, DOI 10.1093/emboj/17.2.554; ROTTER V, 1994, SEMIN CANCER BIOL, V5, P229; ROTTER V, 1993, P NATL ACAD SCI USA, V90, P9075, DOI 10.1073/pnas.90.19.9075; Saucedo LJ, 1999, J BIOL CHEM, V274, P8161, DOI 10.1074/jbc.274.12.8161; Shick L, 1997, CELL GROWTH DIFFER, V8, P121; Sigalas I, 1996, NAT MED, V2, P912, DOI 10.1038/nm0896-912; Sun PQ, 1998, SCIENCE, V282, P2270, DOI 10.1126/science.282.5397.2270; Veldhoen N, 1998, ONCOGENE, V16, P1077, DOI 10.1038/sj.onc.1201863; XIAO ZX, 1995, NATURE, V375, P694, DOI 10.1038/375694a0	52	10	13	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 25	1999	18	50					7026	7033		10.1038/sj.onc.1203182	http://dx.doi.org/10.1038/sj.onc.1203182			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	259PH	10597303				2022-12-25	WOS:000083901900009
J	Kivinen, L; Tsubari, M; Haapajarvi, T; Datto, MB; Wang, XF; Laiho, M				Kivinen, L; Tsubari, M; Haapajarvi, T; Datto, MB; Wang, XF; Laiho, M			Ras induces p21(Cip1/Waf1) cyclin kinase inhibitor transcriptionally through Sp1-binding sites	ONCOGENE			English	Article						Ras; p21(Cip1/Waf1); transcriptional activation	TUMOR-SUPPRESSOR GENE; CELL-CYCLE; P21(WAF1/CIP1) EXPRESSION; P53-INDEPENDENT PATHWAY; RETINOBLASTOMA PROTEIN; COOPERATING ONCOGENES; ECTOPIC EXPRESSION; LEUKEMIC-CELLS; PC12 CELLS; 3T3 CELLS	p21(Cip1/WafI) cyclin-dependent kinase inhibitor (p21) is inducible by Raf and mitogen-activated protein kinase kinase (MAPKK), but the level of regulation is unknown. We show here by conditional and transient Ras-expression models that Ras induces p21, Induction of p21 in conditionally Ras-expressing cells is posttranscriptional utilizing mitogen-activated protein kinase (MAPK) pathway. Transient, high-level Ras-expression induces transcriptional activation of p21 mediated by a GC-rich region in p21 promoter -83-54 bp relative to the transcription initiation site containing binding sites for Spl-family transcription factors. Mutation of either Sp1-binding site 2 or 4 in this region decreases the magnitude of induction of promoter activity by Ras, but only the simultaneous mutation of both sites abolishes fully the induction. Electrophoretic mobility shift assays using an oligonucleotide corresponding to Spl-binding site 2 indicate that both Spl and Sp3 transcription factors bind to this region. The results demonstrate that the central cytosolic growth regulator Ras is a potent transcriptional and posttranscriptional inducer of the nuclear growth inhibitor p21.	Univ Helsinki, Dept Virol, Haartman Inst, FIN-00014 Helsinki, Finland; Duke Univ, Med Ctr, Dept Pharmacol, Durham, NC 27710 USA	University of Helsinki; Duke University	Laiho, M (corresponding author), Univ Helsinki, Dept Virol, Haartman Inst, POB 21,Haartmaninkatu 3, FIN-00014 Helsinki, Finland.			Taipale, Minna/0000-0002-1905-2551				Aktas H, 1997, MOL CELL BIOL, V17, P3850, DOI 10.1128/MCB.17.7.3850; ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; Arber N, 1996, ONCOGENE, V12, P1903; BARSAGI D, 1985, CELL, V42, P841, DOI 10.1016/0092-8674(85)90280-6; BENITO M, 1991, SCIENCE, V253, P565, DOI 10.1126/science.1857988; Biggs JR, 1996, J BIOL CHEM, V271, P901, DOI 10.1074/jbc.271.2.901; BRUGAROLAS J, 1995, NATURE, V377, P552, DOI 10.1038/377552a0; Cha HH, 1998, J BIOL CHEM, V273, P1998, DOI 10.1074/jbc.273.4.1998; CHEN JJ, 1995, NATURE, V374, P386, DOI 10.1038/374386a0; Chin YE, 1996, SCIENCE, V272, P719, DOI 10.1126/science.272.5262.719; Chuang LSH, 1997, SCIENCE, V277, P1996, DOI 10.1126/science.277.5334.1996; Cram EJ, 1998, J BIOL CHEM, V273, P2008, DOI 10.1074/jbc.273.4.2008; DATTO MB, 1995, J BIOL CHEM, V270, P28623, DOI 10.1074/jbc.270.48.28623; DATTO MB, 1995, P NATL ACAD SCI USA, V92, P5545, DOI 10.1073/pnas.92.12.5545; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; DOBROWOLSKI S, 1994, MOL CELL BIOL, V14, P5441, DOI 10.1128/MCB.14.8.5441; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Englert C, 1997, CANCER RES, V57, P1429; FLORESROZAS H, 1994, P NATL ACAD SCI USA, V91, P8655, DOI 10.1073/pnas.91.18.8655; FRANZA BR, 1986, CELL, V44, P409, DOI 10.1016/0092-8674(86)90462-9; Funaoka K, 1997, BIOCHEM BIOPH RES CO, V236, P79, DOI 10.1006/bbrc.1997.6909; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; Haapajarvi T, 1997, MOL CELL BIOL, V17, P3074, DOI 10.1128/MCB.17.6.3074; Hiyama H, 1997, ONCOGENE, V14, P2533, DOI 10.1038/sj.onc.1201080; Hunter T, 1997, CELL, V88, P333, DOI 10.1016/S0092-8674(00)81872-3; KEARSEY JM, 1995, ONCOGENE, V11, P1675; Kivinen L, 1996, CELL GROWTH DIFFER, V7, P1705; KIVINEN L, 1993, ONCOGENE, V8, P2703; LaBaer J, 1997, GENE DEV, V11, P847, DOI 10.1101/gad.11.7.847; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; Leone G, 1997, NATURE, V387, P422, DOI 10.1038/387422a0; Li JM, 1998, NUCLEIC ACIDS RES, V26, P2449, DOI 10.1093/nar/26.10.2449; LIU HS, 1992, CANCER RES, V52, P983; LIU JJ, 1995, MOL CELL BIOL, V15, P3654; Liu M, 1996, GENE DEV, V10, P142, DOI 10.1101/gad.10.2.142; Liu M, 1996, J BIOL CHEM, V271, P31723, DOI 10.1074/jbc.271.49.31723; Liu Y, 1996, CANCER RES, V56, P31; Lloyd AC, 1997, GENE DEV, V11, P663, DOI 10.1101/gad.11.5.663; MACLEOD KF, 1995, GENE DEV, V9, P935, DOI 10.1101/gad.9.8.935; MAKELA TP, 1992, SCIENCE, V256, P373, DOI 10.1126/science.256.5055.373; MICHIELI P, 1994, CANCER RES, V54, P3391; Michieli P, 1996, ONCOGENE, V12, P775; Missero C, 1996, GENE DEV, V10, P3065, DOI 10.1101/gad.10.23.3065; Olson MF, 1998, NATURE, V394, P295, DOI 10.1038/28425; Owen GI, 1998, J BIOL CHEM, V273, P10696, DOI 10.1074/jbc.273.17.10696; Peeper DS, 1997, NATURE, V386, P177, DOI 10.1038/386177a0; Pitkanen K, 1998, ONCOGENE, V16, P459, DOI 10.1038/sj.onc.1201528; Prabhu S, 1997, MOL CELL BIOL, V17, P5888, DOI 10.1128/MCB.17.10.5888; Prowse DM, 1997, J BIOL CHEM, V272, P1308, DOI 10.1074/jbc.272.2.1308; RIDLEY AJ, 1988, EMBO J, V7, P1635, DOI 10.1002/j.1460-2075.1988.tb02990.x; RUSSO T, 1995, J BIOL CHEM, V270, P29386, DOI 10.1074/jbc.270.49.29386; SCHWALLER J, 1995, J CLIN INVEST, V95, P973, DOI 10.1172/JCI117806; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Sewing A, 1997, MOL CELL BIOL, V17, P5588, DOI 10.1128/MCB.17.9.5588; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Somasundaram K, 1997, NATURE, V389, P187, DOI 10.1038/38291; Takuwa N, 1997, MOL CELL BIOL, V17, P5348, DOI 10.1128/MCB.17.9.5348; Winston JT, 1996, ONCOGENE, V12, P127; Woods D, 1997, MOL CELL BIOL, V17, P5598, DOI 10.1128/MCB.17.9.5598; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; Yan GZ, 1997, J NEUROSCI, V17, P6122; Zauberman A, 1997, ONCOGENE, V15, P1705, DOI 10.1038/sj.onc.1201348; Zeng YX, 1997, NAT GENET, V15, P78, DOI 10.1038/ng0197-78; Zeng YX, 1996, ONCOGENE, V12, P1557	65	60	61	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 4	1999	18	46					6252	6261		10.1038/sj.onc.1203000	http://dx.doi.org/10.1038/sj.onc.1203000			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	260DK	10597223				2022-12-25	WOS:000083934100008
J	Eguchi, S; Iwasaki, H; Ueno, H; Frank, GD; Motley, ED; Eguchi, K; Marumo, F; Hirata, Y; Inagami, T				Eguchi, S; Iwasaki, H; Ueno, H; Frank, GD; Motley, ED; Eguchi, K; Marumo, F; Hirata, Y; Inagami, T			Intracellular signaling of angiotensin II-induced p70 S6 kinase phosphorylation at Ser(411) in vascular smooth muscle cells - Possible requirement of epidermal growth factor receptor, Ras, extracellular signal-regulated kinase, and Akt	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; BETA-GAMMA-SUBUNITS; PHOSPHATIDYLINOSITOL 3-KINASE; COUPLED RECEPTORS; TYROSINE KINASE; IN-VIVO; PHOSPHOINOSITIDE 3-KINASE; CARDIAC-HYPERTROPHY; EGF RECEPTOR; PATHWAYS	Activation of p70 S6 kinase (p70(S6K)) by growth factors requires multiple signal inputs involving phosphoinositide 3-kinase (PI3K), its effector Akt, and an unidentified kinase that phosphorylates Ser/Thr residues (Ser(411), Ser(418), Ser(424), and Thr(421)) clustered at its autoinhibitory domain. However, the mechanism by which G protein-coupled receptors activate p70(S6K) remains largely uncertain, By using vascular smooth muscle cells in which we have demonstrated Ras/extracellular signal-regulated kinase (ERK) activation through Ca2+- dependent, epidermal growth factor (EGF) receptor transactivation by G(q)-coupled angiotensin II (Ang II) receptor, we present a unique cross-talk required for Ser(411) phosphorylation of p70(S6K) by Ang II. Both p70(S6K) Ser(411) and Akt Ser(473) phosphorylation by Ang II appear to involve EGF receptor transactivation and were inhibited by dominant-negative Ras, whereas the phosphorylation of p70(S6K) and ERK but not Akt was sensitive to the MEK inhibitor. By contrast, the phosphorylation of p70(S6K) and Akt but not ERK was sensitive to PI3K inhibitors. Similar inhibitory pattern on these phosphorylation sites by EGF but not insulin was observed. Taken together with the inhibition of Ang II-induced p70(S6K) activation by dominant-negative Ras and the MEK inhibitor, we conclude that Ang II-initiated activation of p70(S6K) requires both ERK cascade and PI3K/Akt cascade that bifurcate at the point of EGF receptor-dependent Ras activation.	Vanderbilt Univ, Sch Med, Dept Biochem, Nashville, TN 37232 USA; Tokyo Med & Dent Univ, Dept Internal Med 2, Tokyo 1138519, Japan; Kyushu Univ, Sch Med, Dept Cardiol, Fukuoka 8128582, Japan; Meharry Med Coll, Dept Anat & Physiol, Nashville, TN 37208 USA	Vanderbilt University; Tokyo Medical & Dental University (TMDU); Kyushu University; Meharry Medical College	Eguchi, S (corresponding author), Vanderbilt Univ, Sch Med, Dept Biochem, Nashville, TN 37232 USA.				NHLBI NIH HHS [HL03220, HL-58205, HL-35323] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL058205, R01HL058205, R01HL035323, K08HL003220] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Akimoto K, 1998, BIOCHEM J, V335, P417, DOI 10.1042/bj3350417; Alessi DR, 1998, CURR OPIN GENET DEV, V8, P55, DOI 10.1016/S0959-437X(98)80062-2; ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; Alessi DR, 1998, CURR BIOL, V8, P69, DOI 10.1016/S0960-9822(98)70037-5; Avruch J, 1998, MOL CELL BIOCHEM, V182, P31, DOI 10.1023/A:1006823109415; BALLOU LM, 1991, NATURE, V349, P348, DOI 10.1038/349348a0; Berk BC, 1999, J AM SOC NEPHROL, V10, pS62; Bokemeyer D, 1998, HYPERTENSION, V32, P661, DOI 10.1161/01.HYP.32.4.661; Brinson AE, 1998, J BIOL CHEM, V273, P1711, DOI 10.1074/jbc.273.3.1711; BROWN EJ, 1995, NATURE, V377, P441, DOI 10.1038/377441a0; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; Burnett PE, 1998, P NATL ACAD SCI USA, V95, P1432, DOI 10.1073/pnas.95.4.1432; Chou MM, 1996, CELL, V85, P573, DOI 10.1016/S0092-8674(00)81257-X; CHOU MM, 1995, CURR OPIN CELL BIOL, V7, P806, DOI 10.1016/0955-0674(95)80064-6; CHUNG JK, 1994, NATURE, V370, P71, DOI 10.1038/370071a0; Conus NM, 1998, J BIOL CHEM, V273, P4776, DOI 10.1074/jbc.273.8.4776; Datta K, 1996, J BIOL CHEM, V271, P30835, DOI 10.1074/jbc.271.48.30835; Daub H, 1996, NATURE, V379, P557, DOI 10.1038/379557a0; Daub H, 1997, EMBO J, V16, P7032, DOI 10.1093/emboj/16.23.7032; DellaRocca GJ, 1997, J BIOL CHEM, V272, P19125, DOI 10.1074/jbc.272.31.19125; Dennis PB, 1998, J BIOL CHEM, V273, P14845, DOI 10.1074/jbc.273.24.14845; Dikic I, 1996, NATURE, V383, P547, DOI 10.1038/383547a0; Downward J, 1998, CURR OPIN CELL BIOL, V10, P262, DOI 10.1016/S0955-0674(98)80149-X; EGUCHI S, 1994, ENDOCRINOLOGY, V134, P222, DOI 10.1210/en.134.1.222; Eguchi S, 1999, HYPERTENSION, V33, P201, DOI 10.1161/01.HYP.33.1.201; Eguchi S, 1998, J BIOL CHEM, V273, P8890, DOI 10.1074/jbc.273.15.8890; Eguchi S, 1996, J BIOL CHEM, V271, P14169, DOI 10.1074/jbc.271.24.14169; Eguchi S, 1999, EUR J PHARMACOL, V376, P203, DOI 10.1016/S0014-2999(99)00357-X; Foschi M, 1997, EMBO J, V16, P6439, DOI 10.1093/emboj/16.21.6439; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; GIASSON E, 1995, J BIOL CHEM, V270, P5225, DOI 10.1074/jbc.270.10.5225; Graves LM, 1997, J BIOL CHEM, V272, P1920, DOI 10.1074/jbc.272.3.1920; Griendling KK, 1997, HYPERTENSION, V29, P366, DOI 10.1161/01.HYP.29.1.366; Gutkind JS, 1998, J BIOL CHEM, V273, P1839, DOI 10.1074/jbc.273.4.1839; Herrlich A, 1998, P NATL ACAD SCI USA, V95, P8985, DOI 10.1073/pnas.95.15.8985; Inagami T, 1999, J AM SOC NEPHROL, V10, pS57; KauffmanZeh A, 1997, NATURE, V385, P544, DOI 10.1038/385544a0; Khwaja A, 1997, EMBO J, V16, P2783, DOI 10.1093/emboj/16.10.2783; Kitamura T, 1998, MOL CELL BIOL, V18, P3708, DOI 10.1128/MCB.18.7.3708; Klippel A, 1996, MOL CELL BIOL, V16, P4117; Kohn AD, 1996, J BIOL CHEM, V271, P21920, DOI 10.1074/jbc.271.36.21920; Kohn AD, 1998, J BIOL CHEM, V273, P11937, DOI 10.1074/jbc.273.19.11937; Koyama H, 1998, CIRC RES, V82, P713, DOI 10.1161/01.RES.82.6.713; Laser M, 1998, J BIOL CHEM, V273, P24610, DOI 10.1074/jbc.273.38.24610; Lenormand P, 1996, J BIOL CHEM, V271, P15762, DOI 10.1074/jbc.271.26.15762; LEV S, 1995, NATURE, V376, P737, DOI 10.1038/376737a0; LEVITZKI A, 1995, SCIENCE, V267, P1782, DOI 10.1126/science.7892601; LINSEMAN DA, 1995, J BIOL CHEM, V270, P12563, DOI 10.1074/jbc.270.21.12563; LopezIlasaca M, 1997, SCIENCE, V275, P394, DOI 10.1126/science.275.5298.394; Luttrell LM, 1997, J BIOL CHEM, V272, P4637, DOI 10.1074/jbc.272.7.4637; Luttrell LM, 1996, J BIOL CHEM, V271, P19443, DOI 10.1074/jbc.271.32.19443; Marte BM, 1997, CURR BIOL, V7, P63, DOI 10.1016/S0960-9822(06)00028-5; MING XF, 1994, NATURE, V371, P426, DOI 10.1038/371426a0; MUKHOPADHYAY NK, 1992, J BIOL CHEM, V267, P3325; Murga C, 1998, J BIOL CHEM, V273, P19080, DOI 10.1074/jbc.273.30.19080; MURPHY TJ, 1991, NATURE, V351, P233, DOI 10.1038/351233a0; Papst PJ, 1998, J BIOL CHEM, V273, P15077, DOI 10.1074/jbc.273.24.15077; PETRITSCH C, 1995, EUR J BIOCHEM, V230, P431, DOI 10.1111/j.1432-1033.1995.0431h.x; Polakiewicz RD, 1998, J BIOL CHEM, V273, P23534, DOI 10.1074/jbc.273.36.23534; Pullen N, 1997, FEBS LETT, V410, P78, DOI 10.1016/S0014-5793(97)00323-2; Pullen N, 1998, SCIENCE, V279, P707, DOI 10.1126/science.279.5351.707; RODRIGUEZ VP, 1994, NATURE, V370, P527; Rosen LB, 1996, P NATL ACAD SCI USA, V93, P1113, DOI 10.1073/pnas.93.3.1113; Sabri A, 1998, CIRC RES, V83, P841, DOI 10.1161/01.RES.83.8.841; SADOSHIMA J, 1995, CIRC RES, V77, P1040, DOI 10.1161/01.RES.77.6.1040; SAKAUE M, 1995, MOL CELL BIOL, V15, P379, DOI 10.1128/MCB.15.1.379; SASAKI K, 1991, NATURE, V351, P230, DOI 10.1038/351230a0; Saward L, 1997, CIRC RES, V81, P249, DOI 10.1161/01.RES.81.2.249; Schmitz U, 1998, CIRC RES, V82, P1272, DOI 10.1161/01.RES.82.12.1272; Scott PH, 1998, P NATL ACAD SCI USA, V95, P7772, DOI 10.1073/pnas.95.13.7772; Scott PH, 1997, FEBS LETT, V409, P171, DOI 10.1016/S0014-5793(97)00500-0; Servant MJ, 1996, J BIOL CHEM, V271, P16047, DOI 10.1074/jbc.271.27.16047; Sharma PM, 1998, J BIOL CHEM, V273, P18528, DOI 10.1074/jbc.273.29.18528; Takahashi T, 1999, AM J PHYSIOL-HEART C, V276, pH1927, DOI 10.1152/ajpheart.1999.276.6.H1927; Thomas G, 1997, CURR OPIN CELL BIOL, V9, P782, DOI 10.1016/S0955-0674(97)80078-6; TIMMERMANS PBMWM, 1993, PHARMACOL REV, V45, P205; Ueno H, 1997, ARTERIOSCL THROM VAS, V17, P898, DOI 10.1161/01.ATV.17.5.898; Ushio-Fukai M, 1998, J BIOL CHEM, V273, P15022, DOI 10.1074/jbc.273.24.15022; van Weering DHJ, 1998, MOL CELL BIOL, V18, P1802, DOI 10.1128/MCB.18.4.1802; Welch H, 1998, J BIOL CHEM, V273, P11248, DOI 10.1074/jbc.273.18.11248; Weng QP, 1998, J BIOL CHEM, V273, P16621, DOI 10.1074/jbc.273.26.16621; Wilson M, 1996, J BIOL CHEM, V271, P8537, DOI 10.1074/jbc.271.15.8537; Yamakawa T, 1998, HYPERTENSION, V31, P248, DOI 10.1161/01.HYP.31.1.248; Yan J, 1998, J BIOL CHEM, V273, P24052, DOI 10.1074/jbc.273.37.24052; Zwick E, 1997, J BIOL CHEM, V272, P24767, DOI 10.1074/jbc.272.40.24767	85	154	159	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 24	1999	274	52					36843	36851		10.1074/jbc.274.52.36843	http://dx.doi.org/10.1074/jbc.274.52.36843			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	267WR	10601235	hybrid			2022-12-25	WOS:000084382700006
J	Kanaani, J; Lissin, D; Kash, SF; Baekkeskov, S				Kanaani, J; Lissin, D; Kash, SF; Baekkeskov, S			The hydrophilic isoform of glutamate decarboxylase, GAD67, is targeted to membranes and nerve terminals independent of dimerization with the hydrophobic membrane-anchored isoform, GAD65	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GAMMA-AMINOBUTYRIC-ACID; PANCREATIC BETA-CELLS; 67-KDA ISOFORM; 65-KDA ISOFORM; GOLGI-COMPLEX; CLEFT-PALATE; BINDING-SITE; 2 FORMS; RAT; BRAIN	GAD67, the larger isoform of the gamma-aminobutyric acid-synthesizing enzyme glutamic acid decarboxylase, is a hydrophilic soluble molecule, postulated to localize at nerve terminals and membrane compartments by heterodimerization with the smaller membrane-anchored isoform GAD65. We here show that the dimerization region in GAD65 is distinct from the NH2-terminal membrane-anchoring region and that a membrane anchoring GAD65 subunit can indeed target a soluble subunit to membrane compartments by dimerization. However, only a fraction of membrane-bound GAD67 is engaged in a heterodimer with GAD65 in rat brain. Furthermore, in GAD65-/- mouse brain, GAD67, which no longer partitions into the Triton X-114 detergent phase, still anchors to membranes at similar levels as in wild-type mice. Similarly, in primary cultures of neurons derived from GAD65-/- mice, GAD67 is targeted to nerve terminals, where it co-localizes with the synaptic vesicle marker SV2, Thus, axonal targeting and membrane anchoring is an intrinsic property of GAD67 and does not require GAD65. The results suggest that three distinct moieties of glutamate decarboxylase localize to membrane compartments, an amphiphilic GAD65 homodimer, an amphiphilic GAD65/67 heterodimer, tethered to membranes via the GAD65 subunit, and a hydrophilic GAD67 homodimer, which associates with membranes by a distinct mechanism.	Univ Calif San Francisco, Hormone Res Inst, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Microbiol Immunol, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Psychiat, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Baekkeskov, S (corresponding author), Univ Calif San Francisco, Hormone Res Inst, 513 Parnassus Ave, San Francisco, CA 94143 USA.			Baekkeskov, Steinunn/0000-0003-0878-3188	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK041822] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK41822, DK47043] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Asada H, 1997, P NATL ACAD SCI USA, V94, P6496, DOI 10.1073/pnas.94.12.6496; BAEKKESKOV S, 1990, NATURE, V347, P151, DOI 10.1038/347151a0; BORDIER C, 1981, J BIOL CHEM, V256, P1604; BREWER GJ, 1993, J NEUROSCI RES, V35, P567, DOI 10.1002/jnr.490350513; BU DF, 1992, P NATL ACAD SCI USA, V89, P2115, DOI 10.1073/pnas.89.6.2115; BUCKLEY K, 1985, J CELL BIOL, V100, P1284, DOI 10.1083/jcb.100.4.1284; CHANG YC, 1988, J NEUROSCI, V8, P2123; CHRISTGAU S, 1991, J BIOL CHEM, V266, P21257; CHRISTGAU S, 1992, J CELL BIOL, V118, P309, DOI 10.1083/jcb.118.2.309; Condie BG, 1997, P NATL ACAD SCI USA, V94, P11451, DOI 10.1073/pnas.94.21.11451; DIRKX R, 1995, J BIOL CHEM, V270, P2241, DOI 10.1074/jbc.270.5.2241; ERLANDER MG, 1991, NEUROCHEM RES, V16, P215, DOI 10.1007/BF00966084; ERLANDER MG, 1991, NEURON, V7, P91, DOI 10.1016/0896-6273(91)90077-D; ESCLAPEZ M, 1994, J NEUROSCI, V14, P1834, DOI 10.1523/JNEUROSCI.14-03-01834.1994; Hensch TK, 1998, SCIENCE, V282, P1504, DOI 10.1126/science.282.5393.1504; ITOH M, 1981, NEUROCHEM RES, V6, P1283, DOI 10.1007/BF00964349; Kash SF, 1997, P NATL ACAD SCI USA, V94, P14060, DOI 10.1073/pnas.94.25.14060; Kash SF, 1999, P NATL ACAD SCI USA, V96, P1698, DOI 10.1073/pnas.96.4.1698; KAUFMAN DL, 1991, J NEUROCHEM, V56, P720, DOI 10.1111/j.1471-4159.1991.tb08211.x; KAUFMAN DL, 1986, SCIENCE, V232, P1138, DOI 10.1126/science.3518061; KIM J, 1993, DIABETES, V42, P1799, DOI 10.2337/diabetes.42.12.1799; LEGAY F, 1987, J NEUROCHEM, V48, P1022, DOI 10.1111/j.1471-4159.1987.tb05620.x; LESTER RAJ, 1989, MOL PHARMACOL, V35, P565; MARTIN DL, 1991, J NEUROSCI, V11, P2725; MARTIN DL, 1993, J NEUROCHEM, V60, P395, DOI 10.1111/j.1471-4159.1993.tb03165.x; MICHALIK M, 1993, DIABETES, V42, P1506, DOI 10.2337/diabetes.42.10.1506; MILLER LP, 1980, BRAIN RES BULL, V5, P89, DOI 10.1016/0361-9230(80)90014-3; Namchuk M, 1997, J BIOL CHEM, V272, P1548, DOI 10.1074/jbc.272.3.1548; OKADA Y, 1976, SCIENCE, V194, P620, DOI 10.1126/science.185693; Qu KB, 1998, PROTEIN SCI, V7, P1092, DOI 10.1002/pro.5560070503; REETZ A, 1991, EMBO J, V10, P1275, DOI 10.1002/j.1460-2075.1991.tb08069.x; RICHTER W, 1993, P NATL ACAD SCI USA, V90, P2832, DOI 10.1073/pnas.90.7.2832; Schwartz HL, 1999, J MOL BIOL, V287, P983, DOI 10.1006/jmbi.1999.2655; Sheikh SN, 1996, J NEUROCHEM, V66, P2082; SHI YG, 1994, J CELL BIOL, V124, P927, DOI 10.1083/jcb.124.6.927; Sloviter RS, 1996, J COMP NEUROL, V373, P593; SOLIMENA M, 1993, P NATL ACAD SCI USA, V90, P3073, DOI 10.1073/pnas.90.7.3073; SOLIMENA M, 1994, J CELL BIOL, V126, P331, DOI 10.1083/jcb.126.2.331; SOLIMENA M, 1990, NEW ENGL J MED, V322, P1555, DOI 10.1056/NEJM199005313222202; Sukhareva B S, 1994, Mol Biol (Mosk), V28, P1407; Zekzer D, 1998, J CLIN INVEST, V101, P68, DOI 10.1172/JCI119878	41	53	56	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 24	1999	274	52					37200	37209		10.1074/jbc.274.52.37200	http://dx.doi.org/10.1074/jbc.274.52.37200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	267WR	10601283	hybrid			2022-12-25	WOS:000084382700054
J	Fyfe, GK; Zhang, P; Canessa, CM				Fyfe, GK; Zhang, P; Canessa, CM			The second hydrophobic domain contributes to the kinetic properties of epithelial sodium channels	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SENSITIVE NA+ CHANNEL; MEMBRANE TOPOLOGY; AMILORIDE; SUBUNITS; MUTATION; RESIDUES	The epithelial sodium channel (ENaC) is the prototype of a new class of ion channels known as the ENaC/Deg family. The hallmarks of ENaC are a high selectivity for Na+, block by amiloride, small conductance, and slow kinetics that are voltage-independent. We have investigated the contribution of the second hydrophobic domain of each of the homologous subunits alpha, beta, and gamma to the kinetic properties of ENaC. Chimeric subunits were constructed between alpha and beta subunits (alpha-beta) and between gamma and beta subunits (gamma-beta), Chimeric and wild-type subunits were expressed in various combinations in Xenopus oocytes. Analysis of whole-cell and unitary currents made it possible to correlate functional properties with specific sequences in the subunits. Functional channels were generated without the second transmembrane domain from a subunits, indicating that it is not essential to form functional pores. The open probability and kinetics varied with the different channels and were influenced by the second hydrophobic domains. Amiloride affinity, Li+/Na+ selectivity, and single channel conductance were also affected by this segment.	Yale Univ, Sch Med, Dept Cellular & Mol Physiol, New Haven, CT 06520 USA	Yale University	Canessa, CM (corresponding author), Yale Univ, Sch Med, Dept Cellular & Mol Physiol, 333 Cedar St, New Haven, CT 06520 USA.	cecilia.canessa@yale.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL055007] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK054062] Funding Source: NIH RePORTER; NHLBI NIH HHS [I-P50HL55007] Funding Source: Medline; NIDDK NIH HHS [5-RO1-DK54062] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Adams CM, 1998, J CELL BIOL, V140, P143, DOI 10.1083/jcb.140.1.143; CANESSA CM, 1994, NATURE, V367, P463, DOI 10.1038/367463a0; CANESSA CM, 1994, AM J PHYSIOL-CELL PH, V267, pC1682, DOI 10.1152/ajpcell.1994.267.6.C1682; Coscoy S, 1999, J BIOL CHEM, V274, P10129, DOI 10.1074/jbc.274.15.10129; Fuller CM, 1997, BIOPHYS J, V72, P1622, DOI 10.1016/S0006-3495(97)78808-8; Fyfe GK, 1998, J GEN PHYSIOL, V112, P423, DOI 10.1085/jgp.112.4.423; GarciaAnoveros J, 1996, CURR BIOL, V6, P541, DOI 10.1016/S0960-9822(02)00537-7; Grunder S, 1997, EMBO J, V16, P899, DOI 10.1093/emboj/16.5.899; Kellenberger S, 1999, P NATL ACAD SCI USA, V96, P4170, DOI 10.1073/pnas.96.7.4170; Kellenberger S, 1999, J GEN PHYSIOL, V114, P13, DOI 10.1085/jgp.114.1.13; LINGUEGLIA E, 1995, NATURE, V378, P730, DOI 10.1038/378730a0; McNicholas CM, 1997, J GEN PHYSIOL, V109, P681, DOI 10.1085/jgp.109.6.681; RENARD S, 1994, J BIOL CHEM, V269, P12981; Schild L, 1997, J GEN PHYSIOL, V109, P15, DOI 10.1085/jgp.109.1.15; SCHILD L, 1995, P NATL ACAD SCI USA, V92, P5699, DOI 10.1073/pnas.92.12.5699; SNYDER PM, 1994, J BIOL CHEM, V269, P24379; SUI J, 1995, NPO ANAL PROGRAM; Waldmann R, 1998, CURR OPIN NEUROBIOL, V8, P418, DOI 10.1016/S0959-4388(98)80070-6; WALDMANN R, 1995, J BIOL CHEM, V270, P11735, DOI 10.1074/jbc.270.20.11735	19	15	15	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 17	1999	274	51					36415	36421		10.1074/jbc.274.51.36415	http://dx.doi.org/10.1074/jbc.274.51.36415			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	266AV	10593937	hybrid			2022-12-25	WOS:000084279200056
J	Katz, SS; Weinrauch, Y; Munford, RS; Elsbach, P; Weiss, J				Katz, SS; Weinrauch, Y; Munford, RS; Elsbach, P; Weiss, J			Deacylation of lipopolysaccharide in whole Escherichia coli during destruction by cellular and extracellular components of a rabbit peritoneal inflammatory exudate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SALMONELLA-TYPHIMURIUM LIPOPOLYSACCHARIDES; PERMEABILITY-INCREASING PROTEIN; BACTERIAL LIPOPOLYSACCHARIDES; ACYLOXYACYL HYDROLASE; LEUKOCYTE ENZYME; APOPTOTIC CELLS; OUTER-MEMBRANE; HUMAN-SERUM; LIPID-A; ENDOTOXIN	Deacylation of purified lipopolysaccharides (LPS) markedly reduces its toxicity toward mammals, However, the biological significance of LPS deacylation during infection of the mammalian host is uncertain, particularly because the ability of acyloxyacyl hydrolase, the leukocyte enzyme that deacylates purified LPS, to attack LPS residing in the bacterial cell envelope has not been established, We recently showed that the cellular and extracellular components of a rabbit sterile inflammatory exudate are capable of extensive and selective removal of secondary acyl chains from purified LPS, We now report that LPS as a constituent of the bacterial envelope is also subject to deacylation in the same inflammatory setting, Using Escherichia coli LCD25, a strain that exclusively incorporates radiolabeled acetate into fatty acids, we quantitated LPS deacylation as the loss of radiolabeled secondary (laurate and myristate) and primary fatty acids (5-hydroxymyristate) from the LPS backbone. Isolated mononuclear cells and neutrophils removed 50% and 20-30%, respectively, of the secondary acyl chains of the LPS of ingested whole bacteria. When bacteria were killed extracellularly during incubation with ascitic fluid, no LPS deacylation occurred, In this setting, the addition of neutrophils had no effect, but addition of mononuclear cells resulted in removal of >40% of the secondary acyl chains by 20 h, Deacylation of LPS was always restricted to the secondary acyl chains. Thus, in an inflammatory exudate, primarily in mononuclear phagocytes, the LPS in whole bacteria undergoes substantial and selective acyloxyacyl hydrolase-like deacylation, both after phagocytosis of intact bacteria and after uptake of LPS shed from extracellularly killed bacteria, This study demonstrates for the first time that the destruction of Gram-negative bacteria by a mammalian host is not restricted to degradation of phospholipids, protein, and RNA, but also includes extensive deacylation of the envelope LPS.	NYU, Sch Med, Dept Microbiol, New York, NY 10016 USA; Univ Texas, SW Med Ctr, Dept Internal Med, Dallas, TX USA; Univ Texas, SW Med Ctr, Dept Microbiol, Dallas, TX USA; Univ Iowa, Sch Med, Dept Med & Microbiol, Inflammat Program, Iowa City, IA 52242 USA	New York University; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Iowa	Elsbach, P (corresponding author), NYU, Sch Med, Dept Microbiol, 550 1St Ave, New York, NY 10016 USA.			Weiss, Jerrold/0000-0003-1476-4485; Katz, Seth/0000-0001-8941-950X	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R56AI018188, R01AI018188, R37AI018188] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK005472] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 18188] Funding Source: Medline; NIDDK NIH HHS [R37 DK 05472] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bligh E., 1959, CAN J BIOCH PHYSL, V37, P11; CRONAN JE, 1973, CHEM PHYS LIPIDS, V11, P196, DOI 10.1016/0009-3084(73)90019-4; DEDRICK RL, 1995, INFECT IMMUN, V63, P1362, DOI 10.1128/IAI.63.4.1362-1368.1995; Devitt A, 1998, NATURE, V392, P505, DOI 10.1038/33169; DEVOE IW, 1976, J BACTERIOL, V125, P258, DOI 10.1128/JB.125.1.258-266.1976; DUNCAN RL, 1984, J IMMUNOL, V132, P1416; DUNCAN RL, 1986, J IMMUNOL, V136, P2924; ELSBACH P, 1973, J BACTERIOL, V115, P490, DOI 10.1128/JB.115.2.490-497.1973; ERWIN AL, 1991, LAB INVEST, V65, P138; ERWIN AL, 1992, BACTERIAL ENDOTOXIC, V1, P405; Fadok VA, 1998, J CLIN INVEST, V101, P890, DOI 10.1172/JCI1112; FREUDENBERG MA, 1984, REV INFECT DIS, V6, P483; FREUDENBERG MA, 1991, MICROB PATHOGENESIS, V10, P93, DOI 10.1016/0882-4010(91)90070-Q; GE YM, 1994, J INFECT DIS, V169, P95, DOI 10.1093/infdis/169.1.95; HALL CL, 1983, P NATL ACAD SCI-BIOL, V80, P6671, DOI 10.1073/pnas.80.21.6671; HANTKE K, 1973, EUR J BIOCHEM, V34, P284, DOI 10.1111/j.1432-1033.1973.tb02757.x; HARRIS HW, 1993, J CLIN INVEST, V91, P1028, DOI 10.1172/JCI116259; Iovine NM, 1997, P NATL ACAD SCI USA, V94, P10973, DOI 10.1073/pnas.94.20.10973; Katz SS, 1996, INFECT IMMUN, V64, P3592, DOI 10.1128/IAI.64.9.3592-3600.1996; MUNFORD RS, 1992, J IMMUNOL METHODS, V148, P115, DOI 10.1016/0022-1759(92)90164-O; MUNFORD RS, 1985, INFECT IMMUN, V48, P464, DOI 10.1128/IAI.48.2.464-473.1985; MUNFORD RS, 1992, J BIOL CHEM, V267, P10116; MUNFORD RS, 1989, J BIOL CHEM, V264, P15613; MUNFORD RS, 1982, J CLIN INVEST, V70, P877, DOI 10.1172/JCI110684; PATRIARC.P, 1972, BIOCHIM BIOPHYS ACTA, V280, P45, DOI 10.1016/0005-2760(72)90211-1; Savill J, 1998, NATURE, V392, P442, DOI 10.1038/33025; Somerville JE, 1996, J CLIN INVEST, V97, P359, DOI 10.1172/JCI118423; TAKADA H, 1989, CRIT REV MICROBIOL, V16, P477, DOI 10.3109/10408418909104475; TESH VL, 1986, J IMMUNOL, V137, P1329; Watson RWG, 1996, J IMMUNOL, V156, P3986; Weinrauch Y, 1999, INFECT IMMUN, V67, P3376, DOI 10.1128/IAI.67.7.3376-3382.1999; WEINRAUCH Y, 1995, J CLIN INVEST, V95, P1916, DOI 10.1172/JCI117873; Weinrauch Y, 1996, J CLIN INVEST, V97, P250, DOI 10.1172/JCI118399; WEISS J, 1987, INFECT IMMUN, V55, P2142, DOI 10.1128/IAI.55.9.2142-2147.1987; WENSINK J, 1981, EUR J BIOCHEM, V116, P331, DOI 10.1111/j.1432-1033.1981.tb05338.x; WRIGHT GC, 1990, J CLIN INVEST, V85, P1925, DOI 10.1172/JCI114655; WRIGHT SD, 1991, J EXP MED, V173, P1281, DOI 10.1084/jem.173.5.1281; WURFEL MM, 1994, J EXP MED, V180, P1025, DOI 10.1084/jem.180.3.1025	38	35	37	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 17	1999	274	51					36579	36584		10.1074/jbc.274.51.36579	http://dx.doi.org/10.1074/jbc.274.51.36579			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	266AV	10593958	hybrid			2022-12-25	WOS:000084279200077
J	Ladomery, MR; Slight, J; McGhee, S; Hastie, ND				Ladomery, MR; Slight, J; McGhee, S; Hastie, ND			Presence of WT1, the Wilm's tumor suppressor gene product, in nuclear Poly(A)(+) ribonucleoprotein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRE-MESSENGER-RNA; SPLICING FACTOR; FRASIER-SYNDROME; SUBNUCLEAR LOCALIZATION; KIDNEY DEVELOPMENT; HNRNP PARTICLES; PROTEINS; TRANSCRIPTION; CELLS; EXPRESSION	The tumor suppressor gene WT1 encodes a zinc finger protein, which consists of four C-terminal C-2-H-2 zinc fingers of the Kruppel type, and at the N terminus a Q/P-rich trans-regulatory domain, both characteristic of transcription factors. However, recent findings suggest that WT1 may also be involved in a post-transcriptional process. Specifically, WT1 isoforms containing the alternatively spliced exon 9 (+lysine-threonine-serine (BTrS)) preferentially associate with nuclear speckles and coimmunoprecipitate splicing antigens (Larsson, S. H., Charlieu, J.-P., Miyagawa, K., Engelkamp, D., Rassoulzadegan, IM., Ross, A., Cuzin, F., van Heyningen, V., and Hastie, N. D. (1995) Cell 81, 391-401); furthermore, WT1 has been shown to interact with the ubiquitous splicing factor U2AF65 (Davies, R. C., Calvo, C., Larsson, S. H, Lamond, A. I., and Hastie, N. D. (1998) Genes Dev. 12, 3217-3225) and binds to RNA in vitro (Caricasole, A., Duarte, A., Larsson, S. H., Hastie, N. D., Little, M., Holmes, G., Todorov, I., and Ward, A. (1996) Proc. Natl. Acad, Sci. U: S. A. 93, 7562-7566; Bardeesy, N., and Pelletier, J. (1998) Nucleic Acids Res. 26, 1784-1792), To extend these findings, we have fractionated nuclear extracts to see if particles containing WT1 have the properties of ribonucleoprotein (RNP). In summary, WT1 is enriched by oligo(dT) chromatography, as are U2AF65, the U5 small nuclear RNP-associated protein pile and hnRNP Al. Gel filtration and sedimentation profiles suggest that WT1 is present in RNase-sensitive particles, >2 MDa in size, peaking at similar to 60 S, and similar to 1.27 g/cm(3) on Nycodenz. Similar results were obtained from two cell lines expressing WT1, fetal kidneys (day E17), and transiently transfected cells, suggesting that the presence of WT1 protein in nuclear poly(A)(+) RNP is a general aspect of WT1 function.	Western Gen Hosp, MRC, Human Genet Unit, Edinburgh EH4 2XU, Midlothian, Scotland	University of Edinburgh	Hastie, ND (corresponding author), Western Gen Hosp, MRC, Human Genet Unit, Crewe Rd, Edinburgh EH4 2XU, Midlothian, Scotland.	Nick.Hastie@hgu.mrc.ac.uk						Barbaux S, 1997, NAT GENET, V17, P467, DOI 10.1038/ng1297-467; Bardeesy N, 1998, NUCLEIC ACIDS RES, V26, P1784, DOI 10.1093/nar/26.7.1784; BEYER AL, 1977, CELL, V11, P127, DOI 10.1016/0092-8674(77)90323-3; BIRNIE GD, 1976, BIOL SEPARATIONS IOD, P193; Bomsztyk K, 1997, FEBS LETT, V403, P113, DOI 10.1016/S0014-5793(97)00041-0; BROSI R, 1993, SCIENCE, V262, P102, DOI 10.1126/science.8211112; Bruening W, 1996, J BIOL CHEM, V271, P8646, DOI 10.1074/jbc.271.15.8646; BUCKINGHAM ME, 1976, BIOL SEPARATIONS IOD, P71; BUCKLER AJ, 1991, MOL CELL BIOL, V11, P1707, DOI 10.1128/MCB.11.3.1707; CALL KM, 1990, CELL, V60, P509, DOI 10.1016/0092-8674(90)90601-A; Caricasole A, 1996, P NATL ACAD SCI USA, V93, P7562, DOI 10.1073/pnas.93.15.7562; CARTER KC, 1991, J CELL BIOL, V115, P1191, DOI 10.1083/jcb.115.5.1191; DARNBROUGH CH, 1981, EUR J BIOCHEM, V113, P415, DOI 10.1111/j.1432-1033.1981.tb05081.x; Davies RC, 1998, GENE DEV, V12, P3217, DOI 10.1101/gad.12.20.3217; DAVIS MR, 1992, INT J CANCER, V52, P881, DOI 10.1002/ijc.2910520609; DREYFUSS G, 1984, MOL CELL BIOL, V4, P1104, DOI 10.1128/MCB.4.6.1104; DREYFUSS G, 1984, MOL CELL BIOL, V4, P415, DOI 10.1128/MCB.4.3.415; Englert C, 1995, P NATL ACAD SCI USA, V92, P11960, DOI 10.1073/pnas.92.26.11960; Fabrizio P, 1997, EMBO J, V16, P4092, DOI 10.1093/emboj/16.13.4092; FEINBERG AP, 1994, J CELL SCI, P7; FORD T, 1983, ANAL BIOCHEM, V128, P232, DOI 10.1016/0003-2697(83)90370-6; GamaCarvalho M, 1997, J CELL BIOL, V137, P975, DOI 10.1083/jcb.137.5.975; GESSLER M, 1990, NATURE, V343, P774, DOI 10.1038/343774a0; Graves LE, 1999, NATURE, V399, P802, DOI 10.1038/21682; HABER DA, 1991, P NATL ACAD SCI USA, V88, P9618, DOI 10.1073/pnas.88.21.9618; HASTIE ND, 1994, ANNU REV GENET, V28, P523; Herbert TP, 1999, NUCLEIC ACIDS RES, V27, P1747, DOI 10.1093/nar/27.7.1747; HOUSSAIS JF, 1976, BIOL SEPARATIONS IOD, P81; HUANG S, 1994, J CELL BIOL, V126, P877, DOI 10.1083/jcb.126.4.877; JEFFERY WR, 1977, J BIOL CHEM, V252, P3525; JIMENEZGARCIA LF, 1993, CELL, V73, P47, DOI 10.1016/0092-8674(93)90159-N; Kennedy D, 1996, NAT GENET, V12, P329, DOI 10.1038/ng0396-329; KENT J, 1995, ONCOGENE, V11, P1781; Kikuchi H, 1998, J MED GENET, V35, P45, DOI 10.1136/jmg.35.1.45; KISH VM, 1975, J MOL BIOL, V95, P227, DOI 10.1016/0022-2836(75)90392-7; Klamt B, 1998, HUM MOL GENET, V7, P709, DOI 10.1093/hmg/7.4.709; Kramer A., 1995, PREMRNA PROCESSING, P35; KREIDBERG JA, 1993, CELL, V74, P679, DOI 10.1016/0092-8674(93)90515-R; Ladomery M, 1997, NUCLEIC ACIDS RES, V25, P965, DOI 10.1093/nar/25.5.965; Ladomery M, 1997, BIOESSAYS, V19, P903, DOI 10.1002/bies.950191010; LARSSON SH, 1995, CELL, V81, P391, DOI 10.1016/0092-8674(95)90392-5; LEE KAW, 1990, METHOD ENZYMOL, V181, P20; Maheswaran S, 1998, GENE DEV, V12, P1108, DOI 10.1101/gad.12.8.1108; Mayo MW, 1999, EMBO J, V18, P3990, DOI 10.1093/emboj/18.14.3990; Medalia O, 1997, J STRUCT BIOL, V120, P228, DOI 10.1006/jsbi.1997.3926; Menke AL, 1998, INT REV CYTOL, V181, P151, DOI 10.1016/S0074-7696(08)60418-0; MIRIAMI E, 1995, J MOL BIOL, V246, P254, DOI 10.1006/jmbi.1994.0081; Misteli T, 1997, NATURE, V387, P523, DOI 10.1038/387523a0; Nachtigal MW, 1998, CELL, V93, P445, DOI 10.1016/S0092-8674(00)81172-1; OKEEFE RT, 1994, J CELL BIOL, V124, P249, DOI 10.1083/jcb.124.3.249; PRITCHARDJONES K, 1990, NATURE, V346, P194, DOI 10.1038/346194a0; Puvion E, 1996, EXP CELL RES, V229, P217, DOI 10.1006/excr.1996.0363; RASSOULZADEGAN M, 1993, CELL, V75, P997, DOI 10.1016/0092-8674(93)90543-Y; RAUSCHER FJ, 1990, SCIENCE, V250, P1259, DOI 10.1126/science.2244209; Reddy JC, 1996, BBA-REV CANCER, V1287, P1, DOI 10.1016/0304-419X(95)00014-7; RICKWOOD D, 1975, FEBS LETT, V50, P102, DOI 10.1016/0014-5793(75)80467-4; Samarina OP, 1996, BIOESSAYS, V18, P595, DOI 10.1002/bies.950180712; Schmidt-Zachmann MS, 1998, MOL BIOL CELL, V9, P143, DOI 10.1091/mbc.9.1.143; SHARMA PM, 1994, GENE DEV, V8, P720, DOI 10.1101/gad.8.6.720; SPANN P, 1989, P NATL ACAD SCI USA, V86, P466, DOI 10.1073/pnas.86.2.466; Sperling R, 1997, J MOL BIOL, V267, P570, DOI 10.1006/jmbi.1997.0898; TAFURI SR, 1993, J BIOL CHEM, V268, P24255; VISA N, 1993, EXP CELL RES, V208, P19, DOI 10.1006/excr.1993.1218; WAGENMAKERS AJM, 1980, EUR J BIOCHEM, V112, P323, DOI 10.1111/j.1432-1033.1980.tb07207.x; Wolffe AP, 1996, INT J BIOCHEM CELL B, V28, P247, DOI 10.1016/1357-2725(95)00141-7; YAMANAKA A, 1995, SOIL SCI PLANT NUTR, V41, P183, DOI 10.1080/00380768.1995.10419575; Yitzhaki S, 1996, P NATL ACAD SCI USA, V93, P8830, DOI 10.1073/pnas.93.17.8830; ZAMORE PD, 1992, NATURE, V355, P609, DOI 10.1038/355609a0	68	60	61	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 17	1999	274	51					36520	36526		10.1074/jbc.274.51.36520	http://dx.doi.org/10.1074/jbc.274.51.36520			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	266AV	10593950	hybrid			2022-12-25	WOS:000084279200069
J	Alessandri-Haber, N; Lecoq, A; Gasparini, S; Grangier-Macmath, G; Jacquet, G; Harvey, AL; de Medeiros, C; Rowan, EG; Gola, M; Menez, A; Crest, M				Alessandri-Haber, N; Lecoq, A; Gasparini, S; Grangier-Macmath, G; Jacquet, G; Harvey, AL; de Medeiros, C; Rowan, EG; Gola, M; Menez, A; Crest, M			Mapping the functional anatomy of BgK on Kv1.1, Kv1.2, and Kv1.3 - Clues to design analogs with enhanced selectivity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POTASSIUM-CHANNEL TOXIN; GATED K+ CHANNELS; ANEMONE BUNODOSOMA-GRANULIFERA; AMINO-ACID-SEQUENCE; SEA-ANEMONE; ALPHA-DENDROTOXIN; SCORPION TOXINS; SHK TOXIN; BIOLOGICAL-ACTIVITY; BLOCKING TOXINS	BgK is a peptide from the sea anemone Bunodosoma granulifera, which blocks Kv1.1, Kv1.2, and Kv1.3 potassium channels. Using 25 analogs substituted at a single position by an alanine residue, we performed the complete mapping of the BgK binding sites for the three Kv1 channels. These binding sites included three common residues (Ser-23, Lys-25, and Tyr-26) and a variable set of additional residues depending on the particular channel. Shortening the side chain of Lys-25 by taking out the four methylene groups dramatically decreased the BgK affinity to all Kv1 channels tested. However, the analog K250rn displayed increased potency an Kv1.2, which makes this peptide a selective blocker for Kv1.2 (K-D 50- and 300-fold lower than for Kv1.1 and Kv1.3, respectively). BgK analogs with enhanced selectivity could also be made by substituting residues that are differentially involved in the binding to some of the three Kv1 channels. For example, the analog F6A was found to be >500-fold more potent for Kv1.1 than for Kv1.2 and Kv1.3. These results provide new information about the mechanisms by which a channel blocker distinguishes individual channels among closely related isoforms and give clues for designing analogs with enhanced selectivity.	CNRS UPR 9024, Neurobiol Lab, F-13402 Marseille, France; Univ Strathclyde, Dept Physiol & Pharmacol, Glasgow G1 1XW, Lanark, Scotland; CEA, Dept Ingn & Etud Prot, F-91191 Gif Sur Yvette, France	Centre National de la Recherche Scientifique (CNRS); University of Strathclyde; CEA; UDICE-French Research Universities; Universite Paris Saclay	Crest, M (corresponding author), CNRS UPR 9024, Neurobiol Lab, 31 Chemin J Aiguier, F-13402 Marseille, France.		Alessandri-Haber, Nicole/A-5572-2009; Aguglia, Umberto/AAB-9898-2019	Aguglia, Umberto/0000-0002-4574-2951; Rowan, Edward/0000-0002-9960-3308				AIYAR J, 1995, NEURON, V15, P1169, DOI 10.1016/0896-6273(95)90104-3; Aiyar J, 1996, J BIOL CHEM, V271, P31013, DOI 10.1074/jbc.271.49.31013; ANEIROS A, 1993, BIOCHIM BIOPHYS ACTA, V1157, P86, DOI 10.1016/0304-4165(93)90082-J; BEDNAREK MA, 1996, PEPTIDES CHEM STRUCT, V133; BERNDT KD, 1993, J MOL BIOL, V234, P735, DOI 10.1006/jmbi.1993.1623; BONTEMS F, 1991, SCIENCE, V254, P1521, DOI 10.1126/science.1720574; BROWNE DL, 1994, NAT GENET, V8, P136, DOI 10.1038/ng1094-136; CASTANEDA O, 1995, TOXICON, V33, P603, DOI 10.1016/0041-0101(95)00013-C; CHANDY KG, 1984, J EXP MED, V160, P369, DOI 10.1084/jem.160.2.369; CHANDY KG, 1995, HDB RECEPTORS CHANNE, P1; Cotton J, 1997, EUR J BIOCHEM, V244, P192, DOI 10.1111/j.1432-1033.1997.00192.x; CREST M, 1992, J BIOL CHEM, V267, P1640; Dauplais M, 1997, J BIOL CHEM, V272, P4302, DOI 10.1074/jbc.272.7.4302; Dauplais M, 1995, BIOCHEMISTRY-US, V34, P16563, DOI 10.1021/bi00051a004; Doyle DA, 1998, SCIENCE, V280, P69, DOI 10.1126/science.280.5360.69; GARCIA ML, 1994, BIOCHEMISTRY-US, V33, P6834, DOI 10.1021/bi00188a012; Gasparini S, 1998, J BIOL CHEM, V273, P25393, DOI 10.1074/jbc.273.39.25393; Gendeh GS, 1997, BIOCHEMISTRY-US, V36, P11461, DOI 10.1021/bi970253d; GOLA M, 1993, J PHYSIOL-LONDON, V460, P327, DOI 10.1113/jphysiol.1993.sp019474; GOLDSTEIN SAN, 1993, BIOPHYS J, V65, P1613, DOI 10.1016/S0006-3495(93)81200-1; GOLDSTEIN SAN, 1994, NEURON, V12, P1377, DOI 10.1016/0896-6273(94)90452-9; GRISSMER S, 1994, MOL PHARMACOL, V45, P1227; GROSS A, 1994, NEURON, V13, P961, DOI 10.1016/0896-6273(94)90261-5; Harvey AL, 1997, GEN PHARMACOL-VASC S, V28, P7, DOI 10.1016/S0306-3623(96)00173-5; HARVEY LY, 1991, SNAKE TOXINS, P131; HURST RS, 1991, MOL PHARMACOL, V40, P572; Jan LY, 1997, ANNU REV NEUROSCI, V20, P91, DOI 10.1146/annurev.neuro.20.1.91; Kalman K, 1998, J BIOL CHEM, V273, P32697, DOI 10.1074/jbc.273.49.32697; Koch RO, 1997, J BIOL CHEM, V272, P27577, DOI 10.1074/jbc.272.44.27577; Koo GC, 1997, J IMMUNOL, V158, P5120; Koschak A, 1998, J BIOL CHEM, V273, P2639, DOI 10.1074/jbc.273.5.2639; LANCELIN JM, 1994, NAT STRUCT BIOL, V1, P246, DOI 10.1038/nsb0494-246; MacKinnon R, 1998, SCIENCE, V280, P106, DOI 10.1126/science.280.5360.106; Martinez F, 1998, FEBS LETT, V429, P381, DOI 10.1016/S0014-5793(98)00636-X; MILLER C, 1995, NEURON, V15, P5, DOI 10.1016/0896-6273(95)90057-8; Minagawa S, 1998, FEBS LETT, V427, P149, DOI 10.1016/S0014-5793(98)00403-7; Naini AA, 1996, BIOCHEMISTRY-US, V35, P6181, DOI 10.1021/bi960067s; Naranjo D, 1996, NEURON, V16, P123, DOI 10.1016/S0896-6273(00)80029-X; Pennington MW, 1996, BIOCHEMISTRY-US, V35, P16407, DOI 10.1021/bi962463g; Pennington MW, 1996, BIOCHEM BIOPH RES CO, V219, P696, DOI 10.1006/bbrc.1996.0297; Ranganathan R, 1996, NEURON, V16, P131, DOI 10.1016/S0896-6273(00)80030-6; Robertson B, 1997, TRENDS PHARMACOL SCI, V18, P474, DOI 10.1016/S0165-6147(97)90686-6; SCHWEITZ H, 1995, J BIOL CHEM, V270, P25121, DOI 10.1074/jbc.270.42.25121; SCOTT VES, 1994, BIOCHEMISTRY-US, V33, P1617, DOI 10.1021/bi00173a001; Shamotienko OG, 1997, BIOCHEMISTRY-US, V36, P8195, DOI 10.1021/bi970237g; SKARZYNSKI T, 1992, J MOL BIOL, V224, P671, DOI 10.1016/0022-2836(92)90552-U; Smart SL, 1998, NEURON, V20, P809, DOI 10.1016/S0896-6273(00)81018-1; Smith LA, 1997, BIOCHEMISTRY-US, V36, P7690, DOI 10.1021/bi963105g; STOCKER M, 1991, P ROY SOC B-BIOL SCI, V245, P101, DOI 10.1098/rspb.1991.0094; Terlau H, 1996, NATURE, V381, P148, DOI 10.1038/381148a0; Tudor JE, 1996, NAT STRUCT BIOL, V3, P317, DOI 10.1038/nsb0496-317; TYTGAT J, 1995, J BIOL CHEM, V270, P24776, DOI 10.1074/jbc.270.42.24776	52	57	63	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 10	1999	274	50					35653	35661		10.1074/jbc.274.50.35653	http://dx.doi.org/10.1074/jbc.274.50.35653			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	264NG	10585444	hybrid			2022-12-25	WOS:000084187900056
J	Chen, AP; Davis, BH; Bissonnette, M; Scaglione-Sewell, B; Brasitus, TA				Chen, AP; Davis, BH; Bissonnette, M; Scaglione-Sewell, B; Brasitus, TA			1,25-dihydroxyvitamin D-3 stimulates activator protein-1-dependent CaCo-2 cell differentiation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; HUMAN OSTEOCALCIN GENE; DNA-BINDING ACTIVITY; OSTEOBLASTIC CELLS; PKC-ALPHA; TRANSCRIPTIONAL ACTIVATION; 1,25(OH)(2) VITAMIN-D-3; SIGNALING PATHWAYS; RESPONSE ELEMENT; AP-1 ACTIVITY	1,25-Dihydroxyvitamin D-3 (1,25(OH)(2)D-3) is a potential chemopreventive agent for human colon cancer. We have reported that 1,25(OH)(2)D-3 specifically activated protein kinase C-alpha (PKC-alpha) and also caused a reduction in proliferation while increasing apoptosis and differentiation in CaCo-2 cells, a cell line derived from a human colon cancer. The mechanisms by which this secosteroid influences these important cellular processes, however, remain unclear. The transcription factor, activator protein-1 (AP-1), regulates many genes involved in these processes. Therefore, we asked whether 1,25(OH)(2)D-3 activated AP-1 in CaCo-2 cells and, if so, by what mechanisms? 1,25(OH)(2)D-3 caused a time-dependent increase in AP-I DNA binding activity and significantly enhanced the protein and mRNA abundance of c-Jun, a component of AP-1. 1,25(OH)(2)D-3 also induced a rapid and transient activation of ERK2 (where ERK is extracellular signal-regulated kinase) and a more persistent activation of JNK1 (where JNK Jun N-terminal kinase). Transfection experiments revealed that 1,25(OH)(2)D3 also increased AP-1 gene-transactivating activity. This AP-I activation was completely blocked by PD 098059, a specific mitogen-activated protein kinase/ERK kinase inhibitor, as well as by a dominant negative JNK or a dominant negative Jun, indicating that the AP-1 activation induced by 1,25(OH)(2)D-3 was mediated by ERK and JNK. Using a specific inhibitor of the Ca2+-dependent PKC isoforms, Go6976, and CaCo-2 cells stably transfected with antisense PKC-alpha cDNA, demonstrated that PKC-alpha mediated the AP-1 activation induced by this secosteroid. Inhibition of JNK activation or c-Jun protein expression significantly reduced 1,25(OH)(2)D-3-induced alkaline phosphatase activity, a marker of CaCo-2 cell differentiation, in secosteroid-treated cells. Taken together, the present study demonstrated that 1,25(OH)(2)D-3 stimulated AP-1 activation in CaCo-2 cells by a PKC-alpha- and JNK-dependent mechanism leading to increases in cellular differentiation.	Univ Chicago, Dept Med, Gastroenterol Sect, Chicago, IL 60637 USA	University of Chicago	Brasitus, TA (corresponding author), Univ Chicago, Dept Med, Gastroenterol Sect, MC4076,5841 S Maryland Ave, Chicago, IL 60637 USA.	tbrasitu@medicine.bsd.uchicago.edu			NCI NIH HHS [CA 36745] Funding Source: Medline; NIDDK NIH HHS [D30DK42086, DK39573] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R37CA036745, R01CA036745] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK042086, R01DK039573] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Abraham C, 1998, GASTROENTEROLOGY, V114, P503, DOI 10.1016/S0016-5085(98)70533-5; ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; ANESKIEVICH BJ, 1992, MOL CELL BIOL, V12, P4862, DOI 10.1128/MCB.12.11.4862; Arnould T, 1998, J BIOL CHEM, V273, P6013, DOI 10.1074/jbc.273.11.6013; BISSONNETTE M, 1994, AM J PHYSIOL, V267, pG465, DOI 10.1152/ajpgi.1994.267.3.G465; BOHMANN D, 1989, CELL, V59, P709, DOI 10.1016/0092-8674(89)90017-2; BOYLE WJ, 1991, CELL, V64, P573, DOI 10.1016/0092-8674(91)90241-P; BRASITUS TA, 1997, CHEMOPREVENTION COLO, P1141; Cadwallader K, 1997, BIOCHEM J, V321, P795, DOI 10.1042/bj3210795; CASINI A, 1994, ALCOHOL ALCOHOLISM, V29, P303; Chen AP, 1999, J BIOL CHEM, V274, P158, DOI 10.1074/jbc.274.1.158; Chen YR, 1998, ONCOGENE, V17, P173, DOI 10.1038/sj.onc.1201941; DENG TL, 1994, NATURE, V371, P171, DOI 10.1038/371171a0; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; Ding QM, 1998, LIFE SCI, V64, P175, DOI 10.1016/S0024-3205(98)00549-9; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; Grolli S, 1997, BIOCHEM BIOPH RES CO, V239, P566, DOI 10.1006/bbrc.1997.7498; HALLINE AG, 1994, ENDOCRINOLOGY, V134, P1710, DOI 10.1210/en.134.4.1710; HAM J, 1995, NEURON, V14, P927, DOI 10.1016/0896-6273(95)90331-3; HATA A, 1993, J BIOL CHEM, V268, P9122; Heusch WL, 1998, CARCINOGENESIS, V19, P551, DOI 10.1093/carcin/19.4.551; HUANG TS, 1991, P NATL ACAD SCI USA, V88, P5292, DOI 10.1073/pnas.88.12.5292; JOHNSON RS, 1993, GENE DEV, V7, P1309, DOI 10.1101/gad.7.7b.1309; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; Karin M, 1997, CURR OPIN CELL BIOL, V9, P240, DOI 10.1016/S0955-0674(97)80068-3; Kawakami Y, 1998, J IMMUNOL, V161, P1795; Khare S, 1999, AM J PHYSIOL-GASTR L, V276, pG1005; KUROKI Y, 1995, J CELL PHYSIOL, V164, P459, DOI 10.1002/jcp.1041640303; LANG JC, 1988, BRIT J CANCER, V58, P62; Leppa S, 1998, EMBO J, V17, P4404, DOI 10.1093/emboj/17.15.4404; Levi NL, 1998, MOL ENDOCRINOL, V12, P815, DOI 10.1210/me.12.6.815; LIEBERHERR M, 1987, J BIOL CHEM, V262, P13168; Lin JK, 1997, J CELL BIOCHEM, P39; McBride K, 1998, MOL CELL BIOL, V18, P5073, DOI 10.1128/MCB.18.9.5073; MINGHETTI PP, 1988, FASEB J, V2, P3043, DOI 10.1096/fasebj.2.15.2847948; Nagata Y, 1998, BLOOD, V92, P1859, DOI 10.1182/blood.V92.6.1859.418k37_1859_1869; OKAZAKI T, 1990, J BIOL CHEM, V265, P15823; OZONO K, 1990, J BIOL CHEM, V265, P21881; PFAHL M, 1993, ENDOCR REV, V14, P651, DOI 10.1210/er.14.5.651; PFARR CM, 1994, CELL, V76, P747, DOI 10.1016/0092-8674(94)90513-4; PIECHACZYK M, 1994, CRIT REV ONCOL HEMAT, V17, P93, DOI 10.1016/1040-8428(94)90021-3; QIU MS, 1992, NEURON, V9, P705, DOI 10.1016/0896-6273(92)90033-A; Scaglione-Sewell B, 1998, CANCER RES, V58, P1074; SCHULE R, 1990, CELL, V61, P497, DOI 10.1016/0092-8674(90)90531-I; Skarosi S, 1997, GASTROENTEROLOGY, V112, pA658; SONNENBERG JL, 1989, J NEUROSCI RES, V24, P72, DOI 10.1002/jnr.490240111; Studzinski GP, 1996, CANCER RES, V56, P5513; Takeshita A, 1998, J BIOL CHEM, V273, P14738, DOI 10.1074/jbc.273.24.14738; TAKESHITA A, 1995, J IMMUNOL, V155, P419; VANDAM H, 1993, EMBO J, V12, P479, DOI 10.1002/j.1460-2075.1993.tb05680.x; WALI RK, 1995, CANCER RES, V55, P3050; WALI RK, 1990, J CLIN INVEST, V85, P1296, DOI 10.1172/JCI114567; WANG HL, 1994, P NATL ACAD SCI USA, V91, P4649, DOI 10.1073/pnas.91.11.4649; Wang HL, 1996, J CELL BIOL, V135, P1151, DOI 10.1083/jcb.135.4.1151; Whitmarsh AJ, 1996, J MOL MED-JMM, V74, P589, DOI 10.1007/s001090050063; Zhang JH, 1998, AM J RESP CELL MOL, V19, P324, DOI 10.1165/ajrcmb.19.2.3209	56	107	108	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 10	1999	274	50					35505	35513		10.1074/jbc.274.50.35505	http://dx.doi.org/10.1074/jbc.274.50.35505			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	264NG	10585423	hybrid			2022-12-25	WOS:000084187900035
J	Tomasevic, N; Peculis, B				Tomasevic, N; Peculis, B			Identification of a U8 snoRNA-specific binding protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMALL NUCLEOLAR RNAS; RIBOSOMAL-RNA; PSEUDOURIDINE SYNTHASE; YEAST; FIBRILLARIN; ELEMENTS; SEQUENCE; CBF5P; COMPLEX; U3	Eukaryotic nucleoli contain a large and diverse population of small nucleolar ribonucleoprotein particles (snoRNPs) that play diverse and essential roles in ribosome biogenesis. We previously demonstrated that U8 snoRNP is essential for processing of both 5.8 and 28 S rRNA. The RNA component of the U8 RNP particle is necessary but not sufficient for processing. Using an electrophoretic mobility sift assay, we enriched for U8-specific binding proteins from Xenopus ovary extracts. UV cross-linking reactions with partially purified fractions implicated a 29-kDa protein directly binding to U8 RNA. This protein interacted specifically and with high affinity with U8 snoRNA; it did not bind other snoRNAs and is probably not a common component of all snoRNPs. This is the first report of a protein component specific to an snoRNP essential for processing of the large ribosomal subunit in vertebrates.	NIDDK, Genet & Biochem Branch, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	Peculis, B (corresponding author), NIDDK, Genet & Biochem Branch, NIH, 10 Ctr Dr 10-8N322, Bethesda, MD 20892 USA.							AMIRI KA, 1994, J BACTERIOL, V176, P2124, DOI 10.1128/jb.176.7.2124-2127.1994; APOSTOL BL, 1991, NUCLEIC ACIDS RES, V19, P1853, DOI 10.1093/nar/19.8.1853; ARIS JP, 1988, J CELL BIOL, V107, P17, DOI 10.1083/jcb.107.1.17; Balakin AG, 1996, CELL, V86, P823, DOI 10.1016/S0092-8674(00)80156-7; BENSADOUN A, 1976, ANAL BIOCHEM, V70, P241, DOI 10.1016/S0003-2697(76)80064-4; BURGE B, 1999, SPLICING PRECURSORS; Cadwell C, 1997, MOL CELL BIOL, V17, P6175, DOI 10.1128/MCB.17.10.6175; Ganot P, 1997, GENE DEV, V11, P941, DOI 10.1101/gad.11.7.941; Giordano E, 1999, J CELL BIOL, V144, P1123, DOI 10.1083/jcb.144.6.1123; GIRARD JP, 1992, EMBO J, V11, P673, DOI 10.1002/j.1460-2075.1992.tb05099.x; Gunnewiek JMTK, 1997, CLIN EXP RHEUMATOL, V15, P549; Heiss NS, 1998, NAT GENET, V19, P32, DOI 10.1038/ng0598-32; Henras A, 1998, EMBO J, V17, P7078, DOI 10.1093/emboj/17.23.7078; JANSEN RP, 1991, J CELL BIOL, V113, P715, DOI 10.1083/jcb.113.4.715; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lafontaine DLJ, 1998, GENE DEV, V12, P527, DOI 10.1101/gad.12.4.527; Lafontaine DLJ, 1999, RNA, V5, P455, DOI 10.1017/S135583829998192X; MAXWELL ES, 1995, ANNU REV BIOCHEM, V64, P897, DOI 10.1146/annurev.bi.64.070195.004341; MEIER UT, 1994, J CELL BIOL, V127, P1505, DOI 10.1083/jcb.127.6.1505; O'Reilly Marc, 1999, Current Opinion in Structural Biology, V9, P56, DOI 10.1016/S0959-440X(99)80008-6; OCHS RL, 1985, BIOL CELL, V54, P123, DOI 10.1111/j.1768-322X.1985.tb00387.x; PARKER KA, 1987, MOL CELL BIOL, V7, P2899, DOI 10.1128/MCB.7.8.2899; Peculis B, 1997, CURR BIOL, V7, pR480, DOI 10.1016/S0960-9822(06)00242-9; Peculis BA, 1996, CURR BIOL, V6, P1413, DOI 10.1016/S0960-9822(96)00745-2; PECULIS BA, 1994, GENE DEV, V8, P2241, DOI 10.1101/gad.8.18.2241; PECULIS BA, 1993, CELL, V73, P1233, DOI 10.1016/0092-8674(93)90651-6; TOLLERVEY D, 1991, EMBO J, V10, P573, DOI 10.1002/j.1460-2075.1991.tb07984.x; Tollervey D, 1997, CURR OPIN CELL BIOL, V9, P337, DOI 10.1016/S0955-0674(97)80005-1; TYC K, 1989, EMBO J, V8, P3113, DOI 10.1002/j.1460-2075.1989.tb08463.x; VENEMA J, 1999, IN PRESS ANN REV GEN, V33; Watkins NJ, 1998, RNA, V4, P1549, DOI 10.1017/S1355838298980761; Watkins NJ, 1996, RNA, V2, P118; Watkins NJ, 1998, RNA, V4, P582, DOI 10.1017/S1355838298980128; Wu P, 1998, J BIOL CHEM, V273, P16453, DOI 10.1074/jbc.273.26.16453	34	25	26	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 10	1999	274	50					35914	35920		10.1074/jbc.274.50.35914	http://dx.doi.org/10.1074/jbc.274.50.35914			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	264NG	10585477	hybrid			2022-12-25	WOS:000084187900089
J	Copani, A; Condorelli, F; Caruso, A; Vancheri, C; Sala, A; Stella, AMG; Canonico, PL; Nicoletti, F; Sortino, MA				Copani, A; Condorelli, F; Caruso, A; Vancheri, C; Sala, A; Stella, AMG; Canonico, PL; Nicoletti, F; Sortino, MA			Mitotic signaling by beta-amyloid causes neuronal death	FASEB JOURNAL			English	Article						neuronal apoptosis; cell cycle; Alzheimer's disease	CYCLIN-DEPENDENT KINASES; MAMMALIAN-CELL CYCLE; ALZHEIMERS-DISEASE BRAIN; PC12 CELLS; SYMPATHETIC NEURONS; INDUCED APOPTOSIS; CULTURED NEURONS; SENILE PLAQUES; G1 PHASE; A-BETA	Aggregates of beta-amyloid peptide (beta AP), the main constituent of amyloid plaques in Alzheimer's brain, kill neurons by a not yet defined mechanism, leading to apoptotic death, Here, we report that both full-length beta AP((1-40)) or ((1-42)) and its active fragment beta AP((25-35)) act as proliferative signals for differentiated cortical neurons, driving them into the cell cycle. The cycle followed some of the steps observed in proliferating cells, including induction of cyclin D1, phosphorylation of retinoblastoma, and induction of cyclin E and A, but did not progress beyond S phase. Inactivation of cyclin-dependent protein kinase-4 or -2 prevented both the entry into S phase and the development of apoptosis in beta AP((25-35))-treated neurons. We conclude that neurons must cross the G1/S transition before succumbing to PAP signaling, and therefore multiple steps within this pathway may be targets for neuroprotective agents.	Univ Catania, Sch Pharm, Dept Pharmaceut Sci, Pharmacol Sect, I-95125 Catania, Italy; Univ Catania, Sch Med, I-95125 Catania, Italy; Osped Tomaselli, Inst Resp Dis, I-95125 Catania, Italy; Consorzio Mario Negri Sud, I-66030 Chieti, Italy; Univ Pavia, Dept Internal Med & Med Therapy, I-27100 Pavia, Italy; INM Neuromed, I-86077 Pozzilli, Isernia, Italy	University of Catania; University of Catania; Consorzio Mario Negri Sud; University of Pavia; IRCCS Neuromed	Nicoletti, F (corresponding author), Univ Catania, Sch Pharm, Dept Pharmaceut Sci, Pharmacol Sect, Viale A Doria 6, I-95125 Catania, Italy.		sala, arturo/C-4959-2008; Condorelli, Fabrizio/AAT-1953-2020; VANCHERI, Carlo/K-9417-2016; Nicoletti, Ferdinando/A-2446-2010	Condorelli, Fabrizio/0000-0002-9943-0857; Sala, Arturo/0000-0002-2841-7866; VANCHERI, Carlo/0000-0002-5120-9926; NICOLETTI, Ferdinando/0000-0003-3366-7269; Sortino, Maria Angela/0000-0002-2734-1521; Nicoletti, Ferdinando/0000-0003-0917-443X				ANDERSON AJ, 1995, J NEUROCHEM, V65, P1487; ANDERSON AJ, 1994, EXP NEUROL, V125, P286, DOI 10.1006/exnr.1994.1031; ARAUJO DM, 1992, BRAIN RES, V569, P141, DOI 10.1016/0006-8993(92)90380-R; Arendt T, 1996, NEUROREPORT, V7, P3047; BHAT NR, 1992, J NEUROSCI RES, V32, P340, DOI 10.1002/jnr.490320306; BI N, 1994, EXP CELL RES, V212, P105, DOI 10.1006/excr.1994.1124; BOLAND K, 1995, J BIOL CHEM, V270, P28022; BOZYCZKOCOINE D, 1997, SOC NEUROSCI ABSTR, V23; BRODIE C, 1993, CANCER RES, V53, P3968; Busser J, 1998, J NEUROSCI, V18, P2801; CHAO CC, 1994, MOL CHEM NEUROPATHOL, V23, P159, DOI 10.1007/BF02815409; COPANI A, 1995, MOL PHARMACOL, V47, P890; COPANI A, 1996, SOC NEUROSCI ABSTR, V22; DERYNCK R, 1994, TRENDS BIOCHEM SCI, V19, P548, DOI 10.1016/0968-0004(94)90059-0; ElKhoury J, 1996, NATURE, V382, P716; Estus S, 1997, J NEUROSCI, V17, P7736; Farinelli SE, 1996, J NEUROSCI, V16, P1150, DOI 10.1523/jneurosci.16-03-01150.1996; Ferrer I, 1996, NEUROPATH APPL NEURO, V22, P521, DOI 10.1111/j.1365-2990.1996.tb01130.x; FORLONI G, 1993, NEUROREPORT, V4, P523, DOI 10.1097/00001756-199305000-00015; FREEMAN RS, 1994, NEURON, V12, P343, DOI 10.1016/0896-6273(94)90276-3; GAO CY, 1995, EXP CELL RES, V219, P612, DOI 10.1006/excr.1995.1271; HENSLEY K, 1994, P NATL ACAD SCI USA, V91, P3270, DOI 10.1073/pnas.91.8.3270; KATZMAN R, 1986, NEW ENGL J MED, V314, P964, DOI 10.1056/NEJM198604103141506; KRISHAN A, 1975, J CELL BIOL, V66, P188, DOI 10.1083/jcb.66.1.188; LALANDE M, 1990, EXP CELL RES, V186, P332, DOI 10.1016/0014-4827(90)90313-Y; Li JH, 1997, CELL, V90, P917, DOI 10.1016/S0092-8674(00)80356-6; LOO DT, 1993, P NATL ACAD SCI USA, V90, P7951, DOI 10.1073/pnas.90.17.7951; MASTERS CL, 1985, P NATL ACAD SCI USA, V82, P4245, DOI 10.1073/pnas.82.12.4245; McShea A, 1997, AM J PATHOL, V150, P1933; MEDA L, 1995, NATURE, V374, P647, DOI 10.1038/374647a0; MULLER R, 1995, TRENDS GENET, V11, P173, DOI 10.1016/S0168-9525(00)89039-3; Narita M, 1997, J NEUROCHEM, V69, P1904; Nuydens R, 1998, J NEUROCHEM, V70, P1124; Ohtani K, 1995, P NATL ACAD SCI USA, V92, P12146, DOI 10.1073/pnas.92.26.12146; Park DS, 1997, J NEUROSCI, V17, P8975; Park DS, 1997, J NEUROSCI, V17, P1256, DOI 10.1523/jneurosci.17-04-01256.1997; PIKE CJ, 1994, NEUROSCIENCE, V63, P517, DOI 10.1016/0306-4522(94)90547-9; PIKE CJ, 1993, J NEUROSCI, V13, P1676; PINES J, 1993, TRENDS BIOCHEM SCI, V18, P195, DOI 10.1016/0968-0004(93)90185-P; SABO S, 1995, NEUROSCI LETT, V184, P25, DOI 10.1016/0304-3940(94)11159-G; SALA A, 1992, P NATL ACAD SCI USA, V89, P10415, DOI 10.1073/pnas.89.21.10415; Shirvan A, 1997, J NEUROCHEM, V69, P539; SMALE G, 1995, EXP NEUROL, V133, P225, DOI 10.1006/exnr.1995.1025; SU JH, 1994, NEUROREPORT, V5, P2529, DOI 10.1097/00001756-199412000-00031; Suzuki A, 1997, EXP CELL RES, V234, P507, DOI 10.1006/excr.1997.3639; TAMARU T, 1994, NEUROSCI LETT, V168, P229, DOI 10.1016/0304-3940(94)90457-X; VANDENHEUVEL S, 1993, SCIENCE, V262, P2050, DOI 10.1126/science.8266103; Vincent I, 1996, J CELL BIOL, V132, P413, DOI 10.1083/jcb.132.3.413; Vincent I, 1997, J NEUROSCI, V17, P3588; Yaar M, 1997, J CLIN INVEST, V100, P2333, DOI 10.1172/JCI119772; Yan SD, 1996, NATURE, V382, P685, DOI 10.1038/382685a0; ZHANG C, 1994, J BIOL CHEM, V269, P25247	52	235	254	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	DEC	1999	13	15					2225	2234		10.1096/fasebj.13.15.2225	http://dx.doi.org/10.1096/fasebj.13.15.2225			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	266QN	10593870	Bronze			2022-12-25	WOS:000084310800014
J	Takada, S; Shirakata, Y; Kaneniwa, N; Koike, K				Takada, S; Shirakata, Y; Kaneniwa, N; Koike, K			Association of hepatitis B virus X protein with mitochondria causes mitochondrial aggregation at the nuclear periphery, leading to cell death	ONCOGENE			English	Article						HBV X protein; cytoplasmic location; mitochondrial aggregation; p53 protein; cell death	GENE-PRODUCT; TRANSACTIVATOR PX; SERINE-PROTEASE; DNA; TRANSFORMATION; ACTIVATION; INHIBITOR; PROMOTER; RAS	Hepatitis B virus (HBV) X protein activates many viral and cellular genes in trans and functional disruption of the p53 tumor suppressor gene product occurs when X protein is transiently expressed in the cytoplasm of cultured cells. We have carried out investigations to determine the exact location of X protein in X gene transfected cells by using a fluorescent staining technique as well as by biochemical analyses. Aggregation of mitochondrial structures became evident at the periphery of nucleus in the cytoplasm of X transfected cells. X protein was found associated with the aggregated mitochondrial structures. Furthermore, transiently expressed p53 protein co-localized with X protein in X transfected cells, However, the appearance of aggregated mitochondrial structures at the nuclear periphery was independent of the presence of p53 protein in X transfected cells. X protein expression also caused an appearance of TUNEL positive nucleus, cytochrome c release from mitochondrial, the decrease of mitochondrial membrane potential and the membrane blebbing of X transfected cells, which are characteristic of cell death. Our data suggest that X protein causes an abnormal aggregation of mitochondrial structures in the cell, which may be eventually connected with cell death.	Japanese Fdn Canc Res, Inst Canc, Dept Gene Res, Toshima Ku, Tokyo 1708455, Japan	Japanese Foundation for Cancer Research	Koike, K (corresponding author), Japanese Fdn Canc Res, Inst Canc, Dept Gene Res, Toshima Ku, Tokyo 1708455, Japan.							ARII M, 1992, ONCOGENE, V7, P397; BENN J, 1994, P NATL ACAD SCI USA, V91, P10350, DOI 10.1073/pnas.91.22.10350; CROSS JC, 1993, P NATL ACAD SCI USA, V90, P8078, DOI 10.1073/pnas.90.17.8078; GANEM D, 1987, ANNU REV BIOCHEM, V56, P651, DOI 10.1146/annurev.biochem.56.1.651; HOHNE M, 1990, EMBO J, V9, P1137, DOI 10.1002/j.1460-2075.1990.tb08220.x; KEKULE AS, 1993, NATURE, V361, P742, DOI 10.1038/361742a0; KIM CM, 1991, NATURE, V351, P317, DOI 10.1038/351317a0; KIM DW, 1990, GENE, V91, P217, DOI 10.1016/0378-1119(90)90091-5; MAGUIRE HF, 1991, SCIENCE, V252, P842, DOI 10.1126/science.1827531; MASUDA H, 1987, P NATL ACAD SCI USA, V84, P7716, DOI 10.1073/pnas.84.21.7716; NATOLI G, 1994, MOL CELL BIOL, V14, P989, DOI 10.1128/MCB.14.2.989; NATOLI G, 1994, ONCOGENE, V9, P2837; Petit PX, 1996, FEBS LETT, V396, P7, DOI 10.1016/0014-5793(96)00988-X; RAKOTOMAHANINA CK, 1994, ONCOGENE, V9, P2613; Reed JC, 1997, NATURE, V387, P773, DOI 10.1038/42867; ROSSNER MT, 1992, J MED VIROL, V36, P101, DOI 10.1002/jmv.1890360207; Sambrook J., 2002, MOL CLONING LAB MANU; SHAULSKY G, 1991, ONCOGENE, V6, P2055; SHIRAKATA Y, 1989, JPN J CANCER RES, V80, P617, DOI 10.1111/j.1349-7006.1989.tb01686.x; SPANDAU DF, 1988, J VIROL, V62, P427, DOI 10.1128/JVI.62.2.427-434.1988; TAKADA S, 1994, VIROLOGY, V205, P503, DOI 10.1006/viro.1994.1671; Takada S, 1997, ONCOGENE, V15, P1895, DOI 10.1038/sj.onc.1201369; TAKADA S, 1994, ONCOGENE, V9, P341; TAKADA S, 1990, JPN J CANCER RES, V81, P1191, DOI 10.1111/j.1349-7006.1990.tb02675.x; TANAKA S, 1978, BIOCHEM BIOPH RES CO, V81, P791, DOI 10.1016/0006-291X(78)91421-3; Tanaka Y, 1998, CELL, V93, P1147, DOI 10.1016/S0092-8674(00)81459-2; Terradillos O, 1998, ONCOGENE, V17, P2115, DOI 10.1038/sj.onc.1202432; TIOLLAIS P, 1985, NATURE, V317, P489, DOI 10.1038/317489a0; VanderHeiden MG, 1997, CELL, V91, P627, DOI 10.1016/S0092-8674(00)80450-X; Yaffe MP, 1999, SCIENCE, V283, P1493, DOI 10.1126/science.283.5407.1493	30	149	157	0	8	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 25	1999	18	50					6965	6973		10.1038/sj.onc.1203188	http://dx.doi.org/10.1038/sj.onc.1203188			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	259PH	10597295				2022-12-25	WOS:000083901900001
J	Liu, JL; Huang, C; Zhan, X				Liu, JL; Huang, C; Zhan, X			Src is required for cell migration and shape changes induced by fibroblast growth factor 1	ONCOGENE			English	Article						Src; FGF-1; cortactin	TYROSINE KINASE; ACTIN CYTOSKELETON; FACTOR RECEPTOR; POINT MUTATION; EGF-RECEPTOR; FACTOR-I; C-SRC; PROTEIN; CORTACTIN; ASSOCIATION	Fibroblast growth factor 1 (FGF-1) is a potent chemotactic factor and induces tyrosine phosphorylation of a cortical actin-associated protein (cortactin). The tyrosine phosphorylation of cortactin induced by FGF-1 requires the tyrosine residues 421, 482 and 466, which are targeted by the protein tyrosine kinase Src irt vitro. Furthermore, FGF-1 is unable to induce tyrosine phosphorylation of cortactin within the cells derived from Src knockout mice (Src(-/-)), indicating that Src is required for the tyrosine phosphorylation of cortactin induced by FGF-1. Although Src-/- cells are able to undergo rapid proliferation, they are impaired to respond to FGF-1 for the shape change and cell migration. Morphological analysis further reveals that FGF-1 fails to induce the formation of polarized lamellipodia and the translocation of cortactin into the leading edge of Src(-/-) cells. Consistent with the mitogenic response to FGF-1, the lack of Src does not affect the tyrosine phosphorylation of Snt (or Frs2), a FGF-1 early signaling protein that links to Ras, Therefore, our data support the notion that Src and cortactin participate in a FGF signal pathway for cell migration and shape change rather than mitogenesis.	Amer Red Cross, Jerome H Holland Lab, Dept Expt Pathol, Rockville, MD 20855 USA; George Washington Univ, Dept Anat & Cell Biol, Washington, DC 20037 USA	American Red Cross; George Washington University	Zhan, X (corresponding author), Amer Red Cross, Jerome H Holland Lab, Dept Expt Pathol, 15601 Crabbs Branch Way, Rockville, MD 20855 USA.				NHLBI NIH HHS [R29 HL52753] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL052753] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BOGOYEVITCH MA, 1994, J BIOL CHEM, V269, P1110; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; BURGESS WH, 1990, MOL CELL BIOL, V10, P4770, DOI 10.1128/MCB.10.9.4770; BURGESS WH, 1989, ANNU REV BIOCHEM, V58, P575, DOI 10.1146/annurev.bi.58.070189.003043; CHANG JH, 1995, J CELL BIOL, V130, P355, DOI 10.1083/jcb.130.2.355; Cramer Louise P., 1997, Frontiers in Bioscience (online), V2, pD260; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; GOSPODAROWICZ D, 1974, NATURE, V249, P123, DOI 10.1038/249123a0; Hadari YR, 1998, MOL CELL BIOL, V18, P3966, DOI 10.1128/MCB.18.7.3966; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; HolgadoMadruga M, 1996, NATURE, V379, P560, DOI 10.1038/379560a0; Huang C, 1998, J BIOL CHEM, V273, P25770, DOI 10.1074/jbc.273.40.25770; Huang C, 1997, J BIOL CHEM, V272, P13911, DOI 10.1074/jbc.272.21.13911; HUANG SS, 1986, J BIOL CHEM, V261, P9568; Kim L, 1998, J BIOL CHEM, V273, P23542, DOI 10.1074/jbc.273.36.23542; Kouhara H, 1997, CELL, V89, P693, DOI 10.1016/S0092-8674(00)80252-4; LaVallee TM, 1998, J CELL BIOL, V141, P1647, DOI 10.1083/jcb.141.7.1647; MACIAG T, 1982, J BIOL CHEM, V257, P5333; Mogilner A, 1996, BIOPHYS J, V71, P3030, DOI 10.1016/S0006-3495(96)79496-1; MOHAMMADI M, 1992, NATURE, V358, P681, DOI 10.1038/358681a0; Oldham SM, 1998, ONCOGENE, V16, P2565, DOI 10.1038/sj.onc.1201784; Ong SH, 1997, BIOCHEM BIOPH RES CO, V238, P261, DOI 10.1006/bbrc.1997.7272; PETERS KG, 1992, NATURE, V358, P678, DOI 10.1038/358678a0; RODIER JM, 1995, J CELL BIOL, V131, P761, DOI 10.1083/jcb.131.3.761; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; Schieffer B, 1996, J BIOL CHEM, V271, P10329, DOI 10.1074/jbc.271.17.10329; Thomas SM, 1997, ANNU REV CELL DEV BI, V13, P513, DOI 10.1146/annurev.cellbio.13.1.513; THOMAS SM, 1995, NATURE, V376, P267, DOI 10.1038/376267a0; Wang JK, 1996, ONCOGENE, V13, P721; WANG JK, 1994, MOL CELL BIOL, V14, P181, DOI 10.1128/MCB.14.1.181; Weed SA, 1998, J CELL SCI, V111, P2433; WU H, 1993, J CELL BIOL, V120, P1417, DOI 10.1083/jcb.120.6.1417; Xu H, 1998, J BIOL CHEM, V273, P17987, DOI 10.1074/jbc.273.29.17987; ZHAN X, 1993, J BIOL CHEM, V268, P24427; ZHAN X, 1993, J BIOL CHEM, V268, P9611; ZHAN X, 1994, J BIOL CHEM, V269, P20221; ZHAN X, 1986, MOL CELL BIOL, V6, P3541, DOI 10.1128/MCB.6.10.3541	38	74	74	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 18	1999	18	48					6700	6706		10.1038/sj.onc.1203050	http://dx.doi.org/10.1038/sj.onc.1203050			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	257QA	10597276				2022-12-25	WOS:000083792000010
J	Russell, A; Hendley, J; Germain, D				Russell, A; Hendley, J; Germain, D			Inhibitory effect of p21 in MCF-7 cells is overcome by its coordinated stabilization with D-type cyclins	ONCOGENE			English	Article						D-type cyclins; p21; SCF; Skp2; ubiquitin; proteolysis, breast cancer	HUMAN BREAST-CARCINOMA; SUBCELLULAR-LOCALIZATION; OVEREXPRESSION; PROTEOLYSIS; TRANSITION; G(1); DIFFERENTIATION; P21(WAF1/CIP1); ABUNDANCE; RECEPTORS	Coordinated accumulation of cyclin D1 and D3 is observed in 15% of primary breast cancers and in the breast cancer cell line MCF-7 this simultaneous overexpression is due to a defect in their ubiquitin-mediated proteolysis. The F-box protein Skp2 is a component of an SCF ubiquitin ligase complex and can associate with cyclin D1 and the cdk inhibitor p21 (Zhong-Kang ct al., 1998). We extend this observation and show that cyclin D3 can also associate with Skp2 suggesting that cyclins D1, D3 and p21 may share the same SCF complex. In agreement with this hypothesis we report here that in primary breast cancers and in MCF-7 cells where cyclins D1 and D3 are elevated the level of p21 is also elevated. Further, we demonstrate that the turnover of p21 protein is reduced in MCF-7 cells. We show that p21 is active as a cdk inhibitor in this cell line but that the presence of elevated levels of cyclin D3 titrates p21 away from cyclin D1-cdk4/6 complexes and cdk2 complexes resulting in increased kinase activities. Our results suggest that a defect in the SCF complex may occur in 15-20% of breast cancers and that the resulting coordinated elevation of cyclins D1 and D3 overcomes the inhibition of cell cycle progression by p21. We propose that in the context of cyclins D1 and D3 overexpression, p21 may promote cell cycle progression.	Peter MacCallum Canc Inst, Trescowthick Res Labs, Melbourne, Vic 3002, Australia; Univ Melbourne, Dept Biochem & Mol Biol, Parkville, Vic 3052, Australia	Peter Maccallum Cancer Center; University of Melbourne	Germain, D (corresponding author), Peter MacCallum Canc Inst, Trescowthick Res Labs, St-Andrews Pl, Melbourne, Vic 3002, Australia.							ANDO K, 1993, P NATL ACAD SCI USA, V90, P9571, DOI 10.1073/pnas.90.20.9571; Bartkova J, 1998, ONCOGENE, V17, P1027, DOI 10.1038/sj.onc.1202016; Bartkova J, 1996, INT J CANCER, V65, P323, DOI 10.1002/(SICI)1097-0215(19960126)65:3<323::AID-IJC8>3.0.CO;2-1; Cheng MG, 1999, EMBO J, V18, P1571, DOI 10.1093/emboj/18.6.1571; Diehl JA, 1997, GENE DEV, V11, P957, DOI 10.1101/gad.11.8.957; Diehl JA, 1998, GENE DEV, V12, P3499, DOI 10.1101/gad.12.22.3499; GILLETT C, 1994, CANCER RES, V54, P1812; Helin K, 1998, CURR OPIN GENET DEV, V8, P28, DOI 10.1016/S0959-437X(98)80058-0; Krek W, 1998, CURR OPIN GENET DEV, V8, P36, DOI 10.1016/S0959-437X(98)80059-2; LaBaer J, 1997, GENE DEV, V11, P847, DOI 10.1101/gad.11.7.847; Lukas J, 1996, MOL CELL BIOL, V16, P6917; Maki CG, 1997, MOL CELL BIOL, V17, P355, DOI 10.1128/MCB.17.1.355; MATSUSHIME H, 1994, MOL CELL BIOL, V14, P2066, DOI 10.1128/MCB.14.3.2066; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; MUSGROVE EA, 1994, P NATL ACAD SCI USA, V91, P8022, DOI 10.1073/pnas.91.17.8022; Patton EE, 1998, TRENDS GENET, V14, P236, DOI 10.1016/S0168-9525(98)01473-5; Rey MJ, 1998, J PATHOL, V184, P265, DOI 10.1002/(SICI)1096-9896(199803)184:3<265::AID-PATH8>3.0.CO;2-8; Russell A, 1999, ONCOGENE, V18, P1983, DOI 10.1038/sj.onc.1202511; SHEIKH MS, 1995, ONCOGENE, V11, P1899; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; Skowyra D, 1997, CELL, V91, P209, DOI 10.1016/S0092-8674(00)80403-1; WANG TC, 1994, NATURE, V369, P669, DOI 10.1038/369669a0; ZHONGKANG Y, 1998, P NATL ACAD SCI USA, V95, P11324	23	25	27	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 11	1999	18	47					6454	6459		10.1038/sj.onc.1203030	http://dx.doi.org/10.1038/sj.onc.1203030			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	256CW	10597247				2022-12-25	WOS:000083709200007
J	Lee, JH; Takahashi, T; Yasuhara, N; Inazawa, J; Kamada, S; Tsujimoto, Y				Lee, JH; Takahashi, T; Yasuhara, N; Inazawa, J; Kamada, S; Tsujimoto, Y			Bis, a Bcl-2-binding protein that synergizes with Bcl-2 in preventing cell death	ONCOGENE			English	Article						apoptosis; Bcl-2; Bis	SPINAL MUSCULAR-ATROPHY; CYTOCHROME-C; MITOCHONDRIAL-MEMBRANES; ENDOPLASMIC-RETICULUM; KINASE RAF-1; ION-CHANNEL; APOPTOSIS; ACTIVATION; EXPRESSION; BAX	Bcl-2 is the best characterized inhibitor of apoptosis, although the molecular basis of this action is not fully understood. Using a protein interaction cloning procedure, we identified a human gene designated as bis (mapped to chromosome 10q25) that encoded a novel Bcl-2-interacting protein. Eis protein showed no significant homology with Bcl-2 family proteins and had no prominent functional motif. Co-immunoprecipitation analysis confirmed that Eis interacted with Bcl-2 in vivo. DNA transfection experiments indicated that Eis itself exerted only weak anti-apoptotic activity, but was synergistic with Bcl-2 in preventing flax-induced and Fas-mediated apoptosis. These results suggest that Bis is a novel modulator of cellular anti-apoptotic activity that functions through its interaction with Bcl-2.	Osaka Univ, Grad Sch Med, Biomed Res Ctr, Dept Med Genet, Osaka, Japan; Japan Sci & Technol Corp, CREST, Suita, Osaka 5650871, Japan; Tokyo Med & Dent Univ, Med Res Inst, Div Genet, Dept Mol Cytogenet,Bunkyo Ku, Tokyo 1138519, Japan	Osaka University; Japan Science & Technology Agency (JST); Tokyo Medical & Dental University (TMDU)	Tsujimoto, Y (corresponding author), Osaka Univ, Grad Sch Med, Biomed Res Ctr, Dept Med Genet, Osaka, Japan.							Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; AKAO Y, 1994, CANCER RES, V54, P2468; Alnemri ES, 1996, CELL, V87, P171, DOI 10.1016/S0092-8674(00)81334-3; Antonsson B, 1997, SCIENCE, V277, P370, DOI 10.1126/science.277.5324.370; Armstrong RC, 1996, J BIOL CHEM, V271, P16850, DOI 10.1074/jbc.271.28.16850; Bardelli A, 1996, EMBO J, V15, P6205, DOI 10.1002/j.1460-2075.1996.tb01009.x; Boulakia CA, 1996, ONCOGENE, V12, P529; Chinnaiyan AM, 1996, J BIOL CHEM, V271, P4573; Chinnaiyan AM, 1997, SCIENCE, V275, P1122, DOI 10.1126/science.275.5303.1122; EGUCHI Y, 1992, NUCLEIC ACIDS RES, V20, P4187, DOI 10.1093/nar/20.16.4187; Gavva NR, 1997, J BIOL CHEM, V272, P24105, DOI 10.1074/jbc.272.39.24105; HENGARTNER MO, 1994, NATURE, V369, P318, DOI 10.1038/369318a0; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; INAZAWA J, 1993, GENOMICS, V17, P153, DOI 10.1006/geno.1993.1297; Iwahashi H, 1997, NATURE, V390, P413, DOI 10.1038/37144; JACOBSON MD, 1993, NATURE, V361, P365, DOI 10.1038/361365a0; Jiang YP, 1999, SCIENCE, V283, P543, DOI 10.1126/science.283.5401.543; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; Knudson CM, 1997, NAT GENET, V16, P358, DOI 10.1038/ng0897-358; KRAJEWSKI S, 1993, CANCER RES, V53, P4701; LEFEBVRE S, 1995, CELL, V80, P155, DOI 10.1016/0092-8674(95)90460-3; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; MARTIN SJ, 1995, CELL, V82, P349, DOI 10.1016/0092-8674(95)90422-0; Minn AJ, 1997, NATURE, V385, P353, DOI 10.1038/385353a0; MONAGHAN P, 1992, J HISTOCHEM CYTOCHEM, V40, P1819, DOI 10.1177/40.12.1453000; Neupert W, 1997, ANNU REV BIOCHEM, V66, P863, DOI 10.1146/annurev.biochem.66.1.863; NIWA H, 1991, GENE, V108, P193, DOI 10.1016/0378-1119(91)90434-D; OLTAVI ZN, 1993, CELL, V74, P609; PEZZELLA F, 1990, AM J PATHOL, V137, P225; RaasRothschild A, 1996, J MED GENET, V33, P996, DOI 10.1136/jmg.33.12.996; REED JC, 1992, ANAL BIOCHEM, V205, P70, DOI 10.1016/0003-2697(92)90580-Z; Reed JC, 1998, ONCOGENE, V17, P3225, DOI 10.1038/sj.onc.1202591; Sambrook J., 2002, MOL CLONING LAB MANU; Schendel SL, 1997, P NATL ACAD SCI USA, V94, P5113, DOI 10.1073/pnas.94.10.5113; Schild L, 1996, EMBO J, V15, P2381, DOI 10.1002/j.1460-2075.1996.tb00594.x; Schlesinger PH, 1997, P NATL ACAD SCI USA, V94, P11357, DOI 10.1073/pnas.94.21.11357; Shimizu S, 1999, NATURE, V399, P483, DOI 10.1038/20959; Shimizu S, 1996, ONCOGENE, V12, P2251; Shimizu S, 1996, ONCOGENE, V12, P2045; STELLER H, 1995, SCIENCE, V267, P1445, DOI 10.1126/science.7878463; Sudol M, 1996, PROG BIOPHYS MOL BIO, V65, P113, DOI 10.1016/S0079-6107(96)00008-9; TACHIBANA T, 1994, J BIOL CHEM, V269, P24542; TAKAYAMA S, 1995, CELL, V80, P279, DOI 10.1016/0092-8674(95)90410-7; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Verge CF, 1998, J CLIN INVEST, V102, P1569, DOI 10.1172/JCI3379; WANG HG, 1994, ONCOGENE, V9, P2751; Wang HG, 1996, P NATL ACAD SCI USA, V93, P7063, DOI 10.1073/pnas.93.14.7063; Wang HG, 1996, CELL, V87, P629, DOI 10.1016/S0092-8674(00)81383-5; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; Yasuhara N, 1997, ONCOGENE, V15, P1921, DOI 10.1038/sj.onc.1201370; YIN XM, 1994, NATURE, V369, P321, DOI 10.1038/369321a0; Zou H, 1997, CELL, V90, P405, DOI 10.1016/S0092-8674(00)80501-2	52	169	176	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 4	1999	18	46					6183	6190		10.1038/sj.onc.1203043	http://dx.doi.org/10.1038/sj.onc.1203043			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	260DK	10597216				2022-12-25	WOS:000083934100001
J	Bhasin, A; Goryshin, IY; Reznikoff, WS				Bhasin, A; Goryshin, IY; Reznikoff, WS			Hairpin formation in Tn5 transposition	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-POLYMERASE-I; V(D)J RECOMBINATION; TN10 TRANSPOSITION; STRAND TRANSFER; RAG2 PROTEINS; ACTIVE-SITE; 2 STEPS; INTERMEDIATE; CLEAVAGE; MU	The initial chemical steps in Tn5 transposition result in blunt end cleavage of the transposon from the donor DNA. We demonstrate that this cleavage occurs via a hairpin intermediate. The first step is a 3' hydrolytic nick by transposase. The free 3'OH then attacks the phosphodiester bond on the opposite strand, forming a hairpin at the transposon end. In addition to forming precise hairpins, Tn5 transposase can form imprecise hairpins. This is the first example of imprecise hairpin formation on transposon end DNA. To undergo strand transfer, the hairpin must to be resolved by a transposase-catalyzed hydrolytic cleavage. We show that both precise and imprecise hairpins are opened by transposase. A transposition mechanism utilizing a hairpin intermediate allows a single transposase active site to cleave both 3' and 5' strands without massive protein/DNA rearrangements.	Univ Wisconsin, Dept Biochem, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison	Reznikoff, WS (corresponding author), Univ Wisconsin, Dept Biochem, 433 Babcock Dr, Madison, WI 53706 USA.				NIGMS NIH HHS [GM50692] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Agrawal A, 1998, NATURE, V394, P744, DOI 10.1038/29457; BAINTON R, 1991, CELL, V65, P805, DOI 10.1016/0092-8674(91)90388-F; BERG DE, 1989, MOBILE DNA, P185; BOLLAND S, 1995, P NATL ACAD SCI USA, V92, P7814, DOI 10.1073/pnas.92.17.7814; Bolland S, 1996, CELL, V84, P223, DOI 10.1016/S0092-8674(00)80977-0; CHOW SA, 1992, SCIENCE, V255, P723, DOI 10.1126/science.1738845; Colot V, 1998, MOL CELL BIOL, V18, P4337, DOI 10.1128/MCB.18.7.4337; Goryshin IY, 1998, J BIOL CHEM, V273, P7367, DOI 10.1074/jbc.273.13.7367; HANIFORD D, 1994, EMBO J, V13, P3401, DOI 10.1002/j.1460-2075.1994.tb06643.x; Hiom K, 1998, CELL, V94, P463, DOI 10.1016/S0092-8674(00)81587-1; Kennedy AK, 1998, CELL, V95, P125, DOI 10.1016/S0092-8674(00)81788-2; KULKOSKY J, 1995, VIROLOGY, V206, P448, DOI 10.1016/S0042-6822(95)80060-3; Maxam A M, 1980, Methods Enzymol, V65, P499; MCBLANE JF, 1995, CELL, V83, P387, DOI 10.1016/0092-8674(95)90116-7; MIZUUCHI K, 1991, CELL, V66, P129, DOI 10.1016/0092-8674(91)90145-O; MIZUUCHI K, 1983, CELL, V35, P785, DOI 10.1016/0092-8674(83)90111-3; MIZUUCHI K, 1992, ANNU REV BIOCHEM, V61, P1011; MORISATO D, 1984, CELL, V39, P181, DOI 10.1016/0092-8674(84)90204-6; Namgoong SY, 1998, EMBO J, V17, P3775, DOI 10.1093/emboj/17.13.3775; Ramsden DA, 1996, EMBO J, V15, P3197, DOI 10.1002/j.1460-2075.1996.tb00682.x; REZNIKOFF WS, 1993, ANNU REV MICROBIOL, V47, P945, DOI 10.1146/annurev.mi.47.100193.004501; SAKAI J, 1995, EMBO J, V14, P4374, DOI 10.1002/j.1460-2075.1995.tb00112.x; Sambrook J., 2002, MOL CLONING LAB MANU; Sarnovsky RJ, 1996, EMBO J, V15, P6348, DOI 10.1002/j.1460-2075.1996.tb01024.x; SASAKAWA C, 1981, MOL GEN GENET, V182, P19, DOI 10.1007/BF00422761; STEITZ TA, 1993, P NATL ACAD SCI USA, V90, P6498, DOI 10.1073/pnas.90.14.6498; SYVANEN M, 1982, J MOL BIOL, V158, P203, DOI 10.1016/0022-2836(82)90429-6; Ton-Hoang B, 1998, EMBO J, V17, P1169, DOI 10.1093/emboj/17.4.1169; Watson MA, 1996, CELL, V85, P435, DOI 10.1016/S0092-8674(00)81121-6; Zhou M, 1998, J MOL BIOL, V276, P913, DOI 10.1006/jmbi.1997.1579	30	116	120	1	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 24	1999	274	52					37021	37029		10.1074/jbc.274.52.37021	http://dx.doi.org/10.1074/jbc.274.52.37021			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	267WR	10601258	hybrid			2022-12-25	WOS:000084382700029
J	de Mena, IR; Fernandez-Moreno, MA; Bornstein, B; Kaguni, LS; Garesse, R				de Mena, IR; Fernandez-Moreno, MA; Bornstein, B; Kaguni, LS; Garesse, R			Structure and regulated expression of the delta-aminolevulinate synthase gene from Drosophila melanogaster	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ERYTHROID 5-AMINOLEVULINATE SYNTHASE; NUCLEO-MITOCHONDRIAL INTERACTIONS; IRON-RESPONSIVE ELEMENTS; FRIEND-LEUKEMIA CELLS; DNA-BINDING PROTEINS; YEAST ACTIVATOR HAP1; H-CHAIN EXPRESSION; SEA-URCHIN EMBRYO; MESSENGER-RNA; HEME-BIOSYNTHESIS	The structure of the single copy gene encoding the putative housekeeping isoform of Drosophila melanogaster delta-aminolevulinate synthase (ALAS) has been determined. Southern and immunoblot analyses suggest that only the housekeeping isoform of the enzyme exists in Drosophila. We have localized a critical region for promoter activity to a sequence of 121 base pairs that contains a motif that is potentially recognized by factors of the nuclear respiratory factor-1 (NRF-1)/P3A2 family, flanked by two AP4 sites. Heme inhibits the expression of the gene by blocking the interaction of putative regulatory proteins to its 5' proximal region, a mechanism different from those proposed for other hemin-regulated promoters. Northern and in situ RNA hybridization experiments show that maternal alas mRNA is stored in the egg; its steady-state level decreases rapidly during the first hours of development and increases again after gastrulation in a period where the synthesis of several mRNAs encoding metabolic enzymes is activated. In the syncytial blastoderm, the alas mRNA is ubiquitously distributed and decreases in abundance substantially through cellular blastoderm. Late in embryonic development alas shows a specific pattern of expression, with an elevated mRNA level in oenocytes, suggesting an important role of these cells in the biosynthesis of hemoproteins in Drosophila.	Univ Autonoma Madrid, Fac Med, CSIC, Inst Invest Biomed Alberto Sols,Dept Bioquim, E-28029 Madrid, Spain; Michigan State Univ, Dept Biochem, E Lansing, MI 48824 USA	Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Investigaciones Biomedicas Alberto Sols (IIBM); Michigan State University	Garesse, R (corresponding author), Univ Autonoma Madrid, Fac Med, CSIC, Inst Invest Biomed Alberto Sols,Dept Bioquim, C Arzobispo Morcillo 4, E-28029 Madrid, Spain.	rafael.garesse@uam.es	Garesse, Rafael/F-3836-2012; Fernandez-Moreno, Miguel Angel/K-4425-2017	Fernandez-Moreno, Miguel Angel/0000-0002-3461-0726				ARKHIPOVA IR, 1995, GENETICS, V139, P1359; BRAIDOTTI G, 1993, J BIOL CHEM, V268, P1109; Burke TW, 1997, GENE DEV, V11, P3020, DOI 10.1101/gad.11.22.3020; Burke TW, 1996, GENE DEV, V10, P711, DOI 10.1101/gad.10.6.711; CALLEJA M, 1993, J BIOL CHEM, V268, P18891; CALZONE FJ, 1991, DEVELOPMENT, V112, P335; CASEY JL, 1988, SCIENCE, V240, P924, DOI 10.1126/science.2452485; Claros MG, 1996, EUR J BIOCHEM, V241, P779, DOI 10.1111/j.1432-1033.1996.00779.x; COCCIA EM, 1995, BLOOD, V86, P1570, DOI 10.1182/blood.V86.4.1570.bloodjournal8641570; COCCIA EM, 1992, MOL CELL BIOL, V12, P3015, DOI 10.1128/MCB.12.7.3015; Cohen SM., 1993, DEV DROSOPHILA MELAN; CONBOY JG, 1992, J BIOL CHEM, V267, P18753; COSTANZO MC, 1990, ANNU REV GENET, V24, P91; COX TC, 1991, EMBO J, V10, P1891, DOI 10.1002/j.1460-2075.1991.tb07715.x; Demerec M, 1994, BIOL DROSOPHILA; DeSimone S, 1996, DEVELOPMENT, V122, P31; DESIMONE SM, 1993, MOL CELL BIOL, V13, P3641, DOI 10.1128/MCB.13.6.3641; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DORIT RL, 1994, CURRENT PROTOCOLS MO; FERREIRA GC, 1995, J BIOENERG BIOMEMBR, V27, P151, DOI 10.1007/BF02110030; FERREIRA GC, 1995, J BIOENERG BIOMEMBR, V27, P147, DOI 10.1007/BF02110029; FORSBURG SL, 1989, ANNU REV CELL BIOL, V5, P153, DOI 10.1146/annurev.cb.05.110189.001101; Gray NK, 1996, P NATL ACAD SCI USA, V93, P4925, DOI 10.1073/pnas.93.10.4925; GRIVELL LA, 1995, CRIT REV BIOCHEM MOL, V30, P121, DOI 10.3109/10409239509085141; GRIVELL LA, 1989, EUR J BIOCHEM, V182, P477, DOI 10.1111/j.1432-1033.1989.tb14854.x; HALDI ML, 1995, MOL GEN GENET, V248, P229, DOI 10.1007/BF02190805; HAYASHI N, 1983, BIOCHEM BIOPH RES CO, V115, P700, DOI 10.1016/S0006-291X(83)80201-0; Hentze MW, 1996, P NATL ACAD SCI USA, V93, P8175, DOI 10.1073/pnas.93.16.8175; HOOG C, 1991, DEVELOPMENT, V112, P351; KAPPAS A, 1995, METABOLIC MOL BASES, V2; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LATHROP JT, 1993, SCIENCE, V259, P522, DOI 10.1126/science.8424176; Lenka N, 1998, PROG NUCLEIC ACID RE, V61, P309, DOI 10.1016/S0079-6603(08)60830-2; MARTINEZARIAS A, 1993, DEV DROSOPHILA MELAN, V1, P517; Marziali G, 1997, MOL CELL BIOL, V17, P1387, DOI 10.1128/MCB.17.3.1387; MAY BK, 1995, PROG NUCLEIC ACID RE, V51, P1, DOI 10.1016/S0079-6603(08)60875-2; MAY BK, 1986, CURR TOP CELL REGUL, V28, P233; MAY BK, 1990, MOL BIOL MED, V7, P405; Moyes CD, 1998, J EXP BIOL, V201, P299; NORDEEN SK, 1988, BIOTECHNIQUES, V6, P454; PADMANABAN G, 1989, TRENDS BIOCHEM SCI, V14, P492, DOI 10.1016/0968-0004(89)90182-5; PENA P, 1995, BIOCHEM J, P887; Ponka P, 1997, BLOOD, V89, P1; Reddy SV, 1998, BLOOD, V91, P1793, DOI 10.1182/blood.V91.5.1793.1793_1793_1801; Reddy SV, 1996, BLOOD, V88, P2288, DOI 10.1182/blood.V88.6.2288.bloodjournal8862288; RIDDLE RD, 1989, P NATL ACAD SCI USA, V86, P792, DOI 10.1073/pnas.86.3.792; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Scarpulla RC, 1997, J BIOENERG BIOMEMBR, V29, P109, DOI 10.1023/A:1022681828846; SCHOENHAUT DS, 1989, NUCLEIC ACIDS RES, V17, P7013, DOI 10.1093/nar/17.17.7013; SHAWLEE RL, 1991, MOL GEN GENET, V230, P225, DOI 10.1007/BF00290672; SOELLER WC, 1993, MOL CELL BIOL, V13, P7961, DOI 10.1128/MCB.13.12.7961; SRIVASTAVA G, 1988, J BIOL CHEM, V263, P5202; SRIVASTAVA G, 1990, MOL PHARMACOL, V38, P486; Talamillo A, 1998, MOL BIOL REP, V25, P87, DOI 10.1023/A:1006868306735; TAUTZ D, 1989, CHROMOSOMA, V98, P81, DOI 10.1007/BF00291041; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VIRBASIUS CMA, 1993, GENE DEV, V7, P2431, DOI 10.1101/gad.7.12a.2431; Wallace DC, 1997, SCI AM, V277, P40, DOI 10.1038/scientificamerican0897-40; WALLACE DC, 1993, TRENDS GENET, V9, P128, DOI 10.1016/0168-9525(93)90207-X; WIGGLESWORTH VB, 1970, PRINCIPLES INSECT PH, P411; YAMAMOTO M, 1988, J BIOL CHEM, V263, P15973; Yoshima T, 1998, J BIOL CHEM, V273, P25466, DOI 10.1074/jbc.273.39.25466; Zeviani M, 1997, J BIOENERG BIOMEMBR, V29, P121, DOI 10.1023/A:1022633912917; ZHANG L, 1995, EMBO J, V14, P313, DOI 10.1002/j.1460-2075.1995.tb07005.x; ZHANG L, 1994, J BIOL CHEM, V269, P14643; ZHANG L, 1994, GENETICS, V136, P813; Zhang L, 1996, EMBO J, V15, P4676, DOI 10.1002/j.1460-2075.1996.tb00844.x; Zhang L, 1998, MOL CELL BIOL, V18, P3819, DOI 10.1128/MCB.18.7.3819	69	28	29	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 24	1999	274	52					37321	37328		10.1074/jbc.274.52.37321	http://dx.doi.org/10.1074/jbc.274.52.37321			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	267WR	10601299	hybrid			2022-12-25	WOS:000084382700070
J	Plant, PJ; Manolson, MF; Grinstein, S; Demaurex, N				Plant, PJ; Manolson, MF; Grinstein, S; Demaurex, N			Alternative mechanisms of vacuolar acidification in H+-ATPase-deficient yeast	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTON-TRANSLOCATING ATPASE; PLASMA-MEMBRANE ATPASE; SACCHAROMYCES-CEREVISIAE; INTRACELLULAR PH; NEUROSPORA-CRASSA; MOTIVE FORCE; CELLS; TRANSPORT; VESICLES; MUTANTS	Acidification of the endosomal/lysosomal pathway by the vacuolar-type proton translocating ATPase (V-ATPase) is necessary for a variety of essential eukaryotic cellular functions. Nevertheless, yeasts lacking V-ATPase activity (Delta vma) are viable when grown at low pH, suggesting alternative methods of organellar acidification. This was confirmed by directly measuring the vacuolar pH by ratio fluorescence imaging. When Delta vma yeasts were cultured and tested in the acidic conditions required for growth of V-ATPase-deficient mutants, the vacuolar pH was 5.9. Fluid-phase pinocytosis of acidic extracellular medium cannot account for these observations, because the V-ATPase-independent vacuolar acidification was unaffected in mutants deficient in endocytosis, Similarly, internalization of the plasmalemmal H+-ATPase (Pma1p) was-ruled out, because overexpression of Pma1p failed to complement the Delta vma phenotype and did not potentiate the vacuolar acidification. To test whether weak electrolytes present in the culture medium could ferry acid equivalents to the vacuole, wildtype and the Delta vma yeasts were subjected to sudden changes in extracellular pH, In both cell types, the vacuoles rapidly alkalinized when external pH was raised from 5.5 (the approximate pH of the culture medium) to 7.5 and re-acidified when the yeasts were returned to a medium of pH 5.5. Importantly, these rapid pH changes were only observed when NH4+, routinely added as a nitrogen source, was present. The NH4+-dependent acidification was not due to efflux of NH, from the vacuole, as cells equilibrated to pH 7.5 in the absence of weak electrolytes rapidly acidified when challenged with an acidic medium containing NH4+. These findings suggest that although NH, can act as a cell-permeant proton scavenger, NH4+ may function as a protonophore, facilitating equilibration of the pH across the plasma and vacuolar membranes of yeast. The high concentration of NH4+ frequently added as a nitrogen source to yeast culture media together with effective NH4+ transporters thereby facilitate vacuolar acidification when cells are suspended in acidic solutions.	Univ Geneva, Med Ctr, Dept Physiol, CH-1211 Geneva 4, Switzerland; Univ Toronto, Dept Biochem, Toronto, ON M5S 2Z9, Canada; Hosp Sick Children, Div Cell Biol, Toronto, ON M5G 1X8, Canada	University of Geneva; University of Toronto; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids)	Demaurex, N (corresponding author), Univ Geneva, Med Ctr, Dept Physiol, 1 Michel Servet, CH-1211 Geneva 4, Switzerland.	Nicolas.Demaurex@medicine.unige.ch		Manolson, Morris/0000-0001-8755-5460; Demaurex, Nicolas/0000-0002-9933-6772				ANRAKU Y, 1992, J BIOENERG BIOMEMBR, V24, P395, DOI 10.1007/BF00762532; ANRAKU Y, 1996, HDB BIOL PHYS, V2, P93; Ausubel FM, 1992, CURRENT PROTOCOLS MO; BOWMAN BJ, 1992, J BIOENERG BIOMEMBR, V24, P361, DOI 10.1007/BF00762529; BOYER MJ, 1994, METHOD CELL BIOL, V41, P135; Carmelo V, 1997, BBA-BIOMEMBRANES, V1325, P63, DOI 10.1016/S0005-2736(96)00245-3; CIMPRICH P, 1995, FEMS MICROBIOL LETT, V130, P245; CREEK KE, 1984, LYSOSOM BIOL PATHOL, P63; Demaurex N, 1998, J BIOL CHEM, V273, P2044, DOI 10.1074/jbc.273.4.2044; DENHOLLANDER JA, 1981, BIOCHEMISTRY-US, V20, P5871, DOI 10.1021/bi00523a034; Ferea TL, 1996, GENETICS, V143, P147; Forgac M, 1998, FEBS LETT, V440, P258, DOI 10.1016/S0014-5793(98)01425-2; FORGAC M, 1989, PHYSIOL REV, V69, P765, DOI 10.1152/physrev.1989.69.3.765; Forster C, 1999, J BIOL CHEM, V274, P9442, DOI 10.1074/jbc.274.14.9442; FOURY F, 1990, J BIOL CHEM, V265, P18554; GOFFEAU A, 1981, BIOCHIM BIOPHYS ACTA, V639, P197, DOI 10.1016/0304-4173(81)90010-0; GRINSTEIN S, 1992, J EXP BIOL, V172, P179; Guldfeldt LU, 1998, APPL ENVIRON MICROB, V64, P530; HAWORTH RS, 1991, BIOCHIM BIOPHYS ACTA, V1098, P79; HAWORTH RS, 1993, MOL CELL BIOCHEM, V124, P131, DOI 10.1007/BF00929205; IMAI T, 1995, J BIOTECHNOL, V38, P165, DOI 10.1016/0168-1656(94)00130-5; JOHNSON EIM, 1989, J ENDOCRINOL, V122, P391, DOI 10.1677/joe.0.1220391; MAHNENSMITH RL, 1985, CIRC RES, V56, P773, DOI 10.1161/01.RES.56.6.773; MANOLSON MF, 1994, J BIOL CHEM, V269, P14064; Marini AM, 1997, MOL CELL BIOL, V17, P4282, DOI 10.1128/MCB.17.8.4282; MUNN AL, 1994, J CELL BIOL, V127, P373, DOI 10.1083/jcb.127.2.373; Nagaraja TN, 1998, AM J PHYSIOL-CELL PH, V274, pC883, DOI 10.1152/ajpcell.1998.274.4.C883; NAKAMOTO RK, 1991, J BIOL CHEM, V266, P7940; NAKAMOTO RK, 1989, J BIOENERG BIOMEMBR, V21, P621, DOI 10.1007/BF00808117; NEGULESCU PA, 1990, METHOD ENZYMOL, V192, P38; NELSON H, 1990, P NATL ACAD SCI USA, V87, P3503, DOI 10.1073/pnas.87.9.3503; OHSUMI Y, 1981, J BIOL CHEM, V256, P2079; OHSUMI Y, 1983, J BIOL CHEM, V258, P5614; OHYA Y, 1991, J BIOL CHEM, V266, P13971; PREISIG PA, 1990, AM J PHYSIOL, V259, pF587, DOI 10.1152/ajprenal.1990.259.4.F587; PRESTON RA, 1989, P NATL ACAD SCI USA, V86, P7027, DOI 10.1073/pnas.86.18.7027; RATHS S, 1993, J CELL BIOL, V120, P55, DOI 10.1083/jcb.120.1.55; ROBERTS CJ, 1991, METHOD ENZYMOL, V194, P644; SCHLESSER A, 1988, J BIOL CHEM, V263, P19480; SERRANO R, 1986, NATURE, V319, P689, DOI 10.1038/319689a0; SERRANO R, 1988, BIOCHIM BIOPHYS ACTA, V947, P1, DOI 10.1016/0304-4157(88)90017-2; SLAVIK J, 1984, BIOCHIM BIOPHYS ACTA, V766, P679, DOI 10.1016/0005-2728(84)90129-4; SLAVIK J, 1982, FEBS LETT, V140, P22, DOI 10.1016/0014-5793(82)80512-7; SLAYMAN CL, 1994, J EXP BIOL, V196, P419; SZE H, 1985, ANNU REV PLANT PHYS, V36, P175, DOI 10.1146/annurev.pp.36.060185.001135; TANIDA I, 1995, J BIOL CHEM, V270, P10113, DOI 10.1074/jbc.270.17.10113; THEVELEIN JM, 1987, J GEN MICROBIOL, V133, P2191; THOMAS JA, 1979, BIOCHEMISTRY-US, V18, P2210, DOI 10.1021/bi00578a012; VANWEERT AWM, 1995, J CELL BIOL, V130, P821, DOI 10.1083/jcb.130.4.821; Wall SM, 1997, AM J PHYSIOL-RENAL, V273, pF857, DOI 10.1152/ajprenal.1997.273.6.F857; YAMASHIRO CT, 1990, MOL CELL BIOL, V10, P3737, DOI 10.1128/MCB.10.7.3737	51	81	81	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 24	1999	274	52					37270	37279		10.1074/jbc.274.52.37270	http://dx.doi.org/10.1074/jbc.274.52.37270			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	267WR	10601292	Green Published, hybrid			2022-12-25	WOS:000084382700063
J	Lesieur, C; Frutiger, S; Hughes, G; Kellner, R; Pattus, F; van der Goot, FG				Lesieur, C; Frutiger, S; Hughes, G; Kellner, R; Pattus, F; van der Goot, FG			Increased stability upon heptamerization of the pore-forming toxin aerolysin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEMBRANE-CHANNEL; PROTEOLYTIC ACTIVATION; STAPHYLOCOCCUS-AUREUS; MASS-SPECTROMETRY; LIPID BILAYERS; ALPHA-TOXIN; OLIGOMERIZATION; PROAEROLYSIN; PROTEINS; INSERTION	Aerolysin is a bacterial pore-forming toxin that is secreted as an inactive precursor, which is then processed at its COOH terminus and finally forms a circular heptameric ring which inserts into membranes to form a pore. We have analyzed the stability of the precursor proaerolysin and the heptameric complex. Equilibrium unfolding induced by urea and guanidinium hydrochloride was monitored by measuring the intrinsic tryptophan fluorescence of the protein. Proaerolysin was found to unfold in two steps corresponding to the unfolding of the large COOH-terminal lobe followed by the unfolding of the small NH2-terminal domain. We show that proaerolysin contains two disulfide bridges which strongly contribute to the stability of the toxin and protect it from proteolytic attack. The stability of aerolysin was greatly enhanced by polymerization into a heptamer. Two regions of the protein, corresponding to amino acids 130-307 and 401-427, were identified, by limited proteolysis, NH2-terminal sequencing and matrix-assisted laser desorption ionization-time of flight, as being responsible for stability and maintenance of the heptamer. These regions are presumably involved in monomer/monomer interactions in the heptameric protein and are exclusively composed of beta structure. The stability of the aerolysin heptamer is reminiscent of that of pathogenic, fimbrial protein aggregates found in a variety of neurodegenerative diseases.	Univ Geneva, Dept Biochem, CH-1211 Geneva 4, Switzerland; Ctr Med Univ Geneva, Dept Med Biochem, CH-1211 Geneva, Switzerland; Merck KGAA, Preclin Res & Dev, D-64271 Darmstadt, Germany; Ecole Super Biotechnol Strasbourg, UPR 9050 CNRS, F-67400 Illkirch, France	University of Geneva; University of Geneva; Merck KGaA; Centre National de la Recherche Scientifique (CNRS)	van der Goot, FG (corresponding author), Univ Geneva, Dept Biochem, 30 Quai E Ansermet, CH-1211 Geneva 4, Switzerland.		van der Goot, Gisou G/B-2279-2012	van der Goot, Gisou G/0000-0002-8522-274X				Antson AA, 1996, CURR OPIN STRUC BIOL, V6, P142, DOI 10.1016/S0959-440X(96)80067-4; BHAKDI S, 1991, MICROBIOL REV, V55, P733, DOI 10.1128/MMBR.55.4.733-751.1991; Buckley JT, 1995, BIOCHEMISTRY-US, V34, P16450, DOI 10.1021/bi00050a028; BUCKLEY JT, 1990, BIOCHEM CELL BIOL, V68, P221, DOI 10.1139/o90-029; Cabiaux V, 1997, BIOCHEMISTRY-US, V36, P15224, DOI 10.1021/bi971216p; Capaldi RA, 1991, CURR OPIN STRUC BIOL, V1, P562, DOI 10.1016/S0959-440X(05)80078-8; Carrell RW, 1997, LANCET, V350, P134, DOI 10.1016/S0140-6736(97)02073-4; HARDIE KR, 1995, MOL MICROBIOL, V17, P1035, DOI 10.1111/j.1365-2958.1995.mmi_17061035.x; Hough DW, 1999, CURR OPIN CHEM BIOL, V3, P39, DOI 10.1016/S1367-5931(99)80008-8; HOWARD SP, 1985, J BACTERIOL, V163, P336, DOI 10.1128/JB.163.1.336-340.1985; HOWARD SP, 1982, BIOCHEMISTRY-US, V21, P1662, DOI 10.1021/bi00536a029; Jaenicke R, 1996, NATURWISSENSCHAFTEN, V83, P544; Janek K, 1999, BIOCHEMISTRY-US, V38, P8246, DOI 10.1021/bi990510+; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAURIERE M, 1993, ANAL BIOCHEM, V212, P206, DOI 10.1006/abio.1993.1313; Lesieur C, 1997, MOL MEMBR BIOL, V14, P45, DOI 10.3109/09687689709068435; MacKenzie CR, 1999, J BIOL CHEM, V274, P22604, DOI 10.1074/jbc.274.32.22604; Moniatte M, 1996, FEBS LETT, V384, P269, DOI 10.1016/0014-5793(96)00328-6; Moniatte M, 1997, INT J MASS SPECTROM, V169, P179, DOI 10.1016/S0168-1176(97)00213-9; Orpiszewski J, 1999, J MOL BIOL, V289, P413, DOI 10.1006/jmbi.1999.2768; Pace CN, 1989, PROTEIN STRUCTURE PR, P311; Parker MW, 1996, MOL MICROBIOL, V19, P205, DOI 10.1046/j.1365-2958.1996.355887.x; PARKER MW, 1994, NATURE, V367, P292, DOI 10.1038/367292a0; Perrett S, 1999, J MOL BIOL, V290, P331, DOI 10.1006/jmbi.1999.2872; Rossjohn J, 1998, BIOCHEMISTRY-US, V37, P741, DOI 10.1021/bi9721039; SAYLE RA, 1995, TRENDS BIOCHEM SCI, V20, P374, DOI 10.1016/S0968-0004(00)89080-5; SCHRAGGER H, 1987, ANAL BIOCHEM, V166, P368; Van den Burg B, 1998, P NATL ACAD SCI USA, V95, P2056, DOI 10.1073/pnas.95.5.2056; VANDERGOOT FG, 1992, BIOCHEMISTRY-US, V31, P8566, DOI 10.1021/bi00151a026; VANDERGOOT FG, 1994, J BIOL CHEM, V269, P30496; VANDERGOOT FG, 1993, J BIOL CHEM, V268, P18272; VANDERGOOT FG, 1993, BIOCHEMISTRY-US, V32, P2636, DOI 10.1021/bi00061a023; Vecsey-Semjen B, 1999, BIOCHEMISTRY-US, V38, P4296, DOI 10.1021/bi982472k; WALEV I, 1994, MICROB PATHOGENESIS, V17, P187, DOI 10.1006/mpat.1994.1065; WILMSEN HU, 1990, J MEMBRANE BIOL, V115, P71, DOI 10.1007/BF01869107; WILMSEN HU, 1992, EMBO J, V11, P2457, DOI 10.1002/j.1460-2075.1992.tb05310.x; ZITZER A, 1995, MED MICROBIOL IMMUN, V184, P37, DOI 10.1007/BF00216788	37	35	35	2	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 17	1999	274	51					36722	36728		10.1074/jbc.274.51.36722	http://dx.doi.org/10.1074/jbc.274.51.36722			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	266AV	10593978	hybrid			2022-12-25	WOS:000084279200097
J	Lin, X; Sikkink, RA; Rusnak, F; Barber, DL				Lin, X; Sikkink, RA; Rusnak, F; Barber, DL			Inhibition of calcineurin phosphatase activity by a calcineurin B homologous protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LYMPHOCYTE-T ACTIVATION; KEY SIGNALING ENZYME; BINDING DOMAIN; AUTOINHIBITORY DOMAIN; CARDIAC-HYPERTROPHY; CELL ACTIVATION; CYCLOSPORINE-A; NF-AT; CALMODULIN; CALCIUM	Calcineurin, a Ca2+/calmodulin-stimulated protein phosphatase, plays a key role in T-cell activation by regulating the activity of NFAT (nuclear factor of activated (T) under bar cells), a family of transcription factors required for the synthesis of several cytokine genes. Calcineurin is the target of the immunosuppressive drugs cyclosporin A and FK506 complexed with their cytoplasmic receptors cyclophilin and FKBP12, respectively. In this study we report that calcineurin is also the target of a recently identified Ca2+-binding protein, CHP (for calcineurin homologous protein), which shares a high degree of homology with the regulatory B subunit of calcineurin and with calmodulin, In Jurkat and HeLa cells, overexpression of CHP specifically impaired the nuclear translocation and transcriptional activity of NFAT but had no effect on AP-1 transcriptional activity and only a small (<25%) inhibitory effect on the transcriptional activity of NF kappa B. Further study indicated that CHP inhibits calcineurin activity, In cells overexpressing CHP, the phosphatase activity of immunoprecipitated calcineurin was inhibited by similar to 50%; and in a reconstituted assay, the activity of purified calcineurin was inhibited up to 97% by the addition of purified recombinant CHP in a dose-dependent manner. Moreover, pro longed activation of Jurkat cells was associated with a decreased abundance of CHP, suggesting a possible regulatory mechanism allowing activation of calcineurin. CHP, therefore, is a previously unrecognized endogenous inhibitor of calcineurin activity.	Univ Calif San Francisco, Dept Stomatol, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Surg, San Francisco, CA 94143 USA; Mayo Clin & Mayo Fdn, Dept Biochem & Mol Biol, Rochester, MN 55905 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; Mayo Clinic	Barber, DL (corresponding author), Univ Calif San Francisco, Dept Stomatol, Box 0512,HSW 604, San Francisco, CA 94143 USA.				NIDDK NIH HHS [DK40259] Funding Source: Medline; NIGMS NIH HHS [GM46865, GM 47413] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK040259, R29DK040259] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM046865, R01GM047413] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARAI K, 1990, ANNU REV BIOCHEM, V59, P783, DOI 10.1146/annurev.biochem.59.1.783; BABU YS, 1988, J MOL BIOL, V204, P191, DOI 10.1016/0022-2836(88)90608-0; BABU YS, 1985, NATURE, V315, P37, DOI 10.1038/315037a0; Barroso MR, 1996, J BIOL CHEM, V271, P10183, DOI 10.1074/jbc.271.17.10183; CHANG HY, 1995, NATURE, V376, P686, DOI 10.1038/376686a0; CLIPSTONE NA, 1992, NATURE, V357, P695, DOI 10.1038/357695a0; CLIPSTONE NA, 1993, ANN NY ACAD SCI, V696, P20; CRABTREE GR, 1989, SCIENCE, V243, P355, DOI 10.1126/science.2783497; EMMEL EA, 1989, SCIENCE, V246, P1617, DOI 10.1126/science.2595372; FRANTZ B, 1994, EMBO J, V13, P861, DOI 10.1002/j.1460-2075.1994.tb06329.x; GRIFFITH JP, 1995, CELL, V82, P507, DOI 10.1016/0092-8674(95)90439-5; HASHIMOTO Y, 1990, J BIOL CHEM, V265, P1924; HUBBARD MJ, 1989, BIOCHEMISTRY-US, V28, P1868, DOI 10.1021/bi00430a066; JAIN JN, 1993, NATURE, V365, P352, DOI 10.1038/365352a0; Kashishian A, 1998, J BIOL CHEM, V273, P27412, DOI 10.1074/jbc.273.42.27412; KAWAMURA A, 1995, J BIOL CHEM, V270, P15463, DOI 10.1074/jbc.270.26.15463; KINCAID RL, 1988, P NATL ACAD SCI USA, V85, P8983, DOI 10.1073/pnas.85.23.8983; KISSINGER CR, 1995, NATURE, V378, P641, DOI 10.1038/378641a0; KLEE CB, 1988, ADV ENZYMOL RAMB, V61, P149; Lai MM, 1998, J BIOL CHEM, V273, P18325, DOI 10.1074/jbc.273.29.18325; LAWSON MA, 1995, NATURE, V377, P75, DOI 10.1038/377075a0; Lin X, 1996, P NATL ACAD SCI USA, V93, P12631, DOI 10.1073/pnas.93.22.12631; MEANS AR, 1994, FEBS LETT, V347, P1, DOI 10.1016/0014-5793(94)00492-7; MILAN D, 1994, CELL, V79, P437, DOI 10.1016/0092-8674(94)90253-4; Molkentin JD, 1998, CELL, V93, P215, DOI 10.1016/S0092-8674(00)81573-1; MUMBY MC, 1993, PHYSIOL REV, V73, P673, DOI 10.1152/physrev.1993.73.4.673; OKEEFE SJ, 1992, NATURE, V357, P692, DOI 10.1038/357692a0; PERRINO BA, 1995, J BIOL CHEM, V270, P340, DOI 10.1074/jbc.270.1.340; PERRINO BA, 1992, J BIOL CHEM, V267, P15965; POMIES P, 1995, BIOCHEMISTRY-US, V34, P5104, DOI 10.1021/bi00015a022; Raufman JP, 1997, BBA-MOL CELL RES, V1357, P73, DOI 10.1016/S0167-4889(97)00023-2; Renstrom E, 1996, NEURON, V17, P513, DOI 10.1016/S0896-6273(00)80183-X; RUFF VA, 1995, J BIOL CHEM, V270, P22602, DOI 10.1074/jbc.270.38.22602; SCHNEIDER G, 1995, IMMUNOBIOLOGY, V193, P268, DOI 10.1016/S0171-2985(11)80554-1; SCHREIBER SL, 1992, CELL, V70, P365, DOI 10.1016/0092-8674(92)90158-9; SHAW JP, 1988, SCIENCE, V241, P202, DOI 10.1126/science.3260404; SIKKINK R, 1995, BIOCHEMISTRY-US, V34, P8348, DOI 10.1021/bi00026a016; Sun L, 1998, IMMUNITY, V8, P703, DOI 10.1016/S1074-7613(00)80575-0; Sussman MA, 1998, SCIENCE, V281, P1690, DOI 10.1126/science.281.5383.1690; SWANSON SKH, 1992, P NATL ACAD SCI USA, V89, P3741, DOI 10.1073/pnas.89.9.3741; SZOLLOSI J, 1991, CYTOMETRY, V12, P707, DOI 10.1002/cyto.990120804; Timmerman LA, 1996, NATURE, V383, P837, DOI 10.1038/383837a0; ULLMAN KS, 1990, ANNU REV IMMUNOL, V8, P421, DOI 10.1146/annurev.immunol.8.1.421	43	100	113	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 17	1999	274	51					36125	36131		10.1074/jbc.274.51.36125	http://dx.doi.org/10.1074/jbc.274.51.36125			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	266AV	10593895	hybrid			2022-12-25	WOS:000084279200014
J	Amann, KJ; Guo, AWX; Ervasti, JM				Amann, KJ; Guo, AWX; Ervasti, JM			Utrophin lacks the rod domain actin binding activity of dystrophin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DUCHENNE MUSCULAR-DYSTROPHY; TRANSGENIC MDX MICE; DEFICIENT MICE; F-ACTIN; GLYCOPROTEIN-COMPLEX; FULL-LENGTH; NEUROMUSCULAR-JUNCTIONS; SKELETAL-MUSCLE; TERMINAL DOMAIN; GENE-THERAPY	We previously identified a cluster of basic spectrin-like repeats in the dystrophin rod domain that binds F-actin through electrostatic interactions (Amann, K, J,, Renley, B, A., and Ervasti, J,M. (1998) J, Biol. Chem, 273, 28419-28423), Because of the importance of actin binding to the presumed physiological role of dystrophin, we sought to determine whether the autosomal homologue of dystrophin, utrophin, shared this rod domain actin binding activity. We therefore produced recombinant proteins representing the cluster of basic repeats of the dystrophin rod domain (DYSR11-17) or the homologous region of the utrophin rod domain (UTROR11-16). Although UTROR11-16 is 64% similar and 41% identical to DYSR11-17, UTROR11-16 (pI = 4.86) lacks the basic character of the repeats found in DYSR11-17 (pI = 7.44), By circular dichroism, gel filtration, and sedimentation velocity analysis, we determined that each purified recombinant protein had adopted a stable, predominantly ct-helical fold and existed as a highly soluble monomer, DYSR11-17 bound F-actin with an apparent Kd of 7.3 +/- 1.3 mu M and a molar stoichiometry of 1:5, Significantly, UTROR11-16 failed to bind F-actin at concentrations as high as 100 mu M. We present these findings as further support for the electrostatic nature of the interaction of the dystrophin rod domain with F-actin and suggest that utrophin interacts with the cytoskeleton in a manner distinct from dystrophin.	Univ Wisconsin, Sch Med, Dept Physiol, Serv Mem Inst 127, Madison, WI 53706 USA; Univ Wisconsin, Sch Med, Grad Program Cellular & Mol Biol, Madison, WI 53706 USA; Univ Minnesota, Dept Cell Biol & Neuroanat, Minneapolis, MN 55455 USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of Minnesota System; University of Minnesota Twin Cities	Ervasti, JM (corresponding author), Univ Wisconsin, Sch Med, Dept Physiol, Serv Mem Inst 127, 1300 Univ Ave, Madison, WI 53706 USA.		Ervasti, James/AAZ-4786-2020; Roberts, Roland G/C-3596-2009; Zhang, Qiuping/L-3522-2019	Zhang, Qiuping/0000-0002-4000-3957	NIAMS NIH HHS [AR42423, AR01985] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [K02AR001985, R01AR042423] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ACSADI G, 1991, NATURE, V352, P815, DOI 10.1038/352815a0; Amann KJ, 1998, J BIOL CHEM, V273, P28419, DOI 10.1074/jbc.273.43.28419; BEGGS AH, 1991, AM J HUM GENET, V49, P54; BROOKS SPJ, 1992, BIOTECHNIQUES, V13, P906; Calvert R, 1996, BIOPHYS J, V71, P1605, DOI 10.1016/S0006-3495(96)79363-3; Chan YM, 1997, FEBS LETT, V410, P153, DOI 10.1016/S0014-5793(97)00454-7; CORRADO K, 1994, FEBS LETT, V344, P255, DOI 10.1016/0014-5793(94)00397-1; Corrado K, 1996, J CELL BIOL, V134, P873, DOI 10.1083/jcb.134.4.873; Deconinck AE, 1997, CELL, V90, P717, DOI 10.1016/S0092-8674(00)80532-2; Deconinck AE, 1997, J CELL BIOL, V136, P883, DOI 10.1083/jcb.136.4.883; Deconinck N, 1997, NAT MED, V3, P1216, DOI 10.1038/nm1197-1216; ENGLAND SB, 1990, NATURE, V343, P180, DOI 10.1038/343180a0; ERVASTI JM, 1993, J CELL BIOL, V122, P809, DOI 10.1083/jcb.122.4.809; FABBRIZIO E, 1993, BIOCHEMISTRY-US, V32, P10457, DOI 10.1021/bi00090a023; Grady RM, 1997, CELL, V90, P729, DOI 10.1016/S0092-8674(00)80533-4; Grady RM, 1997, J CELL BIOL, V136, P871, DOI 10.1083/jcb.136.4.871; GREENFIE.N, 1969, BIOCHEMISTRY-US, V8, P4108, DOI 10.1021/bi00838a031; Guo WXA, 1996, FEBS LETT, V398, P259; HEMMINGS L, 1992, J CELL BIOL, V116, P1369, DOI 10.1083/jcb.116.6.1369; JARRETT HW, 1995, J BIOL CHEM, V270, P5578, DOI 10.1074/jbc.270.10.5578; KAHANA E, 1994, J MOL BIOL, V235, P1271, DOI 10.1006/jmbi.1994.1080; KAHANA E, 1995, BIOCHEMISTRY-US, V34, P8110, DOI 10.1021/bi00025a017; Kahana E, 1997, CELL MOTIL CYTOSKEL, V36, P246; KOENIG M, 1988, CELL, V53, P219, DOI 10.1016/0092-8674(88)90383-2; KRAMARCY NR, 1994, J BIOL CHEM, V269, P2870; Li XL, 1996, J BIOL CHEM, V271, P15695, DOI 10.1074/jbc.271.26.15695; LOVE DR, 1991, J MED GENET, V28, P860, DOI 10.1136/jmg.28.12.860; Lumeng CN, 1999, HUM MOL GENET, V8, P593, DOI 10.1093/hmg/8.4.593; OHLENDIECK K, 1991, NEURON, V7, P499, DOI 10.1016/0896-6273(91)90301-F; PETROF BJ, 1993, P NATL ACAD SCI USA, V90, P3710, DOI 10.1073/pnas.90.8.3710; PONS F, 1994, J NEUROL SCI, V122, P162, DOI 10.1016/0022-510X(94)90295-X; Rafael JA, 1998, NAT GENET, V19, P79, DOI 10.1038/ng0598-79; RAFAEL JA, 1994, HUM MOL GENET, V3, P1725, DOI 10.1093/hmg/3.10.1725; Rief M, 1999, J MOL BIOL, V286, P553, DOI 10.1006/jmbi.1998.2466; Rybakova IN, 1996, J CELL BIOL, V135, P661, DOI 10.1083/jcb.135.3.661; Rybakova IN, 1997, J BIOL CHEM, V272, P28771, DOI 10.1074/jbc.272.45.28771; Schatzberg SJ, 1999, NEUROMUSCULAR DISORD, V9, P289, DOI 10.1016/S0960-8966(99)00011-5; SIEGEL LM, 1966, BIOCHIM BIOPHYS ACTA, V112, P346, DOI 10.1016/0926-6585(66)90333-5; SUZUKI A, 1992, FEBS LETT, V308, P154, DOI 10.1016/0014-5793(92)81265-N; SUZUKI A, 1994, EUR J BIOCHEM, V220, P283, DOI 10.1111/j.1432-1033.1994.tb18624.x; Taylor J, 1997, NEUROPATH APPL NEURO, V23, P399; Tinsley J, 1998, NAT MED, V4, P1441, DOI 10.1038/4033; Tinsley JM, 1996, NATURE, V384, P349, DOI 10.1038/384349a0; VAINZOF M, 1995, AM J MED GENET, V58, P305, DOI 10.1002/ajmg.1320580403; WAY M, 1992, FEBS LETT, V301, P243, DOI 10.1016/0014-5793(92)80249-G; WELLS DJ, 1995, HUM MOL GENET, V4, P1245, DOI 10.1093/hmg/4.8.1245; Williams MW, 1999, J CELL BIOL, V144, P1259, DOI 10.1083/jcb.144.6.1259; WINDER SJ, 1995, FEBS LETT, V357, P125, DOI 10.1016/0014-5793(94)01347-4; WINDER SJ, 1995, J CELL SCI, V108, P63; WINDER SJ, 1995, FEBS LETT, V369, P27, DOI 10.1016/0014-5793(95)00398-S	50	52	55	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 10	1999	274	50					35375	35380		10.1074/jbc.274.50.35375	http://dx.doi.org/10.1074/jbc.274.50.35375			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	264NG	10585405	hybrid			2022-12-25	WOS:000084187900017
J	Naumann, M; Bech-Otschir, D; Huang, XH; Ferrell, K; Dubiel, W				Naumann, M; Bech-Otschir, D; Huang, XH; Ferrell, K; Dubiel, W			COP9 signalosome-directed c-Jun activation/stabilization is independent of JNK	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATOR PROTEIN-1; KINASE; TRANSDUCTION; DEGRADATION; COMPLEX; PHOSPHORYLATION; INHIBITOR; CELLS	The basic region-leucine zipper transcription factor c-Jun regulates gene expression and cell function. It participates in the formation of homo- or heterodimeric complexes that specifically bind to DNA sequences called activating protein 1 (AP-1) sites, The stability and activity of c-Jun is regulated by phosphorylation within the N-terminal activation domain. Mitogen- and stress-activated c-Jun N-terminal kinases (JNKs) were previously the only described enzymes phosphorylating c-Jun at the N terminus in vivo. In this report we demonstrate a JNK-independent activation of c-Jun in vivo directed by the constitutive photomorphogenesis (COP9) signalosome. The overexpression of signalosome subunit 2 (Sgn2), a subunit of the COP9 signalosome, leads to de novo assembly of the complex with a partial incorporation of the overexpressed subunit, The de novo formation of COP9 signalosome parallels an increase of c-Jun protein resulting in elevated AP-1 transcriptional activity. The c-Jun activation caused by Sgn2 overexpression is independent of JNK and mitogen-activated protein kinase kinase 4. The data demonstrate the existence of a novel COP9 signalosome-directed c-Jun activation pathway.	Max Planck Inst Infekt Biol, Mol Biol Abt, D-10117 Berlin, Germany; Humboldt Univ, Med Fac Charite, Inst Biochem, D-10117 Berlin, Germany	Max Planck Society; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Naumann, M (corresponding author), Max Planck Inst Infekt Biol, Mol Biol Abt, D-10117 Berlin, Germany.		Naumann, Michael/B-5285-2011	Naumann, Michael/0000-0002-8060-2313; Dubiel, Wolfgang/0000-0002-3393-0701				Chamovitz DA, 1996, CELL, V86, P115, DOI 10.1016/S0092-8674(00)80082-3; Claret FX, 1996, NATURE, V383, P453, DOI 10.1038/383453a0; Fuchs SY, 1996, ONCOGENE, V13, P1531; Glickman MH, 1998, CELL, V94, P615, DOI 10.1016/S0092-8674(00)81603-7; Henke W, 1999, MOL BIOL REP, V26, P29, DOI 10.1023/A:1006991419464; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Huang CS, 1997, P NATL ACAD SCI USA, V94, P11957, DOI 10.1073/pnas.94.22.11957; HUANG TS, 1991, P NATL ACAD SCI USA, V88, P5292, DOI 10.1073/pnas.88.12.5292; Ip YT, 1998, CURR OPIN CELL BIOL, V10, P205, DOI 10.1016/S0955-0674(98)80143-9; Karin M, 1997, CURR OPIN CELL BIOL, V9, P240, DOI 10.1016/S0955-0674(97)80068-3; Musti AM, 1997, SCIENCE, V275, P400, DOI 10.1126/science.275.5298.400; Naumann M, 1998, J EXP MED, V188, P1277, DOI 10.1084/jem.188.7.1277; Osterlund MT, 1999, TRENDS CELL BIOL, V9, P113, DOI 10.1016/S0962-8924(99)01499-3; Seeger M, 1998, FASEB J, V12, P469, DOI 10.1096/fasebj.12.6.469; Spain BH, 1996, MOL CELL BIOL, V16, P6698; Tomoda K, 1999, NATURE, V398, P160, DOI 10.1038/18230; TREIER M, 1994, CELL, V78, P787, DOI 10.1016/S0092-8674(94)90502-9; Wei N, 1999, TRENDS GENET, V15, P98, DOI 10.1016/S0168-9525(98)01670-9; Wei N, 1998, CURR BIOL, V8, P919, DOI 10.1016/S0960-9822(07)00372-7	19	123	131	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 10	1999	274	50					35297	35300		10.1074/jbc.274.50.35297	http://dx.doi.org/10.1074/jbc.274.50.35297			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	264NG	10585392	hybrid			2022-12-25	WOS:000084187900004
J	Snoek, GT; Berrie, CP; Geijtenbeek, TBH; van der Helm, HA; Cadee, JA; Iurisci, C; Corda, D; Wirtz, KWA				Snoek, GT; Berrie, CP; Geijtenbeek, TBH; van der Helm, HA; Cadee, JA; Iurisci, C; Corda, D; Wirtz, KWA			Overexpression of phosphatidylinositol transfer protein alpha in NIH3T3 cells activates a phospholipase A	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INOSITOL TRISPHOSPHATE; LYSOPHOSPHATIDIC ACID; SIGNALING PATHWAYS; GOLGI SYSTEM; BOVINE BRAIN; RAS; TRANSFORMATION; RECEPTOR; GLYCEROPHOSPHOINOSITOLS; IDENTIFICATION	In order to investigate the cellular function of the mammalian phosphatidylinositol transfer protein alpha (PI-TP alpha), NIH3T3 fibroblast cells were transfected with the cDNA encoding mouse PI-TP alpha. Two stable cell lines, i.e. SPI6 and SPI8, were isolated, which showed a 2- and 3-fold increase, respectively, in the level of PI-TP alpha. Overexpression of PI-TP alpha resulted in a decrease in the duration of the cell cycle from 21 h for the wild type (nontransfected) NIH3T3 (wtNIH3T3) cells and mock-transfected cells to 13-14 h for SP16 and SP18 cells. Analysis of exponentially growing cultures by fluorescence-activated cell sorting showed that a shorter G(1) phase is mainly responsible for this decrease. The saturation density of the cells increased from 0.20 x 10(5) cells/cm(2) for wtNIH3T3 cells to 0.53 x 10(5) cells/cm(2) for SPI6 and SPI8 cells. However, anchorage-dependent growth was maintained as shown by the inability of the cells to grow in soft agar. Upon equilibrium labeling of the cells with myo-[H-3] inositol, the relative incorporation of radioactivity in the total inositol phosphate fraction was 2-3-fold increased in SPI6 and SPI8 cells when compared with wtNIH3T3 cells. A detailed analysis of the inositol metabolites showed increased levels of glycerophosphoinositol, Ins(1)P, Ins(2)P, and lysophosphatidylinositol (lyso-PtdIns) in SPI8 cells, whereas the levels of phosphatidylinositol (PtdIns) and phosphatidylinositol 4,5-bisphosphate were the same as those in control cells, The addition of PI-TP alpha to a total lysate of myo-[H-3]inositol-labeled wtNIH3T3 cells stimulated the formation of lyso-PtdIns. The addition of Ca2+ further increased this formation. Based on these observations, we propose that PI-TP alpha is involved in the production of lyso-PtdIns by activating a phospholipase A acting on PtdIns, The increased level of lyso-PtdIns that is produced in this reaction could be responsible for the increased growth rate and the partial loss of contact inhibition in SPI8 and SPI6 cells, The addition of growth factors (platelet-derived growth factor, bombesin) to these overexpressers did not activate the phospholipase C-dependent degradation of phosphatidylinositol 4,5-bisphosphate.	Univ Utrecht, Ctr Biomembranes & Lipid Enzymol, Dept Lipid Biochem, Inst Biomembranes, NL-3584 CH Utrecht, Netherlands; Ist Ric Farmacol Mario Negri, Consorzio Mario Negri Sud, Dept Cell Biol & Oncol, I-66030 Santa Maria Imbaro, Chieti, Italy	Utrecht University; Consorzio Mario Negri Sud; Istituto di Ricerche Farmacologiche Mario Negri IRCCS	Snoek, GT (corresponding author), Univ Utrecht, Ctr Biomembranes & Lipid Enzymol, Dept Lipid Biochem, Inst Biomembranes, Padualaan 8, NL-3584 CH Utrecht, Netherlands.	g.t.snoek@chem.uu.nl	Corda, Daniela/K-6385-2016; Geijtenbeek, Teunis/C-2229-2009	Corda, Daniela/0000-0002-3614-751X; 				AITKEN JF, 1990, J BIOL CHEM, V265, P4711; ALONSO T, 1988, P NATL ACAD SCI USA, V85, P4271, DOI 10.1073/pnas.85.12.4271; BANKAITIS VA, 1989, J CELL BIOL, V108, P1271, DOI 10.1083/jcb.108.4.1271; BANKAITIS VA, 1990, NATURE, V347, P561, DOI 10.1038/347561a0; BARAN DT, 1988, ENDOCRINOLOGY, V122, P930, DOI 10.1210/endo-122-3-930; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BLIGH EG, 1959, CAN J BIOCH PHYSL, V96, P634; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; Corda D, 1996, ANTICANCER RES, V16, P1341; CUNNINGHAM E, 1995, CURR BIOL, V5, P775, DOI 10.1016/S0960-9822(95)00154-0; DEVRIES KJ, 1994, EXP CELL RES, V215, P109, DOI 10.1006/excr.1994.1321; DeVries KJ, 1996, EXP CELL RES, V227, P33, DOI 10.1006/excr.1996.0246; DEVRIES KJ, 1995, BIOCHEM J, V310, P643, DOI 10.1042/bj3100643; DICKESON SK, 1989, J BIOL CHEM, V264, P16557; DICKESON SK, 1994, GENE, V142, P301, DOI 10.1016/0378-1119(94)90279-8; Falasca M, 1998, ONCOGENE, V16, P2357, DOI 10.1038/sj.onc.1201758; Falasca M, 1997, MOL BIOL CELL, V8, P443, DOI 10.1091/mbc.8.3.443; FALASCA M, 1995, ONCOGENE, V10, P2113; Falasca M, 1996, EUR J BIOCHEM, V241, P386, DOI 10.1111/j.1432-1033.1996.00386.x; FALASCA M, 1994, EUR J BIOCHEM, V221, P383, DOI 10.1111/j.1432-1033.1994.tb18750.x; Fensome A, 1996, CURR BIOL, V6, P730, DOI 10.1016/S0960-9822(09)00454-0; GEIJTENBEEK TBH, 1994, BBA-LIPID LIPID MET, V1213, P309, DOI 10.1016/0005-2760(94)00063-8; GREEN S, 1988, NUCLEIC ACIDS RES, V16, P369, DOI 10.1093/nar/16.1.369; HAY JC, 1993, NATURE, V366, P572, DOI 10.1038/366572a0; Helmkamp G M Jr, 1990, Subcell Biochem, V16, P129; IACOVELLI L, 1993, J BIOL CHEM, V268, P20402; KAUFFMANNZEH A, 1995, SCIENCE, V268, P1188, DOI 10.1126/science.7761838; KIM HK, 1991, CELL, V65, P435, DOI 10.1016/0092-8674(91)90461-7; KULAR G, 1997, BIOCH J; MAJERUS PW, 1988, J BIOL CHEM, V263, P3051; METZ SA, 1986, BIOCHEM BIOPH RES CO, V138, P720, DOI 10.1016/S0006-291X(86)80556-3; NISHIZUKA Y, 1995, FASEB J, V9, P484, DOI 10.1096/fasebj.9.7.7737456; OHASHI M, 1995, NATURE, V377, P544, DOI 10.1038/377544a0; PANAYOTOU G, 1993, BIOESSAYS, V15, P171, DOI 10.1002/bies.950150305; PIOMELLI D, 1995, CURR BIOL, V5, P274; ROSS TS, 1991, J BIOL CHEM, V266, P9086; ROSS TS, 1992, J BIOL CHEM, V267, P19924; SASAKAWA N, 1995, BIOCHEM PHARMACOL, V50, P137, DOI 10.1016/0006-2952(95)00059-9; SNOEK GT, 1992, J CELL BIOCHEM, V49, P339, DOI 10.1002/jcb.240490404; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; THOMAS GMH, 1993, CELL, V74, P919, DOI 10.1016/0092-8674(93)90471-2; TIMMERMANSHEREIJGERS JLPM, 1995, J BIOL CHEM, V270, P14263, DOI 10.1074/jbc.270.24.14263; Toker A, 1997, NATURE, V387, P673, DOI 10.1038/42648; VALITUTTI S, 1991, CELL SIGNAL, V3, P321, DOI 10.1016/0898-6568(91)90061-X; VANDERBEND RL, 1992, EMBO J, V11, P2495, DOI 10.1002/j.1460-2075.1992.tb05314.x; VANPARIDON PA, 1987, BIOCHEM SOC T, V15, P321, DOI 10.1042/bst0150321; VANPARIDON PA, 1987, BIOCHIM BIOPHYS ACTA, V903, P68, DOI 10.1016/0005-2736(87)90156-8; VANPARIDON PA, 1987, BIOCHIM BIOPHYS ACTA, V898, P172, DOI 10.1016/0005-2736(87)90035-6; VENUTI SE, 1988, BIOCHIM BIOPHYS ACTA, V946, P119, DOI 10.1016/0005-2736(88)90464-6; VIEIRA J, 1991, GENE, V100, P189, DOI 10.1016/0378-1119(91)90365-I; Wirtz KWA, 1997, BIOCHEM J, V324, P353, DOI 10.1042/bj3240353; WIRTZ KWA, 1978, PROTIDES BIOL FLUIDS, P25	52	37	39	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 10	1999	274	50					35393	35399		10.1074/jbc.274.50.35393	http://dx.doi.org/10.1074/jbc.274.50.35393			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	264NG	10585408	hybrid			2022-12-25	WOS:000084187900020
J	Tanhuanpaa, K; Somerharju, P				Tanhuanpaa, K; Somerharju, P			gamma-cyclodextrins greatly enhance translocation of hydrophobic fluorescent phospholipids from vesicles to cells in culture - Importance of molecular hydrophobicity in phospholipid trafficking studies	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMA-MEMBRANE; PHOSPHATIDYLCHOLINE TRANSFER; INTRACELLULAR-TRANSPORT; CHOLESTEROL DEPLETION; TRANSBILAYER MOVEMENT; LIPID DISTRIBUTION; TRANSFER PROTEIN; GOLGI-APPARATUS; MAMMALIAN-CELLS; FIBROBLASTS	Short-chain, fluorescent derivatives are commonly used to investigate intracellular phospholipid trafficking. However, their use can yield misleading results because they, unlike the native species, can rapidly distribute between organelles due to their low hydrophobicity, On the other hand, hydrophobic derivatives are very difficult to introduce to cells and thus have hardly been used. Here we show that carboxyethylated gamma-cyclodextrin (CE-gamma-CD) greatly enhances transfer of a variety of hydrophobic fluorescent phospholipid derivatives from vesicles to cultured cells. Several lines of evidence indicate that CE-gamma-CD enhances transfer of lipid molecules by increasing their effective concentration in the aqueous phase, rather than by inducing membrane fusion or hemifusion, Incubation with CE-gamma-CD and donor lipid vesicles does not extract cholesterol or phospholipids from the cells or compromise plasma membrane intactness or long term cell viability. Using CE-gamma-CD-mediated transfer, we introduced hydrophobic pyrene-labeled phosphatidylserine to the plasma membrane of fibroblast cells and followed their distribution with time. In contrast to what has been previously observed for other, less hydrophobic species, transport of this lipid to the Golgi apparatus or mitochondria was not detected. Rather, much of this fluorescent PS remained in the plasma membrane or was incorporated to various endocytotic compartments. These findings indicate that the native, typically hydrophobic phosphatidylserine molecules efflux only very slowly via the cytoplasm to intracellular organelles. This helps to explain how cells can maintain a very high concentration of phosphatidylserine in the inner leaflet of their plasma membrane. Furthermore, the present results underline the importance of using hydrophobic analogues when studying intracellular trafficking of many phosphoIipid classes.	Univ Helsinki, Dept Med Chem, Inst Biomed, Helsinki 00014, Finland	University of Helsinki	Somerharju, P (corresponding author), Univ Helsinki, Dept Med Chem, Inst Biomed, Siltavuorenpenger 10 A, Helsinki 00014, Finland.	pentti.somerharju@helsinki.fi						Absolom D R, 1986, Methods Enzymol, V132, P95; Allan D, 1996, MOL MEMBR BIOL, V13, P81, DOI 10.3109/09687689609160580; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Brugger B, 1997, P NATL ACAD SCI USA, V94, P2339, DOI 10.1073/pnas.94.6.2339; CHATTOPADHYAY A, 1987, BIOCHEMISTRY-US, V26, P39, DOI 10.1021/bi00375a006; DENNIS EA, 1972, J LIPID RES, V13, P263; DEVAUX PF, 1992, ANNU REV BIOPH BIOM, V21, P417, DOI 10.1146/annurev.bb.21.060192.002221; DIX JA, 1990, BIOCHEMISTRY-US, V29, P1949, DOI 10.1021/bi00459a041; EKLUND KK, 1992, BIOCHEMISTRY-US, V31, P8560, DOI 10.1021/bi00151a025; ENGLANDER SW, 1987, ANAL BIOCHEM, V161, P300, DOI 10.1016/0003-2697(87)90454-4; Furuchi T, 1998, J BIOL CHEM, V273, P21099, DOI 10.1074/jbc.273.33.21099; HAN XL, 1994, P NATL ACAD SCI USA, V91, P10635, DOI 10.1073/pnas.91.22.10635; Heikinheimo L, 1998, J BIOL CHEM, V273, P3327, DOI 10.1074/jbc.273.6.3327; HOEKSTRA D, 1992, BIOCHIM BIOPHYS ACTA, V1113, P277, DOI 10.1016/0304-4157(92)90002-R; JASINSKA R, 1993, BIOCHIM BIOPHYS ACTA, V1152, P161, DOI 10.1016/0005-2736(93)90243-S; JONES JD, 1989, BIOCHEMISTRY-US, V28, P129, DOI 10.1021/bi00427a019; KASURINEN J, 1992, J BIOL CHEM, V267, P6563; KASURINEN J, 1995, BIOCHEMISTRY-US, V34, P2049, DOI 10.1021/bi00006a027; KEENAN TW, 1970, BIOCHEMISTRY-US, V9, P19, DOI 10.1021/bi00803a003; KILSDONK EPC, 1995, J BIOL CHEM, V270, P17250, DOI 10.1074/jbc.270.29.17250; KLEIN U, 1995, BIOCHEMISTRY-US, V34, P13784, DOI 10.1021/bi00042a009; KOBAYASHI T, 1991, J CELL BIOL, V113, P235, DOI 10.1083/jcb.113.2.235; KOVAL M, 1991, BIOCHIM BIOPHYS ACTA, V1082, P113, DOI 10.1016/0005-2760(91)90184-J; Lusa S, 1998, BBA-LIPID LIPID MET, V1389, P112, DOI 10.1016/S0005-2760(97)00164-1; MARTIN OC, 1987, J BIOL CHEM, V262, P5890; MASSEY JB, 1982, J BIOL CHEM, V257, P5444; MASSEY JB, 1984, BIOCHIM BIOPHYS ACTA, V794, P274, DOI 10.1016/0005-2760(84)90156-5; MASSEY JB, 1982, BIOCHEMISTRY-US, V21, P3630, DOI 10.1021/bi00258a016; MCLEAN LR, 1981, BIOCHEMISTRY-US, V20, P2893, DOI 10.1021/bi00513a028; Mukherjee S, 1999, J CELL BIOL, V144, P1271, DOI 10.1083/jcb.144.6.1271; NICHOLS JW, 1985, BIOCHEMISTRY-US, V24, P6390, DOI 10.1021/bi00344a011; OHTANI Y, 1989, EUR J BIOCHEM, V186, P17, DOI 10.1111/j.1432-1033.1989.tb15171.x; PAGANO RE, 1985, SCIENCE, V229, P1051, DOI 10.1126/science.4035344; PAGANO RE, 1983, J BIOL CHEM, V258, P2034; Pike LJ, 1998, J BIOL CHEM, V273, P22298, DOI 10.1074/jbc.273.35.22298; POWNALL HJ, 1989, CHEM PHYS LIPIDS, V50, P191, DOI 10.1016/0009-3084(89)90050-9; ROSENWALD AG, 1993, ADV LIPID RES, V26, P101; ROUSER G, 1970, LIPIDS, V5, P494, DOI 10.1007/BF02531316; SILVIUS JR, 1991, CHEM PHYS LIPIDS, V57, P241, DOI 10.1016/0009-3084(91)90079-Q; SLEIGHT RG, 1984, J CELL BIOL, V99, P742, DOI 10.1083/jcb.99.2.742; SLEIGHT RG, 1985, J BIOL CHEM, V260, P1146; SOMERHARJU P, 1982, CHEM PHYS LIPIDS, V30, P81, DOI 10.1016/0009-3084(82)90009-3; SOMERHARJU PJ, 1987, BIOCHEMISTRY-US, V26, P7193, DOI 10.1021/bi00396a048; SOMERHARJU PJ, 1985, BIOCHEMISTRY-US, V24, P2773, DOI 10.1021/bi00332a027; STORRIE B, 1990, METHOD ENZYMOL, V182, P203; van Meer G, 1998, TRENDS CELL BIOL, V8, P29, DOI 10.1016/S0962-8924(97)01196-3; VAN MEER G, 1983, J CELL BIOL, V97, P1365, DOI 10.1083/jcb.97.5.1365; Van Meer Gerrit, 1994, V23, P1; VANAMERONGEN A, 1989, BIOCHIM BIOPHYS ACTA, V1004, P36, DOI 10.1016/0005-2760(89)90209-9; VANPARIDON PA, 1988, BIOCHEMISTRY-US, V27, P6208, DOI 10.1021/bi00417a003; VIA DP, 1985, BIOCHIM BIOPHYS ACTA, V837, P27, DOI 10.1016/0005-2760(85)90082-7; VOELKER DR, 1991, MICROBIOL REV, V55, P543, DOI 10.1128/MMBR.55.4.543-560.1991; WOLF DE, 1992, BIOCHEMISTRY-US, V31, P2865, DOI 10.1021/bi00126a004	53	34	34	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 10	1999	274	50					35359	35366		10.1074/jbc.274.50.35359	http://dx.doi.org/10.1074/jbc.274.50.35359			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	264NG	10585403	hybrid			2022-12-25	WOS:000084187900015
J	Ueno, M; Masutani, H; Arai, RJ; Yamauchi, A; Hirota, K; Sakai, T; Inamoto, T; Yamaoka, Y; Yodoi, J; Nikaido, T				Ueno, M; Masutani, H; Arai, RJ; Yamauchi, A; Hirota, K; Sakai, T; Inamoto, T; Yamaoka, Y; Yodoi, J; Nikaido, T			Thioredoxin-dependent redox regulation of p53-mediated p21 activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							T-CELL LEUKEMIA; DNA-BINDING ACTIVITY; HTLV-I; CYSTEINE RESIDUES; OXIDATIVE STRESS; REPAIR ENZYME; WILD-TYPE; P53; EXPRESSION; PROTEIN	Thioredoxin (TRX) is a dithiol-reducing enzyme that is induced by various oxidative stresses. TRX regulates the activity of DNA-binding proteins, including Jun/Fos and nuclear factor-KB. TRX also interacts with an intranuclear reducing molecule redox factor 1 (Ref-1), which enhances the activity of Jun/Fos. Here, we have investigated the role of TRX in the regulation of p53 activity. Electrophoretic mobility shift assay showed that TRX augmented the DNA binding activity of p53 and also further potentiated Ref-l-enhanced p53 activity. Luciferase assay revealed that transfection of TRX enhanced p53-dependent expression of p21 and further intensified Ref-1-mediated p53 activation. Furthermore, Western blot analysis revealed that p53-dependent induction of p21 protein was also facilitated by transfection with TRX. Overexpression of transdominant negative mutant TRX (mTRX) suppressed the effects of TRX or Ref-1, showing a functional interaction between TRX and Ref-1. cis-Diamminedichloroplatinum (II) (CDDP) induced p53 activation and p21 transactivation. The p53-dependent p21 transactivation induced by CDDP was inhibited by mTRX overexpression, suggesting that TRX-dependent redox regulation is physiologically involved in p53 regulation. CDDP also stimulated translocation of TRX from the cytosol into the nucleus. Hence, TRX-dependent redox regulation of p53 activity indicates coupling of the oxidative stress response and p53-dependent repair mechanism.	Inst Virus Res, Dept Biol Responses, Shogoin, Japan; Kyoto Univ Hosp, Dept Anaesthesia, Kyoto 6068507, Japan; Kyoto Univ, Grad Sch Med, Dept Surg Gastroenterol, Kyoto 6068507, Japan; Kyoto Prefectural Univ Med, Dept Prevent Med, Kyoto 6020841, Japan; Shinshu Univ, Sch Med, Dept Obstet & Gynecol, Matsumoto, Nagano 3908621, Japan	Kyoto University; Kyoto University; Kyoto Prefectural University of Medicine; Shinshu University	Yodoi, J (corresponding author), Inst Virus Res, Dept Biol Responses, 53 Kawahara Cho, Shogoin, Japan.	yodoi@virus.kyoto-u.ac.jp	Inamoto, Teruo/ABD-2935-2020; Arai, Roberto/I-3590-2012; Masutani, Hiroshi/B-5114-2014; Hirota, Kiichi/E-9181-2010	Hirota, Kiichi/0000-0003-1110-0827; Masutani, Hiroshi/0000-0001-7633-2827				Akamatsu Y, 1997, J BIOL CHEM, V272, P14497, DOI 10.1074/jbc.272.23.14497; Banin S, 1998, SCIENCE, V281, P1674, DOI 10.1126/science.281.5383.1674; BARGONETTI J, 1993, GENE DEV, V7, P2565, DOI 10.1101/gad.7.12b.2565; BOUSSIF O, 1995, P NATL ACAD SCI USA, V92, P7297, DOI 10.1073/pnas.92.16.7297; Canman CE, 1998, SCIENCE, V281, P1677, DOI 10.1126/science.281.5383.1677; CHAE HZ, 1994, P NATL ACAD SCI USA, V91, P7017, DOI 10.1073/pnas.91.15.7017; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; DEMPLE B, 1991, P NATL ACAD SCI USA, V88, P11450, DOI 10.1073/pnas.88.24.11450; Ema M, 1999, EMBO J, V18, P1905, DOI 10.1093/emboj/18.7.1905; FUJII S, 1991, CANCER, V68, P1583, DOI 10.1002/1097-0142(19911001)68:7<1583::AID-CNCR2820680720>3.0.CO;2-N; HAINAUT P, 1993, CANCER RES, V53, P4469; Hayashi S, 1997, NUCLEIC ACIDS RES, V25, P4035, DOI 10.1093/nar/25.20.4035; Hirota K, 1997, P NATL ACAD SCI USA, V94, P3633, DOI 10.1073/pnas.94.8.3633; HOLMGREN A, 1985, ANNU REV BIOCHEM, V54, P237, DOI 10.1146/annurev.bi.54.070185.001321; Jayaraman L, 1997, GENE DEV, V11, P558, DOI 10.1101/gad.11.5.558; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Lotem J, 1996, P NATL ACAD SCI USA, V93, P9166, DOI 10.1073/pnas.93.17.9166; MACLEOD KF, 1995, GENE DEV, V9, P935, DOI 10.1101/gad.9.8.935; MAKINO S, 1992, IMMUNOLOGY, V76, P578; Makino Y, 1996, J CLIN INVEST, V98, P2469, DOI 10.1172/JCI119065; Masutani H, 1996, IMMUNOL LETT, V54, P67, DOI 10.1016/S0165-2478(96)02651-X; MATTHEWS JR, 1992, NUCLEIC ACIDS RES, V20, P3821, DOI 10.1093/nar/20.15.3821; NAKAMURA H, 1994, IMMUNOL LETT, V42, P75, DOI 10.1016/0165-2478(94)90038-8; NAKAMURA H, 1992, CANCER-AM CANCER SOC, V69, P2091, DOI 10.1002/1097-0142(19920415)69:8<2091::AID-CNCR2820690814>3.0.CO;2-X; Nakamura H, 1997, ANNU REV IMMUNOL, V15, P351, DOI 10.1146/annurev.immunol.15.1.351; OBLONG JE, 1994, J BIOL CHEM, V269, P11714; OHIRA A, 1994, LAB INVEST, V70, P279; PAVLETICH NP, 1993, GENE DEV, V7, P2556, DOI 10.1101/gad.7.12b.2556; Pearson GD, 1998, J BIOL CHEM, V273, P5431, DOI 10.1074/jbc.273.10.5431; Pise-Masison CA, 1998, J VIROL, V72, P1165, DOI 10.1128/JVI.72.2.1165-1170.1998; RAINWATER R, 1995, MOL CELL BIOL, V15, P3892; SEKI S, 1991, J BIOL CHEM, V266, P20797; Sowa Y, 1997, BIOCHEM BIOPH RES CO, V241, P142, DOI 10.1006/bbrc.1997.7786; TAKAHASHI R, 1997, LEUKEMIA, V3, P331; WANG Y, 1993, GENE DEV, V7, P2575, DOI 10.1101/gad.7.12b.2575; Woo RA, 1998, NATURE, V394, P700, DOI 10.1038/29343; XANTHOUDAKIS S, 1992, EMBO J, V11, P3323, DOI 10.1002/j.1460-2075.1992.tb05411.x; XANTHOUDAKIS S, 1992, EMBO J, V11, P653, DOI 10.1002/j.1460-2075.1992.tb05097.x; YAMAMOTO M, 1994, EXP CELL RES, V210, P94, DOI 10.1006/excr.1994.1014; YODOI J, 1991, ADV CANCER RES, V57, P381	40	359	370	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 10	1999	274	50					35809	35815		10.1074/jbc.274.50.35809	http://dx.doi.org/10.1074/jbc.274.50.35809			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	264NG	10585464	hybrid, Green Submitted			2022-12-25	WOS:000084187900076
J	Yamasaki, M; Hashiguchi, N; Fujiwara, C; Imanaka, T; Tsukamoto, T; Osumi, T				Yamasaki, M; Hashiguchi, N; Fujiwara, C; Imanaka, T; Tsukamoto, T; Osumi, T			Formation of peroxisomes from peroxisomal ghosts in a peroxisome-deficient mammalian cell mutant upon complementation by protein microinjection	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TARGETING SIGNAL-1 RECEPTOR; ENDOPLASMIC-RETICULUM; BIOGENESIS DISORDERS; PTS1 RECEPTOR; MEMBRANE; IMPORT; PHENOTYPES; PATHWAYS; DISTINCT; INVITRO	Most mammalian cell strains genetically deficient in peroxisome biogenesis have abnormal membrane structures called ghosts, containing integral peroxisomal membrane protein, PMP70, but lacking the peroxisomal matrix proteins. Upon genetic complementation, these mutants regain the ability of peroxisome biogenesis. It is postulated that, in this process, the ghosts act as the precursors of peroxisomes, but there has been no evidence to support this. In the present study, we investigated this issue by protein microinjection to a mutant Chinese hamster ovary cell line defective of PEX5, encoding a peroxisome-targeting signal receptor. When recombinant Pex5p and green fluorescent protein (GFP) carrying a peroxisome-targeting signal were co-injected into the mutant cells, the GFP fluorescence gathered over time to particulate structures where PMP70 was co-localized. This process was dependent on both Pex5p and the targeting signal, and, most importantly, occurred even in the presence of cycloheximide, a protein synthesis inhibitor, These findings suggest that the ghosts act as accepters of matrix proteins in the peroxisome recovery process at least in the PEX5 mutant, and support the view that peroxisomes can grow by incorporating newly synthesized matrix proteins.	Himeji Inst Technol, Fac Sci, Dept Life Sci, Kamigori, Hyogo 6781297, Japan; Toyama Med & Pharmaceut Univ, Fac Pharmaceut Sci, Dept Biol Chem, Cell Biol Lab, Toyama 9300194, Japan	University of Hyogo; University of Toyama	Osumi, T (corresponding author), Himeji Inst Technol, Fac Sci, Dept Life Sci, 3-2-1 Koto, Kamigori, Hyogo 6781297, Japan.			Imanaka, Tsuneo/0000-0003-4677-1356				Albertini M, 1997, CELL, V89, P83, DOI 10.1016/S0092-8674(00)80185-3; Baerends RJS, 1996, J BIOL CHEM, V271, P8887, DOI 10.1074/jbc.271.15.8887; Chang CC, 1999, J CELL SCI, V112, P1579; Distel B, 1996, J CELL BIOL, V135, P1, DOI 10.1083/jcb.135.1.1; Dodt G, 1996, J CELL BIOL, V135, P1763, DOI 10.1083/jcb.135.6.1763; DODT G, 1995, NAT GENET, V9, P115, DOI 10.1038/ng0295-115; Elgersma Y, 1997, EMBO J, V16, P7326, DOI 10.1093/emboj/16.24.7326; Erdmann R, 1997, TRENDS CELL BIOL, V7, P400, DOI 10.1016/S0962-8924(97)01126-4; Faber KN, 1998, MOL CELL BIOL, V18, P936, DOI 10.1128/MCB.18.2.936; FRANSEN M, 1995, J BIOL CHEM, V270, P7731, DOI 10.1074/jbc.270.13.7731; HILL PE, 1995, J CELL SCI, V108, P1469; Honsho M, 1998, AM J HUM GENET, V63, P1622, DOI 10.1086/302161; Imamura A, 1998, HUM MOL GENET, V7, P2089, DOI 10.1093/hmg/7.13.2089; Imamura A, 1998, AM J HUM GENET, V62, P1539, DOI 10.1086/301881; Kinoshita N, 1998, J BIOL CHEM, V273, P24122, DOI 10.1074/jbc.273.37.24122; Kunau WH, 1998, CURR BIOL, V8, pR299, DOI 10.1016/S0960-9822(98)70191-5; LAZAROW PB, 1982, ANN NY ACAD SCI, V386, P285, DOI 10.1111/j.1749-6632.1982.tb21423.x; LAZAROW PB, 1985, ANNU REV CELL BIOL, V1, P489, DOI 10.1146/annurev.cb.01.110185.002421; Matsuzono Y, 1999, P NATL ACAD SCI USA, V96, P2116, DOI 10.1073/pnas.96.5.2116; MIURA S, 1992, J BIOL CHEM, V267, P14405; MIYAZAWA S, 1989, MOL CELL BIOL, V9, P83, DOI 10.1128/MCB.9.1.83; MIYAZAWA S, 1987, J BIOL CHEM, V262, P8131; Passreiter M, 1998, J CELL BIOL, V141, P373, DOI 10.1083/jcb.141.2.373; SANTOS MJ, 1988, J BIOL CHEM, V263, P10502; SANTOS MJ, 1988, SCIENCE, V239, P1536, DOI 10.1126/science.3281254; Schliebs W, 1999, J BIOL CHEM, V274, P5666, DOI 10.1074/jbc.274.9.5666; Shimozawa N, 1999, HUM MOL GENET, V8, P1077, DOI 10.1093/hmg/8.6.1077; SHIMOZAWA N, 1993, AM J HUM GENET, V52, P843; Shimozawa N, 1998, AM J HUM GENET, V63, P1898, DOI 10.1086/302142; South ST, 1999, J CELL BIOL, V144, P255, DOI 10.1083/jcb.144.2.255; Tamura S, 1998, BIOCHEM BIOPH RES CO, V245, P883, DOI 10.1006/bbrc.1998.8522; Titorenko VI, 1997, MOL CELL BIOL, V17, P5210, DOI 10.1128/MCB.17.9.5210; Tsukamoto T, 1997, BIOCHEM BIOPH RES CO, V230, P402, DOI 10.1006/bbrc.1996.5971; TSUKAMOTO T, 1995, NAT GENET, V11, P395, DOI 10.1038/ng1295-395; WIEMER EAC, 1995, J CELL BIOL, V130, P51, DOI 10.1083/jcb.130.1.51; Yamasaki M., 1998, BIOIMAGES, V6, P1	36	24	24	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 10	1999	274	50					35293	35296		10.1074/jbc.274.50.35293	http://dx.doi.org/10.1074/jbc.274.50.35293			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	264NG	10585391	hybrid			2022-12-25	WOS:000084187900003
J	Topcu, Z; Mack, DL; Hromas, RA; Borden, KLB				Topcu, Z; Mack, DL; Hromas, RA; Borden, KLB			The promyelocytic leukemia protein PML interacts with the proline-rich homeodomain protein PRH: a RING may link hematopoiesis and growth control	ONCOGENE			English	Article						PML; PRH; HEX; APL; Z	ALPHA FUSION PROTEIN; HOMEOBOX GENE PRH; NUCLEAR-BODIES; SACCHAROMYCES-CEREVISIAE; ONCOPROTEIN PML; BINDING-PROTEIN; FINGER DOMAIN; CELLS; EXPRESSION; MOUSE	Acute promyelocytic leukemia (APL) is characterized by a block in myeloid cell differentiation. As a result of a chromosomal translocation in these patients, the promyelocytic leukemia protein PML is disrupted as are the nuclear bodies it forms. Disruption of PML and PML nuclear bodies in APL is linked to a loss of growth control and subsequent leukemogenesis, PML contains a zinc-binding domain known as the RING which is required for formation of these bodies. Using yeast 2-hybrid techniques, we found that PML and a related RING protein, Z, bind the proline rich homeodomain protein (PRH) through their RING domains, Previous reports indicate that PRH functions in hematopoiesis and may act as a transcriptional repressor. Our data indicate that PML and Z both bind the repressor domain of PRH and are the first protein partners reported for PRH, We observe that PRH has a punctate pattern in both the nucleus and cytoplasm of chronic myelogenous leukemia K562 cells and in the APL cell line, NB4. Immunoprecipitation and co-localization studies indicate that PML and PRH interact in both cell lines. The effect on cell growth by PML and the hematopoietic actions of PRH raises the possibility that the interaction between PML and PRH represents a link between growth control and hematopoiesis.	CUNY Mt Sinai Sch Med, Dept Physiol & Biophys, New York, NY 10029 USA; Indiana Canc Res Inst, Indianapolis, IN 46202 USA	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai	Borden, KLB (corresponding author), CUNY Mt Sinai Sch Med, Dept Physiol & Biophys, Box 1218, New York, NY 10029 USA.		Mack, David/AAE-5437-2022		NATIONAL CANCER INSTITUTE [R01CA080728] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA80728-01] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; BEDFORD FK, 1993, NUCLEIC ACIDS RES, V21, P1245, DOI 10.1093/nar/21.5.1245; Boddy MN, 1996, ONCOGENE, V13, P971; Borden KLB, 1998, J VIROL, V72, P758, DOI 10.1128/JVI.72.1.758-766.1998; Borden KLB, 1998, BIOCHEM CELL BIOL, V76, P351, DOI 10.1139/bcb-76-2-3-351; Borden KLB, 1996, P NATL ACAD SCI USA, V93, P1601, DOI 10.1073/pnas.93.4.1601; Borden KLB, 1997, FEBS LETT, V418, P30, DOI 10.1016/S0014-5793(97)01344-6; BORDEN KLB, 1995, EMBO J, V14, P1532, DOI 10.1002/j.1460-2075.1995.tb07139.x; Borden KLB, 1996, CURR OPIN STRUC BIOL, V6, P395, DOI 10.1016/S0959-440X(96)80060-1; Borden KLB, 1998, J VIROL, V72, P3819, DOI 10.1128/JVI.72.5.3819-3826.1998; Carlile GW, 1998, BIOCHEM J, V335, P691, DOI 10.1042/bj3350691; CELENZA JL, 1989, MOL CELL BIOL, V9, P5045, DOI 10.1128/MCB.9.11.5045; CROMPTON MR, 1992, NUCLEIC ACIDS RES, V20, P5661, DOI 10.1093/nar/20.21.5661; Doucas V, 1999, P NATL ACAD SCI USA, V96, P2627, DOI 10.1073/pnas.96.6.2627; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; FAGIOLI M, 1992, ONCOGENE, V7, P1083; Ferrucci PF, 1997, P NATL ACAD SCI USA, V94, P10901, DOI 10.1073/pnas.94.20.10901; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; FLENGHI L, 1995, BLOOD, V85, P1871, DOI 10.1182/blood.V85.7.1871.bloodjournal8571871; Gianni M, 1998, BLOOD, V91, P4300, DOI 10.1182/blood.V91.11.4300.411k41_4300_4310; Grande MA, 1996, J CELL BIOCHEM, V63, P280, DOI 10.1002/(SICI)1097-4644(19961201)63:3<280::AID-JCB3>3.0.CO;2-T; GRIGNANI F, 1995, CANCER RES, V55, P440; Guthrie C, 1991, GUIDE YEAST GENETICS; Harlow E., 1988, ANTIBODIES LAB MANUA; HROMAS R, 1993, BIOCHEM BIOPH RES CO, V195, P976, DOI 10.1006/bbrc.1993.2140; Jensen DE, 1998, ONCOGENE, V16, P1097, DOI 10.1038/sj.onc.1201861; LaMorte VJ, 1998, P NATL ACAD SCI USA, V95, P4991, DOI 10.1073/pnas.95.9.4991; Le XF, 1996, J BIOL CHEM, V271, P130, DOI 10.1074/jbc.271.1.130; LOZZIO CB, 1975, BLOOD, V45, P321, DOI 10.1182/blood.V45.3.321.321; MANFIOLETTI G, 1995, BLOOD, V85, P1237, DOI 10.1182/blood.V85.5.1237.bloodjournal8551237; Mayfield S, 1996, CHEM BIOL, V3, P415, DOI 10.1016/S1074-5521(96)90088-5; MELNICK A, 1999, IN PRESS BLOOD; Meza JE, 1999, J BIOL CHEM, V274, P5659, DOI 10.1074/jbc.274.9.5659; Miller J.H., 1972, EXPT MOL GENETICS; MU ZM, 1994, MOL CELL BIOL, V14, P6858, DOI 10.1128/MCB.14.10.6858; Newman CS, 1997, MECH DEVELOP, V66, P83, DOI 10.1016/S0925-4773(97)00092-0; Petter R, 1997, INFECT IMMUN, V65, P4909, DOI 10.1128/IAI.65.12.4909-4917.1997; Quignon F, 1998, NAT GENET, V20, P259, DOI 10.1038/3068; ROGAIA D, 1995, LEUKEMIA, V9, P1467; SALVATO MS, 1996, ARENAVIRUSES, P629; Saurin AJ, 1996, TRENDS BIOCHEM SCI, V21, P208, DOI 10.1016/S0968-0004(96)80017-X; Shao WL, 1998, J NATL CANCER I, V90, P124, DOI 10.1093/jnci/90.2.124; STUURMAN N, 1992, J CELL SCI, V101, P773; TABILIO A, 1983, CANCER RES, V43, P4569; Tanaka T, 1999, BIOCHEM J, V339, P111, DOI 10.1042/0264-6021:3390111; Tanimura S, 1999, FEBS LETT, V447, P5, DOI 10.1016/S0014-5793(99)00254-9; TERRIS B, 1995, CANCER RES, V55, P1590; Thomas PQ, 1998, DEVELOPMENT, V125, P85; Wang ZG, 1998, NAT GENET, V20, P266, DOI 10.1038/3073	49	56	56	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 25	1999	18	50					7091	7100		10.1038/sj.onc.1203201	http://dx.doi.org/10.1038/sj.onc.1203201			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	259PH	10597310				2022-12-25	WOS:000083901900016
J	Suzuki, S; Higuchi, M; Proske, RJ; Oridate, N; Hong, WK; Lotan, R				Suzuki, S; Higuchi, M; Proske, RJ; Oridate, N; Hong, WK; Lotan, R			Implication of mitochondria-derived reactive oxygen species, cytochrome C and caspase-3 in N-(4-hydroxyphenyl)retinamide-induced apoptosis in cervical carcinoma cells	ONCOGENE			English	Article						reactive oxygen species; 4HPR; apoptosis; mitochondrial respiratory chain; caspase-3; cytochrome c	TUMOR-NECROSIS-FACTOR; TRANS-RETINOIC ACID; RESPIRATORY-CHAIN; ELECTRON-TRANSPORT; FREE-RADICALS; PERMEABILITY TRANSITION; SUPEROXIDE FORMATION; HEART-MITOCHONDRIA; MEDIATED APOPTOSIS; COMPLEX-I	N-(4-Hydroxyphenyl)retinamide (4HPR) is currently used in cancer prevention and therapy trials. It is thought that its effects result from induction of apoptosis, 4HPR-induced apoptosis in human cervical carcinoma C33A cells involves enhanced generation of reactive oxygen species (ROS). In this study we explored the mechanism by which 4HPR increases ROS and induces apoptosis in these cells. 4HPR induced cytochrome c release from mitochondria to cytoplasm, activated caspase-3, and caused a membrane permeability transition (MPT). All these 4HPR's effects, as web as the induction of apoptosis, were inhibited by antioxidants, which decrease ROS. Thenoyltrifluoroacetone, a mitochondrial respiratory chain (MRC) complex II inhibitor, and carbonylcyanide m-chlorophenyl hydrazone, which uncouples electron transfer and ATP synthesis and inhibits ROS generation by MRC, inhibited 4HPR-induced ROS generation very effectively. Rotenone, an MRC complex I inhibitor was less effective and azide, an MRC complex IV inhibitor, exhibited a marginal effect, In contrast, antimycin A, an MRC complex III inhibitor, enhanced 4HPR-induced ROS generation. These findings suggest that 4HPR enhances ROS generation by affecting a target between complex II and complex III, presumably coenzyme Q. This effect is followed by release of cytochrome c, increased caspase-3 activity, induction of MPT and eventual DNA fragmentation and cell death.	Univ Texas, MD Anderson Canc Ctr, Dept Thorac Head & Neck Med Oncol, Houston, TX 77030 USA; Univ Texas, Hlth Sci Ctr, Inst Mol Med Prevent Human Dis, Res Ctr Cardiovasc Dis, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; University of Texas Health Science Center Houston	Lotan, R (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Thorac Head & Neck Med Oncol, Box 108,1515 Holcombe Blvd, Houston, TX 77030 USA.		Suzuki, Seigo/G-5378-2012; Oridate, Nobuhiko/ABC-4116-2020; Oridate, Nobuhiko/G-5365-2012	Oridate, Nobuhiko/0000-0002-6968-3028; 	NCI NIH HHS [P01 CA52051] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA052051] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BERRIDGE MV, 1993, ARCH BIOCHEM BIOPHYS, V303, P474, DOI 10.1006/abbi.1993.1311; BEYER RE, 1992, BIOCHEM CELL BIOL, V70, P390, DOI 10.1139/o92-061; BEZKOROVAINY A, 1996, METABOLISM OXIDATIVE; Bossy-Wetzel E, 1998, EMBO J, V17, P37, DOI 10.1093/emboj/17.1.37; CARACENI P, 1995, BBA-MOL CELL RES, V1268, P249, DOI 10.1016/0167-4889(95)00077-6; DAWSON TL, 1993, AM J PHYSIOL, V264, P961; Delia D, 1997, CARCINOGENESIS, V18, P943, DOI 10.1093/carcin/18.5.943; FEDYK ER, 1994, INT J IMMUNOPHARMACO, V16, P533, DOI 10.1016/0192-0561(94)90105-8; FORMAN HJ, 1982, FREE RADICAL BIO MED, V5, P65; Formelli F, 1996, FASEB J, V10, P1014, DOI 10.1096/fasebj.10.9.8801162; GarciaRuiz C, 1997, J BIOL CHEM, V272, P11369; GOODMAN Y, 1994, BRAIN RES, V654, P171, DOI 10.1016/0006-8993(94)91586-5; Gorman A, 1997, FEBS LETT, V404, P27, DOI 10.1016/S0014-5793(97)00069-0; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; HENDERSON LM, 1989, BIOCHEM J, V264, P249, DOI 10.1042/bj2640249; Higuchi M, 1996, J IMMUNOL, V157, P297; Higuchi M, 1998, ONCOGENE, V17, P2515, DOI 10.1038/sj.onc.1202485; Higuchi M, 1997, J CLIN INVEST, V99, P1751, DOI 10.1172/JCI119339; HU HP, 1992, BIOCHIM BIOPHYS ACTA, V1112, P161, DOI 10.1016/0005-2736(92)90387-2; HUNT NH, 1992, BIOCHIM BIOPHYS ACTA, V1133, P261, DOI 10.1016/0167-4889(92)90046-E; Jacobson MD, 1996, J CELL BIOL, V133, P1041, DOI 10.1083/jcb.133.5.1041; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; Kruidering M, 1997, J PHARMACOL EXP THER, V280, P638; LENNON SV, 1991, CELL PROLIFERAT, V24, P203, DOI 10.1111/j.1365-2184.1991.tb01150.x; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; LOTAN R, 1995, J NATL CANCER I, V87, P1655, DOI 10.1093/jnci/87.22.1655; Marchetti P, 1996, CANCER RES, V56, P2033; Marchetti P, 1996, J EXP MED, V184, P1155, DOI 10.1084/jem.184.3.1155; MARTIN SJ, 1995, EMBO J, V14, P5191, DOI 10.1002/j.1460-2075.1995.tb00203.x; MCCORD JM, 1985, NEW ENGL J MED, V312, P159; MEYER M, 1993, EMBO J, V12, P2005, DOI 10.1002/j.1460-2075.1993.tb05850.x; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; NOHL H, 1986, BIOCHEM BIOPH RES CO, V138, P533, DOI 10.1016/S0006-291X(86)80529-0; NOHL H, 1987, FEBS LETT, V214, P269, DOI 10.1016/0014-5793(87)80068-6; ODONNELL VB, 1995, BIOCHEM J, V310, P133, DOI 10.1042/bj3100133; Oishi K, 1997, SCAND J IMMUNOL, V45, P21, DOI 10.1046/j.1365-3083.1997.d01-365.x; Oridate N, 1996, CLIN CANCER RES, V2, P855; Oridate N, 1997, J NATL CANCER I, V89, P1191, DOI 10.1093/jnci/89.16.1191; ORIDATE N, 1995, INT J ONCOL, V7, P433; ORMEROD MG, 1993, ACTA ONCOL, V32, P417, DOI 10.3109/02841869309093620; SANFORD KK, 1992, J CLIN INVEST, V90, P2069, DOI 10.1172/JCI116089; Schlegel J, 1996, J BIOL CHEM, V271, P1841, DOI 10.1074/jbc.271.4.1841; SCHULZEOSTHOFF K, 1992, J BIOL CHEM, V267, P5317; SCHULZEOSTHOFF K, 1993, EMBO J, V12, P3095, DOI 10.1002/j.1460-2075.1993.tb05978.x; Schweizer M., 1997, OXIDATIVE STRESS MOL, P169; Shimizu S, 1996, CANCER RES, V56, P2161; Shimizu S, 1998, P NATL ACAD SCI USA, V95, P1455, DOI 10.1073/pnas.95.4.1455; Skulachev VP, 1996, Q REV BIOPHYS, V29, P169, DOI 10.1017/S0033583500005795; SUN SY, 1999, IN PRESS CANC RES; TAYLOR DE, 1995, ARCH BIOCHEM BIOPHYS, V316, P70, DOI 10.1006/abbi.1995.1011; TRUDEL S, 1991, BIOCHEM J, V276, P611, DOI 10.1042/bj2760611; TURRENS JF, 1985, ARCH BIOCHEM BIOPHYS, V237, P408, DOI 10.1016/0003-9861(85)90293-0; WOLVETANG EJ, 1994, FEBS LETT, V339, P40, DOI 10.1016/0014-5793(94)80380-3; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; Zamzami N, 1996, J EXP MED, V183, P1533, DOI 10.1084/jem.183.4.1533; ZAMZAMI N, 1995, J EXP MED, V181, P1661, DOI 10.1084/jem.181.5.1661; ZORATTI M, 1995, BBA-REV BIOMEMBRANES, V1241, P139, DOI 10.1016/0304-4157(95)00003-A; Zou CP, 1998, CLIN CANCER RES, V4, P1345	59	134	136	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 4	1999	18	46					6380	6387		10.1038/sj.onc.1203024	http://dx.doi.org/10.1038/sj.onc.1203024			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	260DK	10597238				2022-12-25	WOS:000083934100023
J	Decottignies, A; Owsianik, G; Ghislain, M				Decottignies, A; Owsianik, G; Ghislain, M			Casein kinase I-dependent phosphorylation and stability of the yeast multidrug transporter Pdr5p	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING CASSETTE TRANSPORTER; HUMAN P-GLYCOPROTEIN; MEMBRANE H+-ATPASE; SACCHAROMYCES-CEREVISIAE; PLASMA-MEMBRANE; PROTEIN-KINASE; GENE-PRODUCT; ESCHERICHIA-COLI; DRUG-RESISTANCE; ABC PROTEINS	The pleiotropic drug resistance protein, Pdr5p, is an ATP-binding cassette transporter of the plasma membrane of Saccharomyces cerevisiae, Overexpression of Pdr5p results in increased cell resistance to a variety of cytotoxic compounds, a phenotype reminiscent of the multiple drug resistance seen in tumor cells. Pdr5p and two other yeast ATP-binding cassette transporters, Snq2p and Yor1p, were found to be phosphorylated on serine residues in vitro, Mutations in the plasma membrane-bound casein kinase I isoforms, Yck1p and Yck2p, abolished Pdr5p phosphorylation and modified the multiple drug resistance profile. We showed Pdr5p to be ubiquitylated when overexpressed. However, instability of Pdr5p was only seen in Yck1p- and Yck2p-deficient strains, in which it was degraded in the vacuole via a Pep4p-dependent mechanism. Our results suggest that casein kinase I activity is required for membrane trafficking of Pdr5p to the cell surface. In the absence of functional Yck1p and Yck2p, Pdr5p is transported to the vacuole for degradation.	Catholic Univ Louvain, Unite Biochim Physiol, B-1348 Louvain, Belgium	Universite Catholique Louvain	Ghislain, M (corresponding author), Catholic Univ Louvain, Unite Biochim Physiol, Croix Sud 2-20, B-1348 Louvain, Belgium.	ghislain@fysa.ucl.ac.be						AMES GF, 1992, ADV ENZYMOL RAMB, V65, P1; ANTONSSON B, 1994, J BIOL CHEM, V269, P16821; BALZI E, 1994, J BIOL CHEM, V269, P2206; BERBEN G, 1991, YEAST, V7, P475, DOI 10.1002/yea.320070506; BERKOWER C, 1994, MOL BIOL CELL, V5, P1185, DOI 10.1091/mbc.5.11.1185; BISSINGER PH, 1994, J BIOL CHEM, V269, P4180; Bryant NJ, 1998, MICROBIOL MOL BIOL R, V62, P230, DOI 10.1128/MMBR.62.1.230-247.1998; CAPIEAUX E, 1993, J BIOL CHEM, V268, P21895; CHAMBERS TC, 1994, BIOCHEM J, V299, P309, DOI 10.1042/bj2990309; CHAMBERS TC, 1993, J BIOL CHEM, V268, P4592; CHAMBERS TC, 1992, MOL PHARMACOL, V41, P1008; Cui ZF, 1996, J BIOL CHEM, V271, P14712, DOI 10.1074/jbc.271.25.14712; Decottignies A, 1998, J BIOL CHEM, V273, P12612, DOI 10.1074/jbc.273.20.12612; Decottignies A, 1997, NAT GENET, V15, P137, DOI 10.1038/ng0297-137; DECOTTIGNIES A, 1995, J BIOL CHEM, V270, P18150, DOI 10.1074/jbc.270.30.18150; DECOTTIGNIES A, 1994, J BIOL CHEM, V269, P12797; DELAHODDE A, 1995, MOL CELL BIOL, V15, P4043; EGNER R, 1995, MOL CELL BIOL, V15, P5879; Egner R, 1996, FEBS LETT, V378, P177, DOI 10.1016/0014-5793(95)01450-0; Egner R, 1998, MOL BIOL CELL, V9, P523, DOI 10.1091/mbc.9.2.523; Estrada E, 1996, J BIOL CHEM, V271, P32064, DOI 10.1074/jbc.271.50.32064; Galan JM, 1997, EMBO J, V16, P5847, DOI 10.1093/emboj/16.19.5847; Germann UA, 1996, J BIOL CHEM, V271, P1708, DOI 10.1074/jbc.271.3.1708; GERMANN UA, 1993, CYTOTECHNOLOGY, V12, P33, DOI 10.1007/BF00744657; GOFFEAU A, 1988, METHOD ENZYMOL, V157, P528; GOTTESMAN MM, 1993, ANNU REV BIOCHEM, V62, P385, DOI 10.1146/annurev.bi.62.070193.002125; Hicke L, 1996, CELL, V84, P277, DOI 10.1016/S0092-8674(00)80982-4; Hicke L, 1997, FASEB J, V11, P1215, DOI 10.1096/fasebj.11.14.9409540; Hicke L, 1998, J CELL BIOL, V141, P349, DOI 10.1083/jcb.141.2.349; HIGGINS CF, 1992, ANNU REV CELL BIOL, V8, P67, DOI 10.1146/annurev.cb.08.110192.000435; HOFFMAN CS, 1987, GENE, V57, P267, DOI 10.1016/0378-1119(87)90131-4; Katzmann DJ, 1999, MOL CELL BIOL, V19, P2998; KATZMANN DJ, 1995, MOL CELL BIOL, V15, P6875; KATZMANN DJ, 1994, MOL CELL BIOL, V14, P4653, DOI 10.1128/MCB.14.7.4653; Kolaczkowski M, 1996, J BIOL CHEM, V271, P31543, DOI 10.1074/jbc.271.49.31543; Kolaczkowski M, 1998, MICROB DRUG RESIST, V4, P143, DOI 10.1089/mdr.1998.4.143; KOLAROV J, 1988, J BIOL CHEM, V263, P10613; KOLLING R, 1994, EMBO J, V13, P3261, DOI 10.1002/j.1460-2075.1994.tb06627.x; KUCHLER K, 1989, EMBO J, V8, P3973, DOI 10.1002/j.1460-2075.1989.tb08580.x; KUO CL, 1983, MOL CELL BIOL, V3, P1730, DOI 10.1128/MCB.3.10.1730; Lin SJ, 1997, J BIOL CHEM, V272, P9215; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Mahe Y, 1996, J BIOL CHEM, V271, P25167, DOI 10.1074/jbc.271.41.25167; Marchal C, 1998, MOL CELL BIOL, V18, P314, DOI 10.1128/MCB.18.1.314; MCDONOUGH JP, 1982, J BIOL CHEM, V257, P4579; MCGRATH JP, 1989, NATURE, V340, P400, DOI 10.1038/340400a0; MEYERS S, 1992, CURR GENET, V21, P431, DOI 10.1007/BF00351651; Panek HR, 1997, EMBO J, V16, P4194, DOI 10.1093/emboj/16.14.4194; PEARSON RB, 1991, METHOD ENZYMOL, V200, P62; Plemper RK, 1998, J BIOL CHEM, V273, P32848, DOI 10.1074/jbc.273.49.32848; PRINGLE JR, 1991, METHOD ENZYMOL, V194, P565; ROBINSON LC, 1992, P NATL ACAD SCI USA, V89, P28, DOI 10.1073/pnas.89.1.28; SERVOS J, 1993, MOL GEN GENET, V236, P214, DOI 10.1007/BF00277115; Szabo K, 1997, J BIOL CHEM, V272, P23165, DOI 10.1074/jbc.272.37.23165; Taglicht D, 1998, METHOD ENZYMOL, V292, P130; van den Hazel HB, 1999, J BIOL CHEM, V274, P1934, DOI 10.1074/jbc.274.4.1934; Wach A, 1996, YEAST, V12, P259, DOI 10.1002/(SICI)1097-0061(19960315)12:3<259::AID-YEA901>3.0.CO;2-C; WANG PC, 1992, MOL BIOL CELL, V3, P275, DOI 10.1091/mbc.3.3.275; WATANABE M, 1994, J BIOL CHEM, V269, P16829; Wendland B, 1998, CURR OPIN CELL BIOL, V10, P513, DOI 10.1016/S0955-0674(98)80067-7; Ziman M, 1996, MOL BIOL CELL, V7, P1909, DOI 10.1091/mbc.7.12.1909	62	41	42	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 24	1999	274	52					37139	37146		10.1074/jbc.274.52.37139	http://dx.doi.org/10.1074/jbc.274.52.37139			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	267WR	10601275	hybrid			2022-12-25	WOS:000084382700046
J	Kim, PK; Hollerbach, C; Trimble, WS; Leber, B; Andrews, DW				Kim, PK; Hollerbach, C; Trimble, WS; Leber, B; Andrews, DW			Identification of the endoplasmic reticulum targeting signal in vesicle-associated membrane proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOTOACTIVATABLE PHOSPHOLIPIDS; RECOGNITION PARTICLE; MICROSOMAL-MEMBRANES; EMBEDDED SEGMENT; CYTOCHROME B(5); PLASMA-MEMBRANE; CROSS-LINKING; SYNAPTOBREVIN; TRANSPORT; BINDING	The vesicle-associated membrane proteins (Vamp(s)) function as soluble N-ethylmaleimide-sensitive factor attachment receptor proteins in the intracellular trafficking of vesicles. The membrane attachment of Vamps requires a carboxyl-terminal hydrophobic sequence termed an insertion sequence. Unlike other insertion sequence-containing proteins, targeting of the highly homologous Vamp1 and Vamp2 to the endoplasmic reticulum requires ATP and a membrane bound receptor. To determine if this mechanism of targeting to the endoplasmic reticulum extends to other Vamps, we compared the membrane binding of Vamp1 and Vamp2 with the distantly related Vamp8. Similar to the other Vamps, Vamp8 requires both ATP and a membrane component to target to the endoplasmic reticulum, Furthermore, binding curves for the three Vamps overlap, suggesting a common receptor-mediated process. We identified a minimal endoplasmic reticulum targeting domain that is both necessary and sufficient to confer receptor-mediated, ATP-dependent, binding of a heterologous protein to microsomes. Surprisingly, this conserved sequence includes four positively charged amino acids spaced along an amphipathic sequence, which unlike the carboxyl-terminal targeting sequence in mitochondrial Vamp isoforms, is amino-terminal to the insertion sequence. Because Vamps do not bind to phospholipid vesicles, it is likely that these residues mediate an interaction with a protein, rather than bind to acidic phospholipids, Therefore, we suggest that a bipartite motif is required for the specific targeting and integration of Vamps into the endoplasmic reticulum with receptor-mediated recognition of specifically configured positive residues leading to the insertion of the hydrophobic tail into the membrane.	McMaster Univ, Med Ctr, Dept Biochem, Hamilton, ON L8N 3Z5, Canada; McMaster Univ, Dept Med, Hamilton, ON L8N 3Z5, Canada; Hosp Sick Children, Cell Biol Program, Toronto, ON M5G 1X5, Canada	McMaster University; McMaster University; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids)	Andrews, DW (corresponding author), McMaster Univ, Med Ctr, Dept Biochem, Rm 4H-41,1200 Main St W, Hamilton, ON L8N 3Z5, Canada.			Andrews, David/0000-0002-9266-7157; Leber, Brian/0000-0001-5502-1480				ANDERSON DJ, 1983, P NATL ACAD SCI-BIOL, V80, P7249, DOI 10.1073/pnas.80.23.7249; ANDREWS DW, 1993, MOL CELL BIOL, V13, P4703, DOI 10.1128/MCB.13.8.4703; ANDREWS DW, 1989, J CELL BIOL, V108, P797, DOI 10.1083/jcb.108.3.797; Bock JB, 1997, NATURE, V387, P133, DOI 10.1038/387133a0; BUSER CA, 1994, BIOCHEMISTRY-US, V33, P13093, DOI 10.1021/bi00248a019; DESILVESTRIS M, 1995, FEBS LETT, V370, P69, DOI 10.1016/0014-5793(95)00797-D; ELFERINK LA, 1989, J BIOL CHEM, V264, P11061; ENOCH HG, 1979, J BIOL CHEM, V254, P6483; FALCONE D, 1991, MOL CELL BIOL, V11, P2656, DOI 10.1128/MCB.11.5.2656; Gonzalo S, 1999, J BIOL CHEM, V274, P21313, DOI 10.1074/jbc.274.30.21313; Goping IS, 1998, J CELL BIOL, V143, P207, DOI 10.1083/jcb.143.1.207; Greenawalt J W, 1974, Methods Enzymol, V31, P633; Greenawalt J W, 1974, Methods Enzymol, V31, P310; GROTE E, 1995, CELL, V81, P581, DOI 10.1016/0092-8674(95)90079-9; HOPE MJ, 1985, BIOCHIM BIOPHYS ACTA, V812, P55, DOI 10.1016/0005-2736(85)90521-8; HUGHES MJ, 1996, BIOTECHNIQUES, V20, P192; Isenmann S, 1998, MOL BIOL CELL, V9, P1649, DOI 10.1091/mbc.9.7.1649; JANIAK F, 1994, BIOCHEM J, V300, P191, DOI 10.1042/bj3000191; Kim PK, 1997, BIOCHEMISTRY-US, V36, P8873, DOI 10.1021/bi970090t; KUTAY U, 1995, EMBO J, V14, P217, DOI 10.1002/j.1460-2075.1995.tb06994.x; KUTAY U, 1993, TRENDS CELL BIOL, V3, P73; Litovchick L, 1998, J BIOL CHEM, V273, P29043, DOI 10.1074/jbc.273.44.29043; Murray D, 1998, BIOCHEMISTRY-US, V37, P2145, DOI 10.1021/bi972012b; Pedrazzini E, 1996, P NATL ACAD SCI USA, V93, P4207, DOI 10.1073/pnas.93.9.4207; RACHUBINSKI RA, 1980, J CELL BIOL, V84, P705, DOI 10.1083/jcb.84.3.705; Rayner JC, 1997, EMBO J, V16, P1832, DOI 10.1093/emboj/16.8.1832; Rossetto O, 1996, J CELL BIOL, V132, P167, DOI 10.1083/jcb.132.1.167; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SILVERMAN L, 1992, J CELL BIOL, V119, P415, DOI 10.1083/jcb.119.2.415; SUDHOF TC, 1995, NATURE, V375, P645, DOI 10.1038/375645a0; SYMONS LJ, 1987, ANAL BIOCHEM, V164, P382, DOI 10.1016/0003-2697(87)90508-2; TAKAGAKI Y, 1983, J BIOL CHEM, V258, P9128; TAKAGAKI Y, 1983, J BIOL CHEM, V258, P9136; TRIMBLE WS, 1991, ANNU REV NEUROSCI, V14, P93, DOI 10.1146/annurev.ne.14.030191.000521; WALTER P, 1983, METHOD ENZYMOL, V96, P84; Whitley P, 1996, J BIOL CHEM, V271, P7583, DOI 10.1074/jbc.271.13.7583; Zhu WJ, 1996, EMBO J, V15, P4130, DOI 10.1002/j.1460-2075.1996.tb00788.x	37	48	49	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 24	1999	274	52					36876	36882		10.1074/jbc.274.52.36876	http://dx.doi.org/10.1074/jbc.274.52.36876			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	267WR	10601239	hybrid			2022-12-25	WOS:000084382700010
J	O'Sullivan, GA; Mohammed, N; Foran, PG; Lawrence, GW; Dolly, JO				O'Sullivan, GA; Mohammed, N; Foran, PG; Lawrence, GW; Dolly, JO			Rescue of exocytosis in botulinum toxin A-poisoned chromaffin cells by expression of cleavage-resistant SNAP-25 - Identification of the minimal essential C-terminal residues	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SYNAPTOSOMAL-ASSOCIATED PROTEIN; SYNAPTIC VESICLE FUSION; CLOSTRIDIAL NEUROTOXINS; SNARE COMPLEX; SEROTYPE-A; IN-VITRO; SUBSTRATE; INTACT; ACTIVATION; PALMITOYLATION	Botulinum neurotoxin (BoNT) types A and B selectively block exocytosis by cleavage of SNAP-25 and synaptobrevin, respectively; in humans, many months are required for full recovery from the resultant neuromuscular paralysis. To decipher the molecular basis for such prolonged poisoning, intoxication in adreno-chromaffin cells was monitored over 2 months. Exocytosis from BoNT/B-treated cells resumed after 56 days because of the appearance of intact synaptobrevin. However, inhibition continued in BoNT/A-treated cells, throughout the same interval, with a continued predominance of cleaved SNAP-25-(1-197) over the intact protein. When recovery from poisoning was attempted by transfection of the latter cells with the gene encoding full-length SNAP-25-(1-206), no restoration of exocytosis ensued even after 3 weeks. To ascertain if this failure was because of the persistence of the toxin's protease activity, the cells were transfected with BoNT/A-resistant SNAP-25 constructs; importantly, exocytosis was rescued. C-terminal truncation of the toxin-insensitive SNAP-25 revealed that residues 1-201, 1-202, 1-203 afforded a significant return of exocytosis, unlike shorter forms 1-197, -198, -199, or -200; accordingly, mutants M202A or L203A of full-length SNAP-25 rescued secretion. These findings give insights into the C-terminal functional domain of SNAP-25, demonstrate the longevity of BoNT/A protease, and provide the prospect of a therapy for botulism.	Imperial Coll, Dept Biochem, London SW7 2AY, England	Imperial College London	Dolly, JO (corresponding author), Imperial Coll, Dept Biochem, London SW7 2AY, England.		O'Sullivan, Gregory A/F-8355-2011; Dolly, Oliver/G-1532-2012; Dolly, Oliver/ABH-6677-2020; Lawrence, Gary/F-3949-2012	O'Sullivan, Gregory A/0000-0003-0428-041X; Dolly, Oliver/0000-0002-0861-5320; Dolly, Oliver/0000-0002-0861-5320; 				ANGAUTPETIT D, 1990, NEUROSCIENCE, V37, P799, DOI 10.1016/0306-4522(90)90109-H; BARK IC, 1995, P NATL ACAD SCI USA, V92, P1510, DOI 10.1073/pnas.92.5.1510; BARTELS F, 1994, J BIOL CHEM, V269, P8122; BINZ T, 1994, J BIOL CHEM, V269, P1617; Cava TJ, 1995, EUR J NEUROL, V2, P57; Chen YA, 1999, CELL, V97, P165, DOI 10.1016/S0092-8674(00)80727-8; Cherington M, 1998, MUSCLE NERVE, V21, P701, DOI 10.1002/(SICI)1097-4598(199806)21:6<701::AID-MUS1>3.0.CO;2-B; Criado M, 1999, P NATL ACAD SCI USA, V96, P7256, DOI 10.1073/pnas.96.13.7256; de Paiva A, 1999, P NATL ACAD SCI USA, V96, P3200, DOI 10.1073/pnas.96.6.3200; Ekong TAN, 1997, MICROBIOL-SGM, V143, P3337, DOI 10.1099/00221287-143-10-3337; Eleopra R, 1998, NEUROSCI LETT, V256, P135, DOI 10.1016/S0304-3940(98)00775-7; Foran P, 1996, BIOCHEMISTRY-US, V35, P2630, DOI 10.1021/bi9519009; Gonelle-Gispert C, 1999, BIOCHEM J, V339, P159, DOI 10.1042/0264-6021:3390159; Gonzalo S, 1998, MOL BIOL CELL, V9, P585, DOI 10.1091/mbc.9.3.585; HAYASHI T, 1994, EMBO J, V13, P5051, DOI 10.1002/j.1460-2075.1994.tb06834.x; HOLZ RW, 1995, METHOD ENZYMOL, V257, P221; Lane SR, 1997, J NEUROCHEM, V69, P1864; Lawrence GW, 1997, BIOCHEMISTRY-US, V36, P3061, DOI 10.1021/bi9622478; Lawrence GW, 1996, EUR J BIOCHEM, V236, P877, DOI 10.1111/j.1432-1033.1996.00877.x; MCMAHON HT, 1993, NATURE, V364, P346, DOI 10.1038/364346a0; Niemann Heiner, 1994, Trends in Cell Biology, V4, P179, DOI 10.1016/0962-8924(94)90203-8; PELLEGRINI LL, 1995, EMBO J, V14, P4705, DOI 10.1002/j.1460-2075.1995.tb00152.x; Pellizzari R, 1999, PHILOS T R SOC B, V354, P259, DOI 10.1098/rstb.1999.0377; Poirier MA, 1998, NAT STRUCT BIOL, V5, P765, DOI 10.1038/1799; RISINGER C, 1993, J BIOL CHEM, V268, P24408; Sadoul K, 1997, J BIOL CHEM, V272, P33023, DOI 10.1074/jbc.272.52.33023; SCHECHTER I, 1967, BIOCHEM BIOPH RES CO, V27, P157, DOI 10.1016/S0006-291X(67)80055-X; SCHIAVO G, 1993, FEBS LETT, V335, P99, DOI 10.1016/0014-5793(93)80448-4; Schmidt JJ, 1997, J PROTEIN CHEM, V16, P19, DOI 10.1023/A:1026386710428; Shone CC, 1995, CURR TOP MICROBIOL, V195, P143; Sloop RR, 1997, NEUROLOGY, V49, P189, DOI 10.1212/WNL.49.1.189; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SOLLNER T, 1993, CELL, V75, P409, DOI 10.1016/0092-8674(93)90376-2; Vaidyanathan VV, 1999, J NEUROCHEM, V72, P327, DOI 10.1046/j.1471-4159.1999.0720327.x; Williamson LC, 1996, J BIOL CHEM, V271, P7694, DOI 10.1074/jbc.271.13.7694; WILSON SP, 1987, J NEUROSCI METH, V19, P163, DOI 10.1016/0165-0270(87)90031-8	36	55	60	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 24	1999	274	52					36897	36904		10.1074/jbc.274.52.36897	http://dx.doi.org/10.1074/jbc.274.52.36897			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	267WR	10601242	hybrid			2022-12-25	WOS:000084382700013
J	Olson, LJ; Hancock, MK; Dix, D; Kim, JJP; Dahms, NM				Olson, LJ; Hancock, MK; Dix, D; Kim, JJP; Dahms, NM			Mutational analysis of the binding site residues of the bovine cation-dependent mannose 6-phosphate receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR-II; LYSOSOMAL-ENZYME RECOGNITION; LIGAND INTERACTIONS; ARGININE RESIDUES; HUMAN FIBROBLASTS; CLONING; EXPRESSION; CELLS; CDNA; MANNOSE-6-PHOSPHATE	Mannose 6-phosphate receptors (MPRs) deliver soluble acid hydrolases to the lysosome in higher eukaryotic cells. The two MPRs, the cation-dependent MPR (CD-MPR) and the insulin-like growth factor II/cation-independent MPR, carry out this process by binding with high affinity to mannose 6-phosphate residues found on the N-linked oligosaccharides of their ligands, To elucidate the key amino acids involved in conveying this carbohydrate specificity, site-directed mutagenesis studies were conducted on the extracytoplasmic domain of the bovine CD-MPR. Single amino acid substitutions of the residues that form the binding pocket were generated, and the mutant constructs were expressed in transiently transfected COS-l cells. Following metabolic labeling, mutant CD-MPRs were tested for their ability to bind pentamannosyl phosphate-containing affinity columns, Of the eight amino acids mutated, four (Gln-66, Arg-lll, Glu-133, and Tyr-143) were found to be essential for ligand binding. In addition, mutation of the single histidine residue, His-105, within the binding site diminished the binding of the receptor to ligand, but did not eliminate the ability of the CD-MPR to release ligand under acidic conditions.	Med Coll Wisconsin, Dept Biochem, Milwaukee, WI 53226 USA	Medical College of Wisconsin	Dahms, NM (corresponding author), Med Coll Wisconsin, Dept Biochem, 8701 Watertown Plank Rd, Milwaukee, WI 53226 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK042667, R56DK042667, R01DK042667] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK42667] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BABA T, 1988, CARBOHYD RES, V177, P153, DOI 10.1016/0008-6215(88)85049-3; Blanchard F, 1998, J BIOL CHEM, V273, P20886, DOI 10.1074/jbc.273.33.20886; DAHMS NM, 1993, J BIOL CHEM, V268, P5457; DAHMS NM, 1987, CELL, V50, P181, DOI 10.1016/0092-8674(87)90214-5; FISCHER HD, 1980, J BIOL CHEM, V255, P5069; GETHING MJ, 1986, CELL, V46, P939, DOI 10.1016/0092-8674(86)90076-0; KAPLAN A, 1977, J CLIN INVEST, V60, P1088, DOI 10.1172/JCI108860; KORNFELD S, 1992, ANNU REV BIOCHEM, V61, P307, DOI 10.1146/annurev.bi.61.070192.001515; KOVACINA KS, 1989, MOL ENDOCRINOL, V3, P901, DOI 10.1210/mend-3-6-901; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LEE SJ, 1988, J BIOL CHEM, V263, P3521; LI M, 1990, ARCH BIOCHEM BIOPHYS, V283, P150, DOI 10.1016/0003-9861(90)90625-9; LOBEL P, 1988, J BIOL CHEM, V263, P2563; LUDWIG T, 1994, GENE, V142, P311, DOI 10.1016/0378-1119(94)90282-8; MA ZM, 1991, J BIOL CHEM, V266, P10589; MACDONALD RG, 1988, SCIENCE, V239, P1134, DOI 10.1126/science.2964083; Marron-Terada PG, 1998, BIOCHEMISTRY-US, V37, P17223, DOI 10.1021/bi981883y; MunierLehmann H, 1996, BIOCHEM SOC T, V24, P133, DOI 10.1042/bst0240133; Olson LJ, 1999, J BIOL CHEM, V274, P29889, DOI 10.1074/jbc.274.42.29889; OSHIMA A, 1988, J BIOL CHEM, V263, P2553; POHLMANN R, 1987, P NATL ACAD SCI USA, V84, P5575, DOI 10.1073/pnas.84.16.5575; Punnonen EL, 1996, EUR J BIOCHEM, V237, P809, DOI 10.1111/j.1432-1033.1996.0809p.x; PURCHIO AF, 1988, J BIOL CHEM, V263, P14211; Roberts DL, 1998, CELL, V93, P639, DOI 10.1016/S0092-8674(00)81192-7; STEIN M, 1987, BIOL CHEM H-S, V368, P937, DOI 10.1515/bchm3.1987.368.2.937; TONG PY, 1989, J BIOL CHEM, V264, P7962; TONG PY, 1989, J BIOL CHEM, V264, P7970; ULLRICH K, 1978, BIOCHEM J, V170, P643, DOI 10.1042/bj1700643; VONFIGURA K, 1986, ANNU REV BIOCHEM, V55, P167, DOI 10.1146/annurev.biochem.55.1.167; WENDLAND M, 1991, J BIOL CHEM, V266, P2917; WESTLUND B, 1991, J BIOL CHEM, V266, P23233; WOODEN SK, 1991, MOL CELL BIOL, V11, P5612, DOI 10.1128/MCB.11.11.5612; ZHANG Y, 1993, BIOCHEM J, V295, P841, DOI 10.1042/bj2950841; ZHOU M, 1995, P NATL ACAD SCI USA, V92, P9762, DOI 10.1073/pnas.92.21.9762	34	22	24	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 24	1999	274	52					36905	36911		10.1074/jbc.274.52.36905	http://dx.doi.org/10.1074/jbc.274.52.36905			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	267WR	10601243	hybrid			2022-12-25	WOS:000084382700014
J	Wakita, N; Takigawa, M				Wakita, N; Takigawa, M			Activation of epidermal growth factor receptor promotes late terminal differentiation of cell-matrix interaction-disrupted keratinocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; CULTURED HUMAN KERATINOCYTES; LINKED ENVELOPE FORMATION; FACTOR-ALPHA; FACTOR EGF; NEURONAL DIFFERENTIATION; TYROSINE PHOSPHORYLATION; EXPRESSION; TRANSGLUTAMINASE; INTEGRIN	The biological effects of epidermal growth factor receptor (EGFR) activation may differ between epidermal suprabasal and basal keratinocytes, since growth factors are mitogenic in adherent cells only in the presence of cell-extracellular matrix (ECM) interaction, To investigate biological effects of EGFR activation on keratinocytes without cell-ECM interaction, we cultured normal human keratinocytes on polyhydroxyethyl-methacrylate-coated plates, which disrupt cell-ECM but not cell-cell interaction. The cells initially expressed keratin 10 (K10) and then profilaggrin, mimicking sequential differentiation of epidermal suprabasal keratinocytes, The addition of EGF or transforming growth factor-alpha promoted late terminal differentiation (profilaggrin expression, type 1 transglutaminase expression and activity, and cornified envelope formation) of the suspended keratinocytes, while suppressing K10 expression, an early: differentiation marker. These effects were attenuated by EGFR tyrosine kinase inhibitor PD153035 or an anti-EGFR monoclonal antibody, whereas protein kinase C inhibitors H7 and bisindolylmaleimide I or mitogen-activated protein kinase/extracellular signal-regulated kinase kinase inhibitor PD98059 abolished profilaggrin up-regulation but not K10 suppression. Since the antidifferentiative role of EGFR on cell-ECM interaction-conserved keratinocytes has been well documented, our results indicate that the biological effects of EGFR:on keratinocytes are influenced by cell-ECM interaction and suggest that EGFR activation promotes rather than inhibits the terminal differentiation of suprabasal epidermal keratinocytes.	Hamamatsu Univ Sch Med, Dept Dermatol, Hamamatsu, Shizuoka 4313192, Japan	Hamamatsu University School of Medicine	Wakita, N (corresponding author), Hamamatsu Univ Sch Med, Dept Dermatol, 3600 Handa Cho, Hamamatsu, Shizuoka 4313192, Japan.	wakita@hama-med.ac.jp						ADAMS JC, 1989, NATURE, V340, P307, DOI 10.1038/340307a0; CARPENTER G, 1979, ANNU REV BIOCHEM, V48, P193, DOI 10.1146/annurev.bi.48.070179.001205; Cha D, 1996, J INVEST DERMATOL, V106, P590, DOI 10.1111/1523-1747.ep12345083; CHEN JD, 1993, EXP CELL RES, V209, P216, DOI 10.1006/excr.1993.1304; CHEN TC, 1995, J INVEST DERMATOL, V104, P113, DOI 10.1111/1523-1747.ep12613601; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DELUCA M, 1994, JOURNAL OF DERMATOLOGY, VOL 21, NO 11, NOVEMBER 1994, P821, DOI 10.1111/j.1346-8138.1994.tb03296.x; DLUGOSZ AA, 1993, J CELL BIOL, V120, P217, DOI 10.1083/jcb.120.1.217; Drubin DG, 1996, CELL, V84, P335, DOI 10.1016/S0092-8674(00)81278-7; FLECKMAN P, 1985, J INVEST DERMATOL, V85, P507, DOI 10.1111/1523-1747.ep12277306; FRISCH SM, 1994, J CELL BIOL, V124, P619, DOI 10.1083/jcb.124.4.619; Haugh JM, 1999, J BIOL CHEM, V274, P8958, DOI 10.1074/jbc.274.13.8958; Hines MD, 1996, J BIOL CHEM, V271, P6245, DOI 10.1074/jbc.271.11.6245; Hohl D, 1996, J INVEST DERMATOL, V106, P801, DOI 10.1111/1523-1747.ep12346460; Huang CS, 1998, P NATL ACAD SCI USA, V95, P156, DOI 10.1073/pnas.95.1.156; JETTEN AM, 1990, METHOD ENZYMOL, V190, P42; JIANG CK, 1993, P NATL ACAD SCI USA, V90, P6786, DOI 10.1073/pnas.90.14.6786; KUBILUS J, 1985, J INVEST DERMATOL, V85, P513, DOI 10.1111/1523-1747.ep12277310; Lee YS, 1998, J INVEST DERMATOL, V111, P762, DOI 10.1046/j.1523-1747.1998.00365.x; Li LW, 1996, J INVEST DERMATOL, V106, P254, DOI 10.1111/1523-1747.ep12340654; Mainiero F, 1997, EMBO J, V16, P2365, DOI 10.1093/emboj/16.9.2365; MARCHESE C, 1990, J CELL PHYSIOL, V144, P326, DOI 10.1002/jcp.1041440219; Mark MD, 1997, J BIOL CHEM, V272, P17238, DOI 10.1074/jbc.272.27.17238; MCGOVERN UB, 1995, BRIT J DERMATOL, V132, P892; MIETTINEN PJ, 1995, NATURE, V376, P337, DOI 10.1038/376337a0; MITEV V, 1995, BIOCHEM BIOPH RES CO, V208, P245, DOI 10.1006/bbrc.1995.1330; Moghal N, 1998, MOL CELL BIOL, V18, P6666, DOI 10.1128/MCB.18.11.6666; Monzon RI, 1996, ENDOCRINOLOGY, V137, P1727, DOI 10.1210/en.137.5.1727; Morooka T, 1998, J BIOL CHEM, V273, P24285, DOI 10.1074/jbc.273.38.24285; MURILLAS R, 1995, EMBO J, V14, P5216, DOI 10.1002/j.1460-2075.1995.tb00206.x; NANNEY LB, 1984, J INVEST DERMATOL, V83, P385, DOI 10.1111/1523-1747.ep12264708; Pai R, 1998, DIGEST DIS SCI, V43, p14S; Pillai S, 1996, JOURNAL OF INVESTIGATIVE DERMATOLOGY SYMPOSIUM PROCEEDINGS, VOL 1, NO 1, APRIL 1996, V1, P39; REYNOLDS NJ, 1993, BIOCHEM J, V294, P535, DOI 10.1042/bj2940535; RUOSLAHTI E, 1994, CELL, V77, P477, DOI 10.1016/0092-8674(94)90209-7; Rutberg SE, 1996, ONCOGENE, V13, P167; SAKAI Y, 1994, CELL GROWTH DIFFER, V5, P527; SLAUGHTER TF, 1992, ANAL BIOCHEM, V205, P166, DOI 10.1016/0003-2697(92)90594-W; THACHER SM, 1985, CELL, V40, P685, DOI 10.1016/0092-8674(85)90217-X; THREADGILL DW, 1995, SCIENCE, V269, P230, DOI 10.1126/science.7618084; Toker A., 1998, FRONT BIOSCI-LANDMRK, V3, P1134, DOI 10.2741/A350; VEGA QC, 1992, MOL CELL BIOL, V12, P128, DOI 10.1128/MCB.12.1.128; WAKITA H, 1995, J INVEST DERMATOL, V105, P536, DOI 10.1111/1523-1747.ep12323426; WEISS RA, 1984, J CELL BIOL, V98, P1397, DOI 10.1083/jcb.98.4.1397; Xia YP, 1996, J CELL BIOL, V132, P727, DOI 10.1083/jcb.132.4.727	45	50	51	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 24	1999	274	52					37285	37291		10.1074/jbc.274.52.37285	http://dx.doi.org/10.1074/jbc.274.52.37285			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	267WR	10601294	hybrid, Green Submitted			2022-12-25	WOS:000084382700065
J	Regier, DS; Waite, KA; Wallin, R; McPhail, LC				Regier, DS; Waite, KA; Wallin, R; McPhail, LC			A phosphatidic acid-activated protein kinase and conventional protein kinase C isoforms phosphorylate p22(phox) NADPH oxidase component	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHRONIC GRANULOMATOUS-DISEASE; HUMAN POLYMORPHONUCLEAR LEUKOCYTES; STIMULATED HUMAN-NEUTROPHILS; PHOSPHOLIPASE-D ACTIVATION; DIFFERENTIATED HL60 CELLS; RESPIRATORY BURST; PLASMA-MEMBRANE; CYTOCHROME-B; SUPEROXIDE GENERATION; SIGNAL-TRANSDUCTION	Using a phosphorylation-dependent cell-free system to study NADPH oxidase activation (McPhail, L. C., Qualliotine-Mann, D., and Waite, K. A. (1995) Proc. Natl. Acad Sci. U.S.A. 92, 7931-7935), we previously showed that p47(phox), a cytosolic NADPH oxidase component, is phosphorylated, Now, we show that p22(phox), a subunit of the NADPH oxidase component flavocytochrome b(558), also is phosphorylated. Phosphorylation is selectively activated by phosphatidic acid (PA) versus other lipids and occurs on a threonine residue in p22(phox). We identified two protein kinase families capable of phosphorylating p22(phox): 1). potentially novel, partially purified PA-activated protein kinase(s) known to phosphorylate p47(phox) and postulated to mediate the phosphorylation-dependent activation of NADPH oxidase by PA and 2) conventional, but not novel or atypical, isoforms of protein kinase C (PKC). In contrast, all classes of PKC isoforms could phosphorylate p47(phox). In a gel retardation assay both the phosphatidic acid-dependent kinase and conventional PKC isoforms phosphorylated all molecules of p22(phox). These findings suggest that phosphorylation of p22(phox) by conventional PRC and/or a novel PA-activated protein kinase regulates the activation/assembly of NADPH oxidase.	Wake Forest Univ, Sch Med, Dept Biochem, Winston Salem, NC 27157 USA; Wake Forest Univ, Sch Med, Dept Med, Winston Salem, NC 27157 USA; Wake Forest Univ, Sch Med, Div Infect Dis, Winston Salem, NC 27157 USA; Wake Forest Univ, Sch Med, Div Rheumatol, Winston Salem, NC 27157 USA	Wake Forest University; Wake Forest University; Wake Forest University; Wake Forest University	McPhail, LC (corresponding author), Wake Forest Univ, Sch Med, Dept Biochem, Med Ctr Blvd, Winston Salem, NC 27157 USA.		McPhail, Linda C/D-9505-2013	McPhail, Linda C/0000-0002-8670-306X	NATIONAL CANCER INSTITUTE [T32CA009422] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI022564] Funding Source: NIH RePORTER; NCI NIH HHS [CA-09422] Funding Source: Medline; NIAID NIH HHS [R01 AI022564, R01-AI22564] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AGWU DE, 1989, BIOCHEM BIOPH RES CO, V159, P79, DOI 10.1016/0006-291X(89)92407-8; AGWU DE, 1991, J CLIN INVEST, V88, P531, DOI 10.1172/JCI115336; AGWU DE, 1989, J BIOL CHEM, V264, P1405; Ahmed S, 1998, J BIOL CHEM, V273, P15693, DOI 10.1074/jbc.273.25.15693; AKIYAMA T, 1987, J BIOL CHEM, V262, P5592; BAULDRY SA, 1992, J BIOL CHEM, V267, P25141; BAULDRY SA, 1992, J BIOL CHEM, V267, P323; BAULDRY SA, 1991, J BIOL CHEM, V266, P4173; BELLAVITE P, 1988, J BIOL CHEM, V263, P8210; BILLAH MM, 1989, J BIOL CHEM, V264, P17069; BOKOCH GM, 1991, SCIENCE, V254, P1794, DOI 10.1126/science.1763330; BONSER RW, 1989, BIOCHEM J, V264, P617, DOI 10.1042/bj2640617; BOURGOIN S, 1991, AGENTS ACTIONS, V34, P32, DOI 10.1007/BF01993230; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; BURRITT JB, 1995, J BIOL CHEM, V270, P16974, DOI 10.1074/jbc.270.28.16974; CALDWELL SE, 1988, J CLIN INVEST, V81, P1485, DOI 10.1172/JCI113480; COCKCROFT S, 1984, BIOCHIM BIOPHYS ACTA, V795, P37, DOI 10.1016/0005-2760(84)90102-4; COCKCROFT S, 1992, BIOCHIM BIOPHYS ACTA, V1113, P135, DOI 10.1016/0304-4157(92)90036-A; CROSS AR, 1995, J BIOL CHEM, V270, P17075, DOI 10.1074/jbc.270.29.17075; DANG PMC, 1994, FEBS LETT, V349, P338, DOI 10.1016/0014-5793(94)00700-4; DeLeo FR, 1996, J LEUKOCYTE BIOL, V60, P677, DOI 10.1002/jlb.60.6.677; DELLABIANCA V, 1991, BIOCHEM BIOPH RES CO, V177, P948, DOI 10.1016/0006-291X(91)90630-P; DUSI S, 1993, BIOCHEM J, V290, P173, DOI 10.1042/bj2900173; ElBenna J, 1996, J BIOL CHEM, V271, P6374; ElBenna J, 1996, ARCH BIOCHEM BIOPHYS, V334, P395; ELBENNA J, 1994, J BIOL CHEM, V269, P23431; ElBenna J, 1997, J BIOL CHEM, V272, P17204, DOI 10.1074/jbc.272.27.17204; Escriou V, 1996, BIOCHEM BIOPH RES CO, V219, P930, DOI 10.1006/bbrc.1996.0335; FALLMAN M, 1992, J BIOL CHEM, V267, P2656; Fuchs A, 1997, EUR J BIOCHEM, V249, P531, DOI 10.1111/j.1432-1033.1997.00531.x; GARCIA RC, 1988, BIOCHEM J, V252, P901, DOI 10.1042/bj2520901; GERARD C, 1986, J CLIN INVEST, V77, P61, DOI 10.1172/JCI112302; HARPER AM, 1984, BIOCHEM J, V219, P519, DOI 10.1042/bj2190519; Hofmann J, 1997, FASEB J, V11, P649, DOI 10.1096/fasebj.11.8.9240967; Hsu MF, 1997, BRIT J PHARMACOL, V120, P917, DOI 10.1038/sj.bjp.0700974; IMAJOHOHMI S, 1992, J BIOL CHEM, V267, P180; Jaken S, 1996, CURR OPIN CELL BIOL, V8, P168, DOI 10.1016/S0955-0674(96)80062-7; KANAHO Y, 1991, J IMMUNOL, V146, P3536; Kent JD, 1996, J IMMUNOL, V157, P4641; KNAUS UG, 1995, SCIENCE, V269, P221, DOI 10.1126/science.7618083; KORCHAK HM, 1988, J BIOL CHEM, V263, P11098; Korchak HM, 1998, J BIOL CHEM, V273, P27292, DOI 10.1074/jbc.273.42.27292; KOSHKIN V, 1993, FEBS LETT, V327, P57, DOI 10.1016/0014-5793(93)81039-3; Koshkin V, 1995, BBA-BIOENERGETICS, V1232, P225, DOI 10.1016/0005-2728(95)00123-9; KOSHKIN V, 1994, FEBS LETT, V338, P285, DOI 10.1016/0014-5793(94)80285-8; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LETO TL, 1994, P NATL ACAD SCI USA, V91, P10650, DOI 10.1073/pnas.91.22.10650; LHEUREUX GP, 1995, BLOOD, V85, P522, DOI 10.1182/blood.V85.2.522.bloodjournal852522; MAJUMDAR S, 1991, J BIOL CHEM, V266, P9285; MCPHAIL LC, 1983, J CLIN INVEST, V72, P192, DOI 10.1172/JCI110957; MCPHAIL LC, 1995, P NATL ACAD SCI USA, V92, P7931, DOI 10.1073/pnas.92.17.7931; MCPHAIL LC, 1993, NATURAL IMMUNE SYSTE, P63; MESHULAM T, 1995, J LEUKOCYTE BIOL, V57, P842, DOI 10.1002/jlb.57.6.842; MEYER T, 1989, INT J CANCER, V43, P851, DOI 10.1002/ijc.2910430519; NACCACHE PH, 1993, ARTHRITIS RHEUM, V36, P117, DOI 10.1002/art.1780360119; NEWBURGER PE, 1994, J CLIN INVEST, V94, P1205, DOI 10.1172/JCI117437; Newton AC, 1997, CURR OPIN CELL BIOL, V9, P161, DOI 10.1016/S0955-0674(97)80058-0; OLSON SC, 1990, FEBS LETT, V272, P209; Park JW, 1997, J BIOL CHEM, V272, P11035; PARKOS CA, 1987, J CLIN INVEST, V80, P732, DOI 10.1172/JCI113128; QUALLIOTINEMANN D, 1993, J BIOL CHEM, V268, P23843; QUINN MT, 1995, METHOD ENZYMOL, V255, P476; QUINN MT, 1992, J BIOL CHEM, V267, P7303; ROSSI F, 1990, BIOCHEM BIOPH RES CO, V168, P320, DOI 10.1016/0006-291X(90)91711-Z; ROTROSEN D, 1992, SCIENCE, V256, P1459, DOI 10.1126/science.1318579; ROUSER G, 1966, LIPIDS, V1, P85, DOI 10.1007/BF02668129; RUEGG UT, 1989, TRENDS PHARMACOL SCI, V10, P218, DOI 10.1016/0165-6147(89)90263-0; SEGAL AW, 1992, BIOCHEM J, V284, P781, DOI 10.1042/bj2840781; Sergeant S, 1997, J IMMUNOL, V159, P2877; SMALLWOOD JI, 1992, J LEUKOCYTE BIOL, V51, P84, DOI 10.1002/jlb.51.1.84; SOZZANI S, 1994, BLOOD, V84, P3895, DOI 10.1182/blood.V84.11.3895.bloodjournal84113895; SUCHARD SJ, 1994, J BIOL CHEM, V269, P8063; SUMIMOTO H, 1992, BIOCHEM BIOPH RES CO, V186, P1368, DOI 10.1016/S0006-291X(05)81557-8; TAYLOR WR, 1993, PROTEIN SCI, V2, P1675, DOI 10.1002/pro.5560021013; TOULLEC D, 1991, J BIOL CHEM, V266, P15771; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VERHOEVEN AJ, 1989, BLOOD, V73, P1686; Waite KA, 1997, J BIOL CHEM, V272, P15569, DOI 10.1074/jbc.272.24.15569; WOODMAN RC, 1995, BLOOD, V85, P231, DOI 10.1182/blood.V85.1.231.bloodjournal851231	79	63	64	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 17	1999	274	51					36601	36608		10.1074/jbc.274.51.36601	http://dx.doi.org/10.1074/jbc.274.51.36601			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	266AV	10593961	hybrid			2022-12-25	WOS:000084279200080
J	Shumilla, JA; Broderick, RJ; Wang, YP; Barchowsky, A				Shumilla, JA; Broderick, RJ; Wang, YP; Barchowsky, A			Chromium(VI) inhibits the transcriptional activity of nuclear factor-kappa B by decreasing the interaction of p65 with cAMP-responsive element-binding protein-binding protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CBP-INDUCED STIMULATION; HUMAN LUNG-CELLS; IN-VITRO; INFLAMMATORY CYTOKINES; C-JUN; ACTIVATION; DNA; EXPRESSION; COMPLEXES; MECHANISM	Chromium(VI) regulation of gene expression has been attributed to the generation of reactive chromium and oxygen species, DNA damage, and alterations in mRNA stability. However, the effects of Cr(VI) on signal transduction leading to gene expression are not resolved. Therefore, this study investigated the effects of Cr(VI) on basal and tumor necrosis factor-alpha (TNF-alpha)-induced transcriptional competence of nuclear factor-kappa B (NF-kappa B) in A549 human lung carcinoma cells. Pretreatment of A549 cells with nontoxic levels of Cr(VI) inhibited TNF-alpha-stimulated expression of the endogenous gene for interleukin-8 and of an NF-kappa B-driven luciferase gene construct, but not expression of urokinase, a gene with a more complex promoter. Chromium did not inhibit TNF-alpha-stimulated I kappa B alpha degradation or translocation of NF-kappa B-binding proteins to the nucleus, However, Cr(VI) pretreatments prevented TNF-alpha-stimulated interactions between the p65 subunit of NF-kappa B and the transcriptional cofactor cAMP-responsive element-binding protein-binding protein (CBP), This inhibition was not the result of an effect of chromium on the protein kinase A catalytic activity required for p65/CBP interactions. In contrast, Cr(VI) caused concentration-dependent increases in c-Jun/CBP interactions. These data indicate that nontoxic levels of hexavalent chromium selectively inhibit NF-kappa B transcriptional competence by inhibiting interactions with coactivators of transcription rather than DNA binding.	Dartmouth Med Sch, Dept Pharmacol & Toxicol, Hanover, NH 03755 USA; Dartmouth Coll, Dept Chem, Hanover, NH 03755 USA	Dartmouth College; Dartmouth College	Barchowsky, A (corresponding author), Dartmouth Med Sch, Dept Pharmacol & Toxicol, 7650 Remsen, Hanover, NH 03755 USA.				NHLBI NIH HHS [HL52738] Funding Source: Medline; NIEHS NIH HHS [ES07373] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL052738] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P42ES007373] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Alcedo J A, 1990, Int Rev Exp Pathol, V31, P85; ARIAS J, 1994, NATURE, V370, P226, DOI 10.1038/370226a0; BANNISTER AJ, 1995, EMBO J, V14, P4758, DOI 10.1002/j.1460-2075.1995.tb00157.x; Bannister AJ, 1995, ONCOGENE, V11, P2509; Barchowsky A, 1996, FREE RADICAL BIO MED, V21, P783, DOI 10.1016/0891-5849(96)00174-8; Caelles C, 1997, GENE DEV, V11, P3351, DOI 10.1101/gad.11.24.3351; Chen F, 1997, ARCH BIOCHEM BIOPHYS, V338, P165, DOI 10.1006/abbi.1996.9849; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; Dubrovskaya VA, 1998, CARCINOGENESIS, V19, P1401, DOI 10.1093/carcin/19.8.1401; DUDEK EJ, 1994, NEW J CHEM, V18, P411; FUJITA T, 1992, GENE DEV, V6, P775, DOI 10.1101/gad.6.5.775; Gerritsen ME, 1997, P NATL ACAD SCI USA, V94, P2927, DOI 10.1073/pnas.94.7.2927; Hida K, 1997, AM J PATHOL, V150, P2125; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; KWOK RPS, 1994, NATURE, V370, P223, DOI 10.1038/370223a0; Lee SK, 1998, J BIOL CHEM, V273, P16651, DOI 10.1074/jbc.273.27.16651; LENGYEL E, 1995, BBA-MOL CELL RES, V1268, P65, DOI 10.1016/0167-4889(95)00050-3; Martin BD, 1998, CHEM RES TOXICOL, V11, P1402, DOI 10.1021/tx9801559; MATSUSAKA T, 1993, P NATL ACAD SCI USA, V90, P10193, DOI 10.1073/pnas.90.21.10193; MATTAGAJASINGH SN, 1995, MOL CELL BIOCHEM, V142, P61, DOI 10.1007/BF00928914; MILLER CA, 1988, MOL CARCINOGEN, V1, P125; MILLER CA, 1989, CARCINOGENESIS, V10, P667, DOI 10.1093/carcin/10.4.667; MUKAIDA N, 1990, J BIOL CHEM, V265, P21128; Samet JM, 1998, AM J PHYSIOL-LUNG C, V275, pL551, DOI 10.1152/ajplung.1998.275.3.L551; SHAINKINKESTENBAUM R, 1991, J TRACE ELEM ELECT H, V5, P197; Shumilla JA, 1999, TOXICOL APPL PHARM, V158, P288, DOI 10.1006/taap.1999.8704; Shumilla JA, 1998, ARCH BIOCHEM BIOPHYS, V349, P356, DOI 10.1006/abbi.1997.0470; Swope DL, 1996, J BIOL CHEM, V271, P28138, DOI 10.1074/jbc.271.45.28138; Tian L, 1996, TOXICOL APPL PHARM, V141, P540, DOI 10.1006/taap.1996.0320; WETTERHAHN KE, 1989, BIOL TRACE ELEM RES, V21, P405, DOI 10.1007/BF02917282; Xu J, 1996, CARCINOGENESIS, V17, P1511, DOI 10.1093/carcin/17.7.1511; Yang XJ, 1996, NATURE, V382, P319, DOI 10.1038/382319a0; Zhitkovich A, 1996, BIOCHEMISTRY-US, V35, P7275, DOI 10.1021/bi960147w; Zhong HH, 1997, CELL, V89, P413, DOI 10.1016/S0092-8674(00)80222-6; Zhong HH, 1998, MOL CELL, V1, P661, DOI 10.1016/S1097-2765(00)80066-0	35	69	69	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 17	1999	274	51					36207	36212		10.1074/jbc.274.51.36207	http://dx.doi.org/10.1074/jbc.274.51.36207			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	266AV	10593907	hybrid			2022-12-25	WOS:000084279200026
J	Yates, PA; Burman, RW; Mummaneni, P; Krussel, S; Turker, MS				Yates, PA; Burman, RW; Mummaneni, P; Krussel, S; Turker, MS			Tandem B1 elements located in a mouse methylation center provide a target for de novo DNA methylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOSINE METHYLATION; DENOVO METHYLATION; CELLS; GENE; SEQUENCES; REPEATS; PATTERNS; UPSTREAM; REGIONS; LOCUS	A cis-acting methylation center that signals de novo DNA methylation is located upstream of the mouse Aprt gene. In the current study, two approaches were taken to determine if tandem B1 repetitive elements found at the 3' end of the methylation center contribute to the methylation signal. First, bisulfite genomic sequencing demonstrated that CpG sites within the B1 elements were methylated at relative levels of 43% in embryonal stem cells deficient for the maintenance DNA methyltransferase when compared with wild type embryonal stem cells. Second, the ability of the BI elements to signal de novo methylation upon stable transfection into mouse embryonal carcinoma cells was examined, This approach demonstrated that the B1 elements were methylated de novo to a high level in the embryonal carcinoma cells and that the B1 elements acted synergistically, The results from these experiments provide strong evidence that the tandem B1 repetitive elements provide a significant fraction of the methylation center signal. By extension, they also support the hypothesis that one role for DNA methylation in mammals is to protect the genome from expression and transposition of parasitic elements.	Oregon Hlth Sci Univ, Ctr Res Occupat & Environm Toxicol, Portland, OR 97201 USA; Oregon Hlth Sci Univ, Dept Mol & Med Genet, Portland, OR 97201 USA; NICHD, Sect Neuroendocrinol, Dev Neurobiol Lab, NIH, Bethesda, MD 20892 USA	Oregon Health & Science University; Oregon Health & Science University; National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)	Turker, MS (corresponding author), Oregon Hlth Sci Univ, Ctr Res Occupat & Environm Toxicol, L606,3181 SW Sam Jackson Pk Rd, Portland, OR 97201 USA.				PHS HHS [T32] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Baylin SB, 1998, ADV CANCER RES, V72, P141; Bestor TH, 1998, CIBA F SYMP, V214, P187; BOLDEN AH, 1986, MOL CELL BIOL, V6, P1135, DOI 10.1128/MCB.6.4.1135; BOLDEN AH, 1985, NUCLEIC ACIDS RES, V13, P3479, DOI 10.1093/nar/13.10.3479; Garrick D, 1998, NAT GENET, V18, P56, DOI 10.1038/ng0198-56; Graff JR, 1997, J BIOL CHEM, V272, P22322, DOI 10.1074/jbc.272.35.22322; HASSE A, 1994, J BIOL CHEM, V269, P1821; HELLMANNBLUMBERG U, 1993, MOL CELL BIOL, V13, P4523, DOI 10.1128/MCB.13.8.4523; Hertz JM, 1999, J BIOL CHEM, V274, P24232, DOI 10.1074/jbc.274.34.24232; JAHNER D, 1985, NATURE, V315, P594, DOI 10.1038/315594a0; KOCHANEK S, 1993, EMBO J, V12, P1141, DOI 10.1002/j.1460-2075.1993.tb05755.x; LABUDA D, 1991, J MOL EVOL, V32, P405, DOI 10.1007/BF02101280; Lei H, 1996, DEVELOPMENT, V122, P3195; LIU WM, 1994, NUCLEIC ACIDS RES, V22, P1087, DOI 10.1093/nar/22.6.1087; LIU WM, 1993, NUCLEIC ACIDS RES, V21, P1351, DOI 10.1093/nar/21.6.1351; McDonald LE, 1997, BIOTECHNIQUES, V22, P272, DOI 10.2144/97222bm16; MUMMANENI P, 1993, J BIOL CHEM, V268, P552; Paulin R, 1998, NUCLEIC ACIDS RES, V26, P5009, DOI 10.1093/nar/26.21.5009; QUENTIN Y, 1994, NUCLEIC ACIDS RES, V22, P2222, DOI 10.1093/nar/22.12.2222; SCHMID CW, 1982, SCIENCE, V216, P1065, DOI 10.1126/science.6281889; SINNETT D, 1991, J BIOL CHEM, V266, P8675; TURKER M, 1995, MUTAT RES-FUND MOL M, V329, P97, DOI 10.1016/0027-5107(95)00046-L; Turker MS, 1999, SEMIN CANCER BIOL, V9, P329, DOI 10.1006/scbi.1999.0133; TURKER MS, 1991, SOMAT CELL MOLEC GEN, V17, P151, DOI 10.1007/BF01232972; TURKER MS, 1989, SOMAT CELL MOLEC GEN, V15, P159, DOI 10.1007/BF01535077; TURKER MS, 1989, J BIOL CHEM, V264, P11632; TURKER MS, 1994, ADV EXP MED BIOL, V111, P647; Walsh CP, 1998, NAT GENET, V20, P116, DOI 10.1038/2413; WARD C, 1987, J BIOL CHEM, V262, P11057; Warnecke PM, 1998, DEV GENET, V22, P111, DOI 10.1002/(SICI)1520-6408(1998)22:2&lt;111::AID-DVG1&gt;3.0.CO;2-9; Woodcock DM, 1998, GENE, V206, P63, DOI 10.1016/S0378-1119(97)00566-0; Yoder JA, 1997, TRENDS GENET, V13, P335, DOI 10.1016/S0168-9525(97)01181-5	32	71	74	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 17	1999	274	51					36357	36361		10.1074/jbc.274.51.36357	http://dx.doi.org/10.1074/jbc.274.51.36357			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	266AV	10593928	hybrid			2022-12-25	WOS:000084279200047
J	Hirata, H; Yamamura, I; Yasuda, K; Kobayashi, A; Tada, N; Suzuki, M; Hirayoshi, K; Hosokawa, N; Nagata, K				Hirata, H; Yamamura, I; Yasuda, K; Kobayashi, A; Tada, N; Suzuki, M; Hirayoshi, K; Hosokawa, N; Nagata, K			Separate cis-acting DNA elements control cell type- and tissue-specific expression of collagen binding molecular chaperone HSP47	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK PROTEIN; F9 TERATOCARCINOMA CELLS; STRESS PROTEIN; ENDOPLASMIC-RETICULUM; TRANSGENIC MICE; RETINOIC ACID; TRANSCRIPTIONAL SYNERGISM; EMBRYO FIBROBLASTS; GENE-EXPRESSION; MESSENGER-RNA	HSP47 is a collagen-binding heat shock protein and is assumed to act as a molecular chaperone in the biosynthesis and secretion of procollagen. As the synthesis of HSP47 is closely correlated with that of collagen in various cell lines and tissues, we performed a promoter/ reporter assay using HSP47-producing and nonproducing cells. 280 base pairs (bp(s)) of upstream promoter were shown to be necessary for the basal expression but not to be enough for the cell type-specific expression. When the first and the second introns were introduced downstream of this 280-bp region, marked up-regulation of the reporter activity was observed in HSP47-producing cells but not in nonproducing cells. This was confirmed in transgenic mice by staining the lacZ gene product under the control of the 280-bp upstream promoter and the introns, Staining was observed in skin, chondrocytes, precursor of bone, and other HSP47/collagen-producing tissues, A putative Sp1-binding site at -210 bp in the promoter, to which Sp3 and an unidentified protein bind, was shown to be responsible for this up-regulation when combined with the introns, However no difference in the binding to this probe was observed between HSP47-producing and nonproducing cells. The responsible region for cell type-specific upregulation was found to be located in a 500-bp segment in the first intron, On electrophoresis mobility shift assay using this 500-bp probe, specific DNA-protein complexes were only observed in HSP17-producing cell extracts. These results suggest that two separate elements are necessary for the cell type specific expression of the hsp47 gene; one is a putative Spl-binding site at -210 bp necessary for basal expression, and the other is a 500-bp region within the first intron, required for cell type-specific expression.	Kyoto Univ, Dept Mol & Cellular Biol, Inst Frontier Med Sci, Kyoto 6068507, Japan; Taisho Pharmaceut Co Ltd, Med Res Labs, Mol Biol Lab, Oomiya 3300031, Japan; Kumamoto Univ, Ctr Anim Resources & Dev, Kumamoto 8600811, Japan	Kyoto University; Taisho Pharmaceutical Holdings Co Ltd; Kumamoto University	Nagata, K (corresponding author), Kyoto Univ, Dept Mol & Cellular Biol, Inst Frontier Med Sci, Kyoto 6068507, Japan.	nagata@frontier.kyoto-u.ac.jp		Hirata, Hiromi/0000-0002-3769-7441				Bell DM, 1997, NAT GENET, V16, P174, DOI 10.1038/ng0697-174; BONNEROT C, 1993, METHOD ENZYMOL, V225, P451; BouGharios G, 1996, J CELL BIOL, V134, P1333, DOI 10.1083/jcb.134.5.1333; BRIGGS MR, 1986, SCIENCE, V234, P47, DOI 10.1126/science.3529394; Cheng M, 1998, INT J EXP PATHOL, V79, P125; CLARKE EP, 1992, BIOCHIM BIOPHYS ACTA, V1129, P246, DOI 10.1016/0167-4781(92)90498-O; CLARKE EP, 1991, J BIOL CHEM, V266, P17230; HIRAYOSHI K, 1991, MOL CELL BIOL, V11, P4036, DOI 10.1128/MCB.11.8.4036; HOGAN B, 1994, MANIPULATING MOUSE E, P226; Hosokawa N, 1998, J BIOCHEM-TOKYO, V124, P654, DOI 10.1093/oxfordjournals.jbchem.a022162; HOSOKAWA N, 1993, GENE, V126, P187, DOI 10.1016/0378-1119(93)90366-B; KINGSLEY C, 1992, MOL CELL BIOL, V12, P4251, DOI 10.1128/MCB.12.10.4251; Koide T, 1999, J BIOL CHEM, V274, P34523, DOI 10.1074/jbc.274.49.34523; Krebsbach PH, 1996, J BIOL CHEM, V271, P4298, DOI 10.1074/jbc.271.8.4298; Leung KKH, 1998, J CELL BIOL, V141, P1291, DOI 10.1083/jcb.141.6.1291; MAEKAWA T, 1991, ONCOGENE, V6, P627; Maniatis T., 1982, MOL CLONING LAB MANU; MASTRANGELO IA, 1991, P NATL ACAD SCI USA, V88, P5670, DOI 10.1073/pnas.88.13.5670; MASUDA H, 1994, J CLIN INVEST, V94, P2481, DOI 10.1172/JCI117617; MIYAISHI O, 1992, J HISTOCHEM CYTOCHEM, V40, P1021, DOI 10.1177/40.7.1607635; MORIMOTO RI, 1994, BIOL HEAT SHOCK PROT; Moriyama T, 1998, KIDNEY INT, V54, P110, DOI 10.1046/j.1523-1755.1998.00964.x; Moriyama T, 1997, KIDNEY INT, pS232; Nagata K, 1996, TRENDS BIOCHEM SCI, V21, P23, DOI 10.1016/0968-0004(96)80881-4; NAGATA K, 1986, J BIOL CHEM, V261, P7531; NAGATA K, 1988, J BIOL CHEM, V263, P8344; NAGATA K, 1986, J CELL BIOL, V103, P223, DOI 10.1083/jcb.103.1.223; NAKAI A, 1990, J BIOL CHEM, V265, P992; NAKAI A, 1992, J CELL BIOL, V117, P903, DOI 10.1083/jcb.117.4.903; NATSUME T, 1994, J BIOL CHEM, V269, P31224; NIEDERREITHER K, 1992, J CELL BIOL, V119, P1361, DOI 10.1083/jcb.119.5.1361; NISCHT R, 1991, EUR J BIOCHEM, V200, P529, DOI 10.1111/j.1432-1033.1991.tb16214.x; Pak BJ, 1996, BIOCHEM CELL BIOL, V74, P179, DOI 10.1139/o96-018; PASCAL E, 1991, GENE DEV, V5, P1646, DOI 10.1101/gad.5.9.1646; Pearson DS, 1996, DNA CELL BIOL, V15, P263, DOI 10.1089/dna.1996.15.263; PELHAM HRB, 1989, ANNU REV CELL BIOL, V5, P1, DOI 10.1146/annurev.cb.05.110189.000245; POLLNER R, 1990, ANN NY ACAD SCI, V580, P44, DOI 10.1111/j.1749-6632.1990.tb17916.x; POSCHL E, 1988, EMBO J, V7, P2687, DOI 10.1002/j.1460-2075.1988.tb03122.x; RONG L, 1991, CELL, V65, P493; SAGA S, 1987, J CELL BIOL, V105, P517, DOI 10.1083/jcb.105.1.517; Satoh M, 1996, J CELL BIOL, V133, P469, DOI 10.1083/jcb.133.2.469; SAUK JJ, 1994, J BIOL CHEM, V269, P3941; SAVAGNER P, 1995, DNA CELL BIOL, V14, P501, DOI 10.1089/dna.1995.14.501; SHROFF B, 1993, CONNECT TISSUE RES, V29, P273, DOI 10.3109/03008209309016833; SHROFF B, 1994, ARCH ORAL BIOL, V39, P231, DOI 10.1016/0003-9969(94)90049-3; SU W, 1991, GENE DEV, V5, P820, DOI 10.1101/gad.5.5.820; Sunamoto M, 1998, INT J EXP PATHOL, V79, P133, DOI 10.1046/j.1365-2613.1998.00061.x; TAKECHI H, 1992, EUR J BIOCHEM, V206, P323, DOI 10.1111/j.1432-1033.1992.tb16930.x; Tsumaki N, 1996, J CELL BIOL, V134, P1573, DOI 10.1083/jcb.134.6.1573; WANG SY, 1990, J BIOL CHEM, V265, P15818; WANG SY, 1985, DEV BIOL, V107, P75, DOI 10.1016/0012-1606(85)90377-X; WANG SY, 1992, J BIOL CHEM, V267, P15362; Whisstock J, 1998, TRENDS BIOCHEM SCI, V23, P63, DOI 10.1016/S0968-0004(97)01172-9; YIEH L, 1995, P NATL ACAD SCI USA, V92, P6102, DOI 10.1073/pnas.92.13.6102	54	23	24	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 10	1999	274	50					35703	35710		10.1074/jbc.274.50.35703	http://dx.doi.org/10.1074/jbc.274.50.35703			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	264NG	10585450	hybrid			2022-12-25	WOS:000084187900062
J	Ciolino, HP; Yeh, GC				Ciolino, HP; Yeh, GC			The steroid hormone dehydroepiandrosterone inhibits CYP1A1 expression in vitro by a post-transcriptional mechanism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ARYL-HYDROCARBON RECEPTOR; 7,12-DIMETHYLBENZ(A) ANTHRACENE DMBA; BREAST-CANCER CELLS; MAMMARY-CARCINOMA; MICE; GLUCOSE-6-PHOSPHATE-DEHYDROGENASE; SULFATE; DHEA; RAT; TUMORIGENESIS	The adrenal steroid hormone dehydroepiandrosterone (DHEA) is a potent inhibitor of mammary carcinogenesis induced by polycyclic aromatic hydrocarbons (PAH), though its mechanism is unclear. We examined the effect of DHEA on the expression of the carcinogen-activating enzyme cytochrome P450 1A1 (CYP1A1) in MCF-7 human breast epithelial carcinoma cells. DHEA inhibited the increase in CYP1A1 enzyme activity that occurs when MCF-7 cells are exposed to the PAM dimethylbenzanthracene (DMBA) or 2,3,7,8-tetrachloro-dibenzo-p-dioxin (TCDD). However, DHEA did not directly inhibit enzyme activity as it had no effect when added to the cells after induction by DMBA or TCDD. We observed that the increase of CYP1A1 mRNA in MCF-7 cells caused by DMBA or TCDD was inhibited by DHEA in a concentration-dependent manner. However, DHEA did not inhibit CYP1A1 promoter-driven transcription, indicating that it did not affect the aryl hydrocarbon receptor, which regulates transcription of the CYP1A1 gene. Actinomycin D chase experiments showed that DHEA caused a time- and concentration-dependent decrease in CYP1A1 mRNA levels, indicating that DHEA inhibits CYP1A1 expression by decreasing CYP1A1 mRNA stability. These data demonstrate that DHEA inhibits PAM-induced CYP1A1 mRNA expression and enzyme activity in vitro by a post-transcriptional mechanism. This regulation of the expression of carcinogen-activating enzymes may be responsible for the chemopreventive activity of DHEA and may be one of its physiologic functions in vivo.	NCI, Frederick Canc Res & Dev Ctr, Cellular Def & Carcinogenesis Sect, Basic Res Lab,Div Basic Sci,NIH, Ft Detrick, MD 21702 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick	Ciolino, HP (corresponding author), NCI, Frederick Canc Res & Dev Ctr, Cellular Def & Carcinogenesis Sect, Basic Res Lab,Div Basic Sci,NIH, Bldg 560,Rm 12-05,POB B, Ft Detrick, MD 21702 USA.	hciolino@mail.ncifcrf.gov						BARRETTCONNOR E, 1986, NEW ENGL J MED, V315, P1519, DOI 10.1056/NEJM198612113152405; CASAZZA JP, 1986, J NUTR, V116, P304, DOI 10.1093/jn/116.2.304; CHEN YH, 1995, J BIOL CHEM, V270, P22548, DOI 10.1074/jbc.270.38.22548; Ciolino HP, 1999, BIOCHEM J, V340, P715, DOI 10.1042/0264-6021:3400715; Ciolino HP, 1998, CANCER RES, V58, P2754; Ciolino HP, 1998, CANCER RES, V58, P5707; CLEARY MP, 1990, INT J BIOCHEM, V22, P205, DOI 10.1016/0020-711X(90)90331-V; DiMonaco M, 1997, BRIT J CANCER, V75, P589, DOI 10.1038/bjc.1997.102; DOHR O, 1995, ARCH BIOCHEM BIOPHYS, V321, P405, DOI 10.1006/abbi.1995.1411; EBELING P, 1994, LANCET, V343, P1479, DOI 10.1016/s0140-6736(94)92587-9; KALIMI M, 1994, MOL CELL BIOCHEM, V131, P99, DOI 10.1007/BF00925945; Khorram O, 1997, J GERONTOL A-BIOL, V52, pM1, DOI 10.1093/gerona/52A.1.M1; Kohama T, 1997, BREAST CANCER RES TR, V43, P105, DOI 10.1023/A:1005788326534; Larsen MC, 1998, CANCER RES, V58, P2366; LI SM, 1994, BREAST CANCER RES TR, V29, P203, DOI 10.1007/BF00665681; Longcope C, 1996, J ENDOCRINOL, V150, pS125; Longcope C, 1998, SEMIN REPROD ENDOCR, V16, P111, DOI 10.1055/s-2007-1016260; Luo SQ, 1997, ENDOCRINOLOGY, V138, P3387, DOI 10.1210/en.138.8.3387; McCormick DL, 1996, CANCER RES, V56, P1724; MOORE M, 1994, J BIOL CHEM, V269, P11751; NESTLER JE, 1988, J CLIN ENDOCR METAB, V66, P57, DOI 10.1210/jcem-66-1-57; NYCE JW, 1984, CARCINOGENESIS, V5, P57, DOI 10.1093/carcin/5.1.57; PASHKO LL, 1985, CANCER RES, V45, P164; PASHKO LL, 1981, CARCINOGENESIS, V2, P717, DOI 10.1093/carcin/2.8.717; Perkins SN, 1997, CARCINOGENESIS, V18, P989, DOI 10.1093/carcin/18.5.989; PRASANNA HR, 1989, DRUG CHEM TOXICOL, V12, P327, DOI 10.3109/01480548908999162; Ravaglia G, 1996, J CLIN ENDOCR METAB, V81, P1173, DOI 10.1210/jc.81.3.1173; REGELSON W, 1994, ANN NY ACAD SCI, V719, P564, DOI 10.1111/j.1749-6632.1994.tb56860.x; ROSE DP, 1977, EUR J CANCER, V13, P43, DOI 10.1016/0014-2964(77)90228-6; Rowlands JC, 1997, CRIT REV TOXICOL, V27, P109, DOI 10.3109/10408449709021615; Schwartz AG, 1995, ANN NY ACAD SCI, V774, P180, DOI 10.1111/j.1749-6632.1995.tb17381.x; SCHWARTZ AG, 1975, CANCER RES, V35, P2482; SCHWARTZ AG, 1995, J CELL BIOCHEM, P210; SCHWARTZ AG, 1989, CARCINOGENESIS, V10, P1809; Shou M, 1996, BIOCHEMISTRY-US, V35, P15807, DOI 10.1021/bi962042z; Tchernof A, 1996, J ENDOCRINOL, V150, pS155; Tian WN, 1998, J BIOL CHEM, V273, P10609, DOI 10.1074/jbc.273.17.10609; WATTENBERG LW, 1992, CANCER RES, V52, pS2085; Waxman DJ, 1996, J ENDOCRINOL, V150, pS129; Whitlock JP, 1997, DRUG METAB REV, V29, P1107, DOI 10.3109/03602539709002245	40	28	29	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 3	1999	274	49					35186	35190		10.1074/jbc.274.49.35186	http://dx.doi.org/10.1074/jbc.274.49.35186			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	260XW	10575002	hybrid			2022-12-25	WOS:000083979600096
J	Sakiyama, SE; Schense, JC; Hubbell, JA				Sakiyama, SE; Schense, JC; Hubbell, JA			Incorporation of heparin-binding peptides into fibrin gels enhances neurite extension: an example of designer matrices in tissue engineering	FASEB JOURNAL			English	Article						antithrombin III; neural cell adhesion molecule; platelet factor 4; regeneration	MOLECULE HB-GAM; CELL SUBSTRATUM ADHESION; AMINO-ACID SEQUENCE; OUTGROWTH IN-VITRO; NERVE REGENERATION; ANTITHROMBIN-III; SILICONE CHAMBER; A-CHAIN; LAMININ; GROWTH	The goal of this work was to improve the potential of fibrin to promote nerve regeneration by enzymatically incorporating exogenous neurite-promoting heparin-binding peptides. The effects on neurite extension of four different heparin-binding peptides, derived from the heparin-binding domains of antithrombin III, neural cell adhesion molecule and platelet factor 4, were determined. These exogenous peptides were synthesized as bi-domain peptide chimeras, with the second domain being a substrate for factor XIIIa. This coagulation transglutaminase covalently bound the peptides within the fibrin gel during coagulation. The heparin-binding peptides enhanced the degree of neurite extension from embryonic chick dorsal root ganglia through 3-dimensional fibrin gels, and the extent of enhancement was found to correlate positively with the heparin-binding affinity of the individual domains. The enhancement could be inhibited by competition with soluble heparin, by degradation of cell-surface proteoglycans, and by inhibition of the covalent immobilization of the peptide. These results demonstrate an important potential role for proteoglycan-binding components of the extracellular matrix in neurite extension and suggest that fibrin gels modified with covalently bound heparin-binding peptides could serve as a therapeutic agent to enhance peripheral nerve regeneration through nerve guide tubes. More generally, the results demonstrate that the biological responses to fibrin, the body's natural wound healing matrix, can be dramatically improved by the addition of exogenous bioactive peptides in a manner such that they become immobilized during coagulation.	ETH Zurich, Inst Biomed Engn, CH-8044 Zurich, Switzerland; ETH Zurich, Dept Mat, CH-8044 Zurich, Switzerland; Univ Zurich, CH-8006 Zurich, Switzerland; CALTECH, Div Chem & Chem Engn, Pasadena, CA 91125 USA	Swiss Federal Institutes of Technology Domain; ETH Zurich; Swiss Federal Institutes of Technology Domain; ETH Zurich; University of Zurich; California Institute of Technology	Hubbell, JA (corresponding author), ETH Zurich, Inst Biomed Engn, Moussonstr 18, CH-8044 Zurich, Switzerland.		Sakiyama-Elbert, Shelly/A-6753-2008; Hubbell, Jeffrey A/A-9266-2008	Sakiyama-Elbert, Shelly/0000-0003-4832-5851; Hubbell, Jeffrey A/0000-0003-0276-5456				AEBISCHER P, 1990, BRAIN RES, V531, P211, DOI 10.1016/0006-8993(90)90776-8; AUMAILLEY M, 1990, FEBS LETT, V262, P82, DOI 10.1016/0014-5793(90)80159-G; BELLAMKONDA R, 1995, J BIOMED MATER RES, V29, P663, DOI 10.1002/jbm.820290514; Black AF, 1998, FASEB J, V12, P1331, DOI 10.1096/fasebj.12.13.1331; BLASCHUK OW, 1990, DEV BIOL, V139, P227, DOI 10.1016/0012-1606(90)90290-Y; Borkenhagen M, 1998, J BIOMED MATER RES, V40, P392, DOI 10.1002/(SICI)1097-4636(19980603)40:3<392::AID-JBM8>3.3.CO;2-4; Borrajo AMP, 1997, BIOORG MED CHEM LETT, V7, P1185, DOI 10.1016/S0960-894X(97)00180-7; CARRI NG, 1988, J NEUROSCI RES, V19, P428, DOI 10.1002/jnr.490190407; COLE GJ, 1986, J CELL BIOL, V102, P403, DOI 10.1083/jcb.102.2.403; COLE GJ, 1985, J CELL BIOL, V100, P1192, DOI 10.1083/jcb.100.4.1192; EDGAR D, 1984, EMBO J, V3, P1463, DOI 10.1002/j.1460-2075.1984.tb01997.x; FIELDS GB, 1990, INT J PEPT PROT RES, V35, P161, DOI 10.1111/j.1399-3011.1990.tb00939.x; GRAF J, 1987, BIOCHEMISTRY-US, V26, P6896, DOI 10.1021/bi00396a004; GRAF J, 1987, CELL, V48, P989, DOI 10.1016/0092-8674(87)90707-0; Herbert CB, 1996, J COMP NEUROL, V365, P380, DOI 10.1002/(SICI)1096-9861(19960212)365:3<380::AID-CNE4>3.0.CO;2-0; ICHINOSE A, 1983, FEBS LETT, V153, P369, DOI 10.1016/0014-5793(83)80645-0; IGNATIUS MJ, 1990, J CELL BIOL, V111, P709, DOI 10.1083/jcb.111.2.709; KALLAPUR SG, 1992, J NEUROSCI RES, V33, P538, DOI 10.1002/jnr.490330406; Kaneda N, 1996, J BIOCHEM-TOKYO, V119, P1150; Kinnunen T, 1996, J BIOL CHEM, V271, P2243, DOI 10.1074/jbc.271.4.2243; KIRCHHOFER D, 1990, J BIOL CHEM, V265, P615; KLEINMAN HK, 1989, ARCH BIOCHEM BIOPHYS, V272, P39, DOI 10.1016/0003-9861(89)90192-6; L'Heureux N, 1998, FASEB J, V12, P47, DOI 10.1096/fasebj.12.1.47; LIESI P, 1989, FEBS LETT, V244, P141, DOI 10.1016/0014-5793(89)81180-9; Lundborg G, 1990, Restor Neurol Neurosci, V1, P297, DOI 10.3233/RNN-1990-13418; MACCARANA M, 1993, GLYCOBIOLOGY, V3, P271, DOI 10.1093/glycob/3.3.271; Maeda N, 1998, J CELL BIOL, V142, P203, DOI 10.1083/jcb.142.1.203; MAEDA N, 1994, FEBS LETT, V354, P67, DOI 10.1016/0014-5793(94)01093-5; MASSIA SP, 1993, J BIOL CHEM, V268, P8053; Mooney DJ, 1997, J BIOMED MATER RES, V37, P413, DOI 10.1002/(SICI)1097-4636(19971205)37:3<413::AID-JBM12>3.0.CO;2-C; Nolo R, 1996, EUR J NEUROSCI, V8, P1658, DOI 10.1111/j.1460-9568.1996.tb01309.x; Palecek SP, 1997, NATURE, V385, P537, DOI 10.1038/385537a0; PERRIS R, 1989, DEV BIOL, V136, P222, DOI 10.1016/0012-1606(89)90144-9; PITTMAN RN, 1989, J NEUROSCI, V9, P4269; RAOLO E, 1994, J BIOL CHEM, V269, P12999; RAUVALA H, 1994, DEV BRAIN RES, V79, P157, DOI 10.1016/0165-3806(94)90121-X; ROGERS SL, 1985, J NEUROSCI, V5, P369; Schense JC, 1999, BIOCONJUGATE CHEM, V10, P75, DOI 10.1021/bc9800769; SEPHEL GC, 1989, DEV NEUROSCI-BASEL, V11, P313, DOI 10.1159/000111909; Sims CD, 1998, PLAST RECONSTR SURG, V101, P1580, DOI 10.1097/00006534-199805000-00022; SMITH JW, 1987, J BIOL CHEM, V262, P11964; TASHIRO K, 1989, J BIOL CHEM, V264, P16174; THOMPSON JA, 1988, SCIENCE, V241, P1349, DOI 10.1126/science.2457952; TYLERCROSS R, 1994, PROTEIN SCI, V3, P620; VARON S, 1972, METHODS TECHNIQUES N, P203; WILLIAMS LR, 1987, NEUROCHEM RES, V12, P851, DOI 10.1007/BF00966306; WILLIAMS LR, 1987, J COMP NEUROL, V264, P284, DOI 10.1002/cne.902640211; ZUCKER MB, 1991, P SOC EXP BIOL MED, V198, P93	48	149	168	0	24	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	DEC	1999	13	15					2214	2224		10.1096/fasebj.13.15.2214	http://dx.doi.org/10.1096/fasebj.13.15.2214			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	266QN	10593869				2022-12-25	WOS:000084310800013
J	Gassmann, MG; Stanzel, A; Werner, S				Gassmann, MG; Stanzel, A; Werner, S			Growth factor-regulated expression of enzymes involved in nucleotide biosynthesis: a novel mechanism of growth factor action	ONCOGENE			English	Article						keratinocyte growth factor; keratinocytes; purine; pyrimidine; nucleotide biosynthesis; salvage pathway	INFLAMMATORY BOWEL-DISEASE; HUMAN KERATINOCYTES; MOLECULAR-CLONING; ADENYLOSUCCINATE LYASE; FACTOR RECEPTOR; CDNA SEQUENCE; HUMAN HOMOLOG; FACTOR-ALPHA; GENE; SYNTHETASE	Keratinocyte growth factor (KGF) is a potent and specific mitogen for epithelial cells, including the keratinocytes of the skin, We investigated the mechanisms of action of KGF by searching for genes which are regulated by this growth factor in cultured human keratinocytes. Using the differential display RT-PCR technology we identified the gene encoding adenylosuccinate lyase [EC 4.3.2.2] as a novel KGF-regulated gene, Adenylosuccinate lyase plays an important role in purine de novo synthesis. To gain further insight into the potential role of nucleotide biosynthesis in the mitogenic effect of KGF, we cloned cDNA fragments of the key regulatory enzymes involved in purine and pyrimidine metabolism (adenylosuccinate synthetase [EC 6.3.4.4], phosphoribosyl pyrophosphate synthetase [EC 2.7.6.1], amidophosphoribosyl transferase [EC 2.4.2.14], hypoxanthine guanine phosphoribosyl transferase [EC 2.4.2.8] and the multifunctional protein CAD which includes the enzymatic activities of carbamoyl-phosphate synthetase II [EC 6.3.5.59], aspartate transcarbamylase [EC 2.1.3.2] and dihydroorotase [EC 3.5.2.3]), Expression of all of these enzymes was upregulated after treatment with KGF and also with epidermal growth factor (EGF), indicating that these mitogens stimulate nucleotide production by induction of these enzymes. To determine a possible in vivo correlation between the expression of KGF, EGF and the enzymes mentioned above, we analysed the expression of the enzymes during cutaneous wound repair, where high levels of these mitogens are present. Indeed, we found a strong mRNA expression of all of these enzymes in the EGF- and KGF-responsive keratinocytes of the hyperproliferative epithelium at the wound edge, indicating that their expression might also be regulated by growth factors during wound healing.	ETH Honggerberg, Inst Cell Biol, CH-8093 Zurich, Switzerland; Max Planck Inst Biochem, D-82152 Martinsried, Germany	Swiss Federal Institutes of Technology Domain; ETH Zurich; Max Planck Society	Werner, S (corresponding author), ETH Honggerberg, Inst Cell Biol, CH-8093 Zurich, Switzerland.			Werner, Sabine/0000-0001-7397-8710				Ashcroft GS, 1997, J ANAT, V190, P351, DOI 10.1046/j.1469-7580.1997.19030351.x; BAUER D, 1994, PCR METH APPL, V4, P97; Beer HD, 1997, ONCOGENE, V15, P2211, DOI 10.1038/sj.onc.1201383; BOUKAMP P, 1988, J CELL BIOL, V106, P761, DOI 10.1083/jcb.106.3.761; Brauchle M, 1996, AM J PATHOL, V149, P521; Carrey EA, 1995, BIOCHEM SOC T, V23, P899, DOI 10.1042/bst0230899; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DETMAR M, 1990, ARCH DERMATOL RES, V282, P238, DOI 10.1007/BF00371643; ERNER S, 1998, CYTOKINE GROWTH F R, V9, P153; Finch PW, 1997, AM J PATHOL, V151, P1619; Finch PW, 1996, GASTROENTEROLOGY, V110, P441, DOI 10.1053/gast.1996.v110.pm8566591; FON EA, 1993, CYTOGENET CELL GENET, V64, P201, DOI 10.1159/000133575; Frank S, 1996, J BIOL CHEM, V271, P10188, DOI 10.1074/jbc.271.17.10188; Frank S, 1996, J BIOL CHEM, V271, P24337, DOI 10.1074/jbc.271.40.24337; Frank S, 1997, ONCOGENE, V14, P915, DOI 10.1038/sj.onc.1200905; GAME SM, 1992, INT J CANCER, V52, P461, DOI 10.1002/ijc.2910520322; Gold LI, 1997, AM J PATHOL, V150, P209; Guo LF, 1996, GENE DEV, V10, P165, DOI 10.1101/gad.10.2.165; Hubner G, 1996, CYTOKINE, V8, P548, DOI 10.1006/cyto.1996.0074; Igarashi M, 1998, J BIOL CHEM, V273, P13230, DOI 10.1074/jbc.273.21.13230; IWAHANA H, 1993, J BIOL CHEM, V268, P7225; IWAHANA H, 1993, BIOCHEM BIOPH RES CO, V190, P192, DOI 10.1006/bbrc.1993.1030; IWAHANA H, 1995, BBA-GENE STRUCT EXPR, V1261, P369, DOI 10.1016/0167-4781(95)00036-G; Iwahana H, 1996, BIOCHEM BIOPH RES CO, V219, P249, DOI 10.1006/bbrc.1996.0213; JOLLY DJ, 1983, P NATL ACAD SCI-BIOL, V80, P477, DOI 10.1073/pnas.80.2.477; KONECKI DS, 1982, NUCLEIC ACIDS RES, V10, P6763, DOI 10.1093/nar/10.21.6763; LIAO WSL, 1986, J BIOL CHEM, V261, P5577; MARCHESE C, 1995, J EXP MED, V182, P1369, DOI 10.1084/jem.182.5.1369; MARIKOVSKY M, 1993, P NATL ACAD SCI USA, V90, P3889, DOI 10.1073/pnas.90.9.3889; Ogura R, 1983, Curr Probl Dermatol, V11, P145; POWELL SM, 1992, FEBS LETT, V303, P4, DOI 10.1016/0014-5793(92)80465-S; RAO GN, 1988, EXP CELL RES, V178, P449, DOI 10.1016/0014-4827(88)90413-2; RAO GN, 1988, DNA-J MOLEC CELL BIO, V7, P423, DOI 10.1089/dna.1.1988.7.423; RHEINWALD JG, 1977, NATURE, V265, P421, DOI 10.1038/265421a0; RUBIN JS, 1989, P NATL ACAD SCI USA, V86, P802, DOI 10.1073/pnas.86.3.802; RUBIN JS, 1995, CELL BIOL INT, V19, P399, DOI 10.1006/cbir.1995.1085; Schmid P, 1998, AM J PATHOL, V152, P485; SHIPLEY GD, 1986, CANCER RES, V46, P2068; SIMMER JP, 1990, J BIOL CHEM, V265, P10395; SONODA T, 1991, J BIOCHEM-TOKYO, V109, P361; TODD R, 1991, AM J PATHOL, V138, P1307; TREFZER U, 1991, J INVEST DERMATOL, V97, P911, DOI 10.1111/1523-1747.ep12491668; Voet D VJ, 1990, BIOCHEMISTRY; WENCZAK BA, 1992, J CLIN INVEST, V90, P2392, DOI 10.1172/JCI116130; WERNER S, 1994, SCIENCE, V266, P819, DOI 10.1126/science.7973639; WERNER S, 1992, P NATL ACAD SCI USA, V89, P6896, DOI 10.1073/pnas.89.15.6896; WILKINSON DG, 1987, DEVELOPMENT, V99, P493; WONG LJC, 1995, GENOMICS, V28, P341, DOI 10.1006/geno.1995.1152; ZALKIN H, 1992, PROG NUCLEIC ACID RE, V42, P259, DOI 10.1016/S0079-6603(08)60578-4	49	22	22	0	6	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 18	1999	18	48					6667	6676		10.1038/sj.onc.1203120	http://dx.doi.org/10.1038/sj.onc.1203120			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	257QA	10597272				2022-12-25	WOS:000083792000006
J	Fan, W; Richter, G; Cereseto, A; Beadling, C; Smith, KA				Fan, W; Richter, G; Cereseto, A; Beadling, C; Smith, KA			Cytokine response gene 6 induces p21 and regulates both cell growth and arrest	ONCOGENE			English	Article						cytokine; cell cycle; G1 and G2 progression	HUMAN INTERLEUKIN-2; TUMOR-SUPPRESSOR; DNA-REPLICATION; CYCLE; GADD45; P53; PROTEIN; EXPRESSION; INHIBITOR; INTERACTS	Cytokine response gene #6 (CR6), cloned from interleukin 2-stimulated T lymphocytes, is homologous to GADD45 and MyD118, genes which promote cell cycle arrest and apoptosis, To determine how this gene family could possibly mediate both cell survival/proliferation and cell cycle arrest/death, transfectants were generated so that the genes could be expressed ectopically, independently from their normal inducing agents. In cycling retinoblastoma protein-negative (pRb-) cells, ectopic CR6 expression blocked G2/M transition, but did not prevent G1/S transition so that endoreduplication resulted. By comparison, when CR6, GADD45, and MyD118 genes were expressed ectopically in proliferating pRb(+) cells, either G1/S or G2/M transition was effectively blocked, so that there was no endoreduplication, Consistent with these findings, in proliferating pRb-cells, ectopic expression of CR6 promoted the expression of both G1 and G2/M cyclins, By comparison, in pRb+ cells, the expression of G1 cyclins was increased, while expression of the mitotic cyclins was decreased. However, in pRb(+) cells, cyclin-dependent kinase activities associated with both G1 and G2/M cyclins were decreased. Moreover, ectopic expression of all three genes resulted in the expression of the CKI, p21, both in pRb- and pRb(+) cells. The physiologic induction of CR6 expression by IL2 in quiescent normal human T cells occurs transiently in the first half of G1, coordinately with the expression of p21, Therefore, this gene family regulates G1 and G2, and promotes either cell growth or arrest by a common mechanism.	Cornell Univ, Weill Med Coll & Grad Sch Med Sci, New York Presbyterian Cornell Med Ctr, New York, NY 10021 USA; New York Presbyterian Cornell Med Ctr, Dept Med, Div Immunol, New York, NY 10021 USA	Cornell University	Smith, KA (corresponding author), Cornell Univ, Weill Med Coll & Grad Sch Med Sci, New York Presbyterian Cornell Med Ctr, 1300 York Ave, New York, NY 10021 USA.			Cereseto, Anna/0000-0003-4453-2597	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI032031] Funding Source: NIH RePORTER; NIAID NIH HHS [R01 AI 32031-23] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ABDOLLAHI A, 1991, ONCOGENE, V6, P165; BEADLING C, 1993, P NATL ACAD SCI USA, V90, P2719, DOI 10.1073/pnas.90.7.2719; Benito J, 1998, EMBO J, V17, P482, DOI 10.1093/emboj/17.2.482; CANTRELL DA, 1984, SCIENCE, V224, P1312, DOI 10.1126/science.6427923; CorreaBordes J, 1997, EMBO J, V16, P4657, DOI 10.1093/emboj/16.15.4657; CORREABORDES J, 1995, CELL, V83, P1001, DOI 10.1016/0092-8674(95)90215-5; Darzynkiewicz Z, 1996, CYTOMETRY, V25, P1; DARZYNKIEWICZ Z, 1994, METHOD CELL BIOL, V41, P421; FORNACE AJ, 1988, P NATL ACAD SCI USA, V85, P8800, DOI 10.1073/pnas.85.23.8800; HALL PA, 1995, ONCOGENE, V10, P2427; HOLLANDER MC, 1993, J BIOL CHEM, V268, P24385; Kamijo T, 1998, P NATL ACAD SCI USA, V95, P8292, DOI 10.1073/pnas.95.14.8292; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KEARSEY JM, 1995, ONCOGENE, V11, P1675; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Medema RH, 1998, ONCOGENE, V16, P431, DOI 10.1038/sj.onc.1201558; MORENO S, 1994, NATURE, V367, P236, DOI 10.1038/367236a0; Niculescu AB, 1998, MOL CELL BIOL, V18, P629, DOI 10.1128/MCB.18.1.629; NOURSE J, 1994, NATURE, V372, P570, DOI 10.1038/372570a0; Pomerantz J, 1998, CELL, V92, P713, DOI 10.1016/S0092-8674(00)81400-2; SCHULZE A, 1995, P NATL ACAD SCI USA, V92, P11264, DOI 10.1073/pnas.92.24.11264; SELVAKUMARAN M, 1994, MOL CELL BIOL, V14, P2352, DOI 10.1128/MCB.14.4.2352; Sherr CJ, 1998, GENE DEV, V12, P2984, DOI 10.1101/gad.12.19.2984; Smith KA, 1995, ANN NY ACAD SCI, V766, P263, DOI 10.1111/j.1749-6632.1995.tb26674.x; SMITH KA, 1983, J IMMUNOL, V131, P1808; SMITH KA, 1988, SCIENCE, V240, P1169, DOI 10.1126/science.3131876; SMITH ML, 1994, SCIENCE, V266, P1376, DOI 10.1126/science.7973727; Takekawa M, 1998, CELL, V95, P521, DOI 10.1016/S0092-8674(00)81619-0; TANIGUCHI T, 1983, NATURE, V302, P305, DOI 10.1038/302305a0; Vairapandi M, 1996, ONCOGENE, V12, P2579; ZHAN QM, 1994, CANCER RES, V54, P2755; ZHAN QM, 1994, MOL CELL BIOL, V14, P2361, DOI 10.1128/MCB.14.4.2361; Zhang YP, 1998, CELL, V92, P725, DOI 10.1016/S0092-8674(00)81401-4	33	50	54	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 11	1999	18	47					6573	6582		10.1038/sj.onc.1203054	http://dx.doi.org/10.1038/sj.onc.1203054			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	256CW	10597261				2022-12-25	WOS:000083709200021
J	Quinlan, MP				Quinlan, MP			Rac regulates the stability of the adherens junction and its components, thus affecting epithelial cell differentiation and transformation	ONCOGENE			English	Article						adhesion; actin; cadherin; catenin; GTPase	ACTIN FILAMENT ORGANIZATION; CADHERIN-CATENIN COMPLEX; SMALL GTPASES; TUMOR PROGRESSION; ALPHA-CATENIN; MDCK CELLS; MOLECULAR-INTERACTIONS; INDEPENDENT PATHWAYS; PROTEIN INTERACTIONS; SIGNAL-TRANSDUCTION	We have previously reported that activated rac (V12rac) can bring about hypertransformation of ras-transformed epithelial cells, which can be suppressed by the dominant negative form of I ac (N17rac). Starting with primary epithelial cells, a series of cell lines expressing wild type (WT) or mutated forms of rns or rac were generated and analysed for their adhesive function and expression and association of adherens junction (AJ) proteins. Normal, primary epithelial cells were self-adhesive and expressed AJs that were very stable. The expression of constitutively active ras resulted in a decrease in, but not loss of, cell-cell adhesion, with concomitantly decreased stability of AJ components. This was extremely exacerbated by the co-expression of constitutively activate rac, but was suppressed by dominant negative rac, which resulted in increased cell-cell adhesion and extremely stable AJs. alpha-catenin also failed to associate,vith E-cadherin-beta-catenin complexes in cells expressing V12rac. Expression of V12rac resulted in the loss of epithelial morphology. The extent of transformation of each cell type corresponded to the stability of the respective AJ complexes. Thus, I ac seems to be involved in regulating the stability of AJs, which promote epithelial cell differentiation, and consequently, modulating tumor progression.	Univ Tennessee, Dept Microbiol & Immunol, Memphis, TN 38163 USA	University of Tennessee System; University of Tennessee Health Science Center	Quinlan, MP (corresponding author), Univ Tennessee, Dept Microbiol & Immunol, 858 Madison Ave, Memphis, TN 38163 USA.							Aberle H, 1996, J CELL BIOCHEM, V61, P514, DOI 10.1002/(SICI)1097-4644(19960616)61:4<514::AID-JCB4>3.0.CO;2-R; Barth AI, 1997, CURR OPIN CELL BIOL, V9, P683, DOI 10.1016/S0955-0674(97)80122-6; Ben-Ze'ev A, 1998, CURR OPIN CELL BIOL, V10, P629, DOI 10.1016/S0955-0674(98)80039-2; BenZeev A, 1997, CURR OPIN CELL BIOL, V9, P99, DOI 10.1016/S0955-0674(97)80158-5; Birchmeier W, 1996, CURR TOP MICROBIOL, V213, P117; BIRCHMEIER W, 1995, CANCER SURV, V24, P129; BIRCHMEIER W, 1994, BBA-REV CANCER, V1198, P11, DOI 10.1016/0304-419X(94)90003-5; Braga VMM, 1997, J CELL BIOL, V137, P1421, DOI 10.1083/jcb.137.6.1421; Campbell SL, 1998, ONCOGENE, V17, P1395, DOI 10.1038/sj.onc.1202174; del Peso L, 1997, ONCOGENE, V15, P3047; DOUGLAS JL, 1991, ONCOGENE, V6, P2093; EATON S, 1995, J CELL BIOL, V131, P151, DOI 10.1083/jcb.131.1.151; Fischer RS, 1998, VIROLOGY, V249, P427, DOI 10.1006/viro.1998.9337; Fischer RS, 1998, CELL GROWTH DIFFER, V9, P209; Fischer RS, 1998, CELL GROWTH DIFFER, V9, P905; FRIXEN U, 1991, J CELL BIOL, V111, P173; Geiger B, 1995, ACTA ANAT, V154, P46; GOPALAKRISHNAN S, 1995, CELL GROWTH DIFFER, V6, P985; Gumbiner BM, 1996, CELL, V84, P345, DOI 10.1016/S0092-8674(00)81279-9; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Hay ED, 1995, ACTA ANAT, V154, P8; HAY ED, 1995, AM J KIDNEY DIS, V26, P678, DOI 10.1016/0272-6386(95)90610-X; HINCK L, 1994, J CELL BIOL, V125, P1327, DOI 10.1083/jcb.125.6.1327; Hirohashi S, 1998, AM J PATHOL, V153, P333, DOI 10.1016/S0002-9440(10)65575-7; Hordijk PL, 1997, SCIENCE, V278, P1464, DOI 10.1126/science.278.5342.1464; Huber O, 1996, CURR OPIN CELL BIOL, V8, P685, DOI 10.1016/S0955-0674(96)80110-4; Hunter T, 1997, CELL, V88, P333, DOI 10.1016/S0092-8674(00)81872-3; Hynes RO, 1996, DEV BIOL, V180, P402, DOI 10.1006/dbio.1996.0314; Jankowski JA, 1997, J CLIN PATHOL-MOL PA, V50, P289; Janmey PA, 1998, PHYSIOL REV, V78, P763, DOI 10.1152/physrev.1998.78.3.763; Joneson T, 1996, SCIENCE, V271, P810, DOI 10.1126/science.271.5250.810; Joneson T, 1997, J MOL MED-JMM, V75, P587, DOI 10.1007/s001090050143; Jordan MA, 1998, CURR OPIN CELL BIOL, V10, P123, DOI 10.1016/S0955-0674(98)80095-1; Jou TS, 1998, J CELL BIOL, V142, P85, DOI 10.1083/jcb.142.1.85; Keely PJ, 1997, NATURE, V390, P632, DOI 10.1038/37656; KHOSRAVIFAR R, 1995, MOL CELL BIOL, V15, P6443; KINTNER C, 1992, CELL, V69, P225, DOI 10.1016/0092-8674(92)90404-Z; Kobayashi K, 1998, J BIOL CHEM, V273, P291, DOI 10.1074/jbc.273.1.291; Kuroda S, 1997, BIOCHEM BIOPH RES CO, V240, P430, DOI 10.1006/bbrc.1997.7675; Kuroda S, 1998, SCIENCE, V281, P832, DOI 10.1126/science.281.5378.832; Li ZR, 1998, CANCER RES, V58, P4282; Macara IG, 1996, FASEB J, V10, P625, DOI 10.1096/fasebj.10.5.8621061; Mackay DJG, 1997, J CELL BIOL, V138, P927, DOI 10.1083/jcb.138.4.927; Malumbres M, 1998, FRONT BIOSCI-LANDMRK, V3, P887; Mareel M, 1997, J CELL PHYSIOL, V173, P271, DOI 10.1002/(SICI)1097-4652(199711)173:2<271::AID-JCP34>3.0.CO;2-G; MAREEL M, 1995, CANCER DETECT PREV, V19, P451; Marrs JA, 1996, INT REV CYTOL, V165, P159, DOI 10.1016/S0074-7696(08)62222-6; Marshall CJ, 1996, CURR OPIN CELL BIOL, V8, P197, DOI 10.1016/S0955-0674(96)80066-4; MICHIELS F, 1995, NATURE, V375, P338, DOI 10.1038/375338a0; MOLL R, 1982, CELL, V31, P11, DOI 10.1016/0092-8674(82)90400-7; NAGAFUCHI A, 1994, J CELL BIOL, V127, P235, DOI 10.1083/jcb.127.1.235; NATHKE IS, 1994, J CELL BIOL, V125, P1341, DOI 10.1083/jcb.125.6.1341; Nimnual AS, 1998, SCIENCE, V279, P560, DOI 10.1126/science.279.5350.560; Ozawa M, 1998, J BIOL CHEM, V273, P6166, DOI 10.1074/jbc.273.11.6166; Perl AK, 1998, NATURE, V392, P190, DOI 10.1038/32433; Pillay I, 1996, CELL GROWTH DIFFER, V7, P1487; Potempa S, 1998, MOL BIOL CELL, V9, P2185, DOI 10.1091/mbc.9.8.2185; QUI RG, 1995, NATURE, V374, P457; QUINLAN MP, 1988, MOL CELL BIOL, V8, P3191, DOI 10.1128/MCB.8.8.3191; QUINLAN MP, 1992, J VIROL, V66, P2020, DOI 10.1128/JVI.66.4.2020-2030.1992; RIDLEY AJ, 1995, MOL CELL BIOL, V15, P1110; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIMM DL, 1995, P NATL ACAD SCI USA, V92, P8813, DOI 10.1073/pnas.92.19.8813; Roux P, 1997, CURR BIOL, V7, P629, DOI 10.1016/S0960-9822(06)00289-2; Sander EE, 1998, J CELL BIOL, V143, P1385, DOI 10.1083/jcb.143.5.1385; Sasaki T, 1998, BIOCHEM BIOPH RES CO, V245, P641, DOI 10.1006/bbrc.1998.8253; Schmidt A, 1998, ANNU REV CELL DEV BI, V14, P305, DOI 10.1146/annurev.cellbio.14.1.305; Schoenenberger C A, 1991, Trends Cell Biol, V1, P87, DOI 10.1016/0962-8924(91)90035-8; Shiozaki H, 1996, CANCER, V77, P1605, DOI 10.1002/(SICI)1097-0142(19960415)77:8+<1605::AID-CNCR4>3.3.CO;2-R; Steinberg MS, 1996, DEV BIOL, V180, P377, DOI 10.1006/dbio.1996.0312; Symons M, 1996, TRENDS BIOCHEM SCI, V21, P178, DOI 10.1016/S0968-0004(96)10022-0; Takaishi K, 1997, J CELL BIOL, V139, P1047, DOI 10.1083/jcb.139.4.1047; TAKEICHI M, 1995, CURR OPIN CELL BIOL, V7, P619, DOI 10.1016/0955-0674(95)80102-2; Tanaka K, 1998, CURR OPIN CELL BIOL, V10, P112, DOI 10.1016/S0955-0674(98)80093-8; Tapon N, 1997, CURR OPIN CELL BIOL, V9, P86, DOI 10.1016/S0955-0674(97)80156-1; Tsukatani Y, 1997, J CELL PHYSIOL, V173, P54, DOI 10.1002/(SICI)1097-4652(199710)173:1<54::AID-JCP7>3.3.CO;2-G; VanAelst L, 1997, GENE DEV, V11, P2295, DOI 10.1101/gad.11.18.2295; Vermeulen S, 1996, PATHOL RES PRACT, V192, P694, DOI 10.1016/S0344-0338(96)80091-4; Wasserman S, 1998, TRENDS CELL BIOL, V8, P111, DOI 10.1016/S0962-8924(97)01217-8; Westwick JK, 1997, MOL CELL BIOL, V17, P1324, DOI 10.1128/MCB.17.3.1324; Wittinghofer A, 1998, BIOL CHEM, V379, P933; Wojciak-Stothard B, 1998, J CELL PHYSIOL, V176, P150, DOI 10.1002/(SICI)1097-4652(199807)176:1<150::AID-JCP17>3.0.CO;2-B; Yap AS, 1997, ANNU REV CELL DEV BI, V13, P119, DOI 10.1146/annurev.cellbio.13.1.119; YONEMURA S, 1995, J CELL SCI, V108, P127; Zigmond SH, 1996, CURR OPIN CELL BIOL, V8, P66, DOI 10.1016/S0955-0674(96)80050-0; Zohn IM, 1998, ONCOGENE, V17, P1415, DOI 10.1038/sj.onc.1202181	86	35	35	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 11	1999	18	47					6434	6442		10.1038/sj.onc.1203026	http://dx.doi.org/10.1038/sj.onc.1203026			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	256CW	10597245				2022-12-25	WOS:000083709200005
J	Nikiforov, YE; Koshoffer, A; Nikiforova, M; Stringer, J; Fagin, JA				Nikiforov, YE; Koshoffer, A; Nikiforova, M; Stringer, J; Fagin, JA			Chromosomal breakpoint positions suggest a direct role for radiation in inducing illegitimate recombination between the ELE1 and RET genes in radiation-induced thyroid carcinomas	ONCOGENE			English	Article						RET; gene rearrangement; illegitimate recombination; radiation-induced; thyroid	CHERNOBYL NUCLEAR ACCIDENT; IN-SITU HYBRIDIZATION; IONIZING-RADIATION; MAMMALIAN-CELLS; CHILDREN; DNA; MECHANISMS; MUTATIONS; RET/PTC3; ONCOGENE	The RET/PTC3 rearrangement is formed by fusion of the ELE1 and RET genes, and is highly prevalent in radiation-induced post-Chernobyl papillary thyroid carcinomas. We characterized the breakpoints in the ELE1 and RET genes in 12 post-Chernobyl pediatric papillary carcinomas with known RET/PTC3 rearrangement. We found that the breakpoints within each intron were distributed in a relatively random fashion, except for clustering in the Alu regions of ELE1. None of the breakpoints occurred at the same base or within a similar sequence. There was also no evidence of preferential cleavage in AT-rich regions or other target DNA sites implicated in illegitimate recombination in mammalian cells. Modification of sequences at the cleavage sites was minimal, typically involving a 1-3 nucleotide deletion and/or duplication Surprisingly, the alignment of ELE1 and RET introns in opposite orientation revealed that in each tumor the position of the break in one gene corresponded to the position of the break in the other gene, This tendency suggests that the two genes may he next to each other but point in opposite directions in the nucleus, Such a structure would facilitate formation of RET/PTC3 rearrangements because a single radiation track could produce concerted breaks in both genes, leading to inversion due to reciprocal exchange via end-joining.	Univ Cincinnati, Coll Med, Dept Pathol, Cincinnati, OH 45267 USA; Univ Cincinnati, Coll Med, Div Endocrinol, Cincinnati, OH 45267 USA; Univ Cincinnati, Coll Med, Dept Mol Genet, Cincinnati, OH 45267 USA	University System of Ohio; University of Cincinnati; University System of Ohio; University of Cincinnati; University System of Ohio; University of Cincinnati	Nikiforov, YE (corresponding author), Univ Cincinnati, Coll Med, Dept Pathol, POB 670529, Cincinnati, OH 45267 USA.		Koshoffer, Amy E/N-2278-2014	Koshoffer, Amy E/0000-0001-8130-103X	NCI NIH HHS [CA 72597, CA 50706] Funding Source: Medline; NIEHS NIH HHS [ES 05652] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA050706, R01CA072597, R29CA050706] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bongarzone I, 1996, J CLIN ENDOCR METAB, V81, P2006, DOI 10.1210/jc.81.5.2006; Bongarzone I, 1997, GENOMICS, V42, P252, DOI 10.1006/geno.1997.4685; Cremer C, 1996, MUTAT RES-REV GENET, V366, P97, DOI 10.1016/S0165-1110(96)90031-7; EHRLICH SD, 1993, GENE, V135, P161, DOI 10.1016/0378-1119(93)90061-7; FERGUSON M, 1992, CHROMOSOMA, V101, P557, DOI 10.1007/BF00660315; FUGAZZOLA L, 1995, CANCER RES, V55, P5617; GERDES MG, 1994, J CELL BIOL, V126, P289, DOI 10.1083/jcb.126.2.289; GROSOVSKY AJ, 1988, P NATL ACAD SCI USA, V85, P185, DOI 10.1073/pnas.85.1.185; HYRIEN O, 1987, EMBO J, V6, P2401, DOI 10.1002/j.1460-2075.1987.tb02518.x; KAZAKOV VS, 1992, NATURE, V359, P21, DOI 10.1038/359021a0; Klugbauer S, 1995, ONCOGENE, V11, P2459; KOVACS MS, 1994, RADIAT RES, V137, P34, DOI 10.2307/3578788; LICHTER P, 1988, HUM GENET, V80, P222; MANUELIDIS L, 1984, P NATL ACAD SCI-BIOL, V81, P3123, DOI 10.1073/pnas.81.10.3123; MINOLETTI F, 1994, GENE CHROMOSOME CANC, V11, P51, DOI 10.1002/gcc.2870110108; Mizuno T, 1997, ONCOGENE, V15, P1455, DOI 10.1038/sj.onc.1201313; NIKIFOROV Y, 1994, CANCER-AM CANCER SOC, V74, P748, DOI 10.1002/1097-0142(19940715)74:2<748::AID-CNCR2820740231>3.0.CO;2-H; Nikiforov YE, 1997, CANCER RES, V57, P1690; Nikiforov YE, 1996, ONCOGENE, V13, P687; NIKIFOROV YE, 1998, ADV MOL CELL ENDOCR, V2, P169; Pacini F, 1997, J CLIN ENDOCR METAB, V82, P3563, DOI 10.1210/jc.82.11.3563; PINKEL D, 1988, P NATL ACAD SCI USA, V85, P9138, DOI 10.1073/pnas.85.23.9138; SANTORO M, 1993, CELL GROWTH DIFFER, V4, P77; SANTORO M, 1994, ONCOGENE, V9, P509; STARY A, 1992, NUCLEIC ACIDS RES, V20, P4269, DOI 10.1093/nar/20.16.4269; Suchy B, 1998, BRIT J CANCER, V77, P952, DOI 10.1038/bjc.1998.157; WARD JF, 1988, PROG NUCLEIC ACID RE, V35, P95, DOI 10.1016/S0079-6603(08)60611-X; YOKOTA H, 1995, J CELL BIOL, V130, P1239, DOI 10.1083/jcb.130.6.1239	28	81	84	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 4	1999	18	46					6330	6334		10.1038/sj.onc.1203019	http://dx.doi.org/10.1038/sj.onc.1203019			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	260DK	10597232				2022-12-25	WOS:000083934100017
J	Silverstein, AM; Galigniana, MD; Kanelakis, KC; Radanyi, C; Renoir, JM; Pratt, WB				Silverstein, AM; Galigniana, MD; Kanelakis, KC; Radanyi, C; Renoir, JM; Pratt, WB			Different regions of the immunophilin FKBP52 determine its association with the glucocorticoid receptor, hsp90, and cytoplasmic dynein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK-PROTEIN; TETRATRICOPEPTIDE REPEAT DOMAIN; ARYL-HYDROCARBON RECEPTOR; CYCLE CONTROL PROTEIN; ROUS-SARCOMA VIRUS; PROGESTERONE-RECEPTOR; STEROID-RECEPTOR; FK506-BINDING PROTEIN; BINDING-PROTEIN; CYCLOSPORINE-A	FKBP52 is a high molecular mass immunophilin possessing peptidylprolyl isomerase (PPIase) activity that is inhibited by the immunosuppressant drug FK506, FKBP52 is a component of steroid receptor . hsp90 heterocomplexes, and it binds to hsp90 via a region containing three tetratricopeptide repeats (TPRs), Here we demonstrate by cross-linking of the purified proteins that there is one binding site for FKBP52/dimer of hsp90, This accounts for the common heterotetrameric structure of native receptor heterocomplexes being 1 molecule of receptor, 2 molecules of hsp90, and 1 molecule of a TPR domain protein. Immunoadsorption of FKBP52 from reticulocyte lysate also yields co-immunoadsorption of cytoplasmic dynein, and we show that co-immunoadsorption of dynein is competed by a fragment of FKBP52 containing its PPIase domain, but not by a TPR domain fragment that blocks FKBP52 binding to hsp90, Using purified proteins, we also show that FKBP52 binds directly to the hsp90-free glucocorticoid receptor. Because neither the PPIase fragment nor the TPR fragment affects the binding of FKBP52 to the glucocorticoid receptor under conditions in which they block FKBP52 binding to dynein or hsp90, respectively, different regions of FKBP52 must determine its association with these three proteins.	Univ Michigan, Sch Med, Dept Pharmacol, Ann Arbor, MI 48109 USA; Fac Pharm, CNRS, UMR 8612, F-92296 Chatenay Malabry, France	University of Michigan System; University of Michigan; Centre National de la Recherche Scientifique (CNRS); CNRS - Institute of Chemistry (INC); UDICE-French Research Universities; Universite Paris Saclay	Pratt, WB (corresponding author), Univ Michigan, Sch Med, Dept Pharmacol, 1301 Med Sci Res Bldg 3, Ann Arbor, MI 48109 USA.		RADANYI, Christine/A-8921-2008	GALIGNIANA, MARIO/0000-0002-9130-8574	NATIONAL CANCER INSTITUTE [R01CA028010] Funding Source: NIH RePORTER; NCI NIH HHS [CA28010] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Barent RL, 1998, MOL ENDOCRINOL, V12, P342, DOI 10.1210/me.12.3.342; BRUGGE JS, 1986, CURR TOP MICROBIOL, V123, P1; CALLEBAUT I, 1992, P NATL ACAD SCI USA, V89, P6270, DOI 10.1073/pnas.89.14.6270; Carrello A, 1999, J BIOL CHEM, V274, P2682, DOI 10.1074/jbc.274.5.2682; Carver LA, 1997, J BIOL CHEM, V272, P11452; Carver LA, 1998, J BIOL CHEM, V273, P33580, DOI 10.1074/jbc.273.50.33580; CHAMBRAUD B, 1993, BIOCHEM BIOPH RES CO, V196, P160, DOI 10.1006/bbrc.1993.2229; Chambraud B, 1999, P NATL ACAD SCI USA, V96, P2104, DOI 10.1073/pnas.96.5.2104; Chen H, 1997, J BIOL CHEM, V272, P25873, DOI 10.1074/jbc.272.41.25873; Chen MS, 1996, J BIOL CHEM, V271, P32315, DOI 10.1074/jbc.271.50.32315; Chen SY, 1998, CELL STRESS CHAPERON, V3, P118, DOI 10.1379/1466-1268(1998)003<0118:DIOPAT>2.3.CO;2; CUTFORTH T, 1994, CELL, V77, P1027, DOI 10.1016/0092-8674(94)90442-1; CZAR MJ, 1994, MOL ENDOCRINOL, V8, P1731, DOI 10.1210/me.8.12.1731; Dey B, 1996, MOL BIOL CELL, V7, P1405, DOI 10.1091/mbc.7.9.1405; ERHART JC, 1988, ONCOGENE, V3, P595; GRAMMATIKAKIS N, 1995, J BIOL CHEM, V270, P16198, DOI 10.1074/jbc.270.27.16198; HOFFMANN K, 1995, BIOCHEM J, V307, P5, DOI 10.1042/bj3070005; HOLLENBERG SM, 1985, NATURE, V318, P635, DOI 10.1038/318635a0; Hunter T, 1997, TRENDS CELL BIOL, V7, P157, DOI 10.1016/S0962-8924(97)01027-1; HUTCHISON KA, 1994, J BIOL CHEM, V269, P5043; LEBEAU MC, 1994, BIOCHEM BIOPH RES CO, V203, P750, DOI 10.1006/bbrc.1994.2246; LEBEAU MC, 1992, J BIOL CHEM, V267, P4281; LEBIHAN S, 1993, BIOCHEM BIOPH RES CO, V195, P600, DOI 10.1006/bbrc.1993.2088; LIU J, 1991, CELL, V66, P807, DOI 10.1016/0092-8674(91)90124-H; Ma Q, 1997, J BIOL CHEM, V272, P8878; MASSOL N, 1992, BIOCHEM BIOPH RES CO, V187, P1330, DOI 10.1016/0006-291X(92)90448-T; Meyer BK, 1998, MOL CELL BIOL, V18, P978, DOI 10.1128/MCB.18.2.978; Meyer BK, 1999, BIOCHEMISTRY-US, V38, P8907, DOI 10.1021/bi982223w; Nair SC, 1997, MOL CELL BIOL, V17, P594, DOI 10.1128/MCB.17.2.594; OWENSGRILLO JK, 1995, J BIOL CHEM, V270, P20479, DOI 10.1074/jbc.270.35.20479; OwensGrillo JK, 1996, J BIOL CHEM, V271, P13468, DOI 10.1074/jbc.271.23.13468; PEATTIE DA, 1992, P NATL ACAD SCI USA, V89, P10974, DOI 10.1073/pnas.89.22.10974; Perdew GH, 1997, BIOCHEMISTRY-US, V36, P3600, DOI 10.1021/bi9612529; PERROTAPPLANAT M, 1995, J CELL SCI, V108, P2037; PICARD D, 1987, EMBO J, V6, P3333, DOI 10.1002/j.1460-2075.1987.tb02654.x; PRATT WB, 1993, J BIOL CHEM, V268, P21455; Pratt WB, 1997, ENDOCR REV, V18, P306, DOI 10.1210/er.18.3.306; Pratt WB, 1997, ANNU REV PHARMACOL, V37, P297, DOI 10.1146/annurev.pharmtox.37.1.297; RADANYI C, 1994, P NATL ACAD SCI USA, V91, P11197, DOI 10.1073/pnas.91.23.11197; Ratajczak T, 1996, J BIOL CHEM, V271, P2961, DOI 10.1074/jbc.271.6.2961; RATAJCZAK T, 1993, J BIOL CHEM, V268, P13187; REHBERGER P, 1992, P NATL ACAD SCI USA, V89, P8001, DOI 10.1073/pnas.89.17.8001; RENOIR JM, 1995, P NATL ACAD SCI USA, V92, P4977, DOI 10.1073/pnas.92.11.4977; REXIN M, 1991, J BIOL CHEM, V266, P24601; REXIN M, 1988, FEBS LETT, V241, P234, DOI 10.1016/0014-5793(88)81068-8; RUFF VA, 1992, J BIOL CHEM, V267, P21285; Russell LC, 1999, J BIOL CHEM, V274, P20060, DOI 10.1074/jbc.274.29.20060; SEGNITZ B, 1995, P NATL ACAD SCI USA, V92, P2179, DOI 10.1073/pnas.92.6.2179; SIKORSKI RS, 1990, CELL, V60, P307, DOI 10.1016/0092-8674(90)90745-Z; Silverstein AM, 1997, J BIOL CHEM, V272, P16224, DOI 10.1074/jbc.272.26.16224; Silverstein AM, 1998, J BIOL CHEM, V273, P20090, DOI 10.1074/jbc.273.32.20090; SMITH DF, 1993, J BIOL CHEM, V268, P24270; SMITH DF, 1993, J BIOL CHEM, V268, P18365; SMITH DF, 1995, MOL CELL BIOL, V15, P6804; SMITH DF, 1993, MOL CELL BIOL, V13, P869, DOI 10.1128/MCB.13.2.869; STANCATO LF, 1993, J BIOL CHEM, V268, P21711; Stepanova L, 1996, GENE DEV, V10, P1491, DOI 10.1101/gad.10.12.1491; TAI PKK, 1992, SCIENCE, V256, P1315, DOI 10.1126/science.1376003; WHITELAW ML, 1991, J BIOL CHEM, V266, P16436; YEM AW, 1992, J BIOL CHEM, V267, P2868; YEM AW, 1993, BIOCHEMISTRY-US, V32, P12571, DOI 10.1021/bi00210a004; Young JC, 1998, J BIOL CHEM, V273, P18007, DOI 10.1074/jbc.273.29.18007	62	152	159	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 24	1999	274	52					36980	36986		10.1074/jbc.274.52.36980	http://dx.doi.org/10.1074/jbc.274.52.36980			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	267WR	10601253	hybrid			2022-12-25	WOS:000084382700024
J	Wang, QMJ; Bhattacharyya, D; Garfield, S; Nacro, K; Marquez, VE; Blumberg, PM				Wang, QMJ; Bhattacharyya, D; Garfield, S; Nacro, K; Marquez, VE; Blumberg, PM			Differential localization of protein kinase C delta by phorbol esters and related compounds using a fusion protein with green fluorescent protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NONPROMOTING 12-DEOXYPHORBOL 13-ESTERS; NIH 3T3 FIBROBLASTS; CD-1 MOUSE SKIN; 12-MYRISTATE 13-ACETATE; LIVING CELLS; BINDING; BRYOSTATIN; DOMAINS; TRANSLOCATION; ISOZYMES	Enzyme localization often plays a controlling role in determining its activity and specificity. Protein kinase C (PKC) has long been known to translocate in response to physiological stimuli as well as to exogenous ligands such as the phorbol esters, We report here that different phorbol derivatives and related ligands, selected for differences in chemical structure and profile of biological activity, induce distinct patterns of redistribution of PKC delta, Localization of a PKC delta-green fluorescent protein (GFP) fusion construct was monitored in living Chinese hamster ovary cells as a function of ligand, concentration, and time using confocal laser scanning microscopy, delta-PKC-GFP was expressed predominantly in the cytoplasm, with some in the nucleus and perinuclear region. Phorbol 12-myristate 13-acetate (PMA) induced plasma membrane translocation followed by slower nuclear membrane translocation. As the concentration of PMA increased, the proportion of nuclear to plasma membrane localization increased markedly. In contrast to PMA, bryostatin 1, a unique activator of PKC that induces a subset of PIMA mediated responses while antagonizing others, at all doses induced almost exclusively nuclear membrane translocation, Like PMA, the complete tumor promoter 12-deoxyphorbol 13-tetradecanoate induced plasma membrane and slower nuclear membrane translocation, whereas the inhibitor of tumor promotion 12-deoxyphorbol 13-phenylacetate, which differs only in its side chain, induced a distinctive distribution of PKC delta-GFP, Finally, the novel constrained diacylglycerol derivative B8-DL-B8 induced a slow Golgi localization. We speculate that differential control of PRC delta localization may provide an interesting strategy for producing ligands with differential biological consequences.	NCI, Mol Mechanisms Tumor Promot Sect, Cellular Carcinogenesis & Tumor Promot Lab, NIH, Bethesda, MD 20892 USA; NCI, Expt Carcinogenesis Lab, NIH, Bethesda, MD 20892 USA; NCI, Med Chem Lab, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Blumberg, PM (corresponding author), NCI, Mol Mechanisms Tumor Promot Sect, Cellular Carcinogenesis & Tumor Promot Lab, NIH, Bldg 37,Rm 3A01,37 Convent Dr,MSC 4255, Bethesda, MD 20892 USA.	blumberp@dc37a.nci.nih.gov	Marquez, Victor/AAP-3549-2021; Wang, Qiming Jane/B-6064-2012	Wang, Qiming Jane/0000-0002-9502-4851				BERKOW RL, 1985, BIOCHEM BIOPH RES CO, V131, P1109, DOI 10.1016/0006-291X(85)90205-0; BLUMBERG PM, 1992, ALFRED BENZON SYMP S, V33, P273; Caloca MJ, 1999, P NATL ACAD SCI USA, V96, P11854, DOI 10.1073/pnas.96.21.11854; DELLAQUILA ML, 1988, CANCER RES, V48, P3702; DONG LQ, 1993, CELL GROWTH DIFFER, V4, P793; FURSTENBERGER G, 1972, PLANTA MED, V22, P241; GERMANO P, 1994, J BIOL CHEM, V269, P23102; GOODNIGHT J, 1995, J BIOL CHEM, V270, P9991, DOI 10.1074/jbc.270.17.9991; HUG H, 1993, BIOCHEM J, V291, P329, DOI 10.1042/bj2910329; Hurley JH, 1997, PROTEIN SCI, V6, P477; HYATT SL, 1994, BIOCHEMISTRY-US, V33, P1223, DOI 10.1021/bi00171a023; HYATT SL, 1990, MOL CARCINOGEN, V3, P45, DOI 10.1002/mc.2940030202; ISAKOV N, 1993, J IMMUNOL, V150, P1195; KAZANIETZ MG, 1994, J BIOL CHEM, V269, P11590; KIELBASSA K, 1995, J BIOL CHEM, V270, P6156, DOI 10.1074/jbc.270.11.6156; KOPELOVICH L, 1980, EXP CELL BIOL, V48, P207; KRAFT AS, 1986, P NATL ACAD SCI USA, V83, P1334, DOI 10.1073/pnas.83.5.1334; LITTLE JB, 1985, CARCINOGENESIS, V6, P1703, DOI 10.1093/carcin/6.12.1703; Marquez VE, 1999, PHARMACOL THERAPEUT, V82, P251, DOI 10.1016/S0163-7258(98)00048-5; Mochly-Rosen D, 1998, FASEB J, V12, P35; MOCHLYROSEN D, 1990, CELL REGUL, V1, P693, DOI 10.1091/mbc.1.9.693; NEWTON AC, 1995, J BIOL CHEM, V270, P28495, DOI 10.1074/jbc.270.48.28495; NEWTON AC, 1995, CURR BIOL, V5, P973, DOI 10.1016/S0960-9822(95)00191-6; Nishikawa K, 1997, J BIOL CHEM, V272, P952, DOI 10.1074/jbc.272.2.952; Oancea E, 1998, CELL, V95, P307, DOI 10.1016/S0092-8674(00)81763-8; Oancea E, 1998, J CELL BIOL, V140, P485, DOI 10.1083/jcb.140.3.485; Ohmori S, 1998, MOL CELL BIOL, V18, P5263, DOI 10.1128/MCB.18.9.5263; PEARS C, 1995, J BIOSCIENCE, V20, P311, DOI 10.1007/BF02703836; Pluda J M, 1996, Oncology (Williston Park), V10, P740; Prekeris R, 1996, J CELL BIOL, V132, P77, DOI 10.1083/jcb.132.1.77; Sakai N, 1997, J CELL BIOL, V139, P1465, DOI 10.1083/jcb.139.6.1465; SCHMIDT R, 1989, J CANCER RES CLIN, V115, P516, DOI 10.1007/BF00391351; Shirai Y, 1998, J CELL BIOL, V143, P511, DOI 10.1083/jcb.143.2.511; SMITH JB, 1985, BIOCHEM BIOPH RES CO, V132, P939, DOI 10.1016/0006-291X(85)91898-4; SOSSIN WS, 1993, TRENDS BIOCHEM SCI, V18, P207, DOI 10.1016/0968-0004(93)90189-T; SUTTON RB, 1995, CELL, V80, P929, DOI 10.1016/0092-8674(95)90296-1; SZALLASI Z, 1994, J BIOL CHEM, V269, P2118; SZALLASI Z, 1994, MOL PHARMACOL, V46, P840; SZALLASI Z, 1993, CANCER RES, V53, P2507; SZALLASI Z, 1992, CARCINOGENESIS, V13, P2161, DOI 10.1093/carcin/13.11.2161; ZAYED S, 1984, PLANTA MED, V8, P65; ZHANG GG, 1995, CELL, V81, P917, DOI 10.1016/0092-8674(95)90011-X	42	163	172	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 24	1999	274	52					37233	37239		10.1074/jbc.274.52.37233	http://dx.doi.org/10.1074/jbc.274.52.37233			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	267WR	10601287	hybrid			2022-12-25	WOS:000084382700058
J	Bolivar, J; Diaz, I; Iglesias, C; Valdivia, MM				Bolivar, J; Diaz, I; Iglesias, C; Valdivia, MM			Molecular cloning of a zinc finger autoantigen transiently associated with interphase nucleolus and mitotic centromeres and midbodies - Orthologous proteins with nine cxxc motifs highly conserved from nematodes to humans	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AUTOIMMUNE-DISEASES; CELL BIOLOGY; LOCALIZATION; GENES; DOMAINS; MOUSE; KINETOCHORE; SEQUENCE; KRUPPEL; GATA-4	We have cloned a novel human autoimmune antigen in a patient suffering from rheumatoid arthritis with high levels of antibodies to the nucleolus organizer regions. Initially the human autoimmune serum was used to select a cDNA of 317 amino acids from a hamster expression library. Using the hamster DNA as a probe, we isolated the human homologous cDNA of 320 amino acids. Human and hamster polypeptides share a 95% amino acid homology, The deduced 36-kDa protein contains a putative amino-terminal NLS signal, nine cysteine-X-X-cysteine motifs highly conserved, and a carboxyl-terminal poly acidic region. Several homologous expressed sequence tags have been identified in data bases suggesting that orthologous proteins are present throughout evolution from worms to humans. A Drosophila expressed sequence tag was further completely sequenced for a full-length protein with 60% amino acid identity to the human homologue. Northern blot analysis revealed that this novel protein is widely distributed in human tissues with significantly higher expression levels in heart and skeletal muscle, Specific antibodies to the recombinant protein and transfection experiments demonstrated by immunofluorescence the localization of the protein predominantly but not exclusively to the nucleolus of interphase mammalian cells, In actinomycin D-treated cells the protein remains associated with the nucleolus but is not segregated, like other ribosomal factors such as upstream binding factor. In mitosis the protein was found to be associated with centromeres and concentrated at the midbody in cytokinesis. Transient distribution of this evolutionarily conserved zinc finger nucleolar autoantigen to the mitotic centromeres may provide the means for several aspects of cell cycle control and transcriptional regulation.	Univ Cadiz, Fac Ciencias, Dept Bioquim & Biol Mol, Cadiz 11510, Spain	Universidad de Cadiz	Valdivia, MM (corresponding author), Univ Cadiz, Fac Ciencias, Dept Bioquim & Biol Mol, Cadiz 11510, Spain.		BOLIVAR, JORGE/G-4322-2015; Valdivia, Manuel Jesús Martínez/ABG-8867-2020; Diaz, Isabel/I-8840-2014	BOLIVAR, JORGE/0000-0002-2645-9528; Valdivia, Manuel Jesús Martínez/0000-0002-2888-849X; Diaz, Isabel/0000-0001-9865-902X				ARCECI RJ, 1993, MOL CELL BIOL, V13, P2235, DOI 10.1128/MCB.13.4.2235; ASHWORTH A, 1989, GENOMICS, V4, P323, DOI 10.1016/0888-7543(89)90337-6; ASHWORTH A, 1991, MAMM GENOME, V1, P196, DOI 10.1007/BF00351068; BELLEFROID EJ, 1989, DNA-J MOLEC CELL BIO, V8, P377, DOI 10.1089/dna.1.1989.8.377; Bolivar J, 1996, GENE, V176, P257, DOI 10.1016/0378-1119(96)00207-7; BORER RA, 1989, CELL, V56, P379, DOI 10.1016/0092-8674(89)90241-9; CasciolaRosen L, 1996, P NATL ACAD SCI USA, V93, P1624, DOI 10.1073/pnas.93.4.1624; CHAN EKL, 1991, J EXP MED, V174, P1239, DOI 10.1084/jem.174.5.1239; CONDEMI JJ, 1987, JAMA-J AM MED ASSOC, V258, P2920, DOI 10.1001/jama.258.20.2920; FISHKIND DJ, 1995, CURR OPIN CELL BIOL, V7, P23, DOI 10.1016/0955-0674(95)80041-7; FITCH WM, 1970, SYST ZOOL, V19, P99, DOI 10.2307/2412448; Garcia SN, 1999, CELL, V97, P825, DOI 10.1016/S0092-8674(00)80794-1; Garnier J, 1996, METHOD ENZYMOL, V266, P540; Goenechea L. G., 1992, Cellular and Molecular Biology (Noisy-Le-Grand), V38, P841; Haber JE, 1999, CELL, V97, P829, DOI 10.1016/S0092-8674(00)80795-3; HOOVERS JM, 1992, GENOMICS, V2, P254; KAPTEIN R, 1991, CURR OPIN STRUC BIOL, V2, P109; KELLEY C, 1993, DEVELOPMENT, V118, P817; KLUG A, 1987, COLD SPRING HARB SYM, V52, P473, DOI 10.1101/SQB.1987.052.01.054; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; Meisner H, 1991, CURR OPIN CELL BIOL, V3, P474, DOI 10.1016/0955-0674(91)90076-B; MILLER J, 1985, EMBO J, V4, P1609, DOI 10.1002/j.1460-2075.1985.tb03825.x; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; MOROI Y, 1980, P NATL ACAD SCI-BIOL, V77, P1627, DOI 10.1073/pnas.77.3.1627; Mushegian AR, 1998, GENOME RES, V8, P590, DOI 10.1101/gr.8.6.590; OCHS RL, 1985, BIOL CELL, V54, P123, DOI 10.1111/j.1768-322X.1985.tb00387.x; Ochs RL, 1996, MOL BIOL CELL, V7, P1015, DOI 10.1091/mbc.7.7.1015; RATTNER JB, 1993, CELL MOTIL CYTOSKEL, V26, P214, DOI 10.1002/cm.970260305; RATTNER JB, 1990, CELL MOTIL CYTOSKEL, V17, P227, DOI 10.1002/cm.970170309; RENDON MC, 1992, EXP CELL RES, V200, P393, DOI 10.1016/0014-4827(92)90187-D; Rivera MC, 1998, P NATL ACAD SCI USA, V95, P6239, DOI 10.1073/pnas.95.11.6239; ROSEN A, 1995, J EXP MED, V181, P1557, DOI 10.1084/jem.181.4.1557; Sambrook J., 2002, MOL CLONING LAB MANU; SAUER F, 1991, NATURE, V353, P563, DOI 10.1038/353563a0; SCHMIDTZACHMANN MS, 1993, J CELL SCI, V105, P799; SINHA AA, 1990, SCIENCE, V248, P1380, DOI 10.1126/science.1972595; STEITZ JA, 1988, SCI AM, V258, P56, DOI 10.1038/scientificamerican0688-56; STEUER ER, 1990, NATURE, V345, P266, DOI 10.1038/345266a0; TAN EM, 1989, J CLIN INVEST, V84, P1, DOI 10.1172/JCI114127; TAN EM, 1989, ADV IMMUNOL, V44, P93; Towbin H, 1979, 10 1073 PNAS 76 9 43, V76, P4350, DOI [10.1073/pnas.76.9.4350, DOI 10.1073/PNAS.76.9.4350]; Wells WAE, 1996, TRENDS CELL BIOL, V6, P228, DOI 10.1016/0962-8924(96)10018-0; YEN TJ, 1991, EMBO J, V10, P1245, DOI 10.1002/j.1460-2075.1991.tb08066.x	43	20	32	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 17	1999	274	51					36456	36464		10.1074/jbc.274.51.36456	http://dx.doi.org/10.1074/jbc.274.51.36456			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	266AV	10593942	hybrid			2022-12-25	WOS:000084279200061
J	Chen, KS; Tilley, GJ; Sridhar, V; Prasad, GS; Stout, CD; Armstrong, FA; Burgess, BK				Chen, KS; Tilley, GJ; Sridhar, V; Prasad, GS; Stout, CD; Armstrong, FA; Burgess, BK			Alteration of the reduction potential of the [4Fe-4S](2+/+) cluster of Azotobacter vinelandii ferredoxin I	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IRON-SULFUR PROTEINS; SITE-DIRECTED MUTAGENESIS; CONSERVED PROLINE RESIDUES; FERROUS FE4S4 CLUSTER; REDOX POTENTIALS; CYTOCHROME-C; ELECTROSTATIC INTERACTIONS; CLOSTRIDIUM-PASTEURIANUM; ANGSTROM RESOLUTION; CIRCULAR-DICHROISM	The [4Fe-4S]2(+/+) cluster of Azotobacter vinelandii ferredoxin I (FdI) has an unusually low reduction potential (E-0') relative to other structurally similar ferredoxins. Previous attempts to raise that E-0' by modification of surface charged residues were unsuccessful, In this study mutants were designed to alter the E-0' by substitution of polar residues for nonpolar residues near the cluster and by modification of backbone amides, Three FdI variants, P21G;, I40N, and I40Q, were purified and characterized, and electrochemical E-0' measurements show that all had altered E-0' relative to native FdI, For P21G FdI and I40Q FdI, the E-0' increased by +42 and +53 mV, respectively validating the importance of dipole orientation in control of E-0'. Protein Dipole Langevin Dipole calculations based on models for those variants accurately predicted the direction of the change in E-0' while overestimating the magnitude, For I40N Pdl, initial calculations based on the model predicted a +168 mV change in E-0' while a -33 mV change was observed. The x-ray structure of that variant, which was determined to 2.8 Angstrom revealed a number of changes in backbone and side chain dipole orientation and in solvent accessibility, that were not predicted by the model and that were Likely to influence E-0'. Subsequent Protein Dipole Langevin Dipole calculations (using the actual I40N x-ray structures) did quite accurately predict the observed change in E-0'.	Univ Calif Irvine, Dept Mol Biol & Biochem, Irvine, CA 92697 USA; Univ Oxford, Dept Chem, Oxford OX1 3QR, England; Scripps Res Inst, Dept Mol Biol, La Jolla, CA 92037 USA	University of California System; University of California Irvine; University of Oxford; Scripps Research Institute	Burgess, BK (corresponding author), Univ Calif Irvine, Dept Mol Biol & Biochem, Irvine, CA 92697 USA.	bburgess@uci.edu			NIGMS NIH HHS [GM-36325, GM-48495, GM-45209] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P01GM048495, R01GM045209, R01GM036325] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Angove HC, 1997, J AM CHEM SOC, V119, P8730, DOI 10.1021/ja9712837; ARMSTRONG FA, 1993, METHOD ENZYMOL, V227, P479, DOI 10.1016/0076-6879(93)27020-H; BACKES G, 1991, J AM CHEM SOC, V113, P2055, DOI 10.1021/ja00006a027; BEINERT H, 1990, FASEB J, V4, P2483, DOI 10.1096/fasebj.4.8.2185975; Beinert H, 1997, SCIENCE, V277, P653, DOI 10.1126/science.277.5326.653; Beinert H, 1996, CHEM REV, V96, P2335, DOI 10.1021/cr950040z; Bertini I, 1997, J BIOL INORG CHEM, V2, P114, DOI 10.1007/s007750050114; Bertini I, 1996, PROG BIOPHYS MOL BIO, V66, P43, DOI 10.1016/S0079-6107(96)00016-8; Bian SM, 1996, BIOCHEMISTRY-US, V35, P14544, DOI 10.1021/bi961658l; BRUNGER AT, 1989, ACTA CRYSTALLOGR A, V45, P50, DOI 10.1107/S0108767388009195; Busch JLH, 1997, BIOCHEM J, V323, P95, DOI 10.1042/bj3230095; CAMMACK R, 1992, ADV INORG CHEM, V38, P281, DOI 10.1016/S0898-8838(08)60066-5; CHAN MK, 1993, SCIENCE, V260, P792, DOI 10.1126/science.8484118; CHURG AK, 1986, BIOCHEMISTRY-US, V25, P1675, DOI 10.1021/bi00355a035; CRANE BR, 1995, SCIENCE, V270, P59, DOI 10.1126/science.270.5233.59; Dauter Z, 1997, BIOCHEMISTRY-US, V36, P16065, DOI 10.1021/bi972155y; GAILLARD J, 1993, BIOCHEMISTRY-US, V32, P9881, DOI 10.1021/bi00089a002; Gao-Sheridan HS, 1998, J BIOL CHEM, V273, P33692, DOI 10.1074/jbc.273.50.33692; GOLBECK JH, 1991, CURR TOP BIOENERG, V16, P83; HEERING HA, 1995, EUR J BIOCHEM, V232, P811, DOI 10.1111/j.1432-1033.1995.811zz.x; Higuchi Y, 1997, STRUCTURE, V5, P1671, DOI 10.1016/S0969-2126(97)00313-4; Holm RH, 1996, CHEM REV, V96, P2239, DOI 10.1021/cr9500390; Howard JB, 1996, CHEM REV, V96, P2965, DOI 10.1021/cr9500545; HOWARD JB, 1991, ADV PROTEIN CHEM, V42, P199; IISMAA SE, 1991, J BIOL CHEM, V266, P21563; IWAGAMI SG, 1995, PROTEIN SCI, V4, P2562, DOI 10.1002/pro.5560041213; JENSEN GM, 1994, BIOCHEMISTRY-US, V33, P10911, DOI 10.1021/bi00202a010; JOHNSON MK, 1994, ENCY INORGANIC CHEM, P1896; LANGEN R, 1992, J MOL BIOL, V224, P589, DOI 10.1016/0022-2836(92)90546-V; LANGEN R, 1992, J BIOL CHEM, V267, P25625; LESLIE AGW, 1994, ACTA CRYSTALLOGR D, V50, P760; LINDAHL PA, 1990, J CLUST SCI, V1, P29; LUCHINAT C, 1994, BIOCHEM BIOPH RES CO, V203, P436, DOI 10.1006/bbrc.1994.2201; Macedo AL, 1996, BIOCHEM BIOPH RES CO, V229, P524, DOI 10.1006/bbrc.1996.1837; MARTIN AE, 1990, P NATL ACAD SCI USA, V87, P598, DOI 10.1073/pnas.87.2.598; Mauk AG, 1997, J BIOL INORG CHEM, V2, P119, DOI 10.1007/s007750050115; McRee DE, 1999, J STRUCT BIOL, V125, P156, DOI 10.1006/jsbi.1999.4094; MOORE GR, 1983, FEBS LETT, V161, P171, DOI 10.1016/0014-5793(83)81001-1; NaraySzabo G, 1997, J BIOL INORG CHEM, V2, P135, DOI 10.1007/s007750050117; Navaza J, 1997, METHOD ENZYMOL, V276, P581, DOI 10.1016/S0076-6879(97)76079-8; PARSON WW, 1985, BIOCHIM BIOPHYS ACTA, V1017, P251; Peters JW, 1998, SCIENCE, V282, P1853, DOI 10.1126/science.282.5395.1853; PRZYSIECKI CT, 1985, BIOCHEMISTRY-US, V24, P2542, DOI 10.1021/bi00331a022; QUINKAL I, 1994, PROTEIN ENG, V7, P681, DOI 10.1093/protein/7.5.681; REES DC, 1985, P NATL ACAD SCI USA, V82, P3082, DOI 10.1073/pnas.82.10.3082; SCHEJTER A, 1984, BIOCHEMISTRY-US, V23, P1081, DOI 10.1021/bi00301a007; SHEN B, 1995, P NATL ACAD SCI USA, V92, P10064, DOI 10.1073/pnas.92.22.10064; SHEN BH, 1994, J BIOL CHEM, V269, P8564; SHEN BH, 1993, J BIOL CHEM, V268, P25928; SOLA M, 1989, BIOCHEMISTRY-US, V28, P5261, DOI 10.1021/bi00438a051; Soriano A, 1996, BIOCHEMISTRY-US, V35, P12479, DOI 10.1021/bi960974x; STEPHENS PJ, 1991, BIOCHEMISTRY-US, V30, P3200, DOI 10.1021/bi00227a007; Stephens PJ, 1996, CHEM REV, V96, P2491, DOI 10.1021/cr950045w; STOMBAUGH NA, 1976, BIOCHEMISTRY-US, V15, P2633, DOI 10.1021/bi00657a024; STOUT CD, 1989, J MOL BIOL, V205, P545, DOI 10.1016/0022-2836(89)90225-8; Stout CD, 1998, J MOL BIOL, V278, P629, DOI 10.1006/jmbi.1998.1732; VAZQUEZ A, 1994, PROTEIN EXPRES PURIF, V5, P96, DOI 10.1006/prep.1994.1014; VOLBEDA A, 1995, NATURE, V373, P580, DOI 10.1038/373580a0; Warshel A, 1997, J BIOL INORG CHEM, V2, P143, DOI 10.1007/s007750050119; WARSHEL A, 1984, Q REV BIOPHYS, V17, P283, DOI 10.1017/S0033583500005333; WATT GD, 1994, J INORG BIOCHEM, V53, P281, DOI 10.1016/0162-0134(94)85115-8	61	27	28	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 17	1999	274	51					36479	36487		10.1074/jbc.274.51.36479	http://dx.doi.org/10.1074/jbc.274.51.36479			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	266AV	10593945	hybrid			2022-12-25	WOS:000084279200064
J	Hogg, RC; Miranda, LP; Craik, DJ; Lewis, RJ; Alewood, PF; Adams, DJ				Hogg, RC; Miranda, LP; Craik, DJ; Lewis, RJ; Alewood, PF; Adams, DJ			Single amino acid substitutions in alpha-conotoxin PnIA shift selectivity for subtypes of the mammalian neuronal nicotinic acetylcholine receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NMR-SPECTROSCOPY; CRYSTAL-STRUCTURE; PEPTIDE; SUBUNIT; BUNGAROTOXIN; TRANSMISSION; DIVERSITY; BINDING; GANGLIA; LIGAND	The alpha-conotoxins, a class of nicotinic acetylcholine receptor (nAChR) antagonists, are emerging as important probes of the role played by different nAChR subtypes in cell function and communication, In this study, the native alpha-conotoxins PnIA and PnIB were found to cause concentration-dependent inhibition of the ACh-induced current in all rat parasympathetic neurons examined, with IC50 values of 14 and 33 nM, and a maximal reduction in current amplitude of 87% and 71%, respectively. The modified alpha-conotoxin [N11S]PnIA reduced the ACh-induced current with an IC50 value of 375 nM and a maximally effective concentration caused 91% block, [A10L]PnIA was the most potent inhibitor, reducing the ACh-induced current in similar to 80% of neurons, with an IC50 value of 1.4 nM and 46% maximal block of the total current, The residual current was not inhibited further by alpha-bungarotoxin, but was further reduced by the cu-conotoxins PnIA or PnIB, and by mecamylamine. H-1 NMR studies indicate that PnIA, PnIB, and the analogues, [A10L]PnIA and [N11S]PnIA, have identical backbone structures. We propose that positions 10 and II of PnIA and PnIB influence potency and determine selectivity among alpha 7 and other nAChR subtypes, including alpha 3 beta 2 and alpha 3 beta 4, Four distinct components of the nicotinic ACh-induced current in mammalian parasympathetic neurons have been dissected with these conopeptides.	Univ Queensland, Dept Physiol & Pharmacol, Brisbane, Qld 4072, Australia; Univ Queensland, Ctr Drug Design & Dev, Brisbane, Qld 4072, Australia	University of Queensland; University of Queensland	Adams, DJ (corresponding author), Univ Queensland, Dept Physiol & Pharmacol, Brisbane, Qld 4072, Australia.		Lewis, Richard J/E-8674-2013; Adams, David/J-9125-2014; Craik, David/B-1695-2010; Adams, David John/K-3578-2019; Lewis, Richard/T-8763-2019	Lewis, Richard J/0000-0003-3470-923X; Adams, David/0000-0002-7030-2288; Craik, David/0000-0003-0007-6796; Adams, David John/0000-0002-7030-2288; Lewis, Richard/0000-0003-3470-923X; Alewood, Paul/0000-0001-7454-6522				ALKONDON M, 1993, J PHARMACOL EXP THER, V265, P1455; BAX A, 1985, J MAGN RESON, V65, P355, DOI 10.1016/0022-2364(85)90018-6; BRAUNSCHWEILER L, 1983, J MAGN RESON, V53, P521, DOI 10.1016/0022-2364(83)90226-3; Broxton N, 1998, P AUST NEUROSCI SOC, V9, P128; CARPINO LA, 1993, J AM CHEM SOC, V115, P4397, DOI 10.1021/ja00063a082; CARPINO LA, 1996, Patent No. 5580981; Cartier GE, 1996, J BIOL CHEM, V271, P7522, DOI 10.1074/jbc.271.13.7522; Chang KT, 1999, J NEUROSCI, V19, P3701; CHIAPPINELLI VA, 1978, NEUROCHEM RES, V3, P465, DOI 10.1007/BF00966328; COUTURIER S, 1990, NEURON, V5, P847, DOI 10.1016/0896-6273(90)90344-F; Cuevas J, 1998, J NEUROSCI, V18, P10335; FAINZILBER M, 1994, BIOCHEMISTRY-US, V33, P9523, DOI 10.1021/bi00198a018; FIEBER LA, 1991, J PHYSIOL-LONDON, V434, P215, DOI 10.1113/jphysiol.1991.sp018466; Gehrmann J, 1998, J MOL BIOL, V278, P401, DOI 10.1006/jmbi.1998.1701; Gehrmann J, 1999, J MED CHEM, V42, P2364, DOI 10.1021/jm990114p; Hill JM, 1998, BIOCHEMISTRY-US, V37, P15621, DOI 10.1021/bi981535w; Hu SH, 1996, STRUCTURE, V4, P417, DOI 10.1016/S0969-2126(96)00047-0; Hu SH, 1997, BIOCHEMISTRY-US, V36, P11323, DOI 10.1021/bi9713052; JEENER J, 1979, J CHEM PHYS, V71, P4546, DOI 10.1063/1.438208; JOHNSON DS, 1995, MOL PHARMACOL, V48, P194; Lewis TM, 1997, J PHYSIOL-LONDON, V505, P299, DOI 10.1111/j.1469-7793.1997.299bb.x; Li XY, 1998, J NEUROSCI, V18, P1904; Loughnan M, 1998, J BIOL CHEM, V273, P15667, DOI 10.1074/jbc.273.25.15667; MCGEHEE DS, 1995, SCIENCE, V269, P1692, DOI 10.1126/science.7569895; MCINTOSH JM, 1994, J BIOL CHEM, V269, P16733; Miranda LP, 1999, P NATL ACAD SCI USA, V96, P1181, DOI 10.1073/pnas.96.4.1181; PIOTTO M, 1992, J BIOMOL NMR, V2, P661, DOI 10.1007/BF02192855; Poth K, 1997, J NEUROSCI, V17, P586; Quiram PA, 1998, J BIOL CHEM, V273, P11007, DOI 10.1074/jbc.273.18.11007; RAE J, 1991, J NEUROSCI METH, V37, P15, DOI 10.1016/0165-0270(91)90017-T; SARGENT PB, 1993, ANNU REV NEUROSCI, V16, P403, DOI 10.1146/annurev.ne.16.030193.002155; SCHNOLZER M, 1992, INT J PEPT PROT RES, V40, P180; Servent D, 1998, J PHYSIOLOGY-PARIS, V92, P107, DOI 10.1016/S0928-4257(98)80146-0; WISHART DS, 1995, J BIOMOL NMR, V5, P67, DOI 10.1007/BF00227471; Wuthrich K, 1986, NMR PROTEINS NUCL AC; Yu CR, 1998, J PHYSIOL-LONDON, V509, P651, DOI 10.1111/j.1469-7793.1998.651bm.x; ZHANG ZW, 1994, NEURON, V12, P167, DOI 10.1016/0896-6273(94)90161-9	37	78	84	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 17	1999	274	51					36559	36564		10.1074/jbc.274.51.36559	http://dx.doi.org/10.1074/jbc.274.51.36559			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	266AV	10593955	hybrid, Green Published			2022-12-25	WOS:000084279200074
J	Meng, JW; Glick, JL; Polakis, P; Casey, PJ				Meng, JW; Glick, JL; Polakis, P; Casey, PJ			Functional interaction between G alpha(z) and Rap1GAP suggests a novel form of cellular cross-talk	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTPASE-ACTIVATING PROTEIN; HETEROTRIMERIC G-PROTEINS; ALPHA-SUBUNIT; PERTUSSIS TOXIN; BETA-GAMMA; ADENYLYL-CYCLASE; BINDING PROTEIN; HUMAN PLATELETS; DROSOPHILA NF1; P115 RHOGEF	G(z) is a member of the G(i) family of trimeric G proteins whose primary role in cell physiology is still unknown. In an ongoing effort to elucidate the cellular functions of G(z), the yeast two-hybrid system was employed to identify proteins that specifically interact with a mutationally activated form of G alpha(z). One of the molecules uncovered in this screen was Rap1GAP, a previously identified protein that specifically stimulates GTP hydrolytic activity of the monomeric G protein Rap1 and thus is believed to function as a down-regulator of Rap1 signaling. Like G(z), the precise role of Rap1 in cell physiology is poorly understood. Biochemical analysis using purified recombinant proteins revealed that the physical interaction between G alpha(z) and Rap1GAP blocks the ability of RGSs (regulators of G protein signaling) to stimulate GTP hydrolysis of the alpha subunit, and also attenuates the ability of activated G alpha(z) to inhibit adenylyl cyclase, Structure-function analyses indicate that the first 74 amino-terminal residues of Rap1GAP, a region distinct from the catalytic core domain responsible for the GAP activity toward Rap1, is required for this interaction. Co-precipitation assays revealed that G alpha(z), Rap1GAP, and Rap1 can form a stable complex. These data suggest that Rap1GAP acts as a signal integrator to somehow coordinate and/or integrate G(z) signaling and Rap1 signaling in cells.	Duke Univ, Med Ctr, Dept Pharmacol & Canc Biol, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Biochem, Durham, NC 27710 USA; Onyx Pharmaceut, Dept Mol Biol, Emeryville, CA 94608 USA	Duke University; Duke University	Casey, PJ (corresponding author), Duke Univ, Med Ctr, Dept Pharmacol & Canc Biol, Durham, NC 27710 USA.		Meng, Jingwei/K-8880-2015	Casey, Patrick/0000-0002-7366-9309	NIGMS NIH HHS [GM 55717] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R55GM055717, R01GM055717] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ahmadian MR, 1997, FEBS LETT, V408, P315, DOI 10.1016/S0014-5793(97)00422-5; Altschuler DL, 1998, P NATL ACAD SCI USA, V95, P7475, DOI 10.1073/pnas.95.13.7475; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; CASEY PJ, 1990, J BIOL CHEM, V265, P2383; COLEMAN DE, 1994, SCIENCE, V265, P1405, DOI 10.1126/science.8073283; De Vries L, 1999, TRENDS CELL BIOL, V9, P138, DOI 10.1016/S0962-8924(99)01515-9; Dohlman HG, 1997, J BIOL CHEM, V272, P3871, DOI 10.1074/jbc.272.7.3871; FIELDS TA, 1995, J BIOL CHEM, V270, P23119, DOI 10.1074/jbc.270.39.23119; FONG HKW, 1988, P NATL ACAD SCI USA, V85, P3066, DOI 10.1073/pnas.85.9.3066; GAGNON AW, 1991, BLOOD, V78, P1247; Glick JL, 1998, J BIOL CHEM, V273, P26008, DOI 10.1074/jbc.273.40.26008; GRAZIANO MP, 1989, J BIOL CHEM, V264, P409; Guo HF, 1997, SCIENCE, V276, P795, DOI 10.1126/science.276.5313.795; HALENBECK R, 1990, J BIOL CHEM, V265, P21922; Hart MJ, 1998, SCIENCE, V280, P2112, DOI 10.1126/science.280.5372.2112; Hepler JR, 1997, P NATL ACAD SCI USA, V94, P428, DOI 10.1073/pnas.94.2.428; HINTON DR, 1990, J NEUROSCI, V10, P2763; Hunt TW, 1996, NATURE, V383, P175, DOI 10.1038/383175a0; Jiang Y, 1998, NATURE, V395, P808, DOI 10.1038/27454; KOZASA T, 1995, J BIOL CHEM, V270, P1734, DOI 10.1074/jbc.270.4.1734; Kozasa T, 1998, SCIENCE, V280, P2109, DOI 10.1126/science.280.5372.2109; LAMBRIGHT DG, 1994, NATURE, V369, P621, DOI 10.1038/369621a0; LINDER ME, 1991, J BIOL CHEM, V266, P4654; LOUNSBURY KM, 1991, J BIOL CHEM, V266, P22051; LOUNSBURY KM, 1993, J BIOL CHEM, V268, P3494; MATSUOKA M, 1988, P NATL ACAD SCI USA, V85, P5384, DOI 10.1073/pnas.85.15.5384; MOOMAW JF, 1995, METHOD ENZYMOL, V250, P12; MUMBY SM, 1994, METHOD ENZYMOL, V237, P254; NEER EJ, 1995, CELL, V80, P249, DOI 10.1016/0092-8674(95)90407-7; RUBINFELD B, 1991, CELL, V65, P1033, DOI 10.1016/0092-8674(91)90555-D; RUBINFELD B, 1992, MOL CELL BIOL, V12, P4634, DOI 10.1128/MCB.12.10.4634; Sprang SR, 1997, ANNU REV BIOCHEM, V66, P639, DOI 10.1146/annurev.biochem.66.1.639; TAUSSIG R, 1993, J BIOL CHEM, V268, P9; TAUSSIG R, 1994, J BIOL CHEM, V269, P6093; Tesmer JJG, 1997, CELL, V89, P251, DOI 10.1016/S0092-8674(00)80204-4; The I, 1997, SCIENCE, V276, P791, DOI 10.1126/science.276.5313.791; Vossler MR, 1997, CELL, V89, P73, DOI 10.1016/S0092-8674(00)80184-1; Wang J, 1998, J BIOL CHEM, V273, P26014, DOI 10.1074/jbc.273.40.26014; WILSON PT, 1995, J BIOL CHEM, V270, P9667, DOI 10.1074/jbc.270.16.9667; WONG YH, 1995, ONCOGENE, V10, P1927; WONG YH, 1992, SCIENCE, V255, P339, DOI 10.1126/science.1347957	41	73	74	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 17	1999	274	51					36663	36669		10.1074/jbc.274.51.36663	http://dx.doi.org/10.1074/jbc.274.51.36663			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	266AV	10593970	hybrid			2022-12-25	WOS:000084279200089
J	O'Brien, TW; Fiesler, SE; Denslow, ND; Thiede, B; Wittmann-Liebold, B; Mougey, EB; Sylvester, JE; Graack, HR				O'Brien, TW; Fiesler, SE; Denslow, ND; Thiede, B; Wittmann-Liebold, B; Mougey, EB; Sylvester, JE; Graack, HR			Mammalian mitochondrial ribosomal proteins (2) - Amino acid sequencing, characterization, and identification of corresponding gene sequences	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; NUCLEAR GENES; YEAST; L2; NUCLEOTIDES; PREDICTION; CLONING; FETAL	Four different classes of mammalian mitochondrial ribosomal proteins were identified and characterized. Mature proteins were purified from bovine liver and subjected to N-terminal or matrix-assisted laser desorption mass spectroscopic amino acid sequencing after tryptic in-gel digestion and high pressure liquid chromatography separation of the resulting peptides. Peptide sequences obtained were used to virtually screen expressed sequence tag data bases from human, mouse, and rat. Consensus cDNAs were assembled in silico from various expressed sequence tag sequences identified. Deduced mammalian protein sequences were characterized and compared with ribosomal protein sequences of Escherichia coli and yeast mitochondria, Significant sequence similarities to ribosomal proteins of other sources were detected for three out of four different mammalian protein classes determined. However, the sequence conservation between mitochondrial ribosomal proteins of mammalian and yeast origin is much less than the sequence conservation between cytoplasmic ribosomal proteins of the same species. In particular, this is shown for the mammalian counterparts of the E. coli EcoL2 ribosomal protein (MRP-L14), that do not conserve the specific and functional highly important His(229) residue of E. coli and the corresponding yeast mitochondrial Rml2p.	Free Univ Berlin, Inst Biol Genet, AG Kress, D-14195 Berlin, Germany; Univ Florida, Coll Med, Dept Biochem & Mol Biol, Gainesville, FL 32610 USA; Max Delbruck Ctr Mol Med, D-13125 Berlin, Germany; Nemours Childrens Clin, Jacksonville, FL 32207 USA	Free University of Berlin; State University System of Florida; University of Florida; Helmholtz Association; Max Delbruck Center for Molecular Medicine	Graack, HR (corresponding author), Free Univ Berlin, Inst Biol Genet, AG Kress, Arnimallee 7, D-14195 Berlin, Germany.	graack@zedat.fu-berlin.de		Mougey, Edward/0000-0003-1190-6660	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM015438] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM15438] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; BRANDA SS, 1995, J BIOL CHEM, V270, P27366, DOI 10.1074/jbc.270.45.27366; Cooperman BS, 1995, BIOCHEM CELL BIOL, V73, P1087, DOI 10.1139/o95-117; DENSLOW ND, 1991, J BIOL CHEM, V266, P9586; DENSLOW ND, 1984, J BIOL CHEM, V259, P9867; *GEN COMP GROUP, 1997, GCG WISC PACK VERS 9; Goldschmidt-Reisin S, 1998, J BIOL CHEM, V273, P34828, DOI 10.1074/jbc.273.52.34828; Graack HR, 1998, BIOCHEM J, V329, P433, DOI 10.1042/bj3290433; HEROLD M, 1987, J BIOL CHEM, V262, P8826; KITAKAWA M, 1990, NUCLEIC ACIDS RES, V18, P1521, DOI 10.1093/nar/18.6.1521; KOZAK M, 1981, NUCLEIC ACIDS RES, V9, P5233, DOI 10.1093/nar/9.20.5233; Marty L, 1996, J BIOL CHEM, V271, P11468, DOI 10.1074/jbc.271.19.11468; MATSUSHITA Y, 1993, EUR J BIOCHEM, V214, P577, DOI 10.1111/j.1432-1033.1993.tb17956.x; MATTHEWS DE, 1982, J BIOL CHEM, V257, P8788; MYERS AM, 1985, EMBO J, V4, P2087, DOI 10.1002/j.1460-2075.1985.tb03896.x; Nielsen H, 1997, PROTEIN ENG, V10, P1, DOI 10.1093/protein/10.1.1; OBRIEN TW, 1980, ORG EXPRESSION MITOC, P301; Otto A, 1996, ELECTROPHORESIS, V17, P1643, DOI 10.1002/elps.1150171027; OU JH, 1987, NUCLEIC ACIDS RES, V15, P8919, DOI 10.1093/nar/15.21.8919; Pan C, 1997, J BIOL CHEM, V272, P8165, DOI 10.1074/jbc.272.13.8165; PIETROMONACO SF, 1986, J MOL EVOL, V24, P110, DOI 10.1007/BF02099958; SCHIEBER GL, 1982, J BIOL CHEM, V257, P8781; Shah ZH, 1997, GENE, V204, P55, DOI 10.1016/S0378-1119(97)00521-0; TSANG P, 1995, HUM MOL GENET, V4, P1499, DOI 10.1093/hmg/4.9.1499; Uhlein M, 1998, BIOCHEM J, V331, P423; Wool IG, 1995, BIOCHEM CELL BIOL, V73, P933, DOI 10.1139/o95-101	26	30	33	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 17	1999	274	51					36043	36051		10.1074/jbc.274.51.36043	http://dx.doi.org/10.1074/jbc.274.51.36043			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	266AV	10593885	hybrid			2022-12-25	WOS:000084279200004
J	Rohacs, T; Chen, J; Prestwich, GD; Logothetis, DE				Rohacs, T; Chen, J; Prestwich, GD; Logothetis, DE			Distinct specificities of inwardly rectifying K+ channels for phosphoinositides	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLECKSTRIN HOMOLOGY DOMAINS; RECTIFIER POTASSIUM CHANNELS; GTP-BINDING PROTEINS; BETA-GAMMA-SUBUNITS; PHOSPHATIDYLINOSITOL 4,5-BISPHOSPHATE; SIGNALING MOLECULES; CELLULAR ROLES; I-KACH; ACTIVATION; RECEPTOR	Activation of several inwardly rectifying K+ channels (I(ir) requires the presence of phosphatidylinositol 4,5-bisphosphate (PtdIns( 4,5)P-2). The constitutively active Kir2.1 (IRK1) channels interact with PtdIns(4,5)P-2 strongly, whereas the G-protein activated Kir3.1/3.4 channels (GIRK1/GIRK4), show only weak interactions with PtdIns(4,5)P-2. We investigated whether these inwardly rectifying K+ channels displayed distinct specificities for different phosphoinositides. IRK1, but not GIRK1/GIRK4 channels, showed a marked specificity toward phosphates in the 4,5 head group positions. GIRK1/GIRK4 channels were activated with a similar efficacy by PtdIns(3,4)P-2, PtdIns(3,5)P-2, PtdIns(4,5)P-2, and PtdIns(3,4,5)P-3. In contrast, IRK1 channels were not activated by PtdIns(3,4)P-2 and only marginally by high concentrations of PtdIns(3,5)P-2. Similarly, high concentrations of PtdIns(3,4,5)P-3 were required to activate IRK1 channels. For either channel, PtdIns(4)P was much less effective than PtdIns(4,5)P, whereas PtdIns was inactive. In contrast to the dependence on the position of phosphates of the phospholipid head group, GIRK1/GIRK4, but not IRK1 channel activation, showed a remarkable dependence on the phospholipid acyl chains. GIRKI/GIRK4 channels were activated most effectively by the natural arachidonyl stearyl PtdIns(4,5)P, and much less by the synthetic dipalmitoyl analog, whereas IRK1 channels were activated equally by dipalmitoyl and arachidonyl stearyl PtdIns(4,5)P,. Incorporation of PtdInsP(2) into the membrane is necessary for activation, as the short chain water soluble diC(4) PtdIns(4,5)P-2 did not activate either channel, whereas activation by diC(8) PtdIns(4, 5)P-2 required high concentrations.	NYU, Dept Physiol & Biophys, Mt Sinai Sch Med, New York, NY 10029 USA; Univ Utah, Dept Med Chem, Salt Lake City, UT 84112 USA	Icahn School of Medicine at Mount Sinai; New York University; Utah System of Higher Education; University of Utah	Logothetis, DE (corresponding author), NYU, Dept Physiol & Biophys, Mt Sinai Sch Med, 1 Gustave L Levy Pl,Box 1218, New York, NY 10029 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL059949] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-59949] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Alessi DR, 1997, CURR BIOL, V7, P261, DOI 10.1016/S0960-9822(06)00122-9; Baukrowitz T, 1998, SCIENCE, V282, P1141, DOI 10.1126/science.282.5391.1141; Chan KW, 1996, J GEN PHYSIOL, V107, P381, DOI 10.1085/jgp.107.3.381; Downes CPH, 1989, INOSITOL LIPIDS CELL, P1; Doyle DA, 1998, SCIENCE, V280, P69, DOI 10.1126/science.280.5360.69; Fan Z, 1997, J BIOL CHEM, V272, P5388, DOI 10.1074/jbc.272.9.5388; FLANAGAN LA, 1997, BIOPHYS J, V73, P140; Fruman DA, 1998, ANNU REV BIOCHEM, V67, P481, DOI 10.1146/annurev.biochem.67.1.481; Fruman DA, 1999, CELL, V97, P817, DOI 10.1016/S0092-8674(00)80792-8; Hilgemann Donald W., 1995, P307; Hilgemann DW, 1996, SCIENCE, V273, P956, DOI 10.1126/science.273.5277.956; Ho IHM, 1999, J PHYSIOL-LONDON, V520, P645, DOI 10.1111/j.1469-7793.1999.00645.x; Hsuan JJ, 1998, ADV CANCER RES, V74, P167, DOI 10.1016/S0065-230X(08)60767-8; Huang CL, 1998, NATURE, V391, P803, DOI 10.1038/35882; JACQUES JP, 1999, J GEN PHYSIOL, V114, P673; Kavran JM, 1998, J BIOL CHEM, V273, P30497, DOI 10.1074/jbc.273.46.30497; Kim D, 1999, J PHYSIOL-LONDON, V517, P59, DOI 10.1111/j.1469-7793.1999.0059z.x; Kobrinsky E, 1999, BIOPHYS J, V76, pA411; KRAPIVINSKY G, 1995, NATURE, V374, P135, DOI 10.1038/374135a0; KRAPIVINSKY G, 1995, J BIOL CHEM, V270, P29059, DOI 10.1074/jbc.270.49.29059; KUBO Y, 1993, NATURE, V362, P127, DOI 10.1038/362127a0; Lemmon MA, 1996, CELL, V85, P621, DOI 10.1016/S0092-8674(00)81022-3; Liou HH, 1999, P NATL ACAD SCI USA, V96, P5820, DOI 10.1073/pnas.96.10.5820; Logothetis DE, 1999, J PHYSIOL-LONDON, V520, P630, DOI 10.1111/j.1469-7793.1999.00630.x; LOGOTHETIS DE, 1987, NATURE, V325, P321, DOI 10.1038/325321a0; Lupu VD, 1998, J BIOL CHEM, V273, P14067, DOI 10.1074/jbc.273.23.14067; Martin TFJ, 1998, ANNU REV CELL DEV BI, V14, P231, DOI 10.1146/annurev.cellbio.14.1.231; Nichols CG, 1997, ANNU REV PHYSIOL, V59, P171, DOI 10.1146/annurev.physiol.59.1.171; Peng JR, 1998, TETRAHEDRON LETT, V39, P3965, DOI 10.1016/S0040-4039(98)00737-0; Perozo E, 1999, SCIENCE, V285, P73, DOI 10.1126/science.285.5424.73; Pike LJ, 1996, J BIOL CHEM, V271, P26453, DOI 10.1074/jbc.271.43.26453; Prestwich GD, 1996, ACCOUNTS CHEM RES, V29, P503, DOI 10.1021/ar960136v; Rameh LE, 1997, J BIOL CHEM, V272, P22059, DOI 10.1074/jbc.272.35.22059; REUVENY E, 1994, NATURE, V370, P143, DOI 10.1038/370143a0; Rohacs T, 1999, BIOPHYS J, V76, pA410; Shyng SL, 1998, SCIENCE, V282, P1138, DOI 10.1126/science.282.5391.1138; Stauffer TP, 1998, CURR BIOL, V8, P343, DOI 10.1016/S0960-9822(98)70135-6; Sui JL, 1998, P NATL ACAD SCI USA, V95, P1307, DOI 10.1073/pnas.95.3.1307; Sui JL, 1996, J GEN PHYSIOL, V108, P381, DOI 10.1085/jgp.108.5.381; Sui JL, 1999, ADV SEC MESS PHOSPH, V33, P179; Toker A, 1998, CURR OPIN CELL BIOL, V10, P254, DOI 10.1016/S0955-0674(98)80148-8; Varnai P, 1998, J CELL BIOL, V143, P501, DOI 10.1083/jcb.143.2.501; VIVAUDOU MB, 1991, J MEMBRANE BIOL, V122, P165, DOI 10.1007/BF01872639; Willars GB, 1998, J BIOL CHEM, V273, P5037, DOI 10.1074/jbc.273.9.5037; Zhainazarov AB, 1999, J NEUROSCI, V19, P2929; Zhang HL, 1999, NAT CELL BIOL, V1, P183, DOI 10.1038/11103	46	162	163	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 17	1999	274	51					36065	36072		10.1074/jbc.274.51.36065	http://dx.doi.org/10.1074/jbc.274.51.36065			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	266AV	10593888	hybrid			2022-12-25	WOS:000084279200007
J	Shah, OJ; Antonetti, DA; Kimball, SR; Jefferson, LS				Shah, OJ; Antonetti, DA; Kimball, SR; Jefferson, LS			Leucine, glutamine, and tyrosine reciprocally modulate the translation initiation factors eIF4F and eIF2B in perfused rat liver	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							P70 S6 KINASE; NUCLEOTIDE-EXCHANGE FACTOR; AMINO-ACID AVAILABILITY; PROTEIN-SYNTHESIS; PHAS-I; RETICULOCYTE LYSATE; MAMMALIAN TARGET; PLASMA-MEMBRANE; CELL-GROWTH; PHOSPHORYLATION	Leucine, glutamine, and tyrosine, three amino acids playing key modulatory roles in hepatic proteolysis, were evaluated for activation of signaling pathways involved in regulation of liver protein synthesis. Furthermore, because leucine signals to effecters that lie distal to the mammalian target of rapamycin, these downstream factors were selected for study as candidate mediators of amino acid signaling. Using the perfused rat liver as a model system, we observed a 25% stimulation of protein synthesis in response to balanced hyperaminoacidemia, whereas amino acid imbalance due to elevated concentrations of leucine, glutamine, and tyrosine resulted in a protein synthetic depression of roughly 50% compared with normoaminoacidemic controls. The reduction in protein synthesis accompanying amino acid imbalance became manifest at high physiologic concentrations and was dictated by the guanine nucleotide exchange activity of translation initiation factor eIF2B. Paradoxically, this phenomenon occurred concomitantly with assembly of the mRNA cap recognition complex, eIF4F as well as activation of the 70-kDa ribosomal S6 kinase, p70(S6k). Dual and reciprocal modulation of eIF4F and eIF2B was leucine-specific because isoleucine, a structural analog, was ineffective in these regards. Thus, we conclude that amino acid imbalance, heralded by leucine, initiates a liver-specific translational failsafe mechanism that deters protein synthesis under unfavorable circumstances despite promotion of the eIF4F complex.	Penn State Univ Hosp, Coll Med, Dept Cellular & Mol Physiol, Hershey, PA 17033 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health	Jefferson, LS (corresponding author), Penn State Univ Hosp, Coll Med, Dept Cellular & Mol Physiol, POB 850, Hershey, PA 17033 USA.	jjefferson@psu.edu		antonetti, david/0000-0003-1130-6577	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK013499, R01DK013499] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 13499] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AROOR AR, 1994, BIOCHEMISTRY-US, V33, P3350, DOI 10.1021/bi00177a028; Beretta L, 1996, EMBO J, V15, P658, DOI 10.1002/j.1460-2075.1996.tb00398.x; BLOMMAART EFC, 1995, J BIOL CHEM, V270, P2320, DOI 10.1074/jbc.270.5.2320; BROWN EJ, 1995, NATURE, V377, P441, DOI 10.1038/377441a0; Brunn GJ, 1997, SCIENCE, V277, P99, DOI 10.1126/science.277.5322.99; Brunn GJ, 1996, EMBO J, V15, P5256, DOI 10.1002/j.1460-2075.1996.tb00911.x; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; Burnett PE, 1998, P NATL ACAD SCI USA, V95, P1432, DOI 10.1073/pnas.95.4.1432; BUSE MG, 1975, J CLIN INVEST, V56, P1250, DOI 10.1172/JCI108201; CRANDALL EA, 1983, DIABETES, V32, P222, DOI 10.2337/diabetes.32.3.222; FLAIM KE, 1982, J BIOL CHEM, V257, P2932; Fox HL, 1998, AM J PHYSIOL-CELL PH, V274, pC206, DOI 10.1152/ajpcell.1998.274.1.C206; GLANVILLE NT, 1985, CAN J PHYSIOL PHARM, V63, P487, DOI 10.1139/y85-084; GROSS M, 1989, J BIOL CHEM, V264, P21879; Hara K, 1998, J BIOL CHEM, V273, P14484, DOI 10.1074/jbc.273.23.14484; HARPER AE, 1984, ANNU REV NUTR, V4, P409, DOI 10.1146/annurev.nu.04.070184.002205; HAYSTEAD TAJ, 1994, J BIOL CHEM, V269, P23185; Jefferies HBJ, 1997, EMBO J, V16, P3693, DOI 10.1093/emboj/16.12.3693; JEFFERIES HBJ, 1994, P NATL ACAD SCI USA, V91, P4441, DOI 10.1073/pnas.91.10.4441; Jefferson LS, 1999, INT J BIOCHEM CELL B, V31, P191, DOI 10.1016/S1357-2725(98)00141-1; Kawasome H, 1998, P NATL ACAD SCI USA, V95, P5033, DOI 10.1073/pnas.95.9.5033; Kimball SR, 1997, AM J PHYSIOL-CELL PH, V272, pC754, DOI 10.1152/ajpcell.1997.272.2.C754; Kimball SR, 1996, AM J PHYSIOL-CELL PH, V270, pC705, DOI 10.1152/ajpcell.1996.270.2.C705; KIMBALL SR, 1991, BIOCHEM BIOPH RES CO, V177, P1082, DOI 10.1016/0006-291X(91)90649-R; Kimball SR, 1996, PROG NUCLEIC ACID RE, V54, P165, DOI 10.1016/S0079-6603(08)60363-3; Kimball SR, 1996, INT J BIOCHEM CELL B, V28, P285, DOI 10.1016/1357-2725(95)00143-3; KIMBALL SR, 1991, J BIOL CHEM, V266, P1969; KIMBALL SR, 1989, AM J PHYSIOL, V256, pC28, DOI 10.1152/ajpcell.1989.256.1.C28; Kimball SR, 1998, J BIOL CHEM, V273, P30945, DOI 10.1074/jbc.273.47.30945; LIN TA, 1994, SCIENCE, V266, P653, DOI 10.1126/science.7939721; LUNN PG, 1976, BRIT J NUTR, V36, P219, DOI 10.1079/BJN19760074; MIOTTO G, 1994, J BIOL CHEM, V269, P25348; MIOTTO G, 1992, J BIOL CHEM, V267, P22066; Mortimore G. E., 1994, CELLULAR PROTEOLYTIC, P65; MORTIMORE GE, 1989, DIABETES METAB REV, V5, P49, DOI 10.1002/dmr.5610050105; MORTIMORE GE, 1987, J BIOL CHEM, V262, P16322; MORTIMORE GE, 1994, BIOCHEM BIOPH RES CO, V203, P200, DOI 10.1006/bbrc.1994.2168; NAIR KS, 1995, DIABETES ANN, V9; Patti ME, 1998, J CLIN INVEST, V101, P1519, DOI 10.1172/JCI1326; Peterson RT, 1998, CURR BIOL, V8, pR248, DOI 10.1016/S0960-9822(98)70152-6; POSO AR, 1982, J BIOL CHEM, V257, P2114; Rau M, 1996, J BIOL CHEM, V271, P8983, DOI 10.1074/jbc.271.15.8983; ROWLANDS AG, 1988, EUR J BIOCHEM, V175, P93, DOI 10.1111/j.1432-1033.1988.tb14170.x; SCHARFF R, 1966, BIOCHEM J, V99, P173, DOI 10.1042/bj0990173; SMITH R, 1983, P NUTR SOC, V42, P473, DOI 10.1079/PNS19830054; Sonenberg N, 1998, CURR OPIN CELL BIOL, V10, P268, DOI 10.1016/S0955-0674(98)80150-6; Sonenberg N, 1996, TRANSLATIONAL CONTRO, P245; Thomas G, 1997, CURR OPIN CELL BIOL, V9, P782, DOI 10.1016/S0955-0674(97)80078-6; vonManteuffel SR, 1997, MOL CELL BIOL, V17, P5426, DOI 10.1128/MCB.17.9.5426; Wang XM, 1998, BIOCHEM J, V334, P261, DOI 10.1042/bj3340261; Webb BLJ, 1997, INT J BIOCHEM CELL B, V29, P1127, DOI 10.1016/S1357-2725(97)00039-3; Welsh GI, 1997, FEBS LETT, V410, P418, DOI 10.1016/S0014-5793(97)00579-6; Welsh GI, 1998, FEBS LETT, V421, P125, DOI 10.1016/S0014-5793(97)01548-2; WERT JJ, 1992, BIOCHEM BIOPH RES CO, V186, P1327, DOI 10.1016/S0006-291X(05)81551-7; Xu G, 1998, J BIOL CHEM, V273, P4485, DOI 10.1074/jbc.273.8.4485; Yoshizawa F, 1998, AM J PHYSIOL-ENDOC M, V275, pE814, DOI 10.1152/ajpendo.1998.275.5.E814	56	25	26	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 17	1999	274	51					36168	36175		10.1074/jbc.274.51.36168	http://dx.doi.org/10.1074/jbc.274.51.36168			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	266AV	10593901	hybrid			2022-12-25	WOS:000084279200020
J	Henriksen, A; Smith, AT; Gajhede, M				Henriksen, A; Smith, AT; Gajhede, M			The structures of the horseradish peroxidase C-ferulic acid complex and the ternary complex with cyanide suggest how peroxidases oxidize small phenolic substrates	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; COMPOUND-I FORMATION; CRYSTAL-STRUCTURE; ANGSTROM RESOLUTION; ARTHROMYCES-RAMOSUS; LIGNIN PEROXIDASE; HYDROGEN-PEROXIDE; CELL-WALL; HEME; BINDING	We have solved the x-ray structures of the binary horseradish peroxidase C-ferulic acid complex and the ternary horseradish peroxidase C-cyanide-ferulic acid complex to 2.0 and 1.45 Angstrom, respectively. Ferulic acid is a naturally occurring phenolic compound found in the plant cell wall and is an in vivo substrate for plant peroxidases. The x-ray structures demonstrate the flexibility and dynamic character of the aromatic donor binding site in horseradish peroxidase and emphasize the role of the distal arginine (Arg(38)) in both substrate oxidation and ligand binding. Arg(38) hydrogen bonds to bound cyanide, thereby contributing to the stabilization of the horseradish peroxidase-cyanide complex and suggesting that the distal arginine will be able to contribute with a similar interaction during stabilization of a bound peroxy transition state and subsequent O-O bond cleavage. The catalytic arginine is additionally engaged in an extensive hydrogen bonding network, which also includes the catalytic distal histidine, a water molecule and Pro(139), a proline residue conserved within the plant peroxidase superfamily. Based on the observed hydrogen bonding network and previous spectroscopic and kinetic work, a general mechanism of peroxidase substrate oxidation is proposed.	Univ Copenhagen, Dept Chem, Prot Struct Grp, DK-2100 Copenhagen, Denmark; Univ Sussex, Sch Biol Sci, Brighton BN1 9QG, E Sussex, England	University of Copenhagen; University of Sussex	Henriksen, A (corresponding author), Univ Copenhagen, Dept Chem, Prot Struct Grp, Univ Pk 5, DK-2100 Copenhagen, Denmark.			Henriksen, Anette/0000-0003-4051-5079; Smith, Andrew/0000-0002-0926-1878; Gajhede, Michael/0000-0001-9864-2287				ATOR MA, 1987, J BIOL CHEM, V262, P1542; BACON D, 1988, J MOL GRAPHICS, V6, P219, DOI 10.1016/S0263-7855(98)80030-1; BAEK HK, 1992, J AM CHEM SOC, V114, P718, DOI 10.1021/ja00028a046; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Candeias LP, 1996, BIOCHEMISTRY-US, V35, P102, DOI 10.1021/bi9514424; CHILDS RE, 1976, J THEOR BIOL, V63, P1, DOI 10.1016/0022-5193(76)90080-1; Choinowski T, 1999, J MOL BIOL, V286, P809, DOI 10.1006/jmbi.1998.2507; de Ropp JS, 1999, BIOCHEMISTRY-US, V38, P1077, DOI 10.1021/bi982125a; Doyle WA, 1998, BIOCHEMISTRY-US, V37, P15097, DOI 10.1021/bi981633h; Dunford H. B., 1991, PEROXIDASES CHEM BIO, P1; EDWARDS SL, 1984, J BIOL CHEM, V259, P2984; EDWARDS SL, 1990, J BIOL CHEM, V265, P2588; ENGH RA, 1991, ACTA CRYSTALLOGR A, V47, P392, DOI 10.1107/S0108767391001071; ERMAN JE, 1992, J AM CHEM SOC, V114, P6592, DOI 10.1021/ja00042a068; EVERSHED RP, 1988, J CHROMATOGR, V440, P23, DOI 10.1016/S0021-9673(00)94507-2; FREUDENBERG K, 1965, SCIENCE, V148, P595, DOI 10.1126/science.148.3670.595; FRIAS I, 1991, BIOCHEM J, V273, P109, DOI 10.1042/bj2730109; Fry S.C., 1986, MOL PHYSL ASPECTS PL, P169; FULCHER RG, 1972, AUST J BIOL SCI, V25, P23, DOI 10.1071/BI9720023; FULOP V, 1994, STRUCTURE, V2, P201, DOI 10.1016/S0969-2126(00)00021-6; Gajhede M, 1997, NAT STRUCT BIOL, V4, P1032, DOI 10.1038/nsb1297-1032; GREIGSMITH PW, 1989, Patent No. 8829167; Gross G.G., 1985, BIOSYNTHESIS BIODEGR, P229; Henriksen A, 1998, J BIOL CHEM, V273, P2241, DOI 10.1074/jbc.273.4.2241; Henriksen A, 1998, BIOCHEMISTRY-US, V37, P8054, DOI 10.1021/bi980234j; HERRMANN K, 1989, CRIT REV FOOD SCI, V28, P315, DOI 10.1080/10408398909527504; JONES P, 1977, J THEOR BIOL, V69, P457, DOI 10.1016/0022-5193(77)90152-7; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KENTTAMAA J, 1970, SUOM KEMISTIL, V43, P333; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Kunishima N, 1996, FEBS LETT, V378, P291, DOI 10.1016/0014-5793(95)01458-6; KUNISHIMA N, 1994, J MOL BIOL, V235, P331, DOI 10.1016/S0022-2836(05)80037-3; LEIGH JS, 1975, FEBS LETT, V51, P304, DOI 10.1016/0014-5793(75)80913-6; MARKWALDER HU, 1976, PHYTOCHEMISTRY, V15, P836, DOI 10.1016/S0031-9422(00)94474-1; MARTINTANGUY J, 1985, PLANT GROWTH REGUL, V3, P381, DOI 10.1007/BF00117595; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; MEYER K, 1991, FEBS LETT, V290, P209, DOI 10.1016/0014-5793(91)81261-6; MILLER MA, 1994, NAT STRUCT BIOL, V1, P524, DOI 10.1038/nsb0894-524; MORISHIMA I, 1979, J BIOL CHEM, V254, P2814; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; PATTERSON WR, 1995, BIOCHEMISTRY-US, V34, P4331, DOI 10.1021/bi00013a023; PAUL KG, 1978, ACTA CHEM SCAND B, V32, P395, DOI 10.3891/acta.chem.scand.32b-0395; POULOS TL, 1980, J BIOL CHEM, V255, P8199; POULOS TL, 1980, J BIOL CHEM, V255, P575; POULOS TL, 1993, J BIOL CHEM, V268, P4429; PUTMAN LJ, 1989, HOLZFORSCHUNG, V43, P219, DOI 10.1515/hfsg.1989.43.4.219; Rietjens IMCM, 1996, J BIOL INORG CHEM, V1, P372, DOI 10.1007/s007750050068; RodriguezLopez JN, 1996, J BIOL INORG CHEM, V1, P136, DOI 10.1007/s007750050032; RodriguezLopez JN, 1996, J BIOL CHEM, V271, P4023; SAKURADA J, 1990, BIOCHEMISTRY-US, V29, P4093, DOI 10.1021/bi00469a011; Schuller DJ, 1996, STRUCTURE, V4, P311, DOI 10.1016/S0969-2126(96)00035-4; SEITZ LM, 1989, J AGR FOOD CHEM, V37, P662, DOI 10.1021/jf00087a019; Sheldrick GM, 1997, METHOD ENZYMOL, V277, P319, DOI 10.1016/S0076-6879(97)77018-6; SMITH AT, 1992, BIOCHEM SOC T, V20, P340, DOI 10.1042/bst0200340; SMITH AT, 1992, EUR J BIOCHEM, V207, P507, DOI 10.1111/j.1432-1033.1992.tb17077.x; SMITH AT, 1990, J BIOL CHEM, V265, P13335; SUGA T, 1993, PHYTOCHEMISTRY, V33, P1395, DOI 10.1016/0031-9422(93)85098-C; Takahama U., 1996, PLANT PEROXIDASES BI, P118; VEITCH NC, 1995, BIOCHEM SOC T, V23, P232, DOI 10.1042/bst0230232; VITELLO LB, 1993, BIOCHEMISTRY-US, V32, P9807, DOI 10.1021/bi00088a036; WALLACE AC, 1995, PROTEIN ENG, V8, P127, DOI 10.1093/protein/8.2.127	61	177	184	2	43	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 3	1999	274	49					35005	35011		10.1074/jbc.274.49.35005	http://dx.doi.org/10.1074/jbc.274.49.35005			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	260XW	10574977	hybrid			2022-12-25	WOS:000083979600071
J	Li, Y; Blencowe, BJ				Li, Y; Blencowe, BJ			Distinct factor requirements for exonic splicing enhancer function and binding of U2AF to the polypyrimidine tract	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-PROTEIN INTERACTIONS; SR-PROTEINS; AUXILIARY FACTOR; FACTOR ASF/SF2; RS DOMAIN; U1 SNRNP; RNA; IDENTIFICATION; COMPLEX; FAMILY	Exonic splicing enhancer (ESE) sequences are important for the recognition of adjacent splice sites in pre-mRNA and for the regulation of splice site selection. It has been proposed that ESEs function by associating with one or more serine/arginine-repeat (SR) proteins which stabilize the binding of the U2 small nuclear ribonucleoprotein particle (snRNP) auxiliary factor (U2AF) to the polypyrimidine tract upstream of the 3' splice site. We have tested this model by analyzing the composition of splicing complexes assembled on an ESE-dependent pre-mRNA derived from the doublesex gene of Drosophila, Several SR proteins and hTra2 beta, a human homolog of the Drosophila alternative splicing regulator Transformer-a, associate with this pre-mRNA in the presence, but not in the absence, of a purine-rich ESE. By contrast, the 65-kDa subunit of U2AF (U2AF-65 kDa) bound equally to the pre-mRNA in the presence and absence of the ESE, Time course experiments revealed differences in the levels and kinetics of association of individual SR proteins with the ESE-containing pre-mRNA, whereas U2AF-65 kDa bound prior to most SR proteins and hTra2 beta and its level of binding did not change significantly during the course of the splicing reaction. Binding of U2AF-65 kDa to the ESE-dependent pre-mRNA was, however, dependent on U1 snRNP, The results indicate that an ESE promotes spliceosome formation through interactions that are distinct from those required for the binding of U2AF-65 kDa to the polypyrimidine tract.	Univ Toronto, Banting & Best Dept Med Res, CH Best Inst, Toronto, ON M5G 1L6, Canada	University of Toronto	Blencowe, BJ (corresponding author), Univ Toronto, Banting & Best Dept Med Res, CH Best Inst, 112 Coll St, Toronto, ON M5G 1L6, Canada.	b.blencowe@utoronto.ca						Abovich N, 1997, CELL, V89, P403, DOI 10.1016/S0092-8674(00)80221-4; AMREIN H, 1994, CELL, V76, P735, DOI 10.1016/0092-8674(94)90512-6; BARABINO SML, 1990, CELL, V63, P293, DOI 10.1016/0092-8674(90)90162-8; Beil B, 1997, DNA CELL BIOL, V16, P679, DOI 10.1089/dna.1997.16.679; Blencowe BJ, 1999, BIOCHEM CELL BIOL, V77, P277, DOI 10.1139/bcb-77-4-277; BLENCOWE BJ, 1995, RNA, V1, P852; Blencowe BJ, 1998, GENE DEV, V12, P996, DOI 10.1101/gad.12.7.996; Blencowe BJ, 1999, METH MOL B, V118, P275; Bouck J, 1998, J BIOL CHEM, V273, P15169, DOI 10.1074/jbc.273.24.15169; Burge CB, 1999, RNA WORLD, P525; Chabot B, 1996, TRENDS GENET, V12, P472, DOI 10.1016/0168-9525(96)10037-8; COTE J, 1995, J BIOL CHEM, V270, P4031, DOI 10.1074/jbc.270.8.4031; Dauwalder B, 1996, P NATL ACAD SCI USA, V93, P9004, DOI 10.1073/pnas.93.17.9004; DIAMOND RH, 1993, J BIOL CHEM, V268, P15185; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Eldridge AG, 1999, P NATL ACAD SCI USA, V96, P6125, DOI 10.1073/pnas.96.11.6125; Fetzer S, 1997, RNA, V3, P344; FU XD, 1995, RNA, V1, P663; Harlow E., 1988, ANTIBODIES LAB MANUA; HOFFMAN BE, 1992, GENE DEV, V6, P2554, DOI 10.1101/gad.6.12b.2554; Kan JLC, 1999, GENE DEV, V13, P462, DOI 10.1101/gad.13.4.462; KOHTZ JD, 1994, NATURE, V368, P119, DOI 10.1038/368119a0; Kramer A, 1996, ANNU REV BIOCHEM, V65, P367, DOI 10.1146/annurev.biochem.65.1.367; KRAMER A, 1992, MOL CELL BIOL, V12, P4545; LAVIGUEUR A, 1993, GENE DEV, V7, P2405, DOI 10.1101/gad.7.12a.2405; Liu HX, 1998, GENE DEV, V12, P1998, DOI 10.1101/gad.12.13.1998; Lopez AJ, 1998, ANNU REV GENET, V32, P279, DOI 10.1146/annurev.genet.32.1.279; Manley JL, 1996, GENE DEV, V10, P1569, DOI 10.1101/gad.10.13.1569; ROTH MB, 1990, J CELL BIOL, V111, P2217, DOI 10.1083/jcb.111.6.2217; Rudner DZ, 1998, GENE DEV, V12, P1010, DOI 10.1101/gad.12.7.1010; RUSKIN B, 1988, CELL, V52, P207, DOI 10.1016/0092-8674(88)90509-0; RYDER U, 1990, NUCLEIC ACIDS RES, V18, P7373, DOI 10.1093/nar/18.24.7373; Schaal TD, 1999, MOL CELL BIOL, V19, P1705; SCREATON GR, 1995, EMBO J, V14, P4336, DOI 10.1002/j.1460-2075.1995.tb00108.x; SERAPHIN B, 1989, CELL, V59, P349, DOI 10.1016/0092-8674(89)90296-1; Tacke R, 1998, CELL, V93, P139, DOI 10.1016/S0092-8674(00)81153-8; Valcarcel J, 1996, TRENDS BIOCHEM SCI, V21, P296, DOI 10.1016/0968-0004(96)10039-6; Wang J, 1997, CURR OPIN GENET DEV, V7, P205, DOI 10.1016/S0959-437X(97)80130-X; WANG Z, 1995, RNA, V1, P21; WU JY, 1993, CELL, V75, P1061, DOI 10.1016/0092-8674(93)90316-I; Xiao SH, 1998, EMBO J, V17, P6359, DOI 10.1093/emboj/17.21.6359; Xiao SH, 1997, GENE DEV, V11, P334, DOI 10.1101/gad.11.3.334; Yeakley JM, 1996, P NATL ACAD SCI USA, V93, P7582, DOI 10.1073/pnas.93.15.7582; ZAHLER AM, 1992, GENE DEV, V6, P837, DOI 10.1101/gad.6.5.837; ZAMORE PD, 1991, EMBO J, V10, P207, DOI 10.1002/j.1460-2075.1991.tb07937.x; ZAMORE PD, 1992, NATURE, V355, P609, DOI 10.1038/355609a0; ZHANG M, 1992, P NATL ACAD SCI USA, V89, P8769, DOI 10.1073/pnas.89.18.8769; Zuo P, 1996, GENE DEV, V10, P1356, DOI 10.1101/gad.10.11.1356; ZUO P, 1993, EMBO J, V12, P4727, DOI 10.1002/j.1460-2075.1993.tb06161.x	49	39	39	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 3	1999	274	49					35074	35079		10.1074/jbc.274.49.35074	http://dx.doi.org/10.1074/jbc.274.49.35074			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	260XW	10574987	hybrid			2022-12-25	WOS:000083979600081
J	Wittchen, ES; Haskins, J; Stevenson, BR				Wittchen, ES; Haskins, J; Stevenson, BR			Protein interactions at the tight junction - Actin has multiple binding partners, and ZO-1 forms independent complexes with ZO-2 and ZO-3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CANINE KIDNEY-CELLS; EPITHELIAL-CELLS; PARACELLULAR PERMEABILITY; PERIPHERAL COMPONENT; MEMBRANE-PROTEIN; SKELETAL-MUSCLE; CYTOCHALASIN-D; OCCLUDIN; FILAMENTS; BARRIER	Defining how the molecular constituents of the tight junction interact is a prerequisite to understanding tight junction physiology, We utilized in vitro binding assays with purified recombinant proteins and immunoprecipitation analyses to define interactions between ZO-1, ZO-2, ZO-3, occludin, and the actin cytoskeleton, Actin cosedimentation studies showed that ZO-2, ZO-3, and occludin all interact directly with F-actin in vitro, indicating that actin is engaged in multiple interactions at the tight junction. Low speed sedimentation analyses demonstrated that neither ZO-2, ZO-3, nor occludin act as F-actin cross-linking proteins, and further evidence indicates that these proteins do not bind to actin filament ends. The binding interactions of ZO-2, ZO-3, and occludin were corroborated in vivo by immunofluorescence colocalization experiments which showed that all three proteins colocalized with actin aggregates at cell borders in cytochalasin D-treated Madin-Darby canine kidney cells. Exploration of other tight junction protein interactions demonstrated that ZO-2 binds directly to both ZO-1 and occludin, Contrary to previous beliefs, our immunoprecipitation results indicate that ZO-1, ZO-2, and ZO-3 exist in situ primarily as independent ZO-1 ZO-2 and ZO-1 ZO-3 complexes rather than a trimeric ZO-1 ZO-2 ZO-3 grouping. These studies elucidate direct binding interactions among tight junction-associated proteins, giving insight into their organization as a multimolecular structure.	Univ Alberta, Dept Cell Biol, Edmonton, AB T6G 2H7, Canada	University of Alberta	Stevenson, BR (corresponding author), Univ Alberta, Dept Cell Biol, Edmonton, AB T6G 2H7, Canada.	bluce.stevenson@ualberta.ca						ANDERSON JM, 1988, J CELL BIOL, V106, P1141, DOI 10.1083/jcb.106.4.1141; Anderson JM, 1996, CURR BIOL, V6, P382, DOI 10.1016/S0960-9822(02)00501-8; BALDA MS, 1993, J CELL BIOL, V123, P293, DOI 10.1083/jcb.123.2.293; Balda MS, 1996, J CELL BIOL, V134, P1031, DOI 10.1083/jcb.134.4.1031; Beatch M, 1996, J BIOL CHEM, V271, P25723, DOI 10.1074/jbc.271.42.25723; BLANCHARD A, 1989, J MUSCLE RES CELL M, V10, P280, DOI 10.1007/BF01758424; CASELLA JF, 1987, J CELL BIOL, V105, P371, DOI 10.1083/jcb.105.1.371; Chen YH, 1997, J CELL BIOL, V138, P891, DOI 10.1083/jcb.138.4.891; CITI S, 1988, NATURE, V333, P272, DOI 10.1038/333272a0; COTE GP, 1981, J BIOL CHEM, V256, P7257; ESPINDOLA FS, 1992, J CELL BIOL, V118, P359, DOI 10.1083/jcb.118.2.359; Fanning AS, 1998, J BIOL CHEM, V273, P29745, DOI 10.1074/jbc.273.45.29745; FARQUHAR MG, 1963, J CELL BIOL, V17, P375, DOI 10.1083/jcb.17.2.375; FURUSE M, 1993, J CELL BIOL, V123, P1777, DOI 10.1083/jcb.123.6.1777; Furuse M, 1998, J CELL BIOL, V141, P1539, DOI 10.1083/jcb.141.7.1539; FURUSE M, 1994, J CELL BIOL, V127, P1617, DOI 10.1083/jcb.127.6.1617; GUMBINER B, 1991, P NATL ACAD SCI USA, V88, P3460, DOI 10.1073/pnas.88.8.3460; Haskins J, 1998, J CELL BIOL, V141, P199, DOI 10.1083/jcb.141.1.199; HIROKAWA N, 1982, J CELL BIOL, V95, P249, DOI 10.1083/jcb.95.1.249; HOWARTH AG, 1992, AM J PHYSIOL, V262, pC461, DOI 10.1152/ajpcell.1992.262.2.C461; Itoh M, 1997, J CELL BIOL, V138, P181, DOI 10.1083/jcb.138.1.181; Itoh M, 1999, J BIOL CHEM, V274, P5981, DOI 10.1074/jbc.274.9.5981; Izumi Y, 1998, J CELL BIOL, V143, P95, DOI 10.1083/jcb.143.1.95; Jegla T, 1995, J NEUROSCI, V15, P7989; JESAITIS LA, 1994, J CELL BIOL, V124, P949, DOI 10.1083/jcb.124.6.949; Keon BH, 1996, J CELL BIOL, V134, P1003, DOI 10.1083/jcb.134.4.1003; Kojima T, 1999, CELL STRUCT FUNCT, V24, P11, DOI 10.1247/csf.24.11; Li Z, 1998, J CELL SCI, V111, P1005; MACLEANFLETCHER SD, 1980, J CELL BIOL, V85, P414, DOI 10.1083/jcb.85.2.414; MADARA JL, 1986, J CELL BIOL, V102, P2125, DOI 10.1083/jcb.102.6.2125; MADARA JL, 1987, AM J PHYSIOL, V253, pC171, DOI 10.1152/ajpcell.1987.253.1.C171; MADARA JL, 1987, J MEMBRANE BIOL, V100, P149, DOI 10.1007/BF02209147; Martin-Padura I, 1998, J CELL BIOL, V142, P117, DOI 10.1083/jcb.142.1.117; McCarthy KM, 1996, J CELL SCI, V109, P2287; Morita K, 1999, P NATL ACAD SCI USA, V96, P511, DOI 10.1073/pnas.96.2.511; PASDAR M, 1989, J CELL BIOL, V109, P163, DOI 10.1083/jcb.109.1.163; Simon DB, 1999, SCIENCE, V285, P103, DOI 10.1126/science.285.5424.103; STEVENSON BR, 1994, J EXP ZOOL, V268, P224, DOI 10.1002/jez.1402680307; STEVENSON BR, 1988, J CELL BIOL, V107, P2401, DOI 10.1083/jcb.107.6.2401; STEVENSON BR, 1986, J CELL BIOL, V103, P755, DOI 10.1083/jcb.103.3.755; STEVENSON BR, 1994, J CELL SCI, V107, P367; WEBER E, 1994, J CELL BIOL, V125, P583, DOI 10.1083/jcb.125.3.583; Wong V, 1997, J CELL BIOL, V136, P399, DOI 10.1083/jcb.136.2.399; Yamamoto T, 1997, J CELL BIOL, V139, P785, DOI 10.1083/jcb.139.3.785; ZHONG Y, 1993, J CELL BIOL, V120, P477, DOI 10.1083/jcb.120.2.477	45	383	390	3	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 3	1999	274	49					35179	35185		10.1074/jbc.274.49.35179	http://dx.doi.org/10.1074/jbc.274.49.35179			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	260XW	10575001	hybrid			2022-12-25	WOS:000083979600095
J	Xiong, HS; Pegg, AE				Xiong, HS; Pegg, AE			Mechanistic studies of the processing of human S-adenosylmethionine decarboxylase proenzyme - Isolation of an ester intermediate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT HISTIDINE-DECARBOXYLASE; SITE-DIRECTED ALTERATION; ESCHERICHIA-COLI; PROHISTIDINE DECARBOXYLASE; ENZYME TARGET; PROTEIN; POLYAMINES; LACTOBACILLUS-30A; INHIBITORS; ACTIVATION	Human S-adenosylmethionine decarboxylase is synthesized as a proenzyme that undergoes an autocatalytic cleavage reaction generating the alpha and beta subunits and forming the pyruvate prosthetic group, which is derived from an internal Ser residue (Ser-68). The mechanism of this processing reaction was studied using site-directed mutagenesis of conserved residues (His-243 and Ser-229) located close to the cleavage site, Mutant S229A failed to process, and mutant S229C cleaved very slowly, whereas mutant S229T processed normally, suggesting that the hydroxyl group of residue 229 is required for the processing reaction where Ser-229 may act as a proton acceptor. Mutant His-243A cleaved very slowly, forming a small amount of the correctly processed pyruvoyl enzyme but a much larger proportion of the alpha subunit with an amino-terminal Ser, The cleavage to form the latter was greatly enhanced by hydroxylamine. This result suggests that the N-O acyl shift needed for ester formation occurs normally in this mutant but that the next step, which is a beta-elimination reaction leading to the two subunits, does not occur. His-243 may therefore act as the basic residue that extracts the hydrogen of the alpha-carbon of Ser-68 in the ester in order to facilitate this reaction. The availability of the recombinant H243A S-adenosylmethionine decarboxylase proenzyme provides a useful model system to examine the processing reaction in vitro and test the design of specific inactivators aimed at blocking the production of the pyruvoyl prosthetic group.	Penn State Univ, Coll Med, Dept Cellular & Mol Physiol, Milton S Hershey Med Ctr, Hershey, PA 17033 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health	Pegg, AE (corresponding author), Penn State Univ, Coll Med, Dept Cellular & Mol Physiol, Milton S Hershey Med Ctr, 500 Univ Dr, Hershey, PA 17033 USA.				NCI NIH HHS [CA-18138] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA018138, R37CA018138] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Albert A, 1998, NAT STRUCT BIOL, V5, P289, DOI 10.1038/nsb0498-289; Bacchi CJ, 1996, ANTIMICROB AGENTS CH, V40, P1448, DOI 10.1128/AAC.40.6.1448; Bornstein P, 1977, Methods Enzymol, V47, P132; Ekstrom JL, 1999, STRUCTURE, V7, P583, DOI 10.1016/S0969-2126(99)80074-4; GALLAGHER T, 1993, J MOL BIOL, V230, P516, DOI 10.1006/jmbi.1993.1168; GALLAGHER T, 1989, J BIOL CHEM, V264, P12737; GELFMAN CM, 1991, BIOCHEMISTRY-US, V30, P1057, DOI 10.1021/bi00218a025; HACKERT ML, 1997, COMPREHENSIVE BIOL C, P201; HUYNH QK, 1986, J BIOL CHEM, V261, P1521; JANNE J, 1991, ANN MED, V23, P241, DOI 10.3109/07853899109148056; Kabisch UC, 1999, J BIOL CHEM, V274, P8445, DOI 10.1074/jbc.274.13.8445; LI QX, 1990, J BIOL CHEM, V265, P4111; MARKHAM GD, 1982, J BIOL CHEM, V257, P2063; MARTON LJ, 1995, ANNU REV PHARMACOL, V35, P55, DOI 10.1146/annurev.pa.35.040195.000415; MCCANN PP, 1992, PHARMACOL THERAPEUT, V54, P195, DOI 10.1016/0163-7258(92)90032-U; PAJUNEN A, 1988, J BIOL CHEM, V263, P17040; PEGG AE, 1986, BIOCHEM J, V234, P249, DOI 10.1042/bj2340249; Pegg AE, 1998, BIOCHEM SOC T, V26, P580, DOI 10.1042/bst0260580; PEGG AE, 1992, PHARMACOL THERAPEUT, V56, P359, DOI 10.1016/0163-7258(92)90025-U; PEGG AE, 1982, AM J PHYSIOL, V243, P212; RECSEI PA, 1984, ANNU REV BIOCHEM, V53, P357, DOI 10.1146/annurev.bi.53.070184.002041; SHANTZ LM, 1992, BIOCHEMISTRY-US, V31, P6848, DOI 10.1021/bi00144a027; Shao Y, 1997, CHEM BIOL, V4, P187, DOI 10.1016/S1074-5521(97)90287-8; Shao Y, 1996, BIOCHEMISTRY-US, V35, P3810, DOI 10.1021/bi952592h; SHIRAHATA A, 1985, BIOCHEMISTRY-US, V24, P4417, DOI 10.1021/bi00337a024; SHIRAHATA A, 1985, J BIOL CHEM, V260, P9583; STANLEY BA, 1991, J BIOL CHEM, V266, P18502; STANLEY BA, 1989, J BIOL CHEM, V264, P21073; STANLEY BA, 1994, J BIOL CHEM, V269, P7901; TABOR CW, 1987, J BIOL CHEM, V262, P16037; VANDERSLICE P, 1988, J BIOL CHEM, V263, P10583; VANPOELJE PD, 1990, ANNU REV BIOCHEM, V59, P29, DOI 10.1146/annurev.bi.59.070190.000333; Wagner M, 1999, EUR J BIOCHEM, V260, P38, DOI 10.1046/j.1432-1327.1999.00107.x; XIONG H, 1998, THESIS PENNSYLVANIA; Xiong HS, 1999, BIOCHEMISTRY-US, V38, P2462, DOI 10.1021/bi9825201; Xiong HS, 1997, J BIOL CHEM, V272, P28342, DOI 10.1074/jbc.272.45.28342; Xu MQ, 1996, EMBO J, V15, P5146, DOI 10.1002/j.1460-2075.1996.tb00898.x	37	33	34	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 3	1999	274	49					35059	35066		10.1074/jbc.274.49.35059	http://dx.doi.org/10.1074/jbc.274.49.35059			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	260XW	10574985	hybrid			2022-12-25	WOS:000083979600079
J	Greeve, J; Lellek, H; Apostel, F; Hundoegger, K; Barialai, A; Kirsten, R; Welker, S; Greten, H				Greeve, J; Lellek, H; Apostel, F; Hundoegger, K; Barialai, A; Kirsten, R; Welker, S; Greten, H			Absence of APOBEC-1 mediated mRNA editing in human carcinomas	ONCOGENE			English	Article						mRNA editing; APOBEC-1; human carcinoma; apo B; NAT1	B MESSENGER-RNA; TISSUE-SPECIFIC EXPRESSION; CATALYTIC SUBUNIT; KINETOPLASTID PROTOZOA; CYTIDINE DEAMINASE; PROTEIN; GENE; ENZYME; CLONING; MOTIF	The transgene expression of the catalytic subunit APOBEC-1 of the apo B mRNA editing enzyme-complex can cause hepatocellular carcinoma in mice and rabbits. It has been proposed that aberrant editing of mRNA may represent a novel oncogenic principle. This investigation aimed to define whether such aberrant hyperediting mediated by APOBEC-1 occurs in human carcinomas. Editing and hyperediting of apo B, NAT1 or NF1 mRNA was not identified in any of 28 resected tumor specimens, including hepatocellular, bile duct, gastric, colorectal, pancreatic adeno- and neuroendocrine, lung adeno-, medullary thyroid and breast carcinoma, soft tissue sarcoma and neuroblastoma. In most types of carcinoma, significant length for full-length APOBEC-1 mRNA could not be detected. Low level expression of APOBEC-1 was found in colorectal and gastric carcinoma where most of the APOBEC-1 mRNA is inactivated by alternate splicing. The 'auxiliary' components of the apo B mRNA editing enzyme-complex are missing in many tumors including colorectal and gastric carcinoma, but are highly expressed in hepatocellular, lung adeno- and breast carcinoma all of which lack APOBEC-1. Taken together, either APOBEC-1 or the 'auxiliary' components of the apo B mRNA editing enzyme-complex or both are missing in human carcinomas resulting in the absence of mRNA editing. Currently, there is no evidence that aberrant editing mediated by APOBEC-1 contributes to the tumorigenesis of natural human carcinomas.	Univ Hamburg, Hosp Eppendorf, Med Kernklin & Poliklin, D-20246 Hamburg, Germany	University of Hamburg	Greeve, J (corresponding author), Univ Hamburg, Hosp Eppendorf, Med Kernklin & Poliklin, Martinistr 52, D-20246 Hamburg, Germany.							ANANT S, 1995, J BIOL CHEM, V270, P14762, DOI 10.1074/jbc.270.24.14762; Cappione AJ, 1997, AM J HUM GENET, V60, P305; CHEN SH, 1987, SCIENCE, V238, P363, DOI 10.1126/science.3659919; Fujino T, 1998, GENOMICS, V47, P266, DOI 10.1006/geno.1997.5110; GIANNONI F, 1994, J BIOL CHEM, V269, P5932; Greeve J, 1998, ARTERIOSCL THROM VAS, V18, P1079, DOI 10.1161/01.ATV.18.7.1079; Greeve J, 1996, J LIPID RES, V37, P2001; GREEVE J, 1991, NUCLEIC ACIDS RES, V19, P3569, DOI 10.1093/nar/19.13.3569; GREEVE J, 1993, J LIPID RES, V34, P1367; Hirano H, 1997, J LIPID RES, V38, P847; LAU PP, 1994, P NATL ACAD SCI USA, V91, P8522, DOI 10.1073/pnas.91.18.8522; Lee RM, 1998, GASTROENTEROLOGY, V115, P1096, DOI 10.1016/S0016-5085(98)70080-0; Maas S, 1997, CURR OPIN CELL BIOL, V9, P343, DOI 10.1016/S0955-0674(97)80006-3; NAKAMUTA M, 1995, J BIOL CHEM, V270, P13042, DOI 10.1074/jbc.270.22.13042; NAVARATNAM N, 1993, J BIOL CHEM, V268, P20709; NAVARATNAM N, 1995, CELL, V81, P187, DOI 10.1016/0092-8674(95)90328-3; POWELL LM, 1987, CELL, V50, P831, DOI 10.1016/0092-8674(87)90510-1; Powell-Braxton L, 1998, NAT MED, V4, P934, DOI 10.1038/nm0898-934; Qian XB, 1997, J BIOL CHEM, V272, P18060, DOI 10.1074/jbc.272.29.18060; SCOTT J, 1995, CELL, V81, P833, DOI 10.1016/0092-8674(95)90002-0; SHAH RR, 1991, J BIOL CHEM, V266, P16301; SHARMA PM, 1994, GENE DEV, V8, P720, DOI 10.1101/gad.8.6.720; SIMPSON L, 1995, CELL, V81, P837, DOI 10.1016/0092-8674(95)90003-9; Skuse GR, 1996, NUCLEIC ACIDS RES, V24, P478, DOI 10.1093/nar/24.3.478; SMITH HC, 1991, P NATL ACAD SCI USA, V88, P1489, DOI 10.1073/pnas.88.4.1489; SOMMER B, 1991, CELL, V67, P11, DOI 10.1016/0092-8674(91)90568-J; Sowden M, 1996, J BIOL CHEM, V271, P3011, DOI 10.1074/jbc.271.6.3011; TENG BB, 1990, J BIOL CHEM, V265, P20616; TENG BB, 1993, SCIENCE, V260, P1816, DOI 10.1126/science.8511591; Yamanaka S, 1996, J BIOL CHEM, V271, P11506, DOI 10.1074/jbc.271.19.11506; YAMANAKA S, 1994, J BIOL CHEM, V269, P21725; YAMANAKA S, 1995, P NATL ACAD SCI USA, V92, P8483, DOI 10.1073/pnas.92.18.8483; Yamanaka S, 1997, GENE DEV, V11, P321, DOI 10.1101/gad.11.3.321	33	19	19	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 4	1999	18	46					6357	6366		10.1038/sj.onc.1203039	http://dx.doi.org/10.1038/sj.onc.1203039			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	260DK	10597235				2022-12-25	WOS:000083934100020
J	Grignani, F; Gelmetti, V; Fanelli, M; Rogaia, D; De Matteis, S; Ferrara, FF; Bonci, D; Grignani, F; Nervi, C; Pelicci, PG				Grignani, F; Gelmetti, V; Fanelli, M; Rogaia, D; De Matteis, S; Ferrara, FF; Bonci, D; Grignani, F; Nervi, C; Pelicci, PG			Formation of PML/RAR alpha high molecular weight nuclear complexes through the PML coiled-coil region is essential for the PML/RAR alpha-mediated retinoic acid response	ONCOGENE			English	Article						retinoic acid; leukaemia; protein complexes; PML/RAR alpha	ACUTE PROMYELOCYTIC LEUKEMIA; PLZF-RAR-ALPHA; RECEPTOR-ALPHA; FUSION PROTEINS; HISTONE DEACETYLASE; GENE-PRODUCT; CELLS; TRANSLOCATION; ONCOPROTEIN; BINDING	Retinoic Acid (RA) treatment induces disease remission of Acute Promyelocytic Leukaemia (APL) patients by triggering terminal differentiation of neoplastic cells. RA-sensitivity in APL is mediated by its oncogenic protein, which results from the recombination of the PML and the RA receptor alpha (RAR alpha) genes (PML/RAR alpha fusion protein). Ectopic expression of PML/RAR alpha into haemopoietic cell lines results in increased response to RA-induced differentiation. By structure-function analysis of PML/RAR alpha-mediated RA-differentiation, we demonstrated that fusion of PML and RAR alpha sequences and integrity of the PML dimerization domain and of the RAR alpha DNA binding region are required for the effect of PML/RAR alpha on RA-differentiation. Indeed, direct fusion of the PML dimerization domain to the Nor C-terminal extremities' of RAR alpha retained full biological activity. All the biologically active PML/RAR alpha mutants formed high molecular weight complexes in vivo. Functional analysis of mutations within the PML dimerization domain revealed that the capacity to form PML/RAR alpha homodimers, but not PML/RAR alpha-PML heterodimers, correlated with the RA response. These results suggest that targeting of RAR alpha sequences by the PML dimerization domain and formation of nuclear PML/RAR alpha homodimeric complexes are crucial for the ability of PML/RAR alpha to mediate RA-response.	European Inst Oncol, Dept Expt Oncol, I-20141 Milan, Italy; Univ Perugia, Monteluce Policlin, Ist Med Interna & Sci Oncol, I-06100 Perugia, Italy; Ist Super Sanita, Dept Hematol & Oncol, I-00161 Rome, Italy; Univ La Sapienza, Dipartimento Istol & Embriol Umana, I-00161 Rome, Italy	IRCCS European Institute of Oncology (IEO); University of Perugia; Istituto Superiore di Sanita (ISS); Sapienza University Rome	Pelicci, PG (corresponding author), European Inst Oncol, Dept Expt Oncol, Via Ripamonti 435, I-20141 Milan, Italy.		Pelicci, Pier Giuseppe/AAL-6572-2020; Grignani, Francesco/AAC-2565-2022; Bonci, Desiree/K-6488-2016; Fanelli, Mirco/F-2665-2011	Bonci, Desiree/0000-0002-2472-5140; Fanelli, Mirco/0000-0002-9649-8661; NERVI, Clara/0000-0001-9341-0188				Alcalay M, 1998, MOL CELL BIOL, V18, P1084, DOI 10.1128/MCB.18.2.1084; Brown D, 1997, P NATL ACAD SCI USA, V94, P2551, DOI 10.1073/pnas.94.6.2551; CASINI T, 1998, IN PRESS ONCOGENE; Chambon P, 1996, FASEB J, V10, P940, DOI 10.1096/fasebj.10.9.8801176; DETHE H, 1991, CELL, V66, P675, DOI 10.1016/0092-8674(91)90113-D; DYCK JA, 1994, CELL, V76, P333, DOI 10.1016/0092-8674(94)90340-9; Fagioli M, 1998, ONCOGENE, V16, P2905, DOI 10.1038/sj.onc.1201811; FAGIOLI M, 1992, ONCOGENE, V7, P1083; FANELLI M, 1998, IN PRESS BLOOD; FLENGHI L, 1995, BLOOD, V85, P1871, DOI 10.1182/blood.V85.7.1871.bloodjournal8571871; GAUB MP, 1989, P NATL ACAD SCI USA, V86, P3089, DOI 10.1073/pnas.86.9.3089; GRIGNANI F, 1994, BLOOD, V83, P10; Grignani F, 1998, NATURE, V391, P815, DOI 10.1038/35901; Grignani F, 1996, EMBO J, V15, P4949, DOI 10.1002/j.1460-2075.1996.tb00875.x; GRIGNANI F, 1993, CELL, V74, P1; Grisolano JL, 1997, BLOOD, V89, P376, DOI 10.1182/blood.V89.2.376; He LZ, 1998, NAT GENET, V18, P126, DOI 10.1038/ng0298-126; KAKIZUKA A, 1991, CELL, V66, P663, DOI 10.1016/0092-8674(91)90112-C; KASTNER P, 1992, EMBO J, V11, P629, DOI 10.1002/j.1460-2075.1992.tb05095.x; KOKEN MHM, 1994, EMBO J, V13, P1073, DOI 10.1002/j.1460-2075.1994.tb06356.x; Lin RJ, 1998, NATURE, V391, P811, DOI 10.1038/35895; LIU JH, 1995, J EXP MED, V181, P1965, DOI 10.1084/jem.181.6.1965; LIZHEN H, 1997, PNAS, V94, P5302; MU ZM, 1994, MOL CELL BIOL, V14, P6858, DOI 10.1128/MCB.14.10.6858; NERVI C, 1992, CANCER RES, V52, P3687; NERVI C, 1998, IN PRESS BLOOD; PANDOLFI PP, 1991, ONCOGENE, V6, P1285; PEREZ A, 1993, EMBO J, V12, P3171, DOI 10.1002/j.1460-2075.1993.tb05986.x; Raelson JV, 1996, BLOOD, V88, P2826, DOI 10.1182/blood.V88.8.2826.bloodjournal8882826; ROGAIA D, 1995, LEUKEMIA, V9, P1467; Ruthardt M, 1997, MOL CELL BIOL, V17, P4859, DOI 10.1128/MCB.17.8.4859; Wang ZG, 1998, SCIENCE, V279, P1547; WARRELL RP, 1993, NEW ENGL J MED, V329, P177, DOI 10.1056/NEJM199307153290307; WEIS K, 1994, CELL, V76, P345, DOI 10.1016/0092-8674(94)90341-7; Yoshida H, 1996, CANCER RES, V56, P2945	35	39	40	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 4	1999	18	46					6313	6321		10.1038/sj.onc.1203029	http://dx.doi.org/10.1038/sj.onc.1203029			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	260DK	10597230				2022-12-25	WOS:000083934100015
J	Dupuy, C; Ohayon, R; Valent, A; Noel-Hudson, MS; Deme, D; Virion, A				Dupuy, C; Ohayon, R; Valent, A; Noel-Hudson, MS; Deme, D; Virion, A			Purification of a novel flavoprotein involved in the thyroid NADPH oxidase - Cloning of the porcine and human cDNAs	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT H2O2 GENERATION; PHENYLARSINE OXIDE; HYDROGEN-PEROXIDE; PLASMA-MEMBRANE; CA2+; THYROTROPIN; INHIBITION; ACTIVATION; FOLLICLES; FRACTION	Hydrogen peroxide is the final electron acceptor for the biosynthesis of thyroid hormone catalyzed by thyroperoxidase at the apical surface of thyrocytes, Pig and human thyroid plasma membrane contain a Ca2+-dependent NAD(P)H oxidase that generates H2O2 by transferring electrons from NAD(P)H to molecular oxygen. We purified from pig thyroid plasma membrane a flavoprotein which constitutes the main, if not the sole, component of the thyroid NAD(P)H oxidase, Microsequences permitted the cloning of porcine and human full-length cDNAs encoding, respectively, 1207- and 1210-amino acid proteins with a predicted molecular mass of 138 kDa (p138(Tox)). Human and porcine p138(Tox) have 86.7% identity. The strongest similarity was to a predicted polypeptide encoded by a Caenorhabditis cDNA and with rbohA, a protein involved in the Arabidopsis NADPH oxidase. p138(Tox) shows also similarity to the p65(Mox) and to the gp91(Phox) in their C-terminal region and have consensus sequences for FAD- and NADPH-binding sites. Compared with gp91(Phox), p138(Tox) shows an extended N-terminal containing two EF-hand motifs that may account for its calcium-dependent activity, whereas three of four sequences implicated in the interaction of gp91(Phox) With the p47(Phox) cytosolic factor are absent in p138(Tox). The expression of porcine p138(Tox) mRNA analyzed by Northern blot is specific of thyroid tissue and induced by cyclic AMP showing that p138(Tox) is a differentiation marker of thyrocytes. The gene of human p138(Tox) has been localized on chromosome 15q15.	Fac Pharm, INSERM, U486, Inst Signalisat & Innovat Therapeut, F-92296 Chatenay Malabry, France; Inst Gustave Roussy, Lab Cytogenet & Genet Oncol, CNRS, Unite Mixte Rech 1599, F-94805 Villejuif, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Saclay; Centre National de la Recherche Scientifique (CNRS); UNICANCER; Gustave Roussy	Virion, A (corresponding author), Fac Pharm, INSERM, U486, Inst Signalisat & Innovat Therapeut, 5 Rue Jean Baptiste Clement, F-92296 Chatenay Malabry, France.							Babior BM, 1999, BLOOD, V93, P1464, DOI 10.1182/blood.V93.5.1464.405a32_1464_1476; BJORKMAN U, 1981, J ULTRA MOL STRUCT R, V74, P105, DOI 10.1016/S0022-5320(81)80113-X; BJORKMAN U, 1984, ENDOCRINOLOGY, V115, P392; Carvalho DP, 1996, ENDOCRINOLOGY, V137, P1007, DOI 10.1210/en.137.3.1007; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; De Keulenaer GW, 1998, BIOCHEM J, V329, P653; DEME D, 1985, FEBS LETT, V186, P107, DOI 10.1016/0014-5793(85)81349-1; DEME D, 1994, BIOCHEM J, V301, P75, DOI 10.1042/bj3010075; Doussiere J, 1998, EUR J BIOCHEM, V251, P649, DOI 10.1046/j.1432-1327.1998.2510649.x; DUPUY C, 1989, EUR J BIOCHEM, V185, P597, DOI 10.1111/j.1432-1033.1989.tb15155.x; EKHOLM R, 1981, MOL CELL ENDOCRINOL, V24, P141, DOI 10.1016/0303-7207(81)90056-3; Gorin Y, 1996, EUR J BIOCHEM, V240, P807, DOI 10.1111/j.1432-1033.1996.0807h.x; Gorin Y, 1997, BIOCHEM J, V321, P383, DOI 10.1042/bj3210383; HAYE B, 1985, MOL CELL ENDOCRINOL, V43, P41, DOI 10.1016/0303-7207(85)90040-1; Keller T, 1998, PLANT CELL, V10, P255, DOI 10.1105/tpc.10.2.255; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LECABEC V, 1995, J BIOL CHEM, V270, P2067; Leseney AM, 1999, BIOCHIMIE, V81, P373, DOI 10.1016/S0300-9084(99)80084-4; NAKAMURA Y, 1987, J BIOCHEM-TOKYO, V102, P1121, DOI 10.1093/oxfordjournals.jbchem.a122150; RASPE E, 1995, ENDOCRINOLOGY, V136, P965, DOI 10.1210/en.136.3.965; Suh YA, 1999, NATURE, V401, P79, DOI 10.1038/43459; Taurog Alvin, 1996, P47; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Valent A, 1997, EUR J HUM GENET, V5, P102, DOI 10.1159/000484742; Valent A, 1996, HUM GENET, V98, P12, DOI 10.1007/s004390050152; VIRION A, 1984, MOL CELL ENDOCRINOL, V36, P95, DOI 10.1016/0303-7207(84)90088-1; [No title captured]	28	353	370	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 24	1999	274	52					37265	37269		10.1074/jbc.274.52.37265	http://dx.doi.org/10.1074/jbc.274.52.37265			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	267WR	10601291	hybrid			2022-12-25	WOS:000084382700062
J	Luo, DC; Guerin, E; Ludwig, MG; Stoll, I; Basset, P; Anglard, P				Luo, DC; Guerin, E; Ludwig, MG; Stoll, I; Basset, P; Anglard, P			Transcriptional induction of stromelysin-3 in mesodermal cells is mediated by an upstream CCAAT/enhancer-binding protein element associated with a DNase I-hypersensitive site	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOUSE MAMMARY-GLAND; MATRIX METALLOPROTEINASE; GENE-EXPRESSION; BREAST-CANCER; MESSENGER-RNA; C/EBP-BETA; POSTTRANSCRIPTIONAL REGULATION; TISSUE INHIBITOR; RETINOIC ACID; AP-1	Stromelysin-3 (ST3) is a matrix metalloproteinase whose synthesis is markedly increased in stromal fibroblasts of most invasive human carcinomas. In the present study, we have investigated the molecular mechanisms by which high levels of ST3 expression can be induced. In contrast to the early and transient induction of interstitial collagenase by 12-O-tetradecanoylphorbol-13-acetate (TPA), the fibroblastic induction of ST3 was found to be delayed and to require protein neosynthesis. We demonstrated that this induction is transcriptional and does not result from changes in RNA stability. By looking next to promoter regions accessible to DNase I upon gene induction, we have identified two distal elements and have characterized their role in the transcriptional regulation of ST3. The first one is a TPA-responsive element that controls the base-line ST3 promoter activity but is not required for its activation. We demonstrate that ST3 gene induction is actually mediated by the second element, a C/EBP-binding site, by showing: (i) that this element becomes accessible in cells induced to express ST3, (ii) that endogenous C/EBP beta binds to the ST3 promoter, and (iii) that this binding leads to ST3 transcriptional activation. Our study provides new insights into the regulation of ST3 and suggests an additional role for C/EBP transcription factors in tissue remodeling processes associated with this MMP.	Univ Strasbourg 1, INSERM, CNRS,Communaute Urbaine Strasbourg, Inst Genet & Biol Mol & Cellulaire, F-67404 Illkirch Graffenstaden, France	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Anglard, P (corresponding author), Univ Strasbourg 1, INSERM, CNRS,Communaute Urbaine Strasbourg, Inst Genet & Biol Mol & Cellulaire, BP 163, F-67404 Illkirch Graffenstaden, France.	anglard@titus.u-strasbg.fr	Anglard, Patrick/M-6618-2019; Guerin, Eric/R-3426-2016	Anglard, Patrick/0000-0001-5701-441X; GUERIN, ERIC/0000-0003-1388-2834				Ahmad A, 1998, AM J PATHOL, V152, P721; Ahmad A, 1997, INT J CANCER, V73, P290, DOI 10.1002/(SICI)1097-0215(19971009)73:2<290::AID-IJC21>3.0.CO;2-I; An MR, 1996, MOL CELL BIOL, V16, P2295; ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; ANGLARD P, 1995, J BIOL CHEM, V270, P20337, DOI 10.1074/jbc.270.35.20337; Basset P, 1997, CRIT REV ONCOL HEMAT, V26, P43, DOI 10.1016/S1040-8428(97)00010-3; BASSET P, 1990, NATURE, V348, P699, DOI 10.1038/348699a0; Belaaouaj A, 1998, NAT MED, V4, P615, DOI 10.1038/nm0598-615; BELLARD M, 1989, METHOD ENZYMOL, V170, P317; Borden P, 1997, CRIT REV EUKAR GENE, V7, P159, DOI 10.1615/CritRevEukarGeneExpr.v7.i1-2.90; BUTTICE G, 1991, NUCLEIC ACIDS RES, V19, P3723, DOI 10.1093/nar/19.13.3723; Cairns BR, 1998, TRENDS BIOCHEM SCI, V23, P20, DOI 10.1016/S0968-0004(97)01160-2; Chambers AF, 1997, J NATL CANCER I, V89, P1260, DOI 10.1093/jnci/89.17.1260; Chenard MP, 1996, INT J CANCER, V69, P448, DOI 10.1002/(SICI)1097-0215(19961220)69:6<448::AID-IJC5>3.3.CO;2-4; Chinery R, 1997, J BIOL CHEM, V272, P30356, DOI 10.1074/jbc.272.48.30356; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Delany AM, 1998, J BIOL CHEM, V273, P16595, DOI 10.1074/jbc.273.26.16595; Dong ZY, 1997, CELL, V88, P801, DOI 10.1016/S0092-8674(00)81926-1; Doyle GAR, 1997, J BIOL CHEM, V272, P11840, DOI 10.1074/jbc.272.18.11840; Guerin E, 1997, J BIOL CHEM, V272, P11088; Gum R, 1997, ONCOGENE, V14, P1481, DOI 10.1038/sj.onc.1200973; Halpert I, 1996, P NATL ACAD SCI USA, V93, P9748, DOI 10.1073/pnas.93.18.9748; JONAT C, 1990, CELL, V62, P1189, DOI 10.1016/0092-8674(90)90395-U; LEFEBVRE O, 1992, J CELL BIOL, V119, P997, DOI 10.1083/jcb.119.4.997; LEFEBVRE O, 1995, DEVELOPMENT, V121, P947; Lekstrom-Himes J, 1998, J BIOL CHEM, V273, P28545, DOI 10.1074/jbc.273.44.28545; Logan SK, 1996, J BIOL CHEM, V271, P774, DOI 10.1074/jbc.271.2.774; Lotan R, 1996, FASEB J, V10, P1031, DOI 10.1096/fasebj.10.9.8801164; Mari BP, 1998, J BIOL CHEM, V273, P618, DOI 10.1074/jbc.273.1.618; MASIAKOWSKI P, 1982, NUCLEIC ACIDS RES, V10, P7895, DOI 10.1093/nar/10.24.7895; Masson R, 1998, J CELL BIOL, V140, P1535, DOI 10.1083/jcb.140.6.1535; NANBU R, 1994, MOL CELL BIOL, V14, P4920, DOI 10.1128/MCB.14.7.4920; Noel AC, 1996, J CLIN INVEST, V97, P1924, DOI 10.1172/JCI118624; Nuchprayoon I, 1997, BLOOD, V89, P4546, DOI 10.1182/blood.V89.12.4546; Okada A, 1997, J CELL BIOL, V137, P67, DOI 10.1083/jcb.137.1.67; Osada S, 1996, J BIOL CHEM, V271, P3891; OVERALL CM, 1991, J BIOL CHEM, V266, P14064; PATTERTON D, 1995, DEV BIOL, V167, P252, DOI 10.1006/dbio.1995.1021; Poli V, 1998, J BIOL CHEM, V273, P29279, DOI 10.1074/jbc.273.45.29279; RAY A, 1994, MOL CELL BIOL, V14, P4324, DOI 10.1128/MCB.14.6.4324; RODGERS WH, 1994, J CLIN INVEST, V94, P946, DOI 10.1172/JCI117461; ROUYER N, 1994, INVAS METAST, V14, P269; Sabatakos G, 1998, BIOCHEM J, V334, P205, DOI 10.1042/bj3340205; SANTAVICCA M, 1995, INT J CANCER, V64, P336, DOI 10.1002/ijc.2910640510; Schonbeck U, 1999, J EXP MED, V189, P843, DOI 10.1084/jem.189.5.843; Schroen DJ, 1996, GENE EXPRESSION, V6, P197; Singer CF, 1997, J CLIN ENDOCR METAB, V82, P1917, DOI 10.1210/jc.82.6.1917; Vayssiere BM, 1997, MOL ENDOCRINOL, V11, P1245, DOI 10.1210/me.11.9.1245; Vincenti MP, 1996, CRIT REV EUKAR GENE, V6, P391, DOI 10.1615/CritRevEukarGeneExpr.v6.i4.40; Welm AL, 1999, MOL CELL BIOL, V19, P1695; XIE B, 1994, J IMMUNOL, V152, P3637; YANGYEN HF, 1991, NEW BIOL, V3, P1206; YANKULOV K, 1995, J BIOL CHEM, V270, P23922, DOI 10.1074/jbc.270.41.23922	53	11	11	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 24	1999	274	52					37177	37185		10.1074/jbc.274.52.37177	http://dx.doi.org/10.1074/jbc.274.52.37177			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	267WR	10601280	hybrid			2022-12-25	WOS:000084382700051
J	Morillas, M; Swietnicki, W; Gambetti, P; Surewicz, WK				Morillas, M; Swietnicki, W; Gambetti, P; Surewicz, WK			Membrane environment alters the conformational structure of the recombinant human prion protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PH-DEPENDENT STABILITY; DOMAIN PRP(121-231); CULTURED-CELLS; PRP 27-30; SCRAPIE; BINDING; MPRP(23-231); CONVERSION; VESICLES; DISEASE	The prion protein (PrP) in a living cell is associated with cellular membranes. However, all previous biophysical studies with the recombinant prion protein have been performed in an aqueous solution. To determine the effect of a membrane environment on the conformational structure of PrP, we studied the interaction of the recombinant human prion protein with model lipid membranes. The protein was found to bind to acidic lipid-containing membrane vesicles. This interaction is pH-dependent and becomes particularly strong under acidic conditions. Spectroscopic data show that membrane binding of PrP results in a significant ordering of the N-terminal part of the molecule. The folded C-terminal domain, on the other hand, becomes destabilized upon binding to the membrane surface, especially at low pH. Overall, these results show that the conformational structure and stability of the recombinant human PrP in a membrane environment are substantially different from those of the free protein in solution. These observations have important implications for understanding the mechanism of the conversion between the normal (PrPC) and pathogenic (PrPSc) forms of prion protein.	Case Western Reserve Univ, Dept Pathol, Cleveland, OH 44106 USA	Case Western Reserve University	Surewicz, WK (corresponding author), Case Western Reserve Univ, Dept Pathol, 2085 Adelbert Rd, Cleveland, OH 44106 USA.		Swietnicki, Wieslaw/GOP-2576-2022; Swietnicki, Wieslaw/AAU-1536-2020; Swietnicki, Wieslaw/AAL-2452-2021	Swietnicki, Wieslaw/0000-0002-9354-8184; Morillas, Manuel/0000-0002-6489-6737	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS038604] Funding Source: NIH RePORTER; NINDS NIH HHS [NS38604] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BORCHELT DR, 1992, J BIOL CHEM, V267, P16188; Butko P, 1997, BIOCHEMISTRY-US, V36, P12862, DOI 10.1021/bi9702389; CAUGHEY B, 1991, J VIROL, V65, P6597, DOI 10.1128/JVI.65.12.6597-6603.1991; CAUGHEY BW, 1991, BIOCHEMISTRY-US, V30, P7672, DOI 10.1021/bi00245a003; Donne DG, 1997, P NATL ACAD SCI USA, V94, P13452, DOI 10.1073/pnas.94.25.13452; Ehrlich LS, 1996, BIOCHEMISTRY-US, V35, P3933, DOI 10.1021/bi952337x; ETFINK MR, 1981, ANAL BIOCHEM, V114, P199; GAJDUSEK DC, 1977, SCIENCE, V197, P943, DOI 10.1126/science.142303; Hegde RS, 1998, SCIENCE, V279, P827, DOI 10.1126/science.279.5352.827; Hornemann S, 1996, J MOL BIOL, V261, P614, DOI 10.1006/jmbi.1996.0487; Hornemann S, 1997, FEBS LETT, V413, P277, DOI 10.1016/S0014-5793(97)00921-6; Hornemann S, 1998, P NATL ACAD SCI USA, V95, P6010, DOI 10.1073/pnas.95.11.6010; Jackson GS, 1999, SCIENCE, V283, P1935, DOI 10.1126/science.283.5409.1935; James TL, 1997, P NATL ACAD SCI USA, V94, P10086, DOI 10.1073/pnas.94.19.10086; Kelly JW, 1998, P NATL ACAD SCI USA, V95, P930, DOI 10.1073/pnas.95.3.930; LEHMANN S, 1995, J BIOL CHEM, V270, P24589, DOI 10.1074/jbc.270.41.24589; Lehmann S, 1996, J BIOL CHEM, V271, P1633, DOI 10.1074/jbc.271.3.1633; Liemann S, 1999, BIOCHEMISTRY-US, V38, P3258, DOI 10.1021/bi982714g; MCLAUGHLIN S, 1995, TRENDS BIOCHEM SCI, V20, P272, DOI 10.1016/S0968-0004(00)89042-8; MEYER RK, 1986, P NATL ACAD SCI USA, V83, P2310, DOI 10.1073/pnas.83.8.2310; MOSIOR M, 1991, BIOPHYS J, V60, P149, DOI 10.1016/S0006-3495(91)82038-0; MUGA A, 1993, J BIOL CHEM, V268, P1553; MUGA A, 1991, BIOCHEMISTRY-US, V30, P7219, DOI 10.1021/bi00243a025; OESCH B, 1985, CELL, V40, P735, DOI 10.1016/0092-8674(85)90333-2; PAN KM, 1993, P NATL ACAD SCI USA, V90, P10962, DOI 10.1073/pnas.90.23.10962; Petersen RB, 1996, J BIOL CHEM, V271, P12661, DOI 10.1074/jbc.271.21.12661; Pinheiro TJT, 1997, BIOCHEMISTRY-US, V36, P13122, DOI 10.1021/bi971235z; PRUSINER SB, 1982, SCIENCE, V216, P136, DOI 10.1126/science.6801762; Prusiner SB, 1998, P NATL ACAD SCI USA, V95, P13363, DOI 10.1073/pnas.95.23.13363; Riek R, 1997, FEBS LETT, V413, P282, DOI 10.1016/S0014-5793(97)00920-4; Riek R, 1996, NATURE, V382, P180, DOI 10.1038/382180a0; SAFAR J, 1993, PROTEIN SCI, V2, P2206, DOI 10.1002/pro.5560021220; SAFAR J, 1991, J INFECT DIS, V163, P488, DOI 10.1093/infdis/163.3.488; Shin I, 1997, P NATL ACAD SCI USA, V94, P2848, DOI 10.1073/pnas.94.7.2848; STAHL N, 1993, BIOCHEMISTRY-US, V32, P1991, DOI 10.1021/bi00059a016; STAHL N, 1990, BIOCHEMISTRY-US, V29, P5405, DOI 10.1021/bi00474a028; STAHL N, 1987, CELL, V51, P229, DOI 10.1016/0092-8674(87)90150-4; SUREWICZ WK, 1984, BIOCHEMISTRY-US, V23, P6072, DOI 10.1021/bi00320a026; Swietnicki W, 1998, J BIOL CHEM, V273, P31048, DOI 10.1074/jbc.273.47.31048; Swietnicki W, 1997, J BIOL CHEM, V272, P27517, DOI 10.1074/jbc.272.44.27517; Tatulian SA, 1997, J MOL BIOL, V268, P809, DOI 10.1006/jmbi.1997.1014; Viles JH, 1999, P NATL ACAD SCI USA, V96, P2042, DOI 10.1073/pnas.96.5.2042; Weissmann C, 1996, FEBS LETT, V389, P3, DOI 10.1016/0014-5793(96)00610-2; Zahn R, 1997, FEBS LETT, V417, P400, DOI 10.1016/S0014-5793(97)01330-6; Zhang H, 1997, BIOCHEMISTRY-US, V36, P3543, DOI 10.1021/bi961965r	45	227	231	0	24	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 24	1999	274	52					36859	36865		10.1074/jbc.274.52.36859	http://dx.doi.org/10.1074/jbc.274.52.36859			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	267WR	10601237	hybrid			2022-12-25	WOS:000084382700008
J	Ohtaki, T; Kumano, S; Ishibashi, Y; Ogi, K; Matsui, H; Harada, M; Kitada, C; Kurokawa, T; Onda, H; Fujino, M				Ohtaki, T; Kumano, S; Ishibashi, Y; Ogi, K; Matsui, H; Harada, M; Kitada, C; Kurokawa, T; Onda, H; Fujino, M			Isolation and cDNA cloning of a novel galanin-like peptide (GALP) from porcine hypothalamus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR-CLONING; CLONED HUMAN; RECEPTOR; RAT; EXPRESSION; IDENTIFICATION; INTESTINE; SEQUENCE; CELLS	Galanin is a widely distributed neuropeptide with a variety of physiological functions. Three galanin receptor subtypes, GALR1, GALR2, and GALR3, have been reported. We isolated a novel galanin-like peptide (GALP) from porcine hypothalamus by observing its activity for increasing [S-35]GTP gamma S binding to a membrane preparation of GALR2-transfected cells. The peptide had 60 amino acid residues and a non-amidated C terminus. The amino acid sequence of GALP-(9-21) was completely identical to that of galanin-(1-13). A cloned porcine GALP cDNA indicated that GALP was processed from a 120-amino acid GALP precursor protein. The structures of rat and human GALP-(1-60) were deduced from cloned cDNA, which indicated that the amino acid sequences 1-24 and 41-53 were highly conserved between humans, rats, and pigs. Receptor binding studies revealed that porcine GALP-(1-60) had a high affinity for the GALR2 receptor (IC50 = 0.24 nM) and a lower affinity for the GALR1 receptor (IC50 = 4.3 nM). In contrast, galanin showed high affinity for the GALR1 (IC50 = 0.097 nM) and GALR2 receptors (IC50 = 0.48 nM). GALP is therefore an endogenous ligand that preferentially binds the GALR2 receptor, whereas galanin is relatively non-selective.	Takeda Chem Ind Ltd, Pharmaceut Discovery Res Div, Discovery Res Labs 1, Tsukuba, Ibaraki 3004293, Japan; Takeda Chem Ind Ltd, Pharmaceut Discovery Res Div, Discovery Res Labs 3, Yodogawa Ku, Osaka 5328686, Japan; Takeda Chem Ind Ltd, Chuo Ku, Osaka 5408645, Japan	Takeda Chemical Industries; Takeda Chemical Industries; Takeda Chemical Industries	Ohtaki, T (corresponding author), Takeda Chem Ind Ltd, Pharmaceut Discovery Res Div, Discovery Res Labs 1, Wadai 10, Tsukuba, Ibaraki 3004293, Japan.							BARTFAI T, 1993, CRIT REV NEUROBIOL, V7, P229; BELL GI, 1983, NATURE, V302, P716, DOI 10.1038/302716a0; CRAWLEY JN, 1995, REGUL PEPTIDES, V59, P1, DOI 10.1016/0167-0115(95)00083-N; EVANS HF, 1991, ENDOCRINOLOGY, V129, P1682, DOI 10.1210/endo-129-3-1682; HABERTORTOLI E, 1994, P NATL ACAD SCI USA, V91, P9780, DOI 10.1073/pnas.91.21.9780; Howard AD, 1997, FEBS LETT, V405, P285, DOI 10.1016/S0014-5793(97)00196-8; Kolakowski LF, 1998, J NEUROCHEM, V71, P2239; Kozak M, 1996, MAMM GENOME, V7, P563, DOI 10.1007/s003359900171; Masuda Y, 1996, J PHARMACOL EXP THER, V279, P675; Nielsen H, 1997, PROTEIN ENG, V10, P1, DOI 10.1093/protein/10.1.1; Ohtaki T, 1998, J BIOL CHEM, V273, P15464, DOI 10.1074/jbc.273.25.15464; Parker EM, 1995, MOL BRAIN RES, V34, P179, DOI 10.1016/0169-328X(95)00159-P; ROKAEUS A, 1984, NEUROSCI LETT, V47, P161, DOI 10.1016/0304-3940(84)90423-3; ROKAEUS A, 1986, P NATL ACAD SCI USA, V83, P6287, DOI 10.1073/pnas.83.17.6287; SILLARD R, 1992, PEPTIDES, V13, P1055, DOI 10.1016/0196-9781(92)90005-N; Smith KE, 1997, J BIOL CHEM, V272, P24612, DOI 10.1074/jbc.272.39.24612; Smith KE, 1998, J BIOL CHEM, V273, P23321, DOI 10.1074/jbc.273.36.23321; TATEMOTO K, 1983, FEBS LETT, V164, P124, DOI 10.1016/0014-5793(83)80033-7; VRONTAKIS ME, 1987, J BIOL CHEM, V262, P16755; Wang SK, 1997, J BIOL CHEM, V272, P31949, DOI 10.1074/jbc.272.51.31949; Wang ZL, 1997, J CLIN INVEST, V100, P189, DOI 10.1172/JCI119512	21	225	239	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 24	1999	274	52					37041	37045		10.1074/jbc.274.52.37041	http://dx.doi.org/10.1074/jbc.274.52.37041			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	267WR	10601261	hybrid			2022-12-25	WOS:000084382700032
J	Giannoukos, G; Silverstein, AM; Pratt, WB; Simons, SS				Giannoukos, G; Silverstein, AM; Pratt, WB; Simons, SS			The seven amino acids (547-553) of rat glucocorticoid receptor required for steroid and hsp90 binding contain a functionally independent LXXLL motif that is critical for steroid binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK-PROTEIN; CARBOXYL-TERMINAL REGIONS; NUCLEAR-RECEPTOR; ANDROGEN RECEPTOR; PROGESTERONE-RECEPTOR; MOLECULAR CHAPERONES; RETINOIC ACID; DOMAIN; ACTIVATION; CELLS	Hsp90 association with glucocorticoid receptors (GRs) is required for steroid binding. We recently reported that seven amino acids (547-553) overlapping the aminoterminal end of the rat GR ligand-binding domain are necessary for hsp90 binding, and consequently steroid binding. The role of a LXXLL motif at the COOH terminus of this sequence has now been analyzed by determining the properties of Leu to Ser mutations in full-length GR and glutathione S-transferase chimeras. Surprisingly, these mutations decreased steroid binding capacity without altering receptor levels, steroid binding affinity, or hsp90 binding. Single mutations in the context of the full-length receptor did not affect the transcriptional activity but the double mutant (L550S/L553S) was virtually inactive. This biological inactivity was found to be due to an increased rate of steroid dissociation from the activated mutant complex, These results, coupled with those from trypsin digestion studies, suggest a model in which the GR ligand-binding domain is viewed as having a "hinged pocket," with the hinge being in the region of the trypsin digestion site at Arg(651). The pocket would normally be kept shut via the intramolecular interactions of the LXXLL motif at amino acids 550-554 acting as a hydrophobic clasp.	NIDDK, LMCB, Steroid Hormones Sect, NIH, Bethesda, MD 20892 USA; Univ Michigan, Sch Med, Dept Pharmacol, Ann Arbor, MI 48109 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); University of Michigan System; University of Michigan	Simons, SS (corresponding author), NIDDK, LMCB, Steroid Hormones Sect, NIH, Bldg 8,Rm B2A-07, Bethesda, MD 20892 USA.				NIDDK NIH HHS [DK31573] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK031573, R37DK031573, Z01DK057800] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BENHAMOU B, 1992, SCIENCE, V255, P206, DOI 10.1126/science.1372753; BRESNICK EH, 1989, J BIOL CHEM, V264, P4992; Caamano CA, 1998, J BIOL CHEM, V273, P20473, DOI 10.1074/jbc.273.32.20473; CADEPOND F, 1991, J BIOL CHEM, V266, P5834; CHAKRABORTI PK, 1991, J BIOL CHEM, V266, P22075; DALMAN FC, 1991, J BIOL CHEM, V266, P3482; DANZE P M, 1990, Steroids, V55, P10, DOI 10.1016/0039-128X(90)90067-L; deCastro M, 1996, MOL MED, V2, P597, DOI 10.1007/BF03401643; Ding XF, 1998, MOL ENDOCRINOL, V12, P302, DOI 10.1210/me.12.2.302; Dittmar KD, 1996, J BIOL CHEM, V271, P12833, DOI 10.1074/jbc.271.22.12833; Doesburg P, 1997, BIOCHEMISTRY-US, V36, P1052, DOI 10.1021/bi961775g; Enmark E, 1996, MOL ENDOCRINOL, V10, P1293, DOI 10.1210/me.10.11.1293; Freeman BC, 1996, EMBO J, V15, P2969, DOI 10.1002/j.1460-2075.1996.tb00660.x; GIGUERE V, 1987, NATURE, V330, P624, DOI 10.1038/330624a0; Hartl FU, 1996, NATURE, V381, P571, DOI 10.1038/381571a0; Heery DM, 1997, NATURE, V387, P733, DOI 10.1038/42750; HOECK W, 1989, J BIOL CHEM, V264, P14396; HOWARD KJ, 1990, J BIOL CHEM, V265, P11928; HUANG Y, 1999, IN PRESS MOL CELL EN; Ikonen T, 1997, J BIOL CHEM, V272, P29821, DOI 10.1074/jbc.272.47.29821; IniguezLluhi JA, 1997, J BIOL CHEM, V272, P4149, DOI 10.1074/jbc.272.7.4149; KAINE JL, 1975, MOL PHARMACOL, V11, P578; Kraus WL, 1995, P NATL ACAD SCI USA, V92, P12314, DOI 10.1073/pnas.92.26.12314; Langley E, 1998, J BIOL CHEM, V273, P92, DOI 10.1074/jbc.273.1.92; LEE SY, 1995, MOL ENDOCRINOL, V9, P826, DOI 10.1210/me.9.7.826; MANGELSDORF DJ, 1995, CELL, V83, P841, DOI 10.1016/0092-8674(95)90200-7; MATTIONI T, 1994, METHOD CELL BIOL, V43, P335; McInerney EM, 1996, P NATL ACAD SCI USA, V93, P10069, DOI 10.1073/pnas.93.19.10069; MIESFELD R, 1986, CELL, V46, P389, DOI 10.1016/0092-8674(86)90659-8; MILHON J, 1994, J STEROID BIOCHEM, V51, P11, DOI 10.1016/0960-0760(94)90110-4; Modarress KJ, 1997, J BIOL CHEM, V272, P23986, DOI 10.1074/jbc.272.38.23986; MOGUILEWSKY M, 1984, J STEROID BIOCHEM, V20, P271, DOI 10.1016/0022-4731(84)90216-4; PAKDEL F, 1993, J STEROID BIOCHEM, V46, P663, DOI 10.1016/0960-0760(93)90307-I; POWERS JH, 1993, CANCER RES, V53, P4059; Pratt WB, 1997, ENDOCR REV, V18, P306, DOI 10.1210/er.18.3.306; Pratt WB, 1997, ANNU REV PHARMACOL, V37, P297, DOI 10.1146/annurev.pharmtox.37.1.297; PRATT WB, 1993, STEROID HORMONE ACTI, P64; RENAUD JP, 1995, NATURE, V378, P681, DOI 10.1038/378681a0; Ruddon RW, 1997, J BIOL CHEM, V272, P3125, DOI 10.1074/jbc.272.6.3125; SCHERRER LC, 1990, J BIOL CHEM, V265, P21397; SCHMIDT TJ, 1982, PHYSIOL REV, V62, P1131, DOI 10.1152/physrev.1982.62.4.1131; SCHMIDT TJ, 1980, NATURE, V286, P507, DOI 10.1038/286507a0; SCHOWALTER DB, 1991, J BIOL CHEM, V266, P21165; SHYAMALA G, 1980, J BIOL CHEM, V255, P6028; SIMONS SS, 1984, BIOCHEMISTRY-US, V23, P6876, DOI 10.1021/bi00321a092; SIMONS SS, 1989, J BIOL CHEM, V264, P11493; SIMONS SS, 1994, VITAM HORM, V48, P49; Stancato LF, 1996, J BIOL CHEM, V271, P8831, DOI 10.1074/jbc.271.15.8831; SZAPARY D, 1993, MOL ENDOCRINOL, V7, P941, DOI 10.1210/me.7.8.941; Tetel MJ, 1997, MOL ENDOCRINOL, V11, P1114, DOI 10.1210/me.11.8.1114; Torchia J, 1997, NATURE, V387, P677, DOI 10.1038/42652; Williams SP, 1998, NATURE, V393, P392, DOI 10.1038/30775; Wurtz JM, 1996, NAT STRUCT BIOL, V3, P87, DOI 10.1038/nsb0196-87; Xu M, 1999, MOL CELL ENDOCRINOL, V155, P85, DOI 10.1016/S0303-7207(99)00110-0; Xu M, 1998, J BIOL CHEM, V273, P13918, DOI 10.1074/jbc.273.22.13918; Xu M, 1996, J BIOL CHEM, V271, P21430, DOI 10.1074/jbc.271.35.21430; Zhu XT, 1996, SCIENCE, V272, P1606, DOI 10.1126/science.272.5268.1606	57	41	42	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 17	1999	274	51					36527	36536		10.1074/jbc.274.51.36527	http://dx.doi.org/10.1074/jbc.274.51.36527			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	266AV	10593951	hybrid			2022-12-25	WOS:000084279200070
J	Glenn, DJ; Maurer, RA				Glenn, DJ; Maurer, RA			MRG1 binds to the LIM domain of Lhx2 and may function as a coactivator to stimulate glycoprotein hormone alpha-subunit gene expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GONADOTROPIN-RELEASING-HORMONE; MESSENGER RIBONUCLEIC-ACID; TRANSCRIPTIONAL ACTIVATION DOMAIN; LOOP-HELIX PROTEINS; LUTEINIZING-HORMONE; HOMEODOMAIN PROTEINS; ESCHERICHIA-COLI; 2-HYBRID SYSTEM; MAMMALIAN-CELLS; INTERACTOR NLI	Tissue-specific expression of the cr-subunit gene of glycoprotein hormones involves an enhancer element designated the pituitary glycoprotein basal element, which interacts with the LIM homeodomain transcription factor, Lhx2, In the present studies we have explored the function of the LIM domain of Lhx2 in stimulating ct-subunit transcription. When fused to the GAL4 DNA-binding domain, the LIM domain of Lhx2 was shown to contain a transcriptional activation domain. Furthermore, in the context of an cu-subunit reporter gene in which a GAL4-binding site replaced the pituitary glycoprotein basal element, the LIM domain enhanced both basal and Ras-mediated transcription. In addition, a synergistic response to Ras activation was observed when the Lhx2 LIM domain and the transactivation domain of Elk1 are directed to a minimal reporter gene. A yeast two-hybrid screen identified the recently described melanocyte-specific gene-related gene 1 (MRG1) as an Lhx2 LIM-interacting protein. MRG1 was shown to bind Lhx2 in vitro, and a co-immunoprecipitation assay provided evidence that endogenous MRG1 forms a complex with Lhx2 in alpha T3-1 cells. Expression of MRG1 in alpha T3-1 cells enhanced cr-subunit reporter gene activity. MRG1 was also shown to bind in vitro to the TATA-binding protein and the transcriptional coactivator, p300. These data suggest a model in which the Lhx2 LIM domain activates transcription through interaction with MRG1 leading to recruitment of p300/CBP and the TATA-binding protein.	Oregon Hlth Sci Univ, Dept Cell & Dev Biol, Portland, OR 97201 USA	Oregon Health & Science University	Maurer, RA (corresponding author), Oregon Hlth Sci Univ, Dept Cell & Dev Biol, 3181 SW Sam Jackson Pk Rd, Portland, OR 97201 USA.				NIDDK NIH HHS [DK36407] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK036407] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Agulnick AD, 1996, NATURE, V384, P270, DOI 10.1038/384270a0; Akimaru H, 1997, NATURE, V386, P735, DOI 10.1038/386735a0; ANDREWS WV, 1988, J BIOL CHEM, V263, P13755; Arber S, 1996, GENE DEV, V10, P289, DOI 10.1101/gad.10.3.289; ARBER S, 1994, CELL, V79, P221, DOI 10.1016/0092-8674(94)90192-9; ARCHER VEV, 1994, P NATL ACAD SCI USA, V91, P316, DOI 10.1073/pnas.91.1.316; BACH I, 1995, P NATL ACAD SCI USA, V92, P2720, DOI 10.1073/pnas.92.7.2720; Bach I, 1997, GENE DEV, V11, P1370, DOI 10.1101/gad.11.11.1370; BEDOUELLE H, 1988, EUR J BIOCHEM, V171, P541, DOI 10.1111/j.1432-1033.1988.tb13823.x; Bhattacharya S, 1999, GENE DEV, V13, P64, DOI 10.1101/gad.13.1.64; Bisotto S, 1996, J BIOL CHEM, V271, P17746, DOI 10.1074/jbc.271.30.17746; Breen JJ, 1998, J BIOL CHEM, V273, P4712, DOI 10.1074/jbc.273.8.4712; BURRIN JM, 1989, MOL ENDOCRINOL, V3, P1643, DOI 10.1210/mend-3-10-1643; CHIEN CT, 1991, P NATL ACAD SCI USA, V88, P9578, DOI 10.1073/pnas.88.21.9578; DALKIN AC, 1989, ENDOCRINOLOGY, V125, P917, DOI 10.1210/endo-125-2-917; Dawid IB, 1998, TRENDS GENET, V14, P156, DOI 10.1016/S0168-9525(98)01424-3; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; Dunwoodie SL, 1998, MECH DEVELOP, V72, P27, DOI 10.1016/S0925-4773(98)00011-2; Fernandez-Funez P, 1998, EMBO J, V17, P6846, DOI 10.1093/emboj/17.23.6846; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; FREYD G, 1990, NATURE, V344, P876, DOI 10.1038/344876a0; GERMAN MS, 1992, GENE DEV, V6, P2165, DOI 10.1101/gad.6.11.2165; GIOVANE A, 1994, GENE DEV, V8, P1502, DOI 10.1101/gad.8.13.1502; GONG ZY, 1994, BIOCHEMISTRY-US, V33, P15149, DOI 10.1021/bi00254a026; HAMERNIK DL, 1988, ENDOCRINOLOGY, V122, P959, DOI 10.1210/endo-122-3-959; HOLLENBERG SM, 1995, MOL CELL BIOL, V15, P3813; JANKNECHT R, 1993, EMBO J, V12, P5097, DOI 10.1002/j.1460-2075.1993.tb06204.x; Johnson JD, 1997, MOL CELL BIOL, V17, P3488, DOI 10.1128/MCB.17.7.3488; Jurata LW, 1998, J BIOL CHEM, V273, P3152, DOI 10.1074/jbc.273.6.3152; Jurata LW, 1998, CURR TOP MICROBIOL, V228, P75; Jurata LW, 1996, P NATL ACAD SCI USA, V93, P11693, DOI 10.1073/pnas.93.21.11693; Jurata LW, 1997, MOL CELL BIOL, V17, P5688, DOI 10.1128/MCB.17.10.5688; KARLSSON O, 1990, NATURE, V344, P879, DOI 10.1038/344879a0; KING Y, 1997, MOL CELL BIOL, V17, P4750; Konrat R, 1997, J BIOL CHEM, V272, P12001, DOI 10.1074/jbc.272.18.12001; KWOK RPS, 1994, NATURE, V370, P223, DOI 10.1038/370223a0; LALLOZ MRA, 1988, ENDOCRINOLOGY, V122, P1681, DOI 10.1210/endo-122-4-1681; LEUNG K, 1987, MOL ENDOCRINOL, V1, P724, DOI 10.1210/mend-1-10-724; MACGREGOR GR, 1989, NUCLEIC ACIDS RES, V17, P2365, DOI 10.1093/nar/17.6.2365; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; Meier BC, 1999, MOL CELL ENDOCRINOL, V147, P65, DOI 10.1016/S0303-7207(98)00213-5; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; Milan M, 1998, GENE DEV, V12, P2912, DOI 10.1101/gad.12.18.2912; MORCILLO P, 1997, GENE DEV, V11, P2720; PAPAVASILIOU SS, 1986, P NATL ACAD SCI USA, V83, P4026, DOI 10.1073/pnas.83.11.4026; Parker D, 1998, MOL CELL, V2, P353, DOI 10.1016/S1097-2765(00)80279-8; PerezAlvarado GC, 1996, J MOL BIOL, V257, P153, DOI 10.1006/jmbi.1996.0153; Radhakrishnan I, 1997, CELL, V91, P741, DOI 10.1016/S0092-8674(00)80463-8; Richards JP, 1996, J BIOL CHEM, V271, P13716, DOI 10.1074/jbc.271.23.13716; ROBERSON MS, 1995, MOL CELL BIOL, V15, P3531; ROBERSON MS, 1994, MOL CELL BIOL, V14, P2985, DOI 10.1128/MCB.14.5.2985; SANCHEZGARCIA I, 1993, EMBO J, V12, P4243, DOI 10.1002/j.1460-2075.1993.tb06108.x; SCHNEIKERT J, 1992, ONCOGENE, V7, P249; SCHODERBEK WE, 1992, MOL ENDOCRINOL, V6, P893, DOI 10.1210/me.6.6.893; SCHODERBEK WE, 1993, J BIOL CHEM, V268, P3903; Sharma K, 1998, CELL, V95, P817, DOI 10.1016/S0092-8674(00)81704-3; Sheng HZ, 1996, SCIENCE, V272, P1004, DOI 10.1126/science.272.5264.1004; SHIH C, 1982, CELL, V29, P161, DOI 10.1016/0092-8674(82)90100-3; Shioda T, 1998, P NATL ACAD SCI USA, V95, P9785, DOI 10.1073/pnas.95.17.9785; Shioda T, 1997, GENE, V204, P235, DOI 10.1016/S0378-1119(97)00551-9; SHUPNIK MA, 1990, MOL ENDOCRINOL, V4, P1444, DOI 10.1210/mend-4-10-1444; STANLEY HF, 1988, MOL ENDOCRINOL, V2, P1302, DOI 10.1210/mend-2-12-1302; SUN PQ, 1994, GENE DEV, V8, P2527, DOI 10.1101/gad.8.21.2527; Swope DL, 1996, J BIOL CHEM, V271, P28138, DOI 10.1074/jbc.271.45.28138; TAIRA M, 1992, GENE DEV, V6, P356, DOI 10.1101/gad.6.3.356; TAIRA M, 1994, NATURE, V372, P677, DOI 10.1038/372677a0; Wadman IA, 1997, EMBO J, V16, P3145, DOI 10.1093/emboj/16.11.3145; WAY JC, 1988, CELL, V54, P5, DOI 10.1016/0092-8674(88)90174-2; WIERMAN ME, 1989, ENDOCRINOLOGY, V124, P272, DOI 10.1210/endo-124-1-272; WINDLE JJ, 1990, MOL ENDOCRINOL, V4, P597, DOI 10.1210/mend-4-4-597; Yang BS, 1996, MOL CELL BIOL, V16, P538	71	89	94	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 17	1999	274	51					36159	36167		10.1074/jbc.274.51.36159	http://dx.doi.org/10.1074/jbc.274.51.36159			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	266AV	10593900	hybrid			2022-12-25	WOS:000084279200019
J	Roura, S; Miravet, S; Piedra, J; de Herreros, AG; Dunach, M				Roura, S; Miravet, S; Piedra, J; de Herreros, AG; Dunach, M			Regulation of E-cadherin/catenin association by tyrosine phosphorylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL GROWTH-FACTOR; BETA-CATENIN; CELL-ADHESION; FACTOR RECEPTOR; CARCINOMA-CELLS; ALPHA-CATENIN; COMPLEX; PROTEIN; KINASE; SUBSTRATE	Alteration of cadherin-mediated cell-cell adhesion is frequently associated to tyrosine phosphorylation of p120- and beta-catenins. We have examined the role of this modification in these proteins in the control of beta-catenin/E-cadherin binding using in vitro assays with recombinant proteins. Recombinant pp60(c-src) efficiently phosphorylated both catenins in vitro, with stoichiometries of 1.5 and 2.0 mol of phosphate/mol of protein for beta-catenin and p120-catenin, respectively. pp60(c-src) phosphorylation had opposing effects on the affinities of beta-catenin and p120 for the cytosolic domain of E-cadherin; it decreased tin the case of beta-catenin) or increased (for p120) catenin/E-cadherin binding. How ever, a role for p120-catenin in the modulation of beta-catenin/E-cadherin binding was not observed, since addition of phosphorylated p120-catenin did not modify the affinity of phosphorylated (or unphosphorylated) beta-catenin far E-cadherin, The phosphorylated Tyr residues were identified as Tyr-86 and Tyr-654. Experiments using point mutants in these two residues indicated that, although Tyr-86 was a better substrate for pp60(c-src), only modification of Tyr-654 was relevant for the interaction with E-cadherin. Transient transfections of different mutants demonstrated that Tyr-654 is phosphorylated in conditions in which adherens junctions are disrupted and evidenced that binding of beta-catenin to E-cadherin in vivo is controlled by phosphorylation of beta-catenin Tyr-654.	Univ Pompeu Fabra, Inst Municipal Invest Med, Unitat Biol Cellular & Mol, Barcelona 08003, Spain; Univ Autonoma Barcelona, Fac Med, Dept Bioquim & Biol Mol, Unitat Biofis, Bellaterra 08193, Spain	Pompeu Fabra University; Autonomous University of Barcelona	de Herreros, AG (corresponding author), Univ Pompeu Fabra, Inst Municipal Invest Med, Unitat Biol Cellular & Mol, C Dr Aiguader 80, Barcelona 08003, Spain.		Dunach, Mireia/E-3604-2015; de Herreros, A Garcia/H-3104-2014	Dunach, Mireia/0000-0001-9844-5603; de Herreros, A Garcia/0000-0001-5270-0808; Roura, Santiago/0000-0003-4063-9661				ABERLE H, 1994, J CELL SCI, V107, P3655; BARTH AI, 1997, CURR OPIN CELL BIOL, V9, P693; BEHRENS J, 1993, J CELL BIOL, V120, P757, DOI 10.1083/jcb.120.3.757; COOPER JA, 1984, J BIOL CHEM, V259, P7835; Cowin P, 1996, CURR OPIN CELL BIOL, V8, P56, DOI 10.1016/S0955-0674(96)80049-4; Daniel JM, 1997, BIOESSAYS, V19, P883, DOI 10.1002/bies.950191008; DOWNING JR, 1991, ONCOGENE, V6, P607; Fujii K, 1996, EXP CELL RES, V223, P50, DOI 10.1006/excr.1996.0057; HOSCHUETZKY H, 1994, J CELL BIOL, V127, P1375, DOI 10.1083/jcb.127.5.1375; Huber AH, 1997, CELL, V90, P871, DOI 10.1016/S0092-8674(00)80352-9; HULSKEN J, 1994, J CELL BIOL, V127, P2061, DOI 10.1083/jcb.127.6.2061; Johnson TM, 1997, J PEPT RES, V50, P365; KANNER SB, 1991, MOL CELL BIOL, V11, P713, DOI 10.1128/MCB.11.2.713; KINCH MS, 1995, J CELL BIOL, V130, P461, DOI 10.1083/jcb.130.2.461; MCCREA PD, 1991, J BIOL CHEM, V266, P4514; McMurray JS, 1998, ARCH BIOCHEM BIOPHYS, V355, P124, DOI 10.1006/abbi.1998.0707; NAGAFUCHI A, 1989, CELL REGUL, V1, P37, DOI 10.1091/mbc.1.1.37; Obama H, 1997, J BIOL CHEM, V272, P11017; Ozawa M, 1998, J BIOL CHEM, V273, P6166, DOI 10.1074/jbc.273.11.6166; PEIFER M, 1994, CELL, V76, P789, DOI 10.1016/0092-8674(94)90353-0; REYNOLDS AB, 1994, MOL CELL BIOL, V14, P8333, DOI 10.1128/MCB.14.12.8333; Rosato R, 1998, MOL CELL BIOL, V18, P5762, DOI 10.1128/MCB.18.10.5762; RUBINFELD B, 1993, SCIENCE, V262, P1731, DOI 10.1126/science.8259518; SHIBAMOTO S, 1994, CELL ADHES COMMUN, V1, P295, DOI 10.3109/15419069409097261; Shibata T, 1996, ONCOGENE, V13, P883; Skoudy A, 1996, BIOCHEM J, V317, P279, DOI 10.1042/bj3170279; STADDON JM, 1995, J CELL SCI, V108, P609; STAPPERT J, 1994, CELL ADHES COMMUN, V2, P319, DOI 10.3109/15419069409014207; SU LK, 1993, SCIENCE, V262, P1734, DOI 10.1126/science.8259519; Takeda H, 1995, J CELL BIOL, V131, P1839, DOI 10.1083/jcb.131.6.1839; Takeichi M, 1993, CURR OPIN CELL BIOL, V5, P806, DOI 10.1016/0955-0674(93)90029-P; TSUKITA S, 1991, J CELL BIOL, V113, P867, DOI 10.1083/jcb.113.4.867; UEHARA Y, 1989, BIOCHEM BIOPH RES CO, V163, P803, DOI 10.1016/0006-291X(89)92293-6; VOLBERG T, 1992, EMBO J, V11, P1733, DOI 10.1002/j.1460-2075.1992.tb05225.x; Yap AS, 1998, J CELL BIOL, V141, P779, DOI 10.1083/jcb.141.3.779	35	490	502	1	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 17	1999	274	51					36734	36740		10.1074/jbc.274.51.36734	http://dx.doi.org/10.1074/jbc.274.51.36734			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	266AV	10593980	hybrid			2022-12-25	WOS:000084279200099
J	Yokosaki, Y; Matsuura, N; Sasaki, T; Murakami, I; Schneider, H; Higashiyama, S; Saitoh, Y; Yamakido, M; Taooka, Y; Sheppard, D				Yokosaki, Y; Matsuura, N; Sasaki, T; Murakami, I; Schneider, H; Higashiyama, S; Saitoh, Y; Yamakido, M; Taooka, Y; Sheppard, D			The integrin alpha(9)beta(1) binds to a novel recognition sequence (SVVYGLR) in the thrombin-cleaved amino-terminal fragment of osteopontin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEOPLASTIC TRANSFORMATION; ALPHA(4)BETA(1) INTEGRIN; EPITHELIAL INTEGRINS; POTENTIAL ROLES; CELL ATTACHMENT; SMOOTH-MUSCLE; III REPEAT; TENASCIN; EXPRESSION; ADHESION		Natl Hiroshima Hosp, Dept Internal Med, Higashihiroshima 7390041, Japan; Natl Hiroshima Hosp, Dept Neurosurg, Higashihiroshima 7390041, Japan; Natl Hiroshima Hosp, Dept Lab Med, Higashihiroshima 7390041, Japan; Osaka Univ, Sch Allied Hlth Sci, Dept Pathol, Suita, Osaka 5650871, Japan; Osaka Univ, Fac Med, Dept Biochem, Suita, Osaka 5650871, Japan; Univ London Imperial Coll Sci Technol & Med, Gene Therapy Res Grp, Mol Genet Sect, Div Biomed Sci, London SW7 2AZ, England; Kumamoto Univ, Sch Med, Dept Neurosurg, Kumamoto 8600811, Japan; Hiroshima Univ, Sch Med, Dept Internal Med 2, Hiroshima 7348551, Japan; Univ Calif San Francisco, Dept Med, Lung Biol Ctr, San Francisco, CA 94143 USA	Osaka University; Osaka University; Imperial College London; Kumamoto University; Hiroshima University; University of California System; University of California San Francisco	Yokosaki, Y (corresponding author), Natl Hiroshima Hosp, Dept Internal Med, 513 Jike, Higashihiroshima 7390041, Japan.	yokosaki@hirosima.hosp.go.jp			NHLBI NIH HHS [HL53949, HL47412, HL/AI33259] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL053949, R01HL053949, R01HL047412, R01HL033259] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Bayless KJ, 1998, J CELL SCI, V111, P1165; CLARK EA, 1995, SCIENCE, V268, P233, DOI 10.1126/science.7716514; Denda S, 1998, MOL BIOL CELL, V9, P1425, DOI 10.1091/mbc.9.6.1425; DENHARDT DT, 1993, FASEB J, V7, P1475, DOI 10.1096/fasebj.7.15.8262332; HART SL, 1995, GENE THER, V2, P552; HU DD, 1995, J BIOL CHEM, V270, P26232, DOI 10.1074/jbc.270.44.26232; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; LEE JO, 1995, CELL, V80, P631, DOI 10.1016/0092-8674(95)90517-0; LIAW L, 1995, J CLIN INVEST, V95, P713, DOI 10.1172/JCI117718; MIYAUCHI A, 1991, J BIOL CHEM, V266, P20369; Munger JS, 1999, CELL, V96, P319, DOI 10.1016/S0092-8674(00)80545-0; NASU K, 1995, BIOCHEM J, V307, P257, DOI 10.1042/bj3070257; O'Regan AW, 1999, J IMMUNOL, V162, P1024; OBRIEN ER, 1994, ARTERIOSCLER THROMB, V14, P1648, DOI 10.1161/01.ATV.14.10.1648; PALMER EL, 1993, J CELL BIOL, V123, P1289, DOI 10.1083/jcb.123.5.1289; Panda D, 1997, P NATL ACAD SCI USA, V94, P9308, DOI 10.1073/pnas.94.17.9308; PRIETO AL, 1993, P NATL ACAD SCI USA, V90, P10154, DOI 10.1073/pnas.90.21.10154; Ruoslahti E, 1996, ANNU REV CELL DEV BI, V12, P697, DOI 10.1146/annurev.cellbio.12.1.697; SAITOH Y, 1995, LAB INVEST, V72, P55; SCHNAPP LM, 1995, J BIOL CHEM, V270, P23196, DOI 10.1074/jbc.270.39.23196; SENGER DR, 1994, MOL BIOL CELL, V5, P565, DOI 10.1091/mbc.5.5.565; SENGER DR, 1988, CANCER RES, V48, P5770; SENGER DR, 1989, ANTICANCER RES, V9, P1291; Sheppard D, 1996, BIOESSAYS, V18, P655, DOI 10.1002/bies.950180809; SINGH RP, 1990, J EXP MED, V171, P1931, DOI 10.1084/jem.171.6.1931; Smith LL, 1998, EXP CELL RES, V242, P351, DOI 10.1006/excr.1998.4108; Smith LL, 1996, J BIOL CHEM, V271, P28485, DOI 10.1074/jbc.271.45.28485; Taooka Y, 1999, J CELL BIOL, V145, P413, DOI 10.1083/jcb.145.2.413; Wang A, 1996, AM J RESP CELL MOL, V15, P664, DOI 10.1165/ajrcmb.15.5.8918373; Weber Georg F., 1996, Cytokine and Growth Factor Reviews, V7, P241, DOI 10.1016/S1359-6101(96)00030-5; YATOHGO T, 1988, CELL STRUCT FUNCT, V13, P281, DOI 10.1247/csf1975.13.281; YEDNOCK TA, 1995, J BIOL CHEM, V270, P28740, DOI 10.1074/jbc.270.48.28740; YOKOSAKI Y, 1994, J BIOL CHEM, V269, P26691; Yokosaki Y, 1996, J BIOL CHEM, V271, P24144, DOI 10.1074/jbc.271.39.24144; Yokosaki Y, 1998, J BIOL CHEM, V273, P11423, DOI 10.1074/jbc.273.19.11423	35	269	297	1	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 17	1999	274	51					36328	36334		10.1074/jbc.274.51.36328	http://dx.doi.org/10.1074/jbc.274.51.36328			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	266AV	10593924	hybrid			2022-12-25	WOS:000084279200043
J	Zheng, T; Nicchitta, CV				Zheng, T; Nicchitta, CV			Structural determinants for signal sequence function in the mammalian endoplasmic reticulum	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SECRETORY PROTEIN TRANSLOCATION; METHIONINE-RICH DOMAIN; RECOGNITION PARTICLE; MICROSOMAL-MEMBRANES; PRESECRETORY PROTEINS; ESCHERICHIA-COLI; NASCENT PREPROLACTIN; CHEMICAL ALKYLATION; GTP-BINDING; ER-MEMBRANE	Signal sequences function in protein targeting to and translocation across the endoplasmic reticulum membrane. To investigate the structural requirements for signal sequence function, chimeras of the Escherichia coli LamB signal peptide and prolactin were prepared. The LamB signal peptide was chosen by virtue of the extensive biophysical and biological characterization of its activity. In vitro, nascent prolactin chains bearing the LamB signal peptide (LamB) were targeted in a signal recognition particle (SRP)-dependent manner to rough microsomes but remained protease- and salt-sensitive and translocated at low efficiency. Full translocation activity was obtained in a gain of function mutant (LamB*) in which three hydrophobic residues in the LamB hydrophobic core were converted to leucine residues. Cross-linking studies demonstrated that the LamB* signal sequence displayed markedly enhanced interactions with SRP and integral membrane proteins, In contrast, chemically denatured LamB and LamB*-precursors bound with identical efficiencies and in a salt-resistant manner to rough microsomes, suggesting that during de novo synthesis the signal sequence of LamB-bearing precursors assumes a conformation refractory to translocation, These data indicate that a leucine-rich signal sequence is necessary for optimal interaction with SRP and suggest that SRP, by maintaining the signal sequence in a conformation suitable for membrane binding, performs a chaperone function.	Duke Univ, Med Ctr, Dept Cell Biol, Durham, NC 27710 USA	Duke University	Nicchitta, CV (corresponding author), Duke Univ, Med Ctr, Dept Cell Biol, Durham, NC 27710 USA.	c.nicchitta@cellbio.duke.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK047897] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK47897] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Al-Qahtani A, 1998, BIOCHEM J, V331, P521, DOI 10.1042/bj3310521; Belin D, 1996, EMBO J, V15, P468, DOI 10.1002/j.1460-2075.1996.tb00379.x; BERNSTEIN HD, 1989, NATURE, V340, P482, DOI 10.1038/340482a0; BONNER WM, 1974, EUR J BIOCHEM, V46, P83, DOI 10.1111/j.1432-1033.1974.tb03599.x; BRIGGS MS, 1985, SCIENCE, V228, P1096, DOI 10.1126/science.3158076; CONNOLLY T, 1986, J CELL BIOL, V103, P2253, DOI 10.1083/jcb.103.6.2253; DAYHOFF MO, 1972, ATLAS PROTEIN SEQUEN, P89; ENGELMAN DM, 1986, ANNU REV BIOPHYS BIO, V15, P321, DOI 10.1146/annurev.bb.15.060186.001541; GIERASCH LM, 1989, BIOCHEMISTRY-US, V28, P923, DOI 10.1021/bi00429a001; GILMORE R, 1982, J CELL BIOL, V95, P463, DOI 10.1083/jcb.95.2.463; GORLICH D, 1992, NATURE, V357, P47, DOI 10.1038/357047a0; GORLICH D, 1992, CELL, V71, P489, DOI 10.1016/0092-8674(92)90517-G; HANSEN W, 1986, CELL, V45, P397, DOI 10.1016/0092-8674(86)90325-9; HIGH S, 1993, J BIOL CHEM, V268, P26745; HORTSCH M, 1986, J CELL BIOL, V103, P241, DOI 10.1083/jcb.103.1.241; JACKSON RJ, 1983, METHOD ENZYMOL, V96, P50; JONES JD, 1994, BIOPHYS J, V67, P1546, DOI 10.1016/S0006-3495(94)80628-9; JUNGNICKEL B, 1995, CELL, V82, P261, DOI 10.1016/0092-8674(95)90313-5; KRIEG UC, 1986, P NATL ACAD SCI USA, V83, P8604, DOI 10.1073/pnas.83.22.8604; KURZCHALIA TV, 1986, NATURE, V320, P634, DOI 10.1038/320634a0; LUTCKE H, 1992, EMBO J, V11, P1543, DOI 10.1002/j.1460-2075.1992.tb05199.x; MILLER JD, 1993, NATURE, V366, P351, DOI 10.1038/366351a0; Moller I, 1998, FEBS LETT, V441, P1, DOI 10.1016/S0014-5793(98)01440-9; Murphy EC, 1997, J CELL BIOL, V136, P1213, DOI 10.1083/jcb.136.6.1213; Neuhof A, 1998, MOL BIOL CELL, V9, P103, DOI 10.1091/mbc.9.1.103; NICCHITTA CV, 1989, J CELL BIOL, V108, P789, DOI 10.1083/jcb.108.3.789; NICCHITTA CV, 1995, J CELL BIOL, V129, P957, DOI 10.1083/jcb.129.4.957; Nielsen H, 1997, PROTEIN ENG, V10, P1, DOI 10.1093/protein/10.1.1; OKUN MM, 1990, J BIOL CHEM, V265, P7478; Raden D, 1998, MOL BIOL CELL, V9, P117, DOI 10.1091/mbc.9.1.117; ROMISCH K, 1989, NATURE, V340, P478, DOI 10.1038/340478a0; ROSEMAN MA, 1988, J MOL BIOL, V200, P513, DOI 10.1016/0022-2836(88)90540-2; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHLENSTEDT G, 1992, J BIOL CHEM, V267, P24328; SIEGEL V, 1988, EMBO J, V7, P1769, DOI 10.1002/j.1460-2075.1988.tb03007.x; SIMON SM, 1992, CELL, V69, P677, DOI 10.1016/0092-8674(92)90231-Z; THRIFT RN, 1991, J CELL BIOL, V112, P809, DOI 10.1083/jcb.112.5.809; Voglino L, 1998, BIOCHEMISTRY-US, V37, P12241, DOI 10.1021/bi9805792; Voglino L, 1999, BIOCHEMISTRY-US, V38, P7509, DOI 10.1021/bi990099q; WALTER P, 1980, P NATL ACAD SCI-BIOL, V77, P7112, DOI 10.1073/pnas.77.12.7112; WALTER P, 1983, METHOD ENZYMOL, V96, P84; WALTER P, 1981, J CELL BIOL, V91, P551, DOI 10.1083/jcb.91.2.551; WALTER P, 1981, J CELL BIOL, V91, P557, DOI 10.1083/jcb.91.2.557; WALTER P, 1981, J CELL BIOL, V91, P545, DOI 10.1083/jcb.91.2.545; WALTER P, 1994, ANNU REV CELL BIOL, V10, P87, DOI 10.1146/annurev.cb.10.110194.000511; WATANABE M, 1986, NATURE, V323, P71, DOI 10.1038/323071a0; WATERS MG, 1986, J CELL BIOL, V102, P1543, DOI 10.1083/jcb.102.5.1543; WIEDMANN B, 1994, NATURE, V370, P434, DOI 10.1038/370434a0; WIEDMANN M, 1987, NATURE, V328, P830, DOI 10.1038/328830a0; WOLIN SL, 1993, J CELL BIOL, V121, P1211, DOI 10.1083/jcb.121.6.1211; ZIMMERMANN R, 1990, BIOCHIMIE, V72, P95, DOI 10.1016/0300-9084(90)90134-3; ZOPF D, 1993, J CELL BIOL, V120, P1113, DOI 10.1083/jcb.120.5.1113; ZOPF D, 1990, EMBO J, V9, P4511, DOI 10.1002/j.1460-2075.1990.tb07902.x	53	18	21	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 17	1999	274	51					36623	36630		10.1074/jbc.274.51.36623	http://dx.doi.org/10.1074/jbc.274.51.36623			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	266AV	10593964	hybrid			2022-12-25	WOS:000084279200083
J	Delahay, RM; Knutton, S; Shaw, RK; Hartland, EL; Pallen, MJ; Frankel, G				Delahay, RM; Knutton, S; Shaw, RK; Hartland, EL; Pallen, MJ; Frankel, G			The coiled-coil domain of EspA is essential for the assembly of the type III secretion translocon on the surface of enteropathogenic Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TISSUE-CULTURE CELLS; EPITHELIAL-CELLS; SALMONELLA-TYPHIMURIUM; PROTEIN TRANSLOCATION; GENETIC-LOCUS; PATHOGENS; FLAGELLIN; SYSTEMS; ALPHA	Enteropathogenic E. coli (EPEC) utilize a type III secretion system to deliver virulence-associated effector proteins to the host cell. Four proteins, EspA, EspE, EspD, and Tir, which are integral to the formation of characteristic "attaching and effacing" (A/E) intestinal lesions, are known to be exported via the EPEC type III secretion system. Recent work demonstrated that EspA is a major component of a filamentous structure, elaborated on the surface of EPEC, which is required for translocation of EspB and Tir, The carboxyl terminus of EspA is predicted to comprise an alpha-helical region, which demonstrates heptad periodicity whereby positions a and d in the heptad repeat unit abcdefg are occupied by hydrophobic residues, indicating a propensity for coiled-coil interactions. Here we demonstrate multimeric EspA isoforms in EPEC culture supernatants and EspA:EspA interaction on solid phase. Non-conservative amino acid substitution of specific EspA heptad residues generated EPEC mutants defective in filament assembly but which retained the ability to induce A/E lesions; additional mutation totally abolished EspA filament assembly and A/E lesion formation. These results demonstrate a similarity to flagellar biosynthesis and indicate that the coiled-coil domain of EspA is required for assembly of the EspA filament-associated type III secretion translocon.	Univ London Imperial Coll Sci Technol & Med, Dept Biochem, London SW7 2AZ, England; Univ Birmingham, Inst Child Hlth, Birmingham B4 6NH, W Midlands, England; St Bartholomews & Royal London Sch Med & Dent, Dept Med Microbiol, London EC1A 7BE, England	Imperial College London; University of Birmingham; University of London; Queen Mary University London	Frankel, G (corresponding author), Univ London Imperial Coll Sci Technol & Med, Dept Biochem, London SW7 2AZ, England.	g.frankel@ic.ac.uk	Pallen, Mark J./E-7619-2011; Hartland, Elizabeth/O-2569-2014	Hartland, Elizabeth/0000-0003-4254-2863; Delahay, Rob/0000-0002-7108-565X; Pallen, Mark/0000-0003-1807-3657				Adu-Bobie J, 1998, J CLIN MICROBIOL, V36, P662, DOI 10.1128/JCM.36.3.662-668.1998; COHEN C, 1990, PROTEINS, V7, P1, DOI 10.1002/prot.340070102; Elliott SJ, 1999, MOL MICROBIOL, V33, P1176, DOI 10.1046/j.1365-2958.1999.01559.x; Elliott SJ, 1998, MOL MICROBIOL, V28, P1, DOI 10.1046/j.1365-2958.1998.00783.x; Finlay BB, 1997, MICROBIOL MOL BIOL R, V61, P136, DOI 10.1128/.61.2.136-169.1997; Forest KT, 1997, GENE, V192, P165, DOI 10.1016/S0378-1119(97)00008-5; Frankel G, 1998, MOL MICROBIOL, V30, P911, DOI 10.1046/j.1365-2958.1998.01144.x; Frankel GM, 1999, SYMP SOC GEN MICROBI, V57, P197; Hueck CJ, 1998, MICROBIOL MOL BIOL R, V62, P379, DOI 10.1128/MMBR.62.2.379-433.1998; HYMAN HC, 1991, J MOL BIOL, V220, P79, DOI 10.1016/0022-2836(91)90382-G; IKEDA T, 1985, J MOL BIOL, V184, P735, DOI 10.1016/0022-2836(85)90317-1; JARVIS KG, 1995, P NATL ACAD SCI USA, V92, P7996, DOI 10.1073/pnas.92.17.7996; JERSE AE, 1990, P NATL ACAD SCI USA, V87, P7839, DOI 10.1073/pnas.87.20.7839; KANTO S, 1991, J MOL BIOL, V219, P471, DOI 10.1016/0022-2836(91)90187-B; Kelly G, 1999, NAT STRUCT BIOL, V6, P313; Kenny B, 1997, CELL, V91, P511, DOI 10.1016/S0092-8674(00)80437-7; Kenny B, 1996, MOL MICROBIOL, V20, P313, DOI 10.1111/j.1365-2958.1996.tb02619.x; Knutton S, 1998, EMBO J, V17, P2166, DOI 10.1093/emboj/17.8.2166; KNUTTON S, 1989, INFECT IMMUN, V57, P1290, DOI 10.1128/IAI.57.4.1290-1298.1989; KUWAJIMA G, 1988, J BACTERIOL, V170, P3305, DOI 10.1128/jb.170.7.3305-3309.1988; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; Lupas A, 1996, TRENDS BIOCHEM SCI, V21, P375, DOI 10.1016/0968-0004(96)10052-9; MCDANIEL TK, 1995, P NATL ACAD SCI USA, V92, P1664, DOI 10.1073/pnas.92.5.1664; Nataro JP, 1998, CLIN MICROBIOL REV, V11, P403; Pallen MJ, 1997, MOL MICROBIOL, V25, P423, DOI 10.1046/j.1365-2958.1997.4901850.x; PARRY D A D, 1992, Current Opinion in Cell Biology, V4, P94, DOI 10.1016/0955-0674(92)90064-J; ROSQVIST R, 1995, EMBO J, V14, P4187, DOI 10.1002/j.1460-2075.1995.tb00092.x; Wachter C, 1999, MOL MICROBIOL, V31, P1695, DOI 10.1046/j.1365-2958.1999.01303.x; Wainwright LA, 1998, MOL MICROBIOL, V27, P1247, DOI 10.1046/j.1365-2958.1998.00771.x; Wolff C, 1998, MOL MICROBIOL, V28, P143, DOI 10.1046/j.1365-2958.1998.00782.x; YOKOSEKI T, 1995, MICROBIOL-SGM, V141, P1715, DOI 10.1099/13500872-141-7-1715	31	59	62	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 10	1999	274	50					35969	35974		10.1074/jbc.274.50.35969	http://dx.doi.org/10.1074/jbc.274.50.35969			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	264NG	10585486	hybrid			2022-12-25	WOS:000084187900098
J	Loo, TW; Clarke, DM				Loo, TW; Clarke, DM			Identification of residues in the drug-binding domain of human P-glycoprotein - Analysis of transmembrane segment 11 by cysteine-scanning mutagenesis and inhibition by dibromobimane	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STIMULATED ATPASE ACTIVITY; HIV-1 PROTEASE INHIBITORS; AMINO-ACID SUBSTITUTIONS; BLOOD-BRAIN-BARRIER; SUBSTRATE-SPECIFICITY; MULTIDRUG-RESISTANCE; FUNCTIONAL CONSEQUENCES; MUTATIONAL ANALYSIS; EXPRESSION SYSTEM; CROSS-RESISTANCE	The drug-binding domain of the human multidrug resistance P-glycoprotein (P-gp) probably consists of residues from multiple transmembrane (TM) segments. In this study, we tested whether the amino acids in TM11 participate in binding drug substrates, Each residue in TM11 was initially altered by site-directed mutagenesis and assayed for drug-stimulated ATPase activity in the presence of verapamil, vinblastine, or colchicine, Mutants G939V, F942A, T945A, Q946A, A947L, Y953A, A954L, and G955V had altered drug-stimulated ATPase activities. Direct evidence for binding of drug substrate was then determined by cysteine-scanning mutagenesis of the residues in TM11 and inhibition of drug-stimulated ATPase activity by dibromobimane, a thiol-reactive substrate. Dibromobimane inhibited the drug-stimulated ATPase activities of two mutants, F942C and T945C, by more than 75%, These results suggest that residues Phe(942) and Thr(945) in TM11, together with residues previously identified in TM6 (Leu(339) and Ala(342)) and TM12 (Leu(975), Val(982), and Ala(985)) (Loo, T. W., and Clarke, D. M. (1997) J. Biol. Chem. 272, 31945-31948) form part of the drug-binding domain of P-gp.	Univ Toronto, Dept Med, MRC, Grp Membrane Biol, Toronto, ON M5S 1A8, Canada; Univ Toronto, Dept Biochem, Toronto, ON M5S 1A8, Canada	University of Toronto; University of Toronto	Clarke, DM (corresponding author), Univ Toronto, Dept Med, MRC, Grp Membrane Biol, Rm 7342,Med Sci Bldg,1 Kings Coll Circle, Toronto, ON M5S 1A8, Canada.		Clarke, David M./A-1112-2008	Clarke, David M./0000-0003-4335-7184; Loo, Tip W/0000-0003-2108-0188	NCI NIH HHS [R01 CA80900] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA080900] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ambudkar SV, 1997, J BIOL CHEM, V272, P21160, DOI 10.1074/jbc.272.34.21160; Ambudkar SV, 1999, ANNU REV PHARMACOL, V39, P361, DOI 10.1146/annurev.pharmtox.39.1.361; AZZARIA M, 1989, MOL CELL BIOL, V9, P5289, DOI 10.1128/MCB.9.12.5289; BEAUDET L, 1995, J BIOL CHEM, V270, P17159, DOI 10.1074/jbc.270.29.17159; Chan HSL, 1996, EUR J CANCER, V32A, P1051, DOI 10.1016/0959-8049(96)00085-8; CHEN CJ, 1990, J BIOL CHEM, V265, P506; Chen G, 1997, J BIOL CHEM, V272, P5974, DOI 10.1074/jbc.272.9.5974; CHIFFLET S, 1988, ANAL BIOCHEM, V168, P1, DOI 10.1016/0003-2697(88)90002-4; CHOI K, 1988, CELL, V53, P519, DOI 10.1016/0092-8674(88)90568-5; CURRIER SJ, 1992, J BIOL CHEM, V267, P25153; DEVINE SE, 1992, P NATL ACAD SCI USA, V89, P4564, DOI 10.1073/pnas.89.10.4564; GERMANN UA, 1990, BIOCHEMISTRY-US, V29, P2295, DOI 10.1021/bi00461a013; GROS P, 1991, P NATL ACAD SCI USA, V88, P7289, DOI 10.1073/pnas.88.16.7289; Hafkemeyer P, 1998, BIOCHEMISTRY-US, V37, P16400, DOI 10.1021/bi980871+; Hanna M, 1996, BIOCHEMISTRY-US, V35, P3625, DOI 10.1021/bi951333p; HIGGINS CF, 1992, ANNU REV CELL BIOL, V8, P67, DOI 10.1146/annurev.cb.08.110192.000435; HOOF T, 1994, J BIOL CHEM, V269, P20575; KAJIJI S, 1994, BIOCHEMISTRY-US, V33, P5041, DOI 10.1021/bi00183a006; KAJIJI S, 1993, BIOCHEMISTRY-US, V32, P4185, DOI 10.1021/bi00067a005; Kast C, 1996, J BIOL CHEM, V271, P9240, DOI 10.1074/jbc.271.16.9240; Kim RB, 1998, J CLIN INVEST, V101, P289, DOI 10.1172/JCI1269; KIOKA N, 1989, BIOCHEM BIOPH RES CO, V162, P224, DOI 10.1016/0006-291X(89)91985-2; Kwan T, 1998, BIOCHEMISTRY-US, V37, P3337, DOI 10.1021/bi972680x; Lee CGL, 1998, BIOCHEMISTRY-US, V37, P3594, DOI 10.1021/bi972709x; Lehnert M, 1996, EUR J CANCER, V32A, P912, DOI 10.1016/0959-8049(96)00069-X; Loo TW, 1997, J BIOL CHEM, V272, P709, DOI 10.1074/jbc.272.2.709; Loo TW, 1999, BIOCHEM CELL BIOL, V77, P11, DOI 10.1139/bcb-77-1-11; Loo TW, 1999, J BIOL CHEM, V274, P24759, DOI 10.1074/jbc.274.35.24759; Loo TW, 1997, J BIOL CHEM, V272, P20986, DOI 10.1074/jbc.272.34.20986; LOO TW, 1993, J BIOL CHEM, V268, P3143; Loo TW, 1997, J BIOL CHEM, V272, P31945, DOI 10.1074/jbc.272.51.31945; LOO TW, 1995, J BIOL CHEM, V270, P843, DOI 10.1074/jbc.270.2.843; LOO TW, 1994, J BIOL CHEM, V269, P7243; Loo TW, 1998, J BIOL CHEM, V273, P32373, DOI 10.1074/jbc.273.49.32373; LOO TW, 1994, BIOCHEMISTRY-US, V33, P14049, DOI 10.1021/bi00251a013; LOO TW, 1995, J BIOL CHEM, V270, P21449, DOI 10.1074/jbc.270.37.21449; LOO TW, 1994, J BIOL CHEM, V269, P7750; LOO TW, 1995, J BIOL CHEM, V270, P22957, DOI 10.1074/jbc.270.39.22957; LOO TW, 1993, J BIOL CHEM, V268, P19965; Ma JF, 1997, MOL PHARMACOL, V51, P922, DOI 10.1124/mol.51.6.922; Ramachandra M, 1996, MOL BIOL CELL, V7, P1485, DOI 10.1091/mbc.7.10.1485; Schinkel AH, 1996, J CLIN INVEST, V97, P2517, DOI 10.1172/JCI118699; SCHINKEL AH, 1994, CELL, V77, P491, DOI 10.1016/0092-8674(94)90212-7; Sharom FJ, 1997, J MEMBRANE BIOL, V160, P161, DOI 10.1007/s002329900305; Shoshani T, 1998, MOL PHARMACOL, V54, P623; Taguchi Y, 1997, BIOCHEMISTRY-US, V36, P8883, DOI 10.1021/bi970553v; Taguchi Y, 1997, FEBS LETT, V413, P142, DOI 10.1016/S0014-5793(97)00899-5; URBATSCH IL, 1995, J BIOL CHEM, V270, P19383, DOI 10.1074/jbc.270.33.19383; URBATSCH IL, 1995, J BIOL CHEM, V270, P26956, DOI 10.1074/jbc.270.45.26956; WELKER E, 1995, BIOCHEM BIOPH RES CO, V216, P602, DOI 10.1006/bbrc.1995.2665	50	112	112	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 10	1999	274	50					35388	35392		10.1074/jbc.274.50.35388	http://dx.doi.org/10.1074/jbc.274.50.35388			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	264NG	10585407	hybrid			2022-12-25	WOS:000084187900019
J	Foss, GS; Prydz, H				Foss, GS; Prydz, H			Interferon regulatory factor 1 mediates the interferon-gamma induction of the human immunoproteasome subunit multicatalytic endopeptidase complex-like 1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MHC CLASS-I; TRANSCRIPTION FACTOR IRF-2; PROTEASOME SUBUNIT; CHROMOSOMAL LOCALIZATION; FUNCTIONAL DIVERSITY; PEPTIDASE ACTIVITIES; IFN-GAMMA; GENES; EXPRESSION; PROTEINS	Proteasomes generate antigenic peptides from intracellular proteins for presentation to the immune system by the major histocompatibility complex class I molecules. The antiviral cytokine IFN-gamma alters the catalytic specificity of proteasomes by inducing the synthesis of an alternative set of three proteolytically active proteasome subunits, We have analyzed the mechanism of IFN-gamma induction for the IFN-gamma-induced subunit multicatalytic endopeptidase complex-like 1 (MECL1). The human MECL1 promoter contains two interferon-stimulated response elements (ISREs), generally known to bind members of the interferon regulatory factor (IRF) family. The importance of these elements for IFN-gamma induction of MECL1 was addressed by transfecting an endothelial cell line with MECL1 promoter constructs. By deletions and mutations of the ISRE sequences, we demonstrated that both ISREs were needed for full IFN-gamma induction of the reporter gene. The second (downstream) ISRE was essential for both IFN-gamma-induced and basal transcriptional activity of the promoter. in electrophoretic mobility shift assays, anti-IRF-1 antibodies supershifted an LFN-gamma-induced protein binding specifically to both ISRE sequences, whereas IRF-2 bound the second ISRE before induction. Co-transfection of IRF-1 resulted in induced MECL1 promoter activity in the absence of IFN-gamma, These data indicate that the IFN-gamma induction of human MECL1 is mediated by IFN-gamma-induced IRF-1.	Univ Oslo, Biotechnol Ctr Oslo, N-0316 Oslo, Norway	University of Oslo	Prydz, H (corresponding author), Univ Oslo, Biotechnol Ctr Oslo, POB 1125 Blindern, N-0316 Oslo, Norway.							AKI M, 1994, J BIOCHEM, V115, P257, DOI 10.1093/oxfordjournals.jbchem.a124327; AKIYAMA K, 1994, FEBS LETT, V343, P85, DOI 10.1016/0014-5793(94)80612-8; AKIYAMA KY, 1994, SCIENCE, V265, P1231, DOI 10.1126/science.8066462; ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; BELICH MP, 1994, CURR BIOL, V4, P769, DOI 10.1016/S0960-9822(00)00174-3; BLANAR MA, 1989, EMBO J, V8, P1139, DOI 10.1002/j.1460-2075.1989.tb03484.x; Bluyssen Hans A. R., 1996, Cytokine and Growth Factor Reviews, V7, P11, DOI 10.1016/1359-6101(96)00005-6; BLUYSSEN HAR, 1995, P NATL ACAD SCI USA, V92, P5645, DOI 10.1073/pnas.92.12.5645; BOES B, 1994, J EXP MED, V179, P901, DOI 10.1084/jem.179.3.901; Coux O, 1996, ANNU REV BIOCHEM, V65, P801, DOI 10.1146/annurev.bi.65.070196.004101; Cruz M, 1997, GENOMICS, V45, P618, DOI 10.1006/geno.1997.4977; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; DRISCOLL J, 1990, J BIOL CHEM, V265, P4789; DRISCOLL J, 1993, NATURE, V365, P262, DOI 10.1038/365262a0; Escalante CR, 1998, NATURE, V391, P103, DOI 10.1038/34224; FEHLING HJ, 1994, SCIENCE, V265, P1234, DOI 10.1126/science.8066463; Foss GS, 1998, BBA-MOL CELL RES, V1402, P17, DOI 10.1016/S0167-4889(97)00152-3; FRUH K, 1994, EMBO J, V13, P3236, DOI 10.1002/j.1460-2075.1994.tb06625.x; FRUH K, 1992, J BIOL CHEM, V267, P22131; GACZYNSKA M, 1994, P NATL ACAD SCI USA, V91, P9213, DOI 10.1073/pnas.91.20.9213; GACZYNSKA M, 1993, NATURE, V365, P264, DOI 10.1038/365264a0; Groettrup M, 1996, EUR J IMMUNOL, V26, P863, DOI 10.1002/eji.1830260421; HARADA H, 1989, CELL, V58, P729, DOI 10.1016/0092-8674(89)90107-4; Hayashi M, 1997, J IMMUNOL, V159, P2760; Hisamatsu H, 1996, J EXP MED, V183, P1807, DOI 10.1084/jem.183.4.1807; Jesse TL, 1998, J CELL BIOL, V140, P1265, DOI 10.1083/jcb.140.5.1265; LARSEN F, 1993, HUM MOL GENET, V2, P1589, DOI 10.1093/hmg/2.10.1589; MACDONALD NJ, 1990, CELL, V60, P767, DOI 10.1016/0092-8674(90)90091-R; Nandi D, 1996, J IMMUNOL, V156, P2361; Nguyen Hannah, 1997, Cytokine and Growth Factor Reviews, V8, P293, DOI 10.1016/S1359-6101(97)00019-1; Pamer E, 1998, ANNU REV IMMUNOL, V16, P323, DOI 10.1146/annurev.immunol.16.1.323; PARRINGTON J, 1993, EUR J BIOCHEM, V214, P2448; RAMMENSEE HG, 1993, ANNU REV IMMUNOL, V11, P213, DOI 10.1146/annurev.iy.11.040193.001241; REID LE, 1989, P NATL ACAD SCI USA, V86, P840, DOI 10.1073/pnas.86.3.840; Tanaka K, 1998, IMMUNOL REV, V163, P161; TANAKA N, 1993, MOL CELL BIOL, V13, P4531, DOI 10.1128/MCB.13.8.4531; VANKAER L, 1994, IMMUNITY, V1, P533, DOI 10.1016/1074-7613(94)90043-4; VAUGHAN PS, 1995, NATURE, V377, P362, DOI 10.1038/377362a0; WeberNordt RM, 1996, BLOOD, V88, P809; White LC, 1996, IMMUNITY, V5, P365, DOI 10.1016/S1074-7613(00)80262-9; YAMAMOTO H, 1994, ONCOGENE, V9, P1423	41	37	39	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 3	1999	274	49					35196	35202		10.1074/jbc.274.49.35196	http://dx.doi.org/10.1074/jbc.274.49.35196			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	260XW	10575004	hybrid			2022-12-25	WOS:000083979600098
J	Hayashi, Y; Yamagishi, M; Nishimoto, Y; Taguchi, O; Matsukage, A; Yamaguchi, M				Hayashi, Y; Yamagishi, M; Nishimoto, Y; Taguchi, O; Matsukage, A; Yamaguchi, M			A binding site for the transcription factor grainyhead/nuclear transcription factor-1 contributes to regulation of the Drosophila proliferating cell nuclear antigen gene promoter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYMERASE-BETA-GENE; REPLICATION-RELATED ELEMENT; DNA-REPLICATION; FACTOR LSF; PROTEIN; MELANOGASTER; EXPRESSION; PCNA; REPRESSION; E2F	The Drosophila proliferating cell nuclear antigen promoter contains multiple transcriptional regulatory elements, including upstream regulatory element (URE), DNA replication-related element, E2F recognition sites, and three common regulatory factor for DNA replication and DNA replication-related element-binding factor genes recognition sites. In nuclear extracts of Drosophila embryos, we detected a protein factor, the URE-binding factor (UREF), that recognizes the nucleotide sequence 5'-AAACCAGTTGGCA located within URE, Analyses in Drosophila Kc cells and transgenic flies revealed that the UREF-binding site plays an important role in promoter activity both in cultured cells and in living flies. A yeast one-hybrid screen using URE as a bait allowed isolation of a cDNA encoding a transcription factor, Grainyhead/nuclear transcription factor-1 (GRH/NTF-1). The nucleotide sequence required for binding to GRH was indistinguishable from that for UREF detected in embryo nuclear extracts, Furthermore, a specific antibody to GRH reacted with UREF in embryo nuclear extracts, From these results we conclude that GRH is identical to UREF, Although GRH has been thought to be involved in regulation of differentiation-related genes, this study demonstrates, for the first time, involvement of a GRH-binding site in regulation of the DNA replication-related proliferating cell nuclear antigen gene.	Aichi Canc Ctr Res Inst, Cell Biol Lab, Chikusa Ku, Nagoya, Aichi 4648681, Japan; Aichi Canc Ctr Res Inst, Lab Expt Pathol, Chikusa Ku, Nagoya, Aichi 4648681, Japan	Aichi Cancer Center; Aichi Cancer Center	Yamaguchi, M (corresponding author), Aichi Canc Ctr Res Inst, Cell Biol Lab, Chikusa Ku, Nagoya, Aichi 4648681, Japan.			Yamaguchi, Masamitsu/0000-0002-6321-9750				ABRAHAMSEN MS, 1990, MOL CELL BIOL, V10, P5525, DOI 10.1128/MCB.10.10.5525; ATTARDI LD, 1993, GENE DEV, V7, P1341, DOI 10.1101/gad.7.7b.1341; BIGGIN MD, 1988, CELL, V53, P699, DOI 10.1016/0092-8674(88)90088-8; BRAY SJ, 1989, GENE DEV, V3, P1130, DOI 10.1101/gad.3.8.1130; BRAY SJ, 1991, GENE DEV, V5, P1672, DOI 10.1101/gad.5.9.1672; CRABTREE GR, 1989, SCIENCE, V243, P355, DOI 10.1126/science.2783497; CROSS DP, 1978, J EMBRYOL EXP MORPH, V45, P161; DINOCERA PP, 1983, P NATL ACAD SCI-BIOL, V80, P7095; DURONIO RJ, 1995, GENE DEV, V9, P1445, DOI 10.1101/gad.9.12.1445; DYNLACHT BD, 1994, P NATL ACAD SCI USA, V91, P6359, DOI 10.1073/pnas.91.14.6359; DYNLACHT BD, 1991, CELL, V66, P563, DOI 10.1016/0092-8674(81)90019-2; DYNLACHT BD, 1989, GENE DEV, V3, P1677, DOI 10.1101/gad.3.11.1677; ECHALIER G, 1970, IN VITRO CELL DEV B, V6, P162; FEINSTEIN SC, 1985, P NATL ACAD SCI USA, V82, P5761, DOI 10.1073/pnas.82.17.5761; FLORESROZAS H, 1994, P NATL ACAD SCI USA, V91, P8655, DOI 10.1073/pnas.91.18.8655; FRIDELL YWC, 1992, MOL CELL BIOL, V12, P4571, DOI 10.1128/MCB.12.10.4571; FUSE N, 1994, GENE DEV, V8, P2270, DOI 10.1101/gad.8.19.2270; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; HAO XF, 1995, J CELL SCI, V108, P2945; Hayashi Y, 1997, J BIOL CHEM, V272, P22848, DOI 10.1074/jbc.272.36.22848; HENDERSON DS, 1994, EMBO J, V13, P1450, DOI 10.1002/j.1460-2075.1994.tb06399.x; Hirose F, 1996, J BIOL CHEM, V271, P3930; HIROSE F, 1993, J BIOL CHEM, V268, P2092; HUANG HC, 1990, GENE DEV, V4, P287, DOI 10.1101/gad.4.2.287; Huang JD, 1995, GENE DEV, V9, P3177, DOI 10.1101/gad.9.24.3177; JASKULSKI D, 1988, SCIENCE, V240, P1544, DOI 10.1126/science.2897717; JONES KA, 1988, GENE DEV, V2, P1101, DOI 10.1101/gad.2.9.1101; KASAI Y, 1992, P NATL ACAD SCI USA, V89, P3414, DOI 10.1073/pnas.89.8.3414; KATO H, 1991, SCIENCE, V251, P1476, DOI 10.1126/science.2006421; Kelman Z, 1998, TRENDS BIOCHEM SCI, V23, P236, DOI 10.1016/S0968-0004(98)01223-7; KELMAN Z, 1995, NUCLEIC ACIDS RES, V23, P3613, DOI 10.1093/nar/23.18.3613; KRAMER KJ, 1987, ARCH INSECT BIOCHEM, V6, P279, DOI 10.1002/arch.940060406; Liaw GJ, 1995, GENE DEV, V9, P3163, DOI 10.1101/gad.9.24.3163; LIM LC, 1992, MOL CELL BIOL, V12, P828, DOI 10.1128/MCB.12.2.828; LIU YC, 1989, BIOCHEMISTRY-US, V28, P2967, DOI 10.1021/bi00433a034; Matsukage A, 1995, GENE, V166, P233, DOI 10.1016/0378-1119(95)00586-2; MATSUOKA S, 1994, J BIOL CHEM, V269, P11030; NEVINS JR, 1992, SCIENCE, V258, P424; Ohno K, 1996, NUCLEIC ACIDS RES, V24, P3942, DOI 10.1093/nar/24.20.3942; OHTANI K, 1994, MOL CELL BIOL, V14, P1603, DOI 10.1128/MCB.14.3.1603; ROBERTSON HM, 1988, GENETICS, V118, P461; Royzman I, 1997, GENE DEV, V11, P1999, DOI 10.1101/gad.11.15.1999; Ryu JR, 1997, NUCLEIC ACIDS RES, V25, P794, DOI 10.1093/nar/25.4.794; Sambrook J., 2002, MOL CLONING LAB MANU; Sawado T, 1998, BIOCHEM BIOPH RES CO, V251, P409, DOI 10.1006/bbrc.1998.9407; Shibahara K, 1999, CELL, V96, P575, DOI 10.1016/S0092-8674(00)80661-3; Shirra MK, 1998, J BIOL CHEM, V273, P19260, DOI 10.1074/jbc.273.30.19260; SHIVJI MKK, 1992, CELL, V69, P367, DOI 10.1016/0092-8674(92)90416-A; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SMITH ML, 1994, SCIENCE, V266, P1376, DOI 10.1126/science.7973727; Spradling AC, 1986, DROSOPHILA PRACTICAL, P175; Takahashi Y, 1996, J BIOL CHEM, V271, P14541, DOI 10.1074/jbc.271.24.14541; Takahashi Y, 1999, NUCLEIC ACIDS RES, V27, P510, DOI 10.1093/nar/27.2.510; TSURIMOTO T, 1990, NATURE, V346, P534, DOI 10.1038/346534a0; Uv AE, 1997, MOL CELL BIOL, V17, P6727, DOI 10.1128/MCB.17.11.6727; UV AE, 1994, MOL CELL BIOL, V14, P4020, DOI 10.1128/MCB.14.6.4020; Volker JL, 1997, GENE DEV, V11, P1435, DOI 10.1101/gad.11.11.1435; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; Warbrick E, 1998, BIOESSAYS, V20, P195, DOI 10.1002/(SICI)1521-1878(199803)20:3<195::AID-BIES2>3.0.CO;2-R; YAMAGUCHI M, 1991, MOL CELL BIOL, V11, P4909, DOI 10.1128/MCB.11.10.4909; YAMAGUCHI M, 1994, EUR J BIOCHEM, V221, P227, DOI 10.1111/j.1432-1033.1994.tb18733.x; YAMAGUCHI M, 1995, J BIOL CHEM, V270, P15808, DOI 10.1074/jbc.270.26.15808; Yamaguchi M, 1996, GENES CELLS, V1, P47, DOI 10.1046/j.1365-2443.1996.03003.x; YAMAGUCHI M, 1988, NUCLEIC ACIDS RES, V16, P8773, DOI 10.1093/nar/16.18.8773; Yamaguchi Masamitsu, 1995, Gene Expression, V4, P183; YOO MA, 1994, JPN J GENET, V69, P21, DOI 10.1266/jjg.69.21	66	36	39	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 3	1999	274	49					35080	35088		10.1074/jbc.274.49.35080	http://dx.doi.org/10.1074/jbc.274.49.35080			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	260XW	10574988	hybrid			2022-12-25	WOS:000083979600082
J	Liu, JM; Antaya, M; Boerboom, D; Lussier, JG; Silversides, DW; Sirois, J				Liu, JM; Antaya, M; Boerboom, D; Lussier, JG; Silversides, DW; Sirois, J			The delayed activation of the prostaglandin G/H synthase-2 promoter in bovine granulosa cells is associated with down-regulation of truncated upstream stimulatory factor-2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RIBONUCLEIC-ACID; HUMAN CHORIONIC-GONADOTROPIN; RAT PREOVULATORY FOLLICLES; TRANSCRIPTION FACTOR USF; FACTOR KAPPA-B; ENDOPEROXIDE SYNTHASE-2; GENE-EXPRESSION; DEPENDENT INDUCTION; HORMONAL-REGULATION; RESPONSE ELEMENT	To elucidate the molecular mechanisms involved in the delayed induction of PGHS-2 in species with a long ovulatory process, a 1.6-kilobase fragment of the bovine PGHS-2 promoter was isolated, and its activity was characterized in primary cultures of bovine granulosa cells. Promoter activity assays performed with a series of deletion mutants revealed that the promoter region from -149 to -2 (+1 = transcription start site) confers full-length promoter activity in response to forskolin (10 mu M). Four consensus cis-elements were identified within this region, including an E-box, ATF/CRE, C/EBP, and AP2 site. Site-directed mutagenesis showed that the E-box was required for PGHS-2 promoter activity, that disruption of the C/EBP element decreased forskolin inducible activity by 29%, whereas point mutation within the ATF/CRE and AP2 element had no inhibitory effect. Electrophoretic mobility shift assays (EMSAs) performed with the -149/-2 fragment and granulosa cell nuclear extracts obtained before (0 h) and after (18 and 20 h) human chorionic gonadotropin (hCG) revealed the regulation of multiple DNA-protein complexes. The 0-h extract generated four complexes at the E-box, whereas only one complex was produced at this site with the 18 h extract. Supershift EMSAs identified that upstream stimulatory factor-1 and -2 (USF-1 and -2) were part of these complexes. Interestingly, the presence of the amino-terminal truncated USF-2, which lacks the transcription activation domain, was detected in the 0-h extract, but not in extracts prepared post-hCG. Supershift EMSAs also indicated high levels of C/EBP beta binding to its cis-element in the 0-h extract, which contrasts with results previously reported in rats. Thus, high levels of amino-terminal truncated USF-P and C/EBP beta in bovine granulosa cells prior to hCG; treatment could repress gene expression, and be involved in the delayed induction of PGHS-2 in species with a long ovulatory process.	Univ Montreal, Fac Vet Med, CRRA, St Hyacinthe, PQ J2S 7C6, Canada	Universite de Montreal	Sirois, J (corresponding author), Univ Montreal, Fac Vet Med, CRRA, CP 5000, St Hyacinthe, PQ J2S 7C6, Canada.	siroisje@medvet.umontreal.ca						Boerboom D, 1998, ENDOCRINOLOGY, V139, P1662, DOI 10.1210/en.139.4.1662; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; DESCOMBES P, 1991, CELL, V67, P569, DOI 10.1016/0092-8674(91)90531-3; DeWitt D L, 1993, Am J Med, V95, p40S, DOI 10.1016/0002-9343(93)90396-7; DINCHUK JE, 1995, NATURE, V378, P406, DOI 10.1038/378406a0; FLETCHER BS, 1992, J BIOL CHEM, V267, P4338; Ghosh AK, 1997, ONCOGENE, V14, P589, DOI 10.1038/sj.onc.1200866; GREGOR PD, 1990, GENE DEV, V4, P1730, DOI 10.1101/gad.4.10.1730; HEDIN L, 1987, ENDOCRINOLOGY, V121, P722, DOI 10.1210/endo-121-2-722; HEMLER M, 1976, J BIOL CHEM, V251, P5575; HERSCHMAN HR, 1994, CANCER METAST REV, V13, P241, DOI 10.1007/BF00666095; Herschman HR, 1996, BBA-LIPID LIPID MET, V1299, P125, DOI 10.1016/0005-2760(95)00194-8; Inoue H, 1998, BIOCHEM BIOPH RES CO, V244, P143, DOI 10.1006/bbrc.1998.8222; INOUE H, 1994, FEBS LETT, V350, P51, DOI 10.1016/0014-5793(94)00731-4; Inoue H, 1997, ADV EXP MED BIOL, V407, P139; KOSAKA T, 1994, EUR J BIOCHEM, V221, P889, DOI 10.1111/j.1432-1033.1994.tb18804.x; KUJUBU DA, 1991, J BIOL CHEM, V266, P12866; LANGENBACH R, 1995, CELL, V83, P483, DOI 10.1016/0092-8674(95)90126-4; LEFRANCOISMARTINEZ AM, 1995, J BIOL CHEM, V270, P2640, DOI 10.1074/jbc.270.6.2640; Lim H, 1997, CELL, V91, P197, DOI 10.1016/S0092-8674(00)80402-X; Liu JM, 1998, BIOL REPROD, V58, P1527, DOI 10.1095/biolreprod58.6.1527; Liu JM, 1997, BIOL REPROD, V57, P1524, DOI 10.1095/biolreprod57.6.1524; MIYAMOTO T, 1976, J BIOL CHEM, V251, P2629; MORHAM SG, 1995, CELL, V83, P473, DOI 10.1016/0092-8674(95)90125-6; Morris JK, 1996, J BIOL CHEM, V271, P16633, DOI 10.1074/jbc.271.28.16633; Richards JS, 1997, ENDOCRINOLOGY, V138, P4047, DOI 10.1210/en.138.10.4047; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Schmedtje JF, 1997, J BIOL CHEM, V272, P601; SILVER J, 1989, J VIROL, V63, P1924, DOI 10.1128/JVI.63.5.1924-1928.1989; SIMMONS DL, 1992, PROSTAGLANDINS LEUKO, P67; Sirito M, 1998, P NATL ACAD SCI USA, V95, P3758, DOI 10.1073/pnas.95.7.3758; SIRITO M, 1994, NUCLEIC ACIDS RES, V22, P427, DOI 10.1093/nar/22.3.427; SIROIS J, 1992, J BIOL CHEM, V267, P11586; SIROIS J, 1992, J BIOL CHEM, V267, P6382; SIROIS J, 1988, BIOL REPROD, V39, P308, DOI 10.1095/biolreprod39.2.308; SIROIS J, 1994, ENDOCRINOLOGY, V135, P841, DOI 10.1210/en.135.3.841; SIROIS J, 1993, J BIOL CHEM, V268, P21931; SIROIS J, 1993, J BIOL CHEM, V268, P12199; Sirois J, 1997, ENDOCRINOLOGY, V138, P4427, DOI 10.1210/en.138.10.4427; SMITH WL, 1995, SEMIN NEPHROL, V15, P179; SMITH WL, 1992, AM J PHYSIOL, V263, P181; Sterneck E, 1997, GENE DEV, V11, P2153, DOI 10.1101/gad.11.17.2153; TAZAWA R, 1994, BIOCHEM BIOPH RES CO, V203, P190, DOI 10.1006/bbrc.1994.2167; Tsai SJ, 1996, ENDOCRINOLOGY, V137, P3348, DOI 10.1210/en.137.8.3348; Vallet VS, 1997, J BIOL CHEM, V272, P21944, DOI 10.1074/jbc.272.35.21944; VANDEROUDERAA FJ, 1977, BIOCHIM BIOPHYS ACTA, V487, P315, DOI 10.1016/0005-2760(77)90008-X; Williams CS, 1996, AM J PHYSIOL-GASTR L, V270, pG393; WONG WYL, 1991, MOL ENDOCRINOL, V5, P1269, DOI 10.1210/mend-5-9-1269; Xiao CW, 1998, ENDOCRINOLOGY, V139, P2293, DOI 10.1210/en.139.5.2293; XIE WL, 1991, P NATL ACAD SCI USA, V88, P2692, DOI 10.1073/pnas.88.7.2692; XIE WL, 1994, MOL CELL BIOL, V14, P6531, DOI 10.1128/MCB.14.10.6531; Xie WL, 1996, J BIOL CHEM, V271, P31742, DOI 10.1074/jbc.271.49.31742; Yamamoto K, 1995, J BIOL CHEM, V270, P31315, DOI 10.1074/jbc.270.52.31315; YEN SSC, 1986, REPRODUCTIVE ENDOCRI, P200; YOKOYAMA C, 1989, BIOCHEM BIOPH RES CO, V165, P888, DOI 10.1016/S0006-291X(89)80049-X	55	47	48	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 3	1999	274	49					35037	35045		10.1074/jbc.274.49.35037	http://dx.doi.org/10.1074/jbc.274.49.35037			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	260XW	10574982	hybrid			2022-12-25	WOS:000083979600076
J	Ye, JP; Wang, SW; Leonard, SS; Sun, Y; Butterworth, L; Antonini, J; Ding, M; Rojanasakul, Y; Vallyathan, V; Castranova, V; Shi, XL				Ye, JP; Wang, SW; Leonard, SS; Sun, Y; Butterworth, L; Antonini, J; Ding, M; Rojanasakul, Y; Vallyathan, V; Castranova, V; Shi, XL			Role of reactive oxygen species and p53 in chromium(VI)-induced apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HYDROXYL RADICAL GENERATION; KAPPA-B ACTIVATION; HYDROGEN-PEROXIDE; MITOCHONDRIAL CONTROL; TUMOR-SUPPRESSOR; DNA-DAMAGE; REDUCTION; CELLS; CHROMIUM(V); PATHWAY	Apoptosis is a programmed cell death mechanism to control cell number in tissues and to eliminate individual cells that may lead to disease states. The present study investigates chromium(VI) (Cr(VI))-induced apoptosis and the role of reactive oxygen species (ROS) and p53 in this response, Treatment of human lung epithelial cells (A549) with Cr(VI) caused apoptosis as measured by DNA fragmentation, mitochondria damage, and cell morphology, Cr(VI)-induced apoptosis is contributed to ROS generation, resulting from cellular reduction of Cr(VI) as measured by flow cytometric analysis of the stained cells, oxygen consumption and electron spin resonance spin trapping Scavengers of ROS, such as catalase, aspirin, and N-acetyl-L-cysteine, decreased Cr(VI)-induced apoptosis, whereas NADPH and glutathione reductase, enhancers of Cr(VI)-induced BOS generation, increased it. p53 is activated by Cr(VI), mostly by ROS-mediated free radical reactions. Cr(VI)-induced ROS generation occurred within a few minutes after Cr(VI) treatment of the cells, whereas p53 induction took at least 5 h, The level of Cr(VI)-induced apoptosis was similar in both p53-positive cells and p53-negative cells independent of p53 status in the early stage (0-3 h) of Cr(VI) treatment, However, at the later stage (3-24 h), the level of the apoptosis is higher in p53-positive cells than in p53-negative cells. These results suggest that ROS generated through Cr(VI) reduction is responsible to the early stage of apoptosis, whereas p53 contributes to the late stage of apoptosis and is responsible for the enhancement of Cr(VI)-induced apoptosis at this stage.	NIOSH, Pathol & Physiol Res Branch, Hlth Effects Lab Div, Morgantown, WV 26505 USA; W Virginia Univ, Dept Basic Pharmaceut Sci, Morgantown, WV 26506 USA; Warner Lambert Parke Davis, Parke Davis Pharmaceut Res, Dept Mol Biol, Ann Arbor, MI 48105 USA	Centers for Disease Control & Prevention - USA; National Institute for Occupational Safety & Health (NIOSH); West Virginia University; Pfizer	Shi, XL (corresponding author), NIOSH, Pathol & Physiol Res Branch, Hlth Effects Lab Div, 1095 Willowdale Rd, Morgantown, WV 26505 USA.		Shi, Xianglin/B-8588-2012; Ye, Jianping/N-1998-2017	Ye, Jianping/0000-0003-3875-365X; Rojanasakul, Yon/0000-0002-8839-6462				Brown JM, 1999, CANCER RES, V59, P1391; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; CARTER WO, 1994, J LEUKOCYTE BIOL, V55, P253; Chen F, 1997, ARCH BIOCHEM BIOPHYS, V338, P165, DOI 10.1006/abbi.1996.9849; COSSARIZZA A, 1994, EXP CELL RES, V214, P323, DOI 10.1006/excr.1994.1264; DEFLORA S, 1990, MUTAT RES, V238, P99, DOI 10.1016/0165-1110(90)90007-X; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; HOCKENBERY DM, 1993, CELL, V75, P241, DOI 10.1016/0092-8674(93)80066-N; Jabs T, 1999, BIOCHEM PHARMACOL, V57, P231, DOI 10.1016/S0006-2952(98)00227-5; Johnson TM, 1996, P NATL ACAD SCI USA, V93, P11848, DOI 10.1073/pnas.93.21.11848; Kataoka M, 1997, FREE RADICAL RES, V27, P419, DOI 10.3109/10715769709065781; Kroemer G, 1997, IMMUNOL TODAY, V18, P44, DOI 10.1016/S0167-5699(97)80014-X; Leonard S, 1998, J INORG BIOCHEM, V70, P239, DOI 10.1016/S0162-0134(98)10022-3; Lin DL, 1996, J BIOL CHEM, V271, P14649, DOI 10.1074/jbc.271.25.14649; Liu KJ, 1997, BIOCHEM BIOPH RES CO, V235, P54, DOI 10.1006/bbrc.1997.6277; Lotem J, 1996, P NATL ACAD SCI USA, V93, P12507, DOI 10.1073/pnas.93.22.12507; Marchetti P, 1996, J EXP MED, V184, P1155, DOI 10.1084/jem.184.3.1155; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; Prives C, 1998, CELL, V95, P5, DOI 10.1016/S0092-8674(00)81774-2; RUBIN SJ, 1991, J SURG ONCOL, V46, P31, DOI 10.1002/jso.2930460108; Shackelford RE, 1999, ENVIRON HEALTH PERSP, V107, P5, DOI 10.2307/3434468; Shi XL, 1999, J TOXICOL ENV HEAL B, V2, P87, DOI 10.1080/109374099281241; SHI XL, 1994, CARCINOGENESIS, V15, P2475, DOI 10.1093/carcin/15.11.2475; SHI XL, 1989, BIOCHEM BIOPH RES CO, V163, P627, DOI 10.1016/0006-291X(89)92183-9; SHI XL, 1990, ARCH BIOCHEM BIOPHYS, V277, P342, DOI 10.1016/0003-9861(90)90589-Q; SHI XL, 1992, ARCH BIOCHEM BIOPHYS, V299, P154, DOI 10.1016/0003-9861(92)90257-W; SMILEY ST, 1991, P NATL ACAD SCI USA, V88, P3671, DOI 10.1073/pnas.88.9.3671; SNYDER RD, 1988, MUTAT RES, V193, P237, DOI 10.1016/0167-8817(88)90034-X; Ye JP, 1996, MOL CELL BIOL, V16, P4744; YE JP, 1995, CARCINOGENESIS, V16, P2401, DOI 10.1093/carcin/16.10.2401; Zamzami N, 1996, J EXP MED, V183, P1533, DOI 10.1084/jem.183.4.1533; ZAMZAMI N, 1995, J EXP MED, V182, P367, DOI 10.1084/jem.182.2.367; ZAMZAMI N, 1995, J EXP MED, V181, P1661, DOI 10.1084/jem.181.5.1661	33	243	252	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 3	1999	274	49					34974	34980		10.1074/jbc.274.49.34974	http://dx.doi.org/10.1074/jbc.274.49.34974			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	260XW	10574974	hybrid, Green Published			2022-12-25	WOS:000083979600068
J	Jones, MK; Sasaki, E; Halter, F; Pai, R; Nakamura, T; Arakawa, T; Kuroki, T; Tarnawski, AS				Jones, MK; Sasaki, E; Halter, F; Pai, R; Nakamura, T; Arakawa, T; Kuroki, T; Tarnawski, AS			HGF triggers activation of the COX-2 gene in rat gastric epithelial cells: action mediated through the ERK2 signaling pathway	FASEB JOURNAL			English	Article						RGM1 cells; receptor phosphorylation; c-Met/HGF receptor	HEPATOCYTE GROWTH-FACTOR; NITRIC-OXIDE SYNTHASE; PROTEIN-KINASE; MESSENGER-RNA; ARACHIDONIC-ACID; MUCOSAL LESIONS; STOMACH; CYCLOOXYGENASE-2; EXPRESSION; PROSTAGLANDIN	Although it is established that growth factors and prostaglandins function in the maintenance of gastric mucosal integrity and in the healing of gastric mucosal injury and ulceration, the regulatory relationship between growth factors and prostaglandins in the gastric mucosa is not well characterized. Therefore, we investigated whether hepatocyte growth factor (HGF) affects expression of COX-2 (the inducible form of the prostaglandin synthesizing enzyme, cyclooxygenase) in gastric epithelial cells and whether this action is mediated through the MAP (ERK) kinase signaling pathway. In RGM1 cells (an epithelial cell line derived from normal rat gastric mucosa), HGF caused an increase in COX-2 mRNA and protein by 236% and 175%, respectively (both P<0.05). This induction of COX-2 expression was abolished by pretreatment with the MAPK kinase (MEK) inhibitor PD98059. HGF also triggered a 13-fold increase in c-Met/HGF receptor phosphorylation (P<0.005) and increased ERK2 activity by 684% (P<0.01). Pretreatment with PD98059 abolished the HGF-induced increase in ERK2 activity, but not c-Met/HGF receptor phosphorylation. The specific inhibitor of p38 MAP kinase, SB203580, had no effect on HGF-induced COX-2 expression. Thus, HGF triggers activation of the COX-2 gene in gastric epithelial cells through phosphorylation of c-Met/HGF receptor and activation of the ERK2 signaling pathway.	Vet Affairs Med Ctr, Long Beach, CA 90822 USA; Univ Calif Irvine, Irvine, CA 92717 USA; Osaka City Univ, Sch Med, Dept Internal Med 3, Osaka 545, Japan; Osaka City Univ, Sch Med, Biomed Res Ctr, Div Biochem, Osaka 545, Japan	US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Long Beach Healthcare System; University of California System; University of California Irvine; Osaka Metropolitan University; Osaka Metropolitan University	Tarnawski, AS (corresponding author), Vet Affairs Med Ctr, 5901 E 7th St, Long Beach, CA 90822 USA.	atarnawski@yahoo.com						ADACHI T, 1995, HEPATOLOGY, V21, P1668; BASSON MD, 1992, J CLIN INVEST, V90, P15, DOI 10.1172/JCI115828; BOYCE S, 1994, NEUROPHARMACOLOGY, V33, P1609, DOI 10.1016/0028-3908(94)90137-6; CHAN CC, 1995, J PHARMACOL EXP THER, V274, P1531; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Davies NM, 1997, ALIMENT PHARM THERAP, V11, P1101, DOI 10.1046/j.1365-2036.1997.00247.x; Dean JLE, 1999, J BIOL CHEM, V274, P264, DOI 10.1074/jbc.274.1.264; Donnelly MT, 1997, GASTROENTEROLOGY, V112, pA105; Dubois RN, 1998, FASEB J, V12, P1063, DOI 10.1096/fasebj.12.12.1063; EHRLICH K, 1998, AM J PHYSIOL, V247, pG955; Ferraz JGP, 1997, GASTROENTEROLOGY, V113, P195, DOI 10.1016/S0016-5085(97)70095-7; Giardiello FM, 1998, DIGEST DIS SCI, V43, P311; GILLILAND G, 1990, P NATL ACAD SCI USA, V87, P2725, DOI 10.1073/pnas.87.7.2725; Gretzer B, 1998, BRIT J PHARMACOL, V123, P927, DOI 10.1038/sj.bjp.0701673; GustafsonSvard C, 1996, GUT, V38, P79, DOI 10.1136/gut.38.1.79; HORI T, 1993, FEBS LETT, V334, P331, DOI 10.1016/0014-5793(93)80705-Y; Horie-Sakata K, 1998, J CLIN GASTROENTEROL, V27, pS40, DOI 10.1097/00004836-199800001-00008; INAUEN W, 1988, GASTROENTEROLOGY, V95, P636, DOI 10.1016/S0016-5085(88)80009-X; ISEKI S, 1995, HISTOCHEM J, V27, P323, DOI 10.1007/BF00398975; Karim S, 1996, J BIOL CHEM, V271, P12042, DOI 10.1074/jbc.271.20.12042; KINOSHITA Y, 1995, GASTROENTEROLOGY, V109, P1068, DOI 10.1016/0016-5085(95)90564-2; Kishimoto Y, 1998, ARCH BIOCHEM BIOPHYS, V352, P153, DOI 10.1006/abbi.1997.0572; KRAMER MF, 1995, CURRENT PROTOCOLS MO, V2; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANGENBACH R, 1995, CELL, V83, P483, DOI 10.1016/0092-8674(95)90126-4; LEE SH, 1992, J BIOL CHEM, V267, P25934; Majumdar APN, 1996, J LAB CLIN MED, V128, P173, DOI 10.1016/S0022-2143(96)90009-8; MATSUMOTO K, 1995, J BIOCHEM-TOKYO, V117, P458, DOI 10.1093/jb/117.2.458; Matsumoto K, 1997, BIOCHEM BIOPH RES CO, V239, P639, DOI 10.1006/bbrc.1997.7517; Mizuno H, 1997, GASTROENTEROLOGY, V112, P387, DOI 10.1053/gast.1997.v112.pm9024292; MORHAM SG, 1995, CELL, V83, P437; NUDEL U, 1983, NUCLEIC ACIDS RES, V11, P1759, DOI 10.1093/nar/11.6.1759; Ohta M, 1997, GASTROENTEROLOGY, V112, P1920, DOI 10.1053/gast.1997.v112.pm9178684; ONEILL GP, 1993, FEBS LETT, V330, P156, DOI 10.1016/0014-5793(93)80263-T; Pai R, 1998, GASTROENTEROLOGY, V114, P706, DOI 10.1016/S0016-5085(98)70584-0; Rainsford K. D., 1995, Inflammopharmacology, V3, P299, DOI 10.1007/BF02668024; REINHART WH, 1983, GASTROENTEROLOGY, V85, P1003; Ridley SH, 1997, J IMMUNOL, V158, P3165; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; Sasaki E, 1998, J CLIN GASTROENTEROL, V27, pS21, DOI 10.1097/00004836-199800001-00005; Sawaoka H, 1997, J CLIN GASTROENTEROL, V25, pS105, DOI 10.1097/00004836-199700001-00018; Schmassmann A, 1997, GASTROENTEROLOGY, V113, P1858, DOI 10.1016/S0016-5085(97)70005-2; SCHMASSMANN A, 1995, AM J PHYSIOL-GASTR L, V268, pG276, DOI 10.1152/ajpgi.1995.268.2.G276; Schmassmann A, 1998, BRIT J PHARMACOL, V123, P795, DOI 10.1038/sj.bjp.0701672; Schmassmann A, 1997, FALK SYMP, V94, P180; Serhan CN, 1996, FASEB J, V10, P1147, DOI 10.1096/fasebj.10.10.8751717; SIEBERT PD, 1993, BIOTECHNIQUES, V14, P244; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; STOLZ DB, 1994, J CELL BIOCHEM, V55, P445, DOI 10.1002/jcb.240550405; Takahashi M, 1996, J CLIN INVEST, V98, P2604, DOI 10.1172/JCI119080; Tanoue K, 1996, GASTROENTEROLOGY, V110, P549, DOI 10.1053/gast.1996.v110.pm8566603; TARNAWSKI A, 1988, J CLIN INVEST, V81, P1081, DOI 10.1172/JCI113420; Tarnawski A, 1997, GASTROENTEROLOGY, V112, pA309; Tarnawski A, 1995, J CLIN GASTROENTEROL, V21, pS93; Tarnawski A, 1996, GASTROENTEROLOGY, V110, pA275; TSUJI S, 1995, DIGEST DIS SCI, V40, P1132, DOI 10.1007/BF02064211; TYTGAT GNJ, 1986, GASTROENTEROLOGY, V90, P1111, DOI 10.1016/0016-5085(86)90375-6; Ukawa H, 1998, DIGEST DIS SCI, V43, P2003, DOI 10.1023/A:1018846912032; VANE J, 1994, NATURE, V367, P215, DOI 10.1038/367215a0; Vane J. R., 1998, AM J MED, V104, p2S, DOI [DOI 10.1016/S0002-9343(97)00203-9, 10.1016/S0002-9343(97)00203-9]; WATANABE S, 1993, BIOCHEM BIOPH RES CO, V19, P1452; XIE WL, 1991, P NATL ACAD SCI USA, V88, P2692, DOI 10.1073/pnas.88.7.2692; Yeomans ND, 1998, GASTROENTEROLOGY, V115, P227, DOI 10.1016/S0016-5085(98)70388-9	63	87	89	0	6	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	1999	13	15					2186	2194		10.1096/fasebj.13.15.2186	http://dx.doi.org/10.1096/fasebj.13.15.2186			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	266QN	10593866				2022-12-25	WOS:000084310800010
J	Shang, YF; Baumrucker, CR; Green, MH				Shang, YF; Baumrucker, CR; Green, MH			The induction and activation of STAT1 by all-trans-retinoic acid are mediated by RAR beta signaling pathways in breast cancer cells	ONCOGENE			English	Article						retinoic acid; RAR; STAT1; breast cancer; gene expression	PROMYELOCYTIC LEUKEMIA-CELLS; GROWTH-INHIBITION; RECEPTOR-BETA; INTERFERON-ALPHA; GENE-EXPRESSION; UP-REGULATION; LUNG-CANCER; APOPTOSIS; PROTEIN; ARREST	Retinoic acid receptor-beta (RAR beta) and signal transducer and activator of transcription 1 (STAT1) are important mediators of the antiproliferative and apoptotic actions of retinoids and cytokines/growth factors, respectively. Expression of both RAR beta and STAT1 is lost in most breast cancer cell lines but it can be induced by retinoids in estrogen receptor-positive cells, We investigated a possible functional connection between these two mediators and present evidence supporting RAR beta as a tumor suppressor. First, by using different receptor-selective retinoids, we demonstrated that RAR beta induction in MCF-7 cells by all-trans-retinoic acid (atRA) was associated with the activation of STAT1 gene transcription. The direct involvement of RAR beta in atRA-induced STAT1 gene activation was further demonstrated by showing that transfection with an anti-sense RAR beta construct blocked atRA-induced STAT1 expression in MCF-7 cells whereas introduction of a sense-RAR beta construct resulted in STAT1 induction by atRA in MDA-MB 231 cells. In addition, we showed that STAT1 was phosphorylated/activated under atRA treatment of MCF-7 cells; this process required the involvement of RAR beta and protein synthesis. STAT1 phosphorylation/ activation was accompanied by increased tyrosine kinase activity that was not due to the activation of JAK1, JAK2 or Tyk 2, suggesting the possible involvement of an unidentified tyrosine kinase.	Penn State Univ, Dept Nutr, University Pk, PA 16802 USA; Penn State Univ, Dept Dairy & Anim Sci, University Pk, PA 16802 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park	Green, MH (corresponding author), Penn State Univ, Dept Nutr, S-126 Henderson Bldg S, University Pk, PA 16802 USA.				EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD032500] Funding Source: NIH RePORTER; NICHD NIH HHS [R01-HD32500] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Berard J, 1996, FASEB J, V10, P1091, DOI 10.1096/fasebj.10.9.8801172; Bromberg JF, 1996, P NATL ACAD SCI USA, V93, P7673, DOI 10.1073/pnas.93.15.7673; Chin YE, 1996, SCIENCE, V272, P719, DOI 10.1126/science.272.5262.719; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; Fitzgerald P, 1997, CANCER RES, V57, P2642; GEIER A, 1992, IN VITRO CELL DEV-AN, V28A, P725; GERBERT JF, 1991, ONCOGENE, V6, P1859; GIANNI M, 1995, BIOCHEM BIOPH RES CO, V208, P846, DOI 10.1006/bbrc.1995.1413; Gianni M, 1997, BLOOD, V89, P1001, DOI 10.1182/blood.V89.3.1001; HIGUCHI T, 1991, CANCER RES, V51, P3958; HOULE B, 1991, GENE CHROMOSOME CANC, V3, P358, DOI 10.1002/gcc.2870030506; Kalvakolanu DV, 1996, CANCER INVEST, V14, P25, DOI 10.3109/07357909609018435; Kolla V, 1996, J BIOL CHEM, V271, P10508, DOI 10.1074/jbc.271.18.10508; Kumar A, 1997, SCIENCE, V278, P1630, DOI 10.1126/science.278.5343.1630; LANGENFELD J, 1997, P NATL ACAD SCI USA, V94, P12071; Liu Y, 1996, MOL CELL BIOL, V16, P1138; Mangelsdorf David J., 1994, P319; Matikainen S, 1997, CELL GROWTH DIFFER, V8, P687; SCHINDLER C, 1995, ANNU REV BIOCHEM, V64, P621, DOI 10.1146/annurev.bi.64.070195.003201; SEEWALDT VL, 1995, CELL GROWTH DIFFER, V6, P1077; Shang YF, 1998, J BIOL CHEM, V273, P30608, DOI 10.1074/jbc.273.46.30608; SHEIKH MS, 1994, J BIOL CHEM, V269, P21440; Si SP, 1996, EXP CELL RES, V223, P102, DOI 10.1006/excr.1996.0062; Sun WH, 1998, BLOOD, V91, P570, DOI 10.1182/blood.V91.2.570.570_570_576; SWISSHELM K, 1994, CELL GROWTH DIFFER, V5, P133; Widschwendter M, 1997, CANCER RES, V57, P4158; Wong LH, 1997, J BIOL CHEM, V272, P28779, DOI 10.1074/jbc.272.45.28779; Zhang XK, 1996, MUTAT RES-FUND MOL M, V350, P267, DOI 10.1016/0027-5107(95)00102-6	28	33	33	0	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 18	1999	18	48					6725	6732		10.1038/sj.onc.1203084	http://dx.doi.org/10.1038/sj.onc.1203084			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	257QA	10597280				2022-12-25	WOS:000083792000014
J	Singh, KK; Russell, J; Sigala, B; Zhang, YG; Williams, J; Keshav, KF				Singh, KK; Russell, J; Sigala, B; Zhang, YG; Williams, J; Keshav, KF			Mitochondrial DNA determines the cellular response to cancer therapeutic agents	ONCOGENE			English	Article						mitochondria; mitochondrial DNA; cell death; adriamycin	PHOTODYNAMIC THERAPY; CELLS; DOXORUBICIN; APOPTOSIS; AMPLIFICATION; BIOENERGETICS; EXPRESSION; PORPHYRIN; FAILURE; REPAIR	Mutations in the mitochondrial genome leading to mitochondrial dysfunction have been reported in a variety of cancers. However, the potential implication of these findings in the cellular response to cancer therapeutic agents is unclear. To examine the importance of mitochondrial DNA (mitDNA) encoded functions in cancer therapeutic response, we determined the clonogenic survival of HSL2 (Rho(+), HeLa subline), and its derivative cell line lacking mitDNA (Rho(o)) after exposure to different anticancer agents. We found that isogenic Rho(o) cells lacking mitDNA were extremely resistant to adriamycin and photodynamic therapy (PDT) induced cell death, whereas the Rho(+) cell line was sensitive. However, there was no measurable difference in the responses of these cell lines to either alkylating agent or gamma-radiation. We show that the development of resistance to adriamycin was not due to changes in apoptotic cell death, cell cycle response or to the uptake of adriamycin in isogenic Rho(o) cells. We also demonstrate that exposure of HeLa cells to adriamycin leads to mutations in mitDNA. These studies provide direct evidence that mitDNA plays an important role in cellular sensitivity to cancer therapeutic agents.	Johns Hopkins Univ, Sch Med, Johns Hopkins Oncol Ctr, Baltimore, MD 21287 USA; Drexel Univ, Dept Biosci & Biotechnol, Philadelphia, PA 19104 USA	Johns Hopkins University; Johns Hopkins Medicine; Drexel University	Singh, KK (corresponding author), Johns Hopkins Univ, Sch Med, Johns Hopkins Oncol Ctr, 600 N Wolfe St,Room 2-121, Baltimore, MD 21287 USA.				NCI NIH HHS [CA/ES 66204] Funding Source: Medline; NIEHS NIH HHS [ES 09714-01] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES009714] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Boultwood J, 1996, BRIT J HAEMATOL, V95, P426, DOI 10.1046/j.1365-2141.1996.d01-1922.x; CHEVILLARD S, 1990, J CANCER RES CLIN, V116, P633, DOI 10.1007/BF01637086; Eguchi Y, 1997, CANCER RES, V57, P1835; El-Deiry Wafik S., 1997, Current Opinion in Oncology, V9, P79; Fisher AMR, 1999, CANCER RES, V59, P331; Habano W, 1998, ONCOGENE, V17, P1931, DOI 10.1038/sj.onc.1202112; HILF R, 1987, PHOTOCHEM PHOTOBIOL, V46, P806; Isaacs JS, 1997, ONCOGENE, V14, P1669, DOI 10.1038/sj.onc.1201001; ITO H, 1990, P NATL ACAD SCI USA, V87, P4275, DOI 10.1073/pnas.87.11.4275; KESHAV KF, 1998, MITOCHONDRIAL DNA MU; Kiberstis PA, 1999, SCIENCE, V283, P1475; KING MP, 1988, CELL, V52, P811, DOI 10.1016/0092-8674(88)90423-0; KULE C, 1994, MOL PHARMACOL, V46, P1234; Liang BC, 1996, MUTAT RES-FUND MOL M, V354, P27, DOI 10.1016/0027-5107(96)00004-8; Liang BC, 1998, CELL DEATH DIFFER, V5, P694, DOI 10.1038/sj.cdd.4400401; Marchetti P, 1996, CANCER RES, V56, P2033; ModicaNapolitano JS, 1996, CANCER RES, V56, P544; MORAIS R, 1994, CANCER RES, V54, P3889; Munday AD, 1996, BBA-MOL CELL RES, V1311, P1, DOI 10.1016/0167-4889(96)00008-0; NASS MMK, 1972, EXP CELL RES, V72, P211, DOI 10.1016/0014-4827(72)90583-6; Palmeira CM, 1997, BBA-BIOENERGETICS, V1321, P101, DOI 10.1016/S0005-2728(97)00055-8; Pedersen P L, 1978, Prog Exp Tumor Res, V22, P190; Pedersen PL, 1997, J BIOENERG BIOMEMBR, V29, P301, DOI 10.1023/A:1022417911796; PETIT PX, 1998, MITOCHONDRIAL DNA MU; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; Polyak K, 1998, NAT GENET, V20, P291, DOI 10.1038/3108; Rempel A, 1996, CANCER RES, V56, P2468; RICHTER C, 1988, FEBS LETT, V241, P1, DOI 10.1016/0014-5793(88)81018-4; SCHATZ G, 1995, BBA-MOL BASIS DIS, V1271, P123, DOI 10.1016/0925-4439(95)00018-Y; SEGALBENDIRDJIAN E, 1988, CANCER RES, V48, P4982; Shan K, 1996, ANN INTERN MED, V125, P47, DOI 10.7326/0003-4819-125-1-199607010-00008; SHARKEY SM, 1993, CANCER RES, V53, P4994; SHARP MGF, 1992, J PATHOL, V168, P163, DOI 10.1002/path.1711680203; Singal PK, 1997, FASEB J, V11, P931, DOI 10.1096/fasebj.11.12.9337145; SINGH KK, 1998, MITOCHONDRIAL DNA MU; Takao M, 1998, NUCLEIC ACIDS RES, V26, P2917, DOI 10.1093/nar/26.12.2917; TALLINI G, 1997, VIRCHOWS ARCH, V433, P5; Tanaka M, 1996, Methods Enzymol, V264, P407, DOI 10.1016/S0076-6879(96)64037-3; Toffoli G, 1996, EUR J CANCER, V32A, P1591, DOI 10.1016/0959-8049(96)00113-X; VONHOFF DD, 1979, ANN INTERN MED, V91, P710, DOI 10.7326/0003-4819-91-5-710; Wallace KB, 1997, FUND APPL TOXICOL, V38, P23, DOI 10.1006/faat.1997.2320; WELTER C, 1989, GENE CHROMOSOME CANC, V1, P79, DOI 10.1002/gcc.2870010112; WOODBURN KW, 1992, PHOTOCHEM PHOTOBIOL, V55, P697	43	152	162	0	9	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 18	1999	18	48					6641	6646		10.1038/sj.onc.1203056	http://dx.doi.org/10.1038/sj.onc.1203056			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	257QA	10597269				2022-12-25	WOS:000083792000003
J	Thant, AA; Sein, TT; Liu, EB; Machida, K; Kikkawa, F; Koike, T; Seiki, M; Matsuda, S; Hamaguchi, M				Thant, AA; Sein, TT; Liu, EB; Machida, K; Kikkawa, F; Koike, T; Seiki, M; Matsuda, S; Hamaguchi, M			Ras pathway is required for the activation of MMP-2 secretion and for the invasion of src-transformed 3Y1	ONCOGENE			English	Article						Ras; v-Src; matrix metalloproteinase-2; invasion; signaling pathway	ROUS-SARCOMA VIRUS; V-SRC; MATRIX METALLOPROTEINASES; TYROSINE PHOSPHORYLATION; CELL-TRANSFORMATION; STAT3 ACTIVATION; INFECTED CELLS; MESSENGER-RNA; GENE-PRODUCT; TUMOR-CELLS	To search for the signaling pathway critical for tumor invasion, we examined the effects of dominant negative ras (S17N ras) expression on the activation of matrix metalloproteinase-2 (MMP-2) in spc-transformed 3Y1, SR3Y1, under the control of conditionally inducible promoter. In SR3Y1 clones transfected with S17N pas, augmented secretion and proteolytic activation of MMP-2 were dramatically suppressed by S17N Ras expression, while tyrosine phosphorylation of cellular proteins was not suppressed. We found that invasiveness of SR3Y1 cells assayed by the modified Boyden Chamber method was strongly suppressed by S17N Ras expression. In contrast, cell morphology reverted partially and glucose uptake remained unchanged by S17N Ras expression. In addition, treatment of SR3Y1 with manumycin A, a potent inhibitor of Ras farnesyltransferase, strongly suppressed both augmented secretion and proteolytic activation of MMP-2. Contrary, treatment of SR3Y1 with wortmannin or TPA showed no clear effect on MMP-2 activation. Thus, these results strongly suggest that Ras-signaling, but neither P13 kinase- nor protein kinase C-signalings, plays a critical role in activation of MMP-2 and, subsequently, in the invasiveness of src-transformed cells.	Nagoya Univ, Sch Med, Dept Mol Pathogenesis, Showa Ku, Nagoya, Aichi 4668550, Japan; Nagoya Univ, Sch Med, Dept Obstet & Gynecol, Showa Ku, Nagoya, Aichi 4668550, Japan; Univ Tokyo, Inst Med Sci, Dept Canc Cell Res, Minato Ku, Tokyo 1088639, Japan	Nagoya University; Nagoya University; University of Tokyo	Hamaguchi, M (corresponding author), Nagoya Univ, Sch Med, Dept Mol Pathogenesis, Showa Ku, 65 Tsurumai Cho, Nagoya, Aichi 4668550, Japan.		KIKKAWA, Fumitaka/I-7341-2014; Seiki, Motoharu/K-9443-2015					Aftab DT, 1997, P NATL ACAD SCI USA, V94, P3028, DOI 10.1073/pnas.94.7.3028; ALBINI A, 1987, CANCER RES, V47, P3239; Bromberg JF, 1998, MOL CELL BIOL, V18, P2553, DOI 10.1128/MCB.18.5.2553; BURR JG, 1980, P NATL ACAD SCI-BIOL, V77, P3484, DOI 10.1073/pnas.77.6.3484; Campbell SL, 1998, ONCOGENE, V17, P1395, DOI 10.1038/sj.onc.1202174; Cao XM, 1996, MOL CELL BIOL, V16, P1595; Chang HW, 1997, SCIENCE, V276, P1848, DOI 10.1126/science.276.5320.1848; COLLETT MS, 1978, P NATL ACAD SCI USA, V75, P2021, DOI 10.1073/pnas.75.4.2021; COLLIER IE, 1988, J BIOL CHEM, V263, P6579; DECLUE JE, 1991, MOL CELL BIOL, V11, P2819, DOI 10.1128/MCB.11.5.2819; FEIG LA, 1988, MOL CELL BIOL, V8, P3235, DOI 10.1128/MCB.8.8.3235; FUKUI Y, 1989, MOL CELL BIOL, V9, P1651, DOI 10.1128/MCB.9.4.1651; HAMAGUCHI M, 1987, P NATL ACAD SCI USA, V84, P2312, DOI 10.1073/pnas.84.8.2312; HAMAGUCHI M, 1993, EMBO J, V12, P307, DOI 10.1002/j.1460-2075.1993.tb05658.x; HAMAGUCHI M, 1990, MOL CELL BIOL, V10, P830, DOI 10.1128/MCB.10.2.830; HAMAGUCHI M, 1988, MOL CELL BIOL, V8, P3035, DOI 10.1128/MCB.8.8.3035; HAMAGUCHI M, 1995, ONCOGENE, V10, P1037; HAMAGUCHI M, 1993, ONCOGENE, V8, P559; HANAFUSA H, 1977, COMPREHENSIVE VIROLO, V10, P401; HATANAKA M, 1970, VIROLOGY, V41, P647, DOI 10.1016/0042-6822(70)90429-0; Kataoka M, 1996, INT J ONCOL, V8, P773; KAWAI S, 1980, J VIROL, V34, P772, DOI 10.1128/JVI.34.3.772-776.1980; KAWAI S, 1971, VIROLOGY, V46, P470, DOI 10.1016/0042-6822(71)90047-X; Klein NP, 1997, MOL CELL BIOL, V17, P6427, DOI 10.1128/MCB.17.11.6427; LEVINSON AD, 1978, CELL, V15, P561, DOI 10.1016/0092-8674(78)90024-7; LIOTTA LA, 1986, CANCER RES, V46, P1; MATRISIAN LM, 1990, TRENDS GENET, V6, P121, DOI 10.1016/0168-9525(90)90126-Q; MULLINS DE, 1983, BIOCHIM BIOPHYS ACTA, V695, P177, DOI 10.1016/0304-419X(83)90011-2; NORI M, 1991, MOL CELL BIOL, V11, P2812, DOI 10.1128/MCB.11.5.2812; OHTANI H, 1995, JPN J CANCER RES, V86, P833, DOI 10.1111/j.1349-7006.1995.tb03093.x; OKADA A, 1995, P NATL ACAD SCI USA, V92, P2730, DOI 10.1073/pnas.92.7.2730; PYKE C, 1992, CANCER RES, V52, P1336; SATO H, 1994, NATURE, V370, P61, DOI 10.1038/370061a0; SMITH MR, 1986, NATURE, V320, P540, DOI 10.1038/320540a0; STETLERSTEVENSON WG, 1989, J BIOL CHEM, V264, P1353; TAMANOI F, 1993, TRENDS BIOCHEM SCI, V18, P349, DOI 10.1016/0968-0004(93)90072-U; Thant AA, 1997, FEBS LETT, V406, P28, DOI 10.1016/S0014-5793(97)00230-5; Turkson J, 1998, MOL CELL BIOL, V18, P2545, DOI 10.1128/MCB.18.5.2545; WOESSNER JF, 1991, FASEB J, V5, P2145, DOI 10.1096/fasebj.5.8.1850705; XIAO HY, 1995, INT J ONCOL, V6, P405; YU CL, 1995, SCIENCE, V269, P81, DOI 10.1126/science.7541555; ZANG Q, 1995, CELL GROWTH DIFFER, V6, P1367	42	32	32	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 11	1999	18	47					6555	6563		10.1038/sj.onc.1203049	http://dx.doi.org/10.1038/sj.onc.1203049			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	256CW	10597259	Bronze			2022-12-25	WOS:000083709200019
J	Trautwein, C; Will, M; Kubicka, S; Rakemann, T; Flemming, P; Manns, MP				Trautwein, C; Will, M; Kubicka, S; Rakemann, T; Flemming, P; Manns, MP			2-acetaminofluorene blocks cell cycle progression after hepatectomy by p21 induction and lack of Cyclin E expression	ONCOGENE			English	Article						2-acetaminofluorene; hepatectomy; liver regeneration; cell cycle progression; P21; Cyclin E	LIVER STEM-CELLS; RETINOBLASTOMA PROTEIN; OVAL CELLS; DEPENDENT KINASES; G(1) ARREST; TRANSCRIPTION FACTORS; REGENERATING LIVER; GENE-TRANSCRIPTION; DOWN-REGULATION; GROWTH	In the Solt-Faber model DENA and 2-Acetaminofluorene (AAF) treatment combined with hepatectomy induces hepatocellular carcinoma in rats. In this model AAF blocks proliferation of hepatocytes, while oval cells restore liver mass. Here we studied the molecular mechanism involved in blocking AAF-dependent cell cycle progression of hepatocytes. AAF inhibits cell proliferation of hepatocytes shown by the lack of Cyclin E expression before the G1/S phase restriction point. Immunfluorescence studies revealed that Cyclin E positive signals mere restricted to oval cells, while hepatocytes remained negative. Additionally, AAF treatment induces strong nuclear p53 expression which is associated with increased p21 mRNA levels. Inhibition of active Cyclin/CdK (cyclin dependent kinase) complexes is reflected in AAF-treated animals by decreased RE expression and phosphorylation. The decrease in RE expression and phosphorylation, which is essential in triggering DNA synthesis and Cyclin A expression, leads to a deficiency in transcriptionally active E2F complex formation after hepatectomy. Thus, two molecular explanations are evident to account for AAF-dependent cell cycle progression of hepatocytes in vivo: first, induction of p53 expression which leads to higher p21 mRNA levels, and second, a lack of Cyclin E expression at the G1/S phase restriction point after hepatectomy.	Med Hsch Hannover, Dept Gastroenterol & Hepatol, D-30625 Hannover, Germany; Med Hsch Hannover, Dept Pathol, D-30625 Hannover, Germany	Hannover Medical School; Hannover Medical School	Trautwein, C (corresponding author), Med Hsch Hannover, Dept Gastroenterol & Hepatol, Carl-Neuberg-Str 1, D-30625 Hannover, Germany.							Albrecht JH, 1998, ONCOGENE, V16, P2141, DOI 10.1038/sj.onc.1201728; Albrecht JH, 1997, HEPATOLOGY, V25, P557, DOI 10.1002/hep.510250311; Alison MR, 1996, CELL PROLIFERAT, V29, P373, DOI 10.1111/j.1365-2184.1996.tb00982.x; ALMASAN A, 1995, P NATL ACAD SCI USA, V92, P5436, DOI 10.1073/pnas.92.12.5436; ARROYO M, 1992, NUCLEIC ACIDS RES, V20, P5947, DOI 10.1093/nar/20.22.5947; Bisgaard HC, 1996, HEPATOLOGY, V23, P62, DOI 10.1002/hep.510230110; Bock CT, 1997, GASTROENTEROLOGY, V113, P1976, DOI 10.1016/S0016-5085(97)70018-0; CHEN JJ, 1995, NATURE, V374, P386, DOI 10.1038/374386a0; CHIOU K, 1994, MOL CELL BIOL, V15, P2556; CHOWDARY DR, 1994, MOL CELL BIOL, V14, P1997, DOI 10.1128/MCB.14.3.1997; Cressman DE, 1996, SCIENCE, V274, P1379, DOI 10.1126/science.274.5291.1379; CRESSMAN DE, 1995, HEPATOLOGY, V21, P1443, DOI 10.1016/0270-9139(95)90068-3; DEGREGORI J, 1995, GENE DEV, V9, P2873, DOI 10.1101/gad.9.23.2873; DYNLACHT BD, 1994, GENE DEV, V8, P1772, DOI 10.1101/gad.8.15.1772; ELDEIRY WS, 1994, CANCER RES, V54, P1169; ELLEDGE SJ, 1991, EMBO J, V10, P2653, DOI 10.1002/j.1460-2075.1991.tb07808.x; EVARTS RP, 1987, CARCINOGENESIS, V8, P1737, DOI 10.1093/carcin/8.11.1737; FARIS RA, 1991, CANCER RES, V51, P1308; Fausto N, 1990, CURR OPIN CELL BIOL, V2, P1036, DOI 10.1016/0955-0674(90)90153-6; FU XX, 1988, J VIROL, V62, P3422, DOI 10.1128/JVI.62.9.3422-3430.1988; GANNON JV, 1990, EMBO J, V9, P15905; GRANA X, 1995, ONCOGENE, V11, P211; GRISHAM JW, 1962, CANCER RES, V22, P842; HARPER JW, 1995, MOL BIOL CELL, V6, P387, DOI 10.1091/mbc.6.4.387; Herrera RE, 1996, MOL CELL BIOL, V16, P2402; Ikeda M, 1996, P NATL ACAD SCI USA, V93, P3215, DOI 10.1073/pnas.93.8.3215; KASTAN MB, 1991, CANCER RES, V51, P6304; LaBaer J, 1997, GENE DEV, V11, P847, DOI 10.1101/gad.11.7.847; LEES JA, 1993, MOL CELL BIOL, V13, P7813, DOI 10.1128/MCB.13.12.7813; Linke SP, 1997, ONCOGENE, V15, P337, DOI 10.1038/sj.onc.1201200; Livneh E, 1997, EUR J BIOCHEM, V248, P1, DOI 10.1111/j.1432-1033.1997.t01-4-00001.x; Michalopoulos GK, 1997, SCIENCE, V276, P60, DOI 10.1126/science.276.5309.60; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; Nasmyth K, 1996, SCIENCE, V274, P1643, DOI 10.1126/science.274.5293.1643; Niehof M, 1997, MOL CELL BIOL, V17, P3600, DOI 10.1128/MCB.17.7.3600; Nishida N, 1997, HISTOL HISTOPATHOL, V12, P1019; Ohtani K, 1995, P NATL ACAD SCI USA, V92, P12146, DOI 10.1073/pnas.92.26.12146; PAGANO M, 1992, EMBO J, V11, P961, DOI 10.1002/j.1460-2075.1992.tb05135.x; PARDEE AB, 1989, SCIENCE, V246, P603, DOI 10.1126/science.2683075; Petersen BE, 1998, HEPATOLOGY, V27, P433, DOI 10.1002/hep.510270218; SCHIRMACHER P, 1993, VIRCHOWS ARCH B, V63, P71, DOI 10.1007/BF02899246; Schnier JB, 1996, P NATL ACAD SCI USA, V93, P5941, DOI 10.1073/pnas.93.12.5941; SELL S, 1994, MODERN PATHOL, V7, P105; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; SIGAL HS, 1992, AM J PHYSIOL, V26, pG139; SLANSKY JE, 1993, MOL CELL BIOL, V13, P1610, DOI 10.1128/MCB.13.3.1610; SOLT D, 1976, NATURE, V263, P701, DOI 10.1038/263701a0; TEWARI M, 1992, MOL CELL BIOL, V12, P2898, DOI 10.1128/MCB.12.6.2898; THORGEIRSSON SS, 1993, AM J PATHOL, V142, P1331; Trautwein C, 1996, J BIOL CHEM, V271, P22262, DOI 10.1074/jbc.271.36.22262; TRAUTWEIN C, 1993, NATURE, V364, P544, DOI 10.1038/364544a0; Trautwein C, 1996, GASTROENTEROLOGY, V110, P1854, DOI 10.1053/gast.1996.v110.pm8964411; Trautwein C, 1998, J CLIN INVEST, V101, P1960, DOI 10.1172/JCI504; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; Wu H, 1996, GENE DEV, V10, P245, DOI 10.1101/gad.10.3.245; XU GF, 1995, P NATL ACAD SCI USA, V92, P1357, DOI 10.1073/pnas.92.5.1357; Yamada Y, 1997, P NATL ACAD SCI USA, V94, P1441, DOI 10.1073/pnas.94.4.1441	59	32	32	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 11	1999	18	47					6443	6453		10.1038/sj.onc.1203045	http://dx.doi.org/10.1038/sj.onc.1203045			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	256CW	10597246				2022-12-25	WOS:000083709200006
J	Arnold, JJ; Ghosh, SKB; Cameron, CE				Arnold, JJ; Ghosh, SKB; Cameron, CE			Poliovirus RNA-dependent RNA polymerase (3D(pol)) - Divalent cation modulation of primer, template, and nucleotide selection	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VIRUS REVERSE-TRANSCRIPTASE; HEPATITIS-C VIRUS; ESCHERICHIA-COLI; DNA-POLYMERASE; PROTEIN 3AB; VIRAL-RNA; IN-VITRO; IDENTIFICATION; REPLICATION; MECHANISM	We have analyzed the divalent cation specificity of poliovirus RNA-dependent RNA polymerase, 3D(pol). The following preference was observed: Mn2+ > Co2+ > Ni2+ > Fe2+ > Mg2+ > Ca2+ > Cu2+, and Zn2+ was incapable of supporting 3D(pol)-catalyzed nucleotide incorporation. In the presence of Mn2+, 3D(pol) activity was increased by greater than 10-fold relative to that in the presence of Mg2+. Steady-state kinetic analysis revealed that the increased activity observed in the presence of Mn2+ was due, primarily, to a reduction in the K-M value for 3D(pol) binding to primer/template, without any significant effect on the K-M value for nucleotide. The ability of 3D(pol) to catalyze RNA synthesis de novo was also stimulated approximately 10-fold by using Mn2+, and the enzyme was now capable of also utilizing a DNA template for primer-independent RNA synthesis. Interestingly, the use of Mn2+ as divalent cation permitted 3D(pol) activity to be monitored by following extension of 5'-P-32-end- labeled, heteropolymeric RNA primer/templates. The kinetics of primer extension were biphasic because of the enzyme binding to primer/template in both possible orientations. When bound in the incorrect orientation, 3D(pol) was capable of efficient addition of nucleotides to the blunt-ended duplex; this activity was also apparent in the presence of Mg2+. In the presence of Mn2+, 3D(pol) efficiently utilized dNTPs, ddNTPs, and incorrect NTPs. On average, three incorrect nucleotides could be incorporated by 3D(pol). The ability of 3D(pol) to incorporate the correct dNTP, but not the correct ddNTP, was also observed in the presence of Mg2+. Taken together, these results provide the first glimpse into the nucleotide specificity and fidelity of the poliovirus polymerase and suggest novel alternatives for the design of primer/templates to study the mechanism of 3D(pol)-catalyzed nucleotide incorporation.	Penn State Univ, Dept Biochem & Mol Biol, University Pk, PA 16802 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park	Cameron, CE (corresponding author), Penn State Univ, Dept Biochem & Mol Biol, University Pk, PA 16802 USA.		Ghosh, Saikat/AAD-1176-2022		NATIONAL CANCER INSTITUTE [K01CA075118] Funding Source: NIH RePORTER; NCI NIH HHS [CA75118] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adkins S, 1998, RNA, V4, P455; ANDINO R, 1993, EMBO J, V12, P3587, DOI 10.1002/j.1460-2075.1993.tb06032.x; Arnold JJ, 1999, BIOTECHNIQUES, V27, P450, DOI 10.2144/99273bm11; Arnold JJ, 1999, J BIOL CHEM, V274, P2706, DOI 10.1074/jbc.274.5.2706; BARTON DJ, 1995, J VIROL, V69, P5516, DOI 10.1128/JVI.69.9.5516-5527.1995; Beckman MTL, 1998, J BIOL CHEM, V273, P6724, DOI 10.1074/jbc.273.12.6724; Behrens SE, 1996, EMBO J, V15, P12, DOI 10.1002/j.1460-2075.1996.tb00329.x; Binz P. A., 1999, INTERNET RESOURCES P, P277; BROOKS RR, 1978, BIOCHEM J, V171, P725, DOI 10.1042/bj1710725; Buck KW, 1996, ADV VIRUS RES, V47, P159, DOI 10.1016/S0065-3527(08)60736-8; Carroll SS, 1996, METHOD ENZYMOL, V275, P365; CHO MW, 1993, J VIROL, V67, P3010, DOI 10.1128/JVI.67.6.3010-3018.1993; CIRINO NM, 1995, BIOCHEMISTRY-US, V34, P9936, DOI 10.1021/bi00031a016; DIAMOND SE, 1994, J VIROL, V68, P863, DOI 10.1128/JVI.68.2.863-876.1994; Gamarnik AV, 1996, EMBO J, V15, P5988, DOI 10.1002/j.1460-2075.1996.tb00985.x; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; Gohara DW, 1999, PROTEIN EXPRES PURIF, V17, P128, DOI 10.1006/prep.1999.1100; GRABBARA S, 1996, METHOD ENZYMOL, V275, P276; Hansen JL, 1997, STRUCTURE, V5, P1109, DOI 10.1016/S0969-2126(97)00261-X; HOUGHTON M, 1996, FIELDS VIROLOGY, V1, P1035; HSIEH JC, 1993, J BIOL CHEM, V268, P24607; Huang Y, 1997, BIOCHEMISTRY-US, V36, P13718, DOI 10.1021/bi971609o; ISHIHAMA A, 1994, ARCH VIROL, V134, P235, DOI 10.1007/BF01310564; JABLONSKI SA, 1995, J VIROL, V69, P1532, DOI 10.1128/JVI.69.3.1532-1539.1995; Kao CC, 1999, VIROLOGY, V253, P1, DOI 10.1006/viro.1998.9517; KATI WM, 1992, J BIOL CHEM, V267, P25988; KNOLL DA, STRUCTURE EXPRESSION, V2, P123; LAMB RA, 1996, VIROLOGY, V1, P1177; Lohmann V, 1997, J VIROL, V71, P8416, DOI 10.1128/JVI.71.11.8416-8428.1997; NEUFELD KL, 1994, J VIROL, V68, P5811, DOI 10.1128/JVI.68.9.5811-5818.1994; NEUFELD KL, 1991, J BIOL CHEM, V266, P24212; PALMENBERG A, 1974, Proceedings of the National Academy of Sciences of the United States of America, V71, P1371, DOI 10.1073/pnas.71.4.1371; PATA JD, 1995, RNA, V1, P466; Paul AV, 1998, NATURE, V393, P280, DOI 10.1038/30529; PAUL AV, 1994, J BIOL CHEM, V269, P29173; PELISKA JA, 1992, SCIENCE, V258, P1112, DOI 10.1126/science.1279806; PLOTCH SJ, 1989, J VIROL, V63, P216, DOI 10.1128/JVI.63.1.216-225.1989; Richards OC, 1998, J BIOL CHEM, V273, P12832, DOI 10.1074/jbc.273.21.12832; RUECKERT RR, 1996, FIELDS VIROLOGY, V1, P609; Serra MJ, 1995, METHOD ENZYMOL, V259, P242; SPIEGELMAN S, 1968, COLD SPRING HARB SYM, V33, P101, DOI 10.1101/SQB.1968.033.01.015; TABOR S, 1989, P NATL ACAD SCI USA, V86, P4076, DOI 10.1073/pnas.86.11.4076; THOMPSON JE, 1994, J AM CHEM SOC, V116, P5467, DOI 10.1021/ja00091a060; Vazquez AL, 1998, J VIROL, V72, P2999; Xiang WK, 1995, RNA, V1, P892; Xiang WK, 1997, SEMIN VIROL, V8, P256, DOI 10.1006/smvy.1997.0128; Xiang WK, 1998, J VIROL, V72, P6732, DOI 10.1128/JVI.72.8.6732-6741.1998	47	92	97	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 24	1999	274	52					37060	37069		10.1074/jbc.274.52.37060	http://dx.doi.org/10.1074/jbc.274.52.37060			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	267WR	10601264	hybrid			2022-12-25	WOS:000084382700035
J	Hsiang, BN; Zhu, YJ; Wang, ZQ; Wu, YL; Sasseville, V; Yang, WP; Kirchgessner, TG				Hsiang, BN; Zhu, YJ; Wang, ZQ; Wu, YL; Sasseville, V; Yang, WP; Kirchgessner, TG			A novel human hepatic organic anion transporting polypeptide (OATP2) - Identification of a liver-specific human organic anion transporting polypeptide and identification of rat and human hydroxymethylglutaryl-CoA reductase inhibitor transporters	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BILE-ACID; FUNCTIONAL-CHARACTERIZATION; DEHYDROEPIANDROSTERONE-SULFATE; EXPRESSION CLONING; CARDIAC-GLYCOSIDES; UPTAKE SYSTEM; PRAVASTATIN; TAUROCHOLATE; SUBSTRATE; DRUGS	A novel human organic transporter, OATP2, has been identified that transports taurocholic acid, the adrenal androgen dehydroepiandrosterone sulfate, and thyroid hormone, as well as the hydroxymethylglutaryl-CoA reductase inhibitor, pravastatin. OATP2 is expressed exclusively in liver in contrast to all other known transporter subtypes that are found in both hepatic and nonhepatic tissues. OATP2 is considerably diverged from other family members, sharing only 42% sequence identity with the four other subtypes. Furthermore, unlike other subtypes, OATP2 did not transport digoxin or aldosterone. The rat isoform oatp1 was also shown to transport pravastatin, whereas other members of the OATP family, i.e. rat oatp2, human OATP, and the prostaglandin transporter, did not. Cis-inhibition studies indicate that both OATP2 and roatp1 also transport other statins including lovastatin, simvastatin, and atorvastatin. In summary, OATP2 is a novel organic anion transport protein that has overlapping but not identical substrate specificities with each of the other subtypes and, with its liver-specific expression, represents a functionally distinct OATP isoform, Furthermore, the identification of oatp1 and OATP2 as pravastatin transporters suggests that they are responsible for the hepatic uptake of this liver-specific hydroxymethylglutaryl-CoA reductase inhibitor in rat and man.	Bristol Myers Squibb Co, Pharmaceut Res Inst, Dept Metab Res, Princeton, NJ 08543 USA; Bristol Myers Squibb Co, Pharmaceut Res Inst, Hopewell, NJ 08543 USA	Bristol-Myers Squibb; Bristol-Myers Squibb	Kirchgessner, TG (corresponding author), Bristol Myers Squibb Co, Pharmaceut Res Inst, Dept Metab Res, Rm K3111,POB 4000, Princeton, NJ 08543 USA.			wang, zhaoqing/0000-0003-1515-4945				Abe T, 1999, J BIOL CHEM, V274, P17159, DOI 10.1074/jbc.274.24.17159; Abe T, 1998, J BIOL CHEM, V273, P22395, DOI 10.1074/jbc.273.35.22395; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; BATES GW, 1998, CURR OPIN ENDOCRINOL, V5, P357; Bergwerk AJ, 1996, AM J PHYSIOL-GASTR L, V271, pG231, DOI 10.1152/ajpgi.1996.271.2.G231; Bossuyt X, 1996, J PHARMACOL EXP THER, V276, P891; Bossuyt X, 1996, J HEPATOL, V25, P733, DOI 10.1016/S0168-8278(96)80246-7; Crouse JR, 1997, ARCH INTERN MED, V157, P1305, DOI 10.1001/archinte.157.12.1305; Evans AM, 1996, CLIN EXP PHARMACOL P, V23, P970, DOI 10.1111/j.1440-1681.1996.tb01151.x; Fukumura S, 1998, PHARMACEUT RES, V15, P72, DOI 10.1023/A:1011900820409; *GEN COMP GROUP, 1999, WISC PACK VERS 9 1; HAGENBUCH B, 1991, P NATL ACAD SCI USA, V88, P10629, DOI 10.1073/pnas.88.23.10629; HAGENBUCH B, 1994, J CLIN INVEST, V93, P1326, DOI 10.1172/JCI117091; Hamelin BA, 1998, TRENDS PHARMACOL SCI, V19, P26, DOI 10.1016/S0165-6147(97)01147-4; JACQUEMIN E, 1994, P NATL ACAD SCI USA, V91, P133, DOI 10.1073/pnas.91.1.133; Kanai N, 1996, AM J PHYSIOL-RENAL, V270, pF319, DOI 10.1152/ajprenal.1996.270.2.F319; Kanai N, 1996, AM J PHYSIOL-RENAL, V270, pF326, DOI 10.1152/ajprenal.1996.270.2.F326; Kontaxi M, 1996, J PHARMACOL EXP THER, V279, P1507; Kullak-Ublick GA, 1998, FEBS LETT, V424, P173, DOI 10.1016/S0014-5793(98)00168-9; KULLAKUBLICK GA, 1994, HEPATOLOGY, V20, P411; KULLAKUBLICK GA, 1995, GASTROENTEROLOGY, V109, P1274, DOI 10.1016/0016-5085(95)90588-X; Li LQ, 1998, J BIOL CHEM, V273, P16184, DOI 10.1074/jbc.273.26.16184; Longcope C, 1996, J ENDOCRINOL, V150, pS125; Longcope C, 1995, ANN NY ACAD SCI, V774, P143, DOI 10.1111/j.1749-6632.1995.tb17378.x; Meier PJ, 1997, HEPATOLOGY, V26, P1667, DOI 10.1002/hep.510260641; Noe B, 1997, P NATL ACAD SCI USA, V94, P10346, DOI 10.1073/pnas.94.19.10346; OKUDAIRA K, 1992, PHARMACEUT RES, V9, P1152, DOI 10.1023/A:1015895520584; PARKER RA, 1990, J LIPID RES, V31, P1271; Plehn JF, 1999, CIRCULATION, V99, P216, DOI 10.1161/01.CIR.99.2.216; REUTER S, 1995, J STEROID BIOCHEM, V54, P227, DOI 10.1016/0960-0760(95)00132-J; Rosenson RS, 1998, JAMA-J AM MED ASSOC, V279, P1643, DOI 10.1001/jama.279.20.1643; SHI XY, 1995, J BIOL CHEM, V270, P25591, DOI 10.1074/jbc.270.43.25591; SINGHVI SM, 1990, BRIT J CLIN PHARMACO, V29, P239, DOI 10.1111/j.1365-2125.1990.tb03626.x; Smith SC, 1997, AM J CARDIOL, V80, pH10, DOI 10.1016/S0002-9149(97)00815-1; STEEN H, 1992, BIOCHEM PHARMACOL, V44, P2323, DOI 10.1016/0006-2952(92)90676-A; Sweet DH, 1997, J BIOL CHEM, V272, P30088, DOI 10.1074/jbc.272.48.30088; Swirski Richard A., 1992, Methods (Orlando), V4, P133, DOI 10.1016/1046-2023(92)90045-A; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Wolkoff AW, 1996, SEMIN LIVER DIS, V16, P121, DOI 10.1055/s-2007-1007225; YAMAZAKI M, 1993, AM J PHYSIOL, V264, pG36, DOI 10.1152/ajpgi.1993.264.1.G36; Yamazaki M, 1996, BIOPHARM DRUG DISPOS, V17, P775; ZIEGLER K, 1992, BIOCHIM BIOPHYS ACTA, V1139, P203	42	531	557	0	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 24	1999	274	52					37161	37168		10.1074/jbc.274.52.37161	http://dx.doi.org/10.1074/jbc.274.52.37161			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	267WR	10601278	hybrid			2022-12-25	WOS:000084382700049
J	Chang, MS; Sasaki, H; Campbell, MS; Kraeft, SK; Sutherland, R; Yang, CY; Liu, Y; Auclair, D; Hao, LN; Sonoda, H; Ferland, LH; Chen, LB				Chang, MS; Sasaki, H; Campbell, MS; Kraeft, SK; Sutherland, R; Yang, CY; Liu, Y; Auclair, D; Hao, LN; Sonoda, H; Ferland, LH; Chen, LB			HRad17 colocalizes with NHP2L1 in the nucleolus and redistributes after UV irradiation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ATAXIA-TELANGIECTASIA GENE; DNA-DAMAGE CHECKPOINT; SCHIZOSACCHAROMYCES-POMBE RAD1(+); DEPENDENT PROTEIN-KINASE; SACCHAROMYCES-CEREVISIAE; CELL-CYCLE; NUCLEAR-PROTEIN; FISSION YEAST; HUMAN HOMOLOG; RNA	The rad17 gene of Schizosaccharomyces pombe plays an important role as a checkpoint protein following DNA damage and during DNA replication. The human homologue of S, pombe rad17, Hrad17, was recently identified, but its function has not yet been established. Using the yeast two-hybrid system, we determined that HRad17 can interact with a nucleolar protein, NHP2L1. This interaction was also demonstrated biochemically, in human cells. Immunofluorescence studies revealed that HRad17 and NHP2L1 colocalize to the nucleolus, and immunogold labeling further resolved the location of NHP2L1 to the dense fibrillar component of the nucleolus. Interestingly, the localization of HRad17 in the nucleolus was altered in response to UV irradiation. These results provide some insight into the DNA damage and replication checkpoint mechanisms of HRad17.	Dana Farber Canc Inst, Dept Canc Biol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA	Harvard University; Dana-Farber Cancer Institute; Harvard University; Harvard Medical School	Chen, LB (corresponding author), Dana Farber Canc Inst, Dept Canc Biol, Rm SM1058,44 Binney St, Boston, MA 02115 USA.			CHANG, MAU-SUN/0000-0002-3703-2386	NATIONAL CANCER INSTITUTE [P01CA038493] Funding Source: NIH RePORTER; NCI NIH HHS [CA38493-12] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bao SD, 1999, CANCER RES, V59, P2023; BAUDIN A, 1993, NUCLEIC ACIDS RES, V21, P3329, DOI 10.1093/nar/21.14.3329; BAXEVANIS AD, 1995, NUCLEIC ACIDS RES, V23, P1604, DOI 10.1093/nar/23.9.1604; Bentley NJ, 1996, EMBO J, V15, P6641, DOI 10.1002/j.1460-2075.1996.tb01054.x; Brown KD, 1997, P NATL ACAD SCI USA, V94, P1840, DOI 10.1073/pnas.94.5.1840; CARR AM, 1995, SEMIN CELL BIOL, V6, P65, DOI 10.1016/1043-4682(95)90002-0; Cimprich KA, 1996, P NATL ACAD SCI USA, V93, P2850, DOI 10.1073/pnas.93.7.2850; DUNDR M, 1993, EXP CELL RES, V208, P275, DOI 10.1006/excr.1993.1247; Freire R, 1998, GENE DEV, V12, P2560, DOI 10.1101/gad.12.16.2560; Furnari B, 1997, SCIENCE, V277, P1495, DOI 10.1126/science.277.5331.1495; GRIFFITHS DJF, 1995, EMBO J, V14, P5812, DOI 10.1002/j.1460-2075.1995.tb00269.x; GROSSCHEDL R, 1994, TRENDS GENET, V10, P94, DOI 10.1016/0168-9525(94)90232-1; Guarente L, 1997, GENE DEV, V11, P2449, DOI 10.1101/gad.11.19.2449; HARTLEY KO, 1995, CELL, V82, P849, DOI 10.1016/0092-8674(95)90482-4; HARTWELL LH, 1989, SCIENCE, V246, P629, DOI 10.1126/science.2683079; Hoekstra MF, 1997, CURR OPIN GENET DEV, V7, P170, DOI 10.1016/S0959-437X(97)80125-6; HOZAK P, 1994, J CELL SCI, V107, P639; Johnson FB, 1998, CURR OPIN CELL BIOL, V10, P332, DOI 10.1016/S0955-0674(98)80008-2; Kitazono A, 1998, BIOESSAYS, V20, P391, DOI 10.1002/(SICI)1521-1878(199805)20:5<391::AID-BIES6>3.0.CO;2-R; KOLODRUBETZ D, 1991, YEAST, V7, P79, DOI 10.1002/yea.320070202; KOONIN EV, 1994, NUCLEIC ACIDS RES, V22, P2166, DOI 10.1093/nar/22.11.2166; Kostrub CF, 1998, EMBO J, V17, P2055, DOI 10.1093/emboj/17.7.2055; Li L, 1999, ONCOGENE, V18, P1689, DOI 10.1038/sj.onc.1202469; Lieberman HB, 1996, P NATL ACAD SCI USA, V93, P13890, DOI 10.1073/pnas.93.24.13890; Marciniak RA, 1998, P NATL ACAD SCI USA, V95, P6887, DOI 10.1073/pnas.95.12.6887; MURRAY AW, 1995, CURR OPIN GENET DEV, V5, P5, DOI 10.1016/S0959-437X(95)90046-2; Naik UP, 1997, J BIOL CHEM, V272, P4651, DOI 10.1074/jbc.272.8.4651; Park MS, 1996, P NATL ACAD SCI USA, V93, P8368, DOI 10.1073/pnas.93.16.8368; Parker AE, 1998, J BIOL CHEM, V273, P18340, DOI 10.1074/jbc.273.29.18340; Parker AE, 1998, J BIOL CHEM, V273, P18332, DOI 10.1074/jbc.273.29.18332; Paulovich AG, 1997, GENETICS, V145, P45; Peng CY, 1997, SCIENCE, V277, P1501, DOI 10.1126/science.277.5331.1501; Saito H, 1996, CYTOGENET CELL GENET, V72, P191, DOI 10.1159/000134186; Sanchez Y, 1997, SCIENCE, V277, P1497, DOI 10.1126/science.277.5331.1497; SAVITSKY K, 1995, SCIENCE, V268, P1749, DOI 10.1126/science.7792600; SCHEER U, 1984, P NATL ACAD SCI-BIOL, V81, P1431, DOI 10.1073/pnas.81.5.1431; Scully R, 1997, CELL, V90, P425, DOI 10.1016/S0092-8674(00)80503-6; Shaw PJ, 1995, ANNU REV CELL DEV BI, V11, P93, DOI 10.1146/annurev.cb.11.110195.000521; Siede W, 1996, NUCLEIC ACIDS RES, V24, P1669, DOI 10.1093/nar/24.9.1669; Sinclair DA, 1997, CELL, V91, P1033, DOI 10.1016/S0092-8674(00)80493-6; Sinclair DA, 1997, SCIENCE, V277, P1313, DOI 10.1126/science.277.5330.1313; STILLMAN B, 1994, CELL, V78, P725, DOI 10.1016/S0092-8674(94)90362-X; THIRY M, 1989, EUR J CELL BIOL, V50, P235; THIRY M, 1993, J CELL SCI, V105, P33; Walworth NC, 1996, SCIENCE, V271, P353, DOI 10.1126/science.271.5247.353; Wang JYJ, 1998, CURR OPIN CELL BIOL, V10, P240, DOI 10.1016/S0955-0674(98)80146-4; Watters D, 1997, ONCOGENE, V14, P1911, DOI 10.1038/sj.onc.1201037; Weinert T, 1997, SCIENCE, V277, P1450, DOI 10.1126/science.277.5331.1450; Westendorf JM, 1998, MOL BIOL CELL, V9, P437, DOI 10.1091/mbc.9.2.437; Wu XT, 1997, MUTAT RES-DNA REPAIR, V385, P13, DOI 10.1016/S0921-8777(97)00035-9; XU YH, 1994, J HISTOCHEM CYTOCHEM, V42, P1365, DOI 10.1177/42.10.7930519	51	38	42	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 17	1999	274	51					36544	36549		10.1074/jbc.274.51.36544	http://dx.doi.org/10.1074/jbc.274.51.36544			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	266AV	10593953	hybrid			2022-12-25	WOS:000084279200072
J	Eisenreich, W; Rieder, C; Grammes, C; Hessler, G; Adam, KP; Becker, H; Arigoni, D; Bacher, A				Eisenreich, W; Rieder, C; Grammes, C; Hessler, G; Adam, KP; Becker, H; Arigoni, D; Bacher, A			Biosynthesis of a Neo-epi-verrucosane diterpene in the liverwort Fossombronia alaskana - A retrobiosynthetic NMR study	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-13-C-13 COUPLING-CONSTANTS; EUBACTERIUM CHLOROFLEXUS-AURANTIACUS; MEVALONATE-INDEPENDENT PATHWAY; 1-DEOXY-D-XYLULOSE 5-PHOSPHATE; ISOPRENOID BIOSYNTHESIS; TERPENOID BIOSYNTHESIS; ESCHERICHIA-COLI; NEOVERRUCOSANE-TYPE; HIGHER-PLANTS; PRECURSOR	The biosynthesis of the diterpene 8 alpha-acetoxy-13 alpha-hydroxy-5-oxo-13-epi-neoverrucosane in the arctic Liverwort Fossombronia alaskana was studied by incorporation experiments using [1-C-13]- and [U-C-13(6)]glucose as precursors. The C-13-labeling patterns of acetyl-CoA, pyruvate, and phosphoenolpyruvate in intermediary metabolism were reconstructed from the C-13 NMR data of biosynthetic amino acids (leucine, alanine, phenylalanine) and were used to predict hypothetical labeling patterns for isopentenyl pyrophosphate formed via the mevalonate pathway and the deoxyxylulose pathway. The labeling patterns observed for the neoverrucosane diterpene were consistent with the intermediate formation of geranyllinaloyl pyrophosphate assembled from dimethylallyl pyrophosphate and three molecules of isopentenyl pyrophosphate generated predominantly or entirely via 1-deoxyxylulose 5-phosphate. The experimental data can be integrated into a detailed biosynthetic scheme involving a 1,5-hydride shift. The postulated involvement of the 1,5-hydride shift was confirmed by an incorporation experiment with [6,6-H-2(2)]glucose.	Tech Univ Munich, Lehrstuhl Organ Chem & Biochem, Inst Organ Chem & Biochem, D-85747 Garching, Germany; Univ Saarland, D-66041 Saarbrucken, Germany; Swiss Fed Inst Technol, Organ Chem Lab, CH-8092 Zurich, Switzerland	Technical University of Munich; Saarland University; Swiss Federal Institutes of Technology Domain; ETH Zurich	Eisenreich, W (corresponding author), Tech Univ Munich, Lehrstuhl Organ Chem & Biochem, Inst Organ Chem & Biochem, Lichtenbergstr 4, D-85747 Garching, Germany.	wolfgang.eisenreich@ch.tum.de	Eisenreich, Wolfgang/A-1258-2013	Eisenreich, Wolfgang/0000-0002-9832-8279				Adam KP, 1998, ARCH BIOCHEM BIOPHYS, V354, P181, DOI 10.1006/abbi.1998.0666; Adam KP, 1998, PHYTOCHEMISTRY, V48, P953, DOI 10.1016/S0031-9422(97)00992-8; Arigoni D, 1997, P NATL ACAD SCI USA, V94, P10600, DOI 10.1073/pnas.94.20.10600; ASAKAWA Y, 1988, PHYTOCHEMISTRY, V27, P3509, DOI 10.1016/0031-9422(88)80757-X; Bacher A, 1998, FEMS MICROBIOL REV, V22, P567; BARFIELD M, 1975, J AM CHEM SOC, V97, P2631, DOI 10.1021/ja00843a008; BARFIELD M, 1983, J AM CHEM SOC, V105, P3411, DOI 10.1021/ja00349a005; BENESOVA V, 1975, COLLECT CZECH CHEM C, V40, P658, DOI 10.1135/cccc19750658; Broers STJ, 1994, THESIS EIDGENOSSISCH; Cartayrade A., 1994, 2 S EUR NETW PLANT T; COMPAGNONE RS, 1995, J NAT PRODUCTS, V58, P145, DOI 10.1021/np50115a024; DODDRELL D, 1974, J AM CHEM SOC, V96, P1241, DOI 10.1021/ja00811a057; EISENREICH W, 1993, EUR J BIOCHEM, V215, P619, DOI 10.1111/j.1432-1033.1993.tb18073.x; Eisenreich W, 1998, CHEM BIOL, V5, pR221, DOI 10.1016/S1074-5521(98)90002-3; EISENREICH W, 1991, J BIOL CHEM, V266, P9622; FUKUYAMA Y, 1988, PHYTOCHEMISTRY, V27, P1797, DOI 10.1016/0031-9422(88)80446-1; GAMBORG OL, 1968, EXP CELL RES, V50, P151, DOI 10.1016/0014-4827(68)90403-5; Grammes C, 1997, PHYTOCHEMISTRY, V44, P1495, DOI 10.1016/S0031-9422(96)00781-9; HASHIMOTO T, 1995, PHYTOCHEMISTRY, V38, P119, DOI 10.1016/0031-9422(94)00570-J; HAYASHI S, 1978, CHEM LETT, P953, DOI 10.1246/cl.1978.953; HEFTER J, 1993, J GEN MICROBIOL, V139, P2757, DOI 10.1099/00221287-139-11-2757; HORBACH S, 1993, FEMS MICROBIOL LETT, V111, P135, DOI 10.1111/j.1574-6968.1993.tb06375.x; KUBO I, 1984, J ORG CHEM, V49, P4644, DOI 10.1021/jo00198a013; Lange BM, 1998, P NATL ACAD SCI USA, V95, P2100, DOI 10.1073/pnas.95.5.2100; Lois LM, 1998, P NATL ACAD SCI USA, V95, P2105, DOI 10.1073/pnas.95.5.2105; MATSUO A, 1978, J CHEM SOC CHEM COMM, P198, DOI 10.1039/c39780000198; MATSUO A, 1984, Z NATURFORSCH B, V39, P1281, DOI 10.1515/znb-1984-0923; NAKAMURA H, 1990, S PAP 59 ANN M CHEM, P1197; NOZAKI H, 1980, J CHEM SOC PERK T 2, P763, DOI 10.1039/p29800000763; Piel J, 1998, ANGEW CHEM INT EDIT, V37, P2478, DOI 10.1002/(SICI)1521-3773(19981002)37:18<2478::AID-ANIE2478>3.0.CO;2-Q; Putra SR, 1998, TETRAHEDRON LETT, V39, P23, DOI 10.1016/S0040-4039(97)10458-0; QURESHI N, 1981, BIOSYNTHESIS ISOPREN, V1, P47; Rieder C, 1998, J BIOL CHEM, V273, P18099, DOI 10.1074/jbc.273.29.18099; Rohmer M, 1998, PROG DRUG RES, V50, P135; Sagner S, 1998, TETRAHEDRON LETT, V39, P2091, DOI 10.1016/S0040-4039(98)00296-2; Sagner S, 1998, CHEM COMMUN, P221, DOI 10.1039/a707083g; Schwarz M, 1994, THESIS EIDGENOSSISCH; Schwender J, 1997, FEBS LETT, V414, P129, DOI 10.1016/S0014-5793(97)01002-8; Seto H, 1998, TETRAHEDRON LETT, V39, P9497, DOI 10.1016/S0040-4039(98)02154-6; Seto H, 1996, TETRAHEDRON LETT, V37, P7979, DOI 10.1016/0040-4039(96)01787-X; Sprenger GA, 1997, P NATL ACAD SCI USA, V94, P12857, DOI 10.1073/pnas.94.24.12857; Takahashi S, 1998, P NATL ACAD SCI USA, V95, P9879, DOI 10.1073/pnas.95.17.9879; TAKAOKA D, 1979, J CHEM SOC PERK T 1, P2711, DOI 10.1039/p19790002711; TAKAOKA D, 1983, PHYTOCHEMISTRY, V22, P1653, DOI 10.1016/0031-9422(83)80103-4; Tanaka J, 1997, CHEM LETT, P489, DOI 10.1246/cl.1997.489; Toyota M, 1996, PHYTOCHEMISTRY, V43, P1057, DOI 10.1016/S0031-9422(96)00383-4; WU CL, 1988, J HATTORI BOT LAB, V64, P151; Zeidler JG, 1997, Z NATURFORSCH C, V52, P15	48	20	20	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 17	1999	274	51					36312	36320		10.1074/jbc.274.51.36312	http://dx.doi.org/10.1074/jbc.274.51.36312			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	266AV	10593922	hybrid			2022-12-25	WOS:000084279200041
J	Michels, AA; Kanon, B; Bensaude, O; Kampinga, HH				Michels, AA; Kanon, B; Bensaude, O; Kampinga, HH			Heat shock protein (Hsp) 40 mutants inhibit Hsp70 in mammalian cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR CHAPERONE HSP70/HSC70; FINGER-LIKE DOMAIN; SUBSTRATE-BINDING; ATPASE ACTIVITY; REACTION CYCLE; DNAJ HOMOLOG; IN-VIVO; AGGREGATION; HSC70; DENATURATION	Heat shock protein (Hsp) 70 and Hsp40 expressed in mammalian cells had been previously shown to cooperate in accelerating the reactivation of heat-denatured firefly luciferase (Michels, A. A., Kanon, B., Konings, A. W. T., Ohtsuka, K,, Bensaude, O., and Kampinga, H. H. (1997) J. Biol. Chem. 272, 33283-33289), We now provide further evidence for a functional interaction between Hsp70 and the J-domain of Hsp40 with denatured luciferase resulting in reactivation of heat-denatured luciferase within living mammalian cells. The stimulating effect of Hsp40 on the Hsp70-mediated refolding is lost when the proteins cannot interact as accomplished by their expression in different intracellular compartments, Likewise, the cooperation between Hsp40 and Hsp70 is lost by introduction of a point mutation in the conserved HPD motif of the Hsp40 J domain or by deletion of the four C-terminal amino acids of Hsp70 (EEVD motif), Most strikingly, co-expression of a truncated protein restricted to the J-domain of Hsp40 had a dominant negative effect on Hsp70-facilitated luciferase reactivation. Taken together, these experiments indicate for the first time that the Hsp70/Hsp40 chaperones functionally interact with a heat-denatured protein within mammalian cells. The dominant negative effect of the Hsp40 J-domain on the activity of Hsp70 demonstrates the importance of J-domain-containing proteins in Hsp70-dependent processes.	Univ Groningen, Fac Med Sci, Dept Radiobiol, NL-9713 BZ Groningen, Netherlands; Ecole Normale Super, Mol Genet Lab, F-75230 Paris 05, France	University of Groningen; UDICE-French Research Universities; PSL Research University Paris; Ecole Normale Superieure (ENS)	Kampinga, HH (corresponding author), Univ Groningen, Fac Med Sci, Dept Radiobiol, Bloemsingel 1, NL-9713 BZ Groningen, Netherlands.			Michels, Annemieke/0000-0002-1735-1697; Kampinga, Harm/0000-0002-8966-8466; Bensaude, Olivier/0000-0002-0259-6608				Auger I, 1997, J CLIN INVEST, V99, P1818, DOI 10.1172/JCI119348; Bimston D, 1998, EMBO J, V17, P6871, DOI 10.1093/emboj/17.23.6871; Bukau B, 1998, CELL, V92, P351, DOI 10.1016/S0092-8674(00)80928-9; Chamberlain LH, 1997, J BIOL CHEM, V272, P31420, DOI 10.1074/jbc.272.50.31420; Cheetham ME, 1998, CELL STRESS CHAPERON, V3, P28, DOI 10.1379/1466-1268(1998)003<0028:SFAEOD>2.3.CO;2; Cheetham ME, 1996, BIOCHEM J, V319, P103, DOI 10.1042/bj3190103; Cummings CJ, 1998, NAT GENET, V19, P148, DOI 10.1038/502; Demand J, 1998, MOL CELL BIOL, V18, P2023, DOI 10.1128/MCB.18.4.2023; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; DUBOIS MF, 1991, J BIOL CHEM, V266, P9707; Eggers DK, 1997, MOL BIOL CELL, V8, P1559, DOI 10.1091/mbc.8.8.1559; FOECKING MK, 1986, GENE, V45, P101, DOI 10.1016/0378-1119(86)90137-X; FREEMAN BC, 1995, EMBO J, V14, P2281, DOI 10.1002/j.1460-2075.1995.tb07222.x; Gebauer M, 1998, MOL CELL BIOL, V18, P6238, DOI 10.1128/MCB.18.11.6238; Gebauer M, 1997, FEBS LETT, V417, P109, DOI 10.1016/S0014-5793(97)01267-2; GOULD SJ, 1989, J CELL BIOL, V108, P1657, DOI 10.1083/jcb.108.5.1657; Greene MK, 1998, P NATL ACAD SCI USA, V95, P6108, DOI 10.1073/pnas.95.11.6108; Hartl FU, 1996, NATURE, V381, P571, DOI 10.1038/381571a0; Hohfeld J, 1998, BIOL CHEM, V379, P269; HOHFELD J, 1995, CELL, V83, P589; HUNT C, 1985, P NATL ACAD SCI USA, V82, P6455, DOI 10.1073/pnas.82.19.6455; Johnson BD, 1998, J BIOL CHEM, V273, P3679, DOI 10.1074/jbc.273.6.3679; Johnson JL, 1997, CELL, V90, P201, DOI 10.1016/S0092-8674(00)80327-X; KAMPINGA HH, 1993, J CELL SCI, V104, P11; KANG KI, 1994, P NATL ACAD SCI USA, V91, P340, DOI 10.1073/pnas.91.1.340; Karzai AW, 1996, J BIOL CHEM, V271, P11236, DOI 10.1074/jbc.271.19.11236; Kelley WL, 1998, TRENDS BIOCHEM SCI, V23, P222, DOI 10.1016/S0968-0004(98)01215-8; KRIEGLER M, 1990, GENE TRANSFER EXPRES, P96; Leng CH, 1998, PROTEIN SCI, V7, P1186, DOI 10.1002/pro.5560070513; Lu Z, 1998, J BIOL CHEM, V273, P5970, DOI 10.1074/jbc.273.10.5970; Michels AA, 1997, J BIOL CHEM, V272, P33283, DOI 10.1074/jbc.272.52.33283; MICHELS AA, 1995, EUR J BIOCHEM, V234, P382, DOI 10.1111/j.1432-1033.1995.382_b.x; Minami Y, 1996, J BIOL CHEM, V271, P19617, DOI 10.1074/jbc.271.32.19617; Nagata H, 1998, BIOCHEMISTRY-US, V37, P6924, DOI 10.1021/bi980164g; Nollen EAA, 1999, MOL CELL BIOL, V19, P2069; OHTSUKA K, 1993, BIOCHEM BIOPH RES CO, V197, P235, DOI 10.1006/bbrc.1993.2466; PARSELL DA, 1994, NATURE, V372, P475, DOI 10.1038/372475a0; PARSELL DA, 1993, ANNU REV GENET, V27, P437, DOI 10.1146/annurev.ge.27.120193.002253; PELHAM HRB, 1984, EMBO J, V3, P3095, DOI 10.1002/j.1460-2075.1984.tb02264.x; Pellecchia M, 1996, J MOL BIOL, V260, P236, DOI 10.1006/jmbi.1996.0395; PINTO M, 1991, J BIOL CHEM, V266, P13941; Qian YQ, 1996, J MOL BIOL, V260, P224, DOI 10.1006/jmbi.1996.0394; SCHRODER H, 1993, EMBO J, V12, P4137, DOI 10.1002/j.1460-2075.1993.tb06097.x; Sheng Q, 1997, J VIROL, V71, P9410, DOI 10.1128/JVI.71.12.9410-9416.1997; STEGE GJJ, 1994, EXP CELL RES, V214, P279, DOI 10.1006/excr.1994.1259; STEGE GJJ, 1994, INT J HYPERTHER, V10, P659, DOI 10.3109/02656739409022446; SUBJECK JR, 1982, BRIT J RADIOL, V55, P579, DOI 10.1259/0007-1285-55-656-579; Szabo A, 1996, EMBO J, V15, P408, DOI 10.1002/j.1460-2075.1996.tb00371.x; Takayama S, 1997, EMBO J, V16, P4887, DOI 10.1093/emboj/16.16.4887; Terada K, 1997, J CELL BIOL, V139, P1089, DOI 10.1083/jcb.139.5.1089; Tsai J, 1996, J BIOL CHEM, V271, P9347, DOI 10.1074/jbc.271.16.9347; Ungewickell E, 1997, J BIOL CHEM, V272, P19594, DOI 10.1074/jbc.272.31.19594; WALL D, 1994, J BIOL CHEM, V269, P5446; Zeiner M, 1997, EMBO J, V16, P5483, DOI 10.1093/emboj/16.18.5483	54	56	59	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 17	1999	274	51					36757	36763		10.1074/jbc.274.51.36757	http://dx.doi.org/10.1074/jbc.274.51.36757			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	266AV	10593983	hybrid			2022-12-25	WOS:000084279200102
J	Prinz, H; Lavie, A; Scheidig, AJ; Spangenberg, O; Konrad, M				Prinz, H; Lavie, A; Scheidig, AJ; Spangenberg, O; Konrad, M			Binding of nucleotides to guanylate kinase, p21(ras), and nucleoside-diphosphate kinase studied by nano-electrospray mass spectrometry	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							H-RAS P21; ADENYLATE KINASE; PROTEINS; COMPLEXES; MECHANISM; RESOLUTION; EFFECTORS; GENE	The binding of nucleotides to three different nucleotide-binding proteins and to a control protein was studied by means of nano-electrospray mass spectrometry applied to aqueous nondenaturing solutions. The method leads to unambiguous identification of enzyme complexes with substrates and products but does not allow the determination of dissociation constants or even stoichiometries relevant to the binding in solution. For guanylate kinase (EC 2.7.4.8), the transfer of HPO3 between nucleotides was observed whenever a ternary complex with adenylate or guanylate nucleotides was formed. Guanosine 5'-tetraphosphate was generated after prolonged incubation with GDP or GTP, Mg2+ binding was considerably enhanced in functional high affinity complexes, such as observed between guanylate kinase and its bisubstrate inhibitor P-1-(5'-guanosyl)-P-5-(5'-adenosyl) pentaphosphate or with the tight nucleotide-binding protein p21(ras) and GDP. Nucleoside-diphosphate kinase (EC 2.7.4.6) itself was phosphorylated in accordance to its known ping-pong mechanism. All nucleotide-binding proteins were shown to bind sulfate (SO42-) with presumably high affinity and slow exchange rate. The binding of phosphate (PO43-) could be inferred indirectly from competition with SO42-.	Max Planck Inst Mol Physiol, D-44227 Dortmund, Germany; Max Planck Inst Biophys Chem, D-37070 Gottingen, Germany	Max Planck Society; Max Planck Society	Prinz, H (corresponding author), Max Planck Inst Mol Physiol, Otto Hahn 11, D-44227 Dortmund, Germany.	heino.prinz@mpi-dortmund.mpg.de	Scheidig, Axel/C-9141-2011; Lavie, Arnon/H-4927-2012	Lavie, Arnon/0000-0001-5591-8722				BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Briand G, 1997, ARCH BIOCHEM BIOPHYS, V339, P291, DOI 10.1006/abbi.1997.9877; Cheng XH, 1996, P NATL ACAD SCI USA, V93, P7022, DOI 10.1073/pnas.93.14.7022; DUMAS C, 1992, EMBO J, V11, P3203, DOI 10.1002/j.1460-2075.1992.tb05397.x; Fernandes I, 1997, J CLIN INVEST, V100, P2196, DOI 10.1172/JCI119756; Ganguly AK, 1997, BIOORGAN MED CHEM, V5, P817, DOI 10.1016/S0968-0896(97)00021-7; GOODY RS, 1991, TRENDS BIOCHEM SCI, V16, P327, DOI 10.1016/0968-0004(91)90134-H; JOHN J, 1990, BIOCHEMISTRY-US, V29, P6058, DOI 10.1021/bi00477a025; JOHN J, 1988, J BIOL CHEM, V263, P11792; Jorgensen TJD, 1998, ANAL CHEM, V70, P4427, DOI 10.1021/ac980563h; KLEBE C, 1995, BIOCHEMISTRY-US, V34, P12543, DOI 10.1021/bi00039a008; KONRAD M, 1993, J BIOL CHEM, V268, P11326; KUPRIYANOV VV, 1986, BIOCHIM BIOPHYS ACTA, V869, P107, DOI 10.1016/0167-4838(86)90316-X; Laktionov PP, 1997, BIOCHEMISTRY-MOSCOW+, V62, P613; Li Y, 1996, J BIOL CHEM, V271, P28038, DOI 10.1074/jbc.271.45.28038; MANN M, 1995, TRENDS BIOCHEM SCI, V20, P219, DOI 10.1016/S0968-0004(00)89019-2; McCormick F, 1996, CURR OPIN BIOTECH, V7, P449, DOI 10.1016/S0958-1669(96)80123-6; MISTOU MY, 1992, EUR J BIOCHEM, V204, P179, DOI 10.1111/j.1432-1033.1992.tb16621.x; Murer H, 1998, SCHWEIZ MED WSCHR, V128, P1247; PAI EF, 1990, EMBO J, V9, P2351, DOI 10.1002/j.1460-2075.1990.tb07409.x; Potier N, 1997, EUR J BIOCHEM, V243, P274, DOI 10.1111/j.1432-1033.1997.0274a.x; PRINZ H, 1993, J BIOL CHEM, V268, P18580; PRINZ H, 1983, J RECEPTOR RES, V3, P239, DOI 10.3109/10799898309041938; PRINZ H, 1992, RECEPTOR LIGAND INTE, P265; Schaertl S, 1998, J BIOL CHEM, V273, P5662, DOI 10.1074/jbc.273.10.5662; SCHEFFZEK K, 1994, ACTA CRYSTALLOGR D, V50, P521, DOI 10.1107/S0907444994001253; STEHLE T, 1992, J MOL BIOL, V224, P1127, DOI 10.1016/0022-2836(92)90474-X; TUCKER J, 1986, EMBO J, V5, P1351, DOI 10.1002/j.1460-2075.1986.tb04366.x; Wilm M, 1996, ANAL CHEM, V68, P1, DOI 10.1021/ac9509519; Witkowska HE, 1996, STEROIDS, V61, P433, DOI 10.1016/0039-128X(96)00075-X; Wittinghofer A, 1996, TRENDS BIOCHEM SCI, V21, P488, DOI 10.1016/S0968-0004(96)10064-5	31	14	16	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 10	1999	274	50					35337	35342		10.1074/jbc.274.50.35337	http://dx.doi.org/10.1074/jbc.274.50.35337			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	264NG	10585400	hybrid			2022-12-25	WOS:000084187900012
J	Wang, F; Van Brocklyn, JR; Hobson, JP; Movafagh, S; Zukowska-Grojec, Z; Milstien, S; Spiegel, S				Wang, F; Van Brocklyn, JR; Hobson, JP; Movafagh, S; Zukowska-Grojec, Z; Milstien, S; Spiegel, S			Sphingosine 1-phosphate stimulates cell migration through a G(i)-coupled cell surface receptor - Potential involvement in angiogenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTOR; MOUSE MELANOMA-CELLS; LYSOPHOSPHATIDIC-ACID; SIGNALING PATHWAYS; ENDOTHELIAL-CELLS; MOLECULAR-CLONING; GROWTH-FACTOR; TYROSINE PHOSPHORYLATION; KINASE PATHWAY; SPHINGOSINE-1-PHOSPHATE	Sphingosine l-phosphate (SPP) has been shown to inhibit chemotaxis of a variety of cells, in some cases through intracellular actions, while in others through receptor-mediated effects. Surprisingly, we found that low concentrations of SPP (10-100 nm) increased chemotaxis of HEK293 cells overexpressing the G protein-coupled SPP receptor EDG-1. In agreement with previous findings in human breast cancer cells (Wang, F., Nohara, K., Olivera, O., Thompson, E. W., and Spiegel, S. (1999) Exp. Cell Res. 247, 17-28), SPP, at micromolar concentrations, inhibited chemotaxis of both vector- and EDG-1-overexpressing HEK293 cells. Nanomolar concentrations of SPP also induced a marked increase in chemotaxis of human umbilical vein endothelial cells (HUVEC) and bovine aortic endothelial cells (BAEC), which express the SPP receptors EDG-1 and EDG-3, while higher concentrations of SPP were less effective. Treatment with pertussis toxin, which ADP-ribosylates and inactivates G(i)-coupled receptors, blocked SPP-induced chemotaxis. Checkerboard analysis indicated that SPP stimulates both chemotaxis and chemokinesis. Taken together, these data suggest that SPP stimulates cell migration by binding to EDG-1. Similar to SPP, sph-inganine 1-phosphate (dihydro-SPP), which also binds to this family of SPP receptors, enhanced chemotaxis; whereas, another structurally related lysophospholipid, lysophosphatidic acid, did not compete with SPP for binding nor did it have significant effects on chemotaxis of endothelial cells. Furthermore, SPP increased proliferation of HUVEC and BAEC in a pertussis toxin-sensitive manner. SPP and dihydro-SPP also stimulated tube formation of BAEC grown on collagen gels (in vitro angiogenesis), and potentiated tube formation induced by basic fibroblast growth factor. Pertussis toxin treatment blocked SPP-, but not bFGF-stimulated in vitro angiogenesis. Our results suggest that SPP may play a role in angiogenesis through binding to endothelial cell Gi-coupled SPP receptors.	Georgetown Univ, Med Ctr, Dept Biochem & Mol Biol, Washington, DC 20007 USA; Georgetown Univ, Med Ctr, Dept Physiol & Biophys, Washington, DC 20007 USA; NIMH, Lab Cellular & Mol Regulat, NIH, Bethesda, MD 20892 USA	Georgetown University; Georgetown University; National Institutes of Health (NIH) - USA; NIH National Institute of Mental Health (NIMH)	Spiegel, S (corresponding author), Georgetown Univ, Med Ctr, Dept Biochem & Mol Biol, 353 Basic Sci Bldg,3900 Reservoir Rd NW, Washington, DC 20007 USA.		Van Brocklyn, Jim/A-9733-2010		NATIONAL CANCER INSTITUTE [P30CA051008, R01CA061774] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM019209] Funding Source: NIH RePORTER; NCI NIH HHS [1P30-CA-51008, CA61774] Funding Source: Medline; NIGMS NIH HHS [F32GM19209] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		An SZ, 1997, FEBS LETT, V417, P279, DOI 10.1016/S0014-5793(97)01301-X; An SZ, 1998, J BIOL CHEM, V273, P7906, DOI 10.1074/jbc.273.14.7906; An SZ, 1997, BIOCHEM BIOPH RES CO, V231, P619, DOI 10.1006/bbrc.1997.6150; Ancellin N, 1999, J BIOL CHEM, V274, P18997, DOI 10.1074/jbc.274.27.18997; Arai H, 1997, P NATL ACAD SCI USA, V94, P14495, DOI 10.1073/pnas.94.26.14495; BAGGIOLINI M, 1994, ADV IMMUNOL, V55, P97; BERGER A, 1995, P NATL ACAD SCI USA, V92, P5885, DOI 10.1073/pnas.92.13.5885; BORNFELDT KE, 1995, J CELL BIOL, V130, P193, DOI 10.1083/jcb.130.1.193; Brindley DN, 1998, J BIOL CHEM, V273, P24281, DOI 10.1074/jbc.273.38.24281; BUHL AM, 1995, J BIOL CHEM, V270, P24631, DOI 10.1074/jbc.270.42.24631; Cuvillier O, 1996, NATURE, V381, P800, DOI 10.1038/381800a0; DESAI NN, 1991, BIOCHEM BIOPH RES CO, V181, P361, DOI 10.1016/S0006-291X(05)81427-5; FOLKMAN J, 1980, NATURE, V288, P551, DOI 10.1038/288551a0; FOLKMAN J, 1995, NAT MED, V1, P27, DOI 10.1038/nm0195-27; Folkman J, 1996, CELL, V87, P1153, DOI 10.1016/S0092-8674(00)81810-3; GOMEZMUNOZ A, 1995, J BIOL CHEM, V270, P26318, DOI 10.1074/jbc.270.44.26318; Gonda K, 1999, BIOCHEM J, V337, P67, DOI 10.1042/0264-6021:3370067; GOODEMOTE KA, 1995, J BIOL CHEM, V270, P10272, DOI 10.1074/jbc.270.17.10272; Hamada K, 1998, BIOCHEM BIOPH RES CO, V244, P745, DOI 10.1006/bbrc.1998.8328; Hecht JH, 1996, J CELL BIOL, V135, P1071, DOI 10.1083/jcb.135.4.1071; Heringdorf DMZ, 1996, N-S ARCH PHARMACOL, V354, P397; Hisano N, 1999, BLOOD, V93, P4293, DOI 10.1182/blood.V93.12.4293.412k26_4293_4299; HLA T, 1990, J BIOL CHEM, V265, P9308; Imamura F, 1996, INT J CANCER, V65, P627, DOI 10.1002/(SICI)1097-0215(19960301)65:5<627::AID-IJC12>3.0.CO;2-4; Kawa S, 1997, FEBS LETT, V420, P196, DOI 10.1016/S0014-5793(97)01516-0; Kleuser B, 1998, CANCER RES, V58, P1817; Kohama T, 1998, J BIOL CHEM, V273, P23722, DOI 10.1074/jbc.273.37.23722; Kozasa T, 1998, SCIENCE, V280, P2109, DOI 10.1126/science.280.5372.2109; Lee MJ, 1998, SCIENCE, V279, P1552, DOI 10.1126/science.279.5356.1552; Lee MJ, 1996, J BIOL CHEM, V271, P11272, DOI 10.1074/jbc.271.19.11272; Lee MJ, 1998, J BIOL CHEM, V273, P22105, DOI 10.1074/jbc.273.34.22105; Liliom K, 1998, J BIOL CHEM, V273, P13461, DOI 10.1074/jbc.273.22.13461; Liu CH, 1997, GENOMICS, V43, P15, DOI 10.1006/geno.1997.4759; Machwate M, 1998, MOL PHARMACOL, V54, P70, DOI 10.1124/mol.54.1.70; MACLENNAN AJ, 1994, MOL CELL NEUROSCI, V5, P201, DOI 10.1006/mcne.1994.1024; MONTESANO R, 1985, CELL, V42, P469, DOI 10.1016/0092-8674(85)90104-7; Moolenaar WH, 1997, CURR OPIN CELL BIOL, V9, P168, DOI 10.1016/S0955-0674(97)80059-2; Neptune ER, 1997, P NATL ACAD SCI USA, V94, P14489, DOI 10.1073/pnas.94.26.14489; Offermanns S, 1997, SCIENCE, V275, P533, DOI 10.1126/science.275.5299.533; Okamoto H, 1998, J BIOL CHEM, V273, P27104, DOI 10.1074/jbc.273.42.27104; OKAZAKI H, 1993, BIOCHEM BIOPH RES CO, V190, P1104, DOI 10.1006/bbrc.1993.1163; OLIVERA A, 1993, NATURE, V365, P557, DOI 10.1038/365557a0; Panetti TS, 1997, J LAB CLIN MED, V129, P208, DOI 10.1016/S0022-2143(97)90141-4; Perez GI, 1997, NAT MED, V3, P1228, DOI 10.1038/nm1197-1228; Pietruck F, 1997, N-S ARCH PHARMACOL, V355, P1; Postma FR, 1996, EMBO J, V15, P2388, DOI 10.1002/j.1460-2075.1996.tb00595.x; Premack BA, 1996, NAT MED, V2, P1174, DOI 10.1038/nm1196-1174; Rakhit S, 1999, BIOCHEM J, V338, P643, DOI 10.1042/0264-6021:3380643; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; RUSNATI M, 1993, J CELL PHYSIOL, V154, P152, DOI 10.1002/jcp.1041540119; SADAHIRA Y, 1992, P NATL ACAD SCI USA, V89, P9686, DOI 10.1073/pnas.89.20.9686; SADAHIRA Y, 1994, FEBS LETT, V340, P99, DOI 10.1016/0014-5793(94)80180-0; Sakai T, 1999, J BIOL CHEM, V274, P15480, DOI 10.1074/jbc.274.22.15480; Sakai T, 1998, J BIOL CHEM, V273, P19378, DOI 10.1074/jbc.273.31.19378; Sato K, 1999, FEBS LETT, V443, P25, DOI 10.1016/S0014-5793(98)01676-7; Sato K, 1999, MOL PHARMACOL, V55, P126, DOI 10.1124/mol.55.1.126; SLAVIN J, 1995, CELL BIOL INT, V19, P431, DOI 10.1006/cbir.1995.1087; Spiegel S, 1998, ANN NY ACAD SCI, V845, P11, DOI 10.1111/j.1749-6632.1998.tb09658.x; Stam JC, 1998, EMBO J, V17, P4066, DOI 10.1093/emboj/17.14.4066; Sun LY, 1996, J INVEST DERMATOL, V106, P232, DOI 10.1111/1523-1747.ep12340570; TARABOLETTI G, 1990, J CELL BIOL, V111, P765, DOI 10.1083/jcb.111.2.765; Van Brocklyn JR, 1999, J BIOL CHEM, V274, P4626, DOI 10.1074/jbc.274.8.4626; Van Brocklyn JR, 1998, J CELL BIOL, V142, P229, DOI 10.1083/jcb.142.1.229; vanKoppen CJ, 1996, J BIOL CHEM, V271, P2082, DOI 10.1074/jbc.271.4.2082; VOGEL T, 1993, J CELL BIOCHEM, V53, P74, DOI 10.1002/jcb.240530109; Wang F, 1999, EXP CELL RES, V247, P17, DOI 10.1006/excr.1998.4327; Wang F, 1997, BIOCHEM J, V324, P481, DOI 10.1042/bj3240481; WEIDNER KM, 1993, J CELL BIOL, V121, P145, DOI 10.1083/jcb.121.1.145; Weiner JA, 1999, P NATL ACAD SCI USA, V96, P5233, DOI 10.1073/pnas.96.9.5233; WU J, 1995, J BIOL CHEM, V270, P11484, DOI 10.1074/jbc.270.19.11484; Yamaguchi F, 1996, BIOCHEM BIOPH RES CO, V227, P608, DOI 10.1006/bbrc.1996.1553; Yamamura S, 1997, BIOCHEMISTRY-US, V36, P10751, DOI 10.1021/bi970926s; Yamamura S, 1996, FEBS LETT, V382, P193, DOI 10.1016/0014-5793(96)00175-5; Yatomi Y, 1997, J BIOCHEM, V121, P969; Yokomizo T, 1997, NATURE, V387, P620, DOI 10.1038/42506; Zhang GF, 1999, GENE, V227, P89, DOI 10.1016/S0378-1119(98)00589-7; ZHANG H, 1990, J BIOL CHEM, V265, P76; ZHANG H, 1991, J CELL BIOL, V114, P155, DOI 10.1083/jcb.114.1.155; Zondag GCM, 1998, BIOCHEM J, V330, P605, DOI 10.1042/bj3300605; Zukowska-Grojec Z, 1998, CIRC RES, V83, P187, DOI 10.1161/01.RES.83.2.187	80	335	352	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 10	1999	274	50					35343	35350		10.1074/jbc.274.50.35343	http://dx.doi.org/10.1074/jbc.274.50.35343			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	264NG	10585401	hybrid			2022-12-25	WOS:000084187900013
J	Martinez-Pomares, L; Crocker, PR; Da Silva, R; Holmes, N; Colominas, C; Rudd, P; Dwek, R; Gordon, S				Martinez-Pomares, L; Crocker, PR; Da Silva, R; Holmes, N; Colominas, C; Rudd, P; Dwek, R; Gordon, S			Cell-specific glycoforms of sialoadhesin and CD45 are counter-receptors for the cysteine-rich domain of the mannose receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PERFORMANCE LIQUID-CHROMATOGRAPHY; CARBOHYDRATE-RECOGNITION DOMAINS; ACID-BINDING-RECEPTOR; LINKED OLIGOSACCHARIDES; TISSUE MACROPHAGES; GERMINAL-CENTERS; DOWN-REGULATION; PROTEIN; HEMAGGLUTININ; GLYCOPROTEIN	We previously reported that CR-Fc, an Fc chimeric protein containing the cysteine-rich (CR) domain of the mannose receptor, binds to marginal zone metallophilic macrophages (MO) and B cell areas in the spleen and to subcapsular sinus Mr, in lymph nodes of naive mice (CR-Fc(+) cells). Several CR-Fc ligands were found in spleen and lymph node tissue lysates using ligand blots. In this paper we report the identification of two of these ligands as sialoadhesin (Sn), an Mg-specific membrane molecule, and the leukocyte common antigen, CD45. CR-Fc bound selectively to Sn purified from spleen and lymph nodes and to two low molecular weight isoforms of CD45 in a sugar-dependent manner. CR-Fc binding and non-binding forms of Sn, probably derived from CR-Fc(+) and CR-Fc(-) cells respectively, were selected from spleen lysates, Analysis of the glycan pool associated with the CR-Fc-binding form revealed the presence of charged structures resistant to sialidase, absent in the non-binding form, that could correspond to sulfated structures. These results confirm the identification of the CR region of the mannose receptor as a lectin, We also demonstrate that the same glycoprotein expressed in different cells of the same organ can display distinct sugar epitopes that determine its binding properties.	Univ Oxford, Sir William Dunn Sch Pathol, Oxford OX1 3RE, England; Univ Dundee, Dept Biochem, Dundee DD1 4HN, Scotland; Univ Cambridge, Dept Pathol, Div Immunol, Cambridge CB2 1QP, England; Univ Oxford, Glycobiol Inst, Dept Biochem, Oxford OX1 3QU, England	University of Oxford; University of Dundee; University of Cambridge; University of Oxford	Martinez-Pomares, L (corresponding author), Univ Oxford, Sir William Dunn Sch Pathol, S Pk Rd, Oxford OX1 3RE, England.			Martinez-Pomares, Luisa/0000-0002-2331-127X; Crocker, Paul/0000-0001-6230-0293				AUSTYN JM, 1981, EUR J IMMUNOL, V11, P805, DOI 10.1002/eji.1830111013; BIGGE JC, 1995, ANAL BIOCHEM, V230, P229, DOI 10.1006/abio.1995.1468; Byth KF, 1996, J EXP MED, V183, P1707, DOI 10.1084/jem.183.4.1707; CROCKER PR, 1988, IMMUNOLOGY, V65, P515; CROCKER PR, 1991, EMBO J, V10, P1661, DOI 10.1002/j.1460-2075.1991.tb07689.x; CROCKER PR, 1990, BLOOD, V76, P1131; CROCKER PR, 1994, EMBO J, V13, P4490, DOI 10.1002/j.1460-2075.1994.tb06771.x; CROCKER PR, 1986, J EXP MED, V164, P1862, DOI 10.1084/jem.164.6.1862; DHARMESH SM, 1993, J BIOL CHEM, V268, P17096; DOWBENKO D, 1993, J CLIN INVEST, V92, P952, DOI 10.1172/JCI116671; Fiete D, 1997, J BIOL CHEM, V272, P14629, DOI 10.1074/jbc.272.23.14629; FIETE D, 1997, P NATL ACAD SCI USA, V94, P11254; Fiete DJ, 1998, P NATL ACAD SCI USA, V95, P2089, DOI 10.1073/pnas.95.5.2089; GREEN ED, 1988, J BIOL CHEM, V263, P25; Guile GR, 1996, ANAL BIOCHEM, V240, P210, DOI 10.1006/abio.1996.0351; GUILE GR, 1994, ANAL BIOCHEM, V222, P231, DOI 10.1006/abio.1994.1478; HARRIS N, 1992, BLOOD, V80, P2363; Hashimoto Y, 1998, J BIOCHEM-TOKYO, V123, P468; IMAI Y, 1993, NATURE, V361, P555; KELM S, 1994, CURR BIOL, V4, P965, DOI 10.1016/S0960-9822(00)00220-7; Kuster B, 1997, ANAL BIOCHEM, V250, P82, DOI 10.1006/abio.1997.2199; LANE P, 1994, J EXP MED, V179, P819, DOI 10.1084/jem.179.3.819; Linehan SA, 1999, J EXP MED, V189, P1961, DOI 10.1084/jem.189.12.1961; Martinez-Pomares L, 1998, J BIOL CHEM, V273, P23376, DOI 10.1074/jbc.273.36.23376; MartinezPomares L, 1996, J EXP MED, V184, P1927, DOI 10.1084/jem.184.5.1927; MENGELING BJ, 1995, P NATL ACAD SCI USA, V92, P502, DOI 10.1073/pnas.92.2.502; NATH D, 1995, J BIOL CHEM, V270, P26184, DOI 10.1074/jbc.270.44.26184; OKUMURA M, 1995, CURR OPIN IMMUNOL, V7, P312, DOI 10.1016/0952-7915(95)80104-9; PONTOW SE, 1992, INT REV CYTOL, V137B, P221; Rudd PM, 1997, J BIOL CHEM, V272, P7229, DOI 10.1074/jbc.272.11.7229; SALLUSTO F, 1995, J EXP MED, V182, P389, DOI 10.1084/jem.182.2.389; SIMMONS DL, 1993, CELLULAR INTERACTION, V131, P93; Stahl PD, 1998, CURR OPIN IMMUNOL, V10, P50, DOI 10.1016/S0952-7915(98)80031-9; Takahashi K, 1998, CELL TISSUE RES, V292, P311, DOI 10.1007/s004410051062; TAYLOR ME, 1990, J BIOL CHEM, V265, P12156; TAYLOR ME, 1992, J BIOL CHEM, V267, P1719; TAYLOR ME, 1993, J BIOL CHEM, V268, P399; TROWBRIDGE IS, 1994, ANNU REV IMMUNOL, V12, P85, DOI 10.1146/annurev.iy.12.040194.000505; VANDENBERG TK, 1992, J EXP MED, V176, P647, DOI 10.1084/jem.176.3.647; WATT SM, 1987, MOL CELL PROBE, V1, P297, DOI 10.1016/0890-8508(87)90013-2; Williams A.F., 1986, HDB EXPT IMMUNOLOGY	41	80	82	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 3	1999	274	49					35211	35218		10.1074/jbc.274.49.35211	http://dx.doi.org/10.1074/jbc.274.49.35211			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	260XW	10575006	hybrid			2022-12-25	WOS:000083979600100
J	Cao, RH; Farnebo, J; Kurimoto, M; Cao, YH				Cao, RH; Farnebo, J; Kurimoto, M; Cao, YH			Interleukin-18 acts as an angiogenesis and tumor suppressor	FASEB JOURNAL			English	Article						neovascularization; antitumor; interferon-gamma	GAMMA-INDUCING FACTOR; ENDOTHELIAL GROWTH-FACTOR; LEWIS-LUNG-CARCINOMA; X-C CHEMOKINE; IN-VIVO; IFN-GAMMA; INTERFERON-GAMMA; CONVERTING-ENZYME; BLOOD-VESSELS; INHIBITION	Interleukin-18 (IL-18), also called interferon-gamma (IFN-gamma)-inducing factor, has recently been characterized as a potent IFN-gamma-inducing cytokine, We now report that IL-18 is a novel antiangiogenic and antitumor cytokine. In vitro, IL-18 specifically inhibits fibroblast growth factor-2-stimulated proliferation of capillary endothelial cells. In vivo, IL-18 is sufficiently potent to suppress the fibroblast growth factor-induced corneal neovascularization by systemic administration in mice. This cytokine also inhibits embryonic angiogenesis in the chick chorioallantoic membrane assay, Systemic and intralesional administrations of IL-18 produce a significant suppression of the growth of murine T241 fibrosarcoma in syngeneic C57B16/J and immunodeficient SCID mice, The antitumor effect appears to be potent because an average of >75% inhibition of primary tumor growth was observed at a dose of 50 mu g/kg/day, In cell culture, murine T241 fibrosarcoma cells are insensitive to recombinant IL-18 at concentrations that significantly inhibit endothelial cell, proliferation. Immunohistochemical studies of tumor tissues reveal hypovascularization of the IL-18-treated tumors. These results suggest that IL-18 may participate in the regulation of a switch of tumor angiogenesis.	Karolinska Inst, Ctr Microbiol & Tumor Biol, Lab Angiogenesis Res, S-17177 Stockholm, Sweden; Hayashibara Biochem Labs Inc, Fujisaki Inst, Okayama 702, Japan	Karolinska Institutet; Hayashibara Biochemical Laboratories, Inc.	Cao, YH (corresponding author), Karolinska Inst, Ctr Microbiol & Tumor Biol, Lab Angiogenesis Res, S-17177 Stockholm, Sweden.							Ahn HJ, 1997, J IMMUNOL, V159, P2125; ANGIOLILLO AL, 1995, J EXP MED, V182, P155, DOI 10.1084/jem.182.1.155; Arenberg DA, 1996, J EXP MED, V184, P981, DOI 10.1084/jem.184.3.981; Boehm T, 1997, NATURE, V390, P404, DOI 10.1038/37126; BROOKS PC, 1994, CELL, V79, P1157, DOI 10.1016/0092-8674(94)90007-8; Cao Y, 1998, Prog Mol Subcell Biol, V20, P161; Cao YH, 1997, J BIOL CHEM, V272, P22924, DOI 10.1074/jbc.272.36.22924; Cao YH, 1996, J BIOL CHEM, V271, P29461, DOI 10.1074/jbc.271.46.29461; Cao YH, 1996, J CLIN INVEST, V98, P2507, DOI 10.1172/JCI119069; CAO YH, 1995, J EXP MED, V182, P2069, DOI 10.1084/jem.182.6.2069; Cao YH, 1998, J CLIN INVEST, V101, P1055, DOI 10.1172/JCI1558; CERRETTI DP, 1992, SCIENCE, V256, P97, DOI 10.1126/science.1373520; CHEN C, 1995, CANCER RES, V55, P4230; COHN MJ, 1995, CELL, V80, P739, DOI 10.1016/0092-8674(95)90352-6; Coughlin CM, 1998, J CLIN INVEST, V101, P1441, DOI 10.1172/JCI1555; Dao T, 1996, CELL IMMUNOL, V173, P230, DOI 10.1006/cimm.1996.0272; EZEKOWITZ A, 1995, NEW ENGL J MED, V333, P595, DOI 10.1056/NEJM199508313330913; FOLKMAN J, 1979, P NATL ACAD SCI USA, V76, P5217, DOI 10.1073/pnas.76.10.5217; FOLKMAN J, 1971, NEW ENGL J MED, V285, P1182; Folkman J, 1997, NAT BIOTECHNOL, V15, P510, DOI 10.1038/nbt0697-510; Folkman J, 1995, NEW ENGL J MED, V333, P1757, DOI 10.1056/NEJM199512283332608; Folkman J, 1996, CELL, V87, P1153, DOI 10.1016/S0092-8674(00)81810-3; FOLKMAN J, 1995, NAT MED, V1, P2; Fukushi J, 1998, BIOCHEM BIOPH RES CO, V250, P444, DOI 10.1006/bbrc.1998.9334; Ghayur T, 1997, NATURE, V386, P619, DOI 10.1038/386619a0; Gu Y, 1997, SCIENCE, V275, P206, DOI 10.1126/science.275.5297.206; Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7; HU DE, 1993, INFLAMMATION, V17, P135, DOI 10.1007/BF00916100; Jain RK, 1997, NAT MED, V3, P1203, DOI 10.1038/nm1197-1203; KANDEL J, 1991, CELL, V66, P1095, DOI 10.1016/0092-8674(91)90033-U; Kenyon BM, 1996, INVEST OPHTH VIS SCI, V37, P1625; KIM KJ, 1993, NATURE, V362, P841, DOI 10.1038/362841a0; KOCK AE, 1992, SCIENCE, V258, P1798; Lieschke GJ, 1997, NAT BIOTECHNOL, V15, P35, DOI 10.1038/nbt0197-35; LUSTER AD, 1993, J EXP MED, V178, P1057, DOI 10.1084/jem.178.3.1057; LUSTER AD, 1995, J EXP MED, V182, P219, DOI 10.1084/jem.182.1.219; MAIONE TE, 1990, SCIENCE, V247, P77, DOI 10.1126/science.1688470; MAIONE TE, 1991, CANCER RES, V51, P1798; MILLAUER B, 1994, NATURE, V367, P578; MUTHUKKARUPPAN VR, 1979, SCIENCE, V205, P1461; OKAMURA H, 1995, NATURE, V378, P88, DOI 10.1038/378088a0; OReilly MS, 1996, NAT MED, V2, P689, DOI 10.1038/nm0696-689; OREILLY MS, 1994, CELL, V79, P315, DOI 10.1016/0092-8674(94)90200-3; OREILLY MS, 1997, CELL, V88, P1; Risau W, 1997, NATURE, V386, P671, DOI 10.1038/386671a0; Sarvetnick N, 1997, J CLIN INVEST, V99, P371, DOI 10.1172/JCI119167; STRIETER RM, 1995, SHOCK, V4, P155, DOI 10.1097/00024382-199509000-00001; Udagawa N, 1997, J EXP MED, V185, P1005, DOI 10.1084/jem.185.6.1005; Ushio S, 1996, J IMMUNOL, V156, P4274; VOEST EE, 1995, J NATL CANCER I, V87, P581, DOI 10.1093/jnci/87.8.581; Volpert OV, 1998, J EXP MED, V188, P1039, DOI 10.1084/jem.188.6.1039	51	179	208	0	8	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	DEC	1999	13	15					2195	2202		10.1096/fasebj.13.15.2195	http://dx.doi.org/10.1096/fasebj.13.15.2195			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	266QN	10593867				2022-12-25	WOS:000084310800011
J	Fu, LN; Ma, WL; Benchimol, S				Fu, LN; Ma, WL; Benchimol, S			A translation repressor element resides in the 3 ' untranslated region of human p53 mRNA	ONCOGENE			English	Article						p53; translational control; 3 ' UTR	CELLULAR TUMOR-ANTIGEN; DNA-DAMAGING AGENTS; MESSENGER-RNA; ADULT TISSUES; PROTEIN; EXPRESSION; APOPTOSIS; RADIATION; BINDING; CELLS	The 3' untranslated region of human p53 mRNA represses translation both irt vitro and in vivo. Here, we identify a cis-acting 66-nucleotide U-rich sequence in the human p53 mRNA 3' untranslated region that mediates translational repression. Using UV crosslinking, we detect a 40 kDa protein that interacts specifically with the p53 3'UTR containing the repressor element. Enhanced translation of p53 mRNA contributes to the accumulation of p53 protein in cells exposed to gamma-radiation and could be a consequence of relieving the inhibition mediated by the repressor element.	Princess Margaret Hosp, Ontario Canc Inst, Toronto, ON M5G 2M9, Canada; Univ Toronto, Dept Med Biophys, Toronto, ON M5G 2M9, Canada	University of Toronto; University Toronto Affiliates; University Health Network Toronto; Princess Margaret Cancer Centre; University of Toronto	Benchimol, S (corresponding author), Princess Margaret Hosp, Ontario Canc Inst, 610 Univ Ave, Toronto, ON M5G 2M9, Canada.			Benchimol, Samuel/0000-0003-3433-890X				Bashaw GJ, 1997, CELL, V89, P789, DOI 10.1016/S0092-8674(00)80262-7; BAUM EZ, 1988, DEV BIOL, V126, P141, DOI 10.1016/0012-1606(88)90247-3; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; FORT P, 1985, NUCLEIC ACIDS RES, V13, P1431, DOI 10.1093/nar/13.5.1431; FRITSCHE M, 1993, ONCOGENE, V8, P307; Fu LN, 1997, EMBO J, V16, P4117, DOI 10.1093/emboj/16.13.4117; Fu LN, 1996, EMBO J, V15, P4392, DOI 10.1002/j.1460-2075.1996.tb00812.x; Giaccia AJ, 1998, GENE DEV, V12, P2973, DOI 10.1101/gad.12.19.2973; HAKE LE, 1994, CELL, V79, P617, DOI 10.1016/0092-8674(94)90547-9; HARLOW E, 1985, MOL CELL BIOL, V5, P1601, DOI 10.1128/MCB.5.7.1601; HERZOG H, 1990, NUCLEIC ACIDS RES, V18, P4600, DOI 10.1093/nar/18.15.4600; JACKSON RJ, 1990, CELL, V62, P15, DOI 10.1016/0092-8674(90)90235-7; KASTAN MB, 1991, CANCER RES, V51, P6304; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; LU X, 1993, CELL, V75, P765, DOI 10.1016/0092-8674(93)90496-D; Maki CG, 1997, MOL CELL BIOL, V17, P355, DOI 10.1128/MCB.17.1.355; MALTZMAN W, 1984, MOL CELL BIOL, V4, P1689, DOI 10.1128/MCB.4.9.1689; MATLASHEWSKI G, 1984, EMBO J, V3, P3257, DOI 10.1002/j.1460-2075.1984.tb02287.x; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; MOSNER J, 1995, EMBO J, V14, P442; MURATA Y, 1995, CELL, V80, P747, DOI 10.1016/0092-8674(95)90353-4; OREN M, 1981, MOL CELL BIOL, V1, P101, DOI 10.1128/MCB.1.2.101; Ostareck DH, 1997, CELL, V89, P597, DOI 10.1016/S0092-8674(00)80241-X; PENNICA D, 1984, VIROLOGY, V134, P477, DOI 10.1016/0042-6822(84)90316-7; ROGEL A, 1985, MOL CELL BIOL, V5, P2851, DOI 10.1128/MCB.5.10.2851; STANDART N, 1994, BIOCHIMIE, V76, P867, DOI 10.1016/0300-9084(94)90189-9; TISHLER RB, 1993, CANCER RES, V53, P2212; Wickens M, 1997, CURR OPIN GENET DEV, V7, P220, DOI 10.1016/S0959-437X(97)80132-3	33	36	39	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 11	1999	18	47					6419	6424		10.1038/sj.onc.1203064	http://dx.doi.org/10.1038/sj.onc.1203064			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	256CW	10597243				2022-12-25	WOS:000083709200003
